inserm_concat,NCT Number,Title_first,Acronym_first,Status_first,Study Results_first,Conditions_first,Interventions_first,Outcome Measures_first,Sponsor/Collaborators_first,Gender_first,Age_first,Phases_first,Enrollment_first,Funded Bys_first,Study Type_first,Study Designs_first,Other IDs_first,Start Date_first,Primary Completion Date_first,Completion Date_first,First Posted_first,Results First Posted_first,Last Update Posted_first,Locations_first,Study Documents_first,URL_first,nct,pmids
oui,NCT00001671,The Classification and Cause of Leukodystrophies of Unknown Cause,,Completed,No Results Available,Lysosomal Storage Disease,,,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",,400,NIH,Observational,,970170|97-N-0170,"September 9, 1997",,"December 15, 2008","November 4, 1999",,"July 2, 2017","University of California, San Francisco, San Francisco, California, United States|Childrens National Medical Center, Washington, D.C., District of Columbia, United States|Institut National de la Sante' et de la Recherche Medicale, Clermont-Ferrand, Cedex, France|Tel Aviv University, Tel Aviv, Israel|Academiseh Ziuekenhuis Vrije Universiteit, Amsterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT00001671,NCT00001671,28748214
oui,NCT00090051,FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients,,Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Rituximab|Drug: Fludarabine Phosphate|Drug: Cyclophosphamide,Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC)|Number of Participants With Progression-free Survival (PFS) Events Assessed by the Independent Review Committee (IRC)|Final Analysis: Time to Progression-Free Survival Event|Overall Survival (OS)|Number of Participants With Overall Survival (OS) Events|Event-free Survival (EFS)|Number of Participants With Event-free Survival (EFS) Events|Disease-free Survival (DFS)|Number of Participants With Disease-free Survival (DFS) Events|Final Analysis: Time to Overall Survival Event|Final Analysis: Time to Event-Free Survival Event|Final Analysis: Percentage of Participants With Complete Response|Final Analysis: Time to Disease-Free Survival Event|Final Analysis: Duration of Response|Final Analysis: Time to New Chronic Lymphocytic Leukemia (CLL) Treatment,"Hoffmann-La Roche|Biogen|Genentech, Inc.",All,"18 Years and older � (Adult, Older Adult)",Phase 3,552,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,102-14|BO17072,"July 31, 2003","July 23, 2008","May 31, 2012","August 25, 2004","January 23, 2012","August 1, 2017","Uab Comprehensive Cancer Center, Birmingham, Alabama, United States|Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, California, United States|California Cancer Center Woodward Park; Community Medical Centers, Fresno, California, United States|Rush-Presbyterian St. Luke'S Medical Center, Chicago, Illinois, United States|Duke University Medical Center, Durham, North Carolina, United States|Milton S. Hershey Medical Center; Penn State Cancer Inst., Hershey, Pennsylvania, United States|Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia|Mater Hospital; Division of Cancer Services, Brisbane, Queensland, Australia|Frankston Hospital; Oncology/Haematology, Frankston, Victoria, Australia|Peter Maccallum Cancer Institute; Medical Oncology, Melbourne, Victoria, Australia|ZNA Stuivenberg, Antwerpen, Belgium|Institut Jules Bordet, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Uni of Alberta Hospital, Edmonton, Alberta, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Health Science Centre, St. John's, Newfoundland and Labrador, Canada|QEII HSC; Oncology, Halifax, Nova Scotia, Canada|Hamilton Health Sciences - Juravinski Cancer Centre; Hematology, Hamilton, Ontario, Canada|The Ottawa Regional Hospital - General Campus; Division of Hematology, Box 704, Ottawa, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Mcgill University - Royal Victoria Hospital; Oncology, Montreal, Quebec, Canada|Righospitalet, H�matologisk Klinik, K�benhavn �, Denmark|Aarhus Universitetshospital, H�matologisk Afdeling R, �rhus, Denmark|Hopital Avicenne; Hematologie Biologique, Bobigny, France|Hopital Clemenceau; Hematologie Clinique, Caen, France|Chu Estaing; Hematologie Clinique Adultes, Clermont Ferrand, France|Hopital Henri Mondor; Hematologie Clinique, Creteil, France|Clinique Victor Hugo; Chimiotherapie, Le Mans, France|Hopital Claude Huriez; Hematologie, Lille, France|Hopital Edouard Herriot; Bat.E-Hematologie, Lyon, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut J Paolii Calmettes; Onco Hematologie 1, Marseille, France|H�pital Lapeyronie; H�matologie Oncologie M�dicale, Montpellier, France|Hopital Hotel Dieu Et Hme;Hopital De Jour, Nantes, France|Hotel Dieu; Hematologie- Oncologie, Paris, France|Inserm Cic 9504, Paris, France|Hopital Pitie Salpetriere; Hematologie Clinique, Paris, France|Ch Lyon Sud; Hemato Secteur Jules Courmont, Pierre Benite, France|Chu La Miletrie; Hdj Cons Hemato Cancerologie, Poitiers, France|Centre Henri Becquerel; Hematologie, Rouen, France|Hopital Bretonneau; Clinique D'Oncologie & de Radiotherapie, Tours, France|Hopitaux De Brabois; Hematologie Medecine Interne, Vandoeuvre Les Nancy, France|Szent Laszlo Hospital; Hematology Dept, Budapest, Hungary|National Institute of Oncology, A Dept of Internal Medicine, Budapest, Hungary|Orsz�gos Gy�gyint�zeti K�zpont; Haematologiai Osztaly, Budapest, Hungary|Uni of Debrecen; 2Nd Clinic of Internal Medicine, Debrecen, Hungary|University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology, Debrecen, Hungary|Uni of Pecs; Dept of Internal Medicine, Pecs, Hungary|University of Szeged, II Dept of Internal Medicine, Szeged, Hungary|A.O. Universitaria Federico II Di Napoli; Oncologia Ed Endocrinologia Clinica, Napoli, Campania, Italy|A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna, Emilia-Romagna, Italy|Ospedale S. Eugenio; Divisione Di Ematologia, Roma, Lazio, Italy|Az. Osp. S. Camillo Forlanini; Uo Ematologia E Trapianti Di Midollo Osseo, Roma, Lazio, Italy|Universita' Degli Studi La Sapienza-Ist.Di Ematologia;Dip. Biotecnologie Cel CELLULARI ED EMATOLOGIA, Roma, Lazio, Italy|Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia, Milano, Lombardia, Italy|Irccs Policlinico San Matteo; Divisione Di Ematologia, Pavia, Lombardia, Italy|Uni Degli Studi Di Bari, Policlinico; Cattedra Di Ematologia,Dipart. Di Medicina Interna E Publica, Bari, Puglia, Italy|IRCCS Ospedale Casa Sollievo Della Sofferenza; Ematologia E Trapianto Di Midollo Osseo, San Giovanni Rotondo, Puglia, Italy|Ospedale Di Vicenza; Nefrologia, Ematologia, Vicenza, Veneto, Italy|Meander Mc, Locatie Lichtenberg; Dept of Lung Diseases, Amersfoort, Netherlands|Academisch Medisch Centrum Universiteit Amsterdam, Amsterdam, Netherlands|Leyenburg Ziekenhuis; Haematology, Den Haag, Netherlands|Erasmus Mc - Daniel Den Hoed Kliniek; Medical Oncology, Rotterdam, Netherlands|Auckland city hospital; Auckland Regional Cancer Centre and Blood Service, Auckland, New Zealand|Christchurch Hospital; Canterbury Health Laboratories, Christchurch, New Zealand|Wellington Hospital; Regional Oncology Unit, Wellington, New Zealand|Haukeland Universitetshospital; Medicine Dept, Bergen, Norway|Rikshospitalet Uni Hospital, Oslo, Norway|Medical University School; Dept. of Haematology, Lodz, Poland|Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie, Lublin, Poland|Akademii Medycznej W; Klinika Hematologii, Poznan, Poland|Klin. Chorob Wewnetrznych I Hemat. Z Osrodkiem Transplant. Szpiku, Warszawa, Poland|Instytut Hematologii I Transfuzjologii; Klinika Chorob Wewnetrznych I Hematologii, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny; Haematology Dept., Warszawa, Poland|Fundeni Clinical Inst. ; Hematology Dept, Bucharest, Romania|Spitalul Clinic Coltea; Clinica de Hematologie, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie, Targu-mures, Romania|Spitalul Clinic municipal de Urgenta Timisoara; Clinica de Hematologie, Timisoara, Romania|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|Haematology Research Center; Haematology, Moscow, Russian Federation|City Clinical Botkin's Hospital; City Hematological Center, Moscow, Russian Federation|Medical Radiological Research Centre Rams; Dept. of Radiotherapy & Chemotherapy of Hemoblastosis, Obninsk, Russian Federation|Regional Clinical Hospital N.A. Kalinin; Hematology Dept, Samara, Russian Federation|Research Inst. Hematology /Blood Transfusion ; Hemablastosis, Supression Hemopoesis & B M Transplant, St Petersburg, Russian Federation|Regional Clinical Hospital; Hematology Dept. #2 For B M Transplantation & High Dose Chemo., St Petersburg, Russian Federation|Pavlov State Medical Uni ; Bone Marrow Transplantation Clinic, St Petersburg, Russian Federation|S.-Peterburg Pavlov State Medical University ; Haematology, St Petersburg, Russian Federation|State Medical Inst. Municipal Hospital #31; Oncology & Hematology Dept. With the Usechemo. in Adult, St Petersburg, Russian Federation|Hospital Universitario de la Princesa; Servicio de Hematologia, Madrid, Spain|Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Hematologia, Zaragoza, Spain|Karolinska Inst. , Huddinge Uni Hospital; Depart. of Hematology, Huddinge, Sweden|Universitetssjukhuset i Link�ping, Hematologkliniken, Linkoeping, Sweden|Royal Bournemouth General Hospital; Haematology, Bournemouth, United Kingdom|Addenbrookes Hospital; Haematology, Cambridge, United Kingdom|Stobhill Hospital; Dept of Haematology, Glasgow, United Kingdom|Leeds General Infirmary; Medicine, Leeds, United Kingdom|Leicester Royal Infirmary; Dept of Haematology, Leicester, United Kingdom|Royal Liverpool Uni Hospital; Haematology, Liverpool, United Kingdom|St. Bartholomew'S Hospital; Dept of Medical Oncology, London, United Kingdom|King'S College Hospital; Haematology, London, United Kingdom|Royal Marsden Hospital; Academic Dept of Haematology, Sutton, United Kingdom|Pinderfields General Hospital; Dept of Haematology, Wakefield, United Kingdom",,https://ClinicalTrials.gov/show/NCT00090051,NCT00090051,24916506;23525797
anrs,NCT00113282,Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123),,Completed,No Results Available,HIV Infections,Drug: Interleukin-2 (IL-2),"proportion of patients reaching an absolute CD4 count over 200/mm3 at Week 52 (W52)|group B or C events (1993 CDC classification of HIV infection)between Week 00 and Week 96|median value of the CD4 count at W52|evolution of the CD4 count during the study|time to the first visit with a CD4 count ? 200/mm3|tolerance of IL-2|tolerance of antiretroviral drugs|evolution of the plasma HIV RNA load at W64 and W76|evolution of the HIV DNA level in PBMCs at W64 and W76|number of modifications of antiretroviral regimen until W52|clinical status at W64 and W76|CD4 count at W64, W76 and W96|plasma HIV RNA load at W64, W76 and W96|number of modifications of antiretroviral regimen at W64 and W76|proportion of patients increasing their CD4 count over 50/mm3 between Week 00 and Week 24, and between Week 00 and Week 52",French National Agency for Research on AIDS and Viral Hepatitis|Chiron Corporation,All,"18 Years and older � (Adult, Older Adult)",Phase 2,57,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2004-001329-29|ANRS123,June 2004,December 2007,February 2008,"June 8, 2005",,"December 22, 2011","H�pital Necker service des Maladies Infectieuses, Paris, France",,https://ClinicalTrials.gov/show/NCT00113282,NCT00113282,
anrs,NCT00115609,Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129),,Completed,No Results Available,HIV Infections|Tuberculosis,Drug: efavirenz|Drug: tenofovir DF|Drug: emtricitabine,"treatment success rate at week 48 (W48)|course of plasma HIV-1 RNA between W0 and W48|tuberculosis cure rate|safety of trial treatments (number of events, description, time to onset, metabolic disorders, immune restoration syndrome)|frequency of treatment changes or discontinuations|clinical progression of HIV infection|course of CD4 and CD8 T lymphocytes|study of resistance in the case of virological failure|study of compliance and quality of life|pharmacokinetic study of tuberculostatic agents|effect of treatment on hepatitis B viral replication",French National Agency for Research on AIDS and Viral Hepatitis,All,"18 Years and older � (Adult, Older Adult)",Phase 3,70,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-002470-30|ANRS129 BKVIR,January 2006,November 2009,November 2009,"June 24, 2005",,"December 22, 2011","Service des maladies Infectieuses et tropicales Hopital Necker-Enfants Malades, Paris, France",,https://ClinicalTrials.gov/show/NCT00115609,NCT00115609,
anrs,NCT00116454,Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis,Lipiocis,Completed,No Results Available,"Carcinoma, Hepatocellular|Hepatitis, Viral, Human",Drug: 131 I-lipiodol,"to determine if the Lipiocis treatment decreases the % of tumoral recurrence after 24 months, judged on the rise of alpha-fetoprotein and the reappearance of one or more tumours on the hepatic CT scan|overall survival|recurrence-free survival|treatment toxicity|Deterioration of the hepatocellular function","ANRS, Emerging Infectious Diseases",All,"18 Years to 75 Years � (Adult, Older Adult)",Phase 3,73,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2004-003883-31|ANRS HC06 LIPIOCIS,July 2005,August 2013,August 2013,"June 30, 2005",,"September 23, 2013","Service d'H�patologie H�pital Saint Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT00116454,NCT00116454,
anrs,NCT00117494,Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126),,Completed,No Results Available,Hyperlipidemia|HIV Infections,Drug: Pravastatin|Drug: Rosuvastatin,"Compare the change in LDL cholesterol between D0 and D45, in patients receiving rosuvastatin (10 mg/day) or pravastatin (40 mg/day) and treated by antiretroviral agents including a boosted protease inhibitor on D45.|Changes in triglycerides and HDL cholesterol on D45|Percentage of patients with a normal value of LDL cholesterol, HDL cholesterol and triglycerides on D45 Clinical and biological safety parameters of rosuvastatin and pravastatin|Distribution profile of the diameter of LDL cholesterol particles|Cmin of rosuvastatin and pravastatin on D15|Cmin of protease inhibitors on D15.",French National Agency for Research on AIDS and Viral Hepatitis,All,"18 Years and older � (Adult, Older Adult)",Phase 4,86,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-001451-38|ANRS 126,October 2005,March 2007,June 2007,"July 7, 2005",,"December 22, 2011","service de M�decine Interne Hopital Hotel Dieu, Paris, France",,https://ClinicalTrials.gov/show/NCT00117494,NCT00117494,22739396;22318219
anrs,NCT00118677,Long-Term Supervised Treatment Interruption in HIV-Infected Patients,,Completed,No Results Available,HIV Infections,Procedure: Treatment interruption,Proportion of patients who did not resume antiretroviral treatment at 12 months|Time to resume antiretroviral treatment with CD4 cell count equal or below 300/mm3|Proportion of patients who did not resume antiretroviral treatment at M 24 and M 36|Predictive factors associated with the time of restart of antiretroviral therapy: Proviral HIV DNA at baseline and during follow-up|Plasma HIV RNA at baseline and during follow-up|CD4 T cell and CD8 T cell HIV specific responses at baseline and after 12 months|Change in lipodystrophy clinical score and quality of life during the follow-up|Criteria to resume antiretroviral treatment: CD4T cell count below or equal to 300/mm3|The occurrence of an AIDS defining event,French National Agency for Research on AIDS and Viral Hepatitis,All,"18 Years and older � (Adult, Older Adult)",Phase 3,130,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 116 SALTO,February 2003,,May 2007,"July 12, 2005",,"August 30, 2007","Service d'immunologie Clinique, H�pital Europ�en Georges Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT00118677,NCT00118677,20657770
anrs,NCT00120185,Efficacy of Using Interleukin-2 in Antiretroviral Na�ve HIV Patients (ANRS119),,Completed,No Results Available,HIV Infections,Drug: Interleukin-2,"Proportion of patients reaching an absolute CD4 count below 300/mm3 at W96|Group B or C events (1993 CDC classification of HIV infection)|Initiation of antiretroviral therapy|Evolution of the CD4 count during the study|Time to the first visit with a CD4 count below 300/mm3|Tolerance of IL-2|Evolution of the plasma HIV RNA load|Evolution of the HIV DNA level in PBMCs|Quality of life at W96|Assessment of lipodystrophy at W96|Immunological substudies (CD4 homeostasis, anti HIV cellular immune responses) at W96",French National Agency for Research on AIDS and Viral Hepatitis|Chiron Corporation,All,"18 Years and older � (Adult, Older Adult)",Phase 2,130,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2004-003897-27|ANRS119 Interstart,December 2003,November 2006,November 2006,"July 15, 2005",,"December 22, 2011","Service des Maladies Infectieuses, Paris, France",,https://ClinicalTrials.gov/show/NCT00120185,NCT00120185,19508157
anrs,NCT00120367,Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125),,Completed,No Results Available,"Leukoencephalopathy, Progressive Multifocal|HIV Infections",Drug: Enfuvirtide|Drug: Tenofovir-Emtricitabine,Estimation by the method of Kaplan-Meier of the rate of survival at M12|Rate of survival and functional score (Modified Rankin Outcome Scale) at M12|Evolution of the JC viral load in the CSF and percentage of patients with JC virus clearance of the CSF to M3 and M6|Evolution of the CD4 and CD8 T cells sub-populations and of the antivirus JC specific T cell responses at M12|Dosage of the concentration of enfuvirtide in the CSF,French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche|Gilead Sciences,All,"18 Years and older � (Adult, Older Adult)",Phase 2,30,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-000424-16|ANRS 125,April 2005,December 2007,December 2007,"July 18, 2005",,"December 22, 2011","Service de Medecine interne et Maladies Infectieuses, Hopital Bicetre, Le Kremlin Bicetre, France",,https://ClinicalTrials.gov/show/NCT00120367,NCT00120367,21738597
anrs,NCT00120757,Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120),,Completed,No Results Available,Osteoporosis|HIV Infections,Drug: Alendronate,Percentage of variation of lumbar BMD on DEXA scan at month 24 versus month 0 for patients included with lumbar osteoporosis (femoral for those included with only femoral osteoporosis)|Percentage of variation of femoral T-score between M0 and M24|Percentages of variation of lumbar and femoral T score between M0 and M12|Evolution of bone metabolism markers|Occurrence of fractures|Tolerance of alendronate|Measure of the prevalence of osteopenia and osteoporosis in HIV-infected men and women|Description of the evolution of osteoporosis in HIV-infected men and women receiving calcium and vitamin D to define risk factors for osteoporosis in HIV-infected persons,French National Agency for Research on AIDS and Viral Hepatitis,All,"18 Years and older � (Adult, Older Adult)",Phase 3,140,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,2004-002002-30|ANRS120 Fosivir,October 2004,November 2008,November 2008,"July 19, 2005",,"December 22, 2011","Service de Medecine Interne hopital Avicenne, Bobigny, France|Service de Rhumatologie hopital Pitie-Salpetriere, Paris, France|H�pital Necker service des Maladies Infectieuses, Paris, France",,https://ClinicalTrials.gov/show/NCT00120757,NCT00120757,22353022
anrs,NCT00120783,Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance,,Terminated,No Results Available,HIV Infections,Drug: Indinavir|Drug: Lamivudine|Drug: Ritonavir,"Decrease over 25% in CD4 counts (immunological failure-IF), or increase over 0.7 log in plasma HIV RNA (virological failure-VF) at two consecutive monthly visits during the 24-week study|Development of an HIV-1-related AIDS defining event|Death|Change in CD4 cell count between baseline and week 24|Change in plasma HIV-RNA level between baseline and week 4, week 8, week 12 and week 24|Change in genotypic and phenotypic resistance between baseline and week 2",French National Agency for Research on AIDS and Viral Hepatitis,All,"18 Years and older � (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 109 VISTA,February 2002,,August 2003,"July 19, 2005",,"January 18, 2007","Service de Medecine Interne hopital Avicenne, Bobigny, France",,https://ClinicalTrials.gov/show/NCT00120783,NCT00120783,
anrs,NCT00121121,Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers,,Completed,No Results Available,HIV Infections|HIV Seronegativity,Biological: Lipopeptides LIPO-4,"Clinical and biological safety (over or equal to degree two of a adverse event grading scale) of LIPO-4 by ID and IM routes during the study|Comparaison of CD4 positive cells responses using|lymphoprolif�ration test and CD8 positive cells responses using the capacity of these cells to synthesize IFN following stimulation with peptides of interest (ELISPOT IFN test) following IM or ID administration at weeks 2, 6, 14, 24, and 48",French National Agency for Research on AIDS and Viral Hepatitis,All,18 Years to 55 Years � (Adult),Phase 1,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS VAC16,July 2004,,December 2005,"July 21, 2005",,"March 15, 2007","Hopital Cochin Centre Cochin-Pasteur d'Essais vaccinaux, Paris, France",,https://ClinicalTrials.gov/show/NCT00121121,NCT00121121,17712402
oui,NCT00121758,AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers,,Completed,No Results Available,HIV Infections,Biological: LIPO-5,Percentage of patients with CD8 immune response on ELISPOT IFN-gamma at week (W) 48|Local and general adverse events|Percentage of subjects with CD4 immune response against different peptides of LIPO-5|Percentage of subjects with sustained response at week 48|Percentage of subjects with response against more than 1 peptide (multiepitopic response),French National Agency for Research on AIDS and Viral Hepatitis|Aventis Pharmaceuticals,All,21 Years to 55 Years � (Adult),Phase 2,156,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,2004-000233-10|ANRS VAC18,September 2004,November 2007,December 2007,"July 21, 2005",,"June 6, 2008","CIC de Vaccinologie Cochin Pasteur, Paris, France",,https://ClinicalTrials.gov/show/NCT00121758,NCT00121758,23759749;20625264
anrs,NCT00122525,Effect of Male Circumcision on HIV Incidence (ANRS 1265),,Terminated,No Results Available,HIV Infections|Herpes Genitalis|Venereal Diseases,Procedure: Male Circumcision,Measure the protective effect of medicalized male circumcision on HIV infection|Measure the protective effect on infections by the genital herpes agent Herpes simplex virus type 2 (HSV-2)|Measure the protective effect on the incidence of genital ulcer disease,French National Agency for Research on AIDS and Viral Hepatitis,Male,18 Years to 24 Years � (Adult),Phase 3,3274,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS 1265,July 2002,,July 2005,"July 22, 2005",,"April 30, 2009","MC Centre, Orange Farm, Johannesburg, South Africa",,https://ClinicalTrials.gov/show/NCT00122525,NCT00122525,19571722;19220143;19086814;19074928;16231970
anrs,NCT00122551,Intermittent Therapy in HIV-1 Infected Patients With Successful Viral Suppression Under Highly Active Antiretroviral Therapy (HAART),,Terminated,No Results Available,HIV Infections,Procedure: Intermittent antiretroviral therapy,"Immunological failure, defined by a CD4 cell count below 300/�l confirmed by a retest 14 days later during the study|1993 Centers for Disease Control (CDC) classification of HIV infection B or C events|Proportions of patients with CD4 count over 450/�l at week 96|Proportions of patients with plasma HIV load over 400 and 1000/ml thresholds|Plasma and peripheral blood mononuclear cells (PBMC) HIV resistance patterns|Proportions of patients withdrawing initial treatment strategy|Assessment of lipodystrophy and metabolic abnormalities|Antiretroviral therapy (ARTs) adherence assessment|Quality of life assessment|Cost impact of the strategies",French National Agency for Research on AIDS and Viral Hepatitis,All,"18 Years and older � (Adult, Older Adult)",Phase 3,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 106 Window,December 2001,,April 2005,"July 22, 2005",,"August 1, 2005","Service des Maladies Infectieuses, Paris, France|Service des Maladies Infectieuses et Tropicales Hopital Purpan, Toulouse Cedex 9, France",,https://ClinicalTrials.gov/show/NCT00122551,NCT00122551,21738752;18931625
anrs,NCT00122577,Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients,,Terminated,No Results Available,HIV Infections,Drug: Tenofovir|Drug: Atazanavir|Drug: Ritonavir,"Change in plasma HIV RNA level and percentage of patients with undetectable HIV-RNA in plasma at Week 26|Tolerance during the study|Changes in CD4+ counts at week 26|Emergence of drug-resistant viruses|Rate of virus decay in plasma in group 2 during the initial phase (14 days) of therapy according to baseline EC50 of atazanavir|Pharmacokinetic (PK) profile of atazanavir alone at day 14|Blood samples prior to drug administration (Cmin) and after drug administration on day 14 at +1h, +2h, +3h, +5h, +8h, and +24h in 10 patients of group 2|PK assessment on Week 6, of atazanavir, after 4 weeks of co-administration with tenofovir DF. (Blood samples prior to drug administration (Cmin) and after drug administration at +1h, +2h, +3h, +5h, +8h, and +24h in the same 10 patients of group 2)",French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb|Gilead Sciences,All,"18 Years and older � (Adult, Older Adult)",Phase 2,50,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 107 Puzzle 2,March 2002,,July 2004,"July 22, 2005",,"July 28, 2005","Service d'Immunologie clinique Hopital Europeen Georges Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT00122577,NCT00122577,
anrs,NCT00122590,Evaluation of Therapeutic Drug Monitoring of Protease Inhibitors on Virologic Success and Tolerance of Highly Active Antiretroviral Therapy (HAART),,Terminated,No Results Available,HIV Infections,Drug: nelfinavir|Drug: lopinavir/r|Drug: indinavir|Drug: ritonavir,"treatment failure defined as viral load greater than 200 copies/ml between week 16 (W16) and week 48 (W48) (confirmed by 2 samples spiked at least 15 days apart but no more than 45 days after virological failure, assayed by 50 copies/ml method)|toxicity related to PI, defined as adverse event grade 3 or 4 with ANRS quotation, renal colic, diarrhoea grade 2, or cholesterolemia over 10 times the normal value|virological failure: viral load over 200 copies/ml between W16 and W48 (confirmed by 2 samples spiked at least 15 days apart but no more than 45 days after virological failure, assayed by 50 copies/ml method)|toxicity related to PI: adverse events grade 3 or 4 with ANRS quotation, renal colic, diarrhoea grade 2, or cholesterolemia over 10 times the normal value|patients with trough plasma concentrations outside the therapeutic range at W24 and W48|concentration changes with dosage variation|time to obtain a viral load below 200 copies/ml|relationship between adverse events grade 3 or 4 related to PI and plasma concentration at week 2 (W2)|relationship between pharmacokinetic parameters and/or plasma concentrations and the drop of viral load between day 0 (D0) and W2 and between D0 and week 4 (W4)|relationship between pharmacokinetic parameters and viral mutations occurring during the treatment of patients with virological failure (over 1000 copies/ml after week 24 [W24])|PI pharmacokinetic parameter estimation and evaluation of variability|pharmacokinetic variability of nucleoside analogues at W2|intracellular concentration of nucleoside triphosphate derivatives at W2 (trough and maximum) and relationship between virological response and adverse events|relationship between inhibitory quotient of indinavir and virological response",French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,115,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS111 COPHAR 2,July 2002,,March 2005,"July 22, 2005",,"August 1, 2005","Service de Medecine Interne Hopital Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT00122590,NCT00122590,
anrs,NCT00122603,Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127),,Completed,No Results Available,HIV Infections,Drug: Fosamprenavir|Drug: Saquinavir,Virologic success defined as HIV RNA levels below 50 copies/ml after 16 weeks of initial treatment|Safety of protease inhibitors|Percentage of patients with viral load below 400 copies/ml at week 16 (W16)|Body mass index (BMI),French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb|GlaxoSmithKline|Hoffmann-La Roche,All,"18 Years and older � (Adult, Older Adult)",Phase 2,61,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-003470-20|ANRS 127 2 IP,December 2005,,August 2007,"July 22, 2005",,"December 22, 2011","Service des Maladies infectieuses et tropicales Hopital Bichat Claude Bernard, Paris, France",,https://ClinicalTrials.gov/show/NCT00122603,NCT00122603,19420019
anrs,NCT00122655,Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy,,Terminated,No Results Available,HIV Infections|HIV Lipodystrophy Syndrome,Drug: non-nucleoside reverse transcriptase inhibitors|Drug: nucleoside reverse transcriptase inhibitors|Drug: protease inhibitors,Evolution from inclusion to week 48 of the peripheral fat tissue measured on computed tomography (CT) scan by a volumetric fat centralized evaluation of the thighs|Evolution of the viral load (VL) from inclusion to week 48 and proportion of patients with a VL over 400 copies/ml at week 48|Change in CD4 cell count between day 0 (D0) and week 48|Change in lipid profile and glucidic metabolism between D0 and week 48|Evolution of SAT/TAT and VAT/TAT between D0 and week 48,French National Agency for Research on AIDS and Viral Hepatitis,All,"18 Years and older � (Adult, Older Adult)",Phase 4,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS108 NONUKE,January 2001,,June 2005,"July 22, 2005",,"November 15, 2005","Service des Maladies infectieuses et Tropicales Hopital Pitie Salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT00122655,NCT00122655,
anrs,NCT00122668,Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients,,Terminated,No Results Available,HIV Infections|HIV-Associated Lipodystrophy Syndrome,Drug: non-nucleoside reverse transcriptase inhibitors|Drug: nucleoside reverse transcriptase inhibitors|Drug: protease inhibitor,Evolution of subcutaneous fat in the limbs measured by DEXA and CT-scan of the thighs between baseline and Week 96|During the study until 96 weeks|Viro-immunologic efficacy: Proportion of patients with a plasma viral load below 400 and 50 copies/ml|Evolution of viral load|Evolution of CD4 lymphocytes|Evaluation of clinical safety|Evaluation of lipohypertrophic syndrome|Evaluation of glucidic and lipids metabolic profile|Evaluation of mitochondrial toxicity|Evaluation of bone toxicity by measurement of bone density|Evaluation of plasma trough concentration of protease inhibitors and non nucleoside reverse transcriptase inhibitors|Evaluation of intracellular concentration of nucleoside reverse transcriptase inhibitors|Evolution of quality of life using the World Health Organization Quality of Life in persons with HIV Brief Form (WHO-QOL-HIV BREF),French National Agency for Research on AIDS and Viral Hepatitis,All,"18 Years and older � (Adult, Older Adult)",Phase 4,112,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS121 HIPPOCAMPE,November 2003,,July 2005,"July 22, 2005",,"November 15, 2005","Service des Maladies infectieuses et Tropicales Hopital Pitie Salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT00122668,NCT00122668,19487903;19363330;18641035
anrs,NCT00125814,Structured Treatment Interruptions With or Without Pegylated Interferon Alpha for HIV-Infected Patients After Prolonged Viral Suppression,,Terminated,No Results Available,HIV Infections,Drug: Interferon alfa-2b|Procedure: Structured treatment interruptions,Proportion of patients who did not reach the criteria to resume antiretroviral treatment at week 72 [W 72] (viral load over 30000 cp/ml at two consecutive monthly samples and/or CD4 count below 350/mm3 at two consecutive monthly samples)|Viral rebound one and 3 months after stopping all antiviral treatments|Specific anti-HIV CD4 and CD8 response|Proviral HIV DNA at baseline and during follow-up|Description of genetic HIV viral mutations during procedure|Safety,French National Agency for Research on AIDS and Viral Hepatitis|Schering-Plough,All,"18 Years and older � (Adult, Older Adult)",Phase 3,200,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 105 INTERVAC,December 2001,,January 2005,"August 2, 2005",,"August 16, 2005","Service de Medecine Interne, Clamart, France",,https://ClinicalTrials.gov/show/NCT00125814,NCT00125814,
anrs,NCT00126243,"Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma",,Terminated,No Results Available,AIDS Related Lymphoma,Drug: rituximab|Drug: CHOP,Evaluate the response rate of lymphoma treated|Duration of response|Evaluate the time to progression|Survival|Safety of rituximab in HIV patients with lymphoma when sequentially administered with chemotherapy,French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche,All,"18 Years to 75 Years � (Adult, Older Adult)",Phase 2,60,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 085 Rituximab,January 1999,,October 2003,"August 3, 2005",,"August 17, 2005","Service de Medecine Interne Hopital Antoine Beclere, Clamart, France",,https://ClinicalTrials.gov/show/NCT00126243,NCT00126243,
oui,NCT00136630,"Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations",,Completed,No Results Available,Spinocerebellar Ataxias|Spastic Paraplegias,,,"Institut National de la Santé Et de la Recherche Médicale, France|Assistance Publique - Hôpitaux de Paris",All,"18 Years to 80 Years   (Adult, Older Adult)",,175,Other,Observational,Observational Model: Family-Based|Time Perspective: Prospective,RBM01-59 _ AOM03059,May 2005,May 2016,May 2020,"August 29, 2005",,"August 25, 2021","Hôpital Pellegrin, Bordeaux, France|CHU de Grenoble, Grenoble, France|Hôpital Neurologique Pierre Wertheimer, Lyon, France|Hôpital La Timone, Marseille, France|Hôpital Carémeau, Nîmes, France|Hôpital Pitié-Salpêtrière, Paris, France|Hôpital Charles Nicolle, Rouen, France|Hôpital Purpan, Toulouse, France",,https://ClinicalTrials.gov/show/NCT00136630,NCT00136630,24780882;22491195
oui,NCT00136721,Parkin Mutations and Their Functional Consequences,,Unknown status,No Results Available,Parkinson's Disease,,,"Institut National de la Sant� Et de la Recherche M�dicale, France|National Institutes of Health (NIH)",All,"18 Years to 80 Years � (Adult, Older Adult)",,2500,Other|NIH,Observational,Time Perspective: Prospective,9HD01H|R01NS041723-01A1,June 2002,,May 2006,"August 29, 2005",,"December 4, 2007","H�pital Piti�-Salp�tri�re, Paris, France",,https://ClinicalTrials.gov/show/NCT00136721,NCT00136721,
oui,NCT00137904,Sleep Disorders in Patients With Multiple Sclerosis,,Unknown status,No Results Available,Multiple Sclerosis,,,"Groupe Hospitalier Pitie-Salpetriere|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 55 Years   (Adult),,51,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,RBM0242,,,,"August 30, 2005",,"February 9, 2006","Centre d'Investigation Clinique-Hopital Pitié-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT00137904,NCT00137904,
oui,NCT00139308,High Frequency Stimulation of the GPi or Thalamus in Tourette's Syndrome,,Completed,No Results Available,Tourette's Syndrome,Device: high frequency stimulation,Severity of tics,"Groupe Hospitalier Pitie-Salpetriere|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 55 Years   (Adult),Phase 1,,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,RBM0008,,,,"August 31, 2005",,"August 31, 2005","Centre d'Investigation Clinique-Hôpital Pitié-Salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT00139308,NCT00139308,18625864
oui,NCT00139321,Biomechanical Parameters of Gait in Patients With Parkinson's Disease and Parkinsonian Syndromes,,Terminated,No Results Available,"Gait Disorders, Neurologic",Device: Force platform and electromyography,Biomechanical gait initiation parameters,"Groupe Hospitalier Pitie-Salpetriere|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,110,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RBM0260,June 2004,July 2007,July 2007,"August 31, 2005",,"January 8, 2013","Centre d'Investigation Clinique-Hôpital Pitié-Salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT00139321,NCT00139321,
oui,NCT00139373,Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy,,Unknown status,No Results Available,"Supranuclear Palsy, Progressive",Drug: donepezil,,"Groupe Hospitalier Pitie-Salpetriere|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"30 Years to 80 Years � (Adult, Older Adult)",Phase 2,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,RBM0323,,,,"August 31, 2005",,"September 14, 2007","Centre d'Investigation Clinique-H�PITAL PITI�-SALPETRIERE, Paris, France",,https://ClinicalTrials.gov/show/NCT00139373,NCT00139373,
oui,NCT00140829,SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias,Spatax,Unknown status,No Results Available,Cerebellar Ataxias|Spastic Paraplegias,,,"Institut National de la Santé Et de la Recherche Médicale, France|Institut des Maladies Rares|National Research Agency, France",All,"2 Years to 70 Years   (Child, Adult, Older Adult)",,6000,Other,Observational,Observational Model: Family-Based|Time Perspective: Prospective,RBM01-29|DGS2005/003,July 2003,,December 2012,"September 1, 2005",,"March 27, 2012","CHU Mustapha, Algiers, Algeria|Université Libre de Bruxelles - Hôpital Erasme, Brussels, Belgium|The Panum Institute, Copenhagen, Denmark|CHU d'Angers, Angers, France|Hôpital Pellegrin, Bordeaux, France|Hôpitaux de Clermont-Ferrand, Clermont-Ferrand, France|CHU, Grenoble, France|Hôpital de la Timone, Marseille, France|Hôpital Carémeau, Nîmes, France|Hôpital Armand Trousseau, Paris, France|Pitié-Salpêtrière Hospital, Paris, France|Hôpital Charles Nicolle, Rouen, France|Hôpital Purpan, Toulouse, France|Hadassah-Hebrew University Hospital, Jerusalem, Israel|Dipartimento Di Scienze Neurologiche, Napoli, Italy|Molecular Medicine and Department of Neurosciences, Roma, Italy|Université Saint-Joseph, Beirut, Lebanon|CHU de Rabat, Rabat, Morocco|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands|Ullevål University Hospital, Oslo, Norway|University of Porto, Porto, Portugal|Hospital San Sebastião, Santa Maria de Feira, Portugal|King Khalid University Hospital, Riyadh, Saudi Arabia|Clinical Centre of Serbia, Belgrade, Serbia|Hôpital Habib Bourguiba, Sfax, Tunisia|Royal Free and University College Medical School, London, United Kingdom|The National Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00140829,NCT00140829,
oui,NCT00142311,Functional Characterization of Parkin + Patients,,Terminated,No Results Available,Parkinson's Disease,,,"Institut National de la Santé Et de la Recherche Médicale, France|Assistance Publique - Hôpitaux de Paris",All,"18 Years to 80 Years   (Adult, Older Adult)",,97,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,A02094|4CC03H-A02094SP|RAF/03003/P011104/PCR02006,November 2003,,September 2006,"September 2, 2005",,"April 19, 2007","Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France|Hôpital Gabriel Montpied, Clermont-Ferrand, France|CHU, Grenoble, France|Hôpital Roger Salengro, Lille, France|Hôpital Neurologique Pierre Wertheimer, Lyon, France|Hôpital René et Guillaume Laennec, Nantes, France|Hôpital Saint-Antoine, Paris, France|Pitié-Salpêtrière Hospital - Centre of Clinical Investigations, Paris, France|Pitié-Salpêtrière Hospital - Federation of Neurology, Paris, France|Pitié-Salpêtrière Hospital - Service of Psychiatry, Paris, France|Hôpital Haut-Lévêque, Pessac, France|Hôpital Pontchaillou, Rennes, France|Hôpital Civil, Strasbourg, France|Hôpital Purpan, Toulouse, France",,https://ClinicalTrials.gov/show/NCT00142311,NCT00142311,
oui,NCT00142363,Cohorts and Collections: Clinical and Genetic Study of Parkinson's Disease and Epilepsies,,Terminated,No Results Available,Parkinson's Disease|Epilepsy,,,"Institut National de la Santé Et de la Recherche Médicale, France|Ministry of Health, France",All,"1 Year to 90 Years   (Child, Adult, Older Adult)",,1700,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,4CH03G,May 2004,,December 2006,"September 2, 2005",,"March 1, 2006","Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France|Hôpital Gabriel Montpied, Clermont-Ferrand, France|CHU de Grenoble, Grenoble, France|Hôpital Roger Salengro, Lille, France|Hôpital Neurologique Pierre Wertheimer, Lyon, France|Hôpital René et Guillaume Laennec, Nantes, France|Hôpital Pasteur, Nice, France|Hôpital Saint-Antoine, Paris, France|Hôpital Pitié-Salpêtrière, Paris, France|Pitié-Salpêtrière Hospital - Centre of Clinical Investigations, Paris, France|Hôpital Robert Debré, Paris, France|Hôpital Haut-Lévêque, Pessac, France|Hôpital Pontchaillou, Rennes, France|Hôpital Civil, Strasbourg, France|Hôpital Purpan, Toulouse, France",,https://ClinicalTrials.gov/show/NCT00142363,NCT00142363,
oui,NCT00147797,Influence of Pravastatin on Carotid Artery Structure and Function in HIV-infected Patients Under Antiretroviral Therapy,,Completed,No Results Available,HIV Infection|Carotid Atherosclerosis|Dyslipidemia,,,Saint Antoine University Hospital|French Cardiology Society,All,"30 Years and older � (Adult, Older Adult)",,84,Other,Observational,Time Perspective: Prospective,2003-01|53-03,May 2003,,June 2005,"September 7, 2005",,"October 25, 2016","Department of Pharmacology and INSERM U652, H�pital Europ�en Georges Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT00147797,NCT00147797,
anrs,NCT00148824,Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.,,Completed,No Results Available,HIV Infections,Biological: 7-valent pneumococcal conjugate vaccine (vaccine)|Biological: 23-valent pneumococcal conjugate vaccine (vaccine),Proportion of patients responders to 7 pneumococcal polysaccharides at W8|Persistence of antibody responses at W24 and W96|Clinical tolerance of pneumococcal vaccines at W8|Evolution of the CD4 count and plasma HIV RNA load|Immunological substudy (predictive factors of the antibody responses) at W24,French National Agency for Research on AIDS and Viral Hepatitis|Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years and older � (Adult, Older Adult)",Phase 2,212,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS 114 PNEUMOVAC,February 2003,,January 2006,"September 8, 2005",,"March 21, 2008",,,https://ClinicalTrials.gov/show/NCT00148824,NCT00148824,20210645
anrs,NCT00148837,Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis,,Unknown status,No Results Available,"Hepatitis C, Chronic|Fibrosis",Drug: Peg-interferon alpha 2b (drug)|Drug: Ribavirin (drug)|Drug: Prazosin (drug),Proportion of patients presenting a decrease of fibrosis as measured on the liver biopsy and considered as clinically interesting (decrease of fibrosis pre- and post-therapeutic (W96) measures of at least 10 percent)|Metavir scoring system  immunostaining of alpha-smooth muscle actin  indirect markers of fibrosis (Fibrotest) at W96|Sustained virological response: undetectable HCV RNA at W96|Sustained biochemical response: ALT level at W96,French National Agency for Research on AIDS and Viral Hepatitis,All,"18 Years and older � (Adult, Older Adult)",Phase 2,112,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,2004-001326-24|ANRSHC17 Prazor,September 2004,,,"September 8, 2005",,"February 8, 2008","Hopital du haut Leveque, Pessac, France",,https://ClinicalTrials.gov/show/NCT00148837,NCT00148837,
anrs,NCT00148850,"Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients",,Terminated,No Results Available,HIV-Associated Lipodystrophy Syndrome|HIV Infections,Drug: Pioglitazone,Evolution from inclusion to week 48 of limb fat using DEXA Scan (Dual Energy X-ray Absorptiometry)|Changes from inclusion to week 48:|Lipid profile and the glucidic metabolism|SAT/TAT and VAT/TAT ratios evaluated with scanner|X ray of L4|Anthropometric measurements and the quality of life (WHO-QOL-HIV BREF)|Evaluation of clinical and biological safety,French National Agency for Research on AIDS and Viral Hepatitis|Takeda,All,"18 Years and older � (Adult, Older Adult)",Phase 3,130,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,ANRS 113 LIPIOT,February 2003,,October 2004,"September 8, 2005",,"October 20, 2005","Service des Maladies Infectieuses et Tropicales, Hopital Tenon, Paris, France",,https://ClinicalTrials.gov/show/NCT00148850,NCT00148850,18389900
anrs,NCT00148863,Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C,,Completed,No Results Available,"Hepatitis C, Chronic",Drug: Peg-interferon alpha 2a (drug)|Drug: Ribavirin (drug)|Drug: Interferon gamma (drug),Virological response as defined by an HCV RNA measure non detectable at W28 with qualitative PCR (centralized measure)|Virological response at W72|Biochemical response at W72 (ALT below normal value)|Quality of life|Immunologic response (CD4 and CD8 HCV specific)|Safety,French National Agency for Research on AIDS and Viral Hepatitis|InterMune|Hoffmann-La Roche,All,"18 Years and older � (Adult, Older Adult)",Phase 2,65,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2004-005033-19|ANRS HC16 Gammatri,June 2004,,August 2007,"September 8, 2005",,"August 30, 2007","Hopital Haut Leveque Service d'Hepato-Gastro-Enterologie, Pessac, France|H�pital du Haut-Lev�que, Pessac, France",,https://ClinicalTrials.gov/show/NCT00148863,NCT00148863,23190183
oui,NCT00149175,Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment,,Unknown status,No Results Available,Alzheimer's Disease|Dementia|Neurodegenerative Disorders,"Other: Blood sampling, skin biopsy",,"Institut National de la Santé Et de la Recherche Médicale, France|Aventis Pharmaceuticals",All,"18 Years to 90 Years   (Adult, Older Adult)",,4000,Other|Industry,Observational,Observational Model: Case-Control|Time Perspective: Prospective,02-156|02-346A10,December 2002,,October 2007,"September 8, 2005",,"March 15, 2010","CHU de la Côte de Nacre, Caen, France|Hôpital Sainte-Marguerite, Marseille, France|Hôpital Guillaume et René Laennec, Nantes, France|Hôpital de l'Archet, Nice, France|Pitié-Salpêtrière Hospital - Centre du Langage et de Neuropsychologie, Paris, France|Pitié-Salpêtrière Hospital - Fédération de Neurologie, Paris, France|Pitié-Salpêtrière Hospital, Paris, France|Hôpital Pontchaillou, Rennes, France|Hôpital Charles Nicolle, Rouen, France|Centre Hospitalier, Saint-Brieuc, France|Hôpital Bellevue, Saint-Etienne, France|Hôpital Civil, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT00149175,NCT00149175,
anrs,NCT00158405,Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN),,Completed,No Results Available,HIV Infections,Procedure: Structured Treatment Interruption|Drug: Zidovudine (ZDV)|Drug: Lamivudine (3TC)|Drug: Efavirenz (EFV)|Drug: Ritonavir (NRV)|Drug: Indinavir (IDV),To assess the non-inferiority at 24 months of two STI strategies of HAART compared with a continuous HAART in terms of :|Percentage of patients with CD4 count over 350 per mm3|Incidence of severe morbidity|Incidence of mortality|To compare at 24 months two STI strategies of HAART with a continuous HAART in terms of :|HIV resistance to antiretroviral drugs|Cost-utility|Compliance to treatment,French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb,All,"18 Years and older � (Adult, Older Adult)",Phase 3,840,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 1269 TRIVACAN,December 2002,,December 2006,"September 12, 2005",,"December 30, 2008","Centre de Prise en Charge et de Formation ACONDA, Abidjan, C�te D'Ivoire|Centre de Suivi des donneurs de sang, Centre National de Transfusion Sanguine, Abidjan, C�te D'Ivoire|Centre Int�gr� de Recherches Biocliniques d'Abidjan, Abidjan, C�te D'Ivoire|Service des Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, C�te D'Ivoire|Unit� de Soins Ambulatoires et de Conseil, CHU de Treichville, Abidjan, C�te D'Ivoire",,https://ClinicalTrials.gov/show/NCT00158405,NCT00158405,18986246;16782488
oui,NCT00169351,National Gilles De La Tourette Study Group,,Unknown status,No Results Available,Tourette Syndrome,,,"Groupe Hospitalier Pitie-Salpetriere|Institut National de la Santé Et de la Recherche Médicale, France",All,"15 Years to 80 Years   (Child, Adult, Older Adult)",,,Other,Observational,Observational Model: Defined Population|Time Perspective: Prospective,RBM0418,,,,"September 15, 2005",,"September 15, 2005","Centre d'Investigation Clinique-HÔPITAL PITIÉ-SALPETRIERE, Paris, France",,https://ClinicalTrials.gov/show/NCT00169351,NCT00169351,20885982
oui,NCT00169390,Monoamine Oxidases in Smoking Pregnant Women and Newborns,,Completed,No Results Available,Smoking|Pregnancy|Newborn,,monoamine oxidase markers,"Groupe Hospitalier Pitie-Salpetriere|Mission Interminist�rielle de Lutte contre la Drogue et la Toxicomanie (MILDT)|Mutuelle G�n�rale de l'Education Nationale (MGEN)|Institut National de la Sant� Et de la Recherche M�dicale, France",Female,"18 Years and older � (Adult, Older Adult)",,59,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RBM0344,March 2004,November 2007,November 2007,"September 15, 2005",,"March 19, 2015",,,https://ClinicalTrials.gov/show/NCT00169390,NCT00169390,19615672
oui,NCT00190216,Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression (rTMS),,Terminated,No Results Available,Depression,Device: Magnetic stimulator,"The primary outcome will be measured at 2 weeks, using depression scales scores : Hamilton depression rating scale, and Montgomery and Asberg Depression Rating Scale|Depressive psychomotor retardation will be assessed at 2 weeks|All depression measures will be assessed at 4 weeks, 2 weeks after the end of the trial to evaluate the lasting effects.","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|International Atomic Energy Agency",All,18 Years to 55 Years   (Adult),Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment",AOM98099|P000606,December 2001,,October 2007,"September 19, 2005",,"November 8, 2007","Albert Chenevier Hospital, Department of psychiatry, Creteil, France",,https://ClinicalTrials.gov/show/NCT00190216,NCT00190216,
anrs,NCT00196586,Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients,,Completed,No Results Available,HIV Infections|Chronic Hepatitis C,Drug: Interleukin 2|Drug: pegylated interferon alpha 2a|Drug: ribavirin,"Sustained virologic response, defined by undetectable serum HCV-RNA at week 72, six months after the end of treatment; Safety of IL-2 in combination with pegylated interferon and ribavirin|Virologic response at the end of treatment at week 48, Biochemical response, CD4 cell counts and HIV-RNA plasma levels from baseline to week 72",French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche,All,"18 Years to 65 Years � (Adult, Older Adult)",Phase 2,75,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS HC09 SECOIIA,April 2003,,November 2006,"September 20, 2005",,"November 16, 2007","Hopital Europ�en Georges Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT00196586,NCT00196586,
anrs,NCT00196599,"Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults",,Completed,No Results Available,HIV Infections|Antiretroviral Naive,"Drug: emtricitabine, FTC (drug)|Drug: didanosine, ddI (drug)|Drug: efavirenz (drug)",Virological success|Treatment adherence|CD4 cell count|Safety|Progression of HIV infection|Pharmacokinetics criteria,French National Agency for Research on AIDS and Viral Hepatitis|Triangle Pharmaceuticals|Gilead Sciences|Bristol-Myers Squibb|Dupont Applied Biosciences,All,"18 Years and older � (Adult, Older Adult)",Phase 2,39,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 091 MONTANA,February 1999,,September 2004,"September 20, 2005",,"September 20, 2005",,,https://ClinicalTrials.gov/show/NCT00196599,NCT00196599,
anrs,NCT00196612,Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART,,Completed,No Results Available,HIV Infections,"Drug: emtricitabine, FTC (drug)|Drug: didanosine, ddI (drug)|Drug: efavirenz (drug)",Virological success from W0 to W48|Progression of HIV infection|CD4 cell count|Safety|Treatment adherence|Quality of life|Viral mutations|Therapeutic strategy failure,French National Agency for Research on AIDS and Viral Hepatitis|Triangle Pharmaceuticals|Gilead Sciences|Bristol-Myers Squibb|Dupont Applied Biosciences,All,"18 Years and older � (Adult, Older Adult)",Phase 3,350,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 099 ALIZE,April 2001,,September 2004,"September 20, 2005",,"September 20, 2005",,,https://ClinicalTrials.gov/show/NCT00196612,NCT00196612,
anrs,NCT00196625,"Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.",,Completed,No Results Available,HIV Infections,Drug: Amprenavir (drug)|Drug: ABT-378/r (drug)|Drug: Ritonavir (drug),Mean change of VIH RNA between week 0 and week 26|Disease progression|CD4 cell count|Safety|Pharmacokinetics|Genotypic resistance,French National Agency for Research on AIDS and Viral Hepatitis,All,"18 Years and older � (Adult, Older Adult)",Phase 2,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 104 PUZZLE1,November 2000,,February 2002,"September 20, 2005",,"September 20, 2005",,,https://ClinicalTrials.gov/show/NCT00196625,NCT00196625,
anrs,NCT00196638,Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection,,Terminated,No Results Available,HIV Infections|Primary Acute Infection,Drug: Antiretroviral combination (drugs)|Drug: Pegylated Interferon alpha (drug),Plasma HIV RNA at Week 92 and 96 (mean)|Plasma HIV RNA kinetics after treatment interruption|CD4 cell count|Proviral DNA|Adherence,French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche,All,"18 Years and older � (Adult, Older Adult)",Phase 2|Phase 3,90,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 112 INTERPRIM,May 2002,,March 2006,"September 20, 2005",,"August 29, 2006",,,https://ClinicalTrials.gov/show/NCT00196638,NCT00196638,
oui,NCT00196651,HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection,,Terminated,No Results Available,HIV Infection,Drug: IL-2|Biological: LIPO-6T|Biological: ALVAC VIH 1433,"Evolution of CD4-CD8 non specific and HIV specific cells, vaccinal peptids and viral load with DNA proviral at W36|Safety of IL-2, ALVAC and LIPO-6T|Tolerability of HAART|Kinetic of viral load rebound with frequency and delay of cv over 10 000 cp and 50 000 cp|Evolution on immune response and predictive value of immunologic parameters on viral load",French National Agency for Research on AIDS and Viral Hepatitis|Aventis Pharmaceuticals,All,"18 Years and older � (Adult, Older Adult)",Phase 2,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 095 PRIMOVAC,August 2000,,February 2004,"September 20, 2005",,"September 20, 2005",,,https://ClinicalTrials.gov/show/NCT00196651,NCT00196651,17919105
oui,NCT00200538,Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients,,Completed,No Results Available,Dementia,Drug: memantine,,Nantes University Hospital,All,"45 Years to 75 Years � (Adult, Older Adult)",Phase 2,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BRD 05/1-E,September 2005,,,"September 20, 2005",,"May 3, 2013","Martine Vercelletto, Nantes, France",,https://ClinicalTrials.gov/show/NCT00200538,NCT00200538,22922703;21157021
oui,NCT00202657,Observational Study of Heart Valve Disease in Patients With Parkinson's Disease Treated With Pergolide,,Completed,No Results Available,Parkinson's Disease|Pergolide,Procedure: echocardiography,,"Société Française de Cardiologie|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,149,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2005-03,April 2005,,February 2007,"September 20, 2005",,"December 6, 2011","Clinical Investigation Centre, Pitie-Salpetriere Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT00202657,NCT00202657,18071034
oui,NCT00202683,Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness,,Completed,No Results Available,Altitude Intolerance|High-Altitude Illness,,,Société Française de Cardiologie,All,"18 Years to 65 Years   (Adult, Older Adult)",,83,Other,Observational,Observational Model: Defined Population|Time Perspective: Retrospective,2004-04,March 2005,,December 2006,"September 20, 2005",,"May 17, 2007","Centre d'Investigation Clinique, Hopital Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT00202683,NCT00202683,
oui,NCT00219362,Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients,MANON 02,Completed,No Results Available,HIV Infection,"Biological: one injection of vCP1452 at W0, W4, W8 and W20|Biological: one injection of vCP1452 at W4, W8 and W20|Biological: one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20","Change from baseline of the frequency of HIV-specific PBMC (CD4/CD8) at W24 (4 weeks after the last immunization)|- Percentage of responders as defined by an increase of at least 0.7 log10 from baseline of the frequencies of HIV-specific PBMC and/or CD4 and/or CD8 T cells four weeks after the last immunization(W24) as measured by ELISpot IFN?|- Change from baseline of the frequency of HIV-specific PBMC and/or CD4 and/or CD8 T cells at week 4, 6, 8, 12, 20 and 24 in the study arms as measured by ELISpot IFN?|- Evaluation of the magnitude of CD4 and CD8 T cell response at W4, W6, W8, W12, W20, W24 in the study arms|- Evaluation of the immune responses, HIV-specific PBMC and/or CD4 and/or CD8 T cells at W48|- Percentage of patients who generate a primary immune response against the artificial pol/nef sequences present in the vaccine but not in the HIV strain|- Evaluation of the immune responses directed to vCP1452 in the study arms at all study point during the immunization phase|- Percentage of patients who do not reach the restart therapy criteria from W24 to W48|- Percentage of patients who remain off therapy at W48|- Evaluation of the safety and tolerability of the vCP1452",Objectif Recherche Vaccins SIDA,All,"18 Years and older � (Adult, Older Adult)",Phase 2,65,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ORVACS 002,April 2004,November 2005,September 2006,"September 22, 2005",,"November 25, 2009","Northwestern University Medical School, Chicago, Illinois, United States|Service des maladies infectieuses et tropicales, Hopital Piti�-Salp�tri�re, Pavillon Laveran, Paris, France|Klinikum der Johann Nolfgang Goethe Universitat Zentrum des Innerin Medizin, Frankfurt Am Main, Germany|Fundacio Irsi Caixa Retrovirology Laboratory, Hospital Universitari Germans, Badalona, Spain|Servicios de Infecciosos, Hospital y clinic Provincial, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT00219362,NCT00219362,
oui,NCT00221793,"Weight Changes in Parkinsonian Patients, Treated With Deep Brain Stimulation",,Completed,No Results Available,Parkinson Disease,Procedure: Deep brain stimulation,"Measurement of energy expenditure with indirect calorimetry in open chamber: at rest in the morning, without 24h-dopaminergic treatment, and after dopaminergic treatment intake; and post prandial thermogenesis after a test meal.|Weight gain|increase of energy intake|leptin, glucose, insulin blood levels|cognitive and psychological assessments|UDPRS scale","University Hospital, Bordeaux",All,"35 Years to 70 Years � (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,9212-02,December 2002,December 2006,December 2006,"September 22, 2005",,"September 18, 2008","Service de neurologie H�pital Haut-L�v�que, Pessac, France",,https://ClinicalTrials.gov/show/NCT00221793,NCT00221793,
oui,NCT00221806,Comparison of Two Under Knee Lower Limb Bypass Types:Endothelialised Prosthesis Versus Autologous Vein Graft,,Unknown status,No Results Available,Arteritis,Device: endothelialised prosthesis,"Bypass permeability during 5 years after surgery, assessed trough Doppler echography|Mortality and morbidity, primary and secondary permeability, quality of life, leg salvage, cost/benefit ratio.. All patients will be followed up at 1, 3, 6, and 12 months and each year during 5 years","University Hospital, Bordeaux|Ministry of Health, France|W.L.Gore & Associates",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9256-01,June 2004,,June 2012,"September 22, 2005",,"September 22, 2005","Service de chirurgie vasculaire, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT00221806,NCT00221806,
oui,NCT00221845,Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients,ESCAPE,Completed,No Results Available,Children|Chronic Renal Failure|Hypertension|Acquired Kidney Disease|Congenital Kidney Disease,Drug: ACE Inhibition|Drug: Intensified Blood Pressure Control|Drug: Add-on Angiotensin Receptor Blockade,Time interval to renal 'loss' as defined by an absolute decrease in creatinine clearance by 50 % or attainment of renal replacement therapy.|Effect of treatment on urinary protein excretion|Effect of treatment on blood pressure|Safety of treatment,Heidelberg University|European Commission|Boehringer Ingelheim|Baxter Healthcare Corporation|Aventis Pharmaceuticals,All,"3 Years to 18 Years � (Child, Adult)",Phase 3,400,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QLRT-2001-00908,January 1998,July 2007,January 2010,"September 22, 2005",,"January 12, 2010","University Hospital Motol, 1st Department of Pediatrics, Prague, Czech Republic|Hopital Necker, Division of Pediatric Nephrology, Paris, France|Inserm U574, Paris, France|Hopiteaux Universitaires de Strasbourg, Strasbourg, France|Humboldt University Berlin, Charit� Children's Hospital, Department of Pediatric Nephrology, Berlin, Germany|University Hospital Essen, Department of Pediatrics, Pediatric Nephrology Unit, Essen, Germany|University Hospital Hamburg-Eppendorf, University Children's Hospital, Dept. of Pediatric Nephrology, Hamburg, Germany|Hannover Medical School, Children's Hospital Div. II, Pediatric Nephrology, Hannover, Germany|Division of Pediatric Nephrology, Children's Hospital, University of Heidelberg, Heidelberg, Germany|Urban Hospital St. Georg, Department of Pediatrics, Pediatric Nephrology Unit, Leipzig, Germany|Johannes Gutenberg University Mainz, Department of Pediatrics,, Mainz, Germany|Philipps University Marburg, Dept. of Pediatrics, Marburg, Germany|University Children's Hospital, Dept. of Nephrology, Rostock, Germany|Semmelweis University Budapest, 1st Department of Pediatrics, Budapest, Hungary|G.Gaslini Institute, Nephrology Unit, Genoa, Italy|Azienda Ospedaliera, Istitui Clinici di Perfezionamento, Servizio die Emodialisi Pediatrica, Milano, Italy|Azienda Ospedaliera die Padova. U.O. Nefrologia Dialisi e Trapianto - Dipartimento di Pediatria, Padova, Italy|Ospedale Pediatrico Bambino Ges�, Division of Nephrology and Dialysis, Rome, Italy|Ospedale Infantile Regina Margherita, U.O.A. Nefrologia, Dialisi, Trapianto, Torino, Italy|Vilnius University Children's Hospital, Pediatric Department, Nephrology Unit, Vilnius, Lithuania|Jagellonian University Medical College, Department of Pediatric Nephrology, Cracow, Poland|Medical University of Gdansk, Pediatric Nephrology Department, Gdansk, Poland|Clinic of Pediatrics, Pomeranian Academy of Medicine, Szczecin, Poland|Children's Memorial Health Hospital, Nephrology and Kidney Transplantation Department, Warsaw, Poland|Hospital S. Joao-Faculade de Medicina do Porto, Dept. of Pediatrics, Porto, Portugal|Faculty of Medicine Belgrade, University Children's Hospital, Nephrology Unit, Belgrade, Serbia|Karolinska Institute, Huddinge University Hospital, Dept. of Pediatrics, Stockholm, Sweden|University Children's Hospital, Nephrology Unit, Z�rich, Switzerland|Cukurova University School of Medicine, Dept. of Pediatric Nephrology, Adana, Turkey|Hacettepe University, Faculty of Medicine, Pediatric Nephrology and Rheumatology, Ankara, Turkey|Istanbul University, Cerrahpasa Medical Faculty, Dept, of Pediatrics, Istanbul, Turkey|University of Istanbul, Istanbul Medical Faculty, Dept. of Pediatrics, Istanbul, Turkey|Ege University Medical Faculty, Dept. of Pediatric Nephrology, Izmir, Turkey",,https://ClinicalTrials.gov/show/NCT00221845,NCT00221845,37119829;19846849
oui,NCT00222404,"Pharmacogenomic Study Realized on ""Non-small Cell Lung Carcinoma""",Pharmacogenos,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",,,"University Hospital, Grenoble|Ministry of Health, France",All,"18 Years and older � (Adult, Older Adult)",,556,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,DCIC 04 40,July 2005,,August 2010,"September 22, 2005",,"November 5, 2010","University Hospital of Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00222404,NCT00222404,26493785;25527907;25323247
oui,NCT00224562,The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists,,Unknown status,No Results Available,Rheumatoid Arthritis|Crohn's Disease|Ankylosing Spondylitis|Psoriasis,Drug: TNF-alpha antagonists,,Assistance Publique - H�pitaux de Paris,All,"0 Years and older � (Child, Adult, Older Adult)",,,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,1|INSERM,February 2004,,,"September 23, 2005",,"October 26, 2005","All French departments of rheumatology, internal medicine, gastro-enterology, dermatology, infectious diseases, intensive care unit, oncology and haematology, paediatrics and chest medicine, All Cities, France",,https://ClinicalTrials.gov/show/NCT00224562,NCT00224562,23744173;19565495
oui,NCT00225446,Micron Tracker: Computer-Assisted Orthognathic Surgery With a Third Generation Optic Repositioning System,,Suspended,No Results Available,Computer-Assisted Surgery|Maxillofacial Surgery,Device: MicronTracker,spatial coordinates of the target (3 translations and 3 rotations)|time to install the eyebrow mark with each technique.|adverse events due to the transcutaneous pins.|number of handling realized by the nurse for each technique.|evaluation of cost: number of cable versus number of marker.,"University Hospital, Grenoble",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)",DCIC 04 14,February 2006,January 2009,January 2009,"September 23, 2005",,"June 4, 2008","Maxillofacial and Plastic Surgery Department - University Hospital of Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00225446,NCT00225446,
oui,NCT00227097,Educ'Avk: Recommendations for the Antivitamin K's Gestion,,Terminated,No Results Available,AVK Treatment,Behavioral: Education Notebook for anticoagulant treatment,,"University Hospital, Grenoble",All,"18 Years and older   (Adult, Older Adult)",,300,Other,Observational,Observational Model: Defined Population|Time Perspective: Prospective,DCIC 02 03,December 2002,,December 2004,"September 27, 2005",,"July 7, 2006","Cardiovascular Departement - University Hospital of Grenoble - BP 217, La tronche, Grenoble Cédex 9, France",,https://ClinicalTrials.gov/show/NCT00227097,NCT00227097,
oui,NCT00234273,APAD2: Effects of Rehabilitation Programme in Adapted Physical Activity (APA) Among Type 2 Diabetics,,Terminated,No Results Available,NIDDM,Procedure: Rehabilitation programme in Adapted Physical Activity (APA)|Behavioral: Therapeutic education primarily focused on dietary,Increase physical activity compliance long-term|Lessen insulin resistance|Improve the quality of life|Improve the arterial tension|Lessen the weight,"University Hospital, Grenoble",All,"40 Years and older   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),DCIC 03 09,November 2004,June 2008,June 2008,"October 6, 2005",,"June 19, 2013","Endocrinology, Diabetology and Nutrition - University Hospital of Grenoble, Grenoble, Rhone-alpes, France|Department of Endocrinology, Diabetology and Nutrition, Grenoble, Rhône-Alpes, France|Endocrinology, Diabetology and Nutrition Department - University Hospital of Grenoble, Grenoble, France|HALIMI Serge, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00234273,NCT00234273,
oui,NCT00236340,Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.,,Completed,No Results Available,Polyhydramnios,Device: syringe aspiration|Device: Wall suction,"maternal pain (Analogic visual scale)|Volume of amniotic fluid drained, duration of the drainage, uterine activity,frequency of significative alterations of FHR and histologic evidence of placental abruption.","Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 40 Years   (Adult),Phase 3,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AMNIO-2000,January 2002,,February 2005,"October 12, 2005",,"April 19, 2007","CHU Bretonneau, Tours, Centre, France",,https://ClinicalTrials.gov/show/NCT00236340,NCT00236340,
oui,NCT00237653,MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus,,Terminated,No Results Available,Cytomegalovirus Infections|Inflammatory Bowel Diseases,Drug: Valganciclovir,"Improvement of Crohns disease activity index score|Diminution or disappearance of gravity criteria|Endoscopy: improvement in appearance of lesions, or healing|Anatomopathology: improvement of histological criteria, or total regression|Anatomopathology: disappearance of viral infection criteria|Virology: reversal of CMV IgG serology and PCR results","University Hospital, Grenoble",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,DCIC 03 21,February 2004,,December 2007,"October 12, 2005",,"April 3, 2009","Gastroenterology Department - University Hospital of Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00237653,NCT00237653,
oui,NCT00245804,Developmental Dyslexia and Functional Maturation of Auditory Cortex,DYS-AUT,Completed,No Results Available,Developmental Reading Disorder|Dyslexia,,,"University Hospital, Tours",All,"8 Years to 25 Years � (Child, Adult)",,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,PHRR02/CH/DYS-AUT,March 2003,,February 2005,"October 28, 2005",,"June 30, 2010","University Hospital of Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT00245804,NCT00245804,
oui,NCT00263146,Recruitment Maneuvers in ARDS: Effects on Respiratory Function and Inflammatory Markers.,,Terminated,No Results Available,Acute Lung Injury,Procedure: recruitment maneuver,proteasis activity as measured in broncho alveolar fluid (BAL)|pro- and antiinflammatory cytokines activity as measured in the BAL and in the blood.|gaz exchange|respiratory mechanics|systemic hemodynamics|visceral dysfunction scores.,"University Hospital, Tours",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,ARAMIS,September 2005,January 2006,January 2006,"December 7, 2005",,"January 16, 2017","University Hospital of Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT00263146,NCT00263146,
anrs,NCT00265642,Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C,Fibrosar,Completed,No Results Available,"Hepatitis C, Chronic",Drug: Irbesartan|Drug: placebo,Assessment of liver fibrosis changes by measurement of area of porto-septal fibrosis (morphometry)at M24|Assessment of liver fibrosis changes at M24 by non-invasive tests ((blood test mainly and also elastometry),"ANRS, Emerging Infectious Diseases|Sanofi",All,"18 Years to 75 Years � (Adult, Older Adult)",Phase 3,166,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2005-006027-37|ANRS HC 19 Fibrosar,October 2006,April 2013,November 2013,"December 15, 2005",,"February 7, 2014","CHU Angers, Service d'h�pato-gastroent�rologie, Angers, France",,https://ClinicalTrials.gov/show/NCT00265642,NCT00265642,
oui,NCT00265772,Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis,,Unknown status,No Results Available,Crohn's Disease|Pediatric,Drug: MODULEN IBD (R) (specific Enteral Nutrition)|Drug: prednisolon,Mucosal Healing (decrease >70% of the Crohn's disease endoscopic index score after 8 weeks of treatment)|clinical remission (Harvey Bradshaw Index <5)|biological remission (decrease of systemic and mucosal inflammatory markers)|improvement of the anti-bacterial defense,"H�pital Necker-Enfants Malades|Institut National de la Sant� Et de la Recherche M�dicale, France|Soci�t� des Produits Nestl� (SPN)",All,"6 Years to 18 Years � (Child, Adult)",Phase 4,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCNF0105,November 2005,,April 2008,"December 15, 2005",,"December 15, 2005","H�pital Necker Enfants Malades, Facult� de M�decine Necker, INSERM EMI0212, Paris, France",,https://ClinicalTrials.gov/show/NCT00265772,NCT00265772,
oui,NCT00272428,Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.,,Completed,No Results Available,Healthy,"Behavioral: ascorbic acid, vitamin E, beta carotene, selenium, zinc",Major fatal and non fatal ischemic cardiovascular events|Cancer any kind except for basal cell skin carcinoma|All cause mortality|Health-related quality of life|Intermediate criteria of clinical status|Intermediate criteria of biological status|Intermediate criteria of anthropometric status,"Institut National de la Santé Et de la Recherche Médicale, France|French private agencies",All,35 Years to 60 Years   (Adult),Phase 3,13000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,94-706,October 1994,,September 2005,"January 6, 2006",,"December 17, 2009","U557 Inserm, Paris, France",,https://ClinicalTrials.gov/show/NCT00272428,NCT00272428,33738534;31927670;31164347;30517725;29649036;29546305;28494135;28356432;28033414;27055851;27000099;26962176;26864363;26817718;26812508;26447153;26409628;26156743;25994566;25651444;24553693;24527713;24089418;24027184;23284983;23283500;23082222;22633793;22378736;22158670;21955649;21775560;21490142;21106918;20605091;20431391;20176858;19828715;19491388
oui,NCT00273767,Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB,EPOetCEC,Completed,No Results Available,Myocardial Ischemia,Drug: epoetin beta|Drug: placebo,"Area under curve and maximal plasmatic level of troponin-T, NT-pro-BNP, and creatine kinase-MB (CK-MB) after cardiopulmonary bypass|Area under curve and maximal plasmatic level of protein S-100 after cardiopulmonary bypass|Blood level of erythropoietin","University Hospital, Grenoble|Roche Pharma AG",All,"18 Years and older   (Adult, Older Adult)",Phase 2,50,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",DCIC 05 04,January 2006,July 2009,November 2009,"January 9, 2006",,"December 7, 2009","Cardiac Surgery Department - CHU de Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00273767,NCT00273767,
oui,NCT00289159,Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up,,Unknown status,No Results Available,Multiple Sclerosis,,,"Groupe Hospitalier Pitie-Salpetriere|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 50 Years   (Adult),,,Other,Observational,Observational Model: Defined Population|Time Perspective: Prospective,RBM0110,,,,"February 9, 2006",,"February 9, 2006",,,https://ClinicalTrials.gov/show/NCT00289159,NCT00289159,
oui,NCT00289575,MBCP Safety and Performance in the Osteonecrosis of Femur Head,,Unknown status,No Results Available,Osteonecrosis,Device: MBCP,Infection and inflammation of the drilled area (blood and clinical assessment).|Adverse events.|Pain (Analogic Visual Scale)|Hip function|Bone reconstruction evaluation through scanner and radiography,Biomatlante|CIC Bordeaux,All,18 Years to 50 Years � (Adult),Phase 2,12,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,63,February 2006,,February 2008,"February 10, 2006",,"March 2, 2007","Service de chirurgie orthop�dique et traumatologique- H�pital Pellegrin, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT00289575,NCT00289575,
oui,NCT00299143,Pilot Study on Shear-induced Platelet Aggregation in Acute Coronary Syndromes,REACS,Completed,No Results Available,"Angina, Unstable",,,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years to 85 Years � (Adult, Older Adult)",,97,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RBM 04-24,June 2005,September 2009,June 2010,"March 6, 2006",,"December 29, 2011","Bichat Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT00299143,NCT00299143,
anrs,NCT00302822,Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130),,Completed,No Results Available,HIV Infections|AIDS,Drug: enfuvirtide|Drug: emtricitabine/tenofovir|Drug: lopinavir or efavirenz,"Immunological success defined as a CD4 cell count above 200 cells per mm3 after 24 weeks of initial antiretroviral treatment|Virological response, clinical progression, tolerance,toxicity, quality of life under therapy, adherence and resistance mutations emerging in case of virological failure.","French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche|Gilead Sciences|ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",Phase 3,195,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-004722-12,April 2006,December 2009,December 2009,"March 15, 2006",,"July 10, 2013","Service des Maladies Infectieuses A H�pital Bichat-Claude Bernard, Paris, France",,https://ClinicalTrials.gov/show/NCT00302822,NCT00302822,
oui,NCT00313469,Sources of the Variability of the Response to Fluindione in Elderly Patients (PREPA),,Completed,No Results Available,Cardiovascular Disease,,,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|GIS Institut de la Longévité",All,80 Years and older   (Older Adult),,152,Other,Observational,Time Perspective: Prospective,INSERM|GIS Institut Longévité 2003,September 2005,April 2008,April 2008,"April 12, 2006",,"August 25, 2011","CHU d'Angers, Angers, France|Hôpital Bichat-Claude Bernard, Paris, France",,https://ClinicalTrials.gov/show/NCT00313469,NCT00313469,
oui,NCT00314834,Effect of Intradialytic Parenteral Nutrition on Morbidity and Mortality of Malnourished Hemodialysis Patients,,Terminated,No Results Available,Hemodialysis|Malnutrition,Drug: Intradialytic parenteral nutrition,"mortality|hospitalization rate, Karnofsky score, BMI, serum albumin and prealbumin","EZUS-LYON 1|Institut National de la Santé Et de la Recherche Médicale, France|Societe Francaise de Dialyse|Societe Francophone de Nutrition Enterale et Parenterale",All,"18 Years to 82 Years   (Adult, Older Adult)",Phase 4,204,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EZUS-A1244,January 2001,,December 2004,"April 17, 2006",,"April 17, 2006",,,https://ClinicalTrials.gov/show/NCT00314834,NCT00314834,17656473
oui,NCT00319345,Sodium-Lactate and Traumatic Brain Injury,,Terminated,No Results Available,Severe Trauma Brain Injury|Intracranial Hypertension,"Drug: Mannitol, Sodium-Lactate","Efficiency to decrease ICP during IHE episodes|Number of successful treatment, neurological status (Glasgow outcome score) after one year of evolution","Institut d'Anesthesiologie des Alpes Maritimes|Institut National de la Santé Et de la Recherche Médicale, France|PT Kalbe Farma Tbk",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,34,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Treatment,CHUN-LM-0001,November 2003,,November 2005,"April 27, 2006",,"June 23, 2010","CHU de Nice, Nice, Alpes Maritimes, France",,https://ClinicalTrials.gov/show/NCT00319345,NCT00319345,
oui,NCT00324584,Web-Based Follow-Up Using Cellular Phone in Type 1 Diabetic Patients Under Insulin Pump Therapy : The PumpNet Study,,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Telemonitoring of glucose values using GlucoNet device,Glycated hemoglobin HbA1c|monthly mean capillary blood glucose value|blood glucose variability index (MAGE Index and LBGI index)|quality of life score (DQOL score)|frequency of hypoglycemic episodes (<70 mg/dl),"University Hospital, Grenoble",All,"18 Years and older � (Adult, Older Adult)",Phase 3,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCIC 03 01,April 2003,,September 2004,"May 11, 2006",,"July 7, 2006","University Hospital, Department of Endocrinology, Grenoble, France|University Hospital, Department of Endocrinology, Toulouse, France",,https://ClinicalTrials.gov/show/NCT00324584,NCT00324584,
oui,NCT00336167,Bezafibrate Trial in CPT2 Deficiency,,Unknown status,No Results Available,Carnitine Palmitoyl Transferase 2 Deficiency,Drug: bezafibrate (drug),Rate of 3H-palmitate oxidation in the patients'lymphocytes and skeletal muscle|Rate of CPT2 enzymatic activity in the patients'lymphocytes and skeletal muscle|Rate of palmitoyl-L-carnitine oxidation in the patients' skeletal muscle|Steady-state amount of CPT2 mRNA in the patients'skeletal muscle,"Assistance Publique - H�pitaux de Paris|Association Fran�aise contre les Myopathies (AFM), Paris|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",Phase 3,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,05/05/2019,June 2006,,July 2007,"June 13, 2006",,"April 9, 2007","Jean Paul Bonnefont, Paris, France",,https://ClinicalTrials.gov/show/NCT00336167,NCT00336167,
oui,NCT00338234,Observational Study of Iron Metabolism in Anemia in ICU and Post-Operative Patients,FAIRe,Completed,No Results Available,Anemia|Intensive Care|Cardiac Surgery,,Functional iron deficiency|fatigue assessed by the MFI20 score for cardiac surgery patients,"Assistance Publique - Hôpitaux de Paris|Société Française d'Anesthésie et de Réanimation|Institut National de la Santé Et de la Recherche Médicale, France",All,"20 Years to 88 Years   (Adult, Older Adult)",,153,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,FAIRe,June 2006,December 2007,December 2007,"June 20, 2006",,"May 6, 2008","APHP, hopital Bichat, Paris, France",,https://ClinicalTrials.gov/show/NCT00338234,NCT00338234,
oui,NCT00339157,Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS,,Completed,No Results Available,Systemic-Onset Juvenile Idiopathic Arthritis,Drug: Anakinra|Biological: Pneumo23,"30% improvement of JIA activity after 1 month compared to day 1 according to Giannini's core-set criteria, ie 30% improvement of at least 3 of the 6 items and no more than one item worsened by 30% or more.|Number of active arthritis|Number of joints with limitation of motion|Physician assessment of disease activity|Parent or patient's assessment of disease activity|Childhood health assessment questionnaire|First hour ESR)|Improvement of systemic symptoms between day 1 and month 1 as assessed by the resolution of the fever if present initially, by a 50% decrease or a normalization of the C-reactive protein and of the first hour ES|Number, severity and type of adverse events over 12 months|Proportion of patients reaching 50%, 70% and 100% improvement of JIA activity according to Giannini's core-set criteria at each visit (day 15, month 1 to 6, month 9 and month 12)|Proportion of patients in whom the daily dose of corticosteroids can be reduced to less than 0.3 mg/kg (less than 10 mg in patients over 34 kg) at month 6|Proportion of patients with a normalization of the glycosylated ferritin / ferritin ratio (if lower than 1/4 initially) after 1, 2 and 6 months|Variation of cytokine expression by PBMC between Day 1 and Month 1 and Month 6|Antibody response at month 1 and month 6 to Pneumo 23® immunization: immunization on day 1 against Streptococcus pneumoniae|Pharmacokinetic study at month 2 and month 6","Institut National de la Santé Et de la Recherche Médicale, France",All,"2 Years to 20 Years   (Child, Adult)",Phase 2|Phase 3,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,C05-40,June 2006,,July 2008,"June 20, 2006",,"July 20, 2010","Bordeaux CHU, Bordeaux, France|Kremlin-Bicetre Hospital, Kremlin-Bicetre, France|Hopital Lyon Edouard Herriot, Lyon, France|Nancy Hopital d'Enfants, Nancy, France|Pediatric Immuno-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, 149 rue de Sevres, Paris, France|Robert Debre Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT00339157,NCT00339157,21173013
oui,NCT00347321,Early Percutaneous Tracheostomy for Cardiac Surgery (ETOC),ETOC,Completed,No Results Available,Respiratory Failure|Cardiovascular Surgery,Procedure: Dilatational Percutaneous tracheostomy,"Number of ventilator-free days defined as the number of days between successful weaning from MV and day 60 after study enrolment.|VFDs = 0 if the patient dies before 60days.|VFDs= (60- X) : if the patient is successfully weaned from MV within 60 days, where X is the number of days spent receiving MV|VFDs = 0: if the patient requires MV for 60 days or more|The trial will be considered positive if early tracheostomy increases the number VFDs of at least 7 days (mean)|Other outcomes will be compared between the two arms:|Mortality rate (day 60, in-ICU, in-hospital)|ICU length of stay|Hospital length of stay|Duration of MV in survivors|Organ failure evolution|Infectious complications|Early laryngeal and tracheal complications|Sedation needs|Patient comfort|Outcome on day 90","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,212,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P051013,July 2006,March 2009,June 2009,"July 4, 2006",,"December 3, 2009","Institut de Cardiologie - Chu Pitie Salpetriere Ap-Hp, Paris, France",,https://ClinicalTrials.gov/show/NCT00347321,NCT00347321,21403073
oui,NCT00348764,ESGVS: Sclerotherapy With Lauromacrogol,,Completed,No Results Available,Venous Insufficiency|Saphenous Vein,Drug: lauromacrogol,"Removal of truncular GSV incompetence evaluated at 6 months by echo doppler: no persistence of ""sus gonal"" saphenous reflux > 1 second.","University Hospital, Grenoble",All,"25 Years to 75 Years   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,DCIC 03 38,March 2004,,December 2006,"July 6, 2006",,"July 6, 2006","Center of Vascular Medecine - 7 rue Lesdiguières, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00348764,NCT00348764,
oui,NCT00348855,Study to Improve Quality of Care and Patient Health in the Field of Cardiovascular Risk Factors in General Practice,ESCAPE,Completed,No Results Available,High Risk Hypertensive Patients,Other: Cardiovascular drugs strategies|Behavioral: Compliance|Behavioral: Exercise|Behavioral: Stop Smoking|Behavioral: Diet|Other: Feed Back,"Number of patients who reach all the therapeutic goals defined by the guidelines in the total study population, in the sub-group of patients with hypertension, but free of type-2 diabetes (T2D), and in the sub-group with hypertension and T2D.|Number of targets reached by the patients|Quality of life measured with SF8|Compliance|Exercise|Diet|Levels of blood pressure, LDL-Cholesterol, tobacco consumption in the whole population plus levels of HbA1c and aspirin use in the TD2 population","Collège National des Généralistes Enseignants|Institut National de la Santé Et de la Recherche Médicale, France|Assistance Publique - Hôpitaux de Paris|Laboratoires Takeda|Merck Serono International SA",All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 4,1836,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,CNGE20060702,November 2006,September 2009,March 2010,"July 6, 2006",,"November 15, 2011","Service de Pharmacologie Clinique, Lyon, France|French National College of GP Teatchers, Vincennes, France",,https://ClinicalTrials.gov/show/NCT00348855,NCT00348855,27178974;24083783
oui,NCT00350805,Measuring Time Windows in Patients With Schizophrenia and Healthy Controls,,Completed,No Results Available,Schizophrenia,Procedure: EEG,,"University Hospital, Strasbourg, France|Institut National de la Santé Et de la Recherche Médicale, France|Centre National de la Recherche Scientifique, France|Institut de Physique Biologique de Strasbourg",All,18 Years to 50 Years   (Adult),,126,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,3494,September 2005,April 2012,December 2012,"July 11, 2006",,"October 5, 2017","Service de Psychiatrie Adulte & INSERM U841, Hôpital Albert Chenevier et Henri Mondor (AP-HP), Créteil, France|Centre Hospitalier de Rouffach, Rouffach, France|INSERM U666 - Département de Psychiatrie - Hôpitaux Universitaires de Strasbourg, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT00350805,NCT00350805,
oui,NCT00350935,Attention and Visual Perception in Schizophrenia: A Functional Magnetic Resonance Imaging (fMRI) Study,,Completed,No Results Available,Schizophrenia,Procedure: fMRI,,"University Hospital, Strasbourg, France|Institut National de la Sant� Et de la Recherche M�dicale, France|Centre National de la Recherche Scientifique, France|R�gion Alsace|Facult� de M�decine de Strasbourg",All,18 Years to 50 Years � (Adult),,52,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,3456,September 2006,,April 2009,"July 11, 2006",,"June 28, 2010","Inserm U666 - D�partement de Psychiatrie, H�pitaux Universitaires de Strasbourg, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT00350935,NCT00350935,
oui,NCT00359554,Influenza Vaccination of Nursing Home Workers.,,Terminated,No Results Available,Influenza Disease,Biological: VAXIGRIPPE,"all-cause mortality of residents at one year|hospitalizations of residents,morbidity of nursing home workers.|A cost-effectiveness ratio of influenza vaccination will be calculated",Assistance Publique - H�pitaux de Paris,All,"60 Years and older � (Adult, Older Adult)",Not Applicable,4000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AOM 05050,September 2006,,October 2007,"August 2, 2006",,"February 7, 2007","Hopital Saint Antoine Inserm U707, Paris, France",,https://ClinicalTrials.gov/show/NCT00359554,NCT00359554,
oui,NCT00361465,DYSCAR: Characterization of Dystonia,,Completed,No Results Available,Dystonia|Parkinson Disease,Other: EMG and Kinematics recording,,"University Hospital, Grenoble|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years to 75 Years � (Adult, Older Adult)",,75,Other,Observational,Time Perspective: Prospective,610,August 2006,,December 2010,"August 8, 2006",,"March 28, 2011","Grenoble University Hospital, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00361465,NCT00361465,
oui,NCT00361725,Comparative Study of the Protein C Pathway in Septic and Non Septic Patients With Organ Failure,,Terminated,No Results Available,Severe Sepsis|Organ Failure,,,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,90,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,PROCAS,March 2003,,October 2003,"August 8, 2006",,"August 15, 2006",,,https://ClinicalTrials.gov/show/NCT00361725,NCT00361725,17673691
oui,NCT00366041,Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries,,Terminated,No Results Available,Burns,Drug: Dermal substrate cellularised LG002 (10x10cm)|Device: Dermal substrate uncellularised LG002 (10x10 cm),"Percentage of take of thin skin autografts 6 days after their application on dermal substrate cellularised LG002 or uncellularised LG002 (visual assessment + photography)|Short and medium term: Percentage of take of thin skin autografts 12 and 30 days after their application|Long term: Clinical evaluation (Vancouver scale 1, 3, 6, 12 months) and histological evaluation (3mm biopsy) to investigate the dermal-epidermal junction and the extra-cellular matrix (1 and 6 month) in order to evaluate the scar quality|Tolerance parameter: Investigator's global judgement, post grafting infection (swabbing during each new dressing for staphylococcus aureus detection), adverse event for intolerance|Supplementary parameter: Allogenic fibroblasts survival : chimerism study with biopsy (1 and 6 months)","Laboratoires Gen�vrier|H�pital d'Instruction des Arm�es de Percy|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years to 75 Years � (Adult, Older Adult)",Phase 2,20,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,03F/DE01,February 2006,December 2008,December 2009,"August 18, 2006",,"January 21, 2010","H�pital d' Instruction des Arm�es de Percy, Service des Br�l�s, Clamart, France|H�pital Cochin, Service des Br�l�s, Paris, France",,https://ClinicalTrials.gov/show/NCT00366041,NCT00366041,
oui,NCT00367185,Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma,,Completed,No Results Available,Multiple Myeloma,Drug: Thalidomide,Overall survival|Best response rate|Progression-free survival|Survival after progression|Toxicity,"University Hospital, Lille",All,65 Years to 75 Years � (Older Adult),Phase 3,500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IFM 99-06,May 2000,,October 2005,"August 22, 2006",,"August 22, 2006","Lille University Hospital, Lille, France",,https://ClinicalTrials.gov/show/NCT00367185,NCT00367185,17920916
oui,NCT00367861,Prospective Multicentric Randomized Study of Glivec� in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance,,Completed,No Results Available,Sarcoma|Gastro-intestinal Stromal Tumors (GIST),Drug: interruption of Glivec�,Progression free survival|Overall survival|Toxicity,"Centre Leon Berard|Gustave Roussy, Cancer Campus, Grand Paris",All,"18 Years and older � (Adult, Older Adult)",Phase 3,564,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CST1571BFR14|ET2002-021,May 2002,April 2012,May 2013,"August 23, 2006",,"February 24, 2014","Institut Bergoni�, Bordeaux, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Hopital Edouard Herriot, Lyon, France|Institut Paoli Calmette, Marseilles, France|Hopitaux de La Timone, Marseille, France|Centre Alexis Vautrin, Nancy, France|Institut Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT00367861,NCT00367861,26687836;20864406
oui,NCT00371982,Effect of Fish Oil on Adiposity and Atherogenic Factors in Type 2 Diabetic Women,,Terminated,No Results Available,Type 2 Diabetes,Drug: Fish oil (Maxepa),"The effect of 2 month treatment on:|adiposity (total fat mass, adipocyte morphology), atherogenic markers and insulin sensitivity|the underlying mechanisms of the observed results and tried to define new targets of fish oil metabolic effects|and the impact of fish oil on systemic inflammatory markers and adipose tissue inflammatory genes.","Assistance Publique - H�pitaux de Paris|Institut National de la Sant� Et de la Recherche M�dicale, France",Female,40 Years to 60 Years � (Adult),Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"INSERM-237-6900, Paris 6-069",December 2002,,April 2005,"September 4, 2006",,"September 4, 2006","Department of Diabetes-Hotel Dieu Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT00371982,NCT00371982,
oui,NCT00372684,PALUREA: Severe Imported Malaria in Adults,PALUREA,Completed,No Results Available,Malaria,Genetic: with severe malaria hospitalized in ICU|Genetic: with uncomplicated malaria,,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,302,Other,Observational,Time Perspective: Prospective,P051063|AOR05007,September 2006,March 2010,March 2010,"September 7, 2006",,"June 22, 2010","Ch Versailles, Le Chesnay, France",,https://ClinicalTrials.gov/show/NCT00372684,NCT00372684,
oui,NCT00374673,Efficacy of Transcranial Magnetic Stimulation (TMS) in Chronic Idiopathic Pain Disorders,,Completed,No Results Available,Fibromyalgia|Irritable Bowel Syndrome|Burning Mouth Syndrome,Device: Repetitive transcranial magnetic stimulation,Average pain over the last 24 hours at each visit -pain diary at baseline to see the stability of the measures|Sensory and affective pain scores (McGill pain questionnaire)|Quality of life (brief pain inventory)|Disability ( FIQ)|Comorbidities (HAD)|Catastrophizing (PCS)|Predictors of the response based on psychological factors and measures of cortical excitability|Safety including cognitive evaluation|Comparison of the efficacy of TMS between 3 different pain disorders|assessment of cortical excitability,Hospital Ambroise Par� Paris,All,"18 Years to 80 Years � (Adult, Older Adult)",Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TMS-chronic pain 1,October 2006,March 2012,April 2012,"September 11, 2006",,"December 3, 2015","H�pital Ambroise Par�, Boulogne, France",,https://ClinicalTrials.gov/show/NCT00374673,NCT00374673,
oui,NCT00374712,Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia,,Terminated,No Results Available,Chronic Kidney Disease|End Stage Renal Disease|Hyperphosphatemia|Renal Osteodystrophy,,,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 80 Years   (Adult, Older Adult)",,40,Other,Observational,Time Perspective: Prospective,P031010|CRC 03161,January 2005,,November 2007,"September 11, 2006",,"November 8, 2007","Clinique de l'Orangerie - Service de Néphrologie et Dialyse, Aubervilliers, France",,https://ClinicalTrials.gov/show/NCT00374712,NCT00374712,
oui,NCT00376428,Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients,,Terminated,No Results Available,Cystic Fibrosis,Drug: Gentamicin,CFTR-dependant chlorate secretion|CFTR expression in nasal cells|Clinical beneficial effects,Assistance Publique - Hôpitaux de Paris,All,"Child, Adult, Older Adult",Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,02-03-10,January 2003,,June 2005,"September 14, 2006",,"February 25, 2015","Necker-Enfants malades, Paris, France",,https://ClinicalTrials.gov/show/NCT00376428,NCT00376428,
oui,NCT00376766,Clinical Trial : TROCC (Quick Oral Treatment of Cluster Epileptic Seizures),,Terminated,No Results Available,Epilepsy|Drug Resistant,Drug: levetiracetam,"Ratio of patients who are free of seizure between H3 and H24 in both groups.|Items 1,2,3 of the Clinical Global Impression scale.|Side effects during the study.|Time between H0 and the last seizure.|Type and ratio of epileptic fit between H0 and H24.|Number of seizures occured between H3 and H10, H10 and H17, H17 and H24, corresponding to the half-time of the treatment (7 hours).|Description of therapeutic adaptation at 1 month after patient enrolment.","University Hospital, Grenoble|Institut National de la Santé Et de la Recherche Médicale, France|UCB Pharma",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,112,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,DTCIC 05 24,February 2007,April 2008,April 2008,"September 15, 2006",,"May 28, 2015","Neurology department, Nice, Alpes de Haute provence, France|Etablissement la Teppe, Tain l'Hermitage, Drome, France|Neurology department, Grenoble, Isere, France|Neurology department, St Etienne, Loire, France|Neurology department, Lille, Nord, France|Neurology department, Clermont-Ferrand, Puy de Dome, France|Neurology department, Lyon, Rhone, France|Neurology Department, Chambery, Savoie, France|Neurology department, Nancy, France|Neurology department, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT00376766,NCT00376766,
oui,NCT00389909,Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants,,Completed,No Results Available,Premature Infants|Apnea,Drug: Doxapram,Plasma level of Doxapram and its active metabolite (ketodoxapram) at 48 hours after the onset of treatment.|Efficacy (rate of significant apnea),Jean Michel Hascoet|Maternite Regionale Universitaire,All,1 Week to 3 Months � (Child),Phase 4,85,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",MRAP060309,November 2006,November 2010,November 2010,"October 19, 2006",,"February 27, 2017","Maternite Regionale Universitaire, Nancy, France|Hopital des Enfants, Toulouse, France",,https://ClinicalTrials.gov/show/NCT00389909,NCT00389909,27612991
non,NCT00391313,CuraChik : A Trial of the Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease,,Terminated,No Results Available,Chikungunya Virus,Drug: Chloroquine,,Assistance Publique Hopitaux De Marseille,All,"18 Years to 66 Years � (Adult, Older Adult)",Phase 3,,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,2006-002624-42,May 2006,,March 2007,"October 23, 2006",,"August 28, 2015","Cellule Coordination Nivachik, Saint Pierre, ile de la Reunion, France",,https://ClinicalTrials.gov/show/NCT00391313,NCT00391313,
anrs,NCT00391638,Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients,HB01EMVIPEG,Completed,No Results Available,Hepatitis B|HIV Infections,Drug: TRUVADA (EMTRICITABINE + TENOFOVIR DF)|Biological: PEGASYS 180?g (Interf�ron p�gyl� alpha -2a),proportion of patients with seroconversion HBe (loose of HBe antigen and acquisition of HBe antibody) and HBV DNA below 2.3 log10 copies per ml|proportion of patients with negative HBe antigen.|proportion of patients with HBV DNA under 2.3 log 10 copies per ml.|proportion of seroconversion HBs.|proportion of patients with no more HBs antigen.|proportion of patients with HBV DNA below 2.3 log 10 copies per ml in relation with 3TC resistance or not before tenofovir treatment  increased of ALT before tenofovir treatment duration of tenofovir treatment before study.|Biological evolution and histological of hepatic activity and fibrosis.|Biochemical response (ALT at normal value).|proportion of patients with :seroconversion HBe and HBV DNA below 2.3 log 10 copies per ml|HBV and HIV resistance mutations to tenofovir DF and Emtricitabine.|Immunological and virological evolution of HIV infection.|Safety|Quality of life|Treatment adherence,"French National Agency for Research on AIDS and Viral Hepatitis|Gilead Sciences|Roche Pharma AG|ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",Phase 2|Phase 3,56,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2006-004137-15|ANRS HB 01 EMVIPEG,January 2007,May 2011,October 2012,"October 24, 2006",,"January 15, 2015","Service des Maladies Infectieuses CHU, Dijon cedex, France|Service d'H�pato-Gastroent�rologie Hopital H�tel-Dieu, Lyon Cedex 02, France",,https://ClinicalTrials.gov/show/NCT00391638,NCT00391638,
oui,NCT00400413,Neuroanatomy of Reading in Congenital Deafness.,,Completed,No Results Available,Congenital Deafness,Procedure: fMRI,,"University Hospital, Strasbourg, France|Institut National de la Santé Et de la Recherche Médicale, France|Centre National de la Recherche Scientifique, France|Conseil Régional d'Alsace",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),2865,November 2003,,August 2011,"November 16, 2006",,"August 30, 2011","Clinique Neurologique - Hôpital Civil, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT00400413,NCT00400413,
oui,NCT00402376,Evaluation of Myocardial Improvement in Patients Supported by Ventricular Assist Device Under Optimal Pharmacological Therapy,,Terminated,No Results Available,Heart Failure,"Drug: Pravastatin, Carvedilol, Perindopril|Device: Biventricular assist device (Thoratec paracorporeal assist device)","Mitochondrial function|Inflammation: IL-6; IL-8; IL-10, IL-18, TNF-α|Exercise testing : stress echocardiography, peak oxygen consumption|Hormonal cardiac function: ANP, BNP|Ventricular remodelling: echocardiography|All those parameters will be measured in the post-operative course and every 4 weeks during all the VAD support period.","University Hospital, Strasbourg, France|Service de Chirurgie Cardiaque|Institut de Physiologie, Strasbourg, France|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 4,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,3212,April 2007,,,"November 22, 2006",,"August 30, 2011","Service de Chirurgie Cardiovasculaire - Hôpital Civil, Strasbourg, France|Service de Physiologie Clinique - Hôpital Civil, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT00402376,NCT00402376,
oui,NCT00405145,Mapping of the Epileptic Brain,,Unknown status,No Results Available,Epilepsy,,,"University Hospital, Grenoble|Institut National de la Santé Et de la Recherche Médicale, France|Centre National de la Recherche Scientifique, France",All,"18 Years to 70 Years   (Adult, Older Adult)",,400,Other,Observational,Time Perspective: Other,618,July 2006,,July 2011,"November 29, 2006",,"November 29, 2006","UniversityHospitalGrenoble, Grenoble, Isere, France",,https://ClinicalTrials.gov/show/NCT00405145,NCT00405145,
oui,NCT00410839,Studies of the Prevention of Atrial Fibrillation by ALA,,Unknown status,No Results Available,Atrial Fibrillation|Diet Therapy,Procedure: ALA rich diet,rate of recurrence and length of time to first recurrence of atrial fibrillation.,"University of Toronto|University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 77 Years   (Adult, Older Adult)",Phase 2,130,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,99-04 (CPPRB Bordeaux B),June 1999,,June 2003,"December 13, 2006",,"December 13, 2006","Emile Roux Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT00410839,NCT00410839,
oui,NCT00421395,Safety Study of NHL With 90Y-hLL2 IgG,,Completed,No Results Available,NHL|B-cell NHL|Non-Hodgkins Lymphoma,Biological: 90Y-hLL2,"Safety will be evaluated from physical examinations, hematology and chemistry testing and toxicity evaluation|Determine maximum tolerated dose (MTD)|Evaluate the immunogenicity and safety of repeated infusions of 90Y-hLL2 in NHL patients.|Determine the therapeutic effects, in terms of objective response rate and duration, of the therapeutic agent in NHL patients.",Gilead Sciences,All,"18 Years and older � (Adult, Older Adult)",Phase 1|Phase 2,59,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IM-T-hLL2-06EU,August 2002,October 2007,October 2007,"January 12, 2007",,"August 16, 2021","Research Unit 463 INSERM, Nantes, Cedex, France|Service des Maladies du Sang, Lille, France|University Hospital Dresden, Dresden, Germany|Klinikum der Georg-August-Universitat Gottingen, Gottingen, Germany|Universitatsklinikum University of Saarland, Homburg/Saar, Germany",,https://ClinicalTrials.gov/show/NCT00421395,NCT00421395,
anrs,NCT00421551,Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136,,Completed,No Results Available,HIV Infections,Drug: Darunavir|Drug: ritonavir,"Proportion of patients with virological success, the virological failure is defined as 2 consecutive plasma viral load measurements greater or equal to 400 cp/ml within 2 weeks at W48|Proportion of patients with virological success between W48 and W96,|Proportion of patients with HIV-1 RNA below 50 copies/mL, between 50 to 400 copies/mL and > 400 copies/ml from D0 to W96,|Time to virologic failure,|PI genotypic resistance mutations occurring during the follow-up|Change in proviral DNA at D0, W48 and W96,|Change in CD4 count from D0 to W96.|Comparing plasma HIV-1 RNA genotypic resistance with DNA genotypic resistance at entry|Quantification of HIV RNA in the genital compartment between D0 and W48 (sub-study with 40 patients enrolled, 20 patients in each arm of strategy).|Incidence of clinical endpoints|Modification of treatment strategies and withdrawal of study treatment.|Tolerance of Darunavir (Grade 3 and 4 laboratory abnormalities and signs and symptoms).|Change in lipidic and glucidic profile and distribution of fat tissue by DEXA-scan (sub-study in 160 patients enrolled).|Self-reported adherence and symptom self-evaluation.|The proportion of patients with HIV RNA below 50 copies/mL in darunavir/r monotherapy arm after resuming 2 previous NRTIs in case of virological failure.|Search for predictive factors of virological failure (level of proviral DNA, Cmin LPV, �).|evaluation of the mineral bone density by DEXA-scan (sub-study in 160 patients enrolled).","French National Agency for Research on AIDS and Viral Hepatitis|Tibotec Pharmaceutical Limited|ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",Phase 3,225,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2006-005962-38|ANRS 136 MONOI,March 2007,June 2010,February 2011,"January 12, 2007",,"July 18, 2013","Service des maladies infectieuses et tropicales Hopital Pitie salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT00421551,NCT00421551,29767684;22848481;20802297
anrs,NCT00424814,Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva,,Completed,No Results Available,HIV Infections,Drug: Kaletra (lopinavir/ritonavir)|Drug: Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine),"Proportion of mother with plasma HIV1 below 200 copies per ml after 8 weeks of treatment|Proportion of women maintained with monotherapy until delivery,|Proportion of women with a VL below 50 copies per ml at delivery|Proportion of women harbouring resistant HIV strains four weeks after delivery|Concentrations of studied drug in plasma and in cord-blood|HIV-1 detection and concentrations of studied drug in vaginal secretion before and after treatment|concentrations of studied drugs in the new born gastric fluid, HIV diagnostic in infant (criteria for stopping the trial at second infection)","ANRS, Emerging Infectious Diseases|Abbott",Female,"18 Years and older � (Adult, Older Adult)",Phase 2|Phase 3,105,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2006-006200-11|ANRS 135 PRIMEVA,March 2007,September 2011,November 2012,"January 22, 2007",,"July 18, 2013","Hopital Pitie salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT00424814,NCT00424814,25838291;23766338
oui,NCT00426686,ADAMTS13 in Thrombotic Thrombocytopenic Purpura,ADAMTS13,Completed,No Results Available,Thrombotic Thrombocytopenic Purpura,,,Assistance Publique - H�pitaux de Paris,All,"Child, Adult, Older Adult",,153,Other,Observational,Observational Model: Case-Only,PO51064,November 2006,March 2009,April 2011,"January 25, 2007",,"December 12, 2012","H�pital Antoine B�cl�re, Clamart, France",,https://ClinicalTrials.gov/show/NCT00426686,NCT00426686,27720178;27132698;23846249;22547583
oui,NCT00429195,The Effect of Dietary Fat Modification on Risk Factors Associated With the Metabolic Syndrome,,Completed,No Results Available,Metabolic Syndrome,Behavioral: Dietary Fatty Acid Modification,IVGTT|Lipoprotein metabolism|Cytokine profiles|Coagulation|Fibrinolysis|Oxidative status,"University College Dublin|University of Reading|University of Oslo|Institut National de la Sant� Et de la Recherche M�dicale, France|Maastricht University Medical Center|Universidad Nacional de C�rdoba|Jagiellonian University|Uppsala University",All,"35 Years to 70 Years � (Adult, Older Adult)",Not Applicable,480,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment,LIPGENE Dietary Intervention,February 2004,,January 2007,"January 31, 2007",,"January 21, 2013","Nutrigenomics Research Group, Institute of Molecular Medicine, University of Dublin, Trinity College, Dublin, Ireland",,https://ClinicalTrials.gov/show/NCT00429195,NCT00429195,27029919;26561628;24203067;23647888;23092637;22959058;22916254;22551950;22269963;21839455;21701566;21674002;21389182;20631323;20409549;20125104;20032495;19481310
oui,NCT00432419,Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood Cell Transplantation Following Chemotherapy.,,Terminated,No Results Available,"HIV Infections|Lymphoma, Non-Hodgkin",Procedure: autologous peripheral blood cell transplantation,"Safety criteria defined as the occurrence of grades 3 or 4 adverse events in the 6 months following transplantation.|Evaluation of:|HIV RNA|HIV DNA|Percentage and absolute count of CD3, CD4+ and CD8+ lymphocytes|Lymphocyte phenotypes and functions|TREC analysis|Immune reconstitution in vivo|Duration of aplasia",French National Agency for Research on AIDS and Viral Hepatitis,All,18 Years to 55 Years � (Adult),Phase 1|Phase 2,1,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS131,February 2007,July 2008,October 2008,"February 7, 2007",,"December 22, 2011","Servide d'Immunologie Clinique, Creteil, France",,https://ClinicalTrials.gov/show/NCT00432419,NCT00432419,
oui,NCT00434265,"Obesity, Physical Inactivity or Dietary Fat ?",,Completed,No Results Available,Obesity,Behavioral: Physical training,"Proportion of fat oxidation induced by physical training, according to fat type (oleate vs palmitate)|Variations of oleate and palmitate postprandial kinetic in different lipoprotein fractions|Expression of different muscle and adipose tissue genes","University Hospital, Strasbourg, France|PRNA (INSERM/INRA)|Fondation Coeur et Art�res|Centre National de la Recherche Scientifique, France|Louis Pasteur University, Strasbourg",Male,18 Years to 55 Years � (Adult),Not Applicable,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3493,March 2007,,August 2011,"February 13, 2007",,"August 30, 2011","Service des Explorations Fonctionelles Respiratoires et de l'Exercice - H�pital Civil, Strasbourg, France|Service de M�decine Interne et de Nutrition - H�pital de Hautepierre, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT00434265,NCT00434265,
oui,NCT00445575,Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone,PROFIDYS,Completed,No Results Available,Fibrous Dysplasia of Bone,Drug: risedronate|Drug: placebo,"Intensity of bone pain, assessed by visual analogical scale ranging from 0 to 10, on the most painful site.|Surface of osteolytic lesions at three years. Radiological improvement.|Variation of biochemical markers of bone turnover at three years|Number of painful sites|Improvement in quality of life|Variation in bone mineral density of the femoral neck at three years","Institut National de la Santé Et de la Recherche Médicale, France|ZonMw: The Netherlands Organisation for Health Research and Development|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Charite University, Berlin, Germany",All,"8 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RBM 03-54|AFSSAPS 060834,"July 22, 2007",December 2017,"December 7, 2017","March 9, 2007",,"August 30, 2021","Cliniques Universitaires Saint Luc, Brussels, Belgium|Hopital E Herriot, Lyon, France|Hopital Lariboisiere, Paris, France|Hopital Cochin, Paris, France|Hospital Benjamin Franklin, Berlin, Germany|Cologne Clinical Centre, Cologne, Germany|Heildeberg Clinical Centre, Heidelberg, Germany|Leids Universitair Medisch Centrum, Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT00445575,NCT00445575,
oui,NCT00446264,Islet Allotransplantation With Steroid Free Immunosuppression,,Completed,Has Results,Type 1 Diabetes|Hypoglycemia|Metabolic Diseases,Procedure: islet transplantation|Drug: daclizumab - sirolimus - tacrolimus,Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year|Hypoglycemic Events|Plasma C-peptide|HbA1c < 6.5%|Percentage of Time Spent in Hypoglycemia (<0.70 mg/L)|Number of Adverse Events,"University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,14,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CP 01/48|PHRC|AFSSAPS 030209,May 2003,October 2007,February 2009,"March 12, 2007","May 12, 2010","April 27, 2012","University Hospital of Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT00446264,NCT00446264,31615852;28941330;25393157;22996144
anrs,NCT00454337,Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load,EASIER,Completed,No Results Available,HIV Infections,Drug: FTC/TDF + EFV or LPV/R +T20|Drug: FTC/TDF + EFV or LPV/R,"comparison of the proportions of virologic failure, defined as two consecutive pVL above 400 cp per ml, through 24 weeks in enfuvirtide-maintained arm versus raltegravir arm|comparison of time to onset of virologic failure|proportions of pts with pVL under 50 and 400 cp per ml respectively at week 24 and week 48 ;|plasma viral mutations in the event of virologic failure, compared to HIV-DNA archived mutations at baseline;|change in CD4 levels|incidence of HIV-related events|drug plasma and male genital tract pharmacokinetics;|incidence and type of adverse events, including adverse reactions|proportions of discontinuing allocated treatment strategy|quality of life and adherence|morphological and metabolic disorders outcome","French National Agency for Research on AIDS and Viral Hepatitis|Merck Sharp & Dohme LLC|ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",Phase 3,170,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007-000162-20|ANRS 138 EASIER,May 2007,September 2008,September 2008,"March 30, 2007",,"November 7, 2012","Service des maladies infectieuses et tropicales Hopital Saint Louis, Paris, France",,https://ClinicalTrials.gov/show/NCT00454337,NCT00454337,27042193;21712241;19757993
oui,NCT00456911,Family Dietary Coaching to Improve Nutritional Intakes and Body Weight Control,ELPAS,Completed,No Results Available,Primary Prevention|Obesity Prevention|Body Weight Control,Behavioral: Fat and carbohydrate controlled diet,changes in body mass index throughout the intervention|changes in nutritional intakes throughout the intervention|changes in fat mass throughout the intervention|changes in anthropometric indicators throughout the intervention|changes in physical activity throughout the intervention|changes in fasting blood indicators throughout the intervention (adults only)|changes in food-related quality of life throughout the intervention (adults only),"Centre d'Etudes et de Documentation du Sucre|Ministry of Higher Education and Research, France|Paris Academy (Rectorat de Paris)|Avenance Enseignement|Fondation Louis Bonduelle",All,"6 Years to 65 Years � (Child, Adult, Older Adult)",Not Applicable,2020,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single,ELPAS 2002-RN31,March 2005,,July 2006,"April 5, 2007",,"February 13, 2008","Free-Living Participants, Paris, Ile de France, France",,https://ClinicalTrials.gov/show/NCT00456911,NCT00456911,18180410
anrs,NCT00460382,"Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses",ANRS139 TRIO,Completed,No Results Available,HIV Infections,Drug: raltegravir potassium|Drug: darunavir/ritonavir|Drug: etravirine|Drug: Optimized background regimen,"Proportion of patients with HIV RNA levels of less than 50 copies/ml in an intent to treat analysis at week 24|Proportions of patients with HIV RNA levels of less than 50 copies/ml at week 48, with HIV RNA levels of less than 400 copies/ml at weeks 24 and 48|HIV RNA level evolution between baseline and week 48|HIV proviral DNA and 2LTR circle HIV DNA between baseline and week 48|Number and type of resistance mutations in case of virologic failure occurrence|CD4 lymphocyte count and proportion evolution between baseline and week 48|HIV infection progression|Frequency of the study regimen modifications and interruption|Study regimen tolerance|Study regimen adherence|Association between study drugs' minimum concentrations at week 4 and week 12 and virologic success at week 24|Evolution of pharmacokinetics parameters of study drugs in the PK substudy",French National Agency for Research on AIDS and Viral Hepatitis|Merck Sharp & Dohme LLC|Janssen-Cilag Tibotec,All,"18 Years and older � (Adult, Older Adult)",Phase 2,103,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007-000670-23|ANRS 139 TRIO,May 2007,March 2008,September 2009,"April 13, 2007",,"September 17, 2010","H�pital Gustave Dron, Service Maladies Infectieuses, Tourcoing, France",,https://ClinicalTrials.gov/show/NCT00460382,NCT00460382,
oui,NCT00461461,a Multifaceted Program for Improving Quality of Care in ICU,,Completed,No Results Available,Adverse Event|Indicator|Intensive Care Units,"Procedure: meeting nurses / physicians, quality improvement sessions",decreased of occured of iatrogenic event in ICU|severity of iatrogenic event|preventability of iatrogenic event,Groupe Hospitalier Paris Saint Joseph|The Outcomerea Group for Intensive Care Research|the Regional Direction of Clinical Research|the High Health Authority,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,2117,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),AOM04-108,January 2007,January 2008,June 2008,"April 18, 2007",,"June 25, 2009","Intensive Care Unit, Grenoble, France|Medical and surgical Intensive Care unit, Paris, France|Intensive Care Unit, Saint Denis, France",,https://ClinicalTrials.gov/show/NCT00461461,NCT00461461,21963581
oui,NCT00463983,Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide,FIBROSAND,Completed,No Results Available,Idiopathic Pulmonary Fibrosis,Drug: octreotide,FVC changes|DLCO changes,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"40 Years and older � (Adult, Older Adult)",Phase 1|Phase 2,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C05-32,October 2006,January 2010,January 2012,"April 20, 2007",,"September 21, 2012",,,https://ClinicalTrials.gov/show/NCT00463983,NCT00463983,22379151
oui,NCT00465790,Research of Biomarkers in Parkinson Disease,Genepark,Completed,No Results Available,Parkinson Disease|Multiple System Atrophy|Progressive Supranuclear Palsy|Huntington Disease|Dystonia|Diffuse Lewy Body Disease,,,"Institut National de la Santé Et de la Recherche Médicale, France|European Union",All,"18 Years to 90 Years   (Adult, Older Adult)",,219,Other,Observational,,C06-56|2007-A00208-45,October 2007,June 2012,June 2012,"April 25, 2007",,"September 27, 2012","Meditterranean Institute for Life Sciences, Split, Croatia|INSERM Unit 679, Paris, France|University of Lübeck and Neuroimage Nord, Lübeck, Germany|University Hospital Tübingen, Tübingen, Germany|University Medical Center Ljubljana, Ljubljana, Slovenia",,https://ClinicalTrials.gov/show/NCT00465790,NCT00465790,
anrs,NCT00480792,Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients,VIHVAC-B,Completed,No Results Available,HIV Infections,Biological: GenHevac B Pasteur,"HIV-infected patients who seroconvert in the first two months after the last vaccination. Seroconversion is defined as antibodies AbHBs titers equal or above 10 mUI per ml.|According to the vaccine administration (IM or ID) comparison of AbHBs titers,permanence of the humoral response,intensity of clinical and biological events and predicting factors related to seroconversion","ANRS, Emerging Infectious Diseases|MCM Vaccines B.V.",All,"18 Years and older � (Adult, Older Adult)",Phase 3,437,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2006-003940-50|ANRS HB 03 VIHVAC-B,June 2007,December 2008,September 2012,"May 31, 2007",,"July 23, 2013","Hopital Cochin CIC de vaccinologie, Paris, France",,https://ClinicalTrials.gov/show/NCT00480792,NCT00480792,27064975;21486976
oui,NCT00489697,Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases,,Completed,No Results Available,Metastatic Colorectal Cancer,Device: real-time contrast-enhanced ultrasound imaging (CEUS),functional vascular changes in tumour vascularity of hepatic metastases|Pharmacokinetic of bevacizumab between each cure of bevacizumab based chemotherapy|ratio cost/benefit of a strategy of therapeutic monitoring by contrast-enhanced ultrasound|evaluation of the response to bevacizumab based chemotherapy by RECIST criteria|bevacizumab-related toxicity|response duration|time to disease progression|survival time,"University Hospital, Tours",All,"18 Years to 80 Years � (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,INCA06-FT/STIC-AVASTIN,January 2007,November 2012,November 2012,"June 21, 2007",,"January 4, 2017","CHRU d'ANGERS, Angers, France|CRLCC, Centre Paul Papin, Angers, France|CHRU Besancon, Besan�on, France|H�pital Saint-Andr�, CHRU Bordeaux, Bordeaux, France|CRLCC, Centre Ren� Gauducheau, Nantes St Herblain, France|H�pital Piti� Salp�tri�re, Assistance Publique H�pitaux de Paris, Paris, France|H�pital Haut-L�v�que, Pessac, France|H�pital La Mil�trie, CHRU Poitiers, Poitiers, France|H�pital Robert Debr�, CHRU Reims, Reims, France|CHU Pontchaillou, Rennes, France|CRLCC, Centre Eug�ne Marquis, Rennes, France|Chru Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT00489697,NCT00489697,32164981;28347290;27472156
oui,NCT00498459,Intervention Centered on Adolescents' Physical Activity and Sedentary Behavior (ICAPS),ICAPS,Completed,No Results Available,Physical Activity|Overweight|Cardiovascular Disease,Behavioral: Physical activity,body-mass index|fat mass (impedancemetry)|physical activity (MOSPA)|Attitudes and motivation toward physical activity|clinical and biological cardiovascular risk factors,"Louis Pasteur University, Strasbourg|Institut National de la Santé Et de la Recherche Médicale, France|Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement|National Nutritional Health Program, France|Minister of Youth Affairs and Sports, France",All,"Child, Adult, Older Adult",Not Applicable,954,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2007_01,September 2002,June 2006,June 2006,"July 10, 2007",,"March 7, 2018","Louis Pasteur University of Strasbourg, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT00498459,NCT00498459,
oui,NCT00507403,Infliximab and Methotrexate in Ankylosing Spondylitis,SPAXIM,Completed,No Results Available,Ankylosing Spondylitis,Drug: infliximab,Pharmacokinetic properties of infliximab in AS patients with or without methotrexate|Individual pharmacokinetic modelisation of infliximab,"University Hospital, Tours|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PHRR/04/PG-SPAXIM,October 2007,October 2009,December 2009,"July 26, 2007",,"January 16, 2017","University Hospital Jean MINJOZ -Besançon, Besancon, France|University hospital of Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT00507403,NCT00507403,21639907
oui,NCT00526383,Do Antidepressants Induce Metabolic Syndromes METADAP Study,METADAP,Completed,No Results Available,Major Depressive Disorder,Drug: Tricyclic antidepressants,"Definition criteria of the metabolic syndromes: Weight and waist circumference Systolic and diastolic blood pressure Glycemia Triglyceridemia Cholesterolemia Insulinemia|Antidepressant efficacy (HAM-D, quickIDS-C, quickIDS-SR, CGI)","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,624,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P060219,November 2007,April 2013,April 2013,"September 10, 2007",,"April 17, 2014","Assistance Publique hopital Bicêtre, Paris, France",,https://ClinicalTrials.gov/show/NCT00526383,NCT00526383,36386175;35878676;33420804;32524920
oui,NCT00527202,Efficacy Study of Botox to Treat Neuropathic Pain,,Completed,No Results Available,Postherpetic Neuralgia|Nerve Trauma,Drug: botulinum toxin A,Self-reported pain (numerical scales) on patients diaries|mean pain (VAS) at each visit Quality of life Proportion of responders % pain relief Clinical global impression Assessment of blindedness,Hospital Ambroise Par� Paris,All,"18 Years and older � (Adult, Older Adult)",Phase 4,29,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BTXneurop-1,June 2004,March 2007,March 2007,"September 10, 2007",,"May 5, 2021","H�pital Ambroise Par�, AP-HP, Boulogne-billancourt, France",,https://ClinicalTrials.gov/show/NCT00527202,NCT00527202,
anrs,NCT00528060,Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada,ANRS134COPHAR3,Completed,No Results Available,HIV Infections,Drug: Atazanavir|Drug: Ritonavir|Drug: Tenofovir/emtricitabine,pharmacokinetic parameters of atazanavir (ATV) when combined with ritonavir (RTV) and tenofovir/emtricitabine|pharmacokinetics of emtricitabine and tenofovir  intraindividual variability in ARVs concentrations  adherence measured with MEMS records and validated ANRS observance autoquestionnaire  relationships between virological response or side event occurrence,French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb|Gilead Sciences,All,"18 Years and older � (Adult, Older Adult)",Phase 2,35,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007-003203-12,January 2008,November 2008,November 2008,"September 11, 2007",,"December 22, 2011","Hopital du Kremlin Bic�tre Service de m�decine interne, Kremlin Bic�tre, France|Hopital Bichat CIC, Paris cedex 18, France",,https://ClinicalTrials.gov/show/NCT00528060,NCT00528060,23459496
oui,NCT00529490,"Efficacy, Safety of Hypertonic Lactate Soln. as Fluid Resuscitation Compared With Ringer's Lactate in Post-CABG Pats",,Completed,No Results Available,Low Cardiac Output,Drug: Hypertonic lactate|Drug: Ringer's lactate,hemodynamic stability|Safety of hypertonic sodium lactate for maintaining the hemodynamic stability,Innogene Kalbiotech Pte. Ltd,All,"18 Years to 75 Years � (Adult, Older Adult)",Phase 3,230,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,001/CT-KB/DNA/02,March 2002,,June 2003,"September 14, 2007",,"September 14, 2007","National Cardiac Center, Department of Surgery and Intensive Care Unit, Harapan Kita Hospital, Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT00529490,NCT00529490,
oui,NCT00529711,The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients,,Completed,No Results Available,Low Cardiac Output,Drug: Hypertonic lactate|Drug: Ringer's lactate,Hemodynamic status|Safety of hypertonic sodium lactate for maintaining hemodynamic stability,Innogene Kalbiotech Pte. Ltd,All,"45 Years to 80 Years � (Adult, Older Adult)",Phase 3,66,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,001/IGK-KAL/DNA/04,July 2005,,July 2006,"September 14, 2007",,"September 14, 2007","National Cardiac Center, Department of Surgery and Intensive Care Unit, Harapan Kita Hospital, Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT00529711,NCT00529711,
oui,NCT00531908,Physiopathology of Sodium Retention in Acromegaly,AcromEnaC,Completed,No Results Available,Acromegaly,Drug: furosemide,"To compare natriuretic effect of a single dose administration of amiloride (20 mg) in patients with acromegaly|To compare natriuretic effect of a single dose of furosemide (bolus 5 mg, then 10 mg over 2 hrs) in patients with acromegaly|To study the difference of the intranasal potential","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P061012,September 2007,December 2009,December 2009,"September 19, 2007",,"December 7, 2011","Hopital Bicetre, Paris, France",,https://ClinicalTrials.gov/show/NCT00531908,NCT00531908,22496496;21508131
anrs,NCT00536627,Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis,VAC-ADN,Completed,No Results Available,Chronic Hepatitis B,Biological: DNA vaccine pCMVS2.S,"Primary endpoint is virologic failure defined by 1) reactivation after analogs' treatment interruption, 2) virologic breakthrough during treatment with analogs, 3) the impossibility for the patients to interrupt treatment at week 48|Delay of appearance of virologic failure|Biological and clinical tolerance of DNA vaccine|Immunological responses|Clinical progression of hepatitis B",French National Agency for Research on AIDS and Viral Hepatitis,All,"18 Years to 75 Years � (Adult, Older Adult)",Phase 1|Phase 2,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2007-001682-15|ANRS HB02 VAC-ADN,January 2008,November 2010,November 2010,"September 28, 2007",,"December 19, 2011","FONTAINE H�l�ne, Paris, France",,https://ClinicalTrials.gov/show/NCT00536627,NCT00536627,24555998;24394187
oui,NCT00545194,Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess,,Completed,No Results Available,"Cervical Ripening|Labor, Induced",Drug: Prostaglandin E2,"Percentage of vaginal deliveries within the 48 hours after cervical ripening|Proportion of total vaginal deliveries|Vaginal deliveries at 12 hours, 24 hours and 36 hours|Number of hyperkinesia with or without fetal heart rate monitoring abnormalities|Number of hypertonia with or without fetal heart rate monitoring abnormalities|Apgar score at 5 min less or equal 7|Apgar score at 10 min less or equal 7|Arterial pH less or equal 7.20|Arterial base excess more than 12|Number of maternal post-partum haemorrhage|Time to reach 3cm cervical dilatation","Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 45 Years   (Adult),Phase 3,446,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PROPESS Study,January 2002,,October 2004,"October 17, 2007",,"October 17, 2007","Olympe de Gouges Women Health Centre, Bretonneau University Hospital, Tours, France",,https://ClinicalTrials.gov/show/NCT00545194,NCT00545194,
oui,NCT00545350,Exercise Intervention to Prevent Fall-related Fractures and Other Injuries : The Ossébo Study,Ossébo,Completed,No Results Available,Accidental Falls|Fractures|Fall-related Injuries,Other: Fall prevention exercise program,"Incidence of serious fall-related injuries and of all injurious falls including those leading to more moderate injuries|Changes in physical functional capacity, global physical activity level, feeling of self-efficacy (fear of falling), and general physical and psychological well-being (quality of life) at 1 year (mid-intervention) and 2 years (end of intervention)","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Institut national de prevention et d'education pour la sante|Partenariats institutions-citoyens pour la recherche et l'innovation, Région Ile de France",Female,75 Years to 90 Years   (Older Adult),Not Applicable,706,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"AOM06076, K060209|ANR 06BLAN009001,|047/06-DAS (INPES)|0900342",November 2007,June 2013,June 2013,"October 17, 2007",,"April 3, 2014","Centre de Recherche Clinique, CHU Amiens Sud, Amiens, France|Centre d'Examen et de Santé (CPAM), Annecy, France|Clinique Les Abondances, Boulogne-Billancourt, France|Centre Hospitalier Universitaire, Caen, France|Hôpital Corentin Celton, Issy-les-moulineaux, France|Hôpital gériatrique les Bateliers, Lille, France|Centre Régional de Prévention, Lyon, France|Centre de Prévention et de Traitement des Maladies du Vieillissement, CHRU Montpellier, Montpellier, France|Hôpital Bellier (CHU), Nantes, France|Centre d'Examens de Santé (CPAM), Nimes, France|Hôpital La Collégiale, Paris, France|Centre de Gérontologie Sainte Périne, Paris, France|Observatoire de l'âge, Paris, France|Hôpital Bretonneau, Paris, France|Hôpital Tenon, Paris, France|Centre Marnais de Promotion de la Santé, Reims, France|Centre Hospitalier Universitaire Charles Nicolle, Rouen, France|Hôpital de La Charité, Saint-etienne, France|Hôpital de la Robertsau, Strasbourg, France|Hôpital Paul Brousse, Villejuif, France",,https://ClinicalTrials.gov/show/NCT00545350,NCT00545350,26201510;24114665
oui,NCT00551551,Prenatal Pelvic Floor Prevention (3PN),,Completed,No Results Available,Urinary Incontinence|Anal Incontinence|Genital Prolapse,Other: Pelvic floor muscle training with physiotherapist|Other: Written information about kegel exercises,"Urinary incontinence score assessed with ICIQ-SF questionnaire|Urinary incontinence prevalence|Other pelvic floor symptoms (anal incontinence, pain, sexual troubles)|Genital prolapse assessed by POP-Q|Pelvic floor strength|Quality of life (Euroquol 5D, Contilife)|pad-test|need to medical care","Centre Hospitalier Universitaire de la Réunion|CIC-EC Réunion|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,280,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,3PN|AFSSAPS-2007-A00641-52,November 2007,September 2011,September 2011,"October 31, 2007",,"July 26, 2013","CHR Réunion, CH Félix-Guyon, Saint-Denis, Réunion, France|CHU Antoine-Béclère, Clamart, France|CHU Clermont, Clermont-Ferrand, France|CHU Caremeau, Nimes, France|CH Poissy-Saint-Germain, Saint-Germain, France",,https://ClinicalTrials.gov/show/NCT00551551,NCT00551551,32378735;26241428
oui,NCT00560664,Comparison of Autologous Chondrocyte Implantation Versus Mosaicoplasty: a Randomized Trial,Cartipatch,Completed,No Results Available,Knee Chondral or Osteochondral Defect,Procedure: Autologous chondrocytes transplantation|Procedure: Mosaicoplasty,Clinical evaluation scoring system|MRI|Arthroscopy with biopsy,"University Hospital, Brest|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 50 Years   (Adult),Phase 3,58,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BB-01-C-01-OT|RB 06.031,April 2007,October 2012,August 2013,"November 20, 2007",,"July 31, 2014","Orthopaedic surgery Departement Brest University Hospital, Brest, France|CHU de Caen, Caen, France|Centre médico chirurgical de Dracy-Le-Fort, Dracy-Le-Fort, France|CHU de Grenoble, Grenoble, France|Ch Versailles, Le Chesnay, France|Clinique Chenieux, Limoges, France|CHU de Lyon, Lyon, France|CH Nord Mayenne, Mayenne, France|CHU de Nancy, Nancy, France|HIA Bégin, Saint Mandé, France|CHU de Strasbourg, Strasbourg, France|Clinique du cours Dillon, Toulouse, France",,https://ClinicalTrials.gov/show/NCT00560664,NCT00560664,
oui,NCT00572754,Phase II Trial to Evaluate the Safety and Efficacy of the Dry Circumcision Method,,Unknown status,No Results Available,Circumcision|Male,Procedure: Circumcision,The operative and short-term post-operative safety rates|Mobibidity and mortality The length of the residual foreskin.,Progressus,Male,"21 Years and older � (Adult, Older Adult)",Phase 2,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Drycirc Vz10d|NEB002180,November 2007,,March 2008,"December 13, 2007",,"December 13, 2007","University Teaching Hospital, Lusaka, Zambia",,https://ClinicalTrials.gov/show/NCT00572754,NCT00572754,
oui,NCT00574873,Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML,,Completed,Has Results,Chronic Myeloid Leukemia,Drug: Bosutinib|Drug: imatinib,Percentage of Participants With Complete Cytogenetic Response (CCyR) at Year 1|Percentage of Participants With Major Molecular Response (MMR) at Year 1|Kaplan-Meier Estimate of Probability of Retaining CCyR at 192 Weeks|Kaplan-Meier Estimate of Probability of Retaining Complete Hematologic Response (CHR) at 192 Weeks|Kaplan-Meier Estimate of Probability of Retaining Derived MMR at 144 Weeks|Cumulative Incidence of On-Treatment Transformation to Accelerated Phase (AP) or Blast Phase (BP) at 192 Weeks,Pfizer|Wyeth is now a wholly owned subsidiary of Pfizer,All,"18 Years and older � (Adult, Older Adult)",Phase 3,502,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3160A4-3000|B1871008|2007-003780-50,"February 5, 2008","August 31, 2010","May 27, 2015","December 17, 2007","November 4, 2012","January 8, 2019","Pacific Cancer Medical Center Inc, Anaheim, California, United States|Tower Cancer Research Foundation (TCRF), Beverly Hills, California, United States|Robert A Moss, MD, FACP, Inc, Fountain Valley, California, United States|UCSD Medical Center-Thornton, La Jolla, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|UCSD Medical Center-Hillcrest, San Diego, California, United States|Stanford Hospital and Clinics Investigational Drug Services, Stanford, California, United States|Stanford Hospitals and Clinics, Stanford, California, United States|Stanford University Medical Center, Stanford, California, United States|Cancer Care Centers of Florida, Hudson, Florida, United States|Cancer Care Centers of Florida, New Port Richey, Florida, United States|Pasco Pinellas Cancer Center, New Port Richey, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|Pasco Pinellas Cancer Center, Tarpon Springs, Florida, United States|Northside Hospital, Inc. - GCS/Annex, Atlanta, Georgia, United States|Indiana Blood and Marrow Transplantation Research Franciscan St. Francis Health Center Inc., Indianapolis, Indiana, United States|Indiana Blood and Marrow Transplantation Research, Indianapolis, Indiana, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Cancer Center of Kansas, Salinas, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Josephine Ford Cancer - Downriver, Brownstown, Michigan, United States|Henry Ford Medical Center- Fairlane, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Henry Ford Hospital - West Bloomfield, Detroit, Michigan, United States|Regional Cancer Care Associates, Cherry Hill, New Jersey, United States|Study Supplies: Regional Cancer Care Associates, Cherry Hill, New Jersey, United States|Somerset Hematology Oncology Associates, Somerville, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Associates In Oncology and Hematology, Chattanooga, Tennessee, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Hospital Italiano de la Plata, La Plata, Buenos Aires, Argentina|Hospital Privado de Cordoba, Cordoba, Prov. DE Cordoba, Argentina|Centro de Investigaciones Oncologicas, Bahia Blanca, Provincia Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Buenos Aires, Argentina|Cliniques Universitaires Saint Luc, Brussels, Belgium|C.H.R.ST. - R. Fabiola (N-D), Charleroi, Belgium|University Hospital Gent - Department of Hematology, Gent, Belgium|Centre Hospitalier de Jolimont - Lobbes, La Louviere, Belgium|CHU de Charleroi - Hopital civil Marie Curie, Lodelinsart, Belgium|H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|Centro De Hematologia E Hemoterapia Da Unicamp, Campinas/ SP, Brazil|Vancouver General Hospital, Vancouver, British Columbia, Canada|University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada|Hopital Maisonneuve Rosemont, Montreal, Quebec, Canada|Instituto Oncologico del Sur, Temuco, Chile|Instituto Oncologico, Vina del Mar, Chile|Ruiging Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China, China|Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, China|The Chinese PLA General Hospital, Beijing, China|The Hematology Hospital of Chinese Academy of Medical Science, Tianjin, China|Fundacion Santa Fe de Bogota, Bogota, Cundinamarca, Colombia|Fundacion Cardiovascular de Colombia, Floridablanca, Santander, Colombia|CIOSAD Centro de Investigaciones Oncologicas, Bogota, Colombia|Institut Bergonie, Bordeaux, France|CHU Caen - Cote de Nacre, Caen, France|Centre Hospitalier de Versailles Hopital Andre Mignot, Le Chesnay Cedex, France|Hopital EDOUARD HERRIOT, Lyon, France|Hopital HOTEL DIEU, Nantes, France|Hospital Archet 1, Nice Cedex 3, France|Centre d'Investigation Clinique- CIC INSERM802, Poitiers, France|CHU de Poitiers, Poitiers, France|Clinique Sainte Anne, Strasbourg, France|Hopitaux Universitaires de Strasbourg - Hopital Civil, Strasbourg, France|Charite University Medical Center - Campus Virchow Klinikum, Berlin, Germany|Universit�tsklinikum Carl Gustav Carus, Dresden, Germany|Univeristatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Leipzig Zentrum fur Innere Medizin, Leipzig, Germany|III. Medizinische Klinik, Universitaetsklinikum Mannheim gGmbH, Mannheim, Germany|III. Medizinischen Klinik und Poliklinik des Klinikums Rechts der Isar der TU-MUNCHEN, Muenchen, Germany|Prince Of Wales Hospital, Shatin N.T., Hong Kong|Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Kaposi Mor Oktato Korhaz, Belgyogyaszati Osztaly, Kaposvar, Hungary|Josa Andras Hospital, Nyiregyhaza, Hungary|Tata Memorial Center, Tata Memorial Hospital, Mumbai, Maharashtra, India|Advanced Centre for Treatment, Research and Education in Cancer, Mumbai, Maharashtra, India|Jehangir Clinical Development Centre,, Pune, Maharashtra, India|Birla Cancer Centre, Jaipur, Rajasthan, India|SEAROC Cancer Center, Soni Manipal Hospital, Jaipur, Rajasthan, India|Azienda Ospedaliera San Gerardo, Monza, Lombardia, Italy|Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Torino, Italy|Ospedale Ferrarotto - Divisione di Ematologia, Catania, Italy|Dipartimento Di Ematologia Ospedale Santo Eugenio, Roma, Italy|Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan|Akita University Hospital, Akita City, Akita, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-Shi, Fukuoka, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Tohoku Univesity Hospital, Sendai, Miyagi, Japan|Kinki University School Of Medicine, Osakasayama, Osaka, Japan|Jikei University Hospital Daisan, Komae-shi, Tokyo, Japan|Japanese Red Cross Nagoya First Hospital, Aichi, Japan|Aichi Cancer Center Hospital, Aichi, Japan|Chiba University Hospital, Chiba, Japan|Tokai University Hospital, Kanagawa, Japan|Nagasaki University Hospital, Nagasaki, Japan|Niigata University Medical and Dental Hospital, Niigata, Japan|Osaka University Hospital, Osaka, Japan|Hamamatsu Medical University Hospital Faculty of Medicine, Shizuoka, Japan|Tokyo Metropolitan Cancer & Infectious Disease Centre Komagome Hp, Tokyo, Japan|The Catholic University of Korea, Seoul St. Mary's Hospital/Division of Hematology, Seoul, Korea, Republic of|Riga Centre Of Haematology, Riga, Latvia|Hematology, Oncology & Transfusion Medicine Center, Vilnius, Lithuania|Centro Medico de las Americas, Merida, Mexico|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Samodzielny Publiczny Szpital Kliniczny Im. A. Mieleckiego Slaskiego Uniwersytetu Medycznego, Katowice, Poland|SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin, Poland|GUZ Komi Republican Oncology Center, Syktyvkar, KOMI Republic, Russian Federation|Regional State Budgetary Healthcare Institution ""Barnaul City Hospital #8"", Barnaul, Russian Federation|Sverdlovsk Regional Clinical Hospital #1, Ekaterinburg, Russian Federation|Central City Hospital #7, Ekaterinburg, Russian Federation|Kirov Research Institute of Hematology and Blood Transfusion of, Kirov, Russian Federation|Federal State Budget Institution Hematology Scientific Center of Minzdravsotsrazvitiya of Russia, Moscow, Russian Federation|State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russian Federation|Perm Territory State Budgetary Healthcare Inst, Perm, Russian Federation|Republican Hospital na Baranov, Petrozavodsk, Russian Federation|Rostov Regional Clinical Hospital, Rostov-on-Don, Russian Federation|Rostov State Medical University of the Minzdravsotsrazvitiya of Russia, Rostov-On-Don, Russian Federation|Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation|St-Petersburg Pavlov's State Medical University, Saint Petersburg, Russian Federation|St-Petersburg State Medical University, Saint Petersburg, Russian Federation|Samara Regional Clinical Hospital M.I. Kalinin, Samara, Russian Federation|St-Petersburg Pavlov's State Medical University, St. Petersburg, Russian Federation|Yaroslavl Region State Budgetary Healthcare Institution Regional Clinical Hospital, Yaroslavl, Russian Federation|Singapore General Hospital, Singapore, Singapore|University Witwatersrand and Oncology, Johannesburg, South Africa|Johannesburg Hospital, Department of Medical Oncology, Parktown, South Africa|Clinical Haematology Unit - Department of Medicine, Soweto, South Africa|Department of Cardiology, Chris Hani Baragwanath Hospital, Soweto, South Africa|Department of Radiology, Chris Hani Baragwanath Hospital, Soweto, South Africa|Hospital Universitari Clinic de Barcelona, Barcelona, Spain|Hospital De La Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital de Madrid Norte-Sanchinarro Centro Integral Oncologico, Madrid, Spain|Complejo Hospitalario de Toledo- Servicio de Hematologia., Toledo, Spain|Hospital Clinico Universitario de Valencia (CHUV), Valencia, Spain|Changhua Christian Hospital, Changhua City, Taiwan|National Taiwan University Hospital, Taipei TOC, Taiwan|Division of Hematology, Department of Medicine, Bangkoknoi, Bangkok, Thailand|Hacettepe Universitesi Tip Fakultesi, Ankara, Sihhiye, Turkey|Ankara Universitesi Tip Fakultesi Cebeci Hastanesi, Ankara, Turkey|Gaziantep Universitesi Tip Fakultesi, Gaziantep, Turkey|Cherkaskiy oblasniy onkologichniy dispanser, Cherkassy, Ukraine|Clinical Assocation of Emergency Care, Dnipropetrovsk, Ukraine|Clinical Diagnostic Laboratory of Komunalnyj Zaklad, Dnipropetrovsk, Ukraine|Komunalnyj Zaklad ""Dnipropetrovska Miska Bagatoprofilna Klinichna Likarnja #4"", Dnipropetrovsk, Ukraine|Instytut Nevidkladnoi ta Vidnovnoi Hirurgii im. P.K. Husaka NAMN Ukrainy, Viddilennja Hematologii, Donetsk, Ukraine|Oleksandrovska clinical hospital cardiological rehabilitation department, Kiev, Ukraine|Miska klinichna likarnja # 9, Kyev, Ukraine|Institut Klinichnoi Radiologii DU ""Natsionalnyj Naukovyj Centr Radiacijnoi Medicini NAMN Ukraini"", Kyiv, Ukraine|Institut Klinichnoi Radiologii Naukovogo Centru Radiacijnoi Medicini NAMN Ukraini, Kyiv, Ukraine|Institut Klinichnoi Radiologii Naukovogo, Kyiv, Ukraine|Ultrasaund Educational and Diagnostic Center, Lviv, Ukraine|Instutut Patologii Krovi to Transfuziynoi Medicinu AMN Ukraini, Lviv, Ukraine|Polyclinic of 5th Municipal Hospital, Lviv, Ukraine|3rd Floor Centre for Clinical Haematology, Nottingham, EAST Midlands, United Kingdom|The Park Hospital, Nottingham, EAST Midlands, United Kingdom|Hammersmith Hospital Clinical Trial Units, Hammersmith, London, United Kingdom|Good Hope Hospital, Birmingham, WEST Midlands, United Kingdom|Birmingham Heartlands Hospital, Birmingham, WEST Midlands, United Kingdom|Department of Haematology - Level 3, Bexley Wing, Leeds, WEST Yorkshire, United Kingdom|Department of Haematology, London, United Kingdom|Hammersmith Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00574873,NCT00574873,35235189;24944159;24919837;23116602;22949154;22825216
oui,NCT00601276,Comparison of Two Pharmacological Treatments of Pedophilia,PCNET,Terminated,No Results Available,Pedophilia,Drug: leuprorelin|Drug: Cyproterone acetate,Questionnaire on sexual behavior|Recidivism,"Institut National de la Sant� Et de la Recherche M�dicale, France|Assistance Publique - H�pitaux de Paris|Ministry of Health, France|Ministry of Higher Education and Research, France",Male,18 Years to 60 Years � (Adult),Phase 3,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RBM-0315,December 2007,June 2009,June 2009,"January 28, 2008",,"July 13, 2009","Federation d'Endocrinologie, Hopital NeuroCardiologique, Bron, France|Centre M�dicoPsychologique CMPG21, EPS Perray Vaucluse, Paris, France|Service de Psychiatrie, Hopital Foch, Suresnes, France|SMPR, Hopital Paul Guiraud, Villejuif, France",,https://ClinicalTrials.gov/show/NCT00601276,NCT00601276,21518701
oui,NCT00604149,Cardiac AResT And GENEtic,CARTAGENE,Completed,No Results Available,Out-of-hospital Cardiac Arrest,,,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 75 Years   (Adult, Older Adult)",,2332,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C07-35|2007-A01048-45,January 2008,January 2014,January 2014,"January 30, 2008",,"June 25, 2015","Hôpital Européen Georges Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT00604149,NCT00604149,
oui,NCT00617721,Markers of Defective Membrane Remodelling in Scott-like Syndromes,,Terminated,No Results Available,Unexplained Isolated Provoked Hemorrhages|Familial Bleeding Disorder|Scott Syndrome,Other: Blood withdrawal,,"University Hospital, Strasbourg, France|Louis Pasteur University, Strasbourg|Institut National de la Santé Et de la Recherche Médicale, France|Aventis, Génopôle d'Evry.",All,"2 Years to 80 Years   (Child, Adult, Older Adult)",,29,Other,Observational,Observational Model: Family-Based|Time Perspective: Prospective,3930,June 2008,,,"February 18, 2008",,"June 17, 2016","Hôpital Antoine Béclère, Service d'Hématologie Biologique, Clamart, France|Laboratoire d'Hémostase et d'Immunologie, Centre Hospitalier, Le Mans, France|Laboratoire d'Hématologie, Hôpital Robert Debré, Reims, France|Laboratoire d'Hématologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Service d'Hématologie Biologique, Hôpital Pierre Zobda Quitman, Fort de France, Martinique",,https://ClinicalTrials.gov/show/NCT00617721,NCT00617721,
anrs,NCT00623051,Evaluation of the Extension at Community Level of Safe Male Circumcision (ANRS 12126 ORANGE FARM 2),ORANGE FARM 2,Completed,No Results Available,HIV Infections,Procedure: Male Circumcision,"HIV prevalence in population|Sexual behavior, HSV-2 prevalence, circumcision prevalence, knowledge regarding HIV, AIDS and male circumcision","French National Agency for Research on AIDS and Viral Hepatitis|ANRS, Emerging Infectious Diseases",Male,"Child, Adult, Older Adult",Not Applicable,27000,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS 12126 ORANGE FARM 2,January 2008,December 2012,December 2012,"February 25, 2008",,"July 17, 2013","Male Circumcision Centre, Orange Farm, Johannesburg, South Africa",,https://ClinicalTrials.gov/show/NCT00623051,NCT00623051,
oui,NCT00635115,The VEPRO Trial: A Cross-Over Randomised Controlled Trial Comparing 2 Corrective Lenses for Patients With Presbyopia,VEPRO,Completed,No Results Available,Presbyopia,"Device: a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)|Device: an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)",patient preference for a corrective lens|subjective measures of different areas of visual performance.,Sant�clair,All,43 Years to 60 Years � (Adult),Not Applicable,127,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",FFSA-2005-01,February 2006,January 2007,January 2007,"March 13, 2008",,"March 13, 2008","INSERM, U738, Paris, France ; Universit� Paris 7 Denis Diderot, UFR de M�decine, Paris, France ; AP-HP, H�pital Bichat, D�partement d'Epid�miologie, Biostatistique et Recherche Clinique, Paris, France",,https://ClinicalTrials.gov/show/NCT00635115,NCT00635115,18803826
non,NCT00641498,Effectiveness of Standard Emergency Department Psychiatric Treatment Associated With Treatment Delivery by a Suicide Prevention Center,,Completed,No Results Available,Suicide Attempted,Behavioral: Psychotherapy,"Suicide behavior defined by self poisoning or other suicidal attempts in the emergency departments of the region. Death by suicide will be identified by the examination of information obtained from the national death statistics office (INSERM).|Level of depression, suicide ideation, level of despair, level of alexithymia","University Hospital, Toulouse",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,607,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,0601401|PHRC suicide,March 2007,December 2009,October 2011,"March 24, 2008",,"March 30, 2015","Service d'Accueil des Urgences, Brive-la Gaillarde, France|Laboratoire de Stress Post-Traumatique, Toulouse, France",,https://ClinicalTrials.gov/show/NCT00641498,NCT00641498,33884617
oui,NCT00646269,Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease,ETNA3,Completed,No Results Available,Alzheimer's Disease,"Behavioral: Standard intervention protocol|Behavioral: Standard intervention protocol + Cognitive training therapy|Behavioral: Standard intervention protocol + Reminiscence therapy|Behavioral: Standard intervention protocol + ""Made-to-measure"" program",Proportion of progression to the severe stage of Alzheimer's disease (MMSE score of 15 or lower)|Cognitive abilities (ADAS-cog)|Functional abilities in activities of daily living (DAD scale)|Behavioural disturbance (NPI)|Apathy (Apathy Inventory)|Quality of life (Quol-AD)|Depression (MADRS),"University Hospital, Bordeaux|Caisse Nationale de Solidarité pour l'Autonomie|National Health Insurance Fund for Unemployed Workers|Direction Générale de la Santé, France|Institut National de la Santé Et de la Recherche Médicale, France|Université Victor Segalen Bordeaux 2",All,"50 Years and older   (Adult, Older Adult)",Phase 3,640,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,2007/17,March 2008,December 2010,December 2012,"March 28, 2008",,"August 1, 2013","CH Agen, Agen, France|CHU Amiens Nord, Amiens, France|Centre Mémoire de Ressources et de Recherches de Bordeaux, CHU de Bordeaux, Bordeaux, France|Hôpital Pellegrin, Bordeaux, France|CHU Côte de Nacre, Caen, France|Centre pour Personnes Agées, Colmar, France|Centre de Gériatrie, DAX, France|Hôpital Dupuytren, Draveil, France|Pôle de Gérontologie CHICAS, Gap, France|Les Fontaines de Monjous, Gradignan, France|CMRR & Neuropsychologie, Pavillon de Neurologie, CHU de Grenoble, Grenoble, France|Centre Hospitalier La Rochelle, La rochelle, France|Association AA83 Alzheimer Aidants Var Etablissement "" Les pensées "", La Seyne sur Mer, France|Centre Hospitalier de Libourne, Libourne, France|CHU Limoges, Limoges, France|Hôpital Privé Gériatrique Les Magnolias, Longjumeau, France|Centre Hospitalier Bretagne Sud, Lorient, France|Groupe Hospitalier Saint-Augustin, Malestroit, France|Hôpital Sainte-Marguerite, Marseille, France|Centre Antonin Balmes, Montpellier, France|Hôpital Gui de Chauliac, Montpellier, France|Clinique Neurologique, CHU Nord, Nantes, France|Centre Mémoire, Hôpital Pasteur,, Nice, France|Hôpital Broca, Paris, France|Hôpital de la Salpétrière,, Paris, France|Centre Hospitalier des Pyrénées, Pau, France|Hôpital de Jour Gériatrique, Pau, France|Hôpital Xavier-Arnozan, Pessac, France|CHI Poissy-saint-germain-en-laye, Poissy, France|Hôpital de Jour gériatrique, Poitiers, France|CHU de Rennes, Rennes, France|Hôpital de Jour Gériatrique, Saint Raphaël, France|CHRU de Saint-Etienne, Saint-Etienne, France|Centre hospitalier Ariège Couserans, Saint-Girons, France|Hôpitaux universitaires de Strasbourg, Strasbourg, France|Bagatelle, Talence, France|CHIC Marmande - Tonneins, Tonneins, France|CHU Purpan-Casselardit, Toulouse, France|Hôpital des Charpennes, Villeurbanne, France",,https://ClinicalTrials.gov/show/NCT00646269,NCT00646269,
oui,NCT00647088,Genetic of Aortic Valve Stenosis - Clinical and Therapeutic Implications,GENERAC,Unknown status,No Results Available,Aortic Valve Stenosis,,"Identification of genetic polymorphisms of fetuin-A, matrix-GLA protein, vitamin D receptor|Identification of other genetic polymorphisms","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,2200,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,P070141,March 2008,December 2017,December 2017,"March 31, 2008",,"March 1, 2017","Assistance Publique - Hôpitaux de Paris, Bichat Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT00647088,NCT00647088,31141105;29555836;28415102;26896466;26553695;26491110;26156015;25655063;24597398;23349346
anrs,NCT00657397,"Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices",Methaville,Completed,No Results Available,Hepatitis C|Substance Dependence|Methadone,Drug: Methadone,"prevalence of non-users of street opioid after one year of treatment will be compared between arms.|Prevalence of non users of street opioids after three months of treatment|Retention in treatment|Decrease in HCV risk behaviors, addictive behaviors, improvement in quality of life, psychiatric comorbidities, social insertion, reduction in criminal acts|cost-effectiveness|surveillance of severe adverse events and overdose cases in each arm","French National Agency for Research on AIDS and Viral Hepatitis|ANRS, Emerging Infectious Diseases",All,"18 Years to 70 Years � (Adult, Older Adult)",Phase 3,197,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS Methaville,January 2009,December 2011,December 2011,"April 14, 2008",,"July 24, 2012","CSST Le trait d'union, Boulogne, France",,https://ClinicalTrials.gov/show/NCT00657397,NCT00657397,27770695;27048152;25393311;25209306;24268548;22741944
oui,NCT00657969,Looking For Genetic and Environmental Risk Factors and Therapeutic Aspects in Cervical Artery Dissections,CADISP,Unknown status,No Results Available,Cervical Artery Dissection|Stroke|Brain Infarction,,association of genetic polymorphisms with cervical artery dissections|association of environmental risk factors with cervical artery dissections|gene-environment interactions,Cervical Artery Dissections and Ischemic Stroke Patients - Consortium,All,"18 Years and older � (Adult, Older Adult)",,4169,Other,Observational,Observational Model: Case-Control,CADISP,July 2005,January 2009,September 2009,"April 14, 2008",,"October 21, 2009","Sanatorio Allende, Cordoba, Argentina|Department of Neurology, University Hospital of Brussels (ULB), Brussels, Belgium|Department of Neurology, University Hospital of Leuven, Leuven, Belgium|Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland|Department of Neurology, University Hospital of Amiens, Amiens, France|Department of Neurology, University Hospital of Besan�on, Besan�on, France|Department of Neurology, University Hospital of Dijon, Dijon, France|Department of Neurology, University Hospital of Lille, Lille, France|Inserm U744 Institut Pasteur de Lille, Lille, France|Department of Neurology, University Hospital Piti�-Salp�tri�re, Paris, France|Department of Neurology, University Hospital Sainte-Anne, Paris, France|Rehabilitation Center, Schmieder-Klinik, Heidelberg, Germany|Department of Neurology, University Hospital of Heidelberg, Heidelberg, Germany|Department of Neurology, Hospital of Ludwigshafen, Ludwigshafen, Germany|Department of Neurology, University Hospital of Munich, Munich, Germany|Department of Neurology, University Hospital of Brescia, Brescia, Italy|Department of Neurology, Ospedale Maggiore Policlinico di Milano, Milano, Italy|Ospedale Milano San Raffaele, Milano, Italy|Department of Neurology, University Hospital Milano-Bicocca, Monza, Italy|Department of Neurology, University Hospital of Perugia, Perugia, Italy|Rehabilitation Center, IRCCS Santa Lucia, Roma, Rome, Italy|Department of Neurology, University Hospital of Basel, Basel, Switzerland|Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey|Department of Neuroscience, St George's University Hospital of London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00657969,NCT00657969,
oui,NCT00668252,Circulating Endothelium Progenitor Cells and Endogenous Oestrogen in Healthy Subjects,Oestropec,Completed,No Results Available,Healthy,,Number of endothelial progenitor cells by cytometry|To compare the number of EPC in young women to older men and menopausal women. To evaluate the correlation between the number of EPC and 17 b-estradiol plasma level.,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 79 Years   (Adult, Older Adult)",,48,Other,Observational,Time Perspective: Cross-Sectional,P050904,April 2006,April 2007,April 2007,"April 29, 2008",,"April 29, 2008","Assistance Publique Hopitaux de Paris - Hopital Saint Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT00668252,NCT00668252,
anrs,NCT00670839,Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST),B-BOOST,Completed,No Results Available,Hepatitis B|HIV Infection,Biological: GenHevac-B,"rate of HIV-infected patients who seroconvert one month after the last vaccination. Seroconversion is defined as anti-HBs titers equal or above 10 mUI per ml|According to the vaccine strategy (single-dose or double-dose), comparison of AbHBs titers, permanence of humoral response, intensity of clinical and biological events, and predicting factors related to seroconversion|immunological substudy: to understand genetic link between some alleles of HLA-DR and non-response to immunization","ANRS, Emerging Infectious Diseases|MCM Vaccines B.V.",All,"18 Years and older � (Adult, Older Adult)",Phase 3,178,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2007-005023-15|ANRS HB04 B-BOOST,May 2008,December 2011,February 2013,"May 2, 2008",,"August 12, 2013","Centre de Soins de l'Infection par le VIH NHC, H�pitaux Universitaires Strasbourg, 1 place de l'h�pital, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT00670839,NCT00670839,26257021
oui,NCT00680082,Observational Usage Study of Statins in Primary Care in France,,Completed,No Results Available,Healthy,,,AstraZeneca,All,"Child, Adult, Older Adult",,2100,Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,NIS-CFR-CRE-2007/2,February 2008,July 2009,July 2009,"May 19, 2008",,"December 2, 2010","Research Site, Hefei, Anhui, China|Research Site, Chongqing, Chongqing, China|Research Site, Fuzhou, Fujian, China|Research Site, Guangzhou, Guangdong, China|Research Site, Shenzhen, Guangdong, China|Research Site, Xiamen, Guangdong, China|Research Site, Zhongshan, Guangdong, China|Research Site, Zhengzhou, Henan, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Nanjing, Jiangsu, China|Research Site, Suzhou, Jiangsu, China|Research Site, Wuxi, Jiangsu, China|Research Site, Nanchang, Jiangxi, China|Research Site, Jinan, Shandong, China|Research Site, Qingdao, Shandong, China|Research Site, Shanghai, Shanghai, China|Research Site, Taiyuan, Shanxi, China|Research Site, Xi'an, Shanxi, China|Research Site, Chengdu, Sichuan, China|Research Site, Kunming, Yunnan, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Ningbo, Zhejiang, China|Research Site, Rui'an, Zhejiang, China|Research Site, Wenzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT00680082,NCT00680082,
oui,NCT00701532,Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction,CAIMAN,Completed,No Results Available,Cocaine Addiction|Cocaine Dependence,Drug: Modafinil and PET (brain imaging)|Drug: placebo,"Decreased DAT occupation rates in the modafinil group versus placebo from day 3 to day of cocaine detoxification.|Evaluation of the clinical efficacy of modafinil during therapeutic cocaine withdrawal.|Correlation between craving measurements, depressive symptom measurements and cognitive deficit measurements observed and modifications of DAT density.|Study of DAT from D3 to D21 versus a pre-existing data base of control subjects.|Tolerance and safety evaluation of high modafinil doses, measured by adverse events and biological parameters.",Assistance Publique - H�pitaux de Paris|Mission Interminist�rielle de Lutte contre la Drogue et la Toxicomanie,Male,"18 Years to 65 Years � (Adult, Older Adult)",Phase 3,29,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P070150,April 2009,October 2012,January 2013,"June 19, 2008",,"April 11, 2013","Unit� de recherche U797 Inserm - CEA - Universit� Paris-Sud. "" Neuroimagerie & Psychiatrie "" Service Hospitalier Fr�d�ric Joliot, Orsay, France|Centre d'Enseignement, de Recherche et de Traitements des Addictions - Hopital Universitaire Paul Brousse, Villejuif, France",,https://ClinicalTrials.gov/show/NCT00701532,NCT00701532,
oui,NCT00710099,Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate in Healthy Volunteers,INFLUX-VS,Completed,No Results Available,Healthy,Drug: sildenafil|Drug: nitroprussiate iontophoresis,"variation of conductance of nitroprussiate iontophoresis associated with oral sildenafil|To assess the effect of oral sildenafil (50 mg and 100 mg) on skin microvascular reactivity to local cooling, on the forearm and the finger","University Hospital, Grenoble",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCIC/08/08,July 2008,June 2011,June 2011,"July 4, 2008",,"October 6, 2011","Clinical Researsh Centre, Grenoble, Isere, France",,https://ClinicalTrials.gov/show/NCT00710099,NCT00710099,
oui,NCT00741728,"Heart Rate, Baroreflex Sensitivity and Cardiovascular Morbidity and Mortality in the Population",PPSIII,Unknown status,No Results Available,Community Based Study|Cardiovascular Disease|Sudden Death|Blood Pressure,"Other: Spider flash EKG, echocardiography tracking, step test",cardiovascular disease|heart rate parameters and baroreflex sensitivity,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"50 Years to 75 Years � (Adult, Older Adult)",,10000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C07-39|2007-A01386-47,June 2008,June 2012,December 2019,"August 26, 2008",,"December 9, 2011","Investigations Pr� cliniques et Preventives de Paris, Paris, France",,https://ClinicalTrials.gov/show/NCT00741728,NCT00741728,34875909;29593025;28754808;27354274
oui,NCT00748111,Thrombus and Inflammation Study in Sudden Cardiac DEath,TIDE,Completed,No Results Available,Sudden Cardiac Death|Acute Myocardial Infarction,Other: Blood sample,"Age of thrombus collected at the site of acute coronary occlusion.|Local and systemic inflammation and endothelial cell apoptosis in patients with sudden death due to acute coronary occlusion, acute myocardial infarction and stable angina treated with coronary angioplasty.","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,380,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,P080201,August 2008,April 2012,December 2012,"September 8, 2008",,"December 16, 2015","Hopital Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT00748111,NCT00748111,
oui,NCT00763217,Clinical Biological and Pharmacological Factors Influencing Stroke Outcome,biostroke,Completed,No Results Available,Stroke,,"severity of stroke measured by NIH severity score|clinical, pharmacological and biological (metabolic, inflammation, hemostasis...) cognitive status","University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France",All,"40 Years and older   (Adult, Older Adult)",,550,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CP 05/15|PHRC 2004/1901,June 2005,June 2009,June 2012,"September 30, 2008",,"May 13, 2015","Lille University Hospital - Service de Neurologie vasculaire, Lille, France",,https://ClinicalTrials.gov/show/NCT00763217,NCT00763217,30782684;26502812
oui,NCT00764049,Single Pass Albumin Dialysis in Patients With Cirrhosis,DACAR,Completed,No Results Available,Cirrhosis|Acute on Chronic Hepatic Failure|Hepatorenal Syndrome|Encephalopathy,Device: Single pass albumin dialysis,Effects on clinical and biochemical variables|Safety,"Assistance Publique - Hôpitaux de Paris|Laboratoire français de Fractionnement et de Biotechnologies|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,11,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P050902,June 2009,January 2012,July 2012,"October 1, 2008",,"February 25, 2015","Hôpital Beaujon, Clichy, France",,https://ClinicalTrials.gov/show/NCT00764049,NCT00764049,
oui,NCT00774462,Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis,FORCE,Completed,No Results Available,Myositis|Myasthenia Gravis,Drug: Rituximab,Score of muscular strength (Kendall's muscular testing for myositis or MG muscular score for myasthenia)|- Score of muscular strength (Kendall's muscular testing for myositis or MG muscular score for myasthenia)|- Improvement of functional scale score (SF36)|- Decrease of CK levels|- Evolution of auto-antibody titers|- Improvement of extra-muscular activity of the disease such as the level of lung involvement by pulmonary function tests|- Improvement in the treatment burden defined as the possibility to decrease the dose or stop some of the drugs used at entry,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Roche Pharma AG",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,30,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P051204,January 2008,December 2011,December 2011,"October 17, 2008",,"December 11, 2012","Service de Médecine Interne 1 / Groupe Hospitalier Pitié-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT00774462,NCT00774462,26539981
oui,NCT00774709,Karolinska-Rennes (KaRen) Prospective Study of Exercise Stress Echocardiography in Heart Failure With Preserved Ejection Fraction,KaRen,Completed,No Results Available,Heart Failure,,Echocardiographic parameter,French Cardiology Society|F�d�ration Fran�aise de Cardiologie,All,"18 Years and older � (Adult, Older Adult)",,90,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,CCP 08 / 20- 679,October 2008,October 2012,November 2012,"October 17, 2008",,"September 30, 2013","Service de Cardiologie et CIT-IC 804, LTSI INSERM U 642, Rennes, France",,https://ClinicalTrials.gov/show/NCT00774709,NCT00774709,34811954;31981321;29622288;29430747;28329385;28100627;28028584;26568833;24388161
oui,NCT00777985,Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea,BOSAS,Completed,No Results Available,Obstructive Sleep Apnea|Hypertension,Drug: bosentan|Device: nasal continuous positive airway pressure (CPAP),"24 hour mean diastolic blood pressure|Peripheral Arterial Tonometry measure|mean 24 hour systemic systolic blood pressure|mean 24 hour nocturnal blood pressure|carotid Intima Media Thickness|Circulating inflammation markers (RANTES, MCP-1, TNF-alpha, INF-gamma, IL-6, IL-10 and TGF-gamma|Circulating Big ET1 and ET1 levels","University Hospital, Grenoble|Institut National de la Santé Et de la Recherche Médicale, France|Actelion",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,19,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0722|2007-005333-11,December 2007,January 2012,January 2012,"October 23, 2008",,"May 21, 2014","CHU de Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00777985,NCT00777985,
associ�,NCT00780949,Immunological Consequences of CARD15/NOD2 Mutations in Crohn's Disease,PLAC,Completed,No Results Available,Crohn's Disease,Other: intestinal biopsies,cytokine production and cell phenotype in Peyer patches,Assistance Publique - H�pitaux de Paris,All,"5 Years to 65 Years � (Child, Adult, Older Adult)",Not Applicable,110,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,P071206,January 2009,January 2012,January 2012,"October 28, 2008",,"August 3, 2012","Hopital Robert Debre, Paris, France",,https://ClinicalTrials.gov/show/NCT00780949,NCT00780949,
oui,NCT00789789,Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials,,Terminated,No Results Available,HIV Infection|HIV Seronegativity,,"Description of severe health events (grade 3-4), as well as neurological, ophtalmological, and immunological events (any grade), starting from the first injection of a HIV candidate vaccine.|Evaluation of HIV serologic status by two ELISA tests and Western blot test ( only if ELISA is positive).|Evaluation of psycho-behavioral consequences, associated to participation in a HIV preventive trial, on entourage, familial, professional and social relations, with a self-questionnaire and an interview with a clinician.|Incidence of HIV infection (frequency, description of contamination).","ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",,488,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2007-002219-14|ANRS COV1 COHVAC,December 2008,September 2016,"September 30, 2016","November 13, 2008",,"June 1, 2017","CIC Cochin Pasteur, h�pital Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT00789789,NCT00789789,
oui,NCT00799565,Mitral Valve Prolapse (MVP) - France Study,MVP-France,Completed,No Results Available,Mitral Valve Prolapse,Genetic: catch of blood,Genetic polymorphism identification,"French Cardiology Society|Leducq Foundation|Institut National de la Santé Et de la Recherche Médicale, France|Centre National de Génotypage",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1179,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2008-01,December 2008,July 2011,July 2011,"December 1, 2008",,"July 14, 2011","Hôpital Sud, Amiens, France|Clinique Saint Augustin, Bordeaux, France|Hôpital Ambroise Paré, Boulogne, France|Hôpital de la Cavale Blanche, Brest, France|Hôpital Gabriel Montpied, Clermont-Ferrand, France|Hôpital Henri Mondor, Créteil, France|Hôpital du Bocage, Dijon, France|Hôpital Front-Pré, La Seyne sur Mer, France|Hôpital Cardiologique, Lille, France|Hôpital Dupuytren, Limoges, France|Groupement Hospitalier Est, Lyon, France|Hôpital de la Timone, Marseille, France|Institut Hospitalier Jacques Cartier, Massy, France|Hôpital Arnaud de Villeneuve, Montpellier, France|Hôpital G and R Laennec, Nantes, France|Hôpital Lariboisière, Paris, France|Hôpital Pitié Salpêtrière, Paris, France|Hôpital Européen Georges Pompidou, Paris, France|Hôpital Bichat, Paris, France|Hôpital Saint Antoine, Paris, France|Hôpital Cochin, Paris, France|Hôpital Cardiologique du Haut Lévêque, Pessac, France|Hôpital Pontchaillou, Rennes, France|Hôpital Charles Nicolle, Rouen, France|Hôpital Rangueil, Toulouse, France|CHU Nancy, Vandoeuvre-les-Nancy, France",,https://ClinicalTrials.gov/show/NCT00799565,NCT00799565,
oui,NCT00820820,IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis,IDA-Adult,Completed,No Results Available,Atopic Dermatitis,Biological: ROUVAX|Biological: placebo,"Effect of anti-measles vaccination on the T cell responses in patients|Clinical evolution of AD, as measured by the SCORAD|blood level of measles specific IgE and antibodies|Biomarkers - E selectin, CD25, soluble CD30, CCL 17 and CCL 18|phenotypic characteristics of T lymphocytes","Institut National de la Santé Et de la Recherche Médicale, France|Ministry of Health, France",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",C07-38|2007-007267-25,"January 9, 2009","March 26, 2012","March 26, 2012","January 12, 2009",,"February 12, 2020","Unité de Recherche Clinique et Immunologique, Pierre-Bénite, Lyon, France",,https://ClinicalTrials.gov/show/NCT00820820,NCT00820820,
oui,NCT00822666,Clopidogrel and Response Variability Investigation Study 2,CLOVIS2,Completed,No Results Available,Coronary Artery Disease,Drug: clopidogrel,"Inhibition of residual platelet activity 6 hours after a loading dose of clopidogrel|Maximum platelet aggregation instead of IRPA|RPA with 5µM and 50 µM of ADP|3. Measure of clopidogrel and its active metabolites (carboxylated and thiol) at different time points following the loading dose (H0, H1, H2 ,H6) with respect to the presence of the genetic variant CYP2C19*2|Relationship between active metabolites concentration and IRPA|Relationship between active metabolites and dose of clopidogrel","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",Male,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,109,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P070117,October 2008,December 2009,December 2009,"January 14, 2009",,"December 11, 2012","Hopital la Pitié-Salpétrière Institut de cardiologie, Paris, France",,https://ClinicalTrials.gov/show/NCT00822666,NCT00822666,21972404;21511218
oui,NCT00827411,"Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy",ARCTIC,Completed,No Results Available,Coronary Artery Disease|Acute Coronary Syndrome,Drug: Aspirin and clopidogrel / Prasugrel|Device: VerifyNow|Drug: Aspirin,"Composite endpoint of death, myocardial infarction, stroke, urgent coronary revascularization, stent thrombosis assessed at one year for the first hypothesis and between 6 up to 18 months of follow-up for the second hypothesis|Stent thrombosis and urgent coronary revascularization|Rate of individual event at one year follow-up in both "" monitoring "" and "" conventional "" arms but also during the period from one year up to 24 months in the "" interruption "" and "" pursuit "" arms.|Time delay from treatment interruption (randomization 2) to any thrombotic event (stent thrombosis, urgent revascularization, acute myocardial infarction, cardiac death) treatment interruption(randomisation 2)|Treatment compliance evaluated by the number of oral antiplatelet treatment in both arms and with respect to all individual events of the primary composite endpoint|Rate of use of GP IIb/IIIa receptor antagonists in both "" monitoring "" and "" conventional "" arms before percutaneous coronary intervention and in bail out situations and in both.|Rate of suboptimal responders as defined by ARU>550 for aspirin or by a % of inhibition <15% and or a PRU<235) and the average dosage of aspirin and clopidogrel (in mg) will evaluated before and after dose adjustment (J0) and after each dose adjustment|Net clinical benefit (death, myocardial infarction, urgent revascularization, stent thrombosis, stroke, major bleeding)|Medico-economic evaluations will be performed for both hypotheses. The rate of rehospitalisation and the length of stay will be used as economic indicators","Assistance Publique - Hôpitaux de Paris|Allies in Cardiovascular Trials Initiatives and Organized|Institut National de la Santé Et de la Recherche Médicale, France|Sanofi|Bristol-Myers Squibb|Medtronic|Cordis Corporation|Fondation de France|Diagnostica Stago|Boston Scientific Corporation",All,"18 Years and older   (Adult, Older Adult)",Phase 4,2500,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P080403,January 2009,March 2012,January 2013,"January 22, 2009",,"April 12, 2013","Institut de Cardiologie- Hopital la Pitié Salpétrière, Paris, France",,https://ClinicalTrials.gov/show/NCT00827411,NCT00827411,31694410;26265231;25037988;24718568;23121439
oui,NCT00839033,Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders,Nemucough,Terminated,No Results Available,Duchenne Muscular Dystrophy|Amyotrophic Lateral Sclerosis|Neuromuscular Diseases,Device: mechanical insufflation - exsufflation|Device: Standard respiratory physiotherapy,"Reduction of the number of patients requiring invasive ventilatory support in the group treated with MI-E (MI-E group) compared to the group treated with traditional chest physiotherapy without MI-E (Control group).|Decrease in the length of hospitalization in the intensive care unit (ICU) (if necessary)|Decrease in the total length of hospitalization|Decrease in the incidence of bronchoscopy-assisted aspiration|Decrease in the duration of oxygen therapy|Decrease in the daily length of noninvasive positive pressure ventilation (NPPV)|Improvement in blood gases on room air during hospitalization and improvement of the peak cough flow (PCF)|Improvement of the vital capacity (VC), maximal inspiratory (PImax) and expiratory (PEmax) pressures, sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF) and dyspnea during hospitalization|Decrease in the number of secondary tracheotomies (for weaning of ventilatory support)",Assistance Publique - H�pitaux de Paris,All,"4 Years and older � (Child, Adult, Older Adult)",Phase 3,14,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P080406,June 2009,February 2011,December 2011,"February 9, 2009",,"May 28, 2015","Hospital Armand Trousseau, Pediatric Pulmonology Department and INSERM UMR S-893, Paris, France",,https://ClinicalTrials.gov/show/NCT00839033,NCT00839033,
oui,NCT00841347,Sleep and Obesity in Teenagers,,Completed,No Results Available,Obesity,Behavioral: habitual sleep length period + extended sleep length period|Behavioral: extended sleep length period + habitual sleep length period,"The influence of sleep extension on leptin level for the obese teens group.|Difference between the two groups (obese vs non-obese) regarding sleep length and delta waves activity.|Study the correlation between delta waves activity and habitual sleep length|Study the correlation between delta waves activity and psychological, behavioural, anthropometric and physiological markers of obesity and its co morbidities",Hospices Civils de Lyon,All,15 Years to 17 Years   (Child),Not Applicable,41,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2008.525,February 2009,May 2014,May 2014,"February 11, 2009",,"August 3, 2017","Hospices Civils de Lyon, Lyon, France",,https://ClinicalTrials.gov/show/NCT00841347,NCT00841347,
oui,NCT00843076,Impact of Hepatitis C Virus Variability on Steatosis,Viro-steatosis,Terminated,No Results Available,Chronic Hepatitis C,,,"University Hospital, Tours",All,"18 Years to 75 Years � (Adult, Older Adult)",,27,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AORT08-PR/VIRO-St�atose,January 2009,April 2011,April 2011,"February 13, 2009",,"November 11, 2013","CH de Blois, Blois, France|CH de Bourges, Bourges, France|CH de Ch�teauroux, Chateauroux, France|CH de Dreux, Dreux, France|CHR Orl�ans, Orleans, France|CHRU de Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT00843076,NCT00843076,
oui,NCT00852865,Lactobacillus Farciminis and Hyperalgesia,,Completed,No Results Available,Inflammation|Pain,Drug: Lactobacillus farciminis|Drug: Placebo,Measurement of the mchanical pain threshold in primary and secondary areas by using a punctate stimulus.|Measurement of cutaneous temperature of hyperalgesia areas,Lallemand SAS,All,18 Years to 60 Years � (Adult),Phase 1,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HN 08-17|2008-A01380-55,February 2009,April 2009,April 2009,"February 27, 2009",,"May 1, 2009","Cpc / Cic-Inserm 501, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT00852865,NCT00852865,
oui,NCT00862615,Relationships Between Quality of Ageing and Age-related Degenerated Disease (Compalimage),Compalimage,Unknown status,No Results Available,Age-related Degenerated Disease,Other: Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.,"Isotopic enrichments in expired gas, in plasma cetoisocaproate and in free or protein-bound leucine in muscle will be measured to determine proteolysis and proteosynthesis rate of muscle proteins.|Splanchnic extraction of amino acids, bone metabolism, muscular strength, global metabolism and quality of life.","University Hospital, Clermont-Ferrand|Centre de Recherche en Nutrition Humaine d'Auvergne|Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement|Institut National de la Santé Et de la Recherche Médicale, France",Male,65 Years and older   (Older Adult),Not Applicable,32,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CHU-0048|IDRCB 2008-A00593-52|AU750,January 2009,July 2010,January 2011,"March 17, 2009",,"September 29, 2010","CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT00862615,NCT00862615,
oui,NCT00870649,Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium,Bilhvax3,Completed,No Results Available,Urinary Schistosomiasis|Schistosoma Haematobium,Biological: Bilhvax vaccine (Sh28GST)|Biological: placebo,A significant delay of recurrence of the schistosomiasis pathology in vaccine group compared to control group.|Evaluation of safety Percentage of children presenting at least one adverse event of degree ≥ 2. Percentage of children presenting at least one adverse event implying modification of the vaccine strategy.,"Institut National de la Santé Et de la Recherche Médicale, France",All,6 Years to 9 Years   (Child),Phase 3,250,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",BT05-01|2008-006757-40,February 2009,June 2012,December 2012,"March 27, 2009",,"November 8, 2016","ESPOIR Pour La Santé, Saint Louis, Senegal",,https://ClinicalTrials.gov/show/NCT00870649,NCT00870649,30532268
oui,NCT00875654,Intravenous Stem Cells After Ischemic Stroke,ISIS,Completed,No Results Available,Ischemia|Stroke,Genetic: Autologous mesenchymal stem cells,feasibility and tolerance of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke|Clinical and functional effects of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke|Determination of the most effective dose of stem cells|To define the best criteria for a future trial (phase III)|To define the best target population for a future study,"University Hospital, Grenoble|Commissariat A L'energie Atomique|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,31,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCIC 06 25,August 2010,"October 20, 2017","October 20, 2017","April 3, 2009",,"November 1, 2017","Neuroradiology/MRI, University Hospital of Grenoble, Grenoble, France|Stroke Unit, University Hospital of Grenoble, Grenoble, France|Tissular and cell therapy unit, UniversityHospitalof Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00875654,NCT00875654,32462427;32438012
oui,NCT00904774,Genetic Susceptibility for Bronchopulmonary Dysplasia in Preterm Infants,GENBPD,Unknown status,No Results Available,Bronchopulmonary Dysplasia,,bronchopulmonary dysplasia,Centre Hospitalier Intercommunal Creteil,All,up to 8 Weeks � (Child),,800,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AOR 07 018,May 2009,,,"May 20, 2009",,"May 20, 2009","Centre Hospitalier Intercommunal, Creteil, France",,https://ClinicalTrials.gov/show/NCT00904774,NCT00904774,
oui,NCT00905268,"A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients",MICONOS,Completed,Has Results,Friedreich's Ataxia,Drug: idebenone|Drug: Placebo,Absolute Change in International Cooperative Ataxia Rating Scale (ICARS) Scores From Baseline Assessment to Week 52|Absolute Change in Friedreich's Ataxia Rating Scale (FARS) Scores From Baseline Assessment to Week 52|Proportion of Patients Improving (Responding) on ICARS by a Clinically Relevant Margin|Proportion of Patients Improving on Left Ventricular Peak Systolic Strain Rate or Showing a Reduction in Left Ventricular Mass Index (LVMI) With no Worsening in Strain Rate|Change in Peak Systolic Strain Rate From Baseline to Week 52|Change in Peak Workload From Baseline to Week 52,Santhera Pharmaceuticals,All,"8 Years and older � (Child, Adult, Older Adult)",Phase 3,232,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SNT-III-001,April 2006,January 2010,January 2010,"May 20, 2009","June 27, 2016","June 27, 2016","Universit�tsklinik Innsbruck, Innsbruck, Austria|H�pital Erasme - Universit� Libre de Bruxelles, Bruxelles, Belgium|H�pital de la Salp�tri�re - INSERM U679, Neurologie et Th�rapeutique exp�rimentale, Paris, France|HELIOS Klinikum BerlinBuch, Berlin, Germany|Neurologische Universit�tsklinik und Poliklinik- Universit�tsklinikum Bonn, Bonn, Germany|Klinik II, Neurop�diatrie u.Muskelerkrankungen- Universit�tsklinik Freiburg, Freiburg, Germany|Zentrum f�r Neurologische Medizin, G�ttingen, Germany|UKE Hamburg Neurop�diatrie-Zentum f�r Frauen, Kinder und Jugendmedizin, Hamburg, Germany|Neurologische Klinik- klinikum Grosshadern, M�nchen, Germany|Neurologische Universit�tsklinik und Poliklinik, T�bingen, Germany|University Medical Center Groningen, Groningen, Netherlands|National Hospital for Neurology & Neurosurgery, London, United Kingdom|University of Newcastle upon Tyne -Mitochondrial Research Group, Newcastle, United Kingdom",,https://ClinicalTrials.gov/show/NCT00905268,NCT00905268,
oui,NCT00905892,Metabolic Fate Modifications of Saturated Fats After an Overfeeding,SURNUT,Completed,No Results Available,Obesity|Lipid Metabolism|Inflammation,Dietary Supplement: Hyperlipidic overfeeding,Post prandial partitioning of exogenous lipids|Genes expression in adipose and muscle tissues,"Centre de Recherche en Nutrition Humaine Rhone-Alpe|Institut National de la Santé Et de la Recherche Médicale, France",Male,18 Years to 55 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CRNHRA-09-002,September 2005,December 2009,March 2010,"May 21, 2009",,"June 23, 2011","Centre de recherche en nutrition humaine Rhone-Alpes, Pierre-Bénite, France",,https://ClinicalTrials.gov/show/NCT00905892,NCT00905892,30260393;24684464;22162470
oui,NCT00910169,Evaluation of Hospitalization for Anorexia Nervosa (EVALuation de l'Apport de l'HOSPITalisation Pour Anorexie Mentale : EVALHOSPITAM),EVHAN,Unknown status,No Results Available,Anorexia Nervosa,Other: inpatient treatment,Morgan and Russell score|Nutritional status|Eating disorders symptoms and diagnosis|Psychiatric symptoms and disorders|Cognitive functioning|Somatic symptoms and complications|Social adjustment|Quality of life|Family relationships|Re-hospitalization,"Institut Mutualiste Montsouris|Institut National de la Sant� Et de la Recherche M�dicale, France|Ministry of Health, France|National Research Agency, France|National Health Insurance Fund|Fondation de la Mutuelle G�n�rale de l'Education Nationale|Fondation de France",All,"8 Years to 65 Years � (Child, Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Eudract: 2007 -A01110-53|ANR-0-JC0719-6328|PHRC AOM 06 020,March 2009,October 2012,October 2012,"May 29, 2009",,"August 7, 2012","Insitut Mutualiste Montsouris, Paris, France",,https://ClinicalTrials.gov/show/NCT00910169,NCT00910169,36807834
oui,NCT00912600,Intensive Care Unit (ICU) Admission Decisions in the Elderly : the ICE-CUB Study,IceCub,Completed,No Results Available,Patient Admission|Death|Activities of Daily Living,Other: Intensive Care Unit admission,ICU eligibility as assessed by emergency and ICU physicians|Hospital death|Change in functional status|Six-month death,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,80 Years and older   (Older Adult),,2643,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AOR 03 035,November 2004,January 2006,February 2009,"June 3, 2009",,"July 26, 2012","Hôpital Saint-Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT00912600,NCT00912600,22509296
oui,NCT00912886,Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease,STERMEM,Completed,No Results Available,Alzheimer Disease,,Plasma concentrations of PREGS determined by GC-MS|Memory scores of the RL-RI test according to the GROBER and BUSCKE test|Plasma concentrations of PREGS metabolites,Assistance Publique - H�pitaux de Paris,All,70 Years and older � (Older Adult),,90,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,P071237,September 2009,September 2011,September 2011,"June 3, 2009",,"April 11, 2013","Assistance publique - H�pitaux de Paris H�pital Bic�tre, Le Kremlin Bic�tre, France|Inserm Umr 788, Le Kremlin Bic�tre, France|AP-HP H�pital Rothschild, Paris, France|Assistance Publique - H�pitaux de Paris H�pital Broca, Paris, France|Assistance Publique - H�pitaux de Paris, H�pital Piti�-Salp�tri�re, Paris, France|Assistance Publique - H�pitaux de Paris, H�pital Paul Brousse, Villejuif, France",,https://ClinicalTrials.gov/show/NCT00912886,NCT00912886,
oui,NCT00914030,Visual Exploration and Attention: Studies in Patients With Schizophrenia and Autism Spectrum Disorders,,Unknown status,No Results Available,Autism Spectrum Disorders|Schizophrenia,Other: Neuropsychological evaluation,,"University Hospital, Strasbourg, France",All,"7 Years to 55 Years   (Child, Adult)",,140,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,2008-A01459-46,June 2009,December 2016,December 2016,"June 4, 2009",,"August 26, 2016","Pôle départemental du Centre de Ressources Autisme pour adultes (67) - Etablissement public de santé Alsace-Nord (site de Brumath), Brumath, France|Centre de Ressources Autisme Pôle adultes (68) - Espace Autisme 68, Colmar, France|Clinique Lautréamont, Loos, France|Pôle régional du Centre de Ressources Autisme pour enfants et adolescents - Unité d'évaluation des troubles du développement Hôpital de l'Elsau - Pôle de Psychiatrie - Unité d'évaluation des troubles du développement Hôpital de l'Elsau - HUS, Strasbourg, France|INSERM U666 ; Pôle de Psychiatrie - Service de Psychiatrie Adulte- HUS, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT00914030,NCT00914030,
anrs,NCT00918307,Efficacy and Safety of Varenicline Among HIV-infected Patients,Inter-ACTIV,Completed,No Results Available,HIV Infections|Tobacco Dependence,Drug: Varenicline|Drug: Placebo,Continuous abstinence from smoking from week 9 to week 48 without the use of any other smoking cessation treatments other than trials' treatment|Continuous abstinence from smoking from week 9 to week 12 without the use of any other smoking cessation treatments other than trials' treatment|Change in Lung capacity (FEV1 and FVC) between inclusion and week 48|Frequency of depressive episodes. Diagnosed by a psychiatrist|Change in cardiovascular risk score (Framingham and PROCAM scores) between inclusion and week 48.|Quality of life evaluation (SF-12),"ANRS, Emerging Infectious Diseases|Pfizer",All,"18 Years and older � (Adult, Older Adult)",Phase 3,248,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2008-007948-34|ANRS 144,October 2009,January 2014,July 2014,"June 11, 2009",,"July 29, 2014","CHU de Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT00918307,NCT00918307,34611902;29329763
oui,NCT00942370,Electromyographic (EMG) and Mechanomyographic (MMG) Comparison,EMG-MMG,Completed,No Results Available,Stress Urinary Incontinence,Device: non invasive mechanomyographic device based on a 3 axes accelerometer,"Delay between the detection by mechanomyography (MMG) of rectus abdominis contraction and the detection of cough in cough effort|Lower and upper spectral band frequencies values for which the majority of the MMG signal is present, thresholds for detection of rectus abdominis contraction by mechanical myography","University Hospital, Grenoble",All,"18 Years to 65 Years � (Adult, Older Adult)",,16,Other,Observational,Time Perspective: Prospective,DCIC 0904,July 2009,July 2009,July 2009,"July 20, 2009",,"September 15, 2016","Clinical Investigation Center - INSERM - University Hospital of Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT00942370,NCT00942370,
oui,NCT00957073,Rheos System for the Treatment of HFpEF Heart Failure,HOPE4HF,Completed,No Results Available,Heart Failure,Device: Rheos� system,To ascertain long-term adverse events for subjects implanted with the device.,"CVRx, Inc.",All,"21 Years and older � (Adult, Older Adult)",Not Applicable,19,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,360017-001,August 2009,October 2012,"April 1, 2021","August 12, 2009",,"April 8, 2021","Cardiology Associates of Mobile, Inc., Mobile, Alabama, United States|Apex Cardiology Consultants, Inglewood, California, United States|University of Southern California, Los Angeles, California, United States|St. Francis Hospital and Medical Center, Hartford, Connecticut, United States|Florida Hospital Cardiovascular Institute/Florida Heart Group, Orlando, Florida, United States|Orlando Regional Medical Center, Orlando, Florida, United States|Heart and Vascular Institute of Florida, Saint Petersburg, Florida, United States|Florida Cardiovascular Institute, Tampa, Florida, United States|The Care Group, Indianapolis, Indiana, United States|Iowa Heart Center, West Des Moines, Iowa, United States|Cardiovascular Institute of the South, Houma, Louisiana, United States|Liberty Cardiovascular Specialists, Liberty, Missouri, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester Medical Center, Rochester, New York, United States|Forsyth Cardiovascular Research, Winston-Salem, North Carolina, United States|Lindner Research Center, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Northwest Ohio Cardiology Consultants, Toledo, Ohio, United States|Oklahoma Cardiovascular Research Group, Oklahoma City, Oklahoma, United States|Drexel University, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,https://ClinicalTrials.gov/show/NCT00957073,NCT00957073,21300307
oui,NCT00966628,Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS),,Unknown status,No Results Available,Dengue Shock Syndrome,Drug: Hypertonic sodium lactate|Drug: Ringer's lactate,To assess the effect of solution containing half molar sodium lactate (Totilac�) infusion on the plasma sVCAM-1 level|To assess the effect of solution containing half molar sodium lactate (Totilac�) infusion on other efficacy and safety parameters,Innogene Kalbiotech Pte. Ltd,All,2 Years to 14 Years � (Child),Phase 3,50,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,006/IGK-KAL/08,May 2008,April 2009,December 2009,"August 27, 2009",,"August 28, 2009","Hasan Sadikin Hospital, Dept. of Pediatrics, Bandung, West Java, Indonesia",,https://ClinicalTrials.gov/show/NCT00966628,NCT00966628,25189175
oui,NCT00973570,Smoking Cessation Program Among Adolescents in Vocational Training Centers,TABADO,Unknown status,No Results Available,Tobacco Use,Behavioral: TABADO program,"The primary outcome is the rate of smoking abstinence after 12 months, measured on the basis of the statements of the whole sample, not only among volunteers.|Overall prevalence of tobacco use in the institutions concerned at 12 months.|Students' motivation to quit smoking (motivational score) and frequency of attempts to quit within the 12 months after the intervention|Rate of withdrawal from the program among the volunteers after 12 months.","Institut National de la Sant� Et de la Recherche M�dicale, France|University of Nancy|Central Hospital, Nancy, France",All,"15 Years to 20 Years � (Child, Adult)",Not Applicable,2000,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,C07-43,February 2008,December 2009,December 2009,"September 9, 2009",,"September 9, 2009","CHU Nancy, Nancy, Lorraine, France|CHU Nancy, Nancy, Lorraine, France",,https://ClinicalTrials.gov/show/NCT00973570,NCT00973570,19912627
oui,NCT00977223,Effects of Substance P Antagonists on Adrenal Secretion,APHOS,Completed,No Results Available,Healthy Volunteers,Drug: aprepitant/placebo,"Plasma aldosterone variation during orthostatic test|Basal aldosterone alteration; Aldosterone variation during metoclopramide & hypoglycaemia tests; Basal and stimulated (3 different tests) alterations of renin, cortisol & ACTH","University Hospital, Rouen",Male,18 Years to 30 Years � (Adult),Phase 4,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",2007/049/HP|2008-003367-40,June 2009,April 2010,June 2010,"September 15, 2009",,"February 16, 2012","Rouen Clinical research Centre (CIC 0204), Rouen, Haute Normandie, France",,https://ClinicalTrials.gov/show/NCT00977223,NCT00977223,32471973
oui,NCT00988767,Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B,RBM99026,Completed,No Results Available,Chronic Hepatitis B,Biological: DNA vaccine,Safety and tolerability (local and general) of the DNA vaccine injections|Immunological responses,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,18 Years to 60 Years � (Adult),Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INSERM RBM99.026,February 2001,November 2003,October 2004,"October 2, 2009",,"October 5, 2009","Service d'Hepatologie, Hopital Necker Enfants Malades, Paris, France",,https://ClinicalTrials.gov/show/NCT00988767,NCT00988767,20090916
oui,NCT00993967,Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension),,Completed,Has Results,Freidreich's Ataxia,Drug: idebenone,Measures of Safety and Tolerability: Nature and Frequency of Adverse Events (AEs)|Absolute Change in The International Cooperative Ataxia Rating Scale (ICARS),Santhera Pharmaceuticals,All,"9 Years and older � (Child, Adult, Older Adult)",Phase 3,200,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SNT-III-001-E,June 2007,June 2012,June 2012,"October 14, 2009","March 5, 2018","March 5, 2018","Universit�tsklinik Innsbruck, Innsbruck, Austria|H�pital Erasme - Univerist� Libre de Bruxelles, Bruxelles, Belgium|H�pital de la Salp�tri�re - INSERM U679, Neurologie et Th�rapeutique exp�rimentale, Paris, France|HELIOS Klinikum Berlin, Berlin, Germany|Neurologische Universit�tsklinik und Ploklinik - Universit�tsklimikum Bonn, Bonn, Germany|Klinik II, Neurop�diatrie und Muskelerkrankungen - Universit�tsklinik Freiburg, Freiburg, Germany|Zentrum f�r Neurologische Medizin, G�ttingen, Germany|UKE Hamburg Neurop�diatrie - Zentrum f�r Frauen, Kinder und Jugendmedizin, Hamburg, Germany|Neurologische Klinik - Klinikum Grosshadern, M�nchen, Germany|Neurologische Universit�tsklinik und Poliklinik, T�bingen, Germany|University medical Center Groningen, Groningen, Netherlands",,https://ClinicalTrials.gov/show/NCT00993967,NCT00993967,
oui,NCT01002638,The Occlusive Dressing,,Terminated,No Results Available,Fingertips Traumatic Amputations,Other: TEGADERM�|Procedure: Surgery,the tactile sensibility will be tested by standardized monofilaments,"University Hospital, Strasbourg, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,51,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4436,December 2009,May 2018,July 2018,"October 27, 2009",,"August 28, 2018","University Hospital, Besan�on, France|University Hospital, Bordeaux, France|University Hospital, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT01002638,NCT01002638,
oui,NCT01003873,Gastric Bypass and Peripheral Activity of the Endocannabinoid System,CCENDO,Completed,No Results Available,Obesity,Biological: Evaluation of the endocannabinoid system|Procedure: Biopsy of visceral and peripheral adipose tissue|Biological: Evaluation of metabolic parameters|Behavioral: Evolution of behavioral parameters|Behavioral: Dietician consultation|Behavioral: Psychologist consultation,Plasmatic endocannabinoïd concentration variation|Plasma concentration of the endocannabinoids during food exposure|Post prandial pic of the plasma concentration of the endocannabinoids|Adipose tissue concentration of the endocannabinoids|Plasma concentration of adipokines|Body mass index|Body composition|Insulin sensitivity|Area under the curve of plasma concentration of 2AG|Questionaries scores,"University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),,44,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,CHUBX 2008/19,October 2009,June 2014,June 2014,"October 29, 2009",,"October 16, 2018","Haut Lévêque Hospital, Endocrine department, Pessac, France",,https://ClinicalTrials.gov/show/NCT01003873,NCT01003873,
oui,NCT01007617,Low-energy Laser Therapy for Prevention of Oral Mucositis in Children,,Unknown status,No Results Available,Oral Mucositis,Device: LLLT :low level laser therapy,Mucositis scale - World Health Organization (WHO)|Mucositis period|Mucositis free survival|Pain intensity|Morphinic administration|Duration of hospitalisation|Febrile neutropenia|Duration of parenteral nutrition|Psychological impact,"University Hospital, Clermont-Ferrand|Centre R�gional de Canc�rologie et Th�rapie Cellulaire P�diatrique, CHU de Clermont-Ferrand|Facult� de chirurgie dentaire, Clermont-Ferrand|Centre de Pharmacologie Clinique, INSERM CIC 501|Laboratoire des Mat�riaux Inorganiques, ESA CNRS 6002 et ENSCCF, Universit� Blaise-Pascal, Aubi�re",All,"up to 18 Years � (Child, Adult)",Phase 2|Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",CHU-0060,June 2009,July 2010,July 2010,"November 4, 2009",,"January 19, 2011","CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT01007617,NCT01007617,
oui,NCT01014611,Impact of Heart Failure on Calcium Homeostasis and Mitochondrial Function in Human Skeletal Muscle,Calcicard,Terminated,No Results Available,Heart Failure,,"To evaluate the skeletal muscular function (calcium homeostasis, mitochondrial function and oxidative stress) in two stages of heart failure patients compared to healthy volunteers|To analyse the link between the hypothetical skeletal muscular function in two stages of heart failure and circulating factors such as cytokines and catecholamines|To investigate the effect of exercise training on skeletal muscular hypothetical dysfunction in two stages of heart failure patients","Institut National de la Santé Et de la Recherche Médicale, France|Ministry of Health, France|National Cancer Institute, France|Institut de Recherches Internationales Servier",Male,"35 Years to 65 Years   (Adult, Older Adult)",,3,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C08-23|2008-A00936-49,April 2010,,November 2011,"November 17, 2009",,"September 27, 2012","Centre Hospitalier Régional Universitaire, Montpellier, France",,https://ClinicalTrials.gov/show/NCT01014611,NCT01014611,
oui,NCT01020032,Effect of Music Therapy on Pain,,Completed,No Results Available,Chronic Pain,"Other: Individual receptive music therapy by ""U sequence"" method",Score on a Visual Analogical Scale (VAS) for actual pain|Score on the Hospital Anxiety and Depression (HAD) Scale|Medicinal consumption,Association de Musicoth�rapie Applications et Recherches Cliniques|Centre d'Evaluation et du Traitement de la Douleur CHU Saint-Eloi|Unit� de Recherche Clinique et Epid�miologie (DIM) CHU Arnaud de Villeneuve|Centre M�moire de Ressource et de Recherche �quipe INSERM U888 CHU Montpellier,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,87,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,AMARC 200801,September 2006,November 2008,December 2008,"November 25, 2009",,"November 25, 2009","CHRU Saint Eloi, Centre d'Evaluation et du Traitement de la Douleur, Montpellier, France",,https://ClinicalTrials.gov/show/NCT01020032,NCT01020032,
oui,NCT01020682,"Apathy in Parkinson Disease: Clinical, Physiopathological and Pharmacological Study",,Unknown status,No Results Available,Apathy in Parkinson Disease,,,"University Hospital, Grenoble|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",,120,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APATHIE,January 2005,February 2006,June 2011,"November 25, 2009",,"November 25, 2009","Hopital neurologique, Lyon, France",,https://ClinicalTrials.gov/show/NCT01020682,NCT01020682,
anrs,NCT01022476,Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients,LIVERAL,Completed,No Results Available,HIV Infection|Liver Failure|Evidence of Liver Transplantation,Drug: Raltegravir potassium,"Pharmacokinetic parameters of raltegravir in patients with severe liver dysfunction and after a liver transplantation when combined to immunosuppressive therapy. Pharmacokinetic parameters of immunosuppressive drugs with or without raltegravir|To assess the maintenance of the virological efficacy on HIV of raltegravir combined with two fully active molecules among NRTI (or NRTI + enfuvirtide). Follow-up over a 3-months period before and after transplantation|To assess the safety of raltegravir before transplantation in patients with impaired liver function, and after transplantation in combination with immunosuppressive treatment|To describe the clinical outcome of patients (such as the onset of opportunistic infections, relapse of HCV infection, morphological and metabolic disorders outcomes)|To describe the changes in liver function (evaluation of liver function during treatment) before and after liver transplantation","ANRS, Emerging Infectious Diseases|Merck Sharp & Dohme LLC",All,"18 Years and older � (Adult, Older Adult)",Phase 1|Phase 2,14,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-014616-36|ANRS 148 LIVERAL,May 2010,May 2013,May 2013,"December 1, 2009",,"July 18, 2013","Service de M�decine Interne, H�pital de Bic�tre, LE KREMLIN-BICETRE cedex, France",,https://ClinicalTrials.gov/show/NCT01022476,NCT01022476,
oui,NCT01022515,Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma,PHEO,Completed,No Results Available,Pheochromocytoma|Paraganglioma|Essential Hypertension,Other: plasma EM66 & CgA levels assessment|Other: usual follow up with regular EM66 & Cga levels assessment,Plasma EM66|Plasma Chromogranin A levels,"University Hospital, Rouen|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years to 90 Years � (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2007/081/HP|2007-AO1004-49,November 2008,December 2013,December 2013,"December 1, 2009",,"June 19, 2014","CIC 9301, Lille, France|Endocrinology Department, Lille, France|Inserm U982/EA 4310; Rouen University (DC2N), Mont Saint Aignan, France|Cardiology Department, Paris, France|CIC 9304, Paris, France|Cic-Crb 0204, Rouen, France|Endocrinology Department, Rouen, France|Endocrinology Department, Gustave-Roussy Institute, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01022515,NCT01022515,
oui,NCT01022749,Efficacy Safety Study of Flu Vaccine in Immunodepression Patients,MICIVAX,Completed,No Results Available,Inflammatory Bowel Disease (IBD),Drug: Vaccine|Biological: Vaccine anti-H1N1,"Seroconversion rate|Seroconversion factor|Seroprotection rate against the three vaccine strains|Seroprotection rate in the general population|Seroconversion rate, geometric mean titers ratio before and after vaccination by haemagglutination inhibition assay|Comparison of seroprotection rates for each of the three vaccine strains obtained in each of three groups|Comparison of seroconversion factors obtained after 1 or 2 vaccinations in each of three groups of inflammatory bowel disease (IBD) and in the entire population|Number of influenza episodes and confirmed flu during each influenza peak season|Occurrence of medical visits, emergency room visits, hospital admissions and deaths throughout the course of the study|Occurrence and intensity of local and general adverse events within 5 days after vaccine administration|Search of the determining factors to the influenza vaccine response|Sub-immunological study","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|University of Paris 5 - Rene Descartes|Pierre and Marie Curie University|Institut Pasteur",All,18 Years to 64 Years   (Adult),Phase 3,228,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P 070165,September 2009,July 2011,July 2013,"December 1, 2009",,"August 5, 2013","CIC Vaccinologie Hopital Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT01022749,NCT01022749,26351392
oui,NCT01024049,Identification Of Blood Markers For Asymptomatic Ventricular Dysfunction,IBLOMAVED,Unknown status,No Results Available,Heart Failure,,,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 80 Years   (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Case-Control,C06-15,July 2007,December 2012,December 2012,"December 2, 2009",,"January 31, 2012","Hospital from Toulouse Rangueil, Pr Galinier department (Cardiology A), Toulouse, Midi-Pyrénées, France",,https://ClinicalTrials.gov/show/NCT01024049,NCT01024049,25786035
oui,NCT01024400,Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women,PREFLUVAC,Completed,No Results Available,Influenza,Biological: Non-adjuvanted A(H1N1)v influenza vaccine,"Immunogenicity: proportion of subjects achieving a serum HAI antibody titer of greater than or equal to 1:40, proportion of subjects with 4-fold or greater HAI antibody titer increases against H1N1 2009 virus following H1N1 vaccine.|Safety: occurence of local and systemic adverse events|Safety:occurence of vaccine-associated serious adverse events","Institut National de la Santé Et de la Recherche Médicale, France|MCM Vaccines B.V.",Female,18 Years to 45 Years   (Adult),Phase 2,110,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,C09-33|2009-016660-36,November 2009,January 2010,July 2010,"December 2, 2009",,"January 2, 2012","CHU de Besançon-Hôpital Saint-Jacques, Besançon, France|Hôpital Antoine Béclère, Clamart, France|Groupe hospitalier Cochin Saint Vincent de Paul, Paris, France|Hôpital Robert Debré, Paris, France|Hôpital Sud de Rennes, Rennes, France",,https://ClinicalTrials.gov/show/NCT01024400,NCT01024400,22147712
anrs,NCT01033760,Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM),,Completed,No Results Available,HIV-1 Infections,Drug: raltegravir,"maraviroc  darunavir  ritonavir  tenofovir/emtricitabine|Drug: darunavir  emtricitabine/tenofovir To compare the 24-month impact of maximized vs. conventional HAART- on HIV reservoirs, as assessed by cell-associated HIV-DNA levels, in patients with acute or primary HIV-1 infection|Plasma HIV-RNA levels and proportion of patients with plasma viral load < 50 copies/ml at M12, M24 and M30|Plasma HIV-RNA levels and proportion of patients with plasma viral load < 5 copies/ml at M24|Changes in cell-associated HIV-DNA between baseline and M24|Evolution of the CD4 and CD8 between D0 and M24|Tolerability of trial treatments|Number and type of ARV mutations in virological failures and change in CCR5 tropism","ANRS, Emerging Infectious Diseases|Gilead Sciences|Merck Sharp & Dohme LLC|Pfizer|Janssen-Cilag Ltd.",All,"18 Years and older � (Adult, Older Adult)",Phase 3,90,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-014742-28|EudraCT,April 2010,July 2013,December 2013,"December 16, 2009",,"February 5, 2014","H�pital Gustave Dron, Tourcoing, France",,https://ClinicalTrials.gov/show/NCT01033760,NCT01033760,28708873;25701561
oui,NCT01037777,"RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7",RISCA,Completed,No Results Available,Spinocerebellar Ataxias,,,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",,37,Other,Observational,Observational Model: Family-Based|Time Perspective: Prospective,C08-37,"May 7, 2009",December 2017,"December 14, 2017","December 23, 2009",,"August 30, 2021","Pitié Salpêtrière Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01037777,NCT01037777,35264424;32822634;24780882;23707147
oui,NCT01038284,Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH),ETHAP,Completed,No Results Available,"Hypertension, Pulmonary",Behavioral: Patient education|Other: Data collection,Medication-related problems|Patient Satisfaction with medication,"University Hospital, Grenoble",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,101,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor),DCIC 09 12,March 2010,February 2014,February 2014,"December 23, 2009",,"March 17, 2014","CHU Bordeaux, Bordeaux, France|CHU Brest, Brest, France|Hopital Antoine Beclere, Clamart, France|Clinical Research Center Inserm CIC03 - Grenoble University Hospital, Grenoble, France|CHU Grenoble, Grenoble, France|CHU de Lille, Lille, France|CHU Nantes, Nantes, France|CHU de Nice, Nice, France|CHU Rouen, Rouen, France|CHU Strasbourg, Strasbourg, France|CHU Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT01038284,NCT01038284,32440738
oui,NCT01038700,Circulating Endothelial Compartment During Normal and Pathological Aging,VIMOPEIL,Completed,No Results Available,Healthy,,"Analyse of CEC, EMP and EPC at different ages of lifespan both in physiological state and in response to an hypoxia- induced vascular stress|Transcriptome analysis on EPC isolated from cord blood and peripheral blood from young and old adults","Assistance Publique - Hôpitaux de Paris|Fondation pour la Recherche Médicale|Assistance Publique Hopitaux De Marseille|Institut National de la Santé Et de la Recherche Médicale, France",Male,"10 Years to 90 Years   (Child, Adult, Older Adult)",,84,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,P070801,December 2008,August 2009,September 2010,"December 24, 2009",,"October 1, 2015","Hegp- Cic, Paris, France",,https://ClinicalTrials.gov/show/NCT01038700,NCT01038700,24105925;22284809
anrs,NCT01038999,"Accelerated Aging, HIV Infection, Antiretroviral Therapies",EP 45,Completed,No Results Available,HIV Infection|Aging Accelerated|Antiretroviral Therapies,Biological: Peripheral blood biological tests,"lamin A measurement by western blotting|Peripheral blood biological tests (cellular, molecular genetic)","French National Agency for Research on AIDS and Viral Hepatitis|ANRS, Emerging Infectious Diseases",All,"18 Years to 65 Years � (Adult, Older Adult)",,200,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,2008-A00905-50,April 2009,April 2010,March 2012,"December 24, 2009",,"December 27, 2012","ANRS center from Marseille, Timone and Montpellier and Nice, country of French, France",,https://ClinicalTrials.gov/show/NCT01038999,NCT01038999,23285253;22829920
oui,NCT01039220,Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients,ANRS 2H,Completed,No Results Available,HIV Infections|Influenza,Biological: naso-pharyngeal swab,Serious forms (see definition above) identified by any clinical site or hospitalisation unit-Controls: Patients of the randomly selected sample (see survey sampling).|Exhaustivity check: The exhaustivity of symptomatic forms will be assessed a posteriori by merging information from all available data sources.,"French National Agency for Research on AIDS and Viral Hepatitis|ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,1266,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2009-AO1115-52,December 2009,November 2010,November 2010,"December 24, 2009",,"April 28, 2017","34 ANRS center, Paris + region of country, France",,https://ClinicalTrials.gov/show/NCT01039220,NCT01039220,
oui,NCT01040715,Immunogenicity and Safety of TNFa Kinoid in Rheumatoid Arthritis With Secondary Resistance to TNFa Antagonists,,Completed,No Results Available,Rheumatoid Arthritis,Biological: TNFa Kinoid|Biological: TNF kinoid,Proportion of patients with at least a 3-fold increase in antibody response to TNFa vs baseline at day 38|Proportion of patients with a decrease of at least 1.2 in DAS28 at month 3 vs baseline,Neovacs,All,"18 Years to 70 Years � (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TNF-K-003|2009-012041-35,December 2009,October 2012,September 2013,"December 30, 2009",,"September 18, 2014","Centro especializado en Investigaciones Medicas (CEIM), Buenos Aires, Argentina|Hospital Sirio Libanes, Buenos Aires, Argentina|Hospital Italiano de Cordoba, Cordoba, Argentina|Centro de Investigaciones Reumatologicas, San Miguel de Tucum�n, Argentina|Centro M�dico Privado de Reumatolog�a, San Miguel de Tucum�n, Argentina|Cliniques Universitaires Saint Luc, Brussels, Belgium|Universiteit ZiekenHuis Katholiek Universiteit Leuven, Leuven, Belgium|Universitaires Cliniques St. Luc (Mont-Godinne), Mont-Godinne, Belgium|Diagnostic and Consulting Center SV, Plovdiv, Bulgaria|Military Medical Academy, Sofia, Bulgaria|National Multiprofile Transport Hospital ""Tzar Boris III"", Sofia, Bulgaria|University Hospital for Active Treatment ""Sveti Ivan Rilski"", Sofia, Bulgaria|MBAL University Stara Zagora, Stara Zagora, Bulgaria|Medical Center ""Chaika"" Ltd, Varna, Bulgaria|""Sociedad M�dica del Aparato Locomotor SA"", Santiago de Chile, Chile|Centro de Estudios Reumatol�gicos- Estudios Cl�nicos Limitada"", Santiago de Chile, Chile|General Hospital Karlovac, Karlovac, Croatia|Thalassotherapia, Opatija, Croatia|KBC Split, Split, Croatia|Clinical Hospital ""Sveti Duh"", Zagreb, Croatia|University Hospital Sisters of Mercy, Zagreb, Croatia|CHU Avicenne, Bobigny, France|Hopital Pellegrin, Bordeaux, France|H�pital Ambroise Par�, Boulogne Billancourt, France|H�pital Bic�tre, Universit� Paris-Sud 11, INSERM U802, Le Kremlin Bic�tre, France|C.H.U. H�pital Roger Salengro, Lille, France|H�pital Lapeyronie, Montpellier, France|H�pital Xavier Bichat, Paris, France|Hopital La Pitie Salpetriere, Paris, France|Hopital Lariboisi�re, Paris, France|CHU Strasbourg-Hautepierre, Strasbourg, France|""Dr. Constantin Opris"" Emergency County Hospital Baia Mare, Baia Mare, Romania|""Dr. I Cantacuzino"" Clinical Hospital, Bucharest, Romania|Ianuli Med Consult SRL, Bucharest, Romania|Rehabilitation Clinical Hospital Iasi, Iasi, Romania",,https://ClinicalTrials.gov/show/NCT01040715,NCT01040715,25517733
oui,NCT01041469,Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome,IMMUTRI,Completed,No Results Available,Down Syndrome With and Without Auto Immune Abnormalities,,Auto-antibodies dosage|specific lymphocytes populations count,Institut Jerome Lejeune|Fondation J�r�me Lejeune,All,"8 Years to 36 Years � (Child, Adult)",,72,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,IJL-IMM-EP10,November 2009,,December 2010,"December 31, 2009",,"March 22, 2012","Institut Jerome Lejeune, Paris, France|Laboratoire d'Immunologie Biologique (Unit� INSERM U580), Paris, France",,https://ClinicalTrials.gov/show/NCT01041469,NCT01041469,
oui,NCT01043549,Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome,rTMSPPCGT,Terminated,No Results Available,Gilles de la Tourette Syndrome|Tics,Device: rTMS|Device: Sham rTMS,Yale global tic severity scale (YTGSS),"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years to 70 Years � (Adult, Older Adult)",Phase 2,5,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",C08-46|2009-A00759-48,February 2010,September 2012,September 2012,"January 6, 2010",,"February 25, 2016","Inserm U975, Paris, France",,https://ClinicalTrials.gov/show/NCT01043549,NCT01043549,
oui,NCT01044082,Prevention of Post-partum Haemorrhage,TRACOR,Completed,No Results Available,Postpartum Haemorrhage|Immediate Postpartum Hemorrhage,Procedure: controlled cord traction|Procedure: Clinical signs of placental separation,"Incidence of postpartum haemorrhage, defined as a measured postpartum blood loss greater than 500 mL|Severe postpartum haemorrhage, defined as a measured postpartum blood loss greater than 1000mL|Measured postpartum blood loss at 30 minutes after delivery|Total measured postpartum blood loss|Curative postpartum uterotonic treatment|Postpartum transfusion|Postpartum embolization or surgery for haemorrhage|Peripartum haemoglobin delta|Peripartum haematocrit delta|Duration of third stage of labour|Deliveries with manual removal of placenta|Potential adverse events: uterine inversion, cord rupture, pain during third stage of labour|Woman's satisfaction","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,4382,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,P081206|AOM09161,January 2010,January 2011,March 2012,"January 7, 2010",,"July 26, 2012","Maternité de Port-Royal, Paris, France",,https://ClinicalTrials.gov/show/NCT01044082,NCT01044082,23538918
oui,NCT01046448,The Cardiovascular Comorbidity in Children With Chronic Kidney Disease Study,4C,Unknown status,No Results Available,Chronic Kidney Disease|Pediatric|Cardiovascular Disease,,"Functional and morphological evidence of cardiovascular disease progression (arterial stiffness, myocardial dysfunction, cIMT, LVMI) and association with clinical, anamnestic, anthropometric, biochemical, drug-related and genetic risk factors|Genetic risk factors for early manifesting progressive vascular lesions and progressive kidney disease by the genome-wide SNP-screening and haplotype analysis.",Heidelberg University|KfH Foundation for Preventive Medicine|German Federal Ministry of Education and Research,All,6 Years to 17 Years � (Child),,650,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,S-32/2009,July 2009,April 2014,April 2014,"January 12, 2010",,"January 12, 2010","Medical University of Vienna, Vienna, Austria|UZ Gent, Gent, Belgium|University Hospital Motol, Prague, Czech Republic|Service de P�diatrie & Inserm U820, Lyon, France|H�pital de Hautepierre, Strasbourg, France|Charit� Children's Hospital, Berlin, Germany|University Children's Hospital, Cologne, Germany|University Children's Hospital, Erlangen, Germany|University Children's Hospital, Essen, Germany|Center for Pediatrics and Adolescent Medicine, Freiburg, Germany|UKE University Children's Hospital, Hamburg, Germany|Hannover Medical School, Hannover, Germany|Center for Pediatrics and Adolescent Medicine, Heidelberg, Germany|City Hospital St. Georg, Leipzig, Germany|KfH Kidney Center for Children, Marburg, Germany|University Children's Hospital, M�nster, Germany|Children's Hospital, Rostock, Germany|Semmelweis University, Budapest, Hungary|S. Orsola-Malphighi Hospital, Bologna, Italy|Istituto Giannina Gaslini, Genova, Italy|Fondazione OSP Maggiore Policlinico, Milano, Italy|University of Padova, Padova, Italy|Bambino Gesu, Rome, Italy|Regina Margherita Children's Hospital, Torino, Italy|Vilnius University Children's Hospital, Vilnius, Lithuania|Medical University Gdansk, Gdansk, Poland|University Children's Hospital, Krakow, Poland|Clinic of Pediatrics, Szczecin, Poland|Children's Memorial Health Institute, Warsaw, Poland|Hospital Sao Joao, Porto, Portugal|University Children's Hospital, Belgrade, Serbia|Karolinska University Hospital, Stockholm, Sweden|Inselspital, Bern, Switzerland|University Children's Hospital, Zurich, Switzerland|Cukurova Universitesi, Adana, Turkey|Ankara University of Medicine, Ankara, Turkey|Hacettepe Medical Faculty, Ankara, Turkey|Gazi University Hospital, Ankara, Turkey|Baskent University, Faculty of Medicine, Ankara, Turkey|Diskapi Childrens Hospital, Ankara, Turkey|Sami Ulus Childrens Hospital, Ankara, Turkey|Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Istanbul Medical Faculty, Istanbul, Turkey|Bakirkoy Children's Hospital, Istanbul, Turkey|Goztepe Educational and Research Hospital, Istanbul, Turkey|Haseki Educational and Research Hospital, Istanbul, Turkey|Marmara University Medical Faculty, Istanbul, Turkey|Sisli Educational and Research Hospital, Istanbul, Turkey|Ege University, Izmir, Turkey|Great Ormond Street Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01046448,NCT01046448,37119829
oui,NCT01050491,Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma,Sitax,Terminated,No Results Available,Effect of Sitaxsentan on Airway Remodeling in Severe Asthma,Drug: sitaxentan|Drug: placebo,"Changes in airway remodeling analyzed on bronchial biopsy specimens at inclusion and after one year by immunohistochemistry and morphometry (smooth muscle area, and submucosal fibroblasts count).|FEV1,clinical status, asthma exacerbations, steroids use, need for emergency care, asthma symptoms and quality of life,exhaled NO and induced sputum cytology.","Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years to 75 Years � (Adult, Older Adult)",Phase 2,17,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C07-25,November 2009,December 2010,December 2010,"January 15, 2010",,"May 10, 2012","Clinical Investigation center 07, Hopital Bichat, Paris, France",,https://ClinicalTrials.gov/show/NCT01050491,NCT01050491,
anrs,NCT01055873,Immunology of the Infection Perinatal,EP38,Completed,No Results Available,HIV Infections,Biological: A single blood sample (30 mL),"To describe the immune and virological status of perinatally infected patients that are above 15 yrs old and|To study their associations with the current virological/clinical and therapeutic status, the duration of uncontrolled viremia (defined by treatment history), the virological, immunological (CD4+ numbers), and clinical status",French National Agency for Research on AIDS and Viral Hepatitis|Institut Pasteur|University of Paris 5 - Rene Descartes|H�pital Necker-Enfants Malades,All,"15 Years and older � (Child, Adult, Older Adult)",,93,Other|Industry,Observational,,2006-AO142-49,February 2007,February 2009,February 2009,"January 26, 2010",,"November 18, 2010",,,https://ClinicalTrials.gov/show/NCT01055873,NCT01055873,22427678
oui,NCT01061827,Validation of the French Version of the Geriatric Mental State (GMS),GMS-Package,Completed,No Results Available,Validate the French Version of GMS Package,,"Diagnostic of dementia and depression|Interjudge concordance for discrimination on control,depression and dementia patients","University Hospital, Tours|Institut National de la Santé Et de la Recherche Médicale, France",All,65 Years and older   (Older Adult),,96,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,AOHP/04/VC-GMS,June 2008,June 2008,November 2013,"February 3, 2010",,"January 16, 2017","CHU-Limoges- CMRR, Limoges, Limouzin, France|University Hospital, Tours, France",,https://ClinicalTrials.gov/show/NCT01061827,NCT01061827,
oui,NCT01061853,Efficacy of Topical Rapamycin to Treat Chronic Erosive Oral Lichen,RALIB,Terminated,No Results Available,Oral Lichen Planus,Drug: TOPICAL SIROLIMUS (RAPAMUNE*)|Drug: TOPICAL BETAMETHASONE 0.05%,COMPLETE CLEARING OF ORAL EROSIVE LESIONS|REGRESSION OF EROSIVE SURFACE AREA,"University Hospital, Tours|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,76,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PHRN06-LV/RALIB|2007-000152-14,February 2008,November 2012,November 2012,"February 3, 2010",,"October 16, 2013","University Hospital of REIMS, Reims, Marne, France|Hospital Avicenne-APHP, Bobigny, France|University Hospital of Bordeaux-St.André, Bordeaux, France|University Hospital of Lille, Lille, France|University Hospital of Nice, Nice, France|Hospital Saint Louis-APHP, Paris, France|Hospital La Pitié-Salpêtrière APHP, Paris, France|Hospital Tenon-APHP, Paris, France|University hospital of Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT01061853,NCT01061853,
oui,NCT01062373,Effect of Docosahexaenoic Acid (DHA)-Enriched Human Milk in Premature Newborns,DHARMA,Terminated,No Results Available,Premature,Dietary Supplement: Supplementation of lactating mothers who has delivered prematurely with DHA,To improve PUFA status in premature newborns|PUFA in human milk (HM) and mothers|Impact on HM bioactives|Change in inflammation and oxydative stress|Genes expression in newborns|Link between mothers genetics and HM DHA level|Newborn survey at 6 month-old,"Institut National de la Santé Et de la Recherche Médicale, France",All,"1 Day to 40 Years   (Child, Adult)",Not Applicable,2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C08-20|2009-A00006-51,February 2010,June 2012,June 2012,"February 4, 2010",,"September 27, 2012","Service de Médecine néonatale, Hôpital de la Conception, Marseille Cedex 05, France",,https://ClinicalTrials.gov/show/NCT01062373,NCT01062373,
oui,NCT01063608,Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.,FLU-HOP,Unknown status,No Results Available,"Influenza A Virus, H1N1 Subtype",Biological: Anti-H1N1v Vaccine,"Evaluation of the intensity of the humoral and cellular immune responses of the anti-A(H1N1)v vaccine in a medical care population as a function of the age and of the prior seasonal anti-influenza vaccinations.|Investigate the quality of the humoral and cellular immune responses induced by the seasonal anti-influenza vaccine as a function of the age and of the prior seasonal vaccinations.|Determine the cross-reactivity of the humoral and cellular immune responses as a function of the age and of the prior seasonal vaccinations|Assess the tolerance to the seasonal and pandemic vaccines|Assess the occurence of flu episodes and their severity during the 2009-2010 season as a function of the age of the population. Then, the correlation between the flu episodes and and the immunologic results is to be evaluated.|Evaluate the perception of the anti-influenza vaccination in a medical care population in the current H1N1v pandemy context.","Institut National de la Santé Et de la Recherche Médicale, France",All,"20 Years and older   (Adult, Older Adult)",Phase 4,147,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,FLU-HOP,October 2009,February 2011,February 2011,"February 5, 2010",,"March 16, 2010","Hopital Pitie Salpetriere, Paris, Ile de France, France|Centre d'Investigations Cliniques (CIC), Hopital Cochin, Paris, Ile de france, France",,https://ClinicalTrials.gov/show/NCT01063608,NCT01063608,
oui,NCT01064427,Factors Correlated With Fatigue in Breast Cancer,FATSEIN,Unknown status,No Results Available,Newly Diagnosed Breast Cancer|Surgery Programmed,,"The Multidimensional Fatigue Inventory (MFI-20) questionnaire is used to assess patient's fatigue.|Questionnaires regarding personality traits (LOT ""Life Orientation Test"" and the trait-version of the STAI ""State Trait Anxiety instrument""), Quality of life questionnaire(EORTC QLQ-C30), and the state-version of the STAI will be also completed.","Central Hospital, Nancy, France",Female,"18 Years to 80 Years � (Adult, Older Adult)",,557,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,08-FATQV,July 2008,September 2012,September 2012,"February 8, 2010",,"February 8, 2010","Centre Alexis Vautrin, Vandoeuvre-les-Nancy, Meurthe et Moselle, France|Centre Georges Fran�ois Leclerc, Dijon, France|Centre Paul Strauss, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT01064427,NCT01064427,21078419
oui,NCT01070004,Effect of Countermeasures on Nocturnal Driving Performance,KILLSLEEP,Completed,No Results Available,Sleepiness,Other: Real driving situation|Other: Driving simulator,"Number of inappropriate line crossings identified from video recordings|Standard deviation of the position of the car identified from the video recordings|Self-rated sleepiness during driving|Self-rated fatigue during driving|Sleep latency during subsequent sleep|sleep efficiency during the subsequent sleep|Time course of EEG slow wave activity during subsequent sleep|Saliva cortisol and amylase concentration|Caffeine sensitivity|Reaction time and percentage of errors at cognitive tests|PER3, COMT, ADORA2A and ADA polymorphism|Habitual sleep patterns|Chronotype","University Hospital, Bordeaux|ERANET|INSERM ERI27 Mobilit�s Cognition et Temporalit�|Hotel Dieu Hospital|IMF, CNRS UMR-5231",Male,20 Years to 50 Years � (Adult),Not Applicable,72,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CHUBX 2009/14,January 2010,August 2011,August 2011,"February 17, 2010",,"June 14, 2012","CHU de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France|Universit� de Caen Basse Normandie, Caen, France",,https://ClinicalTrials.gov/show/NCT01070004,NCT01070004,23094031
oui,NCT01072734,Auto-immunity in Lupus Patients After Influenza Vaccine,GRIPLUP,Completed,No Results Available,Systemic Lupus Erythematosus (SLE),Drug: Vaccine,"The expression of CXCR4 on B cells, T cells, monocytes and granulocytes by FACS on LES patients will be measured the day of the vaccination and then 7 and 30 days post-vaccination|The biological signs of autoimmunity will be followed using the routine laboratory tests such as the complement exploration and the detection of total anti-nuclear antibodies detection","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 2,28,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P090104,September 2009,January 2010,February 2010,"February 22, 2010",,"October 13, 2010","CIC Vaccinologie Hopital Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT01072734,NCT01072734,23764537
oui,NCT01075061,"Study of a Large Family With Congenital Mirror Movements : From Underlying Pathophysiology to Culprit Gene Identification PROJET "" MOMIC """,MOMIC,Completed,No Results Available,Healthy,Other: healthy volunteers|Other: Kallmann|Other: Congenital Mirror Movement,- To unravel the pathophysiology of congenital mirror movements - To identify a locus and candidate genes associated with CMM|- To study patients with Kallmann syndrome and associated MM based on the same methods and hypothesis,"Institut National de la Santé Et de la Recherche Médicale, France",All,"11 Years to 82 Years   (Child, Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C09-06|2009-A00490-57,February 2010,July 2011,July 2011,"February 24, 2010",,"February 24, 2016","Fédération des Maladies du Système Nerveux, Hôpital Pitié Salpétrière, Paris, France",,https://ClinicalTrials.gov/show/NCT01075061,NCT01075061,
oui,NCT01082484,Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers,INFLUX-IT-VS,Completed,No Results Available,Healthy,Drug: treprostinil|Drug: iloprost|Drug: NaCl 0.9%,Amplitude of forearm cutaneous vasodilatation assessed using laser Doppler imaging|Local tolerance assessed clinically,"University Hospital, Grenoble",All,"18 Years and older � (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-016301-42,January 2010,January 2011,January 2011,"March 8, 2010",,"October 6, 2011","Unit� de Pharmacologie Clinique, Inserm CIC3, CHU Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT01082484,NCT01082484,23400744
oui,NCT01084343,Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects,,Completed,No Results Available,HIV-1,Biological: MYM-V101,Adverse events (local and systemic)|Humoral immune response (in blood),"Mymetics Corporation|Kinesis Pharma B.V.|CEVAC|M.A.R.C.O.|Mouton's Safety Consultancy|Pharmafour|Pevion|Chimera|Institut Cochin|San Raffaele University Hospital, Italy|INSERM UMR 721",Female,18 Years to 45 Years � (Adult),Phase 1,24,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",MYM-V101-CT08-101|2008-007306-10,November 2009,September 2010,September 2010,"March 10, 2010",,"July 13, 2012","CEVAC, Ghent, Belgium",,https://ClinicalTrials.gov/show/NCT01084343,NCT01084343,23437055
oui,NCT01085227,"Clinical, Molecular and by Neuroimaging of LRRK2 Mutations",LRRK2,Unknown status,No Results Available,Parkinson's Disease,,,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Family-Based|Time Perspective: Prospective,C06-16.1|2007-A00169-44,April 2008,,,"March 11, 2010",,"September 27, 2012","CEA - Service Hospitalier Frédéric Joliot, Orsay, France|Pitie-Salpetriere Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01085227,NCT01085227,
oui,NCT01085253,"Nucleipark:High Field MR Imaging (7T and 3T) of the Brainstem, the Deep Nuclei and Their Connections in the Parkinsonian Syndromes. Applications to Prognosis, Pathophysiology and Improvement of Therapeutic Strategies",Nucleipark,Unknown status,No Results Available,Parkinson's Disease|MRI,Other: 3T and 7T MR imaging,,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",,85,Other,Observational,Time Perspective: Prospective,C09-15|2009-A00922-55,April 2010,,,"March 11, 2010",,"September 28, 2012","Salpetriere Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01085253,NCT01085253,
oui,NCT01086904,Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients,Transfluvac,Completed,No Results Available,Renal Transplant Recipients|Immunosuppression,Biological: inactivated non adjuvanted pandemic H1N1 vaccine,Specific humoral response 21 days after each administration Seroprotection and seroconversion rates|Seroprotection and seroconversion rates at day 182 Percentage of patients with anti-H1N1v Antibodies >1/40e at day 182  Assessment of cellular immune response against Influenza A H1N1  Number of undesired events and of Influenza A cases  Effect of vacc,"Institut National de la Santé Et de la Recherche Médicale, France|MCM Vaccines B.V.",All,18 Years to 60 Years   (Adult),Phase 2,120,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,C09-32|2009-016659-23,November 2009,January 2010,May 2010,"March 15, 2010",,"January 2, 2012","Centre hospitalier Lyon Sud, service de néphrologie transplantation, Pierre-Bénite cedex, Lyon, France|Hôpital E. Herriot , Service de néphrologie, transplantation et immunologie clinique, Lyon cedex 3, France|Service d'urologie, GH Pitié Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT01086904,NCT01086904,
oui,NCT01087047,Upper Airways in Pregnancy: Evaluation by the Acoustic Reflection Method,MAVAG,Completed,No Results Available,Pregnancy,Device: Acoustic reflection method,Physiological modifications during pregnancy and acoustic reflection method|MRI and acoustic reflection method,"Club d'Anesthésie-Réanimation Pédiatrique Armand Trousseau|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,MAVAG,March 2010,March 2012,March 2012,"March 15, 2010",,"June 12, 2012","Armand Trousseau University Hospital, Paris, France|Hôpital d'Enfants Armand Trousseau, Paris, France",,https://ClinicalTrials.gov/show/NCT01087047,NCT01087047,
oui,NCT01089387,Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction,INSTIN,Completed,No Results Available,Prostate Cancer|Erectile Dysfunction,Biological: injection of bone marrow mononucleated cells,"Absence of serious adverse event (general or local)|Recovery of natural erection, improvement of penile doppler parameters","Institut National de la Santé Et de la Recherche Médicale, France",Male,"45 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BT06-07|2008-A01248-47,May 2010,May 2012,March 2015,"March 18, 2010",,"November 18, 2016","CHU Henri Mondor-Albert Chenevier-Centre Intercommunal de Créteil, Créteil, France",,https://ClinicalTrials.gov/show/NCT01089387,NCT01089387,28753830;26439886;25974235
oui,NCT01089400,Immuno-virological Characterization of Severe H1N1v Influenza Infection in Bronchoalveolar Lavage,FluBAL,Completed,No Results Available,Influenza|Acute Lung Injury|Acute Respiratory Distress Syndrome,,"immunological parameters in blood and bronchoalveolar lavage fluid|virological parameters in nose, broncho-alveolar lavage and peripheral blood","Institut National de la Santé Et de la Recherche Médicale, France|Assistance Publique - Hôpitaux de Paris|Institut Pasteur",All,"13 Years and older   (Child, Adult, Older Adult)",,30,Other|Industry,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C09-39,October 2009,,April 2011,"March 18, 2010",,"January 31, 2012","Pitie-Salpetrière Hospital, Paris, France|Tenon Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01089400,NCT01089400,24646009
oui,NCT01090934,Localizing the Epileptogenic Zone With High Resolution Electroencephalography,EEG-HR,Completed,No Results Available,Partial Epilepsy,Device: High Resolution EEG|Device: Stereo-electroencephalography,Sensitivity and specificity of electrical source localization of inter-ictal and ictal discharges using high-Resolution EEG for localizing the epileptogenic zone (the stereo-electroencephalography will be the reference method)|inter-observer reliability of electrical source localization of inter-ictal and ictal discharges for localizing the epileptogenic zone.|sensitivity and specificity of high resolution EEG and electrical source imaging for surgical decision,"Central Hospital, Nancy, France|University Hospital, Marseille|CHU de Reims|Centre National de la Recherche Scientifique, France|Institut National de la Santé Et de la Recherche Médicale, France",All,"15 Years and older   (Child, Adult, Older Adult)",Not Applicable,115,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2009-A00574-53,October 2009,October 2013,November 2013,"March 23, 2010",,"January 27, 2016","University Hospital of Marseille, Marseille, France|Central Hospital, Nancy, France",,https://ClinicalTrials.gov/show/NCT01090934,NCT01090934,
oui,NCT01093378,Diet and Its Relationship With Couple Infertility,ALIFERT,Completed,No Results Available,Infertility,,"Evaluate the nutritional status of fertile and infertile couples (food questionnaire - biologic, anthropometric and clinical balance).|Impact of genetic polymorphism on clinical and biological phenotypes linked to food behaviour in infertility context (MTHFR polymorphism for folates metabolism)|Impact of lifestyle (alcohol and tabacco consumption, physical activity, anxiety and sleep) on diet and fertility|Impact of nutritional status on fertility and ART parameters|Fertility : time to pregnancy (TTP)|Male infertility : quantitative or qualitative semen abnormalities|Pregnancy and obstetrical pathologies, prematurity, twin birth, weight of the new-born in infertile couples|ART parameters, if appropriate","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|University Paris 7 - Denis Diderot",All,18 Years to 45 Years   (Adult),,400,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,P071224,October 2009,October 2013,June 2015,"March 25, 2010",,"August 31, 2015","Laboratoire d'Histologie- Embryologie - Cytogénétique - CECOS, Bondy, France",,https://ClinicalTrials.gov/show/NCT01093378,NCT01093378,34907216;33781087;31309911;31304019;25552408;24444339
oui,NCT01094899,Abnormal Structure and Bone Density in Diabetes,,Completed,No Results Available,Type 1 Diabetes|Type 2 Diabetes,Radiation: Radiography|Other: Urine and Blood sampling|Other: Echography,"evaluate the MicroScanner, alterations quantitative and qualitative bone in the foot in patients with type 1 diabetes 2 with or without neuropathy|correlation involving bone and extension of neuropathy Assessment criteria associated with biological abnormalities qualitative and quantitative bone in diabetic subjects","Institut National de la Santé Et de la Recherche Médicale, France",Male,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,79,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C08-25|2008-A00937-48,"March 10, 2010",July 2014,"July 10, 2014","March 29, 2010",,"September 1, 2021","Hotel Dieu, Paris, France",,https://ClinicalTrials.gov/show/NCT01094899,NCT01094899,
oui,NCT01095718,Comparison of 3 Learning Methods to Improve Independent Activities of Daily Living (IADLs) in Alzheimer Disease,C3LM-ILAD,Unknown status,No Results Available,Alzheimer Disease,Behavioral: Errorless Learning|Behavioral: Modeling|Behavioral: Trial and Error,The primary outcome of the intervention will be the performance and errors of participants. Each task is comparable as the assessment procedure remains the same across disease stages.|Baseline neuropsychological assessments. Premorbid intelligence level will be estimated by the National Adult Reading Test (NART). The Mini Mental State Examination (MMSE) will be used to assessed cognitive status.,"Department of Clinical Research and Innovation|Institut National de la Santé Et de la Recherche Médicale, France|Fondation Mederic Alzheimer|Centre Hospitalier Universitaire de Nice",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",ID RCB 2009-A01303-54,March 2010,March 2012,,"March 30, 2010",,"March 26, 2012","CHU de Nice Centre Mémoire, Nice, France",,https://ClinicalTrials.gov/show/NCT01095718,NCT01095718,
oui,NCT01095744,Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease,BIOMAGE,Completed,No Results Available,Alzheimer's Disease|Posterior Cortical Atrophy|Logopenic Progressive Aphasia,,PIB-PET imaging of amyloid load|FDG-PET imaging of glucose metabolism|clinical phenotypic assessment|MRI|ApoE gene sequencing|amyloid and Tau measurements in cerebro-spinal fluid (csf),"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C08-30|2008-A00939-46,March 2009,May 2012,May 2012,"March 30, 2010",,"October 10, 2012","Pitie Salp�tri�re Hospital, Paris, Ile de France, France",,https://ClinicalTrials.gov/show/NCT01095744,NCT01095744,
oui,NCT01096537,"Early Incidence of Occupational Asthma Among Bakers, Pastry-makers and Hairdressers",ABCD,Completed,No Results Available,Occupational Asthma,,The early incidence of OA among young workers according to their sector of activity and exposure duration.|The identification of risk factors of OA.,"Central Hospital, Nancy, France|Institut National de la Sant� Et de la Recherche M�dicale, France|University of Nancy",All,"Child, Adult, Older Adult",,866,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2008-A00622-53,December 2008,January 2010,June 2010,"March 31, 2010",,"July 6, 2016","CHU Nancy, Nancy, France",,https://ClinicalTrials.gov/show/NCT01096537,NCT01096537,20420675
oui,NCT01098084,Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML),,Completed,No Results Available,Chronic Myelomonocytic Leukemia,Drug: Decitabine,"To determine response of patients with CMML to 6 courses of Decitabine according to IWG 2006 criteria, adapted for CMML with WBC>12000/mm3|Response duration|Time to progression to AML|Survival|Toxicity (hematological and non-hematological)",Groupe Francophone des Myelodysplasies|Janssen-Cilag Ltd.,All,"18 Years and older � (Adult, Older Adult)",Phase 2,41,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment,GFM-DEC-LMMC-2007,November 2008,June 2009,June 2009,"April 2, 2010",,"March 20, 2014","CHU de Bic�tre, Le Kremlin-Bic�tre, Ile de France, France|CHU d'Amiens, Amiens, France|CH Angers, Angers, France|H�pital Avignon, Avignon, France|Hopital de la Cote Basque, Bayonne, France|H�pital Avicenne, Bobigny, France|CHU Haut-L�v�que, Bordeaux, France|H�pital Boulogne Sur Mer, Boulogne Sur Mer, France|Hopital d'Instruction des Arm�es Percy, Clamart, France|CHU de, Clermont Ferrand, France|Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France|Hopital Henri Mondor, Creteil, France|CHU de Dijon, Dijon, France|H�pital Versailles, Le Chesnay, France|Centre Hospitalier du Mans, Le Mans cedex, France|Institut Paoli Calmettes, Marseille, France|CHU de nantes, Nantes, France|H�pital Archet1, Nice, France|CHU Caremeau, Nimes, France|CHR La Source orl�ans, Orl�ans, France|H�pital Saint-Antoine., Paris-Cedex 12, France|Hopital Cochin, Paris, France|Hopital Necker, Paris, France|Hopital Hotel Dieu, Paris, France|Hoiptal St Louis, Paris, France|Centre Hospitalier Joffre, Perpignan, France|CHU de Reims, Reims, France|Centre Henri Becquerel, Rouen, France|Hematology Dpt, Hopital Purpan, Toulouse, France|CHU Bretoneau, Tours, France|Institut gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01098084,NCT01098084,23690417;21828134
oui,NCT01099852,Cohort of Patients Infected by an Arbovirus,CARBO,Recruiting,No Results Available,Fever|Dengue|Chikungunya|Zika Virus,Other: biological sample collection|Other: Quality of life Questionnaire EuroQol®|Other: Health Assessment Questionnaire - MDHAQ and RAPID3|Other: Neuropathic Pain Questionnaire (DN4),"Occurrence, during follow-up (for 12 weeks following symptom onset), of shock, internal bleeding, failure of one or several organs or systems (brain, heart, lung, liver, kidney, clotting system), or death.|Specific complications: Onset of hemorrhagic fever (dengue) Onset of encephalitis or neurological disorders (West Nile virus, Japanese encephalitis, Zika virus) Onset of chronic form (Chikungunya)","University Hospital Center of Martinique|Institut National de la Santé Et de la Recherche Médicale, France|Clinique Antilles-Guyane",All,"8 Days and older   (Child, Adult, Older Adult)",,1377,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,09/B/08,June 2010,December 2023,December 2023,"April 8, 2010",,"March 16, 2023","Hôpital Saint André, Bordeaux, France|Hôpital La Pitié Salpêtrière, Paris, France|Hôpital Bichat-Claude Bernard, Paris, France|CH André Rosemond, Cayenne, French Guiana|CHU de Pointe à Pitre/Abymes, Pointe à Pitre, Guadeloupe|Centre Hospitalier Universitaire de Martinique, Fort-de-France, Martinique|CHU de la Réunion, Saint-Denis, Réunion|Centre Hospitalier Gabriel Martin, Saint-Paul, Réunion",,https://ClinicalTrials.gov/show/NCT01099852,NCT01099852,37068115;32163420
oui,NCT01100281,Prefrontal Cortex and Abstract Thinking,,Completed,No Results Available,Abstract Thinking|Concept Formation,Behavioral: Neuropsychological examination|Other: MRI,,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",,69,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C09-29,April 2010,,April 2011,"April 8, 2010",,"December 9, 2011","Inserm U 975, Paris, France",,https://ClinicalTrials.gov/show/NCT01100281,NCT01100281,
oui,NCT01103206,Evaluation of a Cincalcet Suppression Test,,Completed,No Results Available,Parathyroid Hormone Suppression Test With Cinacalcet,Drug: cinacalcet|Drug: cinacalcet dose 1|Drug: cinacalcet dose 2,Parathyroid hormone suppression test with cainacalcet|Parathyroid hormone suppression test with cinacalcet in primary hyperparathyroidism,"University Hospital, Rouen|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,36,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2009/172/HP,April 2010,February 2013,February 2013,"April 14, 2010",,"October 16, 2013","University hospital, Rouen, Haute Normandie, France",,https://ClinicalTrials.gov/show/NCT01103206,NCT01103206,
oui,NCT01104740,Dengue Seroprevalence Study in Blood Donors in the French West Indies,DengSeroprevAn,Completed,No Results Available,Blood Donors|Dengue,Other: Biological sample collection,Presence or not of dengue virus-specific immunoglobulin G antibodies|Characterization of dengue virus serotype-specific IgG,"Etablissement Français du Sang, Martinique|Sanofi Pasteur, a Sanofi Company|Institut National de la Santé Et de la Recherche Médicale, France|Clinique Antilles-Guyane",All,"18 Years to 65 Years   (Adult, Older Adult)",,817,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,10/B/01|2010-A00385-34,May 2011,May 2011,May 2012,"April 15, 2010",,"August 20, 2021","French Blood Establishment of Guadeloupe, Pointe-à-Pitre, Guadeloupe|French Blood Establishment of Martinique, Fort-de-France, Martinique",,https://ClinicalTrials.gov/show/NCT01104740,NCT01104740,
oui,NCT01109225,Relation Between Aldosterone and Cardiac Remodeling After Myocardial Infarction,REMI,Completed,No Results Available,Myocardial Infarction,Biological: blood sample|Procedure: MRI|Procedure: echocardiography|Biological: urine sample|Procedure: pulmonary echography|Procedure: vascular check|Procedure: renal echography,Cardiac remodeling within 6 months of myocardial infarction as defined as the change in left ventricle volumes (increase of more than 20 % of the diastolic volume of the left ventricle)|Vascular and cardiac parameters measured during the initial assesment and at 6 months (both functional and structural - by echocardiography or MRI)|Long-term cardiac remodeling measured by echocardiography at 3 to 9 years of initial enrollment,"Central Hospital, Nancy, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,145,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2009-A00537-50,"April 27, 2010",March 2014,"February 4, 2020","April 23, 2010",,"March 24, 2021","Nancy Brabois university hospital, Vandoeuvre les Nancy, Meurthe Et Moselle, France",,https://ClinicalTrials.gov/show/NCT01109225,NCT01109225,28063459;27108156;26512596;25840640;25559651
oui,NCT01123187,Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation,,Completed,No Results Available,Type 1 Diabetes|Organ Transplantation|Immunosuppression,Procedure: islet transplantation,Composite criteria: insulin independence and Glycosylated Hemoglobin (HbA1c) under 8% at one year after the transplantation|The number of adverse events|Number of severe episodes of hypoglycemia|Evaluation of Diabetes complications|Lipid metabolism|Evaluation of kidney function,"University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CP 95/120|98001|DGS 980032,March 2003,March 2014,April 2016,"May 14, 2010",,"January 10, 2018","University Hospital of Lille, Lille, Nord, France",,https://ClinicalTrials.gov/show/NCT01123187,NCT01123187,31615852;28941330;25393157;22996144
anrs,NCT01127204,Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age,,Completed,No Results Available,HIV Infections,Drug: AZT-3TC-LPV/r twice a day|Drug: ABC-3TC-EFV once a day,Initial therapeutic cohort: Virological success|Randomised simplification phase: Virological success|Virological success|Immunological response|Antiretroviral and cotrimoxazol pharmacokinetic parameters|Tolerance|Adherence|Resistance to antiretroviral,"ANRS, Emerging Infectious Diseases|European and Developing Countries Clinical Trials Partnership (EDCTP)|Public Research Centre Health, Luxembourg|Ministry of Foreign Affairs, Luxembourg|University of Ouagadougou, Burkina Faso|Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire|Ministry of Health, Rwanda|Institut National de la Santé Et de la Recherche Médicale, France|University of Bordeaux|Institut de Sante Publique, d'Epidémiologie et de Développement|Université Montpellier|University of Paris 5 - Rene Descartes|Queen Fabiola Children's University Hospital",All,3 Months to 12 Months   (Child),Phase 2|Phase 3,161,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 12206 MONOD|IP.2007.33011.002,June 2011,April 2015,April 2015,"May 20, 2010",,"July 12, 2016","Service de maladies infectieuses - CHU Charles de Gaulle, Ouagadougou, Burkina Faso|Service de pédiatrie - CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso|CEPREF, Abidjan, Côte D'Ivoire|FSU abobo-Avocatier, Abidjan, Côte D'Ivoire",,https://ClinicalTrials.gov/show/NCT01127204,NCT01127204,34723858;31334298;28800382;28483965;28453240;28434406;27015798
oui,NCT01132742,Malnutrition and Outcome in Hospitalized Children in Europe,,Completed,No Results Available,Malnutrition,,"Length of Hospital Stay|infection as a complication during hospital stay|gastrointestinal complications (vomiting, diarrhoea)|muscle strength",Ludwig-Maximilians - University of Munich,All,"1 Month to 18 Years � (Child, Adult)",,2567,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ESPEN,February 2010,December 2012,December 2012,"May 28, 2010",,"January 11, 2013","Children's Hospital Zagreb, Zagreb, Croatia|Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark|Paediatric Clinical Investigation Center Unit (CIC-9301-Inserm-CHU) and U995-Inserm, hospital Jeanne de Flandre, University hospital of Lille., Lille, France|Dr. von Hauner Children's Hospital. Munich, Germany, Munich, Bavaria, Germany|Technological Education Institute, Thessaloniki, Greece|Schneider Children's Hospital, Petah Tikvah, Israel|Fondazione IRCCS C� Granda - Ospedale Maggiore Policlinico - Milano, Milano, Italy|Beatrix Children's Hospital, University Medical Center Groningen, Groningen, Netherlands|Sophia Children's Hospital, Erasmus University, Rotterdam, Netherlands|Medical Univ. of Warsaw, Warsaw, Poland|The Children's Memorial Health Institute, Warsaw, Poland|Spitalul Clinic da Urgenta pentru Copii, Cluj-Napoca, Romania|Oxford Children's Hospital, Oxford, United Kingdom|Royal Hospital for Sick Children, Yorkhill Glasgow, United Kingdom",,https://ClinicalTrials.gov/show/NCT01132742,NCT01132742,27099244;24461472
oui,NCT01147926,Evaluation of Prucalopride in Male Subjects With Chronic Constipation.,,Completed,Has Results,Male Subjects With Chronic Constipation,Drug: Placebo|Drug: Prucalopride,The Percentage of Subjects With an Average of ?3 Spontaneous Complete Bowel Movements (SCBM) Per Week|Percentage of Subjects With an Average Weekly Frequency of at Least 3 SCBM Per Week and an Increase of ? 1 SCBM Per Week for ? 75% of the 12-week Treatment Period and ? 75% of the Last Third of the 12-week Treatment Period|Percentage of Subjects With an Increase of at Least 1 SCBM Per Week|SCBM Per Week|Percent SBM With a Consistency of Normal and Hard/Very Hard|Percent SCBM With No Straining and Severe/Very Severe Straining|Percent SBM With Sensation of Complete Evacuation|Time to First SCBM After Investigational Product Intake on Day 1|Bisacodyl Tablets Taken Per Week|Days With Rescue Medication Taken Per Week|Percent of Subjects With an Improvement of ? 1 Point on the Patient Assessment of Constipation - Symptom (PAC-SYM) Questionnaire Total Score at Final On Treatment Assessment|Percent of Subjects With an Improvement of ? 1 Point on the Patient Assessment of Constipation - Quality of Life (PAC-QOL) Total Score at Final On Treatment Assessment|Percent of Subjects on the Subject Global Evaluation on Severity of Constipation Score Rating Constipation as Severe to Very Severe at Final On-Treatment Assessment|Percent of Subjects on the Subject Global Evaluation on Efficacy of Treatment Score Rating Treatment as Quite a Bit to Extremely Effective at Final On-Treatment Assessment,Shire|Takeda,Male,"18 Years and older � (Adult, Older Adult)",Phase 3,374,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SPD555-302|M0001-C302|2009-015719-42,"September 23, 2010","October 25, 2013","October 25, 2013","June 22, 2010","September 9, 2014","June 10, 2021","Gastro-Kliniek cvba, Antwerpen 7, Belgium|Cliniques Universitaires St Luc, Bruxelles, Belgium|GP / Huisartsenpraktijk De Regenboog, Deurne, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|CHU Sart Tilman, Liege, Belgium|Private Practice, Wetteren, Belgium|4 MHAT, Sofia, Bulgaria|CCBR Czech Republic Brno, Brno, Czechia|KKN a.s., Karlovy Vary, Czechia|CCBR Czech Republic Pardubice, Pardubice, Czechia|Universtiy Hospital Kralovske Vinhorady, Prague 10, Czechia|MONSE s.r.o., Prague, Czechia|Hospital Slany, Slany, Czechia|Orlickoustecka nemocnice, Usti nad Orlici, Czechia|Krajska Nemocnice T. Bati a.s., Interni oddeleni - klinika IPVZ; Nemocnicni Lekarna, Zlin, Czechia|Krajska Nemocnice T. Bati a.s., Zlin, Czechia|CCBR DK Aalborg, Aalborg, Denmark|CCBR DK Ballerup, Ballerup, Denmark|CCBR DK Vejle, Vejle, Denmark|CHU - Hopital Nord, service gastro-enterologie et hepatologie, Amiens, France|ARK Clinical Research (Jean XXIII), Angers, France|ARK Clinical Research (Proust), Angers, France|ARK Clinical Research - Chanzy, Angers, France|ARK Clinical Research, Avrille, France|Hopital Avicenne, Centre d'exploitation fonctionnelle et reducation digestive, Bobigny, France|Service de Gastroenterologie & INSERM CIC-P 803 - CHU de Dijon, Dijon Cedex, France|ARK Clinical Research, Le Plessis-Grammoire, France|H�pital Edouard Herriot, Lyon cedex 3, France|Hopital Archet 2- service gastro-enterologie et hepatologie, Nice, France|H�pital Pontchaillou - Service des Maladies de l'Appareil Digestif, Rennes, France|Cabinet M�dical, Thouars, France|ARK Clinical Research, Vendome, France|emovis GmbH, Berlin, Germany|Gastroenterologie und Hepatologie am Johannisplatz, Leipzig, Germany|Fachartzpraxis f�r Innere Medizin, Wiesbaden, Germany|Meander Medisch Centrum, Amersfoort, Netherlands|VU Medisch Centrum, Amsterdam, Netherlands|PT&R / PreCare Trial & Recruitment, Beek, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Maastricht Universitair medisch Centrum, Maastricht, Netherlands|Erasmus MC, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands|Gabinet Lekarski Janusz Rudzi?ski, Bydgoszcz, Poland|Instytut Medycyny Wsi im. Witolda Chod?ki - Zaklad Endoskopowych Bada? Kliniczncyh, Lublin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland|Endoskopia Sp. z o.o., Sopot, Poland|Indywidualna Specjalistyczna Praktyka Lekarska w Dziedzinie Chirurgii Og�lnej i Gastroenterologii, Torun, Poland|Przychodnia Polskiej Fundacji Gastroenterologii Filia Nr 1 NZOZ, Warszawa, Poland|NZOZ Vivamed, Warszawa, Poland|CMI Dr. Lenghel Augustin, Oradea, Bihor, Romania|Centrul Medical Valahia SRL, Ploiesti, Prahova, Romania|Spitalul Universitar de Urgenta Militar Central ""Dr. Carol Davila"", Bucuresti, Sector 1, Romania|SC Quantum Medical Center SRL, Bucuresti, Sector 1, Romania|Endocenter Medicina Integrativa SRL, Bucuresti, Sector 2, Romania|SC Cabinet Medical Dr. Blaj Stefan SRL, Bucuresti,, Sector 5, Romania|SC Mediclass Sananova SRL, Bucuresti, Sector 5, Romania|Centrul Medical Humanitas, Bucuresti,, Sector 6, Romania|Centrul Medical Tuculanu SRL, Timisoara, Timis, Romania|Centrul Medical Sana, Bucuresti, Romania|Spitalul Clinic Judetean Cluj,Clinica Medicala I, Cluj, Romania|Gastromedica SRL, Iasi, Romania|Cabinet Medical Dr. Lokos Barna-Csaba, Miercurea Ciuc, Romania|Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania|CMI de Gastroenterologie Dobru Daniela, Targu-Mures, Romania|Policlinic Algomed SRL, Timisoara, Romania|Oldfield Surgery, Bath, United Kingdom|Avondale Surgery, Chesterfield, United Kingdom|University Hospital & Warwickshire -, Coventry, United Kingdom|County Durham & Darlington NHS Foundation Trust, Durham, United Kingdom|Burbage Surgery, Hinckley, United Kingdom|Townhead Research, Irvine, United Kingdom|Sherbourne Medical Centre, Leamington Spa, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01147926,NCT01147926,34585675;28983926;25869393
oui,NCT01147978,Proactive Communication Strategy in Intensive Care Unit and Post Traumatic Stress Symptoms,FAMIREAXV,Completed,No Results Available,Critically Ill Patients,Behavioral: End of ICU stay conference,"Symptoms of PTSD in ICU patients|Symptoms of PTSD, anxiety, and depression in ICU patients|Symptoms of PTSD, anxiety, and depression in families","Assistance Publique - Hôpitaux de Paris|University Paris 7 - Denis Diderot|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,303,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,K070101|ID RCB / 2007-A01044-49,April 2009,August 2012,November 2012,"June 22, 2010",,"April 23, 2014","Medical ICU, Paris, France",,https://ClinicalTrials.gov/show/NCT01147978,NCT01147978,
oui,NCT01160276,Drug Interaction Between Colchicine and Calcineurin Inhibitors in Renal Graft Recipients,COLCHINCAL,Completed,No Results Available,Renal Replacement Therapies,Drug: cyclosporine+colchicine|Drug: tacrolimus,"Area under the curve of plasma concentration of colchicine over time 0-∞|Half-life of colchicine (T1/2).|AUC0-3h colchicine to focus the analysis on the absorption phase (argument in favor of an interaction-dependent P-gp)|Cmax observed colchicine.|Residual tacrolimus or cyclosporine concentrations|ABCB1 genotype at position 3435 (rs 1045642) or 3435 cc, 3435TT, heterozygotes could not be included in the tacrolimus group.|ABCB1 Haplotypes composed of 3 SNPs: C3435T, G2677T / A and C1236T.|CYP3A5 Genotype: search for the allele * 1 (rs 776746): 3 possible genotypes CYP3A5 * 3 / * 3 - CYP3A5 * 3 / * 1 - CYP3A5 * 1 / * 1.|GFR calculated by MDRD formula.|BMI|Drug related (azathioprine, mycophenolic acid, diuretics, ACE inhibitors, ARAII)","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 1,17,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P081105,May 2010,January 2012,January 2012,"July 12, 2010",,"April 11, 2013","Assistance publique - Hôpitaux de Paris : Bicêtre Hospital, Le Kremlin Bicêtre, France",,https://ClinicalTrials.gov/show/NCT01160276,NCT01160276,
oui,NCT01167283,Effect of Electrostimulation in Chronic Obstructive Pulmonary Disease (COPD),ExaEMS2005,Completed,No Results Available,Chronic Obstructive Pulmonary Disease,Device: Electrostimulation|Device: Sham stimulation,Fiber-type distribution|Change in the strength of the quadriceps over the 6-week electrostimulation program,"Institut National de la Santé Et de la Recherche Médicale, France|Centre Hospitalier Régional Universitaire Montpellier",All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant),APARD,July 2006,April 2010,April 2010,"July 22, 2010",,"August 6, 2010",,,https://ClinicalTrials.gov/show/NCT01167283,NCT01167283,
oui,NCT01176162,Aldosterone Resistance in Preterm Infants,PREMALDO,Completed,No Results Available,Newborn,,urinary aldosterone|plasma electrolytes concentrations|urinary electrolytes concentrations|hormonal measurements|clinical parameters,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,24 Weeks to 41 Weeks   (Child),,170,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,P081211|B91017-20,January 2010,June 2013,December 2013,"August 5, 2010",,"April 30, 2014","Assistance Publique- Hôpitaux de Paris: Antoine Beclere Hospital, Clamart, Ile de France, France",,https://ClinicalTrials.gov/show/NCT01176162,NCT01176162,26348350
oui,NCT01183039,Effects of Training in Healthy Sedentary Subjects,,Completed,No Results Available,Sedentary Subjects,Other: Training,"Effects of training program on mitochondrial function and oxidative stress|Relationship between mitochondrial function, oxidative stress and exercise tolerance in COPD patients","5 Santé|Centre Hospitalier Régional Universitaire Montpellier|Institut National de la Santé Et de la Recherche Médicale, France",All,"50 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),2008-A00209-46,May 2008,December 2010,December 2010,"August 17, 2010",,"September 5, 2012","Clinique du souffle La valonie, Lodeve, France|hopital Arnaud de Vilneuve, Montpellier, France|Clinique du souffle La solane, Osseja, France",,https://ClinicalTrials.gov/show/NCT01183039,NCT01183039,31806021
oui,NCT01183052,Mitochondrial Dysfunction and Oxidative Stress in Chronic Obstructive Pulmonary Disease (COPD) Patients,,Completed,No Results Available,COPD Patients,Other: Training,Cellular effects of exercise training at the ventilatory threshold intensity,"5 Santé|Centre Hospitalier Régional Universitaire Montpellier|Institut National de la Santé Et de la Recherche Médicale, France",All,"50 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),2009-A00426-51,June 2009,December 2010,December 2010,"August 17, 2010",,"September 5, 2012","Clinique du Souffle La Vallonie, Lodeve, France|Clinique du Souffle la Solane, Osseja, France",,https://ClinicalTrials.gov/show/NCT01183052,NCT01183052,31806021
oui,NCT01183091,Medical Economical Evaluation of the Ablation by Catheter of the Atrial Tissue in the Treatment of AF,EVABLAF,Completed,No Results Available,Atrial Fibrillation,Procedure: Ablation of atrial fibrillation,Success of ablation,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 79 Years   (Adult, Older Adult)",,503,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,P040411,April 2005,July 2008,October 2010,"August 17, 2010",,"September 20, 2012","Service de cardiologie - Hôpital Lariboisière, Paris, France",,https://ClinicalTrials.gov/show/NCT01183091,NCT01183091,
oui,NCT01186445,Morphine In Acute Myocardial Infarction,MIAMI,Completed,No Results Available,Acute Myocardial Infarction,Drug: morphine chlorhydrate|Drug: saline solution,Infarct size evaluated by delayed enhancement-magnetic resonance imaging|Infarct size/area at risk ratio evaluated by MRI|release of creatine kinase (CK) and troponin I (TnI) during reperfusion|the Thrombolysis In Myocardial Infarction (TIMI) myocardial Blush after reperfusion|ST segment resolution after reperfusion|Left Ventricular Ejection Fraction measured by echocardiography|Infarct size measurement by delayed enhancement-magnetic resonance imaging,"French Cardiology Society|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,94,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MIAMI-2008-09,January 2011,December 2016,December 2016,"August 23, 2010",,"February 6, 2017","Henri Mondor Hospital, Creteil, France|Hopital Marie Lannelongue, Plessis Robinson, France",,https://ClinicalTrials.gov/show/NCT01186445,NCT01186445,30340532
oui,NCT01186666,Imaging and Biomarkers of Atherosclerosis in Patients With Stable or Unstable Coronary Artery Disease,BIOCORE-2,Completed,No Results Available,Atherosclerosis|Coronary Artery Disease|Acute Coronary Syndrome,Device: Coronary intervention using IVUS-VH & FDG PET-MDCT,"Three imaging modalities are used to compare plaque phenotypes between patients with ACS vs stable CAD. (coronary IVUS-VH, MDCT coronary angiography, AORTO-carotid FDG PET-CT)|New circulating biomarkers","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,85,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P080703,February 2010,July 2012,August 2013,"August 23, 2010",,"February 25, 2015","Département de Cardiologie, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, Paris, France",,https://ClinicalTrials.gov/show/NCT01186666,NCT01186666,22155453
oui,NCT01188512,First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine,,Completed,No Results Available,Pertussis,Biological: BPZE1|Biological: Placebo,General safety and local tolerability in the respiratory tract of a single ascending dose of the genetically modified B. pertussis strain|Attachment of the BPZE1 strain to the nasopharyngeal mucosa|Immunogenicity,"Institut National de la Santé Et de la Recherche Médicale, France|European Union|Swedish Institute for Infectious Disease Control|Innogenetics",Male,19 Years to 31 Years   (Adult),Phase 1,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",BT06-04|2010-019936-11,August 2010,June 2011,January 2012,"August 25, 2010",,"January 31, 2012","Karolinska University Hospital, Solna, Sweden",,https://ClinicalTrials.gov/show/NCT01188512,NCT01188512,24793938;24421886;24261996
oui,NCT01188525,Pharmacokinetic Study to Characterize Individual Metabolic Profile,CIME1,Completed,No Results Available,Healthy Volunteers,Drug: 10 parents drugs adminstration,"Pharmacokinetic parameters|Tolerance of the concomittant administration of the 10 drugs: 1/number of volunteers with grade 4 adverse events 2/ number of volunteers with any adverse event, (grade 1 to grade 4)|pharmacokinetic|Genotypes","Institut National de la Santé Et de la Recherche Médicale, France|Nuclear Energy Commission (CEA)",All,18 Years to 45 Years   (Adult),Phase 1,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C09-04|2009-014866-24,August 2010,July 2011,July 2011,"August 25, 2010",,"May 15, 2012","Center of clinical investigation, Paris, France",,https://ClinicalTrials.gov/show/NCT01188525,NCT01188525,
oui,NCT01192737,"""COhort Study on A/H1N1 FLU During PREGnancy""",COFLUPREG,Completed,No Results Available,Influenza|Pregnancy,,Frequency of A/H1N1 Influenza virus infection in pregnant women and impact of Flu on pregnancy outcome.|Safety of Flu vaccine,"Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",,919,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C09-24|2009-015160-34,October 2009,September 2010,November 2010,"September 1, 2010",,"April 17, 2012","Maternité Necker-Brune, Paris, France|Maternité Port Royal, Paris, France|Maternité Saint Vincent de Paul, Paris, France",,https://ClinicalTrials.gov/show/NCT01192737,NCT01192737,
oui,NCT01207336,Combined tDCS+PNS After Acute Stroke,,Unknown status,No Results Available,Acute Ischaemic Stroke,Device: combined transcranial direct current stimulation and electrical peripheral nerve stimulation,Jebsen Taylor test|Grip and wrist force Nine peg hole Cortical excitability ofIpsilesional M1 (TMS),"Institut National de la Santé Et de la Recherche Médicale, France|Fondation de l'Avenir",All,"35 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C09-27|2009-A01153-54,September 2010,September 2012,,"September 22, 2010",,"April 6, 2012","Centre d' Investigation Clinique de Toulouse et Hopitaux de Toulouse ( Purpan), Toulouse, France",,https://ClinicalTrials.gov/show/NCT01207336,NCT01207336,33175411
oui,NCT01207349,Type 2 Diabetes Secondary Prevention,RP2,Completed,No Results Available,Type 2 Diabetes,Behavioral: Secondary prevention intervention trial|Behavioral: standard follow up,%HbA1c|anthropometry,"Institut National de la Santé Et de la Recherche Médicale, France|Groupe Hospitalier Sud Réunion",All,"18 Years and older   (Adult, Older Adult)",,398,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RBM01-23,August 2002,December 2004,December 2004,"September 22, 2010",,"January 31, 2012","GHSR, Saint Pierre, La Réunion, France",,https://ClinicalTrials.gov/show/NCT01207349,NCT01207349,22030240
oui,NCT01212120,The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections,,Completed,No Results Available,Diabetic Foot|Staphylococcus Aureus,Biological: Genetic profiling of bacterial cultures,Presence/absence of the same S. aureus genetic profile in the nose and on the foot lesion.,"Centre Hospitalier Universitaire de Nīmes|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,278,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PHRC-I/2009/JPL-02|2009-A00849-48,September 2010,March 2012,March 2012,"September 30, 2010",,"March 27, 2015","CHU de Nîmes - Hôpital Universitaire Carémeau, Nimes, Gard, France|CHU de Nîmes - Hôpital Universitaire de Réadaptation du Grau du Roi, Le Grau du Roi, France|APHM - Hôpital Nord, Marseille, France|CHU de Montpellier - Hôpital Lapeyronie, Montpellier, France",,https://ClinicalTrials.gov/show/NCT01212120,NCT01212120,
oui,NCT01216956,Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia,,Completed,No Results Available,Insulin Sensitivity|Lipoproteins Metabolism|Non Esterified Fatty Acid Kinetics|Lipid Profile,Drug: Extended-release nicotinic acid versus placebo,Evolution of non-esterified fatty acid and triglycerides concentrations over time|Insulin sensitivity after treatment|Lipoproteins metabolism|Lipid profile,"Centre de Recherche en Nutrition Humaine Rhone-Alpe|Institut National de la Santé Et de la Recherche Médicale, France|GlaxoSmithKline",Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,24,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Basic Science,NIASPAN-C05-36,September 2006,June 2009,March 2010,"October 7, 2010",,"October 7, 2010","Centre de Recherche en Nutrition Humaine, Nantes, France",,https://ClinicalTrials.gov/show/NCT01216956,NCT01216956,29540575;28752209
oui,NCT01220388,Effects of L-lysine on Adrenal Secretion,L-Lysine,Completed,No Results Available,Male|Healthy Volunteers,Dietary Supplement: L-lysine|Dietary Supplement: placebo,"Plasma aldosterone variation during orthostatic test|Basal aldosterone alteration; Aldosterone variation during metoclopramide & salt-free diet tests; Basal and stimulated (3 different tests) alterations of renin, cortisol & ACTH","University Hospital, Rouen",Male,18 Years to 45 Years � (Adult),Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",2008/138/HP,October 2010,March 2013,March 2013,"October 13, 2010",,"June 18, 2013","Rouen Clinical research Centre (CIC 0204), Rouen, France",,https://ClinicalTrials.gov/show/NCT01220388,NCT01220388,
oui,NCT01235624,Autosomal Dominant Retinitis Pigmentosa: Prevalence of Known Genes Identification of New Loci / Genes,,Completed,No Results Available,Autosomal Dominant Retinitis Pigmentosa,Genetic: genetic analysis,identification of unknown loci and genes responsible of Autosomal dominant retinitis pigmentosa (adRP),"University Hospital, Montpellier|Ministry of Health, France",All,"5 Years to 80 Years � (Child, Adult, Older Adult)",Not Applicable,1161,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,UF 8300|2008-A01238-47,March 2009,April 2013,April 2013,"November 5, 2010",,"November 6, 2013","CHRU Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT01235624,NCT01235624,
oui,NCT01248195,Optimization of Treatment and Management of Schizophrenia in Europe,OPTIMISE,Completed,No Results Available,Schizophrenia|Schizophreniform Disorder|Schizoaffective Disorder,Drug: Amisulpride open label|Drug: 6-week amisulpride double blind treatment|Drug: 6-week olanzapine double blind treatment|Drug: 12-week clozapine open-label treatment|Behavioral: Psychosocial intervention,PANSS|Sellwood rating scale|Biological profile|MRS measures|SOFAS global functioning|MRI assessments|All cause treatment discontinuation|All cause discontinuation|Biological markers,Rene Kahn|King's College London|Technical University of Munich|University of Manchester|Ludwig-Maximilians - University of Munich|UMC Utrecht,All,18 Years to 40 Years � (Adult),Phase 4,479,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",KP7242114|2010-020185-19,May 2011,April 2016,April 2016,"November 25, 2010",,"May 15, 2018","Melbourne Neuropsychiatry Centre, Melbourne, Australia|Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria|Katholieke Universiteit Leuven (KU Leuven), Leuven, Belgium|University Specialised Hospital for Active Treatment in Neurology and Psychiatry ""St. Naum"", Sofia, Bulgaria|Psychiatrick� centrum Praha, Prague, Ustavni 91, Czechia|Psychiatrick� klinika LF UK, Fakultn� nemocnice, Hradec Kr�lov�, Czechia|Center for Neuropsychiatric Research, Glostrup, Denmark|Institut National de la Sant� et de la Reserche M�dicale (INSERM), Cr�teil Cedex, France|Martin-Luther-University (MLU) of Halle-Wittenberg, Halle, Germany|Deprtment of Psychiatry, University of Heidelberg, Mannheim, Germany|Ludwig-Maximilians University M�nchen, M�nchen, Germany|Technische Universit�t M�nchen (TUM), M�nchen, Germany|Sheba Medical Centre Department of Psychiatry, Tel Hashomer, Israel|Department of Psychiatry University of Naples, Naples, Italy|University Medical Center Utrecht, Utrecht, Netherlands|Department of Adult Psychiatry, University of Medical Sciences, Poznan, Poland|Obregia Psychiatric Hospital, Bucuresti, Romania|Hospital Clinic i Provincial, Barcelona, Spain|Servicio Madrile�o de Salud (SERMAS), Madrid, Spain|Hospital Cl�nico San Carlos, Madrid, Spain|Instituto de Investigaci�n Hospital 12 de Octubre, Madrid, Spain|Universidad de Oviedo, Oviedo, Spain|Clienia Schl�ssli AG, Privatklinik f�r Psychiatrie und Psychotherapie, Oetwil am See, Switzerland|King's College London, Departments of Psychological Medicine, Psychiatry & Cognitive Neuroscience, London, United Kingdom|West London Mental Health Trust, London, United Kingdom|University of Manchester, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01248195,NCT01248195,36988483;33838518;33536130;30115598
oui,NCT01251211,Botulinum Toxin in Peripheral Neuropathic Pain,,Completed,No Results Available,Postherpetic Neuralgia|Diabetic Polyneuropathies|Other Polyneuropathies,Drug: botulinum toxin type A,Average pain intensity on numerical scales in a self diary by the patient|Efficacy of treatment on neuropathic symptoms|Quality of life VAS|Intensity of allodynia to brush|assessment of effects of BTX-A on substance P and CGRP|Side effects|Detection and pain thresholds to mechanical and thermal stimuli and responses to suprathreshold stimuli|Predictors of the response,Hospital Ambroise Par� Paris,All,"18 Years to 85 Years � (Adult, Older Adult)",Phase 4,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BOTNEP,October 2010,January 2014,January 2014,"December 1, 2010",,"March 11, 2016","Divis�o de Cl�nica Neurol�gica do Hospital das Cl�nicas da FMUSP, Sao Paulo, Brazil|H�pital Ambroise Par�, APHP, Boulogne-Billancourt, France|H�pital Dupuytren, Limoges, France",,https://ClinicalTrials.gov/show/NCT01251211,NCT01251211,26947719
oui,NCT01253252,Endoprosthesis Treatment Effects on Human Abdominal Aorta Aneurysms (AAA) Metabolic Activity,AAAendo,Completed,No Results Available,Abdominal Aortic Aneurysm,Radiation: [18F] Fluorodeoxyglucose PET Scan Imaging|Radiation: CT scan|Biological: Blood sampling for biological investigations,Difference of 18FDG PET scan signal (mean and maximal aortic standardized uptake measurements) visualized before and after endoprosthesis implantation for AAA treatment.|Correlation between therapeutic efficacity of endovascular treatment and AAA injury biological markers.|Relationship between efficacity of endovascular surgery and morphology of the AAA as assessed by CT scan.,"Central Hospital, Nancy, France|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2007-A01424-49,August 2009,August 2009,,"December 3, 2010",,"July 28, 2017","Le Bocage - Dijon's Hospital, Dijon, France|Cardiologic Hospital, Lille, France|Brabois Hospital, Nancy, France|Institut du Thorax, Nantes's Hospital, Nantes, France|Bichat Claude Bernard Hospital, Paris, France|Georges Pompidou European Hospital, Paris, France|CH.NICOLLE's Hospital, Rouen, France",,https://ClinicalTrials.gov/show/NCT01253252,NCT01253252,
oui,NCT01258036,Mother Daughter Bone Microarchitecture,MODAM,Unknown status,No Results Available,Bone Fragility,Radiation: HRpQCT|Biological: Sampling|Radiation: Bone absorptiometry,Role of bone microarchitecture in the hereditary determinism of bone fragility|Role of Bone mineral density in the hereditary determinism of bone fragility|Role of bone turnover and hormones in the hereditary determinism of bone fragility,"Institut National de la Sant� Et de la Recherche M�dicale, France",Female,"20 Years and older � (Adult, Older Adult)",,1040,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,C09-37|2009-A01295-52,March 2010,December 2012,March 2013,"December 10, 2010",,"September 28, 2012","Unit� Inserm 831, Pavillon F, H�pital Edouard Herriot, Lyon, France",,https://ClinicalTrials.gov/show/NCT01258036,NCT01258036,
oui,NCT01260428,Effects of Expiratory Pressure on Arterial Oxygenation During Hypoxia,hypex,Unknown status,No Results Available,Hypoxia,Device: threshold PEEP,"SpO2|peripheral HbO2/DeoxyHb|cardiac output|pattern of breathing (fR, VT, PETCO2)",AGIR à Dom,Female,"18 Years to 65 Years   (Adult, Older Adult)",,20,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,10-AGIR-2,February 2011,,,"December 15, 2010",,"February 28, 2012","CHU de Grenoble, La Tronche, Isere, France",,https://ClinicalTrials.gov/show/NCT01260428,NCT01260428,
oui,NCT01270009,Role of BCL-B in Multiple Myeloma,,Unknown status,No Results Available,Multiple Myeloma,,"To determine whether BCL-B is a survival factor in malignant plasmocytes, we will analyse the level of expression of Bcl-B at the both mRNA and protein levels in a cohort of MGUS and MM patients.|To determine whether deregulation of BCL-B expression is associated to chimioresistances commonly observed in Multiple Myeloma, We will compare Bcl-B expression in MM patients either sensitive or resistant to conventional therapies.","Centre Hospitalier Universitaire de Nice|Institut National de la Santé Et de la Recherche Médicale, France|U1065 team number 2",All,"18 Years and older   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,09-PP-10,November 2010,November 2013,November 2013,"January 5, 2011",,"May 16, 2012","Service de Médecine interne et cancérologie - Hôpital de l'Archet, Nice, France",,https://ClinicalTrials.gov/show/NCT01270009,NCT01270009,
oui,NCT01271842,Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study,RESPIFLU,Completed,No Results Available,"Influenza|Pneumonia, Viral|Pulmonary Fibrosis|Quality of Life|Stress Disorders, Post Traumatic",,Carbon monoxide diffusion capacity|Health-related quality of life|Pulmonary function testing|Post traumatic stress disorder|Anxiety and depression|Muscle weakness|Lung abnormalities on CT scan|Alveoli-arterial gradient of oxygen during effort,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",,38,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C10-26|2010-A00741-38,October 2010,,,"January 7, 2011",,"December 28, 2012","CHU Pitié-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT01271842,NCT01271842,22948576
oui,NCT01272154,Cerebellum and Cortical Plasticity: the Case of Dystonia,CERDYS,Unknown status,No Results Available,Dystonia,Other: Transcranial magnetic stimulation,"Comparison of MEP0/MEP10 and MEP0/MEP30 values obtained after sham, cRTBS or iTBS of the cerebellum.|Variation of the appropriate dystonic clinical score (depending on the type of dystonia) after each rTMS session (cTBS, iTBS, sham).|Measurement of number of errors, mean time to reach the target after each rTMS session (cTBS, iTBS, sham).|Measurement of the variation of the motor threshold, intracortical inhibition and intracortical facilitation after each rTMS session (cTBS, iTBS, sham).","Institut National de la Santé Et de la Recherche Médicale, France|Sree Chitra Tirunal Institute for Medical Sciences & Technology|Policlinico G . Martino, Messina Italy",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,C10-01|2010-A00931-38,January 2011,January 2013,January 2014,"January 7, 2011",,"January 31, 2012","Hpôpital Pitié Sapétrière - U 975 Plate forme "" Pole Exploration de l'homme : Gait, Equilibrium, Posture, and Movement "", Paris, France",,https://ClinicalTrials.gov/show/NCT01272154,NCT01272154,
oui,NCT01274455,Gene Therapy of Pancreatic Ductal Adenocarcinoma,TherGAP,Completed,No Results Available,Pancreatic Adenocarcinoma,Genetic: Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes,"Feasability and security : Number of Participants with Adverse Events|Antitumoral effect: secondary resecability, transgenes diffusion","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France|Clinical Research Center, Toulouse|CAYLA-INVIVOGEN",All,"18 Years and older   (Adult, Older Adult)",Phase 1,22,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,401401,December 2010,March 2013,March 2013,"January 11, 2011",,"March 14, 2016","Toulouse Universitary Hospital (Rangueil), Department of Gastroenterology At Rangueil Hospital, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01274455,NCT01274455,
oui,NCT01281735,International Chronic Myeloid Leukemia Pediatric Study,ICMLPed,Recruiting,No Results Available,Chronic Myeloid Leukemia,,,"Poitiers University Hospital|Institut National de la Santé Et de la Recherche Médicale, France|University of Milano Bicocca|University Medical Center Groningen|University of Liege|Imperial College London|University Hospital Dresden|International BFM Study Group",All,"up to 18 Years   (Child, Adult)",,750,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CIC1402|2010-023359-27,January 2011,December 2028,December 2028,"January 24, 2011",,"March 23, 2022","Hospital Italiano, Buenos Aires, Argentina|Women's and children's Hospital, North Adelaide, South Australia, Australia|Children's Cancer Research Institute, Vienna, Austria|National Research Center for Pediatric Oncology and Hematology, Minsk, Belarus|University Hospital of Ghent, Ghent, Belgium|Instituto de Oncologia Pediatrica, Sao Paulo, Brazil|Hospital Roberto Del Rio, Santiago, Chile|Chinese University of Hong Kong, Hong Kong, China|Children's Hospital Zagreb, Zagreb, Croatia|Charles University Motol, Prague, Czechia|Rigshospitalet, Copenhagen, Denmark|Clinical Investigation Center CIC 1402, Poitiers, France|University Hospital Dresden, Dresden, Germany|Agia Sophia Children's Hospital, Athen, Greece|Keio University School of Medicine, Tokyo, Japan|Saint George Hospital University Medical Centre, Beirut, Lebanon|University Medical Centre Groningen, Groningen, Netherlands|Wroclaw Medical University Department, Wrocław, Poland|Faculty of Medicine, Bratislava, Slovakia|Officina Proyectos SEHOP, Palma de Mallorca, Spain|Uludag University, Medical Faculty, Görükle, Turkey",,https://ClinicalTrials.gov/show/NCT01281735,NCT01281735,32799036;31082688;28838993
anrs,NCT01282047,Lenalidomide in Kaposi Disease Associated With HIV Infection,LENAKAP,Terminated,No Results Available,HIV Infection Associated Kaposi Disease,Drug: Lenalidomide,Evaluate the efficacy of treatment with Lenalidomide in progressive Kaposi disease in Human immunodeficiency virus (HIV)-infected patients receiving Combined Antiretroviral Therapy (cART).|To estimate the safety of lenalidomide|To estimate the time to the response and the duration of the response|To evaluate the efficacy of treatment at 48 weeks|To evaluate the efficacy using ACTG criteria|To evaluate the survival and the survival with no progression|To describe the evolution of virologic and immunological parameters,"French National Agency for Research on AIDS and Viral Hepatitis|Celgene Corporation|ANRS, Emerging Infectious Diseases",All,"19 Years to 75 Years � (Adult, Older Adult)",Phase 2,12,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-022898-33|ANRS 154 LENAKAP,October 2011,February 2014,February 2014,"January 24, 2011",,"August 1, 2014","Valerie Martinez, Clamart, France",,https://ClinicalTrials.gov/show/NCT01282047,NCT01282047,27405442
oui,NCT01308372,Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week,,Completed,No Results Available,Healthy,,Evaluation of cardiovascular risk in general practice in France estimated by the SCORE scale|Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 2008 scale D'Agostino|Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 1998 scale Wilson|Evaluation of arteries age evaluation by SCORE,AstraZeneca,All,"50 Years and older � (Adult, Older Adult)",,9246,Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,NIS-CFR-XXX-2011/1,October 2011,October 2011,October 2011,"March 4, 2011",,"November 6, 2011","Research Site, Achenheim, France|Research Site, Aizenay, France|Research Site, Albi, France|Research Site, Alencon, France|Research Site, Ales, France|Research Site, Algrange, France|Research Site, Alignan Du Vent, France|Research Site, Allauch, France|Research Site, Alleins, France|Research Site, Allonnes, France|Research Site, Allouagne, France|Research Site, Ambes, France|Research Site, Ambleteuse, France|Research Site, Amelie Les Bains Palalda, France|Research Site, Amfreville, France|Research Site, Amiens, France|Research Site, Angers, France|Research Site, Aniche, France|Research Site, Annecy Le Vieux, France|Research Site, Annemasse, France|Research Site, Annezin, France|Research Site, Annoeullin, France|Research Site, Anthony, France|Research Site, Antibes, France|Research Site, Anzin, France|Research Site, Arcachon, France|Research Site, Argeliers, France|Research Site, Argentan Cedex, France|Research Site, Armentieres, France|Research Site, Arradon, France|Research Site, Arras, France|Research Site, ARS, France|Research Site, Asfeld, France|Research Site, Asnieres Sur Seine, France|Research Site, Aubagne, France|Research Site, Aubiere, France|Research Site, Auchel, France|Research Site, Audincourt, France|Research Site, Auneau, France|Research Site, Aurillac, France|Research Site, Auxerre, France|Research Site, Avignon, France|Research Site, Avize, France|Research Site, Avord Cedex, France|Research Site, Avranches, France|Research Site, Badonviller, France|Research Site, Bailleul, France|Research Site, Bain de Bretagne, France|Research Site, Baixas, France|Research Site, Ballancourt, France|Research Site, Balma, France|Research Site, Bandol, France|Research Site, Banyuls Sur Mer, France|Research Site, Barbentane, France|Research Site, Basse Goulaine, France|Research Site, Bassussarry, France|Research Site, Bazeilles, France|Research Site, Bazet, France|Research Site, Beaucouze, France|Research Site, Beaumont Hague, France|Research Site, Beaumont Les Valence, France|Research Site, Beaune La Rolande, France|Research Site, Beauvais, France|Research Site, Behren Les Forbach, France|Research Site, Belfort, France|Research Site, Belleville Sur Meuse, France|Research Site, Bergerac, France|Research Site, Bernin, France|Research Site, Besancon, France|Research Site, Bessancourt, France|Research Site, Betaille, France|Research Site, Betheniville, France|Research Site, Beziers, France|Research Site, Biarritz, France|Research Site, Bitche, France|Research Site, Blagnac, France|Research Site, Blangy Sur Bresle, France|Research Site, Blanzat, France|Research Site, Blere, France|Research Site, Blois, France|Research Site, Boen, France|Research Site, Bois Bernard, France|Research Site, Bolquere, France|Research Site, Bonson, France|Research Site, Bordeaux, France|Research Site, Bosmie L Aiguille, France|Research Site, Bouguenais, France|Research Site, Bourbonne Les Bains, France|Research Site, Bourges, France|Research Site, Bousse, France|Research Site, Boynes, France|Research Site, Brassac, France|Research Site, Bresles, France|Research Site, Brest, France|Research Site, Briancon, France|Research Site, Brie Comte Robert, France|Research Site, Bron, France|Research Site, Bruay La Buissiere, France|Research Site, Bruay Sur L Escaut, France|Research Site, Cabannes, France|Research Site, Caen, France|Research Site, Cagnes Sur Mer, France|Research Site, Cahagnes, France|Research Site, Calais, France|Research Site, Calonne Ricouart, France|Research Site, Caluire Et Cuire, France|Research Site, Cambrai, France|Research Site, Campagne Les Wardrecques, France|Research Site, Cancon, France|Research Site, Cannes, France|Research Site, Carnon Plage, France|Research Site, Caromb, France|Research Site, Carpentras, France|Research Site, Carvin, France|Research Site, Castres, France|Research Site, Caudry, France|Research Site, Caunes Minervois, France|Research Site, Cerizay, France|Research Site, Cessy, France|Research Site, Ceyrat, France|Research Site, Chalons En Champagne, France|Research Site, Chambery, France|Research Site, Champagne Sur Oise, France|Research Site, Chanceaux Sur Choisille, France|Research Site, Chaource, France|Research Site, Chatillon Sur Marne, France|Research Site, Chelles, France|Research Site, Chirac, France|Research Site, Claye Souilly, France|Research Site, Clermont Ferrand, France|Research Site, Clermont, France|Research Site, Clisson, France|Research Site, Clouange, France|Research Site, Collioure, France|Research Site, Colmar, France|Research Site, Colombey Les Belles, France|Research Site, Colomiers, France|Research Site, Commercy, France|Research Site, Communay, France|Research Site, Cormeilles En Parisis, France|Research Site, Coudekerque Branche, France|Research Site, Coulanges La Vineuse, France|Research Site, Courcelles Sur Nied, France|Research Site, Cournon D Auvergne, France|Research Site, Coursan, France|Research Site, Creches Sur Saone, France|Research Site, Crecy En Ponthieu, France|Research Site, Crehange, France|Research Site, Crespin, France|Research Site, Cubjac, France|Research Site, Cucuron, France|Research Site, Cugnaux, France|Research Site, Dambach La Ville, France|Research Site, Danjoutin, France|Research Site, Denain, France|Research Site, Dessenheim, France|Research Site, Deuil La Barre, France|Research Site, Deville Les Rouen, France|Research Site, Diebling, France|Research Site, Dieppe, France|Research Site, Dijon, France|Research Site, Domene, France|Research Site, Domont, France|Research Site, Draguignan, France|Research Site, Dunieres, France|Research Site, Echenoz La Meline, France|Research Site, Einville Au Jard, France|Research Site, Elliant, France|Research Site, Emmerin, France|Research Site, Epinac, France|Research Site, Epinal, France|Research Site, Eragny Sur Oise, France|Research Site, Etampes Sur Marne, France|Research Site, Evry, France|Research Site, Excideuil, France|Research Site, Eyguieres, France|Research Site, Fegersheim, France|Research Site, Figeac, France|Research Site, Firminy, France|Research Site, Flavignac, France|Research Site, Fontaine Les Dijon, France|Research Site, Fontaine Notre Dame, France|Research Site, Fontenilles, France|Research Site, Fors, France|Research Site, Fos Sur Mer, France|Research Site, Fosses, France|Research Site, Fraisses, France|Research Site, Francescas, France|Research Site, Frasne, France|Research Site, Fresnes Sur Escaut, France|Research Site, Frontigny, France|Research Site, Frouard, France|Research Site, Gamaches, France|Research Site, GAP, France|Research Site, Gardanne, France|Research Site, Garges Les Gonesse, France|Research Site, Gerbeviller, France|Research Site, Gignac La Nerthe, France|Research Site, Givry En Argonne, France|Research Site, Gonesse, France|Research Site, Grasse, France|Research Site, Greasque, France|Research Site, Grenade Sur L Adour, France|Research Site, Grenoble, France|Research Site, Gresy Sur Aix, France|Research Site, Guesnain, France|Research Site, Guignicourt, France|Research Site, Guiscriff, France|Research Site, Guyancourt, France|Research Site, Hambye, France|Research Site, Hatten, France|Research Site, Hayange, France|Research Site, Hazebrouck, France|Research Site, Hellemmes Lille, France|Research Site, Herblay, France|Research Site, Hericourt, France|Research Site, Heric, France|Research Site, Herlies, France|Research Site, Holtzheim, France|Research Site, Hombourg, France|Research Site, Houilles, France|Research Site, Hyeres, France|Research Site, Illkirch Graffenstaden, France|Research Site, Issy Les Moulineaux, France|Research Site, Ivry Sur Seine, France|Research Site, Jardin, France|Research Site, Josnes, France|Research Site, Joue Sur Erdre, France|Research Site, Jouy Le Chatel, France|Research Site, Juan Les Pins, France|Research Site, Kurtzenhouse, France|Research Site, L Hay Les Roses, France|Research Site, L Isle Sur La Sorgue, France|Research Site, La Boussac, France|Research Site, La Chabossiere, France|Research Site, La Chaussee St Victor, France|Research Site, La Farlede, France|Research Site, La Foret Sur Sevre, France|Research Site, La Garnache, France|Research Site, La Grand Croix, France|Research Site, La Madeleine, France|Research Site, La Motte Servolex, France|Research Site, La Neuville Roy, France|Research Site, La Riche, France|Research Site, La Roche En Brenil, France|Research Site, La Rochelle, France|Research Site, La Saussaye, France|Research Site, La Teste de Buch, France|Research Site, La Tour de Salvagny, France|Research Site, La Turballe, France|Research Site, La Varenne St Hilaire, France|Research Site, Labouheyre, France|Research Site, Laguenne, France|Research Site, Lambersart, France|Research Site, Landeleau, France|Research Site, Landerneau, France|Research Site, Landrecies, France|Research Site, Langoiran, France|Research Site, Lapugnoy, France|Research Site, Lauzun, France|Research Site, Laval, France|Research Site, Lavardac, France|Research Site, Laventie, France|Research Site, Lavoute Sur Loire, France|Research Site, Laxou, France|Research Site, Lay St Christophe, France|Research Site, Le Bono, France|Research Site, Le Bourget, France|Research Site, Le Cannet, France|Research Site, Le Clion Sur Mer, France|Research Site, Le Gouray, France|Research Site, Le Grand Lemps, France|Research Site, Le Grand Quevilly, France|Research Site, Le Havre, France|Research Site, Le Houlme, France|Research Site, Le Lavandou, France|Research Site, Le Mee Sur Seine, France|Research Site, Le Petit Quevilly, France|Research Site, Le Pin En Mauges, France|Research Site, Le Plessis Robinson, France|Research Site, Le Pontet, France|Research Site, Le Roc St Andre, France|Research Site, Le Russey, France|Research Site, Le Temple de Bretagne, France|Research Site, Le Vigan, France|Research Site, Lembach, France|Research Site, Les Clayes Sous Bois, France|Research Site, Les Mureaux, France|Research Site, Les Pavillons Sous Bois, France|Research Site, Les Sables D Olonne, France|Research Site, Levallois Perret, France|Research Site, Liancourt, France|Research Site, Lieuran Les Beziers, France|Research Site, Lievin, France|Research Site, Lille Cedex, France|Research Site, Lille, France|Research Site, Limoges, France|Research Site, Limoux, France|Research Site, Lingolsheim, France|Research Site, Lion Sur Mer, France|Research Site, Loches, France|Research Site, Lodeve, France|Research Site, Loeuilly, France|Research Site, Lomme, France|Research Site, Longpont Sur Orge, France|Research Site, Longueau, France|Research Site, Loos En Gohelle, France|Research Site, Louviers, France|Research Site, Louvigny, France|Research Site, Luneville, France|Research Site, Luxeuil Les Bains, France|Research Site, Mache, France|Research Site, Magland, France|Research Site, Malakoff, France|Research Site, Malataverne, France|Research Site, Marcille Robert, France|Research Site, Margency, France|Research Site, Marignane, France|Research Site, Marles Les Mines, France|Research Site, Maroilles, France|Research Site, Maromme, France|Research Site, Marquette Lez Lille, France|Research Site, Marquion, France|Research Site, Marseillette, France|Research Site, Marseille, France|Research Site, Mauleon Soule, France|Research Site, Maxeville, France|Research Site, Meaux, France|Research Site, Mehun Sur Yevre, France|Research Site, Melisey, France|Research Site, Mereville, France|Research Site, Merignac, France|Research Site, Merlimont, France|Research Site, Merville, France|Research Site, Meslay Du Maine, France|Research Site, Mesvres, France|Research Site, Metz, France|Research Site, Meylan, France|Research Site, Mezin, France|Research Site, Migniers, France|Research Site, Mions, France|Research Site, Molsheim, France|Research Site, Moncrabeau, France|Research Site, Monnieres, France|Research Site, Montcenis, France|Research Site, Montdidier, France|Research Site, Montfaucon Montigne, France|Research Site, Montfort Sur Meu, France|Research Site, Montigny Le Bretonneux, France|Research Site, Montlucon, France|Research Site, Montluel, France|Research Site, Montoir de Bretagne, France|Research Site, Montpellier, France|Research Site, Montreuil L Argille, France|Research Site, Montreuil, France|Research Site, Montrond Le Chateau, France|Research Site, Montrouge, France|Research Site, Morangis, France|Research Site, Moreuil, France|Research Site, Mougins Le Haut, France|Research Site, Mouilleron Le Captif, France|Research Site, Mouliherne, France|Research Site, Moulins Les Metz, France|Research Site, Moutiers Les Mauxfaits, France|Research Site, Mouvaux, France|Research Site, Mulhouse Cedex 1, France|Research Site, Mulhouse, France|Research Site, Mundolsheim, France|Research Site, Murs Erigne, France|Research Site, Nalliers, France|Research Site, Nancy, France|Research Site, Nantes, France|Research Site, Narbonne, France|Research Site, Nasbinals, France|Research Site, Naucelle, France|Research Site, Neuilly Sur Marne, France|Research Site, Neuilly Sur Seine, France|Research Site, Nevers, France|Research Site, Nice, France|Research Site, Nieppe, France|Research Site, Nimes, France|Research Site, Notre Dame D Oe, France|Research Site, Notre Dame de Monts, France|Research Site, Nouan Le Fuzelier, France|Research Site, Noyon, France|Research Site, Oermingen, France|Research Site, Oignies, France|Research Site, Olivet, France|Research Site, Oradour Sur Vayres, France|Research Site, Orchies, France|Research Site, Orleans, France|Research Site, Orthez, France|Research Site, Orvault, France|Research Site, Ostwald, France|Research Site, Paray Le Monial, France|Research Site, Paris, France|Research Site, Parthenay, France|Research Site, Passy, France|Research Site, Pauillac, France|Research Site, PAU, France|Research Site, Pavilly, France|Research Site, Peltre, France|Research Site, Percy, France|Research Site, Pernes Les Fontaines, France|Research Site, Peronne, France|Research Site, Perpignan, France|Research Site, Pessac, France|Research Site, Pfetterhouse, France|Research Site, Phalsbourg, France|Research Site, Pierrefitte Sur Sauldre, France|Research Site, Pithiviers, France|Research Site, Pleubian, France|Research Site, Ploeren, France|Research Site, Plouzane, France|Research Site, Poissy, France|Research Site, Poitiers, France|Research Site, Pompey, France|Research Site, Pont A Mousson, France|Research Site, Pont Aven, France|Research Site, Pont de L Arche, France|Research Site, Portes Les Valence, France|Research Site, Pouilly En Auxois, France|Research Site, Pouilly Sous Charlieu, France|Research Site, Puget Sur Argens, France|Research Site, Puy L Eveque, France|Research Site, Puylaurens, France|Research Site, Puyricard, France|Research Site, Quarouble, France|Research Site, Quevreville La Poterie, France|Research Site, Quincy Voisins, France|Research Site, Quint Fonsegrives, France|Research Site, Raches, France|Research Site, Ramonville St Agne, France|Research Site, Rauzan, France|Research Site, Rebais, France|Research Site, Reims, France|Research Site, Renage, France|Research Site, Rennes, France|Research Site, Reyrieux, France|Research Site, Richebourg, France|Research Site, Richemont, France|Research Site, Riedisheim, France|Research Site, Rieux Minervois, France|Research Site, Rigney, France|Research Site, Riom, France|Research Site, Rive de Gier, France|Research Site, Roeulx, France|Research Site, Rognonas, France|Research Site, Romagnat, France|Research Site, Romagne, France|Research Site, Romainville, France|Research Site, Rosieres Aux Salines, France|Research Site, Roubaix, France|Research Site, Rouen, France|Research Site, Rousies, France|Research Site, Rouvroy, France|Research Site, Royan, France|Research Site, Rueil Malmaison, France|Research Site, Sail Sous Couzan, France|Research Site, Sainghin En Melantois, France|Research Site, Samer, France|Research Site, Sarre Union, France|Research Site, Sarrebourg, France|Research Site, Saverne, France|Research Site, Schiltigheim, France|Research Site, Schirrhein, France|Research Site, Segonzac, France|Research Site, Segre, France|Research Site, Selestat, France|Research Site, Sene, France|Research Site, Senones, France|Research Site, Sessenheim, France|Research Site, Sete, France|Research Site, Sevran, France|Research Site, Six Fours Les Plages, France|Research Site, Sotteville Les Rouen, France|Research Site, Soucy, France|Research Site, St Amant Tallende, France|Research Site, St Aubin Sur Scie, France|Research Site, St Barthelemy, France|Research Site, St Bonnet de Mure, France|Research Site, St Bonnet Le Chateau, France|Research Site, St Brieuc Cedex 1, France|Research Site, St Chamond, France|Research Site, St Claude de Diray, France|Research Site, St Cyr Sur Loire, France|Research Site, St Denis Les Bourg, France|Research Site, St Denis Les Ponts, France|Research Site, St Etienne de Montluc, France|Research Site, St Etienne Du Rouvray, France|Research Site, St Etienne Les Remiremont, France|Research Site, St Etienne, France|Research Site, St Georges de Didonne, France|Research Site, St Georges Du Bois, France|Research Site, St Germain Du Puy, France|Research Site, St Herblain, France|Research Site, St Jean de Braye, France|Research Site, St Jean Pied de Port, France|Research Site, St Jean, France|Research Site, St Julien de Civry, France|Research Site, St Junien, France|Research Site, St Laurent de Neste, France|Research Site, St Laurent Du Var, France|Research Site, St Leger Des Bois, France|Research Site, St Leonard de Noblat, France|Research Site, St Lo, France|Research Site, St Malo, France|Research Site, St Martin D Oney, France|Research Site, St Martin La Plaine, France|Research Site, St Martin Le Vinoux, France|Research Site, St Maurice Les Chateauneuf, France|Research Site, St Maximin La Ste Baume, France|Research Site, St Max, France|Research Site, St Montan, France|Research Site, St Nazaire, France|Research Site, St Omer, France|Research Site, St Orens de Gameville, France|Research Site, St Ouen Du Tilleul, France|Research Site, St Pierre Des Corps, France|Research Site, St Priest, France|Research Site, St Raphael, France|Research Site, St Saturnin Les Apt, France|Research Site, St Sauflieu, France|Research Site, St Savournin, France|Research Site, St Victurnien, France|Research Site, St Vincent de Tyrosse, France|Research Site, St Vrain, France|Research Site, Stains, France|Research Site, Ste Anastasie, France|Research Site, Ste Feyre, France|Research Site, Ste Marguerite, France|Research Site, Ste Marie Aux Chenes, France|Research Site, Ste Savine, France|Research Site, Stiring Wendel, France|Research Site, Strasbourg, France|Research Site, Suce Sur Erdre, France|Research Site, Surgeres, France|Research Site, Tabanac, France|Research Site, Tarbes, France|Research Site, Targon, France|Research Site, Tarnos, France|Research Site, Taverny, France|Research Site, Terminiers, France|Research Site, Thiezac, France|Research Site, Toulouse, France|Research Site, Tourcoing, France|Research Site, Tours, France|Research Site, Tracy Le Mont, France|Research Site, Troarn, France|Research Site, Valenciennes, France|Research Site, Vandoeuvre Les Nancy, France|Research Site, Vannes, France|Research Site, Varennes Vauzelles, France|Research Site, Velizy Villacoublay, France|Research Site, Vemars, France|Research Site, Vence, France|Research Site, Vendenheim, France|Research Site, Venelles, France|Research Site, Vernouillet, France|Research Site, Versailles, France|Research Site, Vertaizon, France|Research Site, Vic La Gardiole, France|Research Site, Vidauban, France|Research Site, Vieux Conde, France|Research Site, Villefranche Sur Saone, France|Research Site, Villefranque, France|Research Site, Villejuif, France|Research Site, Villeneuve Loubet, France|Research Site, Villeneuve Sur Lot Cedex, France|Research Site, Villeurbanne, France|Research Site, Villey St Etienne, France|Research Site, Villiers En Plaine, France|Research Site, Vitrolles, France|Research Site, Vitry Le Francois, France|Research Site, Vittel, France|Research Site, Voiron, France|Research Site, Voisins Le Bretonneux, France|Research Site, Voujeaucourt, France|Research Site, Wallers, France|Research Site, Warmeriville, France|Research Site, Wasquehal, France|Research Site, Wattrelos, France|Research Site, Waziers, France|Research Site, Willems, France|Research Site, Wingles, France|Research Site, Yenne, France|Research Site, Yutz, France",,https://ClinicalTrials.gov/show/NCT01308372,NCT01308372,
oui,NCT01312727,Hereditary Tubulointerstitial Nephritis,NTIH,Completed,No Results Available,"Nephritis, Interstitial|Chronic Renal Failure|Gout|Renal Cysts",Other: Blood and urine sample collections,Genotype of HTIN|Uromodulin dosage in urine,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,225,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,P081258,November 2010,February 2014,July 2016,"March 11, 2011",,"August 26, 2016","Hôpital Necker Enfants Malades, Paris, France",,https://ClinicalTrials.gov/show/NCT01312727,NCT01312727,
oui,NCT01312740,Effects of Two Hypocaloric Diets on Weight Loss,,Completed,No Results Available,Obesity,Other: LC-P-LGI diet|Other: LC-CONV,,"Ceprodi S.A. Kot|Institut National de la Santé Et de la Recherche Médicale, France|Pierre and Marie Curie University|Assistance Publique - Hôpitaux de Paris",All,25 Years to 60 Years   (Adult),Not Applicable,13,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,RCB: 2007-A00329-44,May 2007,December 2007,July 2008,"March 11, 2011",,"March 11, 2011","Assistant pubique-hopitaux Paris, Paris, France",,https://ClinicalTrials.gov/show/NCT01312740,NCT01312740,22170375
oui,NCT01313260,Structural and Functional Connectivity in Partial Epilepsies Studied With MRI and MEG,,Unknown status,No Results Available,Epilepsies,,Epileptic network assessed using structural and functional connectivity measures obtained with MRI and MEG,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 55 Years   (Adult),,45,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C09-21|2010-A00399-30,February 2011,,,"March 11, 2011",,"September 28, 2012","ICM (Brain and Spine Institute), Paris, France",,https://ClinicalTrials.gov/show/NCT01313260,NCT01313260,
oui,NCT01314690,Human Intestinal Microbiota in Obesity and Nutritional Transition,Micro-Obes,Completed,No Results Available,Obesity,Other: Caloric transition,weight loss|intestinal microbiota genes|Body fat mass|Food intake|plasma glucose|adipose tissue genes,"Ceprodi S.A. Kot|Institut National de la Santé Et de la Recherche Médicale, France|Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement|Pierre and Marie Curie University|Assistance Publique - Hôpitaux de Paris",All,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,49,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research,RCB 2008-A00406-49,September 2008,September 2009,March 2011,"March 14, 2011",,"March 14, 2011","Assistance publique-hopitaux de Paris, Paris, France",,https://ClinicalTrials.gov/show/NCT01314690,NCT01314690,30804813;26100928;25330000;24172304
oui,NCT01325025,Imaging Study of the White Matter Lesions in Children With Metachromatic Leucodystrophy,HCIT-MLD,Completed,No Results Available,Late Infantile Metachromatic Leukodystrophy,Other: High-field MRI (3 Teslas),"Assess the natural history of the white matter and cortex lesions in MLD using diffusion tensor imaging (DTI)and relaxometry/ high field MRI.|Assess the natural history of the white matter and cortex lesions in MLD using using multi-voxel spectroscopic imaging.|Assess the evolution of cortical atrophy,|Correlate the neuroimaging parameters with motor function measure (Gross Motor Function Measure) and cognitive tests (BSID, WPPSI).",Assistance Publique - H�pitaux de Paris|European Leukodystrophy Association,All,1 Year to 6 Years � (Child),Not Applicable,29,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),P071232,November 2010,March 2016,July 2016,"March 29, 2011",,"August 2, 2016","Unit� de recherche biom�dicale, Neurospin, I2BM / DSV / SAC/ CEA,, Gif-sur-yvette, France|Service de Neurologie P�diatrique, H�pital Bic�tre, Paris, France|B�timent Lavoisier - Unit� INSERM U 663,H�pital Necker Enfants Malades, Paris, France",,https://ClinicalTrials.gov/show/NCT01325025,NCT01325025,
oui,NCT01331876,Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy,TOC TOC,Completed,No Results Available,Obsessive Compulsive Disorder,Behavioral: Cognitive and behavioral Therapy,Changes in brain activity associated with different types of Cognitive Behavioral Therapy Obsessive Compulsive Disorder,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C09-02|2009-A00652-55,October 2009,April 2012,July 2012,"April 8, 2011",,"October 2, 2012","Pitié-Salpêtrière hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01331876,NCT01331876,
anrs,NCT01332955,Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen,TelapreVIH,Completed,No Results Available,"Hepatitis C, Chronic|HIV Infection",Drug: Telaprevir|Biological: pegIFN alfa-2a|Drug: Ribavirin,"Estimation of SVR following a 12 wks treatment by telaprevir combined with a 48 or 72 wks peginterferon-ribavirin treatment, based upon the rapid virological response, and comparison to 20% (which would correspond to a significant therapeutic benefit)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Estimation of the Sustained Virological Response defined as undetectable HCV-RNA at Week 12 after the end of HCV treatment","ANRS, Emerging Infectious Diseases|Janssen-Cilag Ltd.",All,"18 Years and older � (Adult, Older Adult)",Phase 2,70,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-023287-41|ANRS HC26 TelapreVIH,April 2011,September 2013,September 2013,"April 11, 2011",,"January 23, 2014","Service Maladies Infectieuses et Tropicales, H�pital de la Croix-Rousse, Lyon, France",,https://ClinicalTrials.gov/show/NCT01332955,NCT01332955,25139963
oui,NCT01333735,Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon,COG AGE,Completed,No Results Available,Breast Cancer,,impact of memory impairment|correlations between disorders of cognitive functions and parameters of quality of life|Relationship between performance and onco-geriatric cognitive|Biological disturbances|Impact of age|lived of the entourage,"Centre Francois Baclesse|National Cancer Institute, France|Sanofi",Female,66 Years and older � (Older Adult),,114,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,COG AGE,December 2008,July 2015,July 2015,"April 12, 2011",,"September 4, 2015","Universit�, Bruxelles, Belgium|INSERM, Caen, Calvados, France|CHU, Caen, Calvados, France|Centre Fran�ois BACLESSE, Caen, Calvados, France|H�pital Saint-Louis, Paris, Ile de France, France|Hopital Piti�-Sap�tri�re, Paris, Ile de France, France|Hopital TENON, Paris, Ile de France, France|CHRU H�pital Claude Huriez, Lille, Nord, France|Hopital g�riatrique des Bateliers, Lille, Nord, France|Universit�, Lille, Nord, France|CHU, H�pital Bois Guillaume, Rouen, Seine Maritime, France|CHU, Rouen, Seine Maritime, France|Centre Henri BECQUEREL, Rouen, Seine Maritime, France|H�pital Charles FOIX, IVRY sur SEINE, France|Hopitaux universitaires, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT01333735,NCT01333735,
oui,NCT01335828,Elastography Interest in the Management of Thyroid Nodules,SWETHY,Completed,No Results Available,Thyroid Nodules,Device: Medical ultrasound device (ShearWave system),Defined echo/elastography benignity criteria|Evaluate the diagnostic performance of elastography ShearWave for characterization of thyroid nodules in a population of patients referred for needle biopsy or surgery nodule thyroid|Assessing the use of elastography in clinical practice,"AdministrateurCIC|University Hospital, Grenoble",All,"18 Years and older � (Adult, Older Adult)",Phase 2|Phase 3,125,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,DCIC 10 24,November 2010,October 2012,November 2012,"April 14, 2011",,"January 25, 2013","Clinical Investigation Center - Technological Innovation - Inserm 803 - University Hospital France, Grenoble, France",,https://ClinicalTrials.gov/show/NCT01335828,NCT01335828,
oui,NCT01335841,Evaluation of an 3D Imaging Intensifier Coupled to a Navigation Station in the Surgery of the Spine and Pelvis,FLUORONAV,Completed,No Results Available,"Surgical Procedure, Unspecified",Device: Navigation station coupled with a 3D fluoroscopy,Reading number of trips extra-pedicular or extra bone in both groups on a postoperative TDM|measure radiation of the surgeon and the patient in the two groups|Show that the operative time is not increased significantly taking into account the learning curve and the benefit provided from a conventional 2-D amplifier,"AdministrateurCIC|PRAXIM company|University Hospital, Grenoble",All,"18 Years and older � (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant),DCIC-10 25,March 2011,July 2012,July 2012,"April 14, 2011",,"January 25, 2013","Clinical Investigation Center - Technological Innovation - Inserm 803 - University Hospital France, Grenoble, France",,https://ClinicalTrials.gov/show/NCT01335841,NCT01335841,
oui,NCT01338441,Selections of Subjects With Important Changes in Their Cardiac Repolarization Parameters for the Procurement of Skin and Blood Samples,iQTEST,Completed,No Results Available,Cardiology: RR / QT,Drug: Erythromycin|Drug: Placebo,Prolongation of cardiac QT due to erythromycin compare to Placebo reported as Delta QTcf|Comparison Delta QTcf eryhtromycin-sotalol|Assess the effect of erythromycin Twave morphologie changes,"Ectycell SASU|Pierre and Marie Curie University|Institut National de la Sant� Et de la Recherche M�dicale, France",All,18 Years to 40 Years � (Adult),Phase 1,130,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)",2010-022000-41,March 2011,May 2011,August 2011,"April 19, 2011",,"September 15, 2011","BIOTRIAL, Rueil Malmaison, France",,https://ClinicalTrials.gov/show/NCT01338441,NCT01338441,28134617
anrs,NCT01348308,Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients,OPTIMAL,Completed,No Results Available,HIV-1 Infection|AIDS,Drug: Maraviroc (Celsentri)|Drug: Placebo,"To demonstrate the clinical benefit of the adjunction of Maraviroc to a combination of antiretroviral therapy defined as decrease of clinical events|Safety evaluation and Clinical, Immunological and pharmacological evaluation","ANRS, Emerging Infectious Diseases|Pfizer",All,"18 Years and older � (Adult, Older Adult)",Phase 3,407,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2010-022293-14|ANRS 146 OPTIMAL,September 2011,March 2016,March 2016,"May 5, 2011",,"July 12, 2016","H�pital Henri Mondor, Creteil, France",,https://ClinicalTrials.gov/show/NCT01348308,NCT01348308,32040959
oui,NCT01348711,Early Placental Insufficiency Screening,BIODOP-T1,Completed,No Results Available,Pre-eclampsia,,Occurrence for Pre-eclampsia or SGA|Early onset pre-eclampsia|Severe pre-eclampsia,"University Hospital, Tours|Institut National de la Sant� Et de la Recherche M�dicale, France",Female,"18 Years and older � (Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PHRI/06/FP-BIODOP-T1,May 2007,February 2011,May 2011,"May 5, 2011",,"May 5, 2011","Hospital of Blois -Service de Gyn�cologie-Obst�trique, Blois, France|CHRU H�pital H�tel-Dieu D�partement Gyn�cologie Obst�trique, Nantes, France|H�pital La Mil�trie, CHRU Poitiers, Poitiers, France|Olympe de Gouges Women Health Centre, Bretonneau University Hospital, Tours, France",,https://ClinicalTrials.gov/show/NCT01348711,NCT01348711,
oui,NCT01349387,Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing,METFORGENE,Completed,No Results Available,Type 2 Diabetes,Drug: Metformin,Comparison of expression of isoforms A and B of the insulin receptor using quantitative RT PCR,Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diab�te,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,25,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2010-A01389-30|2011-000128-13,May 2011,November 2011,January 2012,"May 6, 2011",,"February 9, 2012","Centre Hospitalier Sud Francilien, Corbeil Essonnes, France",,https://ClinicalTrials.gov/show/NCT01349387,NCT01349387,
oui,NCT01359774,31P-MRS and Huntington Disease,PRO-MH,Completed,No Results Available,Huntington Disease,Other: 31P-MR spectroscopy|Other: 31P-RMN spectroscopy,Brain energy deficit in Huntington patients|Correlating a brain energy deficit with (i) biochemical parameters and (ii) clinical parameters in Huntington patients,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,C10-56|2011-A00137-34,April 2011,April 2012,April 2012,"May 25, 2011",,"September 21, 2012","Hopital de la Pitié-Salpetrière, Paris, France",,https://ClinicalTrials.gov/show/NCT01359774,NCT01359774,
oui,NCT01362777,Rehabilitation Program as an Alternative Therapy for Moderate to Severe Obstructive Sleep Apnea Syndrome,Rehsolvas,Completed,No Results Available,"Sleep Apnea, Obstructive|Metabolic Syndrome",Behavioral: In-patient rehabilitation|Behavioral: Educational activities alone,Delta of the Apnea/Hypopnea Index (AHI)between the two arms,5 Sant�|A.E.R.O.B.I.E.|INSERM U1046 Physiologie et m�decine exp�rimentale du c�ur et des muscles,All,"30 Years to 70 Years � (Adult, Older Adult)",Phase 3,26,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UF062007,November 2007,June 2010,August 2010,"May 30, 2011",,"September 20, 2011","Clinique du souffle ""La Solane"", Osseja, France",,https://ClinicalTrials.gov/show/NCT01362777,NCT01362777,24947878
oui,NCT01374880,Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease,,Unknown status,No Results Available,Heart Failure|Dyspnea|Pulmonary Disease,,"Long term cardiovascular mortality|Cardiac hospitalization(s) at 3, 6,12 and 24 months|Diagnostic value of new biomarkers.","Institut National de la Sant� Et de la Recherche M�dicale, France|Assistance Publique - H�pitaux de Paris|University Paris 7 - Denis Diderot|ThermoFisher Scientific Brahms Biomarkers France|Hoffmann-La Roche|Alere San Diego|Servier|Helsinki University Central Hospital|University Hospital, Basel, Switzerland|Massachusetts General Hospital|The Cleveland Clinic|Maastricht University Medical Center|Department of Laboratory Medicine, Konventhospital Barmherzige Brueder, Linz, Austria|Hospital Universitario Virgen de la Arrixaca|University Hospital Monastir, Tunis|Universit� degli Studi di Brescia|Intensive and Cardiac Care Unit, Nippon Medical School, Tokyo, Japan|Brno University Hospital|University of Cape Town",All,"18 Years and older � (Adult, Older Adult)",,3000,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,CNIL number: 910198|Unit� 942 INSERM,June 2009,September 2013,January 2014,"June 16, 2011",,"August 14, 2013","Lariboisiere hospital, Paris, Ile de France, France",,https://ClinicalTrials.gov/show/NCT01374880,NCT01374880,32248819;28516737;25157115
oui,NCT01391442,4th Visit at 17 Years of Cohort STANISLAS - Stanislas Ancillary Study ESCIF,STANISLASV4,Unknown status,No Results Available,Cardiovascular Diseases,Biological: blood and urine samples|Genetic: blood sample|Other: cardiovascular assessment|Other: Stanislas ancillary study : MRI examination with GRICS technique,investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases|ESCIF ancillary study : pair-wise comparison of functional indices measured in MRI and echocardiography|ESCIF ancillary study : inter-observer reproducibility of each method (MRI and Echocardiography),"Central Hospital, Nancy, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,4006,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2010-A01469-30,July 2011,July 2016,July 2016,"July 12, 2011",,"March 8, 2016","Centre d'Investigation Clinique -Plurith�matique, Nancy, France|Centre d'Investigation Clinique- INNOVATIONS TECHNOLOGIQUES, Nancy, France",,https://ClinicalTrials.gov/show/NCT01391442,NCT01391442,34538625;34523741;32200718;31652401;27312804
oui,NCT01405430,Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab,AVECC,Completed,No Results Available,Colorectal Cancer|Metastasis,Biological: Bevacizumab + blood samples,Response rate to treatment|Clinical benefit|Evaluation of progression-free survival|Evaluation of overall survival|Evaluation of tumoral markers|Evaluation of vascular toxicities,Centre Leon Berard|UMR-S Inserm 1036,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,63,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),AVECC|ET2010-003,May 2010,May 2014,May 2014,"July 29, 2011",,"June 29, 2015","Centre L�on B�rard, LYON Cedex 08, France|H�pital Priv� Jean Mermoz, Lyon, France",,https://ClinicalTrials.gov/show/NCT01405430,NCT01405430,
oui,NCT01405495,PTSD Among Victims of Sexual Abuse and Changes in Structural and Functional Brain Connectivity,COPTSD,Completed,No Results Available,PostTraumatic Stress Disorder,"Procedure: MRI-based techniques (sMRI, fMRI, DTI, ASL)",Changes from baseline brain connectivity in sexual assault female victims who developed PTSD compared to victims without PTSD and healthy control at 6 months.|Changes from baseline cerebral activity between groups during cognitive tasks and difference between groups in measures of specific brain structure volumes at 6 months.,"University Hospital, Tours",Female,18 Years to 50 Years � (Adult),,60,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PHRI/10/WEH/COPTSD,February 2012,February 2016,August 2016,"July 29, 2011",,"May 4, 2017","Bretonneau Regional Universitary Hospital, Tours, France",,https://ClinicalTrials.gov/show/NCT01405495,NCT01405495,
oui,NCT01407640,Diagnosis and Physiopathology of Insulin Allergy,Allerdiab,Completed,No Results Available,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Hypersensitivity|Immediate Hypersensitivity|Allergy",Procedure: Allergy tests,Validation of cutaneous insulin tests|Immunogenetic of patients with IA (Insulin Allergy),"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,55,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P081223,"February 6, 2012","July 27, 2016","July 27, 2016","August 2, 2011",,"March 19, 2018","Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01407640,NCT01407640,35505238
oui,NCT01412515,A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma,,Terminated,No Results Available,Kaposi Sarcoma,Drug: everolimus,"objective response to everolimus after 6 months therapy|response according to physician global assessment, lesions size , lesions infiltration","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 2,11,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C06-46,June 2008,May 2011,May 2011,"August 9, 2011",,"January 2, 2012","Hospital Saint Louis, Paris, France",,https://ClinicalTrials.gov/show/NCT01412515,NCT01412515,
anrs,NCT01420523,Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy,ROCnRAL,Terminated,No Results Available,Human Immunodeficiency Virus|Lipohypertrophy,Drug: Raltegravir-Maraviroc,Virological failure|Viro-immunological efficacy|Tolerability criteria and metabolic impact|Compliance|Quality of life,"ANRS, Emerging Infectious Diseases|Merck Sharp & Dohme LLC|ViiV Healthcare",All,"18 Years and older � (Adult, Older Adult)",Phase 2,48,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011-002483-24,December 2011,April 2013,April 2013,"August 19, 2011",,"July 24, 2015","H�pital Piti� Salp�tri�re, Paris, France",,https://ClinicalTrials.gov/show/NCT01420523,NCT01420523,26396157;24535278
oui,NCT01425957,Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment,,Completed,No Results Available,MILD COGNITIVE IMPAIRMENT,Procedure: Lumbar puncture,Part A: Magnetic Resonance Imagery protocol|Part B: Changes of the hippocampal volume|Part B: Clinical assessment|Part B: Neuropsychology|Part B: Neurophysiology|Part B: Magnetic Resonance Imagery and functional MRI|Part B: Blood drawing|Part B: Actigraphy|Adverse events,Qualissima|European Union,All,"50 Years to 90 Years � (Adult, Older Adult)",Not Applicable,229,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,WP5P001|2011-A00985-36,December 2011,August 2015,October 2015,"August 30, 2011",,"November 1, 2015","Universit� Lille 2, UL2 - Centre d'investigation clinique / Centre de Ressources biologiques 9301 - INSERM - Centre Hospitalier R�gional et Universitaire de LILLE, Lille, France|APHM, Hopital de la Timone, Service de Neurologie et Neuropsychologie, Marseille, France|INSERM - CHU Purpan, Toulouse, France|Hospital and Institute of the University of Duisburg and Essen - Department for Psychiatry and Psychotherapy, LVR Hospital Essen, Essen, Germany|University Hospital of Leipzig - Department of Psychiatry, Leipzig, Germany|Aristotle University of Thessaloniki, Greek Association of Alzheimer's disease and related disorders, Thessaloniki, Greece, Thessaloniki, Greece|IRCCS-FBF - Ordine Ospedaliero San Giovanni di Dio, Fatebenefratelli, Istituto di Ricovero e Cura a Carattere Scientifico, Brescia, Provincia Lombardo-Veneta, Italy|Neurofisiologia Clinica IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Padiglione Specialita' piano Fondi, Genoa, Italy|IRCCS Fondazione SDN per la Ricerca e l'Alta Formazione in Diagnostica Nucleare di Napoli, Napoli, Italy|Dipartimento di Specialit� medico-chirurgiche e Sanit� Pubblica, Sezione di Clinica Neurologica, Centro Disturbi della Memoria, Perugia, Italy, Perugia, Italy|Universit� Cattolica del Sacro Cuore - Policlinico Agostino Gemelli Istituto di Neurologia - Neuropsychological and Neurorehabilitation Unit, Roma, Italy|VUmc Alzheimercentrum, Amsterdam, Netherlands|Institut d'Investigacions Biom�diques August Pi I Sunyer, IDIBAPS, Barcelona, Catalunya, Spain",,https://ClinicalTrials.gov/show/NCT01425957,NCT01425957,
oui,NCT01432821,Blinking and Yawning in Epilepsy: The Role of Dopamine,BYE BYE DOPA,Completed,No Results Available,Idiopathic Generalized Epilepsy,Other: Apomorphine (Experimental product),Number of yawn|Number of eyelid blinking|Number of eyelid blinking in both groups after apomorphin or placebo injection|Neurophysiological assessment of the dopaminergic reactivity|To test the correlation between the behavioral and neurophysiological markers of dopaminergic reactivity in patients with epilepsy|To assess dopaminergic reactivity with biological markers|Number of Adverse Events as a Measure of Safety and Tolerability|Check the absence of spike-wave discharges in healthy volunteers,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 40 Years   (Adult),Not Applicable,31,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",C10-27,September 2011,December 2012,December 2014,"September 13, 2011",,"November 6, 2016","CIC Department - University Hospital of Grenoble, La Tronche, Isere, France",,https://ClinicalTrials.gov/show/NCT01432821,NCT01432821,
oui,NCT01433276,"Efficacy, Safety of Solution Containing Hyperosmolar Sodium Lactate Infusion for Resuscitation of Patients With Hemorrhagic Shock",,Completed,No Results Available,Hemorrhagic Shock,Drug: Hyperosmolar sodium lactate|Drug: Ringer's lactate,Urinary output (UOP)|Blood pressure|Mean arterial pressure|Heart rate|Respiration rate|Glasgow coma scale value|Fluid balance,Innogene Kalbiotech Pte. Ltd,All,"18 Years to 65 Years � (Adult, Older Adult)",Phase 3,71,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,009/IGK-KAL/09,July 2009,January 2011,January 2011,"September 13, 2011",,"September 13, 2011","Department of Surgery, Dr. Hasan Sadikin Hospital, Bandung, Indonesia",,https://ClinicalTrials.gov/show/NCT01433276,NCT01433276,
oui,NCT01437683,PariS-TBI Study : Paris Severe Traumatic Brain Injury Study,PariS-TBI,Completed,No Results Available,Brain Injury|Craniocerebral Trauma|Trauma Nervous System,,Glasgow Outcome Scale-Extended|Neurobehavioural Rating Scale-Revised|Dysexecutive Questionnaire|Questionnaire of complaints (patient and care giver),"Assistance Publique - Hôpitaux de Paris|Institut de Recherche en Santé Publique, France|CRFTC|Caisse Nationale de Solidarité pour l'Autonomie|Institut National de la Santé Et de la Recherche Médicale, France|HAS|DREES",All,"15 Years and older   (Child, Adult, Older Adult)",,252,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2009-A01122-55,February 2010,October 2011,June 2012,"September 21, 2011",,"October 15, 2012","CRFTC Centre Ressources Francilien du Traumatisme Crânien, Paris, France",,https://ClinicalTrials.gov/show/NCT01437683,NCT01437683,35001023
oui,NCT01440088,A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma,,Completed,No Results Available,Soft Tissue Sarcoma,Drug: TH-302 in Combination with Doxorubicin|Drug: Doxorubicin,Efficacy of TH-302 in combination with doxorubicin|Safety of TH-302 in combination with doxorubicin in subjects with locally advanced unresectable or metastatic soft tissue sarcoma compared with doxorubicin alone,Threshold Pharmaceuticals|Sarcoma Alliance for Research through Collaboration (SARC),All,"15 Years and older � (Child, Adult, Older Adult)",Phase 3,640,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TH-CR-406/SARC021,September 2011,December 2015,May 2016,"September 26, 2011",,"June 2, 2016","Mayo Arizona, Scottsdale, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|USC-Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Stanford Comprehensive Cancer Center, Stanford, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Washington Cancer Institute, Washington, District of Columbia, United States|South Florida Center for Gynecologic Oncology, Boca Raton, Florida, United States|Mayo Clinic-Florida-Cancer Clinical Studies Unit, Jacksonville, Florida, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|H.Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Midtown Campus, Atlanta, Georgia, United States|Kootenai Health - Kootenai Cancer Center, Coeur d'Alene, Idaho, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Oncology Specialists, Park Ridge, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|University of Iowa Health Care - University of Iowa Hospital, Iowa City, Iowa, United States|Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana Farber Cancer Institute Center for Sarcoma and Bone Oncology, Boston, Massachusetts, United States|University of Michigan Cancer Center, Ann Arbor, Michigan, United States|Mayo Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Montefiore, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Columbia University Medical Center, NY, New York, United States|Carolinas Hematology-oncology Associates-Blumenthal Cancer Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston Salem, North Carolina, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Arthur G. James Cancer Hospital and Richard J Solove Research Institue, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburg Medical Center, Pittsburg, Pennsylvania, United States|MUSC - Hollings Cancer Center, Charleston, South Carolina, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Vermont, Burlington, Vermont, United States|Virginia Commonwealth Universtiy-Massey Cancer Center, Richmond, Virginia, United States|University of Washington Cancer Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University Klinikum Graz, Graz, Austria|Univ. Klinik fur Innere Medizin I Internistische Onkologie Medizinische Universitat Innsbruck, Innsbruck, Austria|Allgemeines Krankenhaus Wien, Wien, Austria|Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg, Leuven, Belgium|Juravinski Cancer Centre at Hamilton Health Sciences - Department of Medicine, Hamilton, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Tom Baker Cancer Centre, Calgary, Canada|Cross Cancer Institute, Edmonton, Canada|Ottawa Health Research Institue, Ottawa, Canada|BCCA- Vancouver Cancer Centre - Division of Medical Oncology, Vancouver, Canada|Cancer Care Manitoba, Winnipeg, Canada|University Hospital Herlev at Copenhagen, Herlev, Copenhagen, Denmark|ICO Rene Gauducheau, Saint Herblain Cedex, Nantes, France|Institut Bergonie, Bordeaux, France|Departement d'Oncologie Medicale, Dijon, France|Centre Leon Berard, Lyon, France|D�partement d'Oncologie Mol�culaire, Institut Paoli-Calmettes (IPC) and U119 Inserm, Marseille, France|Centre Antoine Lacassagne, Nice, France|CHU Strasbourg, Strasbourg, France|Institut Claudius Regaud, Toulouse Cedex, France|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Helios Klinikum Bad Saarow, Department of Hematology, Oncology, and Palliative Care, Sarcoma Center Berlin-Brandenburg, Berlin, Germany|Universit�tsklinikum Essen, Essen, Germany|Krankenhaus Nordwest GmbH, Frankfurt, Germany|Medizinische Hochschule Hannover (MHH) - Klinik fuer Haemonstaseologie, Onkologie und Stammzelltransplantation, Hannover, Germany|Div. of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Center, Mannheim, Germany|Wilhelm's University, Universitatsklinikum Muenster, Medizinische Klinik und Poliklinik A, Albert-Schweitzer-Campus 1, Munster, Germany|Magyar Honvedseg Honvedkorhaz, Onkologiai Osztaly, Budapest, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Megyei Onkologiai Kozpont, Szolnok, Hungary|Sharette Institute of Oncology, Hadassah-Hebrew University Medical Center, Hadassah Medical Org-Ein Karem, Kiryat Hadassah, Jerusalem, Israel|IRCCS Centro di Riferimento Oncologico-Struttura Operativa, Aviano, Pordenone, Italy|Fondazione del Piemonte per l'Oncologia, Instituto per la Ricerca e la Cura del cancro (I.R.C.C.), Dipartimento Oncologico, Direzione Operativa Oncologia Medica a Direzione Universitaria, Candiolo, Torino, Italy|Centro di Riferimento Oncologico (CRO), Aviano, Italy|Azienda Ospedaliera Garibaldi, Catania, Italy|Azienda Ospedaliero Universitaria-Policlinico Paolo Giacco, Palermo, Italy|ASL TO/2 di TORINO_Presidio Sanitario Gradenigo, S.C. di Oncologia, Torino, Italy|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Centrum Onkologii Instytut im M. Sklodowskiej-Curie, Krakow, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie, Warszawa, Poland|GUZ ""Regional Oncology Dispensay"", Kazan, Kazan, Russian Federation|ROTSN RAMS them. ?.?.??????? NN Blokhin, Moscow, Russian Federation|FGU Moscow Research Institute of Oncology named after P.A. Hertzen of Rosmedtechnology, Moscow, Russian Federation|H.U. Canarias, Hospital Universitario de Canarias. Servicio de Oncolog�a M�dica, Tenerife, Canarias, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Institut Catala d'Oncologia, Barcelona, Spain|Hospital Sant Joan de Deu, Department de Oncologia, Barcelona, Spain|Hospital Universitario Ram�n y Cajal., Madrid, Spain|Universidad Complutense Madrid Facultad de Medicina - Hospital Universitario 12 de Octubre, Servicio de Oncologia Medica Hospital Universitario 12 de Octubre, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01440088,NCT01440088,28651927;25185097
oui,NCT01452113,Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy,DPPNAC,Completed,No Results Available,Diabetes Mellitus,Drug: Vildagliptin,plasma glucagon concentration|GLP-1|GIP,"University Hospital, Toulouse|Institute of Molecular Medicine of Rangueil (I2MR)|Faculty of Medicine, Toulouse|Novartis Pharmaceuticals",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,21,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,1004003,October 2010,January 2013,March 2013,"October 14, 2011",,"March 12, 2014","UH Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01452113,NCT01452113,
anrs,NCT01453192,Renal Transplantation and Raltegravir in HIV-Infected Patients,ANRS153TREVE,Completed,No Results Available,HIV-1 Infection|Chronic Renal Insufficiency,Drug: Raltegravir,Incidence of acute clinical renal graft rejection|Incidence of acute clinical and subclinical renal graft rejection|One year graft survival|Patients' survival|Phenotyping of lymphocytic infiltrates in case of acute rejection|Incidence of AIDS defined diseases and severe morbidity diseases after renal transplantation|Immunological and virologic status after renal transplantation|Evaluation of the switch by raltegravir at the time of renal transplantation|Viral load control after switch by antiretroviral treatment including raltegravir after renal transplantation|Survival and waiting period of HIV patients registered on French biomedicine agency for renal transplantation|Measurement of Area under plasma concentration (AUC) variability of immunosuppressive drugs after introduction of antiretroviral regimen containing Raltegravir,"ANRS, Emerging Infectious Diseases|Merck Sharp & Dohme LLC",All,"18 Years to 70 Years � (Adult, Older Adult)",Phase 3,27,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011-001004-35|ANRS 153 TREVE,December 2011,November 2015,November 2015,"October 17, 2011",,"July 12, 2016","H�pital Pellegrin, Service de Nephrologie, Transplantation R�nale, Dialyse, Bordeaux, France|CHU De Caen, Service de N�phrologie H�modialyse, Caen, France|H�pital Henri Mondor, Service de N�phrologie Transplantation, Cr�teil, France|H�pital Kremlin Bic�tre, Service de N�phrologie, Kremlin Bic�tre, France|CHRU Lille, Service de n�phrologie, Lille, France|CHU de Nantes, Service de N�phrologie et Immunologie Clinique, Nantes, France|H�pital Pasteur, Service de N�phrologie - Transplantation, Nice, France|Hopital Saint Louis, Service de N�phrologie, Paris, France|H�pital Necker, Service de N�phrologie adulte, Paris, France|H�pital TENON, Urgences N�phrologiques et Transplantation R�nale, Paris, France|H�pital civil, Service de N�phrologie et Transplantation, Strasbourg, France|H�pital Foch, Service de N�phrologie Transplantation, Suresnes, France|H�pital Rangueil, Service de N�phrologie, HTA, Dialyse, Transplantation, Toulouse, France|H�pital Bretonneau, Service de N�phrologie, Tours, France",,https://ClinicalTrials.gov/show/NCT01453192,NCT01453192,30688008
oui,NCT01455207,From Uncomplicated Alcoholism to Korsakoff's Syndrome,ALCOBRAIN,Unknown status,No Results Available,Alcoholism|Alcohol Amnestic Disorder,Behavioral: Neuropsychological testing|Biological: blood draw|Genetic: genetic testing|Other: Brain imaging examination,Evidence of brain dysfunctioning measured by neuropsychological testing and brain examination(MRI and PET)|treatment outcomes (sobriety or relapse),"University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France|National Research Agency, France",All,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,220,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011-A00495-36|11-050,January 2012,January 2015,January 2015,"October 19, 2011",,"April 9, 2014","Caen University Hospital, Caen, France",,https://ClinicalTrials.gov/show/NCT01455207,NCT01455207,
oui,NCT01482559,Management of Hypotension In the Preterm Infant,HIP,Terminated,No Results Available,Hypotension|Low Blood Pressure|Intraventricular Hemorrhage of Prematurity,Drug: Dopamine hydrochloride|Drug: Dextrose 5%,First Co-Primary Outcome Measure: Survival to 36 weeks postmenstrual age free of severe brain injury|Second Co-Primary Outcome Measure: Survival without moderate or serious disability as defined using consensus criteria for neurodevelopmental impairment.|All cause mortality at 36 weeks gestational age,"University College Cork|Cork University Hospital|Coombe Women and Infants University Hospital|Royal College of Surgeons, Ireland|National Maternity Hospital, Ireland|University Hospital, Antwerp|KU Leuven|University of Alberta|St. Justine's Hospital|Institute for the Care of Mother and Child, Prague, Czech Republic|GABO:mi|BrePco Biopharma Limited|University College, London|Institut National de la Santé Et de la Recherche Médicale, France|Clininfo S.A.",All,23 Weeks to 27 Weeks   (Child),Phase 3,58,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HIP-FP7-BrePco|2010-023988-17,February 2015,September 2017,October 2019,"November 30, 2011",,"October 2, 2019","University Hospital Antwerp, Antwerp, Edegem, Belgium|Katholieke Universiteit Leuven, Oude God, Leuven, Belgium|University of Alberta, Edmonton, Alberta, Canada|Centre hospitalier universitaire Sainte-Justine, Montreal, Quebec, Canada|Univerzita Karlova v Praze, Prague, Czechia|Coombe Women and Infants University Hospital, Dublin 8, Dublin, Ireland|Cork University Maternity Hospital, Cork, Ireland|Royal College of Surgeons in Ireland, Dublin, Ireland|University College Dublin, Dublin, Ireland|Royal Maternity Hospital, Belfast, United Kingdom",,https://ClinicalTrials.gov/show/NCT01482559,NCT01482559,33627329
oui,NCT01489592,Effect of Curcumin on Iron Metabolism in Healthy Volunteer,CURHEP,Completed,No Results Available,Healthy Volunteers,Drug: curcuma longa,Maximal variation of serum hepcidin level after oral administration of curcumin|Plasmatic iron bioavailability|Evaluation of the inhibitory activity of volunteers's serum on hepcidin expression by hepatocytes,"Institut National de la Santé Et de la Recherche Médicale, France",Male,18 Years to 35 Years   (Adult),Phase 2,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",C11-14|2011-001925-26,October 2011,October 2011,March 2012,"December 9, 2011",,"April 11, 2013","Centre d'Investigation Clinique (CIC) , 2 rue Henri Le Guilloux , CHU Pontchaillou, Rennes, France",,https://ClinicalTrials.gov/show/NCT01489592,NCT01489592,
oui,NCT01489618,"""Prime Boost"" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency",EVAD,Terminated,No Results Available,Common Variable Immunodeficiency,Biological: PPS|Biological: PnCJ PPS,proportion of responders to each serotype,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,45,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,RBM04-34|2007-003235-23,June 2009,March 2013,March 2013,"December 9, 2011",,"February 24, 2016","Service d'Immunologie Clinique Hôpital Henri Mondor, Creteil, France",,https://ClinicalTrials.gov/show/NCT01489618,NCT01489618,
oui,NCT01490489,EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction,EGEVE,Completed,No Results Available,Pre-eclampsia|Intra-uterine Growth Retardation,Other: blood sample and doppler Ultrasound of uterine arteries,Measure of the circulating levels of EG-VEGF in the sera of pregnant woman between 14 and 18 WG|Correlation between the level of uterine artery transformation and the level of EG-VEGF.|Measure the circulating levels of other pro and/or anti-angiogenic factors|Measure the circulating levels of the new angiogenic factor EG-VEGF|Measure the circulating levels of the new angiogenic factor EG-VEGF in the sera,"Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,142,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,C09-43|2009-A01304-53,"July 11, 2011",March 2015,"March 13, 2015","December 13, 2011",,"September 1, 2021","Clinical investigation center of the Grenoble University Hospital, Grenoble, Isere, France",,https://ClinicalTrials.gov/show/NCT01490489,NCT01490489,
oui,NCT01493323,Functional Imaging of Psychic Pain,,Terminated,No Results Available,"Suicide, Attempted|Mood Disorder",Behavioral: Assessment of personality traits|Behavioral: Assessment of suicidal act|Behavioral: Assessment of depression|Procedure: Cyber ball game|Procedure: Iowa Gambling Task|Procedure: Microcomputer|Procedure: blood sample,Cerebral regions associated with psychic pain during a major depressive disorder|Cerebral regions associated with perception of social exclusion,"University Hospital, Montpellier|University Hospital, Geneva|Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 50 Years   (Adult),Not Applicable,123,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,UF 8555,May 2010,August 2014,December 2014,"December 15, 2011",,"December 4, 2014","MontpellierUniversity Hopital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT01493323,NCT01493323,
oui,NCT01493934,Development of a Fast Measurement Technique of Insulin Resistance in Human,GLUCIMAG,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: injection of 6-DIG,Change of glycemia|insulinemia|clinical side effects|dosimetry|insulin resistance,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,35 Years to 60 Years � (Adult),Phase 1|Phase 2,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C09-07|2009-014658-14,April 2010,March 2013,March 2013,"December 16, 2011",,"February 24, 2016","Service de Biophysique et M�decine Nucl�aire, CHU de Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT01493934,NCT01493934,
anrs,NCT01494961,Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries,Prenahtest,Completed,No Results Available,Partner HIV Testing|Couple HIV Counseling|Couple Communication|HIV Incidence,Behavioral: Couple-oriented post-test HIV counseling,Partner HIV testing|Couple HIV counseling|HIV incidence|Couple communication of sexual and reproductive health,French National Agency for Research on AIDS and Viral Hepatitis|Elizabeth Glaser Pediatric AIDS Foundation,Female,"15 Years and older � (Child, Adult, Older Adult)",Not Applicable,1943,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS 12127 Prenahtest,February 2009,August 2011,October 2011,"December 19, 2011",,"December 19, 2011","Centre M�re - Enfant Chantal Biya, Yaound�, Cameroon|Hospital Materno-Infantil ""San Lorenzo"" de los Mina, Santo Domingo, Dominican Republic|Maternity Hospital N�5, Tbilisi, Georgia|Sane Guruji Hospital, Pune, India",,https://ClinicalTrials.gov/show/NCT01494961,NCT01494961,34329355;29178852;23343912
oui,NCT01495897,"Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study",MOUVADOC,Completed,No Results Available,Healthy|Dystonia|Parkinson Disease,Device: Tracking eye movement|Device: Tracking eye movement under deep brain stimulation,Saccadic adaptation|Characteristics of the saccade,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C10-18|2010-A00740-39,March 2011,March 2014,March 2014,"December 20, 2011",,"February 24, 2016",": Fédération des Maladies du Système Nerveux, Paris, France",,https://ClinicalTrials.gov/show/NCT01495897,NCT01495897,
oui,NCT01508494,Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment,COGICRehab,Completed,No Results Available,Stroke|Cognitive Impairment,Drug: Galantamine|Drug: placebo,fMRI,"Institut National de la Santé Et de la Recherche Médicale, France",All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 2,47,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C10-34|2010-024313-32,"June 29, 2011",June 2016,"June 22, 2016","January 12, 2012",,"August 27, 2021","Service de Neurologie, CHU Toulouse Purpan, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01508494,NCT01508494,
anrs,NCT01509508,Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence,TasP,Completed,No Results Available,HIV Infection,Drug: Immediate ARV treatment initiation with TDF/FTC/EFV|Other: South African recommendation guided ARV (TDF/FTC/EFV) initiation,Uptake of initial and repeat HIV counselling and testing (Feasibility phase)|Uptake of ARV treatment among HIV-infected individuals (Feasibility phase)|HIV infection incidence|Sexual partnerships|Safe sex and condom use|Quality of life|Health care use and health care expenditures|Stigma at community level|Adherence to ART|Retention,"ANRS, Emerging Infectious Diseases|Africa Centre For Health and Population Studies|University of KwaZulu",All,"16 Years and older � (Child, Adult, Older Adult)",Not Applicable,28153,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS 12249 TasP,March 2012,June 2016,June 2016,"January 13, 2012",,"July 21, 2016","Hlabisa Hospital, Hlabisa, KwaZulu-Natal, South Africa",,https://ClinicalTrials.gov/show/NCT01509508,NCT01509508,32970730;31637821;30412926;30321314;30027600;29890048;29199100;28329393;27504637;25880823;23880306
oui,NCT01512277,"Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis",Bilhvax1a,Completed,No Results Available,Schistosomiasis|Bilharziasis|Urinary Schistosomiasis,Biological: rSh28GST,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Immunogenicity,"University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France",Male,18 Years to 30 Years   (Adult),Phase 1,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",CP97/104|98002|980056,September 1998,March 1999,September 1999,"January 19, 2012",,"August 27, 2013","Centre d'Investigation Clinique - CHRU de Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT01512277,NCT01512277,
anrs,NCT01514890,"French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin",CUPIC,Completed,No Results Available,Chronic Hepatitis C,,"Rate of sustained virological response (SVR) defined by an undetectable RNA by real-time PCR.|Virological response during and after the treatment with determination of HCV RNA levels as prevised by the French Early Access Program for the use of protease inhibitors and after the approval.|early viral kinetic|Rate of premature discontinuation of protease inhibitor, RBV and/or PEG-IFN|occurrence of resistant mutants in partial responders (detectable RNA) or after the occurrence of virological breakthrough and long term evolution of these mutations (on serum bank)|Evolution of quality of life scores|Evaluation of therapeutic observance with auto-questionnaires|Rate of adaptation of dosage of protease inhibitors, RBV and/or PEG-IFN","ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",,675,Other,Observational,Observational Model: Cohort|Time Perspective: Other,ANRS CO20|2010-A01273-36,February 2011,March 2014,March 2014,"January 23, 2012",,"January 24, 2017","H�pital Henri Mondor, Cr�teil, France",,https://ClinicalTrials.gov/show/NCT01514890,NCT01514890,25556540;24704719;23669289
anrs,NCT01520844,"the ANRS CO21 "" Extreme "" Cohort (CODEX)",CODEX,Recruiting,No Results Available,HIV Infection,Biological: blood sampling,"clinical and immuno-virological|mechanisms leading to the virus control and CD4 homeostasy with physiopathological studies|impact of a prolonged untreated HIV infection,|frequency of the ""immunological escapes"" (CD4 T cell decrease) or ""virological escapes"" (permanent or transient viral load increase)|genetic characteristics of the patients and those of their viruses, the innate and adaptative immune responses directed against HIV and other viruses, the consequences of inflammation, and the characteristics of the loss of control","ANRS, Emerging Infectious Diseases",All,"18 Years to 85 Years � (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,ANRS CO21 CODEX,February 2012,September 2022,September 2023,"January 30, 2012",,"July 24, 2019","Lambotte, Kremlin Bicetre, France",,https://ClinicalTrials.gov/show/NCT01520844,NCT01520844,
oui,NCT01525472,Accelerated Aging of the Cells of Visceral Adipose Tissue in Morbid Obese Subjects,SENAPID,Completed,No Results Available,Morbid Obesity,,,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years to 65 Years � (Adult, Older Adult)",,186,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,C11-18'|2011-A01070-41,"February 13, 2012",October 2015,"October 20, 2015","February 3, 2012",,"August 30, 2021","Hopital Louis Mourier, Colombes, France",,https://ClinicalTrials.gov/show/NCT01525472,NCT01525472,
oui,NCT01530685,Gycabiane and Glycemic Control of Prediabetic Subjects,,Completed,No Results Available,Hyperglycemia,Dietary Supplement: Glycabiane|Dietary Supplement: placebo,Fast Blood Glucose,PiLeJe|Larena SAS,All,"25 Years to 65 Years � (Adult, Older Adult)",Not Applicable,83,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PILEJE-Glyca-0910,"October 27, 2011","September 25, 2012","September 25, 2012","February 10, 2012",,"April 20, 2021","CHU Piti� Salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT01530685,NCT01530685,26406981
oui,NCT01530906,Efficiency of Repetitive Transcranial Magnetic Stimulation (rTMS) in Bulimia,rTMS&bulimia,Unknown status,No Results Available,Bulimia Nervosa,Procedure: Repetitive transcranial Magnetic Stimulation (rTMS)|Procedure: Repetitive transcranial Magnetic Stimulation SHAM,Efficiency of rTMS in bulimia,"University Hospital, Montpellier|Centre Hospitalier Universitaire de Saint Etienne|University Hospital, Marseille|Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 40 Years   (Adult),Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",8709|2011-A01018-33,January 2012,March 2015,September 2015,"February 10, 2012",,"December 3, 2014","Montpellier University Hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT01530906,NCT01530906,30240526
oui,NCT01531036,3D Breast Ultrasound Elastography in Patients Under Neoadjuvant Chemotherapy,,Completed,No Results Available,Malignant Breast Tumours,Device: 3D Ultrasound elastography by means of shear wave propagation into breast tissue,3D volumetric elasticity measurements,"Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C10-02|2010-A00663-36,December 2010,November 2012,November 2012,"February 10, 2012",,"February 25, 2016","Curie Cancer Institute, Paris, France",,https://ClinicalTrials.gov/show/NCT01531036,NCT01531036,
oui,NCT01534728,Identification of Hepatitis C Virus (HCV) Specific T Cells,TETRA,Completed,No Results Available,Hepatitis C,,,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),,40,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,C11-33|2011-A01226-35,February 2012,March 2014,March 2014,"February 17, 2012",,"January 13, 2015","Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01534728,NCT01534728,
oui,NCT01536483,Effects of Recto-colic Enemas of Butyrate on the Digestive Disorders of Very Low Birth Weight Preterms <1250 Grams,NEOTRANS,Terminated,No Results Available,Very Low Birth Weight Preterms,Drug: Butyrate enemas,Efficacy of colonic butyrate enemas in digestive maturation of preterms|Gastrointestinal complications frequency|Nosocomial infections frequency|Iatrogenic effect|whole gut transit time (red carmine test)|Growth|Invasive ventilation support|Bronchopulmonary dysplasia incidence|Hospitalization duration|Neuromotor development,Nantes University Hospital,All,5 Days to 5 Days � (Child),Phase 2|Phase 3,61,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BRD/10/04-H,February 2012,March 2016,March 2016,"February 22, 2012",,"May 11, 2016","Nantes, Nantes, France",,https://ClinicalTrials.gov/show/NCT01536483,NCT01536483,
oui,NCT01538342,Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis,,Unknown status,No Results Available,Psoriasis|Atopic Dermatitis,Other: 3 Biopsies|Other: 2 biopsies|Other: biopsy,"Cleavage of Lyn|Expression levels of Lyn|Specific activity of apoptotic caspases 3, 6, 7, 8 and 9, and inflammatory caspases 1, 4, and 5|Development of a monoclonal antibodyspecific for the cleaved form of caspases by Lyn",Centre Hospitalier Universitaire de Nice,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,170,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11-API-03,July 2012,July 2016,July 2016,"February 24, 2012",,"April 25, 2016","Assistance Publique - Hôpitaux de Marseille, Marseille, France|University Hospital of Nice, Nice, France|University Hospital of Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01538342,NCT01538342,30571969
oui,NCT01545115,Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal,AnoPalAnoVac,Completed,No Results Available,Whooping Cough|Malaria|Malnutrition,,,"Biomedical Research Center EPLS|Institut Pasteur de Lille|Institut de Recherche pour le Developpement, Senegal|Institut de Recherche pour le Developpement|University of Lille Nord de France|Région Nord-Pas de Calais, France|Centre d'Infection et d'Immunité de Lille|Centre National de la Recherche Scientifique, France|Institut National de la Santé Et de la Recherche Médicale, France",All,1 Year to 10 Years   (Child),,410,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EPLS08-JBS,October 2008,February 2010,February 2010,"March 6, 2012",,"March 13, 2012","Biomedical Research Center EPLS, Saint-Louis, Senegal",,https://ClinicalTrials.gov/show/NCT01545115,NCT01545115,24726248
anrs,NCT01545544,Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV),Lympho C,Unknown status,No Results Available,Chronic Hepatitis C,,"presentation of NHL and HCV infection, and treatments of NHL and HCV infection|Summary of intercurrents biological and clinical events|virological response|haematological response","ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",,138,Other,Observational,Observational Model: Case-Only,ANRS HC13 Lympho C,November 2006,November 2014,November 2014,"March 6, 2012",,"February 7, 2014","H�pital Necker, Paris, France",,https://ClinicalTrials.gov/show/NCT01545544,NCT01545544,25417909
oui,NCT01546181,Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases,iPhot,Unknown status,No Results Available,Retinal Dystrophies|Age-related Macular Degeneration|Arterial Hypertension|Diabetes|Traumatic Retinopathy|Toxic Retinopathies,,photoreceptor density,"Institut National de la Santé Et de la Recherche Médicale, France",All,"10 Years and older   (Child, Adult, Older Adult)",,300,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C10-03|2010-A00492-37,October 2010,December 2017,December 2017,"March 7, 2012",,"February 24, 2016","Clinical Investigation Center 503, Paris, France",,https://ClinicalTrials.gov/show/NCT01546181,NCT01546181,30010022;26523388;26418443;25077537;24576889;24406779;23620431
oui,NCT01548586,Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex,,Completed,No Results Available,Excitability of Diaphragmatic Primary Motor Cortex,Device: Eldith DC stimulator ( Magstim Company Ltd. UK),"Change in the right side hemi-diaphragm's motor evoked potentials (MEPs) before and after applications of three different modalities of tDCS (anodal, cathodal and placebo) upon the left primary motor cortex.","Institut National de la Santé Et de la Recherche Médicale, France|Assistance Publique - Hôpitaux de Paris",Male,18 Years to 35 Years   (Adult),Not Applicable,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",C10-52|2011-A00508-33,January 2012,April 2012,May 2012,"March 8, 2012",,"September 1, 2021","Hôpitaux Universitaires Paris Ile de France Ouest - Hôpital Raymond poincaré, Garches, Ile De France, France",,https://ClinicalTrials.gov/show/NCT01548586,NCT01548586,
oui,NCT01551394,"Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis",NeoMero-1,Completed,No Results Available,Sepsis,Drug: Meropenem|Drug: Ampicillin + gentamicin or cefotaxime + gentamicin,"percentage of patients with a favorable outcome in the two arms|Nature, frequency and numbers of clinical and biological adverse events",PENTA Foundation|Chiesi Farmaceutici S.p.A.,All,72 Hours to 90 Days   (Child),Phase 3,272,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011-001515-31,September 2012,December 2014,December 2014,"March 12, 2012",,"February 16, 2015","Ursula TRAFOJER, Padova, Italy",,https://ClinicalTrials.gov/show/NCT01551394,NCT01551394,
oui,NCT01552044,Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis,,Completed,No Results Available,Central Serous Chorioretinitis,Drug: Spironolactone|Drug: Placebo,Change in Central macular thickness,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,17,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C11-21|2011-003046-40,January 2012,January 2013,February 2013,"March 13, 2012",,"February 25, 2016","Hotel-Dieu of Paris, Paris, France",,https://ClinicalTrials.gov/show/NCT01552044,NCT01552044,
oui,NCT01552083,A Community Pharmacist-led Intervention to Improve Screening of Sleep Apnea in Primary Care,,Unknown status,No Results Available,Sleep Apnea,Other: screening of sleep apnea,Proportion of patients referred by the general practitioner to sleep specialist for SAS diagnosis test|Satisfaction of patients and pharmacists|Proportion of patients with sleep apnea,"Institut National de la Sant� Et de la Recherche M�dicale, France|Centre National de la Recherche Scientifique, France",All,"Child, Adult, Older Adult",Not Applicable,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,Etude SAS,January 2012,June 2012,December 2012,"March 13, 2012",,"March 13, 2012","Cermes3, CNRS UMR8211 - Inserm U988, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01552083,NCT01552083,
oui,NCT01553552,"Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal",SchistoVAN,Completed,No Results Available,Schistosomiasis|Anemia|Underweight|Stunting|Intestinal Parasites,,,"Biomedical Research Center EPLS|Institut Pasteur de Lille|University of Lille Nord de France|Région Nord-Pas de Calais, France|Centre d'Infection et d'Immunité de Lille|Centre National de la Recherche Scientifique, France|Institut National de la Santé Et de la Recherche Médicale, France",All,6 Years to 10 Years   (Child),,99,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,EPLS11-MS,October 2011,October 2011,October 2011,"March 14, 2012",,"March 14, 2012","Biomedical Research Center EPLS, Saint-Louis, SL, Senegal",,https://ClinicalTrials.gov/show/NCT01553552,NCT01553552,29351649
oui,NCT01554124,Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis,NeoMero-2,Completed,No Results Available,Meningitis,Drug: Meropenem,"Pharmacokinetics of Meropenem (plasma and CSF) in infants ≤ 90 days of age diagnosed with probable and confirmed bacterial meningitis.|Nature, frequency and numbers of all adverse events under meropenem.|Percentage of patients with a favourable outcome defined at Test of Cure visit (TOC).",PENTA Foundation|Chiesi Farmaceutici S.p.A.,All,up to 90 Days   (Child),Phase 1|Phase 2,51,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011-001521-25,February 2013,December 2014,December 2014,"March 14, 2012",,"February 16, 2015","HEATH, Paul, London, Cranmer Terrace, United Kingdom",,https://ClinicalTrials.gov/show/NCT01554124,NCT01554124,
oui,NCT01554202,Multi-modal Neuroimaging in Alzheimer's Disease,IMAP,Unknown status,No Results Available,Alzheimer's Disease,Behavioral: assessment of memory|Biological: circulating tPA dosage|Genetic: ApoE4|Other: Brain imaging examination MRI and PET examinations,"Rate of volume change of whole brain, hippocampus and other structural MRI measures|Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes|Rates of change on each specified biochemical biomarker|Rates of change of glucose metabolism (FDG-PET)|Extent of amyloid deposition as measured by 18F-AV45|Group differences for each imaging and biomarker measurement|APOE genotype","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,295,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2007-A00414-49,January 2008,December 2021,,"March 14, 2012",,"March 6, 2013","University Hospital Côte de Nacre, Caen, France|University Hospital Roger Salengro, Lille, France|University Hospital Pontchaillou, Rennes, France|University Hospital Rouen, Rouen, France|University Hospital Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT01554202,NCT01554202,
oui,NCT01554540,Treprostinil Iontophoresis : a Pharmacodynamic and Pharmacokinetic Study,TIPPS,Unknown status,No Results Available,"Scleroderma, Systemic",Drug: Cutaneous iontophoresis of treprostinil,Area under the curve (AUC) of cutaneous blood flow|Treprostinil blood concentration|Treprostinil dermal concentration,"University Hospital, Grenoble",All,"18 Years and older � (Adult, Older Adult)",Phase 1|Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DCIC TIPPS 11 18,February 2012,October 2013,February 2014,"March 15, 2012",,"July 18, 2013","CIC pharmacology - University Hopsital of Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT01554540,NCT01554540,28387950
oui,NCT01555450,Study of Patient Navigation to Reduce Social Inequalities,PRADO,Completed,No Results Available,Colorectal Cancer Screening,Other: Patient Navigation,Completion of colorectal cancer screening|Reduction of social inequalities|Estimation of Cost effectiveness|Evaluation of psychological mechanisms,"Institut National de la Santé Et de la Recherche Médicale, France|National Cancer Institute, France",All,"50 Years to 74 Years   (Adult, Older Adult)",Not Applicable,28929,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Screening,R10051EE,March 2011,November 2013,November 2013,"March 15, 2012",,"February 24, 2015","The french screening organization, Amiens, Region of Picardie, France|The french screening organization, Compiegne, Region of Picardie, France|The french screening organization, Laon, Region of Picardie, France",,https://ClinicalTrials.gov/show/NCT01555450,NCT01555450,29909873;28823681
associ�,NCT01556308,Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara,,Completed,No Results Available,Epidermolysis Bullosa Simplex Dowling Meara,Procedure: Taking of liquid and top of blisters,Markers of inflammation in epidermis in patients with severe DM-BS|clinical characterization of DM-EBS Genotype-phenoty,Centre Hospitalier Universitaire de Nice,All,"1 Year and older � (Child, Adult, Older Adult)",Not Applicable,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11-AOI-02,March 2012,March 2012,October 2013,"March 16, 2012",,"July 29, 2014","H�pital Archet 2, Nice, France",,https://ClinicalTrials.gov/show/NCT01556308,NCT01556308,
oui,NCT01564745,Cough Determinants in Mechanically Ventilated Patients,Extu-Cough,Completed,No Results Available,Mechanical Ventilation,Other: Functional respiratory evaluation,Interest of systematically cough evaluation before extubation|Correlation between success of extubation and respiratory parameters,"University Hospital, Caen|INSERM U1075,Caen|Centre d'Investigation Clinique et Technologique 805",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,180,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Extu-Cough,March 2012,December 2015,December 2015,"March 28, 2012",,"April 22, 2019","University Hospital, Caen, Caen, France|University Hospital, Garches, Garches, France",,https://ClinicalTrials.gov/show/NCT01564745,NCT01564745,29404723
oui,NCT01567540,A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients,,Terminated,No Results Available,Hepatitis C,Drug: Sitagliptin,"Safety (Number of adverse events, Toxicity grade > 3)|Change in Viral Load as compared to baseline|Metabolic studies: Oral glucose tolerance will be assessed|Immunologic study","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,3,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C10-54|2011-000823-34,March 2013,January 2014,January 2014,"March 30, 2012",,"January 20, 2014","Centre Hospitalier Victor Dupuy, Argenteuil, France|Centre Hospitalier Intercommunal Créteil, Créteil, France|Henri Mondor Hospital, Créteil, France|Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01567540,NCT01567540,
oui,NCT01569399,Efficacity of rTMS in Alcohol Dependance,,Completed,No Results Available,Alcohol Dependance,Other: rTMS (repetitive transcranial magnetic stimulation),Superiority of left rTMS (DLPFC)on reduction of alcohol consumption in AD patients compared to sham rTMS,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,13,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C10-21|2010-A00727-32,"February 11, 2011",August 2016,August 2016,"April 3, 2012",,"August 30, 2021","Louis Mourier Hospital, Colombes, France",,https://ClinicalTrials.gov/show/NCT01569399,NCT01569399,
oui,NCT01569503,Vagus Nerve Stimulation a New Approach in the Treatment of Crohn's Disease,VNS,Terminated,No Results Available,Crohn's Disease,Device: vagus nerve stimulation (VNS),Clinical remission 12 months after initiation of VNS|Clinical remission 6 months after initiation of VNS|VNS tolerance|Assessment of VNS effectiveness with biological markers|Endoscopic and ultrasound Assessment of VNS effectiveness|Assessment of the central effects of VNS|Evaluation of peripheral effects of VNS on sympatho-vagal balance,"University Hospital, Grenoble|Institut National de la Santé Et de la Recherche Médicale, France|Université Joseph Fourier|CRSSA : Centre Recherche Service Santé Armée",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,9,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCIC11/12,March 2012,"March 30, 2017","May 30, 2017","April 3, 2012",,"May 3, 2018","Grenoble university hospital, Grenoble, Isere, France",,https://ClinicalTrials.gov/show/NCT01569503,NCT01569503,28421634
non,NCT01574196,Assessment of Cardiac Autonomic Function in Adulthood After Chemotherapy or Radiotherapy in Childhood,SALTO-SNA,Completed,No Results Available,Cancer|Sequels|Complications|Autonomic Nervous System,Other: Autonomic nervous system activity records,Autonomic nervous system activity|Doses of radiotherapy,Centre Hospitalier Universitaire de Saint Etienne,All,"18 Years and older � (Adult, Older Adult)",,83,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1108162|2011-A01357-34,September 2012,December 2014,December 2014,"April 10, 2012",,"March 31, 2015","CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Grenoble, Grenoble, France|IHOP, Lyon, France|CHU de Saint-Etienne, Saint-etienne, France",,https://ClinicalTrials.gov/show/NCT01574196,NCT01574196,
oui,NCT01579409,The Impact of the French PNNS Guidelines on Vascular Function Following a Standardised Breakfast.,NUTRIVASC,Unknown status,No Results Available,French PNNS Guidelines in Vascular Function,Other: PNNS guidelines,"Pulse Wave Velocity|Peripheral arterial augmentation index (Aix )|High and low frequency peaks in heart variability spectral analysis|High and low frequency peaks in systolic and diastolic blood pressure spectral analysis|Mean cutaneous blood flow measured by laser doppler flowmetry|Mean cutaneous blood flow measured by laser doppler flowmetry, spectral analysis|Percentage of variation of cutaneous blood flow laser doppler measurements after paced breathing (6/min)|Increase in cutaneous blood flow laser doppler measurements after acetylcholine iontophoresis|Reactive Hyperemia Index after branchial artery occlusion|Aortic , radial,digital artery, systolic, diastolic and pulsatile pressures|Comparison of the above mentioned parameters after a standardised breakfast","Institut National de la Santé Et de la Recherche Médicale, France",All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 4,94,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,C11-20|2011-A01003-38,November 2011,August 2013,December 2013,"April 18, 2012",,"April 18, 2012",,,https://ClinicalTrials.gov/show/NCT01579409,NCT01579409,31802880
oui,NCT01579435,Experimental Therapeutics in Essential Tremor Using Transcranial Direct Current Stimulation,ELECTRE,Completed,No Results Available,Essential Tremor,Device: transcranial direct current stimulation,Change from baseline in tremor amplitude on accelerometric recording 10 minutes after the end of tDCS|Change from baseline in tremor amplitude on electromyographic recordings|Change from baseline in tremor amplitude on digitized tablet|Change from baseline in tremor amplitude on accelerometric recording,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 50 Years   (Adult),Not Applicable,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",C11-37|2011-A01453-38,April 2012,April 2013,April 2013,"April 18, 2012",,"April 11, 2013","Institut du Cerveau et de la Moelle, Hôpital Pitié-Salpétrière, Paris, France",,https://ClinicalTrials.gov/show/NCT01579435,NCT01579435,
oui,NCT01583114,PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors,PRECARDIA,Terminated,No Results Available,Dilated Cardiomyopathy,Drug: perindopril|Drug: placebo,"Change in left ventricle diameter / volume / ejection fraction|Echocardiographic deterioration of LVEDD or Ejection fraction|MRI - deterioration of LVEDVol or Ejection fraction|Occurence of DCM (Echo: EF< 45% and LVEDD>112%, ref Mahon, 2005)|Deterioration of other Echocardiographic parameters|Deterioration of hormonal biomarkers in serum|Clinical end-point|Clinical end-point: death","Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),Phase 3,6,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",C10-44|2010-023184-18,December 2011,January 2014,January 2014,"April 23, 2012",,"February 24, 2016","Skejby University Hospital SUH, Aarhus Universit Hospital, Aarhus, Denmark|Pitié Salpêtrière Hospital, Paris, France|University of Heidelberg UKLHD, Heidelberg, Germany|Academic Hospital IRCCS Foundation Policlinico San Matteo (OSM), Pavia, Italy|Academisch Medisch Centrum AMC and InterUniversity Institute AMC/ICIN, Amsterdam, Netherlands|Health in Code SL (SME) - Hospital Marítimo de Oza., A Coruña, Spain|The Heart Hospital, University College London NHS Foundation Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01583114,NCT01583114,
oui,NCT01588756,Development of a New Non-radioactive Test for Measuring Glomerular Filtration Rate Using the Tetrapeptide N-acetyl-Ser-Asp-Lys-Pro-amide (AcSDKP-NH2),AcSDKP-NH2,Completed,No Results Available,Healthy|Chronic Kidney Disease,Drug: AcSDKP-NH2 inuline|Drug: AcSDKP-NH2 Cr-EDTA,glomerular filtration rate|safety,Assistance Publique - H�pitaux de Paris,All,"18 Years to 80 Years � (Adult, Older Adult)",Phase 1|Phase 2,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AOM08193,October 2010,May 2015,May 2015,"May 1, 2012",,"March 1, 2017","Clinical Investigation Center, European George Pompidou Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01588756,NCT01588756,
oui,NCT01590589,REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN),REGISTRY,Completed,No Results Available,Huntington Disease|Huntington's Disease,,Phenotypical characteristics of HD,European Huntington's Disease Network,All,"Child, Adult, Older Adult",,10000,Other,Observational,Observational Model: Cohort|Time Perspective: Other,REGISTRY 3.0,June 2004,"June 30, 2017","June 30, 2017","May 3, 2012",,"September 15, 2017","Universit�tsklinik f�r Psychiatrie, Neuropsychiatrische Ambulanz, Graz, Austria|Universit�tsklinik Innsbruck, Neurologie, Innsbruck, Austria|UCL-St Luc, Centre de g�n�tique humaine, Brussels, Belgium|Institute of Pathology and Genetics (IPG), Gosselies, Belgium|Universitair Ziekenhuis Gasthuisberg, Dienst Neurologie, Leuven, Belgium|Fakultn� nemocnice Olomouc, Neurologick� klinika, Olomouc, Czechia|Centrum extrapyramidov�ch onemocn?n�, Neurologick� klinika, 1. LFUK, Praha 2, Czechia|University Hospital of Copenhagen - Rigshospitalet, Dept. of Neurology, Copenhagen �, Denmark|The Family Federation of Finland V�est�liitto, Department of Medical Genetics, Helsinki, Finland|Helsinki University Hospital, Dept. of Neurology, HUS, Finland|Kuopio University Hospital, Neurology, Kuopio, Finland|�lands H�lso- och Sjukv�rd, L�ngv�rdsenheten, Mariehamn, Finland|Oulu University Hospital (OUH), Dept. of Neurology, Oulu, Finland|Suomen Terveystalo, Tampere, Finland|Turku University Hospital, Dept. of Neurology, Turku, Finland|The Finnish Parkinson Association, Suvituuli, Turku, Finland|CHU d'Amiens - H�pital Nord, Service de Neurologie, Amiens cedex, France|CHU d'Angers, Service de Neurologie Charcot, Angers cedex 9, France|H�pital Pellegrin, Service de G�n�tique M�dicale (ESF 3e �tage), Bordeaux cedex, France|HU Clermont-Ferrand - H�pital Gabriel Montpied, Service de Neurologie, Clermont-Ferrand, France|H�pital Henri Mondor, Service de Neurologie, Cr�teil cedex, France|Clinique Neurologique H�pital Roger Salengro CHRU, Neurologie et Pathologie du Mouvement, Lille cedex, France|CHU La Timone, Service de Neurologie (9e �tage), Marseille cedex 5, France|H�pital La Piti� Salp�tri�re, G�n�tique & Inserm U679, Paris, France|CHU Rouen Charles Nicolle, Service de Neurologie, Rouen cedex, France|H�pital Civil, Service de Neurologie, Strasbourg cedex, France|H�pital Purpan, INSERM U825, P�le Neurosciences, Toulouse cedex 03, France|Universit�tsklinikum Aachen, Neurologische Klinik, Aachen, Germany|Charit� - Universit�tsmedizin Berlin, Klinik und Poliklinik f�r Neurologie, Klinik f�r Psychiatrie und Psychotherapie, Berlin, Germany|Ruhruniversit�t Bochum, Neurologie, Bochum, Germany|Reha-Zentrum Dinslaken im Gesundheitszentrum Lang, Tagesklinik, Dinslaken, Germany|Universit�tsklinikum Carl Gustav Carus an der Technischen Universit�t Dresden, Klinik und Poliklinik f�r Neurologie, Dresden, Germany|Universtit�t Erlangen, Abteilung f�r Molekulare Neurologie, Erlangen, Germany|Universit�tsklinikum Freiburg, Neurologie, Freiburg, Germany|Universit�tsklinikum Hamburg-Eppendorf, Neurologische Abteilung, Hamburg, Germany|Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische Hochschule Hannover, Hannover, Germany|Psychatrium Gruppe A�R, Haus 2/1, Heiligenhafen, Germany|Schwerpunktpraxis Huntington, Neurologie-Psychiatrie, Itzehoe, Germany|Praxis, Marburg, Germany|Universit�t Marburg, Neurologie, Marburg, Germany|Technische Universit�t M�nchen, Abteilung Neurologie, M�nchen, Germany|Universit�tsklinikum M�nster, Klinik und Poliklinik f�r Neurologie, M�nster, Germany|Isar-Amper-Klinikum - Klinik Taufkirchen (Vils), Taufkirchen, Germany|University Hospital of Ulm, Dept. of Neurology, Ulm, Germany|University of Bari, Dept. of Neurological and Psychiatric Sciences, Bari, Italy|Universit� di Bologna, Dip. di Scienze Neurologiche - Clinica Neurologica, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Clinica Neurologica, Brescia, Italy|University of Florence, Dip. di Scienze Neurologiche e Psichiatriche, Florence, Italy|Universit� di Genova, Dept. of Neurosciences, Genova, Italy|Fondazione IRCCS Istituto Neruologico Carlo Besta, SOSD Genetics of Neurodegenerative and Metabolic Diseases, Milano, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta, I Neurologia, Milano, Italy|Universit� di Napoli Federico II, Dip. Scienze Neurologiche Edificio 17, Napoli, Italy|Azienda Ospedaliera Universitarie Pisana, Dip. di Neuroscienze - UO Neurologia, Pisa, Italy|IRCCS Neuromed, U.O. Neurogenetica, Pozzilli (IS), Italy|Azienda Ospedaliera S. Andrea, UOC Neurologia e Centro Neurologico Terapie Sperimentali CENTERS, Rome, Italy|Universit� Cattolica del Sacro Cuore ""A.Gemelli"", Istituto di Neurologia / CNR, Istituto di Farmacologia Traslazionale, Rome, Italy|Medisch Spectrum Twente, Dept. of Neurology, Enschede, Netherlands|UMC Groningen, Neurology, Groningen, Netherlands|Leiden University Medical Centre (LUMC), Neurology K5-Q, Leiden, Netherlands|MUMC, Dept. Neurology, Maastricht, Netherlands|NKS Olaviken Alderpsykiatriske sykehus, Poliklinikk og Huntington Klinikk, Bergen, Norway|Rikshospitalet, Dept. of Medical Genetics, Oslo, Norway|Ulleval University Hospital, Medical Genetics, Oslo, Norway|St. Olavs Hospital HF, Neurology, Trondheim, Norway|Specialistic Hospital in Gdansk, Dept. of Neurology, Gdansk, Poland|Medical University of Silesia, Dept. of Neurology, Katowice, Poland|Krakowska Akademia Neurologii, Krakow, Poland|Poznan University of Medical Sciences, Dept. of Social Medicine, Poznan, Poland|Medical University of Warsaw, Dept. of Neurology, Warsaw, Poland|Institute of Psychiatry and Neurology, First Dept. of Neurology, Warsaw, Poland|Hospital de Coimbra, Neurology Dept., Coimbra, Portugal|Hospital dos Capuchos, Centro Hospitalar Lisboa Central, Neurology Dept., Lisbon, Portugal|Hospital de Santa Maria, Centro de Estudos Egas Moniz, Neurology Dept., Lisbon, Portugal|Hospital Fernando Fonseca, Neurology Dept., Lisbon, Portugal|Hospital de S�o Jo�o, Neurology Dept., Porto, Portugal|Hospital Geral de Santo Ant�nio, Neurology Dept., Porto, Portugal|Centro Hospitalar de Tr�s-os-Montes e Alto Douro, Neurology Dept., Vila Real, Portugal|Huntington's Disease Society of Russia, Moscow, Russian Federation|Complejo Hospitalario Universitario de Albacete, Neurolog�a, Albacete, Spain|Hospital Infanta Cristina, Neurolog�a, Badajoz, Spain|Hospital Vall d'Hebr�n, Neurolog�a, 3� planta, consultas externas, Barcelona, Spain|Hospital Cl�nic i Provincial, Neurolog�a, Barcelona, Spain|Hospital Bellvitge, Neurolog�a, Barcelona, Spain|Hospital General Yag�e, Neurology, Burgos, Spain|Hospital Puerta del Mar, Neurolog�a, C�diz, Spain|Centro Ram�n y Cajal, Neurolog�a, Madrid, Spain|Fundaci�n Jim�nez D�az, Neurology, Madrid, Spain|Hospital Cl�nico de Madrid, Servicio de Neurolog�a, Madrid, Spain|Hospital de Fuenlabrada, Neurology, Madrid, Spain|Hospital Virgen de la Arrixaca, Neurology, Murcia, Spain|Hospital Central de Oviedo, Neurolog�a, Oviedo, Spain|Hospital Son Dureta, Neurology, Palma de Mallorca, Spain|Hospital Virgen del Camino, Medical Genetics, Pamplona, Spain|Hospital Donostia. Universidad del Pais Vasco, Neurociencias, San Sebasti�n, Spain|Hospital General de Segovia, Neurolog�a, Segovia, Spain|Hospital Universitario Virgen del Roc�o, Servicio de Neurolog�a, Sevilla, Spain|Hospital Virgen Macarena, Neurolog�a, Sevilla, Spain|Hospital Universitario Mutua de Terrassa, Neurologia - Investigaci�n, Terrassa - Barcelona, Spain|Hospital Virgen de la Salud, Neurology, Toledo, Spain|Hospital La Fe, Consultas Externas de Neurolog�a, Valencia, Spain|Hospital Clinico Universario, Department of Neurology, Zaragoza, Spain|Sahlgren University Hospital, Dept. of Clinical Genetics, G�teborg, Sweden|Sk�ne Universitetssjukhus, Neurologiska kliniken, Lund, Sweden|Neuroenheten Utsikten, Stockholm, Sweden|Karolinska University Hospital - Huddinge Division, Neurology, Stockholm, Sweden|Norrlands Universitet Sjukhus, Dept. of Neurology, Ume�, Sweden|Uppsala University Hospital, Neurology, Uppsala, Sweden|Neurologische Klinik des Inselspitals, Praxis, Bern, Switzerland|CHUV - Centre Hospitalier Universitaire Vaudois, D�partement de Neurologie, Lausanne, Switzerland|University Hospital Zurich, Dept. of Neurology, Zurich, Switzerland|Clinical Genetics Centre, Ground Floor, Ashgrove House, Aberdeen, United Kingdom|The Barberry Centre, Dept. of Psychiatry, Birmingham, United Kingdom|Blandford Hospital, Blandford Forum, United Kingdom|Frenchay Hospital, Neurology Dept., Bristol, United Kingdom|Cambridge Centre for Brain Repair, Forvie Site, Cambridge, United Kingdom|Cardiff University, Life Sciences Building, Cardiff, United Kingdom|Ninewells Hospital and Medical School, Human Genetics Unit, Dundee, United Kingdom|Molecular Medicine Centre, Western General Hospital, Dept. of Clinical Genetics, Edinburgh, United Kingdom|Royal Devon and Exeter Foundation Trust Hospital, Department of Neurology, Exeter, United Kingdom|Queen Margaret Hospital, Fife, United Kingdom|Scottish Huntington Association, Units 105/106, Glasgow, United Kingdom|Gloucestershire Royal Hospital, Neurology Dept., Gloucester, United Kingdom|Chapel Allerton Hospital, Yorkshire Regional Genetics Service, Hull, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Leicestershire Partnership NHS Trust, EMD South School, OSL house, Leicester, United Kingdom|The Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom|Guy's Hospital, Dept. of Neurology, London, United Kingdom|The Royal Hospital for Neuro-disability, Research and Development, London, United Kingdom|St George's Hospital Medical School, South West Thames Regional Genetics Unit, London, United Kingdom|National Hospital for Neurology and Neurosurgery, Dept. for Neurology, London, United Kingdom|University of Manchester, Genetic Medicine, St. Mary's Hospital, Manchester, United Kingdom|Institute of Human Genetics, International Centre for Life, Newcastle upon Tyne, United Kingdom|Churchill Hospital, Dept. of Clinical Genetics, Oxford, United Kingdom|Derriford Hospital, Dept. of Clinical Neuropsychology, Plymouth, United Kingdom|Poole Hospital Foundation Trust, Brain Injury Service, Poole, United Kingdom|Lancashire Teaching Hospitals NHS Foundation Trust, Neurosciences Directorate, Royal Preston Hospital, Preston, United Kingdom|Sheffield Children's Hospital, Dept. of Clinical Genetics, Sheffield, United Kingdom|Southampton General Hospital and University of Southampton, Neurology / Wellcome Trust Clinical Research Facility, Southampton, United Kingdom|Bucknall Hospital, Neuropsychiatry Service, Stoke-on-Trent, United Kingdom|Victoria Centre, Swindon, United Kingdom",,https://ClinicalTrials.gov/show/NCT01590589,NCT01590589,36084356;33766994;27402890
oui,NCT01592175,"Magnetoencephalography (MEG), Attention and Conscience",,Completed,No Results Available,Change in Sustained Attention|Awareness|Reaction Time,,Brain activity during visuo-spatial attention tasks,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 40 Years   (Adult),,32,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,C11-49|2011-A01554-37,"March 8, 2012",July 2013,"July 2, 2013","May 7, 2012",,"August 30, 2021","CRICM, Paris, France",,https://ClinicalTrials.gov/show/NCT01592175,NCT01592175,
oui,NCT01602250,Local Anaesthetics Toxicity and Intralipid®,TOXALIP,Completed,No Results Available,Toxicity|Adverse Effects,Drug: placebo|Drug: Intralipid®,Duration of drug infusion|EEG : electroencephalogram|ECG : electrocardiogram|pharmacokinetics of local anesthetics (Area under the plasma concentration versus time curve (AUC)),"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 40 Years   (Adult),Phase 2,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",P100501,January 2011,August 2013,August 2013,"May 18, 2012",,"December 21, 2016","CIC plurithématique Paris-Est (CIC-9304), Paris, France",,https://ClinicalTrials.gov/show/NCT01602250,NCT01602250,
oui,NCT01605565,Functional Analysis by Dynamic Imaging of the Respiratory Epithelium in Infants With Cystic Fibrosis,,Unknown status,No Results Available,Cystic Fibrosis,Procedure: A nasal brushing,"The main objective is to analyze the functionality of the respiratory epithelium in CF infant using a nasal brushing technique: ciliary beating frequency, cAMP-dependent chloride efflux, potassium efflux, tight and gap junctions functionalities.","Institut National de la Santé Et de la Recherche Médicale, France",All,1 Week to 6 Months   (Child),Not Applicable,30,Other,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C11-01|2011-A00384-37,November 2011,November 2013,November 2014,"May 25, 2012",,"May 25, 2012","Chu Reims, Reims, France",,https://ClinicalTrials.gov/show/NCT01605565,NCT01605565,
oui,NCT01605578,Description of Abdominal and Gluteo-femoral Subcutaneous Adipose Tissue Cell Population in Women - GLUTAB,,Unknown status,No Results Available,Adipose Tissue,Procedure: Biopsies,To compare the number and the phenotype of cells between abdominal and gluteo-femoral adipose tissue in women.,"Institut National de la Santé Et de la Recherche Médicale, France",Female,25 Years to 45 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C11-48|2011-A01496-35,May 2012,May 2013,May 2014,"May 25, 2012",,"May 25, 2012","Centre d'Investigation Clinique, CHU Purpan, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01605578,NCT01605578,
oui,NCT01607047,French West Indies Leptospirosis Study,LEPTO,Unknown status,No Results Available,Leptospirosis,,Complicated forms of leptospirosis|quality of life,"University Hospital Center of Martinique|Clinique Antilles-Guyane|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 120 Years   (Adult, Older Adult)",,150,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHU FDF 10/B/13,December 2010,September 2012,August 2018,"May 28, 2012",,"March 20, 2018","CHU Pointe-à-Pitre Abymes, Pointe-à-Pitre, Guadeloupe, France|CHU Martinique, Fort De France, Martinique, France",,https://ClinicalTrials.gov/show/NCT01607047,NCT01607047,
non,NCT01611740,Contribution of Real Time Analyses of CARdio-RESpiratory Signals to the Diagnosis of Infection in PREterM Infants,CARESS_PREMI,Completed,No Results Available,Bacterial Infection,Procedure: Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642,Diagnosis of proven or suspected bacterial infection|Inflammation without proven or suspected bacterial infection defined as follows: a 6 hours period with CRP> 5 mg/L not classified as proven or suspected bacterial infection.|Periods of discomfort defined as at least two EDIN scores above 3 in a 6 hours period,Rennes University Hospital,All,24 Weeks to 32 Weeks � (Child),,525,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2011-A00324-37,May 2012,"December 24, 2018","December 24, 2018","June 5, 2012",,"January 24, 2019","CHU Angers, Angers, Maine Et Loire, France|CHU de Lille, Lille, France|CHU de Rennes, Rennes, France",,https://ClinicalTrials.gov/show/NCT01611740,NCT01611740,
non,NCT01613638,Pregnancy Environment and Newborn Malformations,PENEW,Completed,No Results Available,Congenital Malformation,Other: meconium samples + maternal self-questionnaire,"impact of intra-uterine exposure to solvents, pesticides and alcohol on the risk of congenital malformations diagnosed at births, by measuring the exposure both directly in meconium, and indirectly by questionnaires.|other risk factors such as medicine intake, pregnancy illness�",Rennes University Hospital,All,up to 12 Months � (Child),Not Applicable,1657,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,PHRC/10-02 - PENEW|B110827-40|11/22-811|2010-A01445-34,"October 5, 2012","December 31, 2018","December 31, 2020","June 7, 2012",,"June 1, 2021","Polyclinique de Keraudren, Brest, Brittany, France|Brest University Hospital, Brest, Brittany, France|Lannion Hospital, Lannion, Brittany, France|Lorient Hospital, Lorient, Brittany, France|Ploermel Hospital, Ploermel, Brittany, France|Quimper Hospital, Quimper, Brittany, France|Rennes University Hospital, Rennes, Brittany, France|Saint-Brieuc Hospital, Saint-Brieuc, Brittany, France|Saint-Gr�goire Hospital, Saint-Gr�goire, Brittany, France|Clinique Oc�ane, Vannes, Brittany, France|Vannes Hospital, Vannes, Brittany, France",,https://ClinicalTrials.gov/show/NCT01613638,NCT01613638,
oui,NCT01614080,Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA,OPHELIE,Completed,No Results Available,"Stroke, Acute|Drug Toxicity",,OPHELIE,"University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,700,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,10.677|2010_04,November 2011,November 2014,December 2014,"June 7, 2012",,"December 19, 2014","Lille University Hospital, Lille, France",,https://ClinicalTrials.gov/show/NCT01614080,NCT01614080,32015090;27815401
oui,NCT01614873,Comparison of Breathing Pattern During Neurally Adjusted Ventilatory Assist Ventilation and Pressure Support Ventilation,,Completed,No Results Available,Respiratory System Abnormalities,"Device: Servo-i� ventilator, MAQUET,Critical Care, Sweden",Comparison of breathing pattern during pressure support and Neurally Adjusted Ventilatory Assist (NAVA)|Tidal volume evaluated by optoelectronic plethysmography|Electrical diaphragmatic activity recorded by mechanical ventilator,Centre d'Investigation Clinique et Technologique 805|Adep Assistance,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,2012-A0030043,May 2012,May 2012,August 2012,"June 8, 2012",,"April 12, 2013","Hopital Raymond Poincare, Garches, France",,https://ClinicalTrials.gov/show/NCT01614873,NCT01614873,24508509
oui,NCT01619696,Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During Chemoradiotherapy of Rectal Adenocarcinomas,,Terminated,No Results Available,Rectal Adenocarcinoma,Procedure: Pelvic MRI and F MISO TEP,"acceptation rate of the entire sequence by eligible patients|radiological changes while on chimiotherapy, to tumour regression, and prognosis","University Hospital, Toulouse|Centre National de la Recherche Scientifique, France|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,3,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,932103,March 2011,December 2012,December 2012,"June 14, 2012",,"January 23, 2013","CHU Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01619696,NCT01619696,
oui,NCT01619709,Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage,COGHIC-AV45,Completed,No Results Available,Intracerebral Hemorrhage,Other: Pet AV-45,Pet-AV45 cortical binding|cerebral microbleeds number and distribution on T2EG MRI sequence|White Matter Lesions Volume on 3D-FLAIR MRI sequence|Cortical thickness and hippocampal volume on 3D-T1 MRI sequence|Neuropsychological performances,"University Hospital, Toulouse|Avid Radiopharmaceuticals|Institut National de la Santé Et de la Recherche Médicale, France",All,"40 Years to 90 Years   (Adult, Older Adult)",Not Applicable,70,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11 223 02|AOL 2011,January 2012,June 2017,June 2017,"June 14, 2012",,"September 21, 2018","Service de neurologie, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01619709,NCT01619709,32394598;28570698
oui,NCT01619722,Study of a National Cohort of Adult Patients With Phenylketonuria,ECOPHEN,Completed,No Results Available,PKU|Hyperphenylalaninemia,,Evaluate a possible cognitive decline and incidence of neurological complications|Determine the prognostic factors of neurological complications,"University Hospital, Tours|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,220,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PHRN10/FM-ECOPHEN,"March 15, 2012","February 15, 2020","July 6, 2020","June 14, 2012",,"April 9, 2021","CHRU-Hôpital Bretonneau - Service de Médecine Interne-Nutrition, Tours, Centre, France|CHU-ANGERS -Médecine Interne, Angers, France|CHU_Service de Médecine Interne Nutrition A2-Hôpital du Haut Levèque, Bordeaux, France|CHU du Morvan-Département de Pédiatrie et génétique médicale,, Brest, France|Hôpital Femme-Mère-Enfant-Centre de Référence des Maladies Héréditaires du Métabolisme de Lyon, Bron, France|CHU de Dijon--Hôpital des Enfants-Centre de Génétique, Dijon, France|CHU de Grenoble-Hôpital MICHALLON-Unité de Neurologie Générale, Grenoble, France|CHU de LILLE-Hôpital Claude HURIEZ-Service d'Endocrinologie, Lille, France|APHM-Hôpital de la Conception -Médecine Interne, Marseille, France|CHU-Service de Réanimation Pédiatrique / Néonatalogie, Consultation spécialisée en Maladies Héréditaires du Métabolisme, Nantes, France|Hôpital Necker Enfants Malades, APHP-Maladies Métaboliques -Service de Pédiatrie, Paris, France|CHU-RENNES-Hôpital Sud-Service de Génétique-Clinique, Rennes, France|CHU de Rouen-Service de Pédiatrie, Rouen, France|CHU de St Etienne-Hôpital Nord-Service de Pédiatrie, St-ETIENNE, France|CHU-Toulouse-Hôpital PURPAN-Service de Médecine Interne, Toulouse, France|University Hospital of NANCY, Vandoeuvre Les Nancy, France",,https://ClinicalTrials.gov/show/NCT01619722,NCT01619722,
oui,NCT01620372,French Childhood Cancer Survivor Study,FCCSS,Recruiting,No Results Available,Childhood Solid Tumor,,All health events of interest,"Institut National de la Santé Et de la Recherche Médicale, France|Ligue contre le cancer, France|National Research Agency, France|Programme hospitalier de recherche clinique, France",All,"up to 18 Years   (Child, Adult)",,18000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,C12-25,November 2011,,November 2031,"June 15, 2012",,"October 10, 2012","Centre Hospital-Universitaire Hôpital Nord, Amiens, France|Centre Hospitalier-Universitaire, Angers, France|Centre Hospitalier Régional Universitaire Hôpital Saint-Jacques, Besançon, France|Groupe hospitalier Pellegrin, Bordeaux, France|Centre Hospitalier Universaitaire Hôpital Côte de Nacre, Caen, France|Centre Hospitalier Universitaire Hôpial Hôtel Dieu, Clermont Ferrand, France|Centre Hospitalier Universaitaire hôpital d'enfants, Dijon, France|Hôpital La Tronche, Grenoble, France|Centre Oscar Lambret, Lille, France|Hôpital Jeanne De Flandre, Lille, France|Hôpital de la mère et de l'enfant, Limoges, France|Institut d'Hématologie et Oncologie Pédiatrique, Lyon, France|Centre Régional de Lutte Contre le Cancer Centre Léon Bérard, Lyon, France|Hôpital d'Enfants de Margency (HEM) Croix Rouge Française, Margency, France|AP-HM Hôpital de la Timone, Marseille, France|Hôpital Arnaud De Villeneuve, Montpellier, France|Centre Hospitalier Universaitaire Hôpital mère-enfant, Nantes, France|Centre Antoine Lacassagne, Nice, France|GCS Hôpitaux pédiatriques Centre Hospitalier Universitaire Lenval, Nice, France|Institut Curie, Paris, France|Hôpital Armand Trousseau, Paris, France|CHRU de Poitiers La Miletrie, Poitiers, France|Institut Jean Godinot, Reims, France|Centre Hospitalier Universitaire de Reims Hôpital Maison Blanche, Reims, France|Centre Hospitalier Universitaire Hôpital Sud, Rennes, France|Hôpital Charles-Nicolle, Rouen, France|Centre Hospitalier Universitaire Hôpital Nord, Saint Etienne, France|Centre René Gauducheau de Nantes Atlantique, Saint-Herblain, France|Centre Hospitalier de Saintonge, Saintes, France|Hôpital Hautepierre, Strasbourg, France|Institut Claudius Regaud, Toulouse, France|Hôpital des Enfants, Toulouse, France|Hôpital Clocheville, Tours, France|Hôpital Brabois enfants CHU de Nancy, Vandoeuvre-les-Nancy, France|Centre Régional de Lutte Contre le Cancer de Lorraine ALEXIS VAUTRIN, Vandoeuvre-les-Nancy, France|Institut Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01620372,NCT01620372,26327481
oui,NCT01620957,Longitudinal Study of the Default-mode Network Connectivity in Brain Injured Patients Recovering From Coma,ACI-Coma,Completed,No Results Available,Coma,,Change of DMN resting state fMRI connectivity between 1 and 2 month after severe brain injury|Compare functional and structural DMN connectivity between 1 and 2 month after severe brain injury,"Institut National de la Santé Et de la Recherche Médicale, France|University Hospital, Toulouse|Association des Traumatisés du Crane et de la Face, Paris, France",All,"18 Years to 75 Years   (Adult, Older Adult)",,43,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C11-55 Inserm|2012-A00009-34,"July 10, 2012",July 2017,July 2017,"June 15, 2012",,"August 27, 2021","Institut National de la Santé et de la Recherche Medicale, U825, Toulouse, Haute Garonne, France",,https://ClinicalTrials.gov/show/NCT01620957,NCT01620957,
oui,NCT01638884,Prospective Memory Imaging,IMPRO,Unknown status,No Results Available,Alzheimer Disease,Behavioral: Memory assessment|Other: Structural MRI|Other: Functional MRI|Other: Virtual reality / Memory assessment,Rate of volume change of whole brain and other structural MRI measures|Cerebral regions implicated in prospective memory observed by functional MRI|Episodic memory as measured by Cognitive Tests|Virtual reality evaluation of prospective memory|Group differences for each imaging and neuropsychological measurement,"University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,118,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2010-A00031-38,September 2010,June 2015,June 2015,"July 12, 2012",,"April 9, 2014","GIP Cyceron, Caen, Calvados, France|MRSH - University of Caen, Caen, Calvados, France|University Hospital Côte de Nacre, Caen, France",,https://ClinicalTrials.gov/show/NCT01638884,NCT01638884,
oui,NCT01638949,Multi-modal Neuroimaging in Alzheimer's Disease,IMAP+,Unknown status,No Results Available,Alzheimer's Disease,Behavioral: Memory assessment|Biological: Circulating biomarkers measure|Genetic: ApoE4|Other: Brain imaging examination MRI and PET examinations,"Rate of volume change of whole brain, hippocampus and other structural MRI measures|Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes|Rates of change on each specified biochemical biomarker|Rates of change of glucose metabolism (FDG-PET)|Extent of amyloid deposition as measured by 18F-AV45|Group differences for each imaging and biomarker measurement|APOE genotype","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,295,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2011-A01493-38,May 2012,December 2021,,"July 12, 2012",,"April 9, 2014","GIP Cyceron, Caen, Calvados, France|Inserm - EPHE - University of Caen U1077, Caen, France|University Hospital Côte de Nacre, Caen, France|University Hospital Roger Salengro, Lille, France|University Hospital Pontchaillou, Rennes, France|University Hospital Rouen, Rouen, France|University Hospital Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT01638949,NCT01638949,37085328;31286994;27683850
oui,NCT01641016,BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection,BREATHER,Unknown status,No Results Available,HIV,Drug: efavirenz,"HIV-1 RNA ?50 copies/ml (confirmed on a separate sample within 1 week) at any of week 4, 12, 24, 36 or 48.|HIV-1 RNA <50 c/ml at 24 and 48 weeks|Number of HIV mutations present at week 4, 12, 24, 36 or 48 conferring resistance to drugs taken at randomisation or during the tria|Change in CD4 (absolute and percentage) from randomisation to 24 and 48 weeks|Change in ART (defined as any change from the ART regimen at randomisation)|Grade 3 or 4 clinical and laboratory adverse events|ART treatment modifying adverse events (all grades)|New CDC stage B or C diagnosis or death|Changes in fasting glucose, cholesterol, triglycerides, LDL, HDL and VLDL levels through 48 weeks|Adherence, acceptability, and quality of life over 48 weeks as assessed by patient completed questionnaires","PENTA Foundation|Medical Research Council|ANRS, Emerging Infectious Diseases",All,"8 Years to 24 Years � (Child, Adult)",Phase 2|Phase 3,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BREATHER (PENTA 16)|2009-012947-40,April 2011,June 2014,June 2016,"July 16, 2012",,"March 2, 2015","St Jude Children's Research Hospital, Memphis, Tennessee, United States|INSERM, Villejuif, France|Universit�tsklinikum Frankfurt, Frankfurt, Frankfurt am Main, Germany|Our Lady's Children's Hospital, Dublin, Ireland|Program for HIV Prevention and Treatment (PHPT)/IRD 174, Changklan, Muang, Chiang Mai, Thailand|HIV-NAT Thai Red Cross AIDS Research Centre, Bangkok, Thailand|Joint Clinical Research Centre, Kampala, Uganda|Kiev City AIDS Center, Kiev, Vidpochynku 11, Ukraine|Birmingham Heartlands Hospital, Birmingham, United Kingdom|University Hospital Bristol, Bristol, United Kingdom|Leeds General Infirmary, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Evelina Children's Hospital, London, United Kingdom|Great Ormond Street Hospital, London, United Kingdom|Mortimer Market Centre, London, United Kingdom|St George's Hospital, London, United Kingdom|Nottingham University Hospital, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01641016,NCT01641016,29684092;28213595
oui,NCT01647295,Social Interactions: Ocular Explorations and Pupillometry in Autism,ISEOP,Completed,No Results Available,Autism Spectrum Disorders,,Total time spent on pictures|Interest zones,"Institut National de la Santé Et de la Recherche Médicale, France",All,3 Years to 12 Years   (Child),,150,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C11-60|2012-A00520-43,"February 25, 2013",June 2019,"June 18, 2019","July 23, 2012",,"August 26, 2021","CHRU Bretonneau, Tours, France",,https://ClinicalTrials.gov/show/NCT01647295,NCT01647295,
oui,NCT01648738,"Effectiveness of a Short, Intensive and Standardised Spa Therapy for Low Back Pain on Sick Leave Duration",ITILO,Completed,No Results Available,Low Back Pain,"Other: Spa therapy, exercise and educational therapy|Other: Usual care",Frequency of return to work|Pain|Function|Quality of life|TWIST|Sick leave,Assistance Publique - H�pitaux de Paris|Association Francaise pour la Recherche Thermale,All,18 Years to 60 Years � (Adult),Not Applicable,88,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2010/04,July 2012,December 2015,April 2016,"July 24, 2012",,"January 8, 2018","Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01648738,NCT01648738,
oui,NCT01648868,Transcranial Magnetic Stimulation (rTMS) and Autism.,TMSAUTISME,Completed,No Results Available,Autism Spectrum Disorder,Device: Transcranial Magnetic Stimulation (rTMS),"Fixation time in eyes, mouth and face areas|Eye-tracking or voice human perception correlation|Fractional anisotropy covariation|Fractional anisotropy comparison",Assistance Publique - Hôpitaux de Paris,All,18 Years to 30 Years   (Adult),Not Applicable,97,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P 081232|2009-A01025-52,"April 6, 2011","September 27, 2017","May 13, 2019","July 24, 2012",,"March 23, 2021","Hôpital Necker-Enfants Malades, Paris, France",,https://ClinicalTrials.gov/show/NCT01648868,NCT01648868,
oui,NCT01648881,Imaging of Dissection of the Descending Aorta,DADI,Completed,No Results Available,Dissection of the Descending Aorta,Radiation: TEP-18FDG for every patient after aortic dissection,,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,89,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,P 100505|2011-A00238-33,May 2011,December 2015,August 2019,"July 24, 2012",,"September 18, 2019","Pr Guillaume JONDEAU . Cardiologie. Hôpital Bichat, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT01648881,NCT01648881,
oui,NCT01659437,WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8,,Completed,No Results Available,Mycobacterium Ulcerans Infection,Drug: Clarithromycin Extended Release|Drug: Streptomycin intramuscular injection,healing without recurrence and without excision surgery|Recurrence rate within 12 months of treatment initiation|Rate of treatment failure within 12 months of treatment initiation|Rate of paradoxical response within 12 months of treatment initiation|Proportion of patients with reduction in lesion surface area within 12 months of treatment initiation|Time taken for complete lesion healing within 12 months of treatment initiation|Proportion (%) of patients with complete healing without additional surgery or relapse|Interval between healing and recurrence|Proportion of each type of surgery within 12 months of treatment initiation|Time from treatment initiation to surgery if any|Proportion of patients with residual functional limitations|Treatment discontinuation and compliance rates|Incidence of all adverse effects (AEs) within 12 months of treatment initiation,"University Medical Center Groningen|University of Groningen|Facult� de M�decine P&M Curie, Paris-6 - Site Piti�-Salp�tri�re, France|Drugs for Neglected Diseases|World Alliance for Wound and Lymphoedema Care, Switzerland|Inserm U892/CNRS 699 bact�riologie, Universit� CHU;Angers- IRIS France|Institute of Tropical Medicine, Antwerp, Belgium|National Buruli ulcer Control Programme, Ghana Health Service, Accra, Ghana|School of Med Sciences, Kwame Nkrumah Univ of Sci & Techn, Kumasi, Ghana|Komfo Anokye Teaching Hospital|Kumasi Center for Collaborative Research into Tropical Medicine, Kumasi, Ghana|Plastic Surgery and Burns Centre, Korle-Bu Teaching Hospital, Accra, Ghana|University of Ghana|Noguchi Memorial Institute of Medical Research, Accra, Ghana|Program Nat de Lutte contre la L�pre et l'UB;Ulc�re de Buruli, Cotonou, Benin",All,"5 Years and older � (Child, Adult, Older Adult)",Phase 2|Phase 3,310,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,T9-370-1,December 2012,December 2017,January 2018,"August 7, 2012",,"September 26, 2019","Pob� Treatment Center, Pob�, Benin|Agogo Presbyterian Hospital, Agogo, Ghana|Dunkwa Government Hospital, Dunkwa, Ghana|Nkawie-Toase Government Hospital, Nkawie Panyin, Ghana|Tepa Government Hosital, Tepa, Ghana",,https://ClinicalTrials.gov/show/NCT01659437,NCT01659437,32171422;30102705
oui,NCT01671917,Evaluation of an Educational Program Associated With Exercises (EDEX) Before Total Knee Arthroplasty,EDEX,Completed,No Results Available,Knee Osteoarthritis,Other: Educational and exercise program|Other: Usual care,The percentage of patients able to quit independently the orthopedic department|Changes from baseline in functional recovery|Changes from baseline in mean knee pain in the previous 48 hrs|Changes from baseline in mean function in the previous 48 hrs|Changes from baseline in mean quality of life|Changes from baseline in the mean number of steps in the previous week|Satisfaction with the treatment|Cost-effectiveness|Adverse events,"Assistance Publique - H�pitaux de Paris|Institut National de la Sant� Et de la Recherche M�dicale, France|University of Paris 5 - Rene Descartes",All,"50 Years to 85 Years � (Adult, Older Adult)",Not Applicable,262,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,AOM 10042,"October 4, 2012","September 22, 2016","November 29, 2017","August 24, 2012",,"September 20, 2018","CHU Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT01671917,NCT01671917,35262716
oui,NCT01676194,Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma,CATCH,Terminated,No Results Available,Hepatocellular Carcinoma,Other: Intra-arterial administration of DC BeadsR,Survival|Dropout rate|Post-transplantation survival rate|Allograft survival|Time to dropout|Recurrence rate|TACE-induced complications (local and general)|Contrast agent - induced complications|Doxorubicin-induced complications|Efficacy of TACE,Rennes University Hospital,All,"18 Years and older � (Adult, Older Adult)",Phase 3,7,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2012~A00269-34,August 2012,"May 28, 2014","February 16, 2016","August 30, 2012",,"April 12, 2019","H�pital Henri Mondor - Assistance Publique-H�pitaux de Paris, Cr�teil, France|H�pital Michalon, CHU de Grenoble, Grenoble, France|H�pital Claude Huriez, CHU de Lille, Lille, France|H�pital de la Croix Rousse, HCL, Lyon, Lyon, France|H�pital Saint-Antoine / APHP, Paris, France|H�pital Pontchaillou, Rennes, France|H�pital Trousseau, CHU de Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT01676194,NCT01676194,
oui,NCT01682668,"Subthalamic Nucleus, Akinesia and Parkinson's Disease",GB-MOV,Recruiting,No Results Available,Parkinson's Disease,Procedure: Bilateral subthalamic stimulation,Firing rate of the subthalamic neurons|Evoked related potentials of the STN|Biomechanical parameters of gait initiation,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C11-40|2012-A00225-38,February 2013,May 2024,August 2024,"September 11, 2012",,"January 6, 2023","CIC-GHPS, Paris, France|Groupe Hospitalier Pitie-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT01682668,NCT01682668,
oui,NCT01686516,Synaptic Plasticity Imaging With Diffusion MRI,,Unknown status,No Results Available,"""Brain Aging""",,,"Institut National de la Sant� Et de la Recherche M�dicale, France",Male,"20 Years to 80 Years � (Adult, Older Adult)",,35,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Retrospective,C10-58|2011-A00034-37,June 2011,December 2012,December 2012,"September 18, 2012",,"September 18, 2012","Inserm U 825, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01686516,NCT01686516,
oui,NCT01687647,Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure,AMORCE-CBP,Unknown status,No Results Available,Lung Neoplasms,Other: low-dose CT-scan AND induced sputum sample AND blood test,Risk of false positive|detection of lung cancer|Sensitivity for lung cancer detection compared with CT-scan|Specificity for detection of lung cancer|Predictive Biomarkers,"University Hospital, Caen|Ministry of Health, France",All,"56 Years and older � (Adult, Older Adult)",Phase 3,1000,Other,Interventional,"Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Screening",2011-A01380-41|PHRC11-221,September 2012,March 2015,December 2019,"September 19, 2012",,"April 9, 2014","Caen University Hospital, Caen, France|Le Havre Hospital, Le Havre, France|Rouen University Hospital, Rouen, France",,https://ClinicalTrials.gov/show/NCT01687647,NCT01687647,
oui,NCT01688453,Overweight Management and Social Inequalities,PRALIMAP-INES,Completed,No Results Available,Overweight,Behavioral: Standard care management|Behavioral: The strengthened care management,Change in Body Mass Index from to baseline to 1 and 2 years|Change in overweight and obesity status according to IOTF norms|Change in BMI Z score from baseline to one and two years|Change in waist circumference|change in eating attitude score from baseline to 1 and 2 years|Change in anxiety and depression scores from baseline to 1 and 2 years,"Institut National de la Santé Et de la Recherche Médicale, France",All,13 Years to 17 Years   (Child),Not Applicable,1689,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,C11-46,April 2012,November 2015,November 2015,"September 19, 2012",,"August 26, 2021","School, Vosges, France",,https://ClinicalTrials.gov/show/NCT01688453,NCT01688453,35272723;34087324;32097754;29934380;29776897;29696179
oui,NCT01689181,Apathy in Schizophrenia,,Unknown status,No Results Available,Schizophrenia|Apathy,,apathy as measured by Starkstein's Apathy Evaluation Scale|neuropsychological performance|clinical assessment (for patients only)|volumetric brain abnormalities,"Institut National de la Santé Et de la Recherche Médicale, France",All,20 Years to 55 Years   (Adult),,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,C11-39|2011-A01610-41,June 2012,June 2013,September 2013,"September 21, 2012",,"September 21, 2012","INSERM MEDU 945, Centre de Recherche-Institut du Cerveau et de la Moelle (CR-ICM), Hôpital de la Pitié Salpétrière, Paris, France",,https://ClinicalTrials.gov/show/NCT01689181,NCT01689181,
oui,NCT01693835,"""Cancersensor"": Circadian Rhythms",,Completed,No Results Available,Metastatic Colorectal Cancer,,Circadian rhythms in urinary excretion of modified nucleosides,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",,32,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C11-42|2012-A00010-43,August 2012,June 2014,June 2014,"September 26, 2012",,"December 7, 2016","Paul Brousse Hospital, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01693835,NCT01693835,
oui,NCT01693848,"""Cancersensor"" Metastasis Resection",,Completed,No Results Available,Metastatic Colorectal Cancer,,Effect of resection of metastasis on urinary excretion of modified nucleosides|Identification of modified nucleosides as biomarkers for colorectal cancer,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,10,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C11-58|2012-A00011-42,September 2012,November 2014,November 2014,"September 26, 2012",,"December 7, 2016","Paul Brousse hospital, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01693848,NCT01693848,
oui,NCT01693861,"""Cancersensor"" Chemotherapy",,Completed,No Results Available,Metastatic Colorectal Cancer,,Effect of chemotherapy on urinary excretion of modified nucleosides,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,16,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,C11-59|2012-A00168-35,October 2012,February 2015,February 2015,"September 26, 2012",,"December 7, 2016","Paul Brousse Hospital, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01693861,NCT01693861,
oui,NCT01696708,Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease,PRO-MH2,Completed,No Results Available,Huntington Disease,Other: 31-Phosphorus RMN Spectroscopy,Ratio of Inorganic Phosphate (Pi) over phosphocreatine (PCr): Pi/PCr|Correlation between primary outcome measure and clinical parameters|Study of longitudinal changes in Pi/PCr ratio over time.,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C12-49|2012-A01063-40,"December 6, 2012",November 2015,November 2015,"October 1, 2012",,"March 9, 2017","Brain and Spine Institute (ICM), Paris, France",,https://ClinicalTrials.gov/show/NCT01696708,NCT01696708,25568297
oui,NCT01698411,Study of the Influence of Sleep on Hemodynamic Parameters in Patients With Sleep Disorders,HATS,Completed,No Results Available,Hypertension|Sleep|Insomnia,,hypertension|hemodynamic measures,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 100 Years   (Adult, Older Adult)",,90,Other,Observational,Observational Model: Cohort|Time Perspective: Other,C11-57|2012-A00825-38,October 2012,February 2015,February 2015,"October 3, 2012",,"August 26, 2021","centre du sommeil et de la vigilance, Hotel Dieu, Paris, France",,https://ClinicalTrials.gov/show/NCT01698411,NCT01698411,
oui,NCT01699893,Genetic & Environmental Determinants Of Immune Phenotype Variance: Establishing A Path Towards Personalized Medicine,LabExMI,Completed,No Results Available,Individuality,Other: unique arm,Measurement of cytokine/chemokine stimulated by 40 pattern-recognition receptors agonists (PRR agonists) or immune stimulators.|Determination of genotype-to-phenotype associations at a mechanistic level,Institut Pasteur,All,"20 Years to 69 Years � (Adult, Older Adult)",Not Applicable,1012,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2012-A00238-35,September 2012,August 2013,August 2013,"October 4, 2012",,"May 29, 2015","BIOTRIAL, Rennes, France",,https://ClinicalTrials.gov/show/NCT01699893,NCT01699893,31519223;31051503;30053915
oui,NCT01703962,Non Invasive IDentification of Gliomas With IDH1 Mutation,IDASPE,Completed,No Results Available,Non Invasive Diagnosis of Glioma,,,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",,6,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C11-28|2011-A01356-35,"March 14, 2012",March 2014,"March 20, 2014","October 11, 2012",,"August 26, 2021","GH Pitié-Salpêtrière, 47 Bd de l'Hopital,, Paris, Sélectionner..., France",,https://ClinicalTrials.gov/show/NCT01703962,NCT01703962,
oui,NCT01707602,Routes of Immunization and Flu Immune Responses,FLUWAY,Completed,No Results Available,Influenza,Biological: INTANZA® 15|Biological: Vaxigrip®|Biological: INTANZA® 15 T,CD8 T cell responses|Safety|Haemagglutination Inhibition|CD4 T cell responses|Memory CD8 and CD4 T cell responses|Inflammation,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 45 Years   (Adult),Phase 1|Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),P120201|2012-001967-55,October 2012,December 2012,April 2013,"October 16, 2012",,"August 5, 2013","GH Cochin - Broca - Hôtel-Dieu CIC BT505, PARIS Cedex 14, France",,https://ClinicalTrials.gov/show/NCT01707602,NCT01707602,30843873
oui,NCT01713335,Proteasis Evaluation in COPD,Pro-BPCO,Completed,No Results Available,Chronic Obstructive Pulmonary Disease,,Kallikrein level in sputum by ELISA|Comparison between kallikrein level and clinical or functionnal parameters,"Institut National de la Santé Et de la Recherche Médicale, France",All,"50 Years to 75 Years   (Adult, Older Adult)",,134,Other,Observational,Observational Model: Other|Time Perspective: Prospective,C11-56|2012-A00885-38,"October 18, 2012",April 2017,April 2017,"October 24, 2012",,"August 26, 2021","CHRU Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT01713335,NCT01713335,
oui,NCT01715623,Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies.,PRIERR,Completed,No Results Available,Healthy Volunteers|Children With HSP|Subject With Allergy|Lymphoma,Biological: a blood sample,the percentage of allele B,"University Hospital, Limoges|Institut National de la Santé Et de la Recherche Médicale, France|Direction Générale de la Santé, France",All,"4 Years and older   (Child, Adult, Older Adult)",,486,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,I12002 PRIERR,October 2012,April 2013,"December 16, 2014","October 29, 2012",,"January 22, 2019","Clinical Investigation Center, Limoges, France|Nephrology, Limoges, France|Pediatric, Limoges, France|Pneumology, Limoges, France",,https://ClinicalTrials.gov/show/NCT01715623,NCT01715623,
oui,NCT01716819,Role of the Renin Angiotensin Aldosterone System in the Mechanisms of Transition to Heart Failure in Abdominal Obesity,R2C2-II,Completed,No Results Available,"Obesity, Abdominal",Other: Urine sample|Other: Blood sample|Other: Assessment of sleep apnea syndrome|Other: Electrocardiogram|Other: Glucose tolerance test|Other: Echocardiography|Other: cardiac and abdominal magnetic resonance imaging|Other: Ambulatory blood pressure monitoring|Other: Echotracking|Other: Pulse wave velocity|Other: Composition of body mass by Dual x-ray absorptiometry,cardiac extracellular matrix remodelling|Cardiac and arterial phenotype,"Central Hospital, Nancy, France",All,"43 Years to 72 Years � (Adult, Older Adult)",Not Applicable,101,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),2012-A00574-39,November 2012,March 2015,March 2015,"October 30, 2012",,"August 24, 2015","CIC-P - INSERM - Institut Lorrain du C�ur et des vaisseaux, Vandoeuvre L�s Nancy, Meurthe et Moselle, France",,https://ClinicalTrials.gov/show/NCT01716819,NCT01716819,35004914
oui,NCT01720160,BAROSTIM� Hope for Heart Failure Study,HOPE4HF,Unknown status,No Results Available,Heart Failure,Device: BAROSTIM NEO� System|Other: Standard of care medical managment therapy for heart failure,Heart failure metric improvements from baseline|System and procedure related adverse events,"CVRx, Inc.",All,"21 Years and older � (Adult, Older Adult)",Not Applicable,98,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,360032-001,November 2012,May 2015,March 2021,"November 2, 2012",,"May 14, 2019","Southwest Cardiovascular Associates, Mesa, Arizona, United States|Arizona Heart Rhythm Research Center, Phoenix, Arizona, United States|University of Southern California, Los Angeles, California, United States|George Washington University, Washington, District of Columbia, United States|ACRC - Cardiology, Atlantis, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Piedmont Heart Institute, Atlanta, Georgia, United States|Advocate Medical Group, Naperville, Illinois, United States|Cardiovascular Institute of the South, Houma, Louisiana, United States|St Elizabeth's Medical Center, Brighton, Massachusetts, United States|Mid-Michigan Medical Center Midland, Midland, Michigan, United States|Cardiac & Vascular Research Center of Northern Michigan, Petoskey, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Ohio State University, Columbus, Ohio, United States|Oklahoma Cardiovascular Research Group, Oklahoma City, Oklahoma, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Lonestar Heart Center, Amarillo, Texas, United States|Wheaton Franciscan Healthcare, Milwaukee, Wisconsin, United States|Aspirus Heart & Vascular Institute, Wausau, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01720160,NCT01720160,29705650;26011593;25982108
oui,NCT01722617,A Study to Validate Questionnaires FLARE and OM-RA-FLARE Measuring Disease Flares in Patients With Rheumatoid Arthritis.,FLARE,Completed,No Results Available,"Arthritis, Rheumatoid",Other: Questionnaire,The validity of the questionnaire FLARE.|The discriminating power of the instrument FLARE.|The feasibility of the questionnaire FLARE,"Central Hospital, Nancy, France|Centre Hospitalier Universitaire de Besancon|Centre Hospitalier R�gional et Universitaire de Brest|Centre Hospitalier Universitaire Dijon|University Hospital, Grenoble|University Hospital Center of Martinique|University Hospital, Montpellier|Nantes University Hospital|Bichat Hospital|Groupe Hospitalier Pitie-Salpetriere|Poitiers University Hospital|University Hospital, Rouen|University Hospital, Toulouse",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,207,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),2011-A01349-32,March 2012,June 2014,June 2014,"November 7, 2012",,"September 23, 2015","Service de Rhumatologie, CHU H�pital G�n�ral, Dijon, Bourgogne, France|Service de Rhumatologie, CHU La Cavale Blanche, Brest, Bretagne, France|Service de Rhumatologie, CHRU H�tel Dieu, Nantes, Bretagne, France|Service de Rhumatologie, CHU Jean Minjoz, Besan�on, Franche-Comt�, France|Service de Rhumatologie, CHU Fort de France, Fort de France, La Martinique, France|Service de Rhumatologie, H�pitaux de Rouen, Rouen, Normandie, France|Service de Rhumatologie, CHU - H�pital Sud A. Michallon, Grenoble, Rh�ne-Alpes, France|Service de Rhumatologie, CHU Conception, Marseille, France|F�d�ration de Rhumatologie, CHU Lapeyronie, Montpellier, France|Service de Rhumatologie, APHP - CHU Bichat, Paris, France|Service de Rhumatologie, APHP - GH Piti� Salp�tri�re, Paris, France|Service de Rhumatologie, CHU de Poitiers, Poitiers, France|Service de Rhumatologie, H�pital Larey, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01722617,NCT01722617,27636400
oui,NCT01723631,Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis,TRAP-Myéline,Terminated,No Results Available,Multiple Sclerosis,Device: Trap Myelin Test,Evaluate the diagnostic performance of myelin-TRAP assay for Multiple Sclerosis|Determine the best cut-off rate of myelin-Trap and evaluate the sensitivity and specificity associated,"Nantes University Hospital|Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 55 Years   (Adult),Not Applicable,189,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,BRD/10/06-S|2010-A00892-37,April 2012,December 2014,October 2015,"November 8, 2012",,"May 16, 2017","University Hospital of Bordeaux, Bordeaux, France|Hopital neurologigue Pierre Wertheimer, Bron, France|University Hospital of clermont Ferrand, Clermont Ferrand, France|University Hospital of Lille, Lille, France|University Hospital of Marseille, Marseille, France|University Hospital of Montpellier, Montpellier, France|University Hospital of Nantes, Nantes, France|University Hospital of Nice, Nice, France|University Hospital of Rennes, Rennes, France|University Hospital of Strasbourg, Strasbourg, France|University Hospital of Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01723631,NCT01723631,
oui,NCT01725438,Non Invasive Prenatal Diagnosis of Trisomy 21 by Genetic Analysis of Circulating Fetal Cells,ISETTRI21,"Active, not recruiting",No Results Available,Trisomy 21,Other: sample blood,non-invasive method of PND of Trisomy 21.,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Rarecells|University of Paris 5 - Rene Descartes",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AOM10123|P100118,"June 19, 2012","March 31, 2017","December 31, 2021","November 12, 2012",,"July 7, 2021","Hopital de Béclère, Clamart, France",,https://ClinicalTrials.gov/show/NCT01725438,NCT01725438,
oui,NCT01730612,ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA,iTEPsein,Completed,No Results Available,HER2 Negative Breast Carcinoma Expressing CEA,Drug: TF2 - 68 Ga-IMP-288:,"evaluation of the tumor targeting (no Unit) and signal / noise ratio (no unit) by the immunoTEP with TF2 and 68-Ga-IMP-288|Sensibility, tolerance|To study the contribution of immnoTEP to assess early response to treatment, compare its performance to standard imaging methods","Nantes University Hospital|Institut National de la Santé Et de la Recherche Médicale, France|Gilead Sciences",Female,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,23,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,BRD/10/04-O,December 2012,May 2017,May 2017,"November 21, 2012",,"July 27, 2018","Hospital, Nantes, France|Institut de Cancérologie de l'Ouest, Saint Herblain, France",,https://ClinicalTrials.gov/show/NCT01730612,NCT01730612,
oui,NCT01730638,ImmunoTEP for Patients With Medullary Thyroid Carcinoma.,iTEP-CMT,Completed,No Results Available,Medullary Thyroid Carcinoma,Drug: • TF2 and 68 Ga-IMP-288,Evaluation of the tumor targeting (No Unit) and signal/noise (No Unit)ratio by immunoTEP with TF2 and 68-Ga-IMP-288|Sensibilité,"Nantes University Hospital|Institut National de la Santé Et de la Recherche Médicale, France|Gilead Sciences",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,25,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PROG/10/94,January 2013,December 2016,December 2016,"November 21, 2012",,"July 26, 2022","Angers Hospital, Angers, France|Nantes Hospital, Nantes, France|Institut de Cancérologie de l'ouest, René Gauducheau, Saint-Herblain, France",,https://ClinicalTrials.gov/show/NCT01730638,NCT01730638,
oui,NCT01747044,Prospective Study of the Influence of the Diffuse Noxious Inhibitory Controls of the Pain on the Efficacy of Milnacipran in Fibromyalgia Therapy,,Unknown status,No Results Available,Fibromylagia,Drug: Milnacipran|Drug: Placebo,Pain scores on the verbal numeric scale|sensitivity and pain thresholds to a mechanical stimulus|sensitivity and pain thresholds to a thermal stimulus|scores on cognitive tests|Adverse events record,"University Hospital, Clermont-Ferrand|Dr. Gis�le PICKERING (MCU, PH) Center of clinical pharmacology/CIC Inserm-501 - Main investigator|Dr Pascale PICARD/ Dr No�mie Delage / Dr Fabienne RIAUX - Center of evaluation and treatment of the pain - Investigator|Dr Gilles DUCHEIX/ Center of clinical pharmacology/CIC Inserm-501 - Investigator|Dr Christian DUALE/ Center of clinical pharmacology/CIC Inserm-501 - Investigator",Female,"18 Years and older � (Adult, Older Adult)",Phase 2,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CHU-0130,April 2013,November 2014,November 2014,"December 11, 2012",,"July 8, 2014","CHU de Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT01747044,NCT01747044,25873248
oui,NCT01747967,Immune Biomarkers of Residual Beta-cell Mass in Type 1 Diabetes,IMMADIAB,Completed,No Results Available,Type 1 Diabetes,Other: Meal Test,Correlation between residual insulin secretion and T-cell responses against beta-cell antigens.|Correlation between residual insulin secretion estimated by serum and urine C-peptide measurement.|Correlation between residual insulin and glucagon secretion.,"Assistance Publique - H�pitaux de Paris|Institut National de la Sant� Et de la Recherche M�dicale, France|Recherche Clinique Paris Descartes Necker Cochin Sainte Anne",All,"6 Years to 60 Years � (Child, Adult)",Not Applicable,156,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,K 091101,"November 15, 2011","May 30, 2017","May 30, 2017","December 12, 2012",,"August 1, 2017","INSERM U1016 - DeAR Lab Avenir, H�pital Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT01747967,NCT01747967,
oui,NCT01760356,Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients,3PIGREF,Terminated,No Results Available,End Stage Liver Disease|Rejection|Infection|Malignancy|Toxicity|Diabetes,,"Change in Percentage of expression of CD25High in CD3, CD4 and CD8 T Lymphocytes.|Pharmacogenetic investigations|Anticalcineurin drug concentration through levels|Change in Mean Fluorescence Intensity of NFAT1 Nuclear Translocation Inhibition in PMBC nuclei.|Change in the Percentage of expression of IL-2 in CD4 and CD8 subsets of T lymphocytes.|Acute Cellular Rejection Mild, Moderate and Severe|Infection Episodes which requiere anmicrobials treament|Neurotoxicity to CNIs|Nephrotoxicity to CNIs|Malignancies|Post transplant Diabetes|Cardiovascular disease, post transplant blood pressure augmentation|Death|Post transplant surgical complications","UDA Centro Nacional Hepato-Bilio-Pancre�tico|INSERM UMR-S850, Limoges, France|University Hospital, Limoges|PEDECIBA, Uruguay|Universidad de la Republica|ANII (Agencia Nacional de Investigaci�n e Innovaci�n), Uruguay|Scientific Cooperation Service, French Embassy, Uruguay|Hospital Central de las Fuerzas Armadas, Uruguay|ECOS Sud Program France-Uruguay|National Center for Liver Transplantation, Uruguay",All,"18 Years to 70 Years � (Adult, Older Adult)",,141,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,3PIGREF- 2009 -1165,"May 1, 2011","February 28, 2015","May 17, 2021","January 4, 2013",,"May 19, 2021","National Center for Liver Transplantation and Liver Diseases Department, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay",,https://ClinicalTrials.gov/show/NCT01760356,NCT01760356,29054923
oui,NCT01764152,Clinical Trial to Assess the Influenza Vaccination (FLUVAC 02),FLUVAC EV-02,Unknown status,No Results Available,Adult Hospitalized,Other: nasopharyngeal sample,"Measure of vaccine efficacy in population by comparing the number of influenza cases virologically documented in hospitalized patients vaccinated and unvaccinated.|Measure of vaccine efficacy in population by comparing the number of influenza cases virologically documented in hospitalized patients vaccinated and unvaccinated according to age groups|Measure of vaccine efficacy in population by comparing the number of influenza cases virologically documented in hospitalized patients vaccinated and unvaccinated depending on the subtypes.|Description of the population hospitalized for ILI (socio-demographic characteristics, risk factors, pattern and duration of hospitalization...)","Institut National de la Santé Et de la Recherche Médicale, France|Sanofi",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,C12-57|2012-A01118-35,December 2012,April 2013,May 2013,"January 9, 2013",,"January 9, 2013","Institut National de la Santé Et de la Recherche Médicale, Paris, France",,https://ClinicalTrials.gov/show/NCT01764152,NCT01764152,
oui,NCT01764412,Study of Serum Hepcidin Rate Variations During Menstrual Cycle,HEPMEN,Completed,No Results Available,Healthy Women,,Serum hepcidin rates variations during the menstrual cycle|Seric iron|transferrin saturation|serum transferrin|serum ferritin|hepcidin / ferritin rate|hepcidin / transferrin saturation rate|hepcidin / serum iron rate,Rennes University Hospital,Female,18 Years to 45 Years � (Adult),,147,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012-A01122-41,March 2013,March 2014,February 2015,"January 9, 2013",,"March 30, 2015","CHU Rennes, Rennes, Bretagne, France|Chu Brest, Brest, France|CHU Nantes, Nantes, France|Chru Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT01764412,NCT01764412,
oui,NCT01767649,Inflammatory Signature of Human Chorionic Cells,TROPHY,Completed,No Results Available,Pregnancy,Other: Caesarean|Other: Vaginal delivery,Protein overexpression,Assistance Publique - H�pitaux de Paris,Female,"18 Years and older � (Adult, Older Adult)",,24,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NI10056,November 2010,May 2014,November 2014,"January 14, 2013",,"December 23, 2014","INSERM, Paris, France",,https://ClinicalTrials.gov/show/NCT01767649,NCT01767649,
oui,NCT01769261,Sentinel Patients: Value of an Information System Collecting Patient's Own Report on His Healthcare Management,SENTIPAT,Completed,No Results Available,Patients Returning Home After Discharge From Hospital,"Other: eligible, Internet|Other: eligibles, telephone|Other: non eligibles","proportion of patients reporting at least a clinically significant adverse event (as judged by the validation committee) occuring in the period of 45 days after hospital discharge.|Nature, chronology, severity and avoidability of adverse events. Other second outcome measures are mentioned in the detailed description of the study.","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Pierre and Marie Curie University",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2090,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,AOM09213 - K081204,February 2013,October 2014,October 2014,"January 16, 2013",,"August 2, 2016","Hôpital Saint Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT01769261,NCT01769261,35266869;28835354;26109261
oui,NCT01772394,Cognitive Remediation Therapy in Anorexia Nervosa,TreCogAM,Completed,No Results Available,Teenager|Young Adult|Hospitalized|Anorexia Nervosa (DSM-IV Revised Criteria),Behavioral: Cognitive Remediation Therapy|Behavioral: Sham Therapy,Neuropsychological functioning:Wisconsin Sorting Card Test (WSCT)|Clinical status Evaluation:Morgan and Russell Global Outcome Assessment Scale (GOAS) |Central coherence|Nutritional status|Self-reported eating disorders symptoms|Self-reported Cognitive style |Self-reported treatment satisfaction|Self-reported motivation to change|Self-reported self-esteem|Flexibility evolution : Trail Making Test (TMT),"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",Female,"15 Years to 40 Years   (Child, Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,RCB-2011-A01280-41|P091123,October 2012,June 2016,January 2017,"January 21, 2013",,"January 16, 2017","Clinique Villa Montsouris, Paris, France|Institut Mutualiste Monsouris, Paris, France|Maison de Solenn, Paris, France|Assistance Publique - Hôpitaux de Paris, Hôpital Paul Brousse, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01772394,NCT01772394,33274668;27310229
oui,NCT01779713,Transcriptomic Signature of Vasospasm Consecutive to Sub-arachnoid Aneurismal Hemorrhage,,Completed,No Results Available,Aneurysmal Subarachnoid Hemorrhage|Vasospasm,Genetic: Case-control transcriptomic study,Evidence of clinically definite vasospasm|Rankin Score|Glasgow outcome score (GOS),"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,89,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C10-15|2012-A00935-38,"February 4, 2013",July 2016,"July 4, 2016","January 30, 2013",,"August 30, 2021","Neuro-anesthesia intensive care unit, Pitié-Salpétrière hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01779713,NCT01779713,30354977
oui,NCT01779752,Vestibular Cortex and TMS,CoVest,Completed,No Results Available,Cortical Organisation of Vestibular Integration,,changes in gain of vestibulo-ocular reflex (VOR),"Institut National de la Santé Et de la Recherche Médicale, France",All,20 Years to 35 Years   (Adult),,17,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C12-20|2012-A00839-34,"January 20, 2013",January 2016,January 2016,"January 30, 2013",,"September 1, 2021",,,https://ClinicalTrials.gov/show/NCT01779752,NCT01779752,
oui,NCT01781416,Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk,PERCEPTION,Completed,No Results Available,Cardiovascular Risk,,Cardiovascular risk perceived by patients (before reading the Medical Information Leaflet)|Cardiovascular risk assessed by physicians|Cardiovascular risks perceived by patients before and after reading the Medical Information Leaflet|Actual cardiovascular risk calculated using SCORE|Characteristics of patients whose self-evaluation of their CVR is concordant with their actual CVR|Characteristics of patients whose self-evaluation of their CVR is discordant with their actual CVR|Risk factors considered by patients in self-assessing their CVR,AstraZeneca,All,"Child, Adult, Older Adult",,799,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,NIS-CFR-XXX-2012/1,November 2013,April 2014,April 2014,"February 1, 2013",,"May 20, 2014","Research Site, PARIS Cedex 15, France",,https://ClinicalTrials.gov/show/NCT01781416,NCT01781416,
non,NCT01796028,Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer,TAXOMET,Completed,No Results Available,Prostatic Neoplasms,Drug: METFORMIN|Drug: Placebo|Drug: TAXOTERE�,PSA response rate|Biochemical and clinical progression-free survival,Centre Antoine Lacassagne,Male,"18 Years and older � (Adult, Older Adult)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2012-000530-19|2010/35,January 2013,December 2015,"May 31, 2018","February 21, 2013",,"June 6, 2018","Centre ANTOINE LACASSAGNE, Nice, France",,https://ClinicalTrials.gov/show/NCT01796028,NCT01796028,34629300
oui,NCT01799616,Efficiency and Safety Study of Pamidronate in Inflammatory Back Pain Due to Degenerative Disk Disease,,Unknown status,No Results Available,Intervertebral Disc Degeneration|Modic I Discopathy|Back Pain|Low Back Pain|Magnetic Resonance Imaging (MRI),Drug: Pamidronate|Other: Placebo,"back pain assessed on a100mm VAS|- Functional status using EIFEL, Dallas, FABQ, MacTar, and MCII/PASS questionnaires|Back stiffness assessed by Schober's test and finger-to-floor distance|Inflammatory pain pattern|assess the efficacy of a rigid back brace in treating back pain|Tolerance based on the number and types of side-effects","University Hospital, Clermont-Ferrand|INSERM CIC 501",All,18 Years to 60 Years � (Adult),Phase 2,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CHU-0148|2012-003569-16,January 2013,January 2015,March 2015,"February 27, 2013",,"February 27, 2013","CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT01799616,NCT01799616,24716739
oui,NCT01800136,Analgesic Effect of Non Invasive Stimulation : Comparison of rTMS and tDCS Efficacy,NI-MCS,Completed,No Results Available,Pharmacoresistant Neuropathic Pain,Device: Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation,Change from Baseline in Pain at the end of the stimulation week Change from Baseline in Pain at the end of the first post-stimulation week Change from Baseline in Pain at the end of the second post-stimulation week|objective evaluation of sleep quality|subjective evaluation of sleep quality using a numerical auto-evaluation scale|nociceptive and non-nociceptive thresholds|evaluation of motor cortex plasticity,Hospices Civils de Lyon,All,"18 Years to 80 Years � (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011.662|2008-A01379-32,"January 13, 2013","June 17, 2019","June 17, 2019","February 27, 2013",,"September 3, 2019","Service de Neurologie Fonctionnelle et Epileptologie, H�pital Neurologique de Lyon et Unit� "" Int�gration Centrale de la Douleur "", 1028 Inserm - UCBL, Lyon, France",,https://ClinicalTrials.gov/show/NCT01800136,NCT01800136,
oui,NCT01801709,Intracerebral Gene Therapy for Children With Early Onset Forms of Metachromatic Leukodystrophy,TG-MLD,"Active, not recruiting",No Results Available,Metachromatic Leukodystrophy,Genetic: intracerebral administration of AAVrh.10cuARSA,Evaluate the tolerance of the intracerebral administration of a single dose of AAVrh.10cuARSA|Evaluate the efficacy of intracerebral administration of a single dose of AAVrh.10cuARSA to stop the disease progression.,"Institut National de la Santé Et de la Recherche Médicale, France|European Leukodystrophy Association|Assistance Publique - Hôpitaux de Paris",All,6 Months to 5 Years   (Child),Phase 1|Phase 2,5,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C11-09|2011-004410-42,June 2014,June 2016,May 2029,"March 1, 2013",,"January 11, 2022","Bicêtre Hospital - Paris Sud, Le Kremlin-Bicêtre, France",,https://ClinicalTrials.gov/show/NCT01801709,NCT01801709,25758611
oui,NCT01802099,Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines,NUTRIREA2,Terminated,No Results Available,Acute Respiratory Failure|Shock,Other: Enteral nutrition|Other: Parenteral nutrition,Mortality|Mortality rate|Ventilator-associated pneumonia rate|Nosocomial infections rate|Length of stay in Intensive Care Unit (ICU)|Length of stay in hospital|Variations in Sepsis-related Organ Failure Assessment (SOFA) score|calories intake|Proportion of patients given 100% of the calorie target|cumulative calorie deficit from day 0 to day 7|Hospital mortality rate|Intensive Care Unit (ICU) mortality rate|Acute bowel ischemia rate|Vomiting rate,"Centre Hospitalier Departemental Vendee|Ministry of Health, France|Institut National de la Santé Et de la Recherche Médicale, France|University Hospital, Tours",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2411,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CHD085-11,March 2013,July 2015,September 2015,"March 1, 2013",,"February 25, 2019","CHU Amiens, Amiens, France|CHU d'Angers, Angers, France|Centre hospitalier d'Annecy, Annecy, France|Centre Hospitalier de Beauvais, Beauvais, France|CHU Besançon-Hôpital Jean Minjoz, Besançon, France|CHU Pellegrin Tripode, Bordeaux, France|CH Louis Pasteur, Chartres, France|CHU Gabriel Montpied, Clermont Ferrand, Clermont Ferrand, France|CHU Louis Mourier, Colombes, France|CH de Dieppe, Dieppe, France|CHU Dijon, Dijon, France|Hôpital Raymond Poincarre, Garches, France|CHU Grenoble, Grenoble, France|CHD Vendée - service de réanimation, La Roche sur Yon, France|CHU de Bicêtre, Le Kremlin-Bicêtre, France|CH Docteur Schaffner, Lens, France|CHU Lille, Lille, France|CHU de Lyon- Hôpital de la Croix Rousse, Lyon, France|Hospices Civils de Lyon, Lyon, France|CH Marc Jacquet, Melun, France|CH de Montauban, Montauban, France|CHI André Grégoire, Montreuil, France|Hôpital Emile Muller, Mulhouse, France|CHU de Nantes, Hopital Laennec, Nantes, France|CHU de Nantes - Hôtel Dieu, Nantes, France|Hôpital de La Source, CHR Orléans, Orléans, France|CHU Saint Louis, Paris, France|CHU Saint-Antoine, Paris, France|CHU Paris Cochin, Paris, France|Groupe Hospitalier Paris Saint Joseph, Paris, France|Hôpital Tenon, Paris, France|CHU Pointe à Pitre - Abymes, Pointe À Pitre, France|CHU Poitiers, Poitiers, France|Centre Hospitalier Jacques Puel, Rodez, France|Hôpital Delafontaine, Saint Denis, France|CHU Saint Etienne-Hôpital Nord, Saint Etienne, France|CH de Saint Malo, Saint Malo, France|CHU de Strasbourg - Nouvel Hôpital Civil, Strasbourg, France|CHU de Strasbourg - Hôpital de Hautepierre, Strasbourg, France|Hôpital Foch, Suresnes, France|CHU Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT01802099,NCT01802099,29128300;25539571
oui,NCT01803984,"MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction",MIBRAIN,Terminated,No Results Available,Migraine,Device: MRI|Device: EndoPAT|Other: Neuropsychological battery,"Differences in magnetic resonance imaging (MRI) between migraine without aura and migraine with aura patients (frequency of hyperintensities, white matter lesions....)|Differences in the Total Score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) between migraine without aura and migraine with aura patients.|Differences in the Reactive Hyperemia Index (RHI) and the Augmentation Index (AI) between migraine without aura and migraine with aura patients|Correlation between MRI and Total Score of RBANS with RHI / AI (endothelial function) between migraine groups.","University Hospital, Bordeaux",All,"18 Years and older � (Adult, Older Adult)",,166,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,CHUBX 2012/19,"March 22, 2013","December 3, 2014","December 3, 2014","March 4, 2013",,"June 18, 2020","Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT01803984,NCT01803984,
oui,NCT01805336,Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality,SEPREV,Completed,No Results Available,Relapsing-Remitting Multiple Sclerosis,"Other: Assessment of attentional functions by traditional tests|Other: Assessment of attentional functions by virtual reality tests|Other: Assessment of executive functions by traditional tests|Other: Assessment of executive functions by virtual reality test|Other: Evaluation of cognitive complaint, fatigue, anxiety and depression","Scores for traditional tests|Scores for virtual reality tests|Correlation between traditional and virtual reality tests|Z-scores for traditional and virtual reality tests|Score for cognitive complaint questionnaire|Scores for fatigue, anxiety and depression questionnaires","University Hospital, Caen",All,30 Years to 60 Years � (Adult),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Other,2012-A000000166-37|12-027,"March 28, 2013","July 9, 2020","July 9, 2020","March 6, 2013",,"March 1, 2021","Department of Neurologie, Caen Hospital University, Caen, Basse-Normandie, France|Inserm Unit 1075 Comete, Caen Hospital University, Caen, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT01805336,NCT01805336,
oui,NCT01810822,Sex-specific Association With Kidney Disease,,Completed,No Results Available,Diabetic Nephropathy,,Albumin to Creatinine Ratio,University of Sao Paulo General Hospital,All,"11 Years and older � (Child, Adult, Older Adult)",,1396,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,FMUSP-LIM25-0002,May 1994,May 1994,October 2012,"March 14, 2013",,"March 14, 2013","Faculty of Medicine from University of S�o Paulo, S�o Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT01810822,NCT01810822,
oui,NCT01818895,Terminal Weaning of Mechanical Ventilation or Extubation in Anticipation of Death in the Intensive Care Unit,ARREVE,Completed,No Results Available,Withdrawal|Anxiety|Depression|Posttraumatic Stress Disorder,,Post traumatic Stress Disorder|Anxiety and depression|Complicated grief|Relative's satisfaction|Nurse's satisfaction|Physician's satisfaction|Burn out syndrome of the nurse|Burn out syndrome of the physician,"Centre Hospitalier Departemental Vendee|Poitiers University Hospital|Institut National de la Santé Et de la Recherche Médicale, France|University Hospital, Tours",All,"18 Years and older   (Adult, Older Adult)",,458,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHD 018-13,April 2013,March 2015,May 2015,"March 27, 2013",,"July 10, 2015","Réanimation médicale CHU, Angers, France|Réanimation, CH d'Angoulême, Angoulême, France|Réanimation, CH d'Annecy, Annecy, France|Réanimation, Belfort, France|CHU Pellegrin Tripode, Bordeaux, France|Réanimation, CHU, Bordeaux, France|CHU Ambroise Paré, Boulogne, France|CHU La Cavale Blanche, Brest, France|CHU de Côte de Lumière, Caen, France|Centre Hospitalier, Service de réanimation, Charleville Mézières, France|CH de Chartres, Chartres, France|CHU Gabriel Montpied, Clermont Ferrand, Clermont Ferrand, France|CHU Louis Mourier, Colombes, France|CH de Dieppe, Dieppe, France|CHU Dijon, Dijon, France|CHU Raymond Poincaré, Garches, France|CHU Grenoble, Grenoble, France|CHD de la Vendée, La Roche sur Yon, France|CH de La Rochelle, La Rochelle, France|CH du Mans, Le Mans, France|CH du Puy, Le Puy en Velay, France|CH Docteur Schaffner, Lens, France|CHU de Lille, Lille, France|CH de Lorient, Lorient, France|CHU Marseille, Hopital La Timone, Marseille, France|CHU de Marseille, Hopital Nord, Marseille, France|CH Marc Jacquet, Melun, France|CH de Montauban, Montauban, France|CHI André Grégoire, Montreuil, France|CH de Mulhouse, Mulhouse, France|CHU de Nantes - Hôtel Dieu, Nantes, France|CHU Orléans - Réanimation Médicale, Orleans, France|CHU Saint Louis, Paris, France|CHU Paris Cochin, Paris, France|Groupe Hospitalier Paris Saint Joseph, Paris, France|CHU Hopital Européen Georges Pompidou, Paris, France|CHU Lariboisière, Paris, France|CHU Poitiers, Poitiers, France|CH de Roanne, Roanne, France|Hôpital Delafontaine, Saint Denis, France|CH de Saint-Nazaire, Saint-Nazaire, France|Hôpital Foch, Suresnes, France|CHU Tours, Tours, France|Institut Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01818895,NCT01818895,28936597
oui,NCT01829126,Development and Prevention of Severe Heart Disease in Systemic Sclerosis,,Unknown status,No Results Available,Systemic Sclerosis|Cardiac Diseases|Heart Block|Cardiac Arrhythmia|Congestive Heart Failure,,"Cumulative incidence of CB, VA, pacemaker implantation, congestive heart failure and sudden death","Gabriele Valentini|European Union|University of Giessen|University of Zurich|University of Paris 5 - Rene Descartes|University of Florence|University of Basel|University College, London|Charite University, Berlin, Germany|University of Pecs|University of Leeds|Schoen Klinik Hamburg Eilbek|University of Campania ""Luigi Vanvitelli""",All,"Child, Adult, Older Adult",,765,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HEALTH-F5-2012-305495-OT5,April 2013,August 2016,August 2016,"April 11, 2013",,"November 8, 2013","Universit� Paris Descartes, H�pital Cochin, Service de Rhumatologie A & INSERM 1016, Paris, France|Justus-Liebig-University Gie�en, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology, Bad Nauheim, Germany|Charit� Universit�tsmedizin Berlin, Charit� Centrum 12 f�r Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Berlin, Germany|Centre for Pediatric Rheumatology, Klinikum Eilbek, Hamburg, Germany|Pecsi Tudomanyegyetem - University of Pecs, Pecs, Hungary|University of Florence, Denothe Centre, Division of Rheumatology AOUC, Department of Biomedicine, Firenze, Italy|Policlinico, Via Pansini, Napoli-Italia, Italy|Felix-Platter Spital, University of Basel, Basel, Switzerland|University of Zurich, Department of Rheumatology, Zurich, Switzerland|The Universitiy of Leeds, Division of Rheumatic and Musculoskeletal Disease, St James's University Hospital, Leeds, United Kingdom|Royal Free Hospital, University College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01829126,NCT01829126,
oui,NCT01834157,Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis,,Unknown status,No Results Available,Systemic Sclerosis|Arthritis,,Improvement of HAQ-DI (CHAQ-DI in jSSc) by at least -0.21 in one year|Improvement of the CHFS in one year|Improvement of the CDAI in one year|Improvement of the SDAI in one year|Improvement of the DAS28(We) in one year|Improvement of the DAS28(CRP) in one year,"Prof. Laszlo Czirjak|European Union|University of Giessen|University of Zurich|University of Paris 5 - Rene Descartes|University of Florence|University of Campania ""Luigi Vanvitelli""|University of Basel|University College, London|Charite University, Berlin, Germany|University of Leeds|Schoen Klinik Hamburg Eilbek|University of Pecs",All,"Child, Adult, Older Adult",,160,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HEALTH-F5-2012-305495-OT2,April 2013,November 2017,November 2017,"April 17, 2013",,"December 22, 2015","University of Ghent, Department of Rheumatology, Gent, Belgium|Dubrava University Hospital, Zagreb, Croatia|Assiut and Sohage University Hospital Rheumatology Department Assiut University Hospital, Assiut, Egypt|Department of Internal Medicine H�pital Claude Huriez, Lille cedex, France|Universit� Paris Descartes, H�pital Cochin, Service de Rhumatologie A & INSERM 1016, Paris, France|Justus-Liebig-University Gie�en, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology, Bad Nauheim, Germany|Charit� Universit�tsmedizin Berlin, Charit� Centrum 12 f�r Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Berlin, Germany|Universit�tshautklinik K�ln, Cologne, Germany|Universit�tsklinikum Erlangen, Erlangen, Germany|Endokrinologikum Frankfurt, Frankfurt, Germany|Centre for Pediatric Rheumatology, Klinikum Eilbek, Hamburg, Germany|Medizinische Universit�tsklinik Abt. II, T�bingen, Germany|Krankenhaus St. Josef, Wuppertal, Germany|Pecsi Tudomanyegyetem - University of Pecs, Pecs, Hungary|Istituto di Clinica Medica Generale, Ematologia ed Immunologia Clinica, Universit� Politecnica delle Marche, Polo Didattico, University of Ancona, Ancona, Italy|University of Florence, Denothe Centre, Division of Rheumatology AOUC, Department of Biomedicine, Firenze, Italy|Department of Rheumatology, University of Cagliari-Policlinico Universitario, Monserrato, Italy|Policlinico, Via Pansini, Napoli-Italia, Italy|University of Padova, Padova, Italy|Divisione di Reumatologia, Universit� di Roma La Sapienza, Dipartimento di Clinica e Terapia medica applicata, Policlinico Umberto I, Roma, Italy|Department of Internal Medicine and Rheumatology Clinic, Ion Cantacuzino Clinical Hospital, Bucharest, Romania|Reumatologie, University of Medicine & Pharmacy,""Iuliu Hatieganu"" Cluj, Cluj-Napoca, Romania|GR.T.Popa Center for Biomedical Research, European Center for Translational Research, ""GR.T.Popa"" University of Medicine and Pharmacy, Rehabilitation Hospital, Iasi, Romania|Clinic of Nephrology, Internal and Occupational Diseases, Moscow, Russian Federation|Institute of Rheumatology, Russian Academy of Medical Science, Moscow, Russian Federation|Institute of Rheumatology Belgrade, Belgrade, Serbia|Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain|Felix-Platter Spital, Basel, Switzerland|University of Zurich, Department of Rheumatology, Zurich, Switzerland|University of Marmara, Department of Rheumatology, Istanbul, Turkey|The Universitiy of Leeds, Division of Rheumatic and Musculoskeletal Disease, St James's University Hospital, Leeds, United Kingdom|Royal Free Hospital, University College London, London, United Kingdom|University of Manchester, Rheumatic Diseases Centre, Clinical Sciences, Manchester,Salford, United Kingdom",,https://ClinicalTrials.gov/show/NCT01834157,NCT01834157,
oui,NCT01834768,EPLErenone in CsA-Treated Recipients (EpleCsAT): Safety,EpleCsAT,Unknown status,No Results Available,Chronic Kidney Insufficiency|Kidney Transplantation,Drug: Eplerenone,Occurence of an adverse event requiring the discontinuation of eplerenone,"CHU de Reims|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 2,31,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PA11020,February 2013,April 2013,December 2013,"April 18, 2013",,"April 18, 2013","Centre Hospitalier Universitaire de Reims, Reims, France",,https://ClinicalTrials.gov/show/NCT01834768,NCT01834768,27088859
non,NCT01835938,Clinical Investigation of Erlotinib as an HCV Entry Inhibitor,,Unknown status,No Results Available,Chronic Hepatitis C Infection|HCV Genotype 1b,Drug: 1- Erlotinib|Drug: placebo,Assessment of virologic response and short-term safety of Erlotinib in patients infected with HCV genotype 1b|Assessment of pharmacokinetics of Erlotinib in HCV-infected patients,"University Hospital, Strasbourg, France",All,"18 Years to 65 Years � (Adult, Older Adult)",Phase 1|Phase 2,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",5189,May 2013,May 2015,May 2015,"April 19, 2013",,"June 17, 2014","Service d'H�patogastroent�rologie, NHC1, place de l'h�pital, Strasbourg Cedex, Alsace, France",,https://ClinicalTrials.gov/show/NCT01835938,NCT01835938,
oui,NCT01836263,Prevention and Treatment of Digital Ulcers in Systemic Sclerosis,,Unknown status,No Results Available,Systemic Sclerosis|Ulcer,,Prevention arm: Number of new digital ulcers|Healing arm: Time to healing of manifest digital ulcers|Prevention arm: Time to development of new digital ulcers|Healing arm: Number of healed digital ulcers,"marco matucci cerinic|European Union|University of Giessen|University of Zurich|University of Paris 5 - Rene Descartes|University of Campania ""Luigi Vanvitelli""|University of Basel|University College, London|Charite University, Berlin, Germany|University of Pecs|University of Leeds|Schoen Klinik Hamburg Eilbek|University of Florence",All,"Child, Adult, Older Adult",,420,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HEALTH-F5-2012-305495-OT1,April 2013,June 2017,June 2017,"April 19, 2013",,"April 25, 2013","Universit� Paris Descartes, H�pital Cochin, Service de Rhumatologie A & INSERM 1016, Paris, France|Justus-Liebig-University Gie�en, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology, Bad Nauheim, Germany|Charit� Universit�tsmedizin Berlin, Charit� Centrum 12 f�r Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Berlin, Germany|Centre for Pediatric Rheumatology, Klinikum Eilbek, Hamburg, Germany|Pecsi Tudomanyegyetem - University of Pecs, Pecs, Hungary|University of Florence, Denothe Centre, Division of Rheumatology AOUC, Department of Biomedicine, Firenze, Italy|Policlinico, Via Pansini, Napoli-Italia, Italy|Felix-Platter Spital, University of Basel, Basel, Switzerland|University of Zurich, Department of Rheumatology, Zurich, Switzerland|The Universitiy of Leeds, Division of Rheumatic and Musculoskeletal Disease, St James's University Hospital, Leeds, United Kingdom|Royal Free Hospital, University College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01836263,NCT01836263,30678703
oui,NCT01839409,Biological Rhythms and Vestibular System,REHAB_Rn'V,Unknown status,No Results Available,"Unspecified Disorder of Vestibular Function, Bilateral",Behavioral: vestibular stimulation,Measurements of vestibular reflexes (ocular and spinal) and circadian rhythms of biological functions.,"University Hospital, Caen",All,"20 Years and older � (Adult, Older Adult)",Not Applicable,96,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2011-A001359-32|N� 11P03919 / N�11P03921,April 2013,April 2016,,"April 24, 2013",,"November 3, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT01839409,NCT01839409,
oui,NCT01839422,Imaging of New Learning in Severe Alzheimer's Disease Patients,INCAS,Unknown status,No Results Available,Alzheimer Disease,Behavioral: Memory assessment|Other: Brain imaging examination MRI,"Succesful learning of new songs and paintings, succesful MRI acquisitions.","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France|National Research Agency, France",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2011-A00351-40,January 2012,December 2015,,"April 24, 2013",,"April 9, 2014","GIP Cyceron, Caen, France",,https://ClinicalTrials.gov/show/NCT01839422,NCT01839422,
oui,NCT01840007,Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma,,Completed,No Results Available,Metastatic Melanoma (Stage IIIC Non-r�s�cable or no Surgically Curable or Stage IV With Classification AJCC),Drug: Metformin Group,"Response rate|the overall survival, the survival without progress (PFS), the tolerance, and the quality of life.",Centre Hospitalier Universitaire de Nice,All,"18 Years and older � (Adult, Older Adult)",Phase 2,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-PP-17|2010-024322-38,"August 30, 2011","May 28, 2015","November 18, 2015","April 25, 2013",,"November 29, 2022","Bahadoran, Nice, Alpes-Maritimes, France|MORTIER Laurent, Lille, Nord, France",,https://ClinicalTrials.gov/show/NCT01840007,NCT01840007,
oui,NCT01840748,Development and Prevention of Pulmonary Hypertension in Systemic Sclerosis,,Unknown status,No Results Available,Systemic Sclerosis|Pulmonary Hypertension,,The number of patients with pulmonary hypertension at 2 years|Time to development of precapillary pulmonary hypertension,"University of Paris 5 - Rene Descartes|European Union|University of Giessen|University of Zurich|University of Florence|University of Campania ""Luigi Vanvitelli""|University of Basel|University College, London|Charite University, Berlin, Germany|University of Pecs|University of Leeds|Schoen Klinik Hamburg Eilbek",All,"Child, Adult, Older Adult",,960,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HEALTH-F5-2012-305495-OT4,April 2013,June 2017,June 2017,"April 26, 2013",,"April 26, 2013","Universit� Paris Descartes, H�pital Cochin, Service de Rhumatologie A & INSERM 1016, Paris, France|Justus-Liebig-University Gie�en, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology, Bad Nauheim, Germany|Charit� Universit�tsmedizin Berlin, Charit� Centrum 12 f�r Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Berlin, Germany|Centre for Pediatric Rheumatology, Klinikum Eilbek, Hamburg, Germany|Pecsi Tudomanyegyetem - University of Pecs, Pecs, Hungary|University of Florence, Denothe Centre, Division of Rheumatology AOUC, Department of Biomedicine, Firenze, Italy|Policlinico, Via Pansini, Napoli-Italia, Italy|Felix-Platter Spital, University of Basel, Basel, Switzerland|University of Zurich, Department of Rheumatology, Zurich, Switzerland|The Universitiy of Leeds, Division of Rheumatic and Musculoskeletal Disease, St James's University Hospital, Leeds, United Kingdom|Royal Free Hospital, University College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01840748,NCT01840748,
oui,NCT01842477,Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing,OrthoCT1,Completed,No Results Available,"Delayed Union After Fracture of Humerus, Tibial or Femur",Procedure: Implantation of bone substitute plus autologous cultured mesenchymal cells,Complication rate as percentage of patients with local complications regarding the non-union treatment in the follow-up|Number of patients with proven bone healing|Amount of radiological callus|Clinical consolidation|No reoperation done or scheduled|Changes in serum levels of bone turnover markers,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C11-12|2011-005441-13,May 2013,"February 5, 2016","February 5, 2016","April 29, 2013",,"December 2, 2017","Depatment of Orthopaedic Surgery, Hôpital Henri Mondor, Créteil, France|Department of Orthopaedic Surgery, CHRU Tours, Tours, France|Department of Orthopaedic Trauma, University of Ulm, Ulm, Germany|Istituto Ortopedico Rizzoli, Bologna, Bologna, Italy|Servicio de Cirugía Ortopédica y Traumatología ""A"", Hospital La Paz, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT01842477,NCT01842477,
oui,NCT01842919,Dance and Huntington Disease,,Completed,No Results Available,Huntington Disease,Other: Kinesthetics tests|Other: Psychological questionnaires|Other: structural Magnetic ResonanceImaging (MRI),Detection score,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,53,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,C12-64|2012-A01669-34,April 2013,"July 28, 2015","July 8, 2016","April 30, 2013",,"September 13, 2017",,,https://ClinicalTrials.gov/show/NCT01842919,NCT01842919,
oui,NCT01848522,"Creation and Setting up of Therapeutic Programs, Interprofessional Communication, Patients' Education and Counseling",EMCIQUAL,Completed,No Results Available,Professionals and Patients in the Department of Physical Medicine and Rehabilitation,,Patient management system,Assistance Publique - H�pitaux de Paris|University of Paris 5 - Rene Descartes,All,"18 Years and older � (Adult, Older Adult)",,63,Other,Observational,,NI 10043,October 2012,January 2014,July 2014,"May 7, 2013",,"July 28, 2014","CHU Henri Mondor-Albert Chenevier, Cr�teil, France|CHU Raymond Poincar�- Groupement hospitalier universitaire Ouest, Garches, France|Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01848522,NCT01848522,
oui,NCT01848600,Impact of a Limitation Section on the Meta-analysis Results' Interpretation,ILMARI,Withdrawn,No Results Available,Systematic Review With Metaanalysis,Behavioral: interpretation of the abstract,confidence in the results|interpretation of the quality of the systematic review,Assistance Publique - Hôpitaux de Paris,All,"Child, Adult, Older Adult",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant),RAV003,April 2013,June 2013,June 2013,"May 7, 2013",,"April 21, 2014",,,https://ClinicalTrials.gov/show/NCT01848600,NCT01848600,
oui,NCT01848639,ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial,ALCHEMIST,"Active, not recruiting",No Results Available,End Stage Renal Failure on Dialysis,Drug: Spironolactone|Drug: Placebo,"The time to onset of the first incident :non-fatal MI or acute coronary syndrome or hospitalization for heart failure or nonfatal stroke or cardiovascular (CV) death|composite winratio endpoint of: all-cause mortality|composite winratio endpoint of: time until a cardiovascular event|The time of survival without a major CV event (non fatal MI, acute coronary syndrome, hospitalization for heart failure, non-fatal stroke, cardiac arrest resuscitation)|Incidence of procedures related to stenosis or vascular access thrombosis for hemodialysis (HD)|Incidence of coronary or peripheral revascularizations (including lower limb amputations)|Blood pressure and its inter visit variability|The occurrence of atrial fibrillation|Incidence of hyperkalemia> 6 mmol/l|Estimation of the effect of treatment on quality of life.","University Hospital, Brest|Central Hospital, Nancy, France|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,825,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ALCHEMIST|RB 12-079,June 2013,November 2022,November 2022,"May 7, 2013",,"November 23, 2022","Hôpital Erasme- Bruxelles, Bruxelles, Belgium|CH Ardeche Nord, Annonay, Ardeche, France|CHU Amiens, Amiens, France|CH Avignon, Avignon, France|CHU Besançon, Besançon, France|CH Boulogne Sur Mer, Boulogne Sur Mer, France|CHRU Brest, Brest, France|CHU Caen, Caen, France|CH Cahors, Cahors, France|CH Chambéry, Chambéry, France|CHPC Cherbourg, Cherbourg, France|AURAL Colmar, Colmar, France|Hopitaux Civils de Colmar, Colmar, France|APHP Henri Mondor, Créteil, France|CHU Dijon Hôpital du Bocage, Dijon, France|AGDUC Grenoble, Grenoble, France|AURAL Haguenau, Haguenau, France|CH Haguenau, Haguenau, France|La Roche Sur Yon, La Roche Sur Yon, France|Polyclinique de Lagny, Lagny, France|Clinique Lille, Lille, France|CHU Lille, Lille, France|ALURAD Limoges, Limoges, France|CHU Limoges, Limoges, France|CHU de Lyon, Lyon, France|AURAL La Croix Rousse, Lyon, France|CH St Joseph-St Luc, Lyon, France|AURAL Lyon, Lyon, France|Clinique Bouchard, Marseille, France|Adpc Marseille, Marseille, France|APHM Marseille, Marseille, France|Association de Metz, Metz, France|ALTIR Metz, Metz, France|CHR Metz-Thionville, Metz, France|AURAL Mulhouse, Mulhouse, France|CH Mulhouse, Mulhouse, France|CHU Nancy, Nancy, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|Clinique St Georges, Nice, France|AP-HP La Salpêtrière, Paris, France|AURA Paris 14ème, Paris, France|AURA Paris Plaisance, Paris, France|Hôpital Tenon, Paris, France|AP-HP Necker, Paris, France|Institut Mutualiste Montsouris, Paris, France|CHU Lyon Sud, Pierre-Bénite, France|CHU de Reims, Reims, France|ARPDD Reims, Reims, France|CHU Rennes, Rennes, France|ECHO Confluent, Reze, France|Centre de Perharidy, Roscoff, France|CH Roubaix, Roubaix, France|CHU de la Réunion Hôpital Félix Guyon, Saint Denis, France|Aub Saint Malo, Saint Malo, France|Ch Saint Malo, Saint-Malo, France|CHG St Brieuc, St Brieuc, France|AURAL St Anne (AURAL Strasbourg), Strasbourg, France|CHU Strasbourg, Strasbourg, France|Clinique Sainte Anne, Strasbourg, France|AURAL Strasbourg, Strasbourg, France|CHU Toulouse, Toulouse, France|CHU Tours, Tours, France|CH Troyes, Troyes, France|CH Valenciennes, Valenciennes, France|ALTIR Nancy, Vandoeuvre les Nancy, France|Hôpitaux Privés de Metz- Hôpital Robert Schuman, Vantoux, France|CH Verdun, Verdun, France|CH Vichy, Vichy, France|CH Princesse Grace, Monaco, Monaco",,https://ClinicalTrials.gov/show/NCT01848639,NCT01848639,33586138;30904064
oui,NCT01854424,Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS,IFRA2,Completed,No Results Available,Acute Respiratory Distress Syndrome (ARDS)|Mechanical Ventilation,"Other: Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.",To determine the percentage of alveolar fibrocytes in survivors vs. non survivors during ARDS|To evaluate kinetics of alveolar and circulating fibrocytes between day-1 and day-14 of ARDS evolution|To test the prognostic value of the percentage of alveolar fibrocytes during ARDS|To evaluate the association between the percentage of alveolar fibrocyte and inflammatory and fibroproliferative markers,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,84,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,NI11026|AOM 11005,November 2013,July 2016,"July 11, 2016","May 15, 2013",,"March 22, 2017","Hôpital TENON, département d'anesthésie-réanimation, Paris, France",,https://ClinicalTrials.gov/show/NCT01854424,NCT01854424,
oui,NCT01857089,Characterization of Sitting Postures in Healthy Subjects,CaPAS,Completed,No Results Available,Pressure Ulcer,Device: Orthotest CE,Assessment of intra and inter-subjects variability of the pressure measurements for the whole population included.|Correlation between interface pressure measurements and postural data.,"University Hospital, Grenoble",All,20 Years to 30 Years � (Adult),Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CaPAS-DCIC-1204,May 2013,August 2013,August 2013,"May 20, 2013",,"April 11, 2014","CIC-IT GrenobleUniversityHospital, Grenoble, France",,https://ClinicalTrials.gov/show/NCT01857089,NCT01857089,
oui,NCT01857518,"Depression in Adolescents. A Cerebral Structural, Diffusion, and Functional Magnetic Resonance Imaging Study",ADODEP,Unknown status,No Results Available,Adolescent Depression,"Other: -Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI",Evidence of white matter microstructure changes|Evidence of grey matter volume changes|Correlation between Functional anatomy of emotional/reward responses and white matter and grey matter structure changes|Grey matter and white matter changes in frontal limbic networks at follow-up in treated patients,"Centre Hospitalier St Anne|CENIR Centre de Neuroimagerie de Recherche, Paris|Inserm CEA Research unit U1000 (Neuroimaging in psychiatry)|National Research Agency, France|Assistance Publique - H�pitaux de Paris",All,"15 Years to 18 Years � (Child, Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2012-A01466-37|D500,"August 31, 2013",February 2018,March 2018,"May 20, 2013",,"October 20, 2017","Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01857518,NCT01857518,
oui,NCT01858259,Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis,,Unknown status,No Results Available,Systemic Sclerosis|Interstitial Lung Diseases,,Proportion of patients with 10% decline in FVC|The time to a 15% decline in DLCO or a drop <55% of predicted lung function|The mortality due to lung fibrosis|The need for oxygen support,"Gabriela Riemekasten|European Union|University of Giessen|University of Zurich|University of Paris 5 - Rene Descartes|University of Florence|University of Campania ""Luigi Vanvitelli""|University of Basel|University College, London|Charite University, Berlin, Germany|University of Pecs|University of Leeds|Schoen Klinik Hamburg Eilbek",All,"Child, Adult, Older Adult",,1372,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HEALTH-F5-2012-305495-OT3,May 2013,June 2016,June 2016,"May 21, 2013",,"August 13, 2014","Universit� Paris Descartes, H�pital Cochin, Service de Rhumatologie A & INSERM 1016, Paris, France|Justus-Liebig-University Gie�en, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology, Bad Nauheim, Germany|Charit� Universit�tsmedizin Berlin, Charit� Centrum 12 f�r Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Berlin, Germany|Centre for Pediatric Rheumatology, Klinikum Eilbek, Hamburg, Germany|Pecsi Tudomanyegyetem - University of Pecs, Pecs, Hungary|University of Florence, Denothe Centre, Division of Rheumatology AOUC, Department of Biomedicine, Firenze, Italy|Policlinico, Via Pansini, Napoli-Italia, Italy|Felix-Platter Spital, University of Basel, Basel, Switzerland|University of Zurich, Department of Rheumatology, Zurich, Switzerland|The Universitiy of Leeds, Division of Rheumatic and Musculoskeletal Disease, St James's University Hospital, Leeds, United Kingdom|Royal Free Hospital, University College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01858259,NCT01858259,
oui,NCT01863108,Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma,GeniusVac-Mel4,Completed,No Results Available,Melanoma|Tumor Vaccines|Effects of Immunotherapy,Biological: GeniusVac-Mel4,Tolerability and safety of a multiple sub-cutaneous injections of GeniusVac-Mel4.|Evaluation of the immune response|Evaluation of the clinical response,"University Hospital, Grenoble|Etablissement Fran�ais du Sang|Institut National de la Sant� Et de la Recherche M�dicale, France|Universit� Joseph Fourier",All,"18 Years and older � (Adult, Older Adult)",Phase 1,9,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DCIC 11 19|2012-003124-20,June 2013,"March 23, 2017","March 23, 2017","May 27, 2013",,"November 14, 2017","Grenoble University Hospital, Grenoble, France",,https://ClinicalTrials.gov/show/NCT01863108,NCT01863108,
oui,NCT01866189,Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke,STROKE F-MISO,Withdrawn,No Results Available,Ischemic Stroke,Other: PET and MRI,volume and location of F-MISO uptake in stroke patients|comparison of F-MISO uptake areas and ischemic lesions defined by weighted diffusion and FLAIR on,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,11 252 01,September 2016,September 2016,October 2016,"May 31, 2013",,"May 9, 2016",,,https://ClinicalTrials.gov/show/NCT01866189,NCT01866189,
oui,NCT01867554,Research and Characterization of New Genes Involved in Intellectual Disability,GeneDefi,Unknown status,No Results Available,Intellectual Disability,Genetic: gene analysis,Number of participants with genetic cause identified|genotype-phenotype correlations,"Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,8500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C12-06|2012-A00936-37,December 2012,December 2022,December 2022,"June 4, 2013",,"December 7, 2016","CRICM - UPMC/Inserm UMR_S975/CNRS UMR7225, Groupe Hospitalier de la Pitié-Salpêtrière,, Paris, France",,https://ClinicalTrials.gov/show/NCT01867554,NCT01867554,
non,NCT01872221,Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study,STEMRI,Completed,No Results Available,Glioblastoma,Procedure: Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol,Biologic analysis of the GBM resected samples for the capacity to form neurospheres in vitro|Biologic analysis of the GBM resected samples on the RNA expression of 5 stem cells markers|Biologic analysis of the GBM resected samples for their capacity to form invasive brain tumor after orthotopic implantation of the cells in nude mice|Time to progression|Overall survival,Institut Claudius Regaud,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,12TETE01,May 2013,April 2018,April 2018,"June 7, 2013",,"August 27, 2018","CHU Rangueil, Toulouse, France|Institut Claudius REGAUD, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01872221,NCT01872221,33245115
oui,NCT01874769,Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB),RDEB,Unknown status,No Results Available,Recessive Dystrophic Epidermolysis Bullosa,Other: Blood collection|Other: Skin biopsies,Determination of the proliferative capacity of keratinocytes and fibroblasts in characterized RDEB patients|Clinical evaluation and scoring|Identification of COL7A1 mutations|Assessment of type VII collagen expression and anchoring fibrils formation in the skin,"Institut National de la Santé Et de la Recherche Médicale, France",All,"7 Years to 65 Years   (Child, Adult, Older Adult)",,30,Other,Observational,Observational Model: Cohort,C12-22|2012-A01051-42,June 2013,June 2014,June 2015,"June 11, 2013",,"December 18, 2013","Service de dermatologie Necker Hospital for sick children, Paris, France|Inserm U781 Service de Génétique Necker Hospital for sick children, Paris, France|Guy's and ST Thomas NHS Foundation trust/Guy's Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01874769,NCT01874769,
oui,NCT01874808,From Movement Preparation to Gait Execution in ALS,GAITALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,,Neurophysiological evaluation (braking index)|Evaluation in neuroimaging,"Institut National de la Santé Et de la Recherche Médicale, France|Université Paris Ouest-EA 2931-CEntre de Recherches sur le Sport et le Mouvement",All,"18 Years to 75 Years   (Adult, Older Adult)",,59,Other,Observational,Observational Model: Other|Time Perspective: Other,GAITALS-C12-13|2012-A01247-36,"June 21, 2013",December 2015,"December 21, 2015","June 11, 2013",,"August 30, 2021","Hôpital Pitié-Salpétrière, Département des Maladies du Système Nerveux 47-83 Boulevard de l'Hôpital, Paris, France",,https://ClinicalTrials.gov/show/NCT01874808,NCT01874808,
oui,NCT01880151,Neuroelectrical Biomarkers for Alzheimer's Disease Stages,ESTIMATE,Completed,No Results Available,Alzheimer Disease,Device: EEG,Frequency band charactersitics of the electrophysiological brain response,"Institut National de la Santé Et de la Recherche Médicale, France",All,70 Years to 85 Years   (Older Adult),Not Applicable,87,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,C12-71|2013-A00344-41,"July 12, 2013",January 2019,January 2019,"June 18, 2013",,"August 26, 2021","Institute of Memory and Alzheimer's Disease, Pitie-Salpetriere Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT01880151,NCT01880151,
oui,NCT01882062,Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease,TRIHEP2,Completed,Has Results,Huntington Disease,Drug: Triheptanoin 1g/kg/day,Ratio of Inorganic Phosphate (Pi) Over Phosphocreatine (PCr): Pi/PCr|Correlation Between Primary Outcome Measure and Clinical Parameters,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C12-62,May 2013,July 2013,July 2013,"June 20, 2013","March 24, 2016","March 24, 2016","Brain and Spine Institute, Paris, France",,https://ClinicalTrials.gov/show/NCT01882062,NCT01882062,25568297
anrs,NCT01884779,Prevalence of Histoplasmosis in HIV + Patients With a Rapid Diagnostic Test in West Indies,EDIRAPHIS,Unknown status,No Results Available,HIV,,"Proportion of HIV-infected patients hospitalized or in outpatient awaiting hospitalization for a suspicion of infectious syndrome whose serum and/or urinary antigen detection tests are positive for Histoplasma capsulatum var. capsulatum.|Sensitivity of the ELISA test on urine and blood specimens|Sensibility of the ELISA test on urine and blood specimens|Negative predictive value of the ELISA test on urine and blood specimens|Comparison of the distribution of Histoplasma antigen concentrations in urine and serum specimens according to severity of cases of histoplasmosis due to Histoplasma capsulatum var. capsulatum|Comparison of the socio-demographic, clinical, paraclinical and therapeutic characteristics according to severity of cases of histoplasmosis due to Histoplasma capsulatum var. capsulatum|Comparison of the factors for environmental exposure to Histoplasma capsulatum var capsulatum between patients with a positive ELISA test and/or fungal culture for histoplasmosis and those who tested negative for histoplasmosis|Frequency of histoplasmosis compared to the other main diagnoses according to three sets of comparisons: positive ELISA test and positive fungal culture; positive ELISA test and negative fungal culture; negative ELISA test and positive fungal culture|Comparison of the socio-demographic, clinical, paraclinical, therapeutic and survival outcome characteristics of cases of histoplasmosis compared to those who tested negative for histoplasmosis|Identify the prognostic factors for short-term unfavourable progression of cases of histoplasmosis due to Histoplasma capsulatum var. capsulatum confirmed by ELISA test and/or by fungal culture","ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",,727,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,ANRS 12260 EDIRAPHIS,August 2013,July 2014,December 2018,"June 24, 2013",,"July 11, 2017","Pointe-�-Pitre University Hospital, Pointe-�-Pitre, Guadeloupe, France|Cayenne General Hospital, Cayenne, Guyane, France|Western French Guiana Hospital, Saint-Laurent-du-Maroni, Guyane, France|Fort-de-France University Hospital, Fort-de-France, Martinique, France|'s Lands Hospital, Paramaribo, Suriname|Academisch Ziekenhuis Paramaribo Hospital, Paramaribo, Suriname|Diakonessenhuis hospital, Paramaribo, Suriname",,https://ClinicalTrials.gov/show/NCT01884779,NCT01884779,
oui,NCT01898390,TRANSEURO Open Label Transplant Study in Parkinson's Disease,TRANSEURO,Unknown status,No Results Available,Parkinson's Disease,Procedure: Transplant,UPDRS change|Change in timed motor tasks|Dyskinesias|L-dopa equivalent medication|L-dopa therapy|Off time|Quality of life|F-DOPA PET changes,"University of Cambridge|Lund University|Cardiff University|Imperial College London|University College, London|University Hospital Freiburg|Life Science Governance Institute|Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Life Technologies Ltd, part of Thermo Fisher Scientific|Inomed|Cambridge Cognition Ltd|Skane University Hospital|Imanova Limited",All,"30 Years to 68 Years   (Adult, Older Adult)",Phase 1,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TRANSEURO|FP7-242003,May 2012,March 2021,March 2021,"July 12, 2013",,"April 19, 2019",,,https://ClinicalTrials.gov/show/NCT01898390,NCT01898390,31263283
oui,NCT01899196,Epicardial Adipose Tissue And Coronary Risk In HIV-Infected Patients,ANRS EP 52,Completed,No Results Available,Hiv Infection,"Biological: blood sampling,",comparison of the inflammatory profile of the epicardial adipose (EAT) tissue between HIV-infected and uninfected patients undergoing cardiac surgery for coronary artery bypass graft (CABG)|comparison the volume of EAT between HIV-infected and uninfected patients undergoing cardiac surgery|Evaluation of the relations between the adipocytokines and cytokines profile in the EAT and in the systemic circulation.|Comparison of the histological and inflammatory profiles of the EAT and the subcutaneous adipose tissue of each patients.|Evaluation of the relations between the adipocytokines and cytokines profile in the EAT and coronary artery lesions.,"ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),ANRS EP 52 PIECVIH,July 2013,March 2016,March 2016,"July 15, 2013",,"July 6, 2016","Hospital St Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT01899196,NCT01899196,
oui,NCT01904968,Impact of Methylation Alterations in Colon Cancer: Epidemiology and Prognosis,,Withdrawn,No Results Available,Colon Cancer,,"Quality control DNA|Assessment of methylation level|MSI Phenotype evaluation|Mutational status evaluation of BRAF, KRAS and PI3KCA :",Centre Hospitalier Universitaire Dijon,All,"Child, Adult, Older Adult",,0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,Piard PHRC K 2011,December 2011,December 2015,,"July 22, 2013",,"July 22, 2013","CHU de Dijon, Dijon, France",,https://ClinicalTrials.gov/show/NCT01904968,NCT01904968,
oui,NCT01916018,Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.,HYPOTYGEN,Completed,No Results Available,Congenital Hypothyroidism,Other: Clinical and radiologic exams and blood samples,etiological type of the congenital hypothyroidism|Presence and type of cytogenetic and / or genetic abnormality associated with HC|Presence and type of pathology associated with HC|Presence of abnormal neuropsychological (including delayed psychomotor development)|time to treatment of hypothyroidism|Presence of a prenatal and / or neonatal complication,Assistance Publique - H�pitaux de Paris,All,"Child, Adult, Older Adult",Not Applicable,558,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P11012-IDRCB 2012-A00797-36,"September 17, 2013","March 17, 2017","March 17, 2017","August 5, 2013",,"December 21, 2017","Pediatric endocrinology gynecology and diabetology, H�pital Necker Enfants Malades, Assistance Publique - H�pitaux de Paris , Universit� Paris Descartes, INSERM unit U 845, Paris, France",,https://ClinicalTrials.gov/show/NCT01916018,NCT01916018,36107810;33272083;30446499;28025328
oui,NCT01916057,Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis,CANHPARI,Completed,No Results Available,Invasive Fungal Disease|Chronic Disseminated Candidiasis|Hematological Malignancies|Hematopoietic Stem Cell Transplantation|Neutropenia,Device: 18F-FDG PET Scan,Global response to therapy|18F-FDG PET scan and RMI usefulness in initial diagnosis|Serological and molecular mycological tools assessment|Inflammatory cells and mediators|Genetic susceptibility,"Assistance Publique - Hôpitaux de Paris|University of Lausanne Hospitals|University Hospital, Lille|Institut Pasteur|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P120115|AOM12047,"November 19, 2013","June 1, 2017","February 28, 2018","August 5, 2013",,"May 1, 2018","Service des Maladies Infectieuses et Tropicales - Centre d'Infectiologie Necker-Pasteur, IHU Imagine - Hôpital Necker-Enfants Malades,, Paris, France",,https://ClinicalTrials.gov/show/NCT01916057,NCT01916057,36606049
oui,NCT01919957,Episodic Memory Before and After Surgery in Drug-resistant Partial Epilepsies,MemO-Epi,Unknown status,No Results Available,"Epilepsy, Unspecified, Pharmacologically Resistant|Memory Impairment",Other: No intervention,Measure of successfull encoding,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C12-11|2013-A00343-42,October 2013,December 2021,December 2022,"August 9, 2013",,"February 6, 2015","INSERM - Plateau IRM du CENIR, CR-ICM Hôpital Pitié-Salpêtrière, 47/83 Boulevard de l'Hôpital, Paris, Cedex 13, France",,https://ClinicalTrials.gov/show/NCT01919957,NCT01919957,
oui,NCT01935570,Comparative Study of the Bioavailability of Magnesium Administrated by Two ChronoMag Smart Tablet� 50 mg Versus Three Mag2� Tablets 100mg.,BioChronoMag,Completed,No Results Available,Healthy Volunteers,Drug: Magnesium chloride (ChronoMag Smart Tablet�)|Drug: Magnesium carbonate (Mag2� Tablet),blood magnesium concentration|urine magnesium concentration|Adverse digestive events record,"University Hospital, Clermont-Ferrand|Dr Gis�le PICKERING (MCU-PH)(Clinical Pharmacology center, Inserm 501)|Dr Gilles DUCHEIX (Attach�)(Clinical Pharmacology center, Inserm 501)",Male,18 Years to 50 Years � (Adult),Phase 1,17,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CHU-0162,September 2013,December 2013,December 2013,"September 5, 2013",,"July 7, 2015","CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT01935570,NCT01935570,
oui,NCT01954953,Clinical and Genetic Examination of Usher Syndrome Patients' Cohort in Europe,EURUSH,Unknown status,No Results Available,Usher Syndrome,,Genotype and phenotype correlations in Usher syndrome patients,"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts|Institut National de la Santé Et de la Recherche Médicale, France",All,"6 Months to 70 Years   (Child, Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,P13-02,September 2013,January 2016,,"October 7, 2013",,"February 4, 2015","CHU, Laboratoire de génétique moléculaire, INSERM, Montpellier, France|CIC of CHNO des Quinze-vingts, Paris, France|Johannes Gutenberg University of Mainz, Institute of Zoology, Dept. Cell and Matrix Biology Mainz, Mainz, Germany|Radboud University Nijmegen Medical Centre, Dept. Otorhinolaryngology, Nijmegen, Netherlands|AIBILI, 4C - Coimbra Coordinating Centre for Clinical Research, Coimbra, Portugal|IBILI- Faculty of Medicine - University of Coimbra, Center for Hereditary Diseases and Visual Neurosciences Laboratory, Coimbra, Portugal",,https://ClinicalTrials.gov/show/NCT01954953,NCT01954953,
oui,NCT01956721,Impact of Heart Failure on Calcium Homeostasis and Mitochondrial Function in Human Skeletal Muscle,CALCICARD2,Terminated,No Results Available,Heart Failure,"Procedure: Exercise training,|Procedure: Muscle biopsy",calcium homeostasis|mitochondrial function|skeletal muscular function in two stages of heart failure,"University Hospital, Montpellier|Institut National de la Santé Et de la Recherche Médicale, France|Ministry of Health, France|National Cancer Institute, France|Institut de Recherches Internationales Servier",Male,"35 Years to 65 Years   (Adult, Older Adult)",Not Applicable,22,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,9051,"September 18, 2013","June 21, 2016","June 30, 2020","October 8, 2013",,"August 6, 2020","physiologie clinique, hopital Arnaud de Villeneuve, 371 avenue du Doyen G;Giraud, Montpellier Cedex 5, France",,https://ClinicalTrials.gov/show/NCT01956721,NCT01956721,
oui,NCT01960101,Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication,LactoXeros,Withdrawn,No Results Available,Xerostomia,Other: LactoXeros|Device: Aequasyal,Mouth Dryness Score|Perception of other symptoms of dry mouth|Silness-Loe Index measuring dental plaque|Salivary flow|Biochemical analysis of saliva|Analysis of the mouth coating effect|Release of the aroma compounds,"Institut National de la Santé Et de la Recherche Médicale, France|Centre Hospitalier Universitaire de Besancon|Centre Hospitalier Universitaire Dijon|Centre des Sciences du Goût et de l'Alimentation|Ecole Nationale de l'Industrie Laitière",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C12-58|2012-A01686-37,October 2013,March 2015,,"October 10, 2013",,"December 3, 2015","Service de psychatrie adultes, Besancon, France|Service de Psychiatrie Adultes, Dijon, France",,https://ClinicalTrials.gov/show/NCT01960101,NCT01960101,
oui,NCT01960751,Long Term Neurocognitive Effects of Low-dose Radiation in the Brain: Study of 150 Patients in the French Hemangioma Cohort,CogRad,Unknown status,No Results Available,Patients Treated by Radiotherapy With < One Gy to the Brain,Other: neurocognitive tests battery,All neurocognitive dysfunction or disorder on adults measured by means of eight tests,"Institut National de la Santé Et de la Recherche Médicale, France|European Commission|Gustave Roussy, Cancer Campus, Grand Paris",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,C13-01|2013-A00513-42,October 2013,October 2014,March 2015,"October 11, 2013",,"October 11, 2013","Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT01960751,NCT01960751,
oui,NCT01962064,Social Cognition in Ageing and in Frontotemporal Lobar Degeneration,COSIMAGE,Unknown status,No Results Available,Frontotemporal Lobar Degeneration|Aging,Behavioral: Cognitive assessment|Other: Brain imaging examination MRI,Social cognition scores,"University Hospital, Caen|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"40 Years to 80 Years � (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2011-A00681-40,June 2013,July 2014,November 2014,"October 14, 2013",,"October 14, 2013","Inserm - EPHE - University of Caen U1077, Caen, France",,https://ClinicalTrials.gov/show/NCT01962064,NCT01962064,
oui,NCT01962311,Evaluation of Metabolomic Analysis in Early Diagnosis of ALS,METABALS,Completed,No Results Available,ALS,Procedure: lumbar puncture,"Diagnostic markers studied are metabolites of cerebrospinal fluid, blood and urine measured by three complementary analytical methods","University Hospital, Tours",All,"30 Years to 80 Years � (Adult, Older Adult)",Not Applicable,82,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PHRN11-CA-METABALS|2012-A00145-38,February 2013,February 2017,February 2018,"October 14, 2013",,"July 17, 2019","P�le Neurosciences et Sp�cialit�s ,Service de Neurologie,CHU d'Angers, Angers, France|Service de Neurologie et Pathologie du Mouvement Clinique de Neurologie, P�le des Neurosciences et de l'Appareil Locomoteur INSERM U 837, Lille, France|Centre de Recherche de l'Institut du Cerveau et de la mo�lle UPMC Paris 6,D�partement des Maladies du Syst�me Nerveux, Paris, France|Service de neurologie, CHU La Mil�trie, POITIERS, Facult� de M�decine, Poitiers, France|University Hospital, Strasbourg, France|CHRU -TOURS-Service de Neurologie, Tours, France",,https://ClinicalTrials.gov/show/NCT01962311,NCT01962311,
oui,NCT01963221,Relationship Between Thoracic Aortic Structure Assessed B PET/CT Scan and Arterial Stiffness in Elderly Patients,FICTEP,Completed,No Results Available,Aging|Inflammation,Radiation: fludeoxyglucose(18f)|Other: blood sample|Other: cardiac and aortic magnetic resonance imaging|Other: carotid femoral pulse wave velocity|Radiation: positron emission tomography|Radiation: computed tomography,Aortic inflammation assessed by 18 F FDG maximal standard uptake value measurement|parietal thoracic aorta volume of calcification measured by computed tomography,"Central Hospital, Nancy, France|French Cardiology Society",All,65 Years and older   (Older Adult),Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CentralHNF,January 2010,August 2011,September 2013,"October 16, 2013",,"October 16, 2013","University Hospital of Nancy, Vandoeuvre-les-Nancy, France",,https://ClinicalTrials.gov/show/NCT01963221,NCT01963221,26892585
oui,NCT01970865,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,,"Active, not recruiting",Has Results,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,Drug: PF-06463922|Drug: Crizotinib,"Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1|Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)|Percentage of Participants With Overall and Intracranial Objective Response (Phase 1)|Time to Tumor Response (TTR) and Intracranial TTR (Phase 1)|Duration of Response (DOR) and Intracranial DOR (Phase 1)|Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 Weeks (Phase 1)|Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 1)|Progression-Free Survival (PFS) (Phase 1)|Overall Survival (OS) (Phase 1)|Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1)|Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)|Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1)|Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1)|Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1)|Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1)|Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 Following Single Oral Doses (Phase 1)|Apparent Oral Clearance (CL/F) of PF-06463922 Following Single Oral Doses (Phase 1)|Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1)|Apparent Volume of Distribution (Vz/F) of PF-06463922 Following Single Oral Doses (Phase 1)|Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1)|Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1)|Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 1)|Renal Clearance (CLr) of PF-06463922 (Phase 1)|Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1)|Maximum Observed Plasma Concentration (Cmax) of Midazolam (Phase 1)|Time for Cmax (Tmax) of Midazolam (Phase 1)|Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1)|Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Midazolam (Phase 1)|Apparent Oral Clearance (CL/F) of Midazolam (Phase 1)|Apparent Volume of Distribution (Vz/F) of Midazolam (Phase 1)|Terminal Half-Life of Midazolam (Phase 1)|Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1)|Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1)|Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1)|Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 1)|Change From Baseline in Mini Mental State Examination (MMSE) Score (Phase 1)|Time to Tumor Response (TTR) and Intracranial TTR (Phase 2)|Duration of Response (DOR) and Intracranial DOR (Phase 2)|Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 Weeks (Phase 2)|Time to Progression (TTP) on the Last Prior Therapy (Phase 2)|Time to Tumor Progression ?TTP) and Intracranial TTP (Phase 2)|Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 2)|Progression-Free Survival (PFS) (Phase 2)|Overall Survival (Phase 2)|Maximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2)|Time for Cmax (Tmax) of PF-06463922 (Phase 2)|Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2)|Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 (Phase 2)|Apparent Oral Clearance (CL/F) of PF-06463922 (Phase 2)|Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2)|Terminal Half-Life of PF-06463922 (Phase 2)|Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2)|Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2)|Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 2)|Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 2)|Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2)|Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2)|Number of Participants With Treatment-Emergent Adverse Events (Phase 1 and Phase 2)|Number of Participants With Laboratory Abnormalities (Phase 1 and Phase 2) - Hematology|Number of Participants With Laboratory Abnormalities (Phase 1 and Phase 2) - Chemistry|Number of Participants With Laboratory Abnormalities (Phase 1 and Phase 2) - Coagulation, Lipids and Urinalysis|Number of Participants With Vital Signs Data Meeting Pre-defined Criteria (Phase 1 and Phase 2)|Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1 and Phase 2)|Number of Participants With Absolute Values and Change From Baseline in QTcF Meeting Pre-defined Criteria (Phase 1 and Phase 2)|Number of Participants With Suicidal Ideation and Suicidal Behavior (Phase 2)|Change From Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2)|Change From Baseline in Total Scores for Detection Test (Cognitive Function Assessment) (Phase 2)|Change From Baseline in Total Scores for Identification Test (Cognitive Function Assessment) (Phase 2)|Change From Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2)|Change From Baseline in Total Scores for International Shopping List Test (Cognitive Function Assessment) (Phase 2)|Change From Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2)",Pfizer,All,"18 Years and older � (Adult, Older Adult)",Phase 2,334,Industry,Interventional,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,B7461001|2013-002620-17,"January 8, 2014","March 15, 2017","February 19, 2023","October 28, 2013","May 29, 2018","January 26, 2023","Highlands Oncology Group/Research, Fayetteville, Arkansas, United States|Highlands Oncology Group, Rogers, Arkansas, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|UC Irvine Medical Center, Orange, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|MDZ: Yale-New Haven Hospital, New Haven, Connecticut, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Karmanos Center Institute, Detroit, Michigan, United States|Karmanos Cancer Institute, Farmington Hills, Michigan, United States|Siteman Cancer Center-West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Rockefeller Patient Pavilion - Memorial Sloan Kettering, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Rochester Regional Health System, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|The Ohio State University, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute (Pharmacy), Nashville, Tennessee, United States|Chris O'Brien Lifehouse, Sydney Local Health District [rpa], New South Wales, Australia|Chris O'Brien Lifehouse, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|University Hospital Antwerp, Edegem, Belgium|British Columbia Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHU Grenoble/ H�pital Albert Michallon, Grenoble Cedex 9, France|CHU de Rennes - H�pital Pontchaillou - CIC Inserm, Rennes Cedex 9, France|CHU de Rennes - H�pital Pontchaillou, Rennes Cedex 9, France|Institut Universitaire du Cancer de Toulouse (IUCT-O), Toulouse Cedex 9, France|Institut Gustave Roussy (comite poumon-pneumologie), Villejuif Cedex, France|Institut Gustave Roussy- Pharmacie-Unite Essais Cliniques, Villejuif, France|Universitaetsklinik Koeln, Cologne, Germany|Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong|Struttura Operativa Complessa Oncologia, Aviano (PN), Italy|Dipartimento di Oncologia Medica, UO Medicina 1Q A, Unita' Nuovi Farmaci e Terapie Innovative, Milano, Italy|Unita di Farmacologia Clinica e Nuovi Farmaci, Milano, Italy|Oncologia Medica, Perugia, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Seoul National University Hospital / Department of Internal Medicine, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|National University Hospital Medical Centre, Singapore, Singapore|National Cancer Center, Singapore, Singapore|Hospital Universitario Quiron Madrid, Pozuelo de Alarc�n, Madrid, Spain|Clinica Universidad De Navarra, Pamplona, Navarra, Spain|Hospital Universitario Quiron Dexeus, Barcelona, Spain|Hospital Universitari de la Vall D'Hebron Edificio General. Planta Baja. UITM. Servicio de Oncologia, Barcelona, Spain|Hospital of Lausanne (CHUV), Lausanne, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|National Taiwan University Hospital, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT01970865/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT01970865/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01970865,NCT01970865,36184067;35660971;35026476;33973232;33937954;33639216;32681682;32344248;32060867;31669155;30413378;29074098;26698910
oui,NCT01973478,Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression,STHYM,Completed,No Results Available,Major Depressive Disorder|Recurrent Depressive Disorder|Bipolar Disorder,Device: DBS|Device: SHAM,"Response = 50 % decrease of the HDRS-17 (Hamilton depression rating scale, 17 items version) (yes/no)|Remission (yes/no)|CGI (Clinical global impressions) amelioration (yes/no)|GAF (Global assessment of functioning)|HDRS-17 (Hamilton depression rating scale, 17 items version)|MADRS (Montgomery-Asberg Depression Rating Scale)|BDI (Beck Depression Inventory)|CGI (Clinical global impressions)|LARS (Lille Apathy Rating scale)|Neuropsychological assessment|Cerebral metabolism (PET scans)|Adverse events",Rennes University Hospital,All,"18 Years to 70 Years � (Adult, Older Adult)",Not Applicable,9,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",35RC08_8902,"June 3, 2014","July 3, 2017","November 27, 2018","October 31, 2013",,"December 27, 2019","APHM, Marseille, France|APHP Piti� Salpetriere, Paris, France|CHS, Poitiers, France|CHS, Rouen, France|CHU, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01973478,NCT01973478,
oui,NCT01982019,Influence of Bariatric Surgery on Serum Levels of 26RFa,RFa-Ba-S,Unknown status,No Results Available,Diabetes|Obesity,Behavioral: Meal test taking and hormones measure including 26RFa,Serum 26RFa levels|Kinetics of 26RFa levels during a test meal|kinetics of classical hormones implicated in glucose control and obesity|Levels of 26RFa and classical hormones implicated in glucose control and obesity just after a sleeve gastrectomy|score of satiety,"University Hospital, Rouen|Institut National de la Santé Et de la Recherche Médicale, France",Female,30 Years to 60 Years   (Adult),Not Applicable,59,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2012/129/HP,"February 4, 2014",July 2020,July 2020,"November 13, 2013",,"June 30, 2020","University Hospital Rouen, Rouen, Haute Normandie, France",,https://ClinicalTrials.gov/show/NCT01982019,NCT01982019,
oui,NCT01984957,Differential Study of Muscle Transcriptome,TRANE,Completed,No Results Available,ALS|SMA|SBMA,Procedure: Muscle biopsy,Gene expression levels|muscle denervation|Functional evaluation,"Assistance Publique - Hôpitaux de Paris|Direction Générale de l'Offre de Soins|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,42,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P110401,January 2013,January 2015,January 2015,"November 15, 2013",,"March 23, 2015","Centre d'évaluation Thérapeutique, Dr LACOMBLEZ, Paris, France",,https://ClinicalTrials.gov/show/NCT01984957,NCT01984957,
oui,NCT01985139,Pleasure for Food and Endocannabinoids in Obesity,PLOBEC,Unknown status,No Results Available,Obesity,Behavioral: Computer-based tasks|Biological: Blood sampling,Change in the Point of subjective equality (PSE)|Change in the Percentage of subjective discrimination (PSD)|Circulating endocannabinoids concentrations,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening,C13-33|2013-A00982-43,January 2014,February 2016,February 2016,"November 15, 2013",,"February 24, 2016","Neurocentre Magendie (INSERM U862), Bordeaux, France",,https://ClinicalTrials.gov/show/NCT01985139,NCT01985139,
oui,NCT01988948,Dynamics of Human PApilloma Virus Interactions  Internet-based Students HeAlth Research Enterprise,DyPAVIR,Completed,No Results Available,Infection by Human Papilloma Virus,Other: Various biological sampling,"Proportion of HPV detection at inclusion (all HPV genotypes)|Incidence of oncogenic HPV genotypes, co-infection with different HPV genotypes",Institut Pasteur|Versailles Saint-Quentin-en-Yvelines University|centre national de r�f�rence pour les Papillomavirus Humains|German Cancer Research Center,All,18 Years to 20 Years � (Adult),Not Applicable,49,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2011-42|2012-A00814-39,October 2013,June 2016,June 2016,"November 20, 2013",,"August 31, 2016","Service Universitaire de M�decine Pr�ventive et de Promotion de la Sant� (SUMPPS), Versailles, France",,https://ClinicalTrials.gov/show/NCT01988948,NCT01988948,
oui,NCT01990716,Lipid Mediators in Colonic Biopsies as Biomarkers of Disease Activity of Inflammatory Bowel Diseases,MICILIP,Completed,No Results Available,"Inflammatory Bowel Diseases|Colitis, Ulcerative|Crohn Disease",Other: Colonic Biopsy,"Measure of 5,6-EET quantity in a colonic biopsy|Nature and quantity of Lipid metabolites as a function of the patient clinical profile (mapping)","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,124,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,12 393 02|AOL 2012,February 2013,May 2015,May 2015,"November 21, 2013",,"February 23, 2017","University Hospital Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01990716,NCT01990716,32234475
oui,NCT01993186,Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS),,Completed,Has Results,Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS),Drug: UX007|Drug: Placebo,"Percent Reduction From Baseline to Week 8 in Frequency of Total Seizures (Normalized to a 4-Week Rate)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Discontinuations Due to TEAEs During the Placebo-Controlled Period|Number of Participants With TEAEs, Serious TEAEs and Discontinuations Due to TEAEs During the Extension Period|Percent Reduction From Baseline to Week 8 in Frequency of Observable Seizures (Normalized to a 4-Week Rate)|Percent Reduction From Baseline to Week 8 in Frequency of Absence Seizures (Normalized to a 4-Week Rate)|Percentage of Participants With at Least a 50% Reduction From Baseline to Week 8 in Frequency of Total Seizures|Percentage of Participants With at Least 50% Reduction From Baseline to Week 8 in Frequency of Observable Seizures|Percentage of Participants With at Least 50% Reduction From Baseline to Week 8 in Frequency of Absence Seizures|Change From Baseline to Week 8 in Cambridge Neuropsychological Test Automated Battery (CANTAB), Reaction Time (RTI) Scores, Generalized Estimating Equation (GEE)|Change From Baseline to Week 8 in CANTAB, Paired Associates Learning (PAL) Scores, GEE|Change From Baseline to Week 8 in CANTAB, Spatial Span (SSP) Span Length Scores, GEE|Change From Baseline to Week 8 in CANTAB, Spatial Working Memory (SWM) Scores, GEE|Change From Baseline to Week 8 in Distance Traveled (in Meters) as Measured by 6-Minute Walk Test (6MWT)|Change From Baseline to Week 8 in Distance Traveled (in Percent Predicted) as Measured by 6MWT|Time (in Minutes) to Onset of Paroxysmal Exertional Dyskinesia (PED) as Measured During 6MWT Over Time Through Week 8|Change From Baseline to Week 8 in Gross Motor Function Measure-88 (GMFM-88) Total Score|Percent Reduction From Baseline Over Time in Frequency of Total Seizures (Normalized to a 4-Week Rate)|Percent Reduction From Baseline Over Time in Frequency of Observable Seizures (Normalized to a 4-Week Rate)|Percent Reduction From Baseline Over Time in Frequency of Absence Seizures (Normalized to a 4-week Rate)",Ultragenyx Pharmaceutical Inc,All,"1 Year to 100 Years � (Child, Adult, Older Adult)",Phase 2,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UX007G-CL201,"February 28, 2014","September 20, 2017","September 20, 2017","November 25, 2013","May 29, 2020","June 19, 2020","Children's Hospital Colorado - University of Colorado, Denver, School of Medicine, Aurora, Colorado, United States|Miami Children's Research Institute, Miami, Florida, United States|Neurology & Epilepsy Research Center, Orlando, Florida, United States|Columbia University - Department of Neurology, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Cook Children's Hospital, Fort Worth, Texas, United States|University of Texas Neurometabolic Clinic, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Melbourne Brain Centre, Heidelberg, Victoria, Australia|Service de Neurologie P�diatrique et des Maladies M�taboliques - INSERM U1141 H�pital Robert Debr� - APHP, Paris, Cedex 19, France|Sheba University Medical Center, Tel Aviv, Israel|Unita' Operativa Neurologia Pediatrica e Malattie Muscolari Istituto ""Giannina Gaslini"", Genova, Italy|Hospital Sant Joan de Deu, Barcelona, Spain|Newcastle University, Newcastle Upon Tyne, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT01993186/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT01993186/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01993186,NCT01993186,35441706
oui,NCT01995968,Antenatal Detection of Fetal Growth Restriction and Stillbirths Rate.,REPERE,Unknown status,No Results Available,"Stillbirth|Intrauterine Growth Retardation|Infant, Small for Gestational Age",Other: Antenatal identification of fetal growth restriction,Rate of antenatal detection of FGR|Factors associated with lack of antenatal detection of FGR in a representative sample of SGA births|fetal deaths of SGA newborns with and without antenatal detection of FGR,"University Hospital, Grenoble|Registre de Handicap de l'Enfant et Observatoire P�rinatal (RHEOP) Is�re, Savoie et Haute-Savoie|UMRS 953, Epidemiological Research Unit on Perinatal and Women's and Children's Health, INSERM",All,24 Weeks to 42 Weeks � (Child),,480,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,DCIC12 08,November 2013,July 2015,December 2015,"November 27, 2013",,"August 4, 2015","CH Albertville-Moutiers, Albertville, France|Clinique G�n�rale Annecy, Annecy, France|CH Annecy, Annecy, France|Polyclinique de Savoie Annemasse, Annemasse, France|CHI Annemasse Bonneville, Bonneville, France|CH Bourg Saint Maurice, Bourg Saint Maurice, France|Clinique Saint Vincent de Paul Bourgoin Jallieu, Bourgoin Jallieu, France|Centre Hospitalier Bourgoin Jallieu, Bourgoin-Jallieu, France|Hopital Femme Mere Enfant, Bron, France|CH Chamb�ry, Chamb�ry, France|Clinique des C�dres, Echirolles, France|Chu Grenoble, Grenoble, France|Clinique Mutualiste Eaux Claires, Grenoble, France|Hopital Croix rousse, Lyon, France|Clinique Belledonne, Saint Martin d H�res, France|CH Saint Jean de Maurienne, Saint-Jean-de-Maurienne, France|CH Sud L�man Valserine, Saint-Julien-en-Genevois, France|H�pitaux du Mont Blanc, Sallanches, France|H�pitaux du L�man, Thonon-les-Bains, France|Centre Hospitalier Vienne, Vienne, France|Centre Hospitalier Voiron, Voiron, France",,https://ClinicalTrials.gov/show/NCT01995968,NCT01995968,
oui,NCT02001649,Genetic Variants Associated With Adolescent Suicide Attempts,VGTSA,Completed,No Results Available,Attempt Suicide,Genetic: SNP Genotyping|Genetic: SNP genotyping,Odds ratio (OR) and 95% confidence interval (CI) will be estimated using a logistic regression model to assessing the contribution of each polymorphism as a risk factor in predicting suicidal behavior,"University Hospital, Rouen|Institut National de la Santé Et de la Recherche Médicale, France",All,13 Years to 17 Years   (Child),Not Applicable,250,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2013/092/HP,December 2013,July 2016,July 2016,"December 5, 2013",,"October 10, 2016","Chu Rouen, Rouen, Haute Normandie, France",,https://ClinicalTrials.gov/show/NCT02001649,NCT02001649,
oui,NCT02007902,Plasma Protein Levels and Very Preterm Birth,ProH�mie,Completed,No Results Available,Very Preterm Infants,Other: Evaluation of the relationship plasma protein levels - neonatal hemodynamics,"Evidence of clinical hemodynamic disturbances defined by arterial hypotension (non-invasive measure of MAP - mmHg - pathological for gestational age) or measured at organ colour doppler, echocardiography or NIRS|plasma protein|Albumin level|Mortality rate","Centre Hospitalier Universitaire de la R�union|INSERM CIE1, Dijon, 21000, France",All,1 Minute to 1 Hour � (Child),,125,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013/CHU/02|2013-A00090-45,January 2014,March 2015,March 2015,"December 11, 2013",,"October 1, 2018","Centre Hopsitalier Universitaire de La R�union, Saint Denis, La R�union, France|Centre Hospitalier de La R�union, Saint Pierre, La R�union, France",,https://ClinicalTrials.gov/show/NCT02007902,NCT02007902,
oui,NCT02010229,Clinical Situations at High Risk of Placenta Accreta / Percreta,Paccreta,Completed,No Results Available,Placenta Accreta / Percreta,,Severe postpartum hemorrhage|Incidence of accreta or percreta placenta overall and in women with previous caesarean section and placenta praevia|Predictive value of prenatal ultrasound and MRI for the diagnosis of placenta accreta in women with previous caesarean section and placenta praevia|severe maternal morbidity|Psychological impact,"Assistance Publique - H�pitaux de Paris|Inserm U953 (Epidemiological research unit on perinatal health and women's and children's health) Paris, France|University Hospital, Angers",Female,"18 Years and older � (Adult, Older Adult)",,674,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NI11061,"November 4, 2013","November 30, 2016","August 31, 2017","December 12, 2013",,"December 12, 2017","H�pital Louis Mourier (APHP), Colombes, France",,https://ClinicalTrials.gov/show/NCT02010229,NCT02010229,34914894
oui,NCT02010294,Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and/or Genetic Factors of Predisposition to Infections,StreptoPedia,Completed,No Results Available,Invasive GAS Infection,"Genetic: DNA samples, GAS strains",virulence factors of GAS|Assess the frequency and type of hereditary immune deficiency or Mendelian susceptibility to infections associated with invasive GAS infections in children without risk factors|describe and compare the GAS emm genotypes and virulence factors with the profiles of strains isolated with invasive GAS infection with known risk factors and with the profile of strains isolated with a non-invasive GAS infections|compare GAS emm genotypes and profiles of virulence strains responsible for invasive SGA infections with strains causing noninvasive infections,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,1 Month to 15 Years   (Child),,223,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,P120136,"February 10, 2014","February 10, 2018","July 20, 2018","December 12, 2013",,"November 18, 2019","Robert Debré Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02010294,NCT02010294,
oui,NCT02014727,Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults,AMA1-DiCo,Completed,No Results Available,"Malaria, Falciparum",Biological: Group A1 : 50µg AMA1-DiCo + Alhydrogel|Biological: Group A2 : 50 µg AMA1-DiCo+ GLA-SE|Biological: Group B2 : Placebo,Number of Adverse events|The humoral and cellular responses,"Institut National de la Santé Et de la Recherche Médicale, France|EVI Industries, Inc.|BPRC|Recherche Clinique Paris Descartes Necker Cochin Sainte Anne|Centre national de recherche et de formation sur le paludisme",All,20 Years to 45 Years   (Adult),Phase 1,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C12-18 AMA-DiCo|2013-001920-20,January 2014,March 2015,July 2015,"December 18, 2013",,"February 2, 2016","CNRFP, Ouagadougou, Burkina Faso|CIC BT 505 de vaccinologie Cochin Pasteur, Hôpital Cochin Bâtiment Lavoisier 27 rue du faubourg St Jacqu, Paris, France",,https://ClinicalTrials.gov/show/NCT02014727,NCT02014727,28947345
oui,NCT02014883,Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS,GLUT-HEP,Completed,No Results Available,Glut1 Deficiency Syndrome,Drug: GLUT1 DS,Number of paroxystic events|Safety|6 minutes walk test|9 hole Peg board|Clinical Global Impression Scales|Schwab-England scale|Vineland Scale|Fatigue Severity Scale|Fatigue Visual Scale|Brain 31phosphorus magnetic resonance spectroscopy,"Institut National de la Santé Et de la Recherche Médicale, France|Ultragenyx Pharmaceutical Inc",All,"3 Years and older   (Child, Adult, Older Adult)",Phase 2,20,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C13-37|2013-A01300-45,"December 4, 2013","July 4, 2019","July 4, 2019","December 18, 2013",,"August 25, 2021","Brain and Spine Institute, Paris, France",,https://ClinicalTrials.gov/show/NCT02014883,NCT02014883,26536893
oui,NCT02018484,Positioning of the Tibial Cut in Unicompartmental Medial Knee Replacement by Using Patient Specific Cutting Guides.,PSI-PUC,Completed,No Results Available,Knee Prosthesis,Procedure: Unicompartmental Knee Replacement,Success rate in performing the tibial cut|Success rate in conserving a residual varus.|Variations of other orientation parameters of the tibial cut and limb alignment at the different times of the procedure (per and post operative) .,Rennes University Hospital,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-A01337-38,December 2013,May 2016,May 2016,"December 23, 2013",,"August 19, 2016","Chu Rennes, Rennes, France",,https://ClinicalTrials.gov/show/NCT02018484,NCT02018484,
anrs,NCT02025868,Third Line Antiretroviral Treatment Optimization in Sub-Saharan Africa,THILAO,Unknown status,No Results Available,HIV Infection,Behavioral: adherence reinforcement|Drug: Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators),"Virologic efficacy of the adherence reinforcement intervention|Persistent virologic efficacy of the adherence reinforcement intervention|Virologic efficacy of 3rd-line ART|Immunological efficacy of the adherence reinforcement intervention|Immunological efficacy of 3rd-line ART|Tolerance of 3rd-line ART drugs|Adherence to 3rd-line ART|Resistance to 1st and 2nd-line antiretroviral drugs|Resistance to 1st, 2nd and 3rd-line antiretroviral drugs|Plasma antiretroviral drugs concentration","ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",Phase 2,201,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 12269 THILAO,March 2013,August 2016,May 2017,"January 1, 2014",,"February 17, 2017","CHU Sour� Sanou, Bobo-Dioulasso, Burkina Faso|CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso|Centre de Prise en Charge et de Formation (CePReF), Association ACONDA, Abidjan, C�te D'Ivoire|Service des Maladies Infectieuses et Tropicales (SMIT), Abidjan, C�te D'Ivoire|Centre d'Ecoute, de Soins, d'Animation et de Conseils (CESAC), Bamako, Mali|CHU Point G, Bamako, Mali|CHU Fann, Dakar, Senegal",,https://ClinicalTrials.gov/show/NCT02025868,NCT02025868,
oui,NCT02027051,Etude génétique Des Arméniens,,Completed,No Results Available,Healthy,,Genome wide genotyping of individuals|Principal component analysis of genotypes,"Institut National de la Santé Et de la Recherche Médicale, France",All,"50 Years and older   (Adult, Older Adult)",,500,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,C11-15|2012-A00514-39,January 2014,June 2014,January 2017,"January 3, 2014",,"August 30, 2021","Hovnanian, Paris, France",,https://ClinicalTrials.gov/show/NCT02027051,NCT02027051,
oui,NCT02027233,Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults,FLUVAC EV-03,Recruiting,No Results Available,Severe Acute Respiratory Infection,Other: nasopharyngeal sample,Measure of vaccine efficacy in population by comparing the number of influenza cases virologically documented in hospitalized patients vaccinated and unvaccinated.|Measure of vaccine efficacy in population by age group|Measure of vaccine efficacy in population by influenza type/subtype|Description of the population hospitalized for syndrome acute respiratory infection (SARI),"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,C13-47|2013-A01204-41,January 2014,December 2022,December 2022,"January 6, 2014",,"August 18, 2022","Institut National de la Santé Et de la Recherche Médicale, Paris, France",,https://ClinicalTrials.gov/show/NCT02027233,NCT02027233,
oui,NCT02030626,Comparison of the Efficacy of rTMS and tDCS of the Motor Cortex in Patients With Chronic Neuropathic Pain,,Completed,No Results Available,Lumbar Radiculopathy,Device: active or placebo rTMS or active or placebo tDCS,Comparison of rTMS and tDCS on average pain intensity|Comparison of rTMS and sham stimulation on average pain intensity|comparison of tDCS and sham stimulation on average pain intensity|comparison of rTMS and tDCS on current pain|comparison of rTMS and tDCS on pain intensity|comparison of rTMS versus tDCS and versus sham on BPI interference|comparison of rTMS versus tDCS and sham on pain catastrophizing|comparison of rTMS versus tDCS and sham on anxiety and depression|comparison of rTMS versus tDCS and sham on neuropathic symptoms|comparison of rTMS versus tDCS and sham on thermal testing|comparison of safety between rTMS and tDCS and between neurostimulation and sham,Hospital Ambroise Par� Paris,All,18 Years to 60 Years � (Adult),Phase 4,35,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",rTMS versus tDCS|2010-018309-12,January 2013,January 2015,January 2015,"January 8, 2014",,"December 9, 2015","H�pital Ambroise Par�, Boulogne Billancourt, France|H�pital Henri Mondor, APHP, Cr�teil, France",,https://ClinicalTrials.gov/show/NCT02030626,NCT02030626,
oui,NCT02032225,Generation of a Cellular Model of CADASIL From Skin Fibroblasts,,Unknown status,No Results Available,CADASIL,Other: Skin biopsy,"Derivation of iPS cells from skin biopsies of patients with CADASIL|Differentiation of iPS cells to vascular smooth muscle cells, phenotypic and mechanistic analyses","Institut National de la Sant� Et de la Recherche M�dicale, France",All,30 Years to 60 Years � (Adult),,10,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,C13-34|2013-A00994-41,February 2014,August 2018,August 2018,"January 9, 2014",,"December 7, 2016","INSERM, Paris, France",,https://ClinicalTrials.gov/show/NCT02032225,NCT02032225,
non,NCT02033473,Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers,APELINS,Completed,No Results Available,Healthy,Drug: Apelin|Drug: Placebo,"Rate of glucose infusion|Calculation of the index of insulin sensitivity (Si)|Changes in the measurement of systolic blood pressure during each clamp|Changes in the measurement of diastolic blood pressure during each clamp|Changes in heart rate measurement during each clamp|Changes in ECG during each clamp|Clinical signs of intolerance / allergy / toxicity at visit 2,3 and 4|Determination of plasma insulin at all sampling|Determination of plasma glucagon at all sampling times|Determination of plasma apelin at all sampling times|Determination of plasma leptin at all sampling times|Determination of plasma adiponectin at all sampling times","University Hospital, Toulouse",Male,18 Years to 40 Years � (Adult),Phase 1,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",13 182 03|HAO 2013,January 2014,October 2014,October 2014,"January 10, 2014",,"July 12, 2019","University Hospital of Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02033473,NCT02033473,28681996
oui,NCT02034864,Comparison of the Effectiveness of 2 Manual Therapies on Functional Outcome in Sub-acute and Chronic Non-specific Low Back Pain,LC OSTEO,Completed,No Results Available,Subacute and Chronic Non-specific Low Back Pain,Other: Osteopathic manipulative treatment|Other: Placebo of osteopathic manipulative treatment,Mean improvement from baseline in mean activity limitation|Mean reduction from baseline in mean lumbar pain in the previous 48 hrs|Number of sick leaves|Duration of sick leaves|Recurrence of pain|Mean improvement from baseline in mean quality of life|Pain killer and non-steroidal anti-inflammatory drug consumption,"Assistance Publique - H�pitaux de Paris|Institut National de la Sant� Et de la Recherche M�dicale, France|Universit� Paris Cit�|University of Paris 5 - Rene Descartes|Institut Universitaire Romand de Sante au Travail",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,P110142,"February 17, 2014","October 23, 2017","October 23, 2017","January 14, 2014",,"January 23, 2019","CHU Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT02034864,NCT02034864,33720272
anrs,NCT02038842,Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers,VRI01,Completed,No Results Available,HIV Infection,"Biological: LIPO-5|Biological: MVA HIV-B (MVATG17401)|Biological: GTU�-MultiHIV B: 0.5 mL IM via Biojector� 2000 and 0.5mL IntraDermic, 3 shots","Evaluation of the safety of MVA HIV-B at Week 2 in arm 1|To discard vaccine strategies with an insufficient level of immunogenicity, defined by HIV-specific IFN-?-ELISPOT responses, among 4 HIV prophylactic prime-boost combinations in healthy volunteers at low risk of HIV infection|To assess the tolerance of each prime-boost combination|To assess for each prime-boost combination the type of vaccine-induced T cell response","ANRS, Emerging Infectious Diseases",All,21 Years to 50 Years � (Adult),Phase 1|Phase 2,92,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2012-002456-14,March 2014,October 2015,March 2016,"January 17, 2014",,"June 1, 2016","Service d'Immunologie Clinique 51, avenue du Marechal de Lattre de Tassigny, Creteil, France",,https://ClinicalTrials.gov/show/NCT02038842,NCT02038842,
oui,NCT02040363,Muscle Training Induced Angiogenesis in COPD,COPDµvasc,Completed,No Results Available,Peripheral Muscle Dysfunction|COPD,Procedure: Muscular biopsy|Other: 5-10 weeks sport training,Capillary-o-fiber ratio assessed by immunochemistry on a muscle biopsy of the vastus lateralis of the quadriceps|quadriceps endurance|Pericyte coverage of skeletal muscles capillaries assessed by immunostaining of a muscle biopsy of the vastus lateralis of the quadriceps|Effect of the serum of COPD patients and SHS on pericyte morphology and in vitro|Effect of the serum of COPD patients and SHS on pericyte/endothelial cells interactions in vitro|Effect of the serum of COPD patients and SHS on pericyte/endothelial cells interactions in vivo,"University Hospital, Montpellier|Institut National de la Santé Et de la Recherche Médicale, France|Université Montpellier|5 Santé",All,"40 Years to 78 Years   (Adult, Older Adult)",Not Applicable,22,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science",9224,January 2014,April 2016,August 2016,"January 20, 2014",,"January 14, 2020","Department of clinical Physiology - University Hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02040363,NCT02040363,34750160
anrs,NCT02043418,Outcome at 5 Years of Early Treated HIV Infected Infants in the PEDIACAM Project,PEDIACAM,Unknown status,No Results Available,HIV,,"Number of clinical/biological events related to HIV infection|Number clinical/biological events grade 3 or higher and their potential relationship to ARV therapy, HIV infection or vaccines|Emergence of genotypic mutations of viral resistance to treatment in infants with virologic failure|Survival of infants|Age at switch to second line of ARV treatment|Clinical and immunovirological response to treatment|Regularity of consultations and relationship of the person bringing the child to consultation.|Death of parent or sibling|Changes in living situation.|Communication of child's HIV status to family and community","ANRS, Emerging Infectious Diseases|Centre Pasteur du Cameroun|Centre Mère et Enfant de la Fondation Chantal Biya|Centre Hospitalier D'essos|Hospital General De Douala|Institut Pasteur de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Assistance Publique - Hôpitaux de Paris",All,up to 5 Years   (Child),,460,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ANRS 12140 -12225,November 2007,February 2018,March 2018,"January 23, 2014",,"July 12, 2016","Hôpital Laquintinie, Douala, Cameroon|Centre Hospitalier d'Essos, Yaounde, Cameroon|Centre Mère et Enfant de la Fondation Chantal Biya, Yaounde, Cameroon",,https://ClinicalTrials.gov/show/NCT02043418,NCT02043418,
oui,NCT02050360,"""As Required"" Oral Sildenafil in Raynaud's Phenomenon",PROFIL,Completed,No Results Available,Raynaud's Phenomenon,Drug: Sildenafil 40 mg|Drug: Sildenafil 80 mg|Drug: Placebo,"Mean change in the Raynaud's Condition Score (RCS) during treatment, as compared to placebo.|Frequency of RP: number of RP attacks during treatment, as compared to placebo.|Patients' preference: comparison between the number of patients favoring a treatment to another.|Pain associated with RP: Mean change in the Raynaud's pain score during treatment, as compared to placebo.|Frequency and severity of adverse drug events during treatment, as compared to placebo|Microvascular reactivity: index of skin perfusion in response to local/regional cooling after a single dose of sildenafil, as compared to placebo (laboratory experiments)","University Hospital, Grenoble",All,"18 Years and older � (Adult, Older Adult)",Phase 2|Phase 3,41,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DCIC/12/26|2013-000014-38|12G01,November 2013,May 2015,May 2015,"January 30, 2014",,"January 18, 2016","Clinical Investigation Center - Pharmacology Unit - University Hospital of Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT02050360,NCT02050360,30383134
oui,NCT02051413,Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN),DEPARRESTCLIN,Completed,No Results Available,Major Depressive Disorder|Major Depressive Episode,Drug: Venlafaxine extended release,Change from baseline in depressive symptoms on the Hamilton Depression Rating Scale-17 items,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,67,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C13-25|2013-004326-29,"February 18, 2014",May 2018,May 2018,"January 31, 2014",,"August 26, 2021","CHU de Bicetre, Le Kremlin Bicetre, France",,https://ClinicalTrials.gov/show/NCT02051413,NCT02051413,
oui,NCT02052154,Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults,SPLENEVAC,Completed,No Results Available,Splenectomized Patients,Biological: Prime-boost pneumococcal immunization,"Proportion of subjects responsive to 9 of the 13 serotypes common (serotypes 1, 3, 6A, 7F, 9V, 14, 19A, 19F, 23F).|IgG dosage|ELISA dosages|Identification of predictive factors for immunogenicity|Percentage of patients presenting local or systemic reactions post-immunization|Evaluation of severe infectious episode|OPA dosages",Assistance Publique - Hôpitaux de Paris,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,70,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,P120131|2013-002631-19,"March 10, 2014","July 19, 2016","April 2, 2019","January 31, 2014",,"December 4, 2020","Service des Maladies Infectieuses et Tropicales - Centre d'Infectiologie Necker-Pasteur, IHU Imagine - Hôpital Necker-Enfants, Paris, France",,https://ClinicalTrials.gov/show/NCT02052154,NCT02052154,
oui,NCT02052271,Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation,ELECTRE2,Completed,No Results Available,Essential Tremor,Device: Cathodal cerebellar transcranial direct current stimulation,Change from baseline in tremor amplitude on clinical rating scale|Change from baseline in tremor amplitude on accelerometric recording|Change from baseline in tremor amplitude on electromyographic recordings|Change from baseline in tremor amplitude on digitized tablet|Change from baseline of amplitude of motor evoked potentials elicited by TMS,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other",C13-24|2013-A01404-41,"June 3, 2014","March 27, 2018","March 27, 2018","February 3, 2014",,"February 13, 2020","Institut du Cerveau et de la Moelle, Hôpital Pitié-Salpétrière, Paris, France",,https://ClinicalTrials.gov/show/NCT02052271,NCT02052271,
oui,NCT02058823,Intermittent Hypoxia 2: Cardiovascular and Metabolism,IH2,Terminated,No Results Available,Hypoxia|Sleep Apnea|Obstructive Sleep Apnea,Drug: Placebo|Drug: Valsartan|Drug: Amlodipine,"Change in sympathetic activity|Measure of adrenergic, inflammatory and metabolic markers in adipose tissues by chronic intermittent hypoxia versus placebo in healthy nonobese subjects.|Measure variations in parameters of inflammation in adipose tissue by chronic intermittent hypoxia versus placebo in healthy nonobese subjects.|Measure of metabolic aspects of the OGTT test.|Measure the activation of systemic inflammation by chronic HI versus placebo in healthy nonobese subjects. The systemic inflammation will be assessed in non-stress and during the OGTT.|Assessing markers implicated in the pathophysiology of chronic metabolic diseases after HI versus placebo in healthy nonobese subjects during OGTT.|Change in vascular responsivness|Change in Sympathetic and vascular determinant of Blood pressure","University Hospital, Grenoble|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 4,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",2011-32|P-2011-32-HI2,"August 7, 2013","July 17, 2014","March 16, 2017","February 10, 2014",,"December 31, 2018","Laboratoire EFCR - Functional Cardio-respiratory Exploration Laboratory, La Tronche, Isère, France",,https://ClinicalTrials.gov/show/NCT02058823,NCT02058823,
oui,NCT02061254,Transient Elastography DEdicated to Cosmetology And Dermatology (TEDECAD),TEDECAD,Completed,No Results Available,Venous Insufficiency|Lymphedema,Device: Cutometer|Device: High resolution ultrasonography (echography)|Device: Elastography|Procedure: Skin biopsy,Assessment of dermal/hypodermal fibrosis in lymphedema and venous insuffisency|Cutaneous fibrosis measured by cutometer|Cutaneous fibrosis assessed by histology|Cutaneous thickness measured by high resolution ultrasonography|Clinical score of fibrosis|Echogenicity of the dermis and superficial hypodermis|Assessement of adverse events,"University Hospital, Tours|Echosens|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PFUI 2013 - AM / TEDECAD,April 2014,June 2015,June 2015,"February 12, 2014",,"September 1, 2015","University Hospital of Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT02061254,NCT02061254,
oui,NCT02071784,Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL),MACOUPLING-CAD,Completed,No Results Available,CADASIL,,model-derived parameters of neurovascular coupling,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,18 Years to 60 Years � (Adult),,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,C13-62|2014-A00200-47,"July 8, 2014","October 24, 2016","October 24, 2016","February 26, 2014",,"August 30, 2021","CENIR, Hopital Piti� Salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT02071784,NCT02071784,
oui,NCT02073604,Role of the SMA During Unimanual and Bimanual Movements Preparation: the Mirror Movements Paradigm,MOMIC2,Completed,No Results Available,Congenital Mirror Movements,Other: Healthy volunteers|Other: Congenital mirror movements,SMA activation level and connectivity during preparation of unimanual/bimanual movements|SMA activation level and connectivity during preparation of unimanual/bimanual movements in congenital mirror movements patients,"Institut National de la Santé Et de la Recherche Médicale, France",All,"15 Years to 82 Years   (Child, Adult, Older Adult)",Not Applicable,47,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C13-16|2013-A00616-39,March 2014,February 2016,February 2016,"February 27, 2014",,"August 31, 2016","Fédération des Maladies du Système Nerveux, Hôpital Pitié Salpétrière Paris, France 75013, Paris, France",,https://ClinicalTrials.gov/show/NCT02073604,NCT02073604,
oui,NCT02073630,Contribution of the Cerebellum In Sensory-motor Adaptation Via Gamma Oscillations: the Case of Dystonia,GAMMA,Completed,No Results Available,Primary Dystonia,Other: active cerebellar stimulation|Other: sham cerebellar stimulation,change in gamma oscillations power in the cerebellum during a sensorimotor adaptation task|synchrony in the gamma band between the cerebellum and the sensorimotor cortex,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,63,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,C13-45,February 2014,February 2016,August 2016,"February 27, 2014",,"November 6, 2017","ICM GH Pitié Salpetrière, Paris, France",,https://ClinicalTrials.gov/show/NCT02073630,NCT02073630,
oui,NCT02075918,Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis,InTeam,Completed,No Results Available,Alcoholic Hepatitis|Control Patients,,Diagnosis and Severity of Alcoholic Hepatitis|Major Liver Complications|Death/Transplantation,"University of Pittsburgh|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Wisconsin, Madison|King's College London|Veterans Medical Research Foundation|Hospital Vall d'Hebron|Institut National de la Santé Et de la Recherche Médicale, France|Yale University|Columbia University|Weill Medical College of Cornell University|University of Alberta|Hospital San Jose Tec de Monterrey",All,"18 Years to 70 Years   (Adult, Older Adult)",,376,Other|NIH,Observational,Observational Model: Case-Only|Time Perspective: Prospective,12-2016|1U01AA021908-01,May 2014,May 2019,"May 31, 2019","March 3, 2014",,"June 10, 2019","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02075918,NCT02075918,31228214
oui,NCT02077101,Representations and Acceptability of HIV Therapeutic Vaccine in a Cohort of HIV-1 Infected Outpatients Followed at Hospital,RAVVIH,Completed,No Results Available,HIV,Other: Questionnaire|Other: Interview,VAS scale of acceptability|score of quality of life|confidence score of the patient-physician relationship|perception score of the severity of the disease,"Hopital Foch|Saint-Louis Hospital, Paris, France|INSERM UMR912-SE4S, Marseille, France",All,"18 Years to 75 Years � (Adult, Older Adult)",Not Applicable,220,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),2013/35,December 2013,December 2014,December 2014,"March 4, 2014",,"January 19, 2015","Centre Hospitalo-Universitaire Louis Mourier, Colombes, Hauts de Seine, France|Hopital Foch, Suresnes, Hauts de Seine, France|Centre Hospitalier Regional d'Orl�ans, Orleans, France",,https://ClinicalTrials.gov/show/NCT02077101,NCT02077101,31072394
oui,NCT02077543,Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma,ProTool,Unknown status,No Results Available,Glioma : Oligodendroglioma or Astrocytoma,Device: Brain Tissue Imprint - Medical Device (ProTool),"Clinical examination : neurologic deficiency, allergic reaction, infections, pain, headaches, others adverse events... Postoperative MRI evaluation : no hematoma|Molecular measurements in intra-operative cellular samples : transcriptome, micro-RNA, proteome and cellular cultur analysis","University Hospital, Grenoble|MEDIMPRINT|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,150,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,ProTool,October 2013,June 2020,December 2020,"March 4, 2014",,"March 25, 2020","Angers University Hospital, Angers, France|Henri Mondor University Hospital, Creteil, France|CLINATEC, Grenoble, France|Grenoble University Hospital, Grenoble, France|Sainte-Anne Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02077543,NCT02077543,
oui,NCT02078076,IRM Cardiaque en Respiration Libre Pour Des Patients Atteints de Dystrophinopathie sévère,,Completed,No Results Available,Duchenne or Severe Becker Myopathy,Device: Magnetic Resonance Cardiac Imaging (with Gadolinium),"Number of exams correctly acquired (feasabiliy of the exam)|Number of exams allowing a qualitative assessment of images by the physician|Number of exams allowing a quantitative assessment of the diagnosis|Number of anatomic cardiac segments with significant fibrosis according to the assessment methods (conventional LGE, qualitative detection with GRICS, and quantiative measure with GRICS)|Number of cardiac segments with fibrosis and/or regional dysfunction","Institut National de la Santé Et de la Recherche Médicale, France",All,"8 Years and older   (Child, Adult, Older Adult)",Not Applicable,22,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C13-04|2013-A00179-36,June 2013,November 2015,November 2015,"March 5, 2014",,"February 24, 2016","Service de médecin nucléaire / CHU Nancy Brabois, Vandoeuvre, France",,https://ClinicalTrials.gov/show/NCT02078076,NCT02078076,
oui,NCT02079272,REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity),REBECCA,Withdrawn,No Results Available,Toxicity Due to Radiotherapy|Breast Cancer|Lesion  Cardiac,Other: Helical tomotherapy for breast cancer,"Number of participants with subclinical cardiac lesions in myocardial levels and/or coronary levels|Number of participants with decrease in myocardial contractility (strain or strain rate measured with cardiac ultrasound exam""2D strain"")|Number of participants with modified measures of circulating biomarkers","Sophie JACOB|Institut de Radioprotection et de Surete Nucleaire|Institut Claudius Regaud|University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",Female,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2013-A00929-36,November 2014,November 2018,November 2019,"March 5, 2014",,"April 6, 2015","Institut Claudius Regaud, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02079272,NCT02079272,
oui,NCT02081066,Identification of CETP as a Marker of Atherosclerosis,CETP-ATHERO,Completed,No Results Available,Cardiovascular Disease,Other: cardiovascular risk factors,Endogenous CETP activity|carotid intima-media thickness|Coronary calcium score|plasma efflux capacity from human macrophage|HDL genetic variant,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,99,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C13-20|2013-A00798-37,"September 25, 2014",September 2020,September 2020,"March 7, 2014",,"August 26, 2021","Inserm Umrs1166, Paris, France",,https://ClinicalTrials.gov/show/NCT02081066,NCT02081066,
oui,NCT02081313,Natural History and Biological Study of Netherton Syndrome,NSnatbio,Unknown status,No Results Available,Netherton Syndrome|Healthy,Other: Biopsy|Other: Blood sample,Measurement of seric cytokines levels|Pattern of skin abnormalities,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"Child, Adult, Older Adult",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C12-56|2013-A00275-40,April 2014,November 2016,November 2017,"March 7, 2014",,"February 4, 2015","Imagine Institute for genetic diseases, Paris, France",,https://ClinicalTrials.gov/show/NCT02081313,NCT02081313,
oui,NCT02082171,Multidomain Intervention to Prevent Disability in Elders,MINDED,Completed,No Results Available,Physical Frailty|Physical Disability|Mobility Disability,Other: Multidomain intervention,400-meter walk test|Participants' adherence/retention to the intervention protocol and control groups|Intercurrent illnesses rates|Serious fall injuries|Hospitalizations and institutionalization rates|Mortality|Health-related quality of life|Body composition modifications|Modification of Pain|Fatigue,"Institut National de la Santé Et de la Recherche Médicale, France|National Research Agency, France",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,210,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,C12-55|2013-A00380-45,"October 16, 2013",January 2016,"January 27, 2016","March 10, 2014",,"September 1, 2021","Centre de Rééducation Fonctionnelle ""La Roseraie"", Montfaucon, France",,https://ClinicalTrials.gov/show/NCT02082171,NCT02082171,
oui,NCT02098759,"Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex",EPISTOP,Unknown status,No Results Available,TSC|Tuberous Sclerosis Complex|Epilepsy,Device: epilepsy early diagnosis protocol,number of patients with epilepsy,"Sergiusz Jozwiak|University of Rome Tor Vergata|Institut National de la Santé Et de la Recherche Médicale, France|Vrije Universiteit Brussel|General University Hospital, Prague|Charite University, Berlin, Germany|KU Leuven|Medical University of Vienna|Rudolf Magnus Institute - University of Utrecht|Brigham and Women's Hospital|Children's Memorial Health Institute, Poland",All,up to 4 Months   (Child),Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic",EPISTOP|602391,November 2013,October 2018,October 2018,"March 28, 2014",,"April 4, 2014","Medizinische Universitaet Wien, Vienna, Austria|Vrije Universiteit Brussel, Brussels, Belgium|Katholieke Universiteit Leuven, Leuven, Belgium|Fakultni Nemocnice V Motole, Prague, Czech Republic|Institut National De La Sante et de la Recherche Medicale, Paris, France|Charite - Universitaetsmedizin Berlin, Berlin, Germany|Universita Degli Studi Di Roma Tor Vergata, Rome, Italy|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Children's Memorial Health Institute, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT02098759,NCT02098759,31912454;31163675
oui,NCT02100774,Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability,VITAGENES,Completed,No Results Available,Biological Availability of Vitamins and Micronutrients,,micronutrient concentration in plasma chylomicrons|micronutrient concentration in adipose tissue,"Institut National de la Sant� Et de la Recherche M�dicale, France|Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement",Male,18 Years to 60 Years � (Adult),,45,Other,Observational,,2008-A00955-50,January 2009,July 2010,December 2013,"April 1, 2014",,"April 1, 2014","Centre d'Investigation Clinique de l'h�pital de la Conception, Marseille, France",,https://ClinicalTrials.gov/show/NCT02100774,NCT02100774,27798339;26063065;24808487
oui,NCT02101398,Study of the Effect of Transcranial Stimulations in Aphasic Subject Within a Year of Their Stroke,,Completed,No Results Available,Aphasia|Stroke,"Device: eldith DC-stimulator, configuration F7A|Device: eldith DC-stimulator, configuration F7C|Device: eldith DC-stimulator, configuration T5A|Device: eldith DC-stimulator, configuration T5C|Device: eldith DC-stimulator, configuration Sham",Percentage of improvement of picture naming,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,5,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",C12-09|2013-A00989-36,"October 2, 2014",July 2016,July 2016,"April 2, 2014",,"August 26, 2021","Hôpital Raymond Poincaré, Garches, France",,https://ClinicalTrials.gov/show/NCT02101398,NCT02101398,
oui,NCT02102737,Comparison of A New Technique of Measure of the Insulin Resistance By Scintigraphy With the Reference Technique,GLUCIMAG2,Completed,No Results Available,Diabetes Mellitus|Insulin Resistance|Glucose Metabolism Disorders|Metabolic Diseases|Endocrine System Diseases,Drug: 6-DIG|Procedure: clamp,Correlation between measure of insulin resistance measurement by scintigraphy and hyperinsulinemic euglycemic clamp|SAFETY|Reproducibility|Left ventricule ejection fraction|left ventricle volume|cardiac mass|diastolic function|cardiac output|pulmonary pressure and right ventricular function|strain by speckle tracking echocardiography,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C13-14|2013-003526-92,"May 13, 2014",March 2018,March 2018,"April 3, 2014",,"August 26, 2021","Hôpital Michallon . CHU Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT02102737,NCT02102737,
oui,NCT02109302,Primary Premature Ejaculation Genetics,,Unknown status,No Results Available,Premature Ejaculation,Procedure: Blood sample|Procedure: Skin biopsy|Other: Questionnaire,Number of subjects with genetic mutations of susceptibility to primary PE,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science,C12-32|2012-A01055-38,,April 2018,,"April 9, 2014",,"April 9, 2014","Polyclinique de Blois, La Chaussée Saint Victor, France|Hôpital Saint Joseph, Marseille Cedex 08, France|Hôpital Necker, Paris, France",,https://ClinicalTrials.gov/show/NCT02109302,NCT02109302,
oui,NCT02109926,"A Case-control Study to Assess the Association Between Environmental, Domestic and Occupational Exposures and the Risk of Testicular Germ Cell Tumor",TESTIS,Completed,No Results Available,Testicular Germ Cell Tumor,Other: Phone interview and blood test,Assess the association between pesticide exposure during Antenatal and Early Postnatal Periods and the risk of testicular cancer during adulthood|Assess the association between a combined exposure to pesticides and the risk of testicular cancer during adulthood|Analyse polymorphisms known to be associated with testicular cancer risk to explore gene-environment interactions,"Centre Leon Berard|National Cancer Institute, France|Institut National de la Santé Et de la Recherche Médicale, France",Male,18 Years to 44 Years   (Adult),,1367,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,TESTIS|ET14-004|140184B-12,January 2015,"March 30, 2018",April 2018,"April 10, 2014",,"May 11, 2018","CHRU Jean Minjoz, Besançon, France|CHU Jean Verdier, Bondy, France|Maternité CHU Pellegrin, Bordeaux, France|Hôpital Femme Mère Enfant, Bron, France|CHU de Caen, Caen, France|CHU Estaing, Clermont-Ferrand, France|CHU Dijon, Dijon, France|CHU de Grenoble - Hôpital Couple Enfants, Grenoble, France|CHRU Lille - Hôpital Calmette, Lille, France|Centre Léon Bérard, Lyon, France|CHU La Conception, Marseille, France|Hôpital Arnaud de Villeneuve, Montpellier, France|Maternité Université Régionale, Nancy, France|CHU de Nice - Hôpital l'Archet, Nice, France|Hôpital Cochin, Paris, France|Hôpital Tenon, Paris, France|Hôpital Maison Blanche, Reims, France|CHU de Rennes - Hôpital Sud, Rennes, France|CHU Charles Nicolle, Rouen, France|Centre Médico-Chirurgical Obstétrique, Schiltigheim, France|Hôpital Paule de Viguier, Toulouse, France|CHU Bretonneau, Tours, France",,https://ClinicalTrials.gov/show/NCT02109926,NCT02109926,
oui,NCT02113891,Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation,TAMARCIN,Withdrawn,No Results Available,Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation,Drug: Eculizumab,Microcirculation inflammation|Transplant glomerulopathy|Measured Glomerular Filtration Rate (Iohexol clearance)|Incidence of adverse effects|Incidence of biopsy-proven acute rejection|CH50|Endothelial Microparticles and Progenitors|Molecular diagnosis of AMR|Donor Specific Antibody titers (Luminex SA),"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Alexion",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P101004,February 2015,July 2017,November 2017,"April 15, 2014",,"February 25, 2015",,,https://ClinicalTrials.gov/show/NCT02113891,NCT02113891,
oui,NCT02113943,"Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation",MBBCitalopram,Completed,No Results Available,Normal Volunteers,Drug: Citalopram 30mg,Reward sensitivity,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 50 Years   (Adult),Phase 2,24,Other,Interventional,"Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)",C13-03|2013-003496-35,April 2014,June 2014,June 2014,"April 15, 2014",,"February 24, 2016","CIC Neurologie GHPS, Paris, France",,https://ClinicalTrials.gov/show/NCT02113943,NCT02113943,
oui,NCT02116504,Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients,ABI-RA,Unknown status,No Results Available,Rheumatoid Arthritis|Juvenile Idiopathic Arthritis,Procedure: Sampling of blood,Immunization against the Biopharmaceutical defined by the presence of ADAb within the first 12 months (or W52)|Quantification of ADAb|Clinical response and remission|ADAb-associated adverse clinical events at any time point|Drug levels,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Leiden University Medical Center|University College London (UCL) Cancer Institute|University of Florence|Pediatric Rheumatology International Trials Organization|Istituto Giannina Gaslini|GlaxoSmithKline|University Hospital, Tours",All,"2 Years and older   (Child, Adult, Older Adult)",Not Applicable,156,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,ABI-RA-P01|2013-A01268-37,April 2014,April 2016,November 2017,"April 17, 2014",,"November 28, 2016","CHU Bicêtre, Le Kremlin-Bicêtre, France",,https://ClinicalTrials.gov/show/NCT02116504,NCT02116504,35281074;32192445;29936438
oui,NCT02125682,The HDL Particle Protection Study,HDL PROTECT,Completed,No Results Available,Dyslipidemia in Patients With Diabetes Mellitus,Drug: atovastatin 10 mg/day|Drug: Atorvastatin 80 mg/day,effect on HDL function,Hotel Dieu de France Hospital|Nouvelle Soci�t� Fran�aise d'Ath�roscl�rose|Pfizer,All,"21 Years to 80 Years � (Adult, Older Adult)",Phase 4,16,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,HDLPROTECT,January 2012,"May 14, 2017","May 14, 2017","April 29, 2014",,"February 1, 2018","Hotel Dieu de France Hospital, Beirut, Lebanon",,https://ClinicalTrials.gov/show/NCT02125682,NCT02125682,
oui,NCT02126384,Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response,PNEUMOVACB,Completed,No Results Available,Pneumococcal Diseases,Drug: pneumovax vaccination,Identification of the precursor of B lymphocytes|measure of serum anti-capsular polysaccharide antibody titers,"Institut National de la Sant� Et de la Recherche M�dicale, France",Male,18 Years to 40 Years � (Adult),Not Applicable,9,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,INSERM-C12-10|2013-000850-23,"November 18, 2014",April 2016,"April 5, 2016","April 30, 2014",,"September 1, 2021","Centre d'Investigation Clinique, h�pital Necker Enfants Malades, Paris, France",,https://ClinicalTrials.gov/show/NCT02126384,NCT02126384,
oui,NCT02126475,Temporal Expectations in Parkinson's Disease,PEDUPARK,Unknown status,No Results Available,Parkinsons Disease|Healthy,,oculomotor reaction time: saccade latency,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",,40,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C12-45|2012-A01056-37,April 2014,October 2016,October 2016,"April 30, 2014",,"February 4, 2015","ICM-IHU, Paris, France|ICM, Paris, France",,https://ClinicalTrials.gov/show/NCT02126475,NCT02126475,
oui,NCT02128139,"Infective Endocarditis in Developing Countries, a Prospective, Observational, Multicentre Study",EndoDev,Unknown status,No Results Available,Infective Endocarditis,,Mortality at 1 month follow-up|Mortality at 6 months follow-up,"Institut National de la Santé Et de la Recherche Médicale, France|Ministry of Health, Mozambique|War Memorial Hospital|Centers for Disease Control and Prevention|Oxford University Hospitals NHS Trust",All,"1 Year and older   (Child, Adult, Older Adult)",,500,Other|U.S. Fed,Observational,Observational Model: Case-Only|Time Perspective: Prospective,EndoDev|Cardiology and Development,June 2014,June 2015,June 2015,"May 1, 2014",,"May 1, 2014","Joseph Kado, Suva, Fiji|Paul N. Newton, Vientiane, Lao People's Democratic Republic|Beatriz Ferreira, Maputo, Mozambique|Abdul Kane, Dakar, Senegal|Bara Diop, Dakar, Senegal|Emmy Okello, Kampala, Uganda",,https://ClinicalTrials.gov/show/NCT02128139,NCT02128139,
oui,NCT02129829,PROLIFICA - West African Treatment Cohort for Hepatitis B,WATCH,Completed,No Results Available,"Hepatitis B, Chronic|Hepatocellular Carcinoma",Drug: Tenofovir disoproxil,Incidence of HCC or decompensated cirrhosis|Uptake of screening|Prevalence of HBV infection|Rate of linkage into care|Treatment rate,"Imperial College London|Medical Research Council Unit, The Gambia|Department of State for Health and Social Welfare, The Gambia|UFR Sante de Thies, Senegal|Cheikh Anta Diop University, Senegal|Institut National de la Santé Et de la Recherche Médicale, France|International Agency for Research on Cancer",All,"18 Years and older   (Adult, Older Adult)",,1079,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,WMDH-P34114,October 2011,"July 31, 2018","July 31, 2018","May 2, 2014",,"September 28, 2020","MRC Laboratories Hospital, Fajara, Gambia|UFR Sante Thies,, Thies, Senegal",,https://ClinicalTrials.gov/show/NCT02129829,NCT02129829,25193933
oui,NCT02130557,"A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",,Completed,Has Results,"Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive",Drug: Bosutinib|Drug: Imatinib,Percentage of Participants With Major Molecular Response (MMR) at Month 12|Percentage of Participants With Major Molecular Response (MMR) Up to Month 18|Kaplan-Meier Estimate of Probability of Retaining Major Molecular Response (MMR) at Month 48|Percentage of Participants With Complete Cytogenetic Response (CCyR) Up to Month 12|Kaplan-Meier Estimate of Probability of Retaining Complete Cytogenetic Response (CCyR) at Month 48|Cumulative Incidence of Event Free Survival (EFS) Events|Overall Survival (OS) Rate,Pfizer,All,"18 Years and older � (Adult, Older Adult)",Phase 3,536,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AV001|2013-005101-31|B1871053,"July 15, 2014","August 11, 2016","April 17, 2020","May 5, 2014","November 14, 2018","May 18, 2021","Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Emory University Hospital, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Kaiser Permanente Hawaii, Honolulu, Hawaii, United States|Saint Alphonsus Regional Medical Center, Cancer Care Center, Boise, Idaho, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Saint Alphonsus Caldwell Cancer Care Center, Caldwell, Idaho, United States|Saint Alphonsus Medical Center Nampa, Nampa, Idaho, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States|Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States|PHARMACY Department Franciscan St. Francis Health ATTN:Jill Leslie, Pharm D, Indianapolis, Indiana, United States|Cancer Center of Acadiana at Lafayette General Medical Center, Lafayette, Louisiana, United States|Lafayette General Medical Center, Lafayette, Louisiana, United States|LSU Health Sciences Center-Shreveport, Shreveport, Louisiana, United States|University Health Shreveport, Shreveport, Louisiana, United States|Rcca Md Llc, Bethesda, Maryland, United States|University of Massachusetts Memorial Medical Center, ONC/Research Pharmacy, Worcester, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital - Inpatient Pharmacy, Ann Arbor, Michigan, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|St. Joseph Mercy-Brighton, Brighton, Michigan, United States|St. Joseph Mercy-Canton, Canton, Michigan, United States|Chelsea Community Hospital, Chelsea, Michigan, United States|St. John Hospital&Medical Center, Detroit, Michigan, United States|St. John Hospital&Medical Center-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Van Elslander Cancer Center, Pharmacy, Grosse Pointe Woods, Michigan, United States|Minnesota Oncology Hematology, PA, Edina, Minnesota, United States|Park Nicollet Frauenshuh Cancer center, Saint Louis Park, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|North Mississippi Medical Center Hematology and Oncology Clinic, Tupelo, Mississippi, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|NYU Winthrop Hospital - Oncology / Hematology department, Mineola, New York, United States|NYU Winthrop Hospital - Pharmacy Department, Mineola, New York, United States|Beth Israel Medical Center, New York, New York, United States|University of Rochester Investigational Drug Pharmacy, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States|FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|UC Health Physicians Office South,, West Chester, Ohio, United States|MUSC University Hospital, Charleston, South Carolina, United States|MUSC University of South Carolina, Investigational Drug Services, Charleston, South Carolina, United States|MUSC-Hollings Cancer Center, Charleston, South Carolina, United States|GHS Cancer Institute, Easley, South Carolina, United States|GHS Cancer Institute, Greenville, South Carolina, United States|GHS Cancer Institute, Greenville, South Carolina, United States|GHS Cancer Institute, Greer, South Carolina, United States|GHS Cancer Institute, Seneca, South Carolina, United States|GHS Cancer Institute, Spartanburg, South Carolina, United States|The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Utah Cancer Specialists, Murray, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|HSHS St. Vincent Hospital Regional Cancer Center at HSHS St. Vincent Hospital, Green Bay, Wisconsin, United States|HSHS St. Vincent Hospital, Green Bay, Wisconsin, United States|HSHS St. Vincent Hospital Regional Cancer Center at HSHS St. Mary's Hospital Medical Center, Green Bay, Wisconsin, United States|Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|St George Hospital - Hematology Department, Kogarah, New South Wales, Australia|Eastern Clinical Research Unit, Level 2, Box Hill, Victoria, Australia|UZ Ghent (University Hospital Ghent), Ghent, Belgium|Department of Haematology at UZ Leuven (7 th Floor), Leuven, Belgium|Hematology Department of CHU de Li�ge, Li�ge, Belgium|Hematology Department CHR Verviers, Verviers, Belgium|Horizon Health Network - The Moncton Hospital, Moncton, New Brunswick, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Lakeridge Health, Oshawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|CHU de Qu�bec - Universit� Laval, Quebec, Canada|Fakultn� Nemocnice Brno, Brno, Czechia|Fakultn� Nemocnice Hradec Kr�lov�, Hradec Kr�lov�, Czechia|Fakultn� nemocnice Olomouc, Olomouc, Czechia|V�eobecn� fakultn� Nemocnice v Praze, Prague, Czechia|Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Roskilde Hospital, Roskilde, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Oncologie Centre de Radiotherapie, Strasbourg, NC, France|Institut Bergoni�, Bordeaux, France|private Practice of Pr Philippe Rousselot, Le Chesnay, France|private Practice of Dr. Viviane Dubruille, Nantes cedex 1, France|H�pital L'Archet 1-CHU Nice, Nice, France|Institut de Canc�rologie du Gard - H�matologie Clinique, Nimes, France|Pr Mauricette Michallet Centre Hospitalier Lyon Sud, Pierre B�nite, France|INSERM CIC 1402 - CHU Poitiers, Poitiers, France|Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse cedex 9, France|Universit�tsklinikum Bonn, Bonn, RP, Germany|Uniklinikum Aachen, Aachen, Germany|Charit�, CVK, Med. Klinik m.S H�matologie und Onkologie, Berlin, Germany|Universit�tsklinikum Freiburg, Klinik f�r Innere Medizin I, Freiburg, Germany|Universit�tsklinikum Hamburg-Eppendorf, Onkologisches Zentrum, Hamburg, Germany|Universit�tsklinikum Jena, Klinik f�r Innere Medizin II, Jena Lobeda-Ost, Germany|Schwerpunktpraxis f�r H�matologie und Onkologie, Magdeburg, Germany|Semmelweis Egyetem I. Belgy�gy�szat, Budapest, Hungary|Debreceni Egyetem Klinikai K�zpont, Belgy�gy�szati In�zet Hematol�giai Tansz�k, Debrecen, Hungary|Petz Alad�r Megyei Oktat�K�rh�z, II. Belgy�gy�szati Oszt�ly �s Haematol�giai R�szleg, Gy�r, Hungary|Somogy Megyei Kaposi M�r Oktat� K�rh�z, Kaposv�r, Hungary|Szegedi Tudom�nyegyetem, AOK, Szent-Gy�rgyi Albert Klinikai K�zpont, II. sz., Szeged, Hungary|J�sz-Nagykun-Szolnok Megyei Het�nyi, G�za K�rh�z-Rendel?int�zet, Szolnok, Hungary|Hematology Department, Rambam Medical Centre, Haifa, Israel|Hematology Div. Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel|Azienda Ospedaliero-Universitaria ""Policlinico - Vittorio Emanuele"" - P.O. G. Rodolico, Catania, CT, Italy|USC Ematologia, A. O. Papa Giovanni XXIII, Bergamo, Italy|Policlinico S. Orsola - Malpighi,, Bologna, Italy|A.O. Brozu - P.O. Armando Businco, Cagliari, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|IRCCS - AOU San Martino_IST, Ematologia 1, Genova, Italy|Istituto Scientifico San Raffaele, Milano, Italy|Unit� di Ricerca Clinica, U.O. Ematologia Adulti, Monza, Italy|A.O.U. Policlinico Universit� degli Studi di Napoli ""Federico II"", Napoli, Italy|Dipartimento di ematologia, Reggio Calabria, Italy|ASL Roma 2 - Ospedale Sant'Eugenio, Roma, Italy|Hallym University Sacred Heart Hospital, Anyang-si, Korea, Republic of|Dong A University Hospital, Busan, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Seoul St. Mary's Hospital of the Catholic University of Korea, Seoul, Korea, Republic of|Hospital Angeles del Pedregal (S.A. de C.V.), Mexico City, DF, Mexico|Monterrey International Research Center, Monterrey, Nuevo LEON, Mexico|VU University Medical Center, Amsterdam, Noord Holland, Netherlands|Klinische Farrnacologie en Apotheek, Amsterdam, Noord-holland, Netherlands|Haukeland University Hospital Department of Hematology, Bergen, Norway|St. Olavs Hospital, Trondheim, Norway|Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne, Gdansk, Pomorskie, Poland|SPZOZ ZSM w Chorzowie Oddzial Hematologiczny, Chorzow, Poland|Samodzielny Publiczny Szpital Kliniczny im. A Miel?ckiego, ?UM w Katowicach, Katowice, Poland|Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Hematologii, Krak�w, Poland|SPSK, Klinika Hematoonkologii i Transplantacji Szpiku w Lublinie, Lublin, Poland|Universytet Medyczny im. Piast�w ?l?skich we Wroc?awiu Katedra i, Wroc?aw, Poland|Wojew�dzki Szpital Specjalistyczny im M. Kopernika, Klinika Hematologii Uniwersytetu Medycznego, ?�d?, Poland|National University Hospital, Main Building, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Univerzitn� Nemocnica Bratislava-Nemocnica sv. Cyrila a Metoda, Bratislava, Slovakia|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Department of Medical Oncology, University of Pretoria and Steve Biko, Pretoria, Gauteng, South Africa|Groenkloof Life hospital., Pretoria, Gauteng, South Africa|Department of Haematology, Cape Town, Western CAPE, South Africa|Hospital (Universitari(o)) Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitario La Princesa, Madrid, M�laga, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Cl�nic, Barcelona, Spain|Hospital Universitario Gregorio Mara��n, Madrid, Spain|Hospital Ram�n y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Cl�nico Universitario de Valencia, Valencia, Spain|Link�ping University Hospital, Link�ping, Sweden|Sk�ne University Hospital, Lund, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden|Norrlands University Hospital, Ume�, Sweden|Akademiska Hospital, Uppsala, Sweden|China Medical University Hospital, Taichung city, R.o.c., Taiwan|Chi-Mei Medical Center, Tainan City, R.o.c., Taiwan|Mackay Memorial Hospital, Taipei City, R.o.c., Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan|Division of Hematology, Department of Internal Medicine, Maharaj Nakorn Chiang Mai Hospital, Muang, Chiang MAI, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Phramongkutklao Hospital, Bangkok, Thailand|Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand|MI ""Cherkasy Regional Oncological Dispensary "" of Cherkasy Regional Council, Cherkasy, Ukraine|Regional Clinical Hospital in Ivano-Frankivsk, Hematology Department, Ivano-Frankivsk, Ukraine|Khmelnytskyi Regional Hospital, Hematology Department, Khmelnytskyi, Ukraine|State Institution ""National research center for radiation medicine of NAMS of Ukraine"",, Kyiv, Ukraine|State Institution ""National research center for radiation medicine of NAMS of Ukraine"", Kyiv, Ukraine|transplantation department of hemotology and transplantology division within Clinical Radiology, Kyiv, Ukraine|Chair of internal medicine #2., Kyiv, Ukraine|Kyiv City Clinical Hospital #9, Hematology department #1,, Kyiv, Ukraine|State Institution ""Institute of Blood Pathology and Transfusion Medicine NAMS of Ukraine"", Lviv, Ukraine|Catherine Lewis Centre, Hammersmith Hospital, London, Greater London, United Kingdom|Linda McCartney Centre, Liverpool, Merseyside, United Kingdom|Department of Clinical Haematology, Nottingham, Nottinghamshire, United Kingdom|Cancer & Haematology Centre, Churchill Hospital, Oxford, Oxfordshire, United Kingdom|Department of Haematology The Royal Hallamshire Hospital, Sheffield, South Yorkshire, United Kingdom|Heartlands Hospital, Birmingham, WEST Midlands, United Kingdom|St James's Institute of Oncology, Leeds, WEST Yorkshire, United Kingdom|Department of Haematology, Cardiff, United Kingdom|The Hope Clinical Trials Facility, Leicester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02130557,NCT02130557,35643868;35235189;33851349;31428530;30989330;29091516
oui,NCT02130648,Non Ivasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis,,Unknown status,No Results Available,Noninvasive Mucinous Cystadenocarcinoma of Ovary,Other: A sampling of blood,Analysis circulating free fetal DNA,"University Hospital, Montpellier",Female,"18 Years and older � (Adult, Older Adult)",,50,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,UF9039,October 2012,July 2015,April 2016,"May 5, 2014",,"December 31, 2014","Centre hospitalier Universitaire de Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02130648,NCT02130648,
oui,NCT02140918,Fludrocortisone in Healthy Volunteers (AFLUCO4),AFLUCO4,Completed,No Results Available,Healthy Volunteers,Drug: Fludrocortisone 100 ?g|Drug: Fludrocortisone 200 ?g|Drug: Fludrocortisone 400 ?g|Drug: Placebo,Phenylephrine mean blood pressor dose-response relationship.|Cardiac systolic and diastolic function assessed par transthoracic echocardiography during phenylephrine administration|Systemic hemodynamic parameters|Arterial stiffness : carotid-femoral pulse wave velocity|Central aortic hemodynamic parameters|Plasma parameters|Urinary parameters|Area under the plasma concentration versus time curve (AUC)|Plasma half-life of fludrocortisone|Total Body Clearance|Apparent volume of distribution,Rennes University Hospital,Male,20 Years to 25 Years � (Adult),Phase 2,16,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2013-004794-27,"July 1, 2014","April 20, 2016","April 20, 2016","May 16, 2014",,"August 29, 2018","Rennes University Hospital, Rennes, France",,https://ClinicalTrials.gov/show/NCT02140918,NCT02140918,
oui,NCT02145832,Fluconazole Versus Micafungin in Neonates With Candidiasis,TINN,Unknown status,No Results Available,Candidiasis,Drug: Fluconazole|Drug: Micafungin,Area Under the Concentration / Minimal Inhibitory Concentration ratio (AUC/MIC ratio),"Institut National de la Santé Et de la Recherche Médicale, France",All,24 Weeks to 42 Weeks   (Child),Phase 2|Phase 3,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C11-11|2012-001916-41,June 2014,May 2015,May 2017,"May 23, 2014",,"May 23, 2014","Antwerp, Rocourt, Liège, Louvain, Namur, Belgium|Paris, Lyon, Saint-Pierre de la Réunion, France|Roma, Torino, Catania, Foggia, Reggio Emilia, Italy|Rotterdam, Amsterdam, Utrecht, Isala, Netherlands|Malaga, Salamanca, Spain",,https://ClinicalTrials.gov/show/NCT02145832,NCT02145832,
oui,NCT02146963,Study of the BDNF-Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal,,Completed,No Results Available,Alcohol Dependence,,"Frequency of the Bdnf gene Val/Val, Val/Met and Met/Met phenotypes as a function of relapse|serum BDNF levels variations between inclusion and 6 months later (or 4 months if the participants does not come for the 4 months-follow-up).|existence of a psychiatric co-morbidity at the inclusion (major depression, schizophrenia, anxiety disorder)|presence of a psychiatric co-morbidity at 6 months after withdrawal (major depression, schizophrenia, anxiety disorder)","Centre Hospitalier Esquirol|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,180,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2014-A00613-44,May 2014,April 2016,April 2016,"May 26, 2014",,"January 31, 2017","Centre Hospitalier Esquirol, Limoges, France",,https://ClinicalTrials.gov/show/NCT02146963,NCT02146963,
oui,NCT02147210,Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1,GARRE,Completed,No Results Available,Kidney Transplantation,Other: biological analysis,Expression level of ephrin-B1 in biopsies from kidney transplant|Level of expression of the gene encoding for ephrin-B1|Kinetics of expression of ephrin-B1,"University Hospital, Toulouse",All,"18 Years and older � (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,13 194 02|AOL 2013,September 2013,December 2016,December 2016,"May 26, 2014",,"March 7, 2017","Service d'Anatomie Pathologique et Histologie-Cytologie H�pital Rangueil, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02147210,NCT02147210,
oui,NCT02147548,Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly,,Completed,No Results Available,Healthy Volunteers,Drug: etifoxine|Drug: lorazepam|Drug: Placebo,Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB),Biocodex,All,65 Years to 75 Years � (Older Adult),Phase 3,31,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",ETILANCE - ETI 175,December 2013,October 2015,October 2015,"May 26, 2014",,"July 27, 2016","Centre d'Investigation Clinique, CIC 1403 INSERM/CHRU, Lille, France",,https://ClinicalTrials.gov/show/NCT02147548,NCT02147548,30135030
oui,NCT02160119,Emotional and Change-related Attention in Autism,AUTATTEN,Completed,No Results Available,Autism Spectrum Disorders,Other: MRI-based techniques|Other: EEG,Neural responses to neutral and emotional stimuli,"Institut National de la Santé Et de la Recherche Médicale, France",All,"5 Years to 45 Years   (Child, Adult)",,120,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C13-26|2013-A01315-40,"May 27, 2014",May 2018,"May 27, 2018","June 10, 2014",,"August 30, 2021","University Hospital, Tours, France",,https://ClinicalTrials.gov/show/NCT02160119,NCT02160119,
oui,NCT02164279,Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children,peeDIAB2,Completed,No Results Available,Type 1 Diabetes Mellitus With Diabetic Nephropathy,Other: Urinary sample collection,Identify predictive non-invasive urinary biomarkers|Relation of urinary markers with patient characteristics,"University Hospital, Toulouse|Laboratory Inserm U858 Team 5 - RF-lab",All,"6 Years to 30 Years � (Child, Adult)",,150,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,12 356 03|2012-A01097-36,June 2013,"May 25, 2016","May 25, 2016","June 16, 2014",,"September 23, 2020","Purpan Children Hospital, Toulouse, France|Rangueil Hospital, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02164279,NCT02164279,
oui,NCT02172677,The Influence of Collective Schemas on Individual Memory,MULTIBRAIN_1,Completed,No Results Available,Episodic Memory,Behavioral: Episodic memory task|Device: fMRI,Blood Oxigen Level Dependent (BOLD) response as measured with fMRI|Episodic memory performances - % of accuracy,"Institut National de la Santé Et de la Recherche Médicale, France|La Région Basse-Normandie|Université de Caen Normandie|University Hospital, Caen|Ecole Pratique des Hautes Etudes|Equipement d'Excellence Matrice",All,20 Years to 38 Years   (Adult),Not Applicable,27,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C13-46|2014-A00126-41,October 2014,"October 14, 2016","October 14, 2016","June 24, 2014",,"November 6, 2017","GIP Cyceron, Caen, France",,https://ClinicalTrials.gov/show/NCT02172677,NCT02172677,
oui,NCT02174744,Concordance of Pain Detection in Patients by Doloplus� and Algoplus� Behavioural Scales,CALDOL,Unknown status,No Results Available,Pain in Elderly Patients Having Communication Disorders.,Other: numeric pain rating scale,"Pain scores on Algoplus� and Doloplus� pain scales|Different levels of Algoplus� pain scale: (0-1), (2-3), (4-5)","University Hospital, Clermont-Ferrand|Dr. Gis�le PICKERING (MCU, PH) Center of clinical pharmacology/CIC Inserm-1405 - Main investigator - Coordinating center|Ms Jo�lle DEVOT - Collaborator|Dr Patrice RAT - Investigator|Dr Chandra COLOM - Investigator|Mr Dieudonn� ENDOUGOU - Collaborator|Dr Cyril GUILLAUME - Investigator|Ms Nathalie ROUX - Collaborator|Dr Yves PASSADORI - Investigator|Ms Nathalie DANNENBERGER - Collaborator|Dr Micheline MICHEL - Investigator|Dr Sylvie CHAPIRO- Investigator|Dr Jean-Fran�ois VILLARD - Investigator|Dr Bernard WARY- Investigator|Dr Anne-C�cile BOURJAL - Investigator|Dr Catherine BLUNTZ - Investigator|Dr Fran�oise CAPRIZ - Investigator|Dr Marie FLOCCIA - Investigator|Dr J�r�me BOHATIER - Investigator|Ms Linh NGUYEN PHUONG - Collaborator",All,65 Years and older � (Older Adult),,210,Other,Observational,Time Perspective: Cross-Sectional,CHU-0190,January 2014,July 2014,September 2014,"June 26, 2014",,"June 26, 2014","CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT02174744,NCT02174744,
oui,NCT02175264,Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia,HCD GENE,Completed,No Results Available,Isolated Non Syndromic Left CDH With Postero Lateral Diaphragmatic Defect With Good Perinatal Outcome,Genetic: Blood sample,genes responsible for isolated CDH|prevalence of new identified genes in a cohort of CDH,Assistance Publique - Hôpitaux de Paris,All,"3 Months and older   (Child, Adult, Older Adult)",,73,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,CRC12074,June 2014,February 2016,May 2016,"June 26, 2014",,"June 24, 2016","Hopital béclère, Clamart, France",,https://ClinicalTrials.gov/show/NCT02175264,NCT02175264,
oui,NCT02176941,Telomeres and Arterial Aging,TELARTA,Unknown status,No Results Available,Atherosclerotic Disease,,Telomere Length (LT) dynamics|Skin telomere length|Subcutaneous fat telomere length,"Central Hospital, Nancy, France|National Research Agency, France|Institut National de la Sant� Et de la Recherche M�dicale, France|Assistance Publique Hopitaux De Marseille|University of Lorraine",All,"20 Years and older � (Adult, Older Adult)",,340,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,2014-A00298-39,June 2014,November 2016,November 2016,"June 27, 2014",,"June 16, 2016","AP H�pitaux de Marseille, Marseille, France|Chu Nancy, Nancy, France",,https://ClinicalTrials.gov/show/NCT02176941,NCT02176941,33955230;29242238
oui,NCT02178969,Short Term Observational Study in DEB Patients,,Completed,No Results Available,Dystrophic Epidermolysis Bullosa,,"Wound Surface Area (WSA) of patient- and investigator-selected wounds|Wound Surface Area (WSA) as a percentage of Body Surface Area (BSA) in patients with DEB|The number, severity and relationship to study procedures of adverse events (AEs) and serious AEs (SAEs)",Shire|Takeda,All,"Child, Adult, Older Adult",,29,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,SHP-608-002,"June 24, 2014","February 23, 2015","February 23, 2015","July 1, 2014",,"March 17, 2021","Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Premier Specialists Pty Ltd, Kogarah, Australia|Salzburger Landeskliniken, Salzburg, Austria|Fakultni nemocnice Brno, Brno, Czechia|Service de G�n�tique et INSERM UMR 1163, Laboratoire de G�n�tique des maladies cutan�es - Institut Imagine, Paris, France|Universit�tsklinikum Freiburg, Freiburg im Breisgau, Germany|Ospedale Pediatrico Bambino Ges�, Roma, Italy|Istituto Dermopatico Dell'immacolata IRCCS, Rome, Italy",,https://ClinicalTrials.gov/show/NCT02178969,NCT02178969,35964087
oui,NCT02183779,PORH and Response to Cold in Raynaud's Phenomenon.,REFRAIN,Unknown status,No Results Available,Raynaud Disease|Hyperemia|Cold,Procedure: post-occlusive hyperemia|Procedure: cooling box|Drug: L-NMMA and Fluconazole dermic injection,post occlusive hyperemia amplitude|post occlusive hyperemia amplitude with anesthetic treatment|cold-induced vasoconstriction amplitude|cold-induced vasoconstriction amplitude with anesthetic treatment,"University Hospital, Grenoble",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",DCIC 14 02,June 2014,October 2016,June 2017,"July 8, 2014",,"December 9, 2015","Centre d'investigation clinique CIC1406, GRENOBLE cedex9, France",,https://ClinicalTrials.gov/show/NCT02183779,NCT02183779,
oui,NCT02184676,T1D Risk Assessment in Kids With Relatives,TRAKR,Completed,No Results Available,Type 1 Diabetes,Biological: Analysis of early immune modifications|Other: Collection of clinical and socio-demographic data,Autoreactive T lymphocytes|Metagenomic signatures|Metabolic signatures|Environmental factors|Incidence of autoantibodies,"Assistance Publique - H�pitaux de Paris|Institut National de la Sant� et de la Recherche M�dicale (INSERM) U1016 - Institut Cochin, Immunology of Diabetes Team, Paris, France|INSERM U1153, Epidemiology Research Unit on Perinatal Health and Women and Children Health, Port-Royal Hospital, Paris, France|Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement|Commissariat A L'energie Atomique",All,"1 Day and older � (Child, Adult, Older Adult)",Not Applicable,512,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,P130405|ID RCB : 2014-A00453-44,"May 28, 2015","May 17, 2019","May 17, 2019","July 9, 2014",,"April 5, 2021","Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02184676,NCT02184676,
oui,NCT02188862,Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region,,Completed,No Results Available,Rheumatic Heart Disease|Mitral Stenosis,,Rheumatic heart disease diagnosis|Mitral stenosis diagnosis,"University of Oxford|Ministry of Health, Fiji|Fiji National University|Institut National de la Santé Et de la Recherche Médicale, France|Institut Necker Enfants Malades|Centre Hospitalier Territorial de Nouvelle-Calédonie|University of Melbourne",All,"5 Years and older   (Child, Adult, Older Adult)",,2372,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,PACIFICRHDGEN,September 2012,December 2013,December 2013,"July 14, 2014",,"July 15, 2014","Colonial War Memorial Hospital, Suva, Fiji|Centre Hospitalier Territorial de Nouvelle Caledonie, Noumea, New Caledonia|Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT02188862,NCT02188862,
oui,NCT02189460,Effect of Normal Aging on Language Processing,SEMVIE,Terminated,No Results Available,Cognition,,Blood Oxygen Level Dependent functional MRI|Anatomical MRI,"University Hospital, Grenoble",All,"30 Years and older � (Adult, Older Adult)",,33,Other,Observational,Observational Model: Other|Time Perspective: Prospective,2014-AZ00569-38,July 2014,July 2018,July 2018,"July 14, 2014",,"October 12, 2018","IRMaGe facility, Grenoble, France",,https://ClinicalTrials.gov/show/NCT02189460,NCT02189460,
oui,NCT02210299,TEXTO : Total EXposure To Organic Pollutants,TEXTO,Withdrawn,No Results Available,Healthy,Other: Exposure study,Feasibility recruitment|Protocol validation,"Rennes University Hospital|Institut de Recherche en Sant�, Environnement et le Travail, France|Laboratoire d'Etude des R�sidus et Contaminants dans les Aliments|Institut national de l'environnement industriel et des risques|National Agency for Sanitary Safety of the Food of the Environment and Labor",All,6 Months to 18 Months � (Child),Not Applicable,0,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,35RC13_8917_TEXTO|2014-A00782-45|14/25-941|140682B-82,September 2014,May 2015,May 2015,"August 6, 2014",,"June 10, 2015","Rennes Hospital University, Rennes, Brittany, France",,https://ClinicalTrials.gov/show/NCT02210299,NCT02210299,
oui,NCT02212288,Antioxidant Signature in Adult Patients With Phenylketonuria,StressOX-PCU,Completed,No Results Available,PKU|Hyperphenylalaninemia,Other: Blood sample|Other: Urine sample,Plasma concentrations of oxidative stress markers|Plasma concentrations of amino acids and organic acids concentration,"University Hospital, Tours|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",,20,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,PHAO14/FM-StressOX-PCU,September 2014,January 2015,January 2015,"August 8, 2014",,"January 16, 2017","University Hospital of TOURS, Tours, I&L, France",,https://ClinicalTrials.gov/show/NCT02212288,NCT02212288,
anrs,NCT02212379,Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL,,Completed,Has Results,HIV-1 Infection,Drug: raltegravir and etravirine,"Percentage of Participants With Successful Virological Suppression at Weeks 48 and 96|Percentage of Patients With Therapeutic Success at Week 48 and Week 96|Percentage of Patients With Trial Treatment Interruption at Week 48 and Week 96|Percentage of Patients With With Grade Virological Failure (HIV-RNA Plasma VL Between 51 and 200 Copies/mL)|Median Time of Virological Failure|Percentage of Patients With High Grade of Virological Failure Defined as HIV RNA > 200 Copies/mL|Number of Patients With RAL and/or ETR Resistance Mutations Among Those With Virological Failure|Factors Associated With the Occurrence of Plasma HIV-RNA Viral Load > 50 Copies/mL|Evolution of Total Cell-associated HIV-DNA|Evolution of CD4+, CD8+ T Cells Counts and CD4/CD8 Ratio|Number of Participants Experiencing Adverse Events and Effects|Evolution of Metabolic Parameters (Fasting Triglycerides, Total Cholesterol, HDL-cholesterol, LDL-cholesterol and Fasting Glycemia)|Evolution of the Calibrated 5-year Framingham Risk Score|Percent Change of Renal Function|Evolution of Body Fat Distribution From Day 0 to W96 (DXA Scan Sub-study, 80 Patients)|Sub-study: Bone Mineral Density|Percentage of Participants With Detectable Seminal HIV-RNA Viral Load at Week 48|Inflammatory Parameters|Percentage of Participants Reporting a Very Good or an Excellent Quality of Life at Day 0, Weeks 48 and 96|Percentage of Participants Compliant With Treatment Program.|Evolution of the Ovarian Reserve From D0 to W48 Measured by AMH on Frozen Aliquots|Evolution of the Level of MCP1 From D0 to W48 on Frozen Samples|Sub-study in Women : Comparison of the Metabolic/Inflammatory Profile in Women According to Their Ovarian Reserve and Menopausal Status at D0 and Its Evolution up to Week 96|Sub-study in Women : Comparison of the Evolution Fat Distribution Measured by DXA Scan and Body Weight According to AMH Status","ANRS, Emerging Infectious Diseases|Merck Sharp & Dohme LLC|Janssen-Cilag Ltd.",All,"45 Years and older � (Adult, Older Adult)",Phase 2,170,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-000828-24|ANRS 163 ETRAL,January 2015,October 2017,April 2018,"August 8, 2014","February 5, 2021","April 27, 2021","H�pital Avicenne, Bobigny, France|H�pital Jean Verdier, Bondy, France|H�pital Saint Andr�, Bordeaux, France|H�pital Bic�tre, Le Kremlin Bic�tre, France|H�pital Croix Rousse, Lyon, France|H�pital Sainte marguerite, Marseille, France|H�pital Gui de Chauliac, Montpellier, France|CHU H�tel Dieu, Nantes, France|H�pital de l'Archet, Nice, France|H�pital Saint Louis, Paris, France|H�pital Piti�-Salp�tri�re, Paris, France|H�pital Cochin, Paris, France|H�pital Necker, Paris, France|H�pital Bichat Claude Bernard, Paris, France|H�pital Europ�en Georges Pompidou, Paris, France|H�pital Bretonneau, Tours, France|Hospital de Bellvitge, Barcelona, Spain|Hospital de la santa Creu i San Pau, Barcelona, Spain|Hospital Clinic, Barcelona, Spain","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form: Study protocol, Statistical Analysis"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02212379/Prot_SAP_ICF_000.pdf|""Informed Consent Form: Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02212379/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02212379,NCT02212379,31269208
oui,NCT02212483,Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients,ECENVIR,Completed,No Results Available,Asthma,Other: First home intervention with advice|Other: First home intervention without any advice|Other: Final home visit,Therapeutic pressure versus asthma control|Drug consumption and medical care|Advices compliance|Quality of life questionnaire|Indoor pollutants concentrations,"Rennes University Hospital|Ecole des Hautes Etudes en Santé Publique|Institut de Recherche et Documentation en Economie de la Santé, France|Institut National de la Santé Et de la Recherche Médicale, France",All,"6 Years to 44 Years   (Child, Adult)",Not Applicable,107,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,35RC12_9713_ECENVIR|2012-A01414-39|12/42-875|13.424|913428,"September 5, 2014","December 31, 2018","March 5, 2020","August 8, 2014",,"August 26, 2021","Strasbourg UH, Strasbourg, Alsace, France|Aix-en-Provence Hospital, Aix-en-Provence, France|Bordeaux University Hospital, Bordeaux, France|Caen University Hospital, Caen, France|Chalon, Chalon-sur-Saone, France|Chauny Hospital, Chauny, France|Dijon University Hospital, Dijon, France|Grenoble University Hospital, Grenoble, France|Lille UH, Lille, France|Macon Hospital, Macon, France|Marseille European Hospital, Marseille, France|Marseille University Hospital, Marseille, France|Nantes University Hospital, Nantes, France|Reims University Hospital, Reims, France|Rouen University Hospital, Rouen, France|Vire Hospital, Vire, France",,https://ClinicalTrials.gov/show/NCT02212483,NCT02212483,
oui,NCT02212522,Genetic and Environmental Risk Factors of Type 1 Autoimmune Diabetes and Its Early Complications,ISIS-DIAB,Unknown status,No Results Available,Diabetes Mellitus|Insulin-Dependent,Other: Collect of environmental data on T1D patients before diagnosis|Genetic: Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Other: Collect of clinical data on the disease and its evolution|Other: Collect of environmental data on French controls (age-matched for T1D patients),"Genetic and environmental risk factors of T1D predisposition|Genetic and environmental risk factors of T1D complications|Identify G and E factors influencing the process of remaining beta cells' destruction during the first 3 years after diagnosis|Identify G factors (pharmacogenomics) of the individual response to insulin using the effective insulin dose as a phenotype over a period of 2 years|Undertake a prospective research of G and E risk factors of ""death in bed"" syndrome in diabetic adolescents","Assistance Publique - H�pitaux de Paris|Centre National de G�notypage|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"6 Months and older � (Child, Adult, Older Adult)",,20000,Other,Observational,Observational Model: Case-Control,AOM 08049,November 2004,December 2017,June 2018,"August 8, 2014",,"June 28, 2016","Inserm U986, Le Kremlin Bic�tre, France",,https://ClinicalTrials.gov/show/NCT02212522,NCT02212522,27682602
oui,NCT02214511,Biomarkers of Social Sensitivity in Major Depression,SENSO,Completed,No Results Available,Major Depressive Disorder,Behavioral: emotional facial stimuli|Behavioral: Cyberball game,"Rapid facial reactions : milliVolts amplitude of electromyographic signal of zygomaticus, corrugator, depressor & frontalis muscles|Implicit pro-social behavior : invested money during a 4-round trust game|Explicit pro-social behavior : affiliation desire measured by a questionnaire|Self esteem assessed by questionnaires mediates social pain after rejection and pro-social behavior|Systemic inflammation mediates social pain after rejection and pro-social behavior","Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C13-31|2013-A01484-41,"October 23, 2014",March 2017,"March 1, 2017","August 12, 2014",,"August 30, 2021","ICM, Pitié Salpêtrière Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02214511,NCT02214511,
oui,NCT02220114,Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy,SoluWest,Completed,No Results Available,Infantile Spasms,Drug: Vigabatrin: Vigabatrin new ST formulation then Sabril®,"Individual adherence to the new Soluble Tablets (ST) formulation of Vigabatrin (VGB) using Medication Event Monitoring System (MEMS)|Adherence to the new ST formulation and to Sabril® granules for oral solution, by treatment unit accountability|palatability of the new ST formulation and of Sabril® ""granules for oral solution"".|Ease of use of the new ST formulation and of Sabril® ""granules for oral solution"".|Safety and tolerance|pharmacokinetic parameters for the new ST formulation (1 sample). Pharmacokinetic parameters for the new ST formulation (population PK) : Area under the curve (AUC), Tmax, Cmax, T½, Ka, V/F, Cl/F|Evaluation of the taurine plasma levels in children treated by vigabatrin. Taurine plasma concentration will be measured and a relationship between vigabatrin exposition and taurine plasma levels will be sought.","Orphelia Pharma|Institut National de la Santé Et de la Recherche Médicale, France|Hospices Civils de Lyon|National Research Agency, France",All,1 Month to 6 Years   (Child),Not Applicable,38,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TGO-VGB-III-01,May 2014,December 2016,December 2016,"August 19, 2014",,"April 24, 2018","Service de neurologie pédiatrique - CHU, Amiens, France|Service de neurologie pédiatrique - CHU, Angers, France|Service de neuropédiatrie - CHU Pellegrin Enfants, Bordeaux, France|Service de neurologie infantile - Hôpital Salengro, Lille, France|Service de nuerologie pédiatrique - Hôpital Femme Mère Enfant, Lyon, France|Service de neurologie pédiatrique - Hôpital de la Timone, Marseille, France|Service de neurologie pédiatrique - Hôpital Necker Enfants Malades, Paris, France|Service de neuropédiatrie - Hôpital Robert Debré, Paris, France|Service de neurologie pédiatrique - Hôpital Sud, Rennes, France|Centre référent des épilepsies rares pédiatrique associé - Hôpital de Hautepierre, Strasbourg, France|Service de neuropédiatrie - Hôpital Purpan, Toulouse, France|Service de neuropédiatrie - Hôpital de Clocheville, Tours, France",,https://ClinicalTrials.gov/show/NCT02220114,NCT02220114,
oui,NCT02225717,Identification of Spontaneous Delivery Markers,TrophY2,Completed,No Results Available,Preterm Labor (24 GA - 32 GA),Procedure: Cervicovaginal swab,Delivery|Delivery before 34 GA|composite Prenatal maternal care|composite Neonatal outcome|composite Obstetric outcome,Assistance Publique - H�pitaux de Paris,Female,"18 Years and older � (Adult, Older Adult)",Not Applicable,238,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,P140502,"December 14, 2014","November 14, 2017","April 16, 2018","August 26, 2014",,"June 18, 2018","Maternit� Port Royal-Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT02225717,NCT02225717,
oui,NCT02226731,Intrauterine Tamponade With a Belfort-Dildy Balloon in the Treatment of Immediate Postpartum Hemorrhage,TUB,Completed,No Results Available,Immediate Postpartum Hemorrhage,Device: Early Belfort-Dildy Balloon|Device: Late Belfort-Dildy balloon,Proportion of women who received at least 3 RBC units for the treatment of PPH and /or who had a calculated peripartum blood loss > 1000 ml.|Other markers of severe hemorrhage|other Genital tract infection,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,405,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P130914,"February 8, 2017","June 30, 2020","August 18, 2020","August 27, 2014",,"September 22, 2020","CHI de Poissy Saint Germain en Laye, Poissy, France",,https://ClinicalTrials.gov/show/NCT02226731,NCT02226731,32609374
oui,NCT02229630,Diffusion-weighted Cerebral MRI and Intra Uterine Growth Restriction.,REDIFF,Completed,No Results Available,Pregnant Women With Foetuses Presenting With Intra-uterine Growth Restriction,Radiation: Pregnant women with intra-uterine growth restricted Foetuses,Poor neonatal status|Neonatal status at neonatology unit discharge|Neurological development,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,82,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,P130915|IDRCB: 2014-A00640-47,"March 11, 2015","October 29, 2017","October 17, 2019","September 1, 2014",,"April 5, 2021","Hôpital Armand Trousseau, Paris, France",,https://ClinicalTrials.gov/show/NCT02229630,NCT02229630,
oui,NCT02236832,Study of the Neural Basis of Analogical Reasoning,ANALOG,Completed,No Results Available,Frontotemporal Dementia|Progressive Supranuclear Palsy|Healthy Subjects,Device: transcranial magnetic stimulation|Other: MRI imaging|Other: EEG recording|Behavioral: Neuropsychological examination,Performance in the implicat task|Performance in the Similitude task|recording of EEG|Analysis of MRI,"Institut National de la Santé Et de la Recherche Médicale, France|Fondation pour la Recherche Médicale",All,"20 Years to 85 Years   (Adult, Older Adult)",Not Applicable,130,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C14-17'|140662B-31|2014-A00649-38,February 2015,February 2021,February 2021,"September 11, 2014",,"April 1, 2022","ICM (Institut du cerveau et de la Moelle épinière), Paris, France",,https://ClinicalTrials.gov/show/NCT02236832,NCT02236832,
oui,NCT02247752,Follow-up of HBsAg Inactive Carriers Study,PIBAC,Completed,No Results Available,Hepatitis B,Other: inactive carrier,Incidence of unfavourable liver events,Centre Hospitalier R�gional d'Orl�ans|INSERM U785-CNR H�pital Paul Brousse 94800 VILLEJUIF|Facult� de math�matiques ORLEANS,All,"18 Years to 70 Years � (Adult, Older Adult)",Not Applicable,619,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CHRO -2014-02,"September 16, 2014","March 31, 2016","February 4, 2022","September 25, 2014",,"April 6, 2022","Ch General Du Pays D'Aix, Aix en Provence, France|CH d'AVIGNON, Avignon, France|Clinique de La Chataigneraie, Beaumont, France|Medical Center Besancon, Besancon, France|Clinical Center Bourgoin Jallieu, Bourgoin Jallieu, France|Hopital Sainte Camille, Bry sur Marne, France|Ch de Caen, Caen, France|Ch Sud Fracilien Jean Jaures, Corbeil essonnes, France|CH CREIL, Creil, France|Ch de Creteil, Creteil, France|CH de GONESSE, Gonesse, France|Clinique Du Palais, Grasse, France|Ch D'Hyeres, Hyeres, France|Ch de Lagny Marne La Valee, Jossigny, France|Chd Vendee, La Roche sur yon, France|Ch Du Mans, Le Mans, France|Medical Center La Sauvegarde, Lyon, France|Ch de Meaux, Meaux, France|CH MELUN, Melun, France|Ch Montelimar, Montelimar, France|Ch de Montfermeil, Montfermeil, France|Clinical Center Montpellier, Montpellier, France|Medical Center Nanterre, Nanterre, France|CHR d'ORLEANS, Orleans, France|Medical Center Paris 7, Paris, France|Ch de Pau, Pau, France|Hopital Saint Jean, Perpignan, France|Ch de La Region Annnecienne, Pringy, France|Ch Saint Brieuc, Saint Brieuc, France|Ch de Saint Denis, Saint Denis, France|Ch de Vannes, Vannes, France|Chi Villeneauve Saint Georges, Villeneuve Saint Georges, France",,https://ClinicalTrials.gov/show/NCT02247752,NCT02247752,
oui,NCT02259127,A Randomised Trial of Dolutegravir (DTG)-Based Antiretroviral Therapy vs. Standard of Care (SOC) in Children With HIV Infection Starting First-line or Switching to Second-line ART,,"Active, not recruiting",No Results Available,HIV Infection,Drug: DTG,"Difference in proportion with failure (clinical or virological)|Difference in proportion with clinical or virological failure (as defined above)|Time to any new or recurrent AIDS defining event (WHO 4) or severe WHO 3 events adjudicated by the Endpoint Review Committee|Proportion of children with viral load suppression <50 c/ml|Proportion of children with viral load suppression <400 c/ml|Rate of clinical events : WHO 4, severe WHO 3 events and death|Change in CD4 count and percentage and CD4/CD8 ratio from baseline|Proportion developing new resistance mutations in those with viral load > 400 c/ml|Change in total cholesterol, triglycerides and lipid fractions (LDL, HDL)|Incidence of serious adverse events|Incidence of new clinical and laboratory grade 3 and 4 adverse events|Incidence of adverse events (of any grade) leading to treatment modification|Health-related Quality of Life Questionnaire|Adherence Questionnaire|Acceptability Questionnaire","PENTA Foundation|Institut National de la Santé Et de la Recherche Médicale, France|Program for HIV Prevention and Treatment (PHPT)|Medical Research Council Clinical Trials Unit at University College London (MRC CTU at UCL)",All,"28 Days to 18 Years   (Child, Adult)",Phase 2|Phase 3,792,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ODYSSEY (PENTA 20)|2014-002632-14,"September 20, 2016",June 2021,May 2023,"October 8, 2014",,"April 29, 2021","Universitata Frankfurt, Frankfurt, Germany|UkE Eppendorf Hamburg, Hamburg, Germany|Centro Materno-Infantil de Norte, Porto, Portugal|King Edward VIII Hospital, Durban, South Africa|Africa Health Research Institute (AHRI), Hlabisa, South Africa|PHRU Klerksdorp, Klerksdorp, South Africa|Kid-Cru, Parow, South Africa|PHRU, Soweto, South Africa|Hospital San Joan de Defu, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital La Paz, Madrid, Spain|Nakornping Hospital, Chiang Mai, Thailand|Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand|Khon Kaen Hospital, Khon Kaen, Thailand|Mahasarakam Hospital, Maha Sarakham, Thailand|Prapokklao Hospital, Mueang Chanthaburi District, Thailand|Phayao Hospital, Phayao, Thailand|Baylor, Kampala, Uganda|JCRC, Kampala, Uganda|MUJHU, Kampala, Uganda|JCRC, Mbarara, Uganda|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Leeds General Infirmary, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Great Ormand Street Hospital, London, United Kingdom|Kings College Hospital, London, United Kingdom|St Mary's Hospital, London, United Kingdom|UZCRC, Harare, Zimbabwe",,https://ClinicalTrials.gov/show/NCT02259127,NCT02259127,36055295;35868341;34965338;34817414;33446115;32763217
oui,NCT02261870,Detection of Acute Graft Rejection in Heart Transplant Patients by Estimation of T2,DRAGET,Completed,No Results Available,Acute Graft Rejection|Heart Transplantation,Device: MRI T2 quantification,"Sensitivity and specificity of myocardial T2 assessed with MRI for the diagnosis of histological heart graft rejection (with 95% confidence interval).|Incidence of histological or clinical rejection within months of a couple MRI/biopsy with normal biopsy (grade<2R).|Complications with MRI and with biopsies.|Magnitude of better tolerability of MRI over biopsies for the patient.|Inter-observer reproducibility of T2 quantification with MRI and of pathological grading of the biopsies.|Level of confidence, at the end of the study, of the expert-physicians of each centre concerning the use of T2 quantification as an alternative to routine biopsies.","Central Hospital, Nancy, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,116,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2014-A00848-39|CIC1433,"February 18, 2015","February 27, 2020","February 27, 2020","October 10, 2014",,"May 12, 2020","Hospices Civils de Lyon, Bron, France|CHU Grenoble, La Tronche, France|CHRU Nancy Brabois, Nancy, France|CHU de Nantes, Nantes, France|H�pital Europ�en Georges Pompidou, Paris, France|Groupe Hospitalier Piti�-Salp�tri�re, Paris, France|CHU Bordeaux, Pessac, France|CHU de Rennes, Rennes, France|Hopitaux Universitaires de Strasbourg, Strasbourg, France|CHU de Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT02261870,NCT02261870,26515686
oui,NCT02264431,Severe Obesity Outcome Network Cohort (SOON),SOON,Recruiting,No Results Available,Obesity|Obstructive Sleep Apnea|Sleep,,Sleep breathing disorders|Sleep habits,"University Hospital, Grenoble|Act For Chronic Diseases|HP2 laboratory INSERM U1042|University Grenoble Alps",All,"18 Years and older � (Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1327|2013-A01097-38,January 2014,January 2024,January 2024,"October 15, 2014",,"January 27, 2020","Grenoble University Hospital, Grenoble, Rh�ne-Alpes, France",,https://ClinicalTrials.gov/show/NCT02264431,NCT02264431,33230959
oui,NCT02265094,Associative Memory in Autism Spectrum Disorder,MEM-TA,Unknown status,No Results Available,Autistic Disorder,Other: Electroencephalography|Behavioral: Neuropsychological assessment,Index of discrimination obtained with the task of associative memory,"University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France|Amiens University Hospital",All,"10 Years to 18 Years   (Child, Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2014- A00481-46,"December 22, 2015",December 2018,December 2019,"October 15, 2014",,"February 20, 2018","Caen University Hospital, Caen, France",,https://ClinicalTrials.gov/show/NCT02265094,NCT02265094,
oui,NCT02267304,"Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Morphine and Naloxone on Motivation (MBBAnalgesic)",MBBAnalgesic,Completed,No Results Available,Healthy,"Drug: 50 mL of sodium chloride (0,9%)|Drug: Morphine 0,05mg/kg|Drug: Naloxone 10mg",Cost Accumulation Slope (AU.),"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 50 Years   (Adult),Phase 2,37,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",C13-02|2013-003487-31,"October 30, 2013",August 2016,"August 30, 2016","October 17, 2014",,"August 26, 2021","CIC Neurologie GHPS, Paris, France",,https://ClinicalTrials.gov/show/NCT02267304,NCT02267304,
oui,NCT02268071,Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care (STOP-Trial),,Completed,No Results Available,Hypertension,Drug: Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence,The rate of normotensive patients at 1 year (i.e HBPM <135/85 mmHg)|The rate of normotensive patients at 3 months (i.e HBPM <135/85 mmHg)|The rate of normotensive patients at 6 months (i.e HBPM <135/85 mmHg)|The rate of normotensive patients at 9 months (i.e HBPM <135/85 mmHg)|Evolution of the quality of life scale (part of SF36),"Central Hospital, Nancy, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,403,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-001773-14,"March 10, 2015","October 21, 2020","October 21, 2020","October 20, 2014",,"May 13, 2021","Cabinet de groupe Dr Birg�, Boulay, France|Cabinet de groupe Dr BAUDOIN, Bouzonville, France|Cabinet de groupe Dr Gries, Dettwiller, France|Cabinet du Dr Di Patrizio, Dombasle Sur Meurthe, France|Cabinet m�dical Dr Bouch�, Dombasle Sur Meurthe, France|Cabinet m�dical du Dr Chevillard, Dombasle Sur Meurthe, France|Maison de sant� Dr Millet-Malingrey, Gondrecourt Le Chateau, France|Maison de Sant� Pluridisciplinaire de GROSTENQUIN, Grostenquin, France|Cabinet de groupe Dr Rougerie, Hatten, France|Cabinet du Dr Plane, Jarville La Malgrange, France|Cabinet m�dical prof Boivin, Laxou, France|Cabinet du Dr LARQUE, Le Palais-sur-Vienne, France|Cabinet de groupe Dr Faure Christian, Limoges, France|Cabinet Dr Bleynie, Limoges, France|Cabinet du Dr Poyeton, Neufchateau, France|Cabinet Dr Delage, Nexon, France|Cabinet de groupe Dr Masson,, Remilly, France|Cabinet de groupe en p�le de sant�, Revigny-sur-Ornain, France|Cabinet du Dr Louyot-Keller, Saint-Avold, France|Cabinet m�dical du Dr Carrier, Saint-Max, France|Maison de Sant� du Neuhof, Strasbourg, France|cabinet de groupe Dr Steyer, Talange, France|Centre d'Investigation Clinique module plurith�matique 1433 Inserm/CHRU de Nancy, Vandoeuvre Les Nancy, France|cabinet du Dr Gerard, Vicherey, France",,https://ClinicalTrials.gov/show/NCT02268071,NCT02268071,
oui,NCT02270489,Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA,AFF009,Completed,No Results Available,Multiple System Atrophy|Neurodegenerative Diseases,Biological: AFFITOPE® PD01A + Adjuvant|Biological: AFFITOPE® PD03A + Adjuvant|Biological: Adjuvant without active component,Number of patients who withdraw due to Adverse Events (AEs)|Occurrence of Adverse Events and Serious Adverse Events|Physical Examination|Vital signs|Safety related evaluation of MRI results of patients' brain after visit 5 and visit 8 compared to baseline|Clinical significance/ changes in laboratory parameters over time (study period)|Body mass|Neurological Examination|Immunological activity of AFFITOPE® vaccines PD01A and PD03A.|Change in motor symptoms at Visit 5 and Visit 8 compared to baseline|Change in non-motor symptoms at Visit 5 and Visit 8 compared to baseline,"Affiris AG|University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France|Forschungszentrum Juelich|University Hospital, Toulouse",All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 1,30,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,AFFiRiS 009|2014-000567-40,"December 11, 2014","April 18, 2017","April 18, 2017","October 21, 2014",,"June 5, 2017","University Hospital Bordeaux (Pellegrin Hospital), Bordeaux Cedex, France|University Hospital Toulouse, Toulouse Cedex 9, France",,https://ClinicalTrials.gov/show/NCT02270489,NCT02270489,32882100
oui,NCT02279680,Associative Memory in Adults With an Autism Spectrum Disorder,MEM-T2A,Unknown status,No Results Available,Autistic Disorder,Device: Electroencephalography|Behavioral: Neuropsychological assesments,The associative memory index|theta and gamma oscillations during the associative memory task,"University Hospital, Caen",All,18 Years to 30 Years � (Adult),Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2013-AO1800-45,June 2014,December 2015,December 2016,"October 31, 2014",,"October 31, 2014","UMR1077 Inserm/EPHE/UCBN, Caen, France",,https://ClinicalTrials.gov/show/NCT02279680,NCT02279680,
oui,NCT02281916,Safety Study of P28GST Treatment in Crohn's Disease Patients,ACROHNEM,Completed,No Results Available,Crohn's Ileocolitis,Drug: P28GST,Number of participants wtih adverse events as a measure of safety and tolerability|Main immunologic and inflammatory blood and tissue markers.|Appearance or not of a clinical recurrence assessed by CDAI (Crohn Disease Activity Index) and confirmed by a morphologic examination.|Intestinal microbiota,"University Hospital, Lille|National Research Agency, France|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013_02|2013-000595-15,March 2014,February 2018,February 2018,"November 4, 2014",,"June 11, 2018","Centre hospitalier, Amiens, France|Centre Hospitalier de Boulogne, Boulogne sur mer, France|Centre Hospitalier Dunkerque, Dunkerque, France|CHRU, Hôpital Claude Huriez, Lille, France|Centre Hospitalier,, Valenciennes, France",,https://ClinicalTrials.gov/show/NCT02281916,NCT02281916,31212833
oui,NCT02282176,TINN2: Treat Infection in NeoNates 2,TINN2,Withdrawn,No Results Available,Bronchopulmonary Dysplasia,Drug: Azithromycin|Drug: Placebo,"The proportion of surviving infants without CLD (Chronic Lung Disease) in the azithromycin treatment group when compared to placebo at 36 weeks post-menstrual age.|Mortality rate (at 28 days, 36 weeks PMA, 2 years)|Severity of CLD (Chronic Lung Disease) according to NIH definition|Microbiology assessment|Inflammation Markers|Duration of positive pressure respiratory support (i.e. conventional mechanical ventilation, nasal ventilation, continuous positive airway pressure, CPAP) and supplemental oxygen|Emergence of resistance to azithromycin in Ureaplasma spp. isolated from endotracheal or nasopharyngeal samples at baseline, days 5, 10 and 21|Resistance to azithromycin among microbes isolated from stool or rectal swab obtained at baseline and day 21|Plasma concentrations|Exposure to antibiotics other than azithromycin during the hospital stay|Development of complications of prematurity|Number of Adverse Events|Number of participants with dysrhythmic episodes and QTc interval|C-Reactive Protein|Neurodevelopmental assessment: Assessment of neurodevelopment using the 3rd edition of the Bayley Scales of Infant Development at the corrected age of 24 months|Respiratory function assessment: Assessment of respiratory symptoms using a validated International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire","Institut National de la Sant� Et de la Recherche M�dicale, France|Inserm-Transfert (IT)|University of Liverpool|Cardiff University|University of Nottingham|Erasmus Medical Center|Heinrich-Heine-Universit�t D�sseldorf (UDUS)|Assistance Publique - H�pitaux de Paris|Mario Negri Institute (IRFMN)|Advanced Biological Laboratories ABL (ABL SA)|Simcyp Limited (SimCyp)|Only For Children Pharmaceuticals|University of Ulm|Karolinska Institutet|Centre Hospitalier Chr�tien (CHC)|Semmelweis University",All,23 Weeks to 28 Weeks � (Child),Phase 3,0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",C12-75|2013-003889-14,January 2015,January 2017,January 2018,"November 4, 2014",,"February 25, 2016","Centre Hospitalier Chr�tien (CHC), Li�ge, Belgium|Assistance Publique H�pitaux de Paris (APHP), Paris, France|Inserm-Transfert (IT), Paris, France|Institut National de la Sant� et de la Recherche M�dicale (INSERM), Paris, France|Only for children pharmaceuticals (04CP), Paris, France|Heinrich-Heine-Universit�t D�sseldorf (UDUS), Dusseldorf, Germany|University of Ulm (UUlm), Ulm, Germany|Semmelweis University Budapest, Faculty of Medicine (SOTE), Budapest, Hungary|Pandy Kalman County Hospital, Gyula, Hungary|Mario Negri Institute (IRFMN), Milan, Italy|Advanced Biological Laboratories ABL (ABL SA), Luxembourg, Luxembourg|Erasmus-University Medical Center (ERAMUS), Rotterdam, Netherlands|Karolinska Institutet (KI), Stockholm, Sweden|Cardiff University (CU), Cardiff, United Kingdom|University of Liverpool (UOL), Liverpool, United Kingdom|Simcyp Limited (SimCyp), Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT02282176,NCT02282176,
oui,NCT02284087,Paired Associative Stimulation in Post-stroke Hand Motor Deficits,PAS-stroke,Unknown status,No Results Available,Stroke and Healthy Subjects,Device: PAS,change in lateralization indices in the primary motor cortex using functional magnetic Resonance|change in motor score of the affected hand by the Jebsen Taylor Test|change in corticospinal excitability by the motor evoked potentials,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Other|Time Perspective: Prospective,C14-38|2014-A01165-42,"September 17, 2014",January 2018,March 2018,"November 5, 2014",,"August 30, 2017","ICM, CIC Neurosciences, Paris, France",,https://ClinicalTrials.gov/show/NCT02284087,NCT02284087,35226342
oui,NCT02284776,Preliminary Evaluation Study of Therapeutic Education on Overweight People in Addition to a Hydrotherapeutic Cure,Educatherm,Unknown status,No Results Available,Obesity,Behavioral: Therapeutic education,Change in the weight between the end of the hydrotherapeutic cure and 5 months after the hydrotherapeutic cure|Evolution of the weight.|Quality of life|Physical activity|Individual's readiness to change|Visual and analogical scale for general and psychological well-being and body discomfort.|Felling about the body|Dietary habits,Institut Pasteur de Lille|Association Francaise pour la Recherche Thermale|Soci�t� des Etablissements Thermaux de Brides-les-Bains et Salins-les-Bains|Centre d'Investigation Clinique 9301 INSERM-CHRU de Lille,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),2013-A00226-43,July 2013,February 2016,April 2016,"November 6, 2014",,"December 16, 2015","SET Brides-les-Bains, Brides-les-Bains, Savoir, France",,https://ClinicalTrials.gov/show/NCT02284776,NCT02284776,
oui,NCT02295514,Correlation Between PTP1B Expression and Organ Failure During Sepsis,SEPP1B,Completed,No Results Available,Sepsis,Biological: PTP1B dosage,Change from baseline in PTP1B level expression|Number of patients with organ failure|Dose of insulin administered during the sepsis|Insulin resistance evaluation|Blood glucose Analysis|Number of death participants at ICU discharge|Number of death participants at at the end of the study|Number of death participants at at hospital discharge|Duration of mechanical ventilation,"University Hospital, Rouen|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,54,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),2014/087/HP,January 2015,May 2016,May 2016,"November 20, 2014",,"May 12, 2016","Rouen University Hospital, Rouen, France",,https://ClinicalTrials.gov/show/NCT02295514,NCT02295514,
oui,NCT02296957,Impact of the Decrease of Exposure to Hypnosedative Drugs in the Elderly Through the Discontinuation of Hospital-initiated Prescription,HYPAGE,Unknown status,No Results Available,Sleep Disorders,Procedure: Hypnosedative discontinuation,"Number of patients with deterioration of the quality of sleep in the intervention group compared to control at one year after discharge, assessed by the ISI scale|Number of patients with deterioration of the quality of sleep in the intervention group compared to control at 1 month after discharge, assessed by the ISI scale|Number of patients with deterioration of the quality of sleep in the intervention group compared to control at 3 months after discharge, assessed by the ISI scale|Number of patients with deterioration of the quality of sleep in the intervention group compared to control at 6 months after discharge, assessed by the ISI scale|Frequency of falls in the intervention group compared to usual care at 1 year after discharge, assessed by a fall diary|Frequency of falls in the intervention group compared to usual care at 1 month after discharge, assessed by a fall diary|Frequency of falls in the intervention group compared to usual care at 3 months after discharge, assessed by a fall diary|Frequency of falls in the intervention group compared to usual care at 6 months after discharge, assessed by a fall diary","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Pierre and Marie Curie University",All,65 Years and older   (Older Adult),Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,HYPAGE,November 2014,October 2017,October 2017,"November 21, 2014",,"October 10, 2016","Assistance Publique Hopitaux de Paris - Hopital Saint Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT02296957,NCT02296957,29357377
oui,NCT02302456,Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery,TRAAP,Completed,No Results Available,Immediate Postpartum Hemorrhage,Drug: Tranexamic Acid|Drug: Placebo,Incidence of PPH|Mean blood loss at 15 minutes after birth|Mean total blood loss|Incidence of severe PPH|Need for supplementary uterotonic treatment|Postpartum transfusion|Need for invasive second-line procedures for PPH|Hemoglobin peripartum delta|Hematocrit peripartum delta|Hemodynamic tolerance|Mild adverse effects|Tolerance lab tests|Severe adverse effects,"University Hospital, Angers|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,4079,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",PHRC 2013-01,February 2015,January 2017,April 2017,"November 27, 2014",,"September 6, 2017","Angers University Hospital, Angers, France",,https://ClinicalTrials.gov/show/NCT02302456,NCT02302456,30134136;26071040
oui,NCT02304874,Evaluation of Body Iron Stores in Overweight Healthy Volunteers,FERNORM,Completed,No Results Available,Healthy Volunteers|Overweight,Other: Phlebotomy,Amount of mobilized iron (AMI) in grams collected by phlebotomies to have a ferritin level < 50 �g/L|Serum hepcidin level variation during the phlebotomy|Serum soluble transferrin receptor variation during the phlebotomy,Rennes University Hospital,Male,"18 Years and older � (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),LOC/11-03,July 2011,June 2013,August 2014,"December 2, 2014",,"December 2, 2014","CHU Pontchaillou, Rennes, France",,https://ClinicalTrials.gov/show/NCT02304874,NCT02304874,
oui,NCT02305147,Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson's Disease,ICEBERG,Recruiting,No Results Available,Parkinson Disease,"Other: Clinical, biological and imaging followup","Rates of change of clinical, imaging and biomic outcomes|Clinical milestones in PD patients|Prodromal features in subjects at risk to develop PD|Phenoconversion in subjects at risk to develop PD","Institut National de la Santé Et de la Recherche Médicale, France|IHU-A-ICM, Paris, France",All,"18 Years and older   (Adult, Older Adult)",,360,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C13-74,"November 6, 2014","November 6, 2019","November 6, 2024","December 2, 2014",,"December 7, 2017","Hôpital Pitié-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT02305147,NCT02305147,
oui,NCT02310061,Lung Water by Ultrasound Guided Treatment in Hemodialysis Patients (The Lust Study).,LUST,Completed,No Results Available,"Kidney Failure, Chronic",Procedure: Extra-vascular lung water measurements by ultrasound (LW-US)|Other: Standard protocol of fluid management in hemodialysis,"Cumulative incidence of the composite outcome ""death, myocardial infarction, heart failure"".|All-cause hospitalizations|Cardiovascular hospitalizations|Left ventricular mass index (LVMI)|Left ventricular ejection fraction (LVEF)|Diastolic function.|Left atrial volume","Fondazione C.N.R./Regione Toscana ""G. Monasterio"", Pisa, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli|Universit�t des Saarlandes|Dr. C.I. Parhon Hospital, Iasi|Medical University of Silesia|Hospital Universitari de Bellvitge|INSERM CHU de Nancy|University Hospital, Strasbourg|Shaare Zedek Medical Center|University Medical Centre Maribor|IASIO Hospital - General Clinic of Kallithea|ASL Parma|University Hospital, Ioannina|Wroclaw Medical University|C.T.M.R. Saint-Augustin|Hospital Ambroise Par� Paris|Centre Hospitalier FH Manhes|Aristotle University Of Thessaloniki|Universit� degli Studi di Ferrara|Istituto di Fisiologia Clinica CNR",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,383,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ERA-EDTA-01062012,March 2013,December 2019,July 2020,"December 5, 2014",,"March 14, 2023","C.T.M.R. Saint Augustin, Bordeaux, France|H�pital Ambroise Par� (Assistance-Publique H�pitaux de Paris), Boulogne Billancourt, France|H�pital F.H. Manh�s, Fleury-M�rogis, France|ALTIR - INSERM CHU de Nancy, Nancy, France|University Hospital Strasbourg, Strasbourg, France|Saarland University Medical Centre, Homburg/Saar, Germany|IASIO Hospital - General Clinic of Kallithea, Athens, Greece|University Hospital of Ioannina, Ioannina, Greece|Aristotle University, Thessaloniki, Greece|Shaare Zedek Medical Center, Jerusalem, Israel|CNR Institute of Clinical Physiology, Pisa, PI, Italy|CNR-IFC Clinical Epidemiology of Renal Diseases and Hypertension Unit, Reggio Calabria, RC, Italy|University of Ferrara, Ferrara, Italy|ASL Parma, Parma, Italy|Medical University of Silesia in Katowice, Katowice, Poland|Medical University, Wroclaw, Poland|University Hospital 'Dr C.I. Parhon', Iasi, Romania|University Clinical Centre, Maribor, Slovenia|Bellvitge's University Hispital, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02310061,NCT02310061,34418415
oui,NCT02314208,Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5,SPA-M,Completed,No Results Available,"Spastic Paraplegia, Hereditary",Drug: Xenbilox|Dietary Supplement: Resveratrol|Drug: Tahor,Change of 27-hydroxycholesterol blood level after 2 months of treatment for each treatment|Modification of the serum acid profile after a 2-month treatment measured in blood and urine samples|Change of 25-hydroxycholesterol blood level after 2 months of treatment for each treatment|Number of participants with adverse events related with digestive problems|Number of partcipants with adverse events related with standard biological parameters,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 2,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C14-04,January 2015,"September 27, 2017","January 1, 2018","December 11, 2014",,"April 3, 2018","Pitié-Salpêtrière Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02314208,NCT02314208,
oui,NCT02316665,Effect of Sleep Apnea Treatment on Type 1 Diabetes,DIADEME,Completed,No Results Available,Type 1 Diabetes|Sleep Apnea Syndrome,Device: continuous positive airway pressure|Device: Sham-continuous positive airway pressure,change in mean nocturnal glycemia|Change in blood pressure|Change in the variability of nocturnal glycemia|Change in HbA1c|Changes in sleep duration after intervention|Change in mean systolic blood pressure after intervention|Chang in sleep timing after intervention|Change in daily activity after intervention|Change in mean diastolic blood pressure after intervention|Change in mean heart rate after intervention,"University Hospital, Grenoble|Soci�t� francophone de pneumologie de langue francaise|ResMed",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,81,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2012-A006336-40,April 2013,October 2014,June 2015,"December 15, 2014",,"January 6, 2016","Grenoble University hospital, Grenoble, France",,https://ClinicalTrials.gov/show/NCT02316665,NCT02316665,
oui,NCT02317055,Magnetic Resonance Imaging Evaluation of the Tissular Oxygen Saturation in Brain,GADOXY,Terminated,No Results Available,Cerebral Tumor|Stroke,Other: imaging,MRI measurements of local oxygen saturation in the brain,"University Hospital, Grenoble|Université Joseph Fourier|Institut National de la Santé Et de la Recherche Médicale, France|Centre National de la Recherche Scientifique, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),2013-A00917-38|1321,June 2014,June 2014,September 2016,"December 15, 2014",,"January 18, 2017","University Hospital Grenoble, Grenoble, France",,https://ClinicalTrials.gov/show/NCT02317055,NCT02317055,
oui,NCT02329054,Efficacy of Favipiravir Against Ebola (JIKI),JIKI,Completed,No Results Available,Ebola Virus Disease,Drug: Favipiravir,"Mortality|Evolution of EBOV plasma RNA and infectious loads|Occurrence of grade 3 or 4 clinical or biological adverse events (Common Terminology Criteria for Adverse Events, CTAE, v3.0)|Evolution of viral micro-diversity of EBOV (including potential resistance mutations)|Plasma trough concentrations of favipiravir|Criteria for cure","Institut National de la Santé Et de la Recherche Médicale, France",All,"1 Year and older   (Child, Adult, Older Adult)",Phase 2,126,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C14-63,December 2014,May 2015,September 2015,"December 31, 2014",,"November 15, 2016","The caregivers treatment center, Conakry, Guinea|MSF Ebola treatment centre, Gueckedou, Guinea|French Red Cross Ebola care center, Macenta, Guinea|ALIMA Ebola care center, Nzerekore, Guinea",,https://ClinicalTrials.gov/show/NCT02329054,NCT02329054,28231247;26930627
oui,NCT02330952,Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD,BECOMEG,Completed,No Results Available,Pulmonary Disease|Chronic Obstructive (MeSH),Drug: Prednisone|Drug: Placebo,Treatment failure|Quality of life-adjusted survival (Q-TWIST)|MYMOP (Measure Yourself Medical Outcome Profile)|COPD Assessment Test (CAT)|Dyspnea Medical Research Council (MRC) score|Occurrence of each event|Treatment Failure related to respiratory status|Self-managed relapse or recurrence|Adverse events,Assistance Publique - H�pitaux de Paris,All,"40 Years and older � (Adult, Older Adult)",Phase 4,189,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AOM13195,"February 10, 2015","May 23, 2017","May 23, 2017","January 5, 2015",,"May 15, 2018","Assistance Publique - Hopitaux Paris, Paris, France",,https://ClinicalTrials.gov/show/NCT02330952,NCT02330952,
oui,NCT02339805,Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS,LymphoSeq,Completed,No Results Available,Non Hodgkin Lymphoma,Other: next generation sequencing|Device: Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET),Determine the clonal evolution during and after treatment by Next Generation Sequencing|Progression free survival|Overall survival|Assess the clonal architecture in tumor DNA and bone marrow|Compare the Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) procedure and the kinetic and pattern of somatic mutations identified in cfDNA,Centre Henri Becquerel|U918 ( Inserm unit),All,"18 Years and older � (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,CHB13.03,"November 1, 2014",July 2015,July 2016,"January 15, 2015",,"July 7, 2017","Centre Henri Becquerel, Rouen, France",,https://ClinicalTrials.gov/show/NCT02339805,NCT02339805,26883583
oui,NCT02342171,Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea,Ebola-Tx,Completed,Has Results,"Hemorrhagic Fever, Ebola",Other: Convalescent Plasma,Survival at Day 14 After Start of Intervention|Number of Participants With 30 Days Survival|Titer of Ebola Viral RNA|Number of Participants Who Died Corresponding to EV Antibody Levels (Anti-EBOV IgG)|Number of Participants Who Died Corresponding to EV Antibody Levels (Neutralizing Antibodies)|Number of Transfusion-related Serious Adverse Reactions (SARs)|Number of Professional Safety Incidents|Mortality Risk Factor: Ct|Mortality Risk Factor: Age,"Institute of Tropical Medicine, Belgium|National Blood Transfusion Centre (NBTC), Conakry, Guinea|Gamal Abdel Nasser University of Conakry|National Center for Training and Research of Maferinyah, Guinea|Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo|University of Oxford|University of Liverpool|London School of Hygiene and Tropical Medicine|Aix Marseille Université|UBIVE, Institut Pasteur, Paris, France|Institut National de la Santé Et de la Recherche Médicale, France|Etablissement Français du Sang|Belgian Red Cross|Institut Pasteur, Dakar, Sénégal|Médecins Sans Frontières, Belgium|World Health Organization|International Severe Acute Respiratory and Emerging Infection Consortium",All,"Child, Adult, Older Adult",Phase 2|Phase 3,606,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ITM0614,February 2015,July 2015,July 2015,"January 19, 2015","July 1, 2019","July 22, 2019","Ebola Treatment Center, Donka, Guinea",,https://ClinicalTrials.gov/show/NCT02342171,NCT02342171,26768570;26735992
oui,NCT02346409,Cerebello-thalamo-cortical Coupling in Essential Tremor,CERESTIM,Completed,No Results Available,Essential Tremor,Device: tACS of the cerebellum,The neuronal activity in the cerebello-thalamo-cortical pathway,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C14-44|2014-A01393-44,"February 4, 2015","February 16, 2018","February 16, 2018","January 27, 2015",,"August 30, 2021","ICM, Paris, France",,https://ClinicalTrials.gov/show/NCT02346409,NCT02346409,
oui,NCT02347969,Evaluation of the Effect of the Dietary Supplement X34 on Skin Radiance of Healthy Volunteers With Dull Complexion,,Completed,No Results Available,Healthy Volunteers,Dietary Supplement: X34,Skin radiance: clinical scoring|Subject self-assessments,Nutratech Conseils|Research and Studies Center on the Integument (CERT)|University of Franche-Comt�|Centre Hospitalier Universitaire de Besancon|Clinical Investigation Center (CIC) INSERM 1431|INSERM UMR1098,Female,"40 Years to 70 Years � (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),DE-87,October 2014,March 2016,March 2016,"January 28, 2015",,"September 21, 2016",,,https://ClinicalTrials.gov/show/NCT02347969,NCT02347969,
oui,NCT02363322,Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection,,Completed,Has Results,Ebola Virus Infection,Drug: B/Current Standard of Care Plus ZMapp|Other: A/Current Standard of Care Alone,Mortality|Number of Participants With ZMapp Infusion-related Adverse Events|Plasma Viral Load,"National Institute of Allergy and Infectious Diseases (NIAID)|The Ministry of Health and Social Welfare, Liberia|The Ministry of Health and Sanitation, Sierra Leone|Institut National de la Santé Et de la Recherche Médicale, France|The Ministry of Health and Public Hygiene, Guinea|National Institutes of Health Clinical Center (CC)",All,"Child, Adult, Older Adult",Phase 1|Phase 2,72,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,150083|15-I-0083,"March 13, 2015","December 31, 2017","December 31, 2017","February 16, 2015","May 14, 2019","June 5, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|CTE Forecariah, Forecariah, Guinea|Monrovia Medical Unit, Monrovia, Liberia|ELWA III Hospital, Paynesville, Liberia|Police Training School 1 (PTS1), Western Rural District, Freetown, Sierra Leone|Emergency Ebola Treatment Unit, Goderich, Sierra Leone|Police Training School 2, Hastings, Sierra Leone|Chinese Friendship Hospital, Jui, Sierra Leone|International Medical Corps (IMC) Kambia, Kambia, Sierra Leone|International Medical Corps (IMC) Lunsar, Port Loko, Sierra Leone|Adventist Development and Relief Ebola Treatment Unit, Waterloo, Sierra Leone","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02363322/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02363322,NCT02363322,27732819
associ�,NCT02368704,Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes,GLUCOSTRESS,Unknown status,No Results Available,"Diabetes Mellitus, Type 2|Endoplasmic Reticulum Stress",Other: No intervention,Show an increase in markers of ER stress in fasting patients with type 2 diabetes|Assess whether insulin induces an increase in markers of ER stress|Insulin secretion in response to glucose infusion|Insulin secretion in response to arginine infusion|Lipolysis on insulin,Assistance Publique - H�pitaux de Paris,All,18 Years to 60 Years � (Adult),,40,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,GLUCOSTRESS P 08 11 22,November 2012,November 2016,November 2016,"February 23, 2015",,"April 18, 2016","Saint-Louis Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02368704,NCT02368704,
oui,NCT02375711,Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient,IVVI,Terminated,No Results Available,Chronic Renal Disease,Biological: Blood sample,Cluster of Differentiation (CD) 8+ CD 57+ CD 28- / CD 8+ T lymphocytes Ratio in Peripheral Blood|Calculated Creatinine Clearance (Cockcroft-Gault Equation)|Interferon gamma and Interleukin-10 production of Peripheral blood T lymphocytes|Percentage of Lymphocytes subpopulations in Peripheral Blood Mononuclear Cells|T-cell receptor excision circle (TREC) level in peripheral blood mononuclear cells (PBMC),Centre Hospitalier Universitaire de Besancon,All,"18 Years to 85 Years � (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,P/2013/173,March 2014,September 2016,September 2017,"March 3, 2015",,"April 5, 2018","Service de n�phrologie, CHU de Besan�on, Besan�on, France",,https://ClinicalTrials.gov/show/NCT02375711,NCT02375711,
oui,NCT02377258,IBD Cancer and Serious Infection in Europe,I-CARE,Completed,No Results Available,IBD,Other: Non Interventional,"assess prospectively the presence and the extent of safety concerns (cancers, especially, lymphoma, and serious infections risks) for anti-TNF alone or in combination with thiopurines among IBD patients.|Disease modification|ePRO|Benefit-Risk|Cost Efficacy",Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives,All,"18 Years and older � (Adult, Older Adult)",,13262,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,GETAID 2015-01,"March 4, 2016","May 16, 2022","May 16, 2022","March 3, 2015",,"August 3, 2022","Chu Nancy, Vandoeuvre Les Nancy, France",,https://ClinicalTrials.gov/show/NCT02377258,NCT02377258,36152897
oui,NCT02379611,Study of Neurologic Development of Temporal Voice Area (TVA) in Deaf Infant,Implaneuro,Completed,No Results Available,Profound Congenital Deaf Children Implanted,Procedure: fNIRS (Functional Near Infrared Spectroscopy),"Measure and localization of an increase of brain blood flow during an auditory stimulation ""voice"" type compared to a stimulation ""non-voice"" type at 24 months of age.|Measure and localization of an increase of brain blood flow during an auditory stimulation ""voice"" type compared to a stimulation ""non-voice"" type at 12 months of age.|Brain blood flow by means of fNIRS (Functional Near infrared Spectroscopy)","Assistance Publique - Hôpitaux de Paris|Centre National de la Recherche Scientifique, France|Institut National de la Santé Et de la Recherche Médicale, France|University of Paris 5 - Rene Descartes",All,up to 13 Months   (Child),Not Applicable,41,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,P130706|HAO13016,"September 2, 2015","October 21, 2020","October 21, 2020","March 5, 2015",,"October 26, 2021","Hôpital Necker Enfants malades Service d'ORL, Paris, France",,https://ClinicalTrials.gov/show/NCT02379611,NCT02379611,
oui,NCT02380391,EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome (ST+/ST-) in HIV,EVERE2ST-HIV,Completed,No Results Available,Acute Coronary Syndrome|HIV,,Residual platelet reactivity (measure 1). measured by light transmission aggregometry following stimulation by 20�M of ADP.|Residual platelet reactivity (measure 2). measured by light transmission aggregometry following stimulation by 5�M of arachidonic acid,Saint Antoine University Hospital|Groupe Hospitalier Pitie-Salpetriere,All,"18 Years and older � (Adult, Older Adult)",,260,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,EVERE2ST-HIV,December 2013,June 2014,June 2014,"March 5, 2015",,"March 5, 2015","Cardiology department, Paris, France",,https://ClinicalTrials.gov/show/NCT02380391,NCT02380391,
oui,NCT02383108,Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children,SMILE,Completed,No Results Available,HIV Infection,Drug: DTG +DRV/r|Drug: SOC,Percentage of patients with HIV-1 RNA ever ≥ 50 c/mL (confirmed within 4 weeks)|Percentage of patients with HIV-1 RNA < 50 c/mL|Percentage of patients with HIV-1 RNA ≥ 50 c/mL|Percentage of patients withHIV-1 RNA ≥ 400c/mL|Percentage of patients with any grade 3 or 4 clinical adverse events (particularly lipodystrophy)  any grade 3 or 4 laboratory adverse events|All grade 3 or 4 laboratory adverse events|Any adverse event at least possibly related to study drugs or leading to treatment modifications|Occurrence of new resistance mutations|Changes in CD4 (absolute and percentage)|Change in ART (defined as any change from the ART regimen at randomisation)|New or recurrent CDC/WHO stage C or severe stage B event or death|Blood lipids|Adherence as measured by questionnaire and visual analogue scale|Acceptability and quality of life over 48 weeks as assessed by patient completed questionnaires|Tanner scales (in participants aged over 8 years)|Date of first menses|Height|Weight,"PENTA Foundation|Institut National de la Santé Et de la Recherche Médicale, France|MRC CTU at UCL|PHPT",All,12 Years to 17 Years   (Child),Phase 2|Phase 3,318,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SMILE (PENTA 17)|ANRS1 52,June 2016,August 2020,October 2020,"March 9, 2015",,"March 30, 2021","Hospital Garrahan, Buenos Aires, Argentina|Centre Hospitalier Andrée Rosemon, Cannes, France|CHU Hôtel Dieu - Nantes, Nantes, France|Hospital General Mexico, Mexico City, Mexico|Hospital de Dona Estefânia - CHLC, Lisbon, Portugal|Centro Materno-Infantil de Norte, Porto, Portugal|FAM-CRU, Cape Town, South Africa|PHRU, Soweto, South Africa|Hospital San Joan de Deu, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital General Gregorio Marañón, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Getafe, Madrid, Spain|Inselpital Bern, Bern, Switzerland|Kantonsspital St Gallen, Saint Gallen, Switzerland|Kinderspital Zurich, Zürich, Switzerland|Prapokklao Hospital, Chanthaburi, Thailand|Nakornping Hospital, Chiang Mai, Thailand|Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand|Kalasin hospital, Kalasin, Thailand|Khonkaen hospital, Khon Kaen, Thailand|Phayao hospital, Phayao, Thailand|Baylor, Kampala, Uganda|JCRC, Mbarara, Uganda|Kiev, Kiev, Ukraine|Kryvyi Rih, Kryvyi Rih, Ukraine|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Bristol Hospital, Bristol, United Kingdom|Evelina Children Hospital, St Thomas's Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02383108,NCT02383108,
oui,NCT02383459,Observatory of Food Preferences in Infants and Children,,Completed,No Results Available,Eating Behavior,,Food likes (Evaluation of food likes for a list of 257 foods),"Centre des Sciences du Goût et de l'Alimentation|National Research Agency, France|Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement|Institut National de la Santé Et de la Recherche Médicale, France|University of Burgundy",All,"18 Years and older   (Adult, Older Adult)",,319,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,OPALINE,January 2005,June 2009,July 2011,"March 9, 2015",,"March 9, 2015",,,https://ClinicalTrials.gov/show/NCT02383459,NCT02383459,
oui,NCT02385838,Impact of Nutrition Labels on Consumer Purchasing Intentions,,Completed,No Results Available,Food Labeling|Choice Behavior,Behavioral: 5-CNL|Behavioral: MTL|Behavioral: GDA|Behavioral: Tick,Overall nutritional quality of the shopping cart|Caloric value of the shopping cart|Nutrients content of the shopping cart,"University of Paris 13|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,11981,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,Nutrinet SM1,December 2014,December 2014,June 2015,"March 11, 2015",,"May 11, 2016","Equipe de Recherche en Epidémiologie Nutritionnelle, Bobigny, France",,https://ClinicalTrials.gov/show/NCT02385838,NCT02385838,26699246
oui,NCT02388607,Sustained Attention Abilities in Schizophrenia,ACCRAS,Recruiting,No Results Available,Schizophrenic Psychoses,Other: measurements,Assess sustained attention span of patients with schizophrenia|Study the specific mechanisms underlying attention skills supported in schizophrenic patients,"University Hospital, Strasbourg, France",All,18 Years to 60 Years   (Adult),,80,Other,Observational,Observational Model: Other|Time Perspective: Prospective,5972,March 2015,March 2023,March 2023,"March 17, 2015",,"September 14, 2021","Service de psychiatrie, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT02388607,NCT02388607,
oui,NCT02389660,European Comparative Effectiveness Research on Internet-based Depression Treatment in Poland,E-COMPARED,Completed,No Results Available,Depression,Behavioral: Blended Cognitive Behavioural Therapy (CBT)|Behavioral: Treatment as usual,Change from Baseline Depression at 12 months|Change from Baseline Symptoms of Depression at 12 months|Change from Baseline Diagnosis of Depression at 12 months|Change from Baseline Health Service Uptake and Production Loss Due to Illness at 12 months|Therapeutic Alliance|Patient's Satisfaction with the Treatment|Satisfaction with the Platform|Alliance between the Patient and Technologies|Patients' Expectancy of Treatment|Change from Quality of Life at 12 months,"University of Social Sciences and Humanities, Warsaw|VU University of Amsterdam|Linkoeping University|University of Erlangen-Nürnberg|London School of Hygiene and Tropical Medicine|GGZ inGeest|Universitat Jaume I|Leuphana Universität Lünenberg|University of Limerick|University of Bern|University of Valencia|Inesc Porto|Institut National de la Santé Et de la Recherche Médicale, France|European Commission|Ministry of Science and Higher Education, Poland",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",W73/7. PR/2014,June 2015,June 2018,June 2018,"March 17, 2015",,"June 29, 2018","University of Social Sciences and Humanities, Warsaw, Poland",,https://ClinicalTrials.gov/show/NCT02389660,NCT02389660,34874888;27488181
non,NCT02393027,"Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999",LBT 999,Terminated,No Results Available,Idiopathic Parkinson Disease,Drug: [18F] LBT-999 PET,Binding potential of [18F] LBT-999|DAT striatal density by estimating the LBT-999 distribution volume|presence of lipophilic metabolites,"University Hospital, Tours",All,"45 Years to 75 Years � (Adult, Older Adult)",Early Phase 1,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PHAO14-MJR / LBT-999,March 2015,November 2016,May 2017,"March 19, 2015",,"May 30, 2017","University Hospital, Tours, France",,https://ClinicalTrials.gov/show/NCT02393027,NCT02393027,
oui,NCT02403089,Ontogeny of MAIT Cells in Neonates and Hematopoietic Stem Cell Transplant Recipients,NEOMAIT,Completed,No Results Available,Term and Preterm Neonates (24-41 Weeks Gestational Age)|Hematopoietic Stem Cell Transplant Recipient Children,Other: Tubes fund recovery blood count|Other: the rest of the blood test and stool sample,MAIT cell numbering neonates after birth|Absolute number of MAIT|Absolute number of other immune cell populations,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement|Institut Curie",All,"1 Day to 18 Years   (Child, Adult)",,300,Other,Observational,Observational Model: Other|Time Perspective: Prospective,NI14006,March 2015,February 2018,February 2018,"March 31, 2015",,"February 3, 2023","Hôpital Robert Debré, Paris, France",,https://ClinicalTrials.gov/show/NCT02403089,NCT02403089,34615705
oui,NCT02407782,Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children,SCRATCH,Unknown status,No Results Available,Scabies,Drug: Ivermectin|Drug: Permethrin,"Assessment of skin lesions and healing at day 28|Assessment of skin lesions and healing at day 56|Assessment of skin lesions and healing at day 28 and 56 in children|Number of unaffected members in clusters treated by permethrin versus ivermectin at D0, D28 and D56.|Evaluation of delta wing jet sign(s) and mite egs|Incidence of serious adverse events|adherence of patients","University Hospital, Bordeaux",All,up to 16 Years � (Child),Phase 3,502,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,CHUBX 2011/16,January 2016,September 2017,September 2017,"April 3, 2015",,"June 6, 2016","CHU de Bordeaux H�pital Pellegrin, Bordeaux, Aquitaine, France|CHG de Chalon sur Sa�ne, Chalon sur Sa�ne, Bourgogne, France|CHU de Dijon, Dijon, Bourgogne, France|CHU de Rennes, Rennes, Bretagne, France|CHRU de Tours, Tours, Centre-Val de Loire, France|CH d'Argenteuil, Argenteuil, Ile de France, France|CHU de Cr�teil - H�pital Henry Mondor, Cr�teil, Ile de France, France|AP-HP - H�pital Robert Debr�, Paris, Ile de France, France|CHU de Montpellier, Montpellier, Languedoc-Roussillon, France|CHU de la R�union, Saint-Pierre, Martinique, France|CHU d'Angers, Angers, Pays de La Loire, France|CH du Mans, Le Mans, Pays de la Loire, France|CHU de Nantes, Nantes, Pays de la Loire, France|CHI de Fr�jus, Fr�jus, Provence-Alpes-C�te d'Azur, France|CHU de Nice, Nice, Provence-Alpes-C�te-d'Azur, France|CHU de Lyon, Bron, Rh�ne-Alpes, France",,https://ClinicalTrials.gov/show/NCT02407782,NCT02407782,34061842
oui,NCT02408354,"Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood",HEMIHEP,Completed,No Results Available,Alternating Hemiplegia of Childhood,Drug: Triheptanoin|Drug: Placebo,"Number of neurologic paroxystic events report in patient diary|Composite score allying the number of neurological paroxystic events, their duration and severity.|Clinical Global Impression Scales - Improvement|The Short Form (36) Health Survey|Brain 31phosphorus magnetic resonance spectroscopy|Clinical Safety as measured by questionnaire|Biological Safety as measured by acylcarnitine profile, organic acid dosage","Institut National de la Santé Et de la Recherche Médicale, France",All,"15 Years and older   (Child, Adult, Older Adult)",Phase 2,10,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C14-53,"April 15, 2015","April 5, 2017","April 5, 2017","April 3, 2015",,"February 12, 2020","Groupe hospitalier Pitié Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT02408354,NCT02408354,28969699
oui,NCT02416453,"A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults",,Completed,Has Results,Ebola Viral Disease,Biological: MVA-BN-Filo|Biological: Ad26.ZEBOV|Biological: Placebo,"Number of Participants With Unsolicited Adverse Events (Groups 1, 2 and 3)|Number of Participants With Serious Adverse Events (Groups 1, 2 and 3)|Number of Participants With Immediate Reportable Events (Groups 1, 2 and 3)|Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3)|Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3)|Number of Participants With Unsolicited Adverse Events (Group 4)|Number of Participants With Serious Adverse Events (Group 4)|Number of Participants With Immediate Reportable Events (Group 4)|Number of Participants With Solicited Local Adverse Events (Group 4)|Number of Participants With Solicited Systemic Adverse Events (Group 4)|Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Filovirus Animal Non-Clinical Group (FANG) Enzyme-linked Immunosorbent Assay (ELISA) (Groups 1, 2 and 3)","Janssen Vaccines & Prevention B.V.|Institut National de la Santé Et de la Recherche Médicale, France|University of Oxford",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,423,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CR107227|VAC52150EBL2001|2015-000596-27,"June 15, 2015","January 19, 2018","January 19, 2018","April 15, 2015","February 8, 2021","February 8, 2021","Creteil, France|Marseille, France|Paris, France|Pierre Benite, France|Rennes, France|Saint Etienne, France|Strasbourg, France|Tours, France|London, United Kingdom|Oxford, United Kingdom|Southampton, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02416453/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02416453/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02416453,NCT02416453,36450746;33217361
oui,NCT02423499,Features Emotional Responses in Adults With Autism: Comparison With Bipolar Disorder (REMBAU),REMBAU,Recruiting,No Results Available,Autism Spectrum Disorder|Bipolar Disorder,,"Physiological emotional response during emotion elicitation in a laboratory session (Pupil size measured by eye tracking, heart rate, electrodermal response, breath rate) during emotion elicitation in a laboratory session|Subjective emotional response during emotion elicitation in a laboratory session|Facial emotional response during emotion elicitation in a laboratory session|Experience sampling method in real life during a week (emotions, activities, social context, burden)|Physiological emotional response in real life (heart rate, electrodermal response, breath rate, actimetry)","University Hospital, Tours",All,18 Years to 50 Years � (Adult),,90,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PHAO13-ML/REMBAU|2014-A00431-46,"May 19, 2015","May 26, 2021","May 26, 2021","April 22, 2015",,"May 12, 2021","LEMAIRE, Tours, France",,https://ClinicalTrials.gov/show/NCT02423499,NCT02423499,
oui,NCT02425410,Analysis of Viral Infections' Exposition Preceding the Type 1 Diabetes (T1D) Diagnostic in Children of the Isis-Diab Cohort. Search for Explanations of of the Disease's Early Onset,ISIS-VIRUS,Unknown status,No Results Available,Diabetes Mellitus|Insulin-Dependent,Other: Collect of data on viral environment of T1D patients|Genetic: Collect of blood samples for DNA extraction and genetic characterization (GWAS),Occurrence of viral events before T1D diagnosis|Delay between viral events and T1D diagnosis|Age at T1D diagnosis as a quantitative trait,"Assistance Publique - Hôpitaux de Paris|Centre National de Génotypage|Institut National de la Santé Et de la Recherche Médicale, France",All,"6 Months and older   (Child, Adult, Older Adult)",,2000,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,AOM 10061,March 2010,December 2017,June 2018,"April 24, 2015",,"June 28, 2016","Inserm U986, Le Kremlin Bicêtre, France",,https://ClinicalTrials.gov/show/NCT02425410,NCT02425410,
oui,NCT02428816,Evaluation of a Multimodal Neuroimaging Method for Diagnosis in Parkinsonian Syndromes,MultiPAMS,Completed,No Results Available,Parkinson's Disease|Multiple System Atrophy,Other: MRI acquisition|Behavioral: behavioral evaluations,The primary outcome measure to discriminate individual patients and patients with MPI and AMS through multimodal MRI isolating multiparametric spatial signature resulting from a combination of markers in multimodal imaging.|correlate MP and MSA disease severity with extracted multimodal MRI biomarkers in whole brain,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years to 80 Years � (Adult, Older Adult)",Not Applicable,94,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C12-52|2012-A01252-41,"January 24, 2013","July 28, 2016","July 28, 2016","April 29, 2015",,"February 9, 2021","Inserm Umr 825, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02428816,NCT02428816,
oui,NCT02429492,Spinal Interneuron Excitability in ALS,SpineBioMark,"Active, not recruiting",No Results Available,ALS,Device: Electrophysiology,Excitability of spinal neurons,"Institut National de la Santé Et de la Recherche Médicale, France",All,"30 Years to 80 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C14-21|2014-A01240-47,"November 16, 2015",September 2021,November 2021,"April 29, 2015",,"August 25, 2021","Hopital Pitie Salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT02429492,NCT02429492,34981890
oui,NCT02439047,Preliminary Study to the Manufacturing of a Non-stick Membrane for Surgery Using Patient's Own Cells (MESO-PATCH),MESO-PATCH,Terminated,No Results Available,Cancer,Procedure: Biological samples collection,Morphotype/Phenotype expression,"Centre Oscar Lambret|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,MESO-PATCH-1408,June 2015,November 2015,November 2016,"May 8, 2015",,"November 9, 2018","Centre Oscar Lambret, Lille, France",,https://ClinicalTrials.gov/show/NCT02439047,NCT02439047,
oui,NCT02444624,Clostridium and Neonatal Necrotizing Enterocolitis Pathophysiology : Clinical and Molecular Approaches,CLOSNEC,Completed,No Results Available,Necrotizing Enterocolitis,,"The primary endpoint is the difference in prevalence of colonisation by bacteria from the Clostridium genus between the two study groups, CASE and CONTROL.|Phenotypic comparison of clostridia between the 2 CASE and CONTROL groups","Nantes University Hospital|Institut National de la Santé Et de la Recherche Médicale, France",All,up to 31 Weeks   (Child),,170,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RC14_0295,"May 28, 2015","September 13, 2019","September 13, 2019","May 14, 2015",,"September 13, 2021","Nantes UH, Nantes, France",,https://ClinicalTrials.gov/show/NCT02444624,NCT02444624,
oui,NCT02453048,Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine,,Completed,Has Results,Pertussis|Whooping Cough,Biological: BPZE1|Other: Placebo,"The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28|Proportion of Subjects With BPZE1 Colonization|The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination","Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 32 Years   (Adult),Phase 1,54,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",C14-80|2015-001287-20,September 2015,March 2017,December 2017,"May 25, 2015","January 2, 2020","January 2, 2020","Karolinska University Hospital, Huddinge, Stockholm, Sweden","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02453048/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02453048,NCT02453048,32687804;31945015
oui,NCT02453061,"A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease",TRIHEP3,Completed,No Results Available,Huntington Disease,Drug: Triheptanoin oil|Drug: Placebo,31-Phosphorus Magnetic Resonance Spectroscopy|volumetric magnetic resonance imaging|motor function after 6 months|motor function after 12 months|Patient autonomy after 6 months|Patient autonomy after 12 months|Sustained restoration of brain energy metabolism after 6 months|Sustained restoration of brain energy metabolism after 12 months|Symbol Digit Modalities Test after 6 months|Symbol Digit Modalities Test after 12 months|Stroop test after 6 months|Stroop test after 12 months|Trail making test after 6 months|Trail making test after 12 months|Digit span test after 6 months|Digit span test after 12 months|psychiatric symptoms after 3 months|psychiatric symptoms after 6 months|psychiatric symptoms after 9 months|psychiatric symptoms after 12 months|patients' daily life|quality of life questionnaire after 6 months|quality of life questionnaire after 12 months|Number of adverse events|clinical exam for Long term tolerance|home nurse visits for Long term tolerance,"Institut National de la Santé Et de la Recherche Médicale, France|Ultragenyx Pharmaceutical Inc",All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C14-62,"June 29, 2015","December 3, 2019","December 3, 2019","May 25, 2015",,"August 25, 2021","Département de Génétique, Paris, France|Department of Neurology, Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT02453061,NCT02453061,31381524
oui,NCT02458040,Clinical Benefit of Genetic Biomarkers for Guiding Treatment Decisions in Oncology Drugs,,Completed,No Results Available,Neoplasms,Drug: Drug selected in the study,Overall Survival (OS)|Progression-Free Survival (PFS),"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,1,Other,Observational,Observational Model: Other|Time Perspective: Prospective,BENEBIO01|PHRCK14-051,May 2015,December 2016,December 2016,"May 29, 2015",,"January 28, 2019","Hôpital Hôtel Dieu, Paris, France",,https://ClinicalTrials.gov/show/NCT02458040,NCT02458040,
oui,NCT02458664,BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer,BASE HSP110,Unknown status,No Results Available,Rectum Cancer|Cancer of Colon,Genetic: Genetic analysis on tumor kept in tumor bank,Recurrence free survival and Recurrence free survival after resection of the colon cancer|Overall survival,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,597,Other,Observational,Observational Model: Cohort,NI12029|2013-A01080-45,November 2013,November 2018,November 2018,"June 1, 2015",,"December 2, 2015","Department of Digestive Surgery, Hôpital Saint-Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT02458664,NCT02458664,
oui,NCT02459613,Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis,AnnIE,Terminated,No Results Available,Endocarditis|Thrombosis,Drug: 99mTc-Annexin V-128 SPECT,Diagnostic sensitivity in infective endocarditis and atrial thrombus|Diagnostic value (sensitivity and specificity) in infective endocarditis|Diagnostic sensitivity in atrial thrombus,"Institut National de la Santé Et de la Recherche Médicale, France|Advanced Accelerator Applications",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,11,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C13-38,"February 5, 2016",May 2017,May 2017,"June 2, 2015",,"August 26, 2021","Bichat Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02459613,NCT02459613,
oui,NCT02469350,Serious Game for Parkinson's Disease Patients,PARKGAME,Completed,No Results Available,Parkinson's Disease,Other: Serious game,Feasibility questionnaire|Acceptability questionnaire|biomechanical parameters of gait and balance|kinematics parameters of gait and balance,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,C15-12|RCB,June 2015,"May 4, 2017","October 4, 2017","June 11, 2015",,"November 6, 2017","ICM, CIC Neurosciences, Paris, France",,https://ClinicalTrials.gov/show/NCT02469350,NCT02469350,29636105
oui,NCT02472028,Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals,LEOPOLD,Recruiting,No Results Available,Cerebrovascular Disorders,Other: blood pressure lowering algorithm|Other: usual strategy,"The main criterion is based on the quantitative assessment of White Matter Lesions (WML) volumes at the beginning and at the end of the study for each patient and each arm of the trial. The WML volume from the final MRI is compared to that of the initial|Imaging criteria : changes in the number of large or confluent WML|Imaging criteria : changes in the volume of WML depending on their location (periventricular and deep white matter)|Imaging criteria : changes in the number of silent infarctus|Imaging criteria : changes in the number of microbleeds|Imaging criteria : evolution of brain volumes (gray matter, white matter, CSF, and regional volumes including hippocampus)|Clinical criteria: clinical criteria (changes in neuropsychological tests|Clinical criteria: changes inwalking speed|Clinical criteria: number of incident cases of dementia|Number of incident cases of vascular events validated by an expert committee|Clinical criteria: total mortality by cause",Assistance Publique - H�pitaux de Paris,All,"60 Years to 88 Years � (Adult, Older Adult)",Phase 4,820,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,P100153|2014 A00265-42,September 2015,"September 11, 2026","September 11, 2026","June 15, 2015",,"September 22, 2022","Memory for Research and Resources Center / Neuroscience pole, Bordeaux, Pellegrin Hospital Group, France|Memory Resources Centre and South of Ile de France Search - Broca Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02472028,NCT02472028,
oui,NCT02473328,Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients,ATALOW,Completed,No Results Available,HIV-1 Infection,Drug: Atazanavir 200 mg/r,"Measure of effectiveness assessed by maintaining undetectable plasma HIV viral load (viral load ? 50 copies / ml) during the all period of this study of treatment with ATV / r 200/100 mg + 2 NRTIs, for all patients.|Measure of safety (adverse events)|Measure of tolerability assessed by number of patient interrupting the study treatment for virological failure|Measure of effectiveness assessed by number of patient maintaining a target trough plasma concentration of atazanavir associated to efficacy:|Measure of effectiveness assessed in patient with virological failure number of patient dysplaing HIV strains with mutations associated to treatment resistance|Measure of tolerability assessed by number of patient interrupting the study treatment for in tolerance|Measure of tolerability assessed by quantification of bilirubinemia|Measure of tolerability assessed by quantification of creatininemia",Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida|INSERM UMR S 1136,All,"Child, Adult, Older Adult",Phase 2,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CREPATS 003,June 2015,December 2017,December 2017,"June 16, 2015",,"August 21, 2018","DUDOIT Yasmine, Paris, France",,https://ClinicalTrials.gov/show/NCT02473328,NCT02473328,
oui,NCT02476188,Neutrophil Extracellular Traps and Thrombolysis in the Acute Stroke,NETs,Completed,No Results Available,Acute Stroke,Procedure: Sample of Blood,Rate of recanalisation|Thrombus size on MRI|Stroke volume on MRI,"Centre Hospitalier St Anne|Institut National de la Santé Et de la Recherche Médicale, France|University of Paris 5 - Rene Descartes",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,124,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D15-P007,"July 31, 2015",August 2016,November 2016,"June 19, 2015",,"October 20, 2017","Centre Hospitalier Sainte-Anne, Paris, France",,https://ClinicalTrials.gov/show/NCT02476188,NCT02476188,
oui,NCT02481453,Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis,RAPAMI,Completed,No Results Available,Inclusion Body Myositis (IBM),Drug: Rapamycin|Drug: Placebo,stabilization of quadiceps strength measured by myometry|stabilization of hand grip strength measured by myometry|comparison of 6 minutes walking test|composite measure of the handicap|Quality of life by different scales|measures of muscle fatty replacement by MRI|Measure of the tolerance|measure of inflammation by MRI,"Institut National de la Santé Et de la Recherche Médicale, France",All,"45 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",C12-66|2013-003485-14,"July 15, 2015","January 22, 2018","January 22, 2018","June 25, 2015",,"January 9, 2019","CIC Paris Est _Hôpital Pitié Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT02481453,NCT02481453,
oui,NCT02481622,First Event of Infection by HIV-1 of Uterine Vaginal Tissue,,Unknown status,No Results Available,HIV Infection of the Uterine Vaginal Tissues,,identification of the first HIV-infected cells by a histological analysis,"University Hospital, Strasbourg, France",Female,18 Years to 50 Years � (Adult),,600,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,6197,November 2015,November 2019,November 2019,"June 25, 2015",,"April 24, 2017","INSERM U1109 - Institut de Virologie 3, rue Koeberl� - 67000 Strasbourg, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT02481622,NCT02481622,
oui,NCT02484274,Iron Deficiency (ID) in Infants,CARMA,Completed,No Results Available,Iron Deficiency in Young Children Living in France,Biological: Blood samples,"Serum ferritin level|Haemoglobin blood level|Dosage of biochemical markers (hepcidin, erythrocytic protoporphyrin)|Iron intake related to toddler milk formula|Parents' economical and educational level","Assistance Publique - H�pitaux de Paris|Association Clinique Th�rapeutique Infantile du val de Marne|Association Fran�aise de P�diatrie Ambulatoire- AFPA|CERBA|Laboratoire de Biochimie, CHU Louis Mourier|INSERM 1153, Centre de Recherche Epid�miologique et Biostatistique",All,22 Months to 26 Months � (Child),Not Applicable,830,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,P140314,"January 6, 2016","January 15, 2018",May 2018,"June 29, 2015",,"March 14, 2019","Necker-Enfants Malades hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02484274,NCT02484274,33836187;32507584
oui,NCT02486731,Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes,NOLEO,Completed,No Results Available,Noonan Syndrome|LEOPARD Syndrome,,Phosphorylation of Erk and Akt in fibroblasts|Phosphorylation of Erk and Akt in adipocytes,"Institut National de la Santé Et de la Recherche Médicale, France",All,5 Years to 15 Years   (Child),,27,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,C13-59|2013-A01428-37,"December 16, 2015",December 2018,December 2018,"July 1, 2015",,"August 26, 2021","CIC de Toulouse- Unité pediatrique, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02486731,NCT02486731,
oui,NCT02488395,Superior Colliculus Activity in Parkinson Disease: a Potential Marker?,AGIRPARK,Completed,No Results Available,Parkinson's Disease,Other: fMRI|Other: Ophthalmologic evaluation|Other: visual psychophysics test,Light responses measure in the superior colliculus,"Institut National de la Santé Et de la Recherche Médicale, France",All,"35 Years to 75 Years   (Adult, Older Adult)",,23,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C14-58|IDRCB,"October 7, 2015",January 2018,"January 19, 2018","July 2, 2015",,"August 26, 2021","CHU de Grenoble, Grenoble, Isere, France|Grenoble Institute of Neurosciences, Grenoble, Isere, France|IRMAGE, Grenoble, Isere, France",,https://ClinicalTrials.gov/show/NCT02488395,NCT02488395,
oui,NCT02494375,Sleep and Type 1 Diabetes,SLEEPT1D,Unknown status,No Results Available,Type 1 Diabetes,Other: Sleep and glucose assessments,Association between HbA1c and sleep characteristics|Glucose levels|Daily salivary amylase variation (Enzyme Activity)|Body composition (BMI fat and lean mass percentage),"Hospices Civils de Lyon|Institut National de la Santé Et de la Recherche Médicale, France",All,6 Years to 17 Years   (Child),Not Applicable,70,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL15_0219,"June 28, 2015",December 2022,December 2022,"July 10, 2015",,"October 5, 2020","Hospices Civils de Lyon, Lyon, France",,https://ClinicalTrials.gov/show/NCT02494375,NCT02494375,
oui,NCT02494414,Outcome of Cardiac Arrest Survivors,DESAC,Completed,No Results Available,Cardiac Arrest Survivors,Other: Long-term follow-up,Cerebral Performance Categories Scale|SF-36 (Short-Form General Health Survey)|Overall Performance Categories (OPC)|Activities of Daily Living (ADL) scale|New cardiovascular events|New York Heart Association (NYHA) status,Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",,601,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AOR12068,"July 24, 2015","January 22, 2021","January 22, 2021","July 10, 2015",,"May 3, 2021","INSERM U970 Centre de Recherche Cardiovasculaire de Paris Equipe 4, Epid�miologie Cardiovasculaire et Mort Subite, Paris, France",,https://ClinicalTrials.gov/show/NCT02494414,NCT02494414,
oui,NCT02496312,Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.,ECOCAPTURE,Completed,No Results Available,Apathy|Behavior|Frontotemporal Dementia,Behavioral: Evaluation of Apathy Close to Real Life Situation,Occurrence of each behavior from the ethogram|Frequency of each behavior from the ethogram|Duration of each behavior from the ethogram|Number of different behaviors|Activity classes|Body positions|Energy expenditure|MET|Steps|Activity intensity,"Institut National de la Santé Et de la Recherche Médicale, France",All,"20 Years to 85 Years   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C15-14|2015-A0087-42,"July 10, 2015","October 2, 2015","October 2, 2015","July 14, 2015",,"November 6, 2017",,,https://ClinicalTrials.gov/show/NCT02496312,NCT02496312,
oui,NCT02497274,Obesity and Lipids: a Matter of Taste?,HumanFATaste,Completed,No Results Available,Obesity,Other: taste assessment and epithelium gustatory smear and biopsy,Expression of lipid receptors|Lipids thresholds,"Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 55 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C14-77|2015-A00906-43,"January 11, 2016",January 2019,January 2019,"July 14, 2015",,"August 26, 2021",,,https://ClinicalTrials.gov/show/NCT02497274,NCT02497274,
oui,NCT02503644,Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis,FASST,Completed,No Results Available,"Scleroderma, Diffuse|Diffuse Cutaneous Systemic Sclerosis",Drug: IVA337|Drug: Placebo,Measurement of skin thickness by the Modified Rodnan Skin Score (MRSS)|Response rates based on MRSS improvement|Overall progression of the disease: defined as absence of rescue therapy and absence of severe organ involvement|Lung function measured by FVC% predicted|Lung function by cDLCO% predicted|Scleroderma Health Assessment Questionnaire (SHAQ)|Gastrointestinal tract symptoms severity and its impact on patients' well-being assessed by the UCLA SCTC GIT|Patient-reported health status assessed by PROMIS29|Physical and mental health assessed by SF36|Digital ulcer net burden (defined as total number of ulcers at a certain time point minus number of ulcers at baseline) and proportion of patients who do not develop new ulcers|Hand function assessed by the Cochin Hand Function Scale|Patient global assessment of disease activity assessed by a visual analogue scale|Physician global assessment of disease activity assessed by a visual analogue scale|Change in the Combined Response Index for Systemic Sclerosis (CRISS)|Percent of patients who need escape therapy|Percent of patients who experience a new severe organ involvement|Number of participants with adverse events as a measure of safety and tolerability|Routine and specific laboratory tests (composite) to assess safety and tolerability,Inventiva Pharma,All,"18 Years to 75 Years � (Adult, Older Adult)",Phase 2,145,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IVA_01_337_HSSC_15_001,"October 29, 2015",October 2018,"October 12, 2018","July 21, 2015",,"March 4, 2019","University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski, Pleven, Bulgaria|Multiprofile Hospital for Active Treatment Plovdiv, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment -Kaspela, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment - ""Sveti Ivan Rilski"", Sofia, Bulgaria|H�pital Pellegrin, Bordeaux, France|CHRU de Lille- H�pital Claude Huriez, Lille, France|Hopital Cochin, Paris, France|University Hospital of Strasbourg, Strasbourg, France|Kerckhoff-Klinik, Bad Nauheim, Germany|Charit�- Universit�tsmedizin Berlin, Berlin, Germany|Chait�-Universt�tsmedezin Berlin, Berlin, Germany|Univertaetsklinikum Carl Gustav Carus, Dresden, Germany|University of Erlangen-Nuremberg, Erlangen, Germany|CIRI GmbH Centrum f�r Innovative Diagnostik und Therapie, Frankfurt, Germany|University Medical Center Freiburg, Freiburg, Germany|Klinik fur Dermatologie und Venerologie der Universitat zu K�ln, K�ln, Germany|Kilinik f�r Hautkrankenheiten, M�nster, Germany|Universt�tsklinik Ulm, Ulm, Germany|Istituto di Clinica Medica Generale Polo Didattico, Ancona, Italy|Azienda Ospedalaria Spedali Civili di Brescia, Brescia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Ospedale San Salvatore ASL L'Aquila, L'Aquila, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|University of Padova, Padova, Italy|Ospedale di Alta Specializzazione ""San Camillo"", Roma, Italy|Policlinico Umberto I, Roma, Italy|Universita degli Studi de Verona, Verona, Italy|Leiden University Medical Center, Leiden, Netherlands|Erasmus MC Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands|Centrum Miriada Prywatny, Bialystok, Poland|University Hospital in Bydgoszcz, Bydgoszcz, Poland|CM Plejady, Krakow, Poland|Reumed, Lublin, Poland|Medycine Centrum Hetmanska Poznan, Poznan, Poland|Centrum Medyczne Oporow, Wroclaw, Poland|University Medical centre Ljubljana, Ljubljana, Slovenia|University Medical Centre Maribor, Maribor, Slovenia|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hopital Universitario Gregorio Mara�on, Madrid, Spain|Hopital 12 de Octubre, Madrid, Spain|Hopital Universitario Sanchinarro, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Dr Peset, Valencia, Spain|University Hospital Lausanne, Lausanne, Switzerland|University Hospital Zurich, Zurich, Switzerland|Leeds Institut of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom|Royal Free Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02503644,NCT02503644,
oui,NCT02507453,Influence of Gravity on the Size-mass Illusion,Massper,Unknown status,No Results Available,Healthy,Other: parabolic flight|Other: mass/weight perception estimation|Device: ESA short-arm human centrifuge (SAHC),perceived size and perceived mass of objects in 0G and 1.8G compared to 1G using the size-mass illusion (SMI) (composite),"University Hospital, Caen",All,"21 Years to 65 Years � (Adult, Older Adult)",Not Applicable,36,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,13-028,October 2013,October 2016,,"July 24, 2015",,"July 24, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02507453,NCT02507453,
oui,NCT02507622,E-NOSE for Breath Gas Analysis Under Microgravity Conditions,E-NOSE,Unknown status,No Results Available,Healthy Volunteers,"Other: measurement of the concentration of C02, CO and NH4, 3 exhaled gas with E-Nose system|Other: Parabolic flight","The judgment criteria are the concentration of C02, CO and NH4, 3 exhaled gas","University Hospital, Caen",All,"20 Years to 65 Years � (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14-103,September 2014,November 2017,November 2017,"July 24, 2015",,"July 24, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02507622,NCT02507622,
oui,NCT02508545,Influence of Gravity on the Perception of Egocentric Distance (Blindpulling),Blindpulling,Unknown status,No Results Available,Healthy Volunteers,Other: perceived egocentric distance (PED) measurements|Other: Parabolic flight,"Blind pulling error, i.e. difference between the actual position of the visual target and the final position of the subject between 1G, 1.8G, and 0G during parabolic flight and with blind pulling evaluation method|Blind pulling error, i.e. difference between the actual position of the visual target and the final position of the subject between 1G, 1.8G, and 0G during parabolic flight and with verbal report evaluation method","University Hospital, Caen",All,"21 Years to 65 Years � (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14-002,February 2014,October 2017,,"July 27, 2015",,"July 27, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02508545,NCT02508545,
oui,NCT02508558,"Validation of Methods for Evaluating Operation Force, Motion and Visual Perception in Weightlessness",HopMot,Unknown status,No Results Available,Healthy Volunteers,Other: motion perception and locomotor operation performance measurements|Other: parabolic flight,motion perception performance under different gravity states|locomotor operation performance under different gravity states,"University Hospital, Caen",All,22 Years to 45 Years � (Adult),Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14-102,September 2014,November 2017,November 2017,"July 27, 2015",,"July 27, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02508558,NCT02508558,
oui,NCT02508818,Cardiovascular Response to Orthostatic Fractional Gravity,ORB,Unknown status,No Results Available,Healthy Volunteers,Other: Parabolic flight|Other: Cardiovascular measurements,systolic finger blood pressure|Heart rate,"University Hospital, Caen",All,18 Years to 55 Years � (Adult),Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11-010,June 2011,November 2015,,"July 27, 2015",,"July 27, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02508818,NCT02508818,
oui,NCT02509494,Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo,EBOVAC-Salone,Completed,Has Results,Ebola Virus Disease,Biological: Ad26.ZEBOV|Biological: MVA-BN-Filo|Biological: MenACWY|Biological: Placebo,Stages 1 and 2: Number of Participants With Solicited Local Adverse Events (AEs) (Day 8)|Stages 1 and 2: Number of Participants With Solicited Local AEs (Day 64)|Stage 1: Number of Participants With Solicited Local AEs (Day 738)|Stages 1 and 2: Number of Participants With Solicited Systemic AEs (Day 8)|Stages 1 and 2: Number of Participants With Solicited Systemic AEs (Day 64)|Stage 1: Number of Participants With Solicited Systemic AEs (Day 738)|Stages 1: Number of Participants With Serious Adverse Events (SAEs)|Stages 2: Number of Participants With SAEs|Stage 1: Number of Participants With Unsolicited AEs (Day 759)|Stage 1: Number of Participants With Unsolicited AEs (Day 29)|Stage 2: Number of Participants With Unsolicited AEs (Day 29)|Stage 1: Number of Participants With Unsolicited AEs (Day 85)|Stage 2: Number of Participants With Unsolicited AEs (Day 85)|Stage 1: Number of Participants With Deaths|Stage 2: Number of Participants With Deaths (Children and Adolescents)|Stage 2: Number of Participants With Deaths (Adults)|Stage 1: Number of Participants With Immediate Reportable Event (IREs)|Stage 2: Number of Participants With IREs (Children and Adolescents)|Stage 2: Number of Participants With IREs (Adults)|Stages 1 and 2: Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Enzyme-linked Immunosorbent Assay (ELISA),"Janssen Vaccines & Prevention B.V.|London School of Hygiene and Tropical Medicine|Ministry of Health and Sanitation of Sierra Leone|College of Medicine and Allied Health Sciences (COMAHS)|University of Oxford|Institut National de la Santé Et de la Recherche Médicale, France|Grameen Foundation|World Vision of Ireland",All,"1 Year and older   (Child, Adult, Older Adult)",Phase 3,1023,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",CR107372|VAC52150EBL3001|115854 EBOVAC1|2019-000691-42,"September 30, 2015","June 28, 2019","July 3, 2019","July 28, 2015","July 18, 2022","July 18, 2022","Freetown, Sierra Leone","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02509494/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02509494/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02509494,NCT02509494,36450746;34529963;34529962;29895178
non,NCT02510755,Stress and Emotional Memory,SEME,Completed,No Results Available,"Stress Disorders, Post-Traumatic",Other: MRI,Amplitude of the BOLD fMRI signal measured at rest and during cognitive tasks (activation),"University Hospital, Caen",All,"13 Years to 18 Years � (Child, Adult)",Not Applicable,19,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,10-035,May 2012,April 2015,April 2015,"July 29, 2015",,"July 29, 2015","Service de P�dopsychiatrie, Caen, France",,https://ClinicalTrials.gov/show/NCT02510755,NCT02510755,
oui,NCT02510989,Phenotypic and Genotypic Characterization of Subjects With Syndromic Obesity: Identifying New Candidate Genes by Exome Sequencing (OBEXOME),OBEXOME,Completed,No Results Available,Syndromic Obesity,,"Presence of exonic variants or onsertions/deletions in subjects with syndromic obesity, not founr in related non-obese subjects|Number of shared variants in candidate genes among patients with syndromic obesity|Number of unshared variants but located in the same candidate gene among patients with syndromic obesity","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"1 Year and older   (Child, Adult, Older Adult)",,27,Other,Observational,Observational Model: Family-Based|Time Perspective: Other,NI130008|2014-A00626-41,"July 4, 2016","July 4, 2018","July 4, 2018","July 29, 2015",,"June 8, 2022","Gastroentérologie et Nutrition Pédiatriques , Hôpital Trousseau, Paris, France",,https://ClinicalTrials.gov/show/NCT02510989,NCT02510989,
oui,NCT02516787,Coherence Between Brain Cortical Function and Neurocognitive Performance During Changed Gravity Conditions,CORTICOG,Completed,No Results Available,Healthy,Other: Parabolic flight|Other: EEG measurement|Other: NIRS measurements,alterations in brain cortical activity (EEG)|brain oxygenation level (NIRS),"University Hospital, Caen",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,10-082,November 2010,November 2013,,"August 6, 2015",,"August 6, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02516787,NCT02516787,
oui,NCT02517112,3D Ballistocardiography in Microgravity,B3D,Unknown status,No Results Available,Healthy,Other: Parabolic flight|Other: Cardiovascular parameters measurements|Device: 3D-BCG sensor,Heart rate|stroke volume|ejection fraction,"University Hospital, Caen",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11-126,December 2011,October 2015,,"August 6, 2015",,"August 6, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02517112,NCT02517112,
oui,NCT02517138,Right-front Direction in Parabolic Flight,DROITDEVANT,Completed,No Results Available,Healthy,Other: Parabolic flight|Other: Measurements of eye movements and perception,eye movements|acceleration of the head|perception by the subjects of the right-front.|acceleration of the arms,"University Hospital, Caen",All,"20 Years to 65 Years � (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11-094,November 2011,March 2013,January 2014,"August 6, 2015",,"August 6, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02517138,NCT02517138,
oui,NCT02517177,Alterations in Autonomic Cardiovascular Control Induced at Partial G Forces,AUTOCARD,Completed,No Results Available,Healthy,Other: Parabolic flight|Other: Cardiovascular parameters measurements,"The heart rate (HR) and the heart rate variability (HRV) derived from the ECG|The systolic, diastolic and mean arterial blood pressure (SP, DP, MAP)|The autonomic cardiovascular control evaluated with a spectral analysis of HRV and BPV.|the blood pressure variability (BPV) derived from the continuous blood pressure recording","University Hospital, Caen",Male,20 Years to 35 Years � (Adult),Not Applicable,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11-008,June 2011,December 2012,,"August 6, 2015",,"August 6, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02517177,NCT02517177,
oui,NCT02517190,"Effects of Repeated Short-term Microgravity During Parabolic Flight Conditions on Neuro-endocrine, Immune and Metabolic Changes",COSI@PFC,Completed,No Results Available,Healthy,Other: Parabolic flight|Other: neuro-endocrine measurements|Other: immunological measurements|Other: cellular energy metabolism measurements,neuro-endocrine measurements composite|immunological measurements composite|cellular energy metabolism measurements composite,"University Hospital, Caen",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,12-024,May 2012,January 2014,January 2014,"August 6, 2015",,"August 6, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02517190,NCT02517190,
oui,NCT02517216,Parabolic Flight Induced Neuroplasticity Studied With Advanced Magnetic Resonance Imaging Methods,BrainDTI,Unknown status,No Results Available,Healthy,Other: parabolic flight|Device: MRI,biomarkers of neuroplasticity with MRI|time course of possible changes and signs of neuroplasticity with MRI|motion sickness questionnaires,"University Hospital, Caen",All,"21 Years to 65 Years � (Adult, Older Adult)",Not Applicable,27,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14-004,February 2014,April 2017,,"August 6, 2015",,"August 6, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02517216,NCT02517216,
oui,NCT02517229,The Effect of Altered Gravity Condition on Postural Control,POSTURGRAV,Unknown status,No Results Available,Healthy,Other: Parabolic flight|Other: balance control measurements|Device: electromagnetic maneuverable postural platform,"balance skill, expressed by the postural sway in mm|neuromuscular activity, expressed by the Electromyograpy (EMG)-amplitudes|spinal excitability, expressed by H-Reflexes","University Hospital, Caen",All,"21 Years to 65 Years � (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,12-084,September 2012,October 2015,,"August 6, 2015",,"August 6, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02517229,NCT02517229,
oui,NCT02517944,MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR),CHOLCOEUR,Unknown status,No Results Available,Familial Hypercholesterolemia - Heterozygous,,"Percentage of patients presenting with at least one micro infarction at RMI|LDL-Cholesterol burden (compared to standard values)|Anatomic and functional indexes of the aorta (maximal and minimal areas of aortic lumen, aortic flow)|Correlations between LDL-Cholesterol burden & presence of micro infarction, between LDL-Cholesterol burden & myocardial fibrosis, and between LDL-Cholesterol burden & aortic stiffness indexes","Institute of Cardiometabolism and Nutrition, France|Amgen",All,40 Years to 60 Years � (Adult),,110,Other|Industry,Observational,Observational Model: Case-Control|Time Perspective: Prospective,14DRM_CHOLCOEUR,November 2014,September 2015,November 2015,"August 7, 2015",,"August 7, 2015","Unit� de pr�vention des maladies cardiovasculaires- Unit� INSERM 939 P�le Cardiologie/M�tabolisme Groupe Hospitalier Piti�-Salp�tri�re, Paris, France",,https://ClinicalTrials.gov/show/NCT02517944,NCT02517944,
oui,NCT02518074,Hearing and Vestibular Interactions in the Collection of Own Body and Sense of Self,AUDIOSELF,Unknown status,No Results Available,Healthy,Other: Hearing and Vestibular Interactions,"Responses to the questionnaire ""Botvinick Cohen"" on the sensations of the body out experiments|Answers on the location of auditory stimuli","University Hospital, Caen",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,13-070,October 2013,November 2017,,"August 7, 2015",,"August 7, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02518074,NCT02518074,
oui,NCT02518880,"Dynamics of Stroke Volume and Cardiac Output During Parabolic Flight, and Its Relationship to Intravascular Volume",DYMCO,Completed,No Results Available,Healthy Volunteers,Other: Parabolic flight|Other: plasma volume measurements,haemoglobin concentration,"University Hospital, Caen",All,18 Years to 55 Years � (Adult),Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,09-178,March 2010,February 2012,,"August 10, 2015",,"August 10, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02518880,NCT02518880,
oui,NCT02520492,Non Invasive Measurements of Intracranial Pressure in Patients With Malignant Glioma,GMaPIC,Completed,No Results Available,Glioma,Device: noninvasive method of ICP measurements (Elios),"Presence of an ICP variation or increase when physician has diagnosed a clinical or morphological aggravation of the tumor with standard diagnose methods (composite outcome measure)|evolution of ICP before and after the progression of the relapse tumor according to imaging (RMI)|evolution of ICP before and after the progression of the relapse tumor according to clinical sign|Evaluate efficiency of the measurement device of ICP changes on repetitive measurement as evaluated by composite outcome measure : clinical signs, MRI and RANO criteria",Centre Jean Perrin|Laboratoire de Biophysique Neurosensorielle - UMR INSERM 1107 (Pr Paul AVAN),All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2014-A01568-39,"April 3, 2015","January 15, 2020","January 15, 2020","August 13, 2015",,"January 31, 2020","Centre Jean Perrin, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT02520492,NCT02520492,
associ�,NCT02520908,Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis,CUTALLO,"Active, not recruiting",No Results Available,Epidermotropic T-cell Lymphomas,Procedure: HSCT|Other: Standard Care,Progression-Free Survival (PFS)|overall survival (OS)|Neutrophils Engraftment|Acute and chronic graft-versus-host disease (GVHD)|Cumulative incidence of relapse|Treatment-related mortality (TRM)|Quality of life (QoL),Assistance Publique - H�pitaux de Paris,All,"18 Years to 65 Years � (Adult, Older Adult)",,98,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NI 14018,"September 28, 2016","November 19, 2024","November 19, 2024","August 13, 2015",,"April 18, 2022","Saint Louis hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02520908,NCT02520908,37105210
oui,NCT02520960,Unipolar Atrial Electrogram Modification Combined to the Contact Force Sensing Technology for Pulmonary Vein Isolation,Uniforce,Completed,No Results Available,Atrial Fibrillation|Arrhythmia,,Recurrence of Atrial Arrhythmias|Frequency of Pulmonary Vein Reconnection,"H�pital Priv� Les Franciscaines|Clinique St Pierre, Perpignan, France|Clinique Ambroise Par�, Neuilly sur Seine, France|H�pital Priv� Clairval, Marseille, France|Infirmerie Protestante de Lyon, Lyon, France|Centre Hospitalo-Universitaire de Brabois, Vandoeuvre Les Nancy, France|Centre Hospitalier R�gional Universitaire Montpellier|Paris Cardiovascular Research Center (Inserm U970)|Clinique Pasteur",All,"18 Years to 80 Years � (Adult, Older Adult)",,215,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2014-30605,November 2013,January 2016,January 2016,"August 13, 2015",,"August 19, 2016","H�pital Priv� Les Franciscaines, N�mes, France",,https://ClinicalTrials.gov/show/NCT02520960,NCT02520960,28643171
oui,NCT02536625,Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative),RAPANK,Completed,No Results Available,Breast Cancer,Other: prospective study,Measure of the level of Granzyme B (GzmB)|Objective Response Rate|Progression-Free Survival (PFS)|Overall Survival (OS)|Intercurrent diseases reporting|Circulating NK functions|mTOR activation status,"Centre Leon Berard|The Biostatistics and Therapy Evaluation Unit|Institut National de la Santé Et de la Recherche Médicale, France|Ligue contre le cancer, France",Female,"18 Years and older   (Adult, Older Adult)",,62,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RAPANK,October 2015,April 2019,December 2019,"September 1, 2015",,"February 4, 2021","Centre Leon Berard, Lyon, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France",,https://ClinicalTrials.gov/show/NCT02536625,NCT02536625,
oui,NCT02537041,Non-invasive Evaluation of Myocardial Stiffness by Elastography,Elasto-Cardio,Completed,No Results Available,Diastolic Heart Failure,Procedure: elastography function ShearWave Imaging|Procedure: MRI,myocardial stiffness ( measured by kPa),"French Cardiology Society|Institut National de la Santé Et de la Recherche Médicale, France",All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2014-02,September 2015,March 2017,July 2017,"September 1, 2015",,"November 6, 2017","Hopital Europeen Georges Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT02537041,NCT02537041,29550319
oui,NCT02539862,Evaluating the Efficacy of the Management of an Online Program of Cognitive Behavioral Therapy for Primary Insomnia,NEXPERTSANTE,Completed,No Results Available,Chronic Insomnia,Other: cognitive behavioral therapy online|Other: psychoeducation,insomnia severity measured|sleep efficiency|Sleep latency|duration of night wakings|total sleep time|Sleep quality|quantity of hypnotic treatment|adherence to CBT-I program online,"University Hospital, Montpellier|Institut National de la Santé Et de la Recherche Médicale, France",All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,9454,"July 9, 2015",May 2016,May 2016,"September 3, 2015",,"May 15, 2018",,,https://ClinicalTrials.gov/show/NCT02539862,NCT02539862,
oui,NCT02542800,The Influence of Collective Schemas on Individual Memory,MULTIBRAIN_2,Completed,No Results Available,Episodic Memory,Behavioral: Episodic memory task|Device: fMRI,Blood Oxygen Level Dependent (BOLD) response as measured with fMRI,"Institut National de la Santé Et de la Recherche Médicale, France|La Région Basse-Normandie|Université de Caen Normandie|University Hospital, Caen|Ecole Pratique des Hautes Etudes|Equipement d'Excellence Matrice",All,20 Years to 38 Years   (Adult),Not Applicable,26,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C14-30|2014-A00650-47,September 2015,"June 1, 2017","June 2, 2017","September 7, 2015",,"December 27, 2017","GIP Cyceron, Caen, France",,https://ClinicalTrials.gov/show/NCT02542800,NCT02542800,
oui,NCT02542891,European Comparative Effectiveness Research on Internet-based Depression Treatment,E-COMPARED,Completed,No Results Available,Depressive Disorder,Other: Blended CBT|Other: Treatment as Usual (TAU),Patient Health Questionnaire-9 (PHQ-9)|QIDS-SR16|M.I.N.I|MADRS,"Institut National de la Santé Et de la Recherche Médicale, France|European Commission|Fondation FondaMental|Assistance Publique - Hôpitaux de Paris",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,105,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C15-16,September 2015,"October 31, 2016","September 15, 2018","September 7, 2015",,"February 21, 2019","Centre Hospitalier Charles Perrens, Bordeaux, France|CHU de Brest, Brest, France|Centre Hospitalier Le Vinatier-, Bron, France|CHU de Clermont- Ferrnand, Clermont- Ferrand, France|Hôpital A. Chenevier, Creteil, France|CHU de Grenoble, Grenoble, France|Hôpital de la conception Pôle Psychiatrie Centre, Marseille, France|CHRU Lapeyronie, Montpellier, France|Hôptial Fernand Widal, Paris, France|CHU de Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT02542891,NCT02542891,34874888;27488181
oui,NCT02555202,Validation of French Version of LCADL and Dyspnea-12,LCADL,Completed,No Results Available,Copd,,"the Saint-Georges questionnaire, item Activity|MMRC Dyspnea scale","University Hospital, Brest",All,"18 Years and older � (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,LCADL (RB 15.037),"October 15, 2015","September 30, 2016","September 30, 2016","September 21, 2015",,"March 31, 2017","Brest University hospital, Morlaix, France",,https://ClinicalTrials.gov/show/NCT02555202,NCT02555202,
oui,NCT02555254,Impact of Speed Of Rewarming After CaRdiac Arrest and ThErapeutic Hypothermia,ISOCRATE,Completed,No Results Available,Heart Arrest|Cardiac Arrest|Hypothermia,Procedure: Low Speed of Rewarming|Procedure: High Speed of Rewarming,Interleukine 6 Dosage|Neurological functional prognosis|Quality of Life-SF-36 score|Life Autonomy|Neurocognitive evaluation|Post traumatic stress disorders|Mortality in the ICU|Mortality at hospital|Mortality at day 90|Duration of hospitalization in ICU|Duration of mechanical ventilation|Comparison of Interleukine 2|Comparison of Interleukine 4|Comparison of Interleukine 8|Comparison of Interleukine 10|Comparison of GM-CSF|Comparison of TNF-Alpha|Comparison of serum neurofilament|Comparison of CRP serum level|Comparison of procalcitonin serum level|Need for vasopressor treatment,"Centre Hospitalier Departemental Vendee|Institut National de la Santé Et de la Recherche Médicale, France|University Hospital, Tours",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CHD2015ISOCRATE,"February 12, 2016","May 17, 2020","June 8, 2020","September 21, 2015",,"March 14, 2022","Colin Gwenhael, La Roche Sur Yon, France",,https://ClinicalTrials.gov/show/NCT02555254,NCT02555254,34920723
associ�,NCT02556359,Consequences of DNA Repair and Telomere Defects on the Function of the Immune System: Application to CVID and Immune Deficiencies With Dysmorphic Syndromes,IMMUNEREP,Unknown status,No Results Available,Immune Deficiency and Early BMF in Childhood,,DNA abnormailities,Assistance Publique - H�pitaux de Paris,All,"Child, Adult, Older Adult",,100,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,RTC13005,July 2015,July 2019,September 2019,"September 22, 2015",,"April 18, 2016","Saint Louis hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02556359,NCT02556359,
oui,NCT02556450,Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure,Homage,Completed,No Results Available,Heart Failure,Drug: Spironolacton,Changes in serum concentrations of PIIINP|changes in serum plasma levels of Biomarkers|Cardiac remodelling 1|Cardiac remodelling 2|Cardiac remodelling 3|Cardiorespiratory performance during exercise|Vascular function|heart failure or AF|Adverse events|Worsening renal function|Hyperkalemia,"ACS Biomarker|Institut National de la Santé Et de la Recherche Médicale, France|London School of Hygiene and Tropical Medicine",All,"60 Years and older   (Adult, Older Adult)",Phase 2,528,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,Homage,January 2016,"September 30, 2018","January 31, 2019","September 22, 2015",,"March 8, 2022","Hopital Sud Francilien, Corbeil-Essonnes, France|CHU de Nancy, Nancy, France|Charite Universitatsmedizin Berlin, Kardiologie, Berlin, Germany|St, Michaels Hospital, Dublin, Ireland|Santa Margherita Hospital, Cortona, Italy|Maastricht University Medical Center, Maastricht, Netherlands|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Castle Hill Hospital, Hull, United Kingdom|Central Manchester University Hospitals NHS, Manchester, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02556450/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02556450,NCT02556450,36065795;34933097;34372849;33549556;31950604;31104495
oui,NCT02556489,Transcriptomics Signature of Anti Vaccinia Memory B Cells,,Unknown status,No Results Available,Healthy,,signature of anti vaccinia long-lived memory B cells,"Institut National de la Santé Et de la Recherche Médicale, France",All,20 Years to 50 Years   (Adult),,12,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C15-23|2015-A00752-47,September 2015,September 2016,September 2016,"September 22, 2015",,"September 30, 2015",,,https://ClinicalTrials.gov/show/NCT02556489,NCT02556489,
oui,NCT02563223,The Effect of Gravity on the Muscular Control of Landing From a Jump,SLS-JUMP,Unknown status,No Results Available,Healthy Volunteers,Other: Parabolic flight|Device: Subject Loading System,Electromyography (Amplitude - mV and latency - ms),"University Hospital, Caen",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11-118,November 2011,October 2015,,"September 30, 2015",,"September 30, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02563223,NCT02563223,
oui,NCT02563236,Evaluation of 3D Selection Tasks in Parabolic Flight Conditions: Pointing Task in Augmented Reality User Interfaces,3DPICK,Completed,No Results Available,Healthy Volunteers,Other: Parabolic flight,Gravity induced change in completion time of a pointing task on a virtual keyboard (ms)|Gravity induced change in error rate of the pointing task|Gravity induced change in accuracy (centimeter) of the pointing task,"University Hospital, Caen",All,21 Years to 55 Years � (Adult),Not Applicable,9,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,12-022,March 2012,June 2013,December 2014,"September 30, 2015",,"September 30, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02563236,NCT02563236,
oui,NCT02563249,"Influence of Gravity on Dexterity, Hand-eye Coordination and Perception of Orientation and Distances",DEXTER0g,Unknown status,No Results Available,Healthy Volunteers,"Other: Parabolic flight|Other: movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements",Gravity induced changes in grip strength (newton) exerted between the fingers measured with strain gauges|Gravity induced changes in oculo-manual coordination measured by the latency (ms) of anticipatory eye movement measurement with videooculography,"University Hospital, Caen",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,12-026,May 2012,December 2015,,"September 30, 2015",,"September 30, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02563249,NCT02563249,
oui,NCT02563262,Human Neutral Body Posture in Weightlessness,HYDRONAUT,Completed,No Results Available,Healthy Participants,Other: body angles measurements during weightlessness,Joint angles,"University Hospital, Caen",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,8,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,12-122,September 2012,January 2014,January 2014,"September 30, 2015",,"September 30, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02563262,NCT02563262,
oui,NCT02563275,"The Operation of Control Devices During Parabolic Flights: Influence of Weightlessness, Stress and Motivation",Grafism,Unknown status,No Results Available,Healthy Volunteers,Other: motion analysis system|Other: parabolic flight,Velocity (deg/sec) of the right hand movement measured with a motion analysis system|Forces (Newton) applied by the hand on the objects to be grasped measured with strain gauges|Torques (N.m) applied by the hand on the objects to be grasped measured with strain gauges|Peak velocity (deg/sec) of the right hand measured with a motin analysis system|Initial force (Newton) on the grasped object measured with strain gauges,"University Hospital, Caen",All,"21 Years to 65 Years � (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,13-002,March 2013,October 2015,,"September 30, 2015",,"September 30, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02563275,NCT02563275,
oui,NCT02564523,"Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults",,Completed,Has Results,"Hemorrhagic Fever, Ebola",Biological: Ad26.ZEBOV|Biological: MVA-BN-Filo|Biological: Placebo,Number of Participants With Adverse Events (Day 29)|Number of Participants With Adverse Events (AEs) (28-Day Interval)|Number of Participants With Adverse Events (56-day Interval)|Number of Participants With Adverse Events (84-day Interval)|Number of Participants With Adverse Events Post-dose 3 (Day 393)|Number of Participants With Serious Adverse Events|Number of Participants With Immediate Reportable Events (IREs)|Number of Participants With Solicited Local Adverse Events (Day 8)|Number of Participants With Solicited Local Adverse Events (28-day Interval)|Number of Participants With Solicited Local Adverse Events Post-dose 2 (56-day Interval)|Number of Participants With Solicited Local Adverse Events (84-day Interval)|Number of Participants With Solicited Local Adverse Events (Day 372)|Number of Participants With Solicited Systemic Adverse Events (Day 8)|Number of Participants With Solicited Systemic Adverse Events (28-Day Interval)|Number of Participants With Solicited Systemic Adverse Events (56-Day Interval)|Number of Participants With Solicited Systemic Adverse Events (84-Day Interval)|Number of Participants With Solicited Systemic Adverse Events (Day 372)|Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against Ebola Virus Glycoprotein (EBOV GP) Measured Using Filovirus Animal Non-Clinical Group (FANG) Enzyme-linked Immunosorbent Assay|Number of Participants With Serious Adverse Events Post-dose 3,"Janssen Vaccines & Prevention B.V.|EBOVAC2 Consortium|Institut National de la Sant� Et de la Recherche M�dicale, France|Centre Muraz",All,"4 Years to 70 Years � (Child, Adult, Older Adult)",Phase 2,1075,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CR107249|VAC52150EBL2002|2019-000690-22,"November 6, 2015","February 12, 2019","February 12, 2019","September 30, 2015","March 7, 2022","March 7, 2022","BoboDioulasso, Burkina Faso|Ouagadougou, Burkina Faso|Abidjan, C�te D'Ivoire|Toupah/Ousrou, C�te D'Ivoire|Nairobi, Kenya|Entebbe, Uganda|Kampala, Uganda","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02564523/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02564523/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02564523,NCT02564523,36450746;35015777;34714820
anrs,NCT02566148,"Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France",PARCOURS,Completed,No Results Available,HIV Infection|Chronic Hepatitis B,,Lapse of time from arrival in France to HIV testing|Lapse of time from arrival in France to hepatitis B testing|Lapse of time from HIV diagnostic to access to care|Lapse of time from hepatitis B diagnostic to access to care|Condom use|Evolution in concurrent sexual partnerships after migration in France|Evolution in occasional sexual partnerships after migration in France|Evolution in transactional sexual partnerships after migration in France,"ANRS, Emerging Infectious Diseases|Ministry of Health, France|Institut de Recherche pour le Developpement|Institut National de la Santé Et de la Recherche Médicale, France|Institut national de prevention et d'education pour la sante",All,18 Years to 59 Years   (Adult),,2468,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,ANRS PARCOURS,February 2012,February 2012,May 2013,"October 2, 2015",,"May 15, 2017",,,https://ClinicalTrials.gov/show/NCT02566148,NCT02566148,29982518;29437866;29307383
oui,NCT02566213,Human Fine-motor-skills in Weightlessness: Comparison of a Laboratory and an Everyday-like Context,FINESKILL,Unknown status,No Results Available,Healthy,Other: Parabolic flight|Other: Motor skills measurements,Gravity induced change in movement time (ms)|Gravity induced change in peak velocity of the hand (deg/sec)|Gravity induced change in the maximum grip aperture of the hand (mm)|Gravity induced change in the initial force applied by the hand on the grasped object (newton),"University Hospital, Caen",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,10-084,October 2010,December 2016,,"October 2, 2015",,"October 2, 2015","Umr Ucbn/Inserm U1075 Comete, Caen CEDEX, Basse-Normandie, France",,https://ClinicalTrials.gov/show/NCT02566213,NCT02566213,
oui,NCT02566538,Prospective Population Based Cohort Study on Cognitive and Cardiovascular Aging (MonaLisaPredor),MLP,Completed,No Results Available,Aging,,Test of memorizing and restitution of words|Level of cardiovascular risk|WAIS-DSST|Stroop test,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,"42 Years to 89 Years   (Adult, Older Adult)",,520,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RC31/12/0400|2012-A00943-40,"May 22, 2013",May 2018,June 2018,"October 2, 2015",,"July 31, 2020","Toulouse University Hospital, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02566538,NCT02566538,
non,NCT02567058,Biomechanical and Ultrasonic Assessment of the Achilles Tendon in Vivo (MEDUSAA),MEDUSAA,Completed,No Results Available,Alterations of the Achilles Tendon,Device: Ultrasound exam|Behavioral: IPAQ questionnaire,Measures of received signals of the ultrasound sensors and measures of applied strength on the pedal during|score IPAQ questionnaire|Examination data|time of hyper stress,"University Hospital, Tours",Male,18 Years to 60 Years � (Adult),Not Applicable,62,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AORT 2011-FP / MEDUSAA,December 2012,July 2015,August 2015,"October 2, 2015",,"October 2, 2015","Univesity Hospital of Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT02567058,NCT02567058,
oui,NCT02567071,Natural Microbiota Restoration After C-section Birth,RESTORE,Completed,No Results Available,Insufficient Intestinal Microbiota Diversity After C-section Birth,Other: perineal impregnated swab|Other: clean swab,Diversity of the intestinal microbiota|Health status,"Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,C14-70|2015-A00586-43,"April 6, 2016",April 2019,April 2019,"October 2, 2015",,"August 26, 2021","Service de Gynécologie-Obstétrique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT02567071,NCT02567071,
oui,NCT02568371,Biobank Based on the i-Share Student Cohort,bio-Share,Completed,No Results Available,Healthy,,The acquisition date of blood samples|The number of the aliquots for each of the stored biological samples|The total volume of the aliquots for each of the stored biological samples|Glucose (fasting)|Total cholesterol (fasting)|High-density lipoprotein cholesterol (fasting)|Low-density lipoprotein-cholesterol (fasting)|Triglycerides (fasting),"University Hospital, Bordeaux|National Research Agency, France",All,"18 Years and older � (Adult, Older Adult)",,1997,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHUBX2015/07,"October 6, 2015","November 30, 2017","November 30, 2017","October 5, 2015",,"March 18, 2019","Centre Hospitalier Universitaire de Bordeaux - PELLEGRIN, Bordeaux, Aquitaine, France",,https://ClinicalTrials.gov/show/NCT02568371,NCT02568371,
oui,NCT02570100,Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells (RepriM),,Terminated,No Results Available,Breast Cancer,Procedure: Biological collection,"Complete histopathological response|Evaluation of the expression of genes involved in reprogramming by immunohistochemistry and Reverse Transcription Polymerase Chain Reaction (RT-PCR) according to the rate of CSCs before, during and after chemotherapy.|Evaluation of relapse-free survival|Quantification of the frequency of Cancer Stem Cells (CSCs) among the population of Circulating Tumor Cells (CTCs).","Centre Oscar Lambret|Institut National de la Santé Et de la Recherche Médicale, France|Institut pour la Recherche sur le Cancer de Lille",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,56,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RepriM-1407,April 2015,July 2017,"October 6, 2020","October 7, 2015",,"October 25, 2021","Centre Oscar Lambret, Lille, France",,https://ClinicalTrials.gov/show/NCT02570100,NCT02570100,
oui,NCT02570334,A Cross Sectional Evaluation of the Development in Children Age 4 to 7 Infected or Exposed to HIV From the ANRS 12140 Cohort (Pediacam),PediacamDEV,Unknown status,No Results Available,HIV|HIV-uninfected Children|Children Exposed to HIV,Other: HIV-infected children initiated antiretroviral treatment within the first 7 months of life,"Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments|Compared frequency of motor, cognitive and sensorial impairments between infected and uninfected children|Effect of early ARV (<3 months) versus differed ARV (between 3 and 7 months) on neurocognitive impairments|Prognostic factors and consequences of HIV-associated neuro-cognitive impairments","ANRS, Emerging Infectious Diseases|Centre Pasteur du Cameroun|Hopital Universitaire Robert-Debre|Institut de Recherche pour le Developpement|Centre M�re et Enfant de la Fondation Chantal Biya|Hospital General De Douala|Centre Hospitalier D'essos|Inserm U1018, Equipe 4 VIH & IST",All,4 Years to 7 Years � (Child),Not Applicable,400,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,ANRS 12322 PediacamDEV,December 2015,October 2016,December 2016,"October 7, 2015",,"July 12, 2016","H�pital de Laquintinie, Douala, Cameroon|Centre Hospitalier d'Essos, Yaounde, Cameroon|H�pital de la Fondation M�re-enfant Chantal Biya, Yaounde, Cameroon",,https://ClinicalTrials.gov/show/NCT02570334,NCT02570334,
oui,NCT02573298,Cryotherapy and Doppler in Inflammatory Rheumatic Diseases,CDRI,Completed,No Results Available,Rheumatoid Arthritis|Crystal-induced Arthritides|Spondyloarthritis,Device: ice|Device: cold gas,"Power Doppler score change (Naredo's 0-3 semi-quantitative scale)|IL-6 levels in knee synovial fluid change (Multiplex, cytometry)|pain VAS change (numeric scale)|synovial fluid leukocyte count change (per mm3)|IL-1beta, TNF-alpha, IL-17, VEGF level changes in the synovial fluid (Multiplex, cytometry)|skin temperature change (°C, skin temperature probe in the application area)","Centre Hospitalier Universitaire de Besancon|Clinical Investigation Centre for Innovative Technology Network|Groupement Interrégional de Recherche Clinique et d'Innovation|Etablissement Français du Sang|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,P/2012/148,February 2013,"March 9, 2017","March 9, 2017","October 9, 2015",,"March 20, 2017","Centre hospitalier universitaire de Besançon, Besançon, Franche-Comté, France",,https://ClinicalTrials.gov/show/NCT02573298,NCT02573298,27825572
anrs,NCT02573948,Feasibility of Interventions on People Who Inject Drugs in Vietnam,DRIVE-IN,Completed,Has Results,HIV|Hepatitis Virus|Substance Abuse,Other: no intervention is assessed,Number of Cohort Participants Attending the Last Follow-up Visit at W52|HCV Seroconversion|HIV Seroconversion|Incidence of HCV Infection|HIV Incidence,"ANRS, Emerging Infectious Diseases|National Institute on Drug Abuse (NIDA)",All,"18 Years and older � (Adult, Older Adult)",,603,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ANRS12299 DRIVE IN|P30DA011041,September 2014,June 2015,June 2016,"October 12, 2015","August 8, 2018","September 18, 2018","Hai Phong Medical University, Hai Phong, Vietnam",,https://ClinicalTrials.gov/show/NCT02573948,NCT02573948,
oui,NCT02573974,Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer,METERMUCADIG,Completed,No Results Available,Undernutrition|Gastrointestinal Cancer,Other: Samples,Measurement of muscle mitochondrial bioenergetics|Quantification of muscle lipid droplets|Analysis of the expression of target genes and proteins|Determination of body composition (fat mass / lean mass)|Determining the isotopic composition of nitrogen hair,"University Hospital, Tours|Inserm U1069 - Team Nutrition, Growth and Cancer",All,"18 Years to 80 Years � (Adult, Older Adult)",Not Applicable,51,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,PHAO14-TL/METERMUCADIG|2015-A00683-46|2015-R25|150963B-12,"January 19, 2016","December 4, 2018","December 4, 2018","October 12, 2015",,"September 26, 2019","Service d'H�pato-gastroent�rologie et de Canc�rologie Digestive, CHRU de TOURS, Tours, France",,https://ClinicalTrials.gov/show/NCT02573974,NCT02573974,35316572
oui,NCT02575625,"Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis",TRANSTEATOSE,Unknown status,No Results Available,Liver Steatosis,Device: Fibroscan|Biological: Blood test for biological assessment of liver function|Device: MRI,Viscosity in Pa.s|Elasticity in kPa|Reproductibility quantification in arbitrary unit|Age in years|Liver signal intensity changes in decibel,"University Hospital, Tours|Echosens|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,85,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PHAO2011-FP/TRANSTEATOSE,April 2013,October 2015,October 2015,"October 14, 2015",,"October 16, 2015","University Hospital of Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT02575625,NCT02575625,
oui,NCT02580812,Neurological Consequences of Perinatal Listeriosis Infection,MONALISABABY,Completed,No Results Available,Perinatal Listeriosis,Other: Clinical and neuropsychological evaluation procedure,Reduction of > 20 points of the Intellectual Quotient|Score obtained at M-ABC evaluation test (Movement-ABC)|Score obtained at SDQ evaluation test (Strenghts and Difficulties Questionnaire)|Score obtained at SCQ evaluation test (Social Communication Questionnaire)|Score obtained at BRIEF-P evaluation test (Behavior Rating Inventoring Executive Function)|Score obtained at HOME evaluation test (Home Observation and Measurement of Environment)|Score obtained at Vineland Scale|Scores obtained at NEPSY-2 evaluation tests,"Assistance Publique - Hôpitaux de Paris|Institut Pasteur|Institut National de la Santé Et de la Recherche Médicale, France",All,5 Years to 6 Years   (Child),Not Applicable,53,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P140940,"October 26, 2015","October 29, 2018","October 29, 2018","October 20, 2015",,"April 5, 2021","Hôpital Necker-Enfants Malades, Paris, France",,https://ClinicalTrials.gov/show/NCT02580812,NCT02580812,
oui,NCT02584439,Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC),BRADYVASC,Unknown status,No Results Available,Healthy|Vascular Stiffness|Aging,Drug: ivabradine|Drug: lactose capsule (placebo),Change from baseline in viscosity of the common carotid artery|Change from baseline in diameter of the common carotid artery|Change from baseline in intima-media thickness of the common carotid artery|Change from baseline in carotid distensibility|Change from baseline in carotid-femoral pulse wave velocity|Change from baseline in plasma levels of biomarkers of endothelial function|Change from baseline in peripheral and central pressures|Change from baseline in Buckberg index|Change from baseline in cardiac output,"University Hospital, Rouen|Institut National de la Santé Et de la Recherche Médicale, France",All,"25 Years to 65 Years   (Adult, Older Adult)",Phase 3,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2015/077/HP|2015-002060-17,October 2015,August 2017,September 2017,"October 22, 2015",,"December 7, 2016","Department of Pharmacology, Rouen university Hospital, Rouen, France",,https://ClinicalTrials.gov/show/NCT02584439,NCT02584439,
oui,NCT02586961,Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies.,EPIDEX,Terminated,No Results Available,Children|Bronchiolitis,Drug: 0.9% saline solution|Drug: oral betamethasone placebo|Drug: adrenaline|Drug: oral betamethasone,"Hospital admission up to 7 days after enrollment, which occurred during the visit in the emergency department|PICU admission rate following examination in the emergency ward|Length of hospitalization for infants admitted for bronchiolitis in the following 7 days after inclusion|Variation of RDAI scores before and after nebulization|Adverse events during the following 7 days after inclusion","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,6 Weeks to 12 Months   (Child),Phase 2|Phase 3,195,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P140929|2015-002477-38,October 2015,September 2017,October 2017,"October 27, 2015",,"September 12, 2017","AP-HP, Antoine Béclère Hospital, Clamart, France",,https://ClinicalTrials.gov/show/NCT02586961,NCT02586961,
oui,NCT02592174,"Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study",HAND55-70,Completed,No Results Available,HIV-1 Infection,Other: Health related quality of life and social and demographic informations|Other: Neurocognitive assessment|Radiation: cerebral images sub-study,The Prevalence of Neurocognitive troubles HAND in the HIV-infected and to compare it with the prevalence in the HIV-unexposed population in the CONSTANCES cohort.|The prevalence of Asymptomatic Neurocognitive Impairment (ANI)|The prevalence of HIV-Associated Dementia(HAD)|The prevalence of Mild Neurocognitive Disorder (MND)|Cognitive score distributions untreated or after transformation according to their distribution characteristics|Physical score distributions untreated or after transformation according to their distribution characteristics|A comparison of a global cognitive score in both populations after standardized normal reduction of each test.,"ANRS, Emerging Infectious Diseases|Merck Sharp & Dohme LLC",All,"55 Years to 70 Years � (Adult, Older Adult)",Not Applicable,220,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,ANRS EP58 HAND 55-70,"January 26, 2016","October 27, 2017","October 27, 2017","October 30, 2015",,"January 8, 2018","Centre Hospitalier de Cannes - Service de M�decine Interne Oncologie, Cannes, France|H�pital Michallon- Service des Maladies Infectieuses, Grenoble, France|H�pial Sainte Marguerite - Service d'h�matologie-Cisih, Marseille, France|H�pital Gui de Chauliac - Service des Maladies Infectieuses, Montpellier, France|H�pital Car�meau - Service des Maladies Infectieuses, N�mes, France|H�pital Bretonneau - Service des Maladies Infectieuses, Tours, France",,https://ClinicalTrials.gov/show/NCT02592174,NCT02592174,31755936
oui,NCT02597361,Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE),ARCADE,Completed,No Results Available,"Ehlers-Danlos Syndrome, Vascular Type",Drug: Irbesartan|Drug: Placebo,"Cardiovascular morbidity and mortality|Arterial lesions|Rate of any symptomatic cardiovascular event|Occurrence of new asymptomatic arterial lesions (aneurysm, dissection), detected by a systematic CTA|Time to first symptomatic clinical morbid and fatal events|Number of unplanned hospitalization for any vEDS related event|Total number of arterial lesions detected by vascular DUS|Total number of arterial lesions worsened during follow-up|Changes in PWV (Pulse Wave Velocity)|Changes in large arteries properties (diameter, wall stress, stiffness)|Decrease in office systolic/diastolic BP|Change in estimated glomerular filtration rate (MDRD)|Tolerability and safety of the irbesartan assessed by orthostatic hypotension, plasma creatinine, plasma K+ evaluated at each visit|Compliance to treatment|Quality of life","Assistance Publique - H�pitaux de Paris|Ministry of Health, France",All,"18 Years to 70 Years � (Adult, Older Adult)",Phase 3,61,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P140918|2015-001065-76,January 2016,"February 19, 2020","February 19, 2020","November 5, 2015",,"November 3, 2020","CHU DE BORDEAUX - Hopital Saint Andre, Bordeaux, France|CHU DE LYON - Hopital Femme Mere Enfant, Bron, France|CHU DE CAEN - Hopital Cote de Nacre, Caen, France|CHU DE TOURS - Hopital Trousseau, Chambray-les-Tours, France|CHU DE GRENOBLE - Hopital Albert Michallon, Grenoble, France|CHU DE GRENOBLE - Hopital Couple Enfant, Grenoble, France|CHRU DE LILLE - Hopital Claude Huriez, Lille, France|CHU DE LYON - Hopital Edouard Herriot, Lyon, France|AP-HM - Hopital de la Timone, Marseille, France|CHU DE MONTPELLIER - Hopital Saint Eloi, Montpellier, France|CHU DE NANTES - Hopital Hotel-Dieu, Nantes, France|AP-HP - Hopital Europeen Georges-Pompidou, Paris, France|CHU DE TOULOUSE - Hopital Purpan, Toulouse, France|CHU DE TOULOUSE - Hopital Rangueil, Toulouse, France|CHRU DE NANCY - Institut Lorrain du Coeur et des Vaisseaux, Vandoeuvre-les-Nancy, France",,https://ClinicalTrials.gov/show/NCT02597361,NCT02597361,
oui,NCT02598219,Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.,SENTIRAD,"Active, not recruiting",No Results Available,Endometrial Carcinoma,Drug: Pre-operative SN mapping with radionucleide|Drug: Intra-operative SN mapping with patent V blue dye|Drug: Intra-operative SN mapping with indocyanin green|Procedure: Full bilateral laparoscopic lymphadenectomy and Hysterectomy|Procedure: Current initial staging protocols,Morbidity|Rate of detected sentinel node|Rate of pN1|Disease free survival|Overall survival|Pronostic value of L1CAM on the risk of reccurrence|Proteomic signature of positive SN,"Centre Oscar Lambret|National Cancer Institute, France|Institut National de la Santé Et de la Recherche Médicale, France|Canceropôle Nord Ouest",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,262,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SENTIRAD-1502,November 2015,October 2024,October 2027,"November 5, 2015",,"December 7, 2022","Polyclinique Urbain V, Avignon, France|Centre Hospitalier Régional Universitaire, Besançon, France|Institut Bergonié, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Hôpital Jeanne de Flandres, CHRU Lille, Lille, France|Hôpital Mère-Enfant, CHU Limoges, Limoges, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes, Marseille, France|ICM Val d'Aurelle, Montpellier, France|Hôpital La Pitié-Salpêtrière, Paris, France|Hôpital Européen Georges Pompidou, Paris, France|Institut de Cancérologie de l'Ouest, René Gauducheau, Saint-Herblain, France|Centre Paul Strauss, Strasbourg, France|Institut Claudius Regaud, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02598219,NCT02598219,34195683
non,NCT02602847,Study of Covalently Closed Circular DNA (cccDNA) in Liver Transplant Patients With B Virus Markers,ECOGREFFE-B,Completed,No Results Available,Liver Transplantation,Biological: cccDNA assay on liver biopsy,cccDNA rate on native explant and liver transplant during transplantation and on liver biopsy|Correlation between cccDNA rate and serologic status|Correlation between cccDNA rate and virologic status|Correlation between cccDNA rate and patient's treatment,Hospices Civils de Lyon,All,"18 Years and older � (Adult, Older Adult)",,40,Other,Observational,Observational Model: Other|Time Perspective: Prospective,2012.720,November 2012,November 2018,November 2018,"November 11, 2015",,"January 11, 2019","CHU Grenoble, La Tronche, France|Service d'H�patologie, H�pital de la Croix-Rousse, Lyon, France|H�pital Saint Eloi, Montpellier, France|CHU de Nice, Nice, France|H�pital Paul Brousse, Villejuif, France",,https://ClinicalTrials.gov/show/NCT02602847,NCT02602847,37122357
oui,NCT02603653,Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease,MEMOCUSH,Unknown status,No Results Available,Cushing's Disease,Device: Virtual radial task in 3D,Percentage of right answers at virtual radial task in 3D|General Quality of life|Specific Quality of life for Cushing's Disease|Number of participants with anxiety|Number of participants with depression with MADRS|Number of participants with depression with HADS|Intensity of Cushing's syndrome,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C15-02|IDRCB,November 2015,May 2016,May 2017,"November 13, 2015",,"November 13, 2015","Hôpital du Haut-Lévêque, Pessac, France",,https://ClinicalTrials.gov/show/NCT02603653,NCT02603653,36004342
oui,NCT02605512,BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study,BACCARAT,Unknown status,No Results Available,Breast Cancer|Cardiac Toxicity,Other: Subclinical cardiac lesions and biomarkers,Number of patients with decreased myocardial function assessed by echocardiography|Number of patients with increased coronary plaques assessed by CT coronary angiography|Decrease in the strain or strain rate|Modification in series of circulating biomarkers of cardiac lesions|Correlation between the absorbed radiation dose by the whole heart and different structures of the heart and measurements of strain and strain rate and indices of coronary plaques,"Sophie JACOB|Institut de Radioprotection et de Surete Nucleaire|Clinique Pasteur|Institut National de la Santé Et de la Recherche Médicale, France",Female,"50 Years to 70 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,IRSN_2015-A00990-49,October 2015,September 2019,September 2020,"November 16, 2015",,"June 19, 2018","Clinique Pasteur, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02605512,NCT02605512,32819449;31727075;30732640;27056179
oui,NCT02619565,Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes,MDS04,Completed,No Results Available,Myelodysplastic Syndromes,Other: blood samples,"Number of patients who survived event-free|Number of surviving patients|Number of mutations on event-free survival in myelodysplastic syndromes|Number of medullary blast and Hemoglobin, platelet and neutrophil polynuclear","Assistance Publique - Hôpitaux de Paris|Groupe Francophone des Myelodysplasies|Institut National de la Santé Et de la Recherche Médicale, France|Institut Cochin|Gustave Roussy, Cancer Campus, Grand Paris",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,349,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,AOM09236 - P081246,"April 12, 2010","June 12, 2017","June 12, 2017","December 2, 2015",,"March 19, 2018","Assistance publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT02619565,NCT02619565,
oui,NCT02624817,Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes,SuResponsKIR,Completed,No Results Available,Permanent Neonatal Diabetes Mellitus,Drug: Sulfonylurea,Sulfonylurea efficacy|Metabolic control|All cause mortality|Incidence of hypoglycemia|Incidence of ketoacidosis|Development of diarrhea|Development of discoloured teeth|Insulin secretory response to intravenous glucose|Insulin secretory response to oral glucose|Sulfonylurea dose|Insulin secretory response to a glucagon test,"Haukeland University Hospital|University of Bergen|University of Exeter|Royal Devon and Exeter NHS Foundation Trust|Institut National de la Santé Et de la Recherche Médicale, France|Hôpital Necker-Enfants Malades|University of Rome Tor Vergata",All,"9 Years and older   (Child, Adult, Older Adult)",Phase 4,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,167.06,December 2015,August 2016,August 2016,"December 8, 2015",,"October 3, 2017","Haukeland University Hospital, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT02624817,NCT02624817,31932458;29880308
oui,NCT02624830,Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR),SuResponsSUR,Unknown status,No Results Available,Permanent Neonatal Diabetes Mellitus,Drug: Sulfonylurea,Sulfonylurea efficacy|Metabolic control|All cause mortality|Incidence of hypoglycemia|Incidence of ketoacidosis|Development of diarrhea|Development of discoloured teeth|Insulin secretory response to intravenous glucose|Insulin secretory response to oral glucose|Sulfonylurea dose|Insulin secretory response to a glucagon test,"Haukeland University Hospital|University of Bergen|University of Exeter|Royal Devon and Exeter NHS Foundation Trust|Institut National de la Santé Et de la Recherche Médicale, France|Hôpital Necker-Enfants Malades|University of Rome Tor Vergata",All,"9 Years to 95 Years   (Child, Adult, Older Adult)",Phase 4,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,167.06b,"February 15, 2019",February 2020,February 2020,"December 8, 2015",,"February 12, 2020","Haukeland University Hospital, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT02624830,NCT02624830,33184150
oui,NCT02626286,Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa,CohMSM,Completed,No Results Available,HIV Infection,Other: HIV quarterly global care,Number of people followed after 3 years compared to the number of persons included (retention in the program)|Percentage of performed visits/scheduled visits|Percentage of performed tests/scheduled tests|Incidence of sexually transmitted infections|Number of unprotected anal sex|Antiretroviral therapy initiation probability in HIV-positive MSM|Antiretroviral therapy maintenance probability in HIV-positive MSM|Percentage of antiretroviral therapy observance in HIV-positive MSM|Percentage of HIV-positive MSM with viral load>1000 copies/mL|Percentage of HIV-positive MSM with CD4?reference (or CD4<100/mm3)|Percentage of HIV-positive MSM with new or recurrent AIDS-defining events (clinical stage 4)|Percentage of HIV-positive MSM died under antiretroviral therapy|Percentage of HIV-positive MSM with detectable viral load and inconsistent condom use with a partner seronegative or with unknown HIV status|Number of HIV subtypes / circulating recombinant forms|Number of co-infections with several viral variants|Number of transmitted and acquired resistance mutations|Number of male sex partners,"ANRS, Emerging Infectious Diseases|Expertise France|Universit� Montpellier|IRD Unit� SESSTIM (IRD, Inserm, Universit� Aix-Marseille)|Coalition Internationale Sida|ARCAD-SIDA MALI|Espace Confiance, C�te d'Ivoire|Programme PAC-CI, Abidjan, C�te d'Ivoire|Association African Solidarit�|Centre de Recherche Internationale pour la Sant�, Ouagadougou, Burkina Faso|Espoir Vie-Togo - ONG",Male,"18 Years and older � (Adult, Older Adult)",Not Applicable,885,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS 12324 CohMSM,June 2015,"January 5, 2021","January 5, 2021","December 10, 2015",,"April 22, 2021","Centre Oasis, Association African Solidarit� (AAS), Ouagadougou, Burkina Faso|Clinique de Confiance, Espace Confiance, Abidjan, C�te D'Ivoire|Clinique des Halles, ARCAD-SIDA, Bamako, Mali|Espoir vie Togo, Lome, Togo",,https://ClinicalTrials.gov/show/NCT02626286,NCT02626286,34352834;34022820;33753460
oui,NCT02627196,Baroreflex Activation Therapy for Heart Failure,BeAT-HF,"Active, not recruiting",No Results Available,Heart Failure,Device: BAROSTIM NEO� System|Drug: Medical Management,Rate of Cardiovascular Mortality and Heart Failure Morbidity|Major Adverse Neurological and Cardiovascular Events (MANCE)|Amino-terminal prohormone of brain natriuretic peptide (NT-proBNP)|Six Minute Hall Walk (6MHW)|Minnesota Living With Heart Failure Quality of Life (MLWHF QOL),"CVRx, Inc.",All,"21 Years and older � (Adult, Older Adult)",Not Applicable,1200,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,360043-001,"April 19, 2016",December 2023,December 2023,"December 10, 2015",,"January 23, 2023","Heart and Rhythm Solutions, PLLC, Chandler, Arizona, United States|Chan Heart Rhythm Institute, Mesa, Arizona, United States|Arizona Arrhythmia Research Center, Phoenix, Arizona, United States|Phoenix Cardiovascular Research Group, Phoenix, Arizona, United States|Cardiovascular Consultants, Ltd., Phoenix, Arizona, United States|Washington Regional Medical Center, Fayetteville, Arkansas, United States|Central Cardiology Medical Center, Bakersfield, California, United States|Chula Vista Cardiac Center, Chula Vista, California, United States|Sharp Grossmont, Chula Vista, California, United States|Sharp Chula Vista Medical Center, Chula Vista, California, United States|John Muir Health Clinical Research Center, Concord, California, United States|University of California, San Francisco - Fresno, Fresno, California, United States|Herndon Surgery Center, Fresno, California, United States|Glendale Adventist Medical Center, Glendale, California, United States|Memorial Health Services, Laguna Hills, California, United States|Los Alamitos Cardiovascular, Los Alamitos, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|University of Southern California, Los Angeles, California, United States|Advanced Cardiovascular Specialists, Mountain View, California, United States|Hoag Memorial Hospital, Newport Beach, California, United States|UC Irvine Health, Orange, California, United States|Desert Heart Regional Medical Center, Palm Springs, California, United States|Huntington Hospital, Pasadena, California, United States|Dignity Health, Sacramento, California, United States|Adventist Heart Institute, Saint Helena, California, United States|University of California San Francisco, San Francisco, California, United States|Bonometti, Inc, Santa Barbara, California, United States|North Colorado Medical Center, Greeley, Colorado, United States|Medical Center of the Rockies Research, Loveland, Colorado, United States|Atlantic Clinical Research Center - Cardiology, Atlantis, Florida, United States|Clearwater Cardiovascular Consultants, Clearwater, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Memorial Cardiovascular Institute, Hollywood, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Avanza Medical Research Center, Pensacola, Florida, United States|University of South Florida, Tampa, Florida, United States|Mercer University, Macon, Georgia, United States|WellStar Medical Group, Marietta, Georgia, United States|St. Alphonsus Medical Center, Boise, Idaho, United States|NorthShore University Health System, Evanston, Illinois, United States|Advocate Medical Group, Naperville, Illinois, United States|Prairie Education and Research Cooperative, Springfield, Illinois, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|Via Christi Research, Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Cardiovascular Institute of the South, Houma, Louisiana, United States|Tulane University & Vascular Institute, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|St. Elizabeth's Medical Center, Brighton, Massachusetts, United States|Detroit Medical Center Cardiovascular Institute, Detroit, Michigan, United States|Ascension St. Mary's Research Institute, Saginaw, Michigan, United States|Providence-Providence Park Hospital, Southfield, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University, Saint Louis, Missouri, United States|St. Louis Heart and Vascular, Saint Louis, Missouri, United States|Mercy Hospital St. Louis, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|Nebraska Heart Institute, Lincoln, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Healthcare Partners Clinical Research, Las Vegas, Nevada, United States|Deborah Heart and Lung Center, Browns Mills, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Presbyterian Heart Group, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|St. Francis Hospital - Long Island, Roslyn, New York, United States|Cone Health, Greensboro, North Carolina, United States|WakeMed, Raleigh, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|The Christ Hospital, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oklahoma Cardiovascular Research Group, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Drexel University, Philadelphia, Pennsylvania, United States|Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|McLeod Cardiology Associates, Florence, South Carolina, United States|Stern Cardiovascular Foundation, Germantown, Tennessee, United States|Texas Cardiac Arrhythmia Research Foundation, Austin, Texas, United States|Cardiovascular Research Institute of Dallas, Dallas, Texas, United States|Private Practice Leadership, Houston, Texas, United States|Methodist Richardson Medical Center, Richardson, Texas, United States|Tyler Cardiovascular Consultants, Tyler, Texas, United States|Intermountain Heart Institute, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Mason Medical Center, Seattle, Washington, United States|CHI Franciscan Health Research Center, Tacoma, Washington, United States|Columbia St. Mary's Hospital, Milwaukee, Wisconsin, United States|Royal Papworth Hospital NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom|Liverpool Heart and Chest Hospital, Liverpool, Merseyside, United Kingdom|Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom|Belfast Health & Social Care Trust, Belfast, Northern Ireland, United Kingdom",,https://ClinicalTrials.gov/show/NCT02627196,NCT02627196,33992562;32616150;30118942
oui,NCT02628340,Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients,RESACHRON,Completed,No Results Available,HIV,Other: Ex-vivo analysis,"measure of HIV reservoirs in a selected HIV chronically infected ARV treated population assessed by HIV DNA distribution in PBMCs, total and sorted CD4 T cells subsets.|measure of host molecular signatures and transcriptional activity in each subset assessed by microfluidic qRT-PCR (Fluidigm)|measure of in vitro inducibility of the HIV provirus in the different sorted CD4 subsets harboring the HIV r�servoirs assessed by ultrasensitive real-time RT-PCR assay|measure of defective viral population estimated by the proportion of stop codons in the integrated HIV-DNA assessed by ultra deep sequencing and|measure of levels of unspliced HIV transcripts in total and different subsets of CD4 T cells.|measure of serum inflammatory biomarkers assessed by ELISA assay|measure of immune activation in the different sorted CD4 T cell subsets assessed by flow cytometry on fresh blood",Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida|INSERM UMR S 1136|Bristol-Myers Squibb,All,"18 Years and older � (Adult, Older Adult)",,20,Other|Industry,Observational,Time Perspective: Cross-Sectional,CREPATS 002,June 2014,June 2016,July 2016,"December 11, 2015",,"August 2, 2016","Groupe Hospitalier Piti�-Salp�tri�re - Service des Maladies Infectieuses et Tropicales, Paris, France",,https://ClinicalTrials.gov/show/NCT02628340,NCT02628340,
oui,NCT02628808,Susceptibility Genes in Autism Spectrum Disorders,,Unknown status,No Results Available,Autism Spectrum Disorders,,Prevalence of synaptic gene deleterious mutations in patients with Autism Spectrum Disorder|Identification of biological pathways in Autism Spectrum Disorders,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Months to 70 Years   (Child, Adult, Older Adult)",,1000,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C07-33|2008-A00019-46,August 2008,August 2016,August 2018,"December 11, 2015",,"December 11, 2015","Albert Chenevier Hospital, Creteil, Ile de France, France|Robert Debré Hospital, Paris, Ile de France, France",,https://ClinicalTrials.gov/show/NCT02628808,NCT02628808,34774105;31418129;31123562;28566948
oui,NCT02633150,Assessing the Value of Red Grapes Polyphenol Supplementation on Metabolic Parameters in Obese Insulinoresistant Subjects,POLYGIR,Completed,No Results Available,Obesity|Insulin Resistance|Menopause,Other: Supplementation with red grapes polyphenol,Measure of systemic insulin sensitivity (estimated by GIR :rate glucose infusion) measured by hyperinsulinemic-euglycemic clamp|Measure of insulin sensitivity to tissue (fat and muscle by measure ratio phosphoAKT/AKT measured by Western BLOT) before and after the supplementation|Measure of systemic concentration (by Multiplex),"University Hospital, Montpellier|Institut National de la Santé Et de la Recherche Médicale, France",All,"50 Years to 65 Years   (Adult, Older Adult)",Not Applicable,23,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",9501|2014-A01627-40,"October 6, 2015","June 6, 2020","June 6, 2020","December 17, 2015",,"December 21, 2021","CHU Montpellier - Lapeyronie hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02633150,NCT02633150,
oui,NCT02635854,Study of Platelet Activation in Septic Shock Patients,PASS,Completed,No Results Available,Septic Shock,Other: Septic choc group|Other: Orthopedic surgery group,"Level of platelets activation markers expression (CD62-P, antibody CD63, CD42b)|Level of platelets activation markers expression (CD62-P, CD63, CD42b)|Rate of leukocyte-platelet aggregates|Kinetics of leukocyte-platelet aggregates formation|Correlation of leukocyte-platelet aggregates rate and septic shock severity.|Comparison of platelet activation in subjects treated or not with antiplatelet agents.","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,27,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RC31/15/7738|15 7738 02,March 2016,January 2017,"January 5, 2017","December 21, 2015",,"August 14, 2018","CHU Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02635854,NCT02635854,
oui,NCT02648100,Basal Like Bladder Cancer : Signature and Therapeutic,DIATRIBBE,Unknown status,No Results Available,Muscle Invasive Bladder Cancer|Molecular Taxonomy,Other: biomarker study,Progression free survival|Overall survival|Specific survival,"Assistance Publique - Hôpitaux de Paris|Ministry of Health, France|National Cancer Institute, France|Institut National de la Santé Et de la Recherche Médicale, France|Paris 12 Val de Marne University|Institut Curie",All,"18 Years to 70 Years   (Adult, Older Adult)",,911,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,NI 13021,March 2014,December 2019,December 2019,"January 6, 2016",,"June 20, 2017","Henri Mondor Hospital, Creteil, France",,https://ClinicalTrials.gov/show/NCT02648100,NCT02648100,
oui,NCT02650219,Auto-antibodies Prevalence and CD1 Role in Gaucher Disease,,Completed,Has Results,Gaucher Disease,Genetic: genetic analyses,"Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acid?-glucosidase Activity Activity <15% in Blood Leucocytes Completed When Necsssary by GB1 Mutation Analyses (Analyses From Samples)|Number of Patients With : Splenectomy and/or Bone Events and/or Pulmonary Hypertension and/or Specific Treatment and Non-specific (Medical History,Physiological Parameters and Questionnaire)|Number of Patients With : Photosensitivity and/or Raynaud Phenomenon and/or Sicca Syndrome and/or Arthralgia and/or Arthritis and/or Thrombosis (Medical History and Questionnaire)|Number of Patients With : Antinuclear and/or Anti-SSa and/or Anti-SSb and/or Anti-RNP and/or Anti-DNA and/or Anti-Sm and/or Anticardiolipid and/or Anti ?2Gp1 and/or Antiganglioside Autoantibodies (Genetics Analyses From Blood Samples)","Hospital St. Joseph, Marseille, France",All,"18 Years and older � (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,ID-RCB 2010-A00315-3,January 2010,December 2015,December 2015,"January 8, 2016","January 8, 2016","March 23, 2016","Internal Medicine Department, H�pital Minjoz,, Besan�on, France|Intensive Care Department, H�pital Pellegrin,, Bordeaux, France|Internal Medicine Department, H�pital Beaujon,, Clichy, France|Internal Medicine and Clinical Immunology Department, CHU,, Dijon, France|Internal Medicine Department, Catholic University,, Lille, France|Internal Medicine Department, CHU, Nantes, Nantes, France|Internal Medicine and Rheumatology Department, H�pital La Croix Saint Simon,, Paris, France|Internal Medicine Department, CHU la Piti� Salp�tri�re,, Paris, France|13 Internal Medicine Department, CHU,, Rouen, France|CHRU de Tours, Universit� Fran�ois Rabelais, INSERM 1069,, Tours, France|Internal Medicine and Immunology Department, CHU H�pital Brabois,, Vandoeuvre les Nancy, France",,https://ClinicalTrials.gov/show/NCT02650219,NCT02650219,
oui,NCT02650427,A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection,HCC-DPPIV,Completed,No Results Available,Hepato Carcinoma,Drug: Sitagliptin,Safety (Number of adverse events. Toxicity grade > 3)|DPPIV Activity|CXCL10 truncation|Immune cells trafficking|Infiltration of leucocytes in tumor tissue,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 1,14,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C15-41|2015-002968-17,February 2016,September 2018,September 2018,"January 8, 2016",,"October 18, 2018","Pitié-Salpêtrière Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02650427,NCT02650427,
oui,NCT02654691,Chronic Neuropathy Following Chemotherapy,DOLORISKCIPN,Completed,Has Results,Peripheral Nervous System Diseases|Chronic Pain,,Chemotherapy-induced Peripheral Neuropathy|Chemotherapy-induced Neuropathic Pain|Sensory Abnormalities After Chemotherapy Assessed With Quantitative Sensory Testing (QST).|Neuronal Excitability Changes After Chemotherapy Assessed With Threshold Tracking: Sensory|Anxiety and Depression Using the Patient Reported Outcomes Measurement Information System (PROMIS).|Anxiety and Depression Using the Hospital Anxiety and Depression Scale (HADS).|Fatigue Using the Patient Reported Outcomes Measurement Information System (PROMIS).|Quality of Life Using EuroQol (EQ-5D).|Personality Using the 10-item Personality Inventory (TIPI).|Personality Using the International Personality Item Pool (IPIP).|Pain Catastrophizing Using the Pain Catastrophizing Scale(PCS).|Morphology of Small Fibers in Cornea After Chemotherapy by Corneal Confocal Microscopy (CCM).|Blood Samples DNA|Pain Interference by Patient Reported Outcomes Measurement Information System (PROMIS).|Pain Descriptors by Douleur Neuropathique 4 (DN4).|Pain Descriptors by Neuropathic Pain Symptom Inventory (NPSI).|Neuropathy Using the Toronto Clinical Scoring System (TCSS).|Neuropathy Using the Total Neuropathy Score.|Neuropathy Using the Michigan Neuropathy Screening Instrument (MNSI).|Neuronal Excitability Changes After Chemotherapy Assessed With Threshold Tracking: Motor,"Danish Pain Research Center|University of Oxford|Imperial College London|University of Dundee|Mentis Cura|Institut National de la Santé Et de la Recherche Médicale, France|University of Kiel|Lund University|Technion, Israel Institute of Technology|University Ghent|Neuroscience Technologies S.L.P",All,"18 Years and older   (Adult, Older Adult)",,63,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,CIPN-2015,June 2016,April 2017,"July 1, 2019","January 13, 2016","February 25, 2021","February 25, 2021","Danish Pain Research Center, Aarhus University Hospital, Aarhus, Denmark","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02654691/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02654691,NCT02654691,
oui,NCT02656407,Intraoperative Functional Ultrasound,FUSIMAGINE,Completed,No Results Available,Brain Tumor|Brain Lesion,Device: Ultrasound device,Activation maps through intraoperative ultrasensitive Doppler compared to gold standards cortical simulation mapping and functional MRI|Sensitivity test of the new Doppler mode|In depth micro vessel localization,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,23,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,C14-66|2015-A00661-48,"February 11, 2016",February 2018,February 2018,"January 15, 2016",,"August 26, 2021","Pitié Salpetriere Hospital, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT02656407,NCT02656407,
oui,NCT02658253,Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults,PRIMALVAC,Completed,No Results Available,Malaria,Biological: PRIMVAC|Biological: GLA-SE|Biological: Alhydrogel|Biological: Placebo,Proportion of volunteers with treatment-related adverse events as assessed by FDA scale and the INYVAX EC FP7 Brighton Collaboration Foundation|Proportion of volunteer with at least one Serious Adverse Event Following Immunization (SAEFI) for the entire duration of the study|Proportion of volunteer with at least one of Adverse Event Following Immunization (AEFI) measured until 1 month post-dose 3|Proportion of volunteer with at least one Adverse Event Following Immunization (AEFI) measured between M3 and the end of the study (only phase Ia)|Variation in humoral immune response to the vaccine antigen assessed by ELISA|Cellular immune responses to the vaccine antigen by Elispot|Cellular immune responses to the vaccine antigen by FACS,"Institut National de la Santé Et de la Recherche Médicale, France|EVI Industries, Inc.|Recherche Clinique Paris Descartes Necker Cochin Sainte Anne|Centre national de recherche et de formation sur le paludisme|EUCLID Clinical Trial Platform",Female,18 Years to 35 Years   (Adult),Phase 1,68,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",C14-60|2015-002246-31,January 2016,"September 19, 2018","February 21, 2019","January 18, 2016",,"November 29, 2019","CNRFP, Ouagadougou, Burkina Faso|CIC 1417, Paris, France",,https://ClinicalTrials.gov/show/NCT02658253,NCT02658253,33717176;32032566
oui,NCT02662504,Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma,MesoPDT,Completed,No Results Available,Malignant Pleural Mesothelioma,Device: photodynamic therapy (PDT)|Procedure: thoracic surgery Pleurectomy / extended Decortication|Drug: Adjuvant chemotherapy,Number of Patients having the full multimodal treatment without unacceptable and unexpected toxicities (grade ≥ 3) graded According to NCI CTC Version 4.0|Number of responders or stable patients after surgery|Progression-free survival (PFS)|Quality of life assessed by a specific questionnaire MPM (HCCA EORTC-30),"University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France|University of Pennsylvania|Région Nord-Pas de Calais, France",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,6,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014_01|2015-001554-15,"January 16, 2016","March 12, 2018","March 13, 2018","January 25, 2016",,"June 14, 2018","CHRU de Lille Hôpital Calmette, Lille, France",,https://ClinicalTrials.gov/show/NCT02662504,NCT02662504,
oui,NCT02671864,Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy,ANGIOSAFE2,"Active, not recruiting",No Results Available,Type 2 Diabetes,Other: 1: incretin-based therapy|Other: 2: other antidiabetic,"Prevalence of Severe DR at V1 (inclusion)|Prevalence of severe DR at V2 (after 3 years of treatment)|Plasma concentrations of ANGPT4|Plasma concentrations of VEGF|Plasma concentrations of proinflammatory cytokines such as IL-1beta, IL-6, IL-8, TNF-alpha|Concentrations of blood circulating EPCs and PBMCs","Assistance Publique - Hôpitaux de Paris|Assistance Publique Hopitaux De Marseille|Institut National de la Santé Et de la Recherche Médicale, France|Centre National de la Recherche Scientifique, France|Collège de France|University of Paris 5 - Rene Descartes|Pierre and Marie Curie University|University Paris 7 - Denis Diderot|Aix Marseille Université",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,7200,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,P150601,"April 11, 2016","April 11, 2022","April 11, 2025","February 2, 2016",,"March 6, 2023","Hôpital de la Conception, Marseille, France|Département de Diabétologie - Hopital Lariboisière, Paris, France",,https://ClinicalTrials.gov/show/NCT02671864,NCT02671864,31589290
oui,NCT02672020,Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card,COMETETACTIC,Completed,No Results Available,Adrenal Gland Neoplasms,Biological: omics identity card,Malignant status,"Assistance Publique - Hôpitaux de Paris|Ministry of Health, France|Institut National de la Santé Et de la Recherche Médicale, France|National Cancer Institute, France",All,"15 Years and older   (Child, Adult, Older Adult)",Not Applicable,448,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NI14028|PRTK-14-079,November 2015,"March 26, 2019","March 26, 2019","February 3, 2016",,"September 24, 2019","CHU-Angers, Angers, France|CHU Rouen-Hopital de Bois-Guillaume, Bois-Guillaume, France|CHU Bordeaux, Hopital du Haut Leveque, Bordeaux, France|CHU Brest, Hopital de la Cavale Blanche, Brest, France|HCL- Centre Hospitalier Lyon Est, Bron, France|CHU Clermont-Ferrand, Hopital Gabriel Montpied, Clermont-Ferrand, France|CHU Grenoble- Hopital Albert Michallon, Grenoble, France|Assistance Publique Hopitaux de Pais, Hopital de Bicetre, Le Kremlin Bicetre, France|CHU Limoges, Hopital du Cluzeau, Limoges, France|CHU Montpellier, Hopital Lapeyronie, Montpellier, France|CHU Nantes, Hopital Laënnec, Nantes, France|Assistance Publique Hopitaux de Paris -HEGP, Paris, France|Assistance Publique Hopitaux de Paris, Cochin, Paris, France|Assistance Publique Hopitaux de Paris, Necker, Paris, France|Assistance Publique Hopitaux de Paris, Pitie Salpetriere, Paris, France|CHU Reims, Hopital Robert Debre, Reims, France|CHU Rennes, Hopital Sud, Rennes, France|CHU Strasbourg, Hopital de Hautepierre, Strasbourg, France|CHU Toulouse, IUC Oncopole, Toulouse, France|CHU Tours, Hopital Bretonneau, Tours, France|Institut Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT02672020,NCT02672020,
oui,NCT02672683,Non Invasive Detection of Cardiac Allograft Rejection by Circulating microRNAs,MIRRACLE,Completed,No Results Available,Cardiac Transplantation,,Comparison of circulating MicroRNAs measurement in serum with histopathological diagnosis of rejection on concomitant endomyocardial biopsy,Assistance Publique - H�pitaux de Paris,All,"Child, Adult, Older Adult",,461,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AOR 14086,"September 26, 2016","April 20, 2017","March 26, 2019","February 3, 2016",,"April 19, 2021","PARCC/ INSERM U970, Team 4, Xavier Jouven, Cardiovascular epidemiology and sudden death, Georges Pompidou European Hospital,, Paris, France",,https://ClinicalTrials.gov/show/NCT02672683,NCT02672683,
oui,NCT02672826,Description of the Endothelial Phenotypes From the Subcutaneous Abdominal and Gluteo-femoral Adipose Tissues in Women,ADIPENDO,Completed,No Results Available,Obesity,Procedure: Adipose tissue surgery,number of endothelial cells|number of senescent cells|Correlation between estrogens level on endothelial senescence|Correlation between endothelial senescence and activation state,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",Female,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,12 067 08,"June 1, 2013","April 24, 2016",December 2016,"February 3, 2016",,"November 21, 2017","Explorations fonctionnelles Physiologiques - Toulouse Hospital, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02672826,NCT02672826,
oui,NCT02682290,Assessment of Rheological Parameters of Human Sputum.,RHEOMUCO,Completed,No Results Available,COPD|Asthma|Cystic Fibrosis,Other: Expectoration and measurement of sputum rheological properties,"Reproducibility of the rheological measurements of human sputum|Feasibility of the rheological measurements|Comparison of sputum rheological measurements between the four populations studied (healthy volunteers, Asthma, COPD, Cystic Fibrosis)|Influence of two mucolytic treatments (hypertonic saline solution, RhDNAse) on rheological measurements of patient with cystic fibrosis","University Hospital, Grenoble",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,38RC14.444,"March 3, 2016","July 4, 2017","July 4, 2017","February 15, 2016",,"October 27, 2017","Centre d'Investigation Clinique - INSERM 1406, Grenoble, Isere, France",,https://ClinicalTrials.gov/show/NCT02682290,NCT02682290,
oui,NCT02694484,Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant,TRANSFECMV,Completed,No Results Available,CMV|Healthy Volunteers,Other: Blood and stool samples,Detection frequency of CMV|Presence of CMV in the stool and in blood.|Infectivity of CMV present in faecal,"University Hospital, Limoges|University Hospital, Lille",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,I15033 TRANSFECMV,June 2016,July 2017,July 2017,"February 29, 2016",,"July 18, 2017","Centre de biologie pathologie / Laboratoire de virologie, Lille, France|Cic 1403-Crb Inserm-Chu, Lille, France|Service des Maladies Infectieuses, Lille, France|Cic - Inserm - 1435, Limoges, France|Service de Bact�riologie-Virologie-Hygi�ne/CNR des Cytom�galovirus, Limoges, France",,https://ClinicalTrials.gov/show/NCT02694484,NCT02694484,
oui,NCT02699736,EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV,EuroSIDA,Enrolling by invitation,No Results Available,"HIV|Hepatitis B|Hepatitis C|AIDS|Coinfection|Cardiovascular Diseases|Diabetes Mellitus|Acidosis, Lactic|Renal Insufficiency|Fractures, Bone|End Stage Liver Disease|Kidney Failure, Chronic|Proteinuria",,"Incidence of long-term virological, immunological and morbidity and mortality outcomes across different regions in Europe; and demographic, clinical, therapeutic and viral factors associated with these outcomes|Number of patients experiencing HIV-related events over time|Number of participants experiencing HIV-related events by region|Proportion of HCV infected patients who start treatment with direct acting antiretrovirals|Rate of sustained virologic response 12 (SVR12) in HCV-infected patients|Incidence of liver-related clinical outcomes in HCV-infected patients receiving HCV therapy|Incidence of non-liver-related clinical outcomes in HCV-infected patients receiving HCV therapy|Incidence of liver-related clinical outcomes in HCV-infected patients not receiving HCV therapy|Incidence of non-liver-related clinical outcomes in HCV-infected patients not receiving HCV therapy|Incidence of toxicities related to direct acting antivirals by regions","Rigshospitalet, Denmark|University College, London",All,"16 Years and older � (Child, Adult, Older Adult)",,23000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,The EuroSIDA Study|QLK2-2000-00773|LSHC-CT-2006-018632|Gilead EuroSIDA|GSK EuroSIDA|Janssen EuroSIDA|CT94-1637|CT97-2713|Pfizer EuroSIDA|Merck EuroSIDA|BMS EuroSIDA|SNSF 108787,January 1994,December 2030,December 2030,"March 4, 2016",,"October 21, 2019","Hospital JM Ramos Mejia, Buenos Aires, Argentina|Medical University Insbruck, Innsbruck, Austria|Otto Wagner Spital, Vienna, Austria|GOCGEIOZ - Gomel Regional Centre for Hygiene, Gomel, Belarus|Gomel State Medical University, Gomel, Belarus|Belarus State Medical University, Minsk, Belarus|Institute of Tropical Medicine, Antwerp, Belgium|CHU Saint-Pierre, Brussels, Belgium|University Ziekenhuis Gent, Gent, Belgium|Klinicki centar Univerziteta Sarajevo (KCUS), Sarajevo, Bosnia and Herzegovina|University Hospital of Infectious Diseases, Zagreb, Croatia|Charles University Hospital Plze?, Plze?, Czechia|Faculty Hospital Bulovka, Prague, Czechia|Rigshospitalet, Copenhagen, Denmark|Hilleroed Sygehus, Hiller�d, Denmark|Hvidovre Universitets Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Aarhus Universitetshospital Skejby, Skejby, Denmark|Narva AIDS Centre, Kohtla-J�rve, Estonia|West-Tallinn Central Hospital, Tallinn, Estonia|Helsinki University Central Hospital, Helsinki, Finland|INSERM, Universit� Bordeaux Segalen, Bordeaux, France|Hopital Edouard Herriot, Lyon, France|Hospital de la Croix Rousse, Lyon, France|CHU Nice Hopital de l' Archet 1, Nice, France|Hospital Saint Antoine, Paris, France|H�pital de la Piti�-Salp�ti�re, Paris, France|H�pital Necker-Enfants Malades, Paris, France|H�tel-Dieu Hospital, Paris, France|Georgian AIDS and Clinical Immunology Research Center, Tbilisi, Georgia|University Hospital Bonn, Bonn, Germany|University Hospital Cologne, Cologne, Germany|University Clinic Hamburg Eppendorf, Eppendorf, Germany|J.W.Goethe University Hospital, Frankfurt am Main, Germany|Bernhard Nocht Institut f�r Tropenmedizin, Hamburg, Germany|ICH Study Center, Hamburg, Germany|Mediziniche Hochschule Hannover, Hannover, Germany|Ludwig-Maximilians-Universit�t, Medizinische Poliklinik, M�nchen, Germany|1st I.K.A Hospital of Athens, Athens, Greece|Ippokration General Hospital, Athens, Greece|The General Hospital of Athens ""G. Gennimatas"", Athens, Greece|Szent L�szl� Hospital, Budapest, Hungary|Landspitali University Hospital, Reykjavik, Iceland|St. James' Hospital, Dublin, Ireland|Rambam Health Care Campus, Haifa, Israel|Hadassah Hospital, Jerusalem, Israel|Kaplan Medical Center, AIDS Center Neve Or, Rehovot, Israel|Ichilov Hospital, Tel Aviv, Israel|Ospedale Riuniti, Divisione Malattie Infettive, Bergamo, Italy|Ospedale L. Sacco, Milano, Italy|Ospedale San Paulo, Milano, Italy|Ospedale San Raffaele, Milano, Italy|Universit� degli Studi di Modena, Modena, Italy|Ospedale Cotugno, III Divisione Malattie Infettive, Napoli, Italy|National Institute for Infectious Diseases, Rome, Italy|Poloclinico Umberto 1, Rome, Italy|Infectology Center of Latvia, Riga, Latvia|Infectious Diseases and Tuberculosis Hospital, Vilnius University Hospital branch, Vilnius, Lithuania|Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Academisch Ziekenhuis bij de Universiteit van Amsterdam, Amsterdam, Netherlands|Oslo Universitetssykehus, Oslo, Norway|Uniwersytecki Szpital Kliniczny, Bialystok, Poland|Szpital Specjalistyczny, Osrodek Diagnostyki i Terapii AIDS, Chorzow, Poland|Medical University Gdansk, Gdansk, Poland|Wojewodzki Szpital Specjalistyczny im. WI. Bieganskiego, Lodz, Poland|Poznan University of Medical Sciences, Poznan, Poland|Pomeramian Academy of Medicine (PAM), Szczecin, Poland|Wojewodzki Szpital Zakazny, Warszawa, Poland|EMC Instytut Medyczny SA, Wroclaw, Poland|Hospital Curry Cabral, Lisbon, Portugal|Hospital de Egas Moniz, Lisbon, Portugal|Hospital Santa Maria, Lisbon, Portugal|Dr. Victor Babes Hospital, Bucuresti, Romania|Centre for HIV/AIDS & and infectious diseases, Kaliningrad, Russian Federation|Nizhny Novgorod Scientific and Research Institute, Nizhny Novgorod, Russian Federation|St Petersburgs AIDS Centre, St Petersburg, Russian Federation|Novgorod Centre for AIDS prevention and control, Veliky Novgorod, Russian Federation|The Institute for Infectious and Tropical Diseases, Belgrade, Serbia|Slovak Medical University, Bratislava, Slovakia|University Clinical Centre Ljubljana, Ljubljana, Slovenia|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Cl�nic, University of Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Carlos III, Departamento de Enfermedades Infecciosas, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Consorcio Hospital General Universitario Valencia, Valencia, Spain|Hospital Universitario de Alava, Vitoria-Gasteiz, Spain|Sk�ne University Hospital, Malm�, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|S�dersjukhuset, Stockholm, Sweden|University Hospital Basel, Basel, Switzerland|University Hospital Bern, Bern, Switzerland|Hopital Cantonal Universitaire Geneve, Gen�ve, Switzerland|Centre hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital St. Gallen, St.Gallen, Switzerland|University Hospital Z�rich, Z�rich, Switzerland|Kharkiv State Medical University, Kharkiv, Ukraine|Luhansk AIDS Center, Luhansk, Ukraine|Lviv Regional HIV/AIDS Prevention and Control CTR, Lviv, Ukraine|Odessa Region AIDS Center, Odessa, Ukraine|Crimean Republican AIDS centre, Simferopol, Ukraine|Royal Sussex County Hospital, Brighton, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Royal London Hospital, London, United Kingdom|St. Mary's Hospital, London, United Kingdom|University College London, Mortimer Market Centre, London, United Kingdom|University College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02699736,NCT02699736,36476454
oui,NCT02712892,I-CAN Biocollection,I-CAN,Completed,No Results Available,Intracranial Aneurysm,Genetic: Non Interventional Study,Presence or absence of genetic abnormalitie,"Nantes University Hospital|Institut National de la Santé Et de la Recherche Médicale, France",All,"20 Years and older   (Adult, Older Adult)",,3078,Other,Observational,Observational Model: Family-Based|Time Perspective: Prospective,RC15_0304,"March 3, 2016","December 19, 2019","December 31, 2020","March 18, 2016",,"September 9, 2021","Angers University Hospital, Angers, France|Besançon University Hospital, Besançon, France|Bordeaux University Hospital, Bordeaux, France|Henri Mondor Hospital (AP-HP), Créteil, France|Dijon University Hospital, Dijon, France|Grenoble University Hospital, Grenoble, France|La Reunion University Hospital, La réunion, France|Kremlin-Bicêtre University Hospital (AP-HP), Le Kremlin-Bicêtre, France|Limoges University Hospital, Limoges, France|Nancy University Hospital, Nancy, France|Nantes University Hospital, Nantes, France|Lariboisière University Hospital (AP-HP), Paris, France|La Pitié-Salpétrière University Hospital (AP-HP), Paris, France|Sainte Anne Hospital, Paris, France|Rotschild Fundation, Paris, France|Poitiers University Hospital, Poitiers, France|Rennes University Hospital, Rennes, France|Rouen University Hospital, Rouen, France|Toulouse University Hospital, Toulouse, France|Tours University Hospital, Tours, France",,https://ClinicalTrials.gov/show/NCT02712892,NCT02712892,32374868
oui,NCT02715986,Brain Changes in Severely Depressed Patients Before and After Treatment With Electroconvulsive Therapy,ECT-IM,Completed,No Results Available,Severe Depression,Device: 3T MRI,"Morphological changes in the hippocampus between baseline and after the first ECT effective session as assessed by volume measure in multimodal MRI.|Functional connectivity changes of the hippocampus-related networks between baseline and after the first effective ECT session as assessed by measure of connectivity in multimodal MRI.|Morphological changes of the hippocampus-related networks between baseline and after the first ECT session as assessed by measure of volume in multimodal MRI.|Morphological changes of the hippocampus-related networks between baseline and after the first ECT session as assessed by average diffusivity in multimodal MRI.|Functional changes of the hippocampal-related networks between baseline and after the first ECT session as assessed by measure of connectivity in multimodal MRI.|Morphological changes in the hippocampus and hippocampal-related networks related to ECT between baseline and after remission as assessed by measure of volume in multimodal MRI|Morphological changes in the hippocampus and hippocampal-related networks related to ECT between baseline and after remission as assessed by|Functional changes in the hippocampus and hippocampal-related networks related to ECT after remission as assessed by measure of connectivity in multimodal MRI.|Evolution of Real Life/Real Impact-16 (RLRI-16) score after the first ECT, after ECT first ""effective"" and after remission|Changes in the intensity of depressive symptoms score (Hamilton Depression Rating Scale) after the first ECT, ECT first ""effective"" and after remission","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,"50 Years to 70 Years   (Adult, Older Adult)",Not Applicable,17,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RC31/15/7733|15 7733 02,April 2016,July 2018,July 2018,"March 22, 2016",,"July 29, 2020","CHU Toulouse, Hôpital de psychiatrie, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02715986,NCT02715986,
oui,NCT02717182,Classification of Patient Therapeutic Education Programs Components : Etude CONCErTo,CONCErTo,Unknown status,No Results Available,Chronic Disease,Other: interviews,Patient-reported elements of patient therapeutic education|Heath care professionals-reported elements of patient therapeutic education,"Central Hospital, Nancy, France|Ministry of Health, France",All,"18 Years to 100 Years � (Adult, Older Adult)",,100,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,PREPS1439089,April 2016,December 2019,December 2019,"March 23, 2016",,"May 30, 2019","Rat Anne-Christine, Nancy, France",,https://ClinicalTrials.gov/show/NCT02717182,NCT02717182,
oui,NCT02720744,Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy,,Completed,Has Results,Excessive Daytime Sleepiness|Cataplexy|Narcolepsy,Drug: FT218|Drug: Placebo,Maintenance of Wakefulness Test (MWT)|Proportion of Patients That Were Very Much Improved or Much Improved on Clinical Global Impression of Improvement as Compared to Screening|Number of Cataplexy Attacks at Visit 8 (Week 14) as Compared to Baseline,Avadel,All,"16 Years and older � (Child, Adult, Older Adult)",Phase 3,212,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CLFT218-1501,"November 17, 2016","March 25, 2020","March 25, 2020","March 28, 2016","March 22, 2022","March 22, 2022","Pinnacle Research Group LLC, Anniston, Alabama, United States|University Sleep Disorder Center, Auburn, Alabama, United States|Sleep Disorders Center of Alabama, Birmingham, Alabama, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|California Center for Sleep Disorders, Alameda, California, United States|Stanford Sleep Medicine, Redwood City, California, United States|SDS Clinical Trials Inc, Santa Ana, California, United States|Alpine Research Center, Boulder, Colorado, United States|Yale-New Haven Hospital's Sleep Medicine Center, North Haven, Connecticut, United States|Pulmonary Disease Specialist, PA, Kissimmee, Florida, United States|Sleep Medicine Specialists of South Florida, Miami, Florida, United States|Sleep Medicine Specialist of South Florida, Miami, Florida, United States|NeuroMedical Research Institute/Global Research Holdings, LLC, Panama City, Florida, United States|FL Pediatric REsearch Institute, Winter Park, Florida, United States|Florida Pulmonary Research Institute LLC, Winter Park, Florida, United States|NeuroTrials Research Inc, Atlanta, Georgia, United States|Sleep Disorders Center of Georgia, Atlanta, Georgia, United States|Clinical Research Institute, Stockbridge, Georgia, United States|OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Norton Clinical Research Group, Louisville, Kentucky, United States|Center for Sleep and Wake Disorders, Chevy Chase, Maryland, United States|Infinity Medical Research, North Dartmouth, Massachusetts, United States|Chesterfield, Missouri, United States|Saint Louis, Missouri, United States|Montefiore Sleep-Wake Disorders Center, Bronx, New York, United States|Northwell Health, New Hyde Park, New York, United States|Clinilabs Drug Development Corporation, New York, New York, United States|Research Carolina of Huntersville, Huntersville, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Sleep Management Institute Intrepid Research, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Ohio Sleep Medicine Institute, Dublin, Ohio, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Medical University of South Carolina - Institute of Psychiatry, Charleston, South Carolina, United States|SleepMed Of South Carolina, Columbia, South Carolina, United States|Sleep and Neurology Consultants, Houston, Texas, United States|Sleep Therapy Research Center, San Antonio, Texas, United States|NHMRC CEntre for Translational Sleep and Circadian Neurobiology, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Melbourne Sleep Disorders Centre, Melbourne, Victoria, Australia|Somni Research Inc. Calgary, Calgary, Alberta, Canada|Okanagan Clinical Trials Ltd, Kelowna, British Columbia, Canada|West Parry Sound Health Center, Parry Sound, Ontario, Canada|Somni Research Inc, Toronto, Ontario, Canada|Paediatric Sleep Research Inc, Toronto, Ontario, Canada|CIUSS de Nord-de-I'ile-de- Montreal- Hopital de Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Vseobecna Facultni Nemocnice, Praha, Czechia|CHU Michallon, Grenoble, France|Hospital Gui-de-de-Chauliac, Montpellier, France|INSERM - Centre d'Investigation Clinque Hopital Robert Debre, Paris, France|Charit Universittsmedizin Berlin, Berlin, Germany|Hephata Klinik, Schwalmstadt, Germany|Somni bene GmbH, Schwerin, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02720744/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02720744/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02720744,NCT02720744,35380374;34358324
oui,NCT02721745,Cause and Consequence of Neural Fatigue,Fatstim,Completed,No Results Available,Cognitive Fatigue,Behavioral: Natural Fatigue|Device: tDCS|Device: TMS,Proportion of chosen immediate reward in intertemporal questions between an immediate reward smaller than a delayed reward.|Physiological Measures: EEG|Physiological Measures: indirect calorimetry|Physiological Measures:pupillometry,"Institut National de la Santé Et de la Recherche Médicale, France",All,20 Years to 39 Years   (Adult),Not Applicable,216,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,C15-59|2015-A01445-44,"May 23, 2016",September 2020,December 2020,"March 29, 2016",,"August 26, 2021","ICM, Paris, France",,https://ClinicalTrials.gov/show/NCT02721745,NCT02721745,
oui,NCT02722603,Study to Compare Gabapentin to Tramadol in Children With Chronic Neuropathic or Mixed Pain,GABA-1,Terminated,No Results Available,Chronic Pain,Drug: gabapentin|Drug: tramadol|Other: placebo tramadol|Other: placebo gabapentin,Pain score|Percentage of responders to treatment|Daily pain intensity|Observational assessment of pain|Self-assessment of pain for children ?8 years of age|Extent of pain|Number of episodes of breakthrough pain|Number of rescue interventions|Number of pain-free days|Number of participant dropouts|The total cumulative weight normalized dose of each rescue drug|Total Summary Score from PedsQL� scale|Physical Health Summary Score from PedsQL� scale|Psychosocial Health Summary Score from PedsQL� scale|Acceptability of treatment|Global satisfaction with treatment|Clinical Global Impression of Severity of the subject's condition|Clinical Global Impression of Improvement for pain|Patient/parent Global Impression of Change|CL/F|Vd/F|ka|AUC|Cmax|Tmax|Css|Cmin|Systemic exposure to investigational products during maintenance period|Incidence of Adverse Events at all visits|Percentage of subjects discontinuing the trial due to treatment-emergent adverse events.|Aggressive behaviour in children aged >6 years|Suicidal ideation/behaviour in subjects aged 6 years and older|Assessment of blinding,Pharmaceutical Research Management srl|European Commission,All,3 Months to 17 Years � (Child),Phase 3,2,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2014-004851-30,"September 12, 2018","May 31, 2019","June 18, 2019","March 30, 2016",,"October 3, 2019","Universitaets klinikum Erlangen, Erlangen, Germany|Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT02722603,NCT02722603,30787078
oui,NCT02726243,Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease,DYSCOLIC,Unknown status,No Results Available,Inflammatory Bowel Disease|Colorectal Cancer,,Composition of fecal microbiota by 16S sequencing|Profile of fecal bile acids,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,240,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,NI13006,November 2014,May 2020,August 2020,"April 1, 2016",,"October 25, 2017","Gastroenterology Department of Saint Antoine Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT02726243,NCT02726243,
oui,NCT02730611,"Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma",METSLIVER,Completed,No Results Available,Morbid Obesity|Vertical Sleeve Gastrectomy|Metabolic Syndrome|Hepatocellular Carcinoma|Cholangiocarcinoma|Disorder of Bile Acid and Cholesterol Metabolism,,Blood bile acids (micromols per liter)|Hepatic FXR expression,"Assistance Publique - Hôpitaux de Paris|National Cancer Institute, France|Centre International de la Recherche sur le Cancer|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,124,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PRT-K14-038,March 2016,October 2017,December 2018,"April 6, 2016",,"December 17, 2019","AP-HP, Antoine Béclère Hospital, Clamart, France",,https://ClinicalTrials.gov/show/NCT02730611,NCT02730611,
anrs,NCT02738502,Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors,MONOGEST,Completed,No Results Available,Maternal-fetal Infection Transmission,Drug: darunavir monotherapy,"Success rate, defined by plasma viral load (PVL) <50 copies / mL near delivery with DRV/r monotherapy. Failure is defined as PVL > 50 copies / mL and/or change of antiretroviral therapy during pregnancy for PVL ≥ 50 copies / mL.|Plasma viral load (PVL) <50 copies / mL at delivery, Intention-to-treat (ITT) analysis|Incidence of treatment changes for inefficacy, defined as PVL≥ 50 copies / mL at 2 successive controls.|Incidence of treatment changes for intolerance / toxicity.|Incidence of treatment changes for other reasons.|Factors associated with inefficacy (HIV-1 DNA). Inefficacy is defined as maternal plasma viral load > 50 copies/mL at delivery and/or change of antiretroviral therapy at any time from enrollment through delivery for plasma viral load > 50 copies/mL.|Factors associated with inefficacy (lymphocytes T CD4+ count).|Factors associated with inefficacy (CD4 nadir). Inefficacy is defined as maternal plasma viral load > 50 copies/mL at delivery and/or change of antiretroviral therapy at any time from enrollment through delivery for plasma viral load > 50 copies/mL.|Factors associated with inefficacy (duration of undetectable plasma viral load before pregnancy).|Adverse pregnancy outcomes (preterm birth)|Adverse pregnancy outcomes (fetal loss)|Adverse pregnancy outcomes (low birth weight)|Adverse pregnancy outcomes (low Apgar : < 7 at 5 minutes)|Adverse pregnancy outcomes (congenital malformations)|Tolerance in children (hematological examinations).|Tolerance in children (biochemical examinations).|Interruption rate of postnatal nevirapine (NVP) within 2 weeks of life and patterns;|Any case of mother to child transmission would be considered a serious adverse event (SAE) and analyzed immediately.","ANRS, Emerging Infectious Diseases|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Phase 2,91,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 168 MONOGEST,"July 6, 2016","July 16, 2019","July 16, 2020","April 14, 2016",,"August 6, 2021","CH Victor Dupouy, Argenteuil, France|Hôpital Jean Verdier, Bondy, France|Groupe hospitalier Pellegrin, Bordeaux, France|Hôpital Saint André, Bordeaux, France|Hôpital Antoine Béclère, Clamart, France|Hôpital Louis Mourier, Colombes, France|Hôpital Sud Francilien, Corbeil-essonnes, France|Hôpital Bicêtre, Le Kremlin Bicêtre, France|Hôpital de la croix Rousse, Lyon, France|Hôtel Dieu, Nantes, France|CHU Archet 1, Nice, France|Hôpital Lariboisiere, Paris, France|Hôpital Armand Trousseau, Paris, France|Hôpital la Pitié Salpétrière, Paris, France|Groupe hospitalier Cochin-Broca- Hôtel Dieu, Paris, France|HEGP, Paris, France|Hôpital Necker Enfant malades, Paris, France|Hôpital Bichat - Claude Bernard, Paris, France|Hôpital Tenon, Paris, France|CHU de Perpignan, Perpignan, France|CHU Rennes Hôpital Pontchaillou, Rennes, France|Hôpital Foch, Suresnes, France|CHU Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT02738502,NCT02738502,
oui,NCT02739477,Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen,FORCE,Terminated,No Results Available,Ebola Virus Survivor,Drug: Favipiravir,"Number of patients undergoing grade 3 or 4 clinical or biological adverse events related to Favipiravir (Common Terminology Criteria for Adverse Events, CTCAE, v4.03)|Evolution of EBOV semen RNA and infectious loads|Plasma and semen trough concentrations of favipiravir|Genetic variations associated with favipiravir exposition","Institut National de la Santé Et de la Recherche Médicale, France",Male,"18 Years and older   (Adult, Older Adult)",Phase 2,2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C15-101,April 2016,August 2016,August 2016,"April 15, 2016",,"October 18, 2018","Conakry, Conakry, Guinea|Nzérékoré, Nzérékoré, Guinea",,https://ClinicalTrials.gov/show/NCT02739477,NCT02739477,
oui,NCT02753179,"Covert-saccades, Dynamic Visual Acuity and Quality of Life",COSQOL,Completed,No Results Available,Vestibular Diseases,Other: Head Impulse Tests|Other: Dynamic visual acuity Test (DVAT)|Other: VEMPs & VEMPo|Other: Dizziness Handicap Inventory|Other: Oscillopsia severity questionnaire,Frequency of covert-saccades|Quality of life assessed with the Dizziness Handicap Inventory|Dynamic visual acuity|Oscillopsia severity questionnaire score|Latency of covert-saccades,Hospices Civils de Lyon,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL15_0746,May 2016,January 2017,January 2017,"April 27, 2016",,"January 16, 2017","Unité de Neuro-Ophtalmologie Hôpital Neurologique, Bron, France",,https://ClinicalTrials.gov/show/NCT02753179,NCT02753179,
oui,NCT02765451,Study Evaluating Intervention in the Development of Clinical Research in Non-Academic Health Institution (ERNU),ERNU,Completed,No Results Available,Clinical Research|Cancer,Behavioral: interventions of the Canc�rop�le Nord-Ouest,Number of inclusions in clinical trials of patients|Reduction of social inequalities recruitment in clinical trials associated with the intervention of the Canc�rop�le Nord-Ouest,"Centre Hospitalier Universitaire, Amiens|Centre de traitement des donn�es du Canc�rop�le Nord-Ouest, Centre F. BACLESSE, Caen, France|Institut National de la Sant� et de la Recherche M�dical (INSERM) 1086 (Pr Guy LAUNOY) Centre F. BACLESSE, Caen, France",All,"Child, Adult, Older Adult",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,RNI 2015-05-DR-BARBARE,September 2015,"November 15, 2018","February 21, 2019","May 6, 2016",,"July 24, 2019","Centre hospitalier d'Abbeville, Abbeville, France|Clinique de l'Europe, Amiens, France|Clinique Victor Pauchet, Amiens, France|Hopital Priv� d'Arras, Arras, France|Centre hospitalier d'Arras, Arras, France|Centre de Radioth�rapie de la Baie, Avranches, France|Centre Hospitalier de Bayeux, Bayeux, France|Clinique du Parc Saint Lazare, Beauvais, France|Centre hospitalier de Beauvais, Beauvais, France|Centre de Radioth�rapie Pierre Curie, Beuvry, France|Centre Hospitalier de Boulogne sur Mer, Boulogne sur Mer, France|Centre Hospitalier de B�thune, B�thune, France|Centre de Radioth�rapie Maurice TUBIANA, Caen, France|Polyclinique du Parc, Caen, France|Centre hospitalier de Calais, Calais, France|Centre Hospitalier de Cherbourg, Cherbourg, France|Centre hospitalier Compi�gne-Noyon, Compi�gne, France|Clinique Saint C�me, Compi�gne, France|Clinique de Flandre, Coudekerque Branche, France|Centre hospitalier Creil-Senlis, Creil, France|Centre Hospitalier de Dunkerque, Dunkerque, France|Centre Hospitalier intercommunal Eure-Seine, Evreux, France|Centre hospitalier de Flers, Flers, France|Centre Hospitalier de Granville, Granville, France|Centre Hospitalier d'Hazebrouck, Hazebrouck, France|Centre hospitalier de Saint Omer, Helfaut, France|Centre hospitalier de Laon, Laon, France|Centre Hospitalier du Havre, Le Havre, France|Centre Hospitalier de Lens, Lens, France|Centre de radiuoth�rapie Bourgogne, Lille, France|Centre Hospitalier d'arrondissement de Montreuil sur mer, Rang du Fliers, France|Clinique Mathilde, Rouen, France|Centre Hospitalier intercommunal d'Elbeuf-Louvier, saint Aubin l�s Elbeuf, France|Clinique les Aub�pines, Saint Aubin sur Scie, France|Clinique de la Baie, Saint Martin des Champs, France|Clinique Saint Claude, Saint Quentin, France|Centre hospitalier de Saint Quentin, Saint Quentin, France|Clinique de Saint-Omer, Saint-Omer, France|Centre hospitalier de Soissons, Soissons, France|Centre Hospitalier de Tourcoing, Tourcoing, France|Centre hospitalier de Valenciennes, Valenciennes, France",,https://ClinicalTrials.gov/show/NCT02765451,NCT02765451,
oui,NCT02765880,"Time,Self and Spontaneous Mental Activities in Patients With Psychotic Disorders",Self and Time,Recruiting,No Results Available,Schizophrenia|Bipolar Disorder,Other: fMRI|Other: EEG,"Abnormalities in connectivity during order judgement tasks will be taken as seeds to check whether they account for abnormalities in connectivity at rest, by means of mathematic modelization|Evaluation of the brain' functional coupling dynamics over time (how neuronal networks and connectivity change over time) during rest.|- Evaluation of the brain' functional coupling dynamics over time (how neuronal networks and connectivity change over time) during time ordering.|Comparison of patients with schizophrenia vs. bipolar disorder","University Hospital, Strasbourg, France|Fondation pour la Recherche M�dicale (FRM)",All,18 Years to 60 Years � (Adult),Not Applicable,161,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,6366,"March 16, 2017",September 2023,September 2023,"May 9, 2016",,"August 19, 2022","Service de psychiatrie, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT02765880,NCT02765880,
anrs,NCT02777229,Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings,NAMSAL,Completed,No Results Available,HIV-1 Infection,Drug: Dolutegravir 50 mg|Drug: Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg|Drug: Efavirenz 400 mg,"Proportion of patients with Viral Load (VL) <50 cp/mL|Proportion of patients with Viral Load (VL) < 200 cp/mL|Time to virologic failure|Changes in Cluster of differentiation 4 (CD4)-cell count from baseline to endpoints week-48, -96, -144, -192|Time to death or to disease progression|Time to first toxicity failure|Incidence of first grade 3 or 4 clinical adverse event|Incidence of first grade 3 or 4 laboratory adverse event|AE and SAE|Time to treatment discontinuation|Hemoglobine changes from baseline to endpoints week-48, -96, -144, -192|Changes in creatinine from baseline to endpoints week-48, -96, -144, -192|Changes in estimated glomerular filtration rate from baseline to endpoints week-48, -96, -144, -192|Changes in Aspartate Aminotransferase (AST) ffrom baseline to endpoints week-48, -96, -144, -192|Changes in Alanine Aminotransferase (ALT) from baseline to endpoints week-48, -96, -144, -192|Changes in level of fasting glucose from baseline to endpoints week-48, -96, -144, -192|Changes in level of total cholesterol from baseline to endpoints week-48, -96, -144, -192|Changes in level of triglycerides from baseline to endpoints week-48, -96, -144, -192|Changes in level of HDL from baseline to endpoints week-48, -96, -144, -192|Proportion of patients defaulting clinic schedule|Mean medication adherence level from baseline to endpoints week-48, -96, -144, -192|Mean change in Depression Anxiety Stress Scale from baseline to endpoints week-48, -96, -144, -192|Mean change in Quality of life score assessed by the Short Form health survey from baseline to endpoints week-48, -96, -144, -192|Mean change in EFV-related symptoms questionnaire score from baseline to endpoints week-48, -96, -144, -192|Tobacco status consumtion|HbA1c|hsPCR|Lipodistrophia|CIMT|PWV|Levels of adiponectin|Levels of leptin|Levels of ghrelin","ANRS, Emerging Infectious Diseases|Institut de Recherche pour le Developpement|UNITAID",All,"18 Years and older � (Adult, Older Adult)",Phase 3,616,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 12313 NAMSAL,July 2016,July 2018,July 2021,"May 19, 2016",,"August 31, 2021","Cit� verte Hospital, Yaound�, Cameroon|Hopital Central, Yaound�, Cameroon|Military Hospital, Yaound�, Cameroon",,https://ClinicalTrials.gov/show/NCT02777229,NCT02777229,33355914;33010241;31339676
oui,NCT02784886,Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta,DNA-Accreta,Unknown status,No Results Available,Morbidly Adherent Placenta|Placenta Accreta|Placenta Increta|Placenta Percreta,Biological: Women at high risk of MAP,"Concentration of cell-free fetal DNA circulating in the maternal plasma|Sensitivity of the concentration of cell-free fetal DNA|Specificity of the concentration of cell-free fetal DNA|Positive predictive value of concentration of cell-free fetal DNA|Negative predictive value of the concentration of cell-free fetal DNA|Sensitivity, specificity, positive predictive value (PPV) and negative (NPV) of the concentration of cell-free fetal DNA in association with clinical criteria ( risk factors for MAP)|Sensitivity, specificity, positive predictive value (PPV) and negative (NPV) of concentration of cell-free fetal DNA in association with imaging criteria magnetic resonance|Sensitivity, specificity, positive predictive value (PPV) and negative (NPV) of the concentration of cell-free fetal DNA and clinical criteria in association with clinical criteria, sonographic criteria and with magnetic resonance imaging criteria","University Hospital, Angers|Institut National de la Sant� Et de la Recherche M�dicale, France|Assistance Publique - H�pitaux de Paris",Female,"18 Years and older � (Adult, Older Adult)",,63,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,DC-2011-1467,November 2013,November 2015,November 2016,"May 27, 2016",,"May 27, 2016","Angers University Hospita, Angers, France",,https://ClinicalTrials.gov/show/NCT02784886,NCT02784886,
oui,NCT02790489,Tolerance Study of the Dietary Supplement Valedia,ECPH1-01,Completed,No Results Available,Overweight,Dietary Supplement: Valedia,Effect on urine urea|Effect on urine creatinine|Effect on fasting glycemia|Effect on insulin|Effect on fructosamine|Effect on total cholesterol|Effect on HDL cholesterol|Effect on LDL cholesterol|Effect on triglycerides|Effect on oxidized LDL cholesterol|Effect on inflammation|Effect on AST|Effect on ALT|Effect on gamma GT|Effect on alkaline phosphatase|Effect on bilirubin|Effect on cardiac function|The response during an oral glucide tolerance test after a standardized breakfast,"Valbiotis|Centre d'Investigation Clinique INSERM 501, Clermont-Ferrand, France|Laboratoire des Adaptations M�taboliques � l'Exercice en conditions Physiologiques et Pathologiques",Male,"45 Years to 65 Years � (Adult, Older Adult)",Phase 1,14,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-A01864-45,May 2016,August 2016,August 2016,"June 6, 2016",,"August 9, 2016","Centre d'Investigation Clinique, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT02790489,NCT02790489,
associ�,NCT02798497,Panton Valentine Leucocidin,PVL,Completed,No Results Available,Staphylococcus Aureus Pneumonias,Other: Serum and Blood samples,The survival of the patients according to the character PVL+ or PVL- of the isolated Staphylococcus aureus strains|Gravity Scores : Composite measure between the IGS2 and SOFA scores for an adult and between PIM2 and PLEOD scores for a child|length of stay in Reanimation and ICU|length of stay in hospitalization|Number of participants with presence of a genetic predisposition of Mendelian type or polymorphic character among the patients presenting a PVL+ necrotizing pneumonia (for immunogenetic study),Hospices Civils de Lyon,All,"2 Months to 100 Years � (Child, Adult, Older Adult)",Not Applicable,234,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2010.625,May 2011,"December 21, 2016","December 21, 2016","June 14, 2016",,"March 13, 2019","Centre National de R�f�rences des Staphylocoques Centre de Biologie et Pathologie Est 59 bd Pinel, Bron, France",,https://ClinicalTrials.gov/show/NCT02798497,NCT02798497,
oui,NCT02798549,HBV Virions Bound Proteins,,Completed,No Results Available,Hepatitis B Virus Infection,Other: blood draw,Presence of a virion-bound protein identified by mass spectrometry|Comparison of clinical virions datasets with in vitro grown virions datasets (mass spectrometry),Hospices Civils de Lyon,All,18 Years to 60 Years � (Adult),Not Applicable,14,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science,2013.809,"January 12, 2015",January 2018,August 2018,"June 14, 2016",,"September 12, 2018","Service d'H�pato-Gastroent�rologie, Hopital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, Auvergne-Rh�ne-Alpes, France",,https://ClinicalTrials.gov/show/NCT02798549,NCT02798549,
associ�,NCT02799186,The Study of the Prevalence Fibromuscular Dysplasia in Patient With Haematoma or Spontaneous Coronary Artery Dissection.,DISCO,Completed,No Results Available,Spontaneous Coronary Artery Dissection|Spontaneous Coronary Artery Haematoma,Procedure: blood sample for genetic analysis,"Incidence of the SCAD in the population of patients taken care for a ACS|Prevalence of the FMD in the population SCAD from a tomographic or MRI angiography analysis of renal, cerebrovascular and iliac arteries|Hormonal Parameters ( gynecological factors)|Environmental Factors : physical exercise or an recent intense emotional stress|Genetic Factors (including recently identified genetic risk loci for FMD)|Morbi-mortality to 1 year","University Hospital, Clermont-Ferrand|Heart and Research Foundation|French Coronary Atheroma and Interventional Cardiology Group",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CHU-0267|2016-A00403-48,May 2016,"November 4, 2019","November 4, 2019","June 14, 2016",,"January 24, 2022","CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT02799186,NCT02799186,
oui,NCT02800460,New Approaches in MRI at 3T Dedicated to Targeting Subthalamic Nucleus on Parkinsonian Patients,Optimise_3T,Unknown status,No Results Available,Parkinson Disease,Procedure: fMRI-3T,Measure of the distance between two target points within the NST defined on a optimized Flair sequence on a research 3T MRI and on a routine T2 sequence acquired at 1.5T.|Measure of target contouring with a quantitative scale|Measure of target volume,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,C15-90|2016-A00231-50,"October 10, 2016",December 2018,June 2019,"June 15, 2016",,"November 6, 2017","GHPS, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT02800460,NCT02800460,
oui,NCT02802371,Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program,PHARMAID,Unknown status,No Results Available,Alzheimer Disease,Behavioral: Psychosocial intervention|Other: Pharmaceutical care and psychosocial support,caregiver's burden|caregiver's quality of life|caregiver's anxiety|caregiver's depression|patient's quality of life|patient's behavioral disorders|patient's functional autonomy|Occurrence of medical consultation|Occurrence of recourse to emergency service|Occurrence of hospitalizations|Occurrence of admission in institution,Hospices Civils de Lyon,All,65 Years and older � (Older Adult),Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,69HCL14_0450,August 2016,February 2020,February 2020,"June 16, 2016",,"January 10, 2019","Pharmacy unit and Clinical Research Center VCF ("" Aging Brain Frailty "") University hospital of Lyon, Charpennes Hospital / University Lyon / INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, Villeurbanne, France",,https://ClinicalTrials.gov/show/NCT02802371,NCT02802371,28007635
oui,NCT02804165,Gene-virus Interactions Implicated in Type 1 Diabetes,GENEVIR,Withdrawn,No Results Available,Type 1 Diabetes,Genetic: Enterovirus vaccination,"Identification of gene-enterovirus interaction effect on T1D onset|""Precipitating"" effect of enterovirus infection on T1D.",Hospices Civils de Lyon,All,"1 Year to 60 Years � (Child, Adult)",Not Applicable,0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2013-836,January 2017,July 2022,July 2022,"June 17, 2016",,"May 11, 2018","Hospices Civils de Lyon, Lyon, France",,https://ClinicalTrials.gov/show/NCT02804165,NCT02804165,
oui,NCT02806856,tDCS in Acute Stroke Patients,tDCS,Unknown status,No Results Available,Acute Stroke,Device: tDCS neuroConn|Device: Sham stimulation,Brain MRI diffusion weighted images|NIHSS|Rankin scale|tDCS safety|tDCS tolerability,"Centre Hospitalier St Anne|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D16-P04,"January 26, 2017",October 2018,February 2019,"June 21, 2016",,"October 19, 2017","Centre Hospitalier Sainte Anne, Paris, France",,https://ClinicalTrials.gov/show/NCT02806856,NCT02806856,
oui,NCT02810197,Resilience and Modification of Brain Control Network Following November 13,REMEMBER,Recruiting,No Results Available,Post-Traumatic Stress Disorder,Behavioral: Psychopathological assessment|Behavioral: Neuropsychological assessment|Device: Functional magnetic resonance imaging (fMRI),Blood Oxygen Level Dependent (BOLD) response as measured with fMRI,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 55 Years   (Adult),Not Applicable,180,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,C16-13,June 2016,April 2022,"April 30, 2023","June 22, 2016",,"December 2, 2021","GIP Cyceron, Caen, Calvados, France",,https://ClinicalTrials.gov/show/NCT02810197,NCT02810197,35479300
oui,NCT02810210,Zika Virus Infection's Neonatal and Pediatric Consequences in French Department of America,ZIKA-DFA-BB,Unknown status,No Results Available,Zika Virus Infection on Fetus and Child During the Pregnancy,Other: fundus examination|Other: Head ultrasound,Embryofoetopathy incidence within cohort 1 and 3|Comparison of congenital abnormality incidence rates between cohorts 1 and 3,"Institut National de la Santé Et de la Recherche Médicale, France",All,up to 2 Years   (Child),,2220,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C16-19,June 2016,September 2017,September 2018,"June 22, 2016",,"August 30, 2016","CH de la Basse Terre, Basse-terre Cedex, France|CH Andrée Rosemon (CHAR), Cayenne Cedex, France|CHU de Martinique, Fort de France Cedex, France|CHU de Pointe à Pitre/Les Abymes, Pointe A Pitre, France|CH LC Fleming, Saint Martin Cedex, France|CH de l'Ouest Guyanais Franck Joly (CHOG), Saint-laurent-du-maroni, France",,https://ClinicalTrials.gov/show/NCT02810210,NCT02810210,33472606
oui,NCT02811055,Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin,APHOS-02,Unknown status,No Results Available,Type 2 Diabetes|Hypertension,Biological: Blood sampling|Procedure: Blood Pressure Measurement|Device: electrocardiogram|Procedure: orthostatic test|Drug: Administration of Aprepitant|Drug: Administration of placebo,Difference from baseline in Plasma aldosterone concentration|Difference from baseline in Plasma cortisol|Difference from baseline in plasma renin|Difference from baseline in blood electrolytes measurement|Difference from baseline in HOMA index,"University Hospital, Rouen",All,"18 Years and older � (Adult, Older Adult)",Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2013/142/HP,"July 13, 2017",July 2019,July 2019,"June 23, 2016",,"August 22, 2017","Rouen University Hospital, Rouen, France",,https://ClinicalTrials.gov/show/NCT02811055,NCT02811055,
associ�,NCT02813928,Diagnostic and Prognosis Value of Circulating DNA for CRC Patients' Surveillance After Curative Treatment,ADNCirc,Completed,No Results Available,Colorectal Cancer,Genetic: ccfDNA analysis,The presence of recurrences detected for patients curatively treated for a CRC stages II and III within the 3 years of follow-up.,"University Hospital, Limoges",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,473,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,I15031,July 2016,December 2021,July 2022,"June 27, 2016",,"August 2, 2022","Aurillac Hospital, Aurillac, France|Bergonie institute, Bordeaux, France|Bordeaux University Hospital, Bordeaux, France|Les C�dres clinical, Brive-la-Gaillarde, France|Brive Hospital, Brive, France|Cahors Hospital, Cahors, France|Clermont Ferrand University Hospital, Clermont-Ferrand, France|Gueret Hospital, Gu�ret, France|La marche clinical, Gu�ret, France|Limoges Hospital, Limoges, France|Montpellier Institute, Montpellier, France|Montpellier University Hospital, Montpellier, France|Moulins Hospital, Moulins, France|Saint Antoine AP-HP, Paris, France|Perigueux clinical, P�rigueux, France|P�rigueux Hospital, P�rigueux, France|Saint Junien Hospital, Saint-Junien, France|Sainte feyre Hospital, Sainte feyre, France|Vichy Hospital, Vichy, France",,https://ClinicalTrials.gov/show/NCT02813928,NCT02813928,
oui,NCT02814864,"Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy",PRISME,Recruiting,No Results Available,Pelvic Radiation Therapy|Radiation-induced Hemorrhagic Cystitis,Drug: Mesenchymal Stromal Cell (MSC) injections,"Decrease of one grade on the LENT SOMA|The effect of treatment on analgesic drug consumption (analgesic, opiates).|The effect of treatment on quality of life with SF36 questionnaire|The effect of treatment on quality of life with HADS questionnaire|The effect of treatment on pain|Frequency of diarrhea",Assistance Publique - H�pitaux de Paris,All,"18 Years to 80 Years � (Adult, Older Adult)",Phase 2,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P130935|2014-001462-99,"April 14, 2021",April 2022,April 2022,"June 28, 2016",,"August 3, 2021","H�matologie et th�rapie cellulaire, H�pital Saint Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT02814864,NCT02814864,
oui,NCT02818595,Development of Maternal Voice Recognition in Preterm Neonates,PREMAVOIX,Completed,No Results Available,"Infant, Premature",Device: electroencephalogram (HR-EEG)|Device: Near Infra Red Spectroscopy (NIRS),The difference in amplitude|The difference in latency,"Centre Hospitalier Universitaire, Amiens",All,up to 6 Days � (Child),Not Applicable,22,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PI11-DR-WALLOIS,March 2013,June 2017,June 2017,"June 30, 2016",,"August 10, 2018","CHU Amiens, Amiens, France",,https://ClinicalTrials.gov/show/NCT02818595,NCT02818595,
oui,NCT02820376,Assessment of Differential Renal Function by CT in Living Donors,DOVISCAN,Completed,No Results Available,Living Donor of Kidney,Other: Differential renal function assessment by 4D CT,degree of agreement|Intra- and inter-observer reproducibility of CT DRF measurement|Radiation dose exposure for each technique|Agreement between post-processing methods for CT|Automatic post-processing for Patlak-Ruthland method,"Central Hospital, Nancy, France|Institut National de la Santé Et de la Recherche Médicale, France|University of Lorraine",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,51,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2016-A00543-48|PSS 2016 / DOVISCAN - MANDRY /,"June 28, 2016","June 25, 2018","June 25, 2018","July 1, 2016",,"May 8, 2020","CHRU Nancy, Nancy, France",,https://ClinicalTrials.gov/show/NCT02820376,NCT02820376,
oui,NCT02823821,Randomised Evaluation of Sodium Dialysate Levels on Vascular Events,RESOLVE,Recruiting,No Results Available,End-Stage Kidney Disease,Other: Default dialysate sodium concentration of 137mmol/l|Other: Default dialysate sodium concentration of 140mmol/l,Time to first occurrence of an event in the primary composite outcome|Time to first occurrence of an event in the secondary composite outcome|Time to first occurrence of each of the individual components of the composite outcomes.,"University of Sydney|Australasian Kidney Trials Network|Australia & New Zealand Dialysis & Transplant Registry|The George Institute for Global Health, India|The George Institute for Global Health, China|Peking University People's Hospital|Institute for Clinical Evaluative Sciences|St. Michaels Hospital|University Hospital Wuerzburg, Medizinische Klinik EINS|Malaysian Society of Nephrology|Malaysian Renal Registry",All,"18 Years and older � (Adult, Older Adult)",Phase 4,50000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,GI-AU-RM-2016-01,June 2016,December 2024,December 2024,"July 6, 2016",,"October 10, 2022","Royal Adelaide Hospital, Adelaide, Australia|Auburn Hospital, Auburn, Australia|Moorabbin Hospital, Bentleigh East, Australia|Princess Alexandra Hospital, Brisbane, Australia|Redlands Hospital, Brisbane, Australia|Bundaberg Hospital, Bundaberg, Australia|Caloundra Hospital, Caloundra, Australia|The Canberra Hospital, Canberra, Australia|Peninsula Health, Frankston, Australia|Gympie Hospital, Gympie, Australia|Ipswich Hospital, Ipswich, Australia|Mackay Base Hospital, Mackay, Australia|Logan Hospital, Meadowbrook, Australia|Monash Health Community Dandenong, Melbourne, Australia|Casey Hospital, Melbourne, Australia|Cranbourne Integrated Care Centre, Melbourne, Australia|Nambour General Hospital, Nambour, Australia|Hampstead Dialysis Centre, Northfield, Australia|Hervey Bay Hospital, Pialba, Australia|Sunshine Coast University Hospital, Sunshine Coast, Australia|Sydney Adventist Hospital, Sydney, Australia|Concord Repatriation and General Hospital, Sydney, Australia|Blacktown Regional Dialysis Centre, Sydney, Australia|Mt Druitt Community Dialysis Centre, Sydney, Australia|Nepean Hospital, Sydney, Australia|Westmead Hospital, Sydney, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|Brantford General Hospital, Brantford, Ontario, Canada|Chatam-Kent Health Alliance, Chatham, Ontario, Canada|St Joseph's Healthcare, Hamilton, Ontario, Canada|Hanover District Hospital, Hanover, Ontario, Canada|Adam Linton Dialysis Unit - Victoria Hospital, London, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Westmount Kidney Care Centre, London, Ontario, Canada|Grey Bruce Health Services, Owen Sound, Ontario, Canada|Bluewater Hospital, Sarnia, Ontario, Canada|Huron Perth Hospital Partnership, Stratford, Ontario, Canada|Tillsonburg District Memorial Hospital, Tillsonburg, Ontario, Canada|Woodstock General Hospital, Woodstock, Ontario, Canada|Stoney Creek, Hamilton, Canada|Belleville, Kingston, Canada|Brockville, Kingston, Canada|Kingston General, Kingston, Canada|Napanee, Kingston, Canada|Perth and Smith Falls, Kingston, Canada|Picton, Kingston, Canada|St. Michael's Hospital, Toronto, Canada|Praxis f�r Nierenkrankheiten Berlin Hellersdorf, Berlin, Germany|Dialysezentrum Elsenfeld, Elsenfeld, Germany|Arbeitsgemeinschaft Heimdialyse Saar e.V., Homburg, Germany|KfH Nierenzentrum Lichtenfels, Lichtenfels, Germany|Universit�tsmedizin Mainz, Dialysestation 605-5E, Mainz, Germany|Dialysezentrum Schweinfurt, Schweinfurt, Germany|Nephrologisches Zentrum Villingen-Schwenningen -Tuttlingen, Villingen-Schwenningen, Germany|Area Hospital, Kothapeta Road,Chirala, Andhra Pradesh, Chirala, Andhra Pradesh, India|Medical Superintendent Government Hospital, Gudur, Andhra Pradesh, India|Government General Hospital, Guntur, Andhra Pradesh, India|Medical Superintendent District Hospital, Hindupur PPP, Andhra Pradesh, India|Government Area Hospital, Kanigiri, Andhra Pradesh, Kanigiri, Andhra Pradesh, India|Government General Hospital, Kurnool, Andhra Pradesh, India|Government Hospital, K?kin?da, Andhra Pradesh, India|Government Hospital, Machilipatnam PPP, Andhra Pradesh, Machilipatnam, Andhra Pradesh, India|Government Area Hospital, Markapur, Andhra Pradesh, India|Government Hospital, Nandyal, Andhra Pradesh, India|Area Hospital, Narsipatnam, Andhra Pradesh, India|Government Area Hospital, Palakonda, Srikakulam District, Andhra Pradesh, India|CHC Government Hospital, Palasa, Andhra Pradesh, India|Government Area Hospital, Parvathipuram, Andhra Pradesh, India|Government Hospital, Proddatur, Andhra Pradesh, India|Government Hospital, Rajahmundry, Andhra Pradesh, India|CHC Hospital, Sompeta, Andhra Pradesh, Sompeta, Andhra Pradesh, India|Greater Kailash Hospital, Tadepalligudem, Andhra Pradesh, India|Manasa Kidney Foundation, Tirupati, Andhra Pradesh, India|Government General Hospital, Vijayavada PPP, Andhra Pradesh, Vijayavada, Andhra Pradesh, India|King George Government Hospital, Visakhapatnam, Andhra Pradesh, India|Rajiv Gandhi Institute of Medical Sciences, Srikakulam PPP, Andhra, Srikakulam, Andhra, India|Ford Hospital, Khemnichak, Patna, Patna, Bihar, India|Janak Dulari Hospital, Hanuman Nagar, Patna, Bihar, India|Aysha Hospital, Kilpauk, Chennai, India|Retteri Sri Kumaran Health Centre, Kolathur, Chennai, India|Leelawati Hospital, Amb?la, Haryana, India|Greater Kailash Hospital, Old Palasia, Indore, India|ESI Hospital, Adityapur, Jharkand, India|K.M Memorial Hospital and Research Centre, Bokaro, Jharkhand, India|Asarfi Hospital, Dhanbad, Jharkhand, India|Bhagwan Mahavir Medical Superspeciality Hospital, Ranchi, Jharkhand, India|Guru Nanak Hospital and Research Centre, Ranchi, Jharkhand, India|Koshys Hospital, Ramamurthy Nagar, Bengaluru, Karnataka, India|Nephroplus Basaveshwaranagar, Bengaluru, Karnataka, India|Fortis Suchirayu Hospital, Hubli, Karnataka, India|Main Hospital, SCCL, Kothagudem, Khammam, India|Vishesh Hospital Pvt. Ltd, Geeta Bhawan Chouraha, Indore, Madhya Pradesh, India|Hitwardhak Mandal Hospital, Mumbai, Maharashtra, India|Lokmanya Hospital, Pune, Maharashtra, India|Chirayu Hospital, Th?ne, Maharashtra, India|Nephroplus Borivali Standalone, Borivali West, Mumbai, India|Bharat Baug, Borivali West, Mumbai, India|Jyothi Hospital, Balasore, Odisha, India|Kar Clinic & Hospital Pvt. Ltd., Bhubaneswar, Odisha, India|Neelachal Hospital, Kharvel Nagar, Bhubaneswar, Odisha, India|Satguru Partap Singh Apollo Hospitals, Ludhi?na, Punjab, India|KG Hospital, Coimbatore, Tamil Nadu, India|Sudha Hospital, Vadalur, Neyveli, Tamil Nadu, India|Deepam Hospitals, Pallavaram, Chennai, Tamilnadu, India|Neyveli Lignite Corporation Hospital, Neyveli, Tamilnadu, India|Citizens Specialty Hospital, Hyderabad, Telangana, India|ESI Multi-Specialty Hospital, Hyderabad, Telangana, India|Vintage Plaza Nephroplus, Road no. 10, Banjara Hills, Hyderabad, Telangana, India|Government Hospital, Khammam, Telangana, India|Suraksha Multispecialty Hospital, Nalgonda, Telangana, India|Nephroplus Standalone Dialysis Center, Easy Marredpally, Secunderabad, Telangana, India|Madhuraj Hospital, Kanpur, Uttar Pradesh, India|Ajanta Hospital, Lucknow, Uttar Pradesh, India|Surbhi Hospital Pvt. Ltd, Sector 35, Noida, Uttar Pradish, India|Health Point Hospital, Prannth Pandit Street, Kolkata, West Bengal, India|Minimal Access Surgery Clinic Pvt Ltd, Tamluk, West Bengal, India|Baroma Sirona Hospital, Uttar Mechgram, West Bengal, India",,https://ClinicalTrials.gov/show/NCT02823821,NCT02823821,32889978
oui,NCT02825277,Utero-placental Vascularisation in Normal and Preeclamptic and Intra-uterine Growth Restriction Pregnancies,EVUPA,Unknown status,No Results Available,Preeclampsia|Intra-uterine Growth Restriction,Device: Doppler,Measure of 3D power Doppler indice : the vascularization index (VI)|Measure of 3D power Doppler indice : blood flow (the flow index (FI)|Measure of of 3D power Doppler indice : the vascularization-flow index (VFI)|Measure of volume density (morphological analysis)|Measure of surface density (morphological analysis),"Central Hospital, Nancy, France",Female,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,112,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2013-A01049-36,December 2013,January 2017,,"July 7, 2016",,"July 7, 2016","Pr Olivier MOREL, Vandoeuvre les Nancy, France",,https://ClinicalTrials.gov/show/NCT02825277,NCT02825277,
oui,NCT02826629,"""Manual Dexterity and Oculomotor Control in Schizophrenia""",MADOCS,Unknown status,No Results Available,Schizophrenia,Device: Manual dexterity|Device: Oculomotor movements|Device: TMS coupled to EMG recording|Other: Psychopathological evaluations|Other: Neuropsychological evaluations,Behavioural assessment|Clinical scale : PANSS|Clinical scale : DIGS III|Clinical scale : BPRS|Clinical scale : SAS|Clinical scale : AIMS|Clinical scale : TAP|Clinical scale : Stroop|Clinical scale : WASI|Tracking performance (motor task): RMS Error|Tracking performance (motor task): Coefficient of variability|Tracking performance (motor task): Timing|Ocolomotor performance (eye tracker) : Saccade|Ocolomotor performance (eye tracker): Gain|Ocolomotor performance (eye tracker): Amplitude of eye movements|Motor noise|Cortical excitability (MEP  TMS)|Cortical inhibition (SICI  TMS),"Centre Hospitalier St Anne|University of Paris 5 - Rene Descartes|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 50 Years   (Adult),Not Applicable,105,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,D16-P01,"July 26, 2016",September 2018,January 2019,"July 11, 2016",,"October 19, 2017","Centre de Recherche Clinique (CRC) - CHSA, Paris, France|Service Hospitalo-Universitaire (SHU) - CHSA, Paris, France",,https://ClinicalTrials.gov/show/NCT02826629,NCT02826629,
associ�,NCT02826733,Evaluation of the Implementation of the Hemispheric Dominance During Development,HEMISPHERENOR,"Active, not recruiting",No Results Available,Neuroimaging,Device: Electroencephalogram (EEG)|Device: Near Infra Red Spectroscopy (NIRS)|Device: magnetic resonance imaging (MRI),discrimination of language - EEG|discrimination of language - NIRS,"Centre Hospitalier Universitaire, Amiens",All,0 Days to 10 Weeks � (Child),,120,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,PI08-DR-WALLOIS,"November 4, 2009","November 3, 2021","November 3, 2024","July 11, 2016",,"February 8, 2023","CHU Amiens, Amiens, France",,https://ClinicalTrials.gov/show/NCT02826733,NCT02826733,
oui,NCT02832661,"BIOMARGIN European, Ambispective Cohort of Adult and Paediatric Renal Transplant Patients",BECS,Unknown status,No Results Available,Kidney Transplantation,,predictive value of biomarkers|Number of biopsy-proven acute rejection episodes|graft survival at 3 and 5 years post-transplantation|glomerular filtration rate (GFR in ml/min) estimated using the MDRD formula,"University Hospital, Limoges|Hannover Medical School|KU Leuven|H�pital Necker-Enfants Malades|Hospital Purpan",All,"1 Year and older � (Child, Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort,I15038|grant agreement no: 305499,March 2015,March 2020,March 2020,"July 14, 2016",,"July 14, 2016","University of Leuven - KU Leuven, Leuven, Belgium|University Hospital - INSERM, Limoges, France|University Hospital - INSERM, Limoges, France|Necker Children University Hospital, Paris, France|Purpan Children University Hospital, Toulouse, France|Medizinische Hochschule Hannover (MHH), Hannover, Germany",,https://ClinicalTrials.gov/show/NCT02832661,NCT02832661,36398319;31378695
oui,NCT02833961,Diffusion Spectroscopy in Stroke,ISIS,Completed,No Results Available,ISCHEMIC STROKE,Device: Magnetic resonance imaging,ADC measurements (in mm2/second) of metabolites within the ischemic lesion|Relative change of the ADC values (in %) of the metabolites over time|Diffusivity measure within the ischemic lesion (in mm2/second).|Relative change of the diffusivity measure values (in %) of water over time,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,47,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,C16-04|2016-A00362-49,"July 28, 2016","October 25, 2019","October 25, 2019","July 14, 2016",,"August 26, 2021","Institut du cerveau et de la moelle, Hôpital Pitié-Salpétrière, Paris, France",,https://ClinicalTrials.gov/show/NCT02833961,NCT02833961,36318030
oui,NCT02838069,A Study Evaluating the Efficacy of a Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells in Patients With Knee Osteoarthritis,ADIPOA-2,"Active, not recruiting",No Results Available,Osteoarthritis,Biological: Injection (2x106 ASC/5ml).|Biological: Injection (10x106 ASC/5ml).|Other: Placebo,Improvement of pain or physical function|Disability (WOMAC)|Disability (KOOS)|Disability (SAS)|Change in Quality of life|painkillers consumption|Structural changes (X-Ray)|Structural changes (MRI),"University Hospital, Montpellier|University Hospital, Toulouse|Assistance Publique - Hôpitaux de Paris|NATIONAL UNIVERSITY OF IRELAND, GALWAY (NUIG)|ISTITUTO ORTOPEDICO RIZZOLI (IOR)|Etablissement Français du Sang|Institut National de la Santé Et de la Recherche Médicale, France|ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)|HUMAN MED AG (HM)|Stichting Katholieke Universiteit|SPORTS SURGERY CLINIC LIMITED|UNIVERSITA DEGLI STUDI DI PADOVA (UNIPD)|EVANGELISCHES WALDKRANKENHAUS SPANDAU KRANKENHAUSBETRIEBS GGMBH (EWK)|PINTAIL LTD (PT)|Centre National de la Recherche Scientifique, France|UNIVERSITAET ULM (UULM)|Cambridge University Hospitals NHS Foundation Trust|Aries srl (ARIES)",All,"45 Years to 75 Years   (Adult, Older Adult)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UF 9494,"September 20, 2016",March 2023,March 2024,"July 20, 2016",,"July 11, 2022","UH Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02838069,NCT02838069,
oui,NCT02849613,Regenerative Stem Cell Therapy for Stroke in Europe,RESSTORE,Withdrawn,No Results Available,Stroke,Other: Adipose Derived Stem Cells|Other: Vehicle media,Between-group difference of NIHSS (stroke severity score),"University Hospital, Grenoble|Horizon 2020 - European Commission|University Grenoble Alps|Servicio Madrileño de Salud, Madrid, Spain|St. Anne's University Hospital Brno, Czech Republic|Andaluz Health Service|University of Glasgow|University of Eastern Finland|Etablissement Français du Sang|Tampere University|Histocell SL, Spain|Medfiles CRO, Finland|Institut National de la Santé Et de la Recherche Médicale, France|Hospices Civils de Lyon|Association Groupe ESSEC|NOVADISCOVERY SAS, France|Finovatis|Centre Hospitalier Universitaire de Besancon|Assistance Publique - Hôpitaux de Paris|University Hospital, Toulouse|University Hospital, Bordeaux|University Hospital, Caen|Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Servicio de Salud de Castilla La Mancha, Albacete, Spain|Servizo Galego de Saude, Santiago de Compostela, Spain|Pirkanmaa Hospital District, Tampere, Finland|Hospital Vall d'Hebron|Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",38RC15.337,March 2016,September 2017,September 2017,"July 29, 2016",,"October 6, 2021","University Grenoble Hospital / EFS, Grenoble, France",,https://ClinicalTrials.gov/show/NCT02849613,NCT02849613,
oui,NCT02849834,Cortical Plasticity After Motor Cortex Stimulation in Healthy Subject and Chronic Pain Patients,,Completed,No Results Available,Neuropathic Pain,Device: Repetitive Transcranial Magnetic Stimulation (rTMS),"cortical plasticity induced by rTMS - - Somatosensory evoked potentials|cortical plasticity induced by rTMS -- fMRI|Nonparametric (Chi-2) contrast of dichotomized pain reports before/after rTMS and extent of fMRI activation change (also dichotomized) MRI T1 3D and T2*|Linear and nonlinear correlation between the magnitude of induced cortical plasticity and the magnitude of pain relief induced by rTMS. MRI T1 3D and T2*,",Hospices Civils de Lyon,All,"18 Years to 70 Years � (Adult, Older Adult)",Not Applicable,65,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",2008-505|2008-A01437-38,November 2009,"November 21, 2016","November 21, 2016","July 29, 2016",,"July 11, 2018","Service d'Exploration, Centre Hospitalier Lyon Est, Hospices civils de Lyon, Lyon, F-69495, France et NeuroPain lab - CRNL (Inserm U1028 - UCBL), Bron, France",,https://ClinicalTrials.gov/show/NCT02849834,NCT02849834,
oui,NCT02849886,T Lymphocytes (LT) Expressing iCASP9 and ?CD19 in Allogeneic Haematopoietic Transplantation.,Side_by_Cide,Unknown status,No Results Available,Graft Versus Host Disease|Hematological Malignancies,Drug: T lymphocytes iCASP9 ?CD19|Drug: Dimerizer drug AP1903,GvHD response to Dimerizer AP1903|Haematopoietic reconstitution (Blood)|Haematopoietic engraftment (bone marrow)|Haematopoietic engraftment (chimerism)|Infections post Transplantation|GvL effect,Centre Hospitalier Universitaire de Besancon|Etablissement Fran�ais du Sang|Bellicum Pharmaceuticals,All,40 Years to 55 Years � (Adult),Phase 1|Phase 2,12,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,N/2000/39-B,"April 10, 2019",December 2021,December 2021,"July 29, 2016",,"February 1, 2021","CHU Jean Minjoz, Besan�on, France",,https://ClinicalTrials.gov/show/NCT02849886,NCT02849886,
oui,NCT02850393,Inhibitory Control of the Mind : Neural Bases and Impact for Obsessive-compulsive Disorders,SUPTOC,Unknown status,No Results Available,Obsessive Compulsive Disorder|Healthy,Other: Functional magnetic resonance imaging|Behavioral: behavioral measures|Other: physiological measurements,Blood Oxigen Level Dependent (BOLD) response as measured with fMRI,"University Hospital, Caen|Institut National de la Sant� Et de la Recherche M�dicale, France|Centre National de la Recherche Scientifique, France|Universit� de Caen Normandie",All,18 Years to 55 Years � (Adult),Not Applicable,48,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2015-A01609-40|160028B-31,July 2016,March 2019,December 2019,"August 1, 2016",,"August 1, 2016","GIP Cyceron, Caen, Calvados, France",,https://ClinicalTrials.gov/show/NCT02850393,NCT02850393,
non,NCT02851134,Search for New Genetic Mutations Major Effect in Crohn's Disease,MC-WES,Completed,No Results Available,Crohn Disease,Genetic: genetic analysis|Biological: blood and stools samples,NOD2 gene status|Whole Exome Sequencing,"University Hospital, Lille",All,"5 Years to 80 Years � (Child, Adult, Older Adult)",,20,Other,Observational,Observational Model: Family-Based|Time Perspective: Prospective,2013_53|2014-A00023-44,April 2015,April 2018,April 2018,"August 1, 2016",,"February 28, 2019","CHRU, H�pital Claude Huriez, Lille, France",,https://ClinicalTrials.gov/show/NCT02851134,NCT02851134,
associ�,NCT02851537,Magnetic Resonance Spectroscopy at Term-equivalent Age and Executive Functions at 5 Years of Age Corrected in Very Preterm Infants,EPIRMEX,Unknown status,No Results Available,Children Born Very Prematurely in Relation to Structural Brain Abnormalities,Other: an advanced technique as magnetic resonance spectroscopy (MRS),assessment of the executive dysfunction|intellectual efficiency|perceptual organization and memory,Assistance Publique Hopitaux De Marseille,All,up to 5 Years � (Child),,100,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2015-17,October 2017,November 2018,January 2019,"August 1, 2016",,"August 8, 2017",,,https://ClinicalTrials.gov/show/NCT02851537,NCT02851537,
oui,NCT02852499,Following of Atmospheric Pollution Exposure During Pregnancy and Effects on Health,SEPAGES-1337,Unknown status,No Results Available,Healthy Volunteer,Other: Urine sampling|Other: Carry a GPS and BET|Other: Carry pollution sensor|Other: Sampling at the maternity|Other: Self-questionnaires|Other: Sampling in partum period,Clinical exam : biological sampling,"University Hospital, Grenoble|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,1010,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,38RC13.579,July 2014,February 2018,January 2021,"August 2, 2016",,"December 27, 2019","Hopital Couple Enfant - Grenoble, La Tronche, France",,https://ClinicalTrials.gov/show/NCT02852499,NCT02852499,
oui,NCT02852590,Relationship Between Adverse Drug Reactions and Unlicensed/ Off-label Drug Use in Hospitalized Children,EREMI,Completed,No Results Available,Hospitalized Children,,occurrence of an adverse drug reaction (ADR)|proportion of pediatrics inpatients presenting at least one ADR|indications for which drugs are prescribed in term of licensed/ unlicensed/ off-label manner by age group|Identify the factors influencing the risk of developing ADRs after prescribing a drug|causality of ADRs|severity of ADRs|avoidability of ADRs,Hospices Civils de Lyon,All,up to 15 Years � (Child),,6227,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,D21530,November 2013,January 2016,January 2016,"August 2, 2016",,"August 2, 2016","Pediatric Clinical Research and Investigation Centre CIC 1407 Inserm-UMR 5558 CNRS Lyon University & Hospices Civils de Lyon, Lyon, France",,https://ClinicalTrials.gov/show/NCT02852590,NCT02852590,
oui,NCT02853019,Emotion and Motivation in Patients With Psychosis,,Recruiting,No Results Available,Schizophrenia,Other: Electroencephalogram|Behavioral: Cognitive tasks|Behavioral: subjective evaluation scales,Change in the amplitude of the CNV (Contingent Negative Variation) as a function of the primer displayed on the screen|Change in the amplitude of the LPP (Late Positive Potential) as a function of the primer displayed on the screen,"University Hospital, Strasbourg, France|Institut National de la Sant� Et de la Recherche M�dicale, France",All,18 Years to 55 Years � (Adult),Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,6152,"February 2, 2017",June 2023,June 2023,"August 2, 2016",,"August 19, 2022","Unit� INSERM 1114, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT02853019,NCT02853019,
oui,NCT02853175,Lung MRI and Allergic Broncho-pulmonary Aspergillosis in Cystic Fibrosis,MRAB,Completed,No Results Available,Pulmonary Cystic Fibrosis|ABPA,,"Diagnostic accuracy of lung MRI for ABPA in CF owing to increased T1 and decreased T2 signal intensity of mucus|Diagnostic accuracy of quantitative measurement of central mucoid impaction signal on T1-weighted sequence and T2-weighted sequence|Diagnostic accuracy of hyperattenuated central mucoid impaction on chest computed tomography (CT) to detect ABPA in CF, using reduction of doses down to chest radiograph level|Diagnostic follow-up of patients ABPA status 1 year|Diagnostic accuracy of MRI to detect ABPA in CF using various ABPA classifications|Reproducibility of qualitative and quantitative imaging evaluations|Diagnostic accuracy of morphological imaging using MRI with ultrashort echotimes|Diagnostic accuracy of morphological imaging using CT with reduction of doses down to chest radiograph level|Reproducibility between MRI and CT with reduction of doses down to chest radiograph level to assess structural alterations|Severity of small airway and perfusion alterations using functional MR sequences|Follow-up of disease severity under treatement","Hôpital Haut Lévêque|University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France|Hôpital Haut-Lévêque",All,"6 Years and older   (Child, Adult, Older Adult)",,240,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,ANR-10-LABX-57,January 2014,January 2023,January 2023,"August 2, 2016",,"March 7, 2023","University Hospital Bordeaux, Bordeaux, Aquitaine, France",,https://ClinicalTrials.gov/show/NCT02853175,NCT02853175,
oui,NCT02854124,Tracing Dissemination of Melanoma Cells in Healthy Tissues,DISSEMELA,Completed,No Results Available,Melanoma,Procedure: Melanoma and peritumoral skin excision,Survival at 5 years|Survival at 5 years without tumor recurrence,"Assistance Publique - H�pitaux de Paris|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",,226,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,NI15020,"October 12, 2017","November 12, 2021","November 12, 2021","August 3, 2016",,"September 27, 2022","Name:: INSERM - UMRS 938, UPMC Saint-Antoinen Hospital, Team ""Stem cells and transition from pre-invasive tumors"", Paris, France",,https://ClinicalTrials.gov/show/NCT02854124,NCT02854124,
oui,NCT02855918,Blood Biomarkers in Suicidal Behaviour,2BSB,Completed,No Results Available,Major Depression,Other: Blood sample for genetic purpose,Evolution of the modification of the expression of Adenosine deaminases acting on RNA (ADARs) and of the editing profile of phospho-diesterase 8A (PDE8A)|Modification of the expression of ADAR1a enzymes|Modification of the expression and RNA editing of Spindle And Kinetochore Associated protein 2 (SKA2)|Modification of the expression of ADAR1b enzymes|Modification of the expression of ADAR2 enzymes|Modification of the expression and RNA editing of Spermidine/Spermine N1-Acetyltransferase 1 (SAT1)|Modification of the expression and RNA editing of Interleukins (ILs)|Modification of the expression and RNA editing of Chemokines (CXCLs)|Modification of the expression and RNA editing of Brain derived Neurotrphic factor (BDNF)|Modification of the expression and RNA editing of Cluster of differentiation 24 (CD24)|Modification of the expression and RNA editing of Three prime repair exonuclease 1 (TREX1)|Modification of the expression and RNA editing of Interferon stimulated gene 15 (ISG15)|Modification of the expression and RNA editing of Tumor necrosis factor alpha (TNF alpha)|Modification of the expression and RNA editing of Vascular endothelial growth factor (VEGF)|Modification of the expression and RNA editing of Hydroxytryptamine receptor 2A (HTR2A)|Modification of the expression and RNA editing of insulin-like growth factor protein 7 (IGFB7),"University Hospital, Montpellier|Institut National de la Santé Et de la Recherche Médicale, France|Sys2Diag, Mixt laboratory CNRS/Alcediag, Montpellier",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,600,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,UF 9625|2015-A01978-41,"September 23, 2016","June 24, 2020","June 24, 2020","August 4, 2016",,"December 27, 2021","University Hospital, Montpêllier, France",,https://ClinicalTrials.gov/show/NCT02855918,NCT02855918,
oui,NCT02855957,Evaluation of the Free α-hemoglobin Pool in the Red Blood Cells : Prognostic Marker and Severity Index in Thalassemic Syndromes,ALPHAPOOL,Completed,No Results Available,Thalassemic Syndromes,Other: Free α-Hb pool analysis,Correlation between the pool of free α-Hb and genotype α and β -globin of the patient and if necessary with the genotype AHSP gene|Correlation between the pool of free α-Hb and Hb value|Correlation between the pool of free α-Hb and Mean Corpuscular Hb|Correlation between the pool of free α-Hb and Mean Cell Volume|Correlation between the pool of free α-Hb and percent of reticulocytes|Correlation between the pool of free α-Hb and fetal Hb|Correlation between the pool of free α-Hb and erythrocyte enzymes,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Paris 12 Val de Marne University",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,135,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P120205,June 2013,July 2015,June 2016,"August 4, 2016",,"August 4, 2016","Henri Mondor Hospital, Creteil, France",,https://ClinicalTrials.gov/show/NCT02855957,NCT02855957,
oui,NCT02856165,High-flow Nasal Oxygen Therapy in Hospitalized Infant With Moderate-to-severe Bronchiolitis,BRONCHOPTI,Completed,No Results Available,Bronchiolitis,Device: High-flow nasal canula oxygen therapy|Device: Low-flow oxygen therapy with standard nasal canula,patient in treatment failure in each group (control or HFN) requiring non-invasive (or endotracheal) ventilation and ventilation-support free days|Transfer to pediatrics intensive care unit (PICU)|Length of stay in paediatric general ward unit|Oxgen-support free days|Artificial nutritional-support free days|Assessment of short term respiratory status,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,7 Days to 6 Months   (Child),Not Applicable,268,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,P150931,"October 28, 2016","November 15, 2017","November 23, 2017","August 4, 2016",,"April 30, 2018","AP-HP, Bicêtre Hospital, Le Kremlin Bicêtre, France",,https://ClinicalTrials.gov/show/NCT02856165,NCT02856165,
oui,NCT02861599,Study of the Interest of Proprioceptive Therapy as a Complement to Speech Therapy in Children With Reading Difficulties,2000DYS9,Unknown status,No Results Available,Reading Difficulties,Other: proprioceptive therapy|Other: speech therapy,Percentage of children who had stabilized their delay in reading acquisition at the Tim�-3 test (identification of written words),Centre Hospitalier Universitaire Dijon,All,7 Years to 11 Years � (Child),Not Applicable,150,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),QUERCIA INSERM 2015,September 2015,July 2017,,"August 10, 2016",,"August 10, 2016","CHU Dijon Bourgogne, Dijon, France",,https://ClinicalTrials.gov/show/NCT02861599,NCT02861599,
oui,NCT02868255,Myeloid Derived Suppressor Cells Control by Signal Regulatory Protein-alpha: Investigation in Hepatocellular Carcinoma,MDScan,Completed,No Results Available,Hepatocellular Carcinoma,Procedure: Collection of human samples,evaluation of the SIRP/CD47 expression,"Nantes University Hospital|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,30,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RC16_0156,"January 3, 2016","November 30, 2018","November 30, 2018","August 16, 2016",,"September 13, 2021",,,https://ClinicalTrials.gov/show/NCT02868255,NCT02868255,
oui,NCT02876328,Partnership for Research on Ebola VACcinations,PREVAC,"Active, not recruiting",Has Results,Ebola Virus Disease,Biological: Ad26.ZEBOV|Biological: MVA-BN-Filo|Biological: rVSVΔG-ZEBOV-GP|Biological: Placebo|Biological: rVSV boost,Percentage of Participants With Ebola Virus Glycoprotein (GP-EBOV) Antibody Response|Frequency of Serious Adverse Events (SAEs)|Number of Participants With Ebola Virus Glycoprotein (GP-EBOV) Antibody Response,"National Institute of Allergy and Infectious Diseases (NIAID)|Partnership for Research on Ebola Virus in Liberia (PREVAIL)|Institut National de la Santé Et de la Recherche Médicale, France|London School of Hygiene and Tropical Medicine|European and Developing Countries Clinical Trials Partnership (EDCTP)",All,"1 Year and older   (Child, Adult, Older Adult)",Phase 2,4789,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",C15-33|PREVACEBL3005,"March 27, 2017","December 24, 2019",June 2024,"August 23, 2016","September 28, 2022","February 24, 2023","Centre national de formation et de recherche en santé rurale (Maferyniah), Conakry, Guinea|Landreah, Conakry, Guinea|The Redemption Hospital, Monrovia, Liberia|Centre pour le Développement des Vaccins (CVD), Bamako, Mali|University Clinical Research Center (UCRC), Bamako, Mali|Mambolo Clinic, Kapesseh, Sierra Leone","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02876328/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02876328/SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02876328/ICF_003.pdf",https://ClinicalTrials.gov/show/NCT02876328,NCT02876328,36516078;33485369
oui,NCT02878083,Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT),DETECT,Terminated,No Results Available,ULCERATIVE COLITIS,Drug: VEDOLIZUMAB|Drug: ADALIMUMAB,"Demonstrate the feasibility of an ex vivo labeling of intestinal immune cells with a combination of two markers: vedolizumab-FITC and adalimumab-Alexa Fluor 647|Quantify, ex vivo, the number of cells labeled with FITC-coupled vedolizumab in the intestinal mucosa of patients with moderate to severe UC that are associated with clinical remission at week 22 (W22) after the initiation of treatment with vedolizumab.|Evaluate the association between the number of cells labeled with FITC-coupled vedolizumab in the intestinal mucosa and the rate of clinical response induced by treatment with a standard dose of vedolizumab|Evaluate the association between the number of cells labeled with FITC-coupled vedolizumab in the intestinal mucosa and the rate of endoscopic remission induced by treatment with a standard dose of vedolizumab|Evaluate the association between the number of cells labeled with FITC-coupled vedolizumab in the intestinal mucosa and the rate of histologic remission induced by treatment with a standard dose of vedolizumab|Evaluate the association between the Alexa Fluor 647-coupled adalimumab biomarker, and the rate of clinical response at w30 to adalimumab|Evaluate the association between the Alexa Fluor 647-coupled adalimumab biomarker, and the rate of endoscopic remission at w30 to adalimumab|Evaluate the association between the Alexa Fluor 647-coupled adalimumab biomarker, and the rate of clinical remission at w30 to adalimumab|Compare the number of positive immune cells FITC-coupled vedolizumab in the intestinal mucosa of patients with UC|Compare the number of positive immune cells Alexa Fluor 647-coupled adalimumab in the intestinal mucosa of patients with UC","Nantes University Hospital|Takeda|Mauna Kea Technologies|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,19,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RC15_0457,"January 11, 2017",January 2020,"January 1, 2021","August 25, 2016",,"February 17, 2023","Chu Angers, Angers, France|Chd Vendee, La Roche Sur Yon, France|Chu Nantes, Nantes, France|Chu Rennes, Rennes, France",,https://ClinicalTrials.gov/show/NCT02878083,NCT02878083,
oui,NCT02879786,Study of Hierarchy of Afferents in Postural Control of Children With Dyslexia,EQUIDYS,Completed,No Results Available,Dyslexia,Other: Posturographic tests|Other: Questionnaire of motion sickness susceptibility,Score of evaluation of motion sickness susceptibility|Score of equilibrium evaluated with posturographic test,"Central Hospital, Nancy, France",All,8 Years to 13 Years � (Child),Not Applicable,68,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2011-A00139-32,July 2011,June 2015,June 2015,"August 26, 2016",,"August 26, 2016","Centre de R�f�rence pour les Troubles des Apprentissages - H�pital d'Enfants - CHU de Nancy, Vandoeuvre l�s Nancy, France",,https://ClinicalTrials.gov/show/NCT02879786,NCT02879786,
oui,NCT02880150,Physiological Characteristics of High Altitude Climbers,ALTIPERF,Completed,No Results Available,Hypoxia|Exercise|Sport Performance,Other: Stress test,Performance reduction in hypoxia versus normoxia|Near infrared signals during exercise,"University Hospital, Grenoble|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 40 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2013-A00629-36|ALTIPERF,May 2013,March 2014,May 2014,"August 26, 2016",,"August 26, 2016","Grenoble University Hospital, Grenoble, France",,https://ClinicalTrials.gov/show/NCT02880150,NCT02880150,
oui,NCT02880358,Epidemiology and Prognostic of the Acute Heart Failure,EPICAL2,Unknown status,No Results Available,Decompensated Chronic Heart Failure|Heart Failure NYHA Class III|Acute Pulmonary Edema|Cardiogenic Shock|Heart Failure NYHA Class IV,,Incidence of Acute Heart Failure|Morbi-mortality of patients presenting an acute heart failure,"Central Hospital, Nancy, France",All,"18 Years and older � (Adult, Older Adult)",,2500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,911069,January 2011,December 2015,May 2017,"August 26, 2016",,"August 26, 2016","University Hospital Center, Nancy, Lorraine, France",,https://ClinicalTrials.gov/show/NCT02880358,NCT02880358,30972619
oui,NCT02882334,Finger Individuation Training With a Training Device Versus Conventional Rehabilitation for Writer's Cramp,FIDEX,Terminated,No Results Available,Dystonic Disorders,Device: Finger Force Manipulandum|Other: Conventional physiotherapy,change in writing speed after rehabilitation,Fondation Ophtalmologique Adolphe de Rothschild|Foundation Jacques and Gloria Gossweiler,All,"18 Years to 70 Years � (Adult, Older Adult)",Not Applicable,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other",SSA_2016_15,"November 8, 2016",December 2020,December 2020,"August 29, 2016",,"July 19, 2021","Fondation Ophtalmologique A. de Rothschild, Paris, France",,https://ClinicalTrials.gov/show/NCT02882334,NCT02882334,
oui,NCT02883322,"Adaptation Process of Patient-Reported Outcomes, an eVALuation Study",APPROVALS,Completed,No Results Available,Chronic Disease,Other: Cross cultural adaptation of patient reported outcomes (PRO),heiQ questionnaire,"GUILLEMIN Francis, MD|Societe Francaise de Rhumatologie|R�gion Lorraine|Central Hospital, Nancy, France",All,"18 Years and older � (Adult, Older Adult)",,4000,Other,Observational,Time Perspective: Cross-Sectional,APPROVALS,December 2010,September 2012,,"August 30, 2016",,"August 30, 2016",,,https://ClinicalTrials.gov/show/NCT02883322,NCT02883322,
oui,NCT02883335,Lorraine Registry of Multiple Sclerosis,RelSEP,Recruiting,No Results Available,Multiple Sclerosis,Other: Observational registry,case occurence of multiple sclerosis|EDSS score,"Central Hospital, Nancy, France|Institut National de la Sant� Et de la Recherche M�dicale, France|University of Lorraine",All,"Child, Adult, Older Adult",,6000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RELSEP,May 2003,January 2030,January 2030,"August 30, 2016",,"February 8, 2023","CIC 1433 �pid�miologie clinique, Inserm, Universit� de Lorraine, CHRU de Nancy, Nancy, France",,https://ClinicalTrials.gov/show/NCT02883335,NCT02883335,
oui,NCT02884622,DNA Methylation and Lung Disease in Cystic Fibrosis,METHYLCF,Completed,No Results Available,Cystic Fibrosis,Other: nasal epithelial|Other: Blood sampling,DNA methylation levels (chemical changes),"University Hospital, Montpellier|Vaincre la Mucoviscidose|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,72,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,9133,June 2013,June 2016,August 2016,"August 31, 2016",,"August 31, 2016","UHMontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02884622,NCT02884622,30052057
oui,NCT02884674,Repetitive Transcranial Magnetic Stimulation in Obsessive Compulsive Disorder,MAGTOC,Unknown status,No Results Available,Obsessive-Compulsive Disorder,Device: Active Repetitive Transcranial Magnetic Stimulation|Device: Placebo Repetitive Transcranial Magnetic Stimulation,"Change from baseline of the score at the Yale - Brown Obsessive and Compulsive Scale|Score of Montgomery and Asberg Depression Rating Scale, as a Measure of effects on Mood (depression)|Score of Young Mania Rating Scale, as a Measure of effects on Mood (hyperthymia)|Score of Multidimensional Assessment of Thymic States Scale as a Measure of effects on Emotional Reactivity|Number of patients with Side effects as a measure of Safety and Tolerability|Inferior Frontal Region Activity (percentage of the BOLD signal change (parameter estimates beta)|Fractional Anisotropy (FA), mean and radial diffusivity (MD, RD), tracti integrity of the inhibition network,|Yale - Brown Obsessive and Compulsion Scale score after the TMS treatment as an evaluation of the persistence of the clinical benefit|Cortical Excitability|Evaluation of Impulsivity using specific scales|Evaluation of the Clinical global State|type of side effects (pain, paresthesia, other) as a measure of Safety and Tolerability","University Hospital, Grenoble",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,56,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",38RC14.156|2014-A00668-39,May 2015,November 2019,May 2021,"August 31, 2016",,"May 8, 2020","CHU de Grenoble - Pavillon Dominique Villars, Grenoble, Rhone Alpes, France",,https://ClinicalTrials.gov/show/NCT02884674,NCT02884674,
oui,NCT02886416,Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity,"""ImmunoCo27""",Completed,No Results Available,HIV Infection,Other: Non interventional study,Longitudinal study of the co-adaptation of HIV and immune host factors in 28 patients with HIV followed for 27 years.,"ANRS, Emerging Infectious Diseases",All,"40 Years to 95 Years � (Adult, Older Adult)",,22,Other,Observational,Observational Model: Cohort|Time Perspective: Other,ANRS EP60|2016-A00400-51,August 2016,April 2017,April 2017,"September 1, 2016",,"September 28, 2018",,,https://ClinicalTrials.gov/show/NCT02886416,NCT02886416,
oui,NCT02886624,Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4,SAHIV,Completed,Has Results,Acute Hepatitis C|HIV,Drug: Grazoprevir/Elbasvir,Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Virological Failure|Treatment Adherence|Number of Participants With Undetectable HIV RNA|CD4 Cell Count|Incidence of HCV Re-infection,"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|Merck Sharp & Dohme LLC|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMEA 50,"May 31, 2017","December 31, 2018","September 16, 2019","September 1, 2016","January 29, 2020","January 29, 2020","CHU de Lyon, Lyon, France|CHU de Nice, Nice, France|Hôpital Saint-Antoine, Paris, France|Hôpital La Pitié-Salpêtrière, Paris, France|Hôpital Bichat, Paris, France|Hôpital Tenon, Paris, France","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02886624/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02886624,NCT02886624,
oui,NCT02889094,French HIV-HBV Cohort,COVViB,Unknown status,No Results Available,Hepatitis B|HIV|Liver Cirrhosis|End Stage Liver Disease,Other: Routine care,HBV DNA replication|HBeAg-seroclearance|HBsAg-seroclearance|Liver fibrosis (FibroTest)|Liver fibrosis (FibroScan)|Liver-related morbidity|Liver-related mortality,"Institut de M�decine et d'Epid�miologie Appliqu�e - Fondation Internationale L�on M'Ba|ANRS, Emerging Infectious Diseases|Sidaction",All,"18 Years and older � (Adult, Older Adult)",,152,Other,Observational,Observational Model: Cohort|Time Perspective: Other,IMEA 49,October 2016,"March 31, 2018",September 2018,"September 5, 2016",,"April 26, 2018","Centre hospitalier universitaire de Lyon, Lyon, France|H�pital Saint-Louis, Paris, France|H�pital Saint-Antoine, Paris, France|H�pital Tenon, Paris, France",,https://ClinicalTrials.gov/show/NCT02889094,NCT02889094,
oui,NCT02894632,MR Compatible Accelerometer for Respiratory MOTion Measurement,MARMOT,Completed,No Results Available,Heart Disease,Device: MRI compatible motion sensor (MARMOT),Respiratory movement using respiratory belts|Respiratory movement using MARMOT sensors|Respiratory movement using real-time MR images|Subjective quality (marks between 1 (the best) and 3 (the worst) of the reconstructed MR images),"Central Hospital, Nancy, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2012-A00874-39,July 2013,August 2016,August 2016,"September 9, 2016",,"September 9, 2016","Centre Hospitalier R�gional Universitaire de Nancy Brabois, Vandoeuvre-l�s-Nancy, France",,https://ClinicalTrials.gov/show/NCT02894632,NCT02894632,
oui,NCT02894801,Multistate Relative Survival Model,MRS,Completed,No Results Available,Colorectal Cancer,,death due to cancer|death due to recurrence,"Centre Hospitalier Universitaire Dijon|Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,5194,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,PIOC 2015,January 2013,December 2013,,"September 9, 2016",,"September 9, 2016","Chu Dijon Bourgogne, Dijon, France",,https://ClinicalTrials.gov/show/NCT02894801,NCT02894801,
oui,NCT02895646,Genomic Study of Genetic Polymorphisms Involved in Immediate Allergic Reactions to Beta-lactam Antibiotics,PANGENOMIC-BL,Unknown status,No Results Available,Beta-Lactams Allergy|Hypersensitivity,Other: Collection of blood sample,"Analysis of genetic polymorphisms predictive of risk of beta-lactam immediate allergy|Analysis of allelic homozygosity linked to allergen response, in more than 2 allergic individuals of the same family|Severity of allergic reaction|Reactivity to skin test|Serum concentration of specific IgE","Central Hospital, Nancy, France",All,"Child, Adult, Older Adult",,2356,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,2012/PHRC/PANGENOMIC/GUEANT/MS,June 2012,June 2017,June 2017,"September 12, 2016",,"February 3, 2017",,,https://ClinicalTrials.gov/show/NCT02895646,NCT02895646,
oui,NCT02896387,Ability of a Molecule (Prima) to Restore Physiological Differentiation in Epithelium Expressing Gene p63,PRIMAculture,Terminated,No Results Available,Ectodermal Dysplasia,,the differentiation of corneal epithelium by histological observation,"Fondation Ophtalmologique Adolphe de Rothschild|Institut National de la Santé Et de la Recherche Médicale, France",All,"7 Years and older   (Child, Adult, Older Adult)",,5,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,EGN_2016_14,"March 3, 2017","January 1, 2022","January 1, 2022","September 12, 2016",,"May 3, 2022","Fondation Opthalmologique A de Rothschild, Paris, France|Hopital Necker, Paris, France",,https://ClinicalTrials.gov/show/NCT02896387,NCT02896387,
oui,NCT02897076,Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth,BETADOSE,Completed,No Results Available,Neonatal Complications,Drug: betamethasone 24 mg|Drug: 12mg betamethasone +placebo,severe RDS defined as need for exogenous intra-tracheal surfactant in the first 48 hours of life|highest appropriate fractional inspired oxygen (FiO2)|maximum appropriate Mean Airway Pressure (MAP)|duration of mechanical ventilation|duration of oxygen therapy|oxygen therapy|neonatal death|admission to neonatal intensive care unit|inotropic support|air leak syndrome|patent ductus arteriosus|necrotising enterocolitis|intraventricular hemorrhage and grade|periventricular leukomalacia|use of postnatal steroids|retinopathy of prematurity|length of hospital stay|early onset sepsis|Composite endpoint of any of the 4 prematurity-induced complications related to the use of betamethasone,Assistance Publique - H�pitaux de Paris,Female,18 Years to 60 Years � (Adult),Phase 3,3250,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P150944,January 2017,"January 5, 2020","January 5, 2020","September 13, 2016",,"February 3, 2023","H�pital Robert Debr�, Paris, France",,https://ClinicalTrials.gov/show/NCT02897076,NCT02897076,35988568;30755164
oui,NCT02899442,Cardiovascular Risk Prevention Among Night Workers,Heart-Of-Night,Unknown status,No Results Available,Cardiovascular Diseases,Other: collective prevention in workplace,Change of Metabolic Syndrome Factors|Change of preventive interventions,"University Hospital, Toulouse|assistance of the French National Health Insurance Fund for Employees (CNAMTS)|French Directorate General of Health (DGS)|ARC Foundation for Cancer Research|National Cancer Institute, France|French National Institute for Prevention and Education in Health (INPES)|Institut National de la Santé Et de la Recherche Médicale, France|French Inter-Departemental Agency for the Fight against Drugs and Addictive Behaviors (Mildeca)|French Social Security Scheme for Liberal Professionals (RSI)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3056,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,RC31/14/7341|2015-A00895-44,September 2015,September 2018,September 2019,"September 14, 2016",,"June 1, 2018","Toulouse University Hospital (CHU de Toulouse), Toulouse, France",,https://ClinicalTrials.gov/show/NCT02899442,NCT02899442,
oui,NCT02900521,Population-based Brest Stroke Registry,BREST,Recruiting,No Results Available,"Cerebral (CVAs)|Ischemic Cerebrovascular Accident|Stroke|Brain Ischemia|Brain Hemorrhage|Ischemic Stroke|Hemorrhagic Stroke|Cerebrovascular Disorders|Transient Ischaemic Attack (TIA),",,Type of stroke (ischemic or haemorrhagic)|Patient outcome,"University Hospital, Brest|Santé publique France-InVS (Institut National de Veille sanitaire)|Institut National de la Santé Et de la Recherche Médicale, France",All,"15 Years and older   (Child, Adult, Older Adult)",,900,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,REGISTRE AVC,January 2008,August 2016,December 2026,"September 14, 2016",,"September 14, 2016","CHRU de Brest, Brest, France",,https://ClinicalTrials.gov/show/NCT02900521,NCT02900521,
oui,NCT02900989,Validation of the French Version of Ask Suicide-Screening Questions (ASQ) in Adolescents Managed in Pediatric Emergency Unit,ASQ-Fr,Completed,No Results Available,Suicidal Ideation,Behavioral: Suicide screening,Proportion of adolescents detected at suicide risk by the French version of Ask Suicide-Screening Questions and by the SIQ or SIQ Junior|Type and proportion of answers about perceptions by parents of a questionnaire on suicidal ideation conducted in their child|Type and proportion of answers about perceptions by adolescent of the questionnaires,Centre Hospitalier Universitaire de la R�union,All,"10 Years to 18 Years � (Child, Adult)",Not Applicable,200,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2016/CHU/01,July 2016,January 2017,January 2017,"September 15, 2016",,"July 11, 2017","Centre Hospitalier Universitaire de La R�union, Saint Pierre, France",,https://ClinicalTrials.gov/show/NCT02900989,NCT02900989,
oui,NCT02902016,Modulation of Lactase Expression by a New PPARgamma Ligand in Duodenal Biopsies,,Completed,No Results Available,Lactose Intolerance,Drug: GED,"LCT mRNA expression measured by quantitative RT-PCR in duodenal biopsies stimulated ex-vivo with a new PPARgamma agonist (GED, 1mM)|LCT mRNA expression measured by quantitative RT-PCR in primary intestinal epithelial cells (isolated from duodenal biopsies) stimulated with a new PPARgamma agonist (GED, 1mM)","University Hospital, Lille|French National Society of Gastroenterology|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,22,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2013_68|2015-A00259-40,"July 16, 2015",September 2017,September 2017,"September 15, 2016",,"October 17, 2018","CHRU, Hôpital Claude Huriez, Lille, France",,https://ClinicalTrials.gov/show/NCT02902016,NCT02902016,
oui,NCT02903875,Therapeutic Education Program for Laryngectomised Patients and Their Close Relations,PETAL,Unknown status,No Results Available,Head and Neck Cancer,Other: Patient therapeutic education (PTE) programme,interview of patient and close relatives|transferability of patient therapeutic education (PTE)|quality of patient therapeutic education (PTE)|quality of life (QLQC30),"University Hospital, Caen|University of Lille Nord de France|CERFEP CARSAT Nord-Picardie|INSERM U1086 Cancers et Pr�ventions",All,"18 Years to 70 Years � (Adult, Older Adult)",,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PHRC12-220,April 2013,December 2017,July 2018,"September 16, 2016",,"September 16, 2016","Caen Cancer Institute, Caen, France|Caen University Hospital, Caen, France|Lille Cancer Institute, Lille, France|Lille University Hospital, Lille, France",,https://ClinicalTrials.gov/show/NCT02903875,NCT02903875,
oui,NCT02904005,Predictors of Suicidal Behavior in Depression,SECS,Unknown status,No Results Available,Suicidal Behavior|Depression|Traumatic Events|Impulsivity Aggression,Other: Standardized assessment on depressed patients,Suicide attempt during follow-up|Depressive level|Anxiety,"University Hospital, Montpellier|University Hospital, Lille|Centre Hospitalier Universiatire La Conception, Marseille|Centre Hospitalier R�gional et Universitaire de Brest|H�pital Saint Anne, Paris|Cr�teil Hospital|Centre Hospitalier Charles Perrens, Bordeaux|Centre Hospitalier Universiatire Lyon|Centre Hospitalier Universitaire de N?mes|INSERM U1061 Montpellier|Centre Hospitalier Universitaire de Besancon",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,2000,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,UF 9475|2014-A01316-41,March 2015,March 2018,March 2018,"September 16, 2016",,"September 16, 2016","Montpellier University Hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT02904005,NCT02904005,
oui,NCT02905136,Mechanisms of Auto-immune Encephalitis,MECANO,Completed,No Results Available,Autoimmune Encephalitis,Other: Fundamental research,Pathophysiological study of interaction between specific autoantibodies neuronal synaptic receptors in autoimmune encephalitis : in vivo model,Hospices Civils de Lyon,All,"Child, Adult, Older Adult",,253,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,69HCL14_0439,"May 23, 2017","September 30, 2018","December 3, 2019","September 19, 2016",,"July 29, 2020","Institut NeuroMyoG�ne �quipe Synaptopathies et Autoanticorps (SynatAc) INSERM U1217 / UMR CNRS 5310, Bron, France",,https://ClinicalTrials.gov/show/NCT02905136,NCT02905136,
oui,NCT02906657,Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly,CONCIPAGE,Completed,No Results Available,Adverse Drug Event,Other: Medication reconciliation,Proportion of patients with at least one ADE within the first 30 days of hospital stay.|Distribution of the severity of adverse drug events|Proportion of preventable adverse drug events|30-day mortality rate|Proportion of patients with discrepancy(ies) between pre- and post-reconciliation prescriptions|Incremental hospital costs per ADE avoided,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,65 Years and older   (Older Adult),Not Applicable,2000,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,K14101,"November 3, 2016","January 10, 2019","January 10, 2019","September 20, 2016",,"June 6, 2022","Hopital Saint-Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT02906657,NCT02906657,
oui,NCT02910479,Study Evaluating the Relevance and Reliability of Gastrointestinal Temperature Measurements From a New Device (E-celsius),e-TEMP,Completed,No Results Available,Healthy Volunteers,Device: E-Celsius thermometer|Device: Rectal thermometer|Device: Esophageal thermometer|Device: Vital sense capsule thermometer,body temperature|body temperature during ingestion of cold drinks|temperature of the digestive tract|number of lost data|reliability of measurements,"University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France|La Région Basse-Normandie|Université de Caen Normandie",All,18 Years to 59 Years   (Adult),Phase 1,22,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14-167,November 2015,March 2016,March 2016,"September 22, 2016",,"September 22, 2016","Caen University Hospital, Caen, France",,https://ClinicalTrials.gov/show/NCT02910479,NCT02910479,
oui,NCT02911402,Motion Sickness on Astrolabe's Vessel,SICKVEST,Completed,No Results Available,Sea Sickness,Other: sea sickness questionnaires,Motion Sickness susceptibilty questionnaire (fMSSQ)|STAY-YA questionnaire|STAY-YB questionnaire|Vis-Morgen Questonnaire about sleeping|Fatigue questionnaire|Dietary intake survey|type of movement from the ship using use the data from the Dynamic Positioning System on board|data from individual actigraphs worn by the participants|personnality questionnaire (OCEAN)|anxiety questionnaire (STAY).|treatment taken (international denomination and dose),"University Hospital, Caen",All,"18 Years to 70 Years � (Adult, Older Adult)",,147,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,14-153,October 2014,December 2017,December 2018,"September 22, 2016",,"February 15, 2022","Caen University Hospital, Caen, France",,https://ClinicalTrials.gov/show/NCT02911402,NCT02911402,
oui,NCT02916732,Zika Virus Infection's Pregnancy Consequences in French Department of America,ZIKA-DFA-FE,Completed,No Results Available,Incidence of ZIKV Infection on Fetus During the Pregnancy,,Incidence of ZIKV infection during pregnancy|Incidence of microcephaly and other fetal abnormalities,"Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 60 Years   (Adult),,26980,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C16-08|2016-A00399-42,April 2016,February 2019,February 2019,"September 27, 2016",,"May 6, 2022","CH Andrée Rosemon (CHAR), Cayenne Cedex, France|CHU de Martinique, FORT DE France Cedex, France|CHU de Pointe à Pitre/Les Abymes, Pointe A Pitre, France|CH de l'Ouest Guyanais Franck Joly (CHOG), Saint-laurent-du-maroni, France",,https://ClinicalTrials.gov/show/NCT02916732,NCT02916732,33657112;29539287
oui,NCT02917473,Comparison of Two Strategies for Counseling Skin Examination and Sun Protection in First-degree Relatives of Patients With Melanoma,FADEMELA,Completed,No Results Available,Melanoma|Screening,Behavioral: In-person counseling|Behavioral: Written advice|Behavioral: Medical skin screening,Consulting general practitioner or dermatologist|Self-skin examination reported by the relatives|Sun protection behaviors reported by the relatives|Barriers to skin examination identified from psychological questionnaires in patients and their relatives,"University Hospital, Tours|Institut national de la santé et de la recherche médicale, CIC 1415, TOURS|Institut national de la santé et de la recherche médicale, U930,TOURS|Institut d'Enseignement à Distance,University Paris - 8",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,420,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening,INCA14/LM-FADEMELA|2016-A00186-45,"December 13, 2017","April 26, 2019","July 10, 2019","September 28, 2016",,"July 17, 2019","CHU - ANGERS , Service de Dermatologie, Angers, France|CHRU BREST Hôpital du Morvan, Institut de Cancérologie et d'Hématologie, Brest, France|GH La Rochelle Ré Aunis-Service de Dermatologie, La Rochelle, France|Ch Le Mans, Le Mans, France|CHU NANTES, Service de Dermatologie, Nantes, France|CHU-Poitiers _LA MILETRIE POLE MEDIPOOL-DERMATO-ALLERGOLOGIE, Poitiers, France|CHU -RENNES -Service de Dermatologie-CHU Pontchaillou, Rennes, France|Centre Eugène Marquis -Service d'Oncologie médicale, Rennes, France|University Hospital of Tours, Service de Dermatologie, Tours, France",,https://ClinicalTrials.gov/show/NCT02917473,NCT02917473,
oui,NCT02919631,Triheptanoin in Mc Ardle,,Unknown status,No Results Available,Glycogen Storage Disease Type V,Drug: Triheptanoin|Drug: Placebo oil,"Change in heart rate during constant load cycling exercise (HRconst) with Triheptanoin vs. placebo treatment.|Change in maximal oxidative capacity (VO2max) with Triheptanoin vs. placebo treatment.|Change in self-rated severity of fatigue symptoms with Triheptanoin vs. placebo treatment.|Change in urine concentrations of organic acids with Triheptanoin vs. placebo treatment. Urine concentrations of: 3OH-propionate, heptanoate, methylmalonate, pimelate methylcitrate|Change in maximal workload capacity (Wmax) with Triheptanoin vs. placebo treatment.|Change in plasma concentrations of metabolites, citric acid cycle (CAC) intermediates with Triheptanoin vs. placebo treatment.","Institut National de la Santé Et de la Recherche Médicale, France|Rigshospitalet, Denmark",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C15-54',October 2016,September 2017,,"September 29, 2016",,"September 29, 2016",,,https://ClinicalTrials.gov/show/NCT02919631,NCT02919631,
oui,NCT02922517,Predictive Factors and Consequences of Myocardial Fibrosis in Hypertrophic Cardiomyopathy,HCM,Recruiting,No Results Available,Hypertrophic Cardiomyopathy,,measurement of the overall longitudinal myocardial strain (in 2D strain)|global myocardial longitudinal deformation (three-dimensional)|Transforming growth factor (TGF) blood dosage|Bone morphogenetic protein 2 (BMP2) blood dosage|Periostin blood dosage|Heart Failure Symptoms evaluation|type of heart failure,"Nantes University Hospital|University Hospital, Lille|Rennes University Hospital|Institut National de la Santé Et de la Recherche Médicale, France",All,"16 Years and older   (Child, Adult, Older Adult)",,115,Other,Observational,Observational Model: Family-Based|Time Perspective: Prospective,Prog/11/35,June 2014,December 2021,December 2021,"October 4, 2016",,"September 9, 2021","Nantes University Hospital, Nantes, France",,https://ClinicalTrials.gov/show/NCT02922517,NCT02922517,
oui,NCT02931097,DBS of the MLR for Gait and Balance Disorders in PD Patients,GAITPARK,Completed,No Results Available,Parkinson's Disease,Device: Deep brain stimulation|Device: Sham stimulation,Change in the anticipatory postural adjustments between each deep brain stimulation condition,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 71 Years   (Adult, Older Adult)",Phase 1|Phase 2,6,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C15-46|2016-A00792-49,October 2016,October 2019,October 2020,"October 12, 2016",,"January 11, 2022","Centre d'Investigation Clinique-Institut du Cerveau et de la Moelle Epiniere, Paris, France",,https://ClinicalTrials.gov/show/NCT02931097,NCT02931097,
oui,NCT02931695,Influence of Sex Hormones Variation During Third Trimester of Pregnancy and Post-partum on QT Interval Duration,QuTe,Completed,No Results Available,Pregnancy,Other: evaluation of QT interval duration|Other: circulating sex hormones levels sample,"Difference in QTcF duration (Corrected for heart rate according to Fridericia method) between third trimester of pregnancy and post-partum.|Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).",French Cardiology Society|INSERM 1166 ICAN UPMC|CIC1901-Centre d'Investigation Clinique Paris-Est,Female,"18 Years and older � (Adult, Older Adult)",Not Applicable,71,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening,2016-01,"April 24, 2017","December 17, 2021","December 17, 2021","October 13, 2016",,"April 4, 2022","Centre d'investigation Clinique - Paris est, Paris, France",,https://ClinicalTrials.gov/show/NCT02931695,NCT02931695,
oui,NCT02954705,MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS,MINERVA,Completed,No Results Available,ANCA-associated Vasculitis,Other: Non interventional study,"Expression profile of miRNAs in patients with AAV in circulating neutrophils, plasma and urine.",Nantes University Hospital|INSERM UMRS-1064,All,"18 Years and older � (Adult, Older Adult)",,63,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,RC15_0454,"August 28, 2017","December 31, 2019","September 30, 2020","November 3, 2016",,"October 22, 2020","Nantes University Hospital, Nantes, France",,https://ClinicalTrials.gov/show/NCT02954705,NCT02954705,
oui,NCT02960698,Impulsivity in Tourette Syndrome : Behavioral and Neuroimaging Study,COGIT,Completed,No Results Available,Tourette Syndrome,Other: IRM and comportemental tasks,behavior performance (percentage of correct responses and reaction time)|BOLD signal of functional MRI scan,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,98,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,C16-07|2016-A00936-45,"October 14, 2016","April 24, 2018","April 24, 2018","November 10, 2016",,"August 26, 2021","HARTMANN, Paris, ILE DE France, France",,https://ClinicalTrials.gov/show/NCT02960698,NCT02960698,
oui,NCT02962635,Role of Biomarkers in Patients Undergoing Dialysis Treatment,DRYWEIGHT,Completed,No Results Available,Volemia in Dialysis Patients,Device: bioelectrical impedance measurement and biomarker measurement,Correlation of sCD146 level with overhydration assessed by bioimpedance technology|Correlation of sCD146 level measured after dialysis and ultrafiltration rate|Correlation of sCD146 level and clinical evaluation of volume status|Correlation of sCD146 level and level of NT-proBNP|Correlation of sCD146 level and mortality as assessed prospectively in 6 months follow-up|Correlation of sCD146 level and hospitalizations as assessed prospectively in 6 months follow-up|Correlation of sCD146 level and cardiovascular complications as assessed prospectively in 6 months follow-up|Correlation of sCD146 level and shunt complications as assessed prospectively in 6 months follow-up,"University of Zurich|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,45,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,DRYWEIGHT,October 2016,January 2019,January 2019,"November 11, 2016",,"August 10, 2021","University Hospital Zürich, Zurich, Switzerland",,https://ClinicalTrials.gov/show/NCT02962635,NCT02962635,
oui,NCT02964793,Effects of Serial Plotting on Fundal Height Charts on Identification and Outcomes of Small for Gestational Age Infants,HPAG,Unknown status,No Results Available,Small for Gestational Age,Other: intervention group,Rate detection of FGR|Number of participants presenting the following perinatal outcomes|Performances of screening policies|Modes of onset of labor and of delivery|Resource use and costs,"University Hospital, Grenoble|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,10000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,38RC 14.456,"January 1, 2018","January 1, 2019","January 1, 2020","November 16, 2016",,"September 4, 2018","Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, Bordeaux, France|Department of Obstetrics and Gynecology, Caen University Hospital, Caen, Caen, France|Department of Obstetrics and Gynecology, Louis Mourier Hospital, Assistance Publique-Paris Hospitals (APHP), Colombes, France|Department of Obstetrics and Gynecology, Grenoble University Hospital, Grenoble, France|Department of Obstetrics, Gynecology, and Neonatal Care, Hôpital Jeanne de Flandre, University of Lille, Lille, France|Department of Obstetrics and Gynecology, North Hospital, Assistance Publique-Marseille Hospitals (APHM), Marseille, Marseille, France|Department of Obstetrics and Gynecology, Cochin Hospital, Assistance Publique-Paris Hospitals (APHP), Port Royal, Paris, France|Department of Obstetrics and Gynecology, Trousseau Hospital, Assistance Publique-Paris Hospitals (APHP), Paris, France|Department of Obstetrics and Gynecology, Robert Debré Hospital, Assistance Publique-Paris Hospitals (APHP), Paris, Paris, France|Department of Obstetrics and Gynecology, Antoine Béclère Hospital, Assistance Publique-Paris Hospitals (APHP), Kremlin-Bicêtre, Paris, France|Department of Obstetrics, Hôpital Poissy-Saint Germain, Versailles-St Quentin University, Poissy, France|Department of Obstetrics and Gynecology, Rouen University Hospital, Rouen, France|Department of Perinatality, Obstetrics and Neonatology, Civil hospice Lyon, Saint-Étienne, France|Department of Obstetrics and Gynecology, Hautepierre Hospital, Strasbourg University Hospital, Strasbourg, Strasbourg, France|Department of Obstetrics and Gynecology, Paule de Viguier Hospital, Toulouse University Hospital, Toulouse, France|Department of Obstetrics and Gynecology, Tours University Hospital,, Tours, France",,https://ClinicalTrials.gov/show/NCT02964793,NCT02964793,
oui,NCT02972450,An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection,EHVAT01,Terminated,No Results Available,HIV-1-infection,Biological: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine|Biological: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab|Drug: Vedolizumab 300 MG [Entyvio]|Other: Placebo,"Efficacy: Time from treatment interruption to the earliest of reaching HIV RNA ≥ 10,000 copies/ml or resuming antiretroviral therapy for any reason over a period of 24 weeks.|Safety: A clinical decision to discontinue the regimen for an adverse event that is considered related to product|Grade 3 and worse solicited clinical and laboratory adverse events|Any event leading to interruption in the vaccine schedule|Any event that results in resuming treatment during the ATI|Serious Adverse Events|Other clinical and laboratory adverse events|Time to VL suppression after restarting ART","ANRS, Emerging Infectious Diseases|European Commission|Swiss Government|Medical Research Council|FIT Biotech Ltd.|Fred Hutchinson Cancer Center|University College, London|Centre Hospitalier Universitaire Vaudois|Imperial College London|Istituto Nazionale Malattie Infettive Lazaro Spallanzani|Universitätsklinikum Hamburg-Eppendorf|Institut d'Investigacions Biomèdiques August Pi i Sunyer|Henri Mondor University Hospital|European Georges Pompidou Hospital|Saint-Louis Hospital, Paris, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,1,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EHVA T01/ANRS VRI05,"February 20, 2019","July 11, 2019","July 11, 2019","November 23, 2016",,"August 29, 2019","CHUV, Lausanne, Switzerland|Chelsea & Westminster Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02972450,NCT02972450,
oui,NCT02976298,Effects of Cerebellum or Supplementary Motor Area Functional Inactivation on Gait and Balance Control,CERESMARCHE,Completed,No Results Available,Transcranial Magnetic Stimulation,Other: transcranial magnetic stimulation,postural control during gait initiation|duration of anticipatory postural adjustments,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science",C12-05|2012-A00796-37,February 2013,January 2015,January 2015,"November 29, 2016",,"December 7, 2016","M.L.Welter, Paris, France",,https://ClinicalTrials.gov/show/NCT02976298,NCT02976298,
oui,NCT02977819,Study in Cognitively Intact Seniors Aiming to Assess the Effects of Meditation Training,Age-Well,Unknown status,No Results Available,Cognitive Aging,Other: Meditation practice|Other: Learning English as a foreign language,"Estimate the effect of an 18-month meditation intervention in non-meditating senior participants on the volume of the anterior cingulate cortex compared to a passive control intervention|Estimate the effect of an 18-month meditation intervention in non-meditating senior participants on the perfusion of the anterior cingulate cortex compared to a passive control intervention|Estimate the effect of an 18-month meditation intervention in non-meditating seniors on the volume of the insula compared to an 18 months intervention of learning a foreign language|Estimate the effect of an 18-month meditation intervention in non-meditating seniors on the perfusion of the insula compared to an 18 months intervention of learning a foreign language|Comparison between meditation intervention and language learning intervention on the global metacognitive composite score|Composite score per cognitive area assessed by the neuropsychological tests and the questionnaires|Medical neuroimaging using MRI: grey and white matter volume in all brain voxels|Medical neuroimaging using MRI: hippocampal and hippocampal subfield volumes|Medical neuroimaging using MRI: brain perfusion in all brain voxels|Medical neuroimaging using MRI: fractional anisotropy and mean diffusivity in all brain voxels|Medical neuroimaging using MRI: number, size, type and location of white matter lesions|Medical neuroimaging using MRI: magnetic susceptibility index in all brain voxels|Medical neuroimaging using MRI: brain functional connectivity measures in all brain voxels at rest in a non-meditative state|Beta-amyloid charge (of the radiopharmarceutical Amyvid®) measured in each voxel of the brain and gross mean in gray matter|Glucose Cerebral Consumption at rest (relative to mean consumption measured in the cerebellum)|Medical neuroimaging using fMRI: Brain activity specifically associated with emotional processes (comparing emotional to neutral items) during the Rest-SoVT task.|Medical neuroimaging using fMRI: Brain activity specifically associated with attentional processes (altertness, inhibition, sustained attention) during the AX-CPT task.|Medical neuroimaging using PET-scan and Amyvid® radiotracer|Subjectives sleep measures with sleep quality index z-score mean of the scores at questionnaires|Mean duration of sleep|fragmentation indices during activity and resting states|regularity of the rest-activity cycle|Mean z-score of total sleep time|Mean z-score of sleep onset latency|Mean z-score of sleep efficiency|Biological blood tests|Telomerase properties by blood tests|lymphocytic immunophenotyping|Difference in partner perceptions of participant mindfulness measured by Five-Facet Mindfulness Questionnaire (FFMQ-15, range 15-75, higher scores indicate greater mindfulness)|Difference in partner perceptions of participant compassion towards others measured by Compassionate Love Scale (Range 21-147, higher scores indicate greater compassion)|Difference in partner perceptions of participant depression measured by the Geriatric Depression Scale (range 0-15, higher scores indicate greater depressive symptoms)|Scores to evaluate the impact on volunteers' relatives|Difference in partner perceptions of participant anxiety measured by trait subscale of the state-trait anxiety inventory (trait-STAI, range 20-80, higher scores indicate greater anxiety symptoms)|Difference in partner perceptions of participant prosocialness measured by Prosocialness scale (range 16-80, higher scores indicate greater prosocialness)|Difference in partner perceptions of participant's cognitive difficulties in everyday life, measured by Mc Nair CDS (range 0-156, higher score indicates greater cognitive difficulties)|Neural signature of meditative practices using brain medical imaging (neuronal activity in each cerebral voxel (fMRI) at rest and during the emotional task, in a mindfulness meditative state versus not; in compasional meditative state or not)|Safety and acceptance|evaluation of the practice of the meditation practice and language learning at long-term (29 months post-intervention)|Behavioral measures (questionnaires) to evaluate the psychological impact of the confinement","Institut National de la Santé Et de la Recherche Médicale, France",All,65 Years and older   (Older Adult),Not Applicable,137,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,C16-38|2016-A01767-44,"November 24, 2016","September 23, 2021","November 23, 2022","November 30, 2016",,"February 11, 2021","GIP Cyceron, Caen, Calvados, France",,https://ClinicalTrials.gov/show/NCT02977819,NCT02977819,36433753;36215061;35853750;35418459;32202593
oui,NCT02978924,Trans-spinal Direct Current Stimulation in Primary Orthostatic Tremor,STOP,Completed,No Results Available,Primary Orthostatic Tremor,Device: tsDCS,Change in maximal time in the upright position without support|Quantitative assessment of tremor (EMG)|Cortical excitability assessed by Transcranial Magnetic Stimulation,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,18,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other",C16-26|2016-A01202-49,"January 17, 2017",November 2017,"November 28, 2017","December 1, 2016",,"August 25, 2021","Centre investigation clinique, Paris, France",,https://ClinicalTrials.gov/show/NCT02978924,NCT02978924,
oui,NCT02980146,Impact of HLA-E Overexpression by Tumor Cells on the Biology of TIL in Colorectal Cancer,HLA-E CCR,Completed,No Results Available,ColoRectal Cancer,Other: Non interventional study,"The phenotype of TIL will be precised by immunohistochemisry and flow cytometry using various combinations of monoclonal antibodies to identify different subset of TIL and their frequency, especially those expressing NKG2A or NKG2C chain.",Nantes University Hospital|U892 INSERM Team 3,All,"18 Years to 85 Years � (Adult, Older Adult)",,28,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RC16_0212,"June 1, 2016","June 26, 2017","June 26, 2017","December 2, 2016",,"April 18, 2019","Nantes University Hospital, Nantes, France",,https://ClinicalTrials.gov/show/NCT02980146,NCT02980146,
oui,NCT02985294,Peripheral Physiological Measures as Determinants of Pain Risk,DOLORiskWP51,Unknown status,No Results Available,Polyneuropathies|Peripheral Nerve Injuries|Peripheral Nervous System Diseases|Chemotherapy Effects|Neuralgia,Other: Multiple Excitability Measures of peripheral nerves,Electrophysiological pain phenotypes using MEM. Pain biomarker|Electrophysiological pain phenotypes using MEM. Pain predictor,"Neuroscience Technologies SLP, Barcelona|University of Oxford|Institut National de la Santé Et de la Recherche Médicale, France|University of Aarhus|University of Dundee",All,"18 Years and older   (Adult, Older Adult)",,200,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Neuroscience Technologies,April 2016,March 2019,April 2020,"December 7, 2016",,"August 23, 2018","Neuroscience technologies, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT02985294,NCT02985294,
oui,NCT02987530,National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection,OPTIPRIM-2,Completed,No Results Available,HIV-1 Infection,Drug: Dolutegravir|Drug: Darunavir-cobicistat|Drug: Emtricitabine-Tenofovir,"HIV-DNA levels in the peripheral blood mononuclear cell (PBMC) at week 48|Cumulative cellular viremia up to week 48|Cumulative plasmatic viremia (HIV-1 RNA) at week 48|Cumulative plasmatic viremia using the values obtained by ultrasensitive quantification for all HIV-1-RNA values < 50 copies / mL.|Levels of HIV-1 RNA in plasma at week 2, week 4, week 8, week 12, week 24, week 36, week 48 and changes between week 0 and week 48|Percentage of patients with HIV-1 RNA <50 copies / mL at week 2, week 4, week 8, week 12, week 24, week 36, week 48|Proportion of patients with HIV-1-RNA plasma below the ultrasensitive technique quantification threshold at week 2, week 4, week 8, week 12, week 24, week 36 and week 48|Total DNA-HIV levels measured in PBMC at week 2, week 4, week 8, week 12, week 24, week 36 and week 48|Total DNA-HIV levels measured in PBMC: changes between week 0 and week 48.|CD4 and CD8 counts and percentage at week 2, week 4, week 8, week 12, week 24, week 36, week 48.|CD4 and CD8 counts and percentage changes between week 0 and week 48.|CD4/CD8 ratio at week 2, week 4, week 8, week 12, week 24, week 36, week 48.|CD4/CD8 ratio changes between week 0 and week 48.|Pharmacokinetic: mean concentrations between week 0 and week 48 will be linked to plasma RNA-VIH and DNA-VIH decrease.|Pharmacokinetic: cumulative AUC between week 0 and week 48 will be linked to plasma RNA-VIH and DNA-VIH decrease.|Trial treatments tolerance using self-administered questionnaires of symptoms experienced.|Reported quality of life using self-administered questionnaire (PROQOL-HIV questionnaire).|Number, nature and time of occurrence of stage 3 or 4 clinical and biological adverse events (using ANRS scale to grade severity of adverse events in adults).|HIV infection progression defined by occurrence of B or C stage clinical events or death between week 0 and week 48|Evolution of Metabolic disorders assessed by measurement of cholesterol, triglycerides, blood glucose and lipase|Evolution of Renal function assessed by urea and serum creatinine.|Adherence to treatments using self-administered questionnaires|Adherence to treatments using pills' counts by local pharmacist|Adherence to treatments using MEMS (Medical Event Monitoring System) data collected during the first 3 months","ANRS, Emerging Infectious Diseases|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,101,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 169|2016-001683-11,"April 11, 2017","July 30, 2019","January 31, 2020","December 9, 2016",,"January 4, 2022","All The Regions Of The Country (40 Centers), France",,https://ClinicalTrials.gov/show/NCT02987530,NCT02987530,
oui,NCT03003117,The prEgnanCy and eArly Childhood nutrItion triaL (ECAIL),ECAIL,Recruiting,No Results Available,Diet|Growth|Infant|Physical Activity|Sedentary Behavior,Behavioral: Experimental: Intervention Program|Behavioral: Active comparator: Usual Care,Frequency of vegetable consumption (times/day) at age 2 years|Breastfeeding initiation rate|Predominant and any breastfeeding durations|Age at complementary feeding introduction|Age at first introduction of processed (but not baby-specific) foods|Frequency of vegetable consumption (times/day) at age 1 year|Dietary patterns at age 1 year|Lifestyle patterns at age 1 year|Weight growth velocity over the six first months of life|BMI at age 2 years|Proportion of children that are overweight or obese at age 2 years|Dietary patterns at age 2 years|Lifestyle patterns at age 2 years|Weight growth curves from birth to 2 y|Length growth curves from birth to 2 y|BMI curves from birth to 2 y,"French Red Cross|Institut National de la Santé Et de la Recherche Médicale, France|University Hospital, Lille|Association Programme MALIN|Société Française de Pédiatrie|Association Française de Pédiatrie Ambulatoire",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,800,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,2014-A00849-38|n°CPP 03/010/2014,"April 3, 2017",July 2025,December 2025,"December 26, 2016",,"October 4, 2022","University Hospital, Lille, France|Valenciennes Hospital, Monaco Hospital maternity, Valenciennes, France",,https://ClinicalTrials.gov/show/NCT03003117,NCT03003117,
oui,NCT03005652,Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline,SCD-WELL,Completed,No Results Available,Cognitive Dysfunction,Behavioral: Mindfulness weekly courses for 8 weeks|Behavioral: Health education weekly courses for 8 weeks,Mean change in anxiety after the intervention|Mean change in anxiety from baseline to 24 weeks|Change in depression by the Geriatric Depression Scale (GDS)|Change in behavioural measures of compassion measured by the Self Compassion and Compassionate Love Scale questionnaires|Change in cognitive function assessed by a composite score derived from neuropsychological tests.|Subjective measures of sleep collected via the Pittsburg Sleep Quality Index questionnaire|Change in lifestyle as assessed by The Physical Activity Scale for the Elderly questionnaire|Change in quality of life assessed by the world health organization quality of life - brief questionnaire|Mean change in blood-based biological markers of stress and Alzheimer's disease assessed by DNA methylation patterns and quantities of proteins - neurofilament light and tau,"Institut National de la Santé Et de la Recherche Médicale, France",All,"60 Years and older   (Adult, Older Adult)",Not Applicable,168,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,C16-61,"April 21, 2017","September 18, 2018","September 18, 2018","December 29, 2016",,"February 11, 2021","The Clinical Research Memory Centre of Lyon (CMRR), department of the University Hospitals of Lyon - Hospices Civils de Lyon (HCL), Lyon, France|The Department of Psychiatry at University of Cologne (UKK), Cologne, Germany|The Consorci Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain|The Division of Psychiatry at University College London (UCL)., London, England, United Kingdom",,https://ClinicalTrials.gov/show/NCT03005652,NCT03005652,36068621;35853750;33873195
oui,NCT03007784,Two Intensities of Transcranial Direct Current Stimulation to Improve Consciousness in Severely Brain Injured Patients,STIMCOM,Unknown status,No Results Available,Disorder of Consciousness|Minimally Conscious State|Vegetative State|Cognitive Impairment,Device: transcranial direct current stimulation (tDCS) / Comparison of current intensities,"Change of the Coma Recovery Scale-Revised score according to tDCS current intensity (2mA versus 0.2mA)|Change from baseline of the Coma Recovery Scale-Revised score after 2mA tDCS current intensity|Change from baseline of the Coma Recovery Scale-Revised score after 0.2mA tDCS current intensity|IChange of the ERPS recorded during the ""local global"" auditory paradigm (Bekinschtein et al., PNAS 2009) after 10 days of 2mA tDCS current intensity and after 10 days of 0.2mA tDCS current intensity|Change from baseline of the ERPS recorded during the ""local global"" auditory paradigm (Bekinschtein et al., PNAS 2009) after 2mA tDCS current intensity|Change from baseline of the ERPS recorded during the ""local global"" auditory paradigm (Bekinschtein et al., PNAS 2009) after 0.2mA tDCS current intensity|IChange of the multivariate automatic classification of conscious state from EEG (Sitt et al., Brain et al. 2014) after 10 days of 2mA tDCS current intensity and after 10 days of 0.2mA tDCS current intensity|Change from baseline of the multivariate automatic classification of conscious state from EEG (Sitt et al., Brain et al. 2014) after 10 days of 2mA tDCS current intensity|Change from baseline of the multivariate automatic classification of conscious state from EEG (Sitt et al., Brain et al. 2014) after 10 days of 0.2mA tDCS current intensity",Groupe Hospitalier Pitie-Salpetriere|H�pital Raymond Poincar�|Hospices Civils de Lyon,All,"18 Years to 80 Years � (Adult, Older Adult)",Phase 3,300,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SC20160427,January 2017,January 2021,,"January 2, 2017",,"January 18, 2017","Groupe Hospitalier Piti�-Salp�tri�re, Paris, France",,https://ClinicalTrials.gov/show/NCT03007784,NCT03007784,
oui,NCT03009058,Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer,MODULATE,Terminated,No Results Available,Metastatic Cancer,Biological: IMM-101|Drug: Gemcitabine|Drug: Nabpaclitaxel|Drug: Capecitabine|Drug: Folinic Acid|Drug: Fluorouracil|Drug: Irinotecan|Drug: Oxaliplatin|Biological: cetuximab|Biological: Anti-PD1|Biological: Ipilimumab|Drug: Cyclophosphamide,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Number of participants with treatment-related adverse events when IMM-101 is given in combination with a checkpoint blockade inhibitor|Response to treatment|Overall survival (OS),Immodulon Therapeutics Ltd,All,"18 Years and older � (Adult, Older Adult)",Phase 1|Phase 2,2,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMM-101-011|2016 001459 28|CANC 32085,"May 24, 2017","August 30, 2017","August 30, 2017","January 4, 2017",,"August 9, 2018","Centre L�on B�rard, Dpt Medecine & INSERM, Lyon, France|Gustave Roussy Cancer Center, Villejuif, France|St George's University of London, Institute of Infection and Immunity, London, United Kingdom|Royal Marsden Hospital Foundation Trust, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03009058,NCT03009058,
oui,NCT03015038,Study of the Immune Response in Colon Adenocarcinoma,IMCO,"Active, not recruiting",No Results Available,Colon Adenocarcinoma,,"Immune cells trafficking|Infiltration of leucocytes in tumor tissue|Safety (Number of adverse events, ECOG status)","Institut National de la Santé Et de la Recherche Médicale, France|Innate Pharma",All,"18 Years and older   (Adult, Older Adult)",,100,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,C16-21|2016-A01102-49,"February 5, 2017",February 2024,February 2024,"January 9, 2017",,"August 26, 2021","Hôpital Saint Louis, Paris, France",,https://ClinicalTrials.gov/show/NCT03015038,NCT03015038,
oui,NCT03015558,Analgesic Effect of Non Invasive Stimulation : Transcranial Direct Current Stimulation of Opercular-insular Cortex,STIM-INSULA,Completed,No Results Available,Neuropathic Pain,Device: transcranial direct current stimulation of opercular-insular cortex - anodal active tDCS session|Device: transcranial direct current stimulation of opercular-insular cortex - active control session|Device: transcranial direct current stimulation of opercular-insular cortex - sham control session.,In healthy subjects : Change in subjective pain and (when applicable) in cortical evoked potentials with pain scale|In patients : Changes in daily ratings of global pain|In healthy subjects : Change in subjective pain and (when applicable) in cortical evoked potentials|ongoing pain with pain scale|ongoing pain as assessed by daily ratings,Hospices Civils de Lyon,All,"18 Years to 80 Years � (Adult, Older Adult)",Not Applicable,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",69HCL15_0345|2016-A00022-49,"November 2, 2016","March 28, 2018","March 28, 2018","January 10, 2017",,"December 7, 2021","Hospices Civils de Lyon - NeuroPain lab - CRNL, Bron, France",,https://ClinicalTrials.gov/show/NCT03015558,NCT03015558,
oui,NCT03018860,Alternative to Intensive Management of the Active Phase of the Second Stage of Labor,PASST,Completed,No Results Available,Active Second Stage,"Procedure: ""Moderate"" management|Procedure: ""Intensive"" management",Neonatal morbidity composite measure|Mode of delivery|Immediate postpartum complications|Women satisfaction assessed with the Labour Agentry scale|Women satisfaction assessed with the ICIQ-UI Short Form|Urinary and anal incontinence assessed with the Wexner Score,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,1701,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,P150937,"January 25, 2017","March 25, 2021","December 7, 2021","January 12, 2017",,"December 10, 2021","Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03018860,NCT03018860,35868416
oui,NCT03025763,"Network Of Clinical Research Studies On Craniosynostosis, Skull Malformations With Premature Fusion Of Skull Bones",,Recruiting,No Results Available,Craniosynostosis,Other: Craniosynostosis Network Environmental Survey|Other: 2D/3D Photography|Procedure: Buccal Swab Cell Sampling|Procedure: Blood sampling|Procedure: Skin Biopsy|Procedure: Tissues from a Clinically Indicated Procedure|Procedure: Pre-operative CT Scan Image Files.,Phenotype-genotype gene expression correlations|Incidence of gene mutations,Icahn School of Medicine at Mount Sinai|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,"up to 80 Years � (Child, Adult, Older Adult)",,4000,Other|NIH,Observational,Observational Model: Other|Time Perspective: Other,GCO 13-0147|P01HD078233,"November 25, 2014","January 31, 2027","January 31, 2027","January 20, 2017",,"July 7, 2022","The International Craniosynostosis Consortium at University of California at Davis, Davis, California, United States|Yale University, Hartford, Connecticut, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|National Birth Defects Prevention Study at University of Iowa, Iowa City, Iowa, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Birth Defect Registries of New York State, Albany, New York, United States|New York University, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Pennsylvania State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Pennsylvania State University, University Park, Pennsylvania, United States|Seton Family of Hospitals, Austin, Texas, United States|Medical City Children's Hospital, Dallas, Texas, United States|University of Texas at Southwestern, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Bordeaux, Talence, Aquitaine, France|INSERM/ Hospital Necker-Enfants Malades, Paris, Cedex 14, France|University Hospital Heidelberg, Heidelberg, Germany|Hospital Sant Joan de Deu, Barcelona, Esplugues De Llobregat, Spain|Oxford University, Oxford, Oxfordshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03025763,NCT03025763,
oui,NCT03027479,Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss,METERMUS-IMC,Completed,No Results Available,Weight Loss|Ovarian Carcinoma|Endometrial Carcinoma,Other: Samples,Measurement of muscle mitochondrial bioenergetics according to BMI|on muscle biopsy|on white adipose tissue|on ovarian cancer tumor samples|on computerized tomography,"University Hospital, Tours|Inserm U1069 - Team Nutrition, Growth and Cancer",Female,"18 Years and older � (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,PHAO16-LO/METERMUS-IMC|2016-A01323-48|2016-R27,"March 1, 2017","July 16, 2019","July 16, 2019","January 23, 2017",,"May 6, 2021","Gynecology Department, University Teaching Hospital, Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT03027479,NCT03027479,36675280
oui,NCT03027505,Integrated Treatment Protocol for Acute Malnutrition: A Non Inferiority Trial in Burkina Faso,MUAC-Only,Completed,No Results Available,Global Acute Malnutrition (GAM),Drug: Ready to Use Therapeutic Food (RUTF),Recovery rate|Mortality rate|Default rate|Non-respondent rate|Hospitalization rate|Relapse rate|RUTF rations,"Alliance for International Medical Action|Institut National de la Sant� Et de la Recherche M�dicale, France|Association Keoogo|Institut de Recherche en Sciences de la Sante, Burkina Faso|SOS m�decins Burkina Faso",All,6 Months to 59 Months � (Child),Not Applicable,4958,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MUAC Only Burkina Faso,January 2017,December 2017,April 2018,"January 23, 2017",,"January 30, 2019","ALIMA, Yako, Region Nord, Burkina Faso",,https://ClinicalTrials.gov/show/NCT03027505,NCT03027505,
oui,NCT03032055,Validation of a Predictive Score of Acute Chest Syndrome,Presev2,Recruiting,No Results Available,Vaso Occlusive Crisis|Acute Chest Syndrome,,Primary Outcome Measure of Validation of a Predictive Score of Acute Chest Syndrome|Secondary Outcome Measures: Validation of a Predictive Score of Acute Chest Syndrome,Soutien aux Actions contre les Maladies du Globule Rouge|ADDMEDICA SASA|Pierre Fabre Laboratories,All,"2 Years and older � (Child, Adult, Older Adult)",,800,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,Presev 2 IRB 00003835,"January 1, 2016","December 31, 2023","December 31, 2023","January 26, 2017",,"December 13, 2022","Henri Mondor Hospital, Creteil, France",,https://ClinicalTrials.gov/show/NCT03032055,NCT03032055,
oui,NCT03035305,Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Mali,,Completed,No Results Available,Malaria,Dietary Supplement: Lipid-based Nutrient Supplement (LNS)|Drug: Seasonal malaria chemoprevention,Confirmed malaria case|Fever case|Global acute malnutrition case|Moderate acute malnutrition case|Severe acute malnutrition case|Medical referral case,"Alliance for International Medical Action|Institut National de la Sant� Et de la Recherche M�dicale, France|Alliance m�dicale contre le paludisme, Mali|Programme national de lutte contre le paludisme, Mali|United States Agency for International Development (USAID)|European commission for humanitarian office|Ministry of health, Mali",All,6 Months to 59 Months � (Child),Not Applicable,36717,Other|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,SMC LNS Mali,August 2016,November 2016,November 2016,"January 30, 2017",,"January 30, 2017","Amcp/Alima, Kolokani Circle, Koulikoro region, Mali",,https://ClinicalTrials.gov/show/NCT03035305,NCT03035305,
oui,NCT03047967,Effects of Prenatal Tobacco Smoke Exposure on Lung Function and Respiratory Epithelium Functionality in Newborns,,Completed,No Results Available,Pregnancy Related|Tobacco Smoking|Lung Smokers|Newborn,Diagnostic Test: lung function tests|Diagnostic Test: Nasal brushing,α7-nAChR functionnality|CFTR functionality|Lung function test|ciliary frequency mesurement,"Institut National de la Santé Et de la Recherche Médicale, France",All,2 Days to 6 Days   (Child),Not Applicable,1,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C15-60,"November 10, 2017","February 9, 2018","February 9, 2019","February 9, 2017",,"April 16, 2019","Inserm, Paris, France",,https://ClinicalTrials.gov/show/NCT03047967,NCT03047967,
oui,NCT03048032,Lithuanian Echocardiography Study of Dyspnea in Acute Settings,LEDA,Completed,No Results Available,Acute Heart Failure,Procedure: Blood sampling|Procedure: Echocardiography exam,1-year all-cause mortality and rehospitalization|In-hospital all-cause mortality|Post-discharge all-cause mortality and rehospitalization|Post-discharge cardiovascular mortality and rehospitalization|1-year cardiovascular mortality and rehospitalization,"Vilnius University|Institut National de la Sant� Et de la Recherche M�dicale, France|Lithuanian University of Health Sciences",All,"18 Years and older � (Adult, Older Adult)",,1566,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,MIP-049/2015|L-15-01/1,April 2015,December 2017,November 2018,"February 9, 2017",,"November 23, 2018","Inserm U942, Paris, Ile De France, France|Lithuanian University of Health Sciences, Kaunas, Lithuania|Vilnius University, Vilnius, Lithuania",,https://ClinicalTrials.gov/show/NCT03048032,NCT03048032,
oui,NCT03048240,INtraoperative photoDYnamic Therapy of GliOblastoma,INDYGO,Completed,No Results Available,Glioblastoma,"Device: ""perPDT""|Drug: GLIOLAN","Number of Patients having the full ""PerPDT"" treatment with unacceptable and unexpected toxicities (grade ≥ 3) graded According to NCI CTC Version 4.0|Progression Free Survival (PFS)|Overall Survival (OS)|Response to treatment|Incidence of ""per PDT"" treatment-emergent Adverse Events|Quality of Life Questionnaire -C30 ( QLQ-C30)|Quality of Life Questionnaire - Brain Cancer Module (QLQ-BN20)","University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016_06|2016-002706-39,"May 5, 2017","April 28, 2021","April 28, 2021","February 9, 2017",,"June 6, 2022","Hôpital Roger Salengro, CHRU, Lille, France",,https://ClinicalTrials.gov/show/NCT03048240,NCT03048240,33743128
oui,NCT03052062,Tolerance Study of the Dietary Supplement Lipidrive (ECPH1-03),,Completed,No Results Available,Obese,Dietary Supplement: Lipidrive,"Changes in fasting blood glucose|Changes in fasting insulinemia|Changes in fasting HOMA-IR|Changes in glycated hemoglobin|Changes in fasting fructosamin|Changes in fasting total cholesterol|Changes in fasting HDL cholesterol|Changes in fasting LDL cholesterol|Changes in fasting triglycerides|Changes in oxidized LDL|Changes in us-CRP|Changes in blood creatinine|Changes in fasting blood levels of ASAT (Aspartate aminotransferase) and ALAT (Alanine aminotransferase)|Changes in fasting blood levels of GGT (Gamma glutamyltransferase)|Changes in fasting alkaline phosphatase|Changes in fasting blood bilirubin|Changes in fasting blood urea|Changes in heart rate|Changes in SBP (systolic blood pressure) and DBP (diastolic blood pressure)|Changes in cardiac function (electrocardiogram, ECG)|Changes in body weight|Changes in WC (waist circumference)|Changes in HC (hip circumference)|Changes in WHR (waist to hip ratio)|Changes in body composition|Changes in fasting blood adiponectin|Changes in fasting blood leptin|Changes in the evolution of glycemia during an oral glucid tolerance test|Changes in the incremental area under the curve (glycemia response) during an oral glucid tolerance test|Changes in the glycemia Cmax during an oral glucid tolerance test|Changes in the glycemia ?peak during an oral glucid tolerance test|Changes in the evolution of insulinemia during an oral glucid tolerance test|Changes in the incremental area under the curve (insulinemia response) during an oral glucid tolerance test|Changes in the insulinemia Cmax during an oral glucid tolerance test|Changes in the insulinemia ?peak during an oral glucid tolerance test","Valbiotis|University Hospital, Clermont-Ferrand|Universit� Blaise Pascal, Clermont-Ferrand|Biofortis M�rieux NutriSciences",Male,"45 Years to 65 Years � (Adult, Older Adult)",Phase 1|Phase 2,20,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-A01187-44,"March 2, 2017","July 3, 2018","July 3, 2018","February 14, 2017",,"July 6, 2018","Centre d'Investigation Clinique, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT03052062,NCT03052062,
oui,NCT03060967,Assessment of Hedonic and Motivational States in Major Depression ( MOODDIS),MOODDIS,Unknown status,No Results Available,Major Depression,Behavioral: Computer-based tasks,Point of subjective equality (PSE)|Percentage of subjective discrimination (PSD),"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),Not Applicable,72,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening,C15-88,June 2017,September 2020,September 2020,"February 23, 2017",,"May 12, 2017",,,https://ClinicalTrials.gov/show/NCT03060967,NCT03060967,
non,NCT03068364,Biological and Electrocardiographic Biomarkers for Risk Stratification in Hypertension.,,Completed,No Results Available,Hypertension,,All- cause and cardiovascular mortality in hypertension|All-cause and cardiovascular deaths,Hospices Civils de Lyon,All,"18 Years and older � (Adult, Older Adult)",,1600,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,69HCL17_0151,"November 3, 2016","February 17, 2017","February 17, 2017","March 1, 2017",,"March 9, 2017","Hospices Civils de Lyon - Hopital de la Croix Rousse, Lyon, France",,https://ClinicalTrials.gov/show/NCT03068364,NCT03068364,
oui,NCT03071458,Mutational Landscape in Hepatocellular Carcinoma,MUTHEC,Completed,No Results Available,HepatoCellular Carcinoma|Cirrhosis,,Genetic and transcriptomic landscape|Translation in immunohistochemical markers|Detection and sequencing of circulating tumor DNA as a liquid biopsy in HCC|Validation of the molecular classification by integrative analysis,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",,808,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,C 16-71,January 2008,May 2015,May 2015,"March 7, 2017",,"March 7, 2017","INSERM, Paris, France",,https://ClinicalTrials.gov/show/NCT03071458,NCT03071458,
oui,NCT03074578,Is There a Desensitization During Sleep After Exposure to a Violent Verbal Input ?,COREV,Unknown status,No Results Available,Verbal Abuse,Behavioral: Watching Video-clip 1|Behavioral: Watching Video-clip 2,Heart rate|Sweating|Vasoconstriction|Emotions,"Centre National de la Recherche Scientifique, France|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 25 Years   (Adult),Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,16009|COREV,"November 8, 2016","July 1, 2017","July 1, 2017","March 9, 2017",,"March 9, 2017","Service des pathologies du sommeil, Hôpital Pitié Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT03074578,NCT03074578,31957639
oui,NCT03075397,VIH-1 Colo-rectal Transmission by Infected Semen Cells and Effects of Seminal Plasma ex Vivo (CellspermVIH),CellspermVIH,Completed,No Results Available,HIV-1-infection,Other: blood sample|Other: sperm sample,Characterize seminal HIV infected cells.|Evaluate the potential of seminal HIV infected cells migration and adhesion.|Determine the efficiency of seminal cell associated infection.|Identify molecules expressed and involved in seminal cell adhesion and transmigration.|Identify seminal and mucosal molecules mediating seminal cell translocation.|Determine the impact of seminal plasma/cells exposure on mucosal immune cell.,"University Hospital, Toulouse|ANRS, Emerging Infectious Diseases|Institut National de la Santé Et de la Recherche Médicale, France",Male,18 Years to 45 Years   (Adult),Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RC31/16/8193|2016-A01025-46,"February 27, 2017","June 14, 2021","June 14, 2021","March 9, 2017",,"March 30, 2023","CECOS Bretagne Rennes, Rennes, Bretagne, France|CECOS Hôpital Paule de Viguier, Toulouse, Midi-Pyrénées, France|CECOS Paris Bichat, Paris, France",,https://ClinicalTrials.gov/show/NCT03075397,NCT03075397,
oui,NCT03076892,Evaluation of Non-inferiority and Tolerability of the Device PHOS-ISTOS,PHOS-ISTOS,Completed,No Results Available,"Keratosis, Actinic",Device: Aktilite® Galderma|Device: PHOS ISTOS PDT,Treated lesion response rate|Visual analog scale of pain|Scale for clinical assessment of the subject's skin aspect|Rate of patients with at least 75% of reduction of the lesions|Dermatology Life Quality Index (DLQI )|Satisfaction autoquestionnaire,"University Hospital, Lille|European Commission|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,47,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015_79|2016-A00010-51,September 2016,November 2017,November 2017,"March 10, 2017",,"November 14, 2017","CHRU, Hôpital Claude Huriez, Lille, France|Klinikum Vest Gmbh, Recklinghausen, Germany",,https://ClinicalTrials.gov/show/NCT03076892,NCT03076892,31025953
oui,NCT03076918,Evaluating the Device FLEXITHERALIGHT Compared to the Conventional Photodynamic Therapy,Flexithera,Terminated,No Results Available,"Keratosis, Actinic",Device: FLEXITHERALIGHT PDT|Device: Aktilite® Galderma,Treated lesion response rate|Visual Analog scale of pain|Scale for clinical assessment of the subject's skin aspect|Fluorescence measure of the PpIX|Irradiance measure in mW/cm2 for each AK|Rate of patients with at least 75% of reduction of the lesions|Dermatology Life Quality Index (DLQI)|Satisfaction Questionnaire,"University Hospital, Lille|National Research Agency, France|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013_23|2013-A01096-39,September 2014,February 2017,February 2017,"March 10, 2017",,"May 18, 2018","CHRU, Hôpital Claude Huriez, Lille, France",,https://ClinicalTrials.gov/show/NCT03076918,NCT03076918,31025952
oui,NCT03078439,EPIPAGE2 Cohort Study Follow up at Five and a Half Years,EPIPAGE2,Completed,No Results Available,Very Preterm Birth,Other: Medical and neuropsychological assessments,Health disorders assessed by medical exam|Motor disorders assessed by medical exam|Cognitive disorders assessed by psychological testing|Behavioural disorders by psychological testing|Changes in medical practices collected by questionnaire|Changes in organization of care collected by questionnaire|Set up a DNA Biobank by saliva samples collection,"Institut National de la Santé Et de la Recherche Médicale, France",All,5 Years to 6 Years   (Child),,3404,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C15-95|IDRCB,"September 2, 2016","January 8, 2018","January 8, 2018","March 13, 2017",,"August 25, 2021","Centre Hopsitalier d'Agen, Agen, France|CAMSP Albi, Albi, France|CHU Amiens, Amiens, France|CHU d'Angers, Angers, France|CH d'Arras, Arras, France|CAMSP Auch, Auch, France|CAMSP Basse-Terre, Basse-Terre, France|Centre Hospitalier Côte Basque, Bayonne, France|CH Beauvais, Beauvais, France|CHU Jean Minjoz, Besançon, France|Centre Hospitalier de Bordeaux, Bordeaux, France|CH Bourg en Bresse, Bourg-en-Bresse, France|CHU de Brest, Brest, France|Rezo Camsp, Brioude, France|Hopital Femme, Mère, Enfant, Bron, France|CHU de Caen, Caen, France|CH Cahors, Cahors, France|CMPP de Cahors, Cahors, France|CH de Calais, Calais, France|CH de Carcassonne, Carcassonne, France|CH Castres - Hôpital du pays d'Autan, Castres, France|CH Andrée Rosemon, Cayenne, France|CH Chalon sur Saone - William Morey, Chalon Sur Soane, France|CH Métropole Savoie, Chambery, France|Réseau Eclaur, Chambéry, France|CAMSP de Charleville Mézières, Charleville Mézières, France|CHU Estaing, Clermont Ferrand, France|Centre Hospitalier de Colmar, Colmar, France|CH Compiègne, Compiègne, France|CH Alpes Leman, Contamine-sur-Arve, France|CH Sud Francilien, Corbeil, France|CH Creil, Creil, France|CAMSP de Dax, Dax, France|CHU Dijon - Hôpital du Bocage, Dijon, France|CH de Douai, Douai, France|CH de Maubeuge, Elesme, France|Hôpital d'Epinal, Epinal, France|CAMSP Espaly, Espaly, France|SCM Maison de l'enfant, Essey les Nancy, France|Hôpital de Forbach, Forbach, France|CHU Grenoble / Réseau Naitre et Devenir, Gernoble, France|Centre Hospitalier de Haguenau, Haguenau, France|CH Laon, Laon, France|CHU Le Mans, Le Mans, France|CH de Lens, Lens, France|CHU Pointre à Pitre, Les Abymes, France|Hôpital Saint Vincent de Paul - Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, France|CHRU de Lille, Lille, France|Hôpital Mère-Enfant de Limoges, Limoges, France|CAMSP, CHU de Lorient, Lorient, France|Hopital de la Croix Rousse, Lyon, France|CHU Hôpital Nord, Marseille, France|CHU de la Conception, Marseille, France|CH Annecy Genevois, Metz-Tessy, France|Hôpital de Mercy - CHR Metz Thionville, Metz, France|Centre Hospitalier de Mont de Marsan, Mont de Marsan, France|CAMSP ""l'Escabelle"" Montauban, Montauban, France|CH Montauban, Montauban, France|GHH Havre - Hôpital Jacque Monod, Montivilliers, France|CHU de Montpellier, Montpellier, France|CAMSP - CHU Saint-Eloi, Montpellier, France|Centre Hospitalier de Mulhouse, Mulhouse, France|CH Mâcon, Mâcon, France|CHRU de Nancy (Maternité), Nancy, France|CHRU de Nancy (Neuro-pédiatrie), Nancy, France|CHU de Nantes, Nantes, France|CHU Hôpital l'Archet, Nice, France|CHU de Nimes - Hôpital Caremeau, Nîmes, France|CHR Orléans, Orléans, France|Hôpital Armand Trousseau, Paris, France|CIC Necker, Paris, France|Centre Hospitalier de Pau, Pau, France|CHG de Perpignan (CAMSP), Perpignan, France|CAMSP de Périgueux, Périgueux, France|CHU de Reims / CAMSP, Reims, France|CAMSP, CHU de Rennes, Rennes, France|CHU Felix Guyon, Reunion, France|CH Rodez - Jacques Puel, Rodez, France|CH de Roubaix, Roubaix, France|CHU de Rouen - Pavillon Mère et enfant, Rouen, France|CAMSP de Saint Brieuc, Saint Brieuc, France|CAMSP Nord-ASFA Sainte Clotilde, Saint Denis De La Réunion, France|CH de l'Ouest Guyanais, Saint Laurent Du Maroni, France|CHU Sud Réunion, Saint Pierre, France|CHU St Etienne / Réseau HELENA, Saint Priesr En Jarez, France|CH Saint Quentin, Saint Quentin, France|Centre Hospitalier Hautepierre, Strasbourg, France|CH de Bigorre, Tarbes, France|CAMSP Thionville, Thionville, France|Hôpital Bel Air Thionville - CHR Metz Thionville, Thionville, France|CHU de Toulouse - Hôpital des enfants, Toulouse, France|Clinique Ambroise Paré, Toulouse, France|CHRU de Tours -Hôpital Clocheville, Tours, France|CAMSP de Troyes, Troyes, France|CH Valence, Valence, France|CH de Valenciennes, Valenciennes, France|CH de Vannes, Vannes, France|CH Villefranche sur Saone, Villefranche-sur-Saône, France",,https://ClinicalTrials.gov/show/NCT03078439,NCT03078439,
oui,NCT03087227,Shared Health Information System for Febrile Neutropenia,NEUTROSIS,Completed,No Results Available,Febrile Neutropenia|Solid Tumor|Hematologic Neoplasms,Device: NEUTROSIS,average length of hospital stay for febrile neutropenia|hospitalisation rate|healthcare use rate|Use rate,"Marie-Helene METZGER|Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|University of Paris 13",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,121,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,16-009,"February 22, 2017","October 20, 2019","October 20, 2019","March 22, 2017",,"May 9, 2022","Hôpital Antoine Béclère, Clamart, France|Hôpital d'instruction des Armées de Percy, Clamart, France|Hôpital BICETRE, Le Kremlin-Bicêtre, France",,https://ClinicalTrials.gov/show/NCT03087227,NCT03087227,
oui,NCT03088982,Preventing Decompensation Among Multimorbid Outpatients in Residential Care. A Cohort Study With a Six-month Follow-up.,FDPM,Completed,No Results Available,Multimorbidity,Other: Questionnaire,Evaluation of the multimorbidity criteria,"University Hospital, Brest|ERCR SPURBO|Unit� INSERM 1078, SFR 148 ScInBioS, Brest",All,"18 Years and older � (Adult, Older Adult)",,64,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,FDPM - 05122011,June 2014,December 2014,June 2015,"March 24, 2017",,"March 24, 2017",,,https://ClinicalTrials.gov/show/NCT03088982,NCT03088982,
oui,NCT03090126,Assessment of Therapeutic Education About Non Invasive Ventilation in Patients With Chronic Respiratory Failure (QoVNI),QoVNI,Withdrawn,No Results Available,Alveolar Hypoventilation,Other: Therapeutic education,Score efficacy of therapeutic education|Compliance with the non invasive ventilation|Dyspnea score,Association pour le D�veloppement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil,All,"18 Years and older � (Adult, Older Adult)",,0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2017-A00189-44,"March 17, 2017",October 2020,October 2020,"March 24, 2017",,"July 14, 2020","INSERM-UPC UMR_S 1158 Service de Pneumologie et R�animation, R3S, Groupe Hospitalier Piti�-Salp�tri�re, Paris, France",,https://ClinicalTrials.gov/show/NCT03090126,NCT03090126,
oui,NCT03094065,Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin By French-speaking Patients,,Withdrawn,No Results Available,The Study Focus on no Specific Condition,Other: News items with spin|Other: News items without spin,"Perception of beneficial effect of the treatment X. We ask participants, What do you think is the probability that treatment X would be beneficial to patients?|Perception of efficacy, safety, availability and clinical utility in existing clinical practice for the treatment X. We will ask the participants: What do you think is the size of the potential benefit for patients?|How safe do you think that treatment X would be for patients?|Do you think this treatment should be offered to patients in the short term?|Do you think this treatment will make a difference in the existing clinical practice?",Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,ISB-001,June 2019,December 2019,December 2019,"March 29, 2017",,"February 12, 2021","Assistance Publique - H�pitaux de Paris, Paris, Ile-de-france, France",,https://ClinicalTrials.gov/show/NCT03094065,NCT03094065,
oui,NCT03094091,Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin by English-speaking Population*,,Withdrawn,No Results Available,The Study Focus on no Specific Condition,Other: News items with spin|Other: News items without spin,"Perception of beneficial effect of the treatment X|Perception of efficacy, safety, availability and clinical utility of the treatment X in existing clinical practice|How safe do you think that treatment X would be for patients?|Do you think this treatment should be offered to patients in the short term?|Do you think this treatment will make a difference in the existing clinical practice?",Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,ISB-005,September 2019,November 2019,December 2019,"March 29, 2017",,"February 12, 2021","Assistance Publique - H�pitaux de Paris, Paris, Ile-de-france, France",,https://ClinicalTrials.gov/show/NCT03094091,NCT03094091,
oui,NCT03094104,Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin by English-speaking Population,,Unknown status,No Results Available,The Study Focus on no Specific Condition,Other: News items with spin|Other: News items without spin,"Perception of beneficial effect of the treatment X|Perception of efficacy, safety, availability and clinical utility of the treatment X in existing clinical practice|How safe do you think that treatment X would be for patients?|Do you think this treatment should be offered to patients in the short term?|Do you think this treatment will make a difference in the existing clinical practice?",Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,ISB-006,January 2019,June 2019,June 2019,"March 29, 2017",,"September 11, 2018","Assistance Publique - H�pitaux de Paris, Paris, Ile-de-france, France",,https://ClinicalTrials.gov/show/NCT03094104,NCT03094104,31159786
oui,NCT03094117,Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin by French-speaking Patients,,Withdrawn,No Results Available,The Study Focus on no Specific Condition,Other: News items with spin|Other: News items without spin,"Perception of beneficial effect of the treatment X|Perception of efficacy, safety, availability and clinical utility of the treatment X in existing clinical practice|How safe do you think that treatment X would be for patients?|Do you think this treatment should be offered to patients in the short term?|Do you think this treatment will make a difference in the existing clinical practice?",Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,ISB-007,June 2019,December 2019,December 2019,"March 29, 2017",,"February 12, 2021","Assistance Publique - H�pitaux de Paris, Paris, Ile-de-france, France",,https://ClinicalTrials.gov/show/NCT03094117,NCT03094117,
oui,NCT03094130,Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin by French-speaking Population,,Withdrawn,No Results Available,The Study Focus on no Specific Condition,Other: News items with spin|Other: News items without spin,"Perception of beneficial effect of the treatment X|Perception of efficacy, safety, availability and clinical utility of the treatment X in existing clinical practice|How safe do you think that treatment X would be for patients?|Do you think this treatment should be offered to patients in the short term?|Do you think this treatment will make a difference in the existing clinical practice?",Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,ISB-008,June 2019,December 2019,December 2019,"March 29, 2017",,"February 12, 2021","Assistance Publique - H�pitaux de Paris, Paris, Ile-de-france, France",,https://ClinicalTrials.gov/show/NCT03094130,NCT03094130,
oui,NCT03095586,Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin by English-speaking Patients,,Completed,No Results Available,The Study Focus on no Specific Condition,Other: News items with spin|Other: News items without spin,"Perception of beneficial effect of the treatment X|Perception of efficacy, safety, availability and clinical utility of the treatment X in existing clinical practice|How safe do you think that treatment X would be for patients?|Do you think this treatment should be offered to patients in the short term?|Do you think this treatment will make a difference in the existing clinical practice?",Assistance Publique - H�pitaux de Paris,All,"30 Years and older � (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,ISB-009,"October 16, 2017","November 16, 2017","November 16, 2017","March 29, 2017",,"September 12, 2018","Assistance Publique - H�pitaux de Paris, Paris, Ile-de-france, France",,https://ClinicalTrials.gov/show/NCT03095586,NCT03095586,31159786
oui,NCT03095729,Cognitive Consequences of an Activation of the Cortical Drive to Breath (VENTIPSY),VENTIPSY,Completed,No Results Available,Ondine Syndrome|Healthy|Amyotrophic Lateral Sclerosis,Other: Neuropsychological tests,Score at PASAT (Paced Auditory Serial Addition Test)|Oxygen saturation changes,Association pour le D�veloppement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil|Association Fran�aise du Syndrome d'Ondine|Fonds de Recherche en Sant� Respiratoire,All,"18 Years and older � (Adult, Older Adult)",,65,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,ADOREPS_2017_9,"April 26, 2017","July 4, 2019","July 4, 2019","March 30, 2017",,"July 9, 2021","INSERM-UPC UMR_S 1158, Service de Pneumologie et R�animation, GH Piti�-Salp�tri�re, Paris, France",,https://ClinicalTrials.gov/show/NCT03095729,NCT03095729,
oui,NCT03095911,Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin by English-speaking Population,,Withdrawn,No Results Available,The Study Focus on no Specific Condition,Other: News items with spin|Other: News items without spin,"Perception of beneficial effect of the treatment X|Perception of efficacy, safety, availability and clinical utility of the treatment X in existing clinical practice|How safe do you think that treatment X would be for patients?|Do you think this treatment should be offered to patients in the short term?|Do you think this treatment will make a difference in the existing clinical practice?",Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,ISB-010,June 2019,December 2019,December 2019,"March 30, 2017",,"February 12, 2021","Assistance Publique - H�pitaux de Paris, Paris, Ile-de-france, France",,https://ClinicalTrials.gov/show/NCT03095911,NCT03095911,
oui,NCT03095924,Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin by French-speaking Patients,,Withdrawn,No Results Available,The Study Focus on no Specific Condition,Other: News items with spin|Other: News items without spin,"Perception of beneficial effect of the treatment X|Perception of efficacy, safety, availability and clinical utility of the treatment X in existing clinical practice|How safe do you think that treatment X would be for patients?|Do you think this treatment should be offered to patients in the short term?|Do you think this treatment will make a difference in the existing clinical practice?",Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,ISB-011,June 2019,December 2019,December 2019,"March 30, 2017",,"February 12, 2021","Assistance Publique - H�pitaux de Paris, Paris, Ile-de-france, France",,https://ClinicalTrials.gov/show/NCT03095924,NCT03095924,
oui,NCT03095950,Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin by French-speaking Population,,Withdrawn,No Results Available,The Study Focus on no Specific Condition,Other: News items with spin|Other: News items without spin,"Perception of beneficial effect of the treatment X|Perception of efficacy, safety, availability and clinical utility of the treatment X in existing clinical practice|How safe do you think that treatment X would be for patients?|Do you think this treatment should be offered to patients in the short term?|Do you think this treatment will make a difference in the existing clinical practice?",Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,ISB-012,June 2019,December 2019,December 2019,"March 30, 2017",,"February 12, 2021","Assistance Publique - H�pitaux de Paris, Paris, Ile-de-france, France",,https://ClinicalTrials.gov/show/NCT03095950,NCT03095950,
oui,NCT03097601,ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib,SUNITRES,Completed,No Results Available,Metastatic Kidney Cancers,Diagnostic Test: ELR+CXCL cytokines levels are of sunitinib response,ELR+CXCL cytokines|molecular mechanisms,"Centre Antoine Lacassagne|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2016/09,"June 2, 2016","December 30, 2019","December 30, 2019","March 31, 2017",,"July 21, 2020","Centre Antoine LACASSAGNE, Nice, France",,https://ClinicalTrials.gov/show/NCT03097601,NCT03097601,
oui,NCT03100149,A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease,PASADENA,"Active, not recruiting",Has Results,Parkinson's Disease,Drug: RO7046015|Drug: Placebo,"Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I, II, and III) at Week 52|Change From Baseline in the MDS-UPDRS Part IA, Part IB, Part I Total, Part II Total, Part III Total and Part III Subscores|Change From Baseline in Dopamine Transporter Imaging With Single Photon Emission Computed Tomography (DaT-SPECT) Striatal Binding Ratio (SBR) in the Putamen Ipsilateral to the Clinically Most Affected Side|Change From Baseline in Montreal Cognition Assessment (MoCA) Total Score|Change From Baseline in Clinical Global Impression of Improvement (CGI-I) Score|Change From Baseline in Patient Global Impression of Change (PGIC) Score|Change From Baseline in Schwab and England Activity of Daily Living (SE-ADL) Score|Time to Worsening in Motor or Non-Motor Symptoms|Time to Start of Dopaminergic Parkinson's Disease Treatment|Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)|Percentage of Participants With Anti-Drug Antibodies (ADAs) Against RO7046015|Systemic Clearance (CL) of RO7046015|Apparent Volume of Distribution (Vz/F) of RO7046015|Area Under the Serum Concentration-Time Curve (AUC) of RO7046015 Over the Dosing Interval|Maximum Observed Serum Concentration (Cmax) of RO7046015 at Steady-state|Minimum Observed Serum Concentration (Ctrough) of RO7046015 at Steady-state",Hoffmann-La Roche|Prothena Biosciences Limited,All,"40 Years to 80 Years � (Adult, Older Adult)",Phase 2,316,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BP39529|2017-000087-15,"June 27, 2017","November 27, 2019","September 14, 2026","April 4, 2017","February 8, 2021","February 21, 2023","Uab Medicine, Birmingham, Alabama, United States|Barrow Neurology Clinics; Movement Disorders Program, Phoenix, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|Altman Clinical Translational Research Institute, La Jolla, California, United States|USC Keck Medical Center of USC, Los Angeles, California, United States|University of California at San Francisco, San Francisco, California, United States|CenExel Rocky Mountain Clinical Research, LLC, Englewood, Colorado, United States|Associated Neurologists of Southern CT PC, Fairfield, Connecticut, United States|Molecular Neurolmaging, New Haven, Connecticut, United States|Aventura Neurologic Associates; Department of Research, Aventura, Florida, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Compass Research East, LLC, Orlando, Florida, United States|USF Parkinsons Disease and Movement Disorders Center, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Maryland, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Spectrum Health Medical Group, Grand Rapids, Michigan, United States|Henry Ford Health System, Novi, Michigan, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|The Movement Disorder Clinic of Oklahoma, Tulsa, Oklahoma, United States|Oregon Health & Science Uni, Portland, Oregon, United States|UNIVERSITY of PENNSYLVANIA, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor College, Houston, Texas, United States|Central Texas Neurology Consultants, Round Rock, Texas, United States|University of Vermont Medical Center; Investigational Drug Service, Pharmacy Department/Baird 1, Burlington, Vermont, United States|Medizinische Universit�t Innsbruck; Universit�tsklinik f�r Neuroradiologie, Innsbruck, Austria|Groupe Hospitalier Pellegrin, Bordeaux, France|Hopital Gabriel Montpied, Clermont-ferrand, France|Hopital Henri Mondor; Service de Neurologie, Creteil, France|H�pital Michallon - Centre d'Investigation Clinique; Unit� de Pharmacologie Clinique - Inserm, Grenoble, France|hopital de la Timone, Marseille, France|CHU de Nice Hopital Pasteur, Nice, France|Hopital Pitie-Salpetriere APHP, Paris, France|CHU Poitiers, Poitiers, France|CHU Rouen Charles Nicolle; Centre Expert Parkinson H�pitaux de Rouen, Rouen cedex, France|CHU de Nantes - Hopital Laennec, St Herblain, France|CIC - H�pital Purpan, Toulouse, France|Klinik fur Neurologie; Campus Mittev, Berlin, Germany|Heinrich-Heine Universit�tsklinik D�sseldorf, D�sseldorf, Germany|Paracelsus Elena Klinik Kassel, Kassel, Germany|Neurology UKSH Campus Kiel, Kiel, Germany|Klinik und Poliklinik f�r Neurologie Universit�tsklinikum, Leipzig, Germany|Philipps Universit�t Marburg; Klinik f�r Neurologie, Marburg, Germany|DZNE Clinical Trial Unit, M�nchen, Germany|Universitaettsklinikum T�bingen, T�bingen, Germany|Universit�tsklinikum Ulm; Klinik f�r Neurologie, Ulm, Germany|Hospital General de Catalunya, Sant Cugat del Valles, Barcelona, Spain|Policl�nica Guipuzcoa; Servicio de Neurolog�a, Donostia-san Sebastian, Guipuzcoa, Spain|Fundacion Hospital de Alcorcon, Alcorcon, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona; Neurologia, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain|Hospital Universitario de la Princesa; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03100149/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03100149/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03100149,NCT03100149,35921451;35840753;34966256;34659081;29913017
oui,NCT03107403,Dreams and Bereavement,DreamDeath,Recruiting,No Results Available,Healthy Subjects,Behavioral: web form,Frequency of dreams related to the deceased will be correlated to the score at the scale assessing the bereavement process|Content of dreams related to the deceased will be correlated to the score at the scale assessing the bereavement process,Hospices Civils de Lyon,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL17_0075|2017-A00640-53,"October 9, 2018","April 9, 2023","April 9, 2023","April 11, 2017",,"March 14, 2022","Hospices Civils de Lyon H�pital le Vinatier/Inserm, Bron, France",,https://ClinicalTrials.gov/show/NCT03107403,NCT03107403,
oui,NCT03109067,Genetic and Metabolism of Post-prandial HDL Particles,HDL-PP,Completed,No Results Available,Healthy Volunteers,Other: Standardized meal,Comparison of post-prandial HDL particles|Efflux capacity of postprandial HDL particles|Area under curves of triglyceridemia of apoB100 and apoB48|Plasmatic concentrations of apoB100|Correlation between the area under curve of triglyceridemia and the efflux capacity of HDL particles.,"Institut National de la Santé Et de la Recherche Médicale, France",Male,18 Years to 60 Years   (Adult),Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,C10-57,"September 21, 2011","November 21, 2015","November 21, 2015","April 12, 2017",,"April 12, 2017","Centre d'Investigation Clinique Paris Est, Paris, France",,https://ClinicalTrials.gov/show/NCT03109067,NCT03109067,
oui,NCT03113903,Validation of the French Version of the Pain Sensitivity Questionnaire,PSQ-F,Completed,No Results Available,Scheduled Surgery|Healthy Volunteers,Behavioral: Psychophysical exploration,"The psychometric properties of the French version of the PSQ|The natural smell sensitivity assessed independently by a home-made questionnaire|The natural noise sensitivity assessed independently by a home-made questionnaire|The natural light sensitivity, assessed independently by a home-made questionnaire","University Hospital, Clermont-Ferrand|Inserm U1107 "" Neuro-Dol "", Clermont-Ferrand, France|Centre Jean Perrin|Klinikum der Universit�t M�nchen, Deutschland",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,232,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other,CHU-311|2016-A02079-42,"April 30, 2017","January 23, 2018","January 23, 2018","April 14, 2017",,"May 28, 2019","CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT03113903,NCT03113903,34554698;31020630
oui,NCT03114137,Heart Arteries and Sickle Cell Disease / Coeur Artères DREpanocytose,CADRE,Unknown status,No Results Available,Sickle Cell Anemia|Sickle Cell Disease,,Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: glomerulopathy|Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: cardiopathy|Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: pulmonary hypertension|Prevalence and incidence and the 10 year-incidence of the main SCD-related vascular complications in different phenotypes of SCD: retinopathy|Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD:stroke|Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD:osteonecrosis|Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: leg ulcers|Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: priapism|Potential biological risk marker measured at baseline and follow up visits: carotid-femoral pulse wave velocity|Potential biological risk marker measured at baseline and follow up visits: complete blood count|Potential biological risk marker measured at baseline and follow up visits: LDH level|Potential biological risk marker measured at baseline and follow up visits: bilirubin level|Potential biological risk marker measured at baseline and follow up visits: microparticules measure|Potential biological risk marker measured at baseline and follow up visits: free heme level|Potential biological risk marker measured at baseline and follow up visits: inflammatory cytokines|Potential biological risk marker measured at baseline and follow up visits: neutrophil extracellular traps,"Cardiologie et Développement|Institut National de la Santé Et de la Recherche Médicale, France|University of Paris 5 - Rene Descartes|laboratory of excellence GR-Ex",All,"5 Years and older   (Child, Adult, Older Adult)",,4500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2,March 2012,December 2020,December 2022,"April 14, 2017",,"May 25, 2018","Central Hospital of Yaounde, Yaounde, Cameroon|Centre mère et enfant / fondation Chantal Biya, Yaounde, Cameroon|Centre Pasteur du Cameroun, Yaounde, Cameroon|Pediatrics unit, Centre Hospitalier d'Essos, Yaounde, Cameroon|Centre hospitalier Monkole, Kinshasa, Congo, The Democratic Republic of the|Hematology Unit, CHU Yopougon, Abidjan, Côte D'Ivoire|Institut de cardiologie, Abidjan, Côte D'Ivoire|CIRMF, Libreville, Gabon|Cardiology Unit, Centre gyneco-obstretrique, Bamako, Mali|Centre de Recherche et de Lutte contre la Drepanocytose, Bamako, Mali|Centre hospitalier d'enfants Albert Royer, Dakar, Senegal|Centre hospitalo-universotaire de Fann, Cardiology department, Dakar, Senegal|Centre national de transfusion sanguine, Dakar, Senegal",,https://ClinicalTrials.gov/show/NCT03114137,NCT03114137,33249569
oui,NCT03114345,Correlation Between Pressure Differences and Micro-vascularization Changes in Bedridden Paraplegic Patient,VASCIP,Terminated,No Results Available,Pressure Ulcer|Bedsore|Spinal Cord Injury|Paraplegia,Other: Measurement of interface pressure|Other: Measurement of micro-vascularization related parameters,Measure of the pressure intensity in one area|Measure of the hemoglobin quantity in the same area|Measure of other micro-vascularization related parameters (such as the oxygen saturation and the blood flow) recorded at the same area.,"University Hospital, Montpellier|Hill-Rom|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,4,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,9830,"November 22, 2017","November 22, 2019","November 22, 2019","April 14, 2017",,"December 9, 2021","University Regional Hospital Lapeyronie, Montpellier, Languedoc-Roussillon, France",,https://ClinicalTrials.gov/show/NCT03114345,NCT03114345,
oui,NCT03116217,Validation of a Fetal Urine Peptidome-based Classifier to Predict Post-natal Renal Function in Posterior Urethral Valves,Antenatal,Recruiting,No Results Available,Posterior Urethral Valves,,Renal/patient survival at 2 years post-natally.|Renal function of the survivors at day 4 and 6 and 12 month post-natally.,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years to 65 Years   (Adult, Older Adult)",,400,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,16/8805|2016-A01914-47,"June 26, 2017","December 26, 2023","December 26, 2023","April 17, 2017",,"November 12, 2020","UZ Leuven, Leuven, Belgium|CHU Pellegrin-Bordeaux, Bordeaux, France|CHRU de Brest - Hôpital Morvan, Brest, France|Hôpital Femme Mère Enfant-Lyon, Bron, France|CH René-Dubos, Cergy Pontoise, France|CHU Estaing, Clermont-Ferrand, France|CHU de Grenoble - Hôpital Couple-Enfant - Département de la Génétique, Grenoble, France|CHU de la Timone, Marseille, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Hôpital mère-enfant pédiatrie, Nantes, France|CHU Lenval, Nice, France|AP-HP - Hôpital Necker Enfants malades, Paris, France|Hôpital Robert-Debré, Paris, France|CHU Poitiers, Poitiers, France|CHU Rennes Hôpital Sud, Rennes, France|CHU Hôpitaux de St-Etienne-Hôpital Nord, Saint Etienne, France|Centre hospitalier universitaire Chu Amiens Salouël Hôpital sud, Salouel, France|Sihcus-Cmco, Schiltigheim, France|Hôpital Bagatelle (Talence) - CHU Pellegrin (Bordeaux), Talence, France|Hôpital Paule de Viguier-Hôpital des enfants- Site Purpan, Toulouse, France|Centre Olympe de Gouges du CHRU de Tours, Tours, France|Heidelberg University Hospital, Heidelberg, Germany|Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy|Leiden University Medical Center Dept of prenatal diagnosis and therapy, Leiden, The Netherlands, Netherlands|Radboudumc Amalia Children's Hospital, Nijmegen, The Netherlands, Netherlands|Polish Mothers Memorial Hospital Research Institute, Lodz, Poland|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hôpital des Enfants Hôpitaux universitaire Genève (HUG), Geneve, Switserland, Switzerland|FetalMedicine Centre Birmingham Women's Hospital, Birmingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT03116217,NCT03116217,
non,NCT03118401,Stool Ritual: Impact on the Number of Nights Without Stools Among Dependent Residents in Institutions for Dependent Elderly People,RITUELIM,Completed,No Results Available,Homes for the Aged|Intestinal Elimination,Other: Ritual of stool|Other: Usual practice,Number of nights with stools during the follow-up period|Evolution in number of nights with stool|Evolution in number of laxative medication|Satisfaction questionary,"University Hospital, Limoges",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,I16025 (RITUELIM),"July 21, 2017","October 15, 2019","October 15, 2019","April 18, 2017",,"December 3, 2019","EHPAD les Ecureuils, Ussel, France",,https://ClinicalTrials.gov/show/NCT03118401,NCT03118401,36088731
oui,NCT03119246,Beta Testing of a New Assessment in Huntington's Disease (HD),CAPIT-HD Beta,Unknown status,No Results Available,Huntington Disease,Other: CAPIT-HD beta,All dysfunction or disorder of huntington patient measured by means of a new battery assessments|Difference on motor score between patient and healthy volontary measured by motor tests of the revised Core Assessment Protocol|Difference on cognitive score between patient and healthy volontary measured by cognitive tests of the revised Core Assessment Protocol|Difference on psychiatric score between patient and healthy volontary measured by psychiatric evaluation of the revised Core Assessment Protocol|Difference on functional scale between patient and healthy volontary measured by functional evaluation of the revised Core Assessment Protocol|Number of new assessment battery performed correctly,"Assistance Publique - Hôpitaux de Paris|School of Biosciences - Cardiff University|University Hospital of Wales|National Reference Center for Huntington's disease Cognitive Neurology Unit|Institut National de la Santé Et de la Recherche Médicale, France|Manchester Centre for Genomic Medicine - St. Mary's Hospital University of Manchester|George-Huntington-Institut GmbH",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,P150201,June 2016,March 2018,March 2018,"April 18, 2017",,"April 18, 2017","Henri Mondor Hospital, Creteil, France",,https://ClinicalTrials.gov/show/NCT03119246,NCT03119246,
oui,NCT03128567,Deep Brain Stimulation for Patients With Parkinson's Disease.,STTARTLATE,Unknown status,No Results Available,Parkinson Disease,Device: Stimulation of the subthalamic nucleus,Quality of life,"Institut National de la Santé Et de la Recherche Médicale, France",All,69 Years to 75 Years   (Older Adult),,50,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C 14-01,June 2017,January 2020,March 2021,"April 25, 2017",,"June 2, 2017",,,https://ClinicalTrials.gov/show/NCT03128567,NCT03128567,
oui,NCT03131063,Pharmacokinetic Study of Antibiotics in Patients Assisted by Extracorporeal Membrane Oxygenation (PHARMECMO),PHARMECMO,Completed,No Results Available,Extracorporeal Membrane Oxygenation|Sepsis|Intensive Care Unit|Antibiotics,Other: Antibiotic plasma dosage,Minimum Antibiotics plasma concentration (Cmin) (C min)|Medium Antibiotics plasma concentration (CT 50),Groupe Hospitalier Pitie-Salpetriere,All,"18 Years and older � (Adult, Older Adult)",,45,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,ID RCB : 2014-A00043-44,May 2014,April 2015,March 2017,"April 27, 2017",,"April 27, 2017",,,https://ClinicalTrials.gov/show/NCT03131063,NCT03131063,
oui,NCT03137797,Cohort of Patients Naive of Antiretroviral Treatment at Enrollment,COPANA,Completed,No Results Available,HIV Infection,,"Patients prognosis at short, medium and long term|Antiretroviral treatment impact|Aging population|Impact of inflammatory markers on antiretroviral treatment|Socio-economic conditions (sexuality, education, reproduction, health inequalities)","ANRS, Emerging Infectious Diseases",All,"15 Years and older   (Child, Adult, Older Adult)",,800,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ANRS CO9 COPANA,February 2004,June 2016,June 2016,"May 3, 2017",,"May 3, 2017","Meyer, Kremlin-Bicêtre, France",,https://ClinicalTrials.gov/show/NCT03137797,NCT03137797,
oui,NCT03139630,COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients,COPANA,Completed,No Results Available,HIV Seropositivity|Dyslipidemias|PCSK9,,PCSK9 plasma level change after initiation of ART including protease inhibitor boosted with ritonavir (PI/r)|PCSK9 correlation with lipid parameters|PCSK9 correlation with inflammatory makers/adipocytokines|PCSK9 comparison between HIV-infected and uninfected patients,"Franck Boccara|National Agency for Research on AIDS and Viral Hepatitis (ANRS)|Institut National de la Santé Et de la Recherche Médicale, France|Amgen|Saint Antoine University Hospital",All,"18 Years and older   (Adult, Older Adult)",,193,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,COPANA - A09 PCSK 9 substudy,March 2016,September 2016,September 2016,"May 4, 2017",,"May 4, 2017","Cardiology Department, Saint Antoine University Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03139630,NCT03139630,28857822
oui,NCT03139903,"The Primordial Dwarfisms: Diagnosis, Identification of the Molecular Basis of Seckel Syndrome and Microcephalic Osteodysplastic Primordial Dwarfism Type II",NANPIM,Completed,No Results Available,Microcephalic Osteodysplastic Primordial Dwarfism Type II|Seckel Syndrome,,to visualize any vascular abnormalities according the cerebral angiography-MRI|Assessment of intelligence and cognitive ability according the Wechsler Intelligence Scale for Children (WISC-IV)|Measurement of visual acuity,Assistance Publique - H�pitaux de Paris,All,"2 Months and older � (Child, Adult, Older Adult)",,30,Other,Observational,Observational Model: Family-Based|Time Perspective: Retrospective,P081256,"July 28, 2010","July 16, 2013",July 2015,"May 4, 2017",,"November 20, 2017","Medical Genetics Department and INSERM U781, Necker-Enfants Malades Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03139903,NCT03139903,
oui,NCT03148964,Primary Infection Cohort,PRIMO,Recruiting,No Results Available,HIV-1-infection,Biological: blood sampling,"Improve the physiological, pathological and virological knowledge of primary HIV infection|The impact of early, transient or prolonged treatment versus deferred treatment on the long-term prognosis of patients followed since primary infection, in terms of activation / inflammation|Contribute to knowledge in the epidemiology of HIV infection|Contribute to national recommendations for therapeutic care and evaluate their implementation","ANRS, Emerging Infectious Diseases",All,"15 Years and older � (Child, Adult, Older Adult)",,2800,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ANRS CO6 PRIMO,October 1996,September 2024,September 2025,"May 11, 2017",,"October 19, 2022","Laurence Meyer, Le Kremlin Bic�tre, France",,https://ClinicalTrials.gov/show/NCT03148964,NCT03148964,
oui,NCT03150290,Brown Adipose Tissue in ALS,BATALS,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Other: Indirect Calorimetry.|Device: 18-FDG-PET,Quantification of depots of functional brown adipose tissue in ALS patients (grams),"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,C16-83|2016-A01790-51,"October 26, 2017","April 1, 2019","April 1, 2019","May 12, 2017",,"August 26, 2021","Paris Als Center, Salpetriere Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03150290,NCT03150290,
oui,NCT03154138,Prismatic Adaptation for Rehabilitation of Postural Imbalance After Stroke,PEQUIE,Recruiting,No Results Available,Chronic Right Supratensorial Stroke Patients,Device: The prismatic adaptation (PA)|Device: The sham prismatic adaptation (S-PA),"Balance: The inter-group difference of within-group changes for the Berg Balance Scale (BBS)|Balance: the inter-group difference of within-group changes for the Berg Balance Scale (BBS)|Balance: The inter-group difference of within-group changes for standing static posturographic variables|Lateropulsion: The inter-group difference of within-group changes for the Scale for Contraversive Pushing (SCP)|The inter-group difference of within-group changes for each spatial reference frame (MSSA, VSSA, OLP, LBA)|Autonomy : Inter-group difference of within-group changes for the Barthel index (BI)|Additionnal descriptive anatomic study of cerebral lesions using diffusion tensor Magnetic Resonance Imaginig (MRI) (Tractography)|Relationship between prismatic adaptation induced changes on misperceptions of spatial reference frames and these on postural and balance disorders","Hospices Civils de Lyon|Centre National de la Recherche Scientifique, France|Institut National de la Santé Et de la Recherche Médicale, France|Université Claude Bernard Lyon 1 (UCBL)|Equipe "" ImpAct Trajectoires "" du Centre de Recherche en Neurosciences de Lyon (CRNL)",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other",69HCL17_0172,"December 4, 2017",December 2023,April 2024,"May 16, 2017",,"March 29, 2022","CHU Grenoble, Grenoble, France|Hôpital Henry Gabrielle, service de médecine physique et réadaptation, Saint-Genis-Laval, France|CHU Saint-Etienne, Saint-Étienne, France",,https://ClinicalTrials.gov/show/NCT03154138,NCT03154138,34819284
oui,NCT03157778,Relation Between Pregnenolone Endocannabinoids in Normal-weight and Obese Men,CannaPREG,Completed,No Results Available,Obesity,Other: Obese men|Other: Normal-weight men,Comparison of pregnenolon plasmatic concentration in both groups.|Comparison of neurosteroid plasma concentrations and endocannabinoid plasma concentrations|Comparison of endocannabinoid plasma concentration and pregnenolone plasma concentration,"University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France",Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CHUBX 2015/33,"May 30, 2017","November 2, 2017","November 2, 2017","May 17, 2017",,"January 23, 2018","Hôpital Haut-Lévêque, Pessac, France",,https://ClinicalTrials.gov/show/NCT03157778,NCT03157778,
oui,NCT03158948,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock",,Completed,No Results Available,"Shock, Septic",Drug: MOTREM|Drug: Placebo,Vital signs|ECG|Number of patients with clinically relevant abnormal laboratory values|Presence of anti-LR12 antibodies|Adverse events,Inotrem,All,"18 Years to 80 Years � (Adult, Older Adult)",Phase 2,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MOT-C-201,"July 3, 2017","June 13, 2018","June 13, 2018","May 18, 2017",,"June 21, 2018","Cliniques Universitaires Saint-Luc (there may be other sites in this country), Brussels, Belgium|Inserm Clinical Investigational Center, CHU Dupuytren (there may be other sites in this country), Limoges Cedex, France|Radboudumc (there may be other sites in this country), Nijmegen, Netherlands|Hospital Cl�nico San Carlos, Medicina Intensiva (there may be other sites in this country), Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03158948,NCT03158948,
oui,NCT03160443,Impact of Neuropsychological Alteration of Decision-making Abilities on the Functioning of Patients With Eating Disorders,NEUROPSY_TCA,"Active, not recruiting",No Results Available,Eating Disorder,Behavioral: Ambulatory cares in a day-hospital (University Hospital of Montpellier) specialized in the evaluation of eating disorders,Level of functional impairment assessed by the Work and Social Adjustment Scale (WSAS)|Quality of life assessed by the Eating disorder quality of life (EDQOL) scale.|Level of functional impairment assessed by the clinician with the Functional Assessment Staging Test (FAST) scale|Level of functional impairment assessed by the clinician with the FAST scale|Score to decision making test (Iowa gambling task),"University Hospital, Montpellier|INSERM 1061, "" Neuropsychiatry: epidemiological and clinical research"", Montpellier",All,"15 Years to 65 Years � (Child, Adult, Older Adult)",Not Applicable,340,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,9804,"May 3, 2017","July 30, 2022","July 30, 2022","May 19, 2017",,"December 21, 2021","H�pital Lapeyronie, Montpellier, France",,https://ClinicalTrials.gov/show/NCT03160443,NCT03160443,
oui,NCT03162068,Cushing's Osteoporosis Specificities,SOCS,Recruiting,No Results Available,Osteoporosis in Cushing's Syndrome|Osteoporosis in Post-menopausal Women,Other: Osteodensitometry and pQCT,"Comparison of volumetric bone mineral density|Assessment of strength bone of radius and tibia of the non-dominant limb|Assessment of trabecular and cortical compartment|Comparison of muscle area and surface, adipose tissue","University Hospital, Clermont-Ferrand|Unit� de recherche GReD CNRS UMR6293 / Inserm",All,"18 Years and older � (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,CHU-334|2016-A01482-49,"April 4, 2017",May 2019,May 2024,"May 22, 2017",,"May 22, 2017","CHU Clermont-Ferrand, Clermont-Ferrand, Auvergne, France",,https://ClinicalTrials.gov/show/NCT03162068,NCT03162068,
oui,NCT03182400,Neurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults,PROSCEA,Recruiting,No Results Available,Healthy Volunteer,Behavioral: Neurophysiological assessment|Behavioral: Neuropsychological assessment,ERP amplitude (�V)|Reaction times (ms)|pupil size (mm),"University Hospital, Tours",All,"1 Year to 60 Years � (Child, Adult)",Not Applicable,450,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,PHAO17-FBB/PROSCEA,"June 14, 2017",June 2027,June 2027,"June 9, 2017",,"September 9, 2022","Chru Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT03182400,NCT03182400,
oui,NCT03183401,National Breast and Thyroid Screening After a Treatment Received Against a Cancer During Childhood,DENACAPST,Unknown status,No Results Available,Early Detection of Cancer,,follow of cancer screening recommendations|description of thyroid cancer screening|description of breast cancer screening|description of second cancers|psycho social analyze,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C 16-03,"July 9, 2017","October 31, 2019","October 31, 2019","June 12, 2017",,"June 21, 2017","Charlotte Demoor-Goldschmidt, Villejuif, France",,https://ClinicalTrials.gov/show/NCT03183401,NCT03183401,
oui,NCT03185039,Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents,,Unknown status,No Results Available,Kidney Cancer,Procedure: Blood and tumor samples,Plasma level of the MMP2 and MMP9 markers|Survival without progression,"Institut Paoli-Calmettes|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,MMP-Rein-IPC 2015-029,"May 29, 2017","December 13, 2022","December 13, 2022","June 14, 2017",,"January 10, 2020","Institut Paoli Calmettes, Marseille, France",,https://ClinicalTrials.gov/show/NCT03185039,NCT03185039,
oui,NCT03188731,ZIKAlliance Pregnant Women Cohort,ZIKAlliancePW,Completed,No Results Available,Zika Virus|Pregnancy Related,,Congenital Abnormalities,"University of Heidelberg Medical Center|European Union|ZIKAlliance|Oswaldo Cruz Foundation|University of Sao Paulo|London School of Hygiene and Tropical Medicine|Federal University of Bahia|Universidade Federal de Goias|University Medical Center Groningen|University of Carabobo|Universidad Industrial de Santander|Sosecali Hospital, Guyaquil|Instituto de Medicina Tropical ""Pedro Kour� (IPK), Cuba|Mexican National Institute of Public Health|Instituto Mexicano del Seguro Social|Institut National de la Sant� Et de la Recherche M�dicale, France|Erasmus Medical Center",Female,"16 Years to 45 Years � (Child, Adult)",,3852,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,734548PW (EC   H2020   RIA),"May 24, 2017","September 30, 2021","September 30, 2021","June 15, 2017",,"May 24, 2022","Sosecali Ltd. (SOSE), Guaqui, Bolivia|INSERM, Santa Cruz, Bolivia|Federal University of Bahia (UFB), Bahia, Brazil|Universidade Federal de Minas Gerais, Belo Horizonte, Brazil|Federal University of Goias, Goi�s, Brazil|Fundacao Oswaldo Cruz (FIOCRUZ), Recife, Brazil|Fundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil|University of Sao Paulo, S�o Paulo, Brazil|Industrial University of Santander (UIS), Bucaramanga, Colombia|Pedro Kouri Institute (IPK), Havana, Cuba|INSERM, Pointe-�-Pitre, Guadeloupe|IMSS Mexico (IMSS), Guadalajara, Mexico|National Institute of Public Health (INSP), M�rida, Mexico|Universidad de Carabobo / UMC Groningen (UMCG), Valencia, Venezuela",,https://ClinicalTrials.gov/show/NCT03188731,NCT03188731,31878895
oui,NCT03188900,Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia,APHERESE,Completed,No Results Available,Preeclampsia,Biological: A collection of maternal plasma and serum,ratio sFlt-1/PlGF|Kinetics of these ratios sFlt-1/PlGF during pregnancy,Assistance Publique - H�pitaux de Paris|INSERM UMR-S 1139,Female,18 Years to 50 Years � (Adult),,236,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,SC3455,"June 12, 2017","June 12, 2019","June 12, 2019","June 16, 2017",,"September 27, 2021","Hopital Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT03188900,NCT03188900,
oui,NCT03190681,Motivation and Methylphenidate,MBB_MPH,Unknown status,No Results Available,Motivation|Apathy|Impulsive Behavior,Drug: Ritalin 10Mg Tablet,coefficient of sensitivity to reward|coefficient of sensitivity to effort|coefficient of sensitivity to punishment|coefficient of sensitivity to delay,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 50 Years   (Adult),Early Phase 1,24,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science",C13-08,"July 1, 2017","September 30, 2017","September 30, 2018","June 19, 2017",,"June 19, 2017","Centre d'investigation clinique, Institut du Cerveau et de la Moelle, Paris, France",,https://ClinicalTrials.gov/show/NCT03190681,NCT03190681,
anrs,NCT03191175,Inflammasome Activation Via Circulating Metabolites,InflammoVIH,Completed,No Results Available,Human Immunodeficiency Virus,Other: blood sample,Characterization of NLR (s) implicated in IL-18 up-regulation (inflammasome activation) in HIV|Characterization of circulating metabolites that active the inflammasome machinery|Non-AIDS related comorbidities,"University Hospital, Bordeaux|ANRS, Emerging Infectious Diseases|Sidaction|Centre National de la Recherche Scientifique, France",All,"18 Years and older � (Adult, Older Adult)",,55,Other,Observational,Observational Model: Other|Time Perspective: Prospective,CHUBX 2016/14,"July 3, 2017","December 20, 2017","December 20, 2017","June 19, 2017",,"September 28, 2018","Service d'immunologie, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT03191175,NCT03191175,
oui,NCT03193099,Decoding Presymptomatic White Matter Changes in Huntington Disease,Win-HD,Completed,No Results Available,Huntington Disease|White Matter Alterations,Other: Brain imaging|Other: Neurological assessments|Behavioral: Psychological assessments|Behavioral: Behavioural assessments,Detection by Diffusion-weighted spectroscopy of abnormal white matter changes prior to the onset of Huntington disease comparing HTT mutation carriers and non HTT mutation carriers over one year|Detection by Diffusion-weighted spectroscopy of abnormal white matter changes over one year as an intersubject evolution|Detection by Diffusion Tensor Imaging of abnormal white matter changes prior to the onset of Huntington disease comparing HTT mutation carriers and non HTT mutation carriers over one year.|Detection by Diffusion Tensor Imaging white matter changes over one year as an intersubject evolution.|Detection of abnormal scores from psychological tests to assess possible early non motor changes and their intersubject evolution over one year.|Detection of choice rates and time differences in the behavioral task comparing HTT mutation carriers and non HTT mutation carriers over one year.|Detection of time differences in the behavioral task comparing HTT mutation carriers and non HTT mutation carriers over one year.,"Institut National de la Santé Et de la Recherche Médicale, France|University College, London",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,C16-115|2017-A00589-44,"July 11, 2017","December 30, 2019","December 30, 2019","June 20, 2017",,"February 18, 2020","Brain and Spine Institute, Paris, France",,https://ClinicalTrials.gov/show/NCT03193099,NCT03193099,
oui,NCT03194230,Interest of Cervical Dilators in Second Trimester Termination of Pregnancy,DILATOP,Completed,No Results Available,Termination of Pregnancy (TOP),Other: With cervical dilatator,"Proportion of women achieving vaginal delivery within 12 hours|Induction-to-amniotomy interval|Induction-to-delivery interval|Failure in induction of labor|Pain assessment at the beginning of the procedure|Pain assessment of the whole procedure of TOP|Distress assessment at discharge after TOP|Assessment of acceptability of the whole procedure of TOP|number of complications.|Duration of hospitalization.|Cost of the procedure|Among nullipara, proportion of women achieving vaginal delivery within 12 hours",Assistance Publique - H�pitaux de Paris|INSERM U1153,Female,"18 Years and older � (Adult, Older Adult)",Not Applicable,355,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,P160908,"December 14, 2017","June 30, 2020","November 24, 2020","June 21, 2017",,"January 13, 2021","Maternit� Port Royal, Paris, France",,https://ClinicalTrials.gov/show/NCT03194230,NCT03194230,35926202
oui,NCT03199599,Prognostic PET/CT Model in Non Small Cell Lung Cancer,,Completed,No Results Available,Non Small Cell Lung Cancer,,validation of a multiparametric PET/CT prognostic model,"Poitiers University Hospital|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,150,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PRINCE|PRT-K15-119,"September 1, 2016","August 31, 2019","August 31, 2019","June 27, 2017",,"April 13, 2020","Chu Poitiers, Poitiers, France",,https://ClinicalTrials.gov/show/NCT03199599,NCT03199599,
oui,NCT03206840,Neural Correlates of Self,NeuCoSe,Completed,No Results Available,Healthy Volunteers,"Behavioral: ""control"", ""meditation"", ""hypnosis"".",Reaction time (minutes)|Brain activation with IRM|personality trait with questionnaires|Scores during behavioural tasks|salivary volume (millimeter),Hospices Civils de Lyon,All,"18 Years to 70 Years � (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,69HCL17_0274|2017-A01923-50,"October 26, 2017","November 12, 2018","November 12, 2018","July 2, 2017",,"March 7, 2019","Hospices Civils de Lyon H�pital le Vinatier/Inserm, Bron, France",,https://ClinicalTrials.gov/show/NCT03206840,NCT03206840,
oui,NCT03209102,Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder,ADOLIMIS,"Active, not recruiting",No Results Available,Borderline Personality Disorder|Adolescent Development,Other: Clinical assessment|Behavioral: Stress elicitation experiment|Other: Structural and Functional MRI|Biological: salivary collections of amylase and cortisol,Comparison between subjective and objective acute stress experience in BPD Adolescents vs Healthy controls|Investigating the neural correlates and modulation of motivation and impulsivity using structural and task-based fMRI,"Institut National de la Santé Et de la Recherche Médicale, France",All,"13 Years to 18 Years   (Child, Adult)",Phase 2,66,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C16-58,"October 4, 2017",October 2021,October 2021,"July 6, 2017",,"August 26, 2021","Pôle recherche clinique, Paris, France",,https://ClinicalTrials.gov/show/NCT03209102,NCT03209102,
oui,NCT03213119,Boosting Reward-based Attention Through VEstibular STimulation,BRAVEST,Suspended,No Results Available,Brain Lesion of the Right Hemisphere|Unilateral Spatial Neglect for Half of Them,Procedure: Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.,Center of Gravity (pixels).|Reaction times (ms).|Response accuracy (%),Hospices Civils de Lyon,All,"18 Years to 85 Years � (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,69HCL17_0263|2017-A01784-49,"April 23, 2018","May 8, 2018","February 13, 2023","July 11, 2017",,"February 15, 2023","CRNL, �quipe IMPACT (CNRS UMR5292, INSERM U1028), Bron, France|Service de m�decine et r�adaptation neurologique, H�pital Henry Gabrielle, Saint-Genis-Laval, France",,https://ClinicalTrials.gov/show/NCT03213119,NCT03213119,
oui,NCT03214315,Structural Network on Prostate Cancer in the French Greater West Region,RESCAP,Completed,No Results Available,Prostate Cancer,Procedure: Visceral adipose tissue specimen,Dietary intake of essential fatty acids|Exposure to persistant organic pesticides,"University Hospital, Tours|Institut National de la Santé Et de la Recherche Médicale, France|Nantes University Hospital|Rennes University Hospital|University Hospital, Angers|Poitiers University Hospital|Centre Hospitalier Universitaire de Pointe-a-Pitre",Male,"18 Years and older   (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,AOCGO13-GF-RESCAP|DC-2014-2045,"November 11, 2014","September 27, 2016","September 27, 2016","July 11, 2017",,"November 5, 2019","Urology CHRU-TOURS, Tours, I&L, France|University Hospital, Angers, France|University Hospital, Brest, France|University Hospital, Nantes, France|Uniersity Hospital, Poitiers, France|University Hospital, Rennes, France|University Hospital, Pointe-a-Pitre, Guadeloupe",,https://ClinicalTrials.gov/show/NCT03214315,NCT03214315,
oui,NCT03215732,"Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal",AMBASS,Completed,No Results Available,Chronic Hepatitis b,Diagnostic Test: HBV testing with dried blood spots (DBS) technique,"Prevalence of chronic HBV infection|Prevalence of chronic HBV infection in age classes '0-15 years; 15-35 years, more than 35 years), and in women of childbearing age|HBV vaccine coverage (in children born after 2004, year of the introduction of the vaccine in the national program)|HBV vaccine efficacy (in children born after 2004, year of the introduction of the vaccine in the national program)|Mortality associated with chronic HBV infection in the Niakhar area|Morbidity associated with chronic HBV infection in the Niakhar area|Quality of life and living conditions of HBV-infected individuals and of their households|HBV treatment needs in the Niakhar area and in the country|Number of quality-adjusted life years(QALYs) lost in the absence of HBV treatment|Number of QALYs gained with different scenario of access to HBV treatment|Total cost","ANRS, Emerging Infectious Diseases|Institute of Research for Development, France",All,"6 Months and older � (Child, Adult, Older Adult)",,3119,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,ANRS 12356 AMBASS,"October 19, 2017","July 31, 2019","July 31, 2019","July 12, 2017",,"September 9, 2019","At home, Niakhar, R�gion De Fatick, Senegal",,https://ClinicalTrials.gov/show/NCT03215732,NCT03215732,37143029;31320358
oui,NCT03217903,High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE),MYRAGE,Unknown status,No Results Available,High-risk Myelodysplastic Syndromes With Excess Blasts,Diagnostic Test: Myelogram,Methylation level of the Differentially Methylated Regions (DMR)|Overall response by IWG 2006 response criteria (complete remission / partial remission / non response)|Cytogenetic response by IWG 2006 response criteria (major / minor / no response)|Hematologic improvement by IWG 2006 response criteria (major / minor / no response)|Transfusion independence (yes/no)|General condition improvement (yes/no),"Central Hospital, Nancy, France|Inserm U954 - N-GERE (Nutrition, Genetics and Exposition to Environmental Risk)",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,MYRAGE,"October 12, 2017","January 1, 2022","January 1, 2022","July 14, 2017",,"August 6, 2019","CHRU de Nancy, Nancy, France|BROSEUS, Vandoeuvre les Nancy, France",,https://ClinicalTrials.gov/show/NCT03217903,NCT03217903,
oui,NCT03218514,Venous Thromboprophylaxis in Bariatric Surgery,OBSUD,Completed,No Results Available,Obesity,Drug: Dalteparin,Proportion of patients whose peak plasma anti-Xa levels is in the prophylactic ranges|Proportion of patients with symptomatic VTE|Proportion of patients with major bleeding,Groupe Hospitalier Pitie-Salpetriere|Assistance Publique Hopitaux De Marseille,All,"18 Years to 70 Years � (Adult, Older Adult)",,118,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CIC1421-17-07,July 2014,March 2017,July 2017,"July 14, 2017",,"October 18, 2018",,,https://ClinicalTrials.gov/show/NCT03218514,NCT03218514,
oui,NCT03223090,Motor Language Learning,MOTOLANGUAGE,Recruiting,No Results Available,Healthy Volunteers,Behavioral: Tool-use|Behavioral: Hand,Linguistic performance amelioration ratio,Hospices Civils de Lyon,All,20 Years to 40 Years � (Adult),Not Applicable,1111,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,69HCL17_0359|2017-A02144-49,"January 19, 2018","March 19, 2024","March 19, 2024","July 19, 2017",,"March 7, 2023","Hospices Civils de Lyon, Bron, France",,https://ClinicalTrials.gov/show/NCT03223090,NCT03223090,
oui,NCT03223506,Validation of a Physiological Based Pharmacokinetic Model by the Study of Paracetamol Distribution in the Brain Compartments in Brain Injured Patients,,Completed,No Results Available,Brain Injured Patients,Drug: Paracetamol,"Area under the curve of paracetamol in the CSF, ECF and plasma.|Area under the curve ratio of plasmatic of paracetamol between 2 administrations|Area under the curve ratio of free cerebral concentration (CSF and ECF) of paracetamol between 2 administrations|Maximum concentration of paracetamol in cerebro spinal fluid|Maximum concentration of paracetamol in extra cellular fluid|Minimum concentration of paracetamol in cerebro spinal fluid|Minimum concentration of paracetamol in extra cellular fluid|Elimination half life of paracetamol in cerebro spinal fluid|Elimination half life of paracetamol in extra cellular fluid|Minimum plasma concentration|Volume of distribution|Clearance of paracetamol|Maximum plasma concentration|Elimination half life of paracetamol",Poitiers University Hospital,All,"18 Years and older � (Adult, Older Adult)",Phase 1,17,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PB-PK BRAIN,"March 23, 2013","December 31, 2017","December 31, 2017","July 21, 2017",,"February 18, 2019","CHU de Poitiers, Poitiers, France",,https://ClinicalTrials.gov/show/NCT03223506,NCT03223506,
oui,NCT03228628,Nitrous Oxide for Lumbar Puncture,NO for LP,Unknown status,No Results Available,Pain|Anxiety,Drug: Fixed 50:50 mixture of nitrous oxide and oxygen|Other: Placebo,Proportion of patients with significant pain|Proportion of patients with significant anxiety|Analgesic efficacy measured with pain as a continuous variable|Anxiolytic efficacy measured with anxiety as a continuous variable|Pain during the procedure evaluated one hour after the end of the lumbar puncture|Anxiety during the procedure evaluated one hour after the end of the lumbar puncture|Side effects|Impact of age on side effects|Induced cost,"University Hospital, Clermont-Ferrand|University Hospital, Bordeaux|Hospices Civils de Lyon|Inserm U1107, NeuroDol|Universit� d'Auvergne",All,"18 Years and older � (Adult, Older Adult)",Phase 4,162,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",CHU-342|2017-002750-37,"October 1, 2017","June 6, 2018","September 1, 2019","July 25, 2017",,"July 25, 2017","CHU de Clermont-Ferrand, Clermont-Ferrand, Auvergne, France",,https://ClinicalTrials.gov/show/NCT03228628,NCT03228628,
oui,NCT03231449,A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa,FEVRIER,Unknown status,No Results Available,Acute Coronary Syndrome|Heart Failure|Syncope|Stroke|Pericarditis|Endocarditis|Conduction Abnormalities|Rhythm Abnormal|Pulmonary Embolism|Deep Vein Thrombosis|Other Cardiovascular Conditions,Other: observation of current care,Description of patients in cardiology unit in sub-Saharan Africa:socio-demographic characterization|Description of patients in cardiology unit in sub-Saharan Africa:causes of hospitalization|Description of patients in cardiology unit in sub-Saharan Africa: co-morbidities|Description of patients in cardiology unit in sub-Saharan Africa: hospital examinations|Description of patients in cardiology unit in sub-Saharan Africa: duration of hospitalization|Description of patients in cardiology unit in sub-Saharan Africa: discharge diagnosis|number of patients with heart failure|number of patients with myocardial infarction|number of patients with atrial fibrillation,"Cardiologie et Développement|Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,5000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1,"February 1, 2017",December 2020,February 2021,"July 27, 2017",,"May 25, 2018","Centre national hospitalier et universitaire Koutoukou Maga, Cotonou, Benin|Centre médical Paul IV, Ouagadougou, Burkina Faso|Hopital militaire de Kamenge et polyclinique maison médicale, Bujumbura, Burundi|Hôpital Régional, Bafoussam, Cameroon|Douala General Hospital, Douala, Cameroon|Central Hospital, Yaounde, Cameroon|Hôpital Général de Yaoundé, Yaounde, Cameroon|Clinique Ngaliema, Kinshasa, Congo, The Democratic Republic of the|Clinique universitaire de Kinshasa, Kinshasa, Congo, The Democratic Republic of the|CHU, Brazzaville, Congo|Institut de Cariologie d'Abidjan, Abidjan, Côte D'Ivoire|CHU, Bouake, Côte D'Ivoire|Centre Hospitalier Universitaire (CHUL), Libreville, Gabon|CHU Ignace Deen, Conakry, Guinea|Institut du coeur, Maputo, Mozambique|Hôpital National Lamorde, Niamey, Niger|Hôpital de Fann, Dakar, Senegal|Hôpital général de Grand Yoff, Dakar, Senegal|El Hadj-Ibrahima Niass, Kaolac, Senegal|National Cardiothoracic center / Shab Teaching Hospital, Khartoum, Sudan",,https://ClinicalTrials.gov/show/NCT03231449,NCT03231449,
oui,NCT03234257,Evaluation of the Carotid Plaque Stability by Ultrafast-ultrasound Imaging (UF),UF-Plaques,Completed,No Results Available,Carotid Stenosis,Device: UF-ultrasound,"local stiffness measurement|stiffness between plaque and its adjacent arterial segments|correlation between the plaque's stiffness and the histological quantification of the fibrous tissue.|correlation between the elasticity of the plaque and the histological quantification of the calcifications|the quantification of vascularization by UF Doppler with the number of neovessels histologically quantified|the quantification of the wall shear stress evaluated by UF Doppler between stable and unstable plaque.|compare all the different parameters used to evaluated the plaque's stability, but depending on whether or not the carotid stenosis is symptomatic",French Cardiology Society|INSERM U979 (Institut Langevin),All,"18 Years and older � (Adult, Older Adult)",Not Applicable,69,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2016-03,"May 18, 2017","May 5, 2019","September 30, 2020","July 31, 2017",,"August 9, 2021","Hopital Europeen Georges Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT03234257,NCT03234257,34181190
oui,NCT03235258,Cohort of HIV-infected Children,EPF,Completed,No Results Available,Children Infected by HIV,,Conditions of access to early treatment|Puberty stage|Clinical prognosis|Immuno virological prognosis|Prognosis of patient coinfected by CMV or VHC|Sexuality,"ANRS, Emerging Infectious Diseases",All,up to 13 Years � (Child),,812,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ANRS CO10 EPF,July 2004,June 2020,June 2020,"August 1, 2017",,"April 13, 2021","CHU Angers, Angers, France|CHU H�pital Jean Minjoz, Besancon, France|H�pital Jean Verdier, Bondy, France|Centre Hospitalier Pellegrin, Bordeaux, France|CHU Caen, Caen, France|H�pital Antoine B�cl�re, Clamart, France|H�pital Louis Mourier, Colombes, France|Centre hospitalier Francilien Sud, Corbeil-Essonnes, France|H�pital Bic�tre, Le Kremlin Bic�tre, France|CHR Jeanne de Flandres, Lille, France|Institut d'H�matologie et Oncologie P�diatrique, Lyon, France|CHR Arnaud de Villeneuve, Montpellier, France|Centre Hospitalier Intercommunal, Montreuil, France|CHU Nantes Hotel Dieu, Nantes, France|CHU H�pital de l'Archet II, Nice, France|Groupe Hospitalier Cochin Tarnier Port-Royal, Paris, France|Groupe Hospitalier Necker, Paris, France|H�pital Robert Debr�, Paris, France|H�pital Trousseau, Paris, France|Centre Hospitalier G�n�ral- H�pital Delafontaine, Saint-denis, France|H�pital Civil, Strasbourg, France|CHU Paule de Viguier, Toulouse, France|Centre Hospitalier G�n�ral, Villeneuve Saint Georges, France",,https://ClinicalTrials.gov/show/NCT03235258,NCT03235258,
oui,NCT03235310,Prospective Observational Cohort Study on Mother to Child Transmission HIV1/HIV2 and Prevention,EPF,Recruiting,No Results Available,Mother to Child Transmission of HIV,,"Efficacy of PMTCT strategies by measuring rate of mother to child transmission of HIV|Immuno-virological response during pregnancy|Tolerance and toxicity of different kind of MTCT prophylaxis during pregnancy|Impact of different kind of MTCT prophylaxis on childbirth|Impact of different kind of MTCT prophylaxis during pregnancy on uninfected children|Risk of mother-to-child transmission of VHC, VHB and CMV co-infections","French National Agency for Research on AIDS and Viral Hepatitis|ANRS, Emerging Infectious Diseases",Female,"18 Years and older � (Adult, Older Adult)",,18200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ANRS-CO1-EPF,July 1997,March 2023,March 2023,"August 1, 2017",,"April 13, 2021","Centre Hospitalier Victor Dupuy, Argenteuil, France|H�pital Jean Verdier, Bondy, France|H�pital Antoine B�cl�re, Clamart, France|H�pital de Beaujon, Clichy, France|H�pital Louis Mourrier, Colombes, France|Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France|Centre Hospitalier Intercommunal, Creteil, France|H�pital Bic�tre, Le Kremlin Bicetre, France|CHR Jeanne de Flandres, Lille, France|H�pital de La Croix Rousse, Lyon, France|H�pital Edouard Herriot, Lyon, France|H�pital Femme M�re Enfant, Lyon, France|H�pital de la conception, Marseille, France|CHR Arnaud de Villeneuve, Montpellier, France|Centre Hospitalier Intercommunal, Montreuil, France|H�tel Dieu, Nantes, France|CHU H�pital de l'Archet II, Nice, France|Groupe Hospitalier Cochin Tarnier Port-Royal, Paris, France|Groupe Hospitalier Necker, Paris, France|Groupe Hospitalier Piti� Salp�tri�re, Paris, France|H�pital Bichat- Claude Bernard, Paris, France|H�pital Lariboisi�re, Paris, France|H�pital Robert Debr�, Paris, France|H�pital Tenon, Paris, France|H�pital Trousseau, Paris, France|Centre Hospitalier G�n�ral- H�pital Delafontaine, Saint-denis, France|H�pital Civil / H�pital de Haute Pierre, Strasbourg, France|CHU Paule de Viguier, Toulouse, France",,https://ClinicalTrials.gov/show/NCT03235310,NCT03235310,
oui,NCT03236558,The Role of the Thymus in Type I Diabetes.,TregDiab,Withdrawn,No Results Available,Type1 Diabetes,Procedure: Blood collection,"Variability of the diversity of antigen-receptors' repertoires, expressed by regulatory T cells from type I diabetes patients and healthy controls.|Ratio between TCR diversities expressed by Treg cells vs. conventional T cells.","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France|Centre National de la Recherche Scientifique, France",All,6 Years to 12 Years   (Child),Not Applicable,0,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RC31/16/8254,March 2018,March 2019,March 2019,"August 2, 2017",,"April 1, 2020","CHU de Toulouse, Toulouse, Midi-Pyrénées, France",,https://ClinicalTrials.gov/show/NCT03236558,NCT03236558,
oui,NCT03243175,Avoiding Anticoagulation After IntraCerebral Haemorrhage,A3ICH,Recruiting,No Results Available,Intracerebral Hemorrhage|Atrial Fibrillation|Microhaemorrhage,Drug: Apixaban 5 MG|Device: left atrial appendage closure,Composite of all fatal or non-fatal major cardiovascular/cerebrovascular ischaemic or haemorrhagic intracranial/extracranial events|Each individual component of the composite outcome (fatal or non-fatal major cardiovascular/cerebrovascular ischaemic or haemorrhagic intracranial/extracranial events).|Death of any cause|Modified Rankin Scale|EQ-5D (EuroQoL) Score|neuroradiological biomarkers|Complications of endovascular treatment,"University Hospital, Lille|Ministry of Health, France|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",Phase 3,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,2016_77|2017-004371-31,"January 24, 2019",December 2026,December 2026,"August 8, 2017",,"January 27, 2023","H�pital Roger Salengro, CHU, Lille, France|GHICL, Lomme, France|CH De Tourcoing, Tourcoing, France",,https://ClinicalTrials.gov/show/NCT03243175,NCT03243175,36700520;36309041;34022170
oui,NCT03245957,HDL Dysfunction During the Acute Stage of Stroke,RUSH,Unknown status,No Results Available,"Stroke, Acute",Other: Ischemic stroke|Other: Haemorrhagic stroke,Plasma MPO concentrations|HDL-MPO concentrations,"Centre Hospitalier Universitaire de la Réunion|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,112,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2016/CHU/06,"October 20, 2017",October 2019,March 2020,"August 10, 2017",,"March 7, 2019","Chu Reunion Island, Saint-Pierre, Reunion Island, Réunion",,https://ClinicalTrials.gov/show/NCT03245957,NCT03245957,
oui,NCT03246841,Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.,TUMOSPEC,Recruiting,No Results Available,Hereditary Breast and Ovarian Cancer|Mutation,Other: Genetic testing,Penetrance estimation of the mutations identified in the gene panel|The results for the whole panel sequencing will be formatted to be used by all laboratories allowing the subsequent centralisation of the data.|Relative risk will be determined by the ratio of calculated cancer incidence in mutated and non-mutated families for this gene.,"UNICANCER|Institut Curie|Gustave Roussy, Cancer Campus, Grand Paris|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years to 75 Years � (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,UC-0104/1605 - TUMOSPEC|2016-A00338-43|ONCO04,"September 21, 2017","September 30, 2023","December 31, 2023","August 11, 2017",,"March 15, 2022","Gustave Roussy, Paris, France|Institut Curie - PIGE, Paris, France",,https://ClinicalTrials.gov/show/NCT03246841,NCT03246841,
oui,NCT03249493,Monitoring Of Viral Load In Decentralised Area in Vietnam,MOVIDA-2,Completed,No Results Available,HIV/AIDS|Dried Blood Spot|Viral Load,Other: Blood sample on DBS,"Virological success at 24 months of ART|Outcomes related to DBS transfer|Outcomes related to quality of DBS samples|Outcomes related to delay concerning the return of viral load result|Outcomes related to ability of DBS to provide viral load result|Outcomes related to ability of DBS to provide HIV drug resistance result|Impact of viral load result on second-line ART initiation|Impact of viral load result on second-line ART initiation in term of delay|virological success at 6 and at 12 months of ART|Virological failure at 6, 12 and 24 months of ART|HIV drug resistance in case of virological failure at 6, 12 and 24 months of ART|Description of HIV drug resistance in case of virological failure at 6, 12 and 24 months of ART|Baseline HIV drug resistance in case of virological failure|Baseline HIV drug resistance|Mortality|Attrition","Institut Pasteur|Global Fund|National Institute of Hygiene and Epidemiology, Vietnam|Hanoi University of Public Health|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,584,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2016-001,"August 15, 2017","August 1, 2020","September 1, 2020","August 15, 2017",,"May 20, 2022","Yen Bai medical center, Yen Bai, Vietnam",,https://ClinicalTrials.gov/show/NCT03249493,NCT03249493,36802388
oui,NCT03256084,Tumoral Circulating Cells and Colorectal Cancer Progression,,Recruiting,No Results Available,Colorectal Cancer,Procedure: Blood and tumor samples,Evaluation of CTC features,"Institut Paoli-Calmettes|Institut National de la Santé Et de la Recherche Médicale, France|Beckman Coulter, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CTC-Côlon-IPC 2015-020,"July 17, 2017",May 2022,May 2025,"August 21, 2017",,"May 6, 2021","Institut Paoli Calmettes, Marseille, France",,https://ClinicalTrials.gov/show/NCT03256084,NCT03256084,
oui,NCT03256422,Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients,QUATUOR,Unknown status,No Results Available,HIV Infections,Drug: Treatment discontinuation,"Proportion of patients with therapeutic success at Week 48.|Proportion of patients with therapeutic success at Week 96|Virological success|Number of virological "" blips ""|Percentage of patients with a viral load signal detected|Proportion of patients with acquisition of drugs resistance mutations in case of virological failure detected by Sanger and by next generation sequencing|Frequency of minority resistant variants archived in DNA at Week 0 and their impact on virological failure (2 consecutive VL> 50 copies / mL) and on the acquisition of drugs resistance mutations|Evolution of ultra sensitive viral load and total DNA in the peripheral blood mononuclear cells at Week 0, Week 24, Week 48 and Week 96; evolution of viral genotypic sequence between Week 0, Week 48 and Week 96 (subgroup of 120 patients)|Description of the factors associated with virological rebound (viral load >50 cp/mL).|Evolution of T cluster of differentiation 4 and cluster of differentiation 8 cells count, and T cluster of differentiation 4 /cluster of differentiation 8 ratio|Evolution of fasting metabolic parameters|Evolution of inflammation and immune activation parameters|HIV RNA viral load in semen|Residual plasmatic concentrations of the third antiretroviral agent|Residual plasmatic concentrations of tenofovir (TDF or TAF)|Residual intracellular concentrations of the third antiretroviral agents|Treatment adherence|Quality of life|Patient satisfaction|Pharmaco-economic aspects of the strategy|Median time to virologic failure|Frequency of grade 3 or more adverse events, adverse effects, drug-modifying adverse events, drug-related adverse events and serious adverse events (SAE)","ANRS, Emerging Infectious Diseases|IMEA Leon M'Ba Foundation|Unit 1136 INSERM, Faculty of medecine, University Pierre and Marie Curie",All,"18 Years and older � (Adult, Older Adult)",Phase 3,640,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 170 - QUATUOR,"September 7, 2017",December 2019,December 2020,"August 22, 2017",,"February 5, 2018","CHU Pointe-�-Pitre, Pointe-�-Pitre, Guadeloupe, France|H�pital La Meynard Zobda Quitman, Fort-de-France, Martinique, France|Centre hospitalier Victor Dupouy, Argenteuil, France|H�pital Henri Duffaut, Avignon, France|CHRU Jean Minjoz, Besan�on, France|Avicenne, Bobigny, France|Jean Verdier, Bondy, France|H�pital Saint-Andr�, Bordeaux, France|H�pital Pellegrin, Bordeaux, France|H�pital Ambroise Par�, Boulogne-Billancourt, France|H�pital de la C�te de Nacre, Caen, France|H�pital Louis Pasteur, Chartres, France|Antoine Becl�re, Clamart, France|H�pital Gabriel Montpied, Clermont-Ferrand, France|Centre hospitalier sud francilien, Corbeil-Essonnes, France|CHI de Cr�teil, Cr�teil, France|H�pital Henri Mondor, Cr�teil, France|H�pital du Bocage, Dijon, France|H�pital Raymond Poincar�, Garches, France|H�pital Michallon, Grenoble, France|Bic�tre, Kremlin Bic�tre, France|CHD de la Roche Sur Yon, La Roche-sur-Yon, France|Centre Hospitalier du Mans, Le Mans, France|Institut hospitalier franco-britannique, Levallois-Perret, France|H�pital Dupuytren, Limoges, France|H�pital de la Croix Rousse, Lyon, France|H�pital Edouard Herriot, Lyon, France|H�pital Sainte Marguerite, Marseille, France|H�pital Europ�en, Marseille, France|H�pital Gui de Chauliac, Montpellier, France|H�pital Emile M�ller, Mulhouse, France|H�pital de l'H�tel Dieu, Nantes, France|H�pital de l'Archet, Nice, France|H�pital Car�meau, N�mes, France|H�pital de La Source, Orl�ans, France|H�pital Saint-Antoine, Paris, France|H�pital Necker, Paris, France|H�pital Bichat, Paris, France|H�pital de l'H�tel Dieu, Paris, France|H�tel-Dieu, Paris, France|H�pital Saint-Louis, Paris, France|Lariboisi�re, Paris, France|H�pital Piti�-Salp�tri�re, Paris, France|H�pital Europ�en Georges Pompidou, Paris, France|Tenon, Paris, France|Centre Hospitalier de Perpignan, Perpignan, France|Centre Hospitalier Ren� Dubos, Pontoise, France|Centre hospitalier Annecy Genevois, Pringy, France|H�pital Robert Debr�, Reims, France|H�pital Pontchaillou, Rennes, France|Centre Hospitalier de Saint-Brieuc, Saint-Brieuc, France|H�pital Delafontaine, Saint-Denis, France|Centre Hospitalier G�n�ral de Saint Nazaire, Saint-Nazaire, France|H�pital Nord, Saint-�tienne, France|H�pital Civil, Strasbourg, France|H�pital Foch, Suresnes, France|H�pital La Grave, Toulouse, France|H�pital Purpan, Toulouse, France|H�pital Gustave Dron, Tourcoing, France|H�pital Bretonneau, Tours, France|H�pital de Brabois, Vandoeuvre les Nancy cedex, France|H�pital Andr� Mignot, Versailles, France|Centre Hospitalier Intercommunal, Villeneuve-Saint-Georges, France",,https://ClinicalTrials.gov/show/NCT03256422,NCT03256422,35120640
oui,NCT03272230,"Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System",ECOCAPTURE,Unknown status,No Results Available,Apathy|Frontotemporal Dementia|Parkinson Disease|Depressive Symptoms,Behavioral: ECOCAPTURE|Behavioral: Cognitive and Behavioral experimental tasks|Diagnostic Test: Neuropsychological assessment|Behavioral: ICM_APATHY_TASKS|Other: MRI|Biological: Neurohormonal mechanisms|Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease,Occurrence of each behavior from the ethogram|Frequency of each behavior from the ethogram|Duration of each behavior from the ethogram|Number of different behaviors|Activity classes|Body positions|Energy expenditure|MET|Steps|Acceleration intensity|Pupil Diameter x|Pupil Diameter y|ICM_APATHY_TASKS|MMSE|MATTIS|NART|BREF (FAB english)|HAYLING|HAD|Gray matter volume|White matter volume|Cerebral Spinal Fluid volume|Brain lesion localization|IL-6|Leptin|Adiponectin|Insulin|C-Peptide|FPG|HbA1C|K+|Uric acid|Creatinine|Total Protein|CRP|AST|ALT|GGT|Cholesterol|Triglycerides|HDL cholesterol|LDL cholesterol|Glycerol|FFAs|TSH|DAS|STARKSTEIN (SAS)|MADRS|EBI|ACDD|QUIP|BIS-11|Mini-SEA|STROOP|ECMP|QUIP-RS,"Institut National de la Santé Et de la Recherche Médicale, France",All,"40 Years to 85 Years   (Adult, Older Adult)",Not Applicable,135,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C16-87|2017-A00416-47,"September 6, 2017","July 31, 2019","February 28, 2022","September 5, 2017",,"March 22, 2019","ICM / Pitié-Salpêtrière Hospital AP-HP / CIC, Paris, France",,https://ClinicalTrials.gov/show/NCT03272230,NCT03272230,
oui,NCT03277339,Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders,Insula-TOP,Completed,No Results Available,Generalized Anxious Disorders,Drug: Paroxetine|Other: Thermal cure,"Decrease Insula activity during a resting state task|Changes of HAM-A score between day 1 and day 24.|Sensibility non conscientious to emotional interference in lexical task and in color identification task|Modulation of electrodermal response during presentation of predictive stimuli on aversive images and its links to the subjective view of emotional state|Modulation of electrodermal response during presentation of predictive stimuli on aversive images and insula activation|Lost of significant correlation (Day 24) between HAM-A score, introspective acuity and insula hyperactivation|Evolution (Day 1 and Day 24) of the correlation between HAM-A global score and 1- the measure of heartbeat 2- emotional reactivity during aversive images task.|Difference (Day 1 and Day 24) of correlations between the symptoms severity and the activation of insula cortex during 1-aversive images task, 2-heartbeat measure task.|Evaluation of efficacy of the thermal cure Day 56 using HAM-A score","Centre Hospitalier Henri Laborit|Association Francaise pour la Recherche Thermale|Les thermes de Saujon|Poitiers University Hospital|Centre National de la Recherche Scientifique (CeRCA, umr 7295), France",All,"18 Years to 75 Years � (Adult, Older Adult)",Phase 4,52,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,InsulaTOP,"January 19, 2017","January 8, 2020","February 5, 2020","September 11, 2017",,"October 12, 2022","Centre Hospitalier Henri Laborit, Poitiers, France|Les thermes de Saujon, Saujon, France",,https://ClinicalTrials.gov/show/NCT03277339,NCT03277339,
associ�,NCT03278977,"Apparent Life Threatening Events, Sudden Infant Death Syndrome and Muscarinic Receptors",iALTE,Recruiting,No Results Available,Apparent Life-Threatening Event in Infants Under One Year of Age,Biological: Blood sample for specific analyzes,Muscarinic M2 receptor mRNA expression in blood|Acetylcholinesterase mRNA expression in blood,"University Hospital, Strasbourg, France|Groupement Interr�gional de Recherche Clinique et d'Innovation Est",All,28 Days to 12 Months � (Child),Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,6432,"September 15, 2018",December 2022,December 2023,"September 12, 2017",,"June 30, 2022","Pediatric Intensive Care unit/Emergency unit - Besan�on University Hospital, Besan�on, France|Pediatric Intensive Care Unit - Brabois Hospital - Nancy University Hospital, Nancy, France|Pediatric unit - Maison Blanche Hospital - Reims University Hospital, Reims, France|Pediatric intensive care unit/ Pediatric unit- Strasbourg University Hospital - Hautepierre Hospital, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT03278977,NCT03278977,
oui,NCT03285230,The French E3N Prospective Cohort Study,E3N,"Active, not recruiting",No Results Available,Breast Cancer|Colo-rectal Cancer|Parkinson Disease|Asthma|Diabetes|Inflammatory Bowel Diseases|Melanoma|Endometriosis|Thyroid Cancer|Hypertension|Endometrial Cancer|Crohn Disease|Depression|Cardiovascular Diseases,,Anthropometric measurements|Educational level|Professional activity|Age at cessation of activity|Menstrual factors|Reproductive history|Menopause|Hormonal Treatments|Tobacco consumption|Alcohol consumption|Physical activity|Diet questionnaire|Family history of diseases|Medication use|Medical and surgical history|Mental Health|Health outcomes,"Institut National de la Sant� Et de la Recherche M�dicale, France|Universit� Paris-Sud|Gustave Roussy, Cancer Campus, Grand Paris|Ligue contre le cancer, France",Female,"40 Years and older � (Adult, Older Adult)",,100000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C 95-01,"June 15, 1990","November 15, 1991","December 15, 2025","September 15, 2017",,"September 19, 2017",,,https://ClinicalTrials.gov/show/NCT03285230,NCT03285230,36872016;36726032;35216589;34274072;34236437;33531438;32542873;31380561
oui,NCT03285789,Dyslexics' Visual Attention Field,,"Active, not recruiting",No Results Available,Dyslexia,Other: Passing tests in dyslexics with reduced eva|Other: Passing tests in controls,Respond time in visual search in different condition of view (full view or reduced view) with separable feature.|respond time in function of the distractors' number|visual exploration of the scene|visuo-spatial perception|visual attention span (VAS),Hospices Civils de Lyon,All,3 Years to 12 Years � (Child),Not Applicable,1460,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,69HCL17_0333|2017-A02525-48,"July 25, 2018","October 21, 2026","October 21, 2026","September 18, 2017",,"July 26, 2022","U1028 INSERM - CNRS UMR 5292 Equipe ImpAct, Bron, France",,https://ClinicalTrials.gov/show/NCT03285789,NCT03285789,
oui,NCT03285828,Motivational Interviewing Training for Medical Students: a Pilot Pre-post Study,FEMEM,Completed,No Results Available,"Change; Personality, Due to General Medical Condition",Behavioral: motivationnal interviewing training,GLOBAL MITI scores (MITI = Motivational Interviewing Treatment Integrity version 3.1.1)|perception of student's empathy by the caregivers|self-efficacy of students to engage in a patient-centred relationship|student's satisfaction with the odds of achieving the target goal.,Bicetre Hospital|INSERM SC10-US19|University of Paris 5 - Rene Descartes,All,"Child, Adult, Older Adult",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,FEMEM,"April 4, 2016","June 30, 2016","June 30, 2016","September 18, 2017",,"September 18, 2017",,,https://ClinicalTrials.gov/show/NCT03285828,NCT03285828,
oui,NCT03286387,Contextual Associations During Episodic Recall of Everyday or Virtual Reality,BREAL,Recruiting,No Results Available,Healthy Volunteers,Other: Functional brain imaging without any contrast agent,BOLD cerebral response to contextual recall in medial temporal lobe|BOLD cerebral response to contextual recall in prefrontal cortex|Pattern of gaze fixation during episodic encoding and cerebral activity during recall,Hospices Civils de Lyon,All,18 Years to 40 Years � (Adult),Not Applicable,450,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL17_0404|2017-A02558-45,"October 11, 2018","November 11, 2023","November 11, 2023","September 18, 2017",,"January 5, 2023","U1028 INSERM - CNRS UMR 5292 Equipe ImpAct, Bron, France",,https://ClinicalTrials.gov/show/NCT03286387,NCT03286387,
oui,NCT03286686,Sensori-motor and Perceptual Functions of the PPC.,PPCfonctions,Recruiting,No Results Available,Healthy Volunteers|Optic Ataxia,Behavioral: point targets|Behavioral: tactile stimulation|Behavioral: visual images,response error - number of pointing error|response error -measure of reaction times|response error - percentage of right responses,Hospices Civils de Lyon,All,"18 Years to 75 Years � (Adult, Older Adult)",Not Applicable,160,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL17_0341|2017-A02562-51,"February 22, 2018","February 22, 2029","February 22, 2029","September 18, 2017",,"February 14, 2023","U1028 INSERM - CNRS UMR 5292 Equipe ImpAct, Bron, France",,https://ClinicalTrials.gov/show/NCT03286686,NCT03286686,
oui,NCT03289611,Preeclampsia Ratio (sFlt-1/PlGF),PRECOG,Completed,No Results Available,Preeclampsia,Biological: sFlt-1 / PlGF ratio,number of patients hospitalised for more than 24 hours|Maternal and fetal morbidity|Maternal morbidity|Severe Maternal morbidity (Composite outcome )|Number of days between randomisation and delivery|Mode of delivery|Gestational age|Birth weight centile|Fetal death|Prematurity before 37 WG|Prematurity before 34 WG|Prematurity before 32 WG|Perinatal morbidity (Composite outcome)|Severe Perinatal morbidity (Composite outcome)|Costs|Satisfaction form,Assistance Publique - H�pitaux de Paris|INSERM CESP1018,Female,"18 Years and older � (Adult, Older Adult)",Not Applicable,84,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,P161101,"April 26, 2018","August 27, 2020","August 27, 2020","September 21, 2017",,"August 3, 2021","CHU Cochin, Maternit� Port Royal, Paris, France",,https://ClinicalTrials.gov/show/NCT03289611,NCT03289611,
non,NCT03290261,Hypnosis as a Therapeutic Tool in Patients With Reccurent Cystitis,HYPNOCYST,Unknown status,No Results Available,Reccurent Cystitis,Other: Hypnosis,Score at HAD Scale|Score at Pain evaluation scale|Evolution of HAD scale score|Evolution of Pain evaluation scale score|Patient satisfaction|Ability to manage the symptoms|Sexuality evaluation|Consumption of heath care,Centre Hospitalier Universitaire de Nice,Female,"18 Years and older � (Adult, Older Adult)",Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-PP-10,"August 8, 2017","August 1, 2019","August 1, 2019","September 21, 2017",,"August 6, 2018","H�pital Archet, Nice, France",,https://ClinicalTrials.gov/show/NCT03290261,NCT03290261,
oui,NCT03290755,Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux,HEPCSEX,Completed,No Results Available,Human Immunodeficiency Virus (HIV)|Hepatitis c,Behavioral: semi-directed interviews,"Analyse sexual behaviours among HIV positive MSM in Bordeaux, through semi-directed interviews|Identifying socio-sexual networks through phylogenetic analysis|Describing the natural history of sexual hepatitis C in HIV positive MSM","University Hospital, Bordeaux",Male,"18 Years and older � (Adult, Older Adult)",,29,Other,Observational,Observational Model: Other|Time Perspective: Prospective,CHUBX 2017/01,"November 8, 2017","March 13, 2018","March 13, 2018","September 25, 2017",,"November 14, 2018","Service des Maladies Infectieuses et Tropicales, H�pital Pellegrin, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT03290755,NCT03290755,
oui,NCT03296202,"Risk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV",AquiVIH-NA,Recruiting,No Results Available,HIV Infections|Antiretroviral Agents,,Socio-demographic characteristics of people living with the HIV|HIV infection characteristics of people living with the HIV|comorbidities of people living with the HIV|co-infections of people living with the HIV|Therapeutics description|virological responses,"University Hospital, Bordeaux|National Agency for Research on AIDS and Viral Hepatitis (ANRS)|Institut National de la Santé Et de la Recherche Médicale, France|French Ministry of Health through the COREVIH Aquitaine",All,"18 Years and older   (Adult, Older Adult)",,7200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHUBX 2016/04,"July 18, 2017",July 2025,July 2025,"September 28, 2017",,"September 5, 2021","service de médecine interne - CH d'Agen, Agen, France|Médecine interne - CH d'Angoulême, Angoulême, France|service de maladies infectieuses - CH de la Côte Basque, Bayonne, France|service de médecine inter et maladies infectieuses - Hopital Saint André, Bordeaux, France|service de médecine interne et maladies infectieuses - Hôpital Saint-André, Bordeaux, France|service de maladies infectieuses et médecine tropicale - Hôpital Pellegrin, Bordeaux, France|service de maladies infectieuses et médecine tropicale - Hôpital Pellegrin, Bordeaux, France|service de maladies infectieuses et médecine tropicale - Hôpital Pellegrin, Bordeaux, France|Service D'Urgences Pédiatriques, Bordeaux, France|médecine interne - CH de Châtellerault, Châtellerault, France|service de médecine interne et maladies infectieuses - CH de Dax, Dax, France|Médecine Interne - CH de Jonzac, Jonzac, France|service de médecine interne - CH d'Arcachon, La Teste-de-Buch, France|service de médecine interne - CH de Libourne, Libourne, France|service de médecine interne - CH de Mont de Marsan, Mont-de-Marsan, France|service de médecine interne - CH d'Orthez, Orthez, France|service de médecine interne et maladies infectieuses - CH de Pau, Pau, France|service de médecine interne et maladies infectieuses - CH de Périgueux, Perigueux, France|service de médecine interne et maladies infectieuses - Groupe hospitalier Sud, Pessac, France|Médecine interne et Maladies Infectieuses - CHU de Poitiers, Poitiers, France|Médecine interne - CH de Royan, Royan, France|Médecine Interne - CH de Saint-Jean-D'Angely, Saint-Jean-d'Angély, France|Médecine Interne - CH de Saintonge, Saintes, France|service de maladies infecteieuses - CH Saint-Cyr, Villeneuve sur Lot, France",,https://ClinicalTrials.gov/show/NCT03296202,NCT03296202,36624391;32650781;31850847;29880467
oui,NCT03296384,Influence of Environmental Factors and Schizophrenia,Envschi,Unknown status,No Results Available,Patients With Schizophrenia|Relatives,Other: Clinical and environmental evaluation,"The prevalence of schizophrenia (according to Diagnostic and Statistical Manual of Mental Disorders (DSM IV)) will be estimated from the census population-unit (unit TRIRIS INSEE)|The frequency of populational risk factors (insecurity, disorganization and density of migrants) will be assessed from the variables of INSEE|The frequency of individual risk factors (migration, cannabis, seasonality of birth, childhood trauma, social environment) will be measured from standardized assessments","Assistance Publique - H�pitaux de Paris|Institut national d'�tude d�mographique (INED)|CPN (INSERM U894) CH Sainte-Anne - Paris|Institut National de la Sant� Et de la Recherche M�dicale, France|Fondation FondaMental|University Hospital, Clermont-Ferrand",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,600,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,P100134,March 2014,November 2018,November 2018,"September 28, 2017",,"September 28, 2017","Henri Mondor Hospital, Creteil, France",,https://ClinicalTrials.gov/show/NCT03296384,NCT03296384,
oui,NCT03304028,MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique,MucoExocet,Terminated,No Results Available,Cystic Fibrosis,Device: Connected Devices for 3 months|Behavioral: Educationnal Intervention|Device: Connected Devices for 12 months|Other: Interviews|Behavioral: Refusal Questionnaires,Exacerbations (ExR) concordance|Hospital Anxiety and Depression scale (HADS)|Cystic Fibrosis Questionnaire-Revised (CFQ-R)|Medical data : FEV1|Medical data: Weight|Medical data: Height|Medical data: Heart rate|Medical data: Oxygen saturation|Physiological parameters with connected devices (PP) : FEV1|Physiological parameters with connected devices (PP) : Heart rate|Physiological parameters with connected devices (PP) : Oxygen saturation|Physiological parameters with connected devices (PP) : Weight|Physiological parameters with connected devices (PP) : Duration of sleep|Physiological parameters with connected devices (PP) : Physical activity|Perceptions identified by patients (PRP)|Traitements Number|Traitements Duration|Respiratory symptoms|Exacerbations Number|Exacerbations Timing|Patients and professionals interviews,"Institut National de la Santé Et de la Recherche Médicale, France|Fondation pour la Recherche Médicale|Vertex Pharmaceuticals Incorporated|Fondation Ildys",All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,36,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,C16-119|2017-A00723-50,"October 20, 2017","June 18, 2020","June 18, 2020","October 6, 2017",,"June 13, 2022","CF adults center - Hopital Albert Calmette, Lille, France|CF adults center - Institut du Thorax, Nantes, France|CF pediatrics center - Hopital Mère-Enfant, Nantes, France|CF pediatrics center - Hopital Robert Debré, Paris, France|CF adults and pediatrics center - American Memorial Hospital, Reims, France|CF adults and pediatrics center- Perharidy, Roscoff, France|CF pediatrics center - Hopital André Mignot, Versailles, France",,https://ClinicalTrials.gov/show/NCT03304028,NCT03304028,34406124
oui,NCT03306251,National Cohort of Children Born to HIV-positive Mothers,EPF,Recruiting,No Results Available,Mother to Child Transmission of HIV,,Efficacy of PMTCT strategies by measuring rate of mother to child transmission of HIV|Immuno-virological response during pregnancy|Tolerance and toxicity of different kind of MTCT prophylaxis during pregnancy|Impact of different kind of MTCT prophylaxis on childbirth|Impact of different kind of MTCT prophylaxis during pregnancy on uninfected children,"ANRS, Emerging Infectious Diseases",Female,"18 Years and older � (Adult, Older Adult)",,5200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ANRS-CO11-EPF,June 2005,March 2023,March 2023,"October 11, 2017",,"April 30, 2021","CHU H�pital Nord, Amiens, France|Centre Hospitalier Universitaire, Angers, France|Centre Hosipitalier, Annecy, France|Centre Hospitalier Robert Ballanger, Aulnay, France|Centre Hospitalier G�n�ral de Bastia, Bastia, France|Centre Hospitalier de la C�te Basque, Bayonne, France|CHRU Saint Jacques, Besan�on, France|Groupe Hospitalier Pellegrin, Bordeaux, France|Centre Hospitalier R�gional Universitaire de Brest, Brest, France|Centre hospitalier de B�ziers, B�ziers, France|CHRU Clemenceau, Caen, France|Centre Hospitalier William Morey, Chalon sur Saone, France|Centre Hospitalier G�n�ral, Creil, France|CHRU de Dijon, Dijon, France|Centre Hospitalier G�n�ral, Evreux, France|Centre Hospitalier G�n�ral, Fontainebleau, France|Centre Hospitalier Les Oudayries, La Roche sur Yon, France|Centre Hospitalier de Lagny, Lagny sur Marne, France|H�pital Andr� Mignot, Versailles, Le Chesnay, France|Centre Hospitalier Universitaire, Limoges, France|Centre Hospitalier G�n�ral, Longjumeau, France|Centre Hospitalier Bretagne Sud, Lorient, France|Centre Hospitalier Fran�ois Quesnay, Mantes la Jolie, France|Centre Hospitalier de Meaux, Maux, France|Centre Hospitalier Marc Jacquet, Melun, France|Centre Hospitalier Intercommunal, Montfermeil, France|CHU Nancy, Nancy, France|CHU Caremeau, N�mes, France|Centre Hospitalier R�gional, Orl�ans, France|Centre Hospitalier G�n�ral, Orsay, France|Bon secours-Saint Joseph, Paris, France|CHG Mar�chal Joffre, Perpignan, France|Centre Hospitalier Intercommunal, Poissy, France|Centre Hospitalier Ren� Dubos, Pontoise, France|Centre Hospitalier L�on Binet, Provins, France|H�pital Laennec, Quimper, France|CHR American Memorial Hospital, Reims, France|CHU Pontchaillou, Rennes, France|H�pital Charles Nicolle, Rouen, France|Centre Hopsitalier Yves Le Foll, Saint Brieuc, France|H�pital Bellevue, Saint Etienne, France|Centre hospitalier, Saint Julien, France|Centre Hospitalier de Saint Nazaire-Cit� Sanitaire, Saint Nazaire, France|H�pital de Saint-Martin, Saint-Martin, France|H�pital Font Pr�, Toulon, France|CHRU de Tours, Tours, France|Centre Hospitalier Bretagne Atlantique, Vannes, France|Centre Hospitalier, Vernon, France|Centre Hospitalier Intercommunal, Villeneuve Saint Georges, France|CHG de Cayenne, Cayenne, French Guiana|CHU Pointe � Pitre, Les Abymes, Pointe � Pitre, Guadeloupe|H�pital Victor Fouche, Fort de France, Martinique",,https://ClinicalTrials.gov/show/NCT03306251,NCT03306251,
oui,NCT03311152,Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis,SEPT9-CROSS,Recruiting,No Results Available,Hepatocellular Carcinoma|Cirrhosis,"Diagnostic Test: ""Epi proColon 2.0 CE"" test from Epigenomics, Inc (Berlin, Germany)",Presence of hepatocellular carcinoma.|Presence of early hepatocellular carcinoma. Early hepatocellular carcinoma will be defined as a tumor smaller than 30 mm according to Kudo M (Liver Cancer. 2013 2:69-72).,"Central Hospital, Nancy, France|Institut National de la Sant� Et de la Recherche M�dicale, France|Groupement Interr�gional de Recherche Clinique et d'Innovation|Epigenomics, Inc",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,530,Other|Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic",2017-A01885-48,"February 12, 2018","February 12, 2023","February 12, 2023","October 17, 2017",,"June 9, 2022","University Hospital of Nancy (CHRU de Nancy), Vandoeuvre-l�s-Nancy, France",,https://ClinicalTrials.gov/show/NCT03311152,NCT03311152,
oui,NCT03311178,Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period,NeoCirc-001,Terminated,No Results Available,Shock,Drug: Dobutamine,"Mortality, or intraventricular haemorrhage (IVH) grades 3 or 4, or cystic and non-cystic periventricular leukomalacia (PVL), or porencephalic cysts, ventriculomegaly, or cerebellar haemorrhage.|Half-life of the neonatal formulation of dobutamine.|Arterial blood pressure|Capillary refill time|Urine output|Blood lactate concentration|Base excess|cerebral regional tissue oxygen saturation (rStO2)|Background pattern|Superior vena cava flow|Right cardiac output|Cerebral fractional oxygen extraction (FOE)|Interburst interval (IBI)|Discontinuity|Amplitude|Presence of abnormal transients|Synchrony|Mortality|Intraventricular haemorrhage 2-4|Survival free of severe brain injury|Hypotension|Hypertension|Necrotizing enterocolitis|Patent ductus (PDA)|Retinopathy of prematurity|Chronic lung disease|Oxygen-dependency at discharge|early infection|Nosocomial infection","Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz|Hospital Universitario La Paz|Brighton and Sussex University Hospitals NHS Trust|University of Luebeck|Servicio Vasco de Salud Osakidetza, Spain|University of Liverpool|Vest Children´s Hospital, Germany|Datteln University Witten-Herdecke|Iuliu Hatieganu University of Medicine and Pharmacy|Semmelweis University|University of Pecs|Gazi University|Tufts Medical Center|Hannover Medical School|Onorach Clinical Dundee, Scotland|Proveca Limited Daresbury, England|Institut National de la Santé Et de la Recherche Médicale, France",All,up to 72 Hours   (Child),Phase 1|Phase 2,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Neocirculation 001,"May 30, 2014","October 13, 2015","October 10, 2017","October 17, 2017",,"October 17, 2017","La Paz University Hospital, Department of Neonatology, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03311178,NCT03311178,
oui,NCT03314155,Cerebral Neuroinflammation During Major Depressive Episode,InflaDep,Recruiting,No Results Available,Depressive Disorder,Diagnostic Test: Cerebral neuroinflammation evaluation,distribution pattern of neuroinflammation in Positron Emission Tomography (PET) data|distribution pattern of neuroinflammation in PET data across all groups|patients with depressive symptoms and neuroinflammation (i.e. PET data).|patients with neuroinflammation (i.e. PET analysis) and MRI parameters for functional and structural integrities.|patients with neuroinflammation (i.e. PET analysis) and biological markers of neuroinflammation (i.e. cytokines).,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,25 Years to 55 Years   (Adult),Not Applicable,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RC31/16/8918|2017-001478-40,"December 7, 2018",January 2024,January 2024,"October 19, 2017",,"March 30, 2023","Hôpital de Psychiatrie, Toulouse, Midi-Pyrénées, France|CHU Bordeaux, Bordeaux, Nouvelle Aquitaine, France|CHRU Lapeyronie, Montpellier, Occitanie, France|Clinique Psychiatrique Universitaire CHRU Tours, Tours, Val-De-Loire, France",,https://ClinicalTrials.gov/show/NCT03314155,NCT03314155,30087626
oui,NCT03320902,Sudden Death Counselling and Its Impact on Family Members of Sudden Death Victims,SUIVIPROCHE,Recruiting,No Results Available,Sudden Death,Behavioral: Sudden death counselling,"Hospital Anxiety and Depression Scale, sub-section Depression (HADSD) >10|Hospital Anxiety and Depression Scale, sub-section Anxiety (HADSA) >10|Impact of Event Scale-revised score (IES-R) ? 33|Medical Outcome Study Short Form Health Survey (SF-12)|Visits number to the general physician|Drug use|Visits number to the psychologist and/or psychiatrist|Relatives number integrating a grief recovery support group|Feeling of the sudden death consultation or not by the relatives|Proportion of identified causes of sudden death|Proportion of familial screening",Assistance Publique - H�pitaux de Paris|INSERM U970,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,620,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,K160905|2017-A0098-45,"January 18, 2018","January 18, 2024","May 18, 2024","October 25, 2017",,"December 28, 2022","H�pital Necker-Enfants malades, Paris, France",,https://ClinicalTrials.gov/show/NCT03320902,NCT03320902,
oui,NCT03323281,Neuropsychiatric Factors,Diapepsy,Recruiting,No Results Available,Diabetes,Other: Neuropsychological assessments,Measuring memory,"University Hospital, Montpellier|Inserm U1061 : Neuropsychiatry",All,"45 Years and older � (Adult, Older Adult)",,266,Other,Observational,Observational Model: Other|Time Perspective: Prospective,UF9805,"December 7, 2019","December 7, 2024","June 7, 2025","October 26, 2017",,"December 21, 2021","Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT03323281,NCT03323281,
anrs,NCT03324633,Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV,CO13Hepavih,Unknown status,No Results Available,HIV|Hepatitis C,,Improve effectiveness and quality of medical care in Hepatitis C in HIV patients,"ANRS, Emerging Infectious Diseases|Bristol-Myers Squibb|GlaxoSmithKline|Merck Serono International SA|Roche Pharma AG|Schering-Plough",All,"18 Years and older � (Adult, Older Adult)",,1850,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,ANRS CO13 Hepavih cohort,June 2005,September 2017,December 2018,"October 30, 2017",,"October 30, 2017",,,https://ClinicalTrials.gov/show/NCT03324633,NCT03324633,34212476;32798585;30570526
oui,NCT03325088,Assessing the Expression and the Activity of Rac1 Protein in the Airway Smooth Muscle of Asthmatic Patient,NaRacAS,Recruiting,No Results Available,Asthma,Procedure: Bronchial endoscopy|Procedure: Bronchial biopsies|Procedure: Bronchial alveolar enema,"Activity level and expression of Rac1 protein in airway smooth muscle cells of asthmatics vs non asthmatics samples|Assessing any difference between activity level and expression of Rac1 in airway smooth muscle cells of severe versus non severe asthmatic patients.|Assessing any correlation between Rac1-GTP/Rac1 ratio signal, pulmonary function tests and clinical data",Nantes University Hospital|L'institut du thorax - INSERM UMR 1087 / CNRS UMR6291 - IRS-Universit� de Nantes|IRSR-PL : Institut de Recherche en Sant� Respiratoire des Pays de La Loire,All,"18 Years to 70 Years � (Adult, Older Adult)",Not Applicable,42,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RC16_0469,"March 5, 2019",March 2024,April 2024,"October 30, 2017",,"February 28, 2023","University Hospital, Nantes, France",,https://ClinicalTrials.gov/show/NCT03325088,NCT03325088,
oui,NCT03327493,Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO,ADRECMO,Recruiting,No Results Available,"Shock, Cardiogenic|Extra-Corporeal-Life-Support ( ECLS)|Autonomic Nervous System Diseases|Inflammation",Diagnostic Test: Biological,"Change in Cytokines (plasma TNF α, INF γ, IL4, IL 12, IL1 IL 6 IL 10)|Change in hemodynamic parameters|Cardiac output variation during a weaning ECLS procedure|Mortality|Change in TH1 and TH2 pattern","Central Hospital, Nancy, France|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2016-A00707-44,"October 10, 2017",March 2022,June 2022,"October 31, 2017",,"February 25, 2022","CHRU Nancy, Nancy, France",,https://ClinicalTrials.gov/show/NCT03327493,NCT03327493,
oui,NCT03331068,French Validation of the Memorial Anxiety Scale for Patients With Prostate Cancer.,,Completed,No Results Available,Prostate Cancer,Behavioral: online questionnaire of MAX-PC,Total anxiety score assessed by the Memorial Anxiety Scale for Prostate Cancer (MAX-PC scale)|Quality of Life (QoL) scores assessed by the SF-12 scale|Anxiety score assessed by the HADS scale|Depression score assessed by the HADS scale,"Institut Paoli-Calmettes|Institut National de la Santé Et de la Recherche Médicale, France",Male,"18 Years and older   (Adult, Older Adult)",,180,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,MAC-PROSTATE-IPC 2016-009,"April 26, 2016","November 1, 2017","November 1, 2017","November 6, 2017",,"November 7, 2017","Institut Paoli Calmettes, Marseille, France",,https://ClinicalTrials.gov/show/NCT03331068,NCT03331068,
oui,NCT03335644,The NutriNet-Santé Study,,Recruiting,No Results Available,"Diet, Food, and Nutrition|Exercise|Diseases Category|Cohort Studies|Adult|Anthropometry|Humans|Internet|Surveys and Questionnaires|Mortality",,"cancers using health questionnaire and/or the website for declaration of major health events|CVD using health questionnaire and/or the dedicated website for declaration of major health events|type 2 diabetes using health questionnaire and/or the website for declaration of major health events|hypertension using health questionnaire and/or the website for declaration of major health events|metabolic syndrome using health questionnaire and/or the website for declaration of major health events|depression using health questionnaire and/or the website for declaration of major health events|migraine using health questionnaire and/or the website for declaration of major health events|rheumatoid arthritis using health questionnaire and/or the website for declaration of major health events|cognitive decline using health questionnaire and/or the website for declaration of major health events|quality of life using the SF-36 questionnaire|Weight using anthropometric questionnaire|Height using anthropometric questionnaire|Mortality|Mental health (incl. anxious disorders, sleep disorders, addictive behaviors, eating disorders)|SARSCOV-2 (Covid 19) infection|multi-morbidity (mental and physical health)","University of Paris 13|Institut National de la Santé Et de la Recherche Médicale, France|Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement|Conservatoire national des Arts et Métiers",All,"15 Years and older   (Child, Adult, Older Adult)",,170000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NutriNet-Santé,"May 11, 2009","May 11, 2029","May 11, 2029","November 8, 2017",,"July 26, 2021","EREN, Bobigny, Seine Saint Denis, France",,https://ClinicalTrials.gov/show/NCT03335644,NCT03335644,37019361;36649248;36638072;36231817;36231670;36124645;36055962;36050684;35918246;35694168;35641193;35614475;35324894;34844606;34491326;34261955;34224572;34215307;34212836;33946586;33675635;33558350;33389209;33167995;33121725;32936868;32853224;32734347;32692345;32369545;31887145;31841598;31725157;31340870;31292122;31152670;31142457;30596882;30477513;30301763;29544552;29486784;29444771
oui,NCT03335995,Stroke Prognosis in Intensive CarE,SPICE,Completed,No Results Available,Acute Stroke Patients Requiring Invasive Mechanical Ventilation,,Functional outcome,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",,364,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C17-16,"October 18, 2017","November 18, 2019","November 18, 2020","November 8, 2017",,"August 25, 2021","Bichat Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03335995,NCT03335995,32026446
oui,NCT03339817,Description Des Troubles Respiratoires Chez Les Patients Suivis Pour Une Sclérose en Plaques (SEP) sévère,RespiMuS,Unknown status,No Results Available,Multiple Sclerosis|Respiration Disorders,Diagnostic Test: Polysomnography,Polysomnography|Respiratory function testing|Cerebral and cervical spine MRI|Expanded Disability Status Scale (EDSS)|BICAMS,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,C16-111|2017-A01845-48,"January 11, 2018","November 15, 2019","January 10, 2020","November 13, 2017",,"June 25, 2018","Département de Neurologie-Groupe Hospitalier Pitié-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT03339817,NCT03339817,33538688
oui,NCT03341702,Predictive Factors of Violence in Prison,,Completed,No Results Available,Prisoner,Other: penintetiary's incident reports collection,violent event|suicide attempt|physical assault,"University Hospital, Montpellier|Inserm U1061 : Neuropsychiatry",Male,"18 Years and older � (Adult, Older Adult)",,1200,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RECHMPL17_0324,"April 1, 2015","October 10, 2017","March 1, 2018","November 14, 2017",,"May 7, 2018","Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT03341702,NCT03341702,
oui,NCT03343834,Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation,EBVALLO,Completed,No Results Available,Epstein-Barr Viraemia|Hematologic Diseases|Allogeneic Disease,Biological: biological collection,Respective percentages of latent versus replicative EBV profiles|Characteristics of the patients according to the EBV results|Patients' outcome according to the EBV profile,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,138,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NI15023,"December 21, 2017","August 5, 2021","August 5, 2021","November 17, 2017",,"October 25, 2021","Service d'hématologie Clinique, Paris, France",,https://ClinicalTrials.gov/show/NCT03343834,NCT03343834,
non,NCT03347669,A Pilot Study of Small Fiber Neuropathy Prevalence in Fibromyalgia Patients Compared to Healthy Subjects Using Sudoscan�,NEFI,Unknown status,No Results Available,Fibromyalgia,Device: Sudoscan�,"Measure of the electrochemical conductance (�S) using Sudoscan�|Biometric criteria|Numerical scale|Brief Pain Inventory|Fibromyalgia Impact Questionnaire|Quality of life (SF-12)|Anxiety and Depression (HAD)|Depression (Beck Depression Inventory)|Pittsburgh Sleep Quality Index|Chronic fatigue Severity Scale|Pain Catastrophizing Scale|Assessment of socio-professional category, precariousness and health inequalities (Score EPICES).","University Hospital, Clermont-Ferrand",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CHU-362,"November 6, 2017",April 2018,September 2018,"November 20, 2017",,"December 5, 2017","CHU Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT03347669,NCT03347669,31705738
oui,NCT03350594,Family Therapy and Anorexia Nervosa : Which is the Best Approach?,THERAFAMBEST,Recruiting,No Results Available,Anorexia Nervosa,Behavioral: Systemic Family Therapy|Behavioral: Multiple Family Therapy,Body Mass Index|Change from Baseline overall clinical outcome at 12 months and 18 months|Change from baseline nature and seriousness of eating-disorder symptoms at 12 months and 18 months|Change from baseline patient's Emotional symptoms at 12 months and 18 months|Change from baseline parent's Emotional symptoms at 12 months and at 18 months|Change from baseline quality of family relationships at 12 months and 18 months|Change from baseline patient's quality of life at 12 months and at 18 months|Change from baseline parent's quality of life at 12 months and at 18 months|Change from 12-month Patient and parent satisfaction at 18 months,Institut Mutualiste Montsouris|U1178 INSERM|PHRC Interr�gionnal 2015|Fondation Sandrine Castellotti|Fondation de l'Avenir|CESP - UMR 1018 / INSERM|Direction G�n�rale de l'offre de Soins (DGOS)|Centre Hospitalier Universitaire (CHU) de Rouen|Maison des Adolescents de Cochin (APHP),All,"13 Years to 19 Years � (Child, Adult)",Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PSY-2016-01|2016-A00818-43,"May 11, 2018","November 11, 2023","May 10, 2024","November 22, 2017",,"March 10, 2022","H�pital Salvator - APHM Marseille, Marseille, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Institut Mutualiste Montsouris, Paris, France|Maison de Solenn - Maison des Adolescents Cochin, Paris, France|Clinique M�dicale et P�dagogique Edouard RIST, Paris, France",,https://ClinicalTrials.gov/show/NCT03350594,NCT03350594,31039797
oui,NCT03351218,Agency in Dystonia,AGENT10,"Active, not recruiting",No Results Available,"Dystonia, Primary",Behavioral: Behavioral testing - computerized tasks,agency tasks behavioral outcome measures|MRI measures,"Institut National de la Santé Et de la Recherche Médicale, France",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,113,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C17-04|2017-A01231-52,"October 23, 2017","October 15, 2022","October 15, 2022","November 22, 2017",,"November 29, 2021","Centre d'investigation Clinique, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT03351218,NCT03351218,
oui,NCT03352986,Substudy of CADRE: for People With Extreme Phenotype: BIOCADRE,BIOCADRE,Unknown status,No Results Available,Sickle Cell Disease,Biological: biological analysis|Other: peripheral arterial tonometry,Description of microcirculation by peripheral arterial tonometry|Measure of blood viscosities|Dosage of microparticles|Determination of free hemoglobin|Measurement of neutrophil extracellular trap (NET)|Measurement of proinflammatory cytokines by ELISA|Genotyping of the alpha-globin gene associated with persistence of fetal hemoglobin|Genotyping of the polymorphisms associated with persistence of fetal hemoglobin,"Cardiologie et Développement|Institut National de la Santé Et de la Recherche Médicale, France",All,"10 Years and older   (Child, Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,3,"May 15, 2017",June 2019,December 2019,"November 24, 2017",,"November 24, 2017","Centre de Recherches er de Lutte contre la Drépanocytose, Bamako, Mali|Centre National de Transfusion Sanguine, Dakar, Senegal",,https://ClinicalTrials.gov/show/NCT03352986,NCT03352986,
oui,NCT03364010,"Dyslexia, Motor Control and Proprioception",,Terminated,No Results Available,Dyslexia,Behavioral: Evaluation of proprioception|Behavioral: Evaluation of motor learning|Behavioral: Evaluation of written language,Evaluation of proprioception through velocity perception|Evaluation of proprioception through position perception|Motor learning|Text reading|Phonological awareness: phonemic blending and phonemic elision|Identifying words,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,10 Years to 12 Years � (Child),Not Applicable,56,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C17-14|2017-A01547-46,"January 4, 2018","May 9, 2019","June 2, 2021","December 6, 2017",,"February 21, 2023","Inserm U1093, Dijon, Bourgogne, France",,https://ClinicalTrials.gov/show/NCT03364010,NCT03364010,33431949
oui,NCT03369106,Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study,SEP-BIO-PROG,Unknown status,No Results Available,Multiple Sclerosis,Other: Composite severity score calculation,Change of Expanded disability status scale|Change in neuropsychological scores|Change in T2 lesion volume|Grey matter volume change,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,120,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C16-114|2017-A01844-49,"December 15, 2017","December 15, 2020","June 15, 2022","December 11, 2017",,"December 11, 2017","CIC Neurosciences Institut du Cerveau et de la Moelle Epinière, Paris, France",,https://ClinicalTrials.gov/show/NCT03369106,NCT03369106,
oui,NCT03370809,Assessment of Positron Emission Tomography to Early Detect Frailty in Onco-geriatry,FOGTEP,Completed,No Results Available,Patients Over 75 Years Old With a Cancer Discovery,Radiation: Brain PET/CT step,Volume of brain with damages detected by quantitative analysis SPM (Statistical Parametric Mapping)|Volume of brain with damages detected by quantitative analysis SPM between 2 patient's group with MMSE (MiniMental State Examination) results and threshold value as 24|Volume of brain with damages detected by quantitative analysis SPM between 2 patient's groups with GDS (Geriatric Depression Scale) results and threshold value as 5|Volume of brain with damages detected by quantitative analysis SPM between different groups according to the SIOG-2 scale|Volume of brain with damages detected by quantitative analysis SPM between 2 patient's groups according to an unscheduled hospitalisation over 6 months or no|Volume of brain with damages detected by quantitative analysis SPM between 2 patient's groups according to non cancer related death at 12 months or no,"Central Hospital, Nancy, France",All,75 Years and older � (Older Adult),Not Applicable,37,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PSS2017/FOGTEP-VERGER/VS,"October 1, 2018","May 24, 2022","August 10, 2022","December 12, 2017",,"August 24, 2022","CHRU NANCY Brabois, nuclear medicine department, Vandoeuvre les Nancy cedex, France",,https://ClinicalTrials.gov/show/NCT03370809,NCT03370809,
oui,NCT03371056,Maternal- Fetal Infection,InSPIRe,Recruiting,No Results Available,Neonatal Infection,Biological: Bacteriological analyses on clinical samples performed with swabs,Presence of Streptococcus B|Maternal fetal infection|A positive bacteriological result in the vaginal sample|Vaginal dysmorphism|Antibiotic resistance|Highlighting specific virulence markers|Maternal local biomarkers definition|Bacteriological signature definition|Chorioamnionitis,Assistance Publique - H�pitaux de Paris|Bforcure|BPIfrance|INSERM U1153|Institut Cochin|INSERM IAME UMR 1137,Female,"18 Years and older � (Adult, Older Adult)",Not Applicable,2600,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,K170907J,"August 28, 2018","August 30, 2023","December 30, 2023","December 13, 2017",,"September 27, 2022","Hopital Louis Mourier, Colombes, France|H�pital Cochin, Paris, France|Hopital Bichat, Paris, France",,https://ClinicalTrials.gov/show/NCT03371056,NCT03371056,
oui,NCT03378843,Spermidine Intake and All-cause Mortality,,Completed,No Results Available,Healthy Diet|Mortality,Other: Spermidine content of natural diet,All-cause mortality|Cause-specific mortalities,"Medical University Innsbruck|Krankenhaus Bruneck|University of Graz|Paracelsus Medical University|Institut National de la Santé Et de la Recherche Médicale, France|King's College London|Universitaet Innsbruck",All,"45 Years to 84 Years   (Adult, Older Adult)",,829,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Bruneck_2017_Spermidine,October 1995,October 2015,October 2015,"December 20, 2017",,"December 20, 2017",,,https://ClinicalTrials.gov/show/NCT03378843,NCT03378843,29955838
oui,NCT03379207,Innate Immune Response During Community Acquired Pneumonia,ImPACT,Recruiting,No Results Available,Community-acquired Pneumonia|Acute Respiratory Distress Syndrome|Innate Immunity,Other: Blood samples|Other: Tracheal Aspirates|Other: Surplus of Broncho-alveolar lavage fluid,Blood level of Non-Conventional T Lymphocytes (expressed as % CD3+ lymphocytes)|Airway level of Non-Conventional T Lymphocytes (expressed as % CD3+ lymphocytes)|Blood level of inflammatory cytokines|Airway level of inflammatory cytokines|Blood level of Conventional T Lymphocytes (expressed as % CD3+ lymphocytes)|Airway level of Conventional T Lymphocytes (expressed as % CD3+ lymphocytes)|Metabolic signature of non-conventional T lymphocytes|Transcriptomic signature of non-conventional T lymphocytes|Blood level of Innate Cells (expressed as % CD45+ lymphocytes)|AIrway level of Innate Cells (expressed as % CD45+ lymphocytes),"University Hospital, Tours",All,"18 Years and older � (Adult, Older Adult)",,350,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,PHAO17/YJ-ImPACT,"January 10, 2018","September 9, 2024","March 19, 2025","December 20, 2017",,"February 2, 2023","University Hospital of LIMOGES, Limoges, France|University Hospitakl of TOURS D�partement of Pneumonia, Tours, France|University Hospital -Bretonneau - Intensive Care, Tours, France|University Hospital of Tours; INSERM CIC 1415, Tours, France",,https://ClinicalTrials.gov/show/NCT03379207,NCT03379207,
oui,NCT03381950,Chronic Kidney Disease - Renal Epidemiology and Information Network,CKD-REIN,"Active, not recruiting",No Results Available,"Renal Insufficiency, Chronic",,"Incidence of end-stage renal disease (ESRD)|Mortality|Incidence of major CKD events including acute kidney injury, cardiovascular and metabolic complications|Incidence of major adverse events including infections, cancer, mineral and bone disease, anemia, nutitional status, hospitalizations|Prescription drug use|Health-related Quality of life|Depression|Cognitive function|Physical Activity|Family relationships|Sleep disorders|Women's health|Cost effectiveness of different treatment practices and services","Institut National de la Santé Et de la Recherche Médicale, France|Université Paris-Sud|Agence de La Biomédecine|Arbor Research Collaborative for Health|Hospital Ambroise Paré Paris|Centre Hospitalier Lyon Sud|Central Hospital, Nancy, France|Institut de Formation et de Recherche sur les Organisations Sanitaires et Sociales|Biobanque de Picardie|Centre National de Génotypage|Institut des Maladies Métaboliques et Cardiovasculaires|Etablissement Français du Sang|Amiens University Hospital|University Hospital, Bordeaux",All,"18 Years and older   (Adult, Older Adult)",,3033,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C12-30,July 2013,July 2021,December 2026,"December 22, 2017",,"October 11, 2019",,,https://ClinicalTrials.gov/show/NCT03381950,NCT03381950,37104214;36693722;35433774;32772863;32611662;31890996;29635335
oui,NCT03387540,Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions,RAFALE,Completed,No Results Available,Myocarditis|Cardiac Complication,Drug: ICI,Cardio-vascular toxicity of ICIs.|Causality assessment of reported cardiovascular events according to the WHO system|Description of the type of cardiotoxicity depending on the category of ICIs|Description of the duration of treatment when the toxicity happens (role of cumulative dose)|Description of the drug-drug interactions associated with adverse events|Description of the pathologies (cancer) for which the incriminated drugs have been prescribed|Description of the population of patients having a cardio-vascular adverse event,"Groupe Hospitalier Pitie-Salpetriere|Institute of Cardiometabolism and Nutrition, France|Vanderbilt University|Vanderbilt University Medical Center",All,"18 Years and older � (Adult, Older Adult)",,104,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,CIC1421-17-12,"December 2, 2017","December 4, 2017","December 31, 2017","January 2, 2018",,"September 26, 2019","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris, France",,https://ClinicalTrials.gov/show/NCT03387540,NCT03387540,30442497
oui,NCT03393286,ZIKAlliance Children Cohort (ZIKAllianceCH),ZIKAllianceCH,Completed,No Results Available,Zika Virus,,"Congenital Abnormalities detected after birth as defined by the evolving definition of the congenital zika syndrome|Hearing abnormalities measured after birth|Visual abnormalities measured after birth|Developmental / cognitive abnormalities measured by the Ages and Stages 3rd Edition (ASQ3)|Developmental / cognitive abnormalities measured by the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III)",University of Heidelberg Medical Center,All,up to 6 Months � (Child),,1554,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,734548CH (EC   H2020   RIA),"January 15, 2018","September 30, 2021","March 30, 2022","January 8, 2018",,"May 18, 2022","Sosecali Ltd. (SOSE), Guaqui, Bolivia|Fundacao Oswaldo Cruz (FIOCRUZ), Recife, Brazil|Fundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil|University of Sao Paulo, S�o Paulo, Brazil|Industrial University of Santander (UIS), Bucaramanga, Colombia|Pedro Kouri Institute (IPK), Havana, Cuba|INSERM, Pointe-�-Pitre, Guadeloupe|IMSS Mexico (IMSS), Guadalajara, Mexico|National Institute of Public Health (INSP), M�rida, Mexico|Universidad de Carabobo / UMC Groningen (UMCG), Valencia, Venezuela",,https://ClinicalTrials.gov/show/NCT03393286,NCT03393286,31878895
oui,NCT03395379,Air Dissection in Percutaneous Radiofrequency Ablation of T1a Renal Cell Carcinoma,,Completed,No Results Available,Unrecognized Condition,Procedure: RFA,Failure rate of the air dissection procedure|Post-operative complications,"Centre Hospitalier Universitaire de Nice|Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,90,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,URO-BASE01,"January 11, 2012","March 15, 2016","May 15, 2016","January 10, 2018",,"January 10, 2018",,,https://ClinicalTrials.gov/show/NCT03395379,NCT03395379,
oui,NCT03411447,Impact of Early Enteral vs. Parenteral Nutrition on Risk of Gastric-Content Aspiration in Patients Requiring Mechanical Ventilation and Catecholamines,,Terminated,No Results Available,Acute Respiratory Failure|Shock,Other: Parenteral nutrition|Other: Enteral nutrition,proportion of patients with abundant microaspiration (defined as a pepsin level >200 ng/mL in at least 30% of tracheal aspirates)|Salivary amylase levels in tracheal aspirates.,"Centre Hospitalier Departemental Vendee|Ministry of Health, France|Institut National de la Santé Et de la Recherche Médicale, France|University Hospital, Tours",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,139,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CHD085-13,"January 27, 2015","July 7, 2015","July 7, 2015","January 26, 2018",,"January 26, 2018","CHU Amiens, Amiens, France|Centre hospitalier d'Annecy, Annecy, France|CHU Louis Mourier, Colombes, France|CHU Lille, Lille, France|CHU Saint Louis, Paris, France|CHU Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT03411447,NCT03411447,30953553
oui,NCT03412201,"Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testinG, of Heart Failure Therapies",STRONG-HF,Unknown status,No Results Available,Heart Failure,Other: Usual Care|Other: High Intensity Care,180-day all-cause mortality or heart failure readmission|Change in quality of life|180-day all-cause mortality|90-day all-cause mortality or heart failure readmission,"Heart Initiative|H�pitaux Universitaires Saint-Louis-Lariboisi�re|Momentum Research, Inc.|Roche Diagnostics|Inserm UMRS 942",All,"18 Years to 85 Years � (Adult, Older Adult)",Not Applicable,1800,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHF201701,"May 11, 2018",October 2021,October 2021,"January 26, 2018",,"February 12, 2021","Sanatorio de la Canada, Villa Mar�a, Cordoba, Argentina|Chutro Srl Clinic, C�rdoba, Argentina|Del Prado Private Clinic, C�rdoba, Argentina|San Roque Hospital, C�rdoba, Argentina|Rosario Cardiovascular Institute, Rosario, Argentina|Rosario Clinical Research Institute - Delta, Rosario, Argentina|Modelo Cardiology Center, San Miguel De Tucum�n, Argentina|Diagnostic and Treatment Medical Clinic SA, Santa Fe, Argentina|Santa Rosa Hospital, Santa Rosa, Argentina|San Martin SA Clinic, Venado Tuerto, Argentina|Fusavim Privada SRL Clinic, Villa Mar�a, Argentina|Internal Med. 1, St. Josef Hospital Braunau, Braunau Am Inn, Austria|Clin. Dep. Internal Med 3, University Hospital St. Poelten, St. Poelten, Austria|Internal Med., LKH Villach, Villach, Austria|1. Med. Dep, Donauspital, Wien, Austria|Cardiology Department at Hietzing Hospital with Neurological Center Rosenhugel, Wien, Austria|Dep. Of Cardiology, Medical Univ. Vienna, Wien, Austria|Cardiovascular Diagnostic Center, Cartagena, Bolivar, Colombia|CEQUIN Cardiomet Foundation, Armenia, Quindio, Colombia|Cardiomet Pereira Clinical Research Center Foundation, Pereira, Risaralda, Colombia|Santander Ophthalmological Foundation, Bucaramanga, Santander, Colombia|Auxerre Hospital Center, Auxerre, France|University Hospital of Beziers, B�ziers, France|Center Hospital Regional University of Tours Trousseu Hospital, Chambray-l�s-Tours, France|University Hospital Henri Mondor, Creil, France|CHU Dijon Burgundy F. Mitterand, Dijon, France|H�pitaux Universitaires Saint-Louis-Lariboisi�re, University Paris Diderot, Paris, France|Center Hospital of Toulon, Toulon, France|Buda Hospital of the Hospitaller Order of Saint John of God, Budapest, Hungary|Kanizsai Dorottya Hospital, Nagykanizsa, Hungary|St. Rafael Hospital in Zala County, Zalaegerszeg, Hungary|Barzilay MC Ashkelon, Ashkelon, Israel|Asaf Harofe MC, Zerifin, Israel|Dept of Medicine Research unit, Maputo Central Hospital, Maputo, Mozambique|Mavalane Hospital, National Institute of Health, Maputo, Mozambique|Amino Kano Teaching Hospital, Kano, Nigeria|Murtala Muhammad Specialist Hospital, Kano, Nigeria|State Budget HealthCare Institution ""First City clinical hospital named after E.E. Volosevich"", Arkhangel'sk, Russian Federation|Regional budget Healthcare Institution ""Cardiological dispensary"", Ivanovo, Russian Federation|Federal State Budget Educational Institution of Higher Education ""Moscow State Medico-Dental University n.a. A.I. Evdokimov"", under Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Budget Educational Institution of Higher Education ""Moscow State University n.a. M.V. Lomonosov"", independent division Medical research Educational Centre, Moscow, Russian Federation|Moscow City Hospital # 81, Moscow, Moscow, Russian Federation|Moscow State Budget Healthcare Institution City clinical Hospital 52 of Moscow Healthcare Department, Moscow, Russian Federation|Primary Healthcare Unit of the RF Ministry of Internal Affairs in Moscow, Moscow, Russian Federation|Russian National Research Medical University n.a. N.I.Pirogov based at City Clinical hospital n.a. V.M.Buyanov DZM, Moscow, Russian Federation|SBHI of Moscow City clinical hospital 64 of Moscow Healthcare department, Moscow, Russian Federation|State Budget HealthCare Institution of Moscow ""City clinical hospital 15 n.a. O.M. Filatov under Department of HealthCare of Moscow"", Moscow, Russian Federation|State Budget HealthCare Institution of Moscow ""City clinical hospital 29 n.a. N.E. Bauman under Department of HealthCare of Moscow"", Moscow, Russian Federation|State Budget HealthCare Institution of Mosocw ""City clinical hospital 51 under Department of HealthCare of Moscow"", Moscow, Russian Federation|Saint-Petersburg State Budget HealthCare Institution ""City hospital 38 n.a. N.A. Semashko"", Pushkin, Russian Federation|Municipal Government-financed Institution of Healthcare ""City Emergency Hospital"" of Rostov-on-Don City, Rostov-on-Don, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Ryazan State Medical University named after academician I.P. Pavlov"", Ryazan', Russian Federation|Federal State Budget Educational Institution of Higher Education ""North-West state medical university n.a. I.I. Mechnikov under the Ministry of Health of the Russian Federation"", Saint Petersburg, Russian Federation|Saint Petersburg State Budget Healthcare Institution Pokrovskaya City Hospital, Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Healthcare Institution City Hospital 15, Saint Petersburg, Russian Federation|State Budget Institution ""Saint Petersburg state budget research institution of first aid named after I. I. Dzhanelidze"", Saint Petersburg, Russian Federation|State Budget HealthCare Institution of Vladimir Region ""City Hospital 4 of Vladimir"", Vladimir, Russian Federation|State Institution of Healthcare of Yaroslavl Region ""Clinical Hospital 8"", Yaroslavl, Russian Federation|National Institute of Cardio and Vascular Diseases, Bratislava, Slovakia|V. Internal Clinic, LFUK and UNB Bratislava, Bratislava, Slovakia|Internal Department, Hospital with Polyclinic Brezno, Brezno, Slovakia|Internal Department, Dolnooravian Hospital of Dr. L.N.Jege, Doln� Kub�n, Slovakia|Internal Department, Hospital with Polyclinic Lucenec, Lu?enec, Slovakia|First Internal Clinic, Faculty Hospital with Polyclinic Nove Zamky, Nov� Z�mky, Slovakia|Department of Internal Medicine Hospital Rimavska Sobota, Rimavsk� Sobota, Slovakia|Department of Internal Medicine UVN SNP-FN, Ru�omberok, Slovakia|Internal Department, NsP Spisska Nova Ves, Spi�sk� Nov� Ves, Slovakia|Internal Department Hospital Arm General L. Svobodu Svidnik, Svidn�k, Slovakia|Groote Schuur Hospital, Cape Town, South Africa|Nelson Mandela Academic Hospital, Walter Sisulu University, Mthatha, South Africa|Habib Bougatfa Hospital, Bizerte, Tunisia|Regional Hospital of Jendouba, Jendouba, Tunisia|Fattouma Bourguiba Hospital, Monastir, Tunisia|Hedi chaker Hospital, Sfax, Tunisia|Charles Nicolle Hospital, Tunis, Tunisia|Habib Thameur Hospital, Tunis, Tunisia|La Rabta Hospital, Tunis, Tunisia|Military Hospital, Tunis, Tunisia",,https://ClinicalTrials.gov/show/NCT03412201,NCT03412201,36356631;34529313;31423712
oui,NCT03413176,Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.,VEGAN,Completed,No Results Available,Cardiac Complication|Vascular Diseases,Drug: Cardiac complication induced by VEGF/VEGFR inhibitor,Cardio-vascular toxicity of AAs|Causality assessment of reported cardiovascular events according to the WHO system|Description of the type of cardiotoxicity depending on the category of AAs|Description of the duration of treatment when the toxicity happens (role of cumulative dose)|Description of the drug-drug interactions associated with adverse events|Description of the pathologies (cancer) for which the incriminated drugs have been prescribed|Description of the population of patients having a cardio-vascular adverse event,Groupe Hospitalier Pitie-Salpetriere,All,"18 Years and older � (Adult, Older Adult)",,150000,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,CIC1421-18-02,"January 1, 2018","January 15, 2018","January 31, 2018","January 29, 2018",,"September 26, 2019","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris, France",,https://ClinicalTrials.gov/show/NCT03413176,NCT03413176,
oui,NCT03420105,Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep,PROSOM-K,Completed,No Results Available,Breast Cancer|Memory Disorders,"Other: Neuropsychological, psycho-pathological and quality of life assessments|Drug: Hormonotherapy",The memory components and memory loss mechanisms by questionnaires|The effect of sleep quality on the recovery of intentions in prospective memory by questionnaires|The impact of adjuvant hormone therapy on the functioning of prospective memory by questionnaires|The influence of anxio-depressive factors and fatigue on prospective memory by questionnaires,"Centre Francois Baclesse|Institut National de la Sant� Et de la Recherche M�dicale, France",Female,"18 Years to 70 Years � (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,PROSOM-K,"January 5, 2018","March 6, 2020","March 6, 2020","February 5, 2018",,"March 9, 2020","Centre Fran�ois Baclesse, Caen, France|Inserm-Ephe-Unicaen U1077 (, Caen, France",,https://ClinicalTrials.gov/show/NCT03420105,NCT03420105,30176833
oui,NCT03440749,Rhythm and Multisensoriality's Effects on the Motor Development in Children With Cerebral Palsy,APP-PaC,Unknown status,No Results Available,Cerebral Palsy,Other: luminous stimuli,Time reaction (TR)|Number of errors,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,6 Years to 14 Years   (Child),Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,RC31/17/0158|2017-A01969-44,"February 15, 2018",August 2020,August 2020,"February 22, 2018",,"October 10, 2019","University Hospital Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT03440749,NCT03440749,
oui,NCT03446430,Validation of Laser Doppler Vibrometer (LDV) for Measurement of Arterial Stiffness in Hypertensive Patients,CARDIS-PWV,Completed,No Results Available,Hypertension,Device: PWV measurement by LDV,carotid-femoral PWV measured by LDV|carotid PWV measured by LDV|chest-carotid PWV measured by LDV|carotid-femoral PWV measured by applanation tonometry|carotid PWV measured by Echotracking,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,C17-43,"June 21, 2018","December 4, 2018","December 4, 2018","February 26, 2018",,"September 24, 2019","Hopital Européen Georges Pompidou / Service de Pharmacologie, Paris, France",,https://ClinicalTrials.gov/show/NCT03446430,NCT03446430,
oui,NCT03447431,Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact,,Unknown status,No Results Available,Colorectal Cancer|Microsatellite Instability,,"To identify exon/intron junctions that are specifically affected by aberrant splicing events in MSI CRC|To investigate for functional links between MSI and aberrant splicing events.|To identify splicing events and/or LNCR mutations with clinical relevance in MSI CRC patients.|To initiate functional studies on a limited number of clinically relevant, cancer related genes whose splicing is highly perturbed in MSI cancer cells|To develop biological tools to simplify screening in future clinical assays","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,350,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,NI14027,"April 5, 2018",February 2021,February 2021,"February 27, 2018",,"July 2, 2019","Service d'Anatomie et de Cytologie Pathologique, Paris, France",,https://ClinicalTrials.gov/show/NCT03447431,NCT03447431,
oui,NCT03454282,Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial,DIgesT,Unknown status,No Results Available,"Breast Cancer|Melanoma, Malignant",Other: FMD,Absolute and relative changes in PBMCs|Phenotypic modifications in PBMCs|Functional modifications in PBMCs|Functional modifications in tumor-infiltrating lymphocytes|Phenotypic modifications in tumor-infiltrating lymphocytes|Functional modifications of immune cell population in LNs|mRNA profiling in tumor cells|mRNA profiling in immune cells|miRNA profiling in tumor cells|miRNA profiling in immune cells|Changes in the expression of metabolic genes in PBMCs|FMD-induced changes in blood metabolic parameters|FMD-induced changes in urine metabolites|FMD-induced changes in serum growth factors.|Qualitative changes in tumor-infiltrating immune cells|Quantitative changes in tumor-infiltrating immune cells|Changes in tumor proliferation|Changes in tumor cell apoptosis|Changes in tumor metabolic pathways|Changes in expression of hormone receptors and HER2|Qualitative changes in immune cell suspensions from lymph nodes|Quantitative changes in immune cell suspensions from lymph nodes|Changes in DNA methylomic profiles in lymph node specimens|Changes in DNA methylomic profiles in tumor specimens|Changes in gut microbiota composition.|Short-term modification of blood nutritional parameters.|Long-term modification of blood nutritional parameters.|Short-term and long-term modification of BMI|FMD-induced changes in white blood cell populations|FMD-induced changes in hemoglobin|Assessment of patient compliance to the FMD.|Assessment of FMD tolerability.|Correlation between FMD-induced changes in serum metabolites and changes in PBMCs|Correlation between FMD-induced metabolic and immunological changes,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|National Health Research Institutes, Taiwan|Centro de Investigación en Nanomateriales y Nanotecnología (CINN)|Institut National de la Santé Et de la Recherche Médicale, France|Martin-Luther-Universität Halle-Wittenberg|University of Milan",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INT157/17|B42F17000260006,"July 1, 2018","May 30, 2020","December 31, 2020","March 5, 2018",,"February 26, 2019","Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03454282/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03454282,NCT03454282,
oui,NCT03454711,Functional Magnetic Resonance Imaging (fMRI) Exploration of Neurocognitive Processes Involved in Food Addiction (FA) in Obese Patients: Towards New Phenotypic Markers for an Optimized Care Pathway,AddictO,Completed,No Results Available,Obesity,"Device: fMRI|Device: Indirect calorimetry|Device: Bioimpedance|Biological: Lipid profile, glucose, HBA1c, metabolomic analysis|Behavioral: YFAS questionnaire, Binge Eating Scale, Hospital Anxiety and Depression (HAD) scale, hedonic evaluation test (liking)",Significant change in brain activity of the prefrontal cortex (area involved in the inhibitory control of food intake) measured by modification of BOLD (Blood-Oxygen-Level-Dependent) signal in fMRI during a cognitive task based on food choice making,"Rennes University Hospital|Institut NuMeCan, INRAE 1341",Female,30 Years to 50 Years � (Adult),Phase 2|Phase 3,47,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,35RC17_8949_AddictO|2017-A01269-44,"April 26, 2018","September 8, 2021","September 8, 2021","March 6, 2018",,"September 16, 2021","CHU de Rennes, Rennes, France",,https://ClinicalTrials.gov/show/NCT03454711,NCT03454711,
non,NCT03457155,Assessment of the Link Between Monomeric Functional Form Plasma Level of Vasostatin-1 and Occurrence of New Onset Atrial Fibrillation in Severe Intensive Care Patients,TVASORYTHM,Recruiting,No Results Available,Atrial Fibrillation|Shock,Other: VS-I dosing in plasma samples,Occurrence frequency of atrial fibrillation in patients free of AF|Duration of ventilation (in days)|Duration of extra-renal treatment (in h)|Duration of vasopressor treatment (in days)|Length of stay in intensive care unit (in days)|Mortality|SAPSII score|Increasing of VS-1 plasmatic level in its active form from AF event (T0) to the back in sinusal rythm (T1) after an episode of new onset FA|Occurrence of atrial fibrillation in patients free of AF,"University Hospital, Strasbourg, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,6794,"June 18, 2018",July 2023,July 2023,"March 7, 2018",,"August 18, 2022","H�pitaux Universitaires de Strasbourg, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT03457155,NCT03457155,
oui,NCT03459157,Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP),CohMSM-PrEP,Unknown status,No Results Available,HIV/AIDS,Drug: HIV prevention package including PrEP,Percentage of MSM under PrEP among eligible HIV-seronegative participants|Percentage of MSM using daily and/ord on-demand PrEP|Number of MSM followed after 3 years compared to the number of MSM included (retention in the program)|Percentage of adherence reported by MSM|Counting of TDF/FTC tablets|Plasma concentrations of TDF and FTC|Percentage of HIV tests performed|Clinical and biological adverse events related to TDF and FTC|Frequency of condomless anal intercourse|Frequency of sexual intercourse associated with alcohol and/or drug use|Incidence rate of STIs|Incidence rate of HIV infection|Percentage of TDF/FTC resistance among MSM newly infected by HIV|Total cost of the intervention over the study period and in the long term|Incremental cost-effectiveness ratio of the intervention (versus no intervention) over the study period and in the long term|Conditions of TDF/FTC price and of effectiveness for the intervention to be cost-effective in the study countries,"ANRS, Emerging Infectious Diseases|Expertise France|Universit� Montpellier|SESSTIM (IRD, Inserm, Universit� Aix-Marseille)|Coalition Internationale Sida|Institut de M�decine Tropicale, Anvers, Belgique|ARCAD-SIDA MALI|Association African Solidarit�|Centre de Recherche Internationale pour la Sant�, Universit� de Ouagadougou|Espace Confiance, C�te d'Ivoire|Espoir Vie-Togo - ONG|Laboratoire BIOLIM, Universit� de Lom�",Male,"18 Years and older � (Adult, Older Adult)",Not Applicable,649,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS 12369 CohMSM-PrEP,"November 20, 2017","April 14, 2020","June 30, 2021","March 8, 2018",,"January 22, 2021","Centre Oasis, Association African Solidarit�, Ouagadougou, Burkina Faso|Clinique de Confiance, Espace Confiance, Abidjan, C�te D'Ivoire|Clinique des Halles, ARCAD-SIDA, Bamako, Mali|Centre Lucia, Espoir Vie Togo, Lom�, Togo",,https://ClinicalTrials.gov/show/NCT03459157,NCT03459157,34048794
anrs,NCT03459768,Cohort Study on People Who Inject Drugs in Senegal,CoDISEN,"Active, not recruiting",No Results Available,"Drug Addiction|HIV/AIDS|Hepatitis C, Chronic|Hepatitis C, Acute|Hepatitis B, Chronic|Hepatitis B Acute|Tuberculosis|Sexually Transmitted Diseases|Psychiatric Disorder",,"incidence of HIV|incidence of hepatitis C infection (HCV)|incidence of hepatitis B infection (HBV)|incidence of relevant coinfections and comorbidities|Retention rate and its determinants|mortality rate and determinants|Access to treatment of HCV, HBV infections and other coditions requiring specific therapeutical management|Effectiveness of tuberculosis regimens","French National Agency for Research on AIDS and Viral Hepatitis|ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",,208,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ANRS 12334 CoDISEN,"August 24, 2016","June 30, 2021","June 30, 2021","March 9, 2018",,"June 8, 2021","CEPIAD, Dakar, Senegal",,https://ClinicalTrials.gov/show/NCT03459768,NCT03459768,
oui,NCT03463798,Assesment of New Devices for the Diagnostic Evaluation of Diaphragmatic Dysfunction,DYSDIA,Recruiting,No Results Available,Diaphragmatic Paralysis|Healthy Volunteers,Device: Sonar|Device: Structured light plethysmography (SLP),amplitude of displacement of thoraco-abdominal compartments|displacement speed of thoraco-abdominal compartments,Association pour le D�veloppement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil,All,"18 Years and older � (Adult, Older Adult)",,180,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2017-A03665-48,"June 11, 2018","January 30, 2033","June 11, 2033","March 13, 2018",,"July 23, 2021","INSERM-UPC UMR_S 1158 Service de Pneumologie et R�animation, R3S, Groupe Hospitalier Piti�-Salp�tri�re, Paris, France",,https://ClinicalTrials.gov/show/NCT03463798,NCT03463798,
oui,NCT03474159,Evaluation of Aortic Stiffness as a Prognostic Indicator of Aortic Dilatation in Patients With Bicuspid Aortic Valve by Multimodal Imaging,IRM-BAO,Recruiting,No Results Available,Bicuspid Aortic Valve,Device: Magnetic Resonance Imaging|Device: Transthoracic echocardiography|Device: Echography UltraFast,"Evaluation of the progression of artic dilation with MRI|Comparison of aortic stiffness evaluation with different methods TTE, MRI, UF","French Cardiology Society|Institut National de la Santé Et de la Recherche Médicale, France|Centre National de la Recherche Scientifique, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2016-08,"November 7, 2018","January 31, 2024","May 31, 2024","March 22, 2018",,"March 23, 2022","Hôpital Européen Georges Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT03474159,NCT03474159,
oui,NCT03477071,A 15-year Single Center Experience of Endovascular Treatment of Transplant Renal Artery Stenosis,,Completed,No Results Available,Unrecognized Condition,Procedure: Angioplasty for Transplant Renal Artery Stenosis (TRAS),The technical success rate of endovascular treatment|Morbidity rate|Mortality rate,"Centre Hospitalier Universitaire de Nice|Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,1323,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,URO-BASE03,"January 1, 2010","January 1, 2017","December 1, 2017","March 26, 2018",,"March 26, 2018",,,https://ClinicalTrials.gov/show/NCT03477071,NCT03477071,
oui,NCT03480529,Monitoring the IMmUological TOXicity of Drugs,MIMUTOX,Completed,No Results Available,Arthritis|Systemic Lupus Erythematosus|Rheumatoid Arthritis|Capillary Leak Syndrome|Hepatitis,"Drug: drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom","Arthritis, hepatitis, and lupus induced toxicity of Immune Checkpoint inhibitors (ICI) Identification and report of cases of arthritis or lupus associated with ICIs. The research includes the report with MedDRA terms:|Causality assessment of reported arthritis, hepatitis, or lupus events according to the WHO system|Description of the type of arthritis or lupus or hepatitis or capillary leak syndrom depending on the category of drug|Description of the other immune related adverse events concomitant to the arthritis or lupus or hepatitis or capillary leak syndrom induced by drugs|Description of the duration of treatment when the toxicity happens (role of cumulative dose)|Description of the drug-drug interactions associated with adverse events|Description of the pathologies (cancer) for which the incriminated drugs have been prescribed|Description of the population of patients having a arthritis or lupus or hepatitis or CLS adverse event","Groupe Hospitalier Pitie-Salpetriere|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",,662,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,CIC1421-18-05,"March 1, 2018","March 10, 2018","March 10, 2018","March 29, 2018",,"September 4, 2019","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris, France|Rhumatology department, CHU Strasbourg, Hautepierre hospital, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT03480529,NCT03480529,30793701;30244023
oui,NCT03481491,Interactions Between Striatum and Cerebellum in ADCY5 and PRRT2 Dystonias,AMEDYST,Unknown status,No Results Available,Dystonia,Other: transcranial magnetic stimulation of the cerebellum,Resting state functional connectivity between the cerebellum and the striatum|Amplitude of Low Frequency Fluctuation (ALFF) of blood oxygen level-dependent signal in the cerebellum|Fractional anisotropy (FA) of the cerebello-striatal tract|Creatine concentration in the striatum measured with diffusion weighted spectroscopy.|Amplitude of Low Frequency Fluctuation (ALFF) of blood oxygen level-dependent signal in the striatum|Resting state functional connectivity between the cerebellum and the thalamus,"Institut National de la Santé Et de la Recherche Médicale, France",All,"183 Months and older   (Child, Adult, Older Adult)",Not Applicable,104,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,C16-128|2017-A01843-50,"May 4, 2018","July 3, 2021","July 3, 2022","March 29, 2018",,"March 29, 2018",,,https://ClinicalTrials.gov/show/NCT03481491,NCT03481491,35058336
oui,NCT03483233,Neural Bases of the Check Process,Check,Completed,No Results Available,Healthy Volunteers,Other: fMRI and EEG study,Measuring changes in brain activity in regions of interest when performing cognitive tasks.|Calculation of the correlations in the regions of interest of the individual values of the Blood Oxygen Level Dependent (BOLD) signal with the data of the concentration of Acide ?-aminobutyrique (GABA)|Calculation of the correlations in the regions of interest of the individual values of the Blood Oxygen Level Dependent (BOLD) signal with the data of the amplitude of the electrical signal (EEG),Hospices Civils de Lyon,All,20 Years to 45 Years � (Adult),Not Applicable,51,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL17_0143|2018-A00405-50,"November 23, 2018","January 16, 2020","January 16, 2020","March 30, 2018",,"March 2, 2022","Inserm U1208, Bron, France",,https://ClinicalTrials.gov/show/NCT03483233,NCT03483233,
oui,NCT03483246,Impact of Fecal Microbiota Transplantation in Ulcerative Colitis,REBALANCE-UC,Recruiting,No Results Available,Ulcerative Colitis,Drug: Fecal Microbiota Transplantation (FMT)|Drug: Sham-transplantation Placebo,Steroid-free clinical and endoscopic remission|Steroid-free clinical remission|Steroid-free endoscopic response|Steroid-free endoscopic remission|Microbiota composition and diversity|Proportion of adverse events in each group|Inflammatory biological parameter 1|Inflammatory biological parameter 2|Inflammatory biological parameter 3|Endoscopic lesions,"Assistance Publique - Hôpitaux de Paris|CRB-HUEP|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,P 160931J|2017-003802-42,"September 17, 2018","November 17, 2024","December 24, 2026","March 30, 2018",,"January 9, 2023","Service de Gastroentérologie et Nutrition Hôpital Saint Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT03483246,NCT03483246,
oui,NCT03488082,MRI Study of Saccadic Adaptation,,Completed,No Results Available,Healthy Volunteers,Behavioral: fMRI,BOLD signal|Eye movements,Hospices Civils de Lyon,All,18 Years to 40 Years � (Adult),Not Applicable,36,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL18_0200|2018-A00932-53,"October 17, 2018","July 17, 2020","July 17, 2020","April 4, 2018",,"January 12, 2022","Inserm U1208, Bron, France",,https://ClinicalTrials.gov/show/NCT03488082,NCT03488082,
oui,NCT03492242,Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction,CHIMeRA,Completed,No Results Available,Arthritis|Cancer|Cardiac Disease|Endocrine System Diseases|Autoimmune Diseases|Ophthalmopathy|Myositis|Neuropathy,Drug: Immune checkpoint inhibitor,Adverse drug reactions induced by ICIs and reported in the World Health Organization (WHO) or the Base Nationale de Pharmacovigilance (BNPV)|Causality assessment of reported adverse drug reaction according to the WHO system|Description of the type of adverse drug reaction depending on the category of ICIs|Description of the other immune related adverse events concomitant to the adverse drug reaction induced by ICIs|Description of the duration of treatment when the toxicity happens (role of cumulative dose)|Description of the drug-drug interactions associated with adverse events|Description of the pathologies (cancer) for which the incriminated drugs have been prescribed|Description of the population of patients having adverse event,"Groupe Hospitalier Pitie-Salpetriere|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,CIC1421-18-06,"February 1, 2018","September 30, 2018","September 30, 2018","April 10, 2018",,"September 26, 2019","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris, France",,https://ClinicalTrials.gov/show/NCT03492242,NCT03492242,33613286;32390168;31678768
oui,NCT03492593,Lycopene and Beta-carotene Metabolism in the Digestive Tract of Healthy Men,CarotenoiDig,Completed,No Results Available,Digestion Chambers|Stability and Metabolism of Carotenoids and Vitamin E,Other: lycopene|Other: beta-carotene|Other: control,Lycopene Metabolites|beta-carotene metabolites,"Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement|Aix Marseille Universit�|H�pital de la Conception",Male,18 Years to 50 Years � (Adult),Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,2013-A01398-37,September 2014,March 2016,March 2016,"April 10, 2018",,"April 10, 2018","Centre d'Investigation Clinique de la H�pital Conception, Marseille, France",,https://ClinicalTrials.gov/show/NCT03492593,NCT03492593,30256893
non,NCT03499392,"Primary Headache and Psychological Factors, Mental Functioning and Attachment Modalities.",CEPRIVA,Unknown status,No Results Available,Primary Headache Disorder,Other: psychological tests,Number of headache attacks|Duration of each headache attack|Definition of patient's psychological profile,Centre Hospitalier Universitaire de Besancon,All,25 Years to 60 Years � (Adult),Not Applicable,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,P/2017/344,"April 30, 2017","April 30, 2018","September 30, 2018","April 17, 2018",,"April 17, 2018","Belot, Besan�on, Doubs, France",,https://ClinicalTrials.gov/show/NCT03499392,NCT03499392,
oui,NCT03503461,Major Activation Of NCC in Graft Urinary Exosomes,MANGUE,Completed,No Results Available,Kidney Transplantation,Other: exosomes analysis,NCC cotransporter expression|Phosphorylated NCC cotransporter expression|pendrine expression in kidney transplant group,"University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,67,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,CHUBX 2018/08,"June 21, 2018","August 31, 2018","August 31, 2018","April 19, 2018",,"November 14, 2018","Hopital Pellegrin - Service Néphrologie, transplantation, dialyse et aphérèse, Bordeaux, France|Hopital Felix Guyon - Service d'Explorations Fonctionnelles Rénales, Saint-Denis, Réunion",,https://ClinicalTrials.gov/show/NCT03503461,NCT03503461,
oui,NCT03513822,Ketamine's Efficiency in the Treatment of Chronic Pain: Kynurenin Pathway,KEKU1,Unknown status,No Results Available,Neuralgia|Chronic Pain|Inflammation,Drug: Ketamine 10 MG/ML|Drug: Placebos|Drug: Midazolam 1 MG/ML,Numeric pain rating scale decrease between H0 and H4.|Paraclinical: Kynurenine pathway levels : SEROTONIN|Paraclinical: Kynurenine pathway levels : KYNURENINE|Paraclinical: Kynurenine pathway levels : IDO ACTIVITY|Paraclinical: Kynurenine pathway levels : KYNURENIC ACID|Paraclinical: Kynurenine pathway levels : QUINOLINIC ACID|Paraclinical: Kynurenine pathway levels : IL1|Paraclinical: Kynurenine pathway levels : IL6|Paraclinical: Kynurenine pathway levels: TNF alpha|Clinical: Neuropathic pain symptom inventory|Clinical: Pain timeline|Percentage overall improvement in pain over a week with self assessment|Clinical: Subscore of Neuropathic pain symptom inventory|Clinical: Hospital anxiety and depression scale|Percentage overall improvement in mood over a week with self assessment|Clinical: Pain area on a body cartography|Clinical: Ketamine adverse effects|Paraclinical: Kynurenine pathway activation with ulcer pressure,"Redar|H�pital Raymond Poincar�|Hopital Lariboisi�re|Institut National de la Sant� Et de la Recherche M�dicale, France|Fondation Apicil|Hospital Ambroise Par� Paris|Recherche Clinique Paris Descartes Necker Cochin Sainte Anne",All,"18 Years and older � (Adult, Older Adult)",Phase 3,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",REDAR|2017-003930-10|protocole ph-03-2018,"February 16, 2018",October 2018,November 2018,"May 2, 2018",,"May 2, 2018","Raymond Poincar� Hospital, Garches, Hauts De Seine, France","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03513822/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03513822,NCT03513822,
associ�,NCT03518099,Searching Biomarkers of Acute Intestinal Ischemic Injuries,Survibio,Unknown status,No Results Available,Acute Mesenteric Ischemia,Biological: blood sampling,"observation of clinical-bio-scanographic pain related to a splanchnic-mesenteric, occlusive or non-occlusive vascular insufficiency, to abdominal CT angiography, in the absence of another identifiable cause|mortality and causes|Intestinal resection ratio|acute intestinal ischemic injury relapse ratio|short gut syndrome features|persistency of mesenteric ischemia clinical signs or of ischemic gastric stenosis",Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,163,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2017-A02211-52,"November 16, 2018","May 22, 2020","May 22, 2021","May 8, 2018",,"December 27, 2018","Corcos Olivier, Clichy, France",,https://ClinicalTrials.gov/show/NCT03518099,NCT03518099,
oui,NCT03530215,Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA),EROCA,Unknown status,No Results Available,Cardiac Disease|Cancer,Drug: Antineoplastic and Immunomodulating Agents,Cardio-vascular toxicity of antineoplastic and immunomodulating agents|Causality assessment of reported cardiovascular events according to the WHO system|Description of the type of cardiotoxicity depending on the category of antineoplastic and immunomodulating agents|Description of the duration of treatment when the toxicity happens|Description of the drug-drug interactions associated with adverse events|Description of the pathologies (cancer) for which the incriminated drugs have been prescribed|Description of the population of patients having a cardio-vascular adverse event,Groupe Hospitalier Pitie-Salpetriere,All,"up to 100 Years � (Child, Adult, Older Adult)",,500000,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,CIC1421-18-12,"May 2, 2018","May 1, 2022","September 1, 2022","May 21, 2018",,"September 4, 2019","AP-HP, Piti�-Salp�tri�re Hospital,Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris, France",,https://ClinicalTrials.gov/show/NCT03530215,NCT03530215,34370839;33092403;32408984;32353110;31558250
anrs,NCT03537196,DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C),DRIVE-C,Completed,No Results Available,Hepatitis C|Drug Use|Viral Hepatitis C,Drug: Sofosbuvir 400 mg and Daclatasvir 60 mg|Drug: Sofosbuvir 400 mg and Daclatasvir 90 mg|Drug: Ribavirin|Drug: Sofosbuvir and Daclatasvir for 24 weeks,"Proportion of all patients in success of the model of care|Proportion of patients with detectable HCV RNA|Proportion of patients enrolled in care|Proportion of patients initiating DAA treatment|Proportion of patients cured|Rate of reinfection|Rate of mortality|Frequency, type and time to grade 3 or 4 adverse clinical or biological events.|Frequency, type and time to drug-related clinical or biological adverse reactions|Adherence assessment|Factors associated with HCV treatment failure|Factors associated with HCV reinfection|Effect of the HCV treatment intervention|Incremental cost-effectiveness ratio (ICER)","ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",Phase 4,979,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 12380 DRIVE-C,"November 13, 2018","November 30, 2020","November 30, 2020","May 25, 2018",,"January 29, 2021","Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam|Viet Tiep Hospital, H?i Ph�ng, Vietnam",,https://ClinicalTrials.gov/show/NCT03537196,NCT03537196,33208326
oui,NCT03546127,Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study,MULTIPLI-0,Completed,No Results Available,Colorectal Carcinoma|Soft Tissue Sarcoma,"Genetic: Next Generation Sequencing (NGS): exome, RNA seq",Delay time to send a validated exome sequencing report from sample receipt|The rate of patients with samples received by Platform for whom a validated exome sequencing report is available|Delay time to send a validated exome sequencing report from signature to informed consent by the patient|The rate of patients with signed informed consent for whom a validated exome sequencing report is available|Delay time to receive sample on Platform from signature of informed consent|The rate of patients with signed informed consent for whom samples have been received by platform|Delay time to receipt nucleic acids on CNRGH from samples receipt on platform|The rate of patients with samples sending date completed on electronic case for whom samples have been received by platform|The rate of patients with samples received on platform for whom these samples have been qualified in first step by platform and nucleic acids have been received by CNRGH|The rate of patients with samples received on Platform for whom these samples have been qualified in second step by platform and nucleic acids have been received by CNRGH|The rate of patients with samples received on platform for whom these samples have been qualified in first and second step by Platform and nucleic acids have been received by CNRGH|Delay time to receive all sequencing files from nucleic acids receipt on CNRGH|The rate of patients with nucleic acids received on CNRGH for whom all sequencing files have been qualified by bioinformatics platform|The rate of patients with nucleic acids received on CNRGH for whom sequencing have been qualified by CNRGH|Delay time to receive bioinformatics analysis for interpretation from availability of all sequencing files|The rate of patients with sequencing files received by bioinformatic Platform for whom these files have been qualified for analysis|The rate of patients with sequencing files received by bioinformatic Platform for whom analysis have been transmitted for interpretation|Delay time to send a validated exome sequencing report from availability of bioinformatic analysis|The rate of patients with bioinformatic analysis available for interpretation for whom biological interpretation has been performed|The rate of patients with bioinformatic analysis available for interpretation for whom results has been discussed by MTB,"Institut National de la Santé Et de la Recherche Médicale, France|Institut Bergonié|Plateforme labellisée Inca - Institut Bergonié, Bordeaux|Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris|CNRGH, Evry|EUCLID Clinical Trial Platform",All,"18 Years and older   (Adult, Older Adult)",,24,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C17-11 MULTIPLI,"May 23, 2017","September 21, 2017","September 21, 2017","June 6, 2018",,"June 6, 2018","Institut Bergonié, Bordeaux, France|Hôpital Européen Georges Pompidou, Paris, France|CEA / Centre National de Recherche en Génomique Humaine, Évry, France",,https://ClinicalTrials.gov/show/NCT03546127,NCT03546127,
oui,NCT03560089,Serious Games Rehabilitation Programme to Treat Gait and Balance Disorders in PD Patients,PARKGAME-II,Unknown status,No Results Available,Parkinson Disease,Device: Serious game|Device: Placebo serious game,Duration of the time-up-go test|Step length|step velocity|Movement disorders Unified Parkinson's disease rating scale|freezing of gait questionnaire|Parkinson's disease quality of life scale|gait and balance scale|Montreal Cognitive Assessment|Magnetic resonance imaging,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,C17-07,"July 1, 2018","June 1, 2021","June 1, 2021","June 18, 2018",,"February 5, 2021","Centre Investigation Clinique- ICM, Paris, France",,https://ClinicalTrials.gov/show/NCT03560089,NCT03560089,36602886
oui,NCT03565250,A Study of Identity Building in Children With ADHD,SID-ADHD,Unknown status,No Results Available,Attention Deficit Hyperactivity Disorder,Other: self understanding interview,Identity building|• Intensity score of ADHD|Self esteem|Causal style|Global Assessment of Functioning Scale|working memory|executive functions|Long-term memory,"University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France|Ecole Pratique des Hautes Etudes",All,8 Years to 12 Years   (Child),Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,17-011,"July 20, 2018","August 4, 2020","December 31, 2020","June 21, 2018",,"July 13, 2018","Caen University Hospital, Caen, France",,https://ClinicalTrials.gov/show/NCT03565250,NCT03565250,
oui,NCT03565562,Preventing Psychological Distress and Suicidal Behaviours: a Web-based and Mobile Suicide Prevention Intervention in the General Population,PRINTEMPS,Unknown status,No Results Available,Suicide and Depression|Psychological Distress|Anxiety Disorders|Local Authorities Promotion,Other: Promotion of the e-health tool by local authorities|Other: Promotion of the e-health tool by local authorities and GPs,Number of suicides - Short term|Number of suicide attempts - Short term|Number of suicides - Long term|Number of suicide attempts - Long term|Costs|Level of health-related quality of life and associated utility of StopBlues users|Level of psychological pain of StopBlues users|Level of depression of StopBlues users|Level of anxiety of StopBlues users|Level of suicidal risk of StopBlues users|Help-seeking behaviors and implementation of supportive activities into daily life of StopBlues users|Level of depression (for StopBlues users coming for a relative)|Intention to seek help of StopBlues users|Intensity of the participation to the application and website|Length of use to the application and website|Proportion of StopBlues users who came to know the e-health tool through the different communication channels|Proportion of StopBlues users who came for a relative|StopBlues users with a safety plan,"Institut National de la Santé Et de la Recherche Médicale, France|National Agency of Public Health|Centre Collaborateur OMS pour la recherche et la formation en santé mentale|Institut de Recherche en Santé Publique, France|UMR INSERM 1246 - SPHERE MethodS in Patients-centered outcomes and HEalth ResEarch",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,C 15-45,"April 1, 2018","December 31, 2018","March 31, 2020","June 21, 2018",,"January 27, 2020","Faculté de Médecine Paris Diderot Paris 7, Paris, France",,https://ClinicalTrials.gov/show/NCT03565562,NCT03565562,35451977;32571432
oui,NCT03565809,Quality of the Management of Diabetes in Elderly People With Dementia in France,DIA-FRADEM,Completed,No Results Available,Alzheimer Disease,Other: Incidence analysis,Diabetes control|Ocular Diabetes complications|Hypoglycemia|ketoacidosis without coma|diabetic coma|diabetic nephropathy|diabetic neuropathy|hospitalization for any of the 5 previous diabetes-related cause|hospitalization for falls and femoral fracture,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,65 Years and older   (Older Adult),,87816,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,RC31/16/8256,"May 2, 2017","December 31, 2018","December 31, 2018","June 21, 2018",,"September 8, 2021","University Hospital, Toulouse, France",,https://ClinicalTrials.gov/show/NCT03565809,NCT03565809,
oui,NCT03569488,Validation of the French Version of the Low Anterior Resection Syndrome (LARS) Among Rectal Cancer Patients,LARS,Recruiting,No Results Available,Rectal Cancer Patients,Diagnostic Test: FT-LARS questionnaire,validation of the French version of the LARS score,"University Hospital, Caen|National Cancer Institute, France|French Research Group of Rectal Cancer Surgery (GRECCAR)|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 80 Years   (Adult, Older Adult)",,1100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,17-247,"January 24, 2020","May 30, 2022","May 30, 2023","June 26, 2018",,"June 17, 2020","Chru Amiens, Amiens, France|Caen University Hospital, Caen, France|Chru Lille, Lille, France|Centre Oscar Lambret, Lille, France|Chru Nancy, Nancy, France|Chru Nantes, Nantes, France|Chru Tours, Tours, France|clc VANDEUVRE LES NANCY, Vandœuvre-lès-Nancy, France",,https://ClinicalTrials.gov/show/NCT03569488,NCT03569488,32152168
oui,NCT03570450,Regenerative Stem Cell Therapy for Stroke in Europe 1 ( ),RESSTORE 1,Unknown status,No Results Available,Stroke,Drug: Adipose derived Stem Cell|Drug: placebo,Phase Ia (Toxicity study)|Phase Ib (Dose-effect study)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability|Functionnal recovery|Post stroke handicap|Motor recovery|fMRI recovery|Blood biomarkers for stroke recovery,"University Hospital, Grenoble|Horizon 2020 - European Commission|University Grenoble Alps|Servicio Madrileño de Salud, Madrid, Spain|St. Anne's University Hospital Brno, Czech Republic|Andaluz Health Service|University of Glasgow|University of Eastern Finland|Etablissement Français du Sang|Tampere University|Histocell SL, Spain|Medfiles CRO, Finland|Institut National de la Santé Et de la Recherche Médicale, France|Hospices Civils de Lyon|Association Groupe ESSEC|NOVADISCOVERY SAS, France|Finovatis|Centre Hospitalier Universitaire de Besancon|Assistance Publique - Hôpitaux de Paris|University Hospital, Toulouse|University Hospital, Bordeaux|University Hospital, Caen|Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Servicio de Salud de Castilla La Mancha, Albacete, Spain|Servizo Galego de Saude, Santiago de Compostela, Spain|Pirkanmaa Hospital District, Tampere, Finland|Hospital Vall d'Hebron|Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta|CH Sainte-Anne, Paris, France",All,"18 Years and older   (Adult, Older Adult)",Phase 1,15,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,38RC17.312,"June 2, 2018",February 2020,September 2020,"June 27, 2018",,"June 27, 2018","CHU, Grenoble, France",,https://ClinicalTrials.gov/show/NCT03570450,NCT03570450,
oui,NCT03574883,Consciousness Transcranial Alternative Electric STimulation,CONTEST_1,Unknown status,No Results Available,Healthy,Device: tACS|Device: tDCS,Change in subjective performance on the behavioral task (% of seen masked target) between before and after stimulation.|Change in visual evoked potentials between before and after stimulation.|Change in quantitative EEG measures between before and after stimulation.|Change in objective performance on the behavioral task (% of correct response on the number comparison task for masked target) between before and after stimulation.,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",C17-22|2017-A02761-52,"April 23, 2018",October 2020,October 2020,"July 2, 2018",,"January 10, 2019","Institut du Cerveau et de la Moelle - CR-ICM U 975 / UMRS INSERM 1127, Paris, France",,https://ClinicalTrials.gov/show/NCT03574883,NCT03574883,
oui,NCT03576248,CONsciousness Transcranial Electric STimulation,CONTEST_3,Recruiting,No Results Available,Disorder of Consciousness,Device: In-phase 6 Hz prefronto-parietal tACS|Device: Sham prefronto-parietal tACS|Device: 2 mA left prefrontal tDCS|Device: Sham left prefrontal tDCS,State of consciousness|Evoked response potential during local-global paradigm|Resting state EEG,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C17-56|2017-A02763-50,"November 19, 2018",July 2023,July 2023,"July 3, 2018",,"January 10, 2019","Institut du Cerveau et de la Moelle - CR-ICM U 975 / UMRS INSERM 1127, Paris, France",,https://ClinicalTrials.gov/show/NCT03576248,NCT03576248,
oui,NCT03582436,Rejection Diagnosis in Kidney Transplants Patients,KTD-innov,Completed,No Results Available,Kidney Transplantation|Transplant Rejection|Graft Survival,Procedure: Kidney transplantation,"Concordance of invasive/non-invasive biomarkers with allograft rejection|Association of non-invasive biomarkers with different subtypes of rejection|Association of gene sets with different subtypes of rejection in the biopsy.|Reclassification capacity of gene sets and non-invasive biomarkers to define allograft rejection.|Variation of the non-invasive biomarker signature of allograft rejection|Variation of the gene set signature|Cumulative incidence of antibody-mediated rejection (ABMR)|Cumulative incidence of T-cell-mediated rejection (TCMR)|Treatment failure rate|Graft and patient survival|Histological evidence of ABMR and/or TCMR on protocol biopsies|Overall pathological changes, including chronic ABMR|Incidence of delayed graft function|Cumulative incidence and duration of dialysis.",Assistance Publique - Hôpitaux de Paris,All,"18 Years and older   (Adult, Older Adult)",,824,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,K170909J|2018-A00090-55,"June 25, 2018","March 18, 2021","March 18, 2021","July 11, 2018",,"February 10, 2022","Hopital Saint-Louis, Paris, France",,https://ClinicalTrials.gov/show/NCT03582436,NCT03582436,
oui,NCT03586258,Neuropsychological and Brain Medical Imaging Study in Patients With Brain Damage 2,CORAC2,Recruiting,No Results Available,Cerebrovascular Disorders|Brain Lesion|Degenerative Disease|Developmental Disability,Behavioral: Neuropsychological testing|Other: Brain Imaging|Other: Galvanic Vestibular Stimulation (GVS),Cognitive Deficit,"University Hospital, Caen",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2017-A03062-51,"January 10, 2019",June 2023,June 2024,"July 13, 2018",,"February 8, 2023","Caen University Hospital, Caen, France",,https://ClinicalTrials.gov/show/NCT03586258,NCT03586258,
oui,NCT03596437,Study of Arterial Properties by Ultra-high Frequency Ultrasound in Fibromuscular Dysplasia and Vascular Ehlers-Danlos Syndrome,FUCHSIA-FR,Unknown status,No Results Available,Ehlers-Danlos Syndrome|Fibromuscular Dysplasia,Device: Ultra High Frequency ultrasound system,"Agreement between ultrahigh-frequency and standard ultrasound in the identification of ""triple signal"" in the common carotid artery wall in fibromuscular dysplasia|Agreement between ultrahigh frequency and standard ultrasound in the evaluation of carotid intima-media thickness in fibromuscular dysplasia.|Agreement between ultrahigh frequency and standard ultrasound in the evaluation of carotid intima-media thickness in vascular Ehlers-Danlos syndrome.|Agreement between ultrahigh frequency and standard ultrasound in the evaluation of carotid distensibility in fibromuscular dysplasia.|Agreement between ultrahigh frequency and standard ultrasound in the evaluation of carotid distensibility in vascular Ehlers-Danlos syndrome.|Reproducibility of radial intima-media thickness, measured by ultrahigh frequency ultrasound in fibromuscular dysplasia and vascular Ehlers-Danlos syndrome.|Reproducibility of radial distensibility, measured by ultrahigh frequency ultrasound in fibromuscular dysplasia and vascular Ehlers-Danlos syndrome.","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,P180201J,"January 7, 2019",March 2019,March 2019,"July 23, 2018",,"March 13, 2019","Unité de pharmacologie clinique HEGP, Paris, France",,https://ClinicalTrials.gov/show/NCT03596437,NCT03596437,
oui,NCT03597659,PheWAS of a Polygenic Predictor of Thyroid Function,PHETHYR,Completed,No Results Available,Thyroid|Genetic Predisposition to Disease,Genetic: phenome-wide association study (PheWAS),thyroid disorders associated with a polygenic predictor of thyroid stimulating hormone levels|Clinical diagnoses associated with a polygenic predictor of TSH levels,Groupe Hospitalier Pitie-Salpetriere|Vanderbilt University Medical Center,All,"28 Years to 100 Years � (Adult, Older Adult)",,37154,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,CIC1421-18-09,"September 1, 2017","July 1, 2018","July 1, 2018","July 24, 2018",,"September 26, 2019","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris, France",,https://ClinicalTrials.gov/show/NCT03597659,NCT03597659,
oui,NCT03599960,Combination Chemotherapy in Patients With Newly Diagnosed BPDCN,LpDessai,Recruiting,No Results Available,Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN),Drug: Chemotherapy,Proportion of patients with complete response after 3 cycles of chemotherapy|Proportion of patients with response (complete or partial) after 3 cycles of chemotherapy|Overall survival|Relapse-free survival|Residual L-asparaginase activity|Anti-L-asparaginase antibodies levels,"Centre Hospitalier Universitaire de Besancon|UMR1098, EFS BFC, BESANCON|Centre Henri Becquerel|Maisonneuve-Rosemont Hospital|Centre Hospitalier Universitaire Dijon|Inserm CIC1431, CHU Besancon",All,"18 Years and older � (Adult, Older Adult)",Phase 2,26,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LpDessai,"May 2, 2019",September 2023,May 2025,"July 26, 2018",,"June 2, 2022","Clinique de L'Europe, Amiens, France|Chu Besancon, Besancon, France",,https://ClinicalTrials.gov/show/NCT03599960,NCT03599960,
oui,NCT03603743,High Intensity Interval Training vs Moderate Intensity and Continuous Training in Chronic Heart Failure,HRVFIT2,Completed,No Results Available,Chronic Heart Failure,Behavioral: exercise training in heart failure with HIIT,"High Frequency power in normalized units (HFnu%)|maximal oxygen consumption (VO2peak ml.min.kg)|First ventilatory threshold (VT1) (ml.min.kg)|Heart Rate Recovery (beats per minute, bpm)|Left Ventricular Ejection Fraction (LVEF, %)|premature ventricular contraction, (n/24h)|NT-pro-BNP, (ng/L)","Cardiovascular and Pulmonary Rehabilitation Center of Saint Orens|Institut National de la Sant� Et de la Recherche M�dicale, France|University Hospital, Toulouse|Clinique Pasteur",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,32,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",2-15-12,"May 7, 2015","October 13, 2017","October 13, 2017","July 27, 2018",,"July 30, 2018",,"""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03603743/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03603743,NCT03603743,31352063
oui,NCT03613298,Treatment by HIFU With Focal One® of Posterior Deep Infiltrating Endometriosis Lesions With Intestinal Involvement.,,Completed,No Results Available,Endometriosis,Device: HIFU (Focal One®),Targeting of the endometriosic lesion|Anatomical position of the Focal One probe|Effect of HIFU treatment on endometriosic lesion|Safety of the procedure: assessment of complications during the procedure attributable to the technique|Assessment of Adverse Events during the 6 months follow-up attributable to the technique|Medical Outcome assessment (Study Short Form-36)|endometriosis health profile assessment|Urinary symptom profile assessment|Sexual function assessment|Constipation assessment|Anal continence assessment,"EDAP TMS S.A.|Institut National de la Santé Et de la Recherche Médicale, France",Female,"25 Years and older   (Adult, Older Adult)",Not Applicable,20,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HIFU/F/13.12,"September 21, 2015",May 2019,May 2019,"August 3, 2018",,"July 31, 2019","Hôpital de la Croix Rousse, Lyon, France",,https://ClinicalTrials.gov/show/NCT03613298,NCT03613298,
oui,NCT03619512,Genomic and Proteomic Study of Richter Syndrome (CGPSR),CGPSR,Recruiting,No Results Available,Richter Syndrome,Genetic: Whole exome sequencing.|Genetic: RNA sequencing|Other: Mass spectrometry,Whole exome sequencing data using next generation sequencing method|RNA sequencing data using next generation sequencing method|Proteomic analysis using mass spectrometry,"Central Hospital, Nancy, France|French Innovative Leukemia Organization (FILO)|Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,170,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2017-A01978-45|PSS2017/CGPSR-BROSÉUS/VS,"September 6, 2017","December 31, 2023","September 5, 2024","August 8, 2018",,"March 24, 2023","CHRU de Nancy, Nancy, France",,https://ClinicalTrials.gov/show/NCT03619512,NCT03619512,34000073
oui,NCT03619720,"Emotional Perception and Production in Facial Palsy: Respiratory, Vocal and Facial Markers.",ResPPF,Completed,No Results Available,Facial Palsy,Other: Records,Effects of facial impairment on the respiratory rate|Effects of facial impairment on pitch variation (Hz) during emotional vocal production.|Effects of facial impairment on perception of emotional facial displays.,Association pour le D�veloppement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2018-A01043-52,"August 11, 2018","September 25, 2019","April 10, 2020","August 8, 2018",,"August 14, 2020","Laboratoire de Physiopathologie Respiratoire du Service de Pneumologie et de R�animation, Paris, France","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03619720/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03619720,NCT03619720,
oui,NCT03630874,A Prescription Support Tool for Oral Antithrombotic Combinations,COMBI-AT,Completed,No Results Available,Antithrombotics Prescriptions,Other: Evaluate the impact of a prescription support tool,"The primary outcome measure is the rate of the ""right prescription of oral ATs"" as defined according to the guidelines in terms of number, class, duration and dosage between the two groups.|The rate of the ""right prescription of oral ATs"" performed by physicians' specialty.|The difference between the control and intervention groups in the degree of confidence physicians have in their AT prescriptions in line with the guidelines.","Assistance Publique - H�pitaux de Paris|Sorbonne University|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,478,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,18-492,"November 5, 2018","February 14, 2019","February 14, 2019","August 15, 2018",,"May 16, 2019",,,https://ClinicalTrials.gov/show/NCT03630874,NCT03630874,31717418;31182442
oui,NCT03652090,Primary Nasal Cell Culture as a Tool for Personalized Therapy in Cystic Fibrosis,Epiithelix,Completed,No Results Available,Cystic Fibrosis,Procedure: cell sampling,variation in the short-circuit-current (Isc) after Forskolin (Forskolin)/IBMx and VX-770 (∆IscFsk/IBMx+VX-770)|percentage of cells displaying apical staining,"Institut National de la Santé Et de la Recherche Médicale, France|ABCF2",All,"Child, Adult, Older Adult",,112,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,2010-05-03 A3,"September 1, 2010","March 3, 2016","March 3, 2016","August 29, 2018",,"March 12, 2019",,,https://ClinicalTrials.gov/show/NCT03652090,NCT03652090,
oui,NCT03652402,Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN,EU-TRAIN,Completed,No Results Available,Kidney Transplant Rejection|Kidney Transplantation|Risk Stratification|Prognosis,Procedure: kidney transplantation,"Capacity of non-invasive biomarkers and intragraft gene expression profiles combined to standard of care data (HLA system, clinical and biological data)|Correlation of blood biomarkers concentration with allograft rejection (rejection assessed by histopathology)|Correlation of blood biomarker concentrations with allograft function (function measured by the Glomerular Filtration Rate (GFR)).|Assessment of changes in biomarker levels in serial measurements and association with allograft function (function measured by the GFR)|Correlation of gene expression in kidney allografts with allograft rejection (rejection assessed by histopathology)|Gene expression related risk stratification of response to treatment in kidney allograft rejection (rejection assessed by histopathology)|Assessment of the changes of patient's well-being across time and centres",Assistance Publique - Hôpitaux de Paris,All,"18 Years to 100 Years   (Adult, Older Adult)",,558,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,K170203J|IDRCB 2018-A00733-52,"November 27, 2018","October 28, 2021","October 28, 2021","August 29, 2018",,"March 15, 2023","Hopital Saint Louis, Paris, Ile De France, France|Hôpital du Kremlin Bicêtre, Le Kremlin-Bicêtre, Paris, France|CHU Nantes, Nantes, France|Hôpital Necker, Paris, France|Hospital La Charité, Berlin-Mitte, Berlin, Germany|Hospital La Charité Campus Virchow, Berlin, Germany|Hospital Bellvitge, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hôpitaux Universitaires de Genève, Geneva, Switzerland",,https://ClinicalTrials.gov/show/NCT03652402,NCT03652402,
oui,NCT03655561,Lassa Fever Clinical Course and Prognostic Factors in Nigeria,LASCOPE,Recruiting,No Results Available,Lassa Fever|Lassa Virus Infection|Pregnancy Complications|Acute Kidney Injury|Acute Kidney Failure|Coma,Other: Non interventional research,Overall mortality|Acute kidney injury|Mother status at the end of pregnancy|Type of pregnancy termination|Pregnancy complications|Newborn status at birth|Newborn status at day 30|Newborn status at day 60,"Alliance for International Medical Action|Institut National de la Sant� Et de la Recherche M�dicale, France|University of Oxford|Owo Federal Medical Center|Irrua Specialist Teaching Hospital|Bernhard Nocht Institute for Tropical Medicine|University Hospital, Bordeaux|University of Bordeaux|PACCI Program|African coaLition for Epidemic Research, Response and Training|Institut de Recherche pour le Developpement|ANRS, Emerging Infectious Diseases",All,"Child, Adult, Older Adult",,1200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,LAS001,"April 5, 2018","June 30, 2023","June 30, 2023","August 31, 2018",,"March 29, 2022","Owo Federal Medical Centre (Owo FMC), Owo, Ondo, Nigeria",,https://ClinicalTrials.gov/show/NCT03655561,NCT03655561,31978611
oui,NCT03662347,Patient Acceptable Symptomatic State and Minimal Clinically Important Difference of the Fatigue in Multiple Sclerosis (SeDiF_SEP),SeDiF_SEP,Unknown status,No Results Available,Multiple Sclerosis,,"Fatigue score: EMIF-SEP scale|The quality of life: SF-36|The quality of life: MuSIQoL|Nutritional behaviors (physical activity and sedentary lifestyle)|Psychological state (optimism, anxiety, depression)","Central Hospital, Nancy, France",All,"18 Years and older � (Adult, Older Adult)",,2100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2018-A00403-52|APJC2016/SeDIF_SEP-EPSTEIN/AS,"March 19, 2020",March 2022,March 2022,"September 7, 2018",,"July 8, 2020","CIC 1433 �pid�miologie clinique, Inserm, CHRU de Nancy, Universit� de Lorraine, Vandoeuvre Les Nancy, France",,https://ClinicalTrials.gov/show/NCT03662347,NCT03662347,
oui,NCT03670927,Etiosarc: Environmental Aetiology of Sarcomas From a Multicenter French Population-based Case-control Study Among Adults,ETIOSARC,Recruiting,No Results Available,Sarcoma|Environmental Exposure|Occupational Exposure|Life Style,"Other: Environmental, occupational and lifestyle-related exposures","Odds ratios measuring the association between environmental exposures under study (environmental, occupational and lifestyle exposures) and sarcoma occurence","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,6462,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C17-03,"April 25, 2019","April 25, 2022","April 25, 2022","September 14, 2018",,"August 26, 2021","CHRU, Besançon, France|Institut Bergonié, Bordeaux, France|Centre François Baclesse, Caen, France|Centre Oscar Lambret, Lille, France|CHU Dupuytren, Limoges, France|Centre Léon Bérard, Lyon, France|Institut régional du Cancer Montpellier, Montpellier, France|CHU, Nantes, France|CHRU, Strasbourg, France|Institut Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT03670927,NCT03670927,31217320
oui,NCT03670953,A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations,,Completed,Has Results,Parkinson's Disease (Disorder),Drug: IR CD-LD|Drug: IPX203 ER CD-LD|Other: Placebo Matching IPX203|Other: Placebo Matching IR CD-LD,"Mean Change From Baseline in ""Good on"" Time Per Day at Week 20/Early Termination (ET)|Change From Baseline in ""Off"" Time Per Day at Week 20/ET|Percentage of Participants With Either ""Much Improved"" or ""Very Much Improved"" in Patient Global Impression of Change (PGI-C) Scores at Week 20/ET|Change From Baseline in The Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III at Week 20/ET|Change From Baseline in The Sum of MDS-UPDRS Part II and Part III at Week 20/ET","Impax Laboratories, LLC",All,"40 Years and older � (Adult, Older Adult)",Phase 3,630,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IPX203-B16-02|2018-002233-37,"November 6, 2018","June 15, 2021","June 15, 2021","September 14, 2018","February 9, 2023","February 9, 2023","Xenoscience, Inc. (102), Phoenix, Arizona, United States|St. Joseph's Hospital & Medical Center/ Barrow Neurological Institute (156), Phoenix, Arizona, United States|Clinical Trials, Inc. (113), Little Rock, Arkansas, United States|University of Arkansas for Medical Sciences (117), Little Rock, Arkansas, United States|Loma Linda University Health Care, Department of Neurology (137), Loma Linda, California, United States|Keck School of Medicine of USC/University of Southern California (106), Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian (134), Newport Beach, California, United States|SC3 Research - Pasadena (148), Pasadena, California, United States|SC3 Research - Reseda (146), Reseda, California, United States|University of Colorado Hospital Anschutz Outpatient Pavilion (120), Aurora, Colorado, United States|Rocky Mountain Movement Disorders Center (116), Englewood, Colorado, United States|Christiana Care Neurology Specialists (153), Newark, Delaware, United States|JEM Research Institute (136), Atlantis, Florida, United States|Visionary Investigators Network (168), Aventura, Florida, United States|University of Miami-UHealth at Boca Raton (152), Boca Raton, Florida, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton (121), Boca Raton, Florida, United States|MD Clinical (111), Hallandale Beach, Florida, United States|Infinity Clinical Research (104), Hollywood, Florida, United States|University of Florida Health Science Center(129), Jacksonville, Florida, United States|Neurology Associates, P.A. (125), Maitland, Florida, United States|University of Miami (149), Miami, Florida, United States|Medical Professional Clinical Research Center, INC (163), Miami, Florida, United States|Parkinsons's Disease Treatment Center of Southwest Florida (131), Port Charlotte, Florida, United States|Infinity Clinical Research, LLC (105), Sunrise, Florida, United States|University of South Florida (114), Tampa, Florida, United States|Premiere Research Institute at Palm Beach Neurology (174), West Palm Beach, Florida, United States|Charter Research (166), Winter Park, Florida, United States|Emory Brain Health Center (110), Atlanta, Georgia, United States|NeuroStudies.net, LLC (155), Decatur, Georgia, United States|Northwestern Medical Group Neurology Clinic(145), Chicago, Illinois, United States|Central DuPage Hospital (151), Winfield, Illinois, United States|Indiana University Health Neuroscience Center (164), Indianapolis, Indiana, United States|University of Kansas Medical Center (118), Kansas City, Kansas, United States|Quest Research Institute (103), Farmington Hills, Michigan, United States|Henry Ford West Bloomfield Hospital (100), West Bloomfield, Michigan, United States|Struthers Parkinson's Center (130), Golden Valley, Minnesota, United States|Washington University (109), Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health (142), Las Vegas, Nevada, United States|Roseman Medical Research Institute/Roseman Medical Group (154), Las Vegas, Nevada, United States|Albany Medical College (139), Albany, New York, United States|Mount Sinai West-Department of Neurology(172), New York, New York, United States|Wake Forest Baptist Health Sciences (127), Winston-Salem, North Carolina, United States|Ucgni (133), Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center (123), Cleveland, Ohio, United States|Cleveland Clinic (144), Cleveland, Ohio, United States|University of Toledo, Gardner-McMaster Parkinson Center (122), Toledo, Ohio, United States|Movement Disorder Clinic of Oklahoma (115), Tulsa, Oklahoma, United States|Medical University of South Carolina (150), Charleston, South Carolina, United States|The Vanderbilt Clinic(158), Nashville, Tennessee, United States|Neurology Consultants of Dallas, PA (108), Dallas, Texas, United States|University of Texas Southwestern Medical Center (143), Dallas, Texas, United States|Houston Methodist Neurological Institute/Movement Disorders Clinic (135), Houston, Texas, United States|Inova Medical Group-Neurology I (147), Alexandria, Virginia, United States|VCU Health - Neuroscience, Orthopaedic and Wellness Center (124), Henrico, Virginia, United States|Booth Gardner Parkinson's Care Center (112), Kirkland, Washington, United States|Inland Northwest Research (119), Spokane, Washington, United States|Fakultni nemocnice u sv. Anny v Brne, I. neurologicka klinika (704), Brno, Czechia|Neurohk, s.r.o (701), Choce?, Czechia|Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice, Neurologicka klinika (702), Pardubice, Czechia|Clintrial s.r.o. (703), Praha 10, Czechia|AXON Clinical, s.r.o. (700), Praha 5, Czechia|Neurologicka ordinace FORBELI s.r.o.(706), Praha 6, Czechia|CHU de Clermont-Ferrand - Hopital Gabriel Montpied (404), Clermont-Ferrand Cedex 1, France|CHU de Montpellier, Hopital Gui de Chauliac(405), Montpellier Cedex 5, France|Centre Hospitalier Universitaire de Nice (400), Nice, France|INSERM, Centre d'investigation Clinique 1402, CHU de Poitiers (402), Poitiers Cedex, France|Centre d'Investigation Clinique 1436-CHU Purpan-Hopital Pierre Paul Riquet (403), Toulouse Cedex 9, France|Curiositas ad sanum, Studien und Beratungs GmbH(311), M�nchen, Bavaria, Germany|Klinikum rechts der lsar der TUM, Klinik und Poliklinik fur Neurologie (303), M�nchen, Bavaria, Germany|Kliniken Beelitz GmbH, Neurologisches Fachkrankenhaus fUr Bewegungsstorungen/Parkinson (300), Beelitz-Heilstatten, Brandenburg, Germany|Gemeinschaftspraxis Dr. med. Joachim Springub/ Wolfgang Schwarz, Studienzentrum Nord-West (306), Westerstede, Lower Saxony, Germany|St. Josef-Hospital, Universitatsklinik fur Neurologie, Klinisches Forschungszentrum fur Neurodegeneration (301), Bochum, North Rhine-Westphalia, Germany|Klinik Haag i. OB, Geriatric Hospital (305), Haag In Oberbayern, Oberbayern (Upper Bavaria), Germany|Universitatsklinikum Carl Gustav Carus, Klinik und Poliklinik fur Neurologie (307), Dresden, Saxony, Germany|Dr. med. REINHARDT Ehret Neurologie Berlin Schlobstr. 29 (309), Berlin, Germany|Department ""G.F. Ingrassia"" Section of neuroscience-Policlinico ""Vittorio Emanuele"" (608), Catania, Italy/Catania/Sicily, Italy|Universita G. D'annunzio CeSi Met (604), Chieti, Italy/Chieti/Abbruzzo, Italy|Centro Ricerca Parkinson San Raffaele Cassino (601), Cassino, Italy/Frosinone/Lazio, Italy|Fondazione lstituto Neurologico Nazionale ""C. Mondino"" (606), Pavia, Italy/Pavia/Lombardia, Italy|Azienda Ospedaliero-Universitaria Pisana (602), Pisa, Italy/Pisa/Toscana, Italy|University of Rome Tor Vergata/Hospital Tor Vergata (605), Roma, Italy/Roma/Lazio, Italy|IRCCS San Raffaele Pisana (600), Roma, Italy/Roma/Lazio, Italy|Department of Neuroscience, Mental Health and Sensory System (NeSMOS), Sapienza University (603), Roma, Italy/Roma/Lazio, Italy|Centrum Medyczne Neuromed (803), Bydgoszcz, Poland|Szpital Sw. Rozy (805), Krak�w, Poland|Krakowska Akademia Neurologii Sp. z o.o.(802), Krak�w, Poland|NZOZ Neuromed M. i M Nastaj Spolka Partnerska(800), Lublin, Poland|NZOZ Neuro-Kard Ilkowski i Partnerzy Spolka Partnerska Lekarzy (801), Pozna?, Poland|Neuro-Care Sp. z o.o. sp. k.(804), Siemianowice ?l?skie, Poland|Centrum Medyczne NeuroProtect (806), Warszawa, Poland|Hospital Genral Universitario de Elche (509), Elche, Alicante, Spain|Hospital Universitari General de Catalunya (504), Sant Cugat Del Vall�s, Barcelona, Spain|Hospital Universitari Mutua Terrassa (506), Terrassa, Barcelona, Spain|Policlinica Gipuzkoa, S.A.,(511), San Sebastian, Gipuzkoa, Spain|Clinica Universidad de Navarra (512), Pamplona, Navarra, Spain|Hospital Universitario Quiron Dexeus (501), Barcelona, Spain|Hospital Universitario Vall d' Hebron (505), Barcelona, Spain|Hospitalaries Del Sagrat Cor De Jesus Hospital Sant Rafael (516), Barcelona, Spain|Hospital Clinic de Barcelona (507), Barcelona, Spain|Hospital De La Santa Creu i Sant Pau (502), Barcelona, Spain|Hospital Universitario de la Princesa (508), Madrid, Spain|Hospital Universitario Ramon y Cajal (500), Madrid, Spain|Hospital Universitario Infanta Sofia (513), Madrid, Spain|Hospital Universitario Virgen del Rocio (503), Sevilla, Spain|Hospital Universitario y politecnico La Fe (515), Valencia, Spain|Re: Cognition Health Ltd(205), Plymouth, Devon, United Kingdom|Re:Cognition Health Ltd (202), London, United Kingdom|Imperial College Healthcare NHS Trust (200), London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03670953/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03670953/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03670953,NCT03670953,
oui,NCT03673189,Sensors for HEalth Recording and Physical Activity Monitoring,SHERPAM,Completed,No Results Available,Physical Activity,Device: sensors,asses the continuous acquisition of data by sensors|Test acceptability of SHERPAM Device|Test acceptability of Sherpam Device|Test usability of Sherpam Device,Rennes University Hospital|LTSI-INSERM U1099|CIC-IT 14-14,All,"18 Years to 75 Years � (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,35RC17_8836,"June 28, 2018","September 12, 2019","September 12, 2019","September 17, 2018",,"April 14, 2021","Unit� de Biologie et m�decine du Sport, Rennes, Bretagne, France",,https://ClinicalTrials.gov/show/NCT03673189,NCT03673189,
oui,NCT03687918,External Validation of Prostate MRI QCAD/Lyon,DIJON-CAD,Unknown status,No Results Available,Prostate Cancer,Other: Assessment of the performances of QCAD/Lyon in characterizing Gleason ?7 cancers among contoured lesions,Area under the receiver operating characteristic curve for detection of Gleason ?7 cancers (with 95% confidence interval),Hospices Civils de Lyon,Male,"18 Years and older � (Adult, Older Adult)",,80,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,DIJON-CAD,"June 1, 2018","September 30, 2018","October 1, 2018","September 27, 2018",,"September 27, 2018","Department of pathology, CHU de Dijon, Dijon, France|Department of radiology and nuclear medicine, Centre anti-canc�reux Georges-Fran�ois Leclerc, Dijon, Dijon, France|Department of radiology, CHU de Dijon, Dijon, France|Department of urology, CHU de Dijon, Dijon, France|Department of biostatistics, Universit� Joseph Fourrier, Grenoble, France|Department of vascular and urinary imaging, h�pital Edouard Herriot, Hospices Civils de Lyon, Lyon, France|LabTau, INSERM unit 1032, Lyon, Lyon, France",,https://ClinicalTrials.gov/show/NCT03687918,NCT03687918,
non,NCT03690063,Nice Human Immunodeficiency Virus (HIV) Cohort,,Recruiting,No Results Available,Human Immunodeficiency Virus,Other: Follow up,change of the clinico-biological signs of the patients|number of the various type of adverse events related by type of treatments,Centre Hospitalier Universitaire de Nice,All,"18 Years and older � (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,18-DSP-01,January 1996,January 1996,"December 31, 2024","October 1, 2018",,"October 1, 2018","CHU de Nice, Nice, France",,https://ClinicalTrials.gov/show/NCT03690063,NCT03690063,
oui,NCT03694132,Brain Excitability and Connectivity in Sensory-motor Pathways in ALS,SOM_ALS,Unknown status,No Results Available,Amyotrophic Lateral Sclerosis,Device: functional MRI|Device: structural MRI|Device: EEG/MEG,Brain activity|Brain connectivity,"Institut National de la Santé Et de la Recherche Médicale, France",All,"30 Years to 80 Years   (Adult, Older Adult)",Not Applicable,52,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C17-70,"November 26, 2018","December 31, 2019","April 6, 2022","October 3, 2018",,"December 21, 2018","Hopital Pitie-Salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT03694132,NCT03694132,
oui,NCT03694171,Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study),,Completed,No Results Available,Cancer,,Cancer stage at diagnosis|Cancer treatment|Functional decline|Survival,"Institut Bergonié|Institut National de la Santé Et de la Recherche Médicale, France|University of Bordeaux",All,65 Years and older   (Older Adult),,450,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,IB2013 INCAPAC,November 2013,November 2016,November 2017,"October 3, 2018",,"June 5, 2019","Institut Bergonié, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT03694171,NCT03694171,
non,NCT03698461,Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab,CLIMB,"Active, not recruiting",No Results Available,Colorectal Neoplasms|Neoplasm Metastasis|Colonic Neoplasms|Rectal Neoplasms,Drug: Atezolizumab|Drug: Bevacizumab|Drug: Oxaliplatin|Drug: Levoleucovorin|Drug: 5-FU,"Serial changes in Cluster of Differentiation(CD) 8+ T cell densities|Serial changes of Immune cell biomarkers CD3, CD4, Programmed death-Ligand 1(PD-L1),PD-1, granzyme B, CD45RO, Forkhead Box P3(FOXP3), CD68|Serial changes of Immune cell CD3+, CD8+ densities|Serial changes of Density of Vascular marker CD31, CD34|Serial changes of Gene expression profile|Response Rate|Progression-Free Survival|R0 resection rate|Incidence, nature and severity of adverse events with severity (Safety profile)|Microbiome profile",Asan Medical Center|Hoffmann-La Roche,All,"20 Years and older � (Adult, Older Adult)",Phase 2,20,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ASA-1,"May 15, 2019","December 22, 2021",December 2023,"October 9, 2018",,"July 7, 2022","Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03698461,NCT03698461,
oui,NCT03708263,Evaluation of the New Laser PHOTOLASE PLV-585nm for the Treatment of Rosacea,ROSAPHOTOLASE,Terminated,No Results Available,Erythematotelangiectatic Rosacea,Device: Excel V 532nm (KTP) green Laser|Device: PHOTOLASE PLV 585 nm yellow laser,Degree of improvement in Erythematotelangiectatic Rosacea|Degree of improvement in Erythematotelangiectatic Rosacea evaluated by a blinded physician.|Measures of skin reaction for each treatment arm|Pain evaluation during each treatment|Change in lesion skin color in each treatment arm|Subject satisfaction level|Change in Life Quality|Practitioner's opinion|Adverse Events,"University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France|Medical Research Fund of the Tampere University Hospital, Finland",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,1,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2017_57|2018-A01904-51,"September 8, 2020","September 14, 2021","September 14, 2021","October 17, 2018",,"March 15, 2022","Hop Claude Huriez Chu Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT03708263,NCT03708263,
oui,NCT03713203,PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget's Disease of the Vulva (EMPV).,PAGETEX,Recruiting,No Results Available,"Paget Disease of the Vulva|Paget Disease, Extramammary",Device: pagetex PDT,disease control rate in 30% of patients included|Subject discomfort measured during each treatment using a Visual Analogic Scale Evaluation of pain|Clinical Evolution measured using an erythema 4 points scale and Chroma meter CR400 measures|Presence/absence of Paget cells in vulvar biopsy.|Change in score Dermatology Life Quality Index (DLQI)|Change in SF 36|Change in Hospital Anxiety and Depression Scale. (HADS)|Change in The Female Sexual Function Index (FSFI)|Presence or absence of fluorescence on the Dermoscope Fotofinder® photographs|number of Adverse Events,"University Hospital, Lille|Galderma R&D|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,24,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017_71|2018-A01873-52|2018-002604-13,"August 27, 2019",August 2024,August 2024,"October 19, 2018",,"June 6, 2022","Hôpital Claude Huriez, CHU, Lille, France",,https://ClinicalTrials.gov/show/NCT03713203,NCT03713203,31793891
oui,NCT03720730,SmartCriseS - Smartphone Survey of Suicidal Risk,SmartCriseS,Recruiting,No Results Available,Personal History of a Recent Suicidal Crisis|Suicidal Ideation|Suicidal Behaviour,Other: EMA,Occurrence of suicidal event assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)|Evaluation of insomnia assessed by ecological momentary assessment (EMA)|Evaluation of insomnia assessed by Insomnia Severity Index (ISI)|Evaluation of appetite assessed by ecological momentary assessment (EMA)|Evaluation of sensibility to social exclusion assessed by ecological momentary assessment (EMA)|Evaluation of suicidal ideation intensity assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)|Evaluation of the intensity of death wish assessed by ecological momentary assessment (EMA)|Evaluation of suicide attempts severity assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)|Evaluation of sleep duration assessed by Pittsburgh Sleep Quality Index (PSQI)|Evaluation of physical activity by eB2,"University Hospital, Montpellier|Centre Hospitalier Universitaire de N?mes|Instituto de Investigaci�n Sanitaria de la Fundaci�n Jim�nez D�az|INSERM U1061 Neuropsychiatry Montpellier, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,1044,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,UF 9821,"November 13, 2018","January 13, 2026","April 13, 2026","October 25, 2018",,"December 7, 2021","CHU Montpellier, Montpellier, France|Fundacion Jimenez Diaz Hospital, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03720730,NCT03720730,33884617;31493783
oui,NCT03723668,Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France,USFRKT,Completed,No Results Available,"Kidney Failure|Transplant;Failure,Kidney",,Number of kidneys procured and discarded.|Probability of allograft failure after transplantation.,Paris Translational Research Center for Organ Transplantation|University of Pennsylvania|Agence de La Biom�decine,All,"Child, Adult, Older Adult",,94017,Other,Observational,Observational Model: Cohort|Time Perspective: Other,USFRKT1,"October 9, 2017","October 11, 2018","March 29, 2020","October 29, 2018",,"May 1, 2020","Kidney Transplantation Care at Veteran's Affairs Medical Center, Philadelphia, Pennsylvania, United States|Paris Transplant Group, Paris, France",,https://ClinicalTrials.gov/show/NCT03723668,NCT03723668,31449299
oui,NCT03731845,Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer,ESIGON,"Active, not recruiting",No Results Available,Breast Cancer,Genetic: Blood sample for genetic test|Biological: Blood sample for hormonal measurement|Other: Ovarian ultrasound scan,"Assessment of ovarian reserve|Menstrual profile: amenorrhea, spaniomenorrhea, normal cycle length (28-35 days)|Pregnancy rates|AMH level|Antral Follicle Count (Ultrasound evaluation)|Follicular decline (definition below)","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 36 Years   (Adult),Not Applicable,73,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,K160913J|2017-A02111-52,"April 1, 2019",October 2026,January 2027,"November 6, 2018",,"October 31, 2022","Antoine Béclère Hospital, Clamart, France",,https://ClinicalTrials.gov/show/NCT03731845,NCT03731845,
oui,NCT03739892,Biomarkers to Predict Gain From Therapy in Motor Stroke,GAIN,Unknown status,No Results Available,Stroke|Motor Activity|Biomarker,Behavioral: standard stroke rehabilitation,"Changes in a composite motor score post-pre training is the gain from therapy Candidates biomarkers: MRI, EEG, TMS, genotype|Changes in a composite motor score post-pre training is the gain from therapy","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,C17-54,November 2018,August 2020,October 2020,"November 14, 2018",,"November 14, 2018","ICM, Paris, France",,https://ClinicalTrials.gov/show/NCT03739892,NCT03739892,
oui,NCT03741140,Characterizing the Neural Bases of Motivational Disorders After Stroke,MOTI-stroke,Recruiting,No Results Available,Stroke,Diagnostic Test: Motivation tests,Reward sensitivity|Effort sensitivity,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C17-19|2018-A00511-54 / 1,"October 22, 2020",January 2023,January 2023,"November 14, 2018",,"July 1, 2021","Urgences cérébro-vasculaires hopital Pitié-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT03741140,NCT03741140,
non,NCT03741569,Multisensor Technology for Beat to Beat Fetal Heart Rate Measurement,RCF-ABDO,Completed,No Results Available,Obstetric Labor,Device: Transabdominal Fetal Heart Rate,The fetal heart rate signal|The uterine contraction signal|Measuring the root mean square deviation between the heart rate signals from the device and the Doppler,"University Hospital, Lille",Female,"18 Years and older � (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2017_63|2018-A01194-51,"October 17, 2017","June 14, 2022","July 17, 2022","November 15, 2018",,"December 16, 2022","H�pital Roger Salengro, CHU, Lille, France",,https://ClinicalTrials.gov/show/NCT03741569,NCT03741569,
oui,NCT03743948,NIPD of CFTC by WGA Coupled to Mini-exome Sequencing,DIAFEXOME,Unknown status,No Results Available,Monogenic Diseases,Genetic: Non invasive prenatal diagnosis,Concordance rate between cell-based genetic non invasive prenatal test and gold standard prenatal test (choriocentesis or amniocentesis).|Non Invasive Prenatal Diagnostic test failure rate.,"University Hospital, Montpellier|ABM Industries",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,18,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,RECHMPL18_0281,"December 19, 2018","August 27, 2019","December 30, 2019","November 16, 2018",,"September 27, 2019","INSERM-Hospital,, Montpellier, Herault, France",,https://ClinicalTrials.gov/show/NCT03743948,NCT03743948,
oui,NCT03747315,A Diagnostic Test for Familial Mediterranean Fever,DEPIST-FMF,Completed,No Results Available,Familial Mediterranean Fever,Other: In vitro functional test,Differences in interleukin-1b? levels,Hospices Civils de Lyon,All,"4 Years and older � (Child, Adult, Older Adult)",,107,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,69HCL17_0710,"December 15, 2018","December 15, 2020","December 15, 2020","November 20, 2018",,"June 8, 2021","Service de n�phrologie et rhumatologie p�diatrique, H�pital Femme M�re Enfant, Bron, France|Unit� Inserm U1111 & Service de M�decine Interne, H�pital de la Croix-Rousse, Lyon, France|Service de M�decine Interne, Pavillon O - Hopital Edouard Herriot, Lyon, France|Service de M�decine Interne et pathologies vasculaires, Batiment 1B, Centre Hospitalier Lyon Sud, Pierre-B�nite, France",,https://ClinicalTrials.gov/show/NCT03747315,NCT03747315,
oui,NCT03748225,Incidence and Risk Factors of Prolonged Grief in Palliative Care Units,FAMI-LIFE,Completed,No Results Available,Bereaved Families,,Incidence of prolonged grief in bereaved family members|Risk factors of prolonged grief in bereaved family members|Post traumatic stress disorder in bereaved family members|Anxiety and depression symptoms in bereaved family members|Anxiety and depression symptoms in family members|Report of the families' grief experience in those who have signs of prolonged grief according to the Inventory of Complicated Grief questionnaire with a score > 25,GCS IHFB Cognacq-Jay|Fondation de France,All,"18 Years and older � (Adult, Older Adult)",,609,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IHFB-002,"February 4, 2019","October 1, 2020","February 10, 2021","November 20, 2018",,"February 11, 2021","French British Institute, Levallois-Perret, France",,https://ClinicalTrials.gov/show/NCT03748225,NCT03748225,31818281
oui,NCT03751475,Optimizing Acute Malnutrition Management in Children Aged 6 to 59 Months in Democratic Republic of Congo,OptiMA-DRC,Completed,No Results Available,"Severe Acute Malnutrition|Moderate Acute Malnutrition|Child Malnutrition|Acute Malnutrition|Congo, The Democratic Republic of the|Africa|Randomized Clinical Trial",Other: Nutritional Strategy - OptiMA|Other: Effective nutritional standard strategy,Success rate in each arm|Recovery rate in participants with severe acute malnutrition (WHO definition),"Alliance for International Medical Action|Ministry of Public Health, Democratic Republic of the Congo|The Innocent Foundation|University of Bordeaux, INSERM, Bordeaux Population Health",All,6 Months to 59 Months   (Child),Not Applicable,1071,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OptiMA-DRC,"July 22, 2019","July 20, 2020","July 20, 2020","November 23, 2018",,"November 25, 2020","Health Zone, Kamuesha, Kasai, Congo, The Democratic Republic of the","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03751475/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03751475,NCT03751475,36915287;35303461;33268424
oui,NCT03753308,Mechanism of DCs Dysfunction in Chronic HBV Infection,HepatoDC,Unknown status,No Results Available,HBV|NASH - Nonalcoholic Steatohepatitis,Biological: Blood Sampling|Biological: Liver biopsy,Define the subversion mechanism of dendritic cells (DCs) by hepatitis B virus (HBV)|Demonstrate the correlations between immunological and clinical parameters,"University Hospital, Grenoble|Institut National de la Santé Et de la Recherche Médicale, France|Etablissement Français du Sang",All,"18 Years and older   (Adult, Older Adult)",,132,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,38RC18.198,"December 5, 2018","December 5, 2021","December 31, 2022","November 26, 2018",,"September 1, 2020","Chu Grenoble Alpes, Grenoble, France",,https://ClinicalTrials.gov/show/NCT03753308,NCT03753308,
oui,NCT03753386,Identification of Respiratory Profiles From Nasal Pressure Signals,IPR-SAINS,Completed,No Results Available,Healthy,Other: Oxygen therapy simulation,Pressure,Association pour le D�veloppement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil|SRETT,All,"18 Years to 80 Years � (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2018-A01999-46,"May 16, 2019","May 16, 2019","May 28, 2019","November 27, 2018",,"September 16, 2019","INSERM-UPC UMR_S 1158, Service de Pneumologie et R�animation, GH Piti�-Salp�tri�re, Paris, France",,https://ClinicalTrials.gov/show/NCT03753386,NCT03753386,34275469
oui,NCT03756935,Early Detection of Intra Operative Hypotension (IOH) During the Induction of General Anaesthesia,,Completed,No Results Available,Radiography|Interventional,Procedure: All monitoring,Continuous measure of mean arterial pressure (MAP in mmHg)|Continuous measure of SpO2 in % by photoplethysmography,"Hopital Lariboisi�re|INSERM UMR-942, Paris, France|M3DISIM",All,"18 Years and older � (Adult, Older Adult)",,62,Other,Observational,Observational Model: Other|Time Perspective: Prospective,JMATEO,"November 1, 2014","May 23, 2015","May 23, 2015","November 28, 2018",,"November 28, 2018",,,https://ClinicalTrials.gov/show/NCT03756935,NCT03756935,30916032
oui,NCT03761875,NK Cell Deregulation in HBV Patients,LiNKeB,Unknown status,No Results Available,Hepatitis B Virus,Other: blood sample CHB patients|Other: boold sample Control group,"Using a multiparameter flow cytometry approach, we will assess the mean fluorescence intensity (MFI) of the listed molecules expressed on Natural Killer cells","University Hospital, Limoges",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,70,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,87RI18-0021,"December 11, 2018",December 2020,March 2021,"December 3, 2018",,"April 8, 2020","Limoges Hospital, Limoges, France",,https://ClinicalTrials.gov/show/NCT03761875,NCT03761875,
oui,NCT03769142,Cerebral Perfusion During Induction of General Anesthesia,,Completed,No Results Available,Radiography|Interventional,Procedure: All monitoring,Continuous measure of mean arterial pressure in mmHg (MAP)|Measure of cerebral blood flow (CFV in cm/s) with Transcranial Doppler|Continuous measure of Burst Suppression (BS in %) with Bispectral Index (BIS)|Continuous measure of cerebral oxygen saturation (SO2 in %) with Near-infrared spectroscopy (NIRS),"Assistance Publique - H�pitaux de Paris|INSERM UMR-942, Paris, France|Department of Anesthesiology, Hopital Foch, Suresnes, France.|M3DISIM|Ouctomes Research Consortium, Cleveland Clinic, Ohio, USA",All,"18 Years and older � (Adult, Older Adult)",,100,Other,Observational,Observational Model: Other|Time Perspective: Prospective,SRLF 11-356,"February 1, 2014","December 1, 2016","December 1, 2016","December 7, 2018",,"December 7, 2018",,,https://ClinicalTrials.gov/show/NCT03769142,NCT03769142,
oui,NCT03771144,Anatomopathology of the Subscapularis and Infraspinatus Muscles in Children With Brachial Plexus Obstetric Paralysis,POPB,Terminated,No Results Available,Brachial Obstetrical Palsy,Procedure: arthrolysis,"quantity of fibrosis on tissue muscle|quantity of satellit cells (Pax7, MyoD,Actine) on the muscle detected by PCR","University Hospital, Montpellier|PhyMedExp Inserm U1046",All,12 Months to 11 Years � (Child),Not Applicable,7,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,UF7640,"June 11, 2019","June 23, 2020","June 23, 2020","December 10, 2018",,"December 29, 2022","Chu Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT03771144,NCT03771144,
oui,NCT03776630,Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors,GYNO-MIR,"Active, not recruiting",No Results Available,Ovarian Cancer|Endometrial Cancer,Other: Blood sample,For EC: presence or absence of lymph-node metastases according to pathological analysis (reference technique).|For OC: PFS or death for any cause at 24 months.|It aims to investigate the links of the 5-miR index with classical predictors of lymph node involvement in the context of EC.|It aims to investigate the links of the 5-miR index with classical predictors of lymph node involvement in the context of EC (1)|It aims to assess the prognostic value of pre/post-operative plasma miR variations in terms of PFS in EC and OC|It aims to assess the prognostic value of pre/post-operative plasma miR variations in terms of OS in EC and OC|Sensitivity and specificity of plasma miR detection by RCA-FRET applied directly on plasma samples or following RNA extraction.,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,363,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,K160922J|2018-A00018-47,"May 23, 2019",May 2023,May 2027,"December 17, 2018",,"June 30, 2022","Service de chirurgie et oncologie gynécologique et mammaire, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT03776630,NCT03776630,
oui,NCT03782129,Five-year Mortality Rate in People With Diabetic Foot Ulcer,DIAFOOT,Completed,No Results Available,Diabetes Mellitus|Diabetic Foot|Diabetes Complications,Biological: blood samples|Other: Clinical exam and DFU medical cares,Mortality rate 5 years after DFU diagnosis|Risks factors correlated to mortality rate among DFU patients diagnosed in 2010,Groupe Hospitalier Pitie-Salpetriere,All,"18 Years and older � (Adult, Older Adult)",,347,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CIC1421-18-16,March 2009,December 2018,December 2018,"December 20, 2018",,"December 20, 2018","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris, France",,https://ClinicalTrials.gov/show/NCT03782129,NCT03782129,
oui,NCT03784014,Molecular Profiling of Advanced Soft-tissue Sarcomas,MULTISARC,Recruiting,No Results Available,Soft Tissue Sarcoma,Drug: Nilotinib|Drug: Ceritinib|Drug: Capmatinib|Drug: Lapatinib|Drug: Trametinib|Combination Product: Trametinib and Dabrafenib|Combination Product: Olaparib and Durvalumab|Drug: Palbociclib|Drug: Glasdegib|Drug: TAS-120|Other: Next Generation sequencing exome,To assess the feasibility of high throughput molecular analysis (next generation sequencing exome [NGS]|Comparison of the efficacy of the 2 treatment strategies (NGS vs No NGS) in terms of 1-year progression-free survival (PFS)|Comparison of the efficacy of the 2 treatment strategies (NGS vs No NGS) in terms of 2-year progression-free survival (PFS)|Comparison of the efficacy of the 2 treatment strategies (NGS vs No NGS) in terms of 1-year overall survival (OS)|Comparison of the efficacy of the 2 treatment strategies (NGS vs No NGS) in terms of 2-year overall survival (OS)|Assessment of the feasibility of high throughput molecular analysis in terms of delay to obtain a clinical recommendation from the molecular tumor board for patients randomized in arm NGS with interpretable NGS|Assessment of the proportion of patients with Advanced STS presenting at least one targetable genomic alteration|Assessment of the efficacy of first-line systemic treatment in terms of 1-year progression-free survival|Assessment of the efficacy of first-line systemic treatment in terms of 2-year progression-free survival|Assessment of the efficacy of first-line systemic treatment in terms of 1-year overall survival|Assessment of the efficacy of first-line systemic treatment in terms of 2-year overall survival|Assessment of the efficacy of first-line systemic treatment in terms of best overall response under first-line treatment|Assessment of the efficacy of first-line systemic treatment in terms of 6-month objective response|Assessment of the efficacy of first-line systemic treatment in terms of 6-month non progression|Assessment of the efficacy of each targeted treatment in terms of 6-month non progression|Assessment of the efficacy of each targeted treatment in terms of 1-year progression-free survival|Assessment of the efficacy of each targeted treatment in terms of 1-year overall survival|Assessment of the efficacy of each targeted treatment in terms of best overall response under treatment|Assessment of the efficacy of each targeted treatment in terms of objective response under treatment|Assessment of the efficacy of each targeted treatment in terms of change in tumor size (CTS)|Assessment of the safety profile of each targeted treatment using the CTCAE v5|Impact of the results of immunosequencing during first-line treatment|Impact of the results of immunosequencing during targeted treatment|To estimate the cost-effectiveness of the strategy usdin NGS as compared to the strategy without NGS|To assess the feasibility of NGS in participants who have switched treatment arm for NGS arm in terms of proportion of participants with interpretable NGS results|To assess the feasibility of NGS in participants who have switched treatment arm for NGS arm in terms of delays,"Institut National de la Santé Et de la Recherche Médicale, France|Commissariat A L'energie Atomique|Institut Bergonié|Plateforme labellisée Inca - Institut Bergonié, Bordeaux|Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris|EUCLID Clinical Trial Platform",All,"18 Years and older   (Adult, Older Adult)",Phase 3,960,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,C16-40|2017-002851-27,"October 19, 2019",October 2023,October 2025,"December 21, 2018",,"October 5, 2022","Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital La Timone, Marseille, France|Institut Paoli Calmettes, Marseille, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Cochin, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Institut Curie, Paris, France|CHU Poitiers, Poitiers, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|ICANS - Institut de Cancérologie Strasbourg, Strasbourg, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT03784014,NCT03784014,34740331
oui,NCT03784534,Brain Network Models Of Motor Recovery After Stroke,ATTACK,Unknown status,No Results Available,Stroke,Other: Imaging|Behavioral: Clinical and behavioral testing : Motor recovery progress|Behavioral: Clinical and behavioral testing : Motor skills,Predictive value of EEG biomarkers on upper limb motor recovery (at 1 year)|Describe the changes in EEG connectivity during motor recovery,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,C17-75|2018-A02765-50,February 2019,February 2022,February 2022,"December 24, 2018",,"December 24, 2018",,,https://ClinicalTrials.gov/show/NCT03784534,NCT03784534,
oui,NCT03788187,Persistant Organics Pollutants in Breast Cancer.,METAPOP,Completed,No Results Available,Breast Cancer|Persistant Organic Pollutants|Lymph Node Metastases,Other: Blood test sample|Other: Peritumoral adipose tissue sample,Metastatic lymph node status based of persistant organic pollutants level measured by by gas chromatography coupled to high-resolution mass spectrometry.|Pro metastatic genes messenger ribonucleic acid (mARN) expression in the tumor based of metastatic lymph node status and persistant pollutants level.,"European Georges Pompidou Hospital|Institut National de la Santé Et de la Recherche Médicale, France|ONIRIS",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other|Industry,Interventional,"Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",2013-A00663-42,August 2013,"December 27, 2013","September 15, 2017","December 27, 2018",,"December 27, 2018",,,https://ClinicalTrials.gov/show/NCT03788187,NCT03788187,
oui,NCT03791073,New Biomarkers in Pancreatic Cancer Using EXPEL Concept,PANEXPEL,Recruiting,No Results Available,Oncology,,"Predictive value of each protein contained in Cytolyt� for the positive diagnosis of pancreatic ductal adenocarcinoma|Biomarkers that are prognostically significant on disease free or overall survival in patients with pancreatic cancer, identified using the survival analysis","University Hospital, Montpellier|IRCM U1194 INSERM, Tumor Microenvironment and Resistance to Treatment Lab|IRCM U1194 INSERM, Cancer Bioinformatics and Systems Biology's team",All,"18 Years and older � (Adult, Older Adult)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RECHMPL18_0437,"January 1, 2018","January 1, 2019","November 1, 2022","January 2, 2019",,"February 28, 2022","Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT03791073,NCT03791073,34448184
oui,NCT03797053,Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology,EXPEVIVO-CTC,Unknown status,No Results Available,Melanoma|Circulating Tumor Cell,Procedure: Biological sample,Therapeutical response|Survival|Disease free Survival,"Assistance Publique - Hôpitaux de Paris|ScreenCell|Celenys|Imstar|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,450,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NI15009,"April 6, 2015","June 30, 2019","June 30, 2019","January 8, 2019",,"January 8, 2019","Saint-Louis Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03797053,NCT03797053,
oui,NCT03797404,Airway Remodeling During Mepolizumab Treatment,REMOMEPO,Completed,No Results Available,Asthma,,Changes in reticular basement membrane (RBM) thickening|Changes in airway smooth muscle (ASM) area|Number of proliferating muscle cells|Number of nerve endings|Number of vascular sections|Number of infiltrating inflammatory cells in the biopsies|Number of inflammatory cells in the BAL|Proportion of eosinophils expressing MBP/IL3R|Interferon-gamma concentration|IL-13 concentration|Periostin concentration|IL-17A concentration|IL-22 concentration|IL-33 concentration|Thymic Stromal Lymphopoietin (TSLP) concentration|Fibronectin concentration|Tenascin concentration|Fibulin-1 concentration|Monocyte chemoattractant protein-1 (CCL/MCP-1) concentration|EGF concentration|bFGF concentration|PDGF-BB concentration|Total score at Asthma Control Test|Global evaluation of mepolizumab benefit|Forced expiratory volume (FEV1)|Forced expiratory volume/Vital capacity (FEV1/VC)|Total lung capacity (TLC)|Residual volume (RV)|Proportion of patients with pre-bronchodilator FEV1 greater than 80%|Proportion of patients with an increase from baseline in pre-bronchodilator FEV1 greater than 20%,"Assistance Publique - Hôpitaux de Paris|GlaxoSmithKline|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,37,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,P180501J|2018-002591-40,"April 24, 2019","June 21, 2022","June 21, 2022","January 9, 2019",,"January 20, 2023","Bichat hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03797404,NCT03797404,
oui,NCT03797638,Characterization of Manual Dexterity by Finger Force Manipuladum (FFM) in Patients With Writer's Cramp and in Control Subjects,FFM_CT,Completed,No Results Available,Dystonic Disorder|Focal Dystonia|Writer's Cramp,Device: Finger Force Manipuladum (FFM),Manual dexterity by the FFM,"Fondation Ophtalmologique Adolphe de Rothschild|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,SSA_2018_4,"October 1, 2018","July 19, 2019","July 19, 2019","January 9, 2019",,"June 22, 2021","Fondation A de Rothschild, Paris, France",,https://ClinicalTrials.gov/show/NCT03797638,NCT03797638,
oui,NCT03809403,"Influence of the Surgical Technique Used for Colectomies on the Concentration of Circulating Tumor DNA and the Presence of Circulating Tumor Cells: Comparison of the ""no Touch"" Technic With Either First Clamping of the Mesenteric Vessels or First Mobilization of the Tumor Followed by Clamping.",ADNCHIR,Unknown status,No Results Available,Colorectal Cancer,,Presence of ctDNA|Presence of CTC|MSI status,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP180453,"February 5, 2019",August 2019,August 2019,"January 18, 2019",,"March 14, 2019","Department of Digestive Surgery, Hôpital Saint-Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT03809403,NCT03809403,
oui,NCT03820739,EBOVAC-Salone Extension,,Completed,No Results Available,Ebola Virus Disease,Other: Follow-up|Other: Blood sample collection,"Number of Serious Adverse Events in subjects who received an Ebola vaccine prime vaccination in the EBOVAC-Salone trial.|Binding antibody responses against EBOV GP using Filovirus Animal Non-Clinical Group (FANG) enzyme-linked immunosorbent assay (ELISA).|Number of Serious Adverse Events, in infants conceived by an EBOVAC-Salone trial female participant during the 3-month period following vaccination with Ad26.ZEBOV or during the 28 day period following vaccination with MVA-BN®-Filo.|Neutralising antibody responses directed against EBOV GP as measured by a pseudovirion neutralisation assay (psVNA)|Effect of previous infection with malaria, determined using validated ELISA and bead based assays, on the persistence of the humoral immune response to vaccination.","London School of Hygiene and Tropical Medicine|University of Sierra Leone|Janssen Vaccines & Prevention B.V.|Institut National de la Santé Et de la Recherche Médicale, France|Universiteit Antwerpen",All,"1 Year and older   (Child, Adult, Older Adult)",,653,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,VAC52150EBL3005,"July 22, 2019","June 28, 2022","July 14, 2022","January 29, 2019",,"February 8, 2023","EBOVAC Rokupr clinic, Rokupr, Kambia, Sierra Leone|EBOVAC Kambia 1 clinic, Kambia, Sierra Leone",,https://ClinicalTrials.gov/show/NCT03820739,NCT03820739,
oui,NCT03821779,Prefrontal Oscillations in Social Anxiety Disorder (POSAD),POSAD,Unknown status,No Results Available,Anxiety Disorders|Anxiety|Anxiety and Fear,Behavioral: In vivo social exposure|Behavioral: Social exposure in a virtual reality setting|Other: EEG recording|Diagnostic Test: Psychometric evaluation|Diagnostic Test: Visual Analogue Scale of anxiety,Change in power of slow oscillations in prefrontal EEG recordings during anticipation relative to baseline|Duration of prefrontal slow oscillations epochs during anticipation,"Institut National de la Santé Et de la Recherche Médicale, France",All,20 Years to 50 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C17-25,"November 12, 2019","November 10, 2021","December 10, 2021","January 30, 2019",,"November 26, 2019","GENPHASS, SANPSY, CHU de Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT03821779,NCT03821779,
oui,NCT03825601,PET With [18F]Flumazenil as an Index of Neurodegeneration in MS,FLUMA-SEP-T,Unknown status,No Results Available,Multiple Sclerosis|Relapsing-Remitting Multiple Sclerosis,Diagnostic Test: PET with [11C]Flumazenil,Concentration of benzodiazepine receptors (BZR) measured from 11C -Flumazenil binding in different groups|individual maps of neurodegeneration: changes in individual mapping of Flumazenil binding in different groups|volume of cortical lesions assessed on 7T MRI in different groups assessed in Cortical lesion volume|volume of white matter lesions segmented on 3T T2 sequences: white matter lesion load|Volume of gadolinium-enhanced white matter lesions on T1 sequence|Voxel wise assessment of Magnetization transfer ratio (MTR) to assess changes in the grey and in the white matter in different groups|functional connectivity changes in patients,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 55 Years   (Adult),Not Applicable,45,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C16-31,"February 1, 2019","April 1, 2021","April 1, 2021","January 31, 2019",,"January 31, 2019",,,https://ClinicalTrials.gov/show/NCT03825601,NCT03825601,
oui,NCT03827759,Differentiate Children Septic and Inflammatory Arthritis by Comparative Analysis,DIANE,"Active, not recruiting",No Results Available,Septic Arthritis|Inflammatory Arthritis|Children,,Qualitative analysis of new biological markers (proteic) that discriminate inflammatory and infectious arthritis|Qualitative analysis of new biological markers (cytokine) that discriminate inflammatory and infectious arthritis|Qualitative analysis of new cellular markers that discriminate inflammatory and infectious arthritis|Qualitative analysis of inflammatory process markers,"University Hospital, Montpellier|INSERM U1183",All,6 Months to 14 Years � (Child),,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RECHMPL18_0293|7683,"February 4, 2019","July 25, 2022","August 4, 2024","February 1, 2019",,"November 21, 2022","CHU Montpellier - Pediatric emergencies, Montpellier, H�rault, France|Hospices Civils de Lyon - pediatric rheumatology, Lyon, France|H�pital Saint Joseph, Marseille, France|CHU N�mes - Pediatrics, N�mes, France|CHU Toulouse - Pediatric infectious diseases, Toulouse, France",,https://ClinicalTrials.gov/show/NCT03827759,NCT03827759,
oui,NCT03828942,Monitoring the HeMAtological TOXicity of Drugs (HeMATOX),HeMATOX,Unknown status,No Results Available,Hematological Abnormality|Hematotoxicity,Drug: drug inducing hematological toxicity,Hematological toxicities of drugs Identification and report of cases of hematological toxicities associated with drugs.|Causality assessment of reported hematological toxicities events according to the WHO system|Description of the type of hematological toxicity depending on the category of drug|Description of the other immune related adverse events concomitant to the hematological toxicity induced by drugs|Description of the duration of treatment when the toxicity happens (role of cumulative dose)|Description of the drug-drug interactions associated with adverse events|Description of the pathologies (cancer) for which the incriminated drugs have been prescribed|Description of the population of patients having hematological toxicity adverse event,"Groupe Hospitalier Pitie-Salpetriere|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,CIC1421-19-01,"February 1, 2019","February 1, 2022","February 1, 2022","February 4, 2019",,"February 21, 2020","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris, France|Rhumatology department, CHU Strasbourg, Hautepierre hospital, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT03828942,NCT03828942,
oui,NCT03831906,Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia),,Completed,No Results Available,Tuberculosis|Severe Pneumonia|Covid19,Diagnostic Test: Xpert MTB/RIF Ultra (Ultra),All-cause mortality 12 weeks after inclusion|Number of children diagnosed with TB at 12 weeks|• Proportion of children with TB treatment initiated at any time during follow-up|• Time to TB treatment initiation|• Duration of TB treatment at end of trial|• Number of inpatient deaths|• Duration of initial hospitalization|• Number of readmissions following discharge|• Weight gain at 12 weeks|• Proportion of NPA and stool samples with positive TB detection using Ultra•|• Proportion of Ultra-confirmed and clinically-diagnosed TB cases|• Feasibility of NPA and stool samples collection (1)|• Feasibility of NPA and stool samples collection (2)|• Safety of NPA collection|• Tolerability of NPA specimen collection procedures assessed by the child|• Tolerability of NPA specimen collection procedures assessed by the parents|• Tolerability of NPA specimen collection procedures assessed by the nurses|• Acceptability of NPA and stool specimen collection procedures|To assess the prevalence of Covid-19 (confirmed and probable cases) in children below 5 years admitted with WHO-defined severe pneumonia|Number of inpatients death in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Duration of initial hospitalization in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Number of readmissions following discharge in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Weight gain in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Inability to breastfeed or drink in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Lethargy or reduced level of consciousness in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Convulsions in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Stridor in calm child in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Oxygen saturation < 90% in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Central cyanosis in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Grunting in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Nasal flaring in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|Chest in-drawing in children with severe pneumonia (infected with SARS-CoV-2 versus to uninfected children)|To describe the laboratory characteristics (CRP) of Covid-19 cases|To describe the laboratory characteristics (full blood count) of Covid-19 cases|Description by type and frequency of the signs of viral pneumonia on CXR with interstitial changes of Covid-19 cases|To assess the yield of stool as compared to nasal swab for the detection of the SARS-CoV-2 by real time reverse transcription-polymerase chain reaction (RT-PCR)|Number of children having a PCR positive for respiratory syncytial virus|To assess seroprevalence and seroconversion (immunoglobulin M and immunoglobulin G to SARS-CoV-2) at Day 0 and Month 3,"Institut National de la Santé Et de la Recherche Médicale, France|UNITAID",All,2 Months to 59 Months   (Child),Not Applicable,2570,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C18-26,"March 20, 2019","June 30, 2021","June 30, 2021","February 6, 2019",,"November 1, 2021","Kampong Cham Provincial Referral Hospital, Kampong Cham, Cambodia|National Pediatric Hospital, Phnom Penh, Cambodia|Takeo Provincial Referral Hospital, Takeo, Cambodia|Biyem Assi District Hospital, Yaoundé, Cameroon|Chantal Biya Foundation, Yaoundé, Cameroon|Cocody University Teaching Hospital, Abidjan, Côte D'Ivoire|Treichville University Teaching Hospital, Abidjan, Côte D'Ivoire|Yopougon University Teaching Hospital, Abidjan, Côte D'Ivoire|José Macamo General Hospital, Maputo, Mozambique|Maputo Central Hospital, Maputo, Mozambique|Jinja Regional Reference Hospital, Jinja, Uganda|Mulago National Referral Hospital, Kampala, Uganda|Holy Innocents Children's Hospital, Mbarara, Uganda|Lusaka University Teaching Hospital, Lusaka, Zambia|Arthur Davidson Children Hospital, Ndola, Zambia",,https://ClinicalTrials.gov/show/NCT03831906,NCT03831906,36395782;33743621;32853411
oui,NCT03833297,Monitoring the HePAtological TOXicity of Drugs (HePATOX),HePATOX,Unknown status,No Results Available,Liver Diseases|Liver Dysfunction|Liver Failure|Hepatotoxicity,Drug: Drugs inducing hepatological toxicity,Hepatological toxicities of drugs Identification and report of cases of hepatological toxicities associated with drugs.|Causality assessment of reported hepatological toxicities events according to the WHO system|Description of the type of hepatoilogical toxicity depending on the category of drug|Description of the other immune related adverse events concomitant to the hepatological toxicity induced by drugs|Description of the duration of treatment when the toxicity happens (role of cumulative dose)|Description of the drug-drug interactions associated with adverse events|Description of the pathologies (cancer) for which the incriminated drugs have been prescribed|Description of the population of patients having hepatological toxicity adverse event,Groupe Hospitalier Pitie-Salpetriere,All,"18 Years and older � (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,CIC1421-19-02,"February 4, 2019","February 4, 2020","February 4, 2020","February 7, 2019",,"September 4, 2019","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris, France",,https://ClinicalTrials.gov/show/NCT03833297,NCT03833297,
oui,NCT03834207,A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy,C3-Cloud,Unknown status,No Results Available,Diabetes Type 2|Renal Failure|Heart Failure|Depression|Chronic Disease|Aging,Device: Use of the C3-Cloud IT system,Acceptability & usefulness of the C3-Cloud system,"Dr Christopher Marguerie|University of Warwick|Kronikgune|Medixine|SRDC|Institut National de la Santé Et de la Recherche Médicale, France|Eurorec|Empirica|Örebro University, Sweden|Osakidetza|Region Jämtland Härjedalen|Cambio Healthcare|South Warwickshire NHS Foundation Trust",All,"55 Years and older   (Adult, Older Adult)",Not Applicable,672,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,689181,"October 1, 2018","January 31, 2020","April 30, 2020","February 7, 2019",,"February 7, 2019","Osakidetza, Vitoria-Gasteiz, Araba, Spain|Region Jamtland Harjedalen, Ostersund, Sweden|South Warwickshire NHS Foundation Trust, Warwick, Warwickshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03834207,NCT03834207,35830239
oui,NCT03836144,Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria,,Completed,No Results Available,Cystinuria|Renal Lithiasis|Glomerulonephritis|Interstitial Nephritis,Dietary Supplement: Potassium citrate,Change from baseline urine inflammatory profile after 3 months of alkalizing treatment using mass spectrometry in patients with cystinuria.|Assessment of urine inflammatory profile in controls groups using mass spectrometry.|Study of crystalluria (presence of crystals in urine) to assess nephrolithiasis activity.,"European Georges Pompidou Hospital|Institut National de la Santé Et de la Recherche Médicale, France|Sponsor Name Pending",All,"18 Years and older   (Adult, Older Adult)",,63,Other|Industry,Observational,Observational Model: Case-Control|Time Perspective: Prospective,EuropeanGPH,"April 2, 2015","January 31, 2020","December 31, 2020","February 11, 2019",,"March 22, 2022","Eurpean Georges Pompidou Hospital, Paris, Ile-de-France, France",,https://ClinicalTrials.gov/show/NCT03836144,NCT03836144,
oui,NCT03838991,Epigenetic Regulation in Fibrous Dysplasia of Bone: mirDYS Study.,MirDYS,Recruiting,No Results Available,Fibrous Dysplasia of Bone,Other: Blood sample|Other: Waste bone tissue,Evaluation of micro Ribonucleic acids expression in the serum|Evaluation of micro Ribonucleic acids expression in the bone tissue|Comparison of micro Ribonucleic acids expression|Validation of micro Ribonucleic acids identified by NGS (Next Generation Sequencing) in blood samples|Association between micro Ribonucleic acids and severity of fibrous dysplasia.,Hospices Civils de Lyon,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,29,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,69HCL18_0443,"January 10, 2019","February 10, 2025","February 10, 2025","February 12, 2019",,"January 4, 2023","Service de Rhumatologie & INSERM U1033, Pavillon F, Hopital Edouard Herriot, Lyon, France",,https://ClinicalTrials.gov/show/NCT03838991,NCT03838991,32526052
oui,NCT03842319,"Impact of MEditerranean Diet, Inflammation and Microbiome After an Acute Coronary Syndrome",MEDIMACS,Completed,No Results Available,Acute Coronary Syndrome,Other: Microbiota analysis|Other: Immunological analysis|Other: Proteome analysis|Other: Metabolome analysis|Other: Clinical evaluation|Other: Diet evaluation|Other: MedDiet,Fibrous cap thickness change|Endothelial dysfunction|Intestinal microbiota composition changes|Oral microbiota composition changes|Adaptive immune system status changes|Innate immune system status changes|Blood protein profiling changes|Faecal protein profiling changes|Urine metabolome profiling changes|Blood metabolome profiling changes|Faecal metabolome profiling changes,"Consorcio Centro de Investigación Biomédica en Red (CIBER)|Hospital General Universitario Gregorio Marañon|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|University of Navarra|Institut National de la Santé Et de la Recherche Médicale, France|Tel Aviv University|Göteborg University",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,CIBER-MEDIMACS,"May 14, 2019","August 2, 2022","August 2, 2022","February 15, 2019",,"October 3, 2022","Hospital General Universitario Gregorio Marañón, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03842319,NCT03842319,34772433
oui,NCT03852940,Impact of Early Enteral vs. Parenteral Nutrition on Preservation of Gut Mucosa Integrity in Patients Requiring Mechanical Ventilation and Catecholamine,,Terminated,No Results Available,Acute Respiratory Failure|Shock,Other: Parenteral nutrition|Other: Enteral Nutrition,Plasma citrulline level|SOFA score|plasma levels of citrulline|I-FABP|proportion of patients whose plasma I-FABP is ≥100 pg/mL|proportion of patients whose plasma citrulline is ≤10 μL/L|mean plasma I-FABP|mean plasma citrulline|proportion of patients with at least one episode of bacteremia|proportion of patients with at least one episode of gastrointestinal intolerance|proportion of patients with at least one episode of diarrhea,"Centre Hospitalier Departemental Vendee|Ministry of Health, France|Institut National de la Santé Et de la Recherche Médicale, France|University Hospital, Tours",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,169,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CHD085-12,"January 27, 2015","July 7, 2015",July 2017,"February 25, 2019",,"February 25, 2019","CHU Amiens, Amiens, France|Centre hospitalier d'Annecy, Annecy, France|CH de Dieppe, Dieppe, France|CHU Lille, Lille, France|CHU Saint Louis, Paris, France|CHU Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT03852940,NCT03852940,
oui,NCT03853226,Rational for the Use of Velocity-Pressure Loop in the Operating Room,VPLOOP,Completed,No Results Available,Radiography|Interventional,Procedure: All monitoring,Measure of aortic pressure in the ascending aorta and in the descending thoracic aorta in mmHg (PAo)|Aortic velocity in the ascending aorta in cm/s (VAasc.)|Aortic velocity in the descending aorta in cm/s (VAdes.),"Joaquim MATEO|INSERM UMR-942, Paris, France|M3DISIM|Hopital Lariboisi�re",All,"18 Years and older � (Adult, Older Adult)",,55,Other,Observational,Observational Model: Other|Time Perspective: Prospective,SRLF 11-356,"January 5, 2014","January 25, 2016","March 25, 2016","February 25, 2019",,"February 27, 2019",,,https://ClinicalTrials.gov/show/NCT03853226,NCT03853226,
oui,NCT03853252,iPS Cells of Patients for Models of Retinal Dystrophies,RETIPS,Recruiting,No Results Available,Retinal Dystrophies,Other: Skin biopsy,number of human cell models obtained,"University Hospital, Montpellier|Institut National de la Santé Et de la Recherche Médicale, France",All,"5 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,9366,"November 3, 2014",November 2024,November 2024,"February 25, 2019",,"December 20, 2022","CNMR Maolya, Genetic Sensory Diseases, Montpellier, Occitanie, France",,https://ClinicalTrials.gov/show/NCT03853252,NCT03853252,
oui,NCT03855982,Monitoring Drug-induced Myocarditis (CardiTOX),CardiTOX,Unknown status,No Results Available,Myocarditis|Myocardial Failure|Myocardial Dysfunction,Drug: Drug inducing myocarditis,Number of myocarditis induced by drugs and report of cases of myocarditis associated with drugs.|Causality assessment of reported myocarditis events according to the WHO system|Description of the myocarditis depending on the category of drug|Description of the other related adverse events concomitant to the myocarditis induced by drugs|Description of the duration of treatment when the toxicity happens (role of cumulative dose)|Description of the drug-drug interactions associated with adverse events|Description of the population of patients having myocarditis adverse event|Description of the pathologies (cancer) for which the incriminated drugs have been prescribed,Groupe Hospitalier Pitie-Salpetriere,All,"18 Years and older � (Adult, Older Adult)",,6000,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,CIC1421-19-03,"April 9, 2019","February 25, 2020","February 25, 2020","February 27, 2019",,"September 4, 2019","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris, France",,https://ClinicalTrials.gov/show/NCT03855982,NCT03855982,
oui,NCT03859518,Study of the Role of Innate Lymphoid Cells and Natural Killer Cells in Immune Activation of Vitiligo - INNATE Vitiligo,INNATEvitiligo,Completed,No Results Available,Vitiligo,Other: blood and skin samples,study the presence and type of ILC and NK in the blood and skin|study the presence and type of ILC and NK in the skin,"Centre Hospitalier Universitaire de Nice|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,20,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,18-GIRCI-01,July 2016,July 2016,December 2019,"March 1, 2019",,"December 9, 2019","CH de Frejus, Fréjus, France",,https://ClinicalTrials.gov/show/NCT03859518,NCT03859518,
oui,NCT03867149,Involvement of the Mediodorsal Nucleus of the Thalamus in Higher Order Cognitive Processes,THALEM2-0,Recruiting,No Results Available,Thalamic Infarction,Other: neuroimaging|Other: Neuropsychological assessment,Performance at the SET (Six Elements Test)|Performances at the PASAT (Pace Auditory Serial Addition Test) updating during working memory|Performances at the Brown-Petterson task,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RC31/18/0337|IDRCB,"May 14, 2019",April 2023,April 2023,"March 7, 2019",,"January 14, 2020","Hopital Purpan - CHU de Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT03867149,NCT03867149,
oui,NCT03869619,REal World Data in LYmphoma and Survival in Adults,REALYSA,Recruiting,No Results Available,Diffuse Large B Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Mantle Cell Lymphoma (MCL)|Marginal Zone Lymphoma (MZL)|T-cell Lymphoma (T-NHL)|Hodgkin's Lymphoma (HL)|Burkitt Lymphoma (BL)),Other: Real-life epidemiological platform of lymphoma in France,Progression-Free Survival (PFS)|Number of patients included per month in total and according to subtype of lymphoma|Number of patients in each region in total and according to subtype of lymphoma|Event-Free Survival (EFS)|Overall Survival (OS)|Net Survival|Response rate|Duration of response|Time to Next Anti-Lymphoma Treatment (TTNLT)|Duration of Survival after progression|Frequency of Lymphoma transformations|Frequency of Second cancers|Frequency of other chronic disease|Number of exposure factors|Number of comorbidities,Hospices Civils de Lyon|The Lymphoma Academic Research Organisation,All,"18 Years and older � (Adult, Older Adult)",,6000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,69HCL18_0352|2018-A01332-53,"November 14, 2018","November 14, 2027","November 14, 2027","March 11, 2019",,"June 28, 2021","Unit� d'H�matologie Clinique, CH D'ARRAS, Arras, France|Service d'H�matologie, CHU Jean Minjoz, Besan�on, France|Service d'Onco-radioloth�rapie, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Institut Bergoni�, Bordeaux, France|Centre Hospitalier Pierre Oudot, Bourgoin-Jallieu, France|Service d'H�matologie, Institut d'H�matologie de Basse Normandie, Caen, France|METROPOLE SAVOIE - SITE CHAMBERY, place Lucien Biset,, Chamb�ry, France|Service d'H�matologie Clinique et de Th�rapie Cellulaire, H�pital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France|Unit� H�mopathies Lympho�des, H�pital Henri Mondor, Cr�teil, France|CHU Francois MITTERRAND, Dijon, France|Service H�matologie, Centre Hospitalier de Dunkerque, Dunkerque, France|Service Oncologie m�dicale, Groupe Hospitalier Mutualiste de Grenoble, Institut Daniel Hollard,, Grenoble, France|CHD Vend�e, La Roche-sur-Yon, France|Service d'H�matologie Clinique, Centre Hospitalier Universitaire Michallon, La Tronche, France|Clinique Victor Hugo, Le Mans, France|Centre hospitalier Libourne, Libourne, France|Service Oncologie m�dicale, HOPITAL SAINT VINCENT-DE-PAUL, Lille, France|Service des maladies du sang, H�pital Claude Huriez, CHRU de Lille, Lille, France|Service H�matologie Clinique et Th�rapie Cellulaire, CHU DE LIMOGES - HOPITAL DUPUYTREN,, Limoges, France|D�partement d'H�matologie et Oncologie, Centre L�on B�rard, Lyon, France|D�partement d'H�matologie Clinique, H�pital Saint-Eloi,, Montpellier, France|Service H�matologie, GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER,, Mulhouse, France|Service d'H�matologie clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalier de Niort, Niort, France|Service H�matologie, H�pital St Louis, Paris, France|CHU Haut-L�v�que, Pessac, France|Centre Hospitalier Lyon Sud, Pierre-B�nite, France|Service d'H�matologie et Th�rapie Cellulaire, Centre Hospitalier Universitaire de Poitiers, Poitiers, France|H�matologie Clinique, CHU PONTCHAILLOU, Rennes, France|Service H�matologie, Centre Hospitalier de Roubaix - H�pital Victor Provo, Roubaix, France|Service H�matologie, UNIVERSITE DE ROUEN, CENTRE HENRI BECQUEREL, Rouen, France|Service H�matologie, CH YVES LE FOLL, Saint-Brieuc, France|Service H�matologie, Institut Curie - H�pital Ren� HUGUENIN, Saint-Cloud, France|D�partement d'H�matologie Clinique et Th�rapie Cellulaire, Institut de Canc�rologie Lucien Neuwirth, Saint-Priest-en-Jarez, France|H�pitaux Universitaires de Strasbourg, Strasbourg, France|Institut Universitaire du Cancer, Toulouse, France|H�matologie Clinique, CH DE BRETAGNE ATLANTIQUE, Vannes, France",,https://ClinicalTrials.gov/show/NCT03869619,NCT03869619,33653294
oui,NCT03869944,Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV,PREVENIR-PEV,"Active, not recruiting",No Results Available,HIV-1,Drug: Lamivudine Oral Solution,Prevention of HIV-1 transmission from HIV-1-positive mothers to their breastfeeding children|Efficacy of PMTCT cascade - mother|Efficacy of PMTCT cascade - child|Access to ART for HIV-1-positive children|Number of Adverse Events Grade 3 and 4 in the prevention of HIV-1 via breastfeeding [Safety of lamivudine],"ANRS, Emerging Infectious Diseases|Institut National de la Santé Et de la Recherche Médicale, France|Centre Muraz",Female,"15 Years and older   (Child, Adult, Older Adult)",Phase 2,97,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS 12388 PREVENIR-PEV,"December 4, 2019",March 2022,March 2022,"March 11, 2019",,"March 31, 2022","Paulin Fao, Bobo-Dioulasso, Burkina Faso",,https://ClinicalTrials.gov/show/NCT03869944,NCT03869944,33872801
oui,NCT03870438,Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention,PROMISE-EPI,Completed,No Results Available,HIV-1,Drug: Lamivudine Oral Solution,"Prevention of HIV-1 transmission from HIV-1-positive mothers to their breastfeeding children|Assessment of PMTCT cascade|Access to ART for HIV-1 positive children|Evaluation of the diagnostic performance of plasma HIV viral load in comparison to breastmilk viral load to identify infants at risk of transmission at 6-8 weeks, 6 months and 12 months|Evaluation of the efficacy for all the participants of the intervention arm and the comparison arm sub-population following the 2020 Zambian guidelines implementation:|Evaluation of the safety for all the participants of the intervention arm and the comparison arm sub-population following the 2020 Zambian guidelines implementation|Evaluation of the efficacy for all the participants of the intervention arm and the comparison arm sub-population before the introduction of the 2020 Zambian guidelines (including Burkina Faso control arm)|Evaluation of the safety for all the participants of the intervention arm and the comparison arm sub-population before the introduction of the 2020 Zambian guidelines (including Burkina Faso control arm)","ANRS, Emerging Infectious Diseases|University Teaching Hospital, Lusaka, Zambia|Centre Muraz|Institut National de la Santé Et de la Recherche Médicale, France|University of Bergen",Female,"15 Years and older   (Child, Adult, Older Adult)",Phase 3,1506,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS 12397 PROMISE-EPI,"December 14, 2019","September 12, 2022","October 31, 2022","March 12, 2019",,"December 7, 2022","CSPS and CMA of Do and Dafra districts, Bobo-Dioulasso, Burkina Faso|CSPS and CMA of Baskuy and Boulmiougou districts, Ouagadougou, Burkina Faso|Bauleni, Lusaka, Zambia|Chaisa, Lusaka, Zambia|Chilenje Level 1 hospital, Lusaka, Zambia|Matero Main, Lusaka, Zambia",,https://ClinicalTrials.gov/show/NCT03870438,NCT03870438,
oui,NCT03872999,Attentional Control,MACBRAIN,Completed,No Results Available,Attention Control|Healthy Volunteers,Other: Functional brain imaging without any contrast agent,Changes of hemodynamic response in dorsal parietal regions representing specific spatial locations (visual quadrants)|Evaluation of the brain hemodynamic response|Evaluation of the connectivity of the ventral parietal cortex at the time when there is a change of the most relevant spatial location/visual quadrant. x�,Hospices Civils de Lyon,All,18 Years to 40 Years � (Adult),Not Applicable,76,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL19_0127|2019-A00713-54,"July 5, 2019","July 5, 2019","June 21, 2021","March 13, 2019",,"January 11, 2022","Inserm U1028 Equipe Impact, Bron, France",,https://ClinicalTrials.gov/show/NCT03872999,NCT03872999,
oui,NCT03875703,Post-Vaccination Biological Collection,BioCol-VIR,Recruiting,No Results Available,Vaccination|Immune Response,,"Change in transcriptional analysis, analysis of the innate immune response after vaccination|B cell immune response|T cell immune response|Specific antibody response to the used vaccines at M1","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,1200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,K170603J,"September 1, 2019","February 1, 2030","February 1, 2030","March 15, 2019",,"December 14, 2020","Pr Gallien, Créteil, France",,https://ClinicalTrials.gov/show/NCT03875703,NCT03875703,
oui,NCT03876379,Brain Power Spectral Density Under Propofol,PROBRAIN,Completed,No Results Available,Radiography|Orthopedic Surgery|Interventional,,"Values of Patient State Index (PSI-) are collected from frontal electrodes montage (Fp1, Fp2, F7, F8)|Propofol doses administered with Target Controlled Infusion (TCI in �g/ml)|Values of Burst Suppression (in % of time) are collected from frontal electrodes montage (Fp1, Fp2, F7, F8)|Values of the Spectral Edge Frequency (SEF 95 in uV2/Hz) are collected from frontal electrodes montage (Fp1, Fp2, F7, F8)","Joaquim MATEO|INSERM UMR-942, Paris, France|M3DISIM|Hopital Lariboisi�re",All,"18 Years and older � (Adult, Older Adult)",,60,Other,Observational,Observational Model: Other|Time Perspective: Prospective,Brain Spectral 2016,"January 24, 2015","January 5, 2016","January 5, 2016","March 15, 2019",,"March 15, 2019",,,https://ClinicalTrials.gov/show/NCT03876379,NCT03876379,
oui,NCT03876821,"Collect of Cord Blood From Subjects at Risk for Sickle Cell Disease, for the Purpose of Laboratory Research",DREPACORD,Unknown status,No Results Available,Sickle Cell Disease,,Number of samples with HbS/HbS genotype|Number of samples with bio-experimental data,"Institut National de la Santé Et de la Recherche Médicale, France|Centre Hospitalier Sud Francilien",Female,18 Years to 45 Years   (Adult),,36,Other,Observational,Observational Model: Other|Time Perspective: Prospective,C18-31,March 2019,March 2022,March 2022,"March 15, 2019",,"March 15, 2019",,,https://ClinicalTrials.gov/show/NCT03876821,NCT03876821,
oui,NCT03879473,Direct Oral Anticoagulant Management for Cardiac Device Implantation,StimAOD,Unknown status,No Results Available,"Anticoagulant, Perioperative",,number of patients with clinically significant pocket hematoma|number of patients with thromboembolic event,Institut Necker Enfants Malades,All,"18 Years and older � (Adult, Older Adult)",,680,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CV185-614,"February 1, 2019",February 2020,March 2020,"March 18, 2019",,"March 18, 2019","HEGP, Paris, France",,https://ClinicalTrials.gov/show/NCT03879473,NCT03879473,36932714
oui,NCT03879876,Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients,HTLP Necker,Recruiting,No Results Available,Pediatric Patients|Any Type of Severe Combined Immunodeficiency (SCID)|Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT),Drug: Human T Lymphoid Progenitor (HTLP) injection,Dose limiting toxicity (DLT)|reconstitution of the CD3+ TCRαβ+ cell compartment|Time course of reconstitution of the different T cell subpopulations|presence of recent thymic emigrants|T-cell receptor excision circles (TREC ) number in peripheral blood|TCR rearrangements|B-cell reconstitution|Immunoglobulin (Ig) levels|NK cell numbers|Cumulative incidence of infections|Cumulative incidence of acute and chronic episodes of graft versus host disease (GVHD)|Overall survival,Assistance Publique - Hôpitaux de Paris,All,"2 Years to 18 Years   (Child, Adult)",Phase 1|Phase 2,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P150949J|2018-001029-14,"May 13, 2020","September 3, 2023","June 3, 2025","March 19, 2019",,"September 27, 2022","Unité d'Immunologie Hématologie Rhumatologie Pédiatrique (UIHR),, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT03879876,NCT03879876,
oui,NCT03880071,DIalectical Behavior Therapy and Acceptance Commitment Therapy Short Program for BOrderLine persOnality Disorder,DIABOLO,Withdrawn,No Results Available,Female|Borderline Personality Disorder,Behavioral: DBT+ACT|Behavioral: DBT,Number of proven suicide attempts using the Columbia-Suicide severity rating scale (C-SSRS) at 1 year follow-up|Evolution of suicidal symptomatology using the Columbia Suicide Severity Rating Scale (C-SSRS)|Evolution of suicidal symptomatology (Likert scales from 0 (none) to 10 (maximum possible suicidal ideation)|Evolution of suicidal symptomatology (Likert scales from 0 (none) to 10 (maximal intensity of suicidal intent)|Evolution of suicidal symptomatology (Likert scales from 0 (none) to 10 (maximal intensity of imperious need for non-suicidal self-damaging behavior)|Evolution of suicidal symptomatology (Likert scales from 0 (none) to 10 (maximal quality of perceived social support)|Evolution of suicidal symptomatology (Likert scales from 0 (none) to 10 (maximal psychological pain)|Evolution of suicidal symptomatology (Likert scales from 0 (not all characteristic of my way of being) to 10 (completely characteristic of my way of being)|Evolution of para- suicidal symptomatology using the Columbia Suicide Severity Rating Scale (C-SSRS)|Evolution of para-suicidal symptomatology (Likert scales from 0 (none) to 10 (maximum possible suicidal ideation)|Evolution of para-suicidal symptomatology (Likert scales from 0 (none) to 10 (maximal intensity of suicidal intent)|Evolution of para-suicidal symptomatology (Likert scales from 0 (none) to 10 (maximal intensity of imperious need for non-suicidal self-damaging behavior)|Evolution of para-suicidal symptomatology (Likert scales from 0 (none) to 10 (maximal quality of perceived social support)|Evolution of para-suicidal symptomatology (Likert scales from 0 (none) to 10 (maximal psychological pain)|Evolution of para-suicidal symptomatology (Likert scales from 0 (not all characteristic of my way of being) to 10 (completely characteristic of my way of being)|Evolution of the borderline symptomatology using the Borderline Symptom List-23 (BSL-23) scale|Evolution of emotional regulation abilities using the Difficulties in Emotion Regulation Scale (DERS)|Evolution of propensity to dissociation using the Dissociative Experience Scale (DES)|Anxiety state using the State-Trait Anxiety Inventory (STAI-Trait)|Anxiety state using the State-Trait Anxiety Inventory (STAI-State)|Anger state using the Spielberger State-Trait Anger Expression Inventory (STAXI-TRAIT)|Anger state using the Spielberger State-Trait Anger Expression Inventory (STAXI-ETAT)|Hopelessness using the Beck Hopelessness Scale (BHS)|Quality Of Life evaluated by the World Health Organization Quality of Life measure (WHOQOL-BREF)|Acceptance assessment using the Acceptance and Action Questionnaire (AAQII)|Contact with the present moment assessment using the Mindful Attention Awareness Scale (MAAS)|Meaning in life assessment using Life Regard Index (LRI)|Satisfaction of the intervention using the Likert scales rating from 0 (not at all satisfied) to 10 (extremely satisfied)|Quality of life related to health using the EQ5D-3L questionnaire|Depression intensity using the Inventory of Depressive Symptomatology (IDS-C30)|Global functioning using the Global Assessment of Functioning Scale (GAF)|Incremental cost-effectiveness ratio (ICER)|Incremental cost-utility ratio (ICUR),"University Hospital, Montpellier|INSERM 1061, "" Neuropsychiatry: epidemiological and clinical research"", Montpellier",Female,18 Years to 50 Years � (Adult),Not Applicable,0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,RECHMPL18_0044,"November 30, 2019","March 1, 2020","March 9, 2020","March 19, 2019",,"March 11, 2020","CHU Montpellier, Montpellier, H�rault, France",,https://ClinicalTrials.gov/show/NCT03880071,NCT03880071,
oui,NCT03882580,"Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care",UNICO,Recruiting,No Results Available,Cardiovascular Complication|Cardiovascular Insufficiency|Cardiac Complication|Oncologic Complications|Cardiac Insufficiency|Metabolic Disorder|Vascular Disorder|Cardiac Disorder,Drug: Anti-Cancer Agents,"Number of patients having a benefit after this specific cardio-oncology check up and follow up|Evaluating the overall survival of patients suffering from cardiovascular or metabolic side effect of oncology treatments|All relevants staisticals associations between adverse events and anticancer drugs|All relevant statistical associations between cardiovascular toxicities, and anticancer drugs|All relevants statistical associations between cardiovascular side effects induced by oncology treatments , and other potentials kind of side effects induced by oncology treatments|All relevant statistical associations between duration and type of treatement used to manage cardiovascular side effects induced by oncology treatments, and overall survival|All relevants statistical associations between differential features of subgroups of patients, and the occurence of cardiovascular side effects induced by oncology treatments|All relevant statistical associations between new therapies to treat or prevent the cardiovascular side effects induced by oncology treatments, and overall survival|All relevant statistical associations between the pre therapeutic cardiovascular checkup and follow up for patients with cancer or history of cancer, and the occurence of cardiovascular toxicities of oncology treatments.|All relevant statistical associations between metabolic toxicities, and anticancer drugs|All relevants statistical associations between metabolic side effects induced by oncology treatments , and other potentials kind of side effects induced by oncology treatments|All relevant statistical associations between duration and type of treatement used to manage metabolic side effects induced by oncology treatments, and overall survival|All relevants statistical associations between differential features of subgroups of patients, and the occurence of metabloic side effects induced by oncology treatments|All relevant statistical associations between new therapies to treat or prevent the metabolic side effects induced by oncology treatments, and overall survival|All relevant statistical associations between the pre therapeutic metabolic checkup and follow up for patients with cancer or history of cancer, and the occurence of metabolic toxicities of oncology treatments.",Groupe Hospitalier Pitie-Salpetriere,All,"18 Years and older � (Adult, Older Adult)",,5000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CIC1421-19-05,"March 1, 2019","March 1, 2025","March 1, 2025","March 20, 2019",,"September 26, 2019","AP-HP, Saint-Antoine Hospital, Department of cardiology, Paris, France|AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris, France|AP-HP, Tenon Hospital, Department of Cardiology, Paris, France",,https://ClinicalTrials.gov/show/NCT03882580,NCT03882580,31988143
oui,NCT03884426,Genetic and Phenotypic Characteristics of Mitral Valve Prolapse,MVP,Recruiting,No Results Available,Mitral Valve Prolapse|Genetic Disease,,"MVP defined by a superior displacement of at least 2 mm|Comprehensive mitral valve apparatus characterization per size of items (leaflets, chordae, annulus)|Comprehensive mitral valve apparatus characterization per other items (papillary muscle, ventricles)|Comprehensive mitral valve apparatus characterization per size of items (ventricle and atrium sizes)|Comprehensive mitral valve apparatus characterization per size of items","Nantes University Hospital|University Hospital, Brest|Rennes University Hospital",All,"Child, Adult, Older Adult",,1000,Other,Observational,Observational Model: Family-Based|Time Perspective: Prospective,RC12_0143,December 2010,December 2021,December 2021,"March 21, 2019",,"August 30, 2021","Brest University Hospital, Brest, France|Nantes University Hospital, Nantes, France|Rennes University Hospital, Rennes, France",,https://ClinicalTrials.gov/show/NCT03884426,NCT03884426,
oui,NCT03886584,Source Monitoring D�ficit in Neuropsychiatric Population,,Recruiting,No Results Available,Psychiatric Disorder,Other: Monitoring source test,measure source memory performance|measure the recognition of distractors,H�pital le Vinatier,All,"18 Years to 80 Years � (Adult, Older Adult)",Not Applicable,300,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2018-A00584-51,"March 8, 2019","September 30, 2023","December 31, 2023","March 22, 2019",,"August 3, 2022","Centre Hospitalier Le Vinatier, Bron, Rh�ne Alpes, France",,https://ClinicalTrials.gov/show/NCT03886584,NCT03886584,
oui,NCT03887000,"Magnesium, Stress and Fibromyalgia",SeMAFor,Completed,No Results Available,Fibromyalgia,Other: magnesium|Other: placebo,Measure of stress with DASS-42|Evaluation of the impact of fibromyalgia using the FIQ questionnaire|Detection of fibromyalgia using the FIRST questionnaire|Evaluation of stress by the heart rate variability|Assessment Using Numerical Scale (EN)|Concise Pain Questionnaire (QCD)|Evaluation of the impact on cognition by the Trail Making Test A and B (TMT A and B) and the Cantab� test|Evaluation of the impact on cognition by the Trail Making Test A and B (TMT A and B)|Cantab� test|Evaluation of the emotions by visualization of images and scale evaluating the feelings of the patients|Evaluation of the overall impression of change by the Patient Global Impression of Change Questionnaire (PGIC)|Evaluation of the impact on the Pittsburg Sleep Quality Index (PSQI)|Evaluation of the intensity of fatigue by the Fatigue Severity Scale (FSS)|Social Vulnerability Assessment (EPICES)|Evaluation of catastrophism by the PCS (Pain Catastrophizing Scale) scale|Quality of life (Short Form 12 items Short Form survey)|Evaluation of the presence of small fiber neuropathy (Sudoscan� )|Evaluation of the presence of small fiber neuropathy (skin biopsy)|plasma magnesium dosage|erythrocyte magnesium dosage|urinary magnesium dosage|creatinine dosage|Analysis of the microbiota (stool samples)|Evaluation of genetic polymorphism using OpenArray technology|Evaluation of stress response during visual stimulation|Evaluation of pain response during thermal stimulation|Evaluation of electromyography (EMG) of median nerve,"University Hospital, Clermont-Ferrand|CIC Inserm 1405, University Hospital Clermont-Ferrand, France",Female,"18 Years and older � (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,CHU-429|2018-A02059-46,"March 28, 2019","January 12, 2020","May 12, 2020","March 22, 2019",,"October 23, 2020","Chu Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT03887000,NCT03887000,
oui,NCT03887195,Evolution of Empathy and Emotional Intelligence During a Doctor-patient Relationship Training,EMOREL,Completed,No Results Available,Empathy|Emotional Intelligence,Other: Training mandatory module about the therapeutic relationship,Jefferson Scale of Physician Empathy- Medical Student Version (JSPE-MS)|Emotional Expressivity Scale (EES)|Multiple choice questions|CARE grid,Assistance Publique - Hôpitaux de Paris|University of Paris 5 - Rene Descartes,All,"18 Years and older   (Adult, Older Adult)",,403,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP180446,"June 1, 2019","June 30, 2019","June 30, 2019","March 22, 2019",,"April 19, 2021","Paris Descartes University, Sorbonne Paris City, Faculty of Medicine, Paris, France",,https://ClinicalTrials.gov/show/NCT03887195,NCT03887195,
oui,NCT03895736,Transcriptome Assessment After Cardiac Arrest,OMECARD,Completed,No Results Available,Out-Of-Hospital Cardiac Arrest After Initial Successful Resuscitation,Biological: blood sampling,Early Transcriptome at hospital admission|Pittsburgh Cerebral Performance Category at Day 60|Transcriptome at day 1|Transcriptome at day 3|Pittsburgh Cerebral Performance Category at Day 28|Number of participants with death at day 28|Number of participants with death at day 60,"Assistance Publique - Hôpitaux de Paris|National Research Agency, France|University of Paris 5 - Rene Descartes|Institut National de la Santé Et de la Recherche Médicale, France|Université Paris Est Créteil|Ecole Nationale Vétérinaire d'Alfort",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2019-A00239-48,"February 24, 2020","February 10, 2022","February 10, 2022","March 29, 2019",,"September 27, 2022","Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France",,https://ClinicalTrials.gov/show/NCT03895736,NCT03895736,
oui,NCT03896139,Identification of PAthways of Kinase Inhibitors TOxicity,PAKITO,Completed,No Results Available,Kinase Inhibitors Toxicity,Drug: Kinase inhibitor,Comparison of the incidence of kinase inhibitor (KIs) induced toxicities in health records and their associations with co-medications to identify new mechanisms of drug induced toxicity,Groupe Hospitalier Pitie-Salpetriere|Vanderbilt University Medical Center,All,"Child, Adult, Older Adult",,4000,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,CIC1421-1906,"January 1, 2017","March 1, 2019","March 1, 2019","March 29, 2019",,"March 29, 2019","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris, France",,https://ClinicalTrials.gov/show/NCT03896139,NCT03896139,
oui,NCT03898648,Behavioral Adaptation to Negative Social Cues in Depressed Patients According to Personal History of Suicide Attempt- COMPASS,COMPASS,Terminated,No Results Available,Depression|History of Suicide Attempt,Other: Waiting room task,Motivation to avoid anger during the emotional task|Change in the proportion of avoidant choices in reverse trials compared to normal trials|Reaction time before clicking|Reaction time between first and second choices in reverse tests|Iowa Gambling Test score,"University Hospital, Montpellier|INSERM U960 - Cognitive Neuroscience Laboratory - Paris, France",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,66,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,RECHMPL19_0024,"April 9, 2019","April 10, 2021","October 10, 2021","April 2, 2019",,"January 5, 2022","Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT03898648,NCT03898648,
oui,NCT03899922,Monitoring Drug-induced Uveitis,UVETOX,Unknown status,No Results Available,Uveitis|Uveitis Drug-Induced|Eye Diseases|Uvea--Diseases,Drug: Drugs inducing uveitis,"Eye toxicities of drugs Identification and report of cases of uevitis associated with drugs|Causality assessment of reported uveitis according to the WHO system|All relevants statisticals associations between type of uveitis and the category of drug|All relevants statisticals associations between other concomittants immune related adverse events and uveitis induced by drugs|Duration of treatment when uveitis happen (role of cumulative dose)|All relevants statisticals associations between drug-drug interactions and adverse events|All relevants statisticals associations between pathologies (cancer) for which the incriminated drugs have been prescribed, and occurence of uveitis|All relevants statisticals associations between characteristics of the population and occurence of uveitis adverse event",Groupe Hospitalier Pitie-Salpetriere,All,"18 Years and older � (Adult, Older Adult)",,1000,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,CIC1421-19-07,"April 1, 2019","April 1, 2020","April 1, 2020","April 2, 2019",,"September 4, 2019","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris, France",,https://ClinicalTrials.gov/show/NCT03899922,NCT03899922,
oui,NCT03913962,Health and Exercise Response in Children With Chronic and Auto-immune Pathologies,HERCCULE,Recruiting,No Results Available,Juvenile Idiopathic Arthritis|Diabetes|Inflammatory Bowel Disease|Cancer Survivor|Anorexia Nervosa,Other: indirect calorimetry,Maximal lipid oxidation rate during submaximal incremental exercise|Maximal strength during isometric contraction|Muscle architecture|Body composition|Maximal muscular strength|Muscular fatigue|Blood sample IL-17|Blood sample CRP|Blood sample IL-6|Blood sample TNF - a|Blood sample IL-10|Blood sample INF|Blood sample calprotectin,"University Hospital, Clermont-Ferrand|Laboratoire des Adaptations M�taboliques � l'Exercice en conditions Physiologiques et Pathologiques|INSERM CIC 1405",All,"6 Years to 18 Years � (Child, Adult)",Not Applicable,300,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CHU-409|2018-A03247-48,"May 2, 2019","December 31, 2028","December 31, 2028","April 12, 2019",,"May 8, 2019","Chu Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT03913962,NCT03913962,
oui,NCT03915366,Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia,EMPIRICAL,Recruiting,No Results Available,Pneumonia|HIV/AIDS|Tuberculosis|Cytomegalovirus Infections,Drug: Valganciclovir Oral Solution [Valcyte]|Drug: Tuberculostatic Agents,Mortality|Days with oxygen therapy|Days of hospitalization|Serious Adverse Events|Adverse Reactions|Notable Adverse Events|Immune-reconstitution inflammatory syndrome|Baseline cytomegalovirus prevalence|Baseline tuberculosis prevalence|Tuberculosis incidence|Deaths attributable to tuberculosis|CMV prevalence in died participants|CMV Molecular response to treatment|TB-lipoarabinomannan (LAM) sensitivity and specificity|Quality-adjusted life expectancy|Per-patient cost,"Hospital Universitario 12 de Octubre|University Hospital, Bordeaux|Institut National de la Sant� Et de la Recherche M�dicale, France|PENTA Foundation|Centre Hospitalier Cocody|Malawi-Liverpool-Wellcome Trust Clinical Research Programme|Eduardo Mondlane University|Centro de Investiga��o em Sa�de de Manhi�a|Stichting Katholieke Universiteit|Barcelona Institute for Global Health|University of Lincoln|Makerere University|University Teaching Hospital, Lusaka, Zambia|University of Zimbabwe|Kamuzu Central Hospital|Servicio Madrile�o de Salud (SERMAS)",All,28 Days to 365 Days � (Child),Phase 2|Phase 3,624,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,19/096|2019-001749-42|EDCTP RIA2017MC-2013EMPIRICAL|U1111-1231-4736|PACTR201904797961340,"March 1, 2020","March 1, 2025","January 31, 2026","April 16, 2019",,"March 2, 2023","Programme PACCI. Centre Hospitalier Cocody., Abidjan, C�te D'Ivoire|Universit� de Bourdeaux, Bourdeaux, France|INSERM, Toulouse, France|PENTA Foundation, Padova, Italy|Malawi Liverpool Welcome Trust. Queen Elizabeth Central Hospital College of Medicine, Blantyre, Malawi|Cemtro de Investiga�ao em Sa�de da Manhi�a, Manhi�a, Mozambique|Hospital Central Maputo, Maputo, Mozambique|Stichting Katholieke Universiteit Radboudumc, Nimega, Netherlands|Fundaci�n para la Investigaci�n Biom�dica del Hospital 12 de Octubre, Madrid, Spain|Makerere University - Mulago Hospital, Kampala, Uganda|University of Lincoln, Lincoln, United Kingdom|Lusaka Teaching Hospital, Lusaka, Zambia|University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe",,https://ClinicalTrials.gov/show/NCT03915366,NCT03915366,36724434;35761406
oui,NCT03918655,MIF Involvement in AML,MIFAML,"Active, not recruiting",No Results Available,Acute Myeloid Leukemia,,MIF concentration in the blood and the bone marrow and MIF RNA expression|Overall and leukemia free survivals|The number of patients in complete remission with persistent pre-leukemic stem cells that over express MIF|Rate of MIF inhibitors and anti-MIF antibodies will be tested in preclinical models|The molecular mechanisms of MIF overexpression,"Assistance Publique - H�pitaux de Paris|Institut National de la Sant� Et de la Recherche M�dicale, France|CHRU Tours: centre Hospitalier Universitaire de Tours|Gustave Roussy, Cancer Campus, Grand Paris",All,"18 Years and older � (Adult, Older Adult)",,186,Other,Observational,Observational Model: Cohort|Time Perspective: Other,PRT-K16055,"July 7, 2019",June 2025,June 2025,"April 17, 2019",,"November 22, 2022","Laboratoire d'h�matologie H�pital Saint Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT03918655,NCT03918655,
oui,NCT03919110,Immunome Project Consortium for Autoinflammatory Disorders,ImmunAID,Unknown status,No Results Available,"Autoinflammatory Diseases, Hereditary",Diagnostic Test: Collection of biological samples,Area under the curve (AUC),"Institut National de la Santé Et de la Recherche Médicale, France",All,"1 Year and older   (Child, Adult, Older Adult)",,1616,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C18-30,"May 15, 2019","May 15, 2022","May 15, 2022","April 18, 2019",,"April 19, 2019",,,https://ClinicalTrials.gov/show/NCT03919110,NCT03919110,
oui,NCT03921164,Non Invasive Use of Pressure-Volume Loop in the Operating Room,LOOPING,Recruiting,No Results Available,Radiography|Interventional,Procedure: Trans-oesophageal Doppler|Procedure: Trans-thoracic echocardiography|Procedure: Applanation tonometry,Aortic pressure in the descending thoracic aorta in mmHg (PAo)|Aortic velocity in the descending aorta in cm/s (VAdes.)|Central pressure by tonometry (CP in mmHg)|Ventricular diastolic pressure (VdP in mmHg)|Left ventricular volume (LVV in mL),"Assistance Publique - H�pitaux de Paris|INSERM UMR-942, Paris, France|M3DISIM",All,"18 Years and older � (Adult, Older Adult)",,55,Other,Observational,Observational Model: Other|Time Perspective: Prospective,APHP180410|2018-A02737-48,"January 27, 2021",January 2023,July 2023,"April 19, 2019",,"March 2, 2021","Department of Anesthesiology and Intensive Care, Lariboisi�re Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03921164,NCT03921164,
oui,NCT03921398,Identifying New Therapeutic Targets for Lupus Treatment,ELUDIAL,Recruiting,No Results Available,Lupus Nephritis,,Nombre of patients treated by sequential haemodialysis with lupus extinction,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,140,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Cross-Sectional,APHP180500,"June 18, 2019","June 1, 2022","June 1, 2022","April 19, 2019",,"June 18, 2021","Hôpital Bichat, Paris, France",,https://ClinicalTrials.gov/show/NCT03921398,NCT03921398,
oui,NCT03922776,Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer,TILsOV-1805,Recruiting,No Results Available,Ovarian Cancer Stage IIIC|Fallopian Tube Cancer Stage IIIC|Fallopian Tube Cancer Stage IV|Ovarian Cancer Stage IV,Procedure: Blood sample collection,Counting of lymphocyte populations (pre-chemotherapy)|Counting of lymphocyte populations (post-chemotherapy)|Histological type on the initial biopsy|Clinical response to chemotherapy (post-chemotherapy)|Histological response to chemotherapy (no residual disease on excised tissue)|Progression-free survival|Global survival,"Centre Oscar Lambret|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,55,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,TILsOV-1805|Id RCB,"May 16, 2019",February 2023,February 2024,"April 22, 2019",,"October 6, 2021","Centre Oscar Lambret, Lille, France",,https://ClinicalTrials.gov/show/NCT03922776,NCT03922776,
oui,NCT03923569,Epileptiform Activity During REM Sleep in Alzheimer's Disease,EREMAD,Recruiting,No Results Available,"Alzheimer Disease, Early Onset",Diagnostic Test: Overnight polysomnography|Diagnostic Test: blood sample|Diagnostic Test: high-resolution MRI scan|Behavioral: neuropsychological evaluation,Epileptiform activity during REM sleep|Number of epileptiform activity according to sleep-wake cycle|Frequency of epileptiform activity according to sleep-wake cycle|lateralization of epileptiform activity according to sleep-wake cycle|localization of epileptiform activity according to sleep-wake cycle|Comparison of sleep characterization between the two groups: total sleep time|Comparison of sleep characterization between the two groups: number of sleep cycles|Comparison of sleep characterization between the two groups: time spent awake during the night|Comparison of sleep characterization between the two groups: index of micro-awakenings|Comparison of sleep characterization between the two groups: distribution of different sleep stages in time|Comparison of sleep characterization between the two groups: distribution of different sleep stages in percentage|Comparison of sleep characterization between the two groups: index of periodic movements|Comparison of sleep characterization between the two groups: index of hypopnea|Comparison of memory scores at the overnight retention test between the two groups|symptoms of an underlying epileptic syndrome|sleep spindles in different sleep stages|results of the cognitive reserve inventory (CRIq)|speed of cognitive decline.|density of sleep spindles in the different sleep stages,"University Hospital, Toulouse|Centre de Recherches sur la Cognition Animale (CRCA - UMR5169 CNRS/UPS)|Centre de Recherche Cerveau & Cognition (CerCo - UMR5549 CNRS/UPS)|Toulouse NeuroImaging Center (ToNIC - UMR 1214 Inserm/UPS)|Fondation Plan Alzheimer|IHNPS/FHU HoPeS",All,"50 Years to 90 Years � (Adult, Older Adult)",Not Applicable,62,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RC31/18/0265|2018-A02229-46,"April 29, 2019",June 2023,June 2023,"April 22, 2019",,"July 28, 2021","Toulouse University Hospital, Toulouse, Occitanie, France",,https://ClinicalTrials.gov/show/NCT03923569,NCT03923569,
oui,NCT03929757,A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants,,Completed,No Results Available,Ebola Virus Disease,Biological: Ad26.ZEBOV|Biological: MVA-BN-Filo|Biological: MenACWY,Main Study: Percentage of Participants with Solicited Local and Systemic Adverse Events (AEs)|Main Study: Percentage of Participants with Solicited Local and Systemic AEs|Main Study: Percentage of Participants with Unsolicited AEs|Main Study: Percentage of Participants with Serious Adverse Events (SAEs)|Extension Phase: Number of Participants with Completion of the Heterologous 2-dose Vaccination Regimen (Ad26.ZEBOV on Day 1 and MVA-BN-Filo on Day 57)|Main Study: Binding Antibody Levels Against the Ebola Virus Glycoprotein (EBOV GP),"Janssen Vaccines & Prevention B.V.|London School of Hygiene and Tropical Medicine|College of Medicine and Allied Health Sciences (COMAHS)|Institut National de la Santé Et de la Recherche Médicale, France",All,4 Months to 11 Months   (Child),Phase 2,108,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",CR108617|VAC52150EBL2005|2021-001331-10,"August 19, 2019","August 22, 2022","September 22, 2022","April 29, 2019",,"November 25, 2022","Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Conakry, Guinea|College of Med and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone",,https://ClinicalTrials.gov/show/NCT03929757,NCT03929757,
oui,NCT03936634,An Innovative Approach Towards Understanding and Arresting Type 1 Diabetes (INNODIA),INNODIA,Unknown status,No Results Available,Type 1 Diabetes Mellitus,,Arm A - Newly Diagnosed people with Type 1 diabetes|Arm B - Auto-antibody positive first degree family members|Arm A - Newly diagnosed patients with Type 1 diabetes|Arm A - Newly diagnosed patients with Type 1 diabetes - Systematic evaluation of biological samples|Arm A - Newly diagnosed patients with Type 1 diabetes - Framework|Arm B - Auto-antibody positive first degree family members - glucose tolerance|Arm B - Auto-antibody positive first degree family members - Systematic evaluation of biological samples|Arm B - Auto-antibody positive first degree family members - Framework,University of Cambridge|Innovative Medicines Initiative|Juvenile Diabetes Research Foundation|The Leona M. and Harry B. Helmsley Charitable Trust,All,"1 Year to 44 Years � (Child, Adult)",,6000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,INNODIA 01|210497|115797,"November 14, 2016","October 31, 2022","October 31, 2022","May 3, 2019",,"December 21, 2020","Medical University of Graz, Graz, Austria|Universitee Libre de Bruxelles, Brussels, Belgium|Katholieke Universiteit Leuven, Leuven, Belgium|University of Copenhagen, Copenhagen, Denmark|University of Helsinki, Helsinki, Finland|University of Oulu, Oulu, Finland|Turku University Hospital, Turku, Finland|Institut National de la Sante et de la Recherche Medicale (INSERM), Paris, France|Children's Hospital Auf der Bult, Hannover Medical School, Hanover, Germany|University of Ulm, Ulm, Germany|San Raffaele Hospital, Milan, Italy|Ospedale Pediatrico Bambino Gesu, Rome, Italy|University of Studi di Siena, Siena, Italy|University of Luxembourg, Luxembourg, Luxembourg|Oslo Universitetssytehus HF, Oslo, Norway|Medical University of Silesia Katowice, Katowice, Poland|University of Ljubljana, Ljubljana, Slovenia|University of Lund, Malm�, Sweden|University of Cambridge, Cambridge, United Kingdom",,https://ClinicalTrials.gov/show/NCT03936634,NCT03936634,36761922;34876434
oui,NCT03937245,Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care,EurobactII,Completed,No Results Available,Bacteremia|Sepsis|Hospital Acquired Condition|Resistance Bacterial,,Mortality|Progress of organ failures|Days free or organ supportive therapy|Clinical cure|Microbiological cure,"Outcome Rea|European Society of Intensive Care Medicine|European Society of Clinical Microbiology and Infectious Diseases|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,3058,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,EurobactII,"August 30, 2019","June 2, 2021","June 3, 2021","May 3, 2019",,"September 9, 2021","Redcliffe Hospital, Brisbane, Queensland, Australia|Reanimation Medicale et Infectieuse-Hopital Bichat, Paris, France","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03937245/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03937245,NCT03937245,36258239
oui,NCT03941990,Lumbar Puncture in Emergency Under Nitrous OXide,LENOX,Unknown status,No Results Available,Pain|Anxiety,Drug: Fixed 50:50 mixture of nitrous oxide and oxygen|Other: Placebo,Maximal pain perceived during the lumbar puncture evaluated using a simple numeric 0-10 pain scale|Maximal anxiety perceived during lumbar puncture evaluated using a simple numeric 0-10 scale|Side effects|Spinal puncture duration|Number of attempts before successful LP|Patient Satisfaction|Blinding quality|Induced cost,"University Hospital, Clermont-Ferrand|Inserm U1107, NeuroDol|Universit� d'Auvergne",All,"18 Years and older � (Adult, Older Adult)",Phase 4,88,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",RBHP 2018 MOISSET|2018-001296-20,"November 27, 2019",April 2020,September 2020,"May 8, 2019",,"February 20, 2020","CHU de Clermont-Ferrand, Clermont-Ferrand, Auvergne Rh�ne-Alpes, France",,https://ClinicalTrials.gov/show/NCT03941990,NCT03941990,
oui,NCT03942445,In Vivo Analysis of Muscle Stem Cells in Chronic and Acute Lower Limb Ischemia (MyostemIschemia),,Unknown status,No Results Available,Artery Disease|Muscle Disorder,Procedure: Gastrocnemius muscle biopsy,Differential expression of genes involved in myogenesis and angiogenesis|Comparative study of the topography of SC and ECs|Comparative study of myogenic capacity: In vitro differentiation of SC during primary cell culture|In vitro comparative study of angiogenic capacity|Myogenic and Angiogenic capacity of transplanted SC (in mice tibialis anterior),"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,C18-35,"April 30, 2019","April 1, 2021","October 1, 2021","May 8, 2019",,"May 8, 2019",,,https://ClinicalTrials.gov/show/NCT03942445,NCT03942445,
oui,NCT03942835,Psychometric Validation of the Competitive Attention Test,CAT,Terminated,No Results Available,Attention Deficit Hyperactivity Disorder,Other: experience 1 : Competitive attention test in healthy participants|Other: experience 2 : Competitive attention test in patients with ADHD with no treatment|Other: experience 3 :Competitive attention test in patients with ADHD with psychostimulant treatment,Reaction times in healthy subjects and patients with ADHD.|Percentage of correct responses in healthy subjects and patients with ADHD.,Hospices Civils de Lyon,All,"6 Years to 90 Years � (Child, Adult, Older Adult)",Not Applicable,26,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL18_0376|2018-A02597-48,"January 21, 2020","March 20, 2021","April 20, 2021","May 8, 2019",,"November 1, 2021","Centre de Recherche en Neurosciences de Lyon, INSERM U1028, Bron, France",,https://ClinicalTrials.gov/show/NCT03942835,NCT03942835,
oui,NCT03943017,The Inspection Campaign of French Phase I/II Research Sites Following the BIA 10-2474 Accident,HARMONY,Recruiting,No Results Available,"Health Knowledge, Attitudes, Practice|Safety Issues|Health, Subjective",Other: Inspection and safety evaluation by 3 longstanding experience physicians of early clinical researches,Number of observations which have potentially serious medical consequences after experts adjudication|Number on disagreements occuring initially among the 3 adjudicators before adjudication,Groupe Hospitalier Pitie-Salpetriere,All,"Child, Adult, Older Adult",,30,Other,Observational,Observational Model: Other|Time Perspective: Prospective,CIC1421-19-08,"January 1, 2017","July 30, 2019","July 30, 2029","May 9, 2019",,"September 4, 2019","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris, France",,https://ClinicalTrials.gov/show/NCT03943017,NCT03943017,
oui,NCT03947034,Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX),AmmoTOX,Unknown status,No Results Available,Hyperammonemia|Metabolic Disease|Adverse Drug Event|Drug Toxicity,Drug: Drugs inducing hyperammonemia,Metabolic toxicities (such as hyperammnemia) of drugs Identification and report of cases of metabolic toxicities associated with drugs.|Causality assessment of reported metabolic toxicities events according to the WHO system|Description of the type of metabolic toxicity depending on the category of drug|Description of the other immune related adverse events concomitant to the metabolic toxicity induced by drugs|Description of the duration of treatment when the toxicity happens (role of cumulative dose)|Description of the drug-drug interactions associated with adverse events|Description of the pathologies (cancer) for which the incriminated drugs have been prescribed|Description of the population of patients having hematological toxicity adverse event,Groupe Hospitalier Pitie-Salpetriere,All,"18 Years and older � (Adult, Older Adult)",,2700,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,CIC1421-19-09,"May 1, 2019","May 30, 2020","May 30, 2020","May 13, 2019",,"September 4, 2019","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris, France",,https://ClinicalTrials.gov/show/NCT03947034,NCT03947034,
oui,NCT03954054,Therapeutic Education for Harm Reduction in People With Alcohol Use Disorder,ETHER,Completed,No Results Available,Alcohol Use Disorder,"Behavioral: ""Choizitaconso"" - therapeutic patient education programme",Community-validated alcohol-related harms|Health-related Quality of life (SF-12v2 health survey)|Average alcohol consumption (AUDIT-C)|Craving|Stigma|Anxiety and depressive symptoms (HAD)|Alcohol-Related Neuropsychological Impairments (BEARNI)|Coping strategies (Brief COPE)|Capability (ICECAP-A questionnaire)|Treatment self-regulation|Self-confidence to resist drinking (Brief Situational Confidence Questionnaire),"Institut National de la Santé Et de la Recherche Médicale, France|Regional Agency for Health PACA|SESSTIM UMR1252 (Aix-Marseille Univ, INSERM, IRD)",All,"18 Years and older   (Adult, Older Adult)",,110,Other,Observational,Observational Model: Other|Time Perspective: Prospective,C19-03 / ETHER,"October 28, 2019","July 31, 2021","July 31, 2021","May 17, 2019",,"September 17, 2021","CSAPA Convergence, Avignon, France|ANPAA 04, Digne-les-Bains, France|Clinique Saint Barnabé, Marseille, France",,https://ClinicalTrials.gov/show/NCT03954054,NCT03954054,35012570
oui,NCT03956394,Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging,TAK-UF,Completed,No Results Available,Takayasu Arteritis,Diagnostic Test: UltraFast ultrasound,Quantification of the vascularity|Evaluate average local elasticity of the ultrafast imaging results regarding the disease activity|Evaluate the carotid pulse wave velocity of the ultrafast imaging results regarding the disease activity|Evaluate the intima-media thickness of common carotid arteries of the ultrafast imaging results regarding the disease activity|Dosage of C-reactive protein|Calculation of clinical index of disease activity: Indian Takayasu Activity score 2010 (Score <2: inactive disease activity / Score ≥2 active disease activity),"French Cardiology Society|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,16,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2017-02,"January 8, 2020","December 31, 2021","December 31, 2021","May 20, 2019",,"March 23, 2022","Hôpital Européen Georges Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT03956394,NCT03956394,
anrs,NCT03958786,Frailty in People Living With HIV Aged 70 Years or More,,"Active, not recruiting",No Results Available,HIV Infections,Other: Simplified Geriatric Evaluation|Other: Sampling,"Proportion of frail patients at baseline|Proportion of frail subjects at M12, M24, M36, M48 and M60|Correlation between Baseline frailty status and early pejorative events incidence|Correlation between Baseline frailty status and long terme pejorative events incidence|Transition between frail and non-frail status during 5 years of follow up|Proportion of frail subjects accoding different frailty scores","ANRS, Emerging Infectious Diseases",All,70 Years and older � (Older Adult),Not Applicable,512,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,ANRS EP66 SEPTAVIH,"May 15, 2019","June 22, 2021","June 22, 2024","May 22, 2019",,"May 17, 2022","Service de Maladies Infectieuses, CHU H�tel-Dieu, Nantes, France",,https://ClinicalTrials.gov/show/NCT03958786,NCT03958786,
oui,NCT03962699,Impact of Weight Loss on the Human Sperm Epitranscriptome,EPI-SPERM,Unknown status,No Results Available,Obesity,,Impact of weight loss on sperm transcriptome of obese men|Impact of obesity on sperm transcriptome of obese men,"Institut National de la Santé Et de la Recherche Médicale, France",Male,20 Years to 50 Years   (Adult),,45,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,C18-55|2019-A00833-54,July 2019,July 2019,June 2022,"May 24, 2019",,"May 24, 2019","Hopital Archet, Nice, France",,https://ClinicalTrials.gov/show/NCT03962699,NCT03962699,
oui,NCT03963518,Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI),SURROGATE-ICI,Completed,No Results Available,Cancer Treated With Immune-checkpoint Inhibitors,Drug: Immune checkpoint inhibitor,overall survival|Progression-free survival (PFS),"Institut Bergonié|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,300,Other,Observational,Observational Model: Other|Time Perspective: Prospective,IB2017-SURROGATE-ICI,January 2017,November 2020,November 2020,"May 24, 2019",,"December 20, 2021","Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT03963518,NCT03963518,
oui,NCT03964402,Sample Size for Multivariate Time-to-event Data,,"Active, not recruiting",No Results Available,Clinical Trials,Drug: intervention treatment,Overall survival,"Institut Bergonié|Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,200,Other,Observational,Observational Model: Other|Time Perspective: Prospective,IB2018-SAMPLE-SIZE-SURVIVAL,"January 1, 2019","December 31, 2023","December 31, 2024","May 28, 2019",,"February 21, 2023","Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT03964402,NCT03964402,
oui,NCT03965429,Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation,SIA-CSH,Recruiting,No Results Available,Malignant Hemopathy,Other: Blood samples (additional tubes from care) longitudinal|Other: Blood samples (additional tubes from care) at inclusion,Evolution of the immune blood populations in patients who have received allogeneic hematopoietic stem cell transplantation.,Institut Paoli-Calmettes|INSERM-U1068,All,"18 Years and older � (Adult, Older Adult)",,1020,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SIA-CSH-IPC 2015-017|2019-000814-13,"May 14, 2019","May 14, 2029","May 31, 2029","May 29, 2019",,"May 29, 2019","Institut Paoli-Calmettes, Marseille, Bouches-du Rh�ne, France",,https://ClinicalTrials.gov/show/NCT03965429,NCT03965429,
oui,NCT03968198,Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia.,ACellDREAM2,Terminated,No Results Available,Critical Limb Ischemia and Peripheral Artery Disease,Drug: Autologous ASC (for Adipose-derived Stem/Stroma Cell),Number of patients alive without major amputation|Number of patients alive without critical limb ischemia|New vessels|Blood flow|Wound surface reduction|Ulcer healing|Pain reduction|Wound infection|Immuno measures in blood sample|Immuno measures in vitro,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France|Etablissement Français du Sang",All,"18 Years and older   (Adult, Older Adult)",Phase 2,2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RC31/14/7441,"March 4, 2020","March 10, 2023","March 10, 2023","May 30, 2019",,"March 31, 2023","Rangueil Hospital, Toulouse, France",,https://ClinicalTrials.gov/show/NCT03968198,NCT03968198,
oui,NCT03970499,Ultrasound Elastography and Ultrasentive Doppler for Surgery of Brain Tumors,ELASTOGLI,Unknown status,No Results Available,"Brain Tumor, Primary",Procedure: brain tumor resection,ultrasound elastography measurements|ultrasound ultrasensitive doppler measurements|Comparaison between ultrasound results and histology|Correlation between ultrasound results and MRI,"University Hospital, Tours|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,PHA017-IZ/ELASTOGLI,"April 15, 2019",March 2020,June 2020,"May 31, 2019",,"May 31, 2019","Ilyess ZEMMOURA, Tours, France",,https://ClinicalTrials.gov/show/NCT03970499,NCT03970499,
oui,NCT03974139,Impact of Metformin on Leptin Transport in Cerebrospinal Fluid of Obese Patients,LEPTOB,Recruiting,No Results Available,"Obesity Without Type 2 Diabetes, With BMI>30",Drug: Metformin Oral Tablet,cerebrospinal fluid /plasma leptin ratio|cerebrospinal fluid /plasma glucose ratio|cerebrospinal fluid /plasma glucagon like peptide 1 (GLP1) ratio|cerebrospinal fluid /plasma insulin ratio|cerebrospinal fluid /plasma ghrelin ratio|Cerebrospinal fluid levels of Agouti-Related Peptide (AgRP)|Plasma levels of Agouti-Related Peptide (AgRP)|Cerebrospinal fluid levels of proopiomelanocortin (POMC)|Plasma levels of proopiomelanocortin (POMC)|Cerebrospinal fluid levels of neuropeptide Y (NPY)|Plasma levels of neuropeptide Y (NPY)|Cerebrospinal fluid levels of leptin soluble receptor|Plasma levels of leptin soluble receptor|Apparent diffusion coefficient (ADC)|Hypothalamic concentration of N-acetyl-aspartate (NAA)|Hypothalamic concentration of creatine|Hypothalamic concentration of Choline|Hypothalamic concentration of Glutamine / glutamate|Hypothalamic concentration of gamma-aminobutyric acid (GABA)|Weight|Abdominal circumference|Percentage of body fat|Fat free mass (Kg)|Energy expenditure|Score of the Three Factor Eating Questionnaire (TFEQ)|Score of the Dutch Eating Behaviour Questionnaire (DEBQ),Lille Catholic University|Centre Hospitalier Arras,All,18 Years to 40 Years   (Adult),Phase 2,31,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RC-P0054,"September 10, 2019","November 30, 2022","November 30, 2022","June 4, 2019",,"April 5, 2022","Centre hospitalier d'Arras, Arras, France",,https://ClinicalTrials.gov/show/NCT03974139,NCT03974139,
oui,NCT03976063,Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation,TOCOPROM,Recruiting,No Results Available,Preterm Premature Rupture of Membrane,Drug: Nifedipine|Drug: Placebo of Nifedipine,Perinatal morti-morbidity|Prolongation of gestation|Maternal morbidity|Fetal mortality|Neonatal mortality|Neonatal severe morbidity|Neonatal morbidity|Vital status|Frequency of Gross motor impairment among children alive at 2 years of corrected age|Frequency of Neurosensory impairment among children alive at 2 years of corrected age,"Assistance Publique - H�pitaux de Paris|INSERM U1153|Ministry of Health, France|Groupe de Recherche en Obst�trique et Gyn�cologie",Female,"18 Years and older � (Adult, Older Adult)",Phase 3,850,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",P160917,"October 7, 2019",August 2023,July 2025,"June 5, 2019",,"September 21, 2022","Trousseau University Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT03976063,NCT03976063,35947046;34496799
oui,NCT03979079,Modeling Clinical Failure in Prostate Cancer Patients Based on a Two-stage Statistical Model,PREDYC,Completed,Has Results,Prostate Cancer,Radiation: external beam radiation therapy,Number of Participants With Clinical Failure After Initiation of Radiotherapy|Number of Participants With Initiation of Salvage Therapy After Radiotherapy,"Institut Bergoni�|Institut National de la Sant� Et de la Recherche M�dicale, France",Male,"18 Years and older � (Adult, Older Adult)",,2384,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,IB2010-PREDYC,January 2010,"January 1, 2017","January 1, 2017","June 7, 2019","December 21, 2020","January 25, 2021","INSERM, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT03979079,NCT03979079,
oui,NCT03981653,ANgiogenic Function at NOrmal TErm on Placenta,ANNOTEP,Recruiting,No Results Available,Pregnancy Related,,Level of placental angiogenic factors|Level of sFlt-1 (Soluble FMS like tyrosin-kinase-1)|Level of PlGF (Placental Growth Factor),"Centre Hospitalier Intercommunal Creteil|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",,750,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ANNOTEP,"March 20, 2019",March 2029,March 2029,"June 11, 2019",,"December 21, 2022","Centre Hospitalier Intercommunal de Créteil, Creteil, France",,https://ClinicalTrials.gov/show/NCT03981653,NCT03981653,
oui,NCT03987113,Impact of Cold Ischemia on Pulmonary Endothelial Dysfunction in Ex-vivo Pulmonary Reconditioning,Endoth-Exvivo,Completed,No Results Available,Lung Transplant,Other: Plasma concentration analysis during and after ex-vivo pulmonary reconditioning,Correlation between time of cold ischemia and endothelial dysfunction|Correlation between time of cold ischemia and systemic inflammation,Hopital Foch|Institut National de la Santé Et de la Recherche Médicale Rouen U1096,All,"18 Years and older   (Adult, Older Adult)",,20,Other,Observational,Observational Model: Other|Time Perspective: Prospective,2017022F,"November 15, 2018","October 30, 2019","October 30, 2019","June 14, 2019",,"July 14, 2020","Hôpital Foch, Suresnes, France",,https://ClinicalTrials.gov/show/NCT03987113,NCT03987113,
oui,NCT03991091,Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor,STOPOXY,Completed,No Results Available,Neonatal Morbidity,Drug: discontinuation of oxytocin administration|Drug: continuation of oxytocin administration,neonatal morbidity composite measure|umbilical cord pH<7.20|umbilical cord pH<7.10|umbilical cord pH<7.00|Need for hypothermia|other neonatal complications:|neonatal admission|length of the newborn's hospital stay|mode of delivery|labor duration|uterine hyper-stimulation|fetal scalp blood testing|fetal occipito-posterior position|maternal hyperthermia|postpartum hemorrhage|The post-partum women's satisfaction|The post-partum women's satisfaction: labor agentry scale,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years and older   (Adult, Older Adult)",Phase 4,2475,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P180581,"January 17, 2020","April 25, 2022","April 25, 2022","June 19, 2019",,"November 1, 2022","hospital Cochin; port royal Maternity unit, Paris, France",,https://ClinicalTrials.gov/show/NCT03991091,NCT03991091,33081758
anrs,NCT03992313,Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in Cambodia,Cam-C,Unknown status,No Results Available,Hepatitis C|Testing,Other: Community-based HCV rapid test|Other: Facility-based HCV rapid test|Other: Plasmatic HCV viral load|Other: DBS HCV viral load,Combined-testing uptake|HCV antibody testing uptake|Active case detection rate|Linkage to care,"ANRS, Emerging Infectious Diseases|University of Health Sciences, Phnom Penh, Cambodia|Hopital Paul Brousse|Institut National de la Santé Et de la Recherche Médicale, France|Fondation Mérieux|University of Marseille",All,"40 Years and older   (Adult, Older Adult)",Not Applicable,4500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,ANRS 12384,"August 1, 2019","April 30, 2020","October 31, 2020","June 20, 2019",,"June 20, 2019",,,https://ClinicalTrials.gov/show/NCT03992313,NCT03992313,
oui,NCT03994302,Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX),APSTOX,Unknown status,No Results Available,Antiphospholipid Syndrome|Immune Disease|Adverse Drug Event|Drug Toxicity,Drug: Drug inducing antiphospholipid syndrome,Immune toxicities (such as Antiphospholipid Syndrome) of drugs Identification and report of immune toxicities associated with drugs.|Causality assessment of reported metabolic toxicities events according to the WHO system Case reported in the World Health Organization (WHO) database of individual safety case reports|Description of the type of immune toxicity depending on the category of drug Case reported in the World Health Organization (WHO) database of individual safety case reports|Description of the other immune related adverse events concomitant to the immune toxicity induced by drugs Case reported in the World Health Organization (WHO) database of individual safety case reports|Description of the duration of treatment when the toxicity happens (role of cumulative dose) Case reported in the World Health Organization (WHO) database of individual safety case reports|Description of the drug-drug interactions associated with adverse events Case reported in the World Health Organization (WHO) database of individual safety case reports|Description of the pathologies (cancer) for which the incriminated drugs have been prescribed Case reported in the World Health Organization (WHO) database of individual safety case reports|Description of the population of patients having hematological toxicity adverse event Case reported in the World Health Organization (WHO) database of individual safety case reports,Groupe Hospitalier Pitie-Salpetriere,All,"18 Years and older � (Adult, Older Adult)",,2700,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,CIC1421-19-10,"June 1, 2019","June 30, 2021","June 30, 2021","June 21, 2019",,"September 4, 2019","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris, France",,https://ClinicalTrials.gov/show/NCT03994302,NCT03994302,35114404
oui,NCT03994510,SHame prOpensity in bOrderline Personality Disorder,SHOO,Recruiting,No Results Available,Borderline Personality Disorder,Other: Clinical and biological assessments - a 5 Years follow-up,Level of shame propensity|Number of SA compared to the clinical data obtained in baseline|Number of SA compared to the biological data obtained in baseline|Suicidal Ideation|Parasuicidal Behaviours|Sick leave for a psychiatric condition|Hospitalization for a psychiatric condition|The need to emergency psychiatric consult|Major depressive episodes|Global functioning|Life Quality,"University Hospital, Montpellier|INSERM 1061, "" Neuropsychiatry: epidemiological and clinical research"", Montpellier",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,688,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,UF 7681,"September 18, 2020",September 2029,September 2029,"June 21, 2019",,"June 13, 2022","University Hospital of Montpellier, Montpellier, H�rault, France",,https://ClinicalTrials.gov/show/NCT03994510,NCT03994510,
oui,NCT03998020,"Constitution of a Clinical, Neurophysiological and Biological Cohort for Chronic Sleep Disorders Responsible of Hypersomnolence",Somnobank,Recruiting,No Results Available,"Somnolence Disorder, Excessive",Other: scale of severity|Genetic: blood sample,Severity of somnolence|level of somnolence,"University Hospital, Montpellier|INSERM U1061 Montpellier",All,"8 Years and older � (Child, Adult, Older Adult)",Not Applicable,450,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,9895,"June 16, 2020",June 2023,November 2023,"June 25, 2019",,"November 30, 2020","UH Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT03998020,NCT03998020,
oui,NCT04003220,Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker,ICTUS,Recruiting,No Results Available,"Thrombocytopenia|Purpura, Thrombocytopenic|Myelodysplastic Syndromes",Procedure: blood sample|Procedure: Bone marrow sample,Measure of clonality in patients with ICTUS,"University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 80 Years   (Adult, Older Adult)",,80,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,CHUBX 2018/47,"September 7, 2020","September 7, 2023","September 7, 2023","July 1, 2019",,"November 28, 2022","Immunopathologie Clinique - Hôpital Saint Louis - AP HP, Paris, France|Chirurgie cardiaque - Hôpital Haut Lévêque - CHU de Bordeaux, Pessac, France|Service des maladies du sang - Hôpital Haut-Lévêque - avenue de Magellan, Pessac, France|service de médecine interne et maladies infectieuses - Groupe hospitalier Sud, Pessac, France",,https://ClinicalTrials.gov/show/NCT04003220,NCT04003220,
oui,NCT04004039,Understanding Loss of Muscle Mass and Function,SAMANTHA,Withdrawn,No Results Available,Sarcopenia,,Properties and characterization of satellite cells of healthy subjects compared to satellite cells of subjects with sarcopenia.|Reversal of sarcopenia with chemicals compounds extracted from wild aromatic plants from south of France vs control (not treated cells),"University Hospital, Montpellier|INSERM U1046 CNRS UMR 9214, Montpellier University",All,"18 Years and older � (Adult, Older Adult)",,0,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RECHMPL19_0272,"October 1, 2018","August 1, 2019","August 1, 2019","July 1, 2019",,"August 12, 2019","Uh Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04004039,NCT04004039,
oui,NCT04005638,Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia,BIOCAI,Recruiting,No Results Available,Immune Thrombocytopenia|Autoimmune Hemolytic Anemia|Autoimmune Neutropenia,Biological: blood sample|Biological: urine sample,"Number of patients with autoimmune cytopenia at diagnosis, or followed but not treated with a biological library (serum, plasma, DNA)","University Hospital, Bordeaux|Ministry for Health and Solidarity, France",All,"18 Years and older � (Adult, Older Adult)",,200,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,CHUBX 2018/13,"February 2, 2019",January 2023,January 2023,"July 2, 2019",,"January 27, 2022","CHU de Bordeaux - service de m�decine interne, Pessac, France",,https://ClinicalTrials.gov/show/NCT04005638,NCT04005638,
oui,NCT04005833,Blood Fibrocytes During an Exacerbation and Lung Function Decline in Patients With COPD in Primary Care.,FIBRO-COPD,Not yet recruiting,No Results Available,Chronic Obstructive Pulmonary Disease,Diagnostic Test: spirometry,number of blood fibrocytes|Forced Expiratory Volume (FEV)|Score of modified Medical Research Council dyspnea scale|Score of Chronic obstructive pulmonary disease Assessment Test,"University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France",All,"40 Years and older   (Adult, Older Adult)",,230,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHUBX 2017/43,"September 19, 2019","June 1, 2020","June 1, 2023","July 2, 2019",,"July 2, 2019","Cabinet médical, Belin Beliet, France|Cabinet Médical, Cadillac, France",,https://ClinicalTrials.gov/show/NCT04005833,NCT04005833,
oui,NCT04015141,A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy,,Recruiting,No Results Available,Pediatric Epileptic Syndrome|Partial-onset Seizures,Drug: Perampanel Oral Suspension|Drug: Perampanel Tablet,"Proportion of 50% Responders For All Seizures During the Maintenance Period of Core Study|Proportion of 50% Responders During Treatment Period of Core Study and Extension Phase A|Proportion of 25% and 75% Responders for all Seizures, During Maintenance Period of Core Study and During Treatment Period of Core Study and Extension Phase A|Proportion of Participants Who Are Seizure-Free During the Maintenance Period of Core Study and During the Treatment Period of Core Study and Extension Phase A|Change From Baseline in Seizure Frequency For All Seizures During the Treatment Period of Core Study and During the Treatment Period of Core Study and Extension Phase A|Percent Change From Baseline in Seizure Frequency For All Seizures During the Treatment Period of Core Study and During the Treatment Period of Core Study and Extension Phase A|Clinical Global Impression of Change (CGIC) at the End of the Treatment Period of Core Study and at the End of Extension Phase A|Subject Global Impression of Change (SGIC) at the End of the Treatment Period of Core Study and at the End of Extension Phase A|Change From Baseline in the Cognitive Drug Research (CDR) Parameter at the End of the Treatment Period of Core Study and at the End of Extension Phase A|Change from Baseline in CBCL Parameters at the End of the Treatment Period of Core Study and at the End of Extension Phase A|Change from Baseline in Lafayette Grooved Pegboard Test (LGPT) Parameters at the End of the Treatment Period of Core Study and at the End of Extension Phase A|Change from Baseline in Growth and Development Parameter - Height|Change from Baseline in Growth and Development Parameter - Weight|Change from Baseline in Growth and Development Parameter - Free Triiodothyronine (fT3) and Free Thyroxine (fT4) Levels in Blood|Change from Baseline in Growth and Development Parameter - Thyroid-Stimulating Hormone (TSH) Levels in Blood|Change from Baseline in Growth and Development Parameter - Insulin Like Growth Factors (IGF)-1|Change from Baseline in Growth and Development Parameter- Sexual Maturation Assessed by Tanner Staging|Proportion of Participants with any Treatment-Emergent Reports of Suicidal Ideation and Behavior on the Columbia-Suicide Severity Rating Scale (C-SSRS) and Intensity of These Behaviors Assessed using C-SSRS Scores|Change from Baseline in Number of Seizures Recorded on Electroencephalogram (EEG) at the End of the Treatment Period of Core Study and at the End of Extension Phase A|Number of Participants with at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)|Number of Participants with Treatment Emergent Markedly Abnormal Laboratory Values|Number of Participants with Clinically Notable Vital Sign Results|Number of Participants with Clinically Significant Abnormal Electrocardiograms",Eisai Inc.,All,"1 Month to 18 Years � (Child, Adult)",Phase 2,100,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,E2007-G000-236|2018-004456-38,"May 31, 2019","October 6, 2024","June 23, 2025","July 10, 2019",,"November 17, 2022","Phoenix Childrens Hospital, Phoenix, Arizona, United States|Center For Neurosciences, Tucson, Arizona, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Nemours Foundation Alfred Dupont Children's Hospital, Wilmington, Delaware, United States|Nicklaus Children's Hospital, Miami, Florida, United States|Pediatric Neurology PA, Orlando, Florida, United States|Pediatric Epilepsy and Neurology Specialists, Tampa, Florida, United States|Meridian Clinical Research-(Savannah Georgia), Savannah, Georgia, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Northeast Regional Epilepsy Group, Hackensack, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest Baptist Medical Center - PPDS, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|Doernbecher Children's Hospital, Portland, Oregon, United States|Child Neurology Consultants of Austin, Austin, Texas, United States|Road Runner Research Ltd, San Antonio, Texas, United States|Children's Specialty Group, Norfolk, Virginia, United States|Children's Hospital of Richmond at VCU - CHoR-PIN, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Centre Neurologique William Lennox, Ottignies, Brabant Wallon, Belgium|UZ Brussel, Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Brussels, Belgium|H�pital Universitaire des Enfants Reine Fabiola, Bruxelles, Brussels, Belgium|UZ Gent, Gent, Oost-Vlaanderen, Belgium|H�pital Erasme, Anderlecht, Belgium|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Ostrava, Ostrava, Czechia|Fakultni nemocnice Plzen, Plzen, Czechia|Aarhus Universitetshospital, Aarhus N, Central Jutland, Denmark|Regionshospitalet Randers, Randers, Denmark|Hopitaux de La Timone, Marseille, Bouches-du-Rh�ne, France|H�pital Pellegrin-Enfants, Bordeaux, France|Hopital Necker, Paris, France|Hopitaux de Paris CHU Hopital Robert Debre - Inserm U676, Paris, France|CHRU Rennes, Rennes, France|Centre Hospitalier Universitaire de Toulouse, Toulouse Cedex 9, France|Eisai Trial Site #4, Freiburg, Germany|Eisai Trial Site #2, Jena, Germany|Eisai Trial Site #3, Munich, Germany|Eisai Trial Site #1, Radeberg, Germany|Centro Medico Teknon - Grupo Quironsalud, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital General Universitario Gregorio Mara��n, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|CHUS - H. Clinico U. de Santiago, Santiago de Compostela, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain",,https://ClinicalTrials.gov/show/NCT04015141,NCT04015141,
oui,NCT04015713,Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment Onset,LILAC-TB,Unknown status,No Results Available,Tuberculosis,,"Evolution of the plasma concentration of IL-1Ra between baseline (initiation of TB treatment) and Week 2|Evolution of the plasma concentration of IL-1Ra between baseline (initation of TB treatment) and weeks 1, 2, 4 and 8|Evolution of the concentration of sCD163 between baseline (initiation of TB treatment) and weeks 1, 2, 4 and 8|Evolution of the plasma concentration of IP-10 between baseline (initiation of TB treatment) and weeks 1, 2, 4 and 8|Impact of the occurrence of events on the evolution of biomarkers from baseline (initiation of TB treatment) to the end of treatment (Week 24)","ANRS, Emerging Infectious Diseases|Institut Pasteur, Cambodia|Institut National de la Santé Et de la Recherche Médicale, France|European Georges Pompidou Hospital",All,"18 Years to 99 Years   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Other|Time Perspective: Prospective,ANRS 12394 LILAC-TB,"January 21, 2020",March 2021,March 2021,"July 11, 2019",,"February 6, 2020","Institut Pasteur Cambodge, Phon Phen, Cambodia|CEPREF/Programme PACCI, Abidjan, Côte D'Ivoire",,https://ClinicalTrials.gov/show/NCT04015713,NCT04015713,
oui,NCT04021485,BETAmethasone Dose Reduction: Non-Inferiority on the Neurocognitive Outcomes of Children Born Before 32 Weeks of Gestation,BETANINO,Recruiting,No Results Available,Premature Childbirth,Other: neurodevelopmental assessment,neurocognitive development|5-year survival without moderate-to-severe impairment|Parental stress|cerebral palsy,Assistance Publique - H�pitaux de Paris,All,5 Years to 6 Years � (Child),Not Applicable,643,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,K170920J,"March 23, 2022","October 31, 2025","October 31, 2025","July 16, 2019",,"December 8, 2022","H�pital Robert Debr�, Paris, Pa, France",,https://ClinicalTrials.gov/show/NCT04021485,NCT04021485,
anrs,NCT04022967,ANRS 12372 MODERATO Study,MODERATO,Recruiting,No Results Available,HIV-1-infection,Drug: dolutegravir|Drug: atazanavir boosted with ritonavir|Drug: tenofovir + lamivudine +efavirenz|Drug: Lamivudine,"The treatment success|Failure combined endpoint|Plasma HIV-1 RNA|Virological success|CD4 lymphocyte|Virological failure and new resistance mutations|New HIV-1 drug resistance mutations|WHO stage 3-4 morbidity|ANRS grade 3-4 overall morbidity|ANRS grade 3-4 renal morbidity|ANRS grade 3-4 neurologic morbidity|ANRS grade 3-4 hepatic morbidity|Creatinine clearance|Grade 1,2,3 or 4 renal disorders|Grade 1,2,3 or 4 hepatic liver disorders or abnormalities|Grade 1,2,3 or 4 CNS disorders|Bone mineral density|Adherence to treatment using a self-questionnaire|Life quality|Symptoms|ARV drug plasma concentrations in participants with treatment failure|Switched back to triple therapy|Cost-effectiveness of the 3 ARV strategies","ANRS, Emerging Infectious Diseases|Mylan Laboratories",All,"18 Years and older � (Adult, Older Adult)",Phase 3,600,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 12372 MODERATO,"September 21, 2020","August 20, 2023","December 20, 2023","July 17, 2019",,"October 15, 2021","H�pital de jour, Service des maladies infectieuses, CHU Sour� Sanou, Bobo-Dioulasso, Burkina Faso|Service de m�decine interne, CHU Yalgado Ou�draogo, Ouagadougou, Burkina Faso|Service des Maladies Infectieuses, H�pital du jour, H�pital Central, Yaound�, Cameroon|Centre de Prise en Charge et de Formation (CePReF), Association ACONDA, Abidjan, C�te D'Ivoire|Service des Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville, Abidjan, C�te D'Ivoire",,https://ClinicalTrials.gov/show/NCT04022967,NCT04022967,
oui,NCT04024150,"Pregnancy, Anti-integrase and Lymphocyte Repertoire of the Newborn",RAGIIF,Completed,No Results Available,Anti-integrases,Biological: Blood test,Newborn immunity,Assistance Publique - Hôpitaux de Paris,All,"Child, Adult, Older Adult",,29,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,APHP190394|2019-A00926-51,"December 4, 2019","January 14, 2021","January 14, 2021","July 18, 2019",,"March 22, 2023","AP-HP, Hôpital Louis Mourier, Colombes, France|AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France|AP-HP, Hôpital Cochin, Paris, France|AP-HP, Hôpital Necker, Paris, France|AP-HP, Hôpital Bichat-Claude Bernard, Paris, France",,https://ClinicalTrials.gov/show/NCT04024150,NCT04024150,36343360
oui,NCT04026087,Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation,COR-HUM,Completed,No Results Available,Antibody-mediated Rejection,,distribution of DSA IgG subclasses|histological criteria for humoral rejection|degradation of graft function|graft loss,"University Hospital, Montpellier|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Other,RECHMPL18_0455 UF7724,"July 18, 2019","May 6, 2022","February 15, 2023","July 19, 2019",,"February 23, 2023","CHU Lapeyronie, Montpellier, Hérault, France",,https://ClinicalTrials.gov/show/NCT04026087,NCT04026087,34863025;32670261
oui,NCT04026594,Mindfulness-based Therapy Versus Relaxation in Prevention of Burnout in Medical Students,MUSTPrevent,Recruiting,No Results Available,Burnout|Emotional Disturbances|Depression,Other: Mindfulness Based Stress Reduction|Other: Relaxation group,Emotional exhaustion assessed with the Maslach Burnout Inventory (MBI)|Depersonalization assessed with the Maslach Burnout Inventory (MBI)|Professional achievement assessed with the Maslach Burnout Inventory (MBI)|Psychotropic and analgesic consumption|Tobacco consumption|Alcohol consumption|Alcohol consumption assessed with the Alcohol Use Disorders Identification Test (AUDIT)|Drug consumption|Drug consumption assessed with the Drug Abuse Screening Test (DAST)|Cannabis consumption|Cannabis consumption assessed with the Cannabis Abuse Screening Test (CAST)|Anxio-depressive symptomatology assessed with the Montgomery Asberg Depression Rating Scale (MADRS)|Anxio-depressive symptomatology assessed with the Hospital Anxiety and Depression Scale (HADS)|Anxio-depressive symptomatology assessed with the Perceived Stress Scale (PSS)|Anxio-depressive symptomatology assessed with the Numerical Scale for psychological pain|Suicidality assessed with the Columbia Suicide Severity Rating Scale (C-SSRS)|Empathy assessed with the Jefferson Scale of Empathy for students|Quality of life assessed with the World Health Organization Quality of Life (WHOQOL)|Mindfulness assessed with the Five Facets Mindfulness Questionnaire (FFMQ)|Self- compassion assessed with the Self-Compassion Scale (SCS)|Program adherence|Program acceptability,"University Hospital, Montpellier|Centre Hospitalier Universitaire de N?mes|University Hospital, Paris|University Hospital, Angers|University Hospital, Clermont-Ferrand|University Hospital of Saint-Etienne|University Hospital, Tours|University Hospital, Marseille|University Hospital, Strasbourg|INSERM U1061 Montpellier|University Hospital, Toulouse|Hospices Civils de Lyon",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,612,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",RECHMPL19_0063|2019-A01050-57,"October 4, 2019","March 4, 2024","September 4, 2024","July 19, 2019",,"December 22, 2021","CHU Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04026594,NCT04026594,32160891
oui,NCT04028791,"Sickle Cell Trait and Exercise, Effect of Hot Environment",TDex,Completed,No Results Available,Sickle Cell Trait|Environmental Exposure|Adverse Effect,Other: Exercise on ergocycle,Microvascular function|Oxidative stress|Inflammation|Adhesion molecules|Hemorheology|Rhamdomyolysis|Oxydative stress marker,"University of the French West Indies and French Guiana|Institut National de la Santé Et de la Recherche Médicale, France",Male,18 Years to 30 Years   (Adult),Not Applicable,21,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,2017-A02226-47,"September 25, 2017","July 1, 2019","July 1, 2019","July 23, 2019",,"July 23, 2019","ACTES laboratory, Pointe-à-Pitre, Guadeloupe",,https://ClinicalTrials.gov/show/NCT04028791,NCT04028791,
oui,NCT04028895,Diagnostic Interest of the IRAP Protein (Insulin Regulated Amino Peptidase) in Insulin Resistance,IRAP-IR,Terminated,No Results Available,Insulin Resistance Syndrome,Diagnostic Test: Dosage of IRAP during OGTT,IRAP concentration during OGTT.|Kinetic profile of IRAP concentration in 3-hours OGTT|Diagnostic value of IRAP|Diagnostic value of the concentration of other biomarkers (not yet determined),"University Hospital, Grenoble",All,"40 Years to 65 Years � (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,38RC18.326,"September 14, 2020","June 30, 2022","June 30, 2022","July 23, 2019",,"August 11, 2022","Service de Nutrition clinique et CRNH Auvergne, Clermont-Ferrand, France|Inserm CIC1406, clinical research center, Grenoble Alpes university hospital, Grenoble, France|CRNH Rh�ne-Alpes et Centre Hospitalier LYON Sud, Lyon, France|Endocrinologie-Diab�tologie-Nutrition et CIC, CHU DE MONTPELLIER, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04028895,NCT04028895,
oui,NCT04029454,Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule,NEOVAC2BK,Recruiting,No Results Available,Hepatitis B,Biological: birth dose vaccination against hepatitis B strategy,Proportion of positive HBV infection in 9-month-old children vaccinated at birth compared to children receiving their first vaccination at 8 weeks.|Prevalence rate of HBV infection in pregnancy from HBsAg and HBeAg profiles in mothers of 9-month-old children|Sensibility and specificity of low-cost alternative HBV markers,"Institut Pasteur|Agence de Médecine Préventive, France|Centre Muraz|Institut National de la Santé Et de la Recherche Médicale, France|Gilead Sciences|Abbott",Female,"15 Years to 55 Years   (Child, Adult)",Not Applicable,8500,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2017-083,"October 19, 2020","March 31, 2023","March 31, 2023","July 23, 2019",,"April 20, 2022","District sanitaire de Dafra, Bobo-Dioulasso, Dafra, Burkina Faso|District sanitaire de Do, Bobo-Dioulasso, Do, Burkina Faso",,https://ClinicalTrials.gov/show/NCT04029454,NCT04029454,34206058
non,NCT04029870,Psychological Determinants of the Therapeutic Observance of Osteoporotic Patients,OSTEOPSY,Completed,No Results Available,"Osteoporosis, Postmenopausal",,Adherence to therapy|Perception of disease|Perception of treatment|Anxiety,Centre Hospitalier R�gional Metz-Thionville,Female,"50 Years and older � (Adult, Older Adult)",,152,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2019-02Obs-CHRMT,"June 17, 2019","January 31, 2022","January 31, 2022","July 23, 2019",,"March 9, 2023","CHR Metz Thionville, Metz, Moselle, France",,https://ClinicalTrials.gov/show/NCT04029870,NCT04029870,
oui,NCT04034550,Cohort of Hospitalized Patients Suspected of Leptospirosis,COLEPT,Recruiting,No Results Available,Leptospirosis,Other: Blood and urine sampling and blood banking,disease severity,"Institut National de la Santé Et de la Recherche Médicale, France",All,"1 Day and older   (Child, Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,C17-47,"January 6, 2021","January 6, 2027",July 2027,"July 26, 2019",,"May 18, 2022","Groupe Hospitalier Est Réunion (GHER), Saint Benoît, Reunion, France|CHU de La Réunion site Sud (GHSR), Saint Pierre, Reunion, France|CHU de La Réunion site Nord, Saint-Denis, Reunion, France|Centre Hospitalier Ouest Réunion (CHOR), Saint-Paul, Reunion, France",,https://ClinicalTrials.gov/show/NCT04034550,NCT04034550,
oui,NCT04038632,Impact of an Innovative Childhood TB Diagnostic Approach Decentralized to District Hospital and Primary Health Care Levels on Childhood Tuberculosis Case Detection and Management in High Tuberculosis Incidence Countries (TB-Speed Decentralisation Study),,Recruiting,No Results Available,Tuberculosis in Children,Other: Decentralization of Childhood TB Diagnosis,"Children diagnosed with TB|TB case detection|TB screening in outpatient children - 1|TB screening in outpatient children - 2|Feasibility of implementing the different diagnostic approach components - 1|Feasibility of implementing the different diagnostic approach components - 2|Feasibility of implementing the different diagnostic approach components - 3|TB treatment uptake and time to TB treatment initiation - 1|TB treatment uptake and time to TB treatment initiation - 2|Cost-effectiveness from the health services perspective|Acceptability by health care providers, NTPs and health authorities, and beneficiaries|Fidelity of the implementation of the diagnostic approach as compared to the protocol and study procedures - 1|Fidelity of the implementation of the diagnostic approach as compared to the protocol and study procedures - 2|Performance of the diagnostic approach at patient level|TB treatment outcome|Diagnostic performance of CXR reading by clinicians at DH and PHC levels|Added value of CXR in the diagnosis of TB in children as compared to microbiology and clinical evaluation only|Uptake of the quality control of the CXR reading","Institut National de la Santé Et de la Recherche Médicale, France|UNITAID",All,up to 14 Years   (Child),Not Applicable,26000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,C18-25,"March 7, 2020",March 2022,March 2022,"July 31, 2019",,"September 5, 2021","Angroka Rh, Angroka, Cambodia|Taphem Hc, Angroka, Cambodia|Tropang Andert Hc, Angroka, Cambodia|Batheay Rh, Batheay, Cambodia|Choeung Chnok Hc, Batheay, Cambodia|Tumnub Hc, Batheay, Cambodia|KUS HC, KUS, Cambodia|Nhaeng Nhang Hc, Nhaeng Nhang, Cambodia|Sambour Hc, Sambour, Cambodia|Csi Messngssang, Bafia, Cameroon|HD BAFIA, Bafia, Cameroon|Csi Balamba Bafia, Balamba, Cameroon|Cma Batchenga, Batchenga, Cameroon|Cma Bokito Bafia, Bokito, Cameroon|Csi Essong, Essong, Cameroon|Cma Kiiki Bafia, Kiiki, Cameroon|Cma Fomakap, Obala, Cameroon|Csi Ngogo, Obala, Cameroon|Obala Hosp, Obala, Cameroon|Dr Banteapleu, Banteapleu, Côte D'Ivoire|Csu Dakpadou, Dakpadou, Côte D'Ivoire|Csr Daleu, Daleu, Côte D'Ivoire|H G de Danane, Danane, Côte D'Ivoire|Csu Kouan-Houle, Kouan-houle, Côte D'Ivoire|Csu Mahapleu, Mahapleu, Côte D'Ivoire|Csr Medon, Medon, Côte D'Ivoire|CMS SAGO, Sago, Côte D'Ivoire|Dr de Sahoua, Sahoua, Côte D'Ivoire|H G Sassandra, Sassandra, Côte D'Ivoire|Chiaquelane, Chiaquelane, Mozambique|Chibonzane, Chibonzane, Mozambique|Chidenguele, Chidenguele, Mozambique|Chalocuane, Chokwe, Mozambique|HOKWE, Chokwe, Mozambique|Hosp Rural Chokwe, Chokwe, Mozambique|MACUACUA, Macuacua, Mozambique|Hospital Rural de Manjacaze, Manjacaze, Mozambique|Laranjeira, Manjacaze, Mozambique|Babara Chc, Babara, Sierra Leone|Bo Govt Hosp, BO, Sierra Leone|New Police barracks, BO, Sierra Leone|Gbinti Chc, Gbinti, Sierra Leone|Gerihun Chc, Gerihun, Sierra Leone|Koribondo Chc, Koribondo, Sierra Leone|Mange Chc, Mange, Sierra Leone|Njala University Chc, Njala, Sierra Leone|Petifu Chc, Petifu, Sierra Leone|Port Loko Govt Hosp, Port Loko, Sierra Leone|Buyamba Hc Iii, Buyamba, Uganda|Kambuga Hospital, Kambuga, Uganda|Kanungu Hciv, Kanungu, Uganda|Kanyantorogo Hciii, Kanyantorogo, Uganda|Lwamaggwa Hc Iii, Lwamaggwa, Uganda|Lwanda Hc Iii, Lwanda, Uganda|St Bernards Manya Hc Iii, Manya, Uganda|Matanda Hciii, Matanda, Uganda|Rakai Hospital, Rakai, Uganda",,https://ClinicalTrials.gov/show/NCT04038632,NCT04038632,
oui,NCT04051970,Reducing Antiretroviral Treatments,ALTAR,"Active, not recruiting",No Results Available,HIV-1-infection,Drug: Antiretroviral,To demonstrate at W48 the non-inferiority,"ANRS, Emerging Infectious Diseases|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,360,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 173,"November 27, 2019","September 1, 2023","March 1, 2024","August 9, 2019",,"August 9, 2021","Hôpital la Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT04051970,NCT04051970,
oui,NCT04058574,"Proprioceptive Isokinetic Repositioning, Functional Testing, and a Self-reported Questionnaire Before and After Anterior Cruciate Ligament Reconstruction",PRO-ACL,Unknown status,No Results Available,ACL Tear|ACL - Anterior Cruciate Ligament Deficiency,Device: Proprioception measurement on isokinetic dynamometer,Change from Baseline passive proprioceptive evaluation after 7 months|Change from Baseline active proprioceptive evaluation after 7 months|Change from Baseline TDPM (Threshold to Detection of Passive Motion) evaluation after 7 months|Strength|ACL-RSI questionnaire (Anterior Cruciate Ligament-Return to Sport after Injury)|Functional testing,"University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 50 Years   (Adult),Not Applicable,45,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,PRO-ACL,"September 1, 2019","September 1, 2021","January 1, 2022","August 15, 2019",,"July 15, 2020","Caen University Hospital, Caen, France|Caen University Hospital, Caen, France",,https://ClinicalTrials.gov/show/NCT04058574,NCT04058574,
oui,NCT04061811,"Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients",SONGBIRD,Completed,No Results Available,Heart Failure|End Stage Renal Disease,Diagnostic Test: Diagnostic biomarker study,HF diagnosis,"Hannover Medical School|Institut National de la Sant� Et de la Recherche M�dicale, France|F-CRIN",All,"18 Years and older � (Adult, Older Adult)",,153,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,7952_BO_S_2018|KlinStrucMed program,"August 1, 2018","February 28, 2019","February 28, 2019","August 20, 2019",,"August 20, 2019","Inserm Umr S-942, Paris, France|Hannover Medical School, Hannover, Germany",,https://ClinicalTrials.gov/show/NCT04061811,NCT04061811,
oui,NCT04062825,Interaction Between HIV and Platelets,PLAQUEVIH,Recruiting,No Results Available,HIV Seropositivity,,CD4 number will be determined|VIH level in platelet will be quantified|potential interaction between platelets and lymphocytes|analyze if the interaction can be blocked by anti GPIIbIIIa|HIV expression on bone marrow smear|soluble factors secretion,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,240,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,19CCN-VIH-Plaquettes,"April 17, 2020",March 2025,March 2025,"August 20, 2019",,"March 17, 2023","Service Hématologie Immunologie, Hôpital Ambroise Paré, Boulogne Billancourt, France",,https://ClinicalTrials.gov/show/NCT04062825,NCT04062825,
oui,NCT04065750,Exposure to Antibiotics and Incidence of Bacteraemia Caused by Resistant Bacteria,BactHub,Unknown status,No Results Available,Bacteremia,,Incidence of bacteraemia|Mortality|Rehospitalization,"Assistance Publique - H�pitaux de Paris|Institut National de la Sant� Et de la Recherche M�dicale, France|Versailles Saint-Quentin-en-Yvelines University",All,"18 Years and older � (Adult, Older Adult)",,45000,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,19SAA-BactHub,November 2019,December 2019,December 2019,"August 22, 2019",,"August 22, 2019",,,https://ClinicalTrials.gov/show/NCT04065750,NCT04065750,
oui,NCT04070482,Impact of in Utero and Breastfeeding Exposure to Tenofovir on Renal Function in HIV-exposed Uninfected Children,,Unknown status,No Results Available,Renal Injury,Other: Tenofovir exposure in utero and during breastfeeding,"Difference in urinary RBP, NAG, KIM-1and B2M levels at birth between neonates born to mothers living with HIV, exposed in utero to TDF and those born to mothers without HIV and not exposed to TDF|Difference in urinary RBP, NAG, KIM-1and B2M levels after birth and within the first year of life between HEU infants, exposed in utero to TDF and HUU infants, not exposed to TDF","University of Yaounde 1|Institut National de la Santé Et de la Recherche Médicale, France",All,up to 1 Year   (Child),,400,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2016/449-LON,"October 1, 2017","April 30, 2019",December 2019,"August 28, 2019",,"August 29, 2019","CASS, Yaoundé, Cameroon|Cité Verte DH, Yaoundé, Cameroon|Efoulan DH, Yaoundé, Cameroon",,https://ClinicalTrials.gov/show/NCT04070482,NCT04070482,
oui,NCT04071912,Isokinetic Muscular Assessment After ACL Ligamentoplasty: Study of Factors Predictive of Muscle Imbalance.,PREDICT-ACL,Completed,No Results Available,ACL - Anterior Cruciate Ligament Deficiency|Muscle Weakness,,Change in Strength|Individual characteristics|Injury characteristics|Surgery characteristics,"University Hospital, Caen|INSERM U1075 COMETE, UNICAEN, Caen France",All,"16 Years to 55 Years � (Child, Adult)",,113,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,PREDICT-ACL,"October 1, 2019","December 1, 2019","February 1, 2020","August 28, 2019",,"July 14, 2020","CHU Caen Normandie, Caen, France",,https://ClinicalTrials.gov/show/NCT04071912,NCT04071912,35167984
oui,NCT04085835,Evolution of Menstruation,EVOMENS,Unknown status,No Results Available,Menstruation,,Gene expression levels measured by RNA-seq|Active regulatory elements profiled by ATAC-seq,"Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 45 Years   (Adult),,20,Other,Observational,Observational Model: Cohort|Time Perspective: Other,C18-19|2019-A01089-48,"December 1, 2019","December 1, 2020","June 1, 2021","September 11, 2019",,"September 11, 2019","Institut de Biologie de l'Ecole Normale Superieure, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT04085835,NCT04085835,
oui,NCT04089436,SouthEast Asia Encephalitis Project,SEAe,Unknown status,No Results Available,Encephalitis,Diagnostic Test: CSF sampling|Diagnostic Test: Blood sampling|Diagnostic Test: Nasopharyngeal and rectal sampling,"Identify etiologies of encephalitis in South East Asia (Vietnam, Laos, Cambodia and Myanmar).|Describe clinical and biological features of patients with encephalitis|describe clinical outcomes of encephalitis in general and by etiology|Identify factors associated with death or severe neurological sequelea in patients with confirmed infectious encephalitis (survival analyses, sequelea score).","Institut Pasteur|Centre De Coopération International En Recherche Agronomique Pour Le Développement|Institut National de la Santé Et de la Recherche Médicale, France|Institut Pasteur, Cambodia|Institut de Recherche pour le Developpement|National Institute of Hygiene and Epidemiology, Vietnam|University of Oxford|National Health Laboratory, Myanmar",All,"28 Days and older   (Child, Adult, Older Adult)",,800,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2013-024,"July 15, 2014","September 30, 2019","December 31, 2019","September 13, 2019",,"September 25, 2019","Institut Pasteur of Cambodia, Phnom Penh, Cambodia|Kantha Bopha IV children Hospital, Phnom Penh, Cambodia|Mahidol Oxford Tropical Medicine Research Unit, Vientiane, Lao People's Democratic Republic|National Health Laboratory, Yangon, Myanmar|Yangon children hospital, Yangon, Myanmar|National Hospital of Pediatrics, Hanoi, Vietnam|National Institute of Hygiene Epidemiology, Hanoï, Vietnam",,https://ClinicalTrials.gov/show/NCT04089436,NCT04089436,35714649
oui,NCT04091477,Impact of Neuropsychological Alteration of Patients With Eating Disorders,NeuropsyTCA,Completed,No Results Available,Eating Disorder,,Level of functional impairment assessed by the clinician with the FAST scale|Decision making assessed by the Iowa Gambling Task|Level of cognitive flexibility assessed by the Brixton test|Level of central coherence assessed by the Rey Figure Test,"University Hospital, Montpellier|INSERM 1061-Montpellier",All,"15 Years to 65 Years � (Child, Adult, Older Adult)",,200,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,RECHMPL19_0436,"October 1, 2019","December 1, 2019","December 30, 2019","September 16, 2019",,"March 11, 2020","Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04091477,NCT04091477,
oui,NCT04106401,Intravascular Volumes in Hypoxia During Antarctic Confinement,ANTARCV,Enrolling by invitation,No Results Available,Hypoxia|Confinement,Other: carbon-monoxide rebreathing|Other: venous blood sampling|Other: physical activity monitoring|Other: apnea-hypopnea index and nocturnal oxygenation|Other: 24-hour blood pressure,total hemoglobin mass|total red blood cell volume|total blood volume|plasma volume|blood viscosity|serum erythropoietin|serum hepcidin|serum erythroferrone|serum transferrin saturation|serum ferritin|serum soluble transferrin receptor|Physical activity|Apnea-hypopnea index|Nocturnal oxygenation|24-hour blood pressure,"Ecole Nationale des Sports de Montagne|Center for Physical Activity Research, University Hospital of Copenhagen, Denmark|Laboratory Mobility, aging & exercise (MOVE) -EA 6314, Faculty of Sport Sciences, University of Poitiers, France|Department for Biomedical Sciences for Health, University of Milan School of Medicine, Milan, Italy|HP2 Laboratory, INSERM, Grenoble Alpes University, CHU Grenoble Alpes, Grenoble, France",All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2018-A03243-52,"September 27, 2019","December 31, 2022","December 31, 2022","September 27, 2019",,"September 13, 2022","Ecole nationale des sports de montagne, site de l'Ecole nationale de ski et d'alpinisme, Chamonix-Mont-Blanc, Haute Savoie, France",,https://ClinicalTrials.gov/show/NCT04106401,NCT04106401,
oui,NCT04110626,"Realistic Evaluation of Exp�riences Anim�es, a School-based Intervention in Nouvelle Aquitaine",ERIEAS,Completed,No Results Available,Addiction,Other: Questionnaires|Other: Non-directive Interviews,"Daily, alcohol consumption|Weekly, alcohol consumption|Monthly, alcohol consumption|Number of episodes of heavy drinking|Number of drunkenness episodes|Weekly, cannabis consumption|Monthly, cannabis consumption|Yearly, cannabis consumption|Number of consultation of a healthcare professional to discuss about a problematic use of alcohol and/or cannabis","University Hospital, Bordeaux|CMG-EC U1219 Inserm",All,"Child, Adult, Older Adult",,1026,Other,Observational,Observational Model: Other|Time Perspective: Prospective,CHUBX 2018/75,"September 30, 2019","June 16, 2022","June 16, 2022","October 1, 2019",,"October 12, 2022","CIC1401-EC - CHU de Bordeaux Centre Inserm U1219, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT04110626,NCT04110626,32601111
oui,NCT04117529,Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus,CaReLyBP,Unknown status,No Results Available,Pemphigus Vulgaris|Pemphigus Foliaceus,Other: Blood sample,"Involvement of neutrophil extracellular traps (NETs) in the activation of B lymphocytes in Pemphigus|Demonstration that activation of the different sub-populations of B lymphocytes during NET exposure, if shown in pemphigus, is also in lupus, rheumatoid arthritis and Gougerot-Sjögren's syndrome relying on membrane markers for activation of B lymphocytes|Demonstration that activation of the different sub-populations of B lymphocytes during NET exposure, if shown in pemphigus, is also lupus, rheumatoid arthritis and Gougerot-Sjögren's syndrome relying on pro-inflammatory cytokines|Demonstration that activation of the different sub-populations of B lymphocytes during NET exposure, if shown in pemphigus, is also in lupus, rheumatoid arthritis and Gougerot-Sjögren's syndrome relying on immunoglobulins and antibodies|Demonstration that activation of the different sub-populations of B lymphocytes during NET exposure, if shown in pemphigus,is also in lupus,rheumatoid arthritis and Gougerot-Sjögren's syndrome relying on IL-10 and TGFbeta production by regulatory B cells","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,APHP190199|2019-A00533-54,"October 22, 2019",July 2022,July 2022,"October 7, 2019",,"January 8, 2021","Pr Philippe MUSETTE - Hôpital AVICENNE, Bobigny, France",,https://ClinicalTrials.gov/show/NCT04117529,NCT04117529,
anrs,NCT04120415,A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02),,Recruiting,No Results Available,HIV-1-infection,Biological: Vaccine and vedolizumab (Entyvio)|Biological: Placebo vaccine and vedolizumab infusion (Entyvio)|Biological: Placebo vaccine and placebo infusion,Area under the HIV RNA curve|Virological outcome measures,"ANRS, Emerging Infectious Diseases|EuroVacc Foundation|European AIDS Treatment Group (EATG)|Medical Research Council|University College London Hospitals|University of Liverpool|Erasmus Medical Center|Henri Mondor University Hospital|European Georges Pompidou Hospital|Saint-Louis Hospital, Paris, France|Centre Hospitalier Universitaire Vaudois|Chelsea and Westminster Hospital, UK|Universitätsklinikum Hamburg-Eppendorf|Hospital Clinic of Barcelona|Istituto Nazionale Malattie Infettive Lazaro Spallanzani|Imperial College London|Institut d'Investigacions Biomèdiques August Pi i Sunyer|European Commission|Swiss Government",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,69,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EHVA T02/ANRS VRI07,"June 21, 2022",June 2023,December 2023,"October 9, 2019",,"July 13, 2022","Service Immunologie clinique et maladies infectieuses, Hôpital Henri Mondor, Paris, Creteil, France|Hotel Dieu, Paris, France|Centre d'Immunothérapie et Vaccinologie, CHUV, Lausanne, Vaud, Switzerland|St Stephens Centre, Chelsea & Westminster Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT04120415,NCT04120415,
oui,NCT04121026,Validation of a Tuberculosis Treatment Decision Algorithm in HIV-infected Children,TB-Speed HIV,Recruiting,No Results Available,Tuberculosis|HIV,Other: External validation of the PAANTHER TB treatment decision algorithm,Proportion of missed TB cases|Feasibility of the PAANTHER TB treatment decision algorithm (a): Proportion of children with presumptive TB having completed the algorithm.|Feasibility of the PAANTHER TB treatment decision algorithm (b): Time to final TB treatment decision|Proportion of HIV-infected children with unlikely TB among those initiated on treatment as per the PAANTHER TB treatment decision algorithm|Incidence of morbidity|Incidence of mortality|Time to ART initiation in ART-naïve children|CD4 (absolute count and %) gain|TB treatment outcomes (a): Weight gain at 6 months (absolute value and percentage of body weight)|TB treatment outcomes (b): TB symptoms resolution in children on TB treatment|Feasibility of IPT initiation (a): Time to IPT initiation|Feasibility of IPT initiation (b): Proportion of children initiated on IPT|Performance of the Monocyte-to-Lymphocyte Ratio and the C-reactive protein and their potential added value in the PAANTHER score and algorithm to detect TB|Proportion of NPAs (or sputum) and stool samples with mycobacterium tuberculosis (MTB) detected using Ultra|Proportion of children with NPA and stool samples collected as per study protocol|Proportion of NPA-related adverse events (AEs)|Discomfort/pain/distress experienced by the child during NPA as assessed by the child|Discomfort/pain/distress experienced by the child during NPA as assessed by the parents|Discomfort/pain/distress experienced by the child during NPA as assessed by the nurse,"Institut National de la Santé Et de la Recherche Médicale, France|UNITAID",All,1 Month to 14 Years   (Child),Not Applicable,550,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C18-27,"October 2, 2019","June 30, 2022","June 30, 2022","October 9, 2019",,"September 22, 2021","Cocody University Teaching Hospital, Abidjan, Côte D'Ivoire|Treichville University Teaching Hospital, Abidjan, Côte D'Ivoire|José Macamo General Hospital, Maputo, Mozambique|Maputo Central Hospital, Maputo, Mozambique|Mbarara Regional Hospital, Mbarara, Uganda|Lusaka University Teaching Hospital, Lusaka, Zambia|Arthur Davidson Children Hospital, Ndola, Zambia",,https://ClinicalTrials.gov/show/NCT04121026,NCT04121026,
oui,NCT04128722,TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN,TOPGUN,Recruiting,No Results Available,Lingual Microcystic Lymphatic Malformations,Drug: Sirolimus Oral Liquid Product 1mg/mL,"Change in Physical Global Assessment (PGA) after topical application of Sirolimus for 12 weeks|Investigator-assessed PGA|Assessment by the patient regarding severity of oozing, bleeding, sialorrhea, eating impairment, taste modification, aesthetic impairment, pain and global discomfort,|Global evolution assessed by the patient|Global Quality of life assessment|Measurements of the lesion|Time to obtain optimal results|Assessment of tolerance of topical sirolimus:|General side effects|Assessment of sirolimus blood passage|Evaluation of biological safety","University Hospital, Tours",All,"5 Years and older � (Child, Adult, Older Adult)",Phase 2,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DR190041-TOPGUN|2019-001530-33,"February 14, 2020","August 13, 2023","January 28, 2024","October 16, 2019",,"March 4, 2022","Univsersity of TOURS _ Service de Dermatologie, Tours, Indre Et Loire, France|REGIONAL Hospital of ORLEANS -Service de Dermatologie, Orl�ans, Loiret, France|Hospital NECKER -AP-HP - Dermatology, Paris, France",,https://ClinicalTrials.gov/show/NCT04128722,NCT04128722,35804404
oui,NCT04136132,Prospective Monocentric Clinical-biological Database,BCBPancr�as,Recruiting,No Results Available,Pancreatic Cancer,Other: Biological collection,Proportion of patients who gave their consent to participate in the study,Institut du Cancer de Montpellier - Val d'Aurelle,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,PROICM 2018-10 BPA,"May 15, 2019",June 2027,June 2027,"October 23, 2019",,"November 17, 2022","Institut R�gional du Cancer de Montpellier, Montpellier, Occ, France",,https://ClinicalTrials.gov/show/NCT04136132,NCT04136132,
oui,NCT04137978,Study Evaluating Patients With Cystinuria,,Unknown status,No Results Available,Cystinuria,Drug: ADV7103|Drug: Standard of Care,Percentage of urinary pH values ? 7.0 during 24h on Day 7 (after ADV7103 treatment period),Advicenne Pharma,All,"6 Months to 70 Years � (Child, Adult, Older Adult)",Phase 2|Phase 3,97,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,B14CS,"February 1, 2019",August 2022,August 2022,"October 24, 2019",,"October 24, 2019","Cliniques Universitaires Saint-Luc, Brussels, Belgium|UZ Leuven, Gasthuisberg Hospital, Leuven, Belgium|CHU de Bordeaux - H�pital Pellegrin, Bordeaux, France|Centre Hospitalier Universitaire de Lyon, Bron, France|CHU Grenoble, Grenoble Cedex, France|CHRU Lille, Lille, France|CHU Piti�-Salp�tri�re, Paris, France|H�pital Necker AP-HP, Paris, France|H�pital Necker Enfants Malades, Paris, France|H�pital T�non - Explorations fonctionnelles Mutlidisciplinaires et INSERM UMR S 1155, Paris, France|H�pital Am�ricain CHU de Reims, Reims, France|CHU Reims, Reims, France|CHU Purpan, Toulouse cedex 9, France",,https://ClinicalTrials.gov/show/NCT04137978,NCT04137978,
oui,NCT04139096,Genetic Susceptibility to Radiation Induced Thyroid Cancer,,Unknown status,No Results Available,Thyroid Neoplasms|Genetic Susceptibility|Radiation Exposure,,Number of Differentiated thyroid carcinoma,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,C 17-69,"September 22, 2019","April 30, 2020","April 30, 2020","October 25, 2019",,"October 25, 2019","Gustae Roussy, Villejuif, Val De Marne, France",,https://ClinicalTrials.gov/show/NCT04139096,NCT04139096,
associ�,NCT04141540,Molecular Variants Associated With Schizophrenia: Differential Analysis of Monozygotic Twins With Variable Phenotypic 22q11,CSRK05,Completed,No Results Available,Di George Syndrome,Genetic: Molecular analyses,Whole exome sequencing|Transcriptome|Methylome|Microbiotic DNA|Positive And Negative Syndrome Scale (PANSS)|Mini-International Neuropsychiatric Interview (MINI)|Hospital Anxiety and Depression Scale (HADS),H�pital le Vinatier,Male,18 Years to 45 Years � (Adult),Not Applicable,2,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2019-A00852-55,"March 27, 2020","November 30, 2020","December 30, 2020","October 28, 2019",,"February 9, 2021","Hopital Vinatier, Lyon, Rhone Alpes, France",,https://ClinicalTrials.gov/show/NCT04141540,NCT04141540,
non,NCT04142606,LUMIERE on the FETUS,FETUS,Recruiting,No Results Available,Pregnancy,Other: fetal MRI,feasibility of advanced MRI techniques|concordance of information collected by MRI|Concordance of information collected by MRI|Acceptability of the examination for the patient: leackertLikert scale|Reproducibility of the examination analysis|relevance of MRI|Specific Absorption Rate for each type of sequence|feasibility of fusion imaging (echo / MRI)|norms of growth of main organs and placenta|Establishment of an anatomical and functional database on a large group of healthy fetuses|Concordance of diagnosis,Assistance Publique - H�pitaux de Paris|LUMIERE Fondation ( fondation-lumiere.org) under the aegis of Fondation de France|University of Paris 5 - Rene Descartes,Female,"18 Years and older � (Adult, Older Adult)",,950,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP190334,"December 6, 2019",December 2023,June 2024,"October 29, 2019",,"February 13, 2023","Necker - Enfants Malades Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT04142606,NCT04142606,36971038
oui,NCT04147871,Study Evaluating Patients With Cystinuria and Efficacy and Safety Exploratory Study in the Youngest Children,,Unknown status,No Results Available,Cystinuria,Drug: ADV7103|Drug: Placebo,Percentage of urinary pH values ? 7.0 during 24h on Day 7 (after ADV7103 treatment period),Advicenne Pharma,All,"6 Months to 70 Years � (Child, Adult, Older Adult)",Phase 2|Phase 3,72,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B12CS-B13CS,"February 1, 2019","August 1, 2020","August 1, 2020","November 1, 2019",,"November 1, 2019","Cliniques Universitaires Saint-Luc, Brussels, Belgium|UZ Leuven, Gasthuisberg Hospital, Leuven, Belgium|Centre Hospitalier Universitaire de Lyon - H�pital Femme M�re Enfant, Bron, France|CHU Grenoble, Grenoble Cedex, France|CHRU Lille, Lille, France|CHU Piti�-Salp�tri�re, Paris, France|H�pital Necker AP-HP, Paris, France|H�pital Necker Enfants Malades, Paris, France|H�pital T�non - Explorations fonctionnelles Mutlidisciplinaires et INSERM UMR S 1155, Paris, France|H�pital Am�ricain CHU de Reims, Reims, France|CHU Reims, Reims, France|CHU Purpan, Toulouse cedex 9, France",,https://ClinicalTrials.gov/show/NCT04147871,NCT04147871,
oui,NCT04150198,MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY,PET-AL,Not yet recruiting,No Results Available,"Alzheimer Disease, Early Onset|Posterior Cortical Atrophy",Device: TEP/IRM,"highlight of the ""resilient"" neural networks|quantify the impairment (ie brain vulnerability) in AD-Y and in PCA|correlation between the concentration of tau-tauphosphorylated protein in cerebrospinal fluid (CSF) with the lesion load measured in PET|predictive model of functional alterations based on the structural alterations of the gray matter and the white matter.","Institut National de la Santé Et de la Recherche Médicale, France|France Alzheimer",All,"40 Years to 80 Years   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C19-40,"April 15, 2021","July 15, 2023","December 15, 2023","November 4, 2019",,"March 25, 2021","Service Hospitalier Frédéric Joliot SHFJ, Orsay, France|Service de Médecine Nucléaire - Hopital La Pitié Salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT04150198,NCT04150198,
oui,NCT04151797,Impact of a Mobile Geriatric Team With a Pharmacist on the Optimisation of Prescriptions in Elderly Inpatients,PHARMOG,Completed,No Results Available,Medication Therapy Management,Other: Medication therapy management,"Change from baseline patients' number of potentially inappropriate prescription at the patient discharge after optimization by a mobile geriatric team with pharmacist|Change from baseline patients' number of potentially inappropriate prescription at 3 months after optimization by a mobile geriatric team with pharmacist|Change from baseline patients' number with at least one potentially inappropriate drug at 3 months after optimization by a mobile geriatric team with pharmacist|Change from baseline ratio of potentially inappropriate drug per patient at 3 months after optimization by a mobile geriatric team with pharmacist|Change from baseline mean number of medications per patient at 3 months|realisation of a pharmacist-led medication review in primary care|number of falls 3 months after pharmacist-led medication review|mortality 3 months after pharmacist-led medication review|re-hospitalisation, including emergency room transfers|The nursing home transfers","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,75 Years and older   (Older Adult),Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,RC31/17/0353,"November 19, 2019","March 22, 2021","March 22, 2021","November 5, 2019",,"June 1, 2021","Toulouse University Hospital, Toulouse, Occitanie, France",,https://ClinicalTrials.gov/show/NCT04151797,NCT04151797,33268421
oui,NCT04154891,Genome Sequencing Strategies for Genetics Diagnosis of Patients With Intellectual Disability,DEFIDIAG,"Active, not recruiting",No Results Available,Intellectual Disability,Genetic: Trio Whole Genome Sequencing|Genetic: Simplex Whole Genome Sequencing|Genetic: Current French Reference strategy,"Diagnostic Yield|Causal structural change|Incremental cost-effectiveness ratio|Mean cost of wavering diagnostic research|Percentage of at least one modification in medical, medico-social, rehabilitative and psychological follow-up|Number and type of secondary data|Median time and type of skills required for analyzing genetic data and for genetic confirmation|Median time to obtain results","Institut National de la Santé Et de la Recherche Médicale, France|Commissariat A L'energie Atomique|Hospices Civils de Lyon|Centre Hospitalier Universitaire Dijon|University Hospital, Rouen|University Hospital, Strasbourg|APHP",All,"Child, Adult, Older Adult",Not Applicable,3825,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,C16-110|2018-A00680-55,"March 13, 2020",May 2023,May 2024,"November 7, 2019",,"March 16, 2023","CHU d'Angers, Angers, France|CHU Bordeaux, Bordeaux, France|Hospices Civil de Lyon, Bron, France|CHU Dijon, Dijon, France|CHU de Grenoble-Alpes, La Tronche, France|CHRU Lille, Lille, France|Assistance publique - Hôpitaux de Marseille, Marseille, France|CHU Montpellier, Montpellier, France|CHU Nantes, Nantes, France|Assistance publique - Hôpitaux de Paris - Groupe Hospitalier Pitié Salpétrière, Paris, France|Assistance publique - Hôpitaux de Paris - Hôpital Necker - Enfants malades, Paris, France|CHU Rennes, Rennes, France|CHU Rouen, Rouen, France|CHU Strasbourg, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT04154891,NCT04154891,35444683;35178068
oui,NCT04158557,Strategies for Management of Knee Osteoarthritis : Innovation and Medico-economic Study,,Unknown status,No Results Available,Knee Osteoarthritis,,The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)|The Short Form (36) Health Survey (SF-36),"University Hospital, Strasbourg, France|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years to 85 Years � (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,INSERM,"December 1, 2019","December 1, 2021","December 1, 2022","November 8, 2019",,"December 24, 2019","Inserm-Unistra, Umr 1260, Strasbourg, Alsace, France",,https://ClinicalTrials.gov/show/NCT04158557,NCT04158557,
oui,NCT04170881,CRESPI - Respiratory Health of Children in Daycare,CRESPI,Not yet recruiting,No Results Available,Respiratory Health,Other: Exposed/non exposed - Epidemiology,Current wheezing|Longitudinal wheezing|Current cough,"Institut National de la Santé Et de la Recherche Médicale, France|Centre Scientifique et Technique du Bâtiment|EPICONCEPT|Ecole des Hautes Etudes en Santé Publique|ANSES|ADEME|National Research Agency, France|Agence Regionale de Sante d'Ile de France|Fondation de France",All,2 Months to 4 Years   (Child),,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C 18-05,"November 19, 2019","November 19, 2021","December 31, 2023","November 20, 2019",,"November 20, 2019","Nicole LE MOUAL, Villejuif, France",,https://ClinicalTrials.gov/show/NCT04170881,NCT04170881,
associ�,NCT04174066,From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With MGLS and HSFP,BiobankSNI,Recruiting,No Results Available,Nephrotic Syndrome,Other: blood sample|Other: tissue sample|Other: excreta,number of biological samples,Centre Hospitalier Universitaire de Nice,All,"12 Months and older � (Child, Adult, Older Adult)",,144,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,18-PP-16,"May 20, 2020","May 20, 2021","May 20, 2025","November 22, 2019",,"October 19, 2020","Nice Hospital, Nice, France|APHP, Paris, France",,https://ClinicalTrials.gov/show/NCT04174066,NCT04174066,
oui,NCT04175119,Tracking Information Flow in the Brain,BRAINDYN,Recruiting,No Results Available,Healthy Volunteer,Device: Visual attention/perception tasks in healthy participants,"The composite characteristics of the brain oscillations (frequency, synchronization, and interaction between brain oscillations in and between different brain regions and networks)|The coupling of behavioral responses to stimuli with physiological responses in the brain.|Coupling of brain oscillation characteristics in responses to the ""flickering"" effect",Hospices Civils de Lyon,All,20 Years to 36 Years � (Adult),Not Applicable,160,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL18_0854|2019-A01604-53,"November 25, 2019","April 25, 2025","April 25, 2025","November 22, 2019",,"March 1, 2023","Centre de Recherche en Neuroscience de Lyon INSERM, Bron, France",,https://ClinicalTrials.gov/show/NCT04175119,NCT04175119,
oui,NCT04179435,Cognitive and Brain Development in Adolescents With Gilles de la Tourette Syndrome,CADETS,Not yet recruiting,No Results Available,Tourette Syndrome in Adolescence,Behavioral: Behavioral testing on cognitive computerized tasks|Other: brain MRI|Other: TMS,Behavioral test main outcome measures [1]|Behavioral test main outcome measures [2]|Behavioral test main outcome measures [3]|Behavioral test main outcome measures [4]|Brain MRI scan measures|Transcranial magnetic stimulation,"Institut National de la Santé Et de la Recherche Médicale, France",All,"13 Years to 18 Years   (Child, Adult)",Not Applicable,132,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C19-11|2019-A00992-55,December 2019,December 2021,December 2023,"November 27, 2019",,"November 27, 2019",,,https://ClinicalTrials.gov/show/NCT04179435,NCT04179435,36460852
oui,NCT04180059,Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation,CTL-DP 01,Recruiting,No Results Available,Haematologic Disease,Combination Product: CTL 19,determine maximal tolerated dose f infusion of a third party suicide gene-transduced anti-HLA-DPB1*04:01 CD4+ T cell clone in HLA-DPB1*04:01 tumor positive recipients receiving an allo-HSCT from a HLA-DPB1*04:01 negative alternative donor.|survival and persistence of the clone injected|immune reconstitution|incidence of relapse|survival|GVHD incidence|mortality|complete remission|side effects of Clone,Nantes University Hospital|INSERM U01232 CRCINA,All,"18 Years to 75 Years � (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RC16_0157,"February 9, 2020",February 2025,September 2025,"November 27, 2019",,"August 17, 2022","Chu de Nantes, Nantes, France",,https://ClinicalTrials.gov/show/NCT04180059,NCT04180059,
oui,NCT04183023,Population Genomic Diversity of France,POPGEN,"Active, not recruiting",No Results Available,"Genetics, Population",Genetic: Collection of a salivary sample,Genotypes and allele frequencies of the participants,"Institut National de la Sant� Et de la Recherche M�dicale, France|Commissariat A L'energie Atomique",All,"18 Years and older � (Adult, Older Adult)",,10250,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,C19-39|2019-A01862-55,"March 31, 2021","February 19, 2022","March 31, 2025","December 3, 2019",,"October 6, 2022","Inserm - UMR1078 GGB, Brest, France",,https://ClinicalTrials.gov/show/NCT04183023,NCT04183023,
oui,NCT04186650,Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts,EBGraft,"Active, not recruiting",No Results Available,"Epidermolysis Bullosa Dystrophica, Recessive",Biological: COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin,"Safety of grafting SIN RV-mediated COL7A1 gene-modified autologous skin equivalent: Adverse Events (AE), Serious Adverse Events (SAEs), Adverse Reactions (ARs) and Serious Adverse Reactions (SARs)|Change in C7 protein expression|Change in anchoring fibrils number|Change in scar quality: Vancouver Scar Scale (VSS)|Changes in blister number over the grafted skin|Changes in clinical appearance of grafted skin|Changes in pruritus of grafted skin|Change in Quality of life: QOLEB questionnaire (Quality of Life for Epidermolysis Bullosa)|Change in Birmingham Epidermolysis Score (BEBS)|Change in Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) - Activity|Change in Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) - Damage|Change in instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB).|Evaluation of the humoral immune response against recombinant C7|Evaluation of the cytotoxic immune response against recombinant C7","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,3,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C12-48|2016-002790-35,"January 10, 2020","June 9, 2027","June 9, 2027","December 5, 2019",,"October 19, 2021","Institut Imagine Necker Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT04186650,NCT04186650,
oui,NCT04189029,"PACIFIC-PRESERVED : PhenomApping, ClassIFication, and Innovation for Cardiac Dysfunction - HF With PRESERVED LVEF Study",,Recruiting,No Results Available,Heart Failure|Heart Failure With Preserved Ejection Fraction,Other: Extensive phenotyping,Machine learning algorithm to identify distinct phenotypic subgroups among HFpEF patients|Prognosis|Myocardial stiffness|Sarcopenia and muscular capacity|Exercise tolerance|Cardiac fibrosis|Arterial Stiffness|Right heart and pulmonary circulation|Ventricular-arterial coupling|Omics signature|Quality of life evaluation|Telemonitoring of weight|Telemonitoring of cardiac rythm|Telemonitoring of ECG|Telemonitoring of physical activity|Telemonitoring of blood pressure|Telemonitoring of pulmonary function|Telemonitoring of oxygen saturation|Telemonitoring of pulmonary congestion|Digitalized ECG|Cardiac echography|Cardiac calcium scoring|Cardiac MRI|Left atria,"Assistance Publique - Hôpitaux de Paris|BPIfrance|Sanofi|Institut de Recherches Internationales Servier|Institut National de la Santé Et de la Recherche Médicale, France|BioSerenity|Casis|Firalis SA|Fealinx|Centre National de la Recherche Scientifique, France|ESPCI Paris|University of Paris 5 - Rene Descartes|Sorbonne University",All,"18 Years to 90 Years   (Adult, Older Adult)",,2620,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP190558|2019-A01795-52,"December 9, 2019",June 2023,June 2025,"December 6, 2019",,"January 9, 2023","AP - HP, Hôpital Européen Georges-Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT04189029,NCT04189029,35124236
associ�,NCT04190394,Comparison of Two Exercise Training Modes on Left Myocardial Regional Function After Myocardial Infarction Evaluated by 2D Strain Ultrasound,STRAICT,Recruiting,No Results Available,Ischemic Cardiomyopathy,Other: Intermittent retraining program.,"Longitudinal systolic strain on Day 0.|Longitudinal systolic strain at Week 8.|Longitudinal diastolic strain on Day 0|Longitudinal diastolic strain at Week 8|Circumferential strain on Day 0|Circumferential strain at Week 8|Systolic radial strain on Day 0|Systolic radial strain at Week 8|Diastolic radial strain on Day 0|Diastolic radial strain at Week 8|Systolic circumferential strain on Day 0|Systolic circumferential strain at Week 8|Diastolic circumferential strain on Day 0|Diastolic circumferential strain at Week 8|Apical rotation on Day 0|Apical rotation at Week 8|Basal rotation on Day 0|Basal rotation at Week 8|Ventricular torsion on Day 0|Ventricular torsion at Week 8|Intraventricular asynchrony on Day 0|Intraventricular asynchrony at Week 8|Cardiac morphology : Telesystolic volume on Day 0|Cardiac morphology : Telesystolic volume at Week 8|Cardiac morphology : Telediastolic volume on Day 0|Cardiac morphology : Telediastolic volume at Week 8|Cardiac morphology : Left ventricle mass on Day 0|Cardiac morphology : Left ventricle mass at Week 8|Cardiac morphology : FEVG at Day 0|Cardiac morphology : FEVG at Week 8|Cardiac morphology : S' wave on Day 0|Cardiac morphology : S' wave at Week 8|Cardiac morphology : E/A ratio on Day 0|Cardiac morphology : E/A ratio at Week 8|Cardiac morphology : E' wave at Day 0|Cardiac morphology : E' wave at Week 8|Cardiac morphology : A' wave on Day 0|Cardiac morphology : A' wave at Week 8|Cardiac morphology : E/E' ratio on Day 0|Cardiac morphology : E/E' ratio at Week 8|Cardiac morphology : Systolic ejection volume on Day 0|Cardiac morphology : Systolic ejection volume at Week 8|Aerobic capacity: VO2max on Day 0|Aerobic capacity: VO2max at Week 8|Aerobic capacity: Maximal aerobic power (MAP) on Day 0|Aerobic capacity : Maximal aerobic power (MAP) at Week 8|Aerobic capacity: ventilation threshold (mL/min/kg) on Day 0|Aerobic capacity: ventilation threshold (mL/min/kg) at Week 8|Aerobic capacity: walking on Day 0|Aerobic capacity: walking at Week 8|Weight on Day 0|Weight at Week 8|Height on Day 0|Height at Week 8|Waist measurement on Day 0|Waist measurement at Week 8|Body Mass Index on Day 0|Body Mass Index at Week 8|Medicinal treatment on Day 0|Medicinal treatment at Week 8|Hemoglobin in g/dL on Day 0|Hemoglobin in g/dL at Week 8|Percentage volume of Hematocrit on Day 0|Percentage volume of Hematocrit at Week 8|Mean Corpuscular Volume in femtoliters on Day 0|Mean Corpuscular Volume in femtoliters at Week 8|Platelets in G/L on Day 0|Platelets in G/L at Week 8|Leukocytes in G/L on Day 0|Leukocytes in G/L at Week 8|C-reactive Protein on Day 0|C-reactive Protein at Week 8|Potassium in millimoles per liter on Day 0|Potassium in millimoles per liter at Week 8|Sodium in millimoles per liter on Day 0|Sodium in millimoles per liter at Week 8|Urea on Day 0|Urea at Week 8|Creatinine on Day 0|Creatinine at Week 8|Fasting glucose on Day 0|Fasting glucose at Week 8|HbA1c on Day 0|HbA1c at Week 8|Aspartate Aminotransferase on Day 0|Aspartate Aminotransferase at Week 8|Alanine Aminotransferase on Day 0|Alanine Aminotransferase at Week 8|Alkaline phosphatase on Day 0|Alkaline phosphatase at Week 8|Creatine phosphokinase on Day 0|Creatine phosphokinase at Week 8|Bilirubin on Day 0|Bilirubin at Week 8|Gamma-glutamyltransferase on Day 0|Gamma-glutamyltransferase at Week 8|Total cholesterol on Day 0|Total cholesterol at Week 8|Low Density Lipoprotein-cholesterol on Day 0|Low Density Lipoprotein-cholesterol at Week 8|High Density Lipoprotein-cholesterol on Day 0|High Density Lipoprotein-cholesterol at Week 8|Triglycerides on Day 0|Triglycerides at Week 8|NT-proB-type Natriuretic Peptides on Day 0|NT-proB-type Natriuretic Peptides at Week 8|Micro-RNA dosage (miRNA22, miRNA122, miRNA150, miRNA208 a/b and miRNA 423-5p) on Day 0|Micro-RNA dosage (miRNA22, miRNA122, miRNA150, miRNA208 a/b and miRNA 423-5p) at Week 8|Quality of life according to the WHOQOL-BREF Questionnaire on Day 0|Quality of life according to the WHOQOL-BREF Questionnaire at Week 8|Quality of life according to the MacNew Questionnaire at Day 0|Quality of life according to the MacNew Questionnaire at Week 8|Observance of the rehabilitation program",Centre Hospitalier Universitaire de N?mes,All,"18 Years to 75 Years � (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,NIMAO/2018-03/AD-01,"March 12, 2020","October 1, 2023","October 1, 2023","December 9, 2019",,"December 22, 2022","N�mes University Hospital, N�mes, Gard, France|Clinique Lavarin, Centre de R��ducation Cardiaque,1 Rue M�re T�r�sa,, Avignon, Vaucluse, France",,https://ClinicalTrials.gov/show/NCT04190394,NCT04190394,
oui,NCT04191759,Reliability of the Passive Properties of the Calf Muscles in Healthy Subjects Assessed Using Isokinetic Device,ISOSTIFF,Completed,No Results Available,Tendon Injuries|Muscle Tightness,Diagnostic Test: Test-Retest reproducibility,"Change from Baseline stiffness parameters at 15 days to assess the reproducibility of stiffness parameters|Change from Baseline viscoelastic parameters at 15 days to assess the reproducibility of viscoelastic parameters|Patient characteristics|Physical characteristics, popliteal angle|Physical characteristics, Calf Circumference|Physical characteristics, ROM|Physical characteristics, Fingertip-to-Floor (FTF) Test","University Hospital, Caen|INSERM U1075 COMETE, UNICAEN, Caen France",All,18 Years to 45 Years � (Adult),Not Applicable,16,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,ISOSTIFF,"June 12, 2018","July 15, 2018","November 10, 2018","December 10, 2019",,"December 10, 2019","CHU Caen Normandie, Caen, France",,https://ClinicalTrials.gov/show/NCT04191759,NCT04191759,
oui,NCT04198909,Optimization of a Non-invasive Electrophysiological Method for Studying the Functionality of Auditory Nerve Fibers,ECOG,Recruiting,No Results Available,Healthy Volunteer|Without Hearing Disorders,"Diagnostic Test: Electrocochleography, electrophysiology thet for analyse the wave I generated by the auditory pathways",Latency of wave I by electrocochleography|Hearing thresholds in decibels|Acoustic reflex thresholds in decibels,"University Hospital, Clermont-Ferrand|Laboratory of Neurosensory Biophysics - UMR INSERM 1107.|Foundation of Gueules Cass�es|Region of Auvergne-Rh�ne-Alpes",All,18 Years to 25 Years � (Adult),Not Applicable,130,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RBHP 2018 GIRAUDET|2018-A02525-50,"April 29, 2019",January 2024,July 2024,"December 13, 2019",,"December 13, 2019","Chu Clermont Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT04198909,NCT04198909,
oui,NCT04199403,Assessment of Complication Risk Factors in a French National Cohort of Asplenic Patients,SPLEEN,Recruiting,No Results Available,Asplenia,,Assessment of complication risk factors,Poitiers University Hospital|Pr Pierre BUFFET Institut National de la Transfusion Sanguine|Pr Sophie CANDON Laboratoire d'immunologie et bioth�rapies CHU de Rouen|Dr Edouard TUAILLON D�partement Bact�riologie-Virologie/INSERM U1058 CHU de Montpellier,All,"18 Years and older � (Adult, Older Adult)",,6000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SPLEEN,"January 9, 2020",January 2040,January 2040,"December 13, 2019",,"January 13, 2023","C.H. d'Angoul�me, Angoul�me, France|C.H. Victor Dupouy, Argenteuil, France|C.H. de B�thune, B�thune, France|H�pitaux de Chartres, Chartres, France|C.H.U. de Lille, Lille, France|C.H.U. de Montpellier, Montpellier, France|H�tel-Dieu - CHU de Nantes, Nantes, France|C.H.U. de Poitiers, Poitiers, France|C.H.U. de Rouen, Rouen, France|C.H.U. de Toulouse, Toulouse, France|C.H. de Tourcoing, Tourcoing, France|C.H. de Valenciennes, Valenciennes, France",,https://ClinicalTrials.gov/show/NCT04199403,NCT04199403,
oui,NCT04202796,Catheter Ablation in Congenital Heart Disease: French National Prospective Registry,CATCH-Registry,Recruiting,No Results Available,Congenital Heart Disease|Arrhythmia,Procedure: Catheter ablation,Recurrence of targeted arrhythmia|Recurrence of any arrhythmia|Long-term recurrence of targeted and any arrhythmia|Complications|Quality of life assessed by SF36 score|Quality of life assessed by EQ5D3L score,Paris Cardiovascular Research Center (Inserm U970)|European Georges Pompidou Hospital|Centre Chirurgical Marie Lannelongue|Clinique Pasteur Toulouse,All,"Child, Adult, Older Adult",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,MR2C2001,"January 1, 2020","December 31, 2021","December 31, 2023","December 18, 2019",,"March 9, 2021","Georges Pompidou European Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT04202796,NCT04202796,
oui,NCT04203628,Evaluation of Four Stool Processing Methods Combined With Xpert MTB/RIF Ultra for Diagnosis of Intrathoracic Paediatric TB (TB-Speed - Stool Processing),,Recruiting,No Results Available,Tuberculosis,Diagnostic Test: Xpert MTB/Rif Ultra on stool samples|Diagnostic Test: Xpert MTB/Rif Ultra on respiratory sample,"Sensitivity and sensibility of Ultra on stool|Per-protocol analysis of diagnostic accuracy of Ultra on stool using TB culture reference standard|Sensitivities and specificities of each sampling method|Proportion of Ultra ""trace"" results in stools out of the number of stools tested with Ultra|Proportion of Ultra semi-quantitative results ""very low""; ""low""; ""medium"" and ""high"" in stool|Proportion of invalid Ultra results from stool out of the number of stools tested with Ultra|Proportion of Rifampicin resistant results on Ultra (stool and respiratory), LPA and DST|Proportion of children successfully providing a stool sample|Relative gain of the 2nd stool sample as compared to the 1st one|Feasibility assessment of the stool processing methods","Institut National de la Santé Et de la Recherche Médicale, France|UNITAID",All,up to 14 Years   (Child),Not Applicable,274,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C19-34,"January 13, 2020",February 2022,February 2022,"December 18, 2019",,"September 5, 2021","Mbarara Regional Hospital, Mbarara, Uganda|Lusaka University Teaching Hospital, Lusaka, Zambia|Arthur Davidson Children Hospital, Ndola, Zambia",,https://ClinicalTrials.gov/show/NCT04203628,NCT04203628,
oui,NCT04205461,Prospective Evaluation of Programmed Ventricular Stimulation Before Pulmonary Valve Replacement in Patients With Tetralogy of Fallot,,Recruiting,No Results Available,Congenital Heart Disease|Fallot Tetralogy|Ventricular Arrythmia|Pulmonary Valve Regurgitation,Procedure: Programmed ventricular stimulation,Positive programmed ventricular stimulation defined as inducibility of sustained ventricular tachycardia or fibrillation|Critical isthmus involved in ventricular tachycardias induced|Complications associated with programmed ventricular stimulation|Rate of ventricular arrhythmias during the follow-up after pulmonary valve replacement,Paris Cardiovascular Research Center (Inserm U970)|European Georges Pompidou Hospital|Centre Chirurgical Marie Lannelongue|Clinique Pasteur Toulouse|Hopital Louis Pradel|H�pital Necker-Enfants Malades,All,"Child, Adult, Older Adult",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ParisCardioRC,"January 1, 2020","December 31, 2021","December 31, 2023","December 19, 2019",,"March 9, 2021","Paris Cardiovascular Research Center, Paris, France",,https://ClinicalTrials.gov/show/NCT04205461,NCT04205461,
oui,NCT04206969,Assessment of Transcultural Psychotherapy in Child Major Depressive Disorder,EDPT-ADOS,Not yet recruiting,No Results Available,Major Depressive Disorder,Behavioral: Transcultural psychotherapy,Severity Score on the Improved Global Impression Scale (iCGI) to assess remission|Severity score on the iCGI|Score on the French version of the Children's Depression Rating Scale-Revised (CDRS-R)|Score on the French version of the State-Trait Anxiety Inventory for children (STAI-C)|Score changes in Depression and anxiety Scores between Week 34 and week 52|analysis of the content of the clinical data collected during the visits|analysis of the content of the interview with the families and therapists at the end of the treatment,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"6 Years to 20 Years   (Child, Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,P180601|2019-A01830-57,April 2020,October 2022,October 2023,"December 20, 2019",,"March 16, 2020","Service de Psychopathologie de l'enfant, de l'adolescent, CHU Avicenne, Bobigny, France|Service de médecine interne, unité de consultation transculturelle, CHRU Saint-André (CHU Bordeaux), Bordeaux, France|Service de psychiatrie de l'enfant et de l'adolescent, CHRU Gabriel Montpied, Clermont-Ferrand, France|Maison de Solenn, Cochin Hospital, Paris, France|Secteur 75G23, Centre Médico-psychologique (CMP), GHU PARIS, Maison blanche, Paris, France|Centre Médico-psychologique, Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Hôpital La Grave, CHU Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04206969,NCT04206969,
oui,NCT04222335,Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients,LUNG-RESIST,Recruiting,No Results Available,"Lung Cancer, Nonsmall Cell",Other: Blood samples,Rate of EGFR mutated patients for whom phenotypic characterization of DTC-like and osimertinib-tolerant tumor cells is feasible.|Rate of patients for whom the molecular characterization of DTC-like cells is successfully performed.|Progression-free survival (PFS),"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France|National Cancer Institute, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RC31/18/0475|Numéro ID RCB : 2019-A02440-57,"March 26, 2021",January 2023,January 2023,"January 9, 2020",,"May 18, 2022","Toulouse University Hospital, Toulouse, Occitanie, France",,https://ClinicalTrials.gov/show/NCT04222335,NCT04222335,
oui,NCT04223440,Ultrasonographic and MRI Explorations of Infraspinatus Muscle in Postero-superior Rotator Cuff Tear,VISUMIR,Recruiting,No Results Available,Rotator Cuff Tears,Other: MRI|Other: ultrasonographic explorations,MRI Texture Index (MTI)|Ultrasound Texture Index (UTI)|velocity of shear wave in m.s-1,"University Hospital, Tours|Institut National de la Santé Et de la Recherche Médicale, France",All,"35 Years to 75 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,DR190044,"November 24, 2020",August 2023,August 2023,"January 10, 2020",,"September 9, 2022","Chu Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT04223440,NCT04223440,
oui,NCT04223492,Liquid Biopsies and Imaging in Breast Cancer,LIMA,Unknown status,No Results Available,Breast Cancer,Diagnostic Test: Liquid biopsy|Diagnostic Test: Multi-parametric MRI,"Residual Cancer Burden index in surgical resection specimen|Radiological lesion volume on DCE MRI after NAC|pathological complete response, defined as ypT0/ypN0","UMC Utrecht|Horizon 2020 - European Commission|Philips Electronics Nederland BV|Agena Bioscience GmbH|DiaDx|Stilla Technologies|ANGLE Europe Limited|ALS Automated Lab Solutions GmbH|Institut National de la Santé Et de la Recherche Médicale, France|Philips GmbH Innovate Technologies|Institut du Cancer de Montpellier",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,19-396,"January 2, 2019",December 2021,December 2021,"January 10, 2020",,"January 18, 2020","Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",,https://ClinicalTrials.gov/show/NCT04223492,NCT04223492,36127090
oui,NCT04225754,"Identification of Prognostic Parameters in Patients With "" Senile "" Amyloid Cardiomyopathy",EVAMYLOSE,Recruiting,No Results Available,Cardiac Amyloidosis,,Prognostic value of myocardial perfusion heterogeneity index on mortality at 1 year in patients with senile cardiac amyloidosis.|Prognostic value of IHMP on hospitalizations for heart failure in patients with senile cardiac amyloidosis.|Prognostic value of IHPM on the quality of life in patients with senile cardiac amyloidosis|Relationships between IHPM and structural and functional measures in cardiac imaging in cardiac ultrasound|Relationships between IHPM and structural and functional measures in cardiac imaging in MRI.|Correlations between IHMP and geriatric frailty.|Relationships between IHPM in cardiac scintigraphy and the rhythmic evaluations.|Comparison of IHPM between patients with amyloid senile cardiomyopathy and a control population paired with age and sex.|Side effect of tafamidis in this population,"University Hospital, Grenoble",All,"18 Years and older � (Adult, Older Adult)",,142,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,38RC19.386|2019-A03024-53,"July 21, 2020",August 2025,August 2025,"January 13, 2020",,"May 19, 2022","Chu Grenoble Alpes, Grenoble Cedex 9, France",,https://ClinicalTrials.gov/show/NCT04225754,NCT04225754,
oui,NCT04238871,RaDiCo PID Cohort (RaDiCo-ILD Cohort in English),RaDiCo-PID,Unknown status,No Results Available,Idiopathic Interstitial Pneumopathy/Pneumopathy Interstitial Diffuse|Paediatric and Adult Patients,,The phenotypic description idiopathic lung disease|Identify gene factors involved in disease initiation and progression|Investigate the extent to which environmental and co-morbidity factors may influence disease severity and outcome|Identify and validate biomarkers for disease diagnosis and progression,"Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,2500,Other,Observational,Observational Model: Cohort|Time Perspective: Other,C15-64,"March 28, 2017","March 27, 2021","September 27, 2021","January 23, 2020",,"December 14, 2020","CHU Lyon - Hôpital Louis Pradel, Bron, France|AP-HP - Hôpital Armand Trousseau, Paris, France",,https://ClinicalTrials.gov/show/NCT04238871,NCT04238871,34757602
oui,NCT04240990,Development of a Diagnostic Prediction Score for Tuberculosis in Hospitalized Children With Severe Acute Malnutrition,TB-Speed SAM,Unknown status,No Results Available,Tuberculosis|Severe Acute Malnutrition,Other: Development of a score and algorithm for TB treatment decision in hospitalised children with SAM.,Sensitivity of the score obtained|Specificity of the score obtained|Prevalence of TB among hospitalized children with SAM|Clinical characteristics of TB disease in hospitalized children with SAM|Bacteriological characteristics of TB disease in hospitalized children with SAM|Biological characteristics of TB disease in hospitalized children with SAM|Radiological characteristics of TB disease in hospitalized children with SAM|Estimated time to TB treatment decision in hospitalized children with SAM|Diagnostic accuracy measures: 1/ Sensitivity of the different tests evaluated for the diagnosis of TB|Diagnostic accuracy measures: 2/ Specificity of the different tests evaluated for the diagnosis of TB|Diagnostic accuracy measures: 3/ Negative predictive value of the different tests evaluated for the diagnosis of TB|Diagnostic accuracy measures: 4/ Positive predictive value of the different tests evaluated for the diagnosis of TB|Diagnostic accuracy measures: 5/ AUROC of diagnostic prediction models with and without the different tests results|Diagnostic accuracy of Ultra performed on one NPA and one stool sample against mycobacterial culture performed on gastric aspirates|Proportion of children with NPA and stool samples collected as per study protocol|Proportion of NPA-related adverse events (AEs)|Tolerability of NPA collection: 1/ Discomfort/pain/distress experienced by the child as assessed by the child|Tolerability of NPA collection: 2/ Discomfort/pain/distress experienced by the child as assessed by the parents|Tolerability of NPA collection: 3/ Discomfort/pain/distress experienced by the child as assessed by the nurse|Mortality at 6 months|Percentage weight gain 6 months|TB treatment outcomes,"Institut National de la Santé Et de la Recherche Médicale, France|UNITAID",All,up to 59 Months   (Child),Not Applicable,720,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C18-28,"November 4, 2019","November 4, 2020","November 4, 2020","January 27, 2020",,"January 27, 2020","Mulago National Referral Hospital, Kampala, Uganda|Lusaka University Teaching Hospital, Lusaka, Zambia|Arthur Davidson Children Hospital, Ndola, Zambia",,https://ClinicalTrials.gov/show/NCT04240990,NCT04240990,
oui,NCT04253080,Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors,ENZYMELA,Recruiting,No Results Available,Cutaneous Melanoma,Biological: Blood sample|Biological: Cutaneous melanoma biopsy,Role of IL4I1+ cells in prognosis and in response to treatments (targeted and/or antiPD1/CTLA4 based therapies) in cutaneous melanoma,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Association Robert Debré (ARD)|Société de Dermatologie Française|Institut Cochin",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,170,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,APHP190243|2019-A01985-52,"April 12, 2022",October 2024,February 2025,"February 5, 2020",,"October 26, 2022","Dermatology department, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT04253080,NCT04253080,
oui,NCT04259892,Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.,Cov-CONTACT,Suspended,No Results Available,Coronavirus,Biological: 2019-nCoV PCR,"Time to SARS-CoV-2 nasopharyngeal excretion, from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.|Time to apparition of any symptom suggestive of SARS-CoV-2 from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.|Factors associated with the time to SARS-CoV-2 nasopharyngeal excretion|Factors associated with the time to apparition of any symptom suggestive of SARS-CoV-2 infection|Proportion of contact subjects with apparition of any symptom suggestive of SARS-CoV-2 infection|Proportion of contact subjects with positive serology defined as the presence of SARS-CoV-2 IgM or IgG at day 30 (+/-7) following last contact|Host genetic variants|The time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology.","Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,345,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C20-06|2020-A00280-39,"February 4, 2020","December 4, 2021","December 4, 2022","February 7, 2020",,"April 8, 2022","Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon, Besançon, France|Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin, Bordeaux, France|Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand, Clermont-Ferrand, France|Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne, Dijon, France|Centre d'investigation clinique 1406 CHU Grenoble, Grenoble, France|Centre d'Investigation Clinique 1403 -CHU Lille, Lille, France|Centre Investigation Clinique 1433 CHRU de NANCY, Nancy, France|Centre d'Investigation Clinique Hôpital Saint Louis, Paris, France|Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard, Paris, France|Centre Investigation Clinique 1417 Hôpital Cochin Bâtiment Lavoisier, Paris, France|Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou, Rennes, France|Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord, Saint Denis, France|Centre d'Investigation Clinique Ile de la Réunion CHU sud, Saint-Pierre, France|Département maladie infectieux CHU Saint Etienne, Saint-Étienne, France|Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau, Tours, France|Service de Maladies infectieuses et tropicales Centre hospitalier, Cayenne, French Guiana",,https://ClinicalTrials.gov/show/NCT04259892,NCT04259892,37020259
oui,NCT04260490,Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.,MYELODOM,Unknown status,No Results Available,Multiple Myeloma,,Measure of association between exposure to chlordecone and risk of multiple myeloma.|proportion of MM cases attributable to pesticide exposure,Centre Hospitalier Universitaire de Pointe-a-Pitre|Guadeloupe Cancer Registry|Martinique Cancer Registry|INSERM-IRSET U1085|University of Liege|University Hospital Center of Martinique|Centre Hospitalier de Basse-Terre,All,"18 Years and older � (Adult, Older Adult)",,600,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,PAP_RI2_2018/01,"November 19, 2019",November 2022,November 2022,"February 7, 2020",,"February 7, 2020","University Hospital Center of Guadeloupe, Pointe-�-Pitre, Guadeloupe|University Hospital Center of Martinique, Fort-de-France, Martinique",,https://ClinicalTrials.gov/show/NCT04260490,NCT04260490,
oui,NCT04260542,De Novo Lipogenesis and Insulin Sensitivity in Obese,DELISA,Completed,No Results Available,Insulin Resistance|Obesity,Behavioral: Fasting/refeeding|Behavioral: Ketogenic diet/ fasting,Insulin sensitivity|De Novo Lipogenesis in adipose tissue|gene expression profiling of adipose tissue,"Charles University, Czech Republic|Faculty Hospital Kralovske Vinohrady|Institut National de la Santé Et de la Recherche Médicale, France",Female,25 Years to 45 Years   (Adult),Not Applicable,66,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,NV19-01-00263,"May 1, 2019","March 11, 2022","March 11, 2022","February 7, 2020",,"February 15, 2023","Charles University, Prague, Czechia|Faculty Hospital Kralovske Vinohrady, Prague, Czechia",,https://ClinicalTrials.gov/show/NCT04260542,NCT04260542,
oui,NCT04262921,French COVID Cohort,FrenchCOVID,Recruiting,No Results Available,Coronavirus Infections,,"Clinical features|Response to treatment|Pathogen replication, excretion and evolution, within the host|Immune host responses to infection and therapy|Host genetic variants","Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,5000,Other,Observational,Observational Model: Other|Time Perspective: Prospective,C20-05|2020-A00256-33,"February 8, 2020","August 7, 2025","August 7, 2025","February 10, 2020",,"February 25, 2022","CHG Agen, Agen, France|Centre Hospitalier Du Pays D'aix, Aix-en-Provence, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|CH Annecy Genevois, Annecy, France|Hopital privé d'Antony, Antony, France|Hôpital de Mercy. CHR METZ-THIONVILLE, Ars-Laquenexy, France|Centre Hospitalier Henri Duffaut, Avignon, France|Chu Jean Minjoz, Besançon, France|Hôpital Avicenne AP-HP, Bobigny, France|CHU Pellegrin, Bordeaux, France|CHU Ambroise Paré, Boulogne-Billancourt, France|Ch Fleyriat, Bourg-en-Bresse, France|Centre Hospitalier Pierre Oudot, Bourgoin-Jallieu, France|Chru Hopital Cavale Blanche, Brest, France|CHU Brest, Brest, France|Hospices civils de Lyon, Bron, France|Centre hospitalier de Béziers, Béziers, France|CH Cahors, Cahors, France|Centre Hospitalier J.E Techer, Calais, France|Centre Hospitalier Andrée Rosemon, Cayenne, France|Chms Chambery Nh, Chambéry, France|Centre Hospitalier De Cholet, Cholet, France|CHU Gabriel Montpied, Clermont-Ferrand, France|CH Colmar - Hopital Pasteur, Colmar, France|Hôpital Louis Mourier, Colombes, France|Centre hospitalier Alpes Leman, Contamine-sur-Arve, France|Centre hospitalier Intercommunal de Créteil, Créteil, France|Hôpital Henri Mondor, Créteil, France|Centre Hospitalier Dax, Dax, France|CHU Dijon Bourgogne, Dijon, France|CHU de Martinique, Fort De France, France|Hopital Raymond Poincare, Garches, France|CHU Grenoble, Grenoble, France|Grand Hopital de l'Est Francilien site Marne-la-Vallée, Jossigny, France|Chd Les Oudairies, La Roche-sur-Yon, France|Hôpital Universitaire Bicêtre, Le Kremlin-Bicêtre, France|CH du Mans, Le Mans, France|Centre Hospitalier Emile Roux, Le Puy-en-Velay, France|Centre Hospitalier Universitaire de Lille, Lille, France|CHRU Lille, Hôpital Salengro, Lille, France|CHU de Lille, Lille, France|Hôpital de la Croix-Rousse, Lyon, France|Hôpital Louis Raffalli, Manosque, France|Assistance publique hopitaux de Marseille, hopital Nord, Marseille, France|Hopital Européen, Marseille, France|Hôpital Conception, Marseille, France|Groupe Hospitalier Sud Ile De France, Melun, France|CH de Mont Marsan, Mont de Marsan, France|Groupe hospitalier du Havre, Montivilliers, France|CHU Montpellier, Montpellier, France|CHU Nantes, Nantes, France|Hopital Américain de Paris, Neuilly-sur-Seine, France|CHU de Nice, Nice, France|CHU Caremeau, Nîmes, France|APHP Bichat, Paris, France|APHP Tenon, Paris, France|CH Lariboisière, Paris, France|Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France|Hopital Cochin-CIC1417, Paris, France|Hopital Européen Georges Pompidou, Paris, France|Hopital Saint Antoine, Paris, France|Hopital Saint Louis, Paris, France|La pitié salpetrière, Paris, France|Centre Hospitalier de Pau, Pau, France|CH de Perpignan, Perpignan, France|Hopital Lyon Sud-HCL, Pierre-Bénite, France|CHU de Pointe à Pitre, Pointe À Pitre, France|CHU de Poitiers, Poitiers, France|Centre Hospitalier de Périgueux, Périgueux, France|Ch Cornouaille, Quimper, France|Chu Reims, Reims, France|CHU Rennes Hopital Sud, Rennes, France|Hôpital Pontchaillou, Rennes, France|CHU Charles Nicole, Rouen, France|CHU Rouen Normandie, Rouen, France|CHU Réunion-Felix Guyon, Saint denis, France|Hopital d'instruction des armées Begin 69, Saint-Mandé, France|Centre hospitalier Louis Constant Fleming, Saint-Martin, France|Groupe Hospitalier Sud Réunion, Saint-Pierre, France|CHU de Saint-Etienne, Saint-Étienne, France|CH de Saintonge, Saintes, France|Centre Hospitalier de Soissons, Soissons, France|N.H.C. - Nouvel Hopital Civil, Strasbourg, France|Hopital Foch, Suresnes, France|CHR Metz-Thionville -Hopital Bel Air, Thionville, France|Hopitaux du Leman, Thonon-les-Bains, France|Centre Hospitalier Universitaire de Rangueil, Toulouse, France|CHU de Toulouse, Toulouse, France|CHU Toulouse IUCT Institut Universitaire de Cancer de Toulouse, Toulouse, France|CHU Toulouse Larrey, Toulouse, France|Hôpital Gustave Dron, Tourcoing, France|Centre Hospitalier Régional Universitaire de Tours, Tours, France|CHRU de Tours, Tours, France|CHU Nancy, Vandœuvre-lès-Nancy, France|Centre Hospitalier Bretagne Atlantique, Vannes, France|Centre Hospitalier Intercommunal, Villeneuve Saint Georges, France|CH Annecy Genevois, Épagny, France",,https://ClinicalTrials.gov/show/NCT04262921,NCT04262921,37020259;36936553;36825252;36645791;35891471;33876439;33066801;32829467
oui,NCT04265742,Microbiota and Bone Fragility:Study of the Relation Between Gut Microbiota and Bone Microarchitecture,MICROBONE,Completed,No Results Available,"Bone Loss, Age-related",Radiation: bone densitometry|Radiation: High resolution peripheral QCT|Diagnostic Test: Collection of biological samples|Other: questionnaires|Other: clinical tests,Comparison of the composition of the gut microbiota according to fracture status in postmenopausal women with comparable bone mineral density.|Determine the relationship between the composition of the gut microbiota and bone microarchitecture according to fracture status in postmenopausal women with comparable bone mineral density.|Determine the relationship between the composition of the gut microbiota and bone mineral density according to fracture status in postmenopausal women with comparable bone mineral density.|Determine the relationship between the composition of the gut microbiota and muscle mass and strength according to fracture status in postmenopausal women with comparable bone mineral density.|Determine the relationship between the composition of the gut microbiota and physical performance according to fracture status in postmenopausal women with comparable bone mineral density.|Determine the relationship between the composition of the gut microbiota and bone remodeling according to fracture status in postmenopausal women with comparable bone mineral density.|Determine the relationship between the composition of the gut microbiota and regulatory hormones of bone metabolism according to fracture status in postmenopausal women with comparable bone mineral density.|Determine the relationship between the composition of the gut microbiota and genetic factors according to fracture status in postmenopausal women with comparable bone mineral density.,"Institut National de la Santé Et de la Recherche Médicale, France|Merck Sharp & Dohme LLC",Female,"60 Years and older   (Adult, Older Adult)",Not Applicable,440,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,C18-04|2018-A01806-49,"February 8, 2019","February 4, 2022","February 4, 2022","February 12, 2020",,"August 31, 2022","Hopital E. Herriot, Lyon, France",,https://ClinicalTrials.gov/show/NCT04265742,NCT04265742,
oui,NCT04271449,tDCS and Prismatic Adaptation: Roles of the Cerebellum and the Primary Motor Cortex in the Transfer of After-effects,TRANSTIM,Not yet recruiting,No Results Available,Healthy Volunteers,Device: tDCS (transcranial direct current stimulation)|Behavioral: Virtual reality device,Endpoint lateral errors : lateral distance between the endpoint of the movement and the aimed target assessed by motion capture.|Movement velocities of pointing trajectories|Movement directions of pointing trajectories,Hospices Civils de Lyon,All,"18 Years to 70 Years � (Adult, Older Adult)",Not Applicable,240,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,69HCL19_0485|2019-A02373-54,"March 22, 2022",October 2024,October 2024,"February 17, 2020",,"March 22, 2022","Centre de Recherche en Neuroscience de Lyon INSERM U1028, Equipe ImpAct, Bron, France",,https://ClinicalTrials.gov/show/NCT04271449,NCT04271449,
oui,NCT04272515,Molecular Characterization for Understanding Biliary Atresia,CAVB,Recruiting,No Results Available,Biliary Atresia,Other: blood sampling|Other: skin biopsy sampling|Other: explanted liver of BA patients sampling,To identify the molecular mechanisms implicated in the etiology of BA,"Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C19-36,"February 7, 2021","February 7, 2026","February 7, 2032","February 17, 2020",,"June 4, 2021","Hopital Necker enfants malades, Paris, De, France|PRC Inserm, Paris, France",,https://ClinicalTrials.gov/show/NCT04272515,NCT04272515,
oui,NCT04272970,Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH),CATCH,Enrolling by invitation,No Results Available,Thrombocytopenia|Inherited Platelet Disorder,Diagnostic Test: Validation of a new gene / protein variant implicated in familial CT,Validation of new genes potentially involved in the occurrence of CT by determination of the amount of the protein produced and its effect on the megakaryocytes producing platelets aspect in culture|Description of the phenotype of these new CT entities|Search of a potentially platelet dysfunction,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"11 Years to 65 Years � (Child, Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,C19-08|2019-A01351-56,"July 7, 2020",July 2024,December 2024,"February 17, 2020",,"July 21, 2020","Resource and Competence Center for Constitutional Hemorrhagic Diseases (CRCMHC), University Hospital Robert Debr�, Paris, France|Resource and Competence Center for Constitutional Hemorrhagic Diseases (CRCMHC), University Hospital Pontchaillou, Rennes, France",,https://ClinicalTrials.gov/show/NCT04272970,NCT04272970,
oui,NCT04274309,Safety Validation of EndoSWIR Device,ENDO-AMYG,Unknown status,No Results Available,Optical Guided Surgery,Device: EndoSWIR,Tissue integrity,"University Hospital, Grenoble|Institut National de la Santé et de la Recherche Médicale, Institute for Advanced Biosciences|Commissariat A L'energie Atomique|Lynred",All,"18 Years and older   (Adult, Older Adult)",,10,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,38RC19.388|2019-A03333-54,"July 21, 2020","May 1, 2021","May 1, 2021","February 18, 2020",,"July 23, 2020","Chu Grenoble Alpes, Grenoble Cedex 9, France",,https://ClinicalTrials.gov/show/NCT04274309,NCT04274309,
oui,NCT04280497,Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis,RECORDS,Recruiting,No Results Available,Sepsis,Drug: Administration procedures,"3-month mortality|Persistent organ dysfunction|Mortality at 7, 14, 28 day and 6 months|Vasopressor free days|Mechanical ventilation free days|Organ dysfunction free days|HRQoL in 6-month survivors assessed by the EuroQol-5D (EQ-5D)|Proportion of patients with a decision to withhold and/or withdraw active treatments|ICU and hospital length of stay|Rate of re-admission to the ICU during the 180 days after randomization|Safety endpoints: proportion of patients affected by any serious adverse events|Coma|Neurologic sequelae|Proportion of patients affected by hospital-acquired infections|Number of episodes of hyperglycemia|Number of episodes of hypernatremia|Glasgow coma scale at ICU and hospital discharge|Number of patients with an episode of stroke|Gastroduodenal bleeding|Adult cognitive function score","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Versailles Saint-Quentin-en-Yvelines University|Université Paris Saclay|Université Paris Est Créteil|Commissariat A L'energie Atomique|Beckman Coulter, Inc.|Lumedix|Elice|Biothelis",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1800,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",APHP191110|2020-000296-21,"April 10, 2020",October 2024,October 2024,"February 21, 2020",,"May 18, 2022","Department of medical and surgical Intensive Care Unit, Raymond Poincaré Hospital - APHP, Garches, Hauts-de-Seine, France",,https://ClinicalTrials.gov/show/NCT04280497,NCT04280497,36898751
oui,NCT04280510,Pathogenic Study of Adult Immune Enteropathies,ENTEROPAH,Recruiting,No Results Available,Celiac Disease|Autoimmune Enteropathy|Inflammatory Bowel Diseases,Genetic: Blood sample collection,gastrointestinal biopsy Intestinal Lymphocytes count|DNA sequencing,"Institut National de la Santé Et de la Recherche Médicale, France|Imagine Institute",All,"18 Years and older   (Adult, Older Adult)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C19-07|2019-A01594-53,"February 27, 2020","February 27, 2028","February 27, 2028","February 21, 2020",,"July 29, 2020","Hôpital Beaujon, Clichy, France|Hôpital Henri Mondor, Créteil, France|Hôpital Bicêtre, Le Kremlin Bicêtre, France|Hôpital Saint Louis, Paris, France|Hôpital Saint Antoine, Paris, France|Hôpital Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT04280510,NCT04280510,
oui,NCT04288128,Integrated Functional Evaluation of the Cerebellum,CERMOI,Completed,No Results Available,Spinocerebellar Ataxia Type 2|Spinocerebellar Ataxia Type 7,Procedure: Lumbar puncture|Other: Magnetic Resonance Imaging (MRI),"Identification of biological, clinical and/or imaging biomarkers in SCA2 and SCA7 patients mutations carriers and patients through a multimodal assessment over one year to prepare therapeutic trials|To determine the cross-sectional and longitudinal variability of SARA (Scale for the Assessment and Rating of Ataxia) and CCFS (Composite Cerebellar Functional Score) scores in SCA 2 and SCA 7 gene mutation carriers and healthy controls over one|Determine the cross-sectional and longitudinal variability of volumetric MRI and NMR-proto spectroscopy in SCA 2 and SCA 7 gene mutation carriers and healthy controls|Delineate a specific pattern of frontal-like cognitive deficit in SCAs gene carriers|To determine the cross-sectional and longitudinal variability of CSF, blood and urine biomarkers in SCAs gene mutation carriers and controls|To explore the relationship of CSF, blood and urine biomarker levels in relation to clinical and imaging markers of disease progression|To assess the feedback of individuals for the disease (Most bothersome symptoms)|To assess the feedback of individuals for the disease thanks to quality of life questionnaires|To determine the cross-sectional and longitudinal variability of quantitative measures of postural stability, free walking and turning in SCA 2 and SCA 7 mutation carriers and healthy controls|To determine the cross-sectional and longitudinal variability of quantitative measures of oculomotor recording in SCA 2 and SCA 7 gene mutations carriers and healthy controls.|To determine the cross-sectional and longitudinal variability of optical coherence tomography in SCA 2 and SCA 7 gene mutations carriers|To determine the cross-sectional and longitudinal variability of adaptative optics in SCA 2 and SCA 7 gene mutations carriers|To determine the cross-sectional and longitudinal variability of autofluorescence, visual acuity, in SCA 2 and SCA 7 gene mutations carriers|To determine the cross-sectional and longitudinal variability of visual field in SCA 2 and SCA 7 gene mutations carriers|To determine the cross-sectional and longitudinal variability of colour contrast sensitivity in SCA 2 and SCA 7 gene mutations carriers|To determine the cross-sectional and longitudinal variability of electroretinogram in SCA 2 and SCA 7 gene mutations carriers|To determine the cross-sectional and longitudinal variability of static perimetry in SCA 2 and SCA 7 gene mutations carriers|To determine the cross-sectional and longitudinal variability of visual evoked potential in SCA 2 and SCA 7 gene mutations carriers","Institut National de la Santé Et de la Recherche Médicale, France|Biogen|Ionis Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",,40,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,C18-29|2018-A02563-52,"May 28, 2020","May 20, 2022","June 1, 2022","February 28, 2020",,"March 1, 2023","Institut du Cerveau - Paris Brain Institute, Paris, France",,https://ClinicalTrials.gov/show/NCT04288128,NCT04288128,
oui,NCT04288869,Change in Brain Perfusion During Induction of General Anesthesia,CERVO2,Recruiting,No Results Available,Interventional Radiology|Orthopedic Surgery,Other: Continuous monitoring of arterial blood pressure|Other: Transcranial Doppler|Other: Bispectral Index (BIS)|Other: Near-infrared spectroscopy,Mean arterial blood pressure|Cerebral blood flow velocity|Burst Suppression|Cerebral oxygen saturation,"Assistance Publique - H�pitaux de Paris|INSERM UMR-942, Paris, France|LMS Ecole polytechnique|M3DISIM Inria Universit� Paris-Saclay",All,"18 Years and older � (Adult, Older Adult)",,101,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP190945|2019-A02516-51,"January 27, 2021",January 2023,July 2023,"February 28, 2020",,"March 2, 2021","AP-HP, Lariboisi�re Hospital, Department of Anesthesiology and Intensive Care, Paris, France",,https://ClinicalTrials.gov/show/NCT04288869,NCT04288869,
oui,NCT04289909,Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS),RETIMUS,Unknown status,No Results Available,Relapsing Remitting Multiple Sclerosis|Progressive Multiple Sclerosis|Optic Neuritis|Eye Diseases|Optic Nerve Diseases|Nervous System Diseases|Multiple Sclerosis,Other: Adaptive Optics Ophthalmoscopy (AOO),Quantification of retinal perivascular cuff width across MS phenotypes|Variation of size of perivascular sheathing|Clinical disability measure with EDSS|Clinical disability measured with MSFC|Number of relapses|Presence of disc oedema measured at Optical Coherence Tomography (OCT) measurements|RNLF thickness measured at Optical Coherence Tomography (OCT) measurements|parenchymal T2 lesion volume at MRI|gadolinium enhanced T1 lesion at MRI|optic nerve cross-sectional area at MRI|Hyperintensity on the optic nerve at MRI,"Institut National de la Santé Et de la Recherche Médicale, France|Biogen",All,18 Years to 60 Years   (Adult),Not Applicable,60,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,19-25,March 2020,October 2022,October 2022,"February 28, 2020",,"February 28, 2020","Institut du Cerveau et de la Moelle epiniere - Hopital Pitie Salpetriere, Paris, France",,https://ClinicalTrials.gov/show/NCT04289909,NCT04289909,
oui,NCT04291534,Quality of Life and Addiction Among Hospital Night Workers,ALADDIN,Recruiting,No Results Available,Health Services Research|Quality of Life|Addiction|Substance-Related Disorders|Health Personnel,,Substance use prevalence|Quality of working life scale|Intervention preference|Psychoactive substance consumption and associated factors|Impact of substance consumption on quality of life at work|Risk factors associated with tobacco use|Impact of sleep quality on quality of working life and perceived health|Impact of anxiety and depressive symptoms on sleep and QWL.|Impact of sleep and workplace upheaval on anxiety and depressives symptoms|Modification of quality of working life score and psychoactive substances consumption prevalences|Comparison of modification of quality of life score and declared quality of life modification after 18 month,"University Paris 7 - Denis Diderot|Institut National de la Santé Et de la Recherche Médicale, France|Assistance Publique - Hôpitaux de Paris",All,"16 Years to 67 Years   (Child, Adult, Older Adult)",,1800,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Prospective,ALADDIN-QoLHospWork,"June 15, 2020","April 1, 2022","June 1, 2023","March 2, 2020",,"November 4, 2020","Hôpital de Bicêtre, Le Kremlin-Bicêtre, France|Assistance Publique des Hopitaux de Paris, Paris, France",,https://ClinicalTrials.gov/show/NCT04291534,NCT04291534,36814276
oui,NCT04294771,JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors,JOCARDITE,Recruiting,No Results Available,Myocarditis|Cardiomyopathies|Heart Diseases|Cardiovascular Diseases|Pericarditis|Vasculitis,Drug: ICI,"Identifying risk factors of cardio-vascular toxicity of ICIs.|Causality assessment of reported cardiovascular events|Description of the type of cardiotoxicity depending on the category of ICIs|Description of the duration of treatment when the toxicity happens (role of cumulative dose)|Description of the drug-drug interactions associated with adverse events|Description of the pathologies (cancer) for which the incriminated drugs have been prescribed|Description of the population of patients having a cardio-vascular adverse event|Cardio-vascular toxicity of ICIs.|Description and added predictive value of electrocardiographic, echocardiographic, cardiac and muscle pathology, cardiac MRI and positron emission tomograph (PET) manifestations in patients with ICI associated myocarditis",Groupe Hospitalier Pitie-Salpetriere,All,"Child, Adult, Older Adult",,500000,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,CIC1421-20-03,"January 1, 2019","January 1, 2025","January 1, 2025","March 4, 2020",,"August 23, 2022","AP-HP, Piti�-Salp�tri�re Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris, France",,https://ClinicalTrials.gov/show/NCT04294771,NCT04294771,35383117
oui,NCT04303364,CARdiomyopathy in Type 2 DIAbetes Mellitus,CARDIATEAM,Recruiting,No Results Available,"Cardiomyopathy, Diabetic",,"Assess the uniqueness of diabetic cardiomyopathy (DCM) relative to other forms of cardiomyopathy|Identify the best clinical, biological, imaging and multi-OMICs predictors belonging to each identified cluster|Assess prospective health outcomes (i.e. overall mortality, cardiovascular events and cardiac function) in the diabetic cardiomyopathy cluster identified|Explore the pathophysiological and potentially causal pathways characterizing diabetic cardiomyopathy","Institut National de la Santé Et de la Recherche Médicale, France",All,"45 Years to 75 Years   (Adult, Older Adult)",,1600,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C19-10,"October 2, 2020","October 1, 2026","October 1, 2026","March 11, 2020",,"March 6, 2023","Hopital Louis Pradel, Bron, France|Cardiology Outpatient Department at Hôpital Henri Mondor., Créteil, France|Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France|department of diabetology and nutrition, APHM, Marseille, France|Hôpital CHU- Nantes, Nantes, France|Diabetology department, Cochin Institute, Paris, France|Diabetology departement, Lariboisière Hospital, Paris, France|University Hospital Aachen, Aachen, Germany|University Hospital Heidelberg, Heidelberg, Germany|University Medical Center Groningen (UMCG), Cardiology/Cardio Research, Groningen, Netherlands|Academisch ziekenhuis Maastricht, Cardiology, Maastricht, Netherlands|UMC Utrecht, Cardiology (DHL), Utrecht, Netherlands|Hospital Vall Hebrón, Barcelona, Spain|Institut D'Investigacions Biomedica August Pi I Sunyer (IDIBAPS), Barcelona, Spain|Hospital Gregorio Marañón, Madrid, Spain|University of Dundee, Div of Molecular&Clinical Medicine, Dundee, United Kingdom",,https://ClinicalTrials.gov/show/NCT04303364,NCT04303364,
oui,NCT04315948,Trial of Treatments for COVID-19 in Hospitalized Adults,DisCoVeRy,"Active, not recruiting",No Results Available,Corona Virus Infection,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care|Drug: AZD7442|Other: Placebo,"Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Status on an ordinal scale|National Early Warning Score 2 (NEWS-2 score)|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Need for mechanical ventilation or death by Day 15|Hospitalization|Mortality|Occurrence of new hospitalization|Occurrence of confirmed re-infection with SARS-CoV-2|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 1- 2 hypersensitivity- related and infusion related AEs until D29 visit|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Cumulative incidence of AEs of Special Interest","Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",Phase 3,2416,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C20-15|101015736,"March 22, 2020","July 9, 2022",October 2023,"March 20, 2020",,"March 15, 2023","Medizinische Universit�t Innsbruck, Innsbruck, Austria|Kepler Universit�tsklinikum Linz, Linz, Austria|Landeskrankenhaus Salzburg Universit�tsklinikum der Paracelsus Medizinischen Privatuniversit�t, Salzburg, Austria|H�pital Erasme - Cliniques universitaires de Bruxelles, Brussels, Belgium|H�pital Saint Luc, Brussels, Belgium|H�pital La Citadelle, Li�ge, Belgium|P�le Hospitalier Jolimont / site de Mons-Warquignies, Mons, Belgium|Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France|Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France|Centre Hospitalier R�gional Universitaire de Besan�on, Besan�on, France|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France|CHU APHP Ambroise-Par�, Boulogne-Billancourt, France|Centre Hospitalier Andr�e Rosemon, Cayenne, France|Hospices Civil, Colmar, France|APHP - h�pital Henri-Mondor, Cr�teil, France|Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France|Centre Hospitalier Universitaire de Martinique, Fort De France, France|AP-HP H�pital Bic�tre, Kremlin-Bic�tre, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Centre Hospitalier R�gional Universitaire de Lille, Lille, France|Hospices Civils de Lyon, Lyon, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Groupe Hospitalier de la R�gion de Mulhouse Sud Alsace, Mulhouse, France|Centre Hospitalier R�gional et Universitaire de Nancy, Nancy, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalo-Universitaire de Nice, Nice, France|CHU N�mes, N�mes, France|APHP - H�pital Lariboisi�re, Paris, France|APHP - H�pital Saint Louis, Paris, France|APHP - H�pital Saint Antoine, Paris, France|APHP - H�pital Universitaire Piti� Salp�tri�re, Paris, France|APHP - H�pital Cochin, Paris, France|H�pital Paris Saint-Joseph et Marie Lannelongue, Paris, France|APHP - H�pital Necker, Paris, France|APHP- H�pital Europ�en Georges-Pompidou, Paris, France|APHP - H�pital Bichat Claude Bernard, Paris, France|APHP - H�pital Tenon, Paris, France|CHU Poitiers, Poitiers, France|CH Cornouaille, Quimper, France|CHU de Reims, Reims, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Hopital DELAFONTAINE, Saint-Denis, France|H�pital d'Instruction des Arm�es BEGIN, Saint-Mand�, France|Centre Hospitalier Universitaire de Saint Etienne, Saint-�tienne, France|Centre Hospitalier R�gional Universitaire de Strasbourg, Strasbourg, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier de Tourcoing, Tourcoing, France|Centre Hospitalier Universitaire de Tours, Tours, France|CH Bretagne Atlantique, Vannes, France|CH Bretagne Atlantique, Vannes, France|Centre Hospitalier Annecy Genevois, �pagny, France|Evaggelismos General Hospital, Athens, Greece|General University Hospital of Patras, Patras, Greece|Centre Hospitalier Luxembourg, Luxembourg, Luxembourg|H�pitaux Robert Schuman, Luxembourg, Luxembourg|Akershus Unniversity Hospital, Oslo, Norway|Lovisenberg Diaconal Hospital, Oslo, Norway|Oslo University Hospital, Oslo, Norway|Hospital de Cascais, Cascais, Portugal|CHULN- Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar Universit�rio de S�o Jo�o, EPE, Porto, Portugal",,https://ClinicalTrials.gov/show/NCT04315948,NCT04315948,36695483;35512728;35233617;34534511;34473343;34350582;34048876;33264556;32958495;32304640
oui,NCT04321265,Outcomes and Prognostic Factors in COVID-19,COVIP,Recruiting,No Results Available,COVID-19|Elderly Patients|Critical Illness|Survival|Old Age,,Survival|Frailty,"Heinrich-Heine University, Duesseldorf",All,70 Years and older � (Older Adult),,1500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,20-004,"March 19, 2020","December 31, 2022","March 31, 2023","March 25, 2020",,"November 7, 2022","Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark|H�pitaux de Paris, H�pital Saint-Antoine, service de r�animation m�dicale, Paris, France|INSERM, UMR_S 1136, Institut Pierre Louis d'Epid�miologie et de Sant� Publique, Paris, France|Sorbonne Universit�s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epid�miologie et de Sant� Publique, Paris, France|Division of Cardiology, Pulmonary Disease and Vascular Medicine, Duesseldorf, Germany|Department of Anaestesia and Intensive Care, Haukeland University Hospital, Bergen, Norway|Department of Clinical Medecine,University of Bergen, Bergen, Norway",,https://ClinicalTrials.gov/show/NCT04321265,NCT04321265,36854893;36812571;36575394;35945477;35869557;35303201;35274490;35218366;35099394;34955167;34741189;34556171;34487039;34417919;33874987;32645153
oui,NCT04321915,Intestinal Dysbiosis and BBB Integrity in Autism,LEDA,Recruiting,No Results Available,Autism Spectrum Disorder,Other: Analysis of intestinal microbiota in autism spectrum desorder|Other: Analysis of neuroinflammation markers in autism spectrum desorder,Intestinal microbiota assessment|Measuring the severity of ASD|Evaluation of the level of social interaction|Behavioural disorders|Quality of life of children with ASD|Developmental trajectory of children with ASD|IQ (Intellectual Quotient)|Assessment of stools aspect|Repetitive and stereotypical behaviours|Intensity of GI disorders|Measurement of neuroinflammation|Intestinal permeability|Intestinal inflammation|TH1/TH2 immune response|Metabolome analysis,"University Hospital, Montpellier|Inserm1047, CHU N�mes|LBPC, Inserm 1183, IRMB CHU Montpellier|UMR 5203, InsermU1191, IGF, Montpellier",All,6 Years to 16 Years � (Child),Not Applicable,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RECHMPL18_0197,"April 26, 2021","October 26, 2024","February 26, 2025","March 25, 2020",,"April 22, 2022","Centre de Ressources Autisme, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04321915,NCT04321915,
oui,NCT04322279,Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.,,Suspended,No Results Available,Coronavirus,Diagnostic Test: Serology|Genetic: Sequencing,Proportion of subjects with SARS-CoV-2 positive serology at day 30 following the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.|Factors associated with a SARS-CoV-2 positive serology at day 30 (+/-7) |Time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology.,"Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C20-16|2020-A00609-30,"March 9, 2020","December 31, 2021","December 31, 2022","March 26, 2020",,"April 8, 2022","Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon, Besançon, France|Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin, Bordeaux, France|Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand, Clermont Ferrand, France|Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne, Dijon, France|Centre d'investigation clinique 1406 CHU Grenoble, Grenoble, France|Centre d'Investigation Clinique 1403 -CHU Lille, Lille, France|Centre d'Investigation Clinique Hôpital Saint Louis, Paris, France|Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard, Paris, France|Hôpital Cochin CIC 1417 Bâtiment Lavoisier, Paris, France|Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou, Rennes, France|Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord, Saint Denis, France|Département maladie infectieux CHU Saint Etienne, Saint Etienne, France|Centre d'Investigation Clinique Ile de la Réunion CHU sud, Saint-Pierre, France|Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau, Tours, France|Centre Investigation Clinique 1433 CHRU de NANCY, Vandœuvre-lès-Nancy, France|Service de Maladies infectieuses et tropicales Centre hospitalier, Cayenne, French Guiana",,https://ClinicalTrials.gov/show/NCT04322279,NCT04322279,
oui,NCT04324450,"Memory Neuroimaging in Children, Adolescents and Young Adults Following Pediatric Cancer",IMPALA,Recruiting,No Results Available,Cancer Brain|Pediatric Cancer,Device: MRI|Behavioral: Cognitive assessment,Structural characteristics of declarative memory neuronal substrate: volume of the hippocampus|Structural characteristics of declarative memory neuronal substrate: cortical thickness of the hippocampus|Structural characteristics of declarative memory neuronal substrate: Microstructural integrity of the hippocampus|Episodic memory performance|Declarative episodic memory assessment scores|Declarative semantic memory assessment scores|Procedural memory assessment scores|Short-term auditive memory assessment scores|Short-term visual memory assessment scores|Intellectual capacities assessment scores|Language assessment scores|Motor functions assessment scores|Executive functions assessment scores|Attentional capacities assessment scores|Cerebellar volume|Micro-structural integrity of the cerebellum|Cerebral blood volume obtained from brain perfusion imaging|Post-therapeutic hypoxia|Neuronal density|Functional connectivity index|Age at the time of treatment|Radiotherapy doses|Cerebellum and hippocampus Normal Tissue Complication Probability,"Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",Not Applicable,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,C19-17,"February 12, 2020",September 2021,"February 9, 2023","March 27, 2020",,"May 3, 2021","ToNIC / UMR1214, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04324450,NCT04324450,37060708;34988299
anrs,NCT04329195,ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic,ACORES-2,Terminated,No Results Available,History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection,Drug: 1: discontinuation of RAS blocker therapy|Drug: 2: continuation of RAS blocker therapy,"Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)|Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28|Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.|Number of days alive free of oxygen.|Number of days alive outside hospital until day28|Number of days alive free of intensive-care unit (ICU) admission or mechanical Ventilation (invasive or non-invasive) until day28|Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of ICU admission until day28|Rate of all-cause mortality at day 28|Rate of cardiovascular death at day 28|Number of days alive free of acute kidney injury until hospital discharge",Assistance Publique - H�pitaux de Paris|Groupe Hospitalier Piti�-Salp�tri�re,All,"18 Years and older � (Adult, Older Adult)",Phase 3,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200409,"April 9, 2020","December 9, 2020","January 9, 2021","April 1, 2020",,"April 9, 2021","Cardiologie, Groupe Hospitalier Piti�-Salp�tri�re, Paris, France",,https://ClinicalTrials.gov/show/NCT04329195,NCT04329195,
oui,NCT04332601,Assessment of the Efficacy of a Fatigue Management Therapy in Schizophrenia,ENERGY,Not yet recruiting,No Results Available,Schizophrenia,Behavioral: Fatigue Management Therapy|Other: TAU (Treatment as usual),Multidimensional Fatigue Inventory (MFI)|Positive and Negative Syndrome Scale (PANSS)|Clinical Assessment Interview for Negative Symptoms (CAINS)|Calgary Depression Scale for Schizophrenia (CDSS)|Berlin Questionnaire (BQ)|Idiopathic Hypersomnia Severity Scale (IHSS)|Sleep Condition Indicator (SCI)|International Physical Activity Questionnaire short form (IPAQ)|Quality of life (S-QoL)|Functional Remission of General Schizophrenia (FROGS)|Intrinsic Motivation Inventory for Schizophrenia Research (IMI-SR)|French National Adult Reading Test (fNART)|California Verbal Learning Test (CVLT)|Trail Making Test (TMT)|Pedometer|Physical examinations (PE) and vital signs (VS)|Blood samples|Microbial translocation|Inflammatory status|Letter-Number Sequencing subtest (LNS),"University Hospital, Montpellier|Université Montpellier|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),Not Applicable,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",7778,February 2022,November 2025,November 2025,"April 2, 2020",,"February 11, 2022",,,https://ClinicalTrials.gov/show/NCT04332601,NCT04332601,32943079
oui,NCT04344327,Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF,CCF,Completed,No Results Available,"Infection Viral|Infection, Hospital|COVID",,Death rate|Transfer to intensive care unit|Ventilation analysis|Construction of a predictive score for COVID-19 severe form,"French Cardiology Society|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,2878,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020-02,"April 10, 2020","April 21, 2020","April 21, 2020","April 14, 2020",,"April 28, 2020","CHU d'Amiens, Amiens, France|CHU Annecy, Annecy, France|CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|Cotentin hospital, Cherbourg, France|CHU Dijon, Dijon, France|Elbeuf Louviers Val de Reuil, Elbeuf, France|CHU de Fréjus / Saint-Raphael, Fréjus, France|Lille Catholic Institute Hospital Group, Lille, Lille, France|CHU de Lyon, Lyon, France|APHM, Marseille, France|Jacques Cartier Private Hospital, Massy, Massy, France|CHR d'Orléans, Orléans, France|Bichat (APHP), Paris, France|Georges Pompidou European Hospital (AP-HP), Paris, France|Institut Mutualiste Montsouris, Paris, Paris, France|CHU de Reims, Reims, France|CHU de Rouen, Rouen, France|CHU Saint Etienne, Saint-Étienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|Saint Gatien hospital, Tours, France|CHU de Nancy, Vandœuvre-lès-Nancy, France",,https://ClinicalTrials.gov/show/NCT04344327,NCT04344327,33388386
oui,NCT04351360,Pilot Study on Caffeine Efficiency in ADCY5-related Dyskinesia,CAF-ADCY5,Unknown status,No Results Available,Dyskinesias,,Percentage of responders to caffeine|Global change of involuntary movements ranging from 0 (no change) to 10 (disappearance of involuntary movements)|Global clinical change ranging from 0 (no change) to 10 (normalization of the global clinical state)|Change of the duration of paroxysmal episodes of movement disorders with caffeine|Frequency change of paroxysmal episodes of movement disorders with caffeine|Presence or absence of psychiatric symptoms,"Institut National de la Santé Et de la Recherche Médicale, France",All,"8 Years and older   (Child, Adult, Older Adult)",,20,Other,Observational,Observational Model: Other|Time Perspective: Prospective,C19-26|2020-A00166-33,"April 10, 2020","April 10, 2021","April 10, 2021","April 17, 2020",,"April 17, 2020",,,https://ClinicalTrials.gov/show/NCT04351360,NCT04351360,
oui,NCT04355507,Computed Tomography for COVID-19 Diagnosis,STOIC,Completed,No Results Available,COVID-19,Diagnostic Test: Chest computed tomography (CT)|Diagnostic Test: Reverse-transcription polymerase chain reaction (RT-PCR),Predictive values of CT criteria|Accuracy of CT composite severity score|Accuracy of deep-learning based score|Predictive values of deep-learning based diagnostic algorithms|Dice similarity coefficient between manual and automated segmentation of lung disease abnormalities,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|GE Healthcare|Orange healthcare|TheraPanacea",All,"18 Years and older   (Adult, Older Adult)",,10735,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,APHP200434,"March 1, 2020","October 16, 2020","October 16, 2020","April 21, 2020",,"December 21, 2020","Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT04355507,NCT04355507,34184935
oui,NCT04355533,Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,PED-COVID,Completed,No Results Available,COVID-19 Infection,Biological: serology test|Biological: nasopharyngeal swab|Biological: rectal swab|Biological: saliva sample,"Seroconversion against SARS-CoV2 in children|Measure of Ab antiN and Ab anti-S1/2|Neutralization activity|Positive qPCR in children|correlation between different Ab and qPCR and neutralization activity|Protective immunity|Duration of viral carriage in stool, saliva and or nasopharynx|Correlation between antibody profile and viral clearance|Ab profile and memory of immunity|saliva biofluid characteristics of COVID-19 infected|Presence of the virus|Reinfection|Transmission of the virus to the family|Immune response|Mucosal immunity|seroconversion against SARS-CoV2 in parents|Measure of Ab antiN and Ab anti-S1 and neutralization activity|Positive qPCR in parents|Correlation between different Ab and qPCR|Saliva biofluid characteristics of COVID-19 infected","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Commissariat A L'energie Atomique|Institut Pasteur",All,"7 Days and older   (Child, Adult, Older Adult)",Not Applicable,1056,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,APHP200467|2020-A00999-30,"July 29, 2020","May 20, 2022","May 24, 2022","April 21, 2020",,"February 3, 2023","Hôpital necker Enfants-Malades, ¨Paris, France",,https://ClinicalTrials.gov/show/NCT04355533,NCT04355533,
oui,NCT04356495,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,COVERAGEFrance,Completed,No Results Available,Corona Virus Infection|Sars-CoV2,Dietary Supplement: Vitamins|Drug: Telmisartan|Drug: Ciclesonide|Drug: interferon ?-1b,"Pilot Phase: Proportion of participants who had a Grade 3 or 4 adverse event|Efficacy phase: Death|Efficacy phase: oxygen therapy|Efficacy phase: hospitalization|Proportion of hospitalizations, overall and by cause, in each group|Death and causes of death|Proportion of intensive care hospitalizations, overall and by cause, in each group|Proportion of participants with negative SARS-CoV-2 RT-PCR|Haematological markers evolution|Inflammatory markers evolution|Adverse events|Adverse reactions|Acceptability of the treatment|Antibiotic consumption|Oxygen saturation worsening|protocol follow-up","University Hospital, Bordeaux|University of Bordeaux",All,"50 Years and older � (Adult, Older Adult)",Phase 2|Phase 3,412,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CHUBX 2020/12,"July 29, 2020","October 8, 2021","October 22, 2021","April 22, 2020",,"February 4, 2022","Bordeaux university Hospital, Bordeaux, France|CHU de Dijon-Bourgogne, Dijon, France|CHU de Montpellier, Montpellier, France|CHRU de Nancy, Nancy, France|Groupe hospitalier Paris Saint Joseph, Paris, France|CNGE, Paris, France|CHU de Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04356495,NCT04356495,34473343;33050924
oui,NCT04357314,Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study,MODIF,Completed,No Results Available,Myocardial Infarction,,The primary endpoint is a composite of death from all causes and mechanical complications of acute myocardial infarction (MI)|Rates of patients presenting with acute myocardial infarction|Patient profile during admission for acute myocardial infarction|Medical care times analysis|Clinical evolution of patients|STEMI (ST Segment Elevation Myocardial Infarction) admissions incidence rates|Proportion of patients who underwent systemic thrombolysis|Proportion of patients infected with COVID-19,"French Cardiology Society|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,6332,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020-03,"March 1, 2020","May 31, 2020","May 31, 2020","April 22, 2020",,"August 19, 2020","Hôpital Universitaire Carémeau, Nîmes, France",,https://ClinicalTrials.gov/show/NCT04357314,NCT04357314,
oui,NCT04359056,Clinical Pharmacy for Patients With a PICC Line,CLIPICC,Recruiting,No Results Available,Catheter Complications,Other: Clinical pharmacy activities along the care pathways,Assessment of the number of complications during the interventional phase.|Number of consultations and rehospitalizations post-discharge.|Acceptance rate of pharmaceutical interventions (PI) during interventional phase and evaluation of PIs' criticality.|Conformity analysis of the PICC line logistic circuit|Conformity analysis of treatment indication.|Conformity analysis of hospital prescriptions issued in town.|Patient's Quality Of Life assessment|Participants satisfaction survey|healthcare professionals satisfaction survey|Direct hospital costs.,"University Hospital, Toulouse",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,138,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,RC31/18/0459|2019-A02475-52,"May 25, 2020","August 25, 2022","August 25, 2022","April 24, 2020",,"June 9, 2022","CIVADE, Toulouse, Occitanie, France",,https://ClinicalTrials.gov/show/NCT04359056,NCT04359056,33827827
oui,NCT04359875,A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,COVIQuest,Completed,No Results Available,Cardiovascular Diseases|Mental Disorder,Behavioral: Phone-call screening and management by a medical student/general practitioner tandem,Hospitalization(s) at 1 month|Phone-call from the general practitioner (in the experimental group only)|Mortality at 1 month|Use of primary care|Use of secondary care|Number of prescriptions related to the chronic disease dispensed by the pharmacy|Number of hospitalization(s)|Time to hospitalization(s)|Hospitalization(s)' durations|Reasons for hospitalization(s)|Mortality at 6 months|Cardiovascular events (MACE)|Psychotropic drugs,"University Hospital, Tours|INSERM CIC-P 1415",All,"18 Years to 110 Years � (Adult, Older Adult)",Not Applicable,22000,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,2020-CD-COVIQuest (COVID-19)|2020-A01061-38,"April 30, 2020","June 30, 2020","December 31, 2020","April 24, 2020",,"April 12, 2021","Dibao-Dina, Tours, France",,https://ClinicalTrials.gov/show/NCT04359875,NCT04359875,35902188
oui,NCT04363671,Adolescents and Health Professionals Faced With the Necessity for Changing to Remote Care During the COVID-19 Outbreak Quarantine (AdoPro-Cov19),AdoPro-Cov19,Unknown status,No Results Available,Remote Consultation|Covid-19,,Exploration of themes emerging from analysis of the content of the interview with the adolescents and therapists,"Hôpital Cochin|Institut National de la Santé Et de la Recherche Médicale, France",All,"11 Years and older   (Child, Adult, Older Adult)",,30,Other,Observational,Observational Model: Other|Time Perspective: Prospective,P20-670,May 2020,June 2020,December 2020,"April 27, 2020",,"April 27, 2020","Maison de Solenn, Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT04363671,NCT04363671,
oui,NCT04364009,Anakinra for COVID-19 Respiratory Symptoms,ANACONDA,Terminated,No Results Available,COVID-19 Infection|ANAKINRA Treatment|Optimized Standard of Care (oSOC),Drug: Anakinra plus oSOC|Drug: oSOC,"Treatment success|OMS progression scale (on a 7 point ordinal scale)|Overall survival|Time to ICU admission|Time to ventilatory support|Change in National Early Warning Score (NEW)from baseline to Day 3, Day 10, Day 14 and Day 28|Change in inflammatory parameter|Hospital length of stay|ICU parameter|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Predictors of efficacy of Anakinra","University Hospital, Tours|INSERM CIC-P 1415, University Hospital Center of Tours|Swedish Orphan Biovitrum",All,"18 Years and older � (Adult, Older Adult)",Phase 3,71,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANACONDA-COVID-19|2020-001734-36|DR200111,"April 27, 2020","October 20, 2020","November 3, 2020","April 27, 2020",,"January 15, 2021","CHRU de TOURS, Tours, France",,https://ClinicalTrials.gov/show/NCT04364009,NCT04364009,
oui,NCT04365998,"BUBOLight®, a New Phototherapy Device for the Treatment of the Newborn's Jaundice",BUBO,Recruiting,No Results Available,Neonatal Jaundice,Device: BUBOLight® Device,Number of related adverse events (Safety)|Blood bilirubin rate|Transcutaneous bilirubin rate|EDIN (Newborn Pain and Discomfort Scale)|Perceptions of parents with the use of device|Perceptions of the health team with the use of the device,"University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France",All,up to 30 Days   (Child),Not Applicable,15,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018_68|2019-A01417-50,"October 8, 2020",October 2023,October 2023,"April 28, 2020",,"March 16, 2022","Hop Jeanne de Flandre Chu Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT04365998,NCT04365998,34032584
oui,NCT04371835,COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings,,Completed,No Results Available,HIV-infection/Aids|Coronavirus Infection,,Clinical features of symptomatic COVID-19 in people living with HIV (PLWH)|Clinical outcomes of symptomatic COVID-19 in PLWH|Seroprevalence of COVID-19 in all parent study participants,"Kirby Institute|University of Witwatersrand, South Africa|University of Liverpool|Universit� Montpellier|UNITAID|ViiV Healthcare",All,"18 Years and older � (Adult, Older Adult)",,596,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-04-COHIVE,"August 12, 2020","December 31, 2021","December 31, 2021","May 1, 2020",,"March 18, 2022","Hospital G de Agudos JM Ramos Mejia, Buenos Aires, Ciudad De Buenos Aires, Argentina|Laborat�rio de Pesquisa Clinica Em Hiv/Aids - Instituto Nacional de Infectologia - Fiocruz, Rio de Janeiro, Brazil|Central Hospital of Yaound�, Yaound�, Cameroon|Cit� Verte Hospital, Yaound�, Cameroon|H�pital Militaire de R�gion N�1, Yaound�, Cameroon|CART CRS, VHS Hospital, Chennai, Tamil Nadu, India|Univerity of Malaya Medical Centre, Kuala Lumpur, Malaysia|Institute of Human Virology, Nigeria (IHVN), Abuja, Nigeria|Desmond Tutu HIV Foundation, Cape Town, South Africa|Perinatal HIV Research Unit (PHRU), Johannesburg, South Africa|Clinical HIV Research Unit (CHRU), Wits Health Consotium (Pty) Ltd, Johannesburg, South Africa|Ezintsha, Parktown, South Africa|HIV-NAT (The HIV Netherlands Australia Thailand Research Collaboration), Thai Red Cross AIDS Research Centre, Bangkok, Thailand|Infectious Diseases Institute, Kampala, Uganda|University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe",,https://ClinicalTrials.gov/show/NCT04371835,NCT04371835,
oui,NCT04377685,Prediction of Clinical Course in COVID19 Patients,COVID-CTPRED,Completed,No Results Available,COVID 19,Other: CT-Scan,diagnostic of COVID disease composite,"Centre Hospitalier Universitaire de Saint Etienne|INSA Rennes|Institut National de la Santé Et de la Recherche Médicale, France|Centre National pour le Recherche Scientifique (CNRS)|Université de Lyon|Université Jean Monnet",All,"18 Years and older   (Adult, Older Adult)",,826,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,20CH109|IRBN652020/CHUSTE,"March 1, 2020","November 28, 2020","December 26, 2020","May 6, 2020",,"November 17, 2021","Chu Saint-Etienne, Saint-Étienne, France",,https://ClinicalTrials.gov/show/NCT04377685,NCT04377685,
oui,NCT04381845,Immunity and Infections in the Psychiatric Population,COVIDIMMUNOPSY,Unknown status,No Results Available,COVID|Psychiatric Disorders,Diagnostic Test: COVID19 immunization testing,Number of COVID-positive patients,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,APHP200553,"December 10, 2020","March 10, 2021","March 10, 2021","May 11, 2020",,"October 26, 2020",,,https://ClinicalTrials.gov/show/NCT04381845,NCT04381845,
oui,NCT04388449,Place of Intrathecal Analgesia to Improve the Quality of Life of Painful Cancer Patients,QUALITHEC01,Completed,No Results Available,"Injections, Spinal|Cancer",,Evaluate the experience of patients who have an intrathecal analgesia treating nociceptive and/or neuropathic pain of cancerous origin in palliative phase.|Evaluate the mean pain of the past 24 hours|Evaluate the quality of life|Evaluate the pain catastrophizing|Evaluate the consistency of the feeling of the global clinic improvement of the patient|Evaluate the consistency or not of the feeling of the global clinic improvement of the clinician at M1 and M3.,Institut Cancerologie de l'Ouest,All,"18 Years and older � (Adult, Older Adult)",,24,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ICO-2019-18,"February 20, 2020","March 1, 2022","March 1, 2022","May 14, 2020",,"December 28, 2022","Institut de Cancerologie de l'Ouest, Angers, France|INSERM U987 CHU A Par� - Institut Curie, Boulogne-Billancourt, France|Hopital Foch, Suresnes, France",,https://ClinicalTrials.gov/show/NCT04388449,NCT04388449,
oui,NCT04389112,Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions,MITOSKIN,Recruiting,No Results Available,Cutaneous Squamous Cell Carcinoma|Basal Cell Carcinomas,Other: biopsy,Proportion of patients who have a glycolysis profile (proteomic analysis liquid chromatography-mass spectrometry (LC-MS/MS))|Proportion of patients who have an oxidative profile (proteomic analysis liquid chromatography-mass spectrometry (LC-MS/MS))|Evaluation of skin differentiation markers|Evaluation of cSCC aggressiveness markers|Evaluation of skin apoptotic markers|Evaluation of mitochondrial metabolism on skin biopsies|Evaluation of cancer proliferative features on skin biopsies,"University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CHUBX 2019/3,"February 28, 2020","December 31, 2022","December 31, 2022","May 15, 2020",,"November 23, 2022","Hôpital Saint-André - CHU de Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT04389112,NCT04389112,
oui,NCT04391062,Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma,DOSINDYGO,Recruiting,No Results Available,Glioblastoma,Drug: Gliolan|Device: Intraoperative PDT,"Maximum Tolerated Dose-Light Level (MTDL) defined as the light dose associated with an acceptable dose-limiting toxicity level (TDL)|Progression Free Survival (PFS)|Global Progression Free Survival (PFS)|Overall Survival (OS)|Response to treatment|Incidence of ""intraoperative PDT"" treatment-emergent Adverse Events|Quality of Life Questionnaire -C30 ( QLQ-C30|Quality of Life Questionnaire - Brain Cancer Module (QLQ-BN20)","University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France|Hemerion Therapeutics",All,"18 Years and older   (Adult, Older Adult)",Phase 2,21,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2018_58|2019-004796-40|2019-A03157-50,"September 28, 2021",September 2025,September 2025,"May 18, 2020",,"January 18, 2023","Hôpital Erasme, Clinique Universitaire de Bruxelles, Brussels, Belgium|Hopital Roger Salengro, CHU Lille, Lille, France",,https://ClinicalTrials.gov/show/NCT04391062,NCT04391062,
oui,NCT04392388,"Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis",SAPRIS-SERO,Unknown status,No Results Available,SARS-CoV 2,Biological: Non applicable,"Cumulative incidence of SARS-Cov2 infection in the general population.|Maintenance over time of the acquisition of anti-SARS-Cov2 antibodies|Rate of use of care (medical care, hospitalization, center 15) linked to the occurrence of symptoms suggestive of a SARS-Cov2 infection, and share attributable to the infection|Proportion of infections without reported or pauci-symptomatic symptoms and their epidemiological and social determinants|Proportion of tests proposed, accepted, performed, based on social and demographic characteristics|Proportion and intensity of use of barrier measures (hydroalcoholic gel, mask, social distancing, description of outings / reasons, duration, frequency) and association with the level of seroprevalence|Strengths of associations between socio-behavioral factors and level of seroprevalence","Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,110000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C20-26|2020-A01195-34,"May 1, 2020","December 31, 2020","December 31, 2020","May 18, 2020",,"August 5, 2020","Inserm, Paris, France",,https://ClinicalTrials.gov/show/NCT04392388,NCT04392388,34293141
oui,NCT04396288,Ultrasound Imaging-based Measurement of Intra-osseous Vascular Response,,Recruiting,No Results Available,"Blood Circulation Disorder|Bone Diseases, Metabolic",Device: ultrasound imaging at the forearm and at the tibia,"Change of velocity of blood flow in cortical bone and in marrow, before, during, and after the action of an automatic blood pressure cuff at the forearm (radius bone)|Change of direction of blood flow in cortical bone and in marrow, before, during, and after the action of an automatic blood pressure cuff at the forearm (radius bone)|Change of velocity of blood flow in cortical bone and in marrow at the tibia, if changing position from sitting position to supine head-down tilt position|Change of direction of blood flow in cortical bone and in marrow at the tibia, if changing position from sitting position to supine head-down tilt position|Repeatability of the measurement of the change of intraosseous blood circulation at the forearm under the action of an automatic blood pressure cuff|Repeatability of the measurement of the change of intraosseous blood circulation at the tibia when changing position from sitting position to supine head-down tilt position","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,39,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C19-30,"September 14, 2021",September 2023,September 2023,"May 20, 2020",,"December 5, 2022","Service de Radiologie polyvalente et oncologique, hôpital La Pitié-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT04396288,NCT04396288,
oui,NCT04397835,Psychological Impact of COVID-19 Quarantine and Worsening of Cardiovascular Risk in the French General Population,PSYCOV-CV,Completed,No Results Available,COVID-19|Anxiety|Depression|Stress,,worsening of cardiovascular risk (treatments)|worsening of cardiovascular risk (smoking consumption)|worsening of cardiovascular risk (food balance)|worsening of cardiovascular risk (weight gain)|worsening of cardiovascular risk (physical activity)|psychological impact of the quarantine on anxiety|psychological impact of the quarantine on health|psychological impact of the quarantine on stress,"University Hospital, Toulouse",All,"50 Years to 89 Years � (Adult, Older Adult)",,534,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RC31/20/0135,"April 17, 2020","July 17, 2021","July 17, 2021","May 21, 2020",,"April 18, 2022","CHU de Toulouse, Toulouse, Occitanie, France",,https://ClinicalTrials.gov/show/NCT04397835,NCT04397835,35162707
oui,NCT04398394,Single Centre Study: Investigational Medical Device of Transscleral Optical Phase Imaging for Retinal Imaging in Healthy Eyes and Retinal Pathology.,ASSESS,Recruiting,No Results Available,Retinal Disease,Device: Cellularis version 1 imaging,Number RPE [#/mm2]|Qualitative analysis [unitless]|averaged RPE cell area [um2]|Averaged number of neighbors of RPE cells [unitless]|Averaged RPE spacing [um]|Averaged RPE pigmentation parameter [unitless],"Moser Christophe|Institut National de la Santé Et de la Recherche Médicale, France|Eye Hospital Jules Gonin|Ecole Polytechnique Fédérale de Lausanne",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,102,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2019-00429,"July 7, 2020",May 2022,May 2022,"May 21, 2020",,"April 4, 2022","Eye Hospital Jules Gonin, Lausanne, Switzerland",,https://ClinicalTrials.gov/show/NCT04398394,NCT04398394,
oui,NCT04400539,The IMmunotherapy Pleural 5-ALA PDT,IMPALA,Recruiting,No Results Available,Mesotheliomas Pleural|Malignant Pleural Mesothelioma,Device: intrapleural photodynamic therapy with videothoracoscopy|Drug: Nivolumab Injection,the proportion of patients having the full multimodal treatment|objective response rate (ORR) according to modified RECIST 1.1 criteria for mesothelioma for pleural lesions  RECIST 1.1 for all other targets|Kaplan Meier curve for overall survival (mOS)|Kaplan Meier curve for progression free survival (mPFS)|quality of life (QoL) of patients by dedicated EORTC QLQ C30 (or LCSS-30) questionnaire|evaluation of chest pain using visual scale.,"University Hospital, Lille|INSERM U1189 ONCOTHAI",All,"18 Years and older � (Adult, Older Adult)",Phase 2,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019_41|2019-003003-35,"May 9, 2022",May 2026,May 2026,"May 22, 2020",,"January 9, 2023","Institut Coeur-Poumon, CHU, Lille, France",,https://ClinicalTrials.gov/show/NCT04400539,NCT04400539,
oui,NCT04405388,Spermidine Anti-Hypertension Study,SMARTEST,Recruiting,No Results Available,Hypertension,Drug: Placebo|Drug: Spermidine,Systolic blood pressure in an ambulatory 24h blood pressure measurement|Pulse wave velocity|diastolic blood pressure|mean blood pressure|central blood pressure|6 minute walk test,"Medical University of Graz|University of Graz|ETH Zurich|Institut National de la Santé Et de la Recherche Médicale, France|University Hospital Tuebingen",All,"19 Years to 99 Years   (Adult, Older Adult)",Phase 3,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",30-468 ex 17/18,"February 25, 2020","November 15, 2024","November 15, 2024","May 28, 2020",,"January 10, 2023","Medical University of Graz, Graz, Austria","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04405388/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04405388,NCT04405388,
oui,NCT04409405,Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola),,Completed,No Results Available,Ebola Virus Disease,,Cured-participant population co-infections|Cured-participant population co-morbidities at any time in the study|Evolution over time of clinical consequences in cured participants|Evolution over time of immunological consequences in cured participants|Evolution over time of virological consequences in cured participants|Description of contact-participants Ebola-virus-exposure risk|Asymptomatic or pauci-symptomatic Ebola infections in contact participants (clinical assessment)|Asymptomatic or pauci-symptomatic Ebola infections in contact participants (immunological assessment)|Asymptomatic or pauci-symptomatic Ebola infections in contact participants (virological assessment)|Evolution over time of peripheral blood mononuclear cells (PBMC) in cured and contact participants (cellular immunological sub-study)|Evolution over time of concentration of immune response analytes in cured and contact participants (cellular immunological sub-study)|Evolution over time of EBOV-specific T responses in cured and contact participants (cellular immunological sub-study)|Evolution over time of gene-expression profile in cured and contact participants (cellular immunological sub-study)|Evolution over time of genetic heterogeneity in cured and contact participants (cellular immunological sub-study)|Genetic sub-study in cured and contact participants,"Institut National de la Santé Et de la Recherche Médicale, France|Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo|Institut de Recherche pour le Developpement",All,"5 Years and older   (Child, Adult, Older Adult)",,787,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C19-59|ESP/CE/287/2019,"April 16, 2020","October 18, 2021","October 18, 2021","June 1, 2020",,"February 17, 2022","Beni Hospital, Beni, Congo, The Democratic Republic of the|Butembo Hospital, Butembo, Congo, The Democratic Republic of the|Mambasa Hospital, Mambasa, Congo, The Democratic Republic of the|Mangina Hospital, Mangina, Congo, The Democratic Republic of the",,https://ClinicalTrials.gov/show/NCT04409405,NCT04409405,
oui,NCT04416360,Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak,CLIECO,Unknown status,No Results Available,Autism Spectrum Disorder|Attention-deficit Hyperactivity Disorder,Other: Interview by psychologists,Interview of the parents : contextual data|Interview of the children/adolescents/ parents : Experience of the confinement in general|Interview of the referring caregiver : data relating to disease and management of care,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,6 Years to 17 Years   (Child),Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,RC31/20/0151,"May 5, 2020",July 2020,January 2021,"June 4, 2020",,"June 4, 2020","University hospital of Toulouse, Toulouse, Occitanie, France|Centre Hospitalier de Versailles, Le Chesnay, France|Centre Hospitalier Esquirol, Limoges, France|Hôpital Robert-Debré (AP-HP), Paris, France|Maison de Solenn (Hôpital Cochin AP-HP), Paris, France",,https://ClinicalTrials.gov/show/NCT04416360,NCT04416360,
oui,NCT04427826,"Efficacy of Morphine in Reducing the Rate of Early Non-Invasive Ventilation Failure in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Phase I/IIa",MORPHEUS I/IIa,Recruiting,No Results Available,Chronic Obstructive Pulmonary Disease,Drug: Morphine hydrochloride,"The probability of dose - limiting toxicity (DTL), defined as the occurrence of one or more of the following criteria occurring within 4 hours of morphine administration|Efficacy and toxicity|Percentage of adverse events","University Hospital, Grenoble",All,"18 Years and older � (Adult, Older Adult)",Phase 1|Phase 2,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2019-004274-25,"December 8, 2020",June 2024,July 2024,"June 11, 2020",,"November 8, 2022","Emergency Department of Grenoble Alpes University Hospital, Grenoble, Is�re, Auvergne-Rh�ne-Alpes, France",,https://ClinicalTrials.gov/show/NCT04427826,NCT04427826,
oui,NCT04432116,Time and Virtual Reality in Schizophrenia and Bipolar Disorder,VirtualTimes,Not yet recruiting,No Results Available,Schizophrenia|Bipolar Disorder,Behavioral: virtual reality 1|Behavioral: virtual reality 2,EEG index of time expectation|retrospective duration,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),Not Applicable,120,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,C19-48,September 2020,December 2023,December 2023,"June 16, 2020",,"June 16, 2020",,,https://ClinicalTrials.gov/show/NCT04432116,NCT04432116,
oui,NCT04439708,Biomarkers and Choroidal Neovascularization,BioNéoRet,Unknown status,No Results Available,Choroidal Neovascularization|Mineralocorticoid Excess,Other: Blood and aqueous humor biomarker of treatment response,biomarker analysis in blood and aqueous humor of patients with neovascularization and controls|biomarkers and treatment response,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 90 Years   (Adult, Older Adult)",,250,Other,Observational,Observational Model: Other|Time Perspective: Prospective,C18-08|2018-A02099-46,"June 15, 2020","April 1, 2022","April 1, 2022","June 19, 2020",,"June 19, 2020",,,https://ClinicalTrials.gov/show/NCT04439708,NCT04439708,
oui,NCT04440254,Long Duration Holter ECG in Fabry Disease,,Not yet recruiting,No Results Available,Fabry Disease,Diagnostic Test: Implantation (subcutaneous) of a marketed miniaturized Holter ECG recording device,"Occurrence of cardiac arrhythmias and conduction disorders|Correlations between electrical disorders and changes in MRI/ultrasonic data (LV mass, T1 signal, fibrosis extent , systolic strain, ejection fraction), concentrations of BNP, troponin, Lyso-Gb3, MSSI score and renal function","Institut National de la Santé Et de la Recherche Médicale, France",Male,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,C19-57,"September 1, 2020","September 1, 2025","September 1, 2025","June 19, 2020",,"June 19, 2020",,,https://ClinicalTrials.gov/show/NCT04440254,NCT04440254,
oui,NCT04442061,Autism Spectrum Disorders: Double Blind Randomized Placebo-control Active Pilot Study of Transcranial Magnetic Stimulation Applied to the Superior Temporal Sulcus,STIMAUT,Recruiting,No Results Available,Autism Spectrum Disorders,Device: Transcranial magnetic stimulation|Device: MRI|Device: Neuronavigation|Device: Eye-tracking|Genetic: Salivary samples|Other: Clinical scales,"Changes gaze pattern to the eyes|Autistic Behavior Checklist (ABC) scale at v1|Autistic Behavior Checklist (ABC) scale at v2|Autistic Behavior Checklist (ABC) scale at v3|Autistic Behavior Checklist (ABC) scale at v4|""Evaluation des comportements Autistiques r�vis�e"" (ECA-R) scale at v1|""Evaluation des comportements Autistiques r�vis�e""(ECA-R) scale at v2|""Evaluation des comportements Autistiques r�vis�e"" (ECA-R) scale at v3|""Evaluation des comportements Autistiques r�vis�e"" (ECA-R) scale at v4|Clinical Global Impression (CGI) scale at v1|Clinical Global Impression (CGI) scale at v2|Clinical Global Impression (CGI) scale at v3|Clinical Global Impression (CGI) scale at v4|Changes in rest brain fonctionning at v1|Changes in rest brain fonctioning at v2|Changes in rest brain fonctioning at v4|Putative changes on brain functional connectivity at rest at V1|Putative changes on brain functional connectivity at rest at V2|Putative changes on brain functional connectivity at V4|Anatomical connectivity abnormalities|BDNF/COMT polymorphisms",Assistance Publique - H�pitaux de Paris|Fondation de France|Fondation Malakoff M�d�ric,Male,18 Years to 25 Years � (Adult),Phase 2,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",APHP191009,"February 2, 2022",May 2024,October 2024,"June 22, 2020",,"September 9, 2022","H�pital Necker Enfants Malades - Service de radiologie p�diatrique, Paris, France",,https://ClinicalTrials.gov/show/NCT04442061,NCT04442061,
oui,NCT04447196,Prevalence of Rest Dyspnea and Impact of Non Invasive Ventilation on Breathing Sensations in CCHS Patients,DyspnOndine,Not yet recruiting,No Results Available,CCHS|Congenital Central Hypoventilation Syndrome|Dyspnea,Other: MDP,"""Immediate unpleasantness"" corresponding to A.1 item of the multidimensional dyspnea profile",Association pour le D�veloppement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil,All,"18 Years and older � (Adult, Older Adult)",,20,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2020-A00215-34,"December 15, 2021","October 1, 2022","October 1, 2022","June 25, 2020",,"July 12, 2021","INSERM-UPC UMR_S 1158, Service de Pneumologie et R�animation, GH Piti�-Salp�tri�re, Paris, France",,https://ClinicalTrials.gov/show/NCT04447196,NCT04447196,
oui,NCT04459117,Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen,TREOCAPA,Recruiting,No Results Available,Patency of the Ductus Arteriosus|Acetaminophen|Extreme Prematurity,Drug: Acetaminophen|Drug: NACL 0.9%,Closure of Ductus Arteriosus (Primary endpoint of phase II)|The survival without severe morbidity (Primary endpoint of phase III)|Analgesia/sedation drugs consumption during first week after birth (Secondary endpoint of phase III)|Closure of Ductus arteriosus (Secondary endpoint of phase III)|Number of back-up treatment of PDA (Secondary endpoint of phase III)|Number of days during the first week after birth with catecholamines administration (Secondary endpoint of phase III)|Early pulmonary hemorrhage (Secondary endpoint of phase III)|Blood acetaminophen levels in extrem preterm infant (Secondary endpoint of Phase II and Phase III)|Toxicity of Acetaminophen in extrem preterm infant (Secondary endpoint of Phase II and Phase III),"Institut National de la Santé Et de la Recherche Médicale, France|UPCET|PARTNERS for International clinical Research|European Fundation for the Care of the Newborn Infants|Connect for Children",All,23 Weeks to 28 Weeks   (Child),Phase 2|Phase 3,824,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",C19-29|2019-004297-26,"October 29, 2020",April 2023,July 2023,"July 7, 2020",,"February 18, 2022","Centre Hospitalier Universitaire de Liège, Liège, Belgium|The Juliane Marie Centre, Rigshospitalet, Copenhagen University hospital, Copenhagen, Denmark|East Tallinn Central Hospital, Tallinn, Estonia|Tallinn Children's Hospital, Tallinn, Estonia|Tartu University Hospital, Neonatal and Paediatric Intensive Care Unit, Tartu, Estonia|Helsinki University Hospital, Department of Children and Adolecents, Neonatology, Helsinki, Finland|Kuopio University Hospital, Department of Pediatrics, Kuopio, Finland|Oulu University Hospital, Department of Pediatrics, Oulu, Finland|Tampere University Hospital, Department of Pediatrics, Tampere, Finland|Turku University Hospital, Department of Peadiatrics, Turku, Finland|CHU Angers, Angers, France|Hopital Jeanne de Flandre, Lille, France|Hospice civils de Lyon, Hopital Femme Enfant, Lyon, France|Hôpital de la conception, Marseille, France|Hôpital Arnaud de Villeneuve, Département de Pédiatrie Néonatale et Réanimation Pédiatrique, Montpellier, France|CHU Nantes, Hopital mére Enfant, Nantes, France|Hôpital Necker - Enfants malades, Paris, France|CENTRE hospitalier intercommunal de Creteil, Paris, France|Hopital Cochin, Service de Médecine et Réanimation néonatales de Port-Royal, Paris, France|Hopital Robert Debré, Néonatologie, Paris, France|CHU Rennes, Hopital Sud, Rennes, France|CHU Strasbourg, Hôpital de Hautepierre, Strasbourg, France|CHRU de Tours, Tours, France|Bács Kiskun COUNTY HOSPITAL, Kecskemét, Hungary|Cork University Hospital, Cork, Ireland|Oslo University Hospital, Oslo, Norway|Centro Clínico Académico - Braga, Braga, Portugal|Centro Hospitalar Universitário Lisboa Norte, EPE -Hospital Santa Maria, Lisboa, Portugal|Centro Hospitalar e Universitário do Porto, EPE - Centro Materno Infantil do Norte, Porto, Portugal|Karolinska University Hospital, Solna, Sweden|Hopital Universitaire de Geneve (HUG) - Hopital des enfants, Geneva, Switzerland|University Children's Hospital Lausanne, Lausanne, Switzerland|University Hospital of Zürich, Zürich, Switzerland",,https://ClinicalTrials.gov/show/NCT04459117,NCT04459117,
oui,NCT04459780,Characterization and Functionality of Calcium Channels Cav1.4 of Th17 Lymphocytes in Human With Psoriasis,,Completed,No Results Available,Psoriasis,Biological: Skin biopsies|Biological: Blood sample,"Expression of Cav1.4 calcium channels in Th17 lymphocytes|Role of Cav1.4 channels on the activation of Th17 lymphocytes|Transcriptomic signature relating to the signaling channel Cav1.4|Epigenetic signature, in particular changes in overall methylation and specific promoter methylation","Pierre Fabre Dermo Cosmetique|Centre National de la Recherche Scientifique, France|Institut National de la Santé Et de la Recherche Médicale, France",Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,CaPSO17,"October 25, 2016","November 13, 2017","November 13, 2017","July 7, 2020",,"July 14, 2020","Service de Dermatologie - Hôpital Larrey, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04459780,NCT04459780,
oui,NCT04463758,Covid-19 in Pregnancy: a French Population-based Cohort of Women and Newborns,Coropreg,Recruiting,No Results Available,covid19 Infection|Pregnancy Complications|Neonatal Complications,Other: An auto-questionnaire comprising three psychometric scales,Joint evaluation of morbi-mortality for mother and child up to 12 weeks postpartum|Number of women infection COVID-19|Severe forms of COVID-19 infection in the mother|Severe neonatal morbidity,"Assistance Publique - H�pitaux de Paris|INSERM, Epop� team",Female,"Child, Adult, Older Adult",,3060,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP200513,"May 11, 2020",February 2022,October 2022,"July 9, 2020",,"October 4, 2021","AP-HP Cochin, Paris, France",,https://ClinicalTrials.gov/show/NCT04463758,NCT04463758,
oui,NCT04464278,Variation in Body Composition on the Fate of Older Subjects During SSR Hospitalization,VALCOR,Not yet recruiting,No Results Available,Body Weight Changes,,The prognosis value of variation of weight on mortality|Mortality rate|The pprognosis value of variation of weight on unscheduled readmission in SSR|Unscheduled readmission in SSR|Lean mass pronostic value|In fat mass pronostic value|fat / lean mass ratio,Assistance Publique - H�pitaux de Paris|INSERM UMR S 1136,All,70 Years and older � (Older Adult),,360,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,APHP200265|IDRCB 2019-A03287-50,July 2020,October 2023,October 2023,"July 9, 2020",,"July 9, 2020",,,https://ClinicalTrials.gov/show/NCT04464278,NCT04464278,
oui,NCT04470648,COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey,,Completed,No Results Available,SARS-COV2 Infection,Diagnostic Test: blood test for SARS-COV2 serology,SARS-COV-2 seroprevalence in 3 centers for homeless and people in social distress|Morbidity rate|Covid-19 related death rate in the 3 centers from March to May 2020|Ratio of negative serology rate and positive serology rate in the 3 centers|Ratio of SARS-COV2 seroprevalence obtained in these centers to the estimated seroprevalence in the Ile de France region|kinetics of SARS-COV2 antibodies in people with initial positive serology,"Institut National de la Santé Et de la Recherche Médicale, France|Samusocial de Paris|Assistance Publique - Hôpitaux de Paris",All,"18 Years and older   (Adult, Older Adult)",,179,Other,Observational,Observational Model: Other|Time Perspective: Prospective,C20-50,"July 22, 2020","April 8, 2021","August 22, 2021","July 14, 2020",,"March 1, 2023","Haltes pour femmes, Paris, France|LHSS Saint-Michel, Paris, France|LHSS Ridder-Plaisance, Paris, France",,https://ClinicalTrials.gov/show/NCT04470648,NCT04470648,
oui,NCT04470687,Ultrafast Ultrasound Imaging Assesment of Carotid Plaque Neovascularization,ULTRA-VASC,Recruiting,No Results Available,Carotid Stenosis|Carotid Artery Diseases|Carotid Atherosclerosis|Carotid Artery Plaque|Atheroma Carotid Artery,Device: contrast enhanced ultrafast ultrasound imaging,Neovascularization of the carotid plaque|Plaque stable or unstable|Plaque symptomatic or not,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,APHP180482|2019-A03331-56,"March 17, 2021","March 17, 2022","March 17, 2022","July 14, 2020",,"November 16, 2021","Hopital europeen Georges-Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT04470687,NCT04470687,
non,NCT04472546,Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis,,Unknown status,No Results Available,Acne|Atopic Dermatitis|Psoriasis Vulgaris|Rosacea|Seborrheic Dermatitis|Healthy,Other: in-vivo mesure|Other: Scotch|Other: Lipid index|Other: Absorbant paper|Other: Hydratation Index|Other: TransEpidermal Water Loss,"Signals and molecular profiles (including lipid) of the epidermis|Molecular profiles (including lipid) of the epidermis according to sampling method and the measurements of the signals obtained method|Cutaneous hydratation for atopic dermatitis subgroup and its associated control|State of the cutaneous barrier for atopic dermatitis and corresponding control volunteers|Global lipid quantity measured on face acnea, scalp seborrheic dermatitis, face rosacea (papulotelangiectasic stage of erythrocouperosis) and corresponding control volunteers|Skin state evaluation on the lesional and perilesional areas|Impact of several factors (dermatosis, area, gender, age) on the molecular profiles of the epidermis",Pierre Fabre Dermo Cosmetique,All,18 Years to 55 Years � (Adult),Not Applicable,220,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,SMPATHO01|2019-A02105-52,"December 13, 2019","September 15, 2021","September 15, 2021","July 15, 2020",,"March 18, 2021","Centre de Recherche sur la Peau, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04472546,NCT04472546,
oui,NCT04476979,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,TOCIDEX,Completed,No Results Available,Coronavirus Infection|SARS (Severe Acute Respiratory Syndrome)|Virus Diseases|Coronaviridae Infections|Nidovirales Infections|RNA Virus Infections|Respiratory Tract Infections|Respiratory Tract Disease,Drug: Tocilizumab|Drug: Dexamethasone,"Survival without needs of invasive ventilation at day 14|WHO progression scale at day 7 and 14|Overall survival at 14, 28, 60 and 90 days|Cumulative incidence of discharge alive at 14 and 28 days|Survival without needs of mechanical ventilation at day 1|Cumulative incidence of oxygen supply independency at 14 and 28 days|Survival without needs of ventilator utilization at day 14","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 2,453,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP200375-TOCIDEX|2020-001246-18,"July 16, 2020","June 1, 2021","August 11, 2021","July 20, 2020",,"June 8, 2022","CH Andrée Rosemon, Cayenne, French Guiana",,https://ClinicalTrials.gov/show/NCT04476979,NCT04476979,35350097
associ�,NCT04478409,Characterization of a Functional Test for Mediterranean Family Fever Screening - 2,DEPIST-FMF 2,Recruiting,No Results Available,Familial Mediterranean Fever|MEFV Gene Mutation,Biological: one additional blood sample during a planned blood test,Quantification of interleukin-1?,Hospices Civils de Lyon,All,"4 Years and older � (Child, Adult, Older Adult)",,160,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,69HCL20_0236,"July 21, 2021",December 2023,June 2024,"July 20, 2020",,"November 22, 2021","H�pital Femme-M�re-Enfant, Bron, France|CH de Versailles - H�pital Andr� Mignot, Le Chesnay, France|H�pital Edouard Herriot, Lyon, France|H�pital de la Croix-Rousse, Lyon, France|CHU de Montpellier, Montpellier, France|Service de P�diatrie - CHU de N�mes - H�pital Car�meau, N�mes, France|H�pital Tenon, Paris, France|H�pital Lyon Sud, Pierre-B�nite, France",,https://ClinicalTrials.gov/show/NCT04478409,NCT04478409,
oui,NCT04479670,"Psychometric and Patholinguistic Assessment of Psychotrauma Related to Natural Hazards in the Commune of ""Le Prêcheur""",EP3LAN,Completed,No Results Available,Psychological Trauma|Posttraumatic Stress Disorder PTSD|Mass Casualty Incidents,,Word frequency calculation|Repository classification of words|Patholinguistic classification of words|Visualization of reference universes|Application of the patholinguistic scenario|Assess the overall mental health status|Evaluate the symptomatology of psychotrauma patients,"University Hospital Center of Martinique|Centre de recherche en Épidémiologie et Santé des Populations (CESP)|Institut National de la Santé Et de la Recherche Médicale, France|SOS KRIZ",All,"18 Years and older   (Adult, Older Adult)",,59,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,19_RIPH3-20,"March 26, 2021","June 7, 2022","June 7, 2022","July 21, 2020",,"September 13, 2022","CHU of Martinique, Fort-de-France, Martinique",,https://ClinicalTrials.gov/show/NCT04479670,NCT04479670,
oui,NCT04481152,Impact of Environmental Exposures on Tumor Risk in Subjects at Risk of Hereditary SDHx Paraganglioma,PGL-EXPO-1,Not yet recruiting,No Results Available,Genetic Predisposition|SDH Gene Mutation|Environmental Exposure,,Feasability of the protocol of a national case/control study (PGL.EXPO2)|Feasibility of matching cases and controls|Ease of matching cases and controls,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|ANSES",All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,APHP191007|2020-A00567-32,"March 1, 2022","September 1, 2022","September 1, 2022","July 22, 2020",,"January 19, 2022",,,https://ClinicalTrials.gov/show/NCT04481152,NCT04481152,
oui,NCT04481347,"Relationship Between Sleep EEG, Intraoperative EEG and Postoperative Cognitive Dysfunction",SOMEDYSPO,Not yet recruiting,No Results Available,Postoperative Cognitive Dysfunction,Device: Sleep EEG recording using a DREEM� headband|Other: Montreal Cognitive Assessment (MoCA)|Device: Intraoperative EEG recording using a Sedline� monitoring,Early postoperative cognitive dysfunction|Burst suppression duration|Variations in alpha power on sleep EEG|Spindle amplitude on sleep EEG|Spindle frequency on sleep EEG,"Assistance Publique - H�pitaux de Paris|INSERM UMR-942, Paris, France|LMS Ecole polytechnique and M3DISIM, Inria",All,"18 Years and older � (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP200037|2019-A03206-51,March 2022,March 2023,September 2023,"July 22, 2020",,"December 21, 2021","AP-HP, Lariboisi�re Hospital, Department of Anesthesiology and Intensive Care, Paris, France",,https://ClinicalTrials.gov/show/NCT04481347,NCT04481347,
anrs,NCT04482010,ANRS 12392 Sanu Gundo,SANU GUNDO,Unknown status,No Results Available,HIV Infections,Other: Local community-based HIV care,"Lost to follow-up rate 12 months after the HIV diagnosis|Extent of the HIV epidemic in the artisanal gold-mining sites|Comparing linkage-to-care and retention between classic and community-based HIV care|Comparing the impact of classic and community-based HIV care on virological succes, behavioral and psychosocial outcomes","ANRS, Emerging Infectious Diseases|UMR 1252 SESSTIM|ARCAD Sant� PLUS|SEREFO",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,265,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,ANRS 12392,"November 29, 2020","March 28, 2022","December 28, 2022","July 22, 2020",,"February 25, 2021","ARCAD Sant� PLUS mobile care unit for community-based HIV care and study follow-up (Kofoulati�, intervention site), Kofoulat�, Koulikoro, Mali|ARCAD Sant� PLUS mobile care unit for recruitment of participants (Kofoulati�, Intervention site), Kofoulat�, Koulikoro, Mali|ARCAD Sant� PLUS mobile care unit for recruitment of participants (Diassa, control site), Diassa, Sikasso, Mali|Referral health center (CSR�f) Kolondieba, classic HIV care, Kolondieba, Sikasso, Mali",,https://ClinicalTrials.gov/show/NCT04482010,NCT04482010,
oui,NCT04484740,Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue,AB-Direct,Unknown status,No Results Available,"Gonorrhea|Infection, Bacterial",Drug: Gepotidacin,area under the concentration time curve (AUC) from zero to last observed concentration (AUC0-t) in tissue|AUC from zero to infinity (AUC0-∞) in tissue|maximum drug concentration (Cmax) in tissue|half-life (t1/2) in tissue|time to reach maximum drug concentration (tmax) in tissue|area under the concentration time curve (AUC) from zero to last observed concentration (AUC0-t) in plasma|AUC from zero to infinity (AUC0-∞) in plasma|Cmax in plasma|t1/2 in plasma|tmax in plasma|apparent volume of distribution (Vd) in plasma|Clearance (Cl) in plasma|T>MIC in tissue and plasma (if applicable)|Cmax/MIC in tissue and plasma|AUC/MIC in tissue and plasma (if applicable)|collection of adverse events during study participation,"Institut National de la Santé Et de la Recherche Médicale, France|Medizinischen Universität Wien",All,"18 Years and older   (Adult, Older Adult)",Phase 1,60,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C19-28|2019-004308-37,"September 1, 2020","November 1, 2021","December 1, 2021","July 24, 2020",,"July 24, 2020",,,https://ClinicalTrials.gov/show/NCT04484740,NCT04484740,
oui,NCT04488159,Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer,iMAGINE,Not yet recruiting,No Results Available,Colon Cancer Stage III,Drug: Capecitabine|Drug: Oxaliplatin|Drug: Fluorouracil|Drug: Leucovorin|Device: Immunoscore� assay|Other: Physical exercise,Disease-free survival (DFS)|Overall survival (OS)|Time to recurrence (TTR)|Treatment-related adverse events (AE)|Quality of life|Cost analysis,"Johannes Laengle, MD, PhD|Medical University of Vienna",All,"18 Years to 100 Years � (Adult, Older Adult)",Phase 3,1638,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,iMAGINE|2020-000401-91,"December 1, 2023","December 1, 2025","June 1, 2026","July 27, 2020",,"March 15, 2023","Medical University of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT04488159,NCT04488159,
oui,NCT04489199,Dijon Stroke Cohort,DISCO,Recruiting,No Results Available,"CVA, Dijon Registry",Other: Questionnaire and semi-structured interview,Death rate|Disability rate|Quality of Life Questionnaire|Neuropsychological questionnaire,Centre Hospitalier Universitaire Dijon,All,"18 Years and older � (Adult, Older Adult)",,4000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,BEJOT 2020,"January 1, 2021",January 2040,January 2040,"July 28, 2020",,"April 15, 2022","Chu Dijon Bourgogne, Dijon, France",,https://ClinicalTrials.gov/show/NCT04489199,NCT04489199,
oui,NCT04489277,Silent Brain Infarction After Endovascular Arch Procedures,,Completed,No Results Available,Aortic Arch Aneurysm,Device: Endovascular Arch Procedures,frequency of silent cerebral infarcts on DW-MRI|perioperative ischemic stroke,"Medical University of Vienna|Groupe Hospitalier Paris Saint Joseph|Universit�tsklinikum Hamburg-Eppendorf|Vascular Surgical Research Group, Imperial College, London, UK|Sanger Heart and Vascular Institute, Charlotte, NC|Loyola University Medical Center, Maywood, IL|UAB School of Medicine, Birmingham, AL|Heidelberg University Hospital, Heidelberg, Germany|University Hospital of Freiburg, Freiburg, Germany|Stanford University|Massachusetts General Hospital|Baylor Research Hospital, Dallas, TX|Emory University Hospital, Atlanta, GA|University Hospital of Mainz, Mainz, Germany|Diakonie Hospital Jung-Stilling, Siegen, Germany|Mayo Clinic, Rochester, MN|Sentara Vascular/Eastern Virginia Medical School, Norfolk, VA|Maastricht University Medical Centre, Maastricht, Netherlands|I.R.C.C.S. Policlinico San Donato, San Donato Milanese, Italy|Memorial Care Long Beach Heart & Vascular Institute, Long Beach, CA",All,"18 Years to 100 Years � (Adult, Older Adult)",,91,Other,Observational,Observational Model: Cohort|Time Perspective: Other,INSERM UMR_S 999,"September 1, 2018","January 31, 2020","January 31, 2020","July 28, 2020",,"August 6, 2020","Marie Lannelongue Hospital (Paris, France), Paris, France|University Hospital Hamburg-Eppendorf (Hamburg, Germany), Hamburg, Germany",,https://ClinicalTrials.gov/show/NCT04489277,NCT04489277,33358103
oui,NCT04492189,Containment Measures and Eating Disorders,COVITA,Completed,No Results Available,Eating Disorders|COVID 19,,Variation in eating disorders|Vision of the bodily aspect|Variation in physical activity|Identify the clinical factors modulating the psychological state during confinement,"University Hospital, Montpellier|INSERM U1061 (Statistics)",All,"18 Years and older � (Adult, Older Adult)",,40,Other,Observational,Observational Model: Other|Time Perspective: Prospective,RECHMPL20_0220,"April 1, 2020","May 30, 2020","June 30, 2020","July 30, 2020",,"July 30, 2020","Uhmontpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04492189,NCT04492189,
oui,NCT04508985,The McGill RAAS-COVID-19 Trial,RAAS-COVID,Unknown status,No Results Available,COVID-19|Cardiovascular Diseases,Other: Temporarily holding the RAAS inhibitor [intervention]|Other: RAAS inhibitor [continued standard of care],Global rank score,"McGill University Health Centre/Research Institute of the McGill University Health Centre|Jewish General Hospital (Montreal, Quebec, Canada)|Montreal General Hospital (Montreal, Quebec, Canada)|Universit� de Lorraine, Centre d'Investigation Clinique- Plurith�matique Inserm",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MP-37-2021-6614,"September 1, 2020","January 1, 2021","September 1, 2021","August 11, 2020",,"August 19, 2020",,,https://ClinicalTrials.gov/show/NCT04508985,NCT04508985,35143744;33546734
oui,NCT04532944,The Energetic Origin of Neurodegeneration in MS,ENERGYSEP,Not yet recruiting,No Results Available,Multiple Sclerosis,Diagnostic Test: imaging of energy dysfunction,Energy dysregulation in the whole brain with sodium imaging|Energy dysregulation in the motor-sensory region (MSR) with phosphorus spectroscopy|Energy dysregulation in the motor-sensory region with diffusion-weighted spectroscopy|Neurodegeneration in the MSR after 24 months|Patient-specific profiles of energy dysregulation|cortical demyelination and remyelination|neuro-axonal damage over time|functional changes in brain connectivity|serum markers of tissue damage|physical and cognitive dysfunction,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 55 Years   (Adult),Not Applicable,55,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,C19-20|2019-A01931-56,"September 15, 2020","September 15, 2022","March 15, 2024","August 31, 2020",,"August 31, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT04532944/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04532944,NCT04532944,
non,NCT04540432,Evolution of Intestinal Microbiota in Patients With Juvenile Spondylarthropathy According to Typology of Treatment and Response to it,MESAJ,Recruiting,No Results Available,Spondylarthropathies,Other: Stool collection at the patient's home.|Diagnostic Test: Blood test,Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A). Number of species detected in the intestinal microbiota.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A). Distribution of species detected in the intestinal microbiota.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A). Diversity of species detected in the intestinal microbiota.|Response to treatment in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A)|Response to treatment in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A). Number of flare-ups.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM). Number of species detected in the intestinal microbiota.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM). Distribution of species detected in the intestinal microbiota.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM). Diversity of species detected in the intestinal microbiota.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM).Number of species.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM). Distribution of species.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM). Diversity of species.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM). Number of species.|Response to treatment in patients treated with non-steroidal anti-inflammatory drugs for 1 month followed by methotrexate for 5 months (Profile AM)|Response to treatment in patients treated with non-steroidal anti-inflammatory drugs for 1 month followed by methotrexate for 5 months (Profile AM). Number of flare-ups.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB). Number of species.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB). Distribution of species.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB). Diversity of species.|Response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB)|Response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB). Number of flare-ups.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB). Number of species.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB). Distribution of species.|Evolution of the intestinal microbiota in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB). Diversity of species.|Response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB)|Response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB). Number of flare-ups.|A:Correlation between intestinal microbiota of patients treated with non-steroidal anti-inflammatory drugs alone (Profile A) and the clinical stage of evolution of Juvenile Spondylarthitis.|A:Correlation between intestinal microbiota of patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM) and the clinical stage of evolution of Juvenile Spondylarthitis.|A:Correlation between intestinal microbiota of patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB) and the clinical stage of evolution of Juvenile Spondylarthitis.|A: Correlation between intestinal microbiota of patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB) and the clinical stage of evolution of Juvenile Spondylarthitis.|A:Correlation between intestinal microbiota of patients treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy (Profile AMB) and the clinical stage of evolution of Juvenile Spondylarthitis.|B:Correlation between bacterial translocation and response to treatment in patients treated with non-steroidal anti-inflammatory drugs alone (Profile A)|B:Correlation between bacterial translocation and response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate (Profile AM)|B:Correlation between bacterial translocation and response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by biotherapy (Profile AB)|B:Correlation between bacterial translocation and response to treatment in patients treated with non-steroidal anti-inflammatory drugs followed by methotrexate then biotherapy (Profile AMB)|C:Constitution of a biobank of samples from Profile A patients (treated with non-steroidal anti-inflammatory drugs alone)|C: Constitution of a biobank for Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate).|C: Constitution of a biobank for Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy)|C: Constitution of a biobank for AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy)|Age of Profile A patients (treated with non-steroidal anti-inflammatory drugs alone)|Weight of Profile A patients (treated with non-steroidal anti-inflammatory drugs alone)|Height of Profile A patients (treated with non-steroidal anti-inflammatory drugs alone)|Sex of Profile A patients (treated with non-steroidal anti-inflammatory drugs alone)|Previous treatment in Profile A patients (treated with non-steroidal anti-inflammatory drugs alone)|Dietary habits in Profile A patients (treated with non-steroidal anti-inflammatory drugs alone)|Food allergies in Profile A patients (treated with non-steroidal anti-inflammatory drugs alone)|Lifestyle of Profile A patients (treated with non-steroidal anti-inflammatory drugs alone)|Age of Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate)|Weight of Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate)|Height of Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate)|Sex of Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate)|Previous treatment in Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate)|Dietary habits in Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate)|Food allergies in Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate)|Lifestyle in Profile AM patients (treated with non-steroidal anti-inflammatory drugs then methotrexate)|Age of Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy)|Weight of Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy)|Height of Profile AB patients (treated with non-steroidal anti-inflammatory drugs for then biotherapy)|Sex of Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy)|Previous treatment in Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy)|Dietary habits in Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy)|Food allergies in Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy)|Lifestyle in Profile AB patients (treated with non-steroidal anti-inflammatory drugs then biotherapy)|Age of Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate biotherapy)|Weight of Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy)|Height of Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy)|Sex of Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy)|Previous treatment in Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy)|Dietary habits in Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy)|Food allergies in Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy)|Lifestyle in Profile AMB patients (treated with non-steroidal anti-inflammatory drugs then methotrexate then biotherapy),"Centre Hospitalier Universitaire de N?mes|University Hospital, Montpellier|Assistance Publique Hopitaux De Marseille",All,8 Years to 16 Years � (Child),Not Applicable,25,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NIMAO/2019/TAT-01|20.03.20.564,"September 22, 2021","June 28, 2023","June 28, 2023","September 7, 2020",,"July 29, 2022","N�mes University Hospital, N�mes, Gard, France|Montpellier University Hospital, Arnaud de Villeneuve Hospital, Montpellier, H�rault, France",,https://ClinicalTrials.gov/show/NCT04540432,NCT04540432,
non,NCT04545151,Verapamil SR in Adults With Type 1 Diabetes,Ver-A-T1D,Recruiting,No Results Available,"Diabetes Mellitus, Type 1",Drug: Verapamil SR 120 mg|Drug: Placebo,"Area under the stimulated C-peptide response curve|Proinsulin, Insulin, Pro-IAPP and Proglucagon secretion|Fasting C-peptide|DBS C-peptide|Change in HbA1c|Severe hypoglycaemic episodes|DKA|Change in insulin requirements|Change in T1D associated autoantibodies|Continous glucose monitoring (CGM)",Medical University of Graz|Juvenile Diabetes Research Foundation,All,18 Years to 45 Years   (Adult),Phase 2,138,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Ver-A-T1D|2020-000435-45,"February 8, 2021",February 2024,February 2024,"September 10, 2020",,"July 5, 2022","Medical University of Graz, Department of Internal Medicine Division of Endocrinology and Metabolism, Graz, Styria, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Université Libre de Bruxelles/ Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Katholieke Universiteit Leuven, Leuven, Belgium|Institut National de la Santé et de la Recherche Médicale, Paris, France|HKA Hannover, Hanover, Germany|Universität Ulm, Ulm, Germany|Università Vita-Salute San Raffaele, Milano, Italy|Università degli Studi di Siena, Siena, Italy|Slaski Uniwersytet Medyczny w Katowicach, Katowice, Poland|Lunds Universität, Lund, Sweden|Queen Elizabeth Hospital, Birmingham, United Kingdom|Southmead Hospital, Bristol, United Kingdom|Addenbrokes Hospital, Cambridge, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Bart's Hospital QMUL, London, United Kingdom|Guy's Hospital, London, United Kingdom|Queens Medical Centre, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|OCDEM, John Radcliffe Hospital, Oxford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Singleton Hospital, Swansea, United Kingdom",,https://ClinicalTrials.gov/show/NCT04545151,NCT04545151,
oui,NCT04545359,Study on Neurofeedback and Relaxation,NEURORELAX,Unknown status,No Results Available,Healthy People,Behavioral: Alpha-based neurofeedback|Behavioral: Sham neurofeedback,"Change in alpha frequency band power at the end of the 12 neurofeedback training sessions relative to the initial, pre-training, alpha power level.|Change in alpha frequency band power at post-training relative to pre-training across every training session.|Change in the EEG power spectrum at the end of the 12 neurofeedback training sessions relative to the initial, pre-training, EEG spectral content.|Change in the EEG power spectrum at post-training relative to pre-training across every training session.|Change in anxiety trait after the 12 neurofeedback training sessions relative to before the first training session.|Change in affective state after the 12 neurofeedback training sessions relative to before the first training session.|Change in stress level after the 12 neurofeedback training sessions relative to before the first training session.|Changes in anxiety state at post-training relative to pre-training across every training session.|Change in relaxation state at post-training relative to pre-training across every training session.|Correlation between the changes in electrophysiological measurements and the changes in behavioral measures.|Changes in EEG power spectrum during the training sessions from the 1st until the 12th sessions.","Centre National de la Recherche Scientifique, France|Sorbonne University|Institut du Cerveau et de la Moelle Epinière|myBrain Technologies|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",RCB 2017-A02786-47|17001,"December 12, 2018","September 15, 2021","September 15, 2021","September 11, 2020",,"September 11, 2020","Centre de Neuro-Imagerie de recherche (CENIR), ICM, Paris, France",,https://ClinicalTrials.gov/show/NCT04545359,NCT04545359,
oui,NCT04548245,Markers of Executive Attention Development in Preschoolers,MEDiATE,Recruiting,No Results Available,Attention Deficit Disorder,Device: EEG,Amplitude in �V of EEG changes relative to baseline when expected stimulus is omitted in a tactile stimulation sequence,"University Hospital, Caen",All,48 Months to 60 Months � (Child),,70,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,2020-A01503-36,"February 1, 2021","October 1, 2023","October 1, 2023","September 14, 2020",,"February 13, 2023","Comete U1075 Inserm Unicaen, Caen, France",,https://ClinicalTrials.gov/show/NCT04548245,NCT04548245,
oui,NCT04558450,Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN),CARTESIAN,Recruiting,No Results Available,Covid19|Arterial Stiffness|Endothelial Dysfunction|Diastolic Dysfunction,Diagnostic Test: carotid-femoral pulse-wave velocity,PWV|PWV change|arterial distensibility|arterial distensibility change|brachial artery FMD|brachial artery FMD change|central blood pressure|central blood pressure (BP) change|wave separation/wave intensity analysis (WSA/WIA)|WSA/WIA change|cardiac diastolic dysfunction|cardiac diastolic dysfunction change|myocardial stiffness|myocardial stiffness change|carotid femoral and hearth carotid change,"Assistance Publique - Hôpitaux de Paris|The Association for Research into Arterial Structure and Physiology|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,360,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,APHP200762|20.07.24.57438,"September 21, 2020",March 2023,March 2033,"September 22, 2020",,"November 22, 2021","CHRU Nancy, Nancy, France|Hôpital Européen Georges Pompidou - APHP, Paris, France|CHU Rouen, Rouen, France",,https://ClinicalTrials.gov/show/NCT04558450,NCT04558450,
oui,NCT04560517,Remission Factors in Anorexia Nervosa,REMANO,Recruiting,No Results Available,Anorexia Nervosa,,"Delay Discounting Task score after weight recovery|Delay Discounting Task score after weight recovery compared to control|Bold signal difference during Delay Discounting Task in fMRI|Evolution of brain volums in MRI|Evolution of fronto striatal connectivity in MRI|Evolution of total, acyl and desacyl ghrelin plasma level|Evolution of total, acyl and desacyl ghrelin plasma level around a meal|Exome analysis|Evolution of BDNF gene methylation|Evolution of EDI-2 score|Evolution of EAI score|Evolution of GLT score|Evolution of YBS score|Evolution of HADS score|Evolution of Brixton score|Evolution of TMT score|Evolution of Slips of action neurocognitive score|Evolution of pupillometry to social, food and body image pictures","Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years to 65 Years   (Adult, Older Adult)",,225,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C18-39|2019-A01352-55,"April 6, 2021",September 2025,September 2025,"September 23, 2020",,"November 29, 2021","Centre Hospitalier St Anne, Paris, France",,https://ClinicalTrials.gov/show/NCT04560517,NCT04560517,
oui,NCT04560777,"Exploring the Use of the Cognitive Orientation to Daily Occupational Performance Approach (CO-OP) With Children, Teenagers and Young Adults With Executive Functions Deficits Following Severe Acquired Brain Injury",REFECO-OP,Completed,No Results Available,Acquired Brain Injury,Other: CO-OP intervention,"Assessment of Goal Attainment Scaling (GAS) change|Canadian Occupational Performance Measure (COPM)|Behavior Rating Inventory of Executive Function (BRIEF)|Évaluation des Pratiques Éducatives Parentales (EPEP, Parental Childrearing Behavior Scale for French-Speaking Parents, Children, and Adolescents)|Questionnaire Engagement des Proches|Entretien Engagement des Proches","Hopitaux de Saint-Maurice|Institut National de la Santé Et de la Recherche Médicale, France|Hôpital Civil de Strasbourg|Ministry of Health, France",All,"8 Years to 21 Years   (Child, Adult)",Not Applicable,12,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,PHRIP-19-0074,"November 20, 2020","July 27, 2022","July 27, 2022","September 23, 2020",,"July 28, 2022","Centre Médical et Pédagogique pour Adolescents, Neufmoutiers en Brie, France|Hôpitaux de Saint-Maurice, Saint-Maurice, France",,https://ClinicalTrials.gov/show/NCT04560777,NCT04560777,36961228
oui,NCT04570202,Health cAre woRkers exposeD to COVID-19,HARD-COVID19,"Active, not recruiting",No Results Available,"Depression|Burnout, Professional|Post Traumatic Stress Disorder",Behavioral: EMDR,Efficacy on symptoms of Post-Traumatic Stress Disorder|Efficacy on symptoms of Burnout|Efficacy on symptoms of Depression|Short-term efficacy on symptoms of PTSD|Short-term efficacy on symptoms of Burnout|Short-term efficacy on symptoms of Depression|Long-term efficacy on symptoms of PTSD|Long-term efficacy on symptoms of Burnout|Long-term efficacy on symptoms of Depression|Efficacy on symptoms of Anxiety|Long-term efficacy on symptoms of Anxiety|Efficacy on suicide attempts,"University Hospital, Tours|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,900,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DR200160-HARD-COVID-19|2020-A01642-37|1-20-046 ID 48680,"November 20, 2020","January 14, 2023","March 19, 2023","September 30, 2020",,"January 25, 2023","Centre Investigation Clinique 1415, Tours, Centre Val De Loire, France|Bretonneau Regional Universitary Hospital, Tours, France",,https://ClinicalTrials.gov/show/NCT04570202,NCT04570202,37052108
oui,NCT04575064,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,,Unknown status,No Results Available,SARS-CoV-2 Infection|COVID-19|Moderate and Severe COVID-19,Other: Standard of Care (SoC)|Drug: Remdesivir,"Improvement of clinical status on the ordinal 7-point severity-scale at day 15.|Time to an improvement of one category from admission using the 7-point ordinal scale|Mortality: 28 days mortality; in-house mortality|Hospital stay: Duration of hospital stay due to COVID-19|Oxygen: Need of, time to first receiving and duration of oxygen|Intensive care: Need of, time to first receiving and duration of intensive care|Mechanical ventilation: Need of, time to first receiving and duration of mechanical ventilation|ECMO: Need of, time to first receiving and duration for extracorporeal membrane oxygenation|Superinfections, assessed with pathogen testing|Kidney failure|Myocardial failure|Multiple organ failure","Professor Dr. Bernd Mühlbauer|Dept. of Statistics and Medical Biometry, University of Bremen|INSERM (Institut national de la santé et de la recherche médicale), Paris, France|World Health Organization (WHO), R&D Blueprint, Geneva, Switzerland|Klinikum Bremen-Mitte, gGmbH",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WHO-SOLIDARITY-GERMANY|2020-001549-38,"June 29, 2020",March 2022,November 2022,"October 5, 2020",,"October 5, 2020","Gesundheit Nord gGmbH, Bremen, Germany|Universitätsklinikum Gießen, Gießen, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Germany|Technische Universität München (TUM), München, Germany",,https://ClinicalTrials.gov/show/NCT04575064,NCT04575064,
oui,NCT04586894,Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors,AMICI,"Active, not recruiting",No Results Available,Cancer|Immune Defect|Cardiovascular Abnormalities,Diagnostic Test: Cardiac MRI|Device: Smart cloth|Other: Biobanking,Number of patients with major cardiovascular advserse drug reactions|Number of patients with other cardiovascular advserse drug reactions|Number of patients with isolated CMR abnormalities|Number of patients with rhythm abnormalities that do not fullfill major advsere event criteria|Risk factors for cardiovascular adverse drug event,Assistance Publique - H�pitaux de Paris|F�d�ration Fran�aise de Cardiologie|BioSerenity,All,"18 Years and older � (Adult, Older Adult)",,50,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP191048|2020-A01502-37,"November 6, 2020","February 1, 2022",June 2022,"October 14, 2020",,"May 3, 2022","AP-HP - H�pital europ�en Georges-Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT04586894,NCT04586894,
oui,NCT04590261,Myeloid Cells in Patients With Covid-19 Pneumonia,MyeloidCovid,Not yet recruiting,No Results Available,"Covid-19,  SARS-Cov2",Other: Blood sampling|Other: Nasal Brushing,Myeloid cell sub-population phenotype|Myeloid cell functions|Myeloid cell transcriptomic and proteomic study|Transcriptomic study of nasal epithelial cells|Plasma analyte concentration measurement,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,APHP201138|2020-A02700-39,December 2022,December 2025,December 2025,"October 19, 2020",,"October 25, 2022",,,https://ClinicalTrials.gov/show/NCT04590261,NCT04590261,
oui,NCT04604847,Postoperative Painful Chronicization After Knee Replacement Surgery : Exploratory Study of BDNF's Kinetics,KNEE BDNF,Recruiting,No Results Available,Total Knee Arthroplasty|Chronic Postoperative Pain,Diagnostic Test: blood test,BDNF level|Pain level|Neuropathic pain diagnostic|Postoperative rehabilitation|Health related quality of life|Anxiety and Depression|Pain level perception|Assessment of functional capacities in knee arthritis|Oxidative stress marker,"University Hospital, Montpellier|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RECHMPL19_0192,"December 4, 2020","January 1, 2023","October 1, 2024","October 27, 2020",,"October 10, 2022","Department of Anesthesiology and critical care, Lapeyronie University Hospital, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04604847,NCT04604847,
non,NCT04617756,Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract,iNDUCT,Recruiting,No Results Available,Urothelial Carcinoma|Cancer,Drug: Patients receiving neoadjuvant therapy before radical nephrectomy,"Pathological complete response in Cohort 1|Pathological complete response in Cohort 2|Partial pathological response in Cohort 1|Partial pathological response in Cohort 2|Safety and tolerability of treatment - Cohort 1|Safety and tolerability of treatment - Cohort 2|Treatment success - Overall Survival in Cohort 1|Treatment success - bladder recurrence and dissemination in Cohort 1|Treatment success - Overall Survival in Cohort 2|Treatment success - bladder recurrence and dissemination in Cohort 2|Intercycle report : Blood cells & Platelets in Cohort 1|Intercycle report : Blood cells & Platelets in Cohort 2|Intercycle report : Electrolytes in Cohort 1|Intercycle report : Electrolytes in Cohort 2|Intercycle report : Liver in Cohort 1 - AST|Intercycle report : Liver in Cohort 1 - ALT|Intercycle report : Liver in Cohort 1 -GGT|Intercycle report : Liver in Cohort 1 - LDH|Intercycle report : Liver in Cohort 1 - ALP|Intercycle report : Liver in Cohort 1 - bilirubin|Intercycle report : Liver in Cohort 2 - AST|Intercycle report : Liver in Cohort 2 - ALT|Intercycle report : Liver in Cohort 2 - GGT|Intercycle report : Liver in Cohort 2 - LDH|Intercycle report : Liver in Cohort 2 - ALP|Intercycle report : Liver in Cohort 2 - bilirubin|Intercycle report : Creatinine Phosphokinase in Cohort 1|Intercycle report : Creatinine Phosphokinase in Cohort 2|Intercycle report : Thyroid in Cohort 1|Intercycle report : Thyroid in Cohort 2|Intercycle report : Cortisol in Cohort 1|Intercycle report : Cortisol in Cohort 2|Intercycle report : C-reactive protein in Cohort 1|Intercycle report : C-reactive protein in Cohort 2|Intercycle report : Urine in Cohort 1|Intercycle report : Urine in Cohort 2|Intercycle report: N-BNP, troponin in Cohort 1|Intercycle report: N-BNP, troponin in Cohort 2|Intercycle report: Blood cells & platelets in Cohort 1|Intercycle report: Blood cells & Platelets in Cohort 2|Intercycle report: Electrolytes in Cohort 1|Intercycle report : Liver in Cohort 1 - GGT|Intercycle report : Creatine Phosphokinase in Cohort 1|Intercycle report : Creatine Phosphokinase in Cohort 2|Intercycle report : N-BNP, troponin in Cohort 1|Intercycle report : N-BNP, troponin in Cohort 2|Intercycle report: Blood cells & Platelets in Cohort 1|Intercycle report: Electrolytes in Cohort 2|Intercycle report: Liver in Cohort 1|Intercycle report: Liver in Cohort 2|Intercycle report: Creatine Phosphokinase in Cohort 1|Intercycle report: Creatine Phosphokinase in Cohort 2|Intercycle report: Thyroid in Cohort 1|Intercycle report: Thyroid in Cohort 2|Intercycle report: Cortisol in Cohort 1|Intercycle report: Cortisol in Cohort 2|Intercycle report: C-reactive protein in Cohort 1|Intercycle report: C-reactive protein in Cohort 2|Intercycle report: Urine in Cohort 2","Centre Hospitalier Universitaire de N?mes|Piti�-Salp�tri�re Hospital|H�pital Bichat-Claude Bernard, 75018 Paris|Hopital Foch 92151 Suresnes|Institut Paoli-Calmettes|European Georges Pompidou Hospital|Saint-Louis Hospital, Paris, France|Centre Hospitalier Lyon Sud|H�pital Pontchaillou, 35033 Rennes|IUCT ONCOPOLE",All,"18 Years and older � (Adult, Older Adult)",Phase 2,99,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CIVI/2018/NH-1,"September 29, 2021","January 1, 2024","October 1, 2025","November 5, 2020",,"January 12, 2022","H�pital Bichat-Claude Bernard, Paris, Paris Cx 20, France|Institut Paoli Calmette, Marseille, France|H�pital Saint Louis, Paris, France|H�pital Piti� Salp�tri�re, Paris, France|H�pital Europ�en Georges Pompidou, Paris, France|Centre hospitalier Lyon Sud, Pierre B�nite, France|H�pital Foch, Suresnes, France|Iuct Oncopole, Toulouse Cedex 9, France",,https://ClinicalTrials.gov/show/NCT04617756,NCT04617756,
oui,NCT04619199,Influence of Socioeconomic and Environmental Factors on the Natural History of Idiopathic Pulmonary Fibrosis,EXPOSOMFPI,Recruiting,No Results Available,Idiopathic Pulmonary Fibrosis|Pulmonary Disease|Pulmonary Medicine,Diagnostic Test: Blood sample,"Determine if the household income is associated with the severity of the IPF at inclusion|Describe the general and specific external environment of patients with IPF|Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution) on the severity of the IPF|Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution) on the quality of life|Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution) on the occurrence of an Acute Exacerbation|Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution) on the progress of the IPF|Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution) on the mortality|Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution)on the existence and type of comorbidities|Determine the impact of socio-economic factors and environmental factors (occupational domestic exposures and air pollution)on the diagnostic and management delay|Determine the impact of socio-economic factors and environmental factors on therapeutic decisions: anti-fibrotic treatments, access to transplantation|Determine if the deleterious effect of air pollutants on the decline of respiratory function is dependent on the size of the telomeres","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,APHP180343|2019-A00825-52,"April 1, 2021","April 1, 2022","April 1, 2025","November 6, 2020",,"October 25, 2021","001 - Service Pneumologie, Bobigny, Avicenne, France|002 - Service Explorations Fonctionnelles Respiratoires, Bobigny, Avicenne, France|003 - Service Pneumologie, Paris, Bichat, France|016 - Service Pneumologie, Caen, CHU Caen Normandie, France|010 - Service Pneumologie, Dijon, CHU Dijon, France|013 - Service Pneumologie, Grenoble, CHU Grenoble, France|008 - Service Pneumologie, Lille, CHU Lille, France|015 - Service Pneumologie, Montpellier, CHU Montpellier, France|007 - Service Pneumologie, Rennes, CHU Pontchaillou, France|011 - Service Pneumologie, Strasbourg, CHU Strasbourg, France|012 - Service Pneumologie, Tours, CHU Tours, France|014 - Service Pneumologie, Meaux, Ghef, France|005 - Service Pneumologie, Paris, Hegp, France|006 - Service Pneumologie, Lyon, Hospices Civils De Lyon, France|004 - Service de Pneumologie, Paris, Tenon, France|009 - Service Pneumologie, Marseille, France",,https://ClinicalTrials.gov/show/NCT04619199,NCT04619199,
oui,NCT04621747,Trial Investigating the Characteristics of Knismesis - a Lever to Explore Allodynia in Neuropathic Pain,TICKLE,Recruiting,No Results Available,Healthy,Other: Battery of neurophysiological explorations,Intensity of annoying sensation|Muscular aversive response.,"University Hospital, Clermont-Ferrand|NEURO-DOL (UMR 1107 INSERM / UCA)",All,18 Years to 50 Years � (Adult),Not Applicable,24,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RBHP 2020 DUALE,"November 23, 2021","December 1, 2022","December 1, 2022","November 9, 2020",,"December 2, 2021","University Hospital, Clermont Ferrand, Clermont-Ferrand, Auvergne, France",,https://ClinicalTrials.gov/show/NCT04621747,NCT04621747,
oui,NCT04631224,Longitudinal Analysis of Oral Communication in Friedreich's Ataxia,ORFA,Completed,No Results Available,Friedreich Ataxia,,"To identify a sensitive marker of disease progression in Friedreich's Ataxia patients by assessing the speech, voice, oromotor function, and hearing.","Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2011-000389-32,February 2015,December 2016,February 2017,"November 17, 2020",,"November 19, 2020",,,https://ClinicalTrials.gov/show/NCT04631224,NCT04631224,
oui,NCT04631692,Evaluating a Health Literacy Intervention to Improve Colorectal Cancer Screening in Underserved Areas,DECODE,Recruiting,No Results Available,Colorectal Cancer Screening,Behavioral: Health literacy intervention,Colorectal cancer screening uptake,"University Paul Sabatier of Toulouse|National Cancer Institute, France|Institut National de la Sant� Et de la Recherche M�dicale, France|Centre R�gional de Coordination des D�pistages des Cancers en Occitanie CRCDC-OC|Aix Marseille Universit�|Assistance Publique Hopitaux De Marseille|Centre R�gional de Coordination des D�pistages des Cancers Sud PACA|Laboratoire HESPER-EA 7425|INSERM, UMR-S 1123 ECEVE Universit� de Paris|Centre R�gional de Coordination du d�pistage des cancers - Ile-de-France|University Paris 7 - Denis Diderot|Centre R�gional de Coordination du d�pistage des cancers - Auvergne-Rh�ne-Alpes|Institut Paoli-Calmettes",All,"50 Years to 74 Years � (Adult, Older Adult)",Not Applicable,1024,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2020-A01687-32,"October 1, 2021","August 31, 2023","April 30, 2024","November 17, 2020",,"November 2, 2022","Service de recherche et �pid�miologie cliniques, Lyon, France|Espace sant� APHM, Marseille, France|Assistance Publique Hopitaux de Paris, Paris, France|Facult� de m�decine, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04631692,NCT04631692,34530800
oui,NCT04640610,Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids,ACE2-AVG,Withdrawn,No Results Available,Adenoidectomy|Tonsillectomy,Other: Storage of operating waste,Expression of ACE 2 receptor and TMPRSS2 serine protease|Location of ACE 2 receptor and TMPRSS2 serine protease,Assistance Publique - Hôpitaux de Paris,All,"Child, Adult, Older Adult",,0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP201032,"June 30, 2021","June 30, 2021","June 30, 2021","November 23, 2020",,"July 8, 2021","Hôpital Mondor, Créteil, France|Hôpital Bicêtre, Le Kremlin-Bicêtre, France|Hôpital Lariboisière, Paris, France|Hôpital Armand Trousseau, Paris, France|Hôpital Pitié Salpêtrière, Paris, France|HEGP, Paris, France|Hôpital Necker-Enfants Malades, Paris, France|Hôpital Bichat, Paris, France|Hôpital Tenon, Paris, France",,https://ClinicalTrials.gov/show/NCT04640610,NCT04640610,
oui,NCT04642586,Detection of Subclinical Cerebral Suffering Related to Hypertension Using Multimodal MRI,SOUCHY,Recruiting,No Results Available,Hypertension,Diagnostic Test: multimodal magnetic resonance imaging|Diagnostic Test: blood test|Diagnostic Test: neuropsychological assessment,Presence of a cerebral zone with a z-score > 1.96|White matter hypersignals|Microbleeds|Gaps,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,35 Years to 50 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,RC31/19/0055,"January 7, 2021","December 5, 2023","January 5, 2024","November 24, 2020",,"March 14, 2023","CHU de Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04642586,NCT04642586,
oui,NCT04652843,"Single-center Pathophysiological Study of the Role of Inflammation, Changes in the Intestinal Epithelial Barrier and the Intestinal Microbiota in Parkinson's Disease",IBIM-Park,Recruiting,No Results Available,Parkinson's Disease,Procedure: Rectosignoidoscopy|Procedure: Coloscopy,TNF-?|IFN-?|IL-6|IL-1?|IFN-?2|MCP-1 (CCL2)|IL-8 (CXCL8)|IL-10|IL-12p70|IL-17A|IL-18|IL-23|IL-33|Permeability slopes for sulfonic acid|Diversity of the intestinal microbiota|Relative abundance of the intestinal microbiota|Quantification of phosphorylated alpha-synuclein|Duration of progression|Age|Total Unified Parkinson Disease Rating Scale motor score|Unified Parkinson Disease Rating Scale axial sub-score|Montreal Cognitive Assessment score|Presence or absence of a probable Idiopathic REM sleep behavior disorders|Olfactory tests|Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction score,Nantes University Hospital|France Parkinson Association|Luxia Scientific|INSERM - TENS - UMR 1235,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,80,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RC19_0401,"December 17, 2020",March 2023,June 2023,"December 3, 2020",,"January 11, 2022","Nantes Universitary Hospital, Nantes, Loire Atlantique, France",,https://ClinicalTrials.gov/show/NCT04652843,NCT04652843,
oui,NCT04653012,Multi-level Approach of Brain Activity Using Intracranial Electrodes in Epileptic Patients,EpiMicro,Not yet recruiting,No Results Available,"Focal Epilepsy|Electrodes, Implanted|Cognitive Function|Neurophysiology",Device: Intracranial macro-microelectrode recording,Identification of single unit changes at seizure emergence|Identification of local field potential (LFP) changes at seizure emergence|Comparison of single unit activity before seizure according to brain localization|Identification of single unit changes during physiological brain activity|Identification of LFP power changes during physiological brain activity|Multilevel study of brain activity,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C19-55|2020-A00445-34,"December 1, 2020","December 1, 2022","December 1, 2030","December 4, 2020",,"December 4, 2020",,,https://ClinicalTrials.gov/show/NCT04653012,NCT04653012,
oui,NCT04654585,"Preference-based Tools for Smoking Cessation Among Disadvantaged Smokers, a Pragmatic Randomised Controlled Trial",STOP,Recruiting,No Results Available,Smoking|Smoking Cessation,Other: The STOP intervention|Other: Standard Care,Smoking abstinence at 6 months after inclusion (yes/no)|Total number of days of abstinence at 6 months|Smoking abstinence at 1 and 3 months after inclusion (yes/no)|Number of relapses|The number of cigarettes smoked per day|Proportion of participants who have significantly reduced daily smoking,"Société de Formation Thérapeutique du Généraliste Recherche|National Cancer Institute, France|Institut National de la Santé Et de la Recherche Médicale, France|Société de Formation Thérapeutique du Généraliste",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,528,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",STOP-001,"February 26, 2021","February 1, 2023","February 1, 2024","December 4, 2020",,"May 12, 2021","Centre municipal et universitaire de santé Marcel Trigon, Arcueil, France|Centre d'addictologie et d'alcoologie Guillaume Broutet, Avignon, France|Laura Piras (medical practice), Castelnau-d'Estrétefonds, France|Hôpital Antoine Beclere, Clamart, France|Hôpital Henri Mondor, Créteil, France|Centre Municipal de Santé Savattero, Montreuil, France|Mathilde Roze (medical practice), Paris, France|Ghislaine Hacke Mela (medical practice), Paris, France|Centre Hospitalier Sainte Anne, Paris, France|Hôpital européen Georges-Pompidou, Paris, France|Hôpital Tenon, Paris, France|Anne Kerharo-Nicolas (medical practice), Saint-Rogatien, France|Carole Plaussu (medical practice), Suresnes, France|Kinouani Shérazade (medical practice), Targon, France|Centre de Santé Pierre-Rouquès, Villejuif, France",,https://ClinicalTrials.gov/show/NCT04654585,NCT04654585,34193499
oui,NCT04657783,French National Cohort of People With Type 1 Diabetes,SFDT1,Recruiting,No Results Available,"Diabetes Mellitus, Type 1|Cardiovascular Diseases|Hypoglycemia|Patient Participation",,Major adverse cardiovascular events (MACE)|Non-fatal myocardial infarction (MI)|CV-related death|diabetic retinopathy without macumar edema|diabetic retinopathy with macular edema|diabetic nephropathy|All cause mortality,"Fondation Francophone pour la Recherche sur le Diabete|Société Francophone du Diabète|Sanoia|Institut National de la Santé Et de la Recherche Médicale, France|Eli Lilly and Company|Abbott Diabetes Care|Air Liquide Santé International|Novo Nordisk A/S|Sanofi|Insulet Corporation|DexCom, Inc.|Luxembourg Institute of Health|Creapharm|Medtronic|Ypsomed AG|LifeScan",All,"6 Years to 100 Years   (Child, Adult, Older Adult)",,15000,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,SFDT1,"June 10, 2020","June 10, 2025","June 10, 2035","December 8, 2020",,"February 15, 2023","FFRD, Paris, France",,https://ClinicalTrials.gov/show/NCT04657783,NCT04657783,
oui,NCT04658914,Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa,,"Active, not recruiting",No Results Available,Diarrhea|Diarrhea Rotavirus,Biological: Rotarix|Biological: Trivalent P2-VP8,Vaccine Shedding|Seroconversion following vaccination|Immune boosting,"Centre for Infectious Disease Research in Zambia|Medical Research Council|PATH|University of Liverpool|Institut National de la Santé Et de la Recherche Médicale, France|Imperial College London",All,6 Weeks to 10 Weeks   (Child),Phase 2,720,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MRC Rotavirus HIC,"April 15, 2021",September 2022,October 2023,"December 9, 2020",,"July 20, 2022","Chawama first level hospital, Lusaka, Zambia",,https://ClinicalTrials.gov/show/NCT04658914,NCT04658914,
oui,NCT04661774,Specific Effect of Foot Reflexology on Diaphragm Function,FOOT,Unknown status,No Results Available,Musculoskeletal Manipulations,Other: reflexology massage|Other: sham massage,modulation of brain activity of the specific impact of RP|variation of physiological constants related to the function of the diaphragm|variation in physiological constants linked to the ANS|subjective feelings of the subjects,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,20 Years to 40 Years   (Adult),Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other,RC31/20/0251,"December 1, 2020","June 1, 2022","June 1, 2022","December 10, 2020",,"December 10, 2020",,,https://ClinicalTrials.gov/show/NCT04661774,NCT04661774,
oui,NCT04684758,HIV Acquisition and Life Course of Born-abroad Men Who Have Sex With Men Living in Ile-de-France: the GANYMEDE Study,GANYMEDE,Completed,No Results Available,Men Who Have Sex With Men|People Living With HIV,Other: Self-completion of a questionnaire,Post-migration proportion of HIV acquisition in born-abroad HIV-positive MSM living in Ile-de-France|Timing of HIV infection for people infected in France,"ANRS, Emerging Infectious Diseases|Institut National de la Sant� Et de la Recherche M�dicale, France",Male,"18 Years to 99 Years � (Adult, Older Adult)",,1048,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,ANRS 14058,"April 14, 2021","June 30, 2022","June 30, 2022","December 28, 2020",,"July 22, 2022","H�pital Piti�-Salp�tri�re, AP-HP, Institut Pierre Louis d'�pid�miologie et de Sant� Publique (iPLESP), INSERM 1136, Paris, France",,https://ClinicalTrials.gov/show/NCT04684758,NCT04684758,
oui,NCT04686162,Bae: A Smartphone Application for a Better Following Adolescents at Risk of Suicidal Behavior: Study of Acceptability and Preliminary Results of Efficacy,BAE,Unknown status,No Results Available,Suicide Attempt|Suicidal Ideation,Other: bae application,Acceptability|Prevention modules use|Call module use|Satisfation|Satisfaction|Occurrence of a suicidal event,"University Hospital, Montpellier|University Hospital, Lille|University Hospital, N�mes|La Timone Hospital, Marseille|Association ""Mal �tre des adolescents"", Marseille|Salvator Hospital, Marseille|Unit Inserm U1061, Montpellier|Laboratoire d'Informatique, de Robotique et de Micro�lectronique de Montpellier",All,12 Years to 17 Years � (Child),Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,RECHMPL20-0153|2020-A03150-39,"September 20, 2021","July 11, 2022","July 11, 2022","December 28, 2020",,"August 11, 2021",,,https://ClinicalTrials.gov/show/NCT04686162,NCT04686162,
oui,NCT04687904,Mindfulness Meditation for Epilepsy,MIME,Recruiting,No Results Available,Epilepsy,Behavioral: Mindfulness meditation training|Behavioral: Therapeutic education,Short Form Quality of Life Questionnaire (SF36) score at 3 months|Short Form Quality of Life Questionnaire (SF36) score at 1 months|Depressive symptoms assessed on the Montgomery-�sberg Depression Rating Scale (MADRS) at 1 month|Depressive symptoms assessed on the Evolution of MADRS score at 3 months|Depressive symptoms assessed on the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) at 1 month|Depressive symptoms assessed on the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) at 3 months|Anxiety symptoms assessed on the State-Trait Anxiety Inventory scale (STAI) at 1 month.|Anxiety symptoms assessed on the State-Trait Anxiety Inventory scale (STAI) at 3 months.|Anxiety symptoms assessed on the General Anxiety Disorder 7 scale (GAD-7) at 1 month.|Seizure frequency at 1 month|Seizure frequency at 3 month,"Rennes University Hospital|Laboratoire Traitement du Signal et de l'Image, INSERM UMR1099 Rennes|Centre Hospitalier Guillaume R�gnier, RENNES",All,"16 Years and older � (Child, Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,35RC20_8848|2020-A02336-33,"January 14, 2021","March 15, 2023","March 15, 2023","December 29, 2020",,"December 14, 2022","Centre Hospitalier Universitaire, Rennes, France",,https://ClinicalTrials.gov/show/NCT04687904,NCT04687904,
oui,NCT04690972,"""Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases"".",LivMOD,Not yet recruiting,No Results Available,Chronic Liver Disease and Cirrhosis|Liver Cancer|Non-Alcoholic Fatty Liver Disease|Non-Alcoholic Steatohepatitis|Viral Hepatitis B|Viral Hepatitis C|Viral Hepatitis D,Procedure: Blood sample during surgery|Procedure: Taking an additional biopsy|Diagnostic Test: Blood sample during diagnostic test,Surgery for a hepato-bilio-pancreatic issue,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,800,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C19-76,"December 20, 2020","December 20, 2020","December 4, 2028","December 31, 2020",,"December 31, 2020",,,https://ClinicalTrials.gov/show/NCT04690972,NCT04690972,
oui,NCT04697407,IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis,BREGS,Recruiting,No Results Available,Multiple Sclerosis,Biological: Blood sampling|Biological: CSF sampling,"Frequency of Bregs in blood of MS patients|Frequency of Bregs in the CSF of MS patients|Comparison of IL-2, soluble IL2RA, IL-10, IL-21 and IL-5 protein concentrations|Comparison of the concentrations in Igs",Rennes University Hospital,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,95,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,35RC20_9867_BREGS,"March 23, 2021",March 2023,October 2023,"January 6, 2021",,"April 27, 2022","CHU Rennes, Rennes, France",,https://ClinicalTrials.gov/show/NCT04697407,NCT04697407,
oui,NCT04697589,Acute Effect of a Proprietary Botanical Blend Rich in Polyphenols on Flow-mediated Dilation in Healthy Subjects,,Recruiting,No Results Available,Healthy,Dietary Supplement: Memophenol 300 mg|Dietary Supplement: Memophenol 600 mg|Dietary Supplement: Placebo,Change in endothelium-dependent flow-mediated dilation (ED-FMD)|Change in endothelium-independent vasodilation (EIVD)|Change in diastolic blood pressure|Change in systolic blood pressure,"Activ'inside|CIC Inserm 1405, University Hospital Clermont-Ferrand, France",Male,20 Years to 45 Years � (Adult),Not Applicable,20,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",FMD1-AI-2020,"February 1, 2021","November 30, 2022","November 30, 2022","January 6, 2021",,"June 14, 2022","CIC Inserm 1405, University Hospital Clermont-Ferrand,, Clermont-Ferrand cedex 1, France",,https://ClinicalTrials.gov/show/NCT04697589,NCT04697589,
oui,NCT04698070,Optimizing Acute Malnutrition Management in Children Aged 6 to 59 Months in Niger (OptIMA Niger),,Completed,No Results Available,Acute Malnutrition in Infancy (Disorder),Dietary Supplement: Nutritional Strategy - OptiMA|Dietary Supplement: Nutritional Strategy - ComPAS|Other: National nutritional Strategy (Niger),Success rate|Recovery rate in children with SAM WHO definition|Recovery rate in children with MUAC<115mm,"Alliance for International Medical Action|Harvard School of Public Health (HSPH)|University of Bordeaux, INSERM, Bordeaux Population Health",All,6 Months to 59 Months � (Child),Not Applicable,2304,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,35237,"March 22, 2021","March 22, 2022","June 24, 2022","January 6, 2021",,"September 23, 2022","Diney, Mirriah, Zinder, Niger|Droum, Mirriah, Zinder, Niger|Gada, Mirriah, Zinder, Niger|Gaffati, Mirriah, Zinder, Niger",,https://ClinicalTrials.gov/show/NCT04698070,NCT04698070,35090531
oui,NCT04700852,Efficacy of Puressentiel Protective Nasal Spray in Allergic Rhinitis,EPPNS,Unknown status,No Results Available,Allergic Rhinitis Due to Grass Pollen|Allergic Inflammation,Device: Puressentiel protective nasal spray,Change in concentration of IL-13 in the nasal lavage will be assessed|Change in concentration of IL-5 in the nasal lavage will be assessed|Change in concentration of IL-4 in the nasal lavage will be assessed|Change in Nasal Inspiratory Peak Flow will be assessed|Change in Allergic Rhinitis Control test (ARCT) will be assessed,"Puressentiel|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,15,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2020-A01877-32,"February 1, 2021","July 31, 2021","September 30, 2021","January 8, 2021",,"January 8, 2021",,,https://ClinicalTrials.gov/show/NCT04700852,NCT04700852,
oui,NCT04702633,Immuno-molecular Approaches for Non-invasive Diagnosis of Prostate Cancer,PROSTA-PAP,Recruiting,No Results Available,Prostate Cancer,Other: Results obtained by biopsy and MRI results.|Other: Clinical data,Presence and number of prostate tumour cells in biological samples,"Assistance Publique - H�pitaux de Paris|Rarecells Diagnostics|Institut National de la Sant� Et de la Recherche M�dicale, France",Male,"Child, Adult, Older Adult",,200,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,APHP201309,"March 19, 2021","March 19, 2024","March 19, 2024","January 11, 2021",,"October 25, 2022","Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT04702633,NCT04702633,
oui,NCT04702932,"Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies",GEN-HEMO-INF,Not yet recruiting,No Results Available,Monoclonal Gammopathy of Undetermined Significance|Multiple Myeloma|Waldenstrom Macroglobulinemia,,"Whole exome sequencing of tumoral cells|Cytokine profile measurement, with ELISA or quantitative PCR.",Assistance Publique - H�pitaux de Paris|INSERM UMR 1163,All,"18 Years and older � (Adult, Older Adult)",,30,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP200964,"September 1, 2021","September 1, 2026","September 1, 2036","January 11, 2021",,"January 11, 2021","Service de M�decine Interne, Paris, France",,https://ClinicalTrials.gov/show/NCT04702932,NCT04702932,
oui,NCT04710316,"Study of COVID-19 Outbreak in Hospital Departments of Bamako, Mali",BAMACOV,Unknown status,No Results Available,Covid19,Diagnostic Test: SARS-CoV-2 screening by molecular biology|Diagnostic Test: Serological screening,Incidence rate of positive SARS-Cov-2 RT-PCR in Bamako hospital departments during the study|Number of Cepheid Xpert® Xpress SARS-Cov-2 cartridges available for 19.8 USD/number required for the project|Percentage of positive serological tests among the caregivers of the hospital departments of Bamako.|Percentage of caregivers asymptomatic but immunized to SARS-CoV-2|Percentage of caregivers immunized and re-infected with SARS-CoV-2|Number of SARS-CoV-2 mutations/variants detected during the study|Percentage of SARS-CoV-2 mutations/variants detected during the study,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,450,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,C20-41,"February 15, 2021","April 30, 2022","September 30, 2022","January 14, 2021",,"September 27, 2021","Hopital du Point-G, Bamako, Mali|Hopital Gabriel Toure, Bamako, Mali|Hôpital dermatologique de Bamako, Bamako, Mali|Hôpital du Mali, Bamako, Mali",,https://ClinicalTrials.gov/show/NCT04710316,NCT04710316,
oui,NCT04723979,"NovoSeven� in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL",,Completed,No Results Available,Post Partum Hemorrhage,Drug: Eptacog alfa|Other: Standard of care,"Occurrence of invasive procedures (yes/no)|Occurrence of thromboembolic events, yes/no|Amount of blood products transfused|Estimated blood loss|Occurrence of hysterectomy, yes/no",Leiden University Medical Center|Novo Nordisk A/S|Herlev Hospital|University of Oxford|VU University of Amsterdam,Female,"18 Years and older � (Adult, Older Adult)",,3322,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,ClinEpi_SC_41493|TRIAL NL3909 (NTR4079),"May 1, 2020","January 1, 2021","January 31, 2021","January 26, 2021",,"May 11, 2022","Leiden University Medical Center, Leiden, Netherlands",,https://ClinicalTrials.gov/show/NCT04723979,NCT04723979,
oui,NCT04727489,Study of the Genetic Factors Involved in Autism and Related Disorders,Gene&autism,Recruiting,No Results Available,Autism Spectrum Disorder,Genetic: DNA from subjects will be stored in the biobank of our study.,Prevalence of synaptic gene deleterious mutations in patients with Autism Spectrum Disorder|Prevalence of the deleterious mutations in the major biological pathways in Autism Spectrum Disorder,"Institut National de la Santé Et de la Recherche Médicale, France",All,"24 Months to 70 Years   (Child, Adult, Older Adult)",,3800,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C16-89,"March 30, 2021","December 21, 2022","December 31, 2037","January 27, 2021",,"May 5, 2021","Albert Chenevier Hospital, Creteil, Ile De France, France|Robert Debré Hospital, Paris, Ile De France, France|CIC, CHU Bordeaux, Bordeaux, France|CRA, Hopital Charles Perrens, Bordeaux, Bordeaux, France|CIC, H. Mondor, Creteil, Créteil, France|Centre de rehabilitation psychosociale, Hopital Saint Egreve, Grenoble, France",,https://ClinicalTrials.gov/show/NCT04727489,NCT04727489,
oui,NCT04736381,Impact of the Microbiota on the Likelihood of Renal Graft Rejection,MERRLIN,Not yet recruiting,No Results Available,Kidney Transplant Rejection,Drug: Belatacept Injection [Nulojix],Acute rejection occurence|Gut and circulating microbiota|Lymphocyte phenotype|Glomerular filtration rate,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",,70,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C 19-53,"April 14, 2021","September 29, 2023","September 27, 2024","February 3, 2021",,"February 3, 2021",,,https://ClinicalTrials.gov/show/NCT04736381,NCT04736381,
associ�,NCT04743180,European All-comers' Multicentric Prospective REGISTRY on LUMINOR� Drug Eluting Balloon in the Superficial Femoral Artery and Popliteal Artery With 5 Years Follow-up.,LUMIFOLLOW,Recruiting,No Results Available,Angioplasty|Peripheral Arterial Disease|Drug-eluting Balloon|Femoral Artery|Paclitaxel,Device: LUMINOR� Paclitaxel eluting balloon,"Primary Endpoint Efficacy measured by presence of primary patency of the target lesion based on ultrasound images|Overall Medical Safety|Secondary Endpoint Medical Safety: Major vascular complications|Secondary Endpoint Medical Safety: Composite Safety|Secondary Endpoint Medical Safety: All-cause death|Secondary Endpoint Medical Safety: Major amputation at target limb|Secondary Endpoint Medical Safety: Minor amputation at target limb|Secondary Endpoint Medical Safety: Target Vessel Revascularization (TVR)|Secondary Endpoint Medical Safety: Target Limb Reintervention|Secondary Endpoint Efficacy: Acute Device Success|Secondary Endpoint Efficacy: Technical Success|Secondary Endpoint Efficacy: Procedural Success|Secondary Endpoint Efficacy: Primary Patency|Secondary Endpoint Efficacy: Secondary Patency|Secondary Endpoint Efficacy: Clinically-driven Target Lesion Revascularization (TLR)|Secondary Endpoint Efficacy: Target Lesion Revascularization (TLR)|Secondary Endpoint Efficacy: Change of Rutherford classification from baseline|Secondary Endpoint Efficacy: Change of resting Ankle Brachial Index (ABI) from baseline|Secondary Endpoint Efficacy: Change in Walking Impairment Questionnaire from baseline|Secondary Endpoint Efficacy: Change in quality of life from baseline, as measured by EQ-5D|Secondary Endpoint Cost-Effectiveness (optional): factoring procedure and hospital admission costs",iVascular S.L.U.,All,"18 Years and older � (Adult, Older Adult)",,500,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,LUMIFOLLOW Registry,"January 18, 2021",June 2022,"June 30, 2026","February 8, 2021",,"February 11, 2021","Centre Hospitalier Universitaire Pellegrin, Bordeaux, Nouvelle-Aquitaine, France|Clinique G�n�rale Annecy, Annecy, France|Clinique Rh�ne Durance, Avignon, France|Centre hospitalier de la C�te Basque, Bayonne, France|Polyclinic Bordeaux Nord Aquitaine, Bordeaux, France|H�pital Ambroise Par�, Boulogne-Billancourt, France|Centre Hospitalier R�gional Universitaire Morvan de Brest, Brest, France|CHRU Lille, Lille, France|Clinic Mutualiste Porte de L'Orient, Lorient, France|CHU Timone Marseille, Marseille, France|CH Layn�, Mont-de-Marsan, France|H�pital Priv� des Franciscaines, N�mes, France|Fondation H�pital St Joseph, Paris, France|Clinique Saint Jean, Saint-Jean-de-V�das, France|Clinique Rh�na, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT04743180,NCT04743180,
oui,NCT04746729,Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy,HARMONIC-RT,Recruiting,No Results Available,Neoplasms,Other: No intervention,"Endocrinopathies|Cardiovascular diseases|Neurovascular diseases|Second and subsequent primary neaoplasms|Health-related quality of life (physical, emotional, social, and school functioning) assessed by the PedsQL™ core scale (validated questionnaire)|Academic achievement|Dysfunctions in endocrine hormone levels|Changes in blood markers of cardiovascular diseases|Changes in imaging markers of cardiovascular diseases|Changes in imaging markers of neurovascular damages|Changes in blood/saliva markers of protein activation relating to vascular damages|Changes in blood/saliva markers of oxidative stress response|Changes in blood/saliva markers of inflammatory response|Changes in blood/saliva markers of carcinogenesis|Multidimensional fatigue (general, sleep/rest, and cognitive fatigue)|Clinical events other than those mentioned as primary outcomes|All-cause and cause-specific mortality","Institut National de la Santé Et de la Recherche Médicale, France|Barcelona Institute for Global Health|The West German Proton Therapy Centre, Essen|Gustave Roussy, Cancer Campus, Grand Paris|Centre Francois Baclesse|KU Leuven|University of Aarhus|Princess Maxima Center for Pediatric Oncology|University Medical Center Groningen|Stockholm University|National Research Council, Institute of Clinical Physiology, Italy|University of Zurich|Commissariat A L'energie Atomique|Luxembourg Institute of Science and Technology|University Hospital, Essen|Aarhus University Hospital",All,"up to 22 Years   (Child, Adult)",,2670,Other,Observational,Observational Model: Cohort|Time Perspective: Other,C20-01|2020-A01037-32/1,"March 1, 2022","September 30, 2040","September 30, 2040","February 10, 2021",,"March 16, 2021","KU Leuven, Leuven, Belgium|Aarhus University hospital, Aarhus, Denmark|Centre Régional François Baclesse, Caen, France|Gustave Roussy, Villejuif, France|University Hospital Essen, The West German Proton Therapy Centre Essen, Essen, Germany",,https://ClinicalTrials.gov/show/NCT04746729,NCT04746729,
oui,NCT04748471,Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y),CoviCompareM,Unknown status,No Results Available,Prevention of COVID19,Biological: mRNA-1273,"Titers of anti-SARS-CoV-2 Spike IgG Immunoglobulin in sera|Anti SARS-CoV -2 IgG, IgA and IgM (total and subclasses IgG1-4) as measured by ELISA.|Anti-SARS-CoV-2 neutralizing antibody (in vitro neutralisation assay.|Anti-SARS-CoV-2 -specific neutralizing antibody (Pseudo neutralisation assay using lentiviral phenotypes carrying specific SARS-Cov-2 proteins.|Fluorospot assays (TH1, TH2, TH17, Cytotoxicity). Phenotyping of antigen specific T-Cells via Mass cytometry, B cell repertoire and memory|Mucosal SARS-CoV-2 -specific antibody via measure of sIgA, sIgM and IgG in saliva by specific home-made and commercially available ELISA assays.|Functionality of mucosal sIgA and sIgM by Antibody Dependent Cellular Cytotoxicity (ADCC) assay specific for SARS-CoV-2 mucosal IgA and IgM|Local and systemic reactogenicity|Determination of autoimmunity markers such as antibodies Anti-nuclear (unit measure: titers)|Determination of autoimmunity markers such as antibodies Anti-ACL, Anti-β2-GP1, Rheumatoid factor (unit measure: U/L)|Determination of autoimmunity markers such as antibodies Anti-GM1, Anti-MAG ( unit measure: pos/ne)","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 2,180,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,APHP201504|2020-005889-34,"February 10, 2021","July 1, 2021","January 25, 2023","February 10, 2021",,"February 10, 2021",,,https://ClinicalTrials.gov/show/NCT04748471,NCT04748471,
oui,NCT04751851,Telepsychology for Benzodiazepines Withdrawal in Adults Suffering From Hypnotic-dependent Insomnia,,"Active, not recruiting",No Results Available,Chronic Insomnia|Hypnotic Dependence,Behavioral: Medium duration withdrawal programme with ACT|Behavioral: Long duration withdrawal programme with ACT|Behavioral: Medium duration withdrawal programme without ACT|Behavioral: Long duration withdrawal programme without ACT,Proportion of participants having successfully stopped their benzodiazepine use|Benzodiazepines use 1|Benzodiazepines use 2|Benzodiazepines dependence|Compliance|Assessment of withdrawal symptoms|Sleep Improvement|Psychopathological symptoms improvement|Quality of life improvement|Self-confidence in benzodiazepines reduction|Awareness improvement|Psychological flexibility improvement|Global ACT processes improvement,Association Nationale de Promotion des Connaissances sur le Sommeil,All,"18 Years to 70 Years � (Adult, Older Adult)",Not Applicable,128,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BENZOSTOP,"June 3, 2021","August 22, 2022",June 2025,"February 12, 2021",,"October 14, 2022","PROSOM, Lausanne, Switzerland",,https://ClinicalTrials.gov/show/NCT04751851,NCT04751851,
oui,NCT04760548,Segmentation of Structural Abnormalities in Chronic Lung Diseases,,"Active, not recruiting",No Results Available,Cystic Fibrosis|Asthma|COPD|Interstitial Lung Disease,Other: Observational study,Validity of automated measurement|Correlation with pulmonary function test|Longitudinal variation over time|Reproducibility,"Hôpital Haut Lévêque|Centre National de la Recherche Scientifique, France|Institut National de la Santé Et de la Recherche Médicale, France|University of Cincinnati|Hôpital Haut-Lévêque",All,"3 Years to 70 Years   (Child, Adult, Older Adult)",,800,Other,Observational,Observational Model: Other|Time Perspective: Other,SA-AI,"January 1, 2008","February 17, 2024","February 17, 2024","February 18, 2021",,"March 15, 2022","Hopital Haut Leveque, Pessac, France",,https://ClinicalTrials.gov/show/NCT04760548,NCT04760548,34266943
oui,NCT04765631,Type 2 Diabetes and Bone Microarchitecture,,Completed,No Results Available,Type 2 Diabetes,Other: Patients with Type 2 diabetes|Other: Placebo,"The main outcome is the comparison of total volumetric bone mineral density (vBMD) at the tibia and distal radius, in type 2 diabetics compared to non-diabetic subjects.",Hospices Civils de Lyon,All,"Child, Adult, Older Adult",,582,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,Type 2 diabetes bone,"January 1, 2020","July 1, 2020","July 1, 2020","February 21, 2021",,"February 21, 2021","INSERM U1033, pavillon F, H�pital E. Herriot. 5, place d'Arsonval, Lyon, France",,https://ClinicalTrials.gov/show/NCT04765631,NCT04765631,
non,NCT04768621,Health Consequences of Wintering in the French Southern and Antarctic Territories,MediTAAF,Unknown status,No Results Available,Environmental Exposure|Winter Depression|Endocrine System Diseases|Sleep Disorder|Immunologic Activity Alteration,Other: Questionary,Evaluate incidence health disorders and sociological consequences of wintering of health of winterers (exposed) of TAAF from 2012 to 2017 with that of country people (not exposed) of the same period,Centre Hospitalier Universitaire de la R�union,All,"18 Years to 99 Years � (Adult, Older Adult)",Not Applicable,480,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,2020/CHU/38,February 2021,December 2021,December 2021,"February 24, 2021",,"February 24, 2021",,,https://ClinicalTrials.gov/show/NCT04768621,NCT04768621,
oui,NCT04776005,COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies,COVIDVAC OH,Recruiting,No Results Available,"Solid Tumor|Hematologic Malignancy|Thoracic Cancer|Cancer, Treatment-Related|Vaccine Response Impaired",Other: Data collection,SARS-CoV-2 vaccine response at 12 months|Seroprevalence of antibodies against Sarc-CoV-2 S-protein before vaccination|Seroprevalence of antibodies against Sarc-CoV-2 N-protein before vaccination|SARS-CoV-2 vaccine response after first dose of vaccine|SARS-CoV-2 vaccine response at 3 months|SARS-CoV-2 vaccine response at 6 months|SARS-CoV-2 vaccine safety in the study population,Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP210640,"January 22, 2021",July 2022,January 2023,"March 1, 2021",,"November 29, 2021","Saint-Louis Hospital, AP-HP, Paris, France|Bichat Hospital, AP-HP, Paris, France",,https://ClinicalTrials.gov/show/NCT04776005,NCT04776005,
oui,NCT04777331,A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease,PADOVA,Recruiting,No Results Available,Parkinsons Disease,Drug: Prasinezumab|Drug: Placebo,"Time to Confirmed Motor Progression Event|OLE: Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)|OLE: Number of Participants with Adverse Events of Special Interest (AESI)|OLE: Number of Participants with Infusion Related Reactions (IRRs)|OLE: Change from Baseline in Suicidal Ideation, as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)|Time-to-worsening of Participants Motor Function as Reported by the Participant in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II and Confirmed by the Clinician in MDS-UPDRS Part III|Time to Meaningful Worsening in Patient Global Impression of Change (PGI-C, Overall Disease Subscale)|Time to Meanaingful Worsening in Clinician Global Impression of Change (CGI-C, Overall Disease Subscale)|Time to Onset of Motor Complications as Assessed Through MDS-UPDRS Part IV|Change in Motor Function from Baseline to Week 76, as Measured by the MDS-UPDRS Part III Total Score|Change in Bradykinesia from Baseline to Week 76, as Measured by the MDS-UPDRS Part III Bradykinesia Subscore|Change in Motor Aspects of Experiences of Daily Living from Baseline to Week 76, as Measured by MDS-UPDRS Part II|Percentage of Participants With AEs and SAEs|Number of Participants with AESI|Number of Participants with IRRs|Change from Baseline in Suicidal Ideation, as Measured by the C-SSRS|Serum Concentration of Prasinezumab|Percentage of Participants with Anti-drug Antibodies (ADAs) Against Prasinezumab at Baseline|Percentage of Participants with ADAs Against Prasinezumab During the Study",Hoffmann-La Roche|Prothena Biosciences Limited,All,"50 Years to 85 Years � (Adult, Older Adult)",Phase 2,575,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BN42358|2020-004997-23,"May 5, 2021","July 10, 2024","December 18, 2026","March 2, 2021",,"February 21, 2023","University of Alabama at Birmingham, Birmingham, Alabama, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Banner Sun Health Research Insitute, Sun City, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|Collaborative Neuroscience Network, Inc., Garden Grove, California, United States|UC San Diego; ACTRI, La Jolla, California, United States|Keck School of Medicine of USC, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|CenExel Rocky Mountain Clinical Research, LLC, Englewood, Colorado, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|JEM Research LLC, Atlantis, Florida, United States|Aventura Neurologic Associates; Department of Research, Aventura, Florida, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|University of Florida Center For Movement Disorders And Neurorestoration, Gainesville, Florida, United States|ClinCloud, LLC, Maitland, Florida, United States|Neurology Associates, PA; Research Department, Maitland, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Synexus Clinical Research, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Conquest Research, LLC, Winter Park, Florida, United States|Charter Research - Winter Park/Orlando, Winter Park, Florida, United States|Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Indiana University Health University Hospital, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Henry Ford Hospital; Henry Ford Medical Center, West Bloomfield, Michigan, United States|Meridian Clinical Research, Llc, Omaha, Nebraska, United States|Wr-Crcn, Llc, Las Vegas, Nevada, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Neroscience research institute, Toms River, New Jersey, United States|Dent Neurological Institute, Amherst, New York, United States|Neuroscience Institute at Great Neck, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Movement Disorder Clinic of Oklahoma, Tulsa, Oklahoma, United States|University Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Abington Neurological Associates Willow Grove, Willow Grove, Pennsylvania, United States|Texas Neurology PA, Dallas, Texas, United States|Baylor College of Medicine Medical Center, Houston, Texas, United States|Central Texas Neurology Consultants, Round Rock, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Sentara Neurology Specialists, Norfolk, Virginia, United States|Evergreen Health Care Center, Kirkland, Washington, United States|Inland Northwest Research, Spokane, Washington, United States|Medizinische Universit�t Graz; Universit�tsklinik f�r Neurologie, Graz, Austria|Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie, Innsbruck, Austria|Klinik Ottakring; Neurologische Abteilung, Wien, Austria|Toronto Memory Program, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Clinique Neuro Outaouais, Gatineau, Quebec, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Groupe Hospitalier Pellegrin, Bordeaux, France|Groupement Hospitalier Est - H�pital Neurologique; Neurologie A (U502), Bron cedex, France|Hopital Gabriel Montpied, Clermont-ferrand, France|H�pital Henri Mondor; Centre Expert Parkinson, Creteil, France|H�pital Michallon - Centre d'Investigation Clinique; Unit� de Pharmacologie Clinique - Inserm, Grenoble, France|CHU de Limoges - H�pital Dupuytren, Limoges, France|hopital de la Timone, Marseille, France|CHU Gui de Chauliac, Montpellier, France|CHU de Nice Hopital Pasteur, Nice, France|Hopital Pitie-Salpetriere APHP, Paris, France|CHU Poitiers, Poitiers, France|CHU Rouen Charles Nicolle; Centre Expert Parkinson H�pitaux de Rouen, Rouen cedex, France|CHU de Nantes - Hopital Laennec, St Herblain, France|CHU Strasbourg H�pital Hautepierre, Strasbourg, France|CIC - H�pital Purpan, Toulouse, France|Universit� degli studi della Campania Luigi Vanvitelli; Dip.Ass Int Med Int-I Clinica Neurologica, Napoli, Campania, Italy|Az. Osp. OO.RR. S. Giovanni di Dio e Ruggi D' Aragona; Center for Neurodegenerative Disease, Salerno, Campania, Italy|Ospedale Bellaria; Istituto delle Scienze Neurologiche, Bologna, Emilia-Romagna, Italy|IRCCS San Raffaele Pisana; Clinical Trial Center, Roma, Lazio, Italy|Policlinico Universitario Agostino Gemelli; UOC Neurologia, Roma, Lazio, Italy|Irccs A.O.U.San Martino Ist; Dinogmi, Genova, Liguria, Italy|Azienda Ospedaliera Spedali Civili; Scienze Neurologiche, Brescia, Lombardia, Italy|IRCCS Ospedale San Raffaele; U.O. di Neurologia, Milano, Lombardia, Italy|IRCCS Istituto Neurologico Carlo Besta; UOC Neurologia 1, Milano, Lombardia, Italy|IRCCS Neuromed; Neurologia I, Pozzilli (IS), Molise, Italy|A.O.U. Policlinico ""G.Rodolico - San Marco""; Clinica Neurologica, Catania, Sicilia, Italy|A.O. Universitaria Pisana; Neurologia, Pisa, Toscana, Italy|AO di Perugia - Ospedale S. Maria della Misericordia; Clinica Neurologica, Perugia, Umbria, Italy|Azienda Ospedaliera S. Maria; SC Neurologia, Terni, Umbria, Italy|Azienda Ospedaliera di Padova; Dipartimento di Neuroscienze, Padova, Veneto, Italy|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|NeuroKlinika Gabinet Lekarski Prof. Andrzej Bogucki, ?�d?, Poland|NZOZ Vitamed, Bydgoszcz, Poland|Szpital Sw. Wojciecha; Oddzial Neurologiczny, Gda?sk, Poland|Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii K, Krakow, Poland|Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak., Lublin, Poland|Nzoz Palomed, Rzesz�w, Poland|Samodzielny Publiczny Szpital Kliniczny im. prof. Orlowskiego; Klinika Neurologii i Epileptologii, Warszawa, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Mazowiecki Szpital Br�dnowski w Warszawie Sp. z o.o.; Klinika Neurologii, Warszawa, Poland|Hospital General Universitario de Elche; Servicio de Neurolog�a, Elche, Alicante, Spain|Hospital General De Catalunya; Servicio de Neurologia, Sant Cugat del Valles, Barcelona, Spain|Policl�nica Guipuzkoa; Servicio de Neurolog�a, Donosti-San Sebasti�n, Guipuzcoa, Spain|Complejo Hospitalario Universitario A Coru�a (CHUAC); Servicio de Neurologia, Coru�a, LA Coru�a, Spain|Hospital San Pedro; Servicio de Neurolog�a, Logro�o, LA Rioja, Spain|Hospital San Roque, Mas Palomas, LAS Palmas, Spain|Hospital Universitario Fundaci�n Alcorc�n; Servicio de Neurolog�a, Alcorcon, Madrid, Spain|HM Universitario Puerta del Sur CINAC (C.Integ.Neuroc);; Servicio de Psiquiatr�a, M�stoles, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Neurologia, Pozuelo de Alarcon, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Virgen del Puerto, Plasencia, Palencia, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital Vall d'Hebron; Servicio de Neurolog�a, Barcelona, Spain|Hospital Clinic Servicio de Neurologia, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain|Hospital Universitario de Burgos. Servicio de Neurolog�a, Burgos, Spain|Hospital General Universitario de Ciudad Real; Servicio de Neurologia, Ciudad Real, Spain|Hospital Ruber Juan Bravo, Madrid, Spain|Hospital Universitario de la Princesa; Servicio de Neurologia, Madrid, Spain|Hospital General Universitario Gregorio Mara�on; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Cl�nico San Carlos; Servicio de Neurolog�a, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Neurologia, Malaga, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, Spain|Hospital Virgen del Roc�o; Servicio de Neurolog�a, Sevilla, Spain|Hospital Universitario Dr. Peset; Servicio de Neurologia, Valencia, Spain|Hospital Universitari i Politecnic La Fe; Servicio de Neurolog�a, Valencia, Spain|Servicio de Neurolog�a Hospital Viamed Montecanal., Zaragoza, Spain|Ninewells Hospital, Dundee- Scotland; Neurology, Dundee, United Kingdom|Kings College Hospital, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Campus for Ageing and Vitality, Newcastle, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom|North West Anglia NHS Foundation Trust, Peterborough, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom",,https://ClinicalTrials.gov/show/NCT04777331,NCT04777331,
oui,NCT04778631,Impact of Thermotherapy During Childbirth on Postpartum Perineal Pain (PERISAFE),PERISAFE,Recruiting,No Results Available,Pelvic Pain,Device: Heat therapy|Device: Cryotherapy,Change of perineal pain assessed by the VAS (<H24)|Rate of perineal laceration|Rate of episiotomy|Perineal healing assessed by the REEDA scale|Change of perineal pain assessed by the VAS (<H96)|Consumptions of pain relief medications|Pain interference on daily functioning assessed by the BPI-SF|Perineal complication|Childbirth experience assessed by the QACE|Rate of exclusive breastfeeding|Rate of breastfeeding complications|Urinary incontinence assessed with the ICIQ-UI SF|Anal incontinence assessed with the Wexner Score|Sexual function assessed with the FSFI|Rate of postpartum depression assessed by the EPDS,"Assistance Publique - H�pitaux de Paris|Fondation Apicil|PRIDE prize, Laboratoire Guigoz, D�partement Hopsitalo-universitaire Risques et Grossesse, Universit� de Paris|Institut National de la Sant� Et de la Recherche M�dicale, France",Female,"18 Years and older � (Adult, Older Adult)",Not Applicable,222,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,En cours-|2020-A03399-30,"May 16, 2022",April 2023,June 2023,"March 3, 2021",,"September 27, 2022","Louis Mourier Hospital, Colombes, France|Cochin Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT04778631,NCT04778631,
oui,NCT04780191,Investigation of Treatment Using the MyoRegulator® Device in Patients With Spasticity in the Lower Limb Due to Stroke,SPAST,Completed,No Results Available,Muscle Spasticity|Stroke,Device: MyoRegulator®,Change in spasticity from baseline to after the last treatment session|Change in gait parameters from baseline to 3 months post-treatment|Change in walking performance from baseline to 3 months post-treatment|Change in functional performance from baseline to 3 months post-treatment|Change in muscle reaction from baseline to 3 months post-treatment|Change in subject's self-assessment of their spasticity from baseline to 3 months post-treatment|Change in subject's quality of life from baseline to 3 months post-treatment,"Institut National de la Santé Et de la Recherche Médicale, France|PathMaker Neurosystems Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,44,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C16-124|2017-A02060-53,"July 19, 2018","January 19, 2021","January 19, 2021","March 3, 2021",,"March 23, 2021","Centre d'investigation clinique, Institut du Cerveau et de la Moelle, Paris, France",,https://ClinicalTrials.gov/show/NCT04780191,NCT04780191,
oui,NCT04784832,TMS-based Assessment of Mental Training Effects on Motor Learning in Healthy Participants,IMAP-TMS,Not yet recruiting,No Results Available,Motor Learning,Device: Transcranial magnetic stimulation|Device: Peripheral Nerve Stimulation|Device: Transcranial direct current stimulation|Device: Paired Associative Stimulation|Device: Wrist|Device: Robotic arm,Evolution of movement speed - Sequence 1|Evolution of movement accuracy - Sequence 1|Evolution of trajectory error - Sequence 2|Evolution of maximal deviation - Sequence 2|Evolution of final error - Sequence 2|Evolution of movement speed - Sequence 3|Evolution of movement accuracy - Sequence 3|Evolution of movement speed - Sequence 4|Evolution of movement accuracy - Sequence 4|Evolution of motor evoked potentials amplitude- Sequence 1|Evolution of motor evoked potentials amplitude - Sequence 2|Evolution of motor evoked potentials amplitude - Sequence 3|Evolution of motor evoked potentials amplitude - Sequence 4,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,18 Years to 60 Years � (Adult),Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C19-19|2020-A00305-34,March 2021,March 2026,March 2027,"March 5, 2021",,"March 9, 2021","INSERM - U1093 Cognition, Action, and Sensorimotor Plasticity, Dijon, France","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT04784832/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04784832,NCT04784832,
oui,NCT04785157,Neurotropism and Neuroinflammation in COVID-19 Patients With Delirium.,BRAINSTORM,Recruiting,No Results Available,Covid19|Delirium|Post-traumatic Stress Disorder,Biological: serology testing profiles description|Biological: immune response characterization|Other: in vivo brain PET-TSPO acquisitions|Other: brain MRI assessment|Behavioral: neurocognitive assessment,PET imaging examination|SARS-CoV-2 quasispecies detection in acute delirium phase in blood specimen|SARS-CoV-2 quasispecies detection 3 month after the acute delirium phase in blood specimen|SARS-CoV-2 quasispecies detection in acute delirium phase in cerebrospinal fluid specimen|SARS-CoV-2 quasispecies detection 3 month after the acute delirium phase in cerebrospinal fluid specimen|multimodal MRI in acute delirium phase|multimodal MRI 3 months after the acute delirium phase,"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,25,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RC31/20/0441|2020-005827-35,"June 1, 2021",August 2022,August 2022,"March 5, 2021",,"September 5, 2021","University Hospital of Toulouse, Toulouse, France|CHRU Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT04785157,NCT04785157,
oui,NCT04788784,Patient-Reported Outcomes HIV BItherapy,PROBI,Recruiting,No Results Available,HIV/AIDS and Infections|Patient Preference,,Change of the patient perception (Patient-Reported Outcomes - PRO) after a switch from HIV tritherapy to DOVATO dual therapy on the perceived toxicity of the treatment.|Change of the patient perception (Patient-Reported Outcomes - PRO) after a switch from HIV tritherapy to DOVATO dual therapy on the acceptability of the treatment.|Change of the patient perception (Patient-Reported Outcomes - PRO) after the switch from HIV tritherapy to DOVATO dual therapy on Health-Related Quality of Life (HRQL)|Change of the patient perception (Patient-Reported Outcomes - PRO) after the switch from HIV tritherapy to DOVATO dual therapy on the percieved HIV symptoms|Change of the patient perception (Patient-Reported Outcomes - PRO) after the switch from HIV tritherapy to DOVATO dual therapy on adherence with the dual therapy|Factors associated with high preference versus low preference for dual therapy|Efficacy of the Dovato regimen through Week 24|Kinetic of CD4 through Week 24,University Paris 7 - Denis Diderot|ViiV Healthcare,All,"18 Years and older � (Adult, Older Adult)",,250,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,PROBI,"April 12, 2021","May 1, 2022","August 31, 2022","March 9, 2021",,"April 30, 2021","H�pital de Bic�tre, Le Kremlin-Bic�tre, France|Centre hospitalier de Cornouaille, Quimper, France|Centre Hospitalier de Saint-Denis - H�pital Delafontaine, Saint-Denis, France",,https://ClinicalTrials.gov/show/NCT04788784,NCT04788784,
oui,NCT04798456,Aiming for a Better Understanding and Improvement of the Diagnosis and Prognosis of Patients With Disorders of Consciousness Through Multimodal Observations,PerBrain,Recruiting,No Results Available,Disorders of Consciousness|Minimally Conscious State|Unresponsive Wakefulness Syndrome|Caregivers,"Behavioral: Coma scales|Diagnostic Test: Imaging, electrophysiology, body signals, and brain stimulation|Behavioral: Questionnaires",Patients: Implementation of a hierarchical multi-modal personalized procedure to diagnose and track the change of the state of consciousness in brain-injured patients|Caregivers: use of questionnaires to asses change in factors that impact well-being and treatment decisions of informal caregivers/family members confronted with multimodal technology-based tests for DoC patients|Caregivers: develop a brochure/guide to be applied in clinical practice for the effective communication of technology-based results,Brain & Spine Institute (ICM)|University of Milan|Fondazione Don Carlo Gnocchi Onlus|Weizmann Institute of Science|Ludwig-Maximilians - University of Munich,All,"18 Years to 85 Years � (Adult, Older Adult)",,150,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ERAPERMED2019-101 - PerBrain|01KU2003,"June 1, 2020",June 2023,June 2023,"March 15, 2021",,"March 15, 2021","Paris Brain Institute (ICM), Paris, France|University Hospital of the Ludwig-Maximilians-University of Munich, Munich, Germany|Loewenstein Hospital, Raanana, Israel|Dipartimento di Cura e Riabilitazione delle Gravi Cerebrolesioni Acquisite (GCA), Milan, Italy",,https://ClinicalTrials.gov/show/NCT04798456,NCT04798456,36494776
oui,NCT04808986,Seroprevalence of IgG Antibodies to SARS-CoV-2 (COVID-19) in Primary Health Care Workers and Their Household Contacts,COVID-SeroPRIM,Unknown status,No Results Available,Covid19,Diagnostic Test: Serological test for the detection of IgG anti-SARS-CoV-2,Seroprevalence estimates in health care professionals,"Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",Not Applicable,2000,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,C20-72|ID RCB : 2020-A03298-31,"April 2, 2021","August 31, 2021","November 15, 2021","March 22, 2021",,"March 22, 2021",,,https://ClinicalTrials.gov/show/NCT04808986,NCT04808986,
oui,NCT04812210,Quality of Life and Neurodevelopment Assessment of Children With Congenital Heart Disease Aged 2 to 4 Years,QoLCHD,Completed,No Results Available,Congenital Heart Disease,,Comparison of the total score of the proxy HRQoL questionnaire|Comparison of score by dimensions of the proxy HRQoL questionnaire|Comparison of score of the roxy HRQoL questionnaire|Comparison of score of the proxy HRQoL questionnaire|Comparison of score of the HRQoL questionnaire|Study of the association of the following variables related to the patient and to the CHD with the scores of the proxy HRQoL questionnaire|Evaluation of the psychometric properties of the proxy HRQoL questionnaire,"University Hospital, Montpellier|University of Montpellier - Inserm 1046 - PhyMeddExp|Saint Pierre Institute - Palavas les Flots|Congenital Cardiology Department of university hospital of Bordeaux",All,2 Years to 4 Years � (Child),,248,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,RECHMPL21_0083,"April 1, 2021","December 1, 2021","December 30, 2021","March 23, 2021",,"April 12, 2022","Uh Montpellier, Montpellier, France",,https://ClinicalTrials.gov/show/NCT04812210,NCT04812210,
oui,NCT04816227,Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments,Mac2ALS,Recruiting,No Results Available,Amyotrophic Lateral Sclerosis,,Measure of transcriptome differences between the ALS group and the 3 other groups of participants.,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,180,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C20-55|2020-A03348-31,"September 29, 2021","October 30, 2026","October 30, 2027","March 25, 2021",,"May 25, 2022","Département de Neurologie, Hôpital de la Pitié-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT04816227,NCT04816227,
oui,NCT04817319,Risk of Contamination by COVID-19 During Oral Care With Aerosolization,Bu-Covid,Not yet recruiting,No Results Available,Contamination by COVID 19 During Oral Care,Procedure: Oral care with/without aerosolization,"Evaluate the risk of skin and mucous membrane contamination of practitioners during oral care performed on patients diagnosed with COVID +.|Determine the presence of SARS-CoV 2 on the face and facial mucous membranes of practitioners after the dental procedure depending on whether: • the procedure involves aerosolization (turbine, ultrasonic scaler,…),|Determine the presence of SARS-CoV 2 on the face and facial mucous membranes of practitioners after the dental procedure depending on whether: • the procedure does not involve aerosolization (intraoral examination, intraoral X-ray, biopsy)|Determine the presence of SARS-CoV 2 on personal protective equipment (PPE) depending on whether: • the procedure involves aerosolization (contra-angle, ultrasonic scaler),|Evaluate the risk of contamination of practitioners, PPE and surfaces depending on the type of aerosolization used (contra-angle, ultrasonic scaler)|Evaluate the presence of viral loads in areas used by COVID + patients","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,APHP200933,"July 1, 2023","July 1, 2024","July 1, 2024","March 26, 2021",,"November 1, 2022",,,https://ClinicalTrials.gov/show/NCT04817319,NCT04817319,
oui,NCT04818684,Practices of Accompaniment of the Relatives of Patients in the AGonic Phase by an Interdisciplinary Team,PROPAGE2,Not yet recruiting,No Results Available,Practice Nurse's Scope,Other: questionnaire,"Score of Likert-type scales (rated between 0 and 9), best match what each participant think about support practices for relatives of persons in the agony phase : from 1 (strongly disagree) to 9 (strongly agree).","University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,245,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHUBX 2019/60,"September 1, 2021","July 1, 2024","July 1, 2024","March 26, 2021",,"May 13, 2021",,,https://ClinicalTrials.gov/show/NCT04818684,NCT04818684,
anrs,NCT04824638,BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers,CoviCompareP,"Active, not recruiting",No Results Available,"Healthy|Immunization, Infection",Biological: 3 doses of BNT162b2 vaccine|Biological: 2 dose of BNT162b2 vaccine,IgG humoral response to vaccine 28 days post vaccination|humoral response to vaccine|T cells response to vaccine|Mucosal response to vaccine|B cell response to vaccine|predictive determinants of vaccine response|Safety of BNT162b2 vaccine|SARS-CoV-2 infection|Immunological parameters,"ANRS, Emerging Infectious Diseases|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Phase 2,267,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS0002S,"March 8, 2021","June 30, 2021","November 30, 2023","April 1, 2021",,"September 7, 2022","CIC1412, CHRU Brest, Brest, France|Centre de Recherche Clinique, CHU Côte de Nacre, Caen, France|CIC 1405 , CHU Clermont-Ferrand, Clermont-Ferrand, France|CIC1430, Hôpital Henri Mondor, Creteil, France|CIC1413 , Hôtel Dieu - CHU Nantes, Nantes, France|Service des maladies infectieuses, CHU de Caremeau, Nîmes, France|CIC1417, hôpital Cochin, Paris, France|CIC 1427, Hopital Saint-Louis, Paris, France|URCI, Hôpital Lyon Sud, Pierre-Bénite, France|CIC1434, Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg, Strasbourg, France|CIC1415, CHRU Tours Hôpital Bretonneau, Tours, France",,https://ClinicalTrials.gov/show/NCT04824638,NCT04824638,
oui,NCT04824651,Covid-19 Vaccine Cohort in Specific Populations,COV-POPART,"Active, not recruiting",No Results Available,Immune Deficiency,Biological: COVID-19 vaccine,These primary outcome only concern the adult cohort. Humoral immunity to Covid-19 vaccination using 2 serological criteria:|Humoral immunity to Covid-19 vaccination using 2 serological criteria:|Percentage of participants seroconverting for Anti Nucleoprotein antibodies|Seroconversion or increase of factor 2 titer of antibodies anti-Spike/anti-RBD between the second and the third dose for the participants with 3 injections|Seroconversion or increased levels of anti-Spike/anti-RBD antibodies between the last injection of the initial vaccine regimen and the booster dose|These secondary outcome only concern the adult cohort. Cellular immunity to Covid-19 vaccination|Cellular immunity to Covid-19 vaccination|For participants with first injection with Astra-Zeneca vaccine AZD1222 and second injection with Pfizer ARNm vaccine BNT161b2 : humoral and cellular immunity to Covid-19 vaccination|For participants with first injection with Astra-Zeneca vaccine AZD1222 and second injection with Pfizer ARNm vaccine BNT161b2 : collection of immediate adverse effects|For participants with first injection with Astra-Zeneca vaccine AZD1222 and second injection with Pfizer ARNm vaccine BNT161b2 : collection of adverse effects expected from the database|For participants with first injection with Astra-Zeneca vaccine AZD1222 and second injection with Pfizer ARNm vaccine BNT161b2 : collection of adverse effects,"ANRS, Emerging Infectious Diseases|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,6920,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ANRS0001S,"March 25, 2021","June 25, 2024","June 25, 2024","April 1, 2021",,"February 4, 2022","Cmg-Ec U1219, Bordeaux, France|Nîmes CHU, Nîmes, France|Paris Cochin APHP, Paris, France",,https://ClinicalTrials.gov/show/NCT04824651,NCT04824651,36252789
oui,NCT04831762,Markers of Executive Attention Development in Preschoolers - Behavioral Measures in Various Populations,MEDiATE-PRV,Recruiting,No Results Available,Attention Deficit,Behavioral: Attention Network task (computerized)|Behavioral: Head-toes-knees-schoulders|Behavioral: Laby 5-12|Behavioral: M-ABC 2|Behavioral: Stroop animals,ANT performance|Tactile processing score,"University Hospital, Caen",All,48 Months to 71 Months � (Child),,200,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,2020-A03209-30,"March 1, 2021","October 1, 2023","December 31, 2023","April 5, 2021",,"March 9, 2022","Comete U1075 Inserm Unicaen, Caen, France",,https://ClinicalTrials.gov/show/NCT04831762,NCT04831762,
oui,NCT04842851,Cardiac Resynchronization Therapy in Congenital Heart Diseases With Systemic Right Ventricle,,Completed,No Results Available,Congenital Heart Disease,Device: cardiac resynchronization therapy,Proportion of patients with response to CRT|Overall mortality|Overall mortality or heart transplantation|Complications associated with CRT,"Paris Cardiovascular Research Center (Inserm U970)|Marie Lannelongue Hospital, Le Plessis Robinson, France|Clinique Pasteur Toulouse|Groupe Hospitalier Pitie-Salpetriere|Hopital Louis Pradel|University Hospital, Montpellier|European Georges Pompidou Hospital",All,"Child, Adult, Older Adult",,85,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2219047,"January 1, 2004","December 31, 2020","December 31, 2020","April 13, 2021",,"April 13, 2021",,,https://ClinicalTrials.gov/show/NCT04842851,NCT04842851,
oui,NCT04842916,"InteGRAtive Analysis of tuMor, Microenvironment, immunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer",GRAMMY,"Active, not recruiting",No Results Available,Gastric Cancer,,Genomic alterations in tumoral tissue in responders and non-responders|Quantitative and qualitative analysis of the tumor microenvironment composition in responders and non-responders|Analysis of cell-free DNA (cfDNA) from blood samples in responders and non-responders|Analysis of circulating tumor cells (CTC) from blood samples in responders and non-responders.|Peripheral blood mononuclear cells (PBMCs) and host immunity parameters in responders and non-responders|Psychological status of patients in relation to therapy response,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|ERA PERMED,All,"18 Years to 85 Years � (Adult, Older Adult)",,250,Other,Observational,Observational Model: Cohort|Time Perspective: Other,IRSTB111,"September 22, 2020","September 22, 2023","September 22, 2023","April 13, 2021",,"April 13, 2021","Centre Hospitalier Regional et Universitaire (CHRU), Brest, France|INSERM, Faculty of Medicine (UMR1078), Brest, France|1st Department of Propaedeutic Surgery, National & Kapodistrian University of Athens (NKUA), Athens, Greece|IRST IRCCS UO Oncologia, Meldola, Italy|AUSL Romagna, UO Oncologia, Ravenna, Italy",,https://ClinicalTrials.gov/show/NCT04842916,NCT04842916,
oui,NCT04844853,Neural Correlates of Tactile Prediction,DECODE,Recruiting,No Results Available,Neurodevelopmental Disorders|Premature Birth,Device: electroencephalography|Device: Tactile stimulation|Behavioral: Attention Network task (computerized)|Behavioral: Head-toes-knees-schoulders|Behavioral: Laby 5-12|Behavioral: M-ABC 2|Behavioral: Stroop animals,Repetition suppression at 2|Repetition suppression at 6|Tactile prediction at 2|Tactile prediction at 6,"University Hospital, Caen",All,2 Years to 6 Years � (Child),Not Applicable,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2020-A03208-31,"April 1, 2021","April 30, 2023","September 30, 2023","April 14, 2021",,"August 24, 2022","Comete U1075 Inserm Unicaen, Caen, France",,https://ClinicalTrials.gov/show/NCT04844853,NCT04844853,
non,NCT04846686,Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.,PRE-EVE,Not yet recruiting,No Results Available,Preeclampsia,Biological: Placenta pathological examination,Immuno-localization of EG-VEGF staining (ImageJ�) by immunohistochemistry|Quantification of EG-VEGF staining (ImageJ�) by immunohistochemistry|Immuno-localization of the staining of PROKR1 (ImageJ�) by immunohistochemistry|Quantification of the staining of PROKR1 (ImageJ�) by immunohistochemistry|Immuno-localization of the staining of PROKR2 (ImageJ�) by immunohistochemistry|Quantification of the staining of PROKR2 (ImageJ�) by immunohistochemistry Measure by placenta pathological examination (immunohistochemistry technical).|Presence of at least one chronic maternal pathologies describe below|Obstetric history|Presence of an anticoagulant treatment,Centre Hospitalier Universitaire de Saint Etienne|Commissariat A L'energie Atomique,Female,"18 Years and older � (Adult, Older Adult)",,35,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,IRBN622021/CHUSTE,June 2021,December 2021,December 2021,"April 15, 2021",,"April 20, 2021","Chu Saint-Etienne, Saint-�tienne, France",,https://ClinicalTrials.gov/show/NCT04846686,NCT04846686,
anrs,NCT04849767,National Survey About Trajectory and Life Conditions of HIV Trans People in France,Trans&VIH,Recruiting,No Results Available,HIV Seropositivity,Other: Questionnaire,Statistical analyses of trends in the personal and social situations of vulnerability in TRHIV|Statistical analyses of trends in obstacles that TRHV encounter in terms of medical care and their healthcare needs,"ANRS, Emerging Infectious Diseases|Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",,850,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,ANRS 14056 TRANS&VIH|20-694,"January 1, 2021","January 1, 2022","December 31, 2023","April 19, 2021",,"April 21, 2021","INSERM, Marseille, France",,https://ClinicalTrials.gov/show/NCT04849767,NCT04849767,34916316
oui,NCT04852744,NEUROIMAGING OF ADOLESCENT BORDERLINE PERSONALITY DISORDER WITH AND WITHOUT POST-TRAUMATIC STRESS DISORDER,BorderStress,Not yet recruiting,No Results Available,Borderline Personality Disorder,Other: Brain MRI,Hippocampal volume,"University Hospital, Caen|CHU de Rouen - Accueil|Centre Hospitalier Universitaire de Caen|Université de Caen Normandie|Centre Hospitalier du Rouvray|Institut National de la Santé Et de la Recherche Médicale, France|Groupe Hospitalier du Havre",Female,"13 Years to 18 Years   (Child, Adult)",Not Applicable,99,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2019-A00366-51,"June 1, 2021","December 1, 2023","June 1, 2024","April 21, 2021",,"April 27, 2021",,,https://ClinicalTrials.gov/show/NCT04852744,NCT04852744,
oui,NCT04865172,ECOCAPTURE for the Assessment of Apathy Under Real-life Conditions,@HOME,Not yet recruiting,No Results Available,"Frontotemporal Dementia, Behavioral Variant|Alzheimer Disease",Other: Remote collection of passive and active data for 28 consecutive days,Acceleration (in g)|Electrodermal activity (in microsiemens)|Blood volume pulse (or relative blood flow)|Bedtime and getting up time (Week 1)|Bedtime and getting up time (Week 2)|Bedtime and getting up time (Week 3)|Bedtime and getting up time (Week 4)|Meal times (Week 1)|Meal times (Week 2)|Meal times (Week 3)|Meal times (Week 4)|Autonomy for going to bed and getting up (Week 1)|Autonomy for going to bed and getting up (Week 2)|Autonomy for going to bed and getting up (Week 3)|Autonomy for going to bed and getting up (Week 4)|Signs of tiredness (Week 1)|Signs of tiredness (Week 2)|Signs of tiredness (Week 3)|Signs of tiredness (Week 4)|Involvement in the activities related to meal (Week 1)|Involvement in the activities related to meal (Week 2)|Involvement in the activities related to meal (Week 3)|Involvement in the activities related to meal (Week 4)|Usefulness of involvement in the activities related to meal (Week 1)|Usefulness of involvement in the activities related to meal (Week 2)|Usefulness of involvement in the activities related to meal (Week 3)|Usefulness of involvement in the activities related to meal (Week 4)|Autonomy of the involvement in the activities related to meal (Week 1)|Autonomy of the involvement in the activities related to meal (Week 2)|Autonomy of the involvement in the activities related to meal (Week 3)|Autonomy of the involvement in the activities related to meal (Week 4)|Quantity of interactions during meals (Week 1)|Quantity of interactions during meals (Week 2)|Quantity of interactions during meals (Week 3)|Quantity of interactions during meals (Week 4)|Quality of interactions during meals (Week 1)|Quality of interactions during meals (Week 2)|Quality of interactions during meals (Week 3)|Quality of interactions during meals (Week 4)|Patient's apathy perceived by caregiver (day scale)|Patient's apathy perceived by caregiver (month scale)|Caregiver's burden (day scale)|Caregiver's burden (month scale)|Caregiver's health-related quality of life (day scale)|Caregiver's health-related quality of life (month scale),"Institut National de la Santé Et de la Recherche Médicale, France",All,"40 Years to 85 Years   (Adult, Older Adult)",,120,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,C20-23|2020-A03305-34,September 2021,September 2023,September 2023,"April 29, 2021",,"April 29, 2021",,,https://ClinicalTrials.gov/show/NCT04865172,NCT04865172,34360133
oui,NCT04866940,Validation and Implementation of 3T MRI Research Protocols,VALIDIRM,Not yet recruiting,No Results Available,Magnetic Resonance Imaging,Other: Sequences test,in general,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,230,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,C20-28,April 2021,April 2027,April 2027,"April 30, 2021",,"April 30, 2021",,,https://ClinicalTrials.gov/show/NCT04866940,NCT04866940,
anrs,NCT04867083,Dual Therapy in HIV Patients in 4 Days a Week Versus 7 Days a Week,,Recruiting,No Results Available,HIV Infections,Drug: ARV bitherapie,"Proportion of patients with virological failure at Week 48.|Proportion of participants with therapeutic success until Week 48|Percentage of participants with at least one episode of ""blip""|Percentage of participants with a viral load signal detected|Evolution of ultrasensitive viral load and total DNA in the PBMC at W0 and W48|Proportion of participants with acquisition of drugs resistance mutations in case of virological failure detected by Sanger and by NGS|Description of selected mutations at the virological failure|Frequency of minority resistant variants archived in DNA at W0 and their impact on virological failure (2 consecutive VL> 50 copies / mL) and on the acquisition of drugs resistance mutations|Frequency of grade 3 or more adverse events, adverse effects, drug-modifying adverse events, drug-related adverse events and serious adverse events (SAE)|Evolution of T CD4 and CD8 cells count, and CD4/CD8 ratio|Evolution of fasting metabolic parameters (total cholesterol total, LDL-C, HDL-C, Triglycerides and glycemia) until W0 and W48|Evolution of weight between Week 0 and Week 48|Evolution of inflammation serum parameters|Evolution of semen viral load at Week 0, Week 24 and Week 48|Description and comparison of plasmatic concentrations of antiretroviral agents between the 2 groups at ON and OFF period|Evaluation of the adherence by self-reported questionnaire|Evolution of the quality of life by self-reported questionnaire","ANRS, Emerging Infectious Diseases|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,440,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 177 DUETTO|2020-003951-13,"June 21, 2021",July 2023,July 2024,"April 30, 2021",,"November 8, 2021","Hôpital Louis Pasteur/Service des Maladies Infectieuses, Chartres, Le Coudray, France|Centre hospitalier Victor Dupouy/Service d'Hématologie-Unité d'Immunologie, Argenteuil Cedex, France|Hôpital Avicenne/Service des Maladies Infectieuses et tropicales, Bobigny cedex, France|Hôpital Saint André/Service HDJ Maladies Infectieuses, Bordeaux cedex, France|Hôpital Pellegrin/Service des Maladies Infectieuses et Tropicales, Bordeaux cedex, France|Hôpital Côte de Nacre/Service des Maladies Infectieuses, Caen cedex 9, France|Hôpital Antoine Béclère/Service d'Immunologie Clinique et Médecine Interne, Clamart cedex, France|Centre Hospitalier Sud-Francilien/Service d'Hématologie, Corbeil-Essonnes cedex, France|Hôpital François Mitterrand/Service des Maladies Infectieuses, Dijon cedex, France|Hôpital Raymond Poincaré/Service des Maladies Infectieuses, Garches, France|CHD de La Roche sur Yon/Service de Médecine Interne, La Roche sur Yon cedex 9, France|Hôpital Franco-Britannique-Fondation Cognacq-Jay, Levallois-Perret, France|CHU Dupuytren 1/Service des Maladies Infectieuses et Tropicales, Limoges, France|Hôpital de la Croix Rousse/Service des Maladies Infectieuses, Lyon cedex 4, France|Hôpital Européen/Consultation de Médecine Interne et Maladies Infectieuses, Marseille cedex 01, France|Hôpital Sainte Marguerite/Service d'Immuno-Hématologie Clinique, Marseille cedex 9, France|Hôpital Gui de Chauliac/Service des Maladies Infectieuses, Montpellier cedex 5, France|Hôpital de l'Hôtel Dieu/Service des Maladies Infectieuses, Nantes cedex 1, France|Hôpital de l'Archet/Service des Maladies Infectieuses, Nice cedex 3, France|Hôpital Lariboisière/Service de Médecine Interne, Paris cedex 10, France|Hôpital Saint Louis/Service des Maladies Infectieuses, Paris cedex 10, France|Hôpital Saint Antoine/Service des Maladies Infectieuses, Paris cedex 12, France|Hôpital Pitié-Salpêtrière/Service des Maladies Infectieuses, Paris cedex 13, France|Hôpital Necker/Service des Maladies Infectieuses, Paris cedex 15, France|Hôpital Tenon/Service des Maladies Infectieuses, Paris cedex 20, France|Hôpital Hôtel Dieu/Service d'Immunologie Clinique, Paris cedex 4, France|Hôpital Hôtel Dieu/Unité fonctionnelle de Pathologie Infectieuse, Paris cedex 4, France|Hôpital Bichat/Service des Maladies Infectieuses, Paris, France|Centre hospitalier de Poissy/Service des Maladies Infectieuses, Poissy, France|Centre Hospitalier René Dubos/Service de Dermatologie, Pontoise, France|Hôpital Robert DEBRE/Service des maladies infectieuses, Reims cedex, France|Hôpital Delafontaine/Service des Maladies Infectieuses, Saint Denis cedex 1, France|Hôpital Civil/Service Le Trait D'union UF 2066, Strasbourg Cedex, France|Hôpital Foch/Service de Médecine Interne, Suresnes, France|Hôpital Purpan/Service des Maladies Infectieuses, Toulouse cedex, France|Hôpital Gustave Dron/Service des Maladies Infectieuses, Tourcoing cedex, France|Hôpital Bretonneau/Service des Maladies Infectieuses, Tours, France|Hôpital Pierre Zobda-Quitman/Service de Médecine Interne, Fort-de-France, Martinique",,https://ClinicalTrials.gov/show/NCT04867083,NCT04867083,
oui,NCT04885543,COVID-19 STAndard of Care in Sub-Saharan Africa,COVISTA,Completed,No Results Available,Covid19,,Mortality|Clinical worsening,Alliance for International Medical Action,All,"Child, Adult, Older Adult",,2495,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ALIMA02,"March 1, 2020","March 1, 2021","March 1, 2021","May 13, 2021",,"May 13, 2021","Chu Tengandogo, Ouagadougou, Burkina Faso|Clinique Princesse Sarah, Ouagadougou, Burkina Faso|Chu Donka, Conakry, Guinea",,https://ClinicalTrials.gov/show/NCT04885543,NCT04885543,
oui,NCT04888039,"Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region ""Living With a Myeloma in West-Occitanie""",VAMOS,Recruiting,No Results Available,Multiple Myeloma,Other: quality of life questionnaires (EORTC QLQ-C30,EORTC QLQMY20  EQ-5D-5L   Cohen's stress scale) Treatment lines and procedures followed by the patients|Transplants|Treatments discontinuation|Therapeutic medical care description|Unconventional alternative medicine|Outpatient |Quality of life (QOL) during the treatment course|Second primary cancers (SPC) and grade 3 and higher neuropathies  support structure|Best response (BR)|Progression-free Survival (PFS)|PFS after the second therapeutic line|Overall Survival (OS),"University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France|Takeda|Sanofi",All,"18 Years and older   (Adult, Older Adult)",,2000,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,RC31/20/0482|N° ID RCB: 2020-A03527-32,"December 15, 2021",June 2031,June 2031,"May 17, 2021",,"March 2, 2022","IUCT-Oncopole - Toulouse University Hospital, Toulouse, West-Occitanie, France",,https://ClinicalTrials.gov/show/NCT04888039,NCT04888039,
oui,NCT04888208,Prevention in a Virtual Community Game,SCOTT,Completed,No Results Available,Tabagism,Behavioral: Behavioral,smoking behaviors perception,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"10 Years to 20 Years   (Child, Adult)",Not Applicable,106,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,APHP-INSERM,"October 1, 2020","October 22, 2020","November 15, 2020","May 17, 2021",,"May 17, 2021","Robert Debré Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT04888208,NCT04888208,
oui,NCT04888364,French Parkinson's Disease Cohort - NS-PARK,NS-PARK,Recruiting,No Results Available,Parkinson Disease,,Disease progression|Motor and non-motor complications|Modification of antiparkinsonian treatment doses|Predictive factorsof PD progression: motor or non motor symptoms|Predictive factors of PD progression: genetic variants|Predictive factors of PD progression: brain imaging markers|Clusters of patients with similar disease progression profiles|Clusters of patients with similar genetic and disease progression profiles|Genetic mutations associated with familal forms of PD,"Institut National de la Santé Et de la Recherche Médicale, France",All,"10 Years and older   (Child, Adult, Older Adult)",,30000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C16-56|2019-A01929-48,"June 16, 2021","August 15, 2023","December 31, 2023","May 17, 2021",,"August 26, 2021","Centre 01 Paris, Paris, France",,https://ClinicalTrials.gov/show/NCT04888364,NCT04888364,
oui,NCT04888455,DOLORisk: Research on Risk Factors and Determinants for Neuropathic Pain,,Completed,No Results Available,Neuropathic Pain,Diagnostic Test: Quantitative sensory testing (QST),Presence of Pain measured by Pain severity|Severity of Neuropathy measured by Toronto Neuropathy scale|Somatosensory phenotype measured by Quantitative sensory testing|Emotional well-being|Personality characteristics|Pain Catastrophizing|Presence of family history of chronic pain,"University of Kiel|Horizon 2020 - European Commission|Institut National de la Santé Et de la Recherche Médicale, France|University of Oxford|Imperial College London|Technion, Israel Institute of Technology|University of Aarhus|Aarhus University Hospital",All,"18 Years and older   (Adult, Older Adult)",,1550,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,633491 - DOLORisk WP4,June 2015,June 2019,June 2019,"May 17, 2021",,"November 8, 2022","University of Kiel, Kiel, Schleswig-Holstein, Germany",,https://ClinicalTrials.gov/show/NCT04888455,NCT04888455,
oui,NCT04891133,EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial,Bari-SolidAct,Terminated,No Results Available,COVID-19|Emerging Infectious Disease,Drug: Baricitinib|Drug: Placebo,"Occurrence of death within 60 days (primary end point, EU SolidAct part B)|Occurrence of disease progression within 14 days (primary end point, EU SolidAct part A)|SpO2/FiO2-ratio at day 5 (primary end point, phase 2 trials)|Occurrence of disease progression within 28 days (shared secondary end point for part A and B)|Time to sustained recovery (shared secondary end point for part A and B)|Time to first hospital discharge (shared secondary end point for part A and B)|Disease state at Day 15 and Day 29 (shared secondary end point for part A and B)|Time from randomization to recovery (shared secondary end point for part A and B)|SpO2/FiO2-ratio at Day 3, 5 and 8 (shared secondary end point for part A and B)|Viral clearance during hospitalization (shared secondary end point for part A and B)|Occurrence of serious adverse events within 90 days (shared secondary end point for part A and B)|Patient related outcomes at day 90 (shared secondary end point for part A and B)","Oslo University Hospital|Institut National de la Santé Et de la Recherche Médicale, France|Epidemiological and Clinical Research Information Network",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,290,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EU SolidAct|2022-500385-99-00,"June 3, 2021","December 15, 2022","January 23, 2023","May 18, 2021",,"February 6, 2023","Medical University of Innsbruck (University Hospital for Neurosurgery), Innsbruck, Austria|Medical Unversity of Innsbruck (Joint Institute for Emergency Medicine and Critical Care), Innsbruck, Austria|Medical Unversity of Innsbruck (University Hospital for Anaesthesia and Intensive Care), Innsbruck, Austria|Erasme Hospital, Brussels, Belgium|UZ Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|St Anne University Hospital, Brno, Czechia|CHU Amiens Picardie (ICU), Amiens, France|CHU Amiens Picardie (ID), Amiens, France|CHU de Bordeaux / Hopital Pellegrin (ICU), Bordeaux, France|CHU de Bordeaux / Hopital Pellegrin (ID), Bordeaux, France|Louis Mourier (ID), Colombes, France|Lous Mourier (ICU), Colombes, France|CHU François Mitterrand, Dijon, France|CHU Lille - Hopital Roger Salengro -Pôle Rèanimaition, Lille, France|Hopital de la Croix - Rousse - HCL (ICU), Lyon, France|Hopital de la Croix - Rousse - HCL (ID), Lyon, France|GHRMSA Hopital Emile Muller (ICU), Mulhouse, France|GHRMSA Hopital Emile Muller (IM), Mulhouse, France|Hôpital Saint-Antoine (ICU), Paris, France|Hôpital Saint-Antoine (ID), Paris, France|Hôpital Bichat - Claude Bernard (ICU), Paris, France|Hôpital Bichat - Claude Bernard (ID), Paris, France|Gesundheit Nord gGmbH (GeNo), Bremen, Germany|Technische Universität München (TUM) - Klinikum rechts der Isar, München, Germany|Evangelismos Hospital, Athens, Greece|Attikon University Hospital, Athens, Greece|University of Debrecen (Clinic for Infectology), Debrecen, Hungary|University of Pécs, Pécs, Hungary|University of Szeged (Pandemic Clinics), Szeged, Hungary|Cork University Hospital, Cork, Ireland|St Vincent's University Hospital, Dublin, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|St James's Hospital, Dublin, Dublin, Ireland|Beaumont Hospital, Dublin, Dublin, Ireland|Tallaght University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|University Hospital Limerick, Limerick, Ireland|Ospedale Santa Maria Annunziata, Malattie Infettive, Bagno A Ripoli, Italy|ASST - Spedali Civili di Brescia - University of Brescia, Brescia, Italy|ATS Sardegna - PO SS Trinità, U.O.C. Malattie Infettive, Cagliari, Italy|Azienda Opsedaliera Universitaria Mater Domini, U.O. Malattie Infettive e Tropicali, Catanzaro, Italy|ASL Frosinone - Ospedale Fabrizio Spaziani, U.O.C. Medicina Interna, Frosinone, Italy|Ospedale S.M. Goretti di Latina, U.O.C. Malattie Infettive, Latina, Italy|Ospedale Mater Salutis di Legnago, U.O.C. di Pneumologia, Legnano, Italy|Ospedale Mater Salutis di Legnago, U.O.S. di Malattie Infettive, Legnano, Italy|ASST Santi Paolo e Carlo, S.C. Malattie Infettive, Milano, Italy|Azienda Ospedaliera Universitaria Vanvitelli, U.O.C. Malattie Infettive, Napoli, Italy|AOU Policlinico ""P. Giaccone"", U.O.C. Malattie Infettive, Palermo, Italy|Azienda Ospedaliera Ospedali Riuniti Marche Nord, U.O.C. Malattie Infettive, Pesaro, Italy|ASL Taranto - Ospedale Oncologico San Giuseppe Moscati, U.O.C. Pneumologia, Taranto, Italy|AOU Città della Salute e Scienza Presidio Molinette, Torino, Italy|Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI), S.C. Malattie Infettive, Trieste, Italy|IRCCS Ospedale Sacro Cuore Don Calabria, U.O.S. Malattie Infettive e Tropicali, Verona, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, U.O.C. Malattie Infettive e Tropicali, Verona, Italy|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Drammen (Vestre Viken) Hospital, Drammen, Norway|Østfold sykehuset i Kalnes, Grålum, Norway|Akershus Universitetssykehus, Lørenskog, Norway|Lovisenberg Diaconal Hospital, Oslo, Norway|OUS Ullevål, Oslo, Norway|Bærum Hospital, Sandvika, Norway|Stavanger University Hospital, Stavanger, Norway|University Hospital North Norway, Tromsø, Norway|St. Olavs Hospital, Trondheim, Norway|Vestfold Hospital, Tønsberg, Norway|CHMT - Centro Hospitalar do Médio Tejo- Hospital de Abrantes, Abrantes, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal|CHUA-Faro - Centro Hospitalar Universitário do Algarve, Faro, Portugal|CHLC-HCC - Hospital Curry Cabral, Centro Hospitalar Universitário Lisboa Central, Lisboa, Portugal|CHLN - Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal|CHLO - Centro Hospitalar de Lisboa Ocidental - HEM and HSFX, Lisbon, Portugal|CHSJ - São João Hospital Center, Lisbon, Portugal|HBA - Hospital Beatriz Ângelo, Loures, Portugal|University Hospital Bratislava, Kramare, Bratislava, Slovakia|University Hospital Martin, Martin, Slovakia|Nsp Trebisov, Svet Zdravia a.s., Trebišov, Slovakia|Faculty Hospital Trencin, Trenčín, Slovakia|University Hospital Trnava, Trnava, Slovakia|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Universitario de Jaen, Jaén, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Costa del Sol, Marbella, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitario Virgen de Valme, Sevilla, Spain|Hacettepe Üniversitesi Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı (Site 1), Ankara, Turkey|Hacettepe Üniversitesi Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı (Site 2), Ankara, Turkey|Ankara Üniversitesi Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Ankara, Turkey|İstanbul Üniversitesi İstanbul Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Istanbul, Turkey|Dokuz Eylül Üniversitesi Tıp Fakültesi Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, İzmir, Turkey",,https://ClinicalTrials.gov/show/NCT04891133,NCT04891133,36627655;34473343
oui,NCT04902807,"Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation",ATRACTion,Not yet recruiting,No Results Available,"Autoimmune Lymphoproliferative Syndrome|Autoimmune Cytopenia|Autoimmune Diseases|Autoimmune Anemia|Autoimmune Thrombocytopenia|Autoimmune Hepatitis|Autoimmune Diabetes|Autoimmune Rheumatologic Disease|Systemic Lupus Erythematosus|Juvenile Idiopathic Arthritis|Hemophagocytic Lymphohistiocytoses|EBV Lymphoproliferation|RAS-Associated Autoimmune Leucoproliferative Disease|Primary Immunodeficiency|APECED|IPEX|BENTA|Enteropathy, Autoimmune|Combined Immunodeficiency|IBD",Biological: Collection of samples,Generate a diagnosis and therapeutic-decision tools|1- Development of an atlas of molecular interactions leading to autoimmunity and inflammation|2 - To develop an artificial intelligent online application|3- Ancillary study (pilot study),"Institut National de la Santé Et de la Recherche Médicale, France",All,"1 Year to 18 Years   (Child, Adult)",,500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C20-59,June 2021,December 2024,December 2024,"May 26, 2021",,"May 28, 2021",,,https://ClinicalTrials.gov/show/NCT04902807,NCT04902807,
oui,NCT04907682,"Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever",SAFARI,Completed,No Results Available,Lassa Fever,Drug: Ribavirin iv|Drug: Favipiravir,Pharmacokinetic parameter of favipiravir: Maximum plasma concentration (Cmax)|Pharmacokinetic parameter of favipiravir: Time to maximum concentration (Tmax)|Pharmacokinetic parameter of favipiravir: Area under the concentration-time curve (AUC)|Pharmacokinetic parameter of favipiravir: Half life (T1/2)|Proportion of drug related AEs and SAEs of both study treatments|Mutagenicity|Change from baseline in Viral RNA loads|Change from baseline in Lassa virus titers|Change from baseline in Lassa virus serological status|Pharmacokinetic (PK) modelling and simulations|Correlation between drug exposure and different parameters|Co-variates impacting on drug exposure,"Bernhard Nocht Institute for Tropical Medicine|University of Hamburg-Eppendorf|Alliance for International Medical Action|Institut National de la Santé Et de la Recherche Médicale, France|University of Bordeaux|Federal Medical Centre, Owo|Irrua Specialist Teaching Hospital",All,"18 Years and older   (Adult, Older Adult)",Phase 2,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SAFARI|PACTR202010817169062,"July 30, 2021","November 10, 2022","November 17, 2022","June 1, 2021",,"February 8, 2023","Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria|Federal Medical Center of Owo, Owo, Ondo State, Nigeria","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT04907682/Prot_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04907682,NCT04907682,
oui,NCT04907994,Containment Impact on Primary Care & Adverse Events Unrelated to COVID-19 in Older Patients and/or With Chronic Diseases,COVIMEGE,Not yet recruiting,No Results Available,Covid19,Other: Cohort,"Non-COVID-19 related mortality|Healthcare utilization (Consultation, visits and teleconsultations ; drug delivery ; biological and radiological procedure).|Utilization of hospital services after containment",Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",,100000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,APHP201045,September 2021,September 2022,September 2023,"June 1, 2021",,"June 1, 2021","Assistance Publique H�pitaux de Paris - CHU Henri Mondor, Cr�teil, France",,https://ClinicalTrials.gov/show/NCT04907994,NCT04907994,
oui,NCT04916678,Persistent PostConcussion-Like Symptoms and Post Traumatic Stress Disorder in Patients Presenting at the Emergency Room.,SOFTERIV,Recruiting,No Results Available,Persistent PostConcussion-Like Symptoms|Post-Traumatic Stress Disorder,Other: R-TEP EMDR intervention,Proportion of patients with PostConcussion-Like Syndrome (PCLS) at 4 months.|Proportion of patients with PTSD at 4-months|Establishment of a PCLS Predictive factors list|Assessment of health care consumption|Proportion of patients with chronic pain|Establishment of chronic pain predictive factors,"University Hospital, Bordeaux|Bordeaux Population Health Research Center (Inserm U1219)",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,4956,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CHUBX 2018/63,"October 18, 2021","December 17, 2022","December 17, 2023","June 7, 2021",,"March 22, 2022","Hopital Pellegrin, Bordeaux, France|H�pital Beaujon, Clichy, France|H�pital Louis Mourier, Colombes, France|CH de Libourne, Libourne, France|H�pital Edouard Herriot, Lyon, France|H�pital Lariboisi�re, Paris, France|H�pital Purpan, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04916678,NCT04916678,
oui,NCT04919434,Intervention to Reduce Exposure to Environmental COntaminant (IRECO),,Not yet recruiting,No Results Available,Exposure,Other: IRECO,"Modification of exposure to phthalates, phenols and glycol ether|Modification of exposure other than phthalates, phenols and glycol ether|Hazard perception linked to the exposure to chemical product present in personal care product|Barriers to change habits in the use of personal care product","Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 30 Years   (Adult),Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,C20-81|2021-A00215-36,September 2021,December 2023,December 2025,"June 9, 2021",,"June 9, 2021",,,https://ClinicalTrials.gov/show/NCT04919434,NCT04919434,
anrs,NCT04920838,Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection,COVERAGE-A,Recruiting,No Results Available,Covid19|Covid19 Drug Treatment|Severe Acute Respiratory Syndrome Coronavirus 2|SARS-CoV2 Infection,Drug: Nitazoxanide and Ciclésonide|Drug: Telmisartan 20Mg Oral Tablet|Drug: Paracetamol|Drug: Fluoxétine and Budésonide,SpO2 ≤ 93% within 14 days|Death within 14 days|Death within 28 days|Occurence of at least one grade 3 or 4 clinical or biological adverse event within 14 days|Number of hospitalizations due to severe progression,"ANRS, Emerging Infectious Diseases|University of Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France|PACCI Program|Alliance for International Medical Action|Centre Muraz|Barcelona Institute for Global Health",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,600,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS COV33 COVERAGE-Africa,"April 12, 2021",August 2023,August 2023,"June 10, 2021",,"January 31, 2023","Centre Muraz/INSP, Bobo-Dioulasso, Burkina Faso|Centre de traitement des maladies à tendance épidémique de Gbessia, Conakry, Guinea",,https://ClinicalTrials.gov/show/NCT04920838,NCT04920838,36574985
oui,NCT04921618,Partner Notification of Sexually Transmitted Infections (STIs) in Testing Centers,Not'IST,Recruiting,No Results Available,STI|Hiv,Other: 2 online self-administered questionnaires on,Partner notification by index patients|Partners notified by index patients|Notified partners tested positive,"ANRS, Emerging Infectious Diseases",All,"18 Years and older � (Adult, Older Adult)",,2200,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,ANRS MIE Not'IST,"July 12, 2021",December 2022,December 2022,"June 10, 2021",,"July 25, 2022","CeGIDD d'Aix-en-Provence, Aix-en-Provence, France|CeGIDD de Caen, Caen, France|CeGIDD de Lille, Lille, France|CeGIDD - La Joliette, Marseille, France|CeGIDD - Saint Adrien, Marseille, France|CeGIDD de Bich�t, Paris, France|CeGIDD de La Piti� Salp�tri�re, Paris, France|Centre de sant� sexuelle - LE 190, Paris, France|Institut Alfred Fournier, Paris, France",,https://ClinicalTrials.gov/show/NCT04921618,NCT04921618,
oui,NCT04921930,Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA),ARTEMIS,Not yet recruiting,No Results Available,Friedreich Ataxia,Drug: Artesunate Oral Product,Search for the maximal tolerated and effective dose of oral artesunate to regulate iron homeostasis and Transferrin 1 receptor (TfR1) immunofluorescence in Peripheral Blood Mononuclear Cells (PBMCs)|Incidence of Adverse Events with Artesunate in FA patients|Type of Adverse Events with Artesunate in FA patients|Impact of stopping an effective dose of artesunate on the regulation of iron homeostasis and TfR1 immunofluorescence,"Institut National de la Santé Et de la Recherche Médicale, France|Imagine Institute",Male,"16 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C20-54,"July 1, 2021","June 30, 2022","June 30, 2022","June 10, 2021",,"June 14, 2021",,,https://ClinicalTrials.gov/show/NCT04921930,NCT04921930,
associ�,NCT04924712,Cellules B et Microbiote Dans le SNI,,Not yet recruiting,No Results Available,Microbiota|B-lymphocytes|Glomerulosclerosis|T-lymphocytes,Other: Measurement of blood immune populations and microbiota distribution.,Sequencing and analysis of intestinal and urinary microbiota|Cytometric analysis of peripheral immune populations,Nantes University Hospital,All,"18 Years and older � (Adult, Older Adult)",,60,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RC21_0118,"February 15, 2022","October 15, 2023","October 15, 2024","June 14, 2021",,"January 11, 2022","Nantes University Hospital, Nantes, Loire-Atlantique, France",,https://ClinicalTrials.gov/show/NCT04924712,NCT04924712,
oui,NCT04926220,Dynamic Estimation of Cardiac Output in the Operating Room,TRIPLEFLOW,Recruiting,No Results Available,Interventional Radiology|Surgery|General Anesthesia|Organ Failure|Intensive Care|Hemodynamic Instability|Blood Pressure|Cardiac Output,Device: Trans-esophageal Doppler monitoring|Device: MostCareUP Haemodynamic Monitor|Device: Argos Cardiac Output (CO) Monitor,Cardiac output using the trans-esophageal Doppler technique|Cardiac output using the MostCareUp monitor|Cardiac output using the Argos monitor|Measure of the value of the dicrote wave with MostCareUp monitor|Measure of dP/dtmax (myocardial contractility index) with MostCareUp monitor|Measure of the cardiac efficiency (CCE) with MostCareUp monitor|Measure of arterial elastance with MostCareUp monitor|Measure of the total impedance of the system (Ztot) with MostCareUp monitor|Measure of the Global Afterload Angle (GALA) using the trans-esophageal Doppler technique|Measure of arterial elastance using the trans-esophageal Doppler technique,"Assistance Publique - H�pitaux de Paris|INSERM UMR-942, Paris, France",All,"18 Years and older � (Adult, Older Adult)",,92,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP210311|2021-A00088-33,"September 15, 2021",September 2023,March 2024,"June 15, 2021",,"October 18, 2021","AP-HP, Lariboisi�re Hospital, Department of Anesthesiology and Intensive Care, Paris, France",,https://ClinicalTrials.gov/show/NCT04926220,NCT04926220,
oui,NCT04930757,Involvement of Polymorphonuclear Neutrophils and Platelets in Severe Form of COVID-19,NeutroVID,Recruiting,No Results Available,Covid19,,Percentage of circulating neutrophils in reverse migration|Analysis of neutrophils and platelets|SAPS II score|SOFA score|Mortality rate,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP210061,"February 4, 2021",February 2022,April 2022,"June 18, 2021",,"June 18, 2021","Intensive care department, Hôpital Saint Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT04930757,NCT04930757,
oui,NCT04935684,Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation,TMF-Allo,Recruiting,No Results Available,"Acute Leukemia in Remission|Myelodysplastic Syndromes|Myeloproliferative Syndrome|Hodgkin Lymphoma|Lymphoma, Non-Hodgkin|Myeloma|Chronic Lymphocytic Leukemia",Drug: Fecal Microbiota Transplantation,"Graft-versus-host disease and Relapse-Free Survival (GRFS) rate after allogeneic hematopoietic stem cell transplantation|Overall survival|Progression-free survival|Haematopoietic reconstitution|Engraftment rates|Cumulative incidence of acute GvHD|Cumulative incidence of chronic GvHD|Transplant-Related Mortality|Cumulative incidence of infections|Severe infections description|Impact of Fecal Microbiota Transplantation (FMT) on multi-resistant bacteria, extended-spectrum beta-lactamases and Clostridium difficile infection|Unexpected event description that could be in relation with FMT of Fecal Microbiota Transplantation (FMT)|Quality of life assessment|Analysis the intestinal microbiota in patients|Analysis the intestinal microbiota in stool donnors|Blood collection for a metabolomic study in patients|Blood collection for an analysis of anti-microbiota IgG and IgA in patients|Blood collection for a metabolomic study in stool donnors|Blood collection for an analysis of anti-microbiota IgG and IgA in stool donnors|Stool collection for an analysis of the virome in patients|Stool collection for an analysis of the virome in stool donnors","University Hospital, Clermont-Ferrand|Ministry of Health, France|French Society of Hematology",All,"18 Years and older � (Adult, Older Adult)",Phase 2,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PHRC N 2018 BAY|2020-000673-24,"December 20, 2022",October 2026,December 2027,"June 23, 2021",,"March 1, 2023","Service d'H�matologie Clinique et Th�rapie Cellulaire CHU Amiens Picardie - Site Sud, Amiens, France|Service Maladies du sang CHU Angers, Angers, France|H�matologie clinique CHU Besan�on, Besan�on, France|Plateforme d'Investigation Clinique / Centre d'Investigation Clinique - Inserm 1405, CHU Gabriel Montpied Clermont-Ferrand, Clermont-Ferrand, France|Service de th�rapie Cellulaire et d'H�matologie Clinique Adulte CHU Estaing - Clermont-Ferrand, Clermont-Ferrand, France|Service h�matologie CHU Grenoble, Grenoble, France|Service des Maladies du sang H�pital HURIEZ, CHRU de Lille, Lille, France|Service de th�rapie cellulaire et l'h�matologie clinique adulte CHU Limoges, Limoges, France|Service d'H�matologie Centre Hospitalier Lyon Sud, Lyon, France|Service d'H�matologie et de M�decine interne H�pital Brabois CHRU Nancy, Nancy, France|Service d'H�matologie Clinique CHU Nantes, Nantes, France|Service d'h�matologie clinique, d�partement de greffe de moelle CHU Nice, Nice, France|Service d'H�matologie Adultes H�pital Necker, Paris, France|Service d'H�matologie clinique H�pital Piti�-Salp�tri�re, Paris, France|Service d'h�matologie greffe H�pital St Louis, Paris, France|H�matologie clinique et th�rapie cellulaire H�pital Haut-L�v�que, Pessac, France|Service d'h�matologie greffe H�pital St Louis, Poitiers, France|D�partement d'h�matologie CAC Rouen, Rouen, France|H�matologie clinique Institut de Canc�rologie de la Loire, Saint-�tienne, France|IUC T - Oncop�le, Toulouse, France",,https://ClinicalTrials.gov/show/NCT04935684,NCT04935684,37130682
oui,NCT04944550,New Models for the Evaluation of Preclinical Treatment for Urothelial Carcinomas of the Upper Excretory Tract.,CICLOP,Recruiting,No Results Available,Upper Urinary Tract Urothelial Carcinoma|Nephroureterectomy|Tumor|Xenograft Model,,Histological characteristics of patient-derived xenograft models after staining.|Study of genomes of tumor specimens|Alterations in the genomes of patient-derived xenograft tumor models|Alterations in the genomes of patient-derived cell line models|Study of the transcriptome of patient tumor specimens.|Transcriptome of the patient-derived xenograft tumor models.|Transcriptome of the patient-derived cell line models.|Sensitivity to Cisplatin: patient-derived cell line models|Sensitivity to Carboplatin: patient-derived cell line models|Sensitivity to Oxaliplatin: patient-derived cell line models|Sensitivity to Gemcitabin: patient-derived cell line models|Tumor size in non-treated patient-derived xenograft models|Sensitivity to Cisplatin: tumor size in treated patient-derived xenograft models|Sensitivity to Cisplatin: tumor growth rate in patient-derived xenograft models|Sensitivity to Carboplatin: tumor size in treated patient-derived xenograft models|Sensitivity to Carboplatin: tumor growth rate in treated patient-derived xenograft models|Sensitivity to Oxiplatin: tumor size in treated patient-derived xenograft models|Sensitivity to Oxiplatin: tumor growth rate in treated patient-derived xenograft models|Sensitivity to Gemcitabine: tumor size in treated patient-derived xenograft models|Sensitivity to Gemcitabin: tumor growth rate in treated patient-derived xenograft models,"Centre Hospitalier Universitaire de N?mes|INSERM U1194, Institut de Recherche en Canc�rologie de Montpellier, Campus Val d'Aurelle, 34298 Montpellier cedex 5",All,"18 Years and older � (Adult, Older Adult)",,20,Other,Observational,Observational Model: Other|Time Perspective: Other,NIMAO/2020-2/NH01,"March 1, 2021","September 1, 2023","March 1, 2024","June 29, 2021",,"September 28, 2022","Centre Hospitalier Universitaire de N�mes, N�mes, Gard, France",,https://ClinicalTrials.gov/show/NCT04944550,NCT04944550,
oui,NCT04945655,Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability,PrevHPV,Recruiting,No Results Available,HPV Vaccine Acceptability,Other: Adolescents and parents' education and motivation at school (component 1)|Other: General practitioners' training (component 2)|Other: Access to vaccination at school (component 3),"HPV vaccine coverage (≥ 1 dose)|HPV vaccine coverage (2 doses)|HPV vaccination intention|Knowledge, attitude, beliefs and practices towards HPV vaccination and psychological determinants of vaccination intention (""KABP-6C"")|Incremental Cost-Effectiveness Ratio|Intervention components' dose and fidelity|Reached populations|Intervention components' adaptation|Satisfaction of target populations about the activities / tools, assessed by a 4-point Likert scale","Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",Not Applicable,41940,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,C20-76|2020-A02031-38,"November 15, 2021","May 31, 2022","March 31, 2023","June 30, 2021",,"February 9, 2022","Secondary schools and GPs' practices of the participating municipalities, Participating Municipalities, France",,https://ClinicalTrials.gov/show/NCT04945655,NCT04945655,35332045
oui,NCT04946955,Adaptation of a French E-health Tool for Suicide Prevention in Young Populations,E-psYouth,Recruiting,No Results Available,Suicide|Depression|Psychological Distress|Anxiety Disorders,Other: Application and website with or without promotion,number of suicidal acts (completed suicide and suicide attempts),"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"11 Years to 25 Years   (Child, Adult)",Not Applicable,12000000,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,APHP180676,"July 1, 2021","June 30, 2023","December 31, 2023","July 1, 2021",,"October 20, 2021","ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (URC Eco, Hôpital Hôtel-Dieu), Paris, France",,https://ClinicalTrials.gov/show/NCT04946955,NCT04946955,
non,NCT04947618,Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim,DVR-Lym-Nim,Recruiting,No Results Available,"Lymphoma, Malignant",,Overall survival rate among patients with Hodgkin Lymphomas|Overall survival rate among patients with Mantle-cell Lymphomas|Overall survival rate among patients with Primitive Cerebral Lymphomas|Overall survival rate among patients with Follicular Lymphomas|Overall survival rate among patients with Marginal Zone Lymphomas|Overall survival rate among patients with Waldenstr�m's Disease|Differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature.|Differences between management of patients with Mantle-cell Lymphomas and data described in the literature.|Differences between management of patients with Primitive Cerebral Lymphomas and data described in the literature.|Differences between management of patients with Follicular Lymphomas and data described in the literature.|Differences between management of patients with Marginal Zone Lymphomas and data described in the literature.|Differences between management of patients with Waldenstr�m's Disease and data described in the literature.|Reasons for differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature.|Reasons for differences between management of patients with Mantle-cell Lymphomas actually observed and data described in the literature.|Reasons for differences between management of patients with Primitive Cerebral Lymphomas actually observed and data described in the literature.|Reasons for differences between management of patients with Follicular Lymphomas actually observed and data described in the literature.|Reasons for differences between management of patients with Marginal Zone Lymphomas actually observed and data described in the literature.|Reasons for differences between management of patients with Waldenstr�m's Disease actually observed and data described in the literature.|Analysis of the efficacy of treatment of patients with Hodgkin Lymphomas.|Analysis of the efficacy of treatment of patients with Mantle-cell Lymphomas|Analysis of the efficacy of treatment of patients with Primitive Cerebral Lymphomas|Analysis of the efficacy of treatment of patients with Follicular Lymphomas|Analysis of the efficacy of treatment of patients with Marginal Zone Lymphomas|Analysis of the efficacy of treatment of patients with Waldenstr�m's Disease,Centre Hospitalier Universitaire de N?mes,All,"15 Years and older � (Child, Adult, Older Adult)",,400,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,NIMAO/2019-01/EJ-01,"May 1, 2022","June 1, 2023","December 1, 2023","July 1, 2021",,"May 13, 2022","CHU Nimes, N�mes, France",,https://ClinicalTrials.gov/show/NCT04947618,NCT04947618,
oui,NCT04951999,AssocIation of PULSatility and Occurrence of Complications Related to Mechanically Assisted Circulatory Support,IMPULSMACS,Recruiting,No Results Available,End-stage Heart Failure,Other: Blood sampling,Von Willebrand factor high molecular weight multimers (HMWM) ratio|Severe postoperative gastrointestinal bleeding|Post-operative right ventricular failure|Platelet dysfunction|Post-operative transient or permanent ischemic attack|Vascular endothelium dysfunction|Prolonged systemic inflammatory reaction syndrome|Evolution of immune responses|Aortic valve fusion|Aortic valve insufficiency|Evaluation of cardiac recovery,"Assistance Publique - Hôpitaux de Paris|ICAN Nutrition Education and Research|University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,APHP190830|2020-A01450-39,"December 2, 2021","January 2, 2024","June 17, 2024","July 7, 2021",,"August 30, 2022","Groupement Hospitalier pitié Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT04951999,NCT04951999,
oui,NCT04970225,Cystic Fibrosis Blood Neutrophils,MUCO-PNN,Recruiting,No Results Available,Cystic Fibrosis,Other: 1 blood sample|Other: 2 blood samples,Quantification of blood low density neutrophils in cystic fibrosis (CF)|Transcriptomic analysis of blood neutrophils in cystic fibrosis (CF)|Effector function analysis of blood neutrophils in CF.|Phagocytosis potential of blood neutrophils in CF.|Survival/apoptosis balance analysis in CF|Quantification of blood low density neutrophils in CF vs other chronic inflammatory disorders.|Quantification of blood low density neutrophils in CF according to different clinical situations.|Transcriptomic analysis of blood neutrophils in CF according to different clinical situations.|Effector function analysis of blood neutrophils in CF according to different clinical situations.|Phagocytosis potential of blood neutrophils in CF according to different clinical situations.|Survival/apoptosis balance analysis in CF according to different clinical situations.,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,APHP180430|2018-A03017-48,"July 8, 2021",July 2023,August 2023,"July 21, 2021",,"September 16, 2022","Cochin hospital, AP-HP, Paris, France",,https://ClinicalTrials.gov/show/NCT04970225,NCT04970225,
oui,NCT04972903,"Impact of Malnutrition on Pharmacokinetic or Rifampicin, Isoniazid, Pyrazinamide and Ethambutol in TB-HIV Co-infected Children",TB-Speed TB-PK,Not yet recruiting,No Results Available,Tuberculosis|Pulmonary,,"Effect of SAM on Peak plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB|Effect of SAM on minimum plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB|Effect of SAM on Area Under the Curve plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB|Effect of HIV-infection and antiretroviral treatment on Peak plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB and SAM|Effect of HIV-infection and antiretroviral treatment on Minimum plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB and SAM|Effect of HIV-infection and antiretroviral treatment on Area Under the Curve plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol in children with TB and SAM|WHO-based dosages will achieve rifampicin, isoniazid, pyrazinamide, and ethambutol drug concentrations above the target therapeutic concentrations in HIV-TB co-infected children with and without SAM|Effect of personnal parameters (nutritional parameters, HIV-infection, antiretroviral treatment, age, liver enzymes and NAT2 status) on CL/F of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB|Effect of personnal parameters (nutritional parameters, HIV-infection, antiretroviral treatment, age, liver enzymes and NAT2 status) on V/F of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB|Effect of personnal parameters (nutritional parameters, HIV-infection, antiretroviral treatment, age, liver enzymes and NAT2 status) on Ka of rifampicin, isoniazid, pyrazinamide, and ethambutol in HIV-infected children with TB|Relationship between all-cause mortality in children with TB and SAM, and Peak plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol.|Relationship between all-cause mortality in children with TB and SAM, and the minimum plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol.|Relationship between all-cause mortality in children with TB and SAM, and Area Under the Curve plasma concentration of rifampicin, isoniazid, pyrazinamide, and ethambutol.|Rifampicin protein binding in relation with malnutrition and albuminemia","Institut National de la Santé Et de la Recherche Médicale, France|National Agency for Research on AIDS and Viral Hepatitis (ANRS)",All,6 Months to 5 Years   (Child),,80,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C20-17,August 2021,December 2022,December 2022,"July 22, 2021",,"July 22, 2021","Mulago National Referral Hospital, Kampala, Uganda|Mbarara Regional Hospital, Mbarara, Uganda|The University Teaching Hospital, Lusaka, Zambia|Arthur Davison Children Hospital, Ndola, Zambia",,https://ClinicalTrials.gov/show/NCT04972903,NCT04972903,
oui,NCT04987502,Virtual Reality and Subjective Tinnitus,ReVA2,Not yet recruiting,No Results Available,"Tinnitus|Tinnitus, Subjective",Other: Virtual Reality|Behavioral: Standard treatment,Subjective Tinnitus Severity Scale (S.T.S.S.)|Tinnitus Handicap Questionnaire (THI)|Hospital Anxiety Depression Scale|Visual Analog Scale Tinnitus Loudness|Visual Analog Scale Tinnitus Intrusiveness,"Assistance Publique - Hôpitaux de Paris|Institut de recherche et de coordination acoustique/musique|Institut National de la Santé Et de la Recherche Médicale, France|Immersive Therapy",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP210808|2021-A01045-36,"September 1, 2021","March 1, 2023","March 1, 2023","August 3, 2021",,"August 3, 2021","Hôpital européen Georges-Pompidou AP-HP, Paris, France",,https://ClinicalTrials.gov/show/NCT04987502,NCT04987502,
oui,NCT04993872,Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF,KINETIK,Not yet recruiting,No Results Available,HIV-infected Patient Kidney Transplant Recipient,Drug: Biktarvy Tab,Change in calcineurin & mTOR inhibitors' blood concentrations from baseline (BL) to W2 after switch to B/F/TAF,Institut de M�decine et d'Epid�miologie Appliqu�e - Fondation Internationale L�on M'Ba|LAMBERT ASSOUMOU/ UNITE 1136 INSERM|Sebastien GALLIEN/Henri Mondor University Hospital- Infectiology Department|THOMAS STEHL/ HENRI MONDOR HOSPITAL-Department of Nephrology,All,"18 Years to 65 Years � (Adult, Older Adult)",Phase 4,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMEA 064,"October 18, 2021","October 30, 2022","October 30, 2023","August 6, 2021",,"August 6, 2021",,,https://ClinicalTrials.gov/show/NCT04993872,NCT04993872,
oui,NCT04997733,Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal,MIRACLE,Recruiting,No Results Available,Crohn Disease,Drug: Fecal Microbiota Transplantation (FMT)|Drug: Sham-transplantation (placebo),Evaluate the clinical efficacy of FMT versus sham transplantation as a maintenance treatment following anti-TNF agent withdrawal in patients with Crohn's disease in steroid-free clinical remission for at least 6 months under anti-TNF agent|Relapse free survival,"Assistance Publique - Hôpitaux de Paris|CRB-HUEP|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 3,150,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",APHP190183|2019-003816-29,"September 22, 2021","November 22, 2023","January 22, 2026","August 10, 2021",,"June 24, 2022","Gastroenterology Department of Saint Antoine Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT04997733,NCT04997733,
oui,NCT05002764,Thalamic Nuclei Volumes in Multiple Sclerosis,THALNUC-MS,Recruiting,No Results Available,Multiple Sclerosis,,Volume of thalamic nuclei,"University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Other,CHUBX 2021/33,"July 1, 2021","July 1, 2023","July 1, 2023","August 12, 2021",,"August 12, 2021","CHU Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT05002764,NCT05002764,
oui,NCT05007379,Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids,CARMA,Not yet recruiting,No Results Available,Breast Cancer,,"Antitumor activity of the CAR-macrophages against organoids from HER2 negative, HER2 low and HER2 positive breast cancers|Antitumor activity of the CAR-macrophages compared to non-modified macrophages|Antitumor activity of the CAR-macrophages against organoids from early and advanced breast cancers patients","Centre Oscar Lambret|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 100 Years   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CARMA-2101,"September 1, 2021","September 1, 2023","September 1, 2023","August 16, 2021",,"August 16, 2021",,,https://ClinicalTrials.gov/show/NCT05007379,NCT05007379,
oui,NCT05030389,"Vestibular Stimulation, Exercise and Light Optimization for Circadian Clock Enhancement (Velocce)",velocce,Recruiting,No Results Available,Healthy Aging,Behavioral: Adapted Physical Activity (APA)|Behavioral: Bright Light Exposure (BLE)|Behavioral: Galvanic Vestibular Stimulation (GVS)|Behavioral: Health Education program (HE),Change in sleep onset latency measured by polysomnography|Change in total sleep time measured by polysomnography|Change in wake time after sleep onset measured by polysomnography|Change in number of awakenings measured by polysomnography|Change in sleep efficiency measured by polysomnography|Change in percentage of time spent in the different stages sleep measured by polysomnography|Change in sleep quality measured by polysomnography|Change in time in bed measured by actigraphy|Change in sleep onset latency measured by actigraphy|Change in total sleep time measured by actigraphy|Change in wake time after sleep onset measured by actigraphy|Change in sleep efficiency measured by actigraphy|Change in sleep quality measured by actigraphy|Change in quality of life|Change in state anxiety|Change in visual analog scale of anxiety|Change in the Geriatric Depression Scale|Change in cognitive functions: Stroop test|Change in cognitive functions: trail making test (TMT)|Change in cognitive functions: dual-task Baddeley|Change in long term memory|Change in Hand grip strength|Change in Leg extension power|Change in Postural balance|Change in maximum incremental cardiopulmonary test|Change in the Global Physical Activity Questionnaire (GPAQ)|Change in Timed up and go test,Universit� de Caen Normandie|R�gion Normandie,All,"60 Years to 70 Years � (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Universit� de Caen Normandie,"January 25, 2021",June 2022,January 2023,"September 1, 2021",,"September 1, 2021","Antoine Langeard, Caen, France",,https://ClinicalTrials.gov/show/NCT05030389,NCT05030389,
anrs,NCT05033210,Prevention of Mental Health Problems Among Persons Without Personal Housing in the Context of the COVID-19 Epidemic,RESPOND-FR,Recruiting,No Results Available,Psychological Distress|Quality of Life|Psychosocial Intervention,Behavioral: Psychological First Aid (PFA)|Behavioral: Care as Usual (CAU)|Behavioral: Doing What Matters in Times of Stress (DWM)|Behavioral: Problem Management Plus (PM+),"PHQ-ADS|Level of depression (PHQ-9)|Level of anxiety (GAD-7)|Severity of posttraumatic stress disorder (PCL-5)|Self-identified problems (PSYCHLOPS)|Psychotic symptoms (MINI)|Resilience based on exposure to stressful events, general and COVID-19 related (MIMIS)|Quality of life (EQ-5D-5L)|Cost of care: impact on use of health system, other services, time out of employment and other usual activities and need for informal care (CSRI)|Resilience factors: a positive approach (PASSc)","ANRS, Emerging Infectious Diseases",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,210,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,ANRS0065s,"March 1, 2022",March 2023,October 2023,"September 2, 2021",,"July 25, 2022","Normandy Psychotrauma Center, Caen, Normandie, France|CAPSYS, Paris, Île De France, France",,https://ClinicalTrials.gov/show/NCT05033210,NCT05033210,
oui,NCT05040048,Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease,AETIONOMY,Completed,No Results Available,Alzheimer's Disease|Parkinson's Disease,"Other: Clinical, biological and imaging assessment",Performance of the biomarker in discriminating between the taxonomy of interest and the remainder of the AD/PD subjects,"Institut National de la Santé Et de la Recherche Médicale, France|Innovative Medicines Initiative|Institut d'Investigacions Biomèdiques August Pi i Sunyer|ICM Co. Ltd.|University Hospital, Bonn|Karolinska Institutet",All,"18 Years to 80 Years   (Adult, Older Adult)",,220,Other|Industry,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,14-37|2015-A00356-43,"September 4, 2015",February 2018,February 2018,"September 10, 2021",,"December 3, 2021","CIC Neurosciences - ICM - Hôpital Pitié-Salpêtrière, 47-83 Bd de l'Hôpital, Paris, France|Universitaetsklinikum Bonn (UKB), Sigmund-Freud 25 Strasse, Bonn, Germany|Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Rossello 149- 153, Barcelona, Spain|Karolinska Institutet (KI), Karolinska University Hospital S3:01, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT05040048,NCT05040048,
oui,NCT05054361,Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children,MAIT-DT1,Recruiting,No Results Available,Type1diabetes,Diagnostic Test: MAIT cells analysis|Diagnostic Test: MAIT cytokines production analysis|Diagnostic Test: Lactulose/Mannitol Test|Procedure: UGI Endoscopy|Diagnostic Test: Coxsackie virus B infection status,blood MAIT cells frequency|MAIT cells membrane markers analysis|Cytokines production in the cytoplasm of the MAIT|MAIT cell ligands measurements|Presence of CVB in the stools|Blood immunoglobulins against CVB infection statu|Measurement of intestinal gut mucosal permeability|Evaluation of gut mucosal integrity|16 S sequencing in the Subjects stools,"Institut National de la Santé Et de la Recherche Médicale, France|Assistance Publique - Hôpitaux de Paris, FRANCE|Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement|Tampere University",All,12 Months to 15 Years   (Child),,180,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C19-47|2020-A00312-37,"January 1, 2022","October 1, 2024","October 1, 2025","September 23, 2021",,"August 4, 2022","Hopital privé d'Antony, Antony, France|Hopital Necker enfants malades, Paris, France",,https://ClinicalTrials.gov/show/NCT05054361,NCT05054361,
oui,NCT05084521,Interest of Famotidine in Children With Sickle Cell Disease,FAMODREP,Recruiting,No Results Available,Sickle Cell Disease,Drug: Famotidine 400 mg/50 mL,"Difference in plasma concentration of soluble P-selectin|Difference in plasma concentration of soluble adhesion molecule: E-selectin|Difference in plasma concentration of soluble adhesion molecule: VCAM-1|Difference in plasma concentration of soluble adhesion molecule: ICAM-1|Differences in blood values: hemoglobin, reticulocytes, AST, free bilirubin, LDH, and CRP|Occurrence of serious or non-serious adverse event(s)|Occurrence of vaso-occlusive crisis","Assistance Publique - H�pitaux de Paris|INSERM U 1163 - Laboratory of molecular mechanisms of hematologic disorders and therapeutic implications, Paris",All,1 Year to 17 Years � (Child),Phase 2|Phase 3,30,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP201133|2021-001351-13,"January 12, 2022",March 2023,August 2023,"October 19, 2021",,"October 12, 2022","Necker - Enfants malades Hospital; Department of Pediatrics and Infectious Diseases, Paris, France",,https://ClinicalTrials.gov/show/NCT05084521,NCT05084521,
oui,NCT05090956,Developpement of 3T MRI Protocol,(MISAP),Completed,No Results Available,Healthy|Adult ALL|MRI,Other: mri,quality of MRI images,"Institut National de la Sant� Et de la Recherche M�dicale, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,230,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C11-43|2012-A00288-35,"June 8, 2012",January 2020,"January 29, 2020","October 25, 2021",,"October 25, 2021","Inserm U825, Toulouse, France",,https://ClinicalTrials.gov/show/NCT05090956,NCT05090956,
oui,NCT05094856,Effects of Fluid Therapy on Peripheral TIssse Perfusion During Sepsis/Septic Shock,REPTILOS,Recruiting,No Results Available,Septic Shock|Sepsis,,Compare the effect of volume expansion by saline versus albumin on the correction of peripheral tissue hypoperfusion by measuring Index skin recoloration time (CRT) at H0 and H1|CRT Measure|mottling score measure|Diuresis|Variations in cardiac flow|Variations in the biological parameters,"Assistance Publique - Hôpitaux de Paris|Grifols (funder)|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,APHP210918,"February 23, 2022",March 2024,March 2024,"October 26, 2021",,"March 3, 2023","Intensive care department, Hôpital Saint Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT05094856,NCT05094856,
oui,NCT05096000,InterMob: a Randomized Controlled Trial Aimed at Reducing Car Use in Regular Car Users,InterMob,Enrolling by invitation,No Results Available,Automobile Driving|Active Commuting,Behavioral: InterMob: a randomized controlled trial aimed at reducing car use in regular car users|Other: Active control: Air pollution information,"Changes in car use from the baseline and the beginning of the intervention (one month after the beginning of the intervention, Month 1)|Changes in car use from the baseline and half of the intervention (Month 3)|Changes in car use from the baseline the end of the intervention (Month 7)|Changes in car use from the baseline and two months after the end of the intervention (Month 9)|Changes in car use from the baseline and six months after the end of the intervention (Month 12)|Changes in car use from the baseline and one year after the end of the intervention (Month 18)|Changes in car use from the baseline and one year and a half after the end of the intervention (Month 24)|Changes in active commuting (classic or electric bike, public transport, walk, carpooling) from the baseline and and the beginning of the intervention (one month after the beginning of the intervention, Month 1)|Changes in active commuting (classic or electric bike, public transport, walk, carpooling) from the baseline and the half of the intervention (Month 3)|Changes in active commuting (classic or electric bike, public transport, walk, carpooling) from the baseline and the end of the intervention (Month 7)|Changes in active commuting (classic or electric bike, public transport, walk, carpooling) from the baseline and two months after the end of the intervention (Month 9)|Changes in active commuting (classic or electric bike, public transport, walk, carpooling) from the baseline and six months after the end of the intervention (Month 12)|Changes in active commuting (classic or electric bike, public transport, walk, carpooling) from the baseline and one year after the end of the intervention (Month 18)|Changes in active commuting (classic or electric bike, public transport, walk, carpooling) from the baseline and one year and a half after the end of the intervention (Month 24)|Changes in minutes of moderate-to-vigorous physical activity (MVPA) from the baseline and and the beginning of the intervention (one month after the beginning of the intervention, Month 1)|Changes in minutes of moderate-to-vigorous physical activity (MVPA) from the baseline and the half of the intervention (Month 3)|Changes in minutes of moderate-to-vigorous physical activity (MVPA) from the baseline and the end of the intervention (Month 7)|Changes in minutes of moderate-to-vigorous physical activity (MVPA) from the baseline and two months after the end of the intervention (Month 9)|Changes in minutes of moderate-to-vigorous physical activity (MVPA) from the baseline and six months after the end of the intervention (Month 12)|Changes in minutes of moderate-to-vigorous physical activity (MVPA) from the baseline and one year after the end of the intervention (Month 18)|Changes in minutes of moderate-to-vigorous physical activity (MVPA) from the baseline and one year and a half after the end of the intervention (Month 24)|Changes in exposure to air quality from the baseline and the end of the intervention (Month 7)|Changes in exposure to air quality from the baseline and one year after the end of the intervention (Month 18)|Changes in self-reported quality of life from the baseline and the half of the intervention (Month 3)|Changes in self-reported quality of life from the baseline and the end of the intervention (Month 7)|Changes in self-reported quality of life from the baseline and six months after the end of the intervention (Month 12)|Changes in self-reported quality of life from the baseline and one year and a half after the end of the intervention (Month 24)|Changes in self-reported biometrics from the baseline and and the beginning of the intervention (one month after the beginning of the intervention, Month 1)|Changes in self-reported biometrics from the baseline and the half of the intervention (Month 3)|Changes in self-reported biometrics from the baseline and the end of the intervention (Month 7)|Changes in self-reported biometrics from the baseline and one year after the end of the intervention (Month 18)|Motivational stage from the baseline and the end of the intervention (Month 7)|Motivational stage from the baseline and six months after the end of the intervention (Month 12)|Motivational stage from the baseline and one year after the end of the intervention (Month 18)|Motivational stage from the baseline and one year and a half after the end of the intervention (Month 24)|Green self-identity from the baseline and the end of the intervention (Month 7)|Green self-identity from the baseline and six months after the end of the intervention (Month 12)|Green self-identity from the baseline and one year after the end of the intervention (Month 18)|Green self-identity from the baseline and one year and a half after the end of the intervention (Month 24)|Changes in habits of alternative modes to the car and car use from the baseline and and the beginning of the intervention (one month after the beginning of the intervention, Month 1)|Changes in habits of alternative modes to the car and car use from the baseline and the half of the intervention (Month 3)|Changes in habits of alternative modes to the car and car use from the baseline and the end of the intervention (Month 7)|Changes in habits of alternative modes to the car and car use from the baseline and two months after the end of the intervention (Month 9)|Changes in habits of alternative modes to the car and car use from the baseline and six months after the end of the intervention (Month 12)|Changes in habits of alternative modes to the car and car use from the baseline and one year after the end of the intervention (Month 18)|Changes in habits of alternative modes to the car and car use from the baseline and one year and a half after the end of the intervention (Month 24)|Changes in intention toward alternative modes to the car and car use from the baseline and and the beginning of the intervention (one month after the beginning of the intervention, Month 1)|Changes in intention toward alternative modes to the car and car use from the baseline and the half of the intervention (Month 3)|Changes in intention toward alternative modes to the car and car use from the baseline and the end of the intervention (Month 7)|Changes in intention toward alternative modes to the car and car use from the baseline and two months after the end of the intervention (Month 9)|Changes in intention toward alternative modes to the car and car use from the baseline and six months after the end of the intervention (Month 12)|Changes in intention toward alternative modes to the car and car use from the baseline and one year after the end of the intervention (Month 18)|Changes in intention toward alternative modes to the car and car use from the baseline and one year and a half after the end of the intervention (Month 24)|Changes in self-efficacy for alternative modes and for the car from the baseline and and the beginning of the intervention (one month after the beginning of the intervention, Month 1)|Changes in self-efficacy for alternative modes and for the car from the baseline and the half of the intervention (Month 3)|Changes in self-efficacy for alternative modes and for the car from the baseline and the end of the intervention (Month 7)|Changes in self-efficacy for alternative modes and for the car from the baseline and two months after the end of the intervention (Month 9)|Changes in self-efficacy for alternative modes and for the car from the baseline and six months after the end of the intervention (Month 12)|Changes in self-efficacy for alternative modes and for the car from the baseline and one year after the end of the intervention (Month 18)|Changes in self-efficacy for alternative modes and for the car from the baseline and one year and a half after the end of the intervention (Month 24)|Changes in intention implementation from the baseline and and the beginning of the intervention (one month after the beginning of the intervention, Month 1)|Changes in intention implementation from the baseline and the half of the intervention (Month 3)|Changes in intention implementation from the baseline and the end of the intervention (Month 7)|Changes in intention implementation from the baseline and two months after the end of the intervention (Month 9)|Changes in intention implementation from the baseline and six months after the end of the intervention (Month 12)|Changes in intention implementation from the baseline and one year after the end of the intervention (Month 18)|Changes in intention implementation from the baseline and one year and a half after the end of the intervention (Month 24)|Changes in attitudes toward alternative modes to the car and toward car use from the baseline and and the beginning of the intervention (one month after the beginning of the intervention, Month 1)|Changes in attitudes toward alternative modes to the car and toward car use from the baseline and the half of the intervention (Month 3)|Changes in attitudes toward alternative modes to the car and toward car use from the baseline and the end of the intervention (Month 7)|Changes in attitudes toward alternative modes to the car and toward car use from the baseline and two months after the end of the intervention (Month 9)|Changes in attitudes toward alternative modes to the car and toward car use from the baseline and six months after the end of the intervention (Month 12)|Changes in attitudes toward alternative modes to the car and toward car use from the baseline and one year after the end of the intervention (Month 18)|Changes in attitudes toward alternative modes to the car and toward car use from the baseline and one year and a half after the end of the intervention (Month 24)|Changes in perceived susceptibility and perceived severity of getting coronavirus disease from the baseline and and the beginning of the intervention (one month after the beginning of the intervention, Month 1)|Changes in perceived susceptibility and perceived severity of getting coronavirus disease from the baseline and the half of the intervention (Month 3)|Changes in perceived susceptibility and perceived severity of getting coronavirus disease from the baseline and the end of the intervention (Month 7)|Changes in perceived susceptibility and perceived severity of getting coronavirus disease from the baseline and two months after the end of the intervention (Month 9)|Changes in perceived susceptibility and perceived severity of getting coronavirus disease from the baseline and six months after the end of the intervention (Month 12)|Changes in perceived susceptibility and perceived severity of getting coronavirus disease from the baseline and one year after the end of the intervention (Month 18)|Changes in perceived susceptibility and perceived severity of getting coronavirus diseasefrom the baseline and one year and a half after the end of the intervention (Month 24)|Changes in subjective norms toward alternative modes to the car and car use from the baseline and and the beginning of the intervention (one month after the beginning of the intervention, Month 1)|Changes in subjective norms toward alternative modes to the car and car use from the baseline and the half of the intervention (Month 3)|Changes in subjective norms toward alternative modes to the car and car use from the baseline and the end of the intervention (Month 7)|Changes in subjective norms toward alternative modes to the car and car use from the baseline and two months after the end of the intervention (Month 9)|Changes in subjective norms toward alternative modes to the car and car use from the baseline and six months after the end of the intervention (Month 12)|Changes in subjective norms toward alternative modes to the car and car use from the baseline and one year after the end of the intervention (Month 18)|Changes in subjective norms toward alternative modes to the car and car use from the baseline and one year and a half after the end of the intervention (Month 24)|Changes in carbon footprint associated to transport","Aina Chalabaev|IDEX - Univ. Grenoble-Alpes|Région Auvergne-Rhône Alpes|Institut de Recherche en Santé Publique, France|ADEME|Institut National de la Santé Et de la Recherche Médicale, France|Métropole Grenoble-Alpes|Université Joseph Fourier",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",INTERMOBFRUGA,"September 21, 2021","September 30, 2024","September 30, 2025","October 27, 2021",,"October 27, 2021","Univ. Grenoble-Alpes, Saint-Martin-d'Hères, Rhône-Alpes, France",,https://ClinicalTrials.gov/show/NCT05096000,NCT05096000,36114537
oui,NCT05097677,Follow-up of Covid-19 Long Term Sequelae,,Recruiting,No Results Available,COVID-19 Pneumonia|COVID-19 Respiratory Infection|COVID-19 Acute Bronchitis|COVID-19 Acute Respiratory Distress Syndrome|COVID-19 Lower Respiratory Infection|Covid19|Corona Virus Infection|Coronavirus|Coronavirus Infections|SARS-CoV2 Infection|SARS-CoV-2 Acute Respiratory Disease|SARS-Associated Coronavirus|SARS Pneumonia|SARS (Severe Acute Respiratory Syndrome)|SARS (Disease)|Coronavirus Pneumonia|Coronavirus Disease 2019|Coronavirus Sars-Associated,Other: Not applicable (observational study),Clinical assessments of COVID-19 sequelae|Laboratory assessments of COVID-19 sequelae|Radiological assessments of COVID-19 sequelae|Length of COVID-19 sequelae|Association between SARS-CoV-2 variants and COVID-19 sequelae|Association between immunological patterns and COVID-19 sequelae|COVID-19 reinfections|Patterns of intestinal microbiome after SARS-CoV-2 infection|Patterns of pulmonary microbiome after SARS-CoV-2 infection|Human and viral genetic markers related to disease severity,"Azienda Ospedaliera Universitaria Integrata Verona|University of Bologna|Institut National de la Sant� Et de la Recherche M�dicale, France|Universiteit Antwerpen|University of Sao Paulo|Barcelona Institute for Global Health|Fondation pour la Recherche M�dicale|Andaluz Health Service|Charite University, Berlin, Germany|CINECA consorzio universitario italiano|University Medical Center Groningen|Hospital Universitario Virgen Macarena",All,"14 Years and older � (Child, Adult, Older Adult)",,7500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ORCHESTRA WP2,"April 16, 2021","July 16, 2023","July 16, 2023","October 28, 2021",,"January 4, 2022","University of Antwerp - Laboratory of Medical Microbiology, Antwerpen, Belgium|Fondation Congolaise pour la Recherche M�dicale, Brazzaville, Congo|INSERM, Paris, France|Policlinico S.Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento, Verona, Italy|UMCG, University of Groningen, Groningen, Netherland, Netherlands|Hosp. Univ. Virgen Macarena / Universidad de Sevilla, Sevilla, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT05097677/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05097677,NCT05097677,
oui,NCT05098093,"Bioavailabity of the Major Metabolites of a Botanical Extract, in Healthy Adults",,Not yet recruiting,No Results Available,Healthy,Dietary Supplement: SBE|Dietary Supplement: DBE|Dietary Supplement: BP,(AUC 0-t) : Area under the curve of the serum concentration of the main metabolites of the products.|AUC 0-t for the main metabolites of the products.|Serum peak concentration (Cmax) of the metabolites of the tested products.|Time to serum peak concentration (Tmax) of the metabolites of the tested products.|Elimination half-life (T1/2) of serum metabolites of the tested products defined by the time required for the concentration of product metabolites to decrease to half of Cmax.|Concentration of urinary crocetin (ng/mg of creatinine) of the tested products at the end of the visit|Systolic and diastolic blood pressure,"Activ'inside|CIC Inserm 1405, University Hospital Clermont-Ferrand, France",Male,18 Years to 35 Years � (Adult),Not Applicable,17,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BIODAI-2021,"November 1, 2021","February 1, 2022","February 1, 2022","October 28, 2021",,"October 28, 2021","CIC Inserm 1405, University Hospital Clermont-Ferrand,, Clermont-Ferrand cedex 1, France",,https://ClinicalTrials.gov/show/NCT05098093,NCT05098093,
oui,NCT05099341,DEPLIPIDO Study: Functional and Lipidomic Analysis of Plasma HDL in Patients With Depression Compared to Controls,DepLIPIDO,Recruiting,No Results Available,Depression,Other: HDRS-17 depression scale|Biological: Blood sampling,Measurement of cholesterol efflux by fluorescent method on THP-1 cell derived macrophages,Centre Hospitalier Universitaire Dijon,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,CHAUVET CRBFC-E 2019,"October 1, 2021",October 2023,October 2023,"October 29, 2021",,"October 29, 2021","Chu Dijon Bourgogne, Dijon, France",,https://ClinicalTrials.gov/show/NCT05099341,NCT05099341,
oui,NCT05101863,FMRI of Dietary Decision-making in Food Addicted Participants Compared to Non-food Addicted Participants,MOTIVFOOD,Not yet recruiting,No Results Available,"Food Addiction, Obesity, fMRI, Decision-making, Motivational Interviewing",Behavioral: Motivational interviewing,BOLD signal difference between talk types|BOLD signal difference between talk types and participant groups|Self control during dietary decision-making|Food addiction one month after motivational interviewing|dietary habits one month after motivational interviewing,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",,105,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C20-52|2020-A02777-32,"December 1, 2021","December 1, 2023","December 1, 2023","November 1, 2021",,"November 17, 2021","Liane Schmidt, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT05101863,NCT05101863,
oui,NCT05107349,"Cell Signaling, Reinnervation and Metabolism in Kennedy Disease and Amyotrophic Lateral Sclerosis (ALS)",CERMALS,Not yet recruiting,No Results Available,Amyotrophic Lateral Sclerosis|Kennedy Disease,Procedure: Muscle biopsy,Quantification of neuromuscular junctions innervation|Level of the main components of the insulin/IGF-1 system|Correlations between metabolic profiles and muscle function,"Assistance Publique - Hôpitaux de Paris|Association Française contre les Myopathies (AFM), Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,D20180344|2018-A03044-51,November 2021,November 2024,February 2025,"November 4, 2021",,"November 4, 2021","Pitié-Salpêtrière Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT05107349,NCT05107349,
oui,NCT05112770,AI for Allograft Diseases Diagnosis and Prognosis After Kidney Transplantation,AI4ADAPT,Not yet recruiting,No Results Available,Kidney Transplantation,,Diagnostic model accuracy|Prognostic model accuracy|Strenght of the models,Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",,1500,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,APHP210907,April 2023,April 2026,April 2026,"November 9, 2021",,"January 18, 2023","H�pital Necker-Enfants Malades, Paris, France",,https://ClinicalTrials.gov/show/NCT05112770,NCT05112770,
non,NCT05127681,Bone Microarchitecture in Men With Hemophilia,HEMOS,Recruiting,No Results Available,Severe Hemophilia A|Osteoporosis,Radiation: HR-pQCT|Biological: Blood sample|Radiation: Dual energy X-ray absorptiometry|Other: medical data collection,number of trabecular at distal tibia|number of trabecular at distal radius|Sera bone remodeling biomarkers|reflection of bone strength|Trabecular Bone Score (TBS),Hospices Civils de Lyon,Male,20 Years to 60 Years � (Adult),Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,69HCL19_0390|2019-A03281-56,"March 1, 2022","June 1, 2024","June 1, 2024","November 19, 2021",,"March 9, 2022","H�pital Cardio-Vasculaire et Pneumologique, Bron, France",,https://ClinicalTrials.gov/show/NCT05127681,NCT05127681,
oui,NCT05139784,BeAT1D: Benign Autoimmunity and Type 1 Diabetes,BeAT1D,Recruiting,No Results Available,Type 1 Diabetes,Other: Biosampling,To define the frequency and phenotype of autoimmune T lymphocytes reactive to islet antigens in the different study groups.|To define the frequency and phenotype of autoimmune B lymphocytes reactive to islet antigens in the different study groups.|To identify novel islet epitopes recognized by autoimmune T and B lymphocytes.|To define the phenotype of these lymphocytes.|To define the pathogenicity of these lymphocytes against pancreatic beta cells.|To define the antigen receptors used by these lymphocytes to recognize their target epitopes.|To define the correlation between the biomarkers analyzed and insulin secretion.|To define the differences between lymphocytes in the blood and those in pancreatic lymph nodes.,"Institut National de la Santé Et de la Recherche Médicale, France",All,"1 Year and older   (Child, Adult, Older Adult)",,740,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C20-61|2021-A01619-32,"October 24, 2022",December 2027,December 2027,"December 1, 2021",,"December 2, 2022","APHP Hôpital Avicenne, Bobigny, Ile-de-France, France|APHP Hôpital J. Verdier, Bondy, Ile-de-France, France|APHP Hôpital L. Mourier, Colombes, Ile-de-France, France|Hôpital Sud Francilien, Corbeil-Essonnes, Ile-de-France, France|Hôpital Mignot - Service de Pédiatrie, Le Chesnay, Ile-de-France, France|Hôpital Mignot - Services de Diabétologie/Endocrinologie Adultes, Le Chesnay, Ile-de-France, France|APHP Hôpital Kremlin-Bicêtre, Le Kremlin-Bicêtre, Ile-de-France, France|APHP Hôpital Lariboisière, Paris, Ile-de-France, France|APHP Hôpital Saint Antoine, Paris, Ile-de-France, France|APHP Hôpital Pitié-Salpêtrière - Service de Chirurgie, Paris, Ile-de-France, France|Hôpital Pitié-Salpêtrière - Service de Diabétologie, Paris, Ile-de-France, France|APHP Hôpital Cochin - Service de Chirurgie, Paris, Ile-de-France, France|APHP Hôpital Cochin - Service de Diabétologie et Immunologie Clinique, Paris, Ile-de-France, France|APHP Hôpital Européen G. Pompidou, Paris, Ile-de-France, France|APHP Hôpital Bichat, Paris, Ile-de-France, France|APHP Hôpital R. Debré, Paris, Ile-de-France, France|Hôpital René Dubos, Pontoise, Ile-de-France, France",,https://ClinicalTrials.gov/show/NCT05139784,NCT05139784,
oui,NCT05146375,Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2),MSF1-TGFBR2,Recruiting,No Results Available,Thoracic Aortic Aneurysm,Biological: TGFBR2,Clinical phenotype|TGFBR2 and other gene mutations involved in aneurysms|Genotype analysis|Transcriptome analysis,"French Cardiology Society|Fédération Française de Cardiologie|Institut National de la Santé Et de la Recherche Médicale, France",All,"10 Years and older   (Child, Adult, Older Adult)",,53,Other,Observational,Observational Model: Family-Based|Time Perspective: Prospective,2021-02,"November 24, 2022","November 30, 2023","November 30, 2025","December 6, 2021",,"January 13, 2023","Hopital Bichat-Claude Bernard, Paris, France",,https://ClinicalTrials.gov/show/NCT05146375,NCT05146375,
oui,NCT05151718,Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents,EPENDYMOMICS,Recruiting,No Results Available,Ependymoma of Brain|Pediatric Solid Tumor,,Definition of radiogenomics signatures that are predictive of patient outcome|Definition of new RT target volumes based on radiomic features and to choose their indications based on biomolecular prognostic factors|To predict resistance to therapy by using the histological data in digital format and the biomolecular data for analysis by methods based on artificial deep neural networks .,"Institut Claudius Regaud|Institut National de la Santé Et de la Recherche Médicale, France|Centre Leon Berard|Assistance Publique Hopitaux De Marseille|Centre Hospitalier St Anne|Institut Pasteur",All,"up to 25 Years   (Child, Adult)",,370,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,21 HLTETE 01,"September 30, 2021","October 1, 2023","September 29, 2024","December 9, 2021",,"December 23, 2022","Institut Claudius Regaud, Toulouse, France",,https://ClinicalTrials.gov/show/NCT05151718,NCT05151718,
oui,NCT05154383,"Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression",INFLUOMICS,Completed,No Results Available,Vaccine Reaction,Biological: Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda)|Biological: Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine,Change of Transcriptomic profiles|Change of Innate cellular phenotyping|Change of Gene signature|Humoral immune responses,"Centre Hospitalier Annecy Genevois|Sanofi Pasteur, a Sanofi Company|Euraxi Pharma|Hospices Civils de Lyon|Institut National de la Santé Et de la Recherche Médicale, France|Eurofins Optimed",All,65 Years and older   (Older Adult),Phase 4,60,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,21-05,"November 15, 2021","July 21, 2022","July 21, 2022","December 13, 2021",,"August 8, 2022","Centre Hospitalier Annecy Genevois, Annecy, France|Centre Hospitalier Métropole Savoie, Chambéry, France",,https://ClinicalTrials.gov/show/NCT05154383,NCT05154383,
oui,NCT05154799,Developmental Coordination Disorder,DYSENS,Recruiting,No Results Available,Motor Skills Disorders|Neurodevelopmental Disorders,Behavioral: Proprioception and tactile localization with manual or ocular response and/or free hand grasp,Localization error distance|Reaction time of motor localization response|change related to tool-use of amplitude of velocity peak and the peak opening of the thumb-index grip of free reach-to-grasp limb movements|change related to tool-use of latency of velocity peak and the peak opening of the thumb-index grip of free reach-to-grasp limb movements|change related to tool-use of acceleration peak of the upper limb of free reach-to-grasp limb movements|change related to tool-use of deceleration peak of the upper limb of free reach-to-grasp limb movements,Hospices Civils de Lyon,All,"9 Years to 40 Years � (Child, Adult)",Not Applicable,280,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL21_0338,"December 21, 2021","January 21, 2024","January 21, 2024","December 13, 2021",,"January 31, 2023","Equipe IMPACT du CRNL INSERM U1028, CNRS UMR 5292, Bron, Rhone Alpes, France",,https://ClinicalTrials.gov/show/NCT05154799,NCT05154799,
oui,NCT05167396,REtinal and VIsual Cortical Response in Early PSYchosis,REVIPSY,Recruiting,No Results Available,Prodromal Schizophrenia|Psychotic Episode|Prodromal Symptoms|Healthy Controls,Device: Retinaute (BioSerenity)|Device: EEG Headset 64 electrodes (BioSemi)|Device: MonPackOne (Metrovision),N95 wave|a wave|b wave|P100 wave|Visual Object and Space Perception (VOSP)|Verbal Fluency|Working Memory|Betarythm (EEG oscillatory responses)|Contingent Negative Variation (CNV)|CPT-AX (Continuous Performance Task version AX)|fNART (French adaptation of National Adult Reading Test)|TAP (Test of Attentional Performance),"Centre Psychothérapique de Nancy|BioSerenity|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 40 Years   (Adult),Not Applicable,90,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RIPH 2021-04|n° IDRCB 2021-A01700-41,"January 26, 2022","January 26, 2025","January 26, 2026","December 22, 2021",,"February 8, 2023","Centre Psychothérapeutique de Nancy, Laxou, France",,https://ClinicalTrials.gov/show/NCT05167396,NCT05167396,
oui,NCT05186389,"Jejunal Luminal and Colonic Mucosa-Associated Microbiota in Metabolic Diseases: Methods, Identification and Causalities",JE/COL-MIME,Not yet recruiting,No Results Available,Diabetes Mellitus|Obesity|Metabolic Disease,,Metagenomic analysis|Clinical associations with metagenomic analysis,"Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),,90,Other,Observational,Observational Model: Cohort|Time Perspective: Other,C20-86,"January 26, 2022","February 26, 2023","March 26, 2023","January 11, 2022",,"January 11, 2022",,,https://ClinicalTrials.gov/show/NCT05186389,NCT05186389,
oui,NCT05188066,Study of Pregnancy Pathologies Associated With Placental Abnormalities,,Not yet recruiting,No Results Available,Pre-eclampsia|Pre-Term|Fetal Growth Retardation,Diagnostic Test: Histology,To better characterize pregnancy pathologies from implantation to childbirth|Link between the frequencies of histological aberrations and worsening of the pathology,"University Hospital, Grenoble|Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 52 Years   (Adult),,800,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,38RC20.115,"January 6, 2022","January 31, 2027","January 31, 2030","January 12, 2022",,"January 12, 2022",,,https://ClinicalTrials.gov/show/NCT05188066,NCT05188066,
oui,NCT05199896,Touching the World With a Cane: Cognitive and Neural Processes,TOOL_TOUCH,Recruiting,No Results Available,Visual Impairment|Healthy,Behavioral: Behavioral protocol|Device: EEG protocol|Device: fMRI protocol,Perceived location|Brain activity,Hospices Civils de Lyon,All,18 Years to 60 Years � (Adult),Not Applicable,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL21_0882,"April 20, 2022",October 2026,October 2026,"January 20, 2022",,"August 31, 2022","Equipe IMPACT du CRNL, B�timent INSERM, Bron, France",,https://ClinicalTrials.gov/show/NCT05199896,NCT05199896,
non,NCT05201222,Predictive Value of Induced Sleep Endoscopy on Surgical Indication in Obstructive Sleep Apnea Syndromes,SOMMEIL_INDUIT,Completed,No Results Available,Obstructive Sleep Apnea Syndrome,,Interest of sleep endoscopy before making a surgical indication in a patient with sleep apnea syndrome|Reliability of endoscopy under sleep,Groupe Hospitalier Paris Saint Joseph|Institut Arthur Vernes,All,"18 Years and older � (Adult, Older Adult)",,145,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,SOMMEIL_INDUIT,"December 15, 2021","August 30, 2022","October 31, 2022","January 21, 2022",,"November 1, 2022","Institut Arthur Vernes, Paris, France",,https://ClinicalTrials.gov/show/NCT05201222,NCT05201222,
anrs,NCT05202288,Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers,,Not yet recruiting,No Results Available,Ebola Virus Disease,Biological: Ervebo|Drug: Inmazeb,EBOV GP IgG rate at S24 post-vaccination|VSV viremia|EBOV GP IgG rate at W4|EBOV GP IgG rate at W12|Ratel of neutralizing antibodies at W12 post-vaccination|Ratel of neutralizing antibodies at W24 post-vaccination|Proportion of participants with grade 3 or 4 adverse events 2 days after vaccination|Proportion of participants with grade 3 or 4 adverse events 4 weeks after vaccination|Proportion of participants lost to follow-up at W24 after vaccination,"ANRS, Emerging Infectious Diseases|Alliance for International Medical Action|University of Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France|Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire|Agence Nationale de Sécurité Sanitaire de Guinée (ANSS)|Clinical and Operational Research Alliance (CORAL)|Méthodologie et Evaluation pour la Recherche clinique et Epidémiologique sur le VIH en Afrique (MEREVA)",All,"18 Years and older   (Adult, Older Adult)",Phase 2,135,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS 0064S IMOVA,March 2022,March 2023,March 2023,"January 21, 2022",,"January 21, 2022","Research center of Landreah, Conakry, Guinea",,https://ClinicalTrials.gov/show/NCT05202288,NCT05202288,
oui,NCT05206123,Sexual Needs of Adolescents Living With HIV Since Childhood,SSVIH,Recruiting,No Results Available,Hiv|Perinatal HIV Infection,Other: Interview,Qualitative analysis,Assistance Publique - H�pitaux de Paris|INSERM CESP1018,All,18 Years to 25 Years � (Adult),,20,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,APHP211568|2021-A02820-41,"March 17, 2022",March 2023,March 2023,"January 25, 2022",,"September 9, 2022","Maison de Solenn, Paris, France",,https://ClinicalTrials.gov/show/NCT05206123,NCT05206123,
oui,NCT05211401,Rituximab in Patients With ST-elevation Myocardial Infarction,RITA-MI2,Recruiting,No Results Available,ST Elevated Myocardial Infarction,Drug: Active arm 200 mg|Drug: Active arm 1000 mg|Drug: Placebo arm,Left ventricular ejection fraction (LVEF) by CMR at 6 months.|Infarct size by CMR|Oedema extension by CMR|T2 relaxation time at ischemic region by CMR|Microvascular obstruction by CMR|NT-pro-BNP|Adverse event related to treatment,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,558,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",APHP210015|2021-003340-24,"June 1, 2022",October 2026,April 2027,"January 27, 2022",,"August 25, 2022","Cardiology department, Hôpital Bichat, AP-HP, Paris, France",,https://ClinicalTrials.gov/show/NCT05211401,NCT05211401,
oui,NCT05214742,Developing Derived Induced Pluripotent Stem Cells as a Model to Understand Imprinted Disorders,ID-STEM,Enrolling by invitation,No Results Available,Induced Pluripotent Stem Cells,Other: Diagnostic Test,The objective of the study is to understand the consequences of epimutations found,"Institute of Cardiometabolism and Nutrition, France",All,"3 Months and older   (Child, Adult, Older Adult)",,20,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2021-A01597-34,"January 19, 2022","January 30, 2022",December 2026,"January 31, 2022",,"April 28, 2022","Hôpital Trousseau, Paris, France",,https://ClinicalTrials.gov/show/NCT05214742,NCT05214742,
oui,NCT05216705,Study of Exploratory Plasmatic Markers of Alcohol Withdrawal,STEP-AW,Not yet recruiting,No Results Available,Alcohol Withdrawal,,Change in NFL between T1 and T3|Change in Tau protein between T1 and T3|Change in GFAP between T1 and T3|Change in UCHL1 between T1 and T3|Change in biomarkers between T1 and T2|Correlation of the change between T1 and T3 of the four biomarkers|Correlation with the plasmatic glutamate|Association with the intensity of alcohol withdrawal|Association with neurological signs,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",,25,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C20-67,"March 1, 2022","October 1, 2023","October 1, 2024","January 31, 2022",,"January 31, 2022","GHU APHP Nord - Université de Paris, Site Lariboisière Fernand-Widal, Paris, France",,https://ClinicalTrials.gov/show/NCT05216705,NCT05216705,
non,NCT05219916,Selection of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent HIV Proviruses,FXR#2,Terminated,No Results Available,Human Immunodeficiency Virus I Infection,Procedure: Blood collection.,Measurement of the reactivation level and the EC50 of the optimized molecules.,Hospices Civils de Lyon,All,"18 Years to 65 Years � (Adult, Older Adult)",Not Applicable,17,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,69HCL21_0846,"April 12, 2022","July 22, 2022","July 22, 2022","February 2, 2022",,"March 13, 2023","Service des maladies infectieuses et tropicales H�pital de la Croix Rousse, Lyon, France",,https://ClinicalTrials.gov/show/NCT05219916,NCT05219916,
oui,NCT05222139,Monitoring COVID-19 Vaccination Response in Fragile Populations,ORCHESTRA-4,Recruiting,No Results Available,SARS CoV 2 Infection|Vaccination Infection|Breakthrough Infection,Biological: COVID-19 vaccination,Early immune response to COVID-19 vaccine patients|Late immune response to COVID-19 vaccine|Rate of COVID-19 breakthrough infections|Rate of hospital admission for COVID-19 breakthrough infections condition and its impact on the outcome in fragile patients|Rate of death for COVID-19 breakthrough infections patients,"University of Bologna|Universita di Verona|Hospital Universitario Virgen Macarena|Azienda Ospedaliera di Padova|Azienda Ospedaliero-Universitaria di Parma|Azienda Ulss 2 Marca Trevigiana|University College Dublin|Luxembourg Institute of Health|ICONA Foundation|University Medical Center Groningen|University of Buenos Aires|PENTA Foundation|Universiteit Antwerpen|Institut National de la Santé Et de la Recherche Médicale, France|Helmholtz Zentrum München|CINECA consorzio universitario italiano|Charite University, Berlin, Germany|Centre de Recherche Médicale de Lambaréné",All,"Child, Adult, Older Adult",,20000,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,ORCHESTRA-4,"May 24, 2021","July 16, 2023","July 16, 2023","February 3, 2022",,"February 28, 2022","Universidad de Buenos Aires (UBA), Buenos Aires, Argentina|Centre de Recherches Medicales de Lambaréné (CERMEL), Lambaréné, Gabon|Catholics Bishops Conference of India, Society for Medical Education (CBCI), Bangalore, India|Translational Health Science and Technology Institute (THSTI), Faridabad, India|University College Dublin, Dublin, Ireland|University of Bologna, Bologna, Italy|ICONA Foundation, Milano, Italy|Aziena Ospedaliera Universitaria di Padova - Centro Trapianti di fegato, Padova, Italy|Azienda Ospedaliera Universitaria di Padova - Centro trapianti di polmone, Padova, Italy|Azienda Ospedaliera Universitaria di Padova - UOC Chirurgia dei trapianti di rene, Padova, Italy|Azienda Ospedaliera Universitaria di Padova - UOC Nefrologia Pediatrica, Padova, Italy|Azienda Ospedaliero Universitaria di Padova - Clinica Medica 5, Padova, Italy|Azienda Ospedaliero Universitaria di Padova - Trapianto Multiviscerale, Padova, Italy|Azienda Ospedaliero Universitaria di Padova - UOC Cardiochirurgia, Padova, Italy|Azienda Ospedaliero Universitaria di Padova - UOC Clinica Pediatrica, Padova, Italy|PENTA Foundation, Padova, Italy|Azienda Ospedaliera Universitaria di Parma, Parma, Italy|Azienda ULSS2 Marca Trevigiana, Treviso, Italy|University of Verona, Verona, Italy|Luxembourg Institute of Health (LIH), Luxembourg, Luxembourg|University Medical Center Groningen (UMCG), Groningen, Netherlands|Hosp. Univ. Virgen Macarena / Universidad de Sevilla, Sevilla, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT05222139/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT05222139,NCT05222139,
oui,NCT05223608,Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy,ImmuCCo-1905,Recruiting,No Results Available,"Solid Tumor, Adult|Metastasis",Other: ImmuCCo Cohort,Number of patients treated by immunotherapy and registered in the database.|Overall Survival|Progression-Free Survival|Tumor response|Co-medications|Toxicity of immunotherapy,"Centre Oscar Lambret|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ImmuCCo-1905,"March 3, 2022",March 2027,March 2028,"February 4, 2022",,"March 22, 2022","Centre Oscar Lambret, Lille, Hauts-de-France, France",,https://ClinicalTrials.gov/show/NCT05223608,NCT05223608,
oui,NCT05223621,Sexuality and Sexual Quality of Life in Adult Patients With Turner Syndrome (TS) Compared With Patients With Primary Ovarian Insufficiency Different From TS,SEXATURN,Enrolling by invitation,No Results Available,Turner Syndrome|Primary Ovarian Insufficiency,,Sexuality anomalies with score (patient TS),"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 50 Years   (Adult),,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP200833|IDRCB 2020-A01768-31,February 2022,May 2022,May 2022,"February 4, 2022",,"February 4, 2022","Hôpital St Antoine, Sorbonne University, Endocrinology-Diabetology Department, Reproductive medicine, Paris, France",,https://ClinicalTrials.gov/show/NCT05223621,NCT05223621,
oui,NCT05227547,Mapping and Characterization of Alveolar Cells During Smoking and Chronic Obstructive Disease,CoStemCells,Recruiting,No Results Available,Chronic Obstructive Lung Disease|Chronic Obstructive Pulmonary Disease,Other: Thoracic resection surgery,"Number of alveolar organoids|Fibroblast proliferation capacity|Differentiation into myofibroblasts|Fibroblast migration capacity|Modulated signaling pathways in isolated fibroblasts between groups|Modulated signaling pathways in endothelial cells between groups|Evaluation of cytokines in fibroblasts supernatant|Tumor progression|Identification of different cell types on total lung|Severity of pulmonary emphysema,|Type of pulmonary emphysema|Research of pulmonary biomarkers|Identification of biomarkers in the pre and postoperative circulating blood|Identification of biomarkers in the intestinal microbiota|Measurement of Forced expiratory volume at one second (FEV1)|Measurement of Forced Vital Capacity (FVC )|Measurement of pulmonary diffusion capacity of CO (DLCO)|Measurement of CO transfer coefficient (KCO)","Centre Hospitalier Intercommunal Creteil|Henri Mondor University Hospital|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,186,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,CoStemCells,"October 5, 2022","October 31, 2025","October 5, 2030","February 7, 2022",,"March 8, 2023","Rousseau-Bussac, Créteil, France|Hopital Cochin, Paris, France|HEGP, Paris, France|Hopital Tenon, Paris, France",,https://ClinicalTrials.gov/show/NCT05227547,NCT05227547,
associ�,NCT05228262,"Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis",VASCO,Recruiting,No Results Available,"Osteoporosis, Postmenopausal",Other: Cohort follow-up,"Endothelial dysfunction measured by FMD (Flow-Mediated Dilation) in patients with anti-osteoporotic treatment|Measurement of digital volume increase by RHI (Reactive hyperhemia index), (Endo-PAT2000; Itamar Medical Ltd, Israel).|Microcirculation measurement by FLD (Flow Laser Doppler), PeriFlux� (Perimed)|Sphygmocor CPV� (Atcor Medical) large artery stiffness measurement (PWV)|Evaluation of the Abdominal Aorta Calcification (AAC) (Kauppila score)|Strength, Assistance with walking, Rising from a chair, Climbing stairs, and Falls (SARC-F) questionnaire|Short Physical Performance Battery (SPPB) Questionnaire|SPPB Questionnaire|Evaluation of the muscular strength|Body composition measurement on Dual energy X-ray Absorptiometry (DXA)|The Pittsburgh Sleep Quality Index (PSQI)|The Brief Pain Inventory Questionnaire (BPI)|The numerical pain scale|The Hospital Anxiety and Depression Scale (HAD)|The 36-Item Short Form Survey (SF-36)|Sclerostin dosage|Osteocalcin dosage|Periostin dosage|Irisin dosage|N-terminal propeptide of procollagen type 1 (P1NP) dosage|Dickkopf-related protein 1 (DKK1) dosage|C-terminal telopeptides of collagen type 1 (CTX) dosage|Distribution of gene polymorphisms using OpenArray technology|MicroRNA analysis using OpenArray technology|Study of the microbiota|Identification of predictive factors of treatment effectiveness according to variations in vascular and endothelial function parameters and pain, which will be studied first as quantitative parameters and then as categorical data.","University Hospital, Clermont-Ferrand",Female,"50 Years and older � (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RBHP 2021 ME_PICKERING|2021-A02276-35,"February 15, 2022","February 1, 2027","February 1, 2027","February 8, 2022",,"October 10, 2022","CHU de Clermont-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT05228262,NCT05228262,
oui,NCT05230277,OSTEOPATHY IN THE TREATMENT OF IBS SYMPTOMS IN ADULTS,,Not yet recruiting,No Results Available,OSTEOPATHY IN THE TREATMENT OF IBS SYMPTOMS IN ADULTS,Other: the active osteopathic treatment (AOT)|Other: the sham osteopathic treatment,The effectiveness (response to treatment) at 1-month follow-up:|Effectiveness at 3 months (response to treatment based on the IBS-SSS) and changes in total IBS-Quality Of Life (IBS-QOL) scores up to 3 months.,"Centre Hospitalier de Troyes|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,404,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,TREAT OF IBS SYMPTOMS IN ADULT,"March 1, 2023","January 1, 2024","January 1, 2024","February 8, 2022",,"March 2, 2023",,,https://ClinicalTrials.gov/show/NCT05230277,NCT05230277,
oui,NCT05230368,Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load,SYNACTHIV,Recruiting,No Results Available,"HIV-1-infection, Subtype b",Drug: Decitabine cycle 1|Drug: Romidepsin cycle 1|Drug: Decitabine cycle 2|Drug: Romidepsin cycle 2|Drug: Decitabine cycle 3|Drug: Romidepsin cycle 3|Drug: Decitabine cycle 4|Drug: Romidepsin cycle 4,Incidence of Serious Adverse Events (SAE) and severe clinical or biological adverse events (AE) related to the study drugs|Incidence of clinical and biological adverse events (AE) of all grades|Efficacy of the treatment on the HIV reservoir|Capacity of latently-infected cells to be reactivated|Increase in viral load|Blood concentration of decitabine and romidepsin after injection|HIV-1 transcripts measure,"ANRS, Emerging Infectious Diseases|INSERM SC10-US19",Male,"18 Years to 69 Years � (Adult, Older Adult)",Phase 1,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ANRS 171 SYNACTHIV,"December 14, 2022","April 15, 2026","April 15, 2026","February 8, 2022",,"January 31, 2023","CHU Saint-Pierre, Bruxelles, Belgium|H�pitaux Universitaires Paris Sud, Bic�tre, AP-HP, Le Kremlin-Bic�tre, France|CIC Cochin Pasteur, Paris, France",,https://ClinicalTrials.gov/show/NCT05230368,NCT05230368,
oui,NCT05231447,Birth Defect Registry in South West Region of France,ATENA,Not yet recruiting,No Results Available,Congenital Abnormalities,Other: Environmental survey,Number of congenital anomalies|Measure of the incidence of congenital anomalies in south west region of France|Identification of environmental factors associated with congenital anomalies,"University Hospital, Bordeaux|Institut de Recherche en Santé Publique, France|Institut National de la Santé Et de la Recherche Médicale, France",All,1 Minute to 1 Year   (Child),,9000,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,CHUBX 2019/36,"March 1, 2022","March 1, 2025","March 1, 2025","February 9, 2022",,"March 9, 2022","Bordeaux University Hospital, Pessac, France",,https://ClinicalTrials.gov/show/NCT05231447,NCT05231447,
oui,NCT05233072,Prognostic Impact of Neopterin on Resumption of Walking After a Fracture of the Upper Neck of the Femur in the Elderly,MAMI,Recruiting,No Results Available,Fracture of Neck of Femur|Resumption of Walking,Other: Blood sample,Resumption of walking with or without help|Short Physical Performance Battery score|Hand-grip test|Measurement of bioimpedancemetry|Activity of Daily Living score|Medical Outcome Study Short Form 12|Number of participants alive|Number of participants living at home,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,75 Years to 110 Years   (Older Adult),Not Applicable,150,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,APHP210718|2021-A00976-35,"May 16, 2022",May 2024,December 2024,"February 10, 2022",,"August 30, 2022","GH Pitié-Salpêtrière / Service de gériatrie, Paris, Ile-de-France, France",,https://ClinicalTrials.gov/show/NCT05233072,NCT05233072,
oui,NCT05233267,Neopterin on Admission to Intensive Care Unit,NUAGE,Not yet recruiting,No Results Available,Elderly Patient (80 Years Old or More) Admitted to Intensive Care,Other: Blood sample,Survival without significant loss of autonomy|Intra-hospital mortality|Mortality|Functional autonomy|Short Physical Performance Battery|Handgrip test|Neopterin,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,80 Years and older   (Older Adult),,326,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP210083|2021-A02264-37,September 2022,February 2024,February 2024,"February 10, 2022",,"August 30, 2022","Hôpital Saint-Antoine / Service de réanimation, Paris, France",,https://ClinicalTrials.gov/show/NCT05233267,NCT05233267,
oui,NCT05243901,EPIPAGE 2 - 10-year Follow-up (RECONAI PROJECT),EPIPAGE2,Not yet recruiting,No Results Available,"Pre-Term|Development, Child",,"Relationships between prematurity, early growth and cardiometabolic disorders|Relationship between parenting educational skills and children's quality of life|Factors influencing children's puberty development|Factors influencing the child's fitness and motor skills","Institut National de la Santé Et de la Recherche Médicale, France",All,10 Years to 11 Years   (Child),,4000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C20-68,February 2022,August 2022,August 2022,"February 17, 2022",,"February 17, 2022",,,https://ClinicalTrials.gov/show/NCT05243901,NCT05243901,
oui,NCT05251246,Impact of Stress and Sleep Management on Emergency Professionals,REST,Recruiting,No Results Available,Healthy,Behavioral: recovery management program,Comparison of the recovery capacity for self-reported stressful events after the recovery management program|Evaluation of the perceived stress of the emergency professionals across one week of shift work before and after implementation of the recovery management program.|Evaluation of the perceived stress of the emergency professionals during the shift work before and after implementation of the recovery management program|Evaluation of the psychological markers of stress for self-reported stressful events before and after implementation of the recovery management program.|Comparison of the sleep time and latency of sleep times before and after implementation of the recovery management program.|Evaluation of the subjective perception of somnolence before and after implementation of the recovery management program.|Evaluation of mental fatigue before and after implementation of the recovery management program|Evaluation of the overall sleepiness before and after implementation of the recovery management program|Evaluation of the sleep quality before and after implementation of the recovery management program|Evaluation of bedtime arousal before and after implementation of the recovery management program|Evaluation of the evolution of the perceived quality of sleep before and after implementation of the recovery management program.|Evaluation of the job satisfaction before and after implementation of the recovery management program|Evaluation of the reported adverse events before and after implementation of the recovery management program,"Hospices Civils de Lyon|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,62,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,69HCL21_0774|2021-A02218-33,"February 8, 2022",January 2023,February 2023,"February 22, 2022",,"February 22, 2022","Hôpital Lyon Sud, Pierre-Bénite, France",,https://ClinicalTrials.gov/show/NCT05251246,NCT05251246,
non,NCT05254639,Donepezil for Oxaliplatin-induced Neuropathy Peripheral Neuropathy: Proof of Concept Study,DONEPEZOX,Recruiting,No Results Available,Digestive Oncology|Supportive Care,Drug: DONEPEZIL|Drug: PLACEBO,Quality of Life Questionnaire-Chemotherapy Induced Peripheral Neuropathy 20 (QLQ-CIPN20)|11-point pain Numeric Rating Scale (NRS)|Douleur Neuropathique-4 (DN4) interview|Neuropathic Pain Symptoms Inventory (NPSI)|Quality of Life Questionnaire-Cancer 30 (QLQ-C30)|Hospital Anxiety and Depression scale (HADS)|Patients' Global Impression of Change (PGIC),"University Hospital, Clermont-Ferrand|Federation Francophone de Cancerologie Digestive",All,"18 Years and older � (Adult, Older Adult)",Phase 2,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PHRC K 2020 PEZET|2021-005326-23,"June 2, 2022","August 31, 2023","September 30, 2023","February 24, 2022",,"January 9, 2023","H�pital priv� d'Antony, Antony, France|CH d'Argenteuil, Argenteuil, France|CHU de Besan�on, Besan�on, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Centre Hospitalier du Cotentin, Cherbourg, France|CH de Cholet, Cholet, France|CHU clermont-ferrand, Clermont-Ferrand, France|Centre Hospitalier Compi�gne-Noyon, Compi�gne, France|Clinique de Flandre, Coudekerque-Branche, France|CHU de Dijon Bourgogne, Dijon, France|Institut de Canc�rologie de Bourgogne - GRReCC, Dijon, France|CHD de Vend�e, La Roche-sur-Yon, France|CH Le puy, Le Puy-en-Velay, France|H�pital Franco-Britanique, Levallois-Perret, France|chu de Limoges, Limoges, France|CH Saint Joseph Saint Luc, Lyon, France|Clinique de la sauvegarde, Lyon, France|H�pital priv� Jean Mermoz, Lyon, France|Hopital Saint Joseph de Marseille, Marseille, France|H�pital Europ�en de Marseille, Marseille, France|Groupe Hospitalier des Portes de Provence, Mont�limar, France|H�pital Saint-Louis - AP-HP, Paris, France|H�pital Priv� des Cotes d'Armor, Pl�rin, France|CHU de Poitiers, Poitiers, France|Clinique La Croix du Sud, Quint-Fonsegrives, France|CHU de Reims, Reims, France|Institut Godinot, Reims, France|CHU de Saint-Etienne, Saint-�tienne, France|Institut de Canc�rologie Paris Nord, Sarcelles, France|Groupe Hospitalier Saint Vincent - Clinique Saint Anne, Strasbourg, France|CHU de Bordeaux, Talence, France|H�pital d'Instruction des Arm�es Sainte-Anne, Toulon, France|CH de Valence, Valence, France",,https://ClinicalTrials.gov/show/NCT05254639,NCT05254639,35799138
oui,NCT05257759,Use of Neurostimulation as a Tool for Reconditioning the Neuromuscular System of Patients Admitted to the ICU for Septic Shock,STIMUREA,Recruiting,No Results Available,Septic Shock,Other: Usual care|Other: Electrostimulation|Other: Evaluation of the neuromuscular system,change of the muscle force in newton meters (Nm) of the plantar flexors in response to electrical stimulation of the tibial nerve,Centre Hospitalier Universitaire Dijon,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANDREU AOI 2021,"March 25, 2022",April 2024,April 2024,"February 25, 2022",,"January 20, 2023","Chu Dijon Bourgogne, Dijon, France",,https://ClinicalTrials.gov/show/NCT05257759,NCT05257759,
oui,NCT05259293,Characteristics of Pneumothorax Associated With Transthoracic Percutaneous Lung Biopsy in Standard of Care,PNOrate,Recruiting,No Results Available,Pneumothorax Iatrogenic Postprocedural,Other: No intervention - retrospective study,Annual incidence rate of pneumothorax related to transthoracic lung biopsy on total number of lung biopsies|Annual incidence rate of hospitalisation in patients with pneumothorax related to lung biopsies|Annual incidence rate of drainage in patients with pneumothorax related to lung biopsies,"Centre Hospitalier Universitaire de Besancon|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,300,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,2021/625,"December 9, 2021",March 2022,March 2022,"February 28, 2022",,"February 28, 2022","CHU de Besançon, Besançon, France|Institut Bergonié, Bordeaux, France|CHU de Tours, Tours, France|Institut Gustave Roussy, Villejuif, France|Saint James Hospital, Dublin, Ireland",,https://ClinicalTrials.gov/show/NCT05259293,NCT05259293,
oui,NCT05259332,Identification by Transcriptomic Approach of New Prognostic and Predictive Markers in a Cohort of Atypical Meningiomas,TransMenAtyp,Recruiting,No Results Available,Meningioma Atypical,,"Progression-free survival|Tumor volume assessed by imaging pre- and post-operative|mRNA quantities of transcripts of interest|Radiotherapy-induced toxicity|Dose of corticosteroids before and after radiotherapy|Intra-observer, inter-observer and inter-laboratory intra-class correlation coefficients of immunohistochemical markers.","Central Hospital, Nancy, France|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,85,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,2020PI026,"February 25, 2022","April 1, 2022","October 31, 2023","February 28, 2022",,"February 28, 2022","Guillaume GAUCHOTTE, Vandoeuvre Les Nancy, Lorraine, France",,https://ClinicalTrials.gov/show/NCT05259332,NCT05259332,
oui,NCT05264597,Hamstring Stiffness After Anterior Cruciate Ligament Reconstruction,ACLSTIFF,Completed,No Results Available,"ACL Injury|Stiffness of Knee, Not Elsewhere Classified|Sport Injury",,Change in passive hamstring stiffness|Change in Strength|Individual characteristics|Surgery characteristics,"University Hospital, Caen|INSERM U1075 COMETE, UNICAEN, Caen France",All,"16 Years to 50 Years � (Child, Adult)",,135,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,ACLSTIFF 1452,"January 1, 2017","February 1, 2020","October 1, 2021","March 3, 2022",,"February 6, 2023","CHU Caen Normandie, Caen, France",,https://ClinicalTrials.gov/show/NCT05264597,NCT05264597,
oui,NCT05277519,Neuroplasticity After Proprioceptive Rehabiliation,VibraLCA,Recruiting,No Results Available,Stroke|Hemiparesis|Traumatic Brain Injury,Device: Vibrations,Baseline EMG|Baseline EEG|EMG change from baseline after 2-week treatment|EEG change from baseline after 2-week treatment|EMG change after the 5-week treatment|EEG change after the 5-week treatment|Baseline MD|Baseline FA|Baseline Muscle Strength|Muscle Strength change from baseline after 2-week treatment|Muscle Strength change from baseline after 5-week treatment|Baseline Spasticity|Spasticity change from baseline after 2-week treatment|Spasticity change from baseline after 5-week treatment|Baseline sensorimotor function|Sensorimotor function change from baseline after 2-week treatment|Sensorimotor function change from baseline after 5-week treatment|Baseline Balance|Balance change from baseline after 2-week treatment|Balance change from baseline after 5-week treatment|Baseline walking|Walking from baseline after 2-week treatment|Walking from baseline after 5-week treatment|Change in MD|Change in FA,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 70 Years   (Adult, Older Adult)",,56,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,C20-11|2021-A00822-39,"June 16, 2022","May 31, 2025","November 30, 2025","March 14, 2022",,"June 23, 2022","Pitié-Salpêtrière Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT05277519,NCT05277519,
anrs,NCT05280392,"Expectation, Motivation and Experience of HIV-patients Regarding Participation to an HIV Cure-related Clinical Trial",AMEP-EHVA T02,Recruiting,No Results Available,HIV Seropositivity,Other: Self-administered questionnaires|Other: Semi-directive individual interviews,Proportion of patients satisfied with their participation and the associated factors|Impact of the participation in the trial on participant quality of life and quality of sexual life,"ANRS, Emerging Infectious Diseases",All,"18 Years to 65 Years   (Adult, Older Adult)",,69,Other,Observational,Observational Model: Other|Time Perspective: Prospective,ANRS 95052,"June 21, 2022","March 1, 2025","March 1, 2025","March 15, 2022",,"July 25, 2022","CHUV, Lausanne, Switzerland",,https://ClinicalTrials.gov/show/NCT05280392,NCT05280392,
oui,NCT05283018,Relationship Between the Depth of Anesthesia and Auditory Evoked Potentials (P3a),MP3,Recruiting,No Results Available,General Anesthesia,Device: Electroencephalogram recording|Other: Auditory stimulation|Device: Transcranial Doppler|Device: Near-infrared spectroscopy,Duration of the P3a subcomponent of the P300|P3a amplitude|P3a frequency|Depth of anesthesia|Mean arterial blood pressure|Cerebral blood flow velocity (CFV)|Burst Suppression (BS)|Spectral Edge Frequency (SEF95)|Cerebral oxygen saturation,"Assistance Publique - H�pitaux de Paris|INSERM UMR-942, Paris, France|Laboratoire de M�canique des Solides, �cole polytechnique|M3DISIM Inria Universit� Paris-Saclay",All,"18 Years and older � (Adult, Older Adult)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP211287|2021-A02322-39,May 2022,May 2023,November 2023,"March 16, 2022",,"April 12, 2022","AP-HP, Lariboisi�re Hospital, Department of Anesthesiology and Intensive Care, Paris, France",,https://ClinicalTrials.gov/show/NCT05283018,NCT05283018,
oui,NCT05284526,EEG Recordings and Analysis in Parkinson's Patients: Towards Adaptive Deep Brain Stimulation by Machine Learning,ElectroPARK,Not yet recruiting,No Results Available,Parkinson Disease,Other: electroencephalogram (EEG) of control and parkinsonian subjects during the preparation and execution of movements,"measure the encoding capacity of the cortical networks of parkinsonian patients, with or without anti-parkinsonian drug treatment, and with or without High-frequency stimulation (HFS) of the subthalamic nucleus (STN).","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,APHP211327,March 2022,March 2022,September 2023,"March 17, 2022",,"March 17, 2022",,,https://ClinicalTrials.gov/show/NCT05284526,NCT05284526,
oui,NCT05285514,Macro- and Microcirculation Crosstalk in Brain-damaged Patients Under Anesthesia or in Intensive Care,MICRONOR,Recruiting,No Results Available,Brain Injury,Diagnostic Test: Comparison of macro- and microcirculatory parameters,Capillary density|Microcirculatory flow,"Assistance Publique - H�pitaux de Paris|INSERM UMR-942, Paris, France|LMS Polytechnique|M3DISIM Inria Universit� Paris-Saclay",All,"18 Years and older � (Adult, Older Adult)",,85,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP211317|2021-A02375-36,April 2022,April 2024,October 2024,"March 17, 2022",,"April 15, 2022","AP-HP, Lariboisi�re Hospital, Department of Anesthesiology and Intensive Care, Paris, France",,https://ClinicalTrials.gov/show/NCT05285514,NCT05285514,
oui,NCT05285579,Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer,ANGIOCOR,Not yet recruiting,No Results Available,Renal Cell Carcinoma|Renal Cancer|Renal Cancer Metastatic,Biological: Blood collection|Other: Tumour samples,Progression-free survival|Objective response rate|Response duration,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|FONCER contre le cancer",All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP211213|IDRCB2021-A02030-41,April 2022,July 2025,July 2025,"March 17, 2022",,"March 17, 2022","Hôpital européen Georges-Pompidou AP-HP, Paris, France|Hôpital Cochin - AP-HP, Paris, France",,https://ClinicalTrials.gov/show/NCT05285579,NCT05285579,
oui,NCT05285761,feediNg gUidelines infanT RandomIzEd coNtrolled Trial,NUTRIENT,Recruiting,No Results Available,Healthy Volunteers,Behavioral: Provision of extended information on the conduct of complementary feeding|Behavioral: Provision of current official information on complementary feeding,Body mass index z-score at the age of 36 months|Body mass index z-score at the age of 48 months|Children's eating behaviour (self-reported by parents)|Infant appetite control abilities (self-reported by parents)|Infant appetite control abilities (behavioral observation)|Parental feeding practices (self-reported by parents)|Parental feeding practices (behavioral observation)|Introduction of complementary foods|Food frequency and food acceptance|Food texture exposure and acceptance|Child feeding skills|Meal context - FPSQ|Meal context - FFBS|Maternal distractions during feeding - Use of technological distractors|Maternal distractions during feeding - Perceived Distraction|Knowledge about infant nutrition,"Centre des Sciences du Goût et de l'Alimentation|Centre Hospitalier Universitaire Dijon|Institut de Recherche en Santé Publique, France|Institut National de la Santé Et de la Recherche Médicale, France|University of Burgundy",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,330,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2020-A01941-38,"March 24, 2022",March 2026,March 2027,"March 18, 2022",,"October 24, 2022","Centre des Sciences du Goût et de l'Alimentation, Dijon, France",,https://ClinicalTrials.gov/show/NCT05285761,NCT05285761,
oui,NCT05290051,Prospective Study to Assess Medical Performance of Optical Mapping and Long Read Sequencing in Detecting Numerical and Structural Chromosome Abnormalities. CHROmosome MAPping and Sequencing (CHROMAPS),,Not yet recruiting,No Results Available,Infertility|Intellectual Disability|Malformation,Genetic: Optical Genome Mapping (Bionano®)|Genetic: Longread sequencing (Nanopore®),Percentage of verified clinically significant chromosomal aberrations detected by Bionano® and Nanopore® compared to the percentage of those detected by karyotyping or CMA according to reason for referral.|Incidence and distribution of different kinds of chromosomal aberrations per category of referral.|Type of chromosome abnormalities that are overlooked by Bionano® and/or Nanopore® while detected by standard-of-care techniques|Percentage of patients for which the detection of a chromosomal aberration by Bionano® or Nanopore® and not by karyotyping or CMA resulted in a change in the disease management|Overall cost and benefit of each technique including delay to diagnosis and changes in the disease management,"Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",Not Applicable,300,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C21-35,April 2022,September 2023,April 2024,"March 22, 2022",,"March 22, 2022",,,https://ClinicalTrials.gov/show/NCT05290051,NCT05290051,
oui,NCT05296720,EEG and Behavioral Correlates of Temporal Prediction in the Tactile Modality in Schizophrenia,SchizPredicT,Not yet recruiting,No Results Available,Schizophrenia,Behavioral: Tactile stimulation,measure of movement speed|Electroencephalographic measure,Centre Psychothérapique de Nancy,All,18 Years to 60 Years   (Adult),Not Applicable,68,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,021-A02434-37,April 2023,April 2025,October 2025,"March 25, 2022",,"December 21, 2022","Anne GIERSCH, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT05296720,NCT05296720,
oui,NCT05305144,"Retinal, Cerebral and Vascular Precursor Markers of Cerebral Small Vessel Disease.",SHIVA-SHARE,Recruiting,No Results Available,Cerebral Small Vessel Diseases,Procedure: Vascular and ophthalmological examinations,"Part 1 VASCULAR PARAMETERS RELATED TO BLOOD PRESSURE - Central arterial pressure by carotid tonometry (systolic, diastolic, mean)","University Hospital, Bordeaux|University of Bordeaux",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CHUBX 2020/42,"June 7, 2021","June 7, 2024","June 7, 2024","March 31, 2022",,"March 31, 2022","CHU de Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT05305144,NCT05305144,
oui,NCT05306834,Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease,SHIVA,Recruiting,No Results Available,Cerebral Small Vessel Diseases|Stroke|Dementia,Procedure: Retinal Imaging|Genetic: Blood sample|Procedure: Evaluation of cardiovascular risks|Procedure: Brain imaging (MRI)|Other: Cognitive Tests|Other: Geriatric Depression Scale (GDS)|Other: Instrumental Activities of Daily Living (IADL)|Diagnostic Test: Unipodal standing test|Other: Walking speed measurement,"Comparison of images and the molecular data|Degree of association between retinal and brain marker|Degree of association between brain, microvascular and retinal marker|Correlation between retinal micovascular biomarkers|Reproducibility and time course of retinal vascular biomarkers|Detecting, classifying and quantifying markers of retinal microvascular lesions|Comparison of the results in the Shiva study and SHIVA share study|Occurrence of incident stroke, dementia and death during follow-up.","University Hospital, Bordeaux",All,"60 Years to 88 Years � (Adult, Older Adult)",Not Applicable,400,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,CHUBX 2021/22,"November 10, 2022",November 2027,November 2027,"April 1, 2022",,"November 15, 2022","Bordeaux Hospital, Bordeaux, France|Broca Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT05306834,NCT05306834,
oui,NCT05307172,"Precision Medicine Approach to Unravel the Risk Factors for Renal, Cardiovascular, Ophthalmologic, Neurologic and Hepatic Complications of Metabolic Disorders",PRECIMETAB,Not yet recruiting,No Results Available,Chronic Kidney Diseases|Diabetes|Obesity,,the rate of annual decline in glomerular filtration rate (GFR year n+1 - GFR year n) measured by iohexol clearance|The evolution of vascular status|Major cardiovascular event|microvascular event|Cognitive performance|The onset of dementia defined as a cognitive disorder|The occurrence of severe liver damage,"Institut National de la Santé Et de la Recherche Médicale, France|Centre Hospitalier Universitaire, Amiens|Biobanque de Picardie",All,"18 Years to 65 Years   (Adult, Older Adult)",,1500,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C21-13|2021-A02192-39,"May 3, 2022","May 3, 2032","November 3, 2032","April 1, 2022",,"April 1, 2022","Centre Hospitalier Universitaire d'AMIENS - Picardie, Amiens, France",,https://ClinicalTrials.gov/show/NCT05307172,NCT05307172,
anrs,NCT05311891,Variants of SARS-CoV-2 Causing COVID-19 in Africa,South-Spike,Not yet recruiting,No Results Available,COVID-19,Diagnostic Test: RT PCR,Number of SARS-CoV-2 sequences generated partially and in whole genome|Number of individuals tested positive for COVID-19|Number of new SARS-CoV-2 variants identify,"ANRS, Emerging Infectious Diseases|Institut de Recherche pour le Developpement|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,12600,Other,Observational,Observational Model: Case-Only|Time Perspective: Other,ANRS 0136s,September 2022,October 2022,October 2022,"April 5, 2022",,"May 27, 2022","Centre de Référence pour les pathogènes émergents et réémergent, Bobo-Dioulasso, Burkina Faso|Centre Hospitalier Universitaire la Référence Nationale (CHU-RN), N'Djamena, Chad|Laboratoire National de Santé Publique Brazzaville, Brazzaville, Congo|CIRBA, Abidjan, Côte D'Ivoire|Unité Mixte de Recherche CIRMF-SSM, Libreville, Gabon|SEREFO, Bamako, Mali",,https://ClinicalTrials.gov/show/NCT05311891,NCT05311891,
oui,NCT05312736,Gyrate Atrophy Ocular and Systemic Study,GYROS,Not yet recruiting,No Results Available,Gyrate Atrophy|Gyrata of Choroid and Retina Atrophy|Ornithine-?-aminotransferase|OAT|Chorioretinal Degeneration,,"Structural Outcome: Characterize Change using Quantitative Measures of Progression of the Area of Preserved Retina|Structural Outcome: Characterize Change using Quantitative Measures of Progression of the Area of Preserved Retina (Use with FAF for assessments)|Metabolic Outcome: Characterize Change in Plasma Ornithine Level|Metabolic Outcome: Characterize Change in Blood Spot Ornithine Level|Structural Outcome: Ellipsoid zone (EZ) area|Structural Outcome: Area of Post Subcapsular Cataract|Structural Outcome: Foveal Avascular Zone (FAZ) Area and Macular Vessel Density|Functional Outcome: Visual Field Sensitivity Measured with Quantitative Topographic Analysis (Hill of Vision)|Functional Outcome: Early Treatment of Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score|Functional Outcome: Low Visual Acuity Test - for participants unable to see ETDRS letters|Functional Outcome: ETDRS Best Corrected Low Luminance Visual Acuity Letter Score|Functional Outcome: Change in Mean Retinal Sensitivity|Functional Outcome: Change in Full-Field Retinal Sensitivity|Functional Outcome: Change in Retinal Function|Metabolic Outcome: Proline, lysine, glutamine, glutamate, arginine, and related metabolite: creatine and its precursor guanidinoacetate|Metabolic Outcome: Level of dietary protein control",Jaeb Center for Health Research|Conquering Gyrate Atrophy Foundation|Food and Drug Administration (FDA)|Department of Health and Human Services,All,"12 Years and older � (Child, Adult, Older Adult)",,45,Other|U.S. Fed,Observational,Observational Model: Cohort|Time Perspective: Prospective,GYROS,"March 7, 2023","August 31, 2027","January 31, 2028","April 5, 2022",,"March 6, 2023","University of California San Francisco, San Francisco, California, United States|Johns Hopkins University, Wilmer Eye Institute, Baltimore, Maryland, United States|Harvard Univ., Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|Duke University, Duke Eye Center, Durham, North Carolina, United States|Center for Advanced Retinal and Ocular Therapeutics, Philadelphia, Pennsylvania, United States|Neuro e Retina LTDA, Santa Efig�nia, Brazil|University of Toronto, Hospital for Sick Children, Toronto, Ontario, Canada|Helsinki University Hospital, Helsinki, Finland|Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, INSERM-DGOS CIC1423, Paris, France|University of Tuebingen, Centre for Ophthalmology, T�bingen, Germany|Hadassah-Hebrew University Medical Center, Jerusalem, Israel|Moorfields Eye Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT05312736,NCT05312736,
oui,NCT05322343,Biobank and Brain Health in Bordeaux.,B-cube,Recruiting,No Results Available,Brain|Aging|Cognitive Aging|Immunosenescence|Mental Processes|Mental Disorders|Neurocognitive Disorders|Cognition|Brain Diseases|Dementia|Alzheimer Disease|Mental Health|Behavioral Symptoms|Depression|Anxiety,Other: Questionnaires|Other: Fasting blood sampling.|Other: Saliva collection and nasal or nasopharyngeal swab|Other: Urine samples|Other: Hair and a tonenail (or hand nail) sampling|Other: Nasal microbiota|Other: Measurements|Other: Neuroimaging|Other: Medical visit,"Number of participants for whom samples are available in the biobank and nutritional and cognitive surveys have been completed.|Biobank inventory|Cognitive performance, assessed through: non-verbal cognition-Neuropsychological|Cognitive performance, assessed through: non-verbal cognition - Verbal fluency|Cognitive performance, assessed through: non-verbal cognition -Dementia|Cognitive performance, assessed through: non-verbal cognition- Mental|Assement anxiety and depressive symptomatology - Anxiety|Assement anxiety and depressive symptomatology - Drepression|Nutrition and Lifestyle evaluated|Study to the microbiota intestinal, nasal and salivary|Immunosenescence mechanism study|Incapacity and dependance","University Hospital, Bordeaux",All,"55 Years to 80 Years � (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHUBX 2020/34,"March 22, 2022","September 21, 2025","September 21, 2025","April 11, 2022",,"September 27, 2022","University Hospital of Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT05322343,NCT05322343,
oui,NCT05328024,Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma,IPRICE,Recruiting,No Results Available,Head and Neck Cancer,Drug: Immunotherapy,prospective validation of the expression of interferon-gamma signature to predict anti-PD1 immunotherapy response.|Prospective validation of the expression of interferon-gamma signature to predict progression free survival.|Prospective validation of the expression of interferon-gamma signature to predict overall survival.|Prospective validation of the expression of interferon-gamma signature to predict duration of objective response.|Exploratory outcome : investigation of the expression of other molecular signatures such as immune cells panel within the tumor microenvironment to predict anti-PD1 immunotherapy response.|Exploratory outcome : investigation of the expression of other molecular signatures such as immune checkpoints protein expression level to predict anti-PD1 immunotherapy response.|Exploratory outcome : investigation of the expression of other molecular signatures such as biomarkers expression level involved in immunogenic cell death and in mitophagy to predict anti-PD1 immunotherapy response.|Exploratory outcome : investigation of the expression of other molecular signatures such as protein expression level involved in hypoxia to predict anti-PD1 immunotherapy response.,"Institut de cancérologie Strasbourg Europe|Centre National de la Recherche Scientifique, France|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2021-003,"December 13, 2021","December 13, 2027","December 13, 2027","April 14, 2022",,"April 22, 2022","Institut de cancérologie Strasbourg Europe, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT05328024,NCT05328024,
associ�,NCT05328154,MAGnesium Effect With ANtiosteoporotic Drugs,MAGELLAN,Recruiting,No Results Available,"Osteoporosis, Postmenopausal","Other: Follow-up of patients with postmenopausal osteoporosis, with or without fractures, requiring initiation of injectable bisphosphonate therapy as part of their usual care|Drug: Follow-up of patients with postmenopausal osteoporosis, fractured or not, requiring initiation of injectable bisphosphonate therapy as part of care with magnesium supplementation","C-terminal telopeptides of collagen type 1 (CTX) dosage|N-terminal propeptide of procollagen type 1 (P1NP) dosage|Osteocalcin dosage|Sclerostin dosage|Periostin dosage|Irisin dosage|Dickkopf-related protein 1 (DKK1) dosage|Magnesium (Mg) dosage|Evaluation of bone densitometric parameters (femoral neck)|Evaluation of bone densitometric parameters (total femur)|Evaluation of bone densitometric parameters (spine)|Endothelial dysfunction measured by FMD (Flow-Mediated Dilation)|Measurement of digital volume increase by RHI (Reactive Hyperhemia Index), (Endo-PAT2000; Itamar Medical Ltd, Israel).|Microcirculation measurement by FLD (Flow Laser Doppler), PeriFlux� (Perimed)|Sphygmocor CPV� (Atcor Medical) large artery stiffness measurement (PWV)|Evaluation of the Abdominal Aorta Calcification (AAC) (Kauppila score)|Strength, Assistance with walking, Rising from a chair, Climbing stairs, and Falls (SARC-F) questionnaire|Short Physical Performance Battery (SPPB) Questionnaire|Evaluation of the muscular strength|Body composition measurement on Dual energy X-ray Absorptiometry (DXA)|The Brief Pain Inventory Questionnaire (BPI)|The Numerical Pain Scale|Measurement of the threshold of sensitivity and pain perception induced by a thermal stimulus (hot and cold) at the Pathway - M�doc�.|Central sensitization tests, measurement of the Conditioned Pain Modulation (CPM) effect|The Pittsburgh Sleep Quality Index (PSQI)|The 36-Item Short Form Survey (SF-36)|The Hospital Anxiety and Depression Scale (HAD)|Distribution of gene polymorphisms using OpenArray technology|MicroRNA analysis using OpenArray technology will be performed on 48 patients|Study of the microbiota will be performed on 48 patients","University Hospital, Clermont-Ferrand",Female,"50 Years and older � (Adult, Older Adult)",Phase 2,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AOI 2021 ME_PICKERING|2021-005401-28,"June 28, 2022","May 1, 2023","May 1, 2024","April 14, 2022",,"June 30, 2022","CHU clermont-ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT05328154,NCT05328154,
oui,NCT05330338,Genetics of Ventriculo-arterial Discordance,PreciPed,Recruiting,No Results Available,"Heart Defects, Congenital",Biological: Genetic analyses: whole genome sequencing,"Identification new genes/variants involved in congenital heart disease with transposition congenitally corrected of the great arteries, based on whole genome sequencing of familial trios.|Evaluation the diagnostic contribution of parental cardiovascular screening in case of ventriculo-arterial discordance (transposition of the great arteries, transposition congenitally corrected of the great arteries) in the index case.|Identification new familial forms of ventriculo-arterial discordance.|Identification epigenetic modifications by analysis of the epigenome of sporadic forms when genome sequencing is not contributory.|Identification allelic variants associated with prognosis and/or response to treatment, with the aim of eventually developing a precision medicine programme in paediatric cardiology|Assessing the quality of life of patients with ventriculo-arterial discordance as well as their parents","Nantes University Hospital|Inserm UMR1087, CNRS UMR6291|Clinique des Donn�es, CIC 1413, CHU Nantes|CIC-FEA, CIC 1413, CHU Nantes",All,"1 Minute to 100 Years � (Child, Adult, Older Adult)",Not Applicable,600,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,RC21_0555,"September 7, 2022","October 1, 2024","October 1, 2042","April 15, 2022",,"March 14, 2023","CHU Marseille, Marseille, Bouches-du-Rh�ne, France|CHU Rennes, Rennes, Bretagne, France|CHU Bordeaux, Bordeaux, Gironde, France|CHU Toulouse, Toulouse, Haute-Garonne, France|Groupe Hospitalier St Joseph - H�pital Marie Lannelongue, Le Plessis-Robinson, Hauts-de-Seine, France|CHU Grenoble, Grenoble, Is�re, France|CHU Nantes, Nantes, Loire-Atlantique, France|H�pital Nord Laennec, Saint-Herblain, Loire-Atlantique, France|CHU Angers, Angers, Maine-et-Loire, France|CHU Nancy, Nancy, Meurthe-et-Moselle, France|Intercard Lille, Lille, Nord, France|CHU Lyon, Lyon, Rh�ne, France|CHU Rouen, Rouen, Seine-Maritime, France|CHU Tours, Tours, Val De Loire, France|H�pital Europ�en Georges Pompidou, Paris, France",,https://ClinicalTrials.gov/show/NCT05330338,NCT05330338,
oui,NCT05332782,Outcomes of Patients tReated wIth Mitral Transcatheter Edge-to-edge Repair for Primary Mitral Regurgitation Registry,PRIME-MR,Recruiting,No Results Available,Mitral Regurgitation,,All-cause mortality|Cardiovascular mortality|Rehospitalization for congestive heart failure|Re-do mitral valve procedure|Residual mitral regurgitation|MVARC (Mitral Valve Academic Research Consortium) Technical success|Functional success,Universit�tsklinikum Hamburg-Eppendorf,All,"18 Years and older � (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,PRIME-MR,"March 1, 2022","January 1, 2025","January 1, 2026","April 18, 2022",,"April 18, 2022","Montefiore Medical Center, New York, New York, United States|Centre Hospitalier de Bordeaux, Bordeaux, France|Universit� Lille, Inserm, Centre Hospitalier Universitaire de Lille, Lille, France|University Hospital of Rennes, Centre Hospitalier de Rennes, Rennes, France|University Heart & Vascular Center Hamburg, Hamburg, Germany|Klinikum der Universit�t M�nchen, Munich, Germany",,https://ClinicalTrials.gov/show/NCT05332782,NCT05332782,
oui,NCT05336604,STUDY OF THE COVID-19 EPIDEMIC AND SOCIO-ECONOMIC LIVING CONDITIONS IN FRANCE,EpiCov,Recruiting,No Results Available,General Population,,Changes in COVID-19 Seroprevalence over time|Changes in living condition|Changes in health condition|COVID-19 IgG antibodies median,"Institut National de la Santé Et de la Recherche Médicale, France|Ministry of Health, France",All,"15 Years and older   (Child, Adult, Older Adult)",,134391,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C20-25|2020-A01191-38,"May 2, 2020","August 9, 2021","August 30, 2022","April 20, 2022",,"April 20, 2022","Inserm U1018, Le Kremlin-Bicêtre, France",,https://ClinicalTrials.gov/show/NCT05336604,NCT05336604,
oui,NCT05348798,Personality Traits and Exercise Addiction in Ultra Endurance Athletes,,Recruiting,No Results Available,Exercise Addiction,Other: Web based survey,Exercise Addiction|Personality traits|Demographics|Sport Practice (sport)|Sport Practice (volume)|Sport Practice (number of events)|Sport Practice (fitness certificate)|Eating habits (dietary supplements)|Eating habits (SCOFF questionnaire),"University Hospital, Caen|INSERM UMR U1075 Com�te GIP Cyceron, unicaen, Caen Normandie",All,"18 Years and older � (Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,UltrAddict 3363,"April 13, 2022","June 15, 2022","July 15, 2022","April 27, 2022",,"April 27, 2022","CHU Caen Normandie, Caen, France",,https://ClinicalTrials.gov/show/NCT05348798,NCT05348798,
oui,NCT05349162,Epicardial vs. Transvenous ICDs in Children,,Completed,No Results Available,Implantable Cardioverter Defibrillator Complications|Implantable Defibrillator User,Device: Implantable cardioverter defibrillator use,Number of patients with implantable cardioverter defibrillator system dysfunction (lead dysfunction requiring reintervention),Paris Cardiovascular Research Center (Inserm U970)|H�pital Necker-Enfants Malades,All,"0 Years to 18 Years � (Child, Adult)",,131,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,134526,"January 1, 2003","January 1, 2021","April 1, 2022","April 27, 2022",,"April 27, 2022",,,https://ClinicalTrials.gov/show/NCT05349162,NCT05349162,36735263
oui,NCT05364294,Molecular Diagnosis of Systemic Autoinflammatory Diseases,SAIDiag,Not yet recruiting,No Results Available,Inflammatory Disease|Genetic Disease|Somatic Mutation|Molecular Sequence Variation|Molecular Pathway Deregulation,,To identify SAIDs disease-causing mutations and genes and to explore specific biological signatures.|To identify novel and better assess the disease pathways|To propose personalized treatment options,"Institut National de la Santé Et de la Recherche Médicale, France",All,"1 Week to 120 Years   (Child, Adult, Older Adult)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,C20-97,"June 30, 2022","May 31, 2032","May 2, 2033","May 6, 2022",,"May 24, 2022","Trousseau Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT05364294,NCT05364294,
oui,NCT05366387,Effect of Intrapulmonary Percussion Ventilation on Deposition of Inhaled Aerosols in Idiopathic Pulmonary Fibrosis,AEROPERC,Recruiting,No Results Available,Idiopathic Pulmonary Fibrosis,Device: intrapulmonary percussive ventilation|Radiation: delivery of 99mTc-DTPA aerosol,"Phase 1: Discomfort during IPV|Phase 2: Change between Control and IPV condition in amount of 99mTc-labelled DTPA aerosol deposited in fibrotic lung regions, reported to loaded dose|Phase 1: Sensations associated with IPV in patients with IPF|Phase 1: IPV-induced variations in dyspnea|Phase 1: IPV-induced variations in cough|Phase 1: IPV-induced variations in Forced Vital Capacity|Phase 1: IPV-induced variations in Carbon monoxide transfer factor (DLCO)|Phase 1: IPV-induced variations in 5 Hz respiratory reactance|Phase 1: Incidence of Treatment-Emergent Adverse Events|Phase 2 : Change between Control and IPV condition in total lung deposition of the 99mTc-labelled DTPA aerosol|Phase 2: Ratio of deposition of the 99mTc-labelled DTPA aerosol in fibrotic lung versus normal lung|Incidence of Treatment-Emergent Adverse Events one month after treatment","University Hospital, Tours|Institut National de la Santé Et de la Recherche Médicale, France",All,"50 Years and older   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,DR210241|2021-A02003-38|22.00149.000065,"November 23, 2022",May 2024,May 2024,"May 9, 2022",,"December 8, 2022","Pulmonology Department, University Hospital, Tours, Tours, France",,https://ClinicalTrials.gov/show/NCT05366387,NCT05366387,
oui,NCT05373069,BENEFIT OF MECHANICAL ISCHEMIC PRECONDITIONING ON TOLERANCE OF ADIPOSE TISSUE TO ISCHEMIA REPERFUSION OF TYPE DIEP (DEEP INFERIOR EPIGASTRIC PERFORATOR) FREE FLAPS.,PRIMIDIEP,Not yet recruiting,No Results Available,Breast Cancer,Procedure: Mechanical ischemic preconditioning of diep-type flap,"Number of successes of the technique defined by the absence of pathological postoperative fat necrosis|to evaluate the efficacy of ischaemic preconditioning on the tolerance of the skin (cutaneous necrosis, scar separation) to the ischemia-reperfusion of DIEP flaps|Presence of skin necrosis within 6 months postoperatively defined by (occurrence of one or more of the three subcited elements|Proportion of overall reconstruction failures: postoperative flap loss at M6: flap removal for total necrosis|Rate of subclinical cystosteatonecrosis (detected by ultrasound at M6: presence of one or more nodules, measuring more than 5mm but having no clinical repercussions)|to evaluate the proportion of overall failure after DIEP type flaps.|to evaluate the proportion of subclinical cytosteatonecrosis",Assistance Publique - H�pitaux de Paris|INSERM Bichat hospital,Female,"18 Years and older � (Adult, Older Adult)",Not Applicable,35,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP201173|2021-A00173-38,May 2022,May 2024,May 2024,"May 13, 2022",,"May 13, 2022","Service Plastique, Reconstruction, Esth�tique, H�pital TENON- APHP, Paris, France",,https://ClinicalTrials.gov/show/NCT05373069,NCT05373069,
oui,NCT05380193,Serotype Distribution in Hospitalized Adult With Pneumococcal Community Acquired Pneumonia in France,CAP'Hospi,Recruiting,No Results Available,Pneumonia|Pneumococcal Infections|Community-acquired Pneumonia,,proportions of S. pneumoniae serotypes included in PCV20|proportion of serotypes of S. pneumoniae by group|Patients hospital trajectories|Patients hospital stay by serotype groups|Prevalence of different bacterial and viral causes of hospitalized CAP|The proportion of patients with a severe CAP|The proportion of patients who required re-hospitalization following hospital discharge,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C21-24|2021-A03157-34,"May 9, 2022",September 2024,January 2025,"May 18, 2022",,"May 18, 2022","CHU Rennes, Rennes, Bretagne, France",,https://ClinicalTrials.gov/show/NCT05380193,NCT05380193,
oui,NCT05381844,Quantification of Antisense HIV RNA in Patients,,Recruiting,No Results Available,HIV-1-infection,Other: Blood sampling,HIV-1 antisense transcripts in PBMCs|Correlation between HIV-1 antisense transcripts and HIV-1 DNA in PBMCs|Correlation between unspliced HIV-1 sense transcripts and HIV-1 DNA in PBMCs|Correlation between HIV-1 sense and antisense transcripts in PBMCs|Comparison of untreated patients vs. patients with virological control on treatment.,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,60,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,C21-16|2021-A02266-35,"October 20, 2022","December 1, 2024","December 1, 2024","May 19, 2022",,"December 22, 2022","Jean-Paul VIARD, Paris, France",,https://ClinicalTrials.gov/show/NCT05381844,NCT05381844,
oui,NCT05383339,"Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases",BIOMAI,Recruiting,No Results Available,Autoimmune Diseases|Vasculitis|Autoinflammatory Disease,Other: Blood collection,"Correlation between cytokine and lymphocyte profile and disease activity|Characterization of new cytokines involved in these pathologies|Characterization of new lymphocytes types involved in these pathologies|Correlation between the cytokine and lymphocyte profile, and the evolution of these pathologies (evolution towards mild forms, towards serious forms, death, frequency of relapses, etc.)|Correlation between the cytokine and lymphocyte profile, and the clinical presentation of each pathology|Description of the cytokine and lymphocyte profile of each pathology.","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,2250,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,APHP220486,"November 29, 2022","November 29, 2031","November 29, 2031","May 20, 2022",,"December 16, 2022","Département de Médecine Interne et Immunologie Clinique (DMIIC), Hôpital Pitié-Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT05383339,NCT05383339,
oui,NCT05388838,Screening for Oculocerebral Lymphoma With the Phenotype of NK Cells in Patients With Uveitis,DeLPHy,Recruiting,No Results Available,Uveitis|Lymphoma|NK-Cell Lymphoma,Biological: Blood sample,percentage of NK Cells in blood with phenotype acquired by trogocytosis (WO/2016/005548) in patients with uveitis with a diagnosis other than ocular lymphoma and without cerebral lymphoma (Negative control)|percentage of NK Cells in blood with phenotype acquired by trogocytosis (WO/2016/005548) in patients with primary ocular lymphoma without brain involvement and never treated,Hospices Civils de Lyon,All,"18 Years and older � (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,69HCL22_0078|2022-A00254-39,"June 1, 2022","June 1, 2023","June 1, 2023","May 24, 2022",,"December 28, 2022","Service d'Ophtalmologie, H�pital de la Croix-Rousse, GHN, Lyon, France|Service d'H�matologie Clinique, H�pital Lyon Sud, Lyon, France",,https://ClinicalTrials.gov/show/NCT05388838,NCT05388838,
oui,NCT05391113,REward SYSTem in Autism Spectrum Disorder and Addictive Disorder,RESYSTAA,Not yet recruiting,No Results Available,Autism Spectrum Disorder,Diagnostic Test: MRI|Diagnostic Test: EEG,"Blood Oxygene Level Dependent (BOLD) MRI signal|Tolerance to an MRI examination for FAD with overweight or obesity|Regulation of sensory, an fMRI measurement of the BOLD physiological signal for sensory responses (sensory block) in terms of brain activation in patients","University Hospital, Tours|INSERM UMR-1253, Tours, France",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,78,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,DR220016-RESYSTAA|2022-A01098-35|22-87,"April 1, 2023","April 1, 2026","October 1, 2026","May 25, 2022",,"March 8, 2023","Center-Val de Loire Region Autism Resource Center, Tours, France|University Addictology Service, Liaison Team and Addictology Care, Tours, France|University Hospital, Medical Imaging Service, Tours, France",,https://ClinicalTrials.gov/show/NCT05391113,NCT05391113,
oui,NCT05393518,Electroclinical Correlation of Anxiety,IRAnxNet,Not yet recruiting,No Results Available,Anxiety Disorder|Generalized Anxiety Disorder|Drug Resistant Epilepsy,Behavioral: Anxiety-induced task|Behavioral: Neuropsychiatric assessment,Change in neuronal coherence in the frontolimbic network|Generalized Anxiety Disorders (GAD) severity score at The Penn State Worry Questionnaire (PSWQ)|SEEG power spectrum changes|Wechsler adult intelligent scale Score (WAIS-R full scale IQ)|Auditory and visual memory index (MEM IV)|Quality of life scale applied to epilepsy (QOLI-E 31)|Neurological Disorders Depression Inventoiry for Epilepsy (NDDI-E)|Generalized Anxiety Disorder 7- items (GAD-7)|Beck Depression Inventory (BDI)|Montgomery and Asberg Depression Rating Scale (MADRS) Score|State Anxiety Inventory (STAI)|Beck Anxiety Inventory (BAI)|Hamilton Antiety rating Scale (HAM-A) Score|Analog Visual Scale (EVA) Anxiety score,"University Hospital, Bordeaux|Centre National de la Recherche Scientifique, France|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,CHUBX 2020/63,"June 1, 2022","June 1, 2024","June 1, 2024","May 26, 2022",,"May 26, 2022","CHU de Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT05393518,NCT05393518,
oui,NCT05394506,Modifying Factors in Striated Muscle Laminopathies,LMNAModifier,Not yet recruiting,No Results Available,Laminopathies|Emery Dreifuss Muscular Dystrophy 2|LMNA-Related Congenital Muscular Dystrophy|Dilated Cardiomyopathy-1A,Procedure: Skin Biopsy|Procedure: Muscle biopsy,Skeletal muscle severity outcome|Cardiac muscle severity outcome|Protective structural variant outcome|Protective differential gene expression outcome|Protective 3D chromatin conformation outcome|Aggravating structural variant outcome|Aggravating differential gene expression outcome|Aggravating 3D chromatin conformation outcome outcome,"Institut National de la Santé Et de la Recherche Médicale, France",All,"2 Years and older   (Child, Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C20-45,"June 20, 2022","June 30, 2027","June 30, 2027","May 27, 2022",,"May 27, 2022","Centre de référence maladies neuromusculaires, Hôpital Femme Mère Enfant, CHU Lyon, Bron, Auvergne-Rhône-Alpes, France|Service de Neuropédiatrie, Centre de Référence Maladies Neuromusculaires, CHU de Montpellier, Montpellier, Hérault, France|Service de Neurologie, Réanimation Pédiatriques, Hôpital Raymond Poincaré, Hôpitaux Universitaires, Paris-Ile-de-France-Ouest, Garches, Ile De France, France|Service de Génétique médicale, CHU Rennes, Rennes, Ille-et-Vilaine, France|Laboratoire d'Explorations Fonctionnelles - Centre de Référence Maladies Neuromusculaires Rares, CHU Nantes, Nantes, Loire-Atlantique, France|Service de cardiologie & Service de Neurophysiologie - CHU de Rouen, Rouen, Normandie, France|Centre de référence maladies neuromusculaires, Institut de myologie, Hôpital Pitié-Salpêtrière, Paris, France|Centre de référence pour les maladies cardiaques héréditaires, Paris, France",,https://ClinicalTrials.gov/show/NCT05394506,NCT05394506,
oui,NCT05400824,Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study),,Recruiting,No Results Available,Infectious Disease|Cardiovascular Diseases|General Population|Metabolic Disease,"Diagnostic Test: Blood, DNA, feces, urine, hair and skin microbiota collection",Prevalence of cardiometabolic diseases|Prevalence of infectious diseases,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 67 Years   (Adult, Older Adult)",,2000,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C19-68|2020A0209435,"May 1, 2022",May 2024,May 2024,"June 2, 2022",,"July 5, 2022","Centre Hospitalier Universitaire de La Réunion, La Réunion, Saint-Pierre, France",,https://ClinicalTrials.gov/show/NCT05400824,NCT05400824,
oui,NCT05403034,Study of the Biological Function of Muscle Satellite Cells From Patients With Obstetric Brachial Plexus Palsy,SCOPE,Not yet recruiting,No Results Available,Obstetrical Brachial Plexus Palsy,Procedure: Muscle biopsy,Assessment of muscle regeneration capacity: proliferation capacity|assessment of muscle regeneration capacity: differenciation capacity|Effect of botulinum toxin on the proliferation potential of satellite cells: proliferation capacity|Effect of botulinum toxin on the proliferation potential of satellite cells: differentiation capacity,"University Hospital, Montpellier|PhyMedExp Inserm U1046",All,2 Years to 15 Years � (Child),Not Applicable,8,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,RECHMPL21-0524 7931|2021-A02669-32,"June 1, 2022","March 1, 2026","March 1, 2026","June 3, 2022",,"June 3, 2022",,,https://ClinicalTrials.gov/show/NCT05403034,NCT05403034,
anrs,NCT05409261,Evaluation of the Immunogenicity and Safety of COVID-19 Vaccines (Ad26.COV2.S and NVX-CoV2373),CoviCompMali,Not yet recruiting,No Results Available,COVID-19|Vaccine Reaction|SARS CoV 2 Infection|Vaccine Adverse Reaction,Biological: Ad26.COV2.S|Biological: NVX-CoV2373,"Anti-SARS-CoV-2 Spike immunoglobulin G (IgG) level|Anti-SARS-CoV-2 Spike IgG level|Anti-SARS-CoV-2 immunoglobulin M (IgM) level|Neutralizing antibody level for SARS-CoV-2|Fluorospot tests (type 1,2, and 17 helper T cell (TH1, TH2, TH17), Cytotoxicity)|Mucosal SARS-CoV-2 specific antibody levels|Determination of Epitope profile|B cell response to vaccine|Measurement of ultrasensitive immunoglobulin A (IgA) and mucosal IgA and IgM functionality|Rate of adverse events|SARS-CoV-2 infection","ANRS, Emerging Infectious Diseases|CEPI|Innovative clinical research network in vaccinology (IREIVAC)|Institut National de la Santé Et de la Recherche Médicale, France|APHP|Center for Vaccine Development - Mali",All,"18 Years and older   (Adult, Older Adult)",Phase 2,400,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS0142S,June 2022,August 2022,July 2024,"June 8, 2022",,"June 8, 2022","CVD-MALI, Bamako, Mali",,https://ClinicalTrials.gov/show/NCT05409261,NCT05409261,
anrs,NCT05409300,Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea,CovicompareG,Recruiting,No Results Available,COVID-19|Vaccine Adverse Reaction|Sars-CoV-2 Infection|Healthy Volunteer,Biological: BBIBP-CorV,"Anti-SARS-CoV-2 Spike IgG level|Anti-SARS-CoV-2 specific IgG level|Anti-SARS-CoV-2 IgA and level|Anti-SARS-CoV-2 IgM level|Neutralizing antibody level for SARS-CoV-2|Fluorospot tests (TH1, TH2, TH17, Cytotoxicity)|Mucosal SARS-CoV-2 specific antibody levels|Epitope profile|B cell response to vaccine|Measurement of ultrasensitive IgA and mucosal IgA and IgM functionality|Rate of adverse events|SARS-CoV-2 infection","ANRS, Emerging Infectious Diseases|CEPI|Alliance for International Medical Action|Centre National de Formation et de Recherche en Sante Rurale|Institut National de la Santé Et de la Recherche Médicale, France|APHP|Agence Nationale de Sécurité Sanitaire de la Guinée (ANSS Guinée)|Innovative clinical research network in vaccinology (IREIVAC)",All,"18 Years and older   (Adult, Older Adult)",Phase 2,200,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,ANRS0144S,"April 25, 2022",August 2023,July 2024,"June 8, 2022",,"February 16, 2023","Centre de recherche de Landreah, Conakry, Guinea|Palais du Peuple, Conakry, Guinea",,https://ClinicalTrials.gov/show/NCT05409300,NCT05409300,
oui,NCT05409560,Core Temperature Afterdrop in Cold-water Swimming,THERMOCOLD,Completed,No Results Available,"Hypothermia, Accidental|Cold Water Swimming",Other: Swimming participants in the 6-hour cold water swim,"Change in Body Core Temperature|Body composition, body mass|Body composition, fat-free mass|Body composition, muscle mass|Distance|Duration|Individual characteristics, gender|Individual characteristics, age|Individual characteristics, swimming habits|Individual characteristics, training in cold environment","University Hospital, Caen|INSERM UMR U1075 Com�te GIP Cyceron, unicaen, Caen Normandie",All,"18 Years to 65 Years � (Adult, Older Adult)",,15,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,THERMOCOLD,"May 21, 2021","May 23, 2021","August 19, 2021","June 8, 2022",,"June 8, 2022","CHU Caen Normandie, Caen, France",,https://ClinicalTrials.gov/show/NCT05409560,NCT05409560,
oui,NCT05412771,Evolutive and Functional Bases of Menstruation in Women - 2,EVOMENS-2,Not yet recruiting,No Results Available,Menstruation,Procedure: Hysteroscopy,Transcriptomics|Open chromatin analysis|Non-coding transcriptomics|3D cell culture - establishment|3D cell culture - structural evaluation|3D cell culture - cell types evaluation|3D cell culture - gene expression,"Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 50 Years   (Adult),Not Applicable,20,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C21-20|2021-A02779-32,"June 19, 2022","June 19, 2024","July 19, 2025","June 9, 2022",,"June 9, 2022",,,https://ClinicalTrials.gov/show/NCT05412771,NCT05412771,
oui,NCT05414357,Impact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer,ICANSLEEP,Not yet recruiting,No Results Available,Breast Cancer|Sleep|Quality of Life,Diagnostic Test: Functional Magnetic Resonance Imaging at rest and in activation with attentional task,Ratio of total sleep time to time spent in bed and the number of awakenings lasting more than one minute measured by polysomnography with actimeter|Amplitude of activity-rest rhythm measured with actimeter|Acrophase of activity-rest rhythm measured with actimeter,Centre Francois Baclesse|UMR_S 1077 Inserm-EPHE-Normandie Universit�,Female,"45 Years to 65 Years � (Adult, Older Adult)",Not Applicable,75,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,2022-A00437-36,October 2022,October 2026,June 2027,"June 10, 2022",,"August 10, 2022","Centre Fran�ois Baclesse, Caen, France|Inserm-Ephe-Unicaen U1077, Caen, France",,https://ClinicalTrials.gov/show/NCT05414357,NCT05414357,
oui,NCT05419622,Analysis of Bronchial Remodeling Using Resonance Magnetic Imaging in Severe Asthmatic childrEn,ARISE,Not yet recruiting,No Results Available,Asthma in Children,Biological: bronchial biopsies,Measure of Bronchial thickness (BT) in UTE-T1 (in mm)|Measure of Signal strength of the bronchial wall (SB) in UTE-T1 (in milliseconds)|Measure of Volume of bronchial edema (VO) in T2-Turbo Spin-Echo (TSE) (in cubic millimeters)|Measure of Bronchial edema (SO) signal intensity in T2-Turbo Spin-Echo (TSE) (in milliseconds)|Comparison each measurable values between 2 Physicians evaluated in the principal outcome measures|Measure of expiratory forced vital capacity (FVC)|Measure of forced expiratory volume in one second (FEV1)|Measure length of reticular basement membrane (RBM) completely denuded or covered by a single layer of basal cells with no intact ciliated or goblet cell over total basement membrane length|Measure of reticular basement membrane thickness (µm)|Measure of density of blood vessels (number/cm²)|Measure of normalized fibrosis area (%)|Measure of reticular basement membrane to bronchial smooth muscle distance (µm),"University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France",All,6 Years to 17 Years   (Child),Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,CHUBX 2020/48,"January 15, 2023","August 30, 2026","August 30, 2026","June 15, 2022",,"January 3, 2023","CHU de Bordeaux - Explorations Fonctionnelles, Bordeaux, France|Centre Hospitalier de Saintonge, Saintes, France",,https://ClinicalTrials.gov/show/NCT05419622,NCT05419622,
oui,NCT05425901,Preclinical Evaluation of Multimodal Therapeutic Strategies in Intestinal Irradiation and Inflammatory Bowel Disease From Organoids,INTRUST,Not yet recruiting,No Results Available,Radiation Enteritis|Inflammatory Bowel Diseases,Other: biopsy,Validation of organoid-production method - quantity|Validation of organoid-production method - size|Validation of organoid-production method - cell growth|Validation of organoid-production method - cell composition|Validation of organoid-production method - cell apoptosis|Validation of organoid-production method - tight junctions|Screening-tool setup - quantity|Screening-tool setup - size|Screening-tool setup - cell growth|Screening-tool setup - cell composition|Screening-tool setup - cell apoptosis|Screening-tool setup - tight junctions|Screening-tool setup - inflammatory cytokines|In-vitro treatment evaluation - quantity|In-vitro treatment evaluation - size|In-vitro treatment evaluation - cell growth|In-vitro treatment evaluation - cell composition|In-vitro treatment evaluation - cell apoptosis|In-vitro treatment evaluation - tight junction|In-vitro treatment evaluation - inflammatory cytokines,"Institut National de la Santé Et de la Recherche Médicale, France|National Research Agency, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C20-53|2021-A02973-38,"June 29, 2022","June 29, 2025","January 31, 2026","June 21, 2022",,"June 21, 2022","Hopital Beaujon, Clichy, Hauts De Seine, France",,https://ClinicalTrials.gov/show/NCT05425901,NCT05425901,
oui,NCT05426187,Follow-up of Immunological Pattern and Pregnancy Outcomes in Women Previously Received Placental Malaria Vaccine,PRIMVACLongT,Recruiting,No Results Available,Malaria in Pregnancy,,Geometric mean titer of antibodies|Cross-reactivity against different VAR2CSA variants expressed on the surface of erythrocytes parasitized by various strains of Plasmodium falciparum by flow cytometry|Percentage of binding inhibitory activity using various VAR2CSA expressing strains by CSA-binding inhibition assay (BIA) at different timepoints during the twelve months of follow up.,"Groupe de Recherche Action en Sante|Institut National de la Santé Et de la Recherche Médicale, France|European Vaccine Initiative",Female,18 Years to 35 Years   (Adult),,90,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PRIMVAC Long Term study,"February 18, 2022","March 23, 2023",December 2023,"June 21, 2022",,"June 21, 2022","Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso",,https://ClinicalTrials.gov/show/NCT05426187,NCT05426187,
oui,NCT05431985,Cross-cultural Validation of a Screening Scale for the Misuse of Opioid Analgesics in Primary Care,VAMOS,Completed,No Results Available,Chronic Pain|Addiction Opiate,,Prescription Opioid Misuse Index - POMI|Sociodemographic characteristics,"University Hospital, Clermont-Ferrand",All,"18 Years and older � (Adult, Older Adult)",,160,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,2015 LAPORTE,"January 1, 2017","March 1, 2019","July 1, 2019","June 24, 2022",,"June 24, 2022","CHU Clermont-Ferrand, UMR INSERM 1107, NEURO-DOL, Clermont-Ferrand, France|D�partement de m�decine G�n�rale, Facult�s de M�decine de Clermont-Ferrand, Clermont-Ferrand, France|D�partement de m�decine g�n�rale, Lyon, Lyon, France|D�partement de m�decine g�n�rale, Facult� de m�decine, Montpellier, Montpellier, France|D�partement de m�decine g�n�rale, Facult� de m�decine, Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT05431985,NCT05431985,
oui,NCT05436756,Chronic Post-leptospirosis Manifestations in Reunion,LEPTONIC,Not yet recruiting,No Results Available,Leptospirosis,Other: Biological sampling and collection,Proportion of patients with chronic post-leptospirosis symptom(s) persisting 2 years after infection.,Centre Hospitalier Universitaire de la R�union,All,"Child, Adult, Older Adult",Not Applicable,198,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2022/CHU/16,"September 22, 2022","April 22, 2023","September 22, 2023","June 29, 2022",,"June 29, 2022",,,https://ClinicalTrials.gov/show/NCT05436756,NCT05436756,
oui,NCT05452733,Toward a Real-time Access to Sleepers' Mental Content,SleepDance,Not yet recruiting,No Results Available,Memory Reactivation|Memory Consolidation|Sleepwalking,Behavioral: differences of behavior between sleepwalking and non sleepwalking patient,Behavioral reaction|Evaluation of targeted memory reactivation (TMR) success in sleepwalkers by movements test|Quantification of movements exhibited during sleep|Determination of the link between dream and sensory cues,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 35 Years   (Adult),Not Applicable,200,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,APHP XX,"January 1, 2023","December 30, 2024","December 30, 2024","July 11, 2022",,"October 18, 2022","Service des Pathologies du Sommeil, Hôpital Pitié-Salpétrière, Paris, France",,https://ClinicalTrials.gov/show/NCT05452733,NCT05452733,
oui,NCT05468073,Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD,IL-2-AD,Recruiting,No Results Available,Alzheimer Disease,Drug: Proleukin|Drug: Placebo,"Change from baseline CDR score at 18 months|Rate of cognitive decline between placebo and treatment groups as assessed by changes in MMSE scores at baseline, 6, 12, and 18 months|Rate of cognitive decline between placebo and treatment groups as assessed by changes in ADAS-Cog 13 items scores at baseline, 6, 12, and 18 months|Rate of functional decline between placebo and treatment groups as assessed by changes in ADCS-ADL MCI scores at baseline, 6, 12, and 18 months|Rate of functional decline between placebo and treatment groups as assessed by changes in CDR (sum of boxes) scores at baseline, 6, 12, and 18 months|Change in neuroimmune reaction as assessed by [18F]-DPA-714 PET global cortical index and regional cortical binding at baseline and 18 months between placebo and treated groups|Change in peripheral frequency of Treg and other immune effectors at 18 months compared to baseline between placebo and treated groups|Change in hippocampal atrophy at 18 month compared to baseline between placebo and treated groups|Number of patients with treatment related adverse events as assessed by clinical safety panel|Number of patients with treatment related adverse events as assessed by blood laboratory safety panel",Centre Hospitalier St Anne|For Drug Consulting,All,"18 Years and older � (Adult, Older Adult)",Phase 2,45,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D20-P012,"October 11, 2022","September 1, 2025","September 1, 2026","July 21, 2022",,"January 13, 2023","GHU Saint Anne, Paris, France",,https://ClinicalTrials.gov/show/NCT05468073,NCT05468073,
oui,NCT05469087,Cohort Primary Hyperparathyroidism,CoHPT,Recruiting,No Results Available,Primary Hyperparathyroidism,,"Occurrence of cardiovascular events, after parathyroidectomy for primary hyperparathyroidism|Change in LDL-cholesterol concentration after surgery|Change in HDL-cholesterol concentration after surgery|Change in plasma triglycerides concentration after surgery|Change in homeostasis model assessment HOMA-IR index after surgery|Change in homeostasis model assessment HOMA-B index after surgery|Change in arterial stiffness after surgery|Change in bone mineral density after parathyroidectomy|Change in bone-specific alkaline phosphatases|Change in P1NP|Change in plasma CTX|Change in the physical component score of the SF-36 questionnaire after surgery|Change in the mental component score of the SF-36 questionnaire after surgery|Change in renal outcomes (estimated glomerular filtration rate) after parathyroidectomy|Medico-economic impact of parathyroidectomy for primary hyperparathyroidism in comparison with simple surveillance","Nantes University Hospital|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,403,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,RC15_0424,"March 31, 2016","February 24, 2022","February 24, 2027","July 21, 2022",,"July 21, 2022","Nantes University Hospital, Nantes, Loire-Atlantique, France",,https://ClinicalTrials.gov/show/NCT05469087,NCT05469087,36917123
oui,NCT05469503,Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure,INSIGHT,Recruiting,No Results Available,Prehypertension|Elevated Blood Pressure|Blood Pressure|Metabolic Syndrome,Dietary Supplement: TOTUM-854|Dietary Supplement: Placebo,Systolic Blood Pressure at V4|Evolution of Systolic Blood Pressure|Evolution of Diastolic Blood Pressure|Evolution of the fasting blood glycemia|Evolution of the fasting blood concentration of triglycerides|Evolution of the fasting blood concentration of total cholesterol|Evolution of the fasting blood concentration of HDL cholesterol|Evolution of the fasting blood concentration of non-HDL cholesterol|Evolution of the fasting blood concentration of LDL cholesterol (Friedewald method)|Evolution of the fasting blood hsCRP concentration|Evolution of the body weight|Evolution of the waist circumference|Evolution of the hip circumference|Evolution of the cardiovascular disease risk (SCORE value)|Delay of occurence of pharmacological treatment requirement for hypertension from V1,Valbiotis|Excelya,All,"18 Years to 75 Years � (Adult, Older Adult)",Not Applicable,400,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",VCT-009|2022-A00131-42,"July 15, 2022","August 1, 2023","August 1, 2023","July 21, 2022",,"August 31, 2022","Multiprofile Hospital for Active Treatment Cardiology Department, Haskovo, Bulgaria|Multiprofile Hospital for Active Treatment - Uni Hospital OOD, Cardiology Department, Panagyurishte, Bulgaria|Diagnostic Consultative Center VII-Plovdiv South district EOOD, Cabinet of Endocrinology, Plovdiv, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Karidad EAD, Cardiology Department, Plovdiv, Bulgaria|Diagnostic Consultative Center XX- Sofia EOOD, Sofia, Bulgaria|CHU Clermont Ferrand PIC/CIC Inserm 1405, Clermont-Ferrand, France|Vitamed Ga?aj i Cichomski sp.j, Bydgoszcz, Poland|Centrum Medyczne Linden, Krak�w, Poland|Przychodnia Zespo?u Lekarza Rodzinnego ""Medyk"", S?upca, Poland|Centrum Medyczne Opor�w, Wroc?aw, Poland",,https://ClinicalTrials.gov/show/NCT05469503,NCT05469503,
oui,NCT05470088,"MRI Study of Subjects With ASD, Their Relatives and TD",,Recruiting,No Results Available,Autism Spectrum Disorder,Other: Neuroimaging (MRI),3DT1 MRI derived variables|Resting state fMRI derived variables|Task based fMRI derived variables|Diffusion MRI derived variables|quantitative T1 and quantitative T2 MRI,"Institut National de la Sant� Et de la Recherche M�dicale, France|APHP|Institut Pasteur|Commissariat A L'energie Atomique",All,"24 Months and older � (Child, Adult, Older Adult)",,1000,Other|Industry,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,C16-90|2017-A02356-47,"March 13, 2022","September 13, 2023","September 13, 2039","July 22, 2022",,"August 4, 2022","NeuroSpin neuroimaging platforme, Gif-sur-Yvette, France|APHP, H�pital Robert Debr�, Paris, France",,https://ClinicalTrials.gov/show/NCT05470088,NCT05470088,
oui,NCT05480826,"Familial and Functional Study of Genetic Variants Identified in People With Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder or Resistant Depression",GENI,Not yet recruiting,No Results Available,Psychiatric Disorder,Genetic: study of the transmission of genetic variants,Measure of the probability of having a psychiatric disorder given the presence of the genetic variant studied.,Fondation FondaMental,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,FF21-GENI|2021-A02551-40,"March 15, 2023","September 15, 2027","September 15, 2028","July 29, 2022",,"February 15, 2023",,,https://ClinicalTrials.gov/show/NCT05480826,NCT05480826,
oui,NCT05512741,Intestinal Microbiota and Postoperative Ileus After Colorectal Surgery,MICRO-IPO,Not yet recruiting,No Results Available,Postoperative Ileus|Surgery-Complications,Other: Feces collection,Composition of the feces microbiota before surgery|Composition of the feces microbiota after surgery,"University Hospital, Angers|Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",,100,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,MicroIPO2022,"September 1, 2022","September 1, 2023","October 1, 2023","August 23, 2022",,"August 23, 2022",,,https://ClinicalTrials.gov/show/NCT05512741,NCT05512741,
oui,NCT05513807,Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant,GABRIEL,Not yet recruiting,No Results Available,Delayed Graft Function,Drug: Nicotinamide treatment|Drug: Placebo treatment,"Efficacy of 3 doses of NAM given orally at 1g/dose immediately pre transplant and during the first 2 post-operative days of renal transplantation versus placebo, on the early graft function, assessed by CRR2.|Verify the safety profile of NAM (liver toxicity and tacrolimus trough levels to detect an interaction)|Evaluate the effect of NAM on the rate of delayed graft function defined conventionally as the need for dialysis before POD7|Evaluate the effect of NAM on renal graft function 3 months after transplantation|Evaluate the effect of NAM on serum NAM levels (difference between NAM at POD2 and NAM at baseline)|Evaluate the effect of NAM on the biopsy-proven rejection rate within three months after transplantation.|Measurement accuracy, and positive predictive value of the urinary quinolinate / tryptophane ratio measured early after transplantation (at POD2) for CRR2, DGF, and graft function estimated by MDRD at 3 months|Evaluate the effect of NAM serum concentration at baseline on the level of risk of DGF|Cost-effectiveness and cost utility of NAM after transplantation of a kidney from a deceased donor|Comparison of different separation techniques (LC, HILIC, IC, EC) for MS quantification of uQ/T and serum NAM","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Centre National de la Recherche Scientifique, France",All,"18 Years and older   (Adult, Older Adult)",Phase 3,204,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",APHP200036,November 2022,August 2023,November 2023,"August 24, 2022",,"October 18, 2022","Department of Renal Transplantation - Hospital Pitié Salpétrière, Paris, France",,https://ClinicalTrials.gov/show/NCT05513807,NCT05513807,
oui,NCT05521776,Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE),RANSPRE,Recruiting,No Results Available,Preeclampsia (PE),Procedure: First-trimester preeclampsia screening (FMF triple test),Severe perinatal morbidity|Incidence of preeclampsia|Incidence of components of moderate and severe maternal morbidity|Incidence of components of moderate and severe perinatal morbidity|Impact of first-trimester PE screening on potential adverse events|Aspirin side effects|Women's anxiety 1|Women's anxiety 2|Women's perception of information received and screening|To evaluate the impact of first-trimester PE screening on costs and cost effectiveness 1|To evaluate the impact of first-trimester PE screening on costs and cost effectiveness 2|To evaluate the impact of first-trimester PE screening on costs and cost effectiveness 3,"Assistance Publique - Hôpitaux de Paris|URC-CIC Paris Descartes Necker Cochin|INSERM, Epopé team",Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,14500,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,APHP211047|2022-A00374-39,"March 6, 2023",October 2025,October 2025,"August 30, 2022",,"March 17, 2023","CHU de Bordeaux, Bordeaux, France|Hôpital Femme Mère Enfant, Bron, France|Hôpital Antoine Béclère, Clamart, France|CHU Estaing, Clermont-Ferrand, France|Hôpital Intercommunal Créteil, Créteil, France|CHU Dijon Bourgogne, Dijon, France|Hôpital de la conception et de la Timone, Marseille, France|Hôpital Nord, Marseille, France|CHRU de Nancy, Nancy, France|Hôpital Femme - Maternité, Nantes, France|Hôpital Armand Trousseau, Paris, France|Hôpital Cochin (site Port-Royal), Paris, France|Hôpital Saint-Joseph, Paris, France|CHI de Poissy, Poissy, France|Hôpital Sud Rennes, Rennes, France|CHU Charles Nicolle, Rouen, France|CHU Strasbourg, CMCO Schiltigheim, Strasbourg, France|Hôpital de Hautepierre, Strasbourg, France|Hôpital Paule de Viguier, Toulouse, France|Hôpital Bretonneau, Tours, France",,https://ClinicalTrials.gov/show/NCT05521776,NCT05521776,
oui,NCT05543525,Myocardial Mechanics in Athlete's Heart,,Completed,No Results Available,Athlete Heart,Other: Echocardiography|Other: Cardiopulmonary exercise testing,Multilayer (= epi- and endocardial) left ventricular global longitudinal strain using Speckle-tracking echocardiography|Age|Height|Weight|BMI|Heart rate|Type of Sport|IVSD|Left ventricle indexed mass|Left ventricular Ejection Fraction|left ventricular End-diastolic volume|Cardiac Index|Maximal E-wave velocity and Maximal A-wave velocity|Left atrium End-systolic volume|left ventricular global longitudinal strain (peak G) assessed by Speckle-tracking echocardiography|PSI (pre stretch index) assessed by Speckle-tracking echocardiography|PST (postsystolic thickening) assessed by Speckle-tracking echocardiography|Peak VO2,"Central Hospital, Nancy, France|INSERM, UMR-1116|INSERM, CIC 1433",Male,"18 Years and older � (Adult, Older Adult)",,191,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,2022PI064,"July 1, 2021","January 1, 2022","January 1, 2022","September 16, 2022",,"September 16, 2022","Chru Nancy, Nancy, France",,https://ClinicalTrials.gov/show/NCT05543525,NCT05543525,
oui,NCT05545384,Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial,IDAR,Not yet recruiting,No Results Available,Acute Demyelinating Syndrome,Drug: Immediate Azathioprine (1st attack)|Drug: Immediate Rituximab (1st attack)|Drug: Standard of care,"annualized relapse rate (ARR) at 24 months|Annualized relapse rate at 12 months|Time to first relapse (2nd attack) will be defined as time from randomization to the date of first relapse, with right-censoring in case of loss of follow-up|Percentage of patients free of relapses over 24 months|Motor disability outcome will be assessed with Expanded Disability Status Scale (EDSS) score|Visual Acuity, Optical Coherence Tomography|Cognitive function: Wechsler Intelligence Scale for Children (WISC)-5|Fatigue Severity Scale (FSS)|Cumulative number of new or newly enlarged lesions detected on T2-weighted MRI and of T1 gadolinium enhancing lesions","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",All,6 Years to 17 Years   (Child),Phase 2|Phase 3,86,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,APHP211057|2022-002385-32,November 2022,November 2024,November 2026,"September 19, 2022",,"September 19, 2022","CHU Besançon, Besançon, France|CHU Bordeaux, Bordeaux, France|CHU Brest, Brest, France|HCL de Bron, Bron, France|Hôpital Bicêtre, Le Kremlin Bicetre, France|CHRU Lille, Lille, France|CHU Monptellier, Montpellier, France|CHU Strasbourg, Strasbourg, France|CHU Toulouse Purpan, Toulouse, France",,https://ClinicalTrials.gov/show/NCT05545384,NCT05545384,
oui,NCT05548322,Studies Into Touch in Healthy Humans to Provide Sensory Feedback in Prostheses,TACTHUM,Not yet recruiting,No Results Available,Somatosensory Disorders|Amputation|Tactile Disorders|Aging|Prosthesis User,Device: Different surfaces to be touched|Behavioral: Emotional state change|Device: Electrical stimulation,Microneurography recording|Electrodermal response|Heart rate|Electromyography|Electroencephalography|Perceptual ratings of pleasantness|Perceptual ratings of roughness|Perceptual ratings of intensity,"Institut National de la Santé Et de la Recherche Médicale, France",All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,210,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,C21-19|2021-A01604-37,"October 3, 2022","October 2, 2032","November 2, 2032","September 21, 2022",,"September 21, 2022","CNRS - Aix-Marseille University UMR7291, Marseille, France|Hôpital HIA Lavéran, Marseille, France",,https://ClinicalTrials.gov/show/NCT05548322,NCT05548322,
oui,NCT05563831,National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS),COSY,Not yet recruiting,No Results Available,PIK3CA-related Overgrowth Spectrum|CLOVES Syndrome|Klippel Trenaunay Syndrome|Megalencephaly|MCAP|Macrodactyly|Vascular Malformations|Lymphatic Malformation|Venous Malformation,Other: national registry,"Description of patients with overgrowth syndromes|Prevalence of overgrowth syndromes in France|Biobanking of samples derived from patients with overgrowth syndromes|Description of patient cares: mumber of consultations and hospitalizations, number of treatment lines, grouping of patients by type of course (clusters)|Economic evaluation of cares for patients with overgrowth syndromes: cost of care, per period and cumulative.","Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,2500,Other,Observational,Observational Model: Cohort|Time Perspective: Other,C20-09,"October 1, 2022","August 31, 2027","August 31, 2028","October 3, 2022",,"October 3, 2022","Translational medicine and Targeted therapies unit, Hôpital Necker Enfants Malades, Paris, France",,https://ClinicalTrials.gov/show/NCT05563831,NCT05563831,
anrs,NCT05581160,Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST),NGS-IST,Recruiting,No Results Available,Sexually Transmitted Infections (Not HIV or Hepatitis)|Chlamydia Trachomatis Infection|Neisseria Gonorrhoeae Infection|Mycoplasma Genitalium Infection,Diagnostic Test: Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST),"To evaluate the performance of NGS metagenomic diagnosis of Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (Ng) compared to reference techniques.|To evaluate the performance of the diagnosis by NGS of the other STIs compared to the reference techniques.|Describe the epidemiology of circulating strains by molecular typing.|Estimate the incidence and describe the natural history of colonization by Mycoplasma genitalium (Mg).|Estimate the incidence of the appearance of Mycoplasma genitalium resistance under antibiotic selection pressure.|Characterize circulating Neisseria gonorrhoeae (Ng) clones.|Characterize the circulating serotypes of Chlamydia trachomatis (Ct).|Estimate the incidence of agents not usually screened for in STI screening (HSV-1, HSV-2, HPV, Mycoplasma hominis, Ureaplasma sp, Haemophilus ducreyi, Campylobacter sp, Shigella sp, Clostridium difficile, Entamoeba histolytica).|Determine the factors associated with STI events.","Institut de M�decine et d'Epid�miologie Appliqu�e - Fondation Internationale L�on M'Ba|ANRS, Emerging Infectious Diseases",Male,"18 Years and older � (Adult, Older Adult)",Not Applicable,207,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IMEA62,"July 11, 2022","February 11, 2024","February 11, 2024","October 14, 2022",,"October 14, 2022","Service des Maladies Infectieuses et Tropicales H�pital Saint-Antoine, Paris, France",,https://ClinicalTrials.gov/show/NCT05581160,NCT05581160,
oui,NCT05584930,"Clusterin, Ptx3 and Pediatric Febrile Neutropenia (CluPPFeN)",CluPPFeN,Recruiting,No Results Available,Cancer Childhood|Febrile Neutropenia,Other: Collection of blood sample,Evaluate serum CLU levels during febrile neutropenia in children followed for cancer|Evaluate serum levels of CLU at the beginning of non-febrile aplasia and during a possible 2nd febrile peak.|Evaluate serum PTX3 levels during febrile neutropenia in children followed for cancer,"University Hospital, Angers",All,"up to 18 Years � (Child, Adult)",Not Applicable,55,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2022-A01750-43,"October 10, 2022",December 2024,March 2025,"October 18, 2022",,"October 18, 2022","University Hospital of Angers, Angers, France",,https://ClinicalTrials.gov/show/NCT05584930,NCT05584930,
oui,NCT05596331,Social Information Processing in Children: an ocUlo-pupillometric Tool for Standard Evaluation,SIRCUS,Not yet recruiting,No Results Available,Autism Spectrum Disorder,Other: eye-tracker,Oculometric measurements 1: Tracking time|Oculometric measurements 2: Fixation time on the screen|Oculometric measurements 3: Fixation time on the eye area during entire stimuli duration|Oculometric measurements 4: Fixation time on the mouth area of face stimuli|Pupillometric measurements|Discriminative power,"University Hospital, Tours|UMR 1253, iBrain, Universit� de Tours, Inserm, Tours, France.|Laboratory of Fundamental and Applied Computer Science of Tours, EA6300|National Research Agency, France|Ministry of Health, France",All,"1 Day to 50 Years � (Child, Adult)",Not Applicable,460,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,DR220031/SIRCUS|2022-A00870-43,November 2022,September 2026,September 2026,"October 27, 2022",,"November 14, 2022",,,https://ClinicalTrials.gov/show/NCT05596331,NCT05596331,
non,NCT05605795,Investigation of Cross-allergies Between Cefazolin and Amoxicillin With Skin Tests and Provocation Test,CEFAZOPE,"Active, not recruiting",No Results Available,Allergic Reaction|Beta Lactam Adverse Reaction,,Proportion of patients with cross-allergies between Cefazolin and Amoxicillin|Diagnostic value of cefazolin skin tests|Description of the safety of our protocol for the reintroduction of cefazolin and amoxicillin in the context of IgE-mediated cross-allergy,Groupe Hospitalier Paris Saint Joseph,All,"18 Years and older � (Adult, Older Adult)",,84,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,CEFAZOPE,"October 28, 2022","November 28, 2022","December 31, 2023","November 4, 2022",,"March 7, 2023","Groupe Hospitalier Paris Saint-Joseph, Paris, France",,https://ClinicalTrials.gov/show/NCT05605795,NCT05605795,
oui,NCT05613868,TPN-101 in Aicardi-Gouti�res Syndrome (AGS),,Not yet recruiting,No Results Available,Aicardi-Gouti�res Syndrome (AGS),Drug: TPN-101,Change in innate immune signaling|Incidence and severity of spontaneously reported treatment-emergent adverse events (TEAEs) of TPN-101,"Transposon Therapeutics, Inc.",All,"12 Months and older � (Child, Adult, Older Adult)",Phase 2,16,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TPN-101-AGS-201,March 2023,December 2024,April 2025,"November 14, 2022",,"March 7, 2023","Laboratory of Neurogenetics and Neuroinflammation Imagine Institute - INSERM U1163, Paris, France|Presidio Ospedale dei Bambini [Children's Hospital], Brescia, Italy|SST Fatebenefratelli Sacco, Milano, Italy|Istituto Neurologico Casimiro Mondino, Pavia, Italy|Royal Hospital for Children and Young People, Edinburgh, United Kingdom",,https://ClinicalTrials.gov/show/NCT05613868,NCT05613868,
oui,NCT05615571,Testing of NBIA Genes: Analysis of Genetic Heterogeneity and Validation of Mitochondrial Markers for Assessing Causality of Sequence Variants.,NBIA MITO,Completed,No Results Available,Neurodegeneration With Brain Iron Accumulation (NBIA),Genetic: Establishment of mitochondrial markers|Genetic: Sequencing tests,Sequencing tests of a panel of 22 genes using a dedicated custom capture and a medium throughput sequencing protocol.|Identification of the dominant form using biochemical analysis in patient's fibroblasts,"University Hospital, Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France",All,"Child, Adult, Older Adult",,70,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,CHUBX 2017/38,"January 4, 2018","November 30, 2020","November 30, 2020","November 14, 2022",,"November 14, 2022","Centre Hospitalier Universitaire de Bordeaux, Talence, France",,https://ClinicalTrials.gov/show/NCT05615571,NCT05615571,
oui,NCT05623150,CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome,CHALNA2,Not yet recruiting,No Results Available,"Non-Alcoholic Fatty Liver Disease|Non-Alcoholic Steatohepatitis|Alcohol-related Liver Disease|Cirrhosis, Liver|Hepatocellular Carcinoma",Diagnostic Test: Liver biopsy,Primary outcome measure CHALNA2|Secondary outcome measure CHALNA2|3th outcome measure CHALNA2|4th outcome measure CHALNA2|5th outcome measure CHALNA2|6th outcome measure CHALNA2|7th outcome measure CHALNA2,"Institut National de la Santé Et de la Recherche Médicale, France|Centre Hospitalier Universitaire de Nice",All,"18 Years and older   (Adult, Older Adult)",,710,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,C20-12,"December 1, 2022",January 2032,March 2032,"November 21, 2022",,"November 21, 2022",,,https://ClinicalTrials.gov/show/NCT05623150,NCT05623150,
oui,NCT05624983,Exploration of High Frequency Otoacoustic Emissions and Developmental Language Disorders,OTOEMHF,Not yet recruiting,No Results Available,Language Development Disorders,Diagnostic Test: acoustic otoemisions|Diagnostic Test: Otoscopy|Diagnostic Test: Audiometry|Diagnostic Test: Tympanometry,HF DPOAE measurement|Presence or absence of HF DPOAE|Functional status of the middle ear|Determination of the average hearing loss (baseline pure tone audiometry)|Laterality of hearing loss at the DPOAE level with a classification into 3 groups|Severity and type of language impairment assessed by the EVALO/ EVALEO,"University Hospital, Clermont-Ferrand",All,2 Years to 17 Years � (Child),Not Applicable,138,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RBHP 2022 SARRET,"January 1, 2023","July 1, 2027","July 1, 2027","November 22, 2022",,"November 22, 2022","CHU Clermont-Ferrand, UMR INSERM 1107, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT05624983,NCT05624983,
oui,NCT05629871,Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?,ALZ-OREX,Not yet recruiting,No Results Available,Neuropathology,Procedure: Polysomnography|Behavioral: Neuropsychological assessment|Behavioral: Questionnaires on sleep and behavioural problems|Procedure: Actimetry|Diagnostic Test: Fractional diuresis|Procedure: Internal temperature measurement|Other: Biomarker assay,Change in the Free and Cued Selective Reminding Test (FCSRT) scale score|Cognitive decline in ADCS-PACC composite score|Cognitive decline in the Alzheimer's Disease Cooperative Study- Preclinical Alzheimer Cognitive Composite (ADCS-PACC) composite score|Concentration of proteins involved in Alzheimer disease|Concentration of orexinA/hypocretin|Changes in sleep duration|Sleep time at stage 1-2 during polysomnography|Sleep time at stage 3 during polysomnography|Time spent in Rapid eye movement (REM) sleep during polysomnography|Apnea Hypopnea Index|Nocturnal oxygen saturation (SaO2)|Urinary melatonin concentration|Internal temperature,"University Hospital, Montpellier|Institut National de la Santé Et de la Recherche Médicale, France",All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,132,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RECHMPL18_0061,"March 15, 2023","June 1, 2027","June 1, 2027","November 29, 2022",,"January 17, 2023","University Hospital, Montpellier, Montpellier, France|University Hospital of Poitiers, Poitiers, France|University Hospital of Toulouse, Toulouse, France",,https://ClinicalTrials.gov/show/NCT05629871,NCT05629871,
oui,NCT05636033,Semantic Networks in Alcohol Use Disorder Patients: Exploratory Study,ALCOOLNET,Not yet recruiting,No Results Available,Alcohol Use Disorder,,"Description of the semantic associations using FGAT|Description of the semantic associations using AJT|Impact of medications on the semantic association performance|Impact of age on the semantic association performance|Impact of the study level on the semantic association performance|Impact of gender on the semantic association performance|Impact of the duration of dependence on the semantic association performance|Impact of cognitive performance on the semantic association performance|Test of the predictive value of FGAT performance assessed at T1 on alcohol consumption during the six weeks following the Baseline|Test of the predictive value of AJT performance assessed at T1 on alcohol consumption during the six weeks following the Baseline|Test of the predictive value of FGAT performance assessed at T1 on alcohol consumption during the three months following the Baseline|Test of the predictive value of AJT performance assessed at T1 on alcohol consumption during the three months following the Baseline|Evolution of FGAT performance, comparison between alcohol use disorder patients and healthy controls|Evolution of AJT performance, comparison between alcohol use disorder patients and healthy controls|Link between the evolution of FGAT performance and the level of alcohol consumption|Link between the evolution of AJT performance and alcohol consumption|Link between the evolution of FGAT performance and the evolution of cognitive performance|Link between the evolution of AJT performance and the evolution of cognitive performance","Institut National de la Santé Et de la Recherche Médicale, France",All,30 Years to 60 Years   (Adult),,60,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,C22-01|2022-A01903-40,March 2023,March 2024,June 2024,"December 5, 2022",,"March 1, 2023","Fernand Widal Hospital, Paris, Ile De France, France",,https://ClinicalTrials.gov/show/NCT05636033,NCT05636033,
oui,NCT05649514,Sleep Impairment in Subjects at Risk of Developing Alzheimer's Disease,WAVE-APOE4,Not yet recruiting,No Results Available,Neuropathology|Cognitive Decline|Sleep Disorder,Procedure: Polysomnography|Behavioral: Neuropsychological assessment|Behavioral: Questionnaires on sleep and behavioural problems|Procedure: Actimetrics|Other: Biomarker assay,Change in the Alzheimer's Disease Cooperative Study - Preclinical Alzheimer Cognitive (ADCS-PACC) scale score|Cognitive decline in ADCS-PACC composite score|Concentration of proteins involved in Alzheimer disease|Sleep time at stage 1-2 during polysomnography|Sleep time at stage 3 during polysomnography|Time spent in Rapide Eye Movement (REM) sleep during polysomnography|Apnea Hypopnea index|Noctural oxygene saturation (SaO2),"University Hospital, Montpellier|Institut National de la Santé Et de la Recherche Médicale, France",All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,RECHMPL22_0392,"February 1, 2023","August 1, 2027","December 1, 2027","December 14, 2022",,"December 14, 2022",,,https://ClinicalTrials.gov/show/NCT05649514,NCT05649514,
oui,NCT05654402,Non-invasive Measurement of Arterial Stiffness,NIVOP,Recruiting,No Results Available,"Anesthesia, Local|Anesthesia",Diagnostic Test: Non-invasive measurement of carotid-femoral transit time by Doppler velocimetry (Athys Medical�) - WAKIe R3 2TC�) (PWV in cm/s),To study the concordance of carotid-femoral pulse wave velocity (PWVcf) values obtained by carotid-femoral Doppler method with those obtained completely noninvasively by continuous PWV estimation under the same conditions during anesthesia.|Study concordance of carotid-femoral pulse wave velocity values obtained by carotid-femoral Doppler method and those obtained completely noninvasively by continuous PWV estimation under the same conditions during anesthesia using mean arterial pressure|To study the concordance of carotid-femoral pulse wave velocity values obtained by carotid-femoral Doppler method with those obtained completely noninvasively by continuous PWV estimation under the same conditions during anesthesia using blood pressure.|To study the concordance of carotid-femoral pulse wave velocity (PWVcf) values obtained by carotid-femoral Doppler method with those obtained completely noninvasively by continuous PWV estimation under the same conditions during anesthesia using ECG.|Study concordance of carotid-femoral pulse wave velocity values obtained by carotid-femoral Doppler method and those obtained by continuous PWV estimation under the same conditions during anesthesia thanks to digital photoplethysmography recording|Study concordance of carotid-femoral pulse wave velocity values obtained by carotid-femoral Doppler method and those obtained completely noninvasively by continuous PWV estimation under the same conditions during anesthesia thanks to administred agents,"Assistance Publique - H�pitaux de Paris|INSERM UMR-942, Paris, France|M3DISIM",All,"18 Years and older � (Adult, Older Adult)",,98,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP2203812,"February 10, 2023",February 2024,August 2024,"December 16, 2022",,"March 6, 2023","AP-HP, Lariboisi�re Hospital, Department of Anesthesiology and Intensive Care, Paris, France",,https://ClinicalTrials.gov/show/NCT05654402,NCT05654402,
anrs,NCT05655702,DRug Use & Infections in ViEtnam: TuBerculosis Control,DRIVE-TB,Not yet recruiting,No Results Available,Tuberculosis,Other: Community based TB intervention,"Prevalence of confirmed TB cases at RDSS 1 and RDSS 4|Assess TB awareness|The feasibility and efficacy of the TB mass screening|Proportion of confirmed TB cases who have initiated TB treatment among those who have attended the referral TB center for confirmation in RDSS 1, 2, 3.|Prevalence of active TB and LTBI among PWID contacts|The incidence of active TB and LTBI among PWID contacts at 6 and 12 months.|The proportion of PWID contacts actually screened for TB at the community study site.|The incidence of TB infection (LTBI and active TB) among PWID in Hai Phong|HIV viremia prevalence at RDSS1|Incremental cost-effectiveness ratio (ICER) and cost per DALY averted.|Acceptability of the 3HP regimen,|Safety of the 3HP regimen,|Proportion of participants who have completed a 12-dose once-weekly regimen of isoniazid/rifapentine (3HP) among those who have initiated 3HP.","ANRS, Emerging Infectious Diseases|Haiphong University of Medicine and Pharmacy|Expertise France|Universit� Montpellier|New York University|CENTER FOR SUPPORTING COMMUNITY DEVELOPMENT INITIATIVES",All,"18 Years and older � (Adult, Older Adult)",Not Applicable,4000,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,ANRS 0092s DRIVE-TB,February 2023,June 2025,June 2025,"December 19, 2022",,"December 19, 2022","Hai Phong University of Medecine and Pharmacy, H?i Ph�ng, Vietnam|Viettiep 2 Hospital, H?i Ph�ng, Vietnam",,https://ClinicalTrials.gov/show/NCT05655702,NCT05655702,
oui,NCT05658341,"An Integrative Intervention Based on Physical Activity, Nutrition and Supportive Care (the ADA Program) to Improve the Quality of Life of Breast Cancer Survivors",ADA,Not yet recruiting,No Results Available,Quality of Life|Breast Cancer,Behavioral: ADA|Behavioral: Usual Care,"Health-related quality of life|Participants' physical, social, emotional, and functional well-being|Physical activity level|Motivation for physical activity Questionnaire-2 (BREQ-2) scale|Sedentary behavior (sitting time)|Relationship to food|Self-efficacy","Siel Bleu|Institut National de la Santé Et de la Recherche Médicale, France",Female,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,160,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,ADA,December 2022,November 2024,November 2025,"December 20, 2022",,"December 20, 2022","Marseille, Marseille, Bouches DU RHON, France|La Rochelle, La Rochelle, Charentes-maritimes, France|Dijon, Dijon, Cote D'or, France|Brest, Brest, Finistere, France|Laval, Laval, Mayenne, France|Lille, Lille, Nord, France|Creil, Creil, Oise, France|Lyon, Lyon, Rhone, France|La Roche sur Yon, La Roche-sur-Yon, Vendée, France|Sens, Sens, Yonne, France",,https://ClinicalTrials.gov/show/NCT05658341,NCT05658341,
associ�,NCT05663216,Determinants of Vascular Leakage During Systemic Inflammatory Response Syndrome,SIRS-PERM,Not yet recruiting,No Results Available,Systemic Inflammatory Response Syndrome,Other: Blood sampling,Fluid balance from Day 0 to day 3 (ml/kg of initial body weight).|Fluid balance (ml/kg of initial body weight).|Extra-vascular lung water index|SOFA score|Serum albuminemia|Catecholamine-free days|Ventilatory-free days|Renal replacement therapy-free Number of days alive without receiving any renal replacement therapy|Mortality,Assistance Publique - H�pitaux de Paris,All,"18 Years and older � (Adult, Older Adult)",,180,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,APHP220418,"February 1, 2023","February 1, 2028","March 1, 2028","December 23, 2022",,"January 3, 2023","Medical Intensive Care Unit, Georges Pompidou European Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT05663216,NCT05663216,
oui,NCT05671068,EMOTION & COGNITION IN MYOCLONUS DYSTONIA (AGENT10-ECODYST),,Not yet recruiting,No Results Available,Myoclonus-Dystonia|DYT11,,BOLD signal derived from the functional magnetic resonance imaging,"Institut National de la Santé Et de la Recherche Médicale, France|Assistance Publique - Hôpitaux de Paris",All,"15 Years to 60 Years   (Child, Adult)",,40,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,C22-18|2022-A00786-37,January 2023,November 2026,November 2026,"January 4, 2023",,"January 4, 2023","Brain Institute, Paris, France",,https://ClinicalTrials.gov/show/NCT05671068,NCT05671068,
oui,NCT05673265,Pediatric and Adult Registry for Patients With ARThrogryposis,PARART,Recruiting,No Results Available,Arthrogryposis Multiplex Congenita (AMC),,Frequency of etiologies|Data from complementary examinations (molecular analyses)|Data from complementary examinations ( medical imaging including muscular MRI)|Data from complementary examinations(biochemical analyses)|Data from complementary examinations (pathology)|Results of phenotypic and functional assessment|Number and types of surgical procedures,"University Hospital, Grenoble",All,"up to 90 Years � (Child, Adult, Older Adult)",,230,Other,Observational,Observational Model: Cohort|Time Perspective: Other,38RC21.055,"November 1, 2021","July 1, 2023","July 1, 2023","January 6, 2023",,"January 6, 2023","CHU Grenoble Alpes, La Tronche, France",,https://ClinicalTrials.gov/show/NCT05673265,NCT05673265,
oui,NCT05675917,MacuTest Website for Personalized AMD Risk Prediction and Prevention,MACUTEST,Not yet recruiting,No Results Available,Macular Degeneration,Device: MacuTest platform,estimation of AMD risk|Socio-demographic characteristics|Lifestyle characteristics|Ophthalmological characteristics|genetic risk score,"University Hospital, Bordeaux|Inserm U1219 Bordeaux University",All,65 Years and older � (Older Adult),Not Applicable,40,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CHUBX 2022/46,"April 1, 2023","July 1, 2024","July 1, 2024","January 9, 2023",,"January 9, 2023","CHU Bordeaux, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT05675917,NCT05675917,
oui,NCT05682196,Rituximab in Patients With Acute Rheumatic Fever,AGRAF-2,Not yet recruiting,No Results Available,Rheumatic Heart Disease in Children,Drug: Rituximab added to standard of care treatment|Drug: standard of care treatment,Rheumatic valvular lesions rate|Incidence of rheumatic valvular lesions|Serious adverse events rates,Paris Cardiovascular Research Center (Inserm U970),All,5 Years to 17 Years � (Child),Phase 2,234,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",AGRAF-2,"February 1, 2023","September 30, 2024","February 1, 2025","January 12, 2023",,"January 12, 2023",,,https://ClinicalTrials.gov/show/NCT05682196,NCT05682196,
oui,NCT05685095,Programmes de Marche Active et qualité de Vie Dans la Maladie de Parkinson,ACTI-PARK,Recruiting,No Results Available,Parkinson Disease,Behavioral: Physical training,Changes in daily energy expenditure|Evolution of gait parameters|Evolution of exercise functional capacity|Evolution over time of the Parkinson's Disease Questionnaire-39 scale score.|Evolution over time of the Parkinsons' Disease Fatigue Scale score.|Adherence to the training program,"University Hospital, Grenoble|University Grenoble Alps|Institut National de la Santé Et de la Recherche Médicale, France",All,"30 Years and older   (Adult, Older Adult)",Not Applicable,65,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",38RC22.0105_ACTI-PARK|2022-A00678-35,February 2023,February 2025,October 2026,"January 13, 2023",,"February 1, 2023","CHU Grenoble Alpes, Grenoble, France",,https://ClinicalTrials.gov/show/NCT05685095,NCT05685095,
oui,NCT05689944,Dance-therapy and Chronic Pain,ALGODANCE,Not yet recruiting,No Results Available,Chronic Pain|Complex Regional Pain Syndromes|Tension-Type Headache,Behavioral: Dance-therapy|Behavioral: Art-therapy|Behavioral: Yoga,Assesment of pain change|Kinesiophobia|Anxiety|Pain catastrophizing|Fear of Pain|Incidence of art therapy on quality of life (adolescents)|Incidence of art therapy on quality of life (adults)|Body satisfaction and global self-perception|Incidence of art therapy on sleep quality,Hospices Civils de Lyon,All,"12 Years to 20 Years � (Child, Adult)",Not Applicable,210,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,69HCL22_0361,January 2023,August 2029,August 2029,"January 19, 2023",,"January 19, 2023","Neuroscience Research Center of Lyon (CRNL)- INSERM U1028 - NEUROPAIN laboratory, Bron, France",,https://ClinicalTrials.gov/show/NCT05689944,NCT05689944,
oui,NCT05696496,"Evaluation of e New Sleep Detection Device ""Easy Sleep Monitoring""",ESM,Not yet recruiting,No Results Available,Sleep Disorder,Device: night recording,Effective sleep duration (in minutes)|Time spent in bed (in minutes)|Sleep efficiency (Total sleep time/Time spent in bed)|Sleep latency (in minutes)|Duration of sleep stages (Deep Wave Sleep vs. Paradoxical Sleep)(in minutes)|Duration of sleep stages (Deep Wave Sleep vs. Paradoxical Sleep) (in minutes)|% of sleep stages (Deep Wave Sleep vs. Paradoxical Sleep)|Number of alarm clocks|Number of position changes|Duration of periodic movements of the lower limbs (in minutes)|Duration of Cheyne-Stokes periodic breathing (in minutes)|number of obstructive and central apneas,"University Hospital, Clermont-Ferrand",All,"18 Years to 85 Years � (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,RBHP 2022 FANTINI,"January 20, 2023","June 30, 2025","December 31, 2025","January 25, 2023",,"January 25, 2023","CHU Clermont-Ferrand, UMR INSERM 1107, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT05696496,NCT05696496,
oui,NCT05698173,Systemic Lupus Erythematosus and Accelerated Aging,LUPAGE,Not yet recruiting,No Results Available,Systemic Lupus Erythematosus,Biological: blood sample,Absolute numbers of naïve T lymphocytes|Absolute numbers of terminally differentiated T lymphocytes|Percentages of terminally differentiated T lymphocytes among total lymphocytes|Percentages of senescent lymphocytes among total lymphocytes|Telomere length in sorted CD4+ and CD8+ T lymphocytes subsets (naïve and memory)|Frequency and phenotype of ELA-specific CD8+ T-cells after 10 days of in vitro priming|Number of naïve T lymphocytes newly produced by thymus evaluated by T-cell receptor excision circles (TRECs) measurement|Concentrations of senescence-associated secretory phenotype (SASP) markers in patients sera|Presence or absence of anti-type I interferons autoantibodies in patients sera|Measurement of disease activity according to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)|Measurement of disease activity according to British Lupus Assessment Group Index 2004 (BILAG-2004)|Quantification of organ damage according to SLICC/ACR Damage Index|Levels of anti-double stranded DNA in patients sera|Levels of complement components C3 and C4 in patients sera,"University Hospital, Bordeaux|University of Bordeaux|Institut National de la Santé Et de la Recherche Médicale, France",All,18 Years to 60 Years   (Adult),Not Applicable,75,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,CHUBX 2022/53,January 2023,January 2025,January 2025,"January 26, 2023",,"January 26, 2023","CHU de Bordeaux - Médecine Interne et Immunologie Clinique, Bordeaux, France",,https://ClinicalTrials.gov/show/NCT05698173,NCT05698173,
oui,NCT05700071,MRS of Glioma Genomics,GLIOMRS,Not yet recruiting,No Results Available,Glioma,Diagnostic Test: MRI,Metabolite concentrations by MRS|Diffusion MRI metrics|Metabolic changes during an anti-tumor treatment|Diffusion MRI and amide proton transfer signal changes during an anti-tumor treatment.,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C21-27|2021-A03015-36,"February 15, 2023","November 24, 2026","November 24, 2026","January 26, 2023",,"January 30, 2023","Pitié-Salpetrière Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT05700071,NCT05700071,
oui,NCT05711693,Measurement of Heart-carotid Pulse Wave Velocity (hcPWV) by Laser Doppler Vibrometry (LDV),InSide-CC,Not yet recruiting,No Results Available,Hypertension|Aortic Aneurysm|Bicuspid Aortic Valve|Marfan Syndrome|Aortic Dilatation,"Device: Laser doppler vibrometry (LDV), heart(cordium) carotid pulse wave velocity (ccPWV)|Procedure: Blood pressure and heart rate measurement|Device: carotid to femoral PWW measurement|Procedure: Questionnaire completion",Heart-carotid pulse wave velocity (hcPWV) measured by LDV compared to MRI|Reproducibility of LDV heart-carotid pulse wave velocity (hcPWV)|Validity of carotid to femoral pulse wave velocity (cfPWV) measured by LDV|Association of heart-carotid pulse wave velocity (hcPWV) measured by LDV with classical cardiovascular (CV) risk factors and disease|Acceptability of heart-carotid pulse wave velocity (hcPWV) measured by LDV compared with MRI,"Institut National de la Santé Et de la Recherche Médicale, France",All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,C21-28|2021-A02896-35,"February 1, 2023","February 1, 2024","July 1, 2024","February 3, 2023",,"February 3, 2023",,,https://ClinicalTrials.gov/show/NCT05711693,NCT05711693,
oui,NCT05729906,Dynamic Predictions of the Links Between Psychological and Physical Health of Older Patients in Nursing Home,BioMIND,Not yet recruiting,No Results Available,Psychological Health|Physical Health,Other: psychological and physical tests,PANAS|PHQ-9|Subjective Age Rating Scale|EVIBE (psychological)|MMSE|SPPB|EVIBE (physical)|Diagnosis of undernutrition|MNA|Charlson score|CIRS|ADLS|CFS|inflammatory measures|metabolomic profiles,"University Hospital, Tours|iBrain, Inserm U1253|Research Center for Respiratory Diseases, Inserm U1100",All,65 Years and older � (Older Adult),,100,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,DR220209-BioMIND,February 2023,August 2023,August 2024,"February 15, 2023",,"February 15, 2023","EHPAD CHIC Amboise/Chateau-Renault, Chateau-Renault, France|EHPAD Les Groussins, Chinon, France|EHPAD Paul Martinais, Loches, France|EHPAD Le Clos Mignot, Luynes, France",,https://ClinicalTrials.gov/show/NCT05729906,NCT05729906,
oui,NCT05739565,Impact of a Physical Activity Intervention With Motivational Support From Peers for Prostate Cancer Patients,ACTI-PAIR2,Not yet recruiting,No Results Available,Prostate Cancer,Behavioral: Acti-Pair program,"Objective measurement of physical activity (in MET-hr/week, Metabolic Equivalent of Task (MET), measures the intensity of physical activity)|Objective measurement of physical activity (in MET-hr/week, Metabolic Equivalent of Task (MET), measures intensity of physical activity)|Objective measure of physical inactivity (in h/d)|Subjective measurement of physical activity (in Metabolic equivalent of task-h/week) and sedentary time (h/d)|Measurement of physical capacity: walking distance (meters)|Measurement of muscle strength: biceps muscle strength (kg)|Level of fatigue assessed by measuring heart rate variability (SDNN and RMSSD in ms)|Level of fatigue|Health-related quality of life|Adoption of Acti-Pair program by physicians|Adoption of Acti-Pair program by peers|Adoption of Acti-Pair program by Adapted Physical Activity (APA) professionals|Time dedicated by peers, Adapted Physical Activity (APA) professionals and health professionals to the Acti-Pair program|Assessment of the context:factors favoring and hindering implementation, achievement, adaptation and sustainability of the programme ; compliance with the programme ; social representations|Percentage of adherence to the intervention|Motivation to engage in physical activity for patients and peers|Alliance between the patient and the peer|Patients, peers and professionals satisfaction|Cost per quality adjusted life year (QALY) gained through the intervention (quality adjusted life year)|Cost per patient continuing physical activity at 12 months through the intervention","Centre Hospitalier Universitaire de Saint Etienne|Sport Health Center of Auvergne-Rh�ne Alpes|INSERM, SAINBIOSE U1059|INSERM, CIC1408|INSERM ECEVE 1123|Ministry of Health, France",Male,"18 Years and older � (Adult, Older Adult)",Not Applicable,850,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,20PH286|2022-A01094-39,March 2023,"July 31, 2025","July 31, 2027","February 22, 2023",,"February 23, 2023","CH Annonay, Annonay, France|Activit� Physique Adapt�e - CDOS Savoie, Chamb�ry, France|CH Chamb�ry, Chamb�ry, France|Activit� Physique Adapt�e - DAHLIR 63, Clermont-Ferrand, France|CHU Clermont-Ferrand - Oncologie, Clermont-Ferrand, France|CHU Clermont-Ferrand - Urologie, Clermont-Ferrand, France|Activit� Physique Adapt�e - CDOS Is�re, Grenoble, France|CHU Grenoble - Urologie, Grenoble, France|Activit� Physique Adapt�e - DAHLIR 43, Le Puy-en-Velay, France|CH Le Puy en Velay, Le Puy-en-Velay, France|Activit� Physique Adapt�e - DAHLIR 69, Lyon, France|CLB - Oncologie, Lyon, France|CLB - Radioth�rapie, Lyon, France|HCL - CH Lyon Sud, Lyon, France|Activit� Physique Adapt�e - CDOS Ard�che, Privas, France|CH Roanne, Roanne, France|Activit� Physique Adapt�e - DAPAP 42, Saint-�tienne, France|CHU Saint-Etienne - Oncologie, Saint-�tienne, France|CHU Saint-Etienne - Radioth�rapie, Saint-�tienne, France|H�pital Priv� de la Loire, Saint-�tienne, France|Activit� Physique Adapt�e - CDOS Dr�me, Valence, France|H�pitaux Dr�me Nord - Valence, Valence, France|Radiologie Dr�me-Ard�che - Valence, Valence, France",,https://ClinicalTrials.gov/show/NCT05739565,NCT05739565,
oui,NCT05744011,Tango for Older People With Dementia,,Recruiting,No Results Available,Old Age  Dementia,Other: Tango intervention|Other: Adapted Physical Activity,"Change from Baseline physical abilities (balance, gait speed and lower limbs strength) at 1 and 3 months|Change from Baseline general physical performance at 1 and 3 months|Change from Baseline ability to perform activities of daily living (ADL) at 1 and 3 months|Change from Baseline questionnaire on Quality of Life (QoL) at 1 and 3 months|Change from Baseline neuropsychiatric symptoms at 1 and 3 months|Change from Baseline signs and symptoms of major depression at 1 and 3 months",University of Burgundy,All,65 Years and older � (Older Adult),Not Applicable,124,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,CERUBFC-2022-09-29-031,"December 1, 2022","June 16, 2023","September 29, 2023","February 24, 2023",,"February 24, 2023","Centre Hospitalier du Mont d'Or, Albigny-sur-Sa�ne, France|Ehpad Du Chg Le Val D'Or, Chasselay, France",,https://ClinicalTrials.gov/show/NCT05744011,NCT05744011,
oui,NCT05745831,Development and Validation of a Therapeutic Decision Aid in Ectopic Pregnancy: GEUDECID Study,GEUDECID,Not yet recruiting,No Results Available,To Validate a Decision Aid for Ectopic Pregnancy,Other: Therapeutic decision tool,Validate acceptability of the therapeutic decision tool in women managed for less active ectopic tubal pregnancy.|Validate acceptability of the therapeutic decision tool in doctors who managed women for less active ectopic tubal pregnancy.|To evaluate satisfaction of women and of doctor in using the tool,"Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 45 Years   (Adult),Not Applicable,100,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,C22-51,March 2023,March 2024,April 2024,"February 27, 2023",,"February 27, 2023",,,https://ClinicalTrials.gov/show/NCT05745831,NCT05745831,
oui,NCT05747820,Multiparametric Assessment of Cardiac Congestion in Outpatient Worsening Heart Failure,EVOLUTION,Recruiting,No Results Available,Heart Failure|Heart Decompensation,Other: Observational study,Change in E/e' ratio|Changes in Left Ventricular End-Diastolic Diameter (LVEDD)|Changes in Left Ventricular End-Systolic Diameter (LVESD)|Changes in Left Ventricular End-Diastolic Volume (LVEDV)|Changes in Left Ventricular End-Systolic Volume (LVESV)|Changes in Left Ventricular Ejection Fraction (LVEF)|Changes in mitral E-velocity|Changes in mitral A-velocity|Changes in E' velocity|Changes in Right Ventricular Systolic Pressure (RVSP)|Changes in Tricuspid Annular Pulmonary Systolic Excursion (TAPSE)|Changes in S' velocity|Changes in Inferior Vena Cava (IVC) diameter|Changes in Left Atrium (LA) surface|Changes in Right Atrium (RA) surface|Changes in patient-reported dyspnea|Changes in clinically-assessed jugular venous pulse|Changes in clinically-assessed peripheral edema|Changes in estimated Glomerular Filtration Rate (eGFR)|Changes in serum creatinine|Changes in NT-proBNP|Changes in high sensitivity Troponin T (HsTnT)|Changes in Kansas City Cardiomyopathy Questionnaire (KCCQ)-12|Weekly changes in telemetered parameters in patients wearing the wrist-worn device (Philips Health Band),Corteria Pharmaceuticals,All,"18 Years to 80 Years � (Adult, Older Adult)",,40,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,CHF202102,"September 28, 2022",March 2023,March 2023,"February 28, 2023",,"February 28, 2023","Institute of Cardiology Levon Hovhannisyan, Yerevan, Armenia|Erebuni Medical Center, Yerevan, Armenia|Health Institution Medico Laser, Cardiology ward, Banja Luka, Bosnia and Herzegovina|Universty Clinical Hospital Mostar, Clinic for Internal diseases with dyalisis center, Clinical ward for cardiology, Mostar, Bosnia and Herzegovina",,https://ClinicalTrials.gov/show/NCT05747820,NCT05747820,
oui,NCT05750134,Endoscopic Sleeve Gastroplasty for Moderate Obesity,PLICATURE,Not yet recruiting,No Results Available,Obesity,"Other: OBPLUS Clinical Database : data analysis|Other: Biological collection ""Liver, bile ducts and pancreas"": sample analysis",Serum metabolite profile using widely targeted metabolomics according to weigh loss amount (less than 10% of total weight versus more than 10% of total weight loss at 12 months post-surgery)|Clinical parameters at baseline and then at 3 and 12 month post-intervention.|Basic serum lipid profile at baseline and then at 3 and 12 month post-intervention.|Glycated hemoglobin at baseline and then at 3 and 12 month post-intervention.|Insulin at baseline and then at 3 and 12 month post-intervention.|C peptide at baseline and then at 3 and 12 month post-intervention.|Ferritin at baseline and then at 3 and 12 month post-intervention.|Liver function test parameter Alanine transaminase (ALT) at baseline and then at 3 and 12 month post-intervention.|Liver function test parameter aspartate transaminase (AST) at baseline and then at 3 and 12 month post-intervention.|Liver function test parameter Gamma-glutamyltransferase (GGT) at baseline and then at 3 and 12 month post-intervention.|Liver function test parameter Alkaline phosphatase (ALP) at baseline and then at 3 and 12 month post-intervention.|Liver fibrosis assessed by transient elastometry at baseline and then at 3 and 12 month post-intervention|Liver steatosis assessed by controlled attenuation parameter (CAP) at baseline and then at 3 and 12 month post-intervention.|Serum metabolites using widely targeted metabolomics at baseline and then at 3 and 12 month post-intervention.|Complications of endoscopic sleeve gastroplasty,Assistance Publique - H�pitaux de Paris|Metabolomics platform/UMR 1138 INSERM|INSERM U996,All,"18 Years and older � (Adult, Older Adult)",,105,Other,Observational,Observational Model: Cohort|Time Perspective: Other,APHP230192,March 2023,September 2023,October 2023,"March 1, 2023",,"March 6, 2023",,,https://ClinicalTrials.gov/show/NCT05750134,NCT05750134,
oui,NCT05761015,A Helping Osteoarthritis Patients to Walk With NSAID,PERIPATEI,Not yet recruiting,No Results Available,"Osteoarthritis, Knee|Osteoarthritis, Hip|Chronic Pain",Drug: therapeutic program including intermittent drug intake and multimodal rehabilitation program,Success|Self-declared physical activity (efficacy outcome)|Actual physical activity (efficacy outcome)|Pain at walk during the two last weeks (efficacy outcome)|Patient's Global Impression of Change (efficacy outcome)|kinesiophobia (efficacy outcome)|level of anxious state (efficacy outcome)|level of depressive state (efficacy outcome),"University Hospital, Clermont-Ferrand|Plateforme d'Investigation Clinique, INSERM CIC1405, CHU de Clermont-Ferrand, France|Fondation Apicil|M�decine Physique et R�adaptation, CHU de Clermont-Ferrand, France|M�decine du Sport et Explorations Fonctionnelles, CHU de Clermont-Ferrand, France|Rhumatologie, CHU de Clermont-Ferrand, France|Direction de la Recherche Clinique et des Innovations, CHU de Clermont-Ferrand, France|SARL BOUCHARENC, Saint-Ch�ly d'Apcher, France|Inserm U1107 "" Neuro-Dol "", Clermont-Ferrand, France|Universit� Clermont-Auvergne, France",All,"50 Years to 70 Years � (Adult, Older Adult)",Phase 4,55,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RBHP 2022 DUALE,"March 1, 2023","July 1, 2025","November 1, 2025","March 9, 2023",,"March 13, 2023","CHU Clemront-Ferrand, Clermont-Ferrand, France",,https://ClinicalTrials.gov/show/NCT05761015,NCT05761015,
oui,NCT05762367,MR Lymphatic Imaging in Idiopathic Intracranial Hypertention,LYMPHIMAGIIH,Not yet recruiting,No Results Available,Idiopathic Intracranial Hypertension,Diagnostic Test: 3T MRI with Gadobutrol injection,Morphometric study of the dural lymphatic network in patients with IIH vs controls|Characterization of lateral sinus stenoses using high resolution vessel wall imaging in patients with IIH|Morphometric study of the cervical lymphatic network in patients with IIH vs controls|Comparison of the volumes of the different compartments of the skull in patients with IIH vs controls,"Institut National de la Santé Et de la Recherche Médicale, France",Female,20 Years to 40 Years   (Adult),Not Applicable,40,Other,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic",C22-13|2022-A01422-41,"March 10, 2023","March 9, 2025","March 10, 2025","March 9, 2023",,"March 13, 2023",,,https://ClinicalTrials.gov/show/NCT05762367,NCT05762367,
